PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Frolov, A; Zielinski, SE; Crowley, JR; Dudley-Rucker, N; Schaffer, JE; Ory, DS				Frolov, A; Zielinski, SE; Crowley, JR; Dudley-Rucker, N; Schaffer, JE; Ory, DS			NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE TYPE-C; PICK TYPE-C; NUCLEAR RECEPTOR; BINDING PROTEIN; LDL; CELLS; HE-1; GENE; MICE; LXR	Mutations in the Niemann-Pick disease genes cause lysosomal cholesterol accumulation and impaired low density lipoprotein (LDL) cholesterol esterification. These findings have been attributed to a block in cholesterol movement from lysosomes to the site of the sterol regulatory machinery. In this study we show that Niemann-Pick type C1 (NPC1) and Niemann-Pick type C2 (NPC2) mutants have increased cellular cholesterol, yet they are unable to suppress LDL receptor activity and cholesterol biosynthesis. Cholesterol overload in both NPC1 and NPC2 mutants results from the failure of LDL cholesterol to both suppress sterol regulatory element-binding protein-dependent gene expression and promote liver X receptor-mediated responses. However, the severity of the defect in regulation of sterol homeostasis does not correlate with endoplasmic reticulum cholesterol levels, but rather with the degree to which NPC mutant fibroblasts fail to appropriately generate 25-hydroxycholesterol and 27-hydroxycholesterol in response to LDL cholesterol. Moreover, we demonstrate that treatment with oxysterols reduces cholesterol in NPC mutants and is able to correct the NPC1(I1061T) phenotype, the most prevalent NPC1 disease genotype. Our findings support a role for NPC1 and NPC2 in the regulation of sterol homeostasis through generation of LDL cholesterol-derived oxysterols and have important implications for the treatment of NPC disease.	Washington Univ, Sch Med, Dept Internal Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Mass Spectrometry Facil, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ory, DS (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Cardiovasc Res Ctr, Box 8086,660 S Euclid Ave, St Louis, MO 63110 USA.	dory@im.wustl.edu			NCRR NIH HHS [P41-RR-00954] Funding Source: Medline; NHLBI NIH HHS [HL67773, HL04482] Funding Source: Medline; NIDDK NIH HHS [DK56341] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL004482, R01HL067773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chan PC, 1998, J LIPID RES, V39, P2261; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ESTERMAN AL, 1983, J LIPID RES, V24, P1304; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Grand-Perret T, 2001, NAT MED, V7, P1332, DOI 10.1038/nm1201-1332; HIGASHI Y, 1993, ACTA NEUROPATHOL, V85, P175; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Millard EE, 2000, J BIOL CHEM, V275, P38445, DOI 10.1074/jbc.M003180200; Millat G, 2001, AM J HUM GENET, V69, P1013, DOI 10.1086/324068; MORRIS MD, 1982, AM J PATHOL, V108, P140; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; Prasad A, 2000, J NEUROCHEM, V75, P1250, DOI 10.1046/j.1471-4159.2000.0751250.x; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6; Steinberg SJ, 1996, J INHERIT METAB DIS, V19, P769, DOI 10.1007/BF01799171; STEINBERG SJ, 1994, J MED GENET, V31, P317, DOI 10.1136/jmg.31.4.317; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Sun XF, 2001, AM J HUM GENET, V68, P1361, DOI 10.1086/320599; TANAKA J, 1988, J NEUROPATH EXP NEUR, V47, P291, DOI 10.1097/00005072-198805000-00008; Vanier MT, 1996, AM J HUM GENET, V58, P118; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Xie CL, 1999, AM J PHYSIOL-ENDOC M, V276, pE336, DOI 10.1152/ajpendo.1999.276.2.E336	48	168	174	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25517	25525		10.1074/jbc.M302588200	http://dx.doi.org/10.1074/jbc.M302588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719428	hybrid			2022-12-25	WOS:000183920200032
J	Lad, SP; Peterson, DA; Bradshaw, RA; Neet, KE				Lad, SP; Peterson, DA; Bradshaw, RA; Neet, KE			Individual and combined effects of TrkA and p75(NTR) nerve growth factor receptors - A role for the high affinity receptor site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; KAPPA-B ACTIVATION; PROTEIN-KINASE-C; PC12 CELLS; SIGNAL-TRANSDUCTION; TYROSINE KINASE; NGF BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; NEURONAL DIFFERENTIATION; RETROGRADE TRANSPORT	A long-standing question in neurotrophin signal transduction is whether heteromeric TrkA-p75(NTR) complexes possess signaling capabilities that are significantly different from homo-oligomeric TrkA or p75(NTR) alone. To address this issue, various combinations of transfected PC12 cells expressing a platelet-derived growth factor receptor-TrkA chimera and the p75(NTR)-selective nerve growth factor mutant (Delta9/13 NGF) were utilized to selectively stimulate TrkA or p75(NTR) signaling, respectively. The contribution of individual and combined receptor effects was analyzed in terms of downstream signaling and certain end points. The results suggest two unique functions for the high affinity heteromeric NGF receptor site: ( a) integration of both the MAPK and Akt pathways in the production of NGF-induced neurite outgrowth, and (b) rapid and sustained activation of the Akt pathway, with consequent long term cellular survival. Whereas activation of TrkA signaling is sufficient for eliciting neurite outgrowth in PC12 cells, signaling through p75(NTR) plays a modulatory role, especially in the increased formation of fine, synaptic "bouton-like" structures, in which both TrkA and p75(NTR) appear to co-localize. In addition, a new interaction in the TrkA/p75(NTR) heteromeric receptor signal transduction network was revealed, namely that NGF-induced activation of the MAPK pathway appears to inhibit the parallel NGF-induced Akt pathway.	Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA; Univ Calif Irvine, Dept Physiol & Biophys, Coll Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Coll Med, Irvine, CA 92697 USA	Chicago Medical School; Chicago Medical School; University of California System; University of California Irvine; University of California System; University of California Irvine	Neet, KE (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.		Bradshaw, Ralph A/K-1515-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER; NIA NIH HHS [AG09735] Funding Source: Medline; NINDS NIH HHS [NS24380] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARKER PA, 1993, J BIOL CHEM, V268, P15150; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; DeFreitas MF, 2001, J NEUROSCI, V21, P5121, DOI 10.1523/JNEUROSCI.21-14-05121.2001; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; Dobrowsky RT, 2000, CELL SIGNAL, V12, P81, DOI 10.1016/S0898-6568(99)00072-8; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Foehr ED, 2000, J NEUROSCI, V20, P7556; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Horton A, 1997, MOL CELL NEUROSCI, V10, P162, DOI 10.1006/mcne.1997.0650; HUBER LJ, 1995, J NEUROSCI RES, V40, P557, DOI 10.1002/jnr.490400415; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; LAD SP, 2003, IN PRESS J NEUROSCI; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; LUO Y, 1992, J BIOL CHEM, V267, P12275; MacInnis BL, 2002, SCIENCE, V295, P1536, DOI 10.1126/science.1064913; MacPhee I, 1999, J NEUROCHEM, V72, P1423, DOI 10.1046/j.1471-4159.1999.721423.x; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; Mamidipudi V, 2002, J NEUROSCI RES, V68, P373, DOI 10.1002/jnr.10244; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; Ross AH, 1996, J CELL BIOL, V132, P945, DOI 10.1083/jcb.132.5.945; Ross GM, 1998, EUR J NEUROSCI, V10, P890, DOI 10.1046/j.1460-9568.1998.00094.x; Samuels IS, 2001, J CELL BIOCHEM, V82, P452, DOI 10.1002/jcb.1177; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wiesmann C, 2001, CELL MOL LIFE SCI, V58, P748, DOI 10.1007/PL00000898; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; Wolf DE, 1998, BIOCHEMISTRY-US, V37, P3178, DOI 10.1021/bi9719253; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yano H, 2000, Pharm Acta Helv, V74, P253, DOI 10.1016/S0031-6865(99)00036-9; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zaccaro MC, 2001, J BIOL CHEM, V276, P31023, DOI 10.1074/jbc.M104630200	54	61	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24808	24817		10.1074/jbc.M212270200	http://dx.doi.org/10.1074/jbc.M212270200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12702729	hybrid			2022-12-25	WOS:000183824800068
J	Seye, CI; Yu, NP; Jain, R; Kong, QM; Minor, T; Newton, J; Erb, L; Gonzalez, FA; Weisman, GA				Seye, CI; Yu, NP; Jain, R; Kong, QM; Minor, T; Newton, J; Erb, L; Gonzalez, FA; Weisman, GA			The P2Y(2) nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; EXTRACELLULAR ATP; E-SELECTIN; ACTIVATION; ICAM-1; VCAM-1; TRANSIENTS; MODULATION; MIGRATION	P2Y(2) receptor up-regulation and activation induces intimal hyperplasia and monocyte/macrophage infiltration in the collared rabbit carotid artery model of vascular injury, suggesting a potential role for P2Y(2) receptors in monocyte recruitment by vascular endothelium. In this study, we addressed the hypothesis that activation of P2Y(2) receptors by extracellular nucleotides modulates the expression of adhesion molecules on vascular endothelial cells that are important for monocyte recruitment. Results indicated that the equipotent P2Y(2) receptor agonists UTP or ATP (1-100 muM) stimulated the expression of vascular cell adhesion molecule-1 (VCAM-1) in human coronary artery endothelial cells (HCAEC) in a time- and dose-dependent manner. P2Y(2) antisense oligonucleotides inhibited VCAM-1 expression induced by UTP but not by tumor necrosis factor-alpha. Furthermore, UTP induced VCAM-1 expression in human 1321N1 astrocytoma cell transfectants expressing the recombinant P2Y(2) receptor, whereas vector-transfected control cells did not respond to UTP. The effect of UTP on VCAM-1 expression in HCAEC was prevented by depletion of intracellular calcium stores with thapsigargin or by inhibition of p38 mitogen-activated protein kinase or Rho kinase, but was not affected by inhibitors of the mitogen-activated protein/extracellular signal-regulated kinase pathway (i.e. MEK1/2). Consistent with a role for VCAM-1 in the recruitment of monocytes, UTP or ATP increased the adherence of monocytic U937 cells to HCAEC, an effect that was inhibited by anti-VCAM-1 antibodies. These findings suggest a novel role for the P2Y(2) receptor in the p38- and Rho kinase-dependent expression of VCAM-1 that mediates the recruitment of monocytes by vascular endothelium associated with the development of atherosclerosis.	Univ Missouri, Dept Biochem, Columbia, MO 65212 USA; Univ Puerto Rico, Dept Chem, Rio Piedras, PR 00931 USA	University of Missouri System; University of Missouri Columbia; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico Rio Piedras	Seye, CI (corresponding author), Univ Missouri, Dept Biochem, M743 Med Sci Bldg, Columbia, MO 65212 USA.		Yu, Ningpu/D-4266-2009	Erb, Laurie/0000-0001-6372-3378				Allen S, 1998, J CLIN INVEST, V101, P1064, DOI 10.1172/JCI445; BEEKHUIZEN H, 1993, J LEUKOCYTE BIOL, V54, P363, DOI 10.1002/jlb.54.4.363; Boarder MR, 1998, TRENDS PHARMACOL SCI, V19, P99, DOI 10.1016/S0165-6147(98)01170-5; BRAUN M, 1995, J MOL CELL CARDIOL, V27, P2571, DOI 10.1006/jmcc.1995.0044; BURNSTOCK G, 1998, P2 NUCLEOTIDE RECEPT, P3; Chaulet H, 2001, CIRC RES, V89, P772, DOI 10.1161/hh2101.098617; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; DE CR, 1995, J CLIN INVEST, V96, P60; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; FARUQI RM, 1993, BR HEART J S, V69, P19; Gerasimovskaya EV, 2002, J BIOL CHEM, V277, P44638, DOI 10.1074/jbc.M203012200; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Koshiba M, 1997, P NATL ACAD SCI USA, V94, P831, DOI 10.1073/pnas.94.3.831; LUSTIG KD, 1992, BIOCHIM BIOPHYS ACTA, V1134, P61, DOI 10.1016/0167-4889(92)90028-A; Parker AL, 1996, AM J PHYSIOL-LUNG C, V270, pL695, DOI 10.1152/ajplung.1996.270.5.L695; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Sauzeau V, 2000, AM J PHYSIOL-HEART C, V278, pH1751, DOI 10.1152/ajpheart.2000.278.6.H1751; Seye CI, 2002, CIRCULATION, V106, P2720, DOI 10.1161/01.CIR.0000038111.00518.35; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Turner JT, 1998, ANN NY ACAD SCI, V842, P70, DOI 10.1111/j.1749-6632.1998.tb09633.x; VENTURA MA, 1995, MOL PHARMACOL, V47, P104; Warny M, 2001, J BIOL CHEM, V276, P26051, DOI 10.1074/jbc.M102568200; Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705; [No title captured]	35	91	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24960	24965		10.1074/jbc.M301439200	http://dx.doi.org/10.1074/jbc.M301439200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714597	hybrid			2022-12-25	WOS:000183824800087
J	Jeon, MJ; Kim, JA; Kwon, SH; Kim, SW; Park, KS; Park, SW; Kim, SY; Shin, CS				Jeon, MJ; Kim, JA; Kwon, SH; Kim, SW; Park, KS; Park, SW; Kim, SY; Shin, CS			Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CELL-LINE; NUCLEAR MATRIX; BONE-FORMATION; MURINE MODEL; DIFFERENTIATION; ADIPOGENESIS; PROTEINS; CBFA1; ACID	Mesenchymal cells are able to differentiate into several distinct cell types, including osteoblasts and adipocytes. The commitment to a particular lineage may be regulated by specific transcription factors. Peroxisome proliferator-activated receptor-gamma (PPARgamma), acting in conjunction with CCAAT/enhancer-binding protein-alpha, has been suggested as a key regulator of adipogenic differentiation. Previous studies have shown that the activation of PPARgamma in osteoblasts suppresses osteoblast differentiation and the expression of osteocalcin, an osteoblast-specific protein. However, the mechanism of this inhibition remains unclear. We investigated the effect of PPARgamma activation on the expression of osteocalcin and analyzed the molecular mechanism. Mouse osteoblastic MC3T3-E1 cells expressed PPARgamma, which was transcriptionally active, whereas rat osteosarcoma ROS 17/2.8 cells did not. Treatment of MC3T3-E1 osteoblasts and ROS 17/2.8 cells stably transfected with PPARgamma2 with the PPARgamma activator 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibited the mRNA expression of osteocalcin and Runx2, the latter of which is a key transcription factor in osteoblast differentiation. This decreased expression of osteocalcin and Runx2 was partly explained by the decreased level of Runx2 resulting from the suppressed transcription from the Runx2 promoter. However, in addition to this indirect effect, the activation of PPARgamma by 15-deoxy-Delta(12,14)-prostaglandin J(2) directly suppressed the Runx2-mediated induction of the activities of the osteocalcin promoter and the artificial promoter p6OSE2, which contains six tandem copies of osteoblast-specific element-2, the Runx2-binding promoter sequence. This inhibition was mediated by a physical interaction between PPARgamma and Runx2 and the subsequent repression of the transcriptional activity at the osteoblast-specific element-2 sequence. Thus, this study demonstrates that the activation of PPARgamma inhibits osteocalcin expression both by suppressing the expression of Runx2 and by interfering with the transactivation ability of Runx2.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Hormone Res Ctr, Seoul 110744, South Korea; Seoul Natl Univ, Med Res Ctr, Inst Endocrinol Nutr & Metab, Seoul 110744, South Korea; Hallym Univ, Coll Med, Dept Internal Med, Gyeonggi 431070, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU); Hallym University	Shin, CS (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yungun Dong, Seoul 110744, South Korea.		Park, Kyong Soo/C-2265-2008; Shin, Chan Soo/I-7320-2012; Kim, Seong Yeon/J-5408-2012; Kim, Sang Wan/J-5399-2012; KIM, SEONG YEON/E-4164-2012	Park, Kyong Soo/0000-0003-3597-342X; Shin, Chan Soo/0000-0002-5829-4465; Kim, Sang Wan/0000-0001-9561-9110; 				Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; Diascro DD, 1998, J BONE MINER RES, V13, P96, DOI 10.1359/jbmr.1998.13.1.96; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ducy Patricia, 1996, P183; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; Gimble JM, 1996, BONE, V19, P421, DOI 10.1016/S8756-3282(96)00258-X; Gouveia CH, 2001, J ENDOCRINOL, V170, P667, DOI 10.1677/joe.0.1700667; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Imbeault P, 2001, J CLIN ENDOCR METAB, V86, P828, DOI 10.1210/jc.86.2.828; Jackson SM, 2000, FEBS LETT, V471, P119, DOI 10.1016/S0014-5793(00)01372-7; Javed A, 2000, J CELL SCI, V113, P2221; Jilka RL, 1996, J CLIN INVEST, V97, P1732, DOI 10.1172/JCI118600; Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Khosla S, 1996, J BONE MINER RES, V11, P857; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lecka-Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJESKA RJ, 1985, ENDOCRINOLOGY, V116, P170, DOI 10.1210/endo-116-1-170; MCKEE MD, 1992, ANAT REC, V234, P479, DOI 10.1002/ar.1092340404; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MEUNIER P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086-197110000-00021; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; YAMAGUCHI A, 1991, CALCIFIED TISSUE INT, V49, P221, DOI 10.1007/BF02556122; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	50	180	189	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23270	23277		10.1074/jbc.M211610200	http://dx.doi.org/10.1074/jbc.M211610200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704187	hybrid			2022-12-25	WOS:000183638600009
J	Lauber, T; Neudecker, P; Rosch, P; Marx, UC				Lauber, T; Neudecker, P; Rosch, P; Marx, UC			Solution structure of human proguanylin - The role of a hormone prosequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; SIDE-CHAIN RESONANCES; GUANYLYL CYCLASE-C; NMR-SPECTROSCOPY; SEQUENTIAL ASSIGNMENT; WATER SUPPRESSION; LARGER PROTEINS; LIGAND-BINDING; BACKBONE AMIDE; NOESY-HMQC	The endogenous ligand of guanylyl cyclase C, guanylin, is produced as the 94-amino-acid prohormone proguanylin, with the hormone guanylin located at the COOH terminus of the prohormone. The solution structure of proguanylin adopts a new protein fold and consists of a three-helix bundle, a small three-stranded beta-sheet of two NH2-terminal strands and one COOH-terminal strand, and an unstructured linker region. The sequence corresponding to guanylin is fixed in its bioactive topology and is involved in interactions with the NH2-terminal beta-hairpin: the hormone region (residues 80-94) partly wraps around the first 4 NH2-terminal residues that thereby shield parts of the hormone surface. These interactions provide an explanation for the negligible bioactivity of the prohormone as well as the important role of the NH2-terminal residues in the disulfide-coupled folding of proguanylin. Since the ligand binding region of guanylyl cyclase C is predicted to be located around an exposed beta-strand, the intramolecular interactions observed between guanylin and its prosequence may be comparable with the guanylin/receptor interaction.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany	University of Bayreuth	Marx, UC (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, Univ Str 30, D-95447 Bayreuth, Germany.	Ute.Marx@uni-bayreuth.de	Rösch, Paul/I-5445-2014; Neudecker, Philipp/G-5265-2013; Neudecker, Philipp/AAP-9005-2020	Rösch, Paul/0000-0003-3330-2446; Neudecker, Philipp/0000-0002-0557-966X; Neudecker, Philipp/0000-0002-0557-966X; Marx, Ute C./0000-0002-7077-9940				Brunger A.T., 1993, X PLOR VERSION 3 1 S; CAVANAGH J, 1992, J MAGN RESON, V96, P670, DOI 10.1016/0022-2364(92)90357-D; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; EGGENBERGER U, 1992, J MAGN RESON, V100, P604, DOI 10.1016/0022-2364(92)90067-H; EMSLEY L, 1990, CHEM PHYS LETT, V165, P469, DOI 10.1016/0009-2614(90)87025-M; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Forte LR, 1999, REGUL PEPTIDES, V81, P25, DOI 10.1016/S0167-0115(99)00033-6; FRENKIEL T, 1990, J MAGN RESON, V90, P420, DOI 10.1016/0022-2364(90)90152-Y; FRIEDRICHS MS, 1995, J BIOMOL NMR, V5, P147, DOI 10.1007/BF00208805; GARCIA KC, 1993, J BIOL CHEM, V268, P22397; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Hasegawa M, 1999, J BIOL CHEM, V274, P31713, DOI 10.1074/jbc.274.44.31713; He XL, 2001, SCIENCE, V293, P1657, DOI 10.1126/science.1062246; Hidaka Y, 2002, FEBS LETT, V526, P58, DOI 10.1016/S0014-5793(02)03114-9; Hidaka Y, 1998, BIOCHEMISTRY-US, V37, P8498, DOI 10.1021/bi9731246; Hidaka Y, 2000, J BIOL CHEM, V275, P25155, DOI 10.1074/jbc.M000543200; Hill JM, 1996, BIOCHEMISTRY-US, V35, P8824, DOI 10.1021/bi960073o; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Klodt J, 1997, J PEPT RES, V50, P222; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; KUHN M, 1993, FEBS LETT, V318, P205, DOI 10.1016/0014-5793(93)80022-M; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauber T, 2002, BIOCHEMISTRY-US, V41, P14602, DOI 10.1021/bi026434j; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; Marx UC, 1998, J PEPT RES, V52, P229; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Neudecker P, 2001, J BIOMOL NMR, V21, P373, DOI 10.1023/A:1013369107271; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; SATTLER M, 1995, J BIOMOL NMR, V6, P11, DOI 10.1007/BF00417487; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; SAYLE R, 1995, RASMOL V2 6 MOL VISU; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Schulz A, 1999, PROTEIN SCI, V8, P1850, DOI 10.1110/ps.8.9.1850; Schulz A, 1998, J PEPT RES, V52, P518; Schweimer K, 2002, BIOCHEMISTRY-US, V41, P5120, DOI 10.1021/bi015986j; SCHWEIMER K, 2000, THESIS U BAYREUTH BA; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SKELTON NJ, 1994, BIOCHEMISTRY-US, V33, P13581, DOI 10.1021/bi00250a010; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van den Akker F, 2001, J MOL BIOL, V311, P923, DOI 10.1006/jmbi.2001.4922; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wada A, 1996, INFECT IMMUN, V64, P5144, DOI 10.1128/IAI.64.12.5144-5150.1996; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P122; ZHANG O, 1990, J BIOMOL NMR, V4, P845; Zhang WX, 1997, J BIOMOL NMR, V10, P263, DOI 10.1023/A:1018386217930; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	76	18	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24118	24124		10.1074/jbc.M300370200	http://dx.doi.org/10.1074/jbc.M300370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707255	Green Submitted, hybrid			2022-12-25	WOS:000183638600117
J	Mackenzie, B; Schafer, MKH; Erickson, JD; Hediger, MA; Weihe, E; Varoqui, H				Mackenzie, B; Schafer, MKH; Erickson, JD; Hediger, MA; Weihe, E; Varoqui, H			Functional properties and cellular distribution of the system A glutamine transporter SNAT1 support specialized roles in central neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; INORGANIC-PHOSPHATE COTRANSPORTER; AMYOTROPHIC-LATERAL-SCLEROSIS; SODIUM-ALANINE COTRANSPORTER; CEREBELLAR GRANULE CELLS; PANCREATIC ACINAR-CELLS; SKELETAL-MUSCLE CELLS; XENOPUS-OOCYTES; RAT-BRAIN; ELECTROGENIC PROPERTIES	Glutamine, the preferred precursor for neurotransmitter glutamate and GABA, is likely to be the principal substrate for the neuronal System A transporter SNAT1 in vivo. We explored the functional properties of SNAT1 (the product of the rat Slc38a1 gene) by measuring radiotracer uptake and currents associated with SNAT1 expression in Xenopus oocytes and determined the neuronal-phenotypic and cellular distribution of SNAT1 by confocal laser-scanning microscopy alongside other markers. We found that SNAT1 mediates transport of small, neutral, aliphatic amino acids including glutamine (K-0.5 approximate to 0.3 mM), alanine, and the System A-specific analogue 2-(methylamino) isobutyrate. Amino acid transport is driven by the Na+ electrochemical gradient. The voltage-dependent binding of Na+ precedes that of the amino acid in a simultaneous transport mechanism. Li+ (but not H+) can substitute for Na+ but results in reduced V-max. In the absence of amino acid, SNAT1 mediates Na+-dependent presteady-state currents (Q(max) approximate to 9 nC) and a nonsaturable cation leak with selectivity Na+, Li+ >> H+, K+. Simultaneous flux and current measurements indicate coupling stoichiometry of 1 Na+ per 1 amino acid. SNAT1 protein was detected in somata and proximal dendrites but not nerve terminals of glutamatergic and GABAergic neurons throughout the adult CNS. We did not detect SNAT1 expression in astrocytes but detected its expression on the luminal membranes of the ependyma. The functional properties and cellular distribution of SNAT1 support a primary role for SNAT1 in glutamine transport serving the glutamate/GABA-glutamine cycle in central neurons. Localization of SNAT1 to certain dopaminergic neurons of the substantia nigra and cholinergic motoneurons suggests that SNAT1 may play additional specialized roles, providing metabolic fuel (via alpha-ketoglutarate) or precursors (cysteine, glycine) for glutathione synthesis.	Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Marburg, Inst Anat & Cell Biol, Dept Mol Neurosci, D-35033 Marburg, Germany	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Philipps University Marburg	Varoqui, H (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.			Mackenzie, Bryan/0000-0002-9661-8838; Hediger, Matthias/0000-0003-1946-027X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036936] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36936] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers A, 2001, PFLUG ARCH EUR J PHY, V443, P92, DOI 10.1007/s004240100663; Armano S, 2002, J BIOL CHEM, V277, P10467, DOI 10.1074/jbc.M110942200; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Blandini F, 1996, MOL NEUROBIOL, V12, P73, DOI 10.1007/BF02740748; Bode BP, 2001, J NUTR, V131, p2475S, DOI 10.1093/jn/131.9.2475S; Boulland JL, 2002, EUR J NEUROSCI, V15, P1615, DOI 10.1046/j.1460-9568.2002.01995.x; BRADFORD HF, 1976, BRAIN RES, V110, P115, DOI 10.1016/0006-8993(76)90212-2; Broer A, 2002, J PHYSIOL-LONDON, V539, P3, DOI 10.1013/jphysiol.2001.013303; Broer A, 1999, J NEUROCHEM, V73, P2184; Broer S, 2001, J NEUROCHEM, V77, P705, DOI 10.1046/j.1471-4159.2001.00322.x; Chaudhry FA, 2002, J NEUROSCI, V22, P62, DOI 10.1523/JNEUROSCI.22-01-00062.2002; Chaudhry FA, 2001, EMBO J, V20, P7041, DOI 10.1093/emboj/20.24.7041; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Cherubini E, 2001, TRENDS NEUROSCI, V24, P155, DOI 10.1016/S0166-2236(00)01724-0; Choi YH, 2000, LIFE SCI, V66, P1105, DOI 10.1016/S0024-3205(00)00414-8; CHRISTENSEN HN, 1977, J MEMBRANE BIOL, V37, P193, DOI 10.1007/BF01940932; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Dringen R, 2001, J NEUROSCI RES, V66, P1003, DOI 10.1002/jnr.10042; Eloqayli H, 2002, NEUROCHEM INT, V40, P181, DOI 10.1016/S0197-0186(01)00073-0; ERECINSKA M, 1994, J NEUROCHEM, V62, P1953; GIBB WRG, 1991, J NEUROL NEUROSUR PS, V54, P388, DOI 10.1136/jnnp.54.5.388; GJESSING LR, 1972, J NEUROCHEM, V19, P1807, DOI 10.1111/j.1471-4159.1972.tb06226.x; Gu SM, 2001, J BIOL CHEM, V276, P24137, DOI 10.1074/jbc.M009003200; HAMBERGER AC, 1979, BRAIN RES, V168, P513, DOI 10.1016/0006-8993(79)90306-8; HATTORI T, 1991, J COMP NEUROL, V309, P391, DOI 10.1002/cne.903090308; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; Hulsmann S, 2000, EUR J NEUROSCI, V12, P856, DOI 10.1046/j.1460-9568.2000.00973.x; Hyde R, 2002, J BIOL CHEM, V277, P13628, DOI 10.1074/jbc.M108609200; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; JAUCH P, 1986, J MEMBRANE BIOL, V94, P99, DOI 10.1007/BF01871191; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; JONES DG, 1975, SYNAPSES SYNAPTOSOME; Kanai Yoshikatsu, 2002, P255; KANEKO T, 1989, NEUROSCIENCE, V32, P79, DOI 10.1016/0306-4522(89)90109-7; KANEKO T, 1990, BRAIN RES, V507, P151, DOI 10.1016/0006-8993(90)90535-J; Khogali SEO, 2002, NUTRITION, V18, P123, DOI 10.1016/S0899-9007(01)00768-7; Klamo EM, 1996, J BIOL CHEM, V271, P14937, DOI 10.1074/jbc.271.25.14937; LAAKE JH, 1995, J NEUROCHEM, V65, P871; Lebon V, 2002, J NEUROSCI, V22, P1523, DOI 10.1523/JNEUROSCI.22-05-01523.2002; LECAM A, 1977, J BIOL CHEM, V252, P148; Levenson J, 2000, P NATL ACAD SCI USA, V97, P12858, DOI 10.1073/pnas.220256497; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; Mackenzie B., 1999, BIOMEMBRANE TRANSPOR, P327; MACKENZIE B, 2003, IN PRESS PFLUGERS AR; Martin DL, 1998, PERSPECT DEV NEUROBI, V5, P119; Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1; McBean GJ, 2002, TRENDS PHARMACOL SCI, V23, P299, DOI 10.1016/S0165-6147(02)02060-6; MCGALE EHF, 1977, J NEUROCHEM, V29, P291, DOI 10.1111/j.1471-4159.1977.tb09621.x; MEISTER B, 1993, NEUROREPORT, V5, P337, DOI 10.1097/00001756-199312000-00040; NI BH, 1995, J NEUROSCI, V15, P5789; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; Oertel W H, 1984, Adv Neurol, V40, P91; Olalla L, 2002, J BIOL CHEM, V277, P38939, DOI 10.1074/jbc.C200373200; OTTERSEN OP, 1984, J COMP NEUROL, V229, P374, DOI 10.1002/cne.902290308; PENG L, 1991, NEUROCHEM RES, V16, P29, DOI 10.1007/BF00965824; POW DV, 1994, NEUROSCIENCE, V60, P355, DOI 10.1016/0306-4522(94)90249-6; Reimer RJ, 2000, P NATL ACAD SCI USA, V97, P7715, DOI 10.1073/pnas.140152797; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SAJI M, 1991, NEUROSCI LETT, V123, P175, DOI 10.1016/0304-3940(91)90924-I; Schafer MKH, 2002, J BIOL CHEM, V277, P50734, DOI 10.1074/jbc.M206738200; SONNEWALD U, 1993, NEUROCHEM INT, V22, P19, DOI 10.1016/0197-0186(93)90064-C; Stumm RK, 2001, J NEUROSCI, V21, P798, DOI 10.1523/JNEUROSCI.21-03-00798.2001; Su TZ, 1997, BRAIN RES, V757, P69, DOI 10.1016/S0006-8993(97)00139-X; Sulzer D, 1998, J NEUROSCI, V18, P4588, DOI 10.1523/jneurosci.18-12-04588.1998; Sulzer D, 2000, AMINO ACIDS, V19, P45, DOI 10.1007/s007260070032; TAKAKUSAKI K, 1989, EXP BRAIN RES, V74, P11; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; Varoqui H, 2002, BIOCHEM BIOPH RES CO, V290, P903, DOI 10.1006/bbrc.2001.6281; Varoqui H, 2002, J NEUROSCI, V22, P142, DOI 10.1523/JNEUROSCI.22-01-00142.2002; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; WAERHAUG O, 1993, ANAT EMBRYOL, V188, P501; Wang HP, 2000, BIOCHEM BIOPH RES CO, V273, P1175, DOI 10.1006/bbrc.2000.3061; Weber WM, 1995, J MEMBRANE BIOL, V148, P263; WESTERGAARD N, 1995, DEV NEUROSCI-BASEL, V17, P203, DOI 10.1159/000111288; Xu GY, 1998, NEUROSCIENCE, V86, P1011, DOI 10.1016/S0306-4522(98)00063-3; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; YUDKOFF M, 1989, J NEUROCHEM, V53, P632, DOI 10.1111/j.1471-4159.1989.tb07380.x; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	87	103	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23720	23730		10.1074/jbc.M212718200	http://dx.doi.org/10.1074/jbc.M212718200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684517	hybrid			2022-12-25	WOS:000183638600066
J	Matousek, J; Gotte, G; Pouckova, P; Soucek, J; Slavik, T; Vottariello, F; Libonati, M				Matousek, J; Gotte, G; Pouckova, P; Soucek, J; Slavik, T; Vottariello, F; Libonati, M			Antitumor activity and other biological actions of oligomers of ribonuclease A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; BULL SEMINAL RIBONUCLEASE; PANCREATIC RIBONUCLEASE; ASPERMATOGENIC SUBSTANCE; CRYSTAL-STRUCTURE; VESICLE FLUID; INHIBITOR; CYTOTOXICITY; TRIMERS; DIMER	Dimers, trimers, and tetramers of bovine ribonuclease A, obtained by lyophilization of the enzyme from 40% acetic acid solutions, were purified and isolated by cation exchange chromatography. The two conformers constituting each aggregated species were assayed for their antitumor, aspermatogenic, or embryotoxic activities in comparison with monomeric RNase A and bovine seminal RNase, which is dimeric in nature. The antitumor action was tested in vitro on ML-2 (human myeloid leukemia) and HL-60 (human myeloid cell line) cells and in vivo on the growth of human non-pigmented melanoma (line UB900518) transplanted subcutaneously in nude mice. RNase A oligomers display a definite antitumor activity that increases as a function of the size of the oligomers. On ML-2 and HL-60 cells, dimers and trimers generally show a lower activity than bovine seminal RNase; the activity of tetramers, instead, is similar to or higher than that of the seminal enzyme. The growth of human melanoma in nude mice is inhibited by RNase A oligomers in the order dimers < trimers < tetramers. The action of the two tetramers is very strong, blocking almost completely the growth of melanoma. RNase A dimers, trimers, and tetramers display aspermatogenic effects similar to those of bovine seminal RNase, but, contrarily, they do not show any embryotoxic activity.	Univ Verona, Fac Med, Dept Neurol & Vis Sci, Sect Biol Chem, I-37134 Verona, Italy; Acad Sci Czech Republ, Inst Anim Physiol & Genet, CR-27721 Libechov, Czech Republic; Charles Univ, Fac Med, Inst Biophys, Prague 12000, Czech Republic; Univ Prague, Inst Hematol & Blood Transfus, Prague 12820, Czech Republic	University of Verona; Czech Academy of Sciences; Institute of Animal Physiology & Genetics of the Czech Academy of Sciences; Charles University Prague; Institute of Hematology Prague	Libonati, M (corresponding author), Univ Verona, Fac Med, Dept Neurol & Vis Sci, Sect Biol Chem, Strada Grazie 8, I-37134 Verona, Italy.		Pouckova, Pavla Miloslava/D-8362-2016; Slavik, Tomas/AAF-1018-2020	Pouckova, Pavla Miloslava/0000-0001-6713-8045; Gotte, Giovanni/0000-0003-3179-7158				Antignani A, 2001, BIOCHEMISTRY-US, V40, P3492, DOI 10.1021/bi002781m; BARTHOLEYNS J, 1976, P NATL ACAD SCI USA, V73, P573, DOI 10.1073/pnas.73.2.573; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; Blackburn P, 1982, ENZYMES, VXV, P317; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Bracale A, 2002, BIOCHEM J, V362, P553, DOI 10.1042/0264-6021:3620553; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DALESSIO G, 1972, EUR J BIOCHEM, V26, P153, DOI 10.1111/j.1432-1033.1972.tb01751.x; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; DOSTAL J, 1973, J REPROD FERTIL, V33, P263, DOI 10.1530/jrf.0.0330263; DOSTAL J, 1972, J REPROD FERTIL, V31, P273, DOI 10.1530/jrf.0.0310273; Garcia-Ortega L, 2002, J BIOL CHEM, V277, P18632, DOI 10.1074/jbc.M200922200; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Gotte G, 1997, FEBS LETT, V415, P308, DOI 10.1016/S0014-5793(97)01147-2; Gotte G, 1999, EUR J BIOCHEM, V265, P680, DOI 10.1046/j.1432-1327.1999.00761.x; HOFSTEENGE J, 1994, CURR OPIN STRUC BIOL, V4, P807, DOI 10.1016/0959-440X(94)90260-7; Ilinskaya ON, 2002, PROTEIN SCI, V11, P2522, DOI 10.1110/ps.0216702; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; LACCETTI P, 1994, CANCER RES, V54, P4253; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; LIBONATI M, 1975, BIOCHIM BIOPHYS ACTA, V407, P292, DOI 10.1016/0005-2787(75)90096-9; Libonati M, 2001, METHOD ENZYMOL, V341, P234, DOI 10.1016/S0076-6879(01)41155-4; Libonati M, 1996, BIOCHEM J, V318, P287, DOI 10.1042/bj3180287; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 1998, P NATL ACAD SCI USA, V95, P3437, DOI 10.1073/pnas.95.7.3437; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; MASTRONICOLA MR, 1995, EUR J BIOCHEM, V230, P242, DOI 10.1111/j.1432-1033.1995.tb20557.x; Matousek J, 1997, COMP BIOCHEM PHYS B, V118, P881, DOI 10.1016/S0305-0491(97)00278-2; MATOUSEK J, 1975, J REPROD FERTIL, V43, P171; MATOUSEK J, 1994, ANIM GENET, V25, P45, DOI 10.1111/j.1365-2052.1994.tb00402.x; Matousek J, 2002, J CONTROL RELEASE, V82, P29, DOI 10.1016/S0168-3659(02)00082-2; MATOUSEK J, 1973, EXPERIENTIA, V29, P848; Nenci A, 2001, PROTEIN SCI, V10, P2017, DOI 10.1110/ps.14101; Piccoli R, 1999, P NATL ACAD SCI USA, V96, P7768, DOI 10.1073/pnas.96.14.7768; SHAPIRO R, 1991, BIOCHEMISTRY-US, V30, P2246, DOI 10.1021/bi00222a030; Sorrentino S, 2000, FEBS LETT, V466, P35, DOI 10.1016/S0014-5793(99)01742-1; SOUCEK J, 1983, FOLIA BIOL-PRAGUE, V29, P250; SOUCEK J, 1979, FOLIA BIOL-PRAGUE, V25, P142; TANIGUCHI T, 1974, BIOCHEM BIOPH RES CO, V58, P280, DOI 10.1016/0006-291X(74)90924-3; TARNOWSKI GS, 1976, CANCER RES, V36, P4074; WANG D, 1977, BIOCHEMISTRY-US, V16, P2937, DOI 10.1021/bi00632a021	49	69	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23817	23822		10.1074/jbc.M302711200	http://dx.doi.org/10.1074/jbc.M302711200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697760	hybrid			2022-12-25	WOS:000183638600076
J	Song, KS; Lee, WJ; Chung, KC; Koo, JS; Yang, EJ; Choi, JY; Yoon, JH				Song, KS; Lee, WJ; Chung, KC; Koo, JS; Yang, EJ; Choi, JY; Yoon, JH			Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCIN GENE-EXPRESSION; MEMBRANE-ASSOCIATED MUCIN; GROWTH-FACTOR RECEPTOR; NORMAL HUMAN NASAL; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; SIGNALING PATHWAYS; KINASE ACTIVATION; MESSENGER-RNA	Mucin hypersecretion is commonly observed in many inflammatory diseases of the respiratory tract. MUC5AC is generally recognized to be a major airway mucin because MUC5AC is highly expressed in the goblet cells of human airway epithelium. Moreover, it is regulated by various inflammatory cytokines. However, the mechanisms by which the interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha induce MUC5AC gene expression in normal nasal epithelial cells, and the signal molecules involved, especially in the downstream signaling of mitogen-activated protein (MAP) kinases, remain unclear. Here we show that pharmacologic or genetic inhibition of either ERK or p38 MAP kinase pathway abolished IL-1beta- and TNF-alpha-induced MUC5AC gene expression in normal human nasal epithelial cells. Our results also indicate that the activation of mitogen- and stress-activated protein kinase 1 (MSK1) and cAMP-response element-binding protein and cAMP-response element signaling cascades via ERK and p38 MAP kinases are crucial aspects of the intracellular mechanisms that mediate MUC5AC gene expression. Taken together, these studies give additional insights into the molecular mechanism of IL-1beta- and TNF-alpha-induced MUC5AC gene expression and enhance our understanding on mucin hypersecretion during inflammation.	Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Ewha Womans University; Yonsei University; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University Health System	Yoon, JH (corresponding author), Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Brain Korea Project Med Sci 21, 134 Shinchon Dong, Seoul 120752, South Korea.		Koo, J Peter/AAE-6700-2019; Yoon, Joo-Heon/E-5781-2016	Yoon, Joo-Heon/0000-0003-2404-7156	NIEHS NIH HHS [K22 ES003662-01] Funding Source: Medline	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Berrou E, 2001, J BIOL CHEM, V276, P39303, DOI 10.1074/jbc.M011751200; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; CHUNG KC, 1995, MOL CELL BIOL, V15, P6139; Chung MH, 2002, LARYNGOSCOPE, V112, P152, DOI 10.1097/00005537-200201000-00027; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gray T, 2001, TOXICOLOGY, V160, P35, DOI 10.1016/S0300-483X(00)00455-8; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; GUM JR, 1994, J BIOL CHEM, V269, P2440; HO SB, 1995, GASTROENTEROLOGY, V109, P735, DOI 10.1016/0016-5085(95)90380-1; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Keates AC, 1997, BIOCHEM J, V324, P295, DOI 10.1042/bj3240295; Kim SS, 2000, LARYNGOSCOPE, V110, P276, DOI 10.1097/00005537-200002010-00017; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Melnick M, 2001, ARCH ORAL BIOL, V46, P745, DOI 10.1016/S0003-9969(01)00027-9; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nadel JA, 2001, RESP RES, V2, P85, DOI 10.1186/rr43; Pallesen LT, 2002, EUR J BIOCHEM, V269, P2755, DOI 10.1046/j.1432-1033.2002.02949.x; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ropert C, 2001, J IMMUNOL, V166, P3423, DOI 10.4049/jimmunol.166.5.3423; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; SPICER AP, 1991, J BIOL CHEM, V266, P15099; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; THRONTON DJ, 1997, J BIOL CHEM, V272, P9561; van de Bovenkamp JHB, 1998, BIOCHEM BIOPH RES CO, V245, P853, DOI 10.1006/bbrc.1998.8535; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; VanKlinken BJW, 1997, BIOCHEM BIOPH RES CO, V238, P143, DOI 10.1006/bbrc.1997.7258; Voynow JA, 1998, LUNG, V176, P345, DOI 10.1007/PL00007616; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wickstrom C, 1998, BIOCHEM J, V334, P685, DOI 10.1042/bj3340685; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yoon JH, 2000, ANN OTO RHINOL LARYN, V109, P594, DOI 10.1177/000348940010900612; Yuta Atsushi, 1997, American Journal of Physiology, V273, pL1203	53	220	238	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23243	23250		10.1074/jbc.M300096200	http://dx.doi.org/10.1074/jbc.M300096200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12690113	hybrid			2022-12-25	WOS:000183638600006
J	Zhang, WY; Shao, Y; Fang, DY; Huang, JY; Jeon, MS; Liu, YC				Zhang, WY; Shao, Y; Fang, DY; Huang, JY; Jeon, MS; Liu, YC			Negative regulation of T cell antigen receptor-mediated Crk-L-C3G signaling and cell adhesion by Cbl-b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; RING-TYPE; C-CBL; ACTIVATION; RAS; PROTEIN; RAP1; PHOSPHORYLATION; TRANSDUCTION; DYNAMICS	It was previously reported that Cbl-b associates with Crk-L in Jurkat T cells. However, the physiological significance of such association remains unclear. Here we examined a regulatory role of Cbl-b in Crk-L-C3G signaling pathway. We found that Cbl-b associates with, and induces, ubiquitin conjugation to Crk-L, which requires a functional RING finger. Cbl-b deficiency does not affect Crk-L stability, but its association with C3G. In Cbl-b(-/-) T cells, the interaction between Crk-L and C3G, and the activity of the small GTPase Rap1, are increased. Cbl-b(-/-) T cells also display increased adhesion and cell surface binding to ICAM-1, a finding that is supported by the enhanced clustering of LFA-1 in Cbl-b(-/-) T cells in response to TCR stimulation. Thus, Cbl-b plays a negative role in Crk-L-C3G-mediated Rap1 and LFA-1 activation in T cells.	La Jolla Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	yuncail@liai.org	Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NIAID NIH HHS [R01AI50280] Funding Source: Medline; NIDDK NIH HHS [R01DK-56558] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Gelkop S, 1999, J BIOL CHEM, V274, P21519, DOI 10.1074/jbc.274.31.21519; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KEANE MM, 1995, ONCOGENE, V10, P2367; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Krawczyk C, 2002, IMMUNITY, V16, P331, DOI 10.1016/S1074-7613(02)00291-1; Krummel MF, 2002, CURR OPIN IMMUNOL, V14, P66, DOI 10.1016/S0952-7915(01)00299-0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shao Y, 2003, EMBO REP, V4, P425, DOI 10.1038/sj.embor.embor813; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Zhang J, 2002, J IMMUNOL, V169, P2236, DOI 10.4049/jimmunol.169.5.2236	30	58	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23978	23983		10.1074/jbc.M212671200	http://dx.doi.org/10.1074/jbc.M212671200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697763	hybrid			2022-12-25	WOS:000183638600097
J	Weitao, T; Budd, M; Hoopes, LLM; Campbell, JL				Weitao, T; Budd, M; Hoopes, LLM; Campbell, JL			Dna2 helicase/nuclease causes replicative fork stalling and double-strand breaks in the ribosomal DNA of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LIFE-SPAN; ENDONUCLEASE ACTIVITY; GENOME INSTABILITY; HOLLIDAY JUNCTIONS; FOB1 PROTEIN; 3' END; YEAST; HELICASE; MUTANTS	We have proposed that faulty processing of arrested replication forks leads to increases in recombination and chromosome instability in Saccharomyces cerevisiae and contributes to the shortened lifespan of dna2 mutants. Now we use the ribosomal DNA locus, which is a good model for all stages of DNA replication, to test this hypothesis. We show directly that DNA replication pausing at the ribosomal DNA replication fork barrier ( RFB) is accompanied by the occurrence of doublestrand breaks near the RFB. Both pausing and breakage are elevated in the early aging, hypomorphic dna2- 2 helicase mutant. Deletion of FOB1, encoding the fork barrier protein, suppresses the elevated pausing and DSB formation, and represses initiation at rDNA ARSs. The dna2- 2 mutation is synthetically lethal with Deltarrm3, encoding another DNA helicase involved in rDNA replication. It does not appear to be the case that the rDNA is the only determinant of genome stability during the yeast lifespan however since strains carrying deletion of all chromosomal rDNA but with all rDNA supplied on a plasmid, have decreased rather than increased lifespan. We conclude that the replication- associated defects that we can measure in the rDNA are symbolic of similar events occurring either stochastically throughout the genome or at other regions where replication forks move slowly or stall, such as telomeres, centromeres, or replication slow zones.	CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA; Pomona Coll, Dept Biol, Seaver S Lab, Claremont, CA 91711 USA; Pomona Coll, Program Mol Biol, Seaver S Lab, Claremont, CA 91711 USA	California Institute of Technology; Claremont Colleges; Pomona College; Claremont Colleges; Pomona College	Campbell, JL (corresponding author), CALTECH, Braun Labs 147 75, Pasadena, CA 91125 USA.	jcampbel@cco.caltech.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Austriaco NR, 1997, P NATL ACAD SCI USA, V94, P9768, DOI 10.1073/pnas.94.18.9768; Bae SH, 1998, J BIOL CHEM, V273, P26880, DOI 10.1074/jbc.273.41.26880; Bae SH, 2002, J BIOL CHEM, V277, P26632, DOI 10.1074/jbc.M111026200; Bae SH, 2001, NUCLEIC ACIDS RES, V29, P3069, DOI 10.1093/nar/29.14.3069; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Benguria A, 2003, NUCLEIC ACIDS RES, V31, P893, DOI 10.1093/nar/gkg188; Bidnenko V, 2002, EMBO J, V21, P3898, DOI 10.1093/emboj/cdf369; Braguglia D, 1998, J MOL BIOL, V281, P631, DOI 10.1006/jmbi.1998.1973; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Budd ME, 2000, MUTAT RES-DNA REPAIR, V459, P173, DOI 10.1016/S0921-8777(99)00072-5; Bussiere DE, 1999, MOL MICROBIOL, V31, P1611, DOI 10.1046/j.1365-2958.1999.01287.x; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Choe W, 2002, MOL CELL BIOL, V22, P4202, DOI 10.1128/MCB.22.12.4202-4217.2002; COURCELLE J, 2003, SCIENCE; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; Dlakic M, 2002, PROTEIN SCI, V11, P1274, DOI 10.1110/ps.4470102; DMELLO NP, 1991, J BACTERIOL, V173, P6709, DOI 10.1128/jb.173.21.6709-6713.1991; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Fiorentino DF, 1997, MOL BIOL CELL, V8, P2519, DOI 10.1091/mbc.8.12.2519; Formosa T, 1999, GENETICS, V151, P1459; GravesWoodward KL, 1997, J BIOL CHEM, V272, P4623, DOI 10.1074/jbc.272.7.4623; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; Grompone G, 2002, MOL MICROBIOL, V44, P1331, DOI 10.1046/j.1365-2958.2002.02962.x; Gruber M, 2000, MOL CELL BIOL, V20, P5777, DOI 10.1128/MCB.20.15.5777-5787.2000; Guthrie C, 1991, GUIDE YEAST GENETICS; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; Hoopes LLM, 2002, MOL CELL BIOL, V22, P4136, DOI 10.1128/MCB.22.12.4136-4146.2002; HORIUCHI T, 1995, J BACTERIOL, V177, P783, DOI 10.1128/jb.177.3.783-791.1995; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Ivessa AS, 2002, GENE DEV, V16, P1383, DOI 10.1101/gad.982902; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; Lee KH, 2000, NUCLEIC ACIDS RES, V28, P2873, DOI 10.1093/nar/28.15.2873; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; McGlynn P, 2001, J BIOL CHEM, V276, P41938, DOI 10.1074/jbc.M107945200; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Muller M, 2000, MOL CELL, V5, P767, DOI 10.1016/S1097-2765(00)80317-2; Myung K, 2001, NATURE, V411, P1073, DOI 10.1038/35082608; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; Pasero P, 2002, GENE DEV, V16, P2479, DOI 10.1101/gad.232902; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Rothstein R, 2000, GENE DEV, V14, P1; SAMBROOK J, 1989, MOL CLONING LAB MANU, P655; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SKRYABIN KG, 1984, NUCLEIC ACIDS RES, V12, P2955, DOI 10.1093/nar/12.6.2955; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; Wai H, 2001, MOL CELL BIOL, V21, P5541, DOI 10.1128/MCB.21.16.5541-5553.2001; Wai HH, 2000, NUCLEIC ACIDS RES, V28, P3524, DOI 10.1093/nar/28.18.3524; Wang YZ, 2001, MOL CELL BIOL, V21, P4938, DOI 10.1128/MCB.21.15.4938-4948.2001; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	78	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22513	22522		10.1074/jbc.M301610200	http://dx.doi.org/10.1074/jbc.M301610200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686542	hybrid, Green Accepted			2022-12-25	WOS:000183503900047
J	Landowski, TH; Olashaw, NE; Agrawal, D; Dalton, WS				Landowski, TH; Olashaw, NE; Agrawal, D; Dalton, WS			Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells	ONCOGENE			English	Article						myeloma; drug resistance; adhesion; NF-kappa B; microarray	INDUCED APOPTOSIS; CONFERS RESISTANCE; EXPRESSION; INHIBITOR; FIBRONECTIN; INDUCTION; DEATH; BCL-2; TRANSCRIPTION; FIBROBLASTS	The microenvironment has been shown to influence tumor cell phenotype with respect to growth, metastasis, and response to chemotherapy. We have utilized oligonucleotide microarray analysis to identify signal transduction pathways and gene products altered by the interaction of myeloma tumor cells with the extracellular matrix component fibronectin that may contribute to the antiapoptotic phenotype conferred by the microenvironment. Genes with altered expression associated with fibronectin cell adhesion, either induced or repressed, were numerically ranked by fold change. FN adhesion repressed the expression of 469 gene products, while 53 genes with known coding sequences were induced by twofold or more. Of these 53 genes with two fold, or greater increase in expression, 11 have been reported to be regulated by the nuclear factor-kappa B (NF-kappaB) family of transcription factors. EMSA analysis demonstrated NF-kappaB binding activity significantly increased in cells adhered to fibronectin compared to cells in suspension. This DNA binding activity consisted primarily of RelB-p50 heterodimers, which was distinct from the NF-kappaB activation of TNFalpha. These data demonstrate the selectivity of signal transduction from the microenvironment that may contribute to tumor cell resistance to programmed cell death.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Cell Biol, Tampa, FL 33612 USA; Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ 85724 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Arizona Center Cancer Care; University of Arizona	Dalton, WS (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA.							Bearz A, 1998, BIOCHEM BIOPH RES CO, V243, P732, DOI 10.1006/bbrc.1997.8017; Bian X, 2001, J BIOL CHEM, V276, P48921, DOI 10.1074/jbc.M108674200; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Do RKG, 2002, CYTOKINE GROWTH F R, V13, P19, DOI 10.1016/S1359-6101(01)00025-9; Feinman R, 1999, BLOOD, V93, P3044; Green SK, 1999, ANTI-CANCER DRUG DES, V14, P153; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kudoh K, 2000, CANCER RES, V60, P4161; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Rosales C, 1996, CANCER RES, V56, P2302; Scupoli MT, 2000, J CELL SCI, V113, P169; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; StCroix B, 1996, NAT MED, V2, P1204; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	33	151	154	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2417	2421		10.1038/sj.onc.1206315	http://dx.doi.org/10.1038/sj.onc.1206315			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717418				2022-12-25	WOS:000182383500004
J	Lee, GH; Nishimori, H; Sasaki, Y; Matsushita, H; Kitagawa, T; Tokino, T				Lee, GH; Nishimori, H; Sasaki, Y; Matsushita, H; Kitagawa, T; Tokino, T			Analysis of lung tumorigenesis in chimeric mice indicates the Pulmonary adenoma resistance 2 (Par2) locus to operate in the tumor-initiation stage in a cell-autonomous manner: detection of polymorphisms in the Poh gene as a candidate for Par2	ONCOGENE			English	Article						chimeric mouse; lung tumor; resistance locus; cell-autonomy; candidate gene	HUMAN DNA-POLYMERASE; URETHANE-INDUCTION; BALB/CBYJ MICE; RAS GENE; IOTA; SUSCEPTIBILITY; CARCINOGENESIS; IDENTIFICATION; HOMOLOG; LESIONS	The Pulmonary adenoma resistance 2 (Par2) locus of the BALB/cByJ mouse, located within 0.5 cM of chromosome 18, is responsible for reducing the mean multiplicity of urethane-induced lung tumors relative to those in C57BL/6J, A/J and C3H/HeJ mice. Thus, BALB/B6-Par2 congenic strain genetically identical to BALB/cByJ except carrying C57BL/6J Par2 alleles develops seven times more tumors than BALB/cByJ. To gain clues for identification of Par2 candidate genes, we analysed lung tumorigenesis in BALB/cByJ <----> BALB.B6-Par2 chimeric animals. Of 100 tumors induced by urethane in 16 chimeras, 82 originated from BALB.B6-Par2 cells, indicating the Par2 phenotype to be cell-autonomous. In addition, the BALB.B6-Par2- and BALB/cByJ-derived tumors were similar in mean size, implying that the phenotype is primarily expressed during initiation rather than in the promotion stage of carcinogenesis. Given these results, we surveyed a comprehensive mouse genome database and physically mapped Par2 within a 2.3 Mbp segment containing three known genes, Poh, Mbd2 and Dcc. Among those, the Poh seemed to be the most reasonable Par2 candidate, since it encodes an extremely error-prone DNA polymerase preferentially incorporating G or T opposite template T in vitro, reminiscent of the Kras2 activation because of an A to G or T point mutation within codon 61 with which most urethane-induced lung tumors are initiated. Indeed, our sequencing of Poh cDNAs from BALB/cByJ, C57BL/6J, A/J and C3H/HeJ lungs revealed 21 BALB/cByJ-specific single-nucleotide polymorphisms in the coding region accompanied by seven amino-acid substitutions and an elevated frequency of alternative splicing, while no polymorphisms associated with tumor susceptibility were found for either Mbd2 or Dcc. Notably, we obtained evidence that BALB/cByJ Par2 alleles may selectively decrease the frequency of Kras2-mutated tumors compared with C57BL/6J alleles. Consequently, the Poh is an intriguing Par2 candidate clearly deserving further evaluation.	Toranomon Gen Hosp, Dept Pathol, Minato Ku, Tokyo 1058470, Japan; Okinaka Mem Inst Med Res, Minato Ku, Tokyo 1058470, Japan; Sapporo Med Univ, Inst Canc Res, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 1708455, Japan	Toranomon Hospital; Sapporo Medical University; Japanese Foundation for Cancer Research	Lee, GH (corresponding author), Toranomon Gen Hosp, Dept Pathol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	lee@toranomon.gr.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Sasaki, Yasushi/0000-0002-3500-8059				Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; Cooper HM, 1995, ONCOGENE, V11, P2243; Devereux TR, 1997, CARCINOGENESIS, V18, P1751, DOI 10.1093/carcin/18.9.1751; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; LEE GH, 1991, CANCER RES, V51, P3257; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; Lee GH, 2001, ONCOGENE, V20, P3979, DOI 10.1038/sj.onc.1204562; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; MANAM S, 1992, MOL CARCINOGEN, V6, P68, DOI 10.1002/mc.2940060111; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Obata M, 1996, ONCOGENE, V13, P1599; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhang YB, 2001, NUCLEIC ACIDS RES, V29, P928, DOI 10.1093/nar/29.4.928; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	25	29	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2374	2382		10.1038/sj.onc.1206387	http://dx.doi.org/10.1038/sj.onc.1206387			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700672				2022-12-25	WOS:000182231500015
J	Jha, BK; Salunke, DM; Datta, K				Jha, BK; Salunke, DM; Datta, K			Structural flexibility of multifunctional HABP1 may be important for regulating its binding to different ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR SF2; DIVALENT-CATION; GLUCOSE-OXIDASE; P-32 PROTEIN; CELL-SURFACE; F-ACTIN; HYALURONAN; STABILIZATION; LOCALIZATION; CLONING	Hyaluronan-binding protein 1 (HABP1)/p32/gC1qR was characterized as a highly acidic and oligomeric protein, which binds to different ligands like hyaluronan, C1q, and mannosylated albumin. It exists as trimer in high ionic and reducing conditions as shown by crystal structure. In the present study, we have examined the structural changes of HABP1 under a wide range of ionic environments. HABP1 exhibits structural plasticity, which is influenced by the ionic environment under in vitro conditions near physiological pH. At low ionic strength HABP1 exists in a highly expanded and loosely held trimeric structure, similar to that of the molten globule-like state, whereas the presence of salt stabilizes the trimeric structure in a more compact fashion. It is likely that the combination of the high net charge asymmetrically distributed along the faces of the molecule and the relatively low intrinsic hydrophobicity of HABP1 result in its expanded structure at neutral pH. Thus, the addition of counter ions in the molecular environment minimizes the intramolecular electrostatic repulsion in HABP1 leading to its stable and compact conformations, which reflect in its differential binding toward different ligands. Whereas the binding of HABP1 toward HA is enhanced on increasing the ionic strength, no significant effect was observed with the two other ligands, C1q and mannosylated albumin. Thus, although HA interacts only with compact HABP1, C1q and mannosylated albumin can bind to loosely held oligomeric HABP1 as well. In other words, structural changes in HABP1 mediated by changes in the ionic environment are responsible for recognizing different ligands.	Jawaharlal Nehru Univ, Sch Environm Sci, Biochem Lab, New Delhi 110067, India; Jawaharlal Nehru Univ, Special Ctr Mol Med, New Delhi 110067, India; Jawaharlal Nehru Univ, Natl Inst Immunol, Struct Biol Unit, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Jawaharlal Nehru University, New Delhi; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Jawaharlal Nehru University, New Delhi	Datta, K (corresponding author), Jawaharlal Nehru Univ, Sch Environm Sci, Biochem Lab, 103, New Delhi 110067, India.		jha, babal k/B-1803-2010	jha, babal k/0000-0002-7660-5255				Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P7142, DOI 10.1021/bi020080e; Brokstad KA, 2001, BIOCHEM BIOPH RES CO, V281, P1161, DOI 10.1006/bbrc.2001.4473; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Deb TB, 1996, J BIOL CHEM, V271, P2206, DOI 10.1074/jbc.271.4.2206; Denning DP, 2002, J BIOL CHEM, V277, P33447, DOI 10.1074/jbc.M203499200; DSOUZA M, 1985, BIOCHEM INT, V10, P43; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FLORES MR, 2002, J BIOL CHEM, V277, P5247; FRASER JRE, 1996, EXTRACELLULAR MATRIX, V2, P141; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUPTA S, 1991, EUR J CELL BIOL, V56, P58; GUPTA S, 1991, EXP CELL RES, V195, P386, DOI 10.1016/0014-4827(91)90388-B; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; Jha BK, 2002, EUR J BIOCHEM, V269, P298, DOI 10.1046/j.0014-2956.2001.02654.x; Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572; KHODA D, 1996, CELL, V86, P767; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Kumar R, 2001, J BIOSCIENCE, V26, P325, DOI 10.1007/BF02703741; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Majumdar M, 2002, BIOCHEM BIOPH RES CO, V291, P829, DOI 10.1006/bbrc.2002.6491; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; OHYASHIKI T, 1974, BIOCHIM BIOPHYS ACTA, V351, P214, DOI 10.1016/0005-2795(74)90183-4; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; RANGANATHAN S, 1994, MOL REPROD DEV, V38, P69, DOI 10.1002/mrd.1080380112; Ranganathan S, 1995, CELL MOL BIOL RES, V41, P467; Record MT, 1998, ADV PROTEIN CHEM, V51, P281; Sakurai K, 2001, PROTEIN SCI, V10, P2325, DOI 10.1110/ps.17001; Sheluho D, 2001, J BIOL CHEM, V276, P39945, DOI 10.1074/jbc.M107252200; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245; SORTZ P, 2000, J BIOL CHEM, V275, P24601; StrzeleckaGolaszewska H, 1996, BIOCHEM J, V316, P713, DOI 10.1042/bj3160713; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; XIE D, 1993, J MOL BIOL, V232, P5, DOI 10.1006/jmbi.1993.1364; YOSHIMURA T, 1993, METHOD ENZYMOL, V221, P72, DOI 10.1016/0076-6879(93)21008-V	41	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27464	27472		10.1074/jbc.M206696200	http://dx.doi.org/10.1074/jbc.M206696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12719421	hybrid			2022-12-25	WOS:000184242700018
J	Fukazawa, T; Walter, B; Owen-Schaub, LB				Fukazawa, T; Walter, B; Owen-Schaub, LB			Adenoviral bid overexpression induces caspase-dependent cleavage of truncated bid and p53-independent apoptosis in human non-small cell lung cancers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; P53 GENE-TRANSFER; IN-VIVO; DEATH; BAX; MITOCHONDRIA; INDUCTION; MEMBRANE; PROTEIN; FAS	Proapoptotic gene transfer to promote death or to augment killing by DNA-damaging agents represents a promising strategy for cancer therapy. We have constructed an adenoviral Tet- Off(TM) vector with tightly controlled expression of Bid (Ad-Bid) (Clontech, Palo Alto, CA). Using the non-small cell lung cancer cell lines H460, H358, and A549, low dose Ad-Bid was shown to induce high levels of full-length Bid as well as caspase-3 and -9 activity. Although only a small fraction of Bid was processed to truncated Bid ( a step inhibited by benzyl-oxycarbonyl-Val-Ala-Asp-fluoromethyl ketone), Ad-Bid gene transfer resulted in mitochondrial changes consistent with apoptosis ( mitochondrial depolarization, cytochrome c release), DNA fragmentation, and a dramatic loss of cell viability. The proapoptotic effects of Ad-Bid were independent of p53 status and were augmented markedly by caspase-8 activators such as the DNA-damaging agent cisplatin. When Ad-Bid and cisplatin were used together, chemosensitivity was restored in p53-null H358 cells, increasing death from 35% following treatment with cisplatin and Ad-LacZ to > 90% death with Ad-Bid and cisplatin (Ad-Bid alone induced 50% cell death under these conditions). Ad-Bid can induce apoptosis in malignant cells and enhance chemosensitivity in the absence of p53, suggesting this approach as a potential cancer therapy.	Univ Calif Riverside, Dept Biomed Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside	Owen-Schaub, LB (corresponding author), Univ Calif Riverside, Dept Biomed Sci, 1274 Webber Hall, Riverside, CA 92521 USA.		Fukazawa, Takuya/GLR-7099-2022		NATIONAL CANCER INSTITUTE [P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA78778] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Fujita T, 1999, INT J ONCOL, V15, P927; FUJIWARA T, 1994, CANCER RES, V54, P2287; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kagawa S, 2000, CANCER RES, V60, P1157; Kondo S, 2000, CANCER RES, V60, P4328; LAUNDANSKI J, 2001, EUR RESPIR J, V17, P660; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Owen-Schaub L, 2000, INT J ONCOL, V17, P5; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pataer A, 2000, CANCER RES, V60, P788; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Swisher SG, 2003, CLIN CANCER RES, V9, P93; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	30	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25428	25434		10.1074/jbc.M302058200	http://dx.doi.org/10.1074/jbc.M302058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12690107	hybrid			2022-12-25	WOS:000183920200022
J	Feng, JW; Bradley, WD; Roberts, MF				Feng, JW; Bradley, WD; Roberts, MF			Optimizing the interfacial binding and activity of a bacterial phosphatidylinositol-specific phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; BACILLUS-CEREUS; LISTERIA-MONOCYTOGENES; PHOSPHATIDIC-ACID; CRYSTAL-STRUCTURE; ACTIVATION; TRYPTOPHAN; PROTEINS; ANALOGS; CATALYSIS	The phosphatidylinositol-specific phospholipase C from Bacillus thuringiensis can be activated by nonsubstrate interfaces such as phosphatidylcholine micelles or bilayers. This activation corresponds with partial insertion into the interface of two tryptophans, Trp-47 in helix B and Trp-242 in a loop, in the rim of the alphabeta-barrel. Both W47A and W242A have much weaker binding to interfaces and considerably lower kinetic interfacial activation. Tryptophan rescue mutagenesis, reinsertion of a tryptophan at a different place in helix B in the W47A mutant or in the loop (residues 232-244) of the W242A mutant, has been used to determine the importance and orientation of a tryptophan in these two structural features. Phosphotransferase and phosphodiesterase assays, and binding to phosphatidylcholine vesicles were used to assess both orientation and position of tryptophans needed for interfacial activity. Of the helix B double mutants, only one mutant, I43W/W47A, has tryptophan in the same orientation as Trp-47. I43W/W47A shows recovery of phosphatidylinositol-specific phospholipase C (PC) activation of D-myo-inositol 1,2-cyclic phosphate hydrolysis. However, the specific activity toward phosphatidylinositol is still lower than wild type enzyme and high activity with phosphatidylinositol solubilized in 30% isopropyl alcohol ( a hallmark of the native enzyme) is lost. Reinserting a tryptophan at several positions in the loop composed of residues 232-244 partially recovers PC activation and affinity of the enzyme for lipid interfaces as well as activation by isopropyl alcohol. G238W/W242A shows an enhanced activation and affinity for PC interfaces above that of wild type. These results provide constraints on how this bacterial phosphatidylinositol-specific phospholipase C binds to activating PC interfaces.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.		Bradley, William/C-3151-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060418] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60418] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BIAN JR, 1992, J COLLOID INTERF SCI, V153, P420, DOI 10.1016/0021-9797(92)90333-H; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; Ellis MV, 1998, J BIOL CHEM, V273, P11650, DOI 10.1074/jbc.273.19.11650; ESSEN LO, 1996, NATURE, V380, P581; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; Griffith OH, 1999, BBA-MOL CELL BIOL L, V1441, P237, DOI 10.1016/S1388-1981(99)00153-5; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; KACHEL K, 1995, BIOCHEMISTRY-US, V34, P15475, DOI 10.1021/bi00047a012; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; LIN TL, 1987, J PHYS CHEM-US, V91, P406, DOI 10.1021/j100286a031; Moser J, 1997, J MOL BIOL, V273, P269, DOI 10.1006/jmbi.1997.1290; Qian XQ, 1998, BIOCHEMISTRY-US, V37, P6513, DOI 10.1021/bi972650u; ROBERTS MF, 1998, ACS SYM SER, V718, P137, DOI DOI 10.1021/BK-1999-0718.CH009; ROBERTS MF, 1999, SIGNAL TRANSDUCTION, P89; Stieglitz K, 1999, J BIOL CHEM, V274, P35367, DOI 10.1074/jbc.274.50.35367; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; Wadsworth SJ, 2002, INFECT IMMUN, V70, P4650, DOI 10.1128/IAI.70.8.4650-4660.2002; Wallace BA, 1999, ADV EXP MED BIOL, V467, P789; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WEHBI H, 2003, IN PRESS BIOCH BIOPH; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P8514, DOI 10.1021/bi970560j; Wu YQ, 1997, BIOCHEMISTRY-US, V36, P11223, DOI 10.1021/bi971039s; ZHONG L, 1994, BIOCHEMISTRY-US, V33, P2121; Zhou C, 1997, BIOCHEMISTRY-US, V36, P347, DOI 10.1021/bi960601w; Zhou C, 1999, J BIOL CHEM, V274, P2786, DOI 10.1074/jbc.274.5.2786; Zhou C, 1998, BIOCHEMISTRY-US, V37, P16430, DOI 10.1021/bi980601r	35	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24651	24657		10.1074/jbc.M301207200	http://dx.doi.org/10.1074/jbc.M301207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714598	hybrid			2022-12-25	WOS:000183824800050
J	Hilpert, K; Wessner, H; Schneider-Mergener, J; Welfle, K; Misselwitz, R; Welfle, H; Hocke, AC; Hippenstiel, S; Hohne, W				Hilpert, K; Wessner, H; Schneider-Mergener, J; Welfle, K; Misselwitz, R; Welfle, H; Hocke, AC; Hippenstiel, S; Hohne, W			Design and characterization of a hybrid miniprotein that specifically inhibits porcine pancreatic elastase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTHALPY-ENTROPY COMPENSATION; CHARANTIA LINN SEEDS; AMINO-ACID-SEQUENCES; SERINE PROTEINASES; SQUASH INHIBITOR; REACTIVE SITE; PEPTIDE-BOND; BINDING; TRYPSIN; WATER	Studying protease/peptide inhibitor interactions is a useful tool for understanding molecular recognition in general and is particularly relevant for the rational design of inhibitors with therapeutic potential. An inhibitory peptide (PMTLEYR) derived from the third domain of turkey ovomucoid inhibitor and optimized for specific porcine pancreatic elastase inhibition was introduced into an inhibitor scaffold to increase the proteolytic stability of the peptide. The trypsin-specific squash inhibitor EETI II from Ecballium elaterium was chosen as the scaffold. The resulting hybrid inhibitor HEI-TOE I ( hybrid inhibitor from E. elaterium and the optimized binding loop of the third domain of turkey ovomucoid inhibitor) shows a specificity and affinity to porcine pancreatic elastase similar to the free inhibitory peptide but with significantly higher proteolytic stability. Isothermal titration calorimetry revealed that elastase binding of HEI-TOE I occurs with a small unfavorable positive enthalpy contribution, a large favorable positive entropy change, and a large negative heat capacity change. In addition, the inhibitory peptide and the hybrid inhibitor HEI-TOE I protected endothelial cells against degradation following treatment with porcine pancreatic elastase.	Humboldt Univ, Med Fac Charite, Dept Biochem, D-10117 Berlin, Germany; Humboldt Univ, Med Fac Charite, Dept Med Immunol, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Humboldt Univ, Med Fac Charite, Dept Internal Med, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hohne, W (corresponding author), Humboldt Univ, Med Fac Charite, Dept Biochem, Monbijoustr 2, D-10117 Berlin, Germany.		Hilpert, Kai/E-1854-2013; Hilpert, Kai/AAI-6020-2021; Hilpert, Kai/F-4497-2011	Hilpert, Kai/0000-0001-7131-0370; Hippenstiel, Stefan/0000-0002-5146-1064				ARDELT W, 1983, ACTA BIOCHIM POL, V30, P115; Ascenzi P, 1991, J Mol Recognit, V4, P113, DOI 10.1002/jmr.300040402; Ay J, 2003, ACTA CRYSTALLOGR D, V59, P247, DOI 10.1107/S0907444902020887; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; Baker BM, 1998, METHOD ENZYMOL, V295, P294; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BIETH JG, 1998, HDB PROTEOLYTIC ENZY, P42; BIGLER TL, 1993, PROTEIN SCI, V2, P786, DOI 10.1002/pro.5560020509; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Christmann A, 1999, PROTEIN ENG, V12, P797, DOI 10.1093/protein/12.9.797; DUNITZ JD, 1995, CHEM BIOL, V2, P709, DOI 10.1016/1074-5521(95)90097-7; FAVEL A, 1989, INT J PEPT PROT RES, V33, P202; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.3.CO;2-F; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hahn M, 2001, J MOL BIOL, V314, P293, DOI 10.1006/jmbi.2001.5135; HAMATO N, 1995, J BIOCHEM-TOKYO, V117, P432, DOI 10.1093/jb/117.2.432; HARA S, 1989, J BIOCHEM-TOKYO, V105, P88, DOI 10.1093/oxfordjournals.jbchem.a122625; Hilpert K, 2002, ACTA CRYSTALLOGR D, V58, P672, DOI 10.1107/S0907444902003840; Hilpert K, 2000, J BIOCHEM-TOKYO, V128, P1051, DOI 10.1093/oxfordjournals.jbchem.a022833; Hippenstiel S, 2000, BLOOD, V95, P3044; Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9; KATO I, 1987, BIOCHEMISTRY-US, V26, P193, DOI 10.1021/bi00375a027; Lavigne P, 2000, PROTEIN SCI, V9, P252; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LUMRY R, 1970, BIOPOLYMERS, V9, P1125, DOI 10.1002/bip.1970.360091002; Luque I, 1998, METHOD ENZYMOL, V295, P100; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; OTLEWSKI J, 1994, BIOCHEMISTRY-US, V33, P208, DOI 10.1021/bi00167a027; Otlewski J, 1996, ACTA BIOCHIM POL, V43, P431; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shotton D. M., 1970, METHOD ENZYMOL, V19, P113, DOI 10.1016/0076-6879(70)19009-4; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; VINCENT JP, 1973, EUR J BIOCHEM, V38, P365, DOI 10.1111/j.1432-1033.1973.tb03069.x; Volkmer-Engert R, 1998, J PEPT RES, V51, P365; VONDERHELM K, 2000, HDB EXPT PHARM; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; Welfle K, 2001, J MOL RECOGNIT, V14, P89, DOI 10.1002/jmr.523; Wentzel A, 1999, J BIOL CHEM, V274, P21037, DOI 10.1074/jbc.274.30.21037; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	42	30	32	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24986	24993		10.1074/jbc.M212152200	http://dx.doi.org/10.1074/jbc.M212152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12700244	hybrid			2022-12-25	WOS:000183824800090
J	Webb, JL; Ravikumar, B; Atkins, J; Skepper, JN; Rubinsztein, DC				Webb, JL; Ravikumar, B; Atkins, J; Skepper, JN; Rubinsztein, DC			alpha-synuclein is degraded by both autophagy and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION-BODY FORMATION; PARKINSONS-DISEASE; LEWY BODIES; CELL-DEATH; IN-VIVO; DEGRADATION; MUTANT; MICE; PROTEINS; SYSTEM	Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and the formation of aggregates ( Lewy bodies) in neurons. alpha-Synuclein is the major protein in Lewy bodies and rare mutations in alpha-synuclein cause early-onset PD. Consequently, alpha-synuclein is implicated in the pathogenesis of PD. Here, we have investigated the degradation pathways of alpha-synuclein, using a stable inducible PC12 cell model, where the expression of exogenous human wild-type, A30P, or A53T alpha-synuclein can be switched on and off. We have used a panel of inhibitors/stimulators of autophagy and proteasome function and followed alpha-synuclein degradation in these cells. We found that not only is alpha-synuclein degraded by the proteasome, but it is also degraded by autophagy. A role for autophagy was further supported by the presence of alpha-synuclein in organelles with the ultrastructural features of autophagic vesicles. Since rapamycin, a stimulator of autophagy, increased clearance of alpha-synuclein, it merits consideration as a potential therapeutic for Parkinsons disease, as it is designed for chronic use in humans.	Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge	Rubinsztein, DC (corresponding author), Addenbrookes Hosp, Dept Med Genet, Cambridge Inst Med Res, Wellcome MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Rubinsztein, David C/C-3472-2011					Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chen PE, 2002, EUR J NEUROSCI, V16, P154, DOI 10.1046/j.1460-9568.2002.02062.x; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Furlong RA, 2000, BIOCHEM J, V346, P577, DOI 10.1042/0264-6021:3460577; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Kahle PJ, 2002, J NEUROCHEM, V82, P449, DOI 10.1046/j.1471-4159.2002.01020.x; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; Mezey E, 1998, MOL PSYCHIATR, V3, P493, DOI 10.1038/sj.mp.4000446; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Ostrowska H, 2000, INT J BIOCHEM CELL B, V32, P747, DOI 10.1016/S1357-2725(00)00021-2; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Skepper JN, 2000, J MICROSC-OXFORD, V199, P1, DOI 10.1046/j.1365-2818.2000.00704.x; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Verhoef LGGC, 2002, HUM MOL GENET, V11, P2689, DOI 10.1093/hmg/11.22.2689; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33	37	1086	1121	0	97	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25009	25013		10.1074/jbc.M300227200	http://dx.doi.org/10.1074/jbc.M300227200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12719433	hybrid			2022-12-25	WOS:000183824800093
J	Collin, V; Issakidis-Bourguet, E; Marchand, C; Hirasawa, M; Lancelin, JM; Knaff, DB; Miginiac-Maslow, M				Collin, V; Issakidis-Bourguet, E; Marchand, C; Hirasawa, M; Lancelin, JM; Knaff, DB; Miginiac-Maslow, M			The Arabidopsis plastidial thioredoxins - New functions and new insights into specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION PROPERTIES; ESCHERICHIA-COLI THIOREDOXIN; NADP-MALATE DEHYDROGENASE; HIGH-LEVEL EXPRESSION; CHLAMYDOMONAS-REINHARDTII; 2-CYSTEINE PEROXIREDOXIN; PLANT THIOREDOXINS; RNA-POLYMERASE; CLONED GENES; CHLOROPLAST	The sequencing of the genome of Arabidopsis thaliana revealed that this plant contained numerous isoforms of thioredoxin (Trx), a protein involved in thiol-disulfide exchanges. On the basis of sequence comparison, seven putative chloroplastic Trxs have been identified, four belonging to the m-type, two belonging to the f-type, and one belonging to a new x-type. In the present work, these isoforms were produced and purified as recombinant proteins without their putative transit peptides. Their activities were tested with two known chloroplast thioredoxin targets: NADP-malate dehydrogenase and fructose-1,6-bisphosphatase and also with a chloroplastic 2-Cys peroxiredoxin. The study confirms the strict specificity of fructose-bisphosphatase for Trx f, reveals that some Trxs are unable to activate NADP-malate dehydrogenase, and shows that the new x-type is the most efficient substrate for peroxiredoxin while being inactive toward the two other targets. This suggests that this isoform might be specifically involved in resistance against oxidative stress. Three-dimensional modeling shows that one of the m-type Trxs, Trx m3, which has no activity with any of the three targets, exhibits a negatively charged surface surrounding the active site. A green fluorescent protein approach confirms the plastidial localization of these Trxs.	Univ Paris 11, Inst Biotechnol Plantes, CNRS, UMR 8618, F-91405 Orsay, France; Univ Paris 11, CNRS,UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, Lab Chim Prot, F-91405 Orsay, France; Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA; Univ Lyon 1, CNRS, Lab Resonance Magnet Nucl Biomol, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Texas Tech University System; Texas Tech University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Issakidis-Bourguet, E (corresponding author), Univ Paris 11, Inst Biotechnol Plantes, CNRS, UMR 8618, Bat 630, F-91405 Orsay, France.	issakidi@ibp.u-psud.fr	Lancelin, Jean-marc/AAC-5686-2019; MARCHAND, Christophe H/B-5854-2008	MARCHAND, Christophe H/0000-0002-0729-3841; Issakidis-Bourguet, Emmanuelle/0000-0002-6144-4364				ali A., 1993, J MOL BIOL, V234, P779; AXELOS M, 1992, PLANT PHYSIOL BIOCH, V30, P123; Baier M, 1997, PLANT J, V12, P179, DOI 10.1046/j.1365-313X.1997.12010179.x; Broin M, 2002, PLANT CELL, V14, P1417, DOI 10.1105/tpc.001644; de Lamotte-Guery F, 1997, PROTEIN ENG, V10, P1425, DOI 10.1093/protein/10.12.1425; Dietz KJ, 2002, J EXP BOT, V53, P1321, DOI 10.1093/jexbot/53.372.1321; FLORENCIO FJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P496, DOI 10.1016/0003-9861(88)90282-2; Geck RK, 1996, J BIOL CHEM, V271, P24736, DOI 10.1074/jbc.271.40.24736; Goyer A, 2002, EUR J BIOCHEM, V269, P272, DOI 10.1046/j.0014-2956.2001.02648.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hirasawa M, 2000, BIOCHEMISTRY-US, V39, P3344, DOI 10.1021/bi9916731; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HODGES M, 1994, PLANT MOL BIOL, V26, P225, DOI 10.1007/BF00039534; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Issakidis-Bourguet E, 2001, PLANT J, V25, P127, DOI 10.1046/j.0960-7412.2000.00943.x; JACQUOT JP, 1995, EUR J BIOCHEM, V229, P675, DOI 10.1111/j.1432-1033.1995.tb20513.x; JACQUOT JP, 1990, BIOCHEM BIOPH RES CO, V173, P1375, DOI 10.1016/S0006-291X(05)80940-4; Jasinski S, 2002, PLANT PHYSIOL, V130, P1871, DOI 10.1104/pp.008573; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; JOHNSON TC, 1987, PLANT PHYSIOL, V85, P446, DOI 10.1104/pp.85.2.446; KAMO M, 1989, EUR J BIOCHEM, V182, P315, DOI 10.1111/j.1432-1033.1989.tb14832.x; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lancelin JM, 2000, PROTEINS, V41, P334, DOI 10.1002/1097-0134(20001115)41:3<334::AID-PROT60>3.3.CO;2-D; Leon S, 2002, BIOCHEM J, V366, P557, DOI 10.1042/BJ20020322; MAEDA K, 1986, EUR J BIOCHEM, V154, P197, DOI 10.1111/j.1432-1033.1986.tb09379.x; Mestres-Ortega D, 1999, GENE, V240, P307, DOI 10.1016/S0378-1119(99)00448-5; Meyer Y, 2002, METHOD ENZYMOL, V347, P394; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Ruelland E, 1997, J BIOL CHEM, V272, P19851, DOI 10.1074/jbc.272.32.19851; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; STEIN M, 1995, PLANT MOL BIOL, V28, P487, DOI 10.1007/BF00020396; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WETTERAUER B, 1992, EUR J BIOCHEM, V209, P643, DOI 10.1111/j.1432-1033.1992.tb17331.x	40	269	277	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23747	23752		10.1074/jbc.M302077200	http://dx.doi.org/10.1074/jbc.M302077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707279	hybrid			2022-12-25	WOS:000183638600069
J	Fujita, N; Watanabe, S; Ichimura, T; Tsuruzoe, S; Shinkai, Y; Tachibana, M; Chiba, T; Nakao, M				Fujita, N; Watanabe, S; Ichimura, T; Tsuruzoe, S; Shinkai, Y; Tachibana, M; Chiba, T; Nakao, M			Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; BINDING PROTEIN MECP2; RETINOBLASTOMA PROTEIN; LYSINE 9; H3; CHROMATIN; DOMAIN; METHYLTRANSFERASE; HP1; PATTERNS	Cytosine methylation and posttranslational modifications of the amino termini of the core histones in the nucleosome provide epigenetic codes for genome regulation. In the nucleus, not only is the DNA methylated, but the methylated DNA is also interpreted by methyl-CpG binding domain (MBD) proteins. MBD1 possesses an MBD involved in mediating DNA methylation-dependent transcriptional repression. The MBD of MBD1 binds a symmetrically methylated CpG sequence, but the precise roles of this domain have not been investigated. In addition, little is understood about the state of histone modifications within MBD1-containing heterochromatin on methylated gene promoters. Here we show that histone H3 methylase Suv39h1 and the methyl lysine-binding protein HP1 directly interact with MBD of MBD1 in vitro and in cells. Suv39h1 was found to enhance MBD1-mediated transcriptional repression via MBD but not via the C-terminal transcriptional repression domain of MBD1. Furthermore, MBD1 links to histone deacetylases through Suv39h1, resulting in methylation and deacetylation of histones for gene inactivation. These data indicate that MBD1 may tether the Suv39h1-HP1 complex to methylated DNA regions, suggesting the presence of a pathway from DNA methylation to the modifications of histones for epigenetic gene regulation.	Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, Kumamoto 8600811, Japan; Kyoto Univ, Inst Virus Res, Dept Cell Biol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Postgrad Med Sch, Dept Internal Med, Div Gastroenterol, Kyoto 6068507, Japan	Kumamoto University; Kyoto University; Kyoto University	Nakao, M (corresponding author), Kumamoto Univ, Inst Mol Embryol & Genet, Dept Regenerat Med, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Shinkai, Yoichi/N-3909-2014; Watanabe, Sugiko/Q-6201-2019	Shinkai, Yoichi/0000-0002-6051-2484; Watanabe, Sugiko/0000-0002-2120-9546				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohki I, 2001, CELL, V105, P487, DOI 10.1016/S0092-8674(01)00324-5; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	36	217	229	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24132	24138		10.1074/jbc.M302283200	http://dx.doi.org/10.1074/jbc.M302283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12711603	hybrid			2022-12-25	WOS:000183638600119
J	Garwood, J; Heck, N; Reichardt, F; Faissner, A				Garwood, J; Heck, N; Reichardt, F; Faissner, A			Phosphacan short isoform, a novel non-proteoglycan variant of phosphacan/receptor protein tyrosine phosphatase-beta, interacts with neuronal receptors and promotes neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION MOLECULES; CENTRAL-NERVOUS-SYSTEM; HIGH-AFFINITY BINDING; 6B4 PROTEOGLYCAN/PHOSPHACAN; ZETA/RPTP-BETA; EXTRACELLULAR VARIANT; RPTP-BETA; NEUROCAN; GROWTH	Phosphacan, one of the principal proteoglycans in the extracellular matrix of the central nervous system, is implicated in neuron-glia interactions associated with neuronal differentiation and myelination. We report here the identification of a novel truncated form of phosphacan, phosphacan short isoform (PSI), that corresponds to the N-terminal carbonic anhydrase- and fibronectin type III-like domains and half of the spacer region. The novel cDNA transcript was isolated by screening of a neonatal brain cDNA expression library using a polyclonal antibody raised against phosphacan. Expression of this transcript in vivo was confirmed by Northern blot hybridization. Analysis of brain protein extracts reveals the presence of a 90-kDa glycosylated protein in the phosphate-buffered saline-insoluble 100,000 x g fraction that reacts with antisera against both phosphacan and a recombinant PSI protein and that has the predicted N-terminal sequence. This protein is post-translationally modified with oligosaccharides, including the HNK-1 epitope, but, unlike phosphacan, it is not a proteoglycan. The expression of the PSI protein varies during central nervous system development in a fashion similar to that observed for phosphacan, being first detected around embryonic day 16 and then showing a dramatic increase in expression to plateau around the second week post-natal. Both the native and recombinant PSI protein can interact with the Ig cell adhesion molecules, F3/contactin and L1, and in neurite outgrowth assays, the PSI protein can promote outgrowth of cortical neurons when used as a coated substrate. Hence, the identification of this novel isoform of phosphacan/receptor protein tyrosine phosphatase-beta provides a new component in cell-cell and cell-extracellular matrix signaling events in which these proteins have been implicated.	CNRS, Ctr Neurochim, Lab Neurobiol Dev & Regenerat, F-67084 Strasbourg, France; Max Planck Inst Med Res, D-69120 Heidelberg, Germany; Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44780 Bochum, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society; Ruhr University Bochum	Garwood, J (corresponding author), CNRS, Ctr Neurochim, Lab Neurobiol Dev & Regenerat, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	garwood@neurochem.u-strasbg.fr	Faissner, Andreas/A-5314-2008	Faissner, Andreas/0000-0002-2211-8259				Adamsky K, 2001, ONCOGENE, V20, P609, DOI 10.1038/sj.onc.1204119; Asher RA, 2000, J NEUROSCI, V20, P2427; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Barker RA, 1996, EXP NEUROL, V141, P79, DOI 10.1006/exnr.1996.0141; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUMMENDORF T, 1993, NEURON, V10, P711; Canoll PD, 1996, J NEUROSCI RES, V44, P199, DOI 10.1002/(SICI)1097-4547(19960501)44:3<199::AID-JNR1>3.0.CO;2-B; Clement AM, 1998, J BIOL CHEM, V273, P28444, DOI 10.1074/jbc.273.43.28444; Deller T, 1997, NEUROSCIENCE, V81, P829, DOI 10.1016/S0306-4522(97)00194-2; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Garwood J, 1999, J NEUROSCI, V19, P3888; Garwood J, 2001, RESTOR NEUROL NEUROS, V19, P51; Garwood Jeremy, 2002, P109; Harroch S, 2000, MOL CELL BIOL, V20, P7706, DOI 10.1128/MCB.20.20.7706-7715.2000; Harroch S, 2002, NAT GENET, V32, P411, DOI 10.1038/ng1004; Haunso A, 1999, BRAIN RES, V834, P219, DOI 10.1016/S0006-8993(99)01596-6; Inatani M, 2001, INVEST OPHTH VIS SCI, V42, P1930; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P1990; Koch T, 1997, GLIA, V19, P199, DOI 10.1002/(SICI)1098-1136(199703)19:3<199::AID-GLIA3>3.0.CO;2-V; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LAYWELL ED, 1991, ANN NY ACAD SCI, V633, P122; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Maeda N, 1996, DEVELOPMENT, V122, P647; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Maleski M, 1997, GLIA, V20, P193, DOI 10.1002/(SICI)1098-1136(199707)20:3<193::AID-GLIA3>3.0.CO;2-9; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; MILEV P, 1995, J BIOL CHEM, V270, P24650, DOI 10.1074/jbc.270.42.24650; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Murai KK, 2002, CURR BIOL, V12, P181, DOI 10.1016/S0960-9822(02)00680-2; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Ratcliffe CF, 2000, NAT NEUROSCI, V3, P437, DOI 10.1038/74805; RATHJEN FG, 1984, EMBO J, V3, P1; Rauch U, 1997, CELL TISSUE RES, V290, P349, DOI 10.1007/s004410050940; Rauch U, 2001, CELL MOL LIFE SCI, V58, P1842, DOI 10.1007/PL00000822; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Sakurai T, 1997, J CELL BIOL, V136, P907, DOI 10.1083/jcb.136.4.907; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295	53	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24164	24173		10.1074/jbc.M211721200	http://dx.doi.org/10.1074/jbc.M211721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700241	hybrid			2022-12-25	WOS:000183638600122
J	Le, XF; Claret, FX; Lammayot, A; Tian, L; Deshpande, D; LaPushin, R; Tari, AM; Bast, RC				Le, XF; Claret, FX; Lammayot, A; Tian, L; Deshpande, D; LaPushin, R; Tari, AM; Bast, RC			The role of cyclin-dependent kinase inhibitor p27(Kip1) in anti-HER2 antibody-induced G(1) cell cycle arrest and tumor growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; PHOSPHORYLATION; P27; LOCALIZATION; PROGRESSION; HER-2/NEU; G1; OVEREXPRESSION; CHEMOTHERAPY	Cyclin-dependent kinase (CDK) inhibitor p27(Kip1) binds to the cyclin E.CDK2 complex and plays a major role in controlling cell cycle and cell growth. Our group and others have reported that anti-HER2 monoclonal antibodies exert inhibitory effects on HER2-overexpressing breast cancers through G(1) cell cycle arrest associated with induction of p27(Kip1) and reduction of CDK2. The role of p27(Kip1) in anti-HER2 antibody-induced cell cycle arrest and growth inhibition is, however, still uncertain. Here we have provided several lines of evidence supporting a critical role for p27(Kip1) in the anti-HER2 antibody-induced G(1) cell cycle arrest and tumor growth inhibition. Induction of p27(Kip1) and G(1) growth arrest by anti-HER2 antibody, murine 4D5, or humanized trastuzumab (Herceptin(R)) are concentration-dependent, time-dependent, irreversible, and long-lasting. The magnitude of G(1) cell cycle arrest induced by trastuzumab or 4D5 is well correlated with the level of p27(Kip1) protein induced. Up-regulation of p27(Kip1) and G(1) growth arrest could no longer be removed with as little as 14 h of treatment with trastuzumab. Anti-HER2 antibody-induced p27(Kip1) protein, G(1) arrest, and growth inhibition persist at least 5 days after a single treatment. The magnitude of growth inhibition of breast cancer cells induced by anti-HER2 antibody closely parallels the level of p27(Kip1) induced. Induced expression of exogenous p27(Kip1) results in a p27(Kip1) level-dependent G(1) cell cycle arrest and growth inhibition similar to that obtained with anti-HER2 antibodies. Reducing p27(Kip1) expression using p27(Kip1) small interfering RNA blocks anti-HER2 antibody-induced p27(Kip1) up-regulation and G(1) arrest. Treatment with anti-HER2 antibody significantly increases the half-life of p27(Kip1) protein. Inhibition of ubiquitin-proteasome pathway, but not inhibition of calpain and caspase activities, up-regulates p27(Kip1) protein to a degree comparable with that obtained with anti-HER2 antibodies. We have further demonstrated that anti-HER2 antibody significantly decreases threonine phosphorylation of p27(Kip1) protein at position 187 (Thr-187) and increases serine phosphorylation of p27(Kip1) protein at position 10 ( Ser-10). Expression of S10A and T187A mutant p27(Kip1) protein increases the fraction of cells in G(1) and reduces a further antibody-induced G(1) arrest. Consequently, p27(Kip1) plays an important role in the anti-HER2 antibody-induced G(1) cell cycle arrest and tumor growth inhibition through post-translational regulation. Regulation of the phosphorylation of p27(Kip1) protein is one of the post-translational mechanisms by which anti-HER2 antibody up-regulates the protein.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunnotherapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.		Bast, Robert C/E-6585-2011; Claret, Francois X/R-2104-2016	Bast, Robert C/0000-0003-4621-8462; Claret, Francois X/0000-0003-4629-6495	NATIONAL CANCER INSTITUTE [R01CA039930, R01CA090853] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA90853, CA39930] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Chopra S, 2002, J BIOL CHEM, V277, P32413, DOI 10.1074/jbc.C200311200; Ciarallo S, 2002, MOL CELL BIOL, V22, P2993, DOI 10.1128/MCB.22.9.2993-3002.2002; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Le XF, 2000, CLIN CANCER RES, V6, P260; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pegram M D, 2000, Cancer Treat Res, V103, P57; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Pietras RJ, 1999, CANCER RES, V59, P1347; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Tokuda Y, 1996, BRIT J CANCER, V73, P1362, DOI 10.1038/bjc.1996.259; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Yakes FM, 2002, CANCER RES, V62, P4132; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	39	121	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23441	23450		10.1074/jbc.M300848200	http://dx.doi.org/10.1074/jbc.M300848200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700233	hybrid			2022-12-25	WOS:000183638600030
J	Lee, HY; Srinivas, H; Xia, DR; Lu, YL; Superty, R; LaPushin, R; Gomez-Manzano, C; Gal, AM; Walsh, GL; Force, T; Ueki, K; Mills, GB; Kurie, JM				Lee, HY; Srinivas, H; Xia, DR; Lu, YL; Superty, R; LaPushin, R; Gomez-Manzano, C; Gal, AM; Walsh, GL; Force, T; Ueki, K; Mills, GB; Kurie, JM			Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; PROSTATE CARCINOMA-CELLS; G(1) GROWTH ARREST; PHOSPHOINOSITIDE 3-KINASES; SIGNALING PATHWAYS; BREAST CARCINOMAS; GLIOMA-CELLS; CYCLE ARREST; PTEN; RAS	Cancer cells in which the PTEN lipid phosphatase gene is deleted have constitutively activated phosphatidylinositol 3-kinase (PI3K)-dependent signaling and require activation of this pathway for survival. In non-small cell lung cancer (NSCLC) cells, PI3K-dependent signaling is typically activated through mechanisms other than PTEN gene loss. The role of PI3K in the survival of cancer cells that express wild-type PTEN has not been defined. Here we provide evidence that H1299 NSCLC cells, which express wild-type PTEN, underwent proliferative arrest following treatment with an inhibitor of all isoforms of class I PI3K catalytic activity (LY294002) or overexpression of the PTEN lipid phosphatase. In contrast, overexpression of a dominant-negative mutant of the p85alpha regulatory subunit of PI3K (Deltap85) induced apoptosis. Whereas PTEN and Delta85 both inhibited activation of AKT/protein kinase B, only Deltap85 inhibited c-Jun NH2-terminal kinase (JNK) activity. Cotransfection of the constitutively active mutant Rac-1 (Val(12)), an upstream activator of JNK, abrogated Deltap85-induced lung cancer cell death, whereas constitutively active mutant mitogen-activated protein kinase kinase (MKK)-1 (R4F) did not. Furthermore, LY294002 induced apoptosis of MKK4-null but not wild-type mouse embryo fibroblasts. Therefore, we propose that, in the setting of wild-type PTEN, PI3K- and MKK4/JNK-dependent pathways cooperate to maintain cell survival.	Univ Texas, MD Anderson Canc Ctr, Unit 432, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Tufts Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Unit 432, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Gal, Annamaria/0000-0001-8171-1389; Force, Thomas/0000-0002-0450-8659	NCI NIH HHS [CA80686, P50 CA70907, CA83639, CA82716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, P50CA083639, R01CA080686, R01CA082716] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bost F, 1999, MOL CELL BIOL, V19, P1938; Brognard J, 2001, CANCER RES, V61, P3986; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Davies MA, 1999, CANCER RES, V59, P2551; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gottschalk AR, 2001, CANCER RES, V61, P2105; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Janssen JWG, 1998, ONCOGENE, V16, P1767, DOI 10.1038/sj.onc.1201695; Ji L, 2002, CANCER RES, V62, P2715; Kang HY, 2002, J BIOL CHEM, V277, P912, DOI 10.1074/jbc.M107648200; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin JQ, 1999, CANCER RES, V59, P2891; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Massion PP, 2002, CANCER RES, V62, P3636; Moore SM, 1998, CANCER RES, V58, P5239; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Teng DHF, 1997, CANCER RES, V57, P4177; Teng DHF, 1997, CANCER RES, V57, P5221; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TUNG TO, 2002, CANCER CELL, V1, P181; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xiao L, 2000, CANCER RES, V60, P400; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; Yoshida BA, 1999, CANCER RES, V59, P5483	56	51	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23630	23638		10.1074/jbc.M300997200	http://dx.doi.org/10.1074/jbc.M300997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12714585	hybrid			2022-12-25	WOS:000183638600054
J	Man, D; He, W; Sze, KH; Gong, K; Smith, DK; Zhu, G; Ip, NY				Man, D; He, W; Sze, KH; Gong, K; Smith, DK; Zhu, G; Ip, NY			Solution structure of the C-terminal domain of the ciliary neurotrophic factor (CNTF) receptor and ligand free associations among components of the CNTF receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; MODEL-FREE APPROACH; CRYSTAL-STRUCTURE; IN-VITRO; COUPLING-CONSTANTS; PROTEIN STRUCTURES; BACKBONE DYNAMICS; HEXAMERIC COMPLEX; HOMOLOGY REGION; BINDING DOMAIN	The functional receptor complex of ciliary neurotrophic factor (CNTF), a member of the gp130 family of cytokines, is composed of CNTF, the CNTF receptor alpha (CNTFR), gp130, and the leukemia inhibitory factor receptor (LIFR). However, the nature of the receptor-mediated interactions in this complex has not yet been resolved. To address this issue we have determined the solution structure of the C-terminal or BC domain of CNTFR and studied the interactions of CNTFR with LIFR and gp130. We reported previously that the membrane distal cytokine-binding domain (CBD1) of LIFR could interact in vitro with soluble CNTFR (sCNTFR) in the absence of CNTF. Here we show that the CBD of human gp130 can also bind in vitro to sCNTFR in the absence of CNTF. In addition, the gp130 CBD could compete with the LIFR CBD1 for the binding of sCNTFR. Substitution of residues in the gp130 CBD, the LIFR CBD1, and the CNTFR BC domain that are expected to be involved in receptor-receptor interactions significantly reduced their interactions. An NMR chemical shift perturbation study of the interaction between the BC domains of CNTFR and gp130 further mapped the interaction surface. These data suggest that both the gp130 CBD and the LIFR CBD1 interact with CNTFR in a similar way and provide insights into the nature of the CNTF receptor complex.	Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; University of Hong Kong	Zhu, G (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.			Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Smith, David/0000-0003-3608-0586				Auguste P, 1996, J BIOL CHEM, V271, P26049, DOI 10.1074/jbc.271.42.26049; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Brooks BR, 1996, ARCH NEUROL-CHICAGO, V53, P141; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Chow DC, 2001, BIOCHEMISTRY-US, V40, P7593, DOI 10.1021/bi010192q; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DESERIO A, 1995, J MOL BIOL, V254, P795, DOI 10.1006/jmbi.1995.0655; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Kernebeck T, 1999, PROTEIN SCI, V8, P5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Man D, 2002, J BIOMOL NMR, V22, P95, DOI 10.1023/A:1013821220610; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PANAYOTATOS N, 1995, J BIOL CHEM, V270, P14007, DOI 10.1074/jbc.270.23.14007; PANAYOTATOS N, 1994, BIOCHEMISTRY-US, V33, P5813, DOI 10.1021/bi00185a020; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; Smith DK, 1998, PROTEIN SCI, V7, P886; Staunton D, 1998, PROTEIN ENG, V11, P1093, DOI 10.1093/protein/11.11.1093; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WARD LD, 1994, J BIOL CHEM, V269, P23286; Xia YL, 2000, J MAGN RESON, V146, P228, DOI 10.1006/jmre.2000.2140; XU RX, 1995, BIOCHEMISTRY-US, V34, P2107, DOI 10.1021/bi00007a003	47	18	20	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23285	23294		10.1074/jbc.M301976200	http://dx.doi.org/10.1074/jbc.M301976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707266	hybrid			2022-12-25	WOS:000183638600011
J	Suzuki, F; Hayakawa, M; Nakagawa, T; Nasir, UM; Ebihara, A; Iwasawa, A; Ishida, Y; Nakamura, Y; Murakami, K				Suzuki, F; Hayakawa, M; Nakagawa, T; Nasir, UM; Ebihara, A; Iwasawa, A; Ishida, Y; Nakamura, Y; Murakami, K			Human prorenin has "gate and handle" regions for its non-proteolytic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RENIN; DIABETES-MELLITUS; MOLECULAR-CLONING; HUMAN-PLASMA; PROSEGMENT; SYSTEM; GENE; SEQUENCE; BIOLOGY; CDNA	We investigated the mechanism for non-proteolytic activation of human prorenin using five kinds of antibodies. Each of the antigens, (LPTDTTTFKRI11P)-P-1P, (TFKRIFLKRMP17P)-F-7P, (IFLKRMPSIRESLKER26P)-F-11P, (MPSIRESLKER26P)-P-16P, and G(27P)VDMARLGPEWSQP-M-41P, was designed from the tertiary structure of predicted prorenin. These antibodies were labeled anti-01/ 06, anti-07/10, anti-11/26, anti-16/26, and anti-27/41, respectively, for their binding specificities. Inactive recombinant human prorenin (0.1 nM) bound to various concentrations of anti-01/ 06, anti-11/26, and anti-27/41 antibodies at 4 degreesC with equilibrium dissociation constants of 138, 41, and 22 nM, respectively. However, intact prorenin ( 0.1 nM) did not show significant binding to 200 nM anti-07/10 and anti-16/26 antibodies for 20 h. Ninety percent of prorenin ( 0.1 nM) was found to be non-proteolytically activated by incubation with anti-11/26 antibodies ( 200 nM) at 4 degreesC for 20 h. Prorenin was not active even under complex with either anti-01/ 06 or anti-27/41 antibodies. Prorenin was also reversibly activated at pH 3.3 and 4 degreesC for 25 h. The acid-activated prorenin bound to anti-07/10 and anti-16/26 antibodies as well as to anti-01/ 06, anti-11/15, and anti-27/41 antibodies at neutral pH and 4 degreesC in 2 h. Their dissociation constants were 13, 40, 8.6, 3.6, and 14 nM, respectively. The acid-activated prorenin was re-inactivated by incubation at pH 7.4 and 4 degreesC in 50 h. Anti-07/10 and anti-11/26 antibodies inhibited such re-inactivation at 25 degreesC by more than 90% and 50%, respectively, whereas other kinds of antibodies did not prevent the re-inactivation at 25 degreesC. These results indicate that prorenin has "gate" ((TFKR10P)-F-7P) and "handle" ((IFLKR15P)-F-11P) regions critical for its nonproteolytic activation.	Gifu Univ, Dept Anim Sci & Technol, Gifu 5011193, Japan; Gifu Univ, Dept Biotechnol, Gifu 5011193, Japan; Gifu Univ, Mol Genet Res Ctr, Gifu 5011193, Japan; Univ Tsukuba, Inst Appl Biochem, Ibaraki 3058577, Japan; Tokiwa Chem Co, Tokyo 1700012, Japan	Gifu University; Gifu University; Gifu University; University of Tsukuba	Suzuki, F (corresponding author), Gifu Univ, Dept Anim Sci & Technol, Gifu 5011193, Japan.	aob3073@cc.gifu-u.ac.jp	Ebihara, Akio/AAI-6155-2020; Suzuki, Fumiaki/M-5577-2014	Ebihara, Akio/0000-0002-1763-9084; Suzuki, Fumiaki/0000-0003-3794-4155				BAXTER JD, 1989, YALE J BIOL MED, V62, P493; CUMIN F, 1985, J BIOL CHEM, V260, P9154; DERKX FHM, 1976, LANCET, V2, P496; DERKX FHM, 1988, CLIN EXP HYPERTENS A, V10, P1213; DERKX FHM, 1987, J BIOL CHEM, V262, P2472; DERKX FHM, 1992, J BIOL CHEM, V267, P22837; FUKAMIZU A, 1988, J MOL BIOL, V201, P443, DOI 10.1016/0022-2836(88)90151-9; HEINRIKSON RL, 1989, AM J HYPERTENS, V2, P367, DOI 10.1093/ajh/2.5.367; HSUEH WA, 1991, HYPERTENSION, V17, P469, DOI 10.1161/01.HYP.17.4.469; HSUEH WA, 1991, CELL BIOPHYS, V19, P63, DOI 10.1007/BF02989880; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; INAGAMI T, 1991, HYPERTENSION, V18, P241, DOI 10.1161/01.HYP.18.3.241; LECKIE BJ, 1994, J CLIN ENDOCR METAB, V79, P1742, DOI 10.1210/jc.79.6.1742; LECKIE BJ, 1980, NATURE, V288, P702, DOI 10.1038/288702a0; LITTLE JR, 1967, METHODS IMMUNOLOGY I; LUETSCHER JA, 1985, NEW ENGL J MED, V312, P1412, DOI 10.1056/NEJM198505303122202; MERCURE C, 1995, J BIOL CHEM, V270, P16355, DOI 10.1074/jbc.270.27.16355; MORRIS BJ, 1992, J HYPERTENS, V10, P209, DOI 10.1097/00004872-199203000-00002; NARUSE M, 1995, ENDOCR J, V42, P225, DOI 10.1507/endocrj.42.225; Nguyen G, 2002, J CLIN INVEST, V109, P1417, DOI 10.1172/JCI200214276; PITARRESI TM, 1992, J BIOL CHEM, V267, P11753; POORMAN R A, 1986, Proteins Structure Function and Genetics, V1, P139, DOI 10.1002/prot.340010206; Reudelhuber TL, 1998, ADV EXP MED BIOL, V436, P229; SCHALEKAMP MADH, 1993, CLIN INVESTIGATOR, V71, pS3; SEALEY JE, 1986, AM J MED, V81, P1041, DOI 10.1016/0002-9343(86)90402-X; SEALEY JE, 1975, CIRC RES, V36, P10, DOI 10.1161/01.RES.36.6.10; SHIRATORI Y, 1990, J MOL GRAPHICS, V8, P163, DOI 10.1016/0263-7855(90)80058-N; SOGAWA K, 1981, J BIOL CHEM, V256, P2561; SOUBRIER F, 1983, NUCLEIC ACIDS RES, V11, P7181, DOI 10.1093/nar/11.20.7181; Suzuki F, 2000, BIOCHEM BIOPH RES CO, V267, P577, DOI 10.1006/bbrc.1999.1997; Suzuki F, 1999, BIOSCI BIOTECH BIOCH, V63, P550, DOI 10.1271/bbb.63.550; SUZUKI F, 1995, ADV EXP MED BIOL, V362, P267; SUZUKI F, 1992, BIOMED RES-TOKYO, V13, P321, DOI 10.2220/biomedres.13.321; YAMAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P27, DOI 10.1093/oxfordjournals.jbchem.a123005	34	162	166	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22217	22222		10.1074/jbc.M302579200	http://dx.doi.org/10.1074/jbc.M302579200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684512	hybrid			2022-12-25	WOS:000183503900006
J	Halkidou, K; Gnanapragasam, VJ; Mehta, PB; Logan, IR; Brady, ME; Cook, S; Leung, HY; Neal, DE; Robson, CN				Halkidou, K; Gnanapragasam, VJ; Mehta, PB; Logan, IR; Brady, ME; Cook, S; Leung, HY; Neal, DE; Robson, CN			Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development	ONCOGENE			English	Article						Tip60; co-activator; CWR22 xenograft; hormone refractory; prostate cancer	HORMONAL-REGULATION; BREAST-CANCER; CELL-LINE; PROTEIN; LNCAP; APOPTOSIS; ANTIGEN; ALPHA; TRANSCRIPTION; METHYLATION	Prostate cancer (CaP) is initially androgen sensitive and responsive to hormone ablation therapy. However, cancer growth recurs despite androgen deprivation in the majority of cases of advanced disease. The molecular basis of this progression still remains unknown. The significance of androgen receptor (AR) coactivator proteins in this androgen-dependent malignancy is only beginning to emerge. In the present study, we examined the role of Tat interactive protein, 60kDa (Tip60), an AR coactivator, in CaP progression. In hormone refractory CaP biopsies, we observed a nuclear accumulation of Tip60 expression in contrast to a more diffuse distribution pattern observed in benign prostate hyperplasia and primary CaP. Furthermore, in both the prostate xenograft model CWR22 and the LNCaP CaP cell line, we observed that androgen withdrawal promoted upregulation of Tip60 as well as nuclear accumulation. In contrast, androgen exposure resulted in decreased Tip60 expression that was more closely linked to a cytoplasmic presence. Chromatin immunoprecipitation analysis revealed Tip60's recruitment to the PSA gene promoter in both androgen dependent and -independent cell lines. Thus, in vitro and in vivo data support a possible role for Tip60 in the molecular pathway leading to the development of androgen-independent CaP following long-term androgen deprivation therapy.	Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Cambridge, Addenbrookes Hosp, Ctr Oncol, Cambridge CB2 2QQ, England	Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Robson, CN (corresponding author), Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Prostate Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; Brawer MK, 2000, SEMIN SURG ONCOL, V18, P3, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<3::AID-SSU2>3.3.CO;2-9; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Chen SL, 2001, MOL ENDOCRINOL, V15, P783, DOI 10.1210/me.15.5.783; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; Cutress RI, 2001, J CLIN ONCOL, V19, P3706, DOI 10.1200/JCO.2001.19.16.3706; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; Gregory CW, 2001, CANCER RES, V61, P4315; Horikawa I, 2001, J CELL BIOCHEM, V82, P415, DOI 10.1002/jcb.1169; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jaffe ES, 1996, J CELL PATHOL, V1, P125; Kinoshita H, 2000, CANCER RES, V60, P3623; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Kurihara I, 2000, ENDOCR RES, V26, P1033, DOI 10.3109/07435800009048635; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lee HJ, 2001, J BIOL CHEM, V276, P16597, DOI 10.1074/jbc.C000909200; Majeed A, 2000, BJU INT, V85, P1058, DOI 10.1046/j.1464-410x.2000.00661.x; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nagabhushan M, 1996, CANCER RES, V56, P3042; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sheridan AM, 2001, MOL CELL BIOL, V21, P4470, DOI 10.1128/MCB.21.14.4470-4481.2001; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sliva D, 1999, BIOCHEM BIOPH RES CO, V263, P149, DOI 10.1006/bbrc.1999.1083; Soto AM, 1995, ONCOL RES, V7, P545; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Tekur S, 2001, MOL CARCINOGEN, V30, P1, DOI 10.1002/1098-2744(200101)30:1<1::AID-MC1008>3.0.CO;2-X; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	46	174	183	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2466	2477		10.1038/sj.onc.1206342	http://dx.doi.org/10.1038/sj.onc.1206342			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717424				2022-12-25	WOS:000182383500010
J	Kim, JH; Leem, SH; Sunwoo, Y; Kouprina, N				Kim, JH; Leem, SH; Sunwoo, Y; Kouprina, N			Separation of long-range human TERT gene haplotypes by transformation-associated recombination cloning in yeast	ONCOGENE			English	Article						hTERT; VNTR; polymorphism; haplotypes; TAR cloning	TELOMERASE ACTIVITY; DNA; MINISATELLITES; AMPLIFICATION; POLYMORPHISMS; CHROMOSOMES; EXPRESSION; SEQUENCE	The hTERT gene encoding a catalytic subunit of human telomerase contains four blocks of variable number of tandem repeats (VNTRs) - two in intron 2 and two in intron 6. The segregation of hTERT VNTRs was analysed in families, revealing that all of them were transmitted through meiosis following a Mendelian inheritance. The work reports a further characterization of the minisatellites in hTERT. We employed transformation-associated recombination (TAR) cloning to isolate parental hTERT alleles and determined the specific combination of minisatellites at each of the polymorphic sites. A long-range haplotyping of hTERT determined by TAR cloning was verified by classical Mendelian analysis. Since such a strategy can be applied for any chromosomal locus, we conclude that recombinational gene capture could greatly facilitate haplotypes analysis.	NCI, Lab Biosyst & Canc, NIH, Bethesda, MD 20892 USA; Dong A Univ, Dept Biol, Pusan 604714, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Dong A University	Kouprina, N (corresponding author), NCI, Lab Biosyst & Canc, NIH, Bldg 37,Room 5032, Bethesda, MD 20892 USA.	kouprinn@mail.nih.gov						Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; FUKE S, 2001, PHARMACOGENOMICS J, V2, P152; JEFFREYS AJ, 1990, CELL, V60, P473, DOI 10.1016/0092-8674(90)90598-9; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kouprina N, 1998, P NATL ACAD SCI USA, V95, P4469, DOI 10.1073/pnas.95.8.4469; KOUPRINA N, 1999, CURRENT PROTOCOLS HU, V1; Larionov V, 1997, P NATL ACAD SCI USA, V94, P7384, DOI 10.1073/pnas.94.14.7384; Larionov V, 1996, P NATL ACAD SCI USA, V93, P491, DOI 10.1073/pnas.93.1.491; Leem SH, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng029; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LUDECKE HJ, 1989, NATURE, V338, P348, DOI 10.1038/338348a0; Noskov V, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e8; Noskov VN, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.6.e32; NOSKOV VN, 2003, IN PRESS J MOL EVOL, V56; Paquette J, 1998, J BIOL CHEM, V273, P14158, DOI 10.1074/jbc.273.23.14158; RUANO G, 1990, P NATL ACAD SCI USA, V87, P6296, DOI 10.1073/pnas.87.16.6296; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Yan P, 1999, J PATHOL, V189, P207, DOI 10.1002/(SICI)1096-9896(199910)189:2<207::AID-PATH424>3.0.CO;2-H; Yoshida R, 1999, ANTICANCER RES, V19, P2167	21	15	17	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2452	2456		10.1038/sj.onc.1206316	http://dx.doi.org/10.1038/sj.onc.1206316			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717422				2022-12-25	WOS:000182383500008
J	Wan, RQ; Camandola, S; Mattson, MP				Wan, RQ; Camandola, S; Mattson, MP			Intermittent fasting and dietary supplementation with 2-deoxy-D-glucose improve functional and metabolic cardiovascular risk factors in rats	FASEB JOURNAL			English	Article						caloric restriction; cardiovascular disease; glucose metabolism; stress response	CALORIC RESTRICTION; INSULIN-RESISTANCE; BLOOD-PRESSURE; FOOD-RESTRICTION; LIFE-SPAN; VOLUNTARY EXERCISE; DIABETES-MELLITUS; FISCHER-344 RATS; BRAIN-DAMAGE; BODY-WEIGHT	Hypertension and insulin resistance syndrome are risk factors for cardiovascular disease, and it is therefore important to identify interventions that can reduce blood pressure and improve glucose metabolism. We performed experiments aimed at determining whether intermittent fasting (IF) can improve cardiovascular health and also tested the hypothesis that beneficial effects of IF can be mimicked by dietary supplementation with 2-deoxy-D-glucose (2DG) a non-metabolizable glucose analog. Four-month-old male rats were implanted with telemetry probes to allow continuous monitoring of heart rate, blood pressure, physical activity, and body temperature. Rats were then maintained for 6 months on one of three different dietary regimens: ad libitum feeding, IF, or 2DG supplementation. Rats on the IF regimen consumed 30% less food over time and had reduced body weights compared with rats fed ad libitum, whereas rats on the 2DG regimen did not reduce their food intake and maintained their body weight. Heart rate and blood pressure were significantly decreased within 1 month in rats on IF and 2DG diets and were maintained at reduced levels thereafter. Body temperature was significantly decreased in group IF, but not in group 2DG. Levels of serum glucose and insulin were significantly decreased in rats maintained on IF and 2DG-supplemented diets, suggesting that IF and 2DG diets affect insulin sensitivity in a similar manner. Finally, rats in groups IF and 2DG exhibited increased levels of plasma adrenocorticotropin and corticosterone, indicating that these diets induced a stress response. We conclude that reductions in blood pressure, heart rate, and insulin levels, similar to or greater than those obtained with regular physical exercise programs, can be achieved by IF and by dietary supplementation with 2DG by a mechanism involving stress responses.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000315, ZIAAG000314, Z01AG000314, Z01AG000315, ZIAAG000312] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANSON M, 2003, IN PRESS P NATL ACAD; Arakawa K, 1999, CLIN EXP HYPERTENS, V21, P797, DOI 10.3109/10641969909061009; BRAUN LT, 1991, NURS CLIN N AM, V26, P135; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Davidson RT, 2002, AM J PHYSIOL-ENDOC M, V282, pE270, DOI 10.1152/ajpendo.00232.2001; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Dwarakanath B. S., 1999, Indian Journal of Experimental Biology, V37, P865; Ehrenfried JA, 1996, ANN SURG, V223, P592, DOI 10.1097/00000658-199605000-00015; FURLAN R, 1993, CARDIOVASC RES, V27, P482, DOI 10.1093/cvr/27.3.482; GAO P, 1992, TOXICOL LETT, V61, P233, DOI 10.1016/0378-4274(92)90150-I; GOODRICK CL, 1982, GERONTOLOGY, V28, P233, DOI 10.1159/000212538; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Grassi G, 1998, CIRCULATION, V97, P2037, DOI 10.1161/01.CIR.97.20.2037; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Henriksen EJ, 2002, J APPL PHYSIOL, V93, P788, DOI 10.1152/japplphysiol.01219.2001; HERLIHY JT, 1992, AM J PHYSIOL, V263, pH1021, DOI 10.1152/ajpheart.1992.263.4.H1021; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; HUGHES TA, 1984, AM J MED, V77, P7, DOI 10.1016/0002-9343(84)90429-7; KALANT N, 1988, MECH AGEING DEV, V46, P89, DOI 10.1016/0047-6374(88)90117-0; KAPLAN O, 1990, CANCER RES, V50, P544; Kinnick TR, 2002, J APPL PHYSIOL, V93, P805, DOI 10.1152/japplphysiol.00236.2002; Klebanov S, 1997, AM J PHYSIOL-HEART C, V273, pH2333, DOI 10.1152/ajpheart.1997.273.5.H2333; KUSHIRO T, 1991, HYPERTENSION, V17, P965, DOI 10.1161/01.HYP.17.6.965; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; NELSON JF, 1995, NEUROBIOL AGING, V16, P837, DOI 10.1016/0197-4580(95)00072-M; Reusch JEB, 2002, AM J CARDIOL, V90, p19G; Roberts SB, 2001, J GERONTOL A-BIOL, V56, P66, DOI 10.1093/gerona/56.suppl_1.66; Roth GS, 2001, ANN NY ACAD SCI, V928, P305; Shahid SK, 2000, CORONARY ARTERY DIS, V11, P103, DOI 10.1097/00019501-200003000-00003; Stewart KJ, 2002, JAMA-J AM MED ASSOC, V288, P1622, DOI 10.1001/jama.288.13.1622; SUZUKI K, 1995, EUR J APPL PHYSIOL O, V71, P240, DOI 10.1007/BF00854985; THOMAS J, 1993, J GERONTOL, V48, pB151, DOI 10.1093/geronj/48.4.B151; VanNess JM, 1999, BRAIN RES, V821, P263, DOI 10.1016/S0006-8993(99)01058-6; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wachsman JT, 1996, MUTAT RES-FUND MOL M, V350, P25, DOI 10.1016/0027-5107(95)00087-9; Wallis EJ, 2002, HEART, V88, P306, DOI 10.1136/heart.88.3.306; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Wilmore JH, 2001, MED SCI SPORT EXER, V33, P107; YOUNG JB, 1978, METABOLISM, V27, P1711, DOI 10.1016/0026-0495(78)90256-1; YOUNG JB, 1982, J CHRON DIS, V35, P879, DOI 10.1016/0021-9681(82)90118-7; Yu BP, 2001, ANN NY ACAD SCI, V928, P39; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2	45	102	105	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1133	+		10.1096/fj.02-0996fje	http://dx.doi.org/10.1096/fj.02-0996fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709404				2022-12-25	WOS:000182580100026
J	Ciana, P; Ghisletti, S; Mussi, P; Eberini, I; Vegeto, E; Maggi, A				Ciana, P; Ghisletti, S; Mussi, P; Eberini, I; Vegeto, E; Maggi, A			Estrogen receptor alpha, a molecular switch converting transforming growth factor-alpha-mediated proliferation into differentiation in neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVATION; FACTOR-I; PROTHYMOSIN-ALPHA; NEURONAL DIFFERENTIATION; PROTEIN-KINASE; CROSS-TALK; PHOSPHORYLATION SITES; GENE-EXPRESSION; BREAST-CANCER; PC12 CELLS	Transforming growth factor-alpha (TGF-alpha) is known to promote both proliferation and differentiation of neural cell progenitors. Using the human neuroblastoma cell line SK-N-BE that is induced to proliferate by TGF-alpha, we demonstrated that the expression of a single transcription factor, the estrogen receptor-alpha (ERalpha), can reroute the TGF-alpha mitogenic signaling toward a path leading to differentiation. With selected mutations in ERalpha and signal transducer and activator of transcription 3 (Stat3), we demonstrated that the blockade of TGF-alpha mitotic potential was not dependent on ERalpha DNA binding activity but required a transcriptionally active Stat3. In neuroblastoma cells, 17beta-estradiol treatment induced a transient increase in the transcription of estrogen-responsive element-containing promoters including those regulating TGF-alpha and prothymosin alpha synthesis. Based on the data presented, we hypothesized that in the presence of prothymosin alpha, ERalpha activates its direct target genes and increases cell proliferation, whereas in the presence of high levels of TGF-alpha, ERalpha preferentially interacts with Stat3 and causes cell differentiation. Our results reveal a novel form of "end-product" regulation of an intracellular receptor that occurs through recruitment of membrane receptors and their signaling effector system. Cross-coupling between membrane and intracellular receptors has been described by several laboratories. This study proves the relevance of these interactions in cellular responses to growth factors.	Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Ctr Biotechnol & Pharmacol, I-20133 Milan, Italy; Univ Milan, Proteom & Prot Struct Study Grp, Dept Pharmacol Sci, I-20133 Milan, Italy	University of Milan; University of Milan; University of Milan	Maggi, A (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Via Balzaretti 9, I-20133 Milan, Italy.		Ghisletti, Serena/AAO-6437-2021; Ciana, Paolo/F-9224-2012	Maggi, Adriana/0000-0001-5700-5273; Ghisletti, Serena/0000-0002-7087-5553; CIANA, PAOLO/0000-0001-5771-5638	Telethon [GGP02336] Funding Source: Medline	Telethon(Fondazione Telethon)		Agrati P, 1997, EUR J NEUROSCI, V9, P1008, DOI 10.1111/j.1460-9568.1997.tb01451.x; Apostolakis EM, 2000, MOL ENDOCRINOL, V14, P1086, DOI 10.1210/me.14.7.1086; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Burrows RT, 2000, DEV NEUROSCI-BASEL, V22, P7, DOI 10.1159/000017422; Cardona-Gomez GP, 2000, NEUROSCIENCE, V99, P751, DOI 10.1016/S0306-4522(00)00228-1; Ciana P, 2001, MOL ENDOCRINOL, V15, P1104, DOI 10.1210/me.15.7.1104; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DEPIEREUX E, 1992, COMPUT APPL BIOSCI, V8, P501; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Duenas M, 1996, NEUROSCIENCE, V74, P531, DOI 10.1016/0306-4522(96)00142-X; ElAshry D, 1996, J STEROID BIOCHEM, V59, P261, DOI 10.1016/S0960-0760(96)00118-5; Garnier M, 1997, J NEUROSCI, V17, P4591; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; Lahooti H, 1998, J MOL ENDOCRINOL, V20, P245, DOI 10.1677/jme.0.0200245; MA ZQ, 1993, P NATL ACAD SCI USA, V90, P3740, DOI 10.1073/pnas.90.8.3740; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; Magdalena C, 2000, BRIT J CANCER, V82, P584, DOI 10.1054/bjoc.1999.0968; Maggi A, 2001, HORM BEHAV, V40, P203, DOI 10.1006/hbeh.2001.1694; Martini PGV, 2000, MOL CELL BIOL, V20, P6224, DOI 10.1128/MCB.20.17.6224-6232.2000; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Patrone C, 1998, MOL ENDOCRINOL, V12, P835, DOI 10.1210/me.12.6.835; Patrone C, 2000, ENDOCRINOLOGY, V141, P1839, DOI 10.1210/en.141.5.1839; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pineiro A, 2000, PEPTIDES, V21, P1433, DOI 10.1016/S0196-9781(00)00288-6; Quesada A, 2002, J NEUROSCI, V22, P2401, DOI 10.1523/JNEUROSCI.22-06-02401.2002; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Shughrue PJ, 2000, NEUROSCIENCE, V96, P41, DOI 10.1016/S0306-4522(99)00520-5; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	50	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 22	2003	278	34					31737	31744		10.1074/jbc.M301525200	http://dx.doi.org/10.1074/jbc.M301525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712DP	12709435	hybrid, Green Published			2022-12-25	WOS:000184782100035
J	Fontes, MRM; Teh, T; Jans, D; Brinkworth, RI; Kobe, B				Fontes, MRM; Teh, T; Jans, D; Brinkworth, RI; Kobe, B			Structural basis for the specificity of bipartite nuclear localization sequence binding by importin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-ANTIGEN NLS; PROTEIN-KINASE; KARYOPHERIN-ALPHA; CRYSTALLOGRAPHIC ANALYSIS; SUBSTRATE-SPECIFICITY; ENHANCES RECOGNITION; IN-VIVO; SIGNAL; SITE; TRANSPORT	Importin-alpha is the nuclear import receptor that recognizes cargo proteins carrying conventional basic monopartite and bipartite nuclear localization sequences (NLSs) and facilitates their transport into the nucleus. Bipartite NLSs contain two clusters of basic residues, connected by linkers of variable lengths. To determine the structural basis of the recognition of diverse bipartite NLSs by mammalian importin-alpha, we co-crystallized a non-autoinhibited mouse receptor protein with peptides corresponding to the NLSs from human retinoblastoma protein and Xenopus laevis phosphoprotein N1N2, containing diverse sequences and lengths of the linker. We show that the basic clusters interact analogously in both NLSs, but the linker sequences adopt different conformations, whereas both make specific contacts with the receptor. The available data allow us to draw general conclusions about the specificity of NLS binding by importin-alpha and facilitate an improved definition of the consensus sequence of a conventional basic/bipartite NLS (KRX10-12KRRK) that can be used to identify novel nuclear proteins.	St Vincents Inst Med Res, Struct Biol Lab, Fitzroy, Vic 3065, Australia; Univ Estadual Paulista, UNESP, Inst Biociencias, Dept Fis & Biofis, BR-18618000 Botucatu, SP, Brazil; Univ Queensland, Dept Biochem & Mol Biol, Inst Mol Biosci, Australian Res Council Special Res Ctr Funct & Ap, Brisbane, Qld 4072, Australia; Univ Queensland, Cooperat Res Ctr Chron Inflammatory Dis, Brisbane, Qld 4072, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signalling Lab, Canberra, ACT 2601, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	St. Vincent's Institute of Medical Research; Universidade Estadual Paulista; University of Queensland; University of Queensland; Australian National University; John Curtin School of Medical Research; Monash University	Kobe, B (corresponding author), St Vincents Inst Med Res, Struct Biol Lab, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.	b.kobe@mailbox.uq.edu.au	Kobe, Bostjan/D-1292-2009; Fontes, Marcos Roberto/B-1941-2009	Kobe, Bostjan/0000-0001-9413-9166; Fontes, Marcos Roberto/0000-0002-4634-6221; Jans, David/0000-0001-5115-4745				Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Conti Elena, 2002, Results Probl Cell Differ, V35, P93; Damelin M, 2002, METHOD ENZYMOL, V351, P587; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Hubner S, 1999, J BIOL CHEM, V274, P22610, DOI 10.1074/jbc.274.32.22610; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Michell BJ, 1996, J BIOL CHEM, V271, P28445, DOI 10.1074/jbc.271.45.28445; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nair R, 2003, NUCLEIC ACIDS RES, V31, P397, DOI 10.1093/nar/gkg001; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Xiao CY, 1998, FEBS LETT, V440, P297, DOI 10.1016/S0014-5793(98)01478-1; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	155	161	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27981	27987		10.1074/jbc.M303275200	http://dx.doi.org/10.1074/jbc.M303275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12695505	hybrid			2022-12-25	WOS:000184242700082
J	Yagi, T; Mahapatra, S; Mikusova, K; Crick, DC; Brennan, PJ				Yagi, T; Mahapatra, S; Mikusova, K; Crick, DC; Brennan, PJ			Polymerization of mycobacterial arabinogalactan and ligation to peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; TEICHOIC-ACID; BACILLUS-LICHENIFORMIS; ENZYMATIC-SYNTHESIS; IN-VIVO; BIOSYNTHESIS; TUBERCULOSIS; ENZYMES; PURIFICATION; ETHAMBUTOL	The cell wall of Mycobacterium spp. consists predominately of arabinogalactan chains linked at the reducing ends to peptidoglycan via a P-GlcNAc-(alpha1-3)-Rha linkage unit (LU) and esterified to a variety of mycolic acids at the nonreducing ends. Several aspects of the biosynthesis of this complex have been defined, including the initial formation of the LU on a polyprenyl phosphate (Pol-P) molecule followed by the sequential addition of galactofuranosyl ( Galf) units to generate Pol-P-P-LU-(Galf)(1,2,3, etc.) and Pol-P-P-LU- galactan, catalyzed by a bifunctional galactosyltransferase (Rv3808c) capable of adding alternating 5- and 6-linked Galf units. By applying cell-free extracts of Mycobacterium smegmatis, containing cell wall and membrane fragments, and differential labeling with UDP-[C-14]Galp and recombinant UDP- Galp mutase as the source of [C-14] Galf for galactan biosynthesis and 5-P-[C-14]ribosyl-P-P as a donor of [C-14]Araf for arabinan synthesis, we now demonstrate sequential synthesis of the simpler Pol-P-P-LU-(Galf)(n)-glycolipid intermediates followed by the Pol-P-P-LU- arabinogalactan and, finally, ligation of the P-LU-arabinogalactan to peptidoglycan. This first time demonstration of in vitro ligation of newly synthesized P-LU-arabinogalactan to newly synthesized peptidoglycan is a necessary forerunner to defining the genetics and enzymology of cell wall polymer-peptidoglycan ligation in Mycobacterium spp. and examining this step as a target for new antibacterial drugs.	Colorado State Univ, dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Colorado State University	Brennan, PJ (corresponding author), Colorado State Univ, dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.		Crick, Dean/H-8251-2017; Mahapatra, Sebabrata/D-6033-2017; Yagi, Tetsuya/J-3303-2012; Mikusova, Katarina/I-3622-2014	Crick, Dean/0000-0001-9281-7058; Mikusova, Katarina/0000-0002-0100-4877	NIAID NIH HHS [AI-46393, AI-49151, AI-18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049151, R22AI018357, R01AI018357, R56AI049151, R37AI018357, P01AI046393] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; [Anonymous], CURRENT OPINION ANTI; Archibald A. R., 1993, P381; Baulard A.R., 1999, MYCOBACTERIA MOL BIO, P240; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Crick DC, 2001, GLYCOBIOLOGY, V11, p107R, DOI 10.1093/glycob/11.9.107R; Escuyer VE, 2001, J BIOL CHEM, V276, P48854, DOI 10.1074/jbc.M102272200; FIEDLER F, 1974, J BIOL CHEM, V249, P2690; FOLCH J, 1957, J BIOL CHEM, V226, P479; HANCOCK IC, 1981, EUR J BIOCHEM, V119, P85, DOI 10.1111/j.1432-1033.1981.tb05580.x; Hancock IC, 2002, MICROBIOL-SGM, V148, P3059, DOI 10.1099/00221287-148-10-3059; HASH JH, 1963, ARCH BIOCHEM BIOPHYS, V102, P379, DOI 10.1016/0003-9861(63)90245-5; HASH JH, 1967, J BIOL CHEM, V242, P5586; Hitchcock SA, 1998, J AM CHEM SOC, V120, P1916, DOI 10.1021/ja973172d; Kremer L, 2001, J BIOL CHEM, V276, P26430, DOI 10.1074/jbc.M102022200; LEAVER J, 1981, J BACTERIOL, V146, P847, DOI 10.1128/JB.146.3.847-852.1981; Lee R, 1996, ANAL BIOCHEM, V242, P1, DOI 10.1006/abio.1996.0419; LUCAS JJ, 1975, J BIOL CHEM, V250, P1992; Mahapatra S, 2000, J BACTERIOL, V182, P6827, DOI 10.1128/JB.182.23.6827-6830.2000; MAUCK J, 1972, J BIOL CHEM, V247, P1180; McNeil M, 1999, GENETICS OF BACTERIALS POLYSACCHARIDES, P207; Mikusova K, 2000, J BIOL CHEM, V275, P33890, DOI 10.1074/jbc.M006875200; Mikusova K, 1996, J BIOL CHEM, V271, P7820, DOI 10.1074/jbc.271.13.7820; POOLEY HM, 1994, BACTERIAL CELL WALL, P187; RATLEDGE C, 1982, BIOL MYCOBACTERIA, V1, P105; Reddy SG, 1999, J AM CHEM SOC, V121, P1175, DOI 10.1021/ja983850b; Scherman MS, 1996, J BIOL CHEM, V271, P29652, DOI 10.1074/jbc.271.47.29652; Schwebach JR, 2002, INFECT IMMUN, V70, P2566, DOI 10.1128/IAI.70.5.2566-2575.2002; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; WARD JB, 1981, MICROBIOL REV, V45, P211, DOI 10.1128/MMBR.45.2.211-243.1981; WARD JB, 1982, EUR J BIOCHEM, V122, P125; WARD JB, 1974, BIOCHEM J, V141, P227, DOI 10.1042/bj1410227; WATKINSON RJ, 1971, NATURE-NEW BIOL, V229, P57, DOI 10.1038/newbio229057a0; WIETZERBIN J, 1974, BIOCHEMISTRY-US, V13, P3471, DOI 10.1021/bi00714a008; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	38	29	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26497	26504		10.1074/jbc.M302216200	http://dx.doi.org/10.1074/jbc.M302216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12719430	hybrid			2022-12-25	WOS:000184155700028
J	Nicolas, V; Kim, CL; Gane, P; Birkenmeier, C; Cartron, JP; Colin, Y; Mouro-Chanteloup, I				Nicolas, V; Kim, CL; Gane, P; Birkenmeier, C; Cartron, JP; Colin, Y; Mouro-Chanteloup, I			Rh-RhAG/ankyrin-R, a new interaction site between the membrane bilayer and the red cell skeleton, is impaired by Rh-null-associated mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP SYSTEM; MOLECULAR-BASIS; HEREDITARY SPHEROCYTOSIS; TARGETED DISRUPTION; HEMOLYTIC-ANEMIA; BINDING-SITES; D-POLYPEPTIDE; ANKYRIN; BAND-3; COMPLEX	Several studies suggest that the Rh complex represents a major interaction site between the membrane lipid bilayer and the red cell skeleton, but little is known about the molecular basis of this interaction. We report here that ankyrin-R is capable of interacting directly with the C-terminal cytoplasmic domain of Rh and RhAG polypeptides. We first show that the primary defect of ankyrin-R in normoblastosis (nb/nb) spherocytosis mutant mice is associated with a sharp reduction of RhAG and Rh polypeptides. Secondly, our flow cytometric analysis of the Triton X-100 extractability of recombinant fusion proteins expressed in erythroleukemic cell lines suggests that the C-terminal cytoplasmic domains of Rh and RhAG are sufficient to mediate interaction with the erythroid membrane skeleton. Using the yeast two-hybrid system, we demonstrate a direct interaction between the cytoplasmic tails of Rh and RhAG and the second repeat domain (D2) of ankyrin-R. This finding is supported by the demonstration that the substitution of Asp-399 in the cytoplasmic tail of RhAG, a mutation associated with the deficiency of the Rh complex in one Rh-null patient, totally impaired interaction with domain D2 of ankyrin-R. These results identify the Rh/RhAG-ankyrin complex as a new interaction site between the red cell membrane and the spectrin-based skeleton, the disruption of which might result in the stomato-spherocytosis typical of Rh-null red cells.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Jackson Lab, Bar Harbor, ME 04609 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Jackson Laboratory	Colin, Y (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	colin@idf.inserm.fr	Isabelle, Mouro-Chanteloup/M-9750-2018; colin, yves/O-1910-2017; le van kim, caroline/O-7030-2017	Isabelle, Mouro-Chanteloup/0000-0002-6368-9904; colin, yves/0000-0001-5196-4254; le van kim, caroline/0000-0002-3251-1310				Avent ND, 2000, BLOOD, V95, P375, DOI 10.1182/blood.V95.2.375; Beckmann R, 2001, BLOOD, V97, P2496, DOI 10.1182/blood.V97.8.2496; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bhattacharyya R, 1999, BIOCHEM J, V340, P505, DOI 10.1042/0264-6021:3400505; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; Bruce LJ, 2002, BLOOD, V100, P1878, DOI 10.1182/blood-2002-03-0706; Cartron JP, 1999, BEST PRACT RES CL HA, V12, P655, DOI 10.1053/beha.1999.0047; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; Dahl KN, 2003, BLOOD, V101, P1194, DOI 10.1182/blood-2002-04-1187; Delaunay J, 2002, ACTA HAEMATOL-BASEL, V108, P210, DOI 10.1159/000065657; DISCHER DE, 1994, SCIENCE, V266, P1032, DOI 10.1126/science.7973655; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; GAHMBERG CG, 1984, J IMMUNOL, V133, P334; GANE P, 2001, BRIT J HAEMATOL, V113, P1; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Gilligan DM, 1999, P NATL ACAD SCI USA, V96, P10717, DOI 10.1073/pnas.96.19.10717; GIMM A, 2000, VOX SANG S1, V78, P14; HERMAND P, 1993, BLOOD, V82, P669; Huang CH, 1999, AM J HEMATOL, V62, P25, DOI 10.1002/(SICI)1096-8652(199909)62:1<25::AID-AJH5>3.0.CO;2-K; Huang CH, 2000, J MOL EVOL, V51, P76, DOI 10.1007/s002390010068; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; Leite R C, 2000, Hum Mutat, V16, P529, DOI 10.1002/1098-1004(200012)16:6<529::AID-HUMU13>3.0.CO;2-N; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; Mouro-Chanteloup I, 2003, BLOOD, V101, P338, DOI 10.1182/blood-2002-04-1285; Mouro-Chanteloup I, 2002, BLOOD, V100, P1038; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Ribeiro ML, 2000, BLOOD, V96, P1602; RIDGWELL K, 1984, FEBS LETT, V174, P7, DOI 10.1016/0014-5793(84)81066-2; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; WHITE RA, 1990, P NATL ACAD SCI USA, V87, P3117, DOI 10.1073/pnas.87.8.3117; Yi SJ, 1997, BIOCHEMISTRY-US, V36, P9596, DOI 10.1021/bi9704966; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O	44	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25526	25533		10.1074/jbc.M302816200	http://dx.doi.org/10.1074/jbc.M302816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719424	hybrid			2022-12-25	WOS:000183920200033
J	Bereczky, Z; Wang, HY; Schubert, V; Ganal, M; Bauer, P				Bereczky, Z; Wang, HY; Schubert, V; Ganal, M; Bauer, P			Differential regulation of nramp and irt metal transporter genes in wild type and iron uptake mutants of tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; ION TRANSPORTER; HIGHER-PLANTS; BHLH PROTEIN; BSD2 GENE; YEAST; FAMILY; NICOTIANAMINE; EXPRESSION; CLONING	Metal transporters regulated by iron can transport a variety of divalent metals, suggesting that iron regulation is important for specificity of iron transport. In plants, the iron-regulated broad-range metal transporter IRT1 is required for uptake of iron into the root epidermis. Functions of other iron-regulated plant metal transporters are not yet established. To deduce novel plant iron transport functions we studied the regulation of four tomato metal transporter genes belonging to the nramp and irt families with respect to environmental and genetic factors influencing iron uptake. We isolated Lenramp1 and Lenramp3 from tomato and demonstrate that these genes encode functional NRAMP metal transporters in yeast, where they were iron-regulated and localized mainly to intracellular vesicles. Lenramp1 and Leirt1 revealed both root-specific expression and up-regulation by iron deficiency, respectively, in contrast to Leirt2 and Lenramp3. Lenramp1 and Leirt1, but not Lenramp3 and Leirt2, were down-regulated in the roots of fer mutant plants deficient in a bHLH gene regulating iron uptake. In chloronerva mutant plants lacking the functional enzyme for synthesis of the plant-specific metal chelator nicotianamine Leirt1 and Lenramp1 were up-regulated despite sufficient iron supply independent of a functional fer gene. Lenramp1 was expressed in the vascular root parenchyma in a similar cellular pattern as the fer gene. However, the fer gene was not sufficient for inducing Lenramp1 and Leirt1 when ectopically expressed. Based on our results, we suggest a novel function for NRAMP1 in mobilizing iron in the vascular parenchyma upon iron deficiency in plants. We discuss fer/nicotianamine synthase-dependent and -independent regulatory pathways for metal transporter gene regulation.	Inst Plant Genet & Crop Plant Res IPK, D-06466 Gatersleben, Germany	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung	Bauer, P (corresponding author), Inst Plant Genet & Crop Plant Res IPK, Corrensstr 3, D-06466 Gatersleben, Germany.		Schmidt, Wolfgang/AAA-2807-2022	Schmidt, Wolfgang/0000-0002-7850-6832; Schubert, Veit/0000-0002-3072-0485				BAUER P, 1994, PLANT PHYSIOL, V105, P585, DOI 10.1104/pp.105.2.585; Belouchi A, 1997, PLANT MOL BIOL, V33, P1085, DOI 10.1023/A:1005723304911; BROWN JC, 1974, PHYSIOL PLANTARUM, V31, P221, DOI 10.1111/j.1399-3054.1974.tb03695.x; BROWN JC, 1971, PHYSIOL PLANTARUM, V25, P48, DOI 10.1111/j.1399-3054.1971.tb01086.x; Chen XZ, 1999, J BIOL CHEM, V274, P35089, DOI 10.1074/jbc.274.49.35089; Connolly EL, 2002, PLANT CELL, V14, P1347, DOI 10.1105/tpc.001263; Curie C, 2000, BIOCHEM J, V347, P749, DOI 10.1042/0264-6021:3470749; Dai YS, 2002, J BIOL CHEM, V277, P12604, DOI 10.1074/jbc.M200283200; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Eckhardt U, 2001, PLANT MOL BIOL, V45, P437, DOI 10.1023/A:1010620012803; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; Fairchild CD, 2000, GENE DEV, V14, P2377; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; Grotewold E, 2000, P NATL ACAD SCI USA, V97, P13579, DOI 10.1073/pnas.250379897; Guerinot ML, 1999, CURR OPIN PLANT BIOL, V2, P244, DOI 10.1016/S1369-5266(99)80042-9; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; JACKSON D, 1991, PRACTICAL APPROACH M, P163; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Kruger C, 2002, J BIOL CHEM, V277, P25062, DOI 10.1074/jbc.M201896200; Kyozuka J, 1998, P NATL ACAD SCI USA, V95, P1979, DOI 10.1073/pnas.95.5.1979; Ling HQ, 1999, P NATL ACAD SCI USA, V96, P7098, DOI 10.1073/pnas.96.12.7098; Ling HQ, 2002, P NATL ACAD SCI USA, V99, P13938, DOI 10.1073/pnas.212448699; Liu XF, 1999, J MOL BIOL, V289, P885, DOI 10.1006/jmbi.1999.2815; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; Lopez-Millan AF, 2000, PLANT PHYSIOL, V124, P873, DOI 10.1104/pp.124.2.873; MINET M, 1992, PLANT J, V2, P417; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; POKALSKY AR, 1989, NUCLEIC ACIDS RES, V17, P4661, DOI 10.1093/nar/17.12.4661; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 2002, BIOCHEM J, V362, P119, DOI 10.1042/bj3620119; ROMHELD V, 1987, PHYSIOL PLANTARUM, V70, P231, DOI 10.1111/j.1399-3054.1987.tb06137.x; STEPHAN UW, 1993, PHYSIOL PLANTARUM, V88, P522, DOI 10.1111/j.1399-3054.1993.tb01367.x; STEPHAN UW, 1989, ACTA BOT NEERL, V38, P147, DOI 10.1111/j.1438-8677.1989.tb02037.x; Takahashi M, 2001, NAT BIOTECHNOL, V19, P466, DOI 10.1038/88143; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; Varotto C, 2002, PLANT J, V31, P589, DOI 10.1046/j.1365-313X.2002.01381.x; Vert G, 2001, PLANT J, V26, P181, DOI 10.1046/j.1365-313x.2001.01018.x; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D	45	134	154	2	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24697	24704		10.1074/jbc.M301365200	http://dx.doi.org/10.1074/jbc.M301365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709425	hybrid			2022-12-25	WOS:000183824800056
J	Ballou, LM; Lin, HY; Fan, GF; Jiang, YP; Lin, RZ				Ballou, LM; Lin, HY; Fan, GF; Jiang, YP; Lin, RZ			Activated G alpha q inhibits p110 alpha phosphatidylinositol 3-kinase and Akt	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SMOOTH-MUSCLE-CELLS; 1321N1 ASTROCYTOMA-CELLS; BETA-GAMMA-SUBUNITS; COUPLED RECEPTORS; PHOSPHOLIPASE-C; ALPHA(1A)-ADRENERGIC RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; GLUT4 TRANSLOCATION; GLUCOSE-TRANSPORT	Some G(q)-coupled receptors have been shown to antagonize growth factor activation of phosphatidylinositol 3-kinase (PI3K) and its downstream effector, Akt. We used a constitutively active Galpha(q)(Q209L) mutant to explore the effects of Galpha(q) activation on signaling through the PI3K/Akt pathway. Transient expression of Galpha(q)(Q209L) in Rat-1 fibroblasts inhibited Akt activation induced by platelet-derived growth factor or insulin treatment. Expression of Galpha(q)(Q209L) also attenuated Akt activation promoted by coexpression of constitutively active PI3K in human embryonic kidney 293 cells. Galpha(q)(Q209L) had no effect on the activity of an Akt mutant in which the two regulatory phosphorylation sites were changed to acidic amino acids. Inducible expression of Galpha(q)(Q209L) in a stably transfected 293 cell line caused a decrease in PI3K activity in p110alpha (but not p110beta) immunoprecipitates. Receptor activation of Galpha(q) also selectively inhibited PI3K activity in p110alpha immunoprecipitates. Active Galpha(q) still inhibited PI3K/Akt in cells pretreated with the phospholipase C inhibitor U73122. Finally, Galpha(q)(Q209L) co-immunoprecipitated with the p110alpha-p85alpha PI3K heterodimer from lysates of COS-7 cells expressing these proteins, and incubation of immunoprecipitated Galpha(q)(Q209L) with purified recombinant p110alpha-p85alpha in vitro led to a decrease in PI3K activity. These results suggest that agonist binding to G(q)-coupled receptors blocks Akt activation via the release of active Galpha(q) subunits that inhibit PI3K. The inhibitory mechanism seems to be independent of phospholipase C activation and might involve an inhibitory interaction between Galpha(q) and p110alpha PI3K.	SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA; Dept Vet Affairs Med Ctr, Res Serv, Northport, NY 11768 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lin, RZ (corresponding author), SUNY Stony Brook, Dept Med, Div Hematol, Stony Brook, NY 11794 USA.	richard.lin@sunysb.edu	Lin, Richard/J-1754-2014	Lin, Richard/0000-0002-3473-7276	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062722] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK62722] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Ballou LM, 2001, J BIOL CHEM, V276, P40910, DOI 10.1074/jbc.M103480200; Ballou LM, 2000, J BIOL CHEM, V275, P4803, DOI 10.1074/jbc.275.7.4803; Batty IH, 1996, BIOCHEM J, V317, P347, DOI 10.1042/bj3170347; Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Hajduch E, 1999, J BIOL CHEM, V274, P13563, DOI 10.1074/jbc.274.19.13563; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Imamura T, 1999, J BIOL CHEM, V274, P33691, DOI 10.1074/jbc.274.47.33691; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Jiang ZY, 1999, DIABETES, V48, P1120, DOI 10.2337/diabetes.48.5.1120; Kanzaki M, 2000, J BIOL CHEM, V275, P7167, DOI 10.1074/jbc.275.10.7167; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kenny BA, 1996, BRIT J PHARMACOL, V118, P871, DOI 10.1111/j.1476-5381.1996.tb15480.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Ruan Y, 1998, J PHARMACOL EXP THER, V284, P576; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Takahashi T, 1999, AM J PHYSIOL-HEART C, V276, pH1927, DOI 10.1152/ajpheart.1999.276.6.H1927; Tang XW, 2002, J BIOL CHEM, V277, P338, DOI 10.1074/jbc.M108927200; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	41	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23472	23479		10.1074/jbc.M212232200	http://dx.doi.org/10.1074/jbc.M212232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704201	hybrid			2022-12-25	WOS:000183638600033
J	Boulanger, RR; Kantrowitz, ER				Boulanger, RR; Kantrowitz, ER			Characterization of a monomeric Escherichia coli alkaline phosphatase formed upon a single amino acid substitution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE; REVERSIBLE DISSOCIATION; BACILLUS-SUBTILIS; METAL-IONS; COMPLEMENTATION; SUBUNITS; ENZYME; REACTIVATION; STABILITY; MECHANISM	Alkaline phosphatase (AP) from Escherichia coli as well as APs from many other organisms exist in a dimeric quaternary structure. Each monomer contains an active site located 32 Angstrom away from the active site in the second subunit. Indirect evidence has previously suggested that the monomeric form of AP is inactive. Molecular modeling studies indicated that destabilization of the dimeric interface should occur if Thr-59, located near the 2-fold axis of symmetry, were replaced by a sterically large and charged residue such as arginine. The T59R enzyme was constructed and characterized by sucrose-density gradient sedimentation, size-exclusion chromatography, and circular dichroism (CD) and compared with the previously constructed T59A enzyme. The T59A enzyme was found to exist as a dimer, whereas the T59R enzyme was found to exist as a monomer. The T59A, T59R, and wild-type APs exhibited almost identical secondary structures as judged by CD. The T59R monomeric AP has a melting temperature (T-m) of 43 degreesC, whereas the wild-type AP dimer has a T-m of 97 degreesC. The catalytic activity of the T59R enzyme was reduced by 10(4)-fold, whereas the T59A enzyme exhibited an activity similar to that of the wild-type enzyme. The T59A and wild-type enzymes contained similar levels of zinc and magnesium, whereas the T59R enzyme has almost undetectable amounts of tightly bound metals. These results suggest that a significant conformational change occurs upon dimerization, which enhances thermal stability, metal binding, and catalysis.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; EGUCHI M, 1995, COMP BIOCHEM PHYS B, V111, P151, DOI 10.1016/0305-0491(94)00248-S; FALK MC, 1982, BIOCHEMISTRY-US, V21, P1471, DOI 10.1021/bi00536a001; FAN DP, 1966, J MOL BIOL, V15, P32, DOI 10.1016/S0022-2836(66)80207-3; GAREN A, 1963, J MOL BIOL, V7, P13, DOI 10.1016/S0022-2836(63)80015-7; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; Hauksson JB, 2000, ENZYME MICROB TECH, V27, P66, DOI 10.1016/S0141-0229(00)00152-6; Hehir MJ, 2000, J MOL BIOL, V304, P645, DOI 10.1006/jmbi.2000.4230; HULETT FM, 1990, J BACTERIOL, V172, P735, DOI 10.1128/jb.172.2.735-740.1990; HULETT FM, 1991, J BIOL CHEM, V266, P1077; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINTHAL C, 1962, P NATL ACAD SCI USA, V48, P1230, DOI 10.1073/pnas.48.7.1230; MacBeath G, 1998, SCIENCE, V279, P1958, DOI 10.1126/science.279.5358.1958; Martin DC, 1999, PROTEIN SCI, V8, P1152, DOI 10.1110/ps.8.5.1152; MCCRACKEN S, 1980, J BIOL CHEM, V255, P2396; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; Ottosen MB, 2002, PROTEIN SCI, V11, P2575, DOI 10.1110/ps.0220302; PLOCKE DJ, 1962, BIOCHEMISTRY-US, V1, P1039, DOI 10.1021/bi00912a014; SCHLESIN MJ, 1963, J MOL BIOL, V7, P1, DOI 10.1016/S0022-2836(63)80014-5; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4284; SCHLESINGER MJ, 1965, J BIOL CHEM, V240, P4293; SCHLESINGER MJ, 1963, COLD SPRING HARB SYM, V28, P539, DOI 10.1101/SQB.1963.028.01.072; Schliebs W, 1997, BIOCHEMISTRY-US, V36, P9655, DOI 10.1021/bi963086a; Sharipova MR, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1178; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; Stec B, 1998, J MOL BIOL, V277, P647, DOI 10.1006/jmbi.1998.1635; Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799; TYLERCROSS R, 1989, J BIOL CHEM, V264, P4523; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31; Zappa S, 2001, APPL ENVIRON MICROB, V67, P4504, DOI 10.1128/AEM.67.10.4504-4511.2001	35	52	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23497	23501		10.1074/jbc.M301105200	http://dx.doi.org/10.1074/jbc.M301105200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707276	hybrid			2022-12-25	WOS:000183638600036
J	Chakrabarti, SK; Francis, J; Ziesmann, SM; Garmey, JC; Mirmira, RG				Chakrabarti, SK; Francis, J; Ziesmann, SM; Garmey, JC; Mirmira, RG			Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; H3 LYSINE-4 METHYLATION; CHROMATIN STRUCTURE; SECRETING CELLS; IN-VITRO; ACETYLATION; DIFFERENTIATION; EXPRESSION; DOMAIN; METHYLTRANSFERASE	Histone modifying enzymes contribute to the activation or inactivation of transcription by ultimately catalyzing the unfolding or further compaction, respectively, of chromatin structure. Actively transcribed genes are typically hyperacetylated at Lys residues of histones H3 and H4 and hypermethylated at Lys-4 of histone H3 (H3-K4). To determine whether covalent histone modifications play a role in the beta cell-specific expression of the insulin gene, we performed chromatin immunoprecipitation assays using anti-histone antibodies and extracts from beta cell lines, non-beta cell lines, and ES cells, and quantitated specific histone modifications at the insulin promoter by real-time PCR. Our studies reveal that the proximal insulin promoter is hyperacetylated at histone H3 only in beta cells. This hyperacetylation is highly correlated to recruitment of the histone acetyltransferase p300 to the proximal promoter in beta cells, and is consistent with the role of hyperacetylation in promoting euchromatin formation. We also observed that the proximal insulin promoter of beta cells is hypermethylated at H3-K4, and that this modification is correlated to the recruitment of the histone methyltransferase SET7/9 to the promoter. ES cells demonstrate a histone modification pattern intermediate between that of beta cells and non-beta cells, and is consistent with their potential to express the insulin gene. We therefore propose a model in which insulin transcription in the beta cell is facilitated by a unique combination of transcription factors that acts in the setting of an open, euchromatic structure of the insulin gene.	Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Ctr Diabet, Charlottesville, VA 22903 USA; Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Mirmira, RG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Internal Med, 450 Ray C Hunt Dr,Box 801407, Charlottesville, VA 22903 USA.		Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075	NIDDK NIH HHS [K08 DK02683, R01 DK60581, T32 DK0732025] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060581, T32DK007320, K08DK002683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An WJ, 2003, J BIOL CHEM, V278, P1504, DOI 10.1074/jbc.M209355200; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Chakrabarti SK, 2003, TRENDS ENDOCRIN MET, V14, P78, DOI 10.1016/S1043-2760(02)00039-5; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; Hui HX, 2001, DIABETES, V50, P785, DOI 10.2337/diabetes.50.4.785; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Kojima H, 2002, DIABETES, V51, P1398, DOI 10.2337/diabetes.51.5.1398; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Martens JHA, 2003, MOL CELL BIOL, V23, P1808, DOI 10.1128/MCB.23.5.1808-1816.2003; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOSLEY AL, 2003, J BIOL CHEM     0328; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2002, P NATL ACAD SCI USA, V99, P16438, DOI 10.1073/pnas.182436399; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Smith CM, 2002, P NATL ACAD SCI USA, V99, P16454, DOI 10.1073/pnas.182424999; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Yoshida S, 2002, DIABETES, V51, P2505, DOI 10.2337/diabetes.51.8.2505; YOSHIDA T, 1994, AM J PATHOL, V145, P671; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	53	113	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23617	23623		10.1074/jbc.M303423200	http://dx.doi.org/10.1074/jbc.M303423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12711597	hybrid			2022-12-25	WOS:000183638600052
J	De Taeye, B; Compernolle, G; Dewilde, M; Biesemans, W; Declerck, PJ				De Taeye, B; Compernolle, G; Dewilde, M; Biesemans, W; Declerck, PJ			Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1 - Identification of a transition state with distinct conformational and functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; FAST-ACTING INHIBITOR; PROTEINASE INHIBITION; PROTEASE COMPLEXES; ANTITHROMBIN-III; STRUCTURAL BASIS; HUMAN-PLASMA; SITE LOOP; SUBSTRATE; TYPE-1	The serpin plasminogen activator inhibitor-1 (PAI-1) plays an important role in the regulation of the fibrinolytic activity in blood. In plasma, PAI-1 circulates mainly in the active conformation. However, PAI-1 spontaneously converts to a latent conformation. This conversion comprises drastic conformational changes in both the distal and the proximal hinge region of the reactive center loop. To study the functional and conformational rearrangements associated solely with the mobility of the proximal hinge, disulfide bonds were introduced to immobilize the distal hinge region. These mutants exhibited specific activities comparable with that of PAI-1-wt. However, the engineered disulfide bond had a major effect on the conformational and associated functional transitions. Strikingly, in contrast to PAI-1-wt, inactivation of these mutants yielded a virtually complete conversion to a substrate-like conformation. Comparison of the digestion pattern (with trypsin and elastase) of the mutants and PAI-1-wt revealed that the inactivated mutants have a conformation differing from that of latent and active PAI-1-wt. Unique trypsin-susceptible cleavage sites arose upon inactivation of these mutants. The localization of these exposed residues provides evidence that a displacement of alphahF has occurred, indicating that the proximal hinge is partly inserted between s3A and s5A. In conclusion, immobilization of the distal hinge region in PAI-1 allowed the identification of an "intermediate" conformation characterized by a partial insertion of the proximal hinge region. We hypothesize that locking PAI-1 in this transition state between active and latent conformations is associated with a displacement of alphahF, subsequently resulting in substrate behavior.	Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharmaceut Sci, B-3000 Louvain, Belgium	KU Leuven	Declerck, PJ (corresponding author), Katholieke Univ Leuven, Lab Pharmaceut Biol & Phytopharmacol, Fac Pharmaceut Sci, E Van Evenstr 4, B-3000 Louvain, Belgium.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105; Dewilde, Maarten/0000-0002-3138-281X				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866; BJORK I, 1992, J BIOL CHEM, V267, P19047; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; DEBROCK S, 1995, FEBS LETT, V376, P243, DOI 10.1016/0014-5793(95)01289-0; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; Egelund R, 1997, EUR J BIOCHEM, V248, P775, DOI 10.1111/j.1432-1033.1997.t01-1-00775.x; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; Gils A, 1998, BBA-PROTEIN STRUCT M, V1387, P291, DOI 10.1016/S0167-4838(98)00139-3; Gils A, 1998, THROMB HAEMOSTASIS, V80, P531; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kruger P, 2001, PROTEIN SCI, V10, P798, DOI 10.1110/ps.40401; KRUITHOF EKO, 1984, BLOOD, V64, P907; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; SANCHO E, 1994, EUR J BIOCHEM, V224, P125, DOI 10.1111/j.1432-1033.1994.tb20003.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SINGH R, 1995, METHOD ENZYMOL, V251, P229, DOI 10.1016/0076-6879(95)51125-3; SINGH R, 1993, ANAL BIOCHEM, V213, P49, DOI 10.1006/abio.1993.1384; Stoop AA, 2001, J MOL BIOL, V305, P773, DOI 10.1006/jmbi.2000.4356; Urano T, 1996, BBA-PROTEIN STRUCT M, V1298, P199, DOI 10.1016/S0167-4838(96)00131-8; URANO T, 1992, EUR J BIOCHEM, V209, P985, DOI 10.1111/j.1432-1033.1992.tb17372.x; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; VANMEIJER M, 1995, FIBRINOLYSIS, V9, P261; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	45	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23899	23905		10.1074/jbc.M302226200	http://dx.doi.org/10.1074/jbc.M302226200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12686544	hybrid			2022-12-25	WOS:000183638600087
J	Knauss, S; Rohrmeier, T; Lehle, L				Knauss, S; Rohrmeier, T; Lehle, L			The auxin-induced maize gene ZmSAUR2 encodes a short-lived nuclear protein expressed in elongating tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT SAUR GENES; REGULATED GENES; MESSENGER-RNAS; GROWTH; CALMODULIN; COLEOPTILES; BINDING; ACID; WALL; CALCIUM/CALMODULIN	By differential screening of a cDNA library from auxin-induced maize coleoptiles we have isolated and characterized a SAUR gene, designated ZmSAUR2, belonging to a not yet characterized subtype of the SAUR family. ZmSAUR2 encodes a 15.3-kDa protein and is specifically induced by auxin in elongating coleoptile tissue but not in primary leaves or in roots. The transcript level rapidly increased within minutes and preceded auxin-stimulated elongation of coleoptile segments. Cycloheximide also induced ZmSAUR2 transcription, as has been shown for other early auxin-induced genes, whereas abscisic acid, brassinolide, ethylene, gibberellic acid, kinetin, and methyl jasmonate did not provoke an increase in ZmSAUR2 mRNA abundance. In pulse-chase experiments using auxin-induced coleoptiles and an anti-ZmSAUR2 antibody we were able to precipitate a protein of the expected molecular mass and to determine a half-life of about 7 min, which is among the shortest known in eukaryotes. In gel shift assays binding of calmodulin to ZmSAUR2 was demonstrated, suggesting the possibility of post-transcriptional regulation. Upon transformation of onion epidermal cells with a ZmSAUR2::GUS construct the corresponding chimeric protein was detected in the nucleus. The results suggest that ZmSAUR2 encodes a short-lived nuclear protein that might be involved in auxin-mediated cell elongation.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany	University of Regensburg	Lehle, L (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ Str 31, D-93053 Regensburg, Germany.	ludwig.lehle@biologie.uni-regensburg.de						Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; ADAM G, 1994, NATURWISSENSCHAFTEN, V81, P210, DOI 10.1007/BF01138545; Anai T, 1998, DNA SEQUENCE, V9, P329, DOI 10.3109/10425179809008472; ARAZI T, 1995, PLANT PHYSIOL, V108, P551, DOI 10.1104/pp.108.2.551; BERGFELD R, 1988, BOT ACTA, V101, P57, DOI 10.1111/j.1438-8677.1988.tb00012.x; BRUMMELL DA, 1987, PLANT CELL ENVIRON, V10, P523, DOI 10.1111/1365-3040.ep11603897; Carpita NC, 2001, PLANT PHYSIOL, V127, P551, DOI 10.1104/pp.010146; Catala C, 2000, PLANT PHYSIOL, V122, P527, DOI 10.1104/pp.122.2.527; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVANS ML, 1985, CRC CR REV PLANT SCI, V2, P317, DOI 10.1080/07352688509382200; FRANCO AR, 1990, J BIOL CHEM, V265, P15845; GEE MA, 1991, PLANT CELL, V3, P419, DOI 10.1105/tpc.3.4.419; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GEHRING CA, 1990, P NATL ACAD SCI USA, V87, P9645, DOI 10.1073/pnas.87.24.9645; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; Gil P, 1996, EMBO J, V15, P1678, DOI 10.1002/j.1460-2075.1996.tb00513.x; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILFOYLE TJ, 1993, AUST J PLANT PHYSIOL, V20, P489, DOI 10.1071/PP9930489; Guilfoyle TJ, 1999, N COMP BIOC, V33, P423; Haga K, 1998, PLANT PHYSIOL, V117, P1473, DOI 10.1104/pp.117.4.1473; Hagen G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117; Hall LN, 1998, PLANT CELL, V10, P925, DOI 10.1105/tpc.10.6.925; Johnson MA, 2000, P NATL ACAD SCI USA, V97, P13991, DOI 10.1073/pnas.240354097; Karcz W, 2002, J EXP BOT, V53, P1089, DOI 10.1093/jexbot/53.371.1089; KOSHIBA T, 1995, J MOL BIOL, V253, P396, DOI 10.1006/jmbi.1995.0562; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUTSCHERA U, 1985, PLANTA, V163, P483, DOI 10.1007/BF00392705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leyser O, 2002, ANNU REV PLANT BIOL, V53, P377, DOI 10.1146/annurev.arplant.53.100301.135227; LI Y, 1994, PLANT PHYSIOL, V106, P37, DOI 10.1104/pp.106.1.37; LI Y, 1994, PLANT MOL BIOL, V24, P715, DOI 10.1007/BF00029853; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; MCCLURE BA, 1989, PLANT CELL, V1, P229, DOI 10.1105/tpc.1.2.229; MCCLURE BA, 1989, SCIENCE, V243, P91, DOI 10.1126/science.11540631; MCCLURE BA, 1987, PLANT MOL BIOL, V9, P611, DOI 10.1007/BF00020537; NEWMAN TC, 1993, PLANT CELL, V5, P701, DOI 10.1105/tpc.5.6.701; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; Philippar K, 1999, P NATL ACAD SCI USA, V96, P12186, DOI 10.1073/pnas.96.21.12186; RAY PM, 1977, PLANT PHYSIOL, V60, P585, DOI 10.1104/pp.60.4.585; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Roux C, 1998, PLANT MOL BIOL, V37, P385, DOI 10.1023/A:1005906316880; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOPFER P, 1989, PLANT PHYSIOL, V90, P202, DOI 10.1104/pp.90.1.202; Sitbon F, 1997, PHYSIOL PLANTARUM, V100, P443, DOI 10.1034/j.1399-3054.1997.1000305.x; Snedden WA, 1996, J BIOL CHEM, V271, P4148; Snedden WA, 1998, TRENDS PLANT SCI, V3, P299, DOI 10.1016/S1360-1385(98)01284-9; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Szymanski DB, 1996, PLANT CELL, V8, P1069, DOI 10.1105/tpc.8.6.1069; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Tiwari SB, 2001, PLANT CELL, V13, P2809, DOI 10.1105/tpc.13.12.2809; Watillon B, 1998, PLANT MOL BIOL, V36, P909, DOI 10.1023/A:1005914506110; YAMAMOTO KT, 1992, PLANT CELL PHYSIOL, V33, P93; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137; Zenser N, 2001, P NATL ACAD SCI USA, V98, P11795, DOI 10.1073/pnas.211312798; ZUREK DM, 1994, PLANT PHYSIOL, V104, P505, DOI 10.1104/pp.104.2.505	58	71	87	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23936	23943		10.1074/jbc.M212585200	http://dx.doi.org/10.1074/jbc.M212585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695517	hybrid			2022-12-25	WOS:000183638600092
J	Yamaguchi, N; Xu, L; Pasek, DA; Evans, KE; Meissner, G				Yamaguchi, N; Xu, L; Pasek, DA; Evans, KE; Meissner, G			Molecular basis of calmodulin binding to cardiac muscle Ca2+ release channel (ryanodine receptor)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; PROTEIN-STRUCTURE; SKELETAL; APOCALMODULIN; EXPRESSION; INHIBITION; ACTIVATION	Calmodulin (CaM) is a ubiquitous Ca2+-binding protein that regulates the ryanodine receptors (RyRs) by direct binding. CaM inhibits the skeletal muscle ryanodine receptor (RyR1) and cardiac muscle receptor (RyR2) at > 1 muM Ca2+ but activates RyR1 and inhibits RyR2 at < 1 &mu;M Ca2+. Here we tested whether CaM regulates RyR2 by binding to a highly conserved site identified previously in RyR1. Deletion of RyR2 amino acid residues 3583-3603 resulted in background [S-35] CaM binding levels. In single channel measurements, deletion of the putative CaM binding site eliminated CaM inhibition of RyR2 at Ca2+ concentrations below and above 1 &mu;M. Five RyR2 single or double mutants in the CaM binding region ( W3587A, L3591D, F3603A, W3587A/L3591D, L3591D/F3603A) eliminated or greatly reduced [ 35S] CaM binding and inhibition of single channel activities by CaM depending on the Ca2+ concentration. An RyR2 mutant, which assessed the effects of 4 amino acid residues that differ between RyR1 and RyR2 in or flanking the CaM binding domain, bound [ 35S] CaM and was inhibited by CaM, essentially identical to wild type (WT)-RyR2. Three RyR1 mutants (W3620A, L3624D, F3636A) showed responses to CaM that differed from corresponding mutations in RyR2. The results indicate that CaM regulates RyR1 and RyR2 by binding to a single, highly conserved CaM binding site and that other RyR type-specific sites are likely responsible for the differential functional regulation of RyR1 and RyR2 by CaM.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR018687, R01AR018687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL27430] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fruen BR, 2000, AM J PHYSIOL-CELL PH, V279, pC724, DOI 10.1152/ajpcell.2000.279.3.C724; Gao L, 2000, BIOPHYS J, V79, P828, DOI 10.1016/S0006-3495(00)76339-9; Gao L, 1997, FEBS LETT, V412, P223, DOI 10.1016/S0014-5793(97)00781-3; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rodney GG, 2001, J BIOL CHEM, V276, P2069, DOI 10.1074/jbc.M008891200; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; STULTZ CM, 1997, ADV MOL CEL A&B, V22, P447; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Xu L, 1998, BIOPHYS J, V75, P2302, DOI 10.1016/S0006-3495(98)77674-X; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200	24	129	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23480	23486		10.1074/jbc.M301125200	http://dx.doi.org/10.1074/jbc.M301125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707260	Green Published, hybrid			2022-12-25	WOS:000183638600034
J	Yoshiike, Y; Chui, DH; Akagi, T; Tanaka, N; Takashima, A				Yoshiike, Y; Chui, DH; Akagi, T; Tanaka, N; Takashima, A			Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN GENE; NEURODEGENERATIVE DISEASE; CEREBRAL-HEMORRHAGE; PRESENILE-DEMENTIA; IN-VIVO; MUTATION; MECHANISM; CLEAVAGE	Alzheimer's disease (AD) may be caused by toxic aggregates formed from amyloid-beta (Abeta) peptides. By using Thioflavin T, a dye that specifically binds to beta-sheet structures, we found that highly toxic forms of Abeta-aggregates were formed at the initial stage of fibrillogenesis, which is consistent with recent reports on Abeta oligomers. Formation of such aggregates depends on factors that affect both nucleation and elongation. As reported previously, addition of Abeta42 systematically accelerated the nucleation of Abeta40, most likely because of the extra hydrophobic residues at the C terminus of Abeta42. At Abeta42-increased specific ratio (Abeta40: Abeta42 = 10: 1), on the other hand, not only accelerated nucleation but also induced elongation were observed, suggesting pathogenesis of early-onset AD. Because a larger proportion of Abeta40 than Abeta42 was still required for this phenomenon, we assumed that elongation does not depend only on hydrophobic interactions. Without any change in the C-terminal hydrophobic nature, elongation was effectively induced by mixing wild type Abeta40 with Italian variant Abeta40 (E22K) or Dutch variant (E22Q). We suggest that Abeta peptides in specific compositions that balance hydrophilic and hydrophobic interactions promote the formation of toxic beta-aggregates. These results may introduce a new therapeutic approach through the disruption of this balance.	RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Neural Architecture, Wako, Saitama 3510198, Japan; Tokyo Inst Technol, Dept Life Sci, Yokohama, Kanagawa 2268503, Japan	RIKEN; RIKEN; Tokyo Institute of Technology	Takashima, A (corresponding author), RIKEN, Brain Sci Inst, Lab Alzheimers Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.							BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; OLSON MI, 1969, BRAIN, V92, P147, DOI 10.1093/brain/92.1.147; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tagliavini F., 1999, ALZHEIMERS REP, V2, P23; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I	28	83	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23648	23655		10.1074/jbc.M212785200	http://dx.doi.org/10.1074/jbc.M212785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12716908	hybrid			2022-12-25	WOS:000183638600056
J	Ben-Chaim, Y; Tour, O; Dascal, N; Parnas, I; Parnas, H				Ben-Chaim, Y; Tour, O; Dascal, N; Parnas, I; Parnas, H			The M-2 muscarinic G-protein-coupled receptor is voltage-sensitive	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNEL; DEPOLARIZATION-INDUCED CHANGES; ACH RELEASE; ACETYLCHOLINE; AGONIST; MODULATION; CALCIUM; BINDING; DESENSITIZATION; CONDUCTANCES	G- protein coupled receptors are not considered to exhibit voltage sensitivity. Here, using Xenopus oocytes, we show that the M-2 muscarinic receptor ( m2R) is voltage-sensitive. The m2R- mediated potassium channel ( GIRK) currents were used to assay the activity of m2R. We found that the apparent affinity of m2R toward acetylcholine ( ACh) was reduced upon depolarization. Binding experiments of [ H-3] ACh to individual oocytes expressing m2R confirmed the electrophysiological findings. When the GIRK channels were activated either by overexpression of Gbetagamma subunits or by injection of GTPgammaS, the ratio between the currents measured at -60 mV and + 40 mV was the same as for the basal activity of the GIRK channel. Thus, the steps downstream to agonist activation of m2R are not voltage- sensitive. We further found that, in contrast to m2R, the apparent affinity of m1R was increased upon depolarization. We also found that the voltage sensitivity of binding of [H-3] ACh to oocytes expressing m2R was greatly diminished following pretreatment with pertussis toxin. The cumulative results suggest that m2R is, by itself, voltage- sensitive. Furthermore, the voltage sensitivity does not reside in the ACh binding site, rather, it most likely resides in the receptor region that couples to the G- protein.	Hebrew Univ Jerusalem, Otto Loewi Minerva Ctr Cellular & Mol Neurobiol, IL-91904 Jerusalem, Israel; Tel Aviv Univ, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	Hebrew University of Jerusalem; Tel Aviv University	Parnas, H (corresponding author), Hebrew Univ Jerusalem, Otto Loewi Minerva Ctr Cellular & Mol Neurobiol, IL-91904 Jerusalem, Israel.	hanna@vms.huji.ac.il	Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146	NIGMS NIH HHS [GM 56260] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056260] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUD C, 1983, J PHYSL, V356, P275; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; Bunemann M, 1996, J PHYSIOL-LONDON, V494, P351; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1984, J PHYSIOL-LONDON, V352, P551, DOI 10.1113/jphysiol.1984.sp015310; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DOLEZAL V, 1993, N-S ARCH PHARMACOL, V348, P228, DOI 10.1007/BF00169149; DOUPNIK CA, 1995, J GEN PHYSIOL, V106, P1, DOI 10.1085/jgp.106.1.1; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Guo DL, 2002, J GEN PHYSIOL, V120, P539, DOI 10.1085/jgp.20028623; Hommers LG, 2003, J BIOL CHEM, V278, P1037, DOI 10.1074/jbc.M205325200; Ilouz N, 1999, J BIOL CHEM, V274, P29519, DOI 10.1074/jbc.274.41.29519; Ishii M, 2002, P NATL ACAD SCI USA, V99, P4325, DOI 10.1073/pnas.072073399; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; KIM D, 1991, J PHYSIOL-LONDON, V437, P133, DOI 10.1113/jphysiol.1991.sp018588; Linial M, 1997, J PHYSIOL-LONDON, V504, P251, DOI 10.1111/j.1469-7793.1997.251be.x; LUQMANI YA, 1979, NATURE, V277, P481, DOI 10.1038/277481a0; MAGLEBY KL, 1972, J PHYSIOL-LONDON, V223, P151, DOI 10.1113/jphysiol.1972.sp009839; MARTY A, 1989, J PHYSIOL-LONDON, V419, P665, DOI 10.1113/jphysiol.1989.sp017892; MAYER ML, 1984, J PHYSIOL-LONDON, V354, P29, DOI 10.1113/jphysiol.1984.sp015360; Minami K, 1997, EUR J PHARMACOL, V339, P237, DOI 10.1016/S0014-2999(97)01354-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Ong BH, 2001, PFLUG ARCH EUR J PHY, V441, P604, DOI 10.1007/s004240000459; Parnas H, 2000, TRENDS NEUROSCI, V23, P60, DOI 10.1016/S0166-2236(99)01498-8; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Raman IM, 1995, BIOPHYS J, V69, P1868, DOI 10.1016/S0006-3495(95)80057-3; SHARIF NA, 1995, NEUROCHEM RES, V20, P669, DOI 10.1007/BF01705534; Shui Z, 1998, J PHYSIOL-LONDON, V507, P325, DOI 10.1111/j.1469-7793.1998.325bt.x; Slutsky I, 1999, J PHYSIOL-LONDON, V514, P769, DOI 10.1111/j.1469-7793.1999.769ad.x; Slutsky I, 2003, J NEUROPHYSIOL, V89, P1954, DOI 10.1152/jn.00668.2002; Slutsky I, 2002, J NEUROSCI, V22, P3426; Slutsky I, 2001, J PHYSIOL-LONDON, V536, P717, DOI 10.1111/j.1469-7793.2001.00717.x; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; Tour O, 1998, BIOPHYS J, V74, P1767, DOI 10.1016/S0006-3495(98)77887-7; Vorobiov D, 1998, PFLUG ARCH EUR J PHY, V436, P56, DOI 10.1007/s004240050604; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166	39	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22482	22491		10.1074/jbc.M301146200	http://dx.doi.org/10.1074/jbc.M301146200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684524	hybrid			2022-12-25	WOS:000183503900043
J	Ralle, M; Lutsenko, S; Blackburn, NJ				Ralle, M; Lutsenko, S; Blackburn, NJ			X-ray absorption spectroscopy of the copper chaperone HAH1 reveals a linear two-coordinate Cu(I) center capable of adduct formation with exogenous thiols and phosphines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; N-TERMINAL DOMAIN; P-TYPE ATPASE; MENKES-DISEASE; SUPEROXIDE-DISMUTASE; BACILLUS-SUBTILIS; CANDIDATE GENE; ATX1 GENE; PROTEIN; METALLOCHAPERONE	The human copper chaperone HAH1 transports copper to the Menkes and Wilson proteins, which are copper-translocating P-type ATPases located in the trans-Golgi apparatus and believed to provide copper for important enzymes such as ceruloplasmin, tyrosinase, and peptidylglycine monooxygenase. Although a substantial amount of structural data exist for HAH1 and its yeast and bacterial homologues, details of the copper coordination remain unclear and suggest the presence of two protein-derived cysteine ligands and a third exogenous thiol ligand. Here we report the preparation and reconstitution of HAH1 with Cu(I) using a protocol that minimizes the use of thiol reagents believed to be the source of the third ligand. We show by x-ray absorption spectroscopy that this reconstitution protocol generates an occupied Cu(I) binding site with linear bis-cysteinate coordination geometry, as evidenced by (i) an intense edge absorption centered at 8982.5 eV, with energy and intensity identical to the rigorously linear two-coordinate model complex bis-2,3,5,6-tetramethylbenzene thiolate Cu(I) and (ii) an EXAFS spectrum that could be fit to two Cu-S interactions at 2.16 Angstrom, a distance typical of digonal Cu(I) coordination. Binding of exogenous ligands (GSH, dithiothreitol, and tris-(2-carboxyethyl)phosphine) to the Cu(I) was investigated. When GSH or dithiothreitol was added to the chaperone during the reconstitution procedure, the resulting Cu(I) HAH1 remained two-coordinate, whereas the addition of the phosphine during reconstitution elicited a three-coordinate species. When the exogenous ligands were titrated into the Cu(I)-HAH1, all formed three-coordinate adducts but with differing affinities. Thus, GSH and dithiothreitol showed weaker binding, with estimated K-D values in the range 10-25 mM, whereas tris-(2-carboxyethyl)-phosphine showed stronger affinity, with a K-D value of <5 mM. The implications of these findings for mechanisms of copper transport are discussed.	Oregon Hlth & Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Blackburn, NJ (corresponding author), Oregon Hlth & Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	ninian@bmb.ogi.edu	Ralle, Martina/H-2936-2019		NIGMS NIH HHS [R01-GM58403, P01-GM067166] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM067166] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Banci L, 2003, BIOCHEMISTRY-US, V42, P2467, DOI 10.1021/bi0205810; Banci L, 2002, J MOL BIOL, V317, P415, DOI 10.1006/jmbi.2002.5430; Banci L, 2001, BIOCHEMISTRY-US, V40, P15660, DOI 10.1021/bi0112715; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Cobine PA, 2002, BIOCHEMISTRY-US, V41, P5822, DOI 10.1021/bi025515c; Cobine PA, 2000, BIOCHEMISTRY-US, V39, P6857, DOI 10.1021/bi000015+; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; George G.N, 1990, EXAFSPAK; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Hamza I, 1999, P NATL ACAD SCI USA, V96, P13363, DOI 10.1073/pnas.96.23.13363; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; Kihlken MA, 2002, BIOCHEM J, V368, P729, DOI 10.1042/BJ20021036; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; KOCH SA, 1984, INORG CHEM, V23, P121, DOI 10.1021/ic00170a001; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; PICKERING IJ, 1993, J AM CHEM SOC, V115, P9498, DOI 10.1021/ja00074a014; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; Schmidt PJ, 2000, J BIOL CHEM, V275, P33771, DOI 10.1074/jbc.M006254200; Schmidt PJ, 1999, J BIOL CHEM, V274, P23719, DOI 10.1074/jbc.274.34.23719; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; Steveson TC, 2003, ENDOCRINOLOGY, V144, P188, DOI 10.1210/en.2002-220716; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	51	100	100	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23163	23170		10.1074/jbc.M303474200	http://dx.doi.org/10.1074/jbc.M303474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686548	hybrid			2022-12-25	WOS:000183503900124
J	Dowen, SE; Neutze, DM; Pett, MR; Cottage, A; Stern, P; Coleman, N; Stanley, MA				Dowen, SE; Neutze, DM; Pett, MR; Cottage, A; Stern, P; Coleman, N; Stanley, MA			Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes	ONCOGENE			English	Article						5p; HPV; SKP2; p27	HUMAN-PAPILLOMAVIRUS TYPE-16; F-BOX PROTEIN; CARCINOMA CELL-LINES; CYTOGENETIC ANALYSIS; RECURRENT PATTERN; GENOMIC CHANGES; CERVIX UTERI; HELA-CELL; IN-SITU; S-PHASE	The oncogenic HPVs immortalize primary genital keratinocytes in vitro and there is evidence that such lines represent suitable models to examine HPV-induced carcinogenesis. Early in vivo studies and more recent CGH analyses have revealed amplification of chromosome 5p in advanced stage carcinoma of the uterine cervix (CaCx). In the present study, a panel of established CaCx-derived cell tines were analysed by M-FISH to identify recurrent karyotypic abnormalities. Amplification of 5p was observed in I I of 13 CaCx cell lines harbouring HR (high-risk) HPV. The region of 5p undergoing amplification was confirmed using human band-specific paints. The F-box protein Skp2 is present at 5p13 and its protein is present at increased levels in many cancers of an advanced stage. The HPV16-harbouring cell line W12 shows progressive morphological abnormality with in vitro passage, culminating in an invasive phenotype. The expression of Skp2 at different stages of this progression was investigated utilizing Western blot and TaqMan quantitative PCR. At medium to late passage, gain of 5p as an isochromosome was observed. Increased expression of Skp2 and a reduction in the expression of its target p27 correlated with increasing passage in this line.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; MRC, Res Ctr, Cambridge CB2 2QH, England; Christie Hosp NHS Trust, Canc Res UK, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England	University of Cambridge; Cancer Research UK; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester	Dowen, SE (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	sally-dowen@hotmail.com						ATKIN NB, 1982, CANCER GENET CYTOGEN, V7, P209, DOI 10.1016/0165-4608(82)90068-1; ATKIN NB, 1984, CANCER GENET CYTOGEN, V13, P189, DOI 10.1016/0165-4608(84)90043-8; Aubele M, 1998, CANCER CYTOPATHOL, V84, P375, DOI 10.1002/(SICI)1097-0142(19981225)84:6<375::AID-CNCR10>3.0.CO;2-1; AUERSPERG N, 1964, J NATL CANCER I, V32, P135; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Ciaparrone M, 1998, CANCER RES, V58, P114; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DURST M, 1987, ONCOGENE, V1, P251; FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; HERZ F, 1977, CANCER RES, V37, P3209; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; *INT AG RES CANC, 1995, IARC MONOGRAPHS EVAL, V74; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; Jee KJ, 2001, MODERN PATHOL, V14, P377, DOI 10.1038/modpathol.3880321; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kudo Y, 2001, CANCER RES, V61, P7044; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; MAEVILLE M, 1999, CANCER RES, V59, P141; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; MILLER OJ, 1971, CYTOGENETICS, V10, P338, DOI 10.1159/000130152; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Roberts I, 1999, GENE CHROMOSOME CANC, V25, P241, DOI 10.1002/(SICI)1098-2264(199907)25:3<241::AID-GCC6>3.0.CO;2-7; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; STANLEY M, 1994, PAPILLOMAVIRUS REV, P131; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STANLEY MA, 1991, CULTURE EPITHELIAL C, P135; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071	49	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2531	2540		10.1038/sj.onc.1206296	http://dx.doi.org/10.1038/sj.onc.1206296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717429				2022-12-25	WOS:000182383500015
J	Kim, SH; Hwang, SB; Chung, IK; Lee, J				Kim, SH; Hwang, SB; Chung, IK; Lee, J			Sequence-specific binding to telomeric DNA by CEH-37, a homeodomain protein in the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISSION YEAST; C-ELEGANS; DOMAIN; TRF1; REPLICATION; RECOGNITION; LENGTH; LOOPS; RAP1; END	Caenorhabditis elegans can serve as a model system to study telomere functions due to its similarity to higher organisms in telomere structures. We report here the identification of the nematode homeodomain protein CEH-37 as a telomere-binding protein using a yeast one-hybrid screen. The predicted three-dimensional model of the homeodomain of CEH-37, which has a typical helix-loop-helix structure, was similar to that of the Myb domain of known telomere-binding proteins, which is also a helix-loop-helix protein, despite little amino acid sequence similarity. We demonstrated the specific binding of CEH-37 to the nematode telomere sequences in vitro by competition assays. We determined that CEH-37 binding required at least 1.5 repeats of TTAGGC and that the core sequence for binding was GGCTTA. We found that CEH-37 had an ability to bend telomere sequence-containing DNA, which is the case for other known telomere-binding proteins such as TRF1 and RAP1, indicating that CEH-37 may be involved in establishing or maintaining a secondary structure of the telomeres in vivo. We also demonstrated that CEH-37 was primarily co-localized to the chromosome ends in vivo, indicating that CEH-37 may play roles in telomere functions. Consistent with this, a ceh-37 mutation resulting in a truncated protein caused a weak high incidence of male phenotype, which may have been caused by chromosome instability. The identification of CEH-37 as a telomere-binding protein may represent an evolutionary conservation of telomere-binding proteins in terms of tertiary protein structure rather than primary amino acid sequence.	Yonsei Univ, Natl Res Lab, Seoul 120749, South Korea; Yonsei Univ, Mol Aging Res Ctr, Dept Biol, Seoul 120749, South Korea	Yonsei University; Yonsei University	Lee, J (corresponding author), Yonsei Univ, Natl Res Lab, 134 Shinchon, Seoul 120749, South Korea.							Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; BLACKBURN EH, 1991, TRENDS BIOCHEM SCI, V16, P378, DOI 10.1016/0968-0004(91)90155-O; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hwang MG, 2001, FEBS LETT, V503, P35, DOI 10.1016/S0014-5793(01)02685-0; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Kurenova EV, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1242; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Muniyappa K, 1998, CRIT REV BIOCHEM MOL, V33, P297, DOI 10.1080/10409239891204242; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; Nishikawa T, 2001, STRUCTURE, V9, P1237, DOI 10.1016/S0969-2126(01)00688-8; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Spink KG, 2000, NUCLEIC ACIDS RES, V28, P527, DOI 10.1093/nar/28.2.527; Stansel RM, 2001, EMBO J, V20, P5532; Stewart Jillian L., 2001, Trends in Cell Biology, V11, P279, DOI 10.1016/S0962-8924(01)02029-3; Wicky C, 1996, P NATL ACAD SCI USA, V93, P8983, DOI 10.1073/pnas.93.17.8983; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	30	13	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28038	28044		10.1074/jbc.M302192200	http://dx.doi.org/10.1074/jbc.M302192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12711598	hybrid			2022-12-25	WOS:000184242700089
J	Kaushik, JK; Bhat, R				Kaushik, JK; Bhat, R			Why is trehalose an exceptional protein stabilizer? An analysis of the thermal stability of proteins in the presence of the compatible osmolyte trehalose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUEOUS POLYOL SOLUTIONS; SACCHAROMYCES-CEREVISIAE; PREFERENTIAL HYDRATION; MOLECULAR-BIOLOGY; HIGH-TEMPERATURES; ENZYME STRUCTURE; SURFACE-TENSION; HEAT-CAPACITIES; RIBONUCLEASE-A; AMINO-ACIDS	Trehalose, a naturally occurring osmolyte, is known to be an exceptional stabilizer of proteins and helps retain the activity of enzymes in solution as well as in the freeze-dried state. To understand the mechanism of action of trehalose in detail, we have conducted a thorough investigation of its effect on the thermal stability in aqueous solutions of five well characterized proteins differing in their various physico-chemical properties. Among them, RNase A has been used as a model enzyme to investigate the effect of trehalose on the retention of enzymatic activity upon incubation at high temperatures. 2 M trehalose was observed to raise the transition temperature, T-m of RNase A by as much as 18degreesC and Gibbs free energy by 4.8 kcal mol(-1) at pH 2.5. There is a decrease in the heat capacity of protein denaturation (DeltaC(p)) in trehalose solutions for all the studied proteins. An increase in the DeltaG and a decrease in the DeltaC(p) values for all the proteins points toward a general mechanism of stabilization due to the elevation and broadening of the stability curve (DeltaG versus T). A direct correlation of the surface tension of trehalose solutions and the thermal stability of various proteins has been observed. Wyman linkage analysis indicates that at 1.5 M concentration 4-7 molecules of trehalose are excluded from the vicinity of protein molecules upon denaturation. We further show that an increase in the stability of proteins in the presence of trehalose depends upon the length of the polypeptide chain. The pH dependence data suggest that even though the charge status of a protein contributes significantly, trehalose can be expected to work as a universal stabilizer of protein conformation due to its exceptional effect on the structure and properties of solvent water compared with other sugars and polyols.	Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Bhat, R (corresponding author), Jawaharlal Nehru Univ, Ctr Biotechnol, New Delhi 110067, India.	rajivbhat@hotmail.com		Kaushik, Jai/0000-0002-8872-0066				ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov IV, 1999, PROTEIN SCI, V8, P1314, DOI 10.1110/ps.8.6.1314; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Carninci P, 1998, P NATL ACAD SCI USA, V95, P520, DOI 10.1073/pnas.95.2.520; CARPENTER JF, 1993, ARCH BIOCHEM BIOPHYS, V303, P456, DOI 10.1006/abbi.1993.1309; CARPENTER JF, 1989, BIOCHEMISTRY-US, V28, P3916, DOI 10.1021/bi00435a044; Celinski SA, 2002, PROTEIN SCI, V11, P2048, DOI 10.1110/ps.0211702; Chalikian TV, 1997, J MOL BIOL, V274, P237, DOI 10.1006/jmbi.1997.1394; COLACO C, 1992, BIO-TECHNOL, V10, P1007, DOI 10.1038/nbt0992-1007; Consalvi V, 2000, PROTEIN ENG, V13, P501, DOI 10.1093/protein/13.7.501; CROOK EM, 1960, BIOCHEM J, V74, P234, DOI 10.1042/bj0740234; Devi YS, 1998, PROGR BIOTECHNOL, V15, P263; DIPAOLA G, 1977, CAN J CHEM, V55, P3825, DOI 10.1139/v77-540; DYSON HJ, 1982, J BIOL CHEM, V257, P2267; Funahashi J, 2001, PROTEIN ENG, V14, P127, DOI 10.1093/protein/14.2.127; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P1643, DOI 10.1093/oxfordjournals.jbchem.a133639; GEKKO K, 1982, J BIOCHEM-TOKYO, V91, P1197, DOI 10.1093/oxfordjournals.jbchem.a133803; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P51, DOI 10.1093/oxfordjournals.jbchem.a133469; GEKKO K, 1981, J BIOCHEM-TOKYO, V90, P1633, DOI 10.1093/oxfordjournals.jbchem.a133638; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; GRIKO YV, 1994, J MOL BIOL, V243, P93, DOI 10.1006/jmbi.1994.1632; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; JASRA RV, 1984, J CHEM THERMODYN, V16, P583, DOI 10.1016/0021-9614(84)90010-7; Kaushik JK, 1999, PROTEIN SCI, V8, P222; Kaushik JK, 1998, J PHYS CHEM B, V102, P7058, DOI 10.1021/jp981119l; Kaushik JK, 2002, J MOL BIOL, V316, P991, DOI 10.1006/jmbi.2001.5355; KITA Y, 1994, BIOCHEMISTRY-US, V33, P15178, DOI 10.1021/bi00254a029; Konno T, 1997, BBA-PROTEIN STRUCT M, V1342, P73, DOI 10.1016/S0167-4838(97)00092-7; Kreilgaard L, 1998, ARCH BIOCHEM BIOPHYS, V360, P121, DOI 10.1006/abbi.1998.0948; Kuhn LA, 1995, PROTEINS, V23, P536, DOI 10.1002/prot.340230408; LEE JC, 1981, J BIOL CHEM, V256, P7193; Lin TY, 1996, PROTEIN SCI, V5, P372; Liu YF, 1996, BIOCHEMISTRY-US, V35, P3059, DOI 10.1021/bi952198j; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; MAEDA Y, 1995, PROTEIN ENG, V8, P201, DOI 10.1093/protein/8.2.201; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; PACE CN, 1989, BIOCHEMISTRY-US, V28, P2520, DOI 10.1021/bi00432a026; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Sampedro JG, 1998, CRYOBIOLOGY, V37, P131, DOI 10.1006/cryo.1998.2109; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; Singer MA, 1998, TRENDS BIOTECHNOL, V16, P460, DOI 10.1016/S0167-7799(98)01251-7; Singer MA, 1998, MOL CELL, V1, P639, DOI 10.1016/S1097-2765(00)80064-7; Sola-Penna M, 1998, ARCH BIOCHEM BIOPHYS, V360, P10, DOI 10.1006/abbi.1998.0906; SolaPenna M, 1997, EUR J BIOCHEM, V248, P24, DOI 10.1111/j.1432-1033.1997.00024.x; SOMERO GN, 1986, AM J PHYSIOL, V251, pR197, DOI 10.1152/ajpregu.1986.251.2.R197; Sun WQ, 1998, BBA-GEN SUBJECTS, V1425, P235, DOI 10.1016/S0304-4165(98)00076-2; TAYLOR LS, 1995, BBA-PROTEIN STRUCT M, V1253, P39, DOI 10.1016/0167-4838(95)00142-H; Timasheff SN, 1998, ADV PROTEIN CHEM, V51, P355; Ueda T, 2001, J BIOCHEM-TOKYO, V130, P491, DOI 10.1093/oxfordjournals.jbchem.a003011; WANG A, 1995, BIOCHEMISTRY-US, V34, P15096, DOI 10.1021/bi00046a016; Weatherly GT, 2001, PROTEIN SCI, V10, P12, DOI 10.1110/ps.29301; Xie GF, 1997, BIOPHYS CHEM, V64, P25, DOI 10.1016/S0301-4622(96)02222-3; Xie GF, 1997, PROTEIN SCI, V6, P211; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	59	449	498	1	99	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26458	26465		10.1074/jbc.M300815200	http://dx.doi.org/10.1074/jbc.M300815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12702728	hybrid			2022-12-25	WOS:000184155700023
J	de Jong, JC; Willems, PHGM; Mooren, FJM; van den Heuvel, LPWJ; Knoers, NVAM; Bindels, RJM				de Jong, JC; Willems, PHGM; Mooren, FJM; van den Heuvel, LPWJ; Knoers, NVAM; Bindels, RJM			The structural unit of the thiazide-sensitive NaCl cotransporter is a homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; NEPHROGENIC DIABETES-INSIPIDUS; SODIUM-CHANNEL ENAC; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CHLORIDE COTRANSPORTER; HETEROTETRAMERIC ARCHITECTURE; MUTATIONS; FAMILY; RAT	The thiazide-sensitive NaCl cotransporter (NCC) is responsible for the reabsorption of 5% of the filtered load of NaCl in the kidney. Mutations in NCC cause Gitelman syndrome. To gain insight into its regulation, detailed information on the structural composition of its functional unit is essential. Western blot analysis of total membranes of Xenopus laevis oocytes heterologously expressing FLAG-tagged NCC revealed the presence of both complex- (140-kDa) and core (100-kDa)-glycosylated monomers and a broad band of high molecular mass (250-350-kDa) complexes. Chemical cross-linking with dithiobispropionimidate eliminated the low molecular weight bands and increased the intensity of the high molecular weight bands, indicating that NCC is present in multimeric complexes. Co-expression of HA- and FLAG-tagged NCC followed by co-immunoprecipitation demonstrated that these multimers contained at least two complex- glycosylated NCC proteins. The dimeric nature of the multimers was further substantiated by sucrose gradient centrifugation yielding a peak of similar to310 kDa. A concatameric construct of two NCC polyproteins exhibited significant Na-22(+) uptake, indicating that the transporter is functional as a homodimer. A concatamer of partially retarded G980R- and wild type (wt)-NCC displayed normal Na+ transport. This demonstrates that G980R- NCC, provided that it reaches the surface, is fully active and that wt-NCC is dominant in its association with this mutant. Conversely a concatamer of fully retarded G741R- and wt-NCC did not reach the cell surface, showing that wt-NCC is recessive in its association with this mutant. Oocytes co-expressing G741R- and wt-NCC did not show G741R staining at the plasma membrane, whereas Na+ transport was normal, indicating that wt-NCC dimerizes preferentially with itself. The results are discussed in relation to the recessive nature of NCC mutants in Gitelman syndrome.	Univ Nijmegen, Med Ctr, Dept Cell Physiol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Bindels, RJM (corresponding author), Univ Nijmegen, Med Ctr, Dept Cell Physiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Bindels, René JM/B-9824-2013; van den Heuvel, Lambertus/AAM-1772-2021; van den Heuvel, L.P.W.J./H-8044-2014; Willems, P.H.G.M./L-4759-2015	Bindels, René JM/0000-0003-1167-1339; van den Heuvel, Lambertus/0000-0003-3917-6727; van den Heuvel, L.P.W.J./0000-0003-3917-6727; Willems, P.H.G.M./0000-0002-0915-1599				Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; De Jong JC, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017904.77985.03; Dijkink L, 2002, PFLUG ARCH EUR J PHY, V444, P549, DOI 10.1007/s00424-002-0855-4; Ellison DH, 2003, J AM SOC NEPHROL, V14, P538, DOI 10.1681/ASN.V142538; ELLISON DH, 1987, AM J PHYSIOL, V253, pF546, DOI 10.1152/ajprenal.1987.253.3.F546; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; GITELMAN HJ, 1969, ANN NY ACAD SCI, V162, P856, DOI 10.1111/j.1749-6632.1969.tb13015.x; Hiki K, 1999, J BIOL CHEM, V274, P10661, DOI 10.1074/jbc.274.15.10661; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Hoover RS, 2003, J AM SOC NEPHROL, V14, P271, DOI 10.1097/01.ASN.0000043903.93452.D0; Kamsteeg EJ, 2000, AM J PHYSIOL-RENAL, V279, pF778, DOI 10.1152/ajprenal.2000.279.4.F778; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Lemmink HH, 1998, KIDNEY INT, V54, P720, DOI 10.1046/j.1523-1755.1998.00070.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; McKee JA, 2000, J AM SOC NEPHROL, V11, P2128, DOI 10.1681/ASN.V11112128; Moore-Hoon ML, 2000, BIOCHEMISTRY-US, V39, P3718, DOI 10.1021/bi992301v; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Mount DB, 2001, CURR OPIN NEPHROL HY, V10, P685, DOI 10.1097/00041552-200109000-00021; Mount DB, 1998, J EXP BIOL, V201, P2091; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; Yin CC, 2000, MOL MICROBIOL, V38, P482, DOI 10.1046/j.1365-2958.2000.02149.x	29	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24302	24307		10.1074/jbc.M303101200	http://dx.doi.org/10.1074/jbc.M303101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704198	Green Published, hybrid			2022-12-25	WOS:000183824800010
J	Gao, ZG; Zuberi, A; Quon, MJ; Dong, ZG; Ye, JP				Gao, ZG; Zuberi, A; Quon, MJ; Dong, ZG; Ye, JP			Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B KINASE; INDUCED TYROSINE PHOSPHORYLATION; IRS-SIGNALING SYSTEM; N-TERMINAL KINASE; PROTEIN-KINASE; FACTOR-ALPHA; TNF-ALPHA; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSGENIC MICE	The hypoglycemic effects of high dose salicylates in the treatment of diabetes were documented before the advent of insulin. However, the molecular mechanisms by which salicylates exert these anti-diabetic effects are not well understood. In this study, we analyzed the effects of aspirin (acetylsalicylic acid) on serine phosphorylation of insulin receptor substrate 1 (IRS-1) in cells treated with tumor necrosis factor (TNF)-alpha. Phosphorylation of IRS-1 at Ser(307), Ser(267), and Ser(612) was monitored by immunoblotting with phospho-specific IRS-1 antibodies. In 3T3-L1 and Hep G2 cells, phosphorylation of IRS-1 at Ser(307) in response to TNF-alpha treatment correlated with phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha. Moreover, phosphorylation of IRS-1 at Ser(307) in embryo fibroblasts derived from either JNK or IKK knockout mice was reduced when compared with that in the wild-type controls. Taken together, these data suggest that serine phosphorylation of IRS-1 in response to TNF-alpha is mediated, in part, by JNK and IKK. Interestingly, aspirin treatment inhibited the phosphorylation of IRS-1 at Ser(307) as well as the phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha. Furthermore, other serine kinases including Akt, extracellular regulated kinase, mammalian target of rapamycin, and PKCzeta were also activated by TNF-alpha (as assessed by phospho-specific antibodies). Phosphorylation of IRS-1 at Ser(267) and Ser(612) correlated with the activation of these kinases. Phosphorylation of Akt and the mammalian target of rapamycin ( but not extracellular regulated kinase or PKCzeta) in response to TNF-alpha was inhibited by aspirin treatment. Finally, aspirin rescued insulin-induced glucose uptake in 3T3-L1 adipocytes pretreated with TNF-alpha. We conclude that aspirin may enhance insulin sensitivity by protecting IRS proteins from serine phosphorylation catalyzed by multiple kinases.	Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; NIH, Diabet Unit, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; University of Minnesota System	Ye, JP (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	yej@pbrc.edu	Quon, Michael/B-1970-2008; Ye, Jianping/N-1998-2017	Ye, Jianping/0000-0003-3875-365X; Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BAGBY GJ, 1992, AM J PHYSIOL, V262, pR628, DOI 10.1152/ajpregu.1992.262.4.R628; BARON SH, 1982, DIABETES CARE, V5, P64, DOI 10.2337/diacare.5.1.64; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen NY, 2002, CANCER RES, V62, P1300; Chen NY, 2001, CANCER RES, V61, P3908; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Ding M, 1999, CANCER RES, V59, P1884; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; GILGORE SG, 1960, DIABETES, V9, P392, DOI 10.2337/diab.9.5.392; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Long SD, 1996, BIOCHEM J, V319, P179, DOI 10.1042/bj3190179; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Ozes ON, 1999, NATURE, V401, P82; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; REID J, 1957, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5053.1071; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sekulic A, 2000, CANCER RES, V60, P3504; She QB, 2002, CANCER RES, V62, P1343; Shi XL, 1999, MOL CELL BIOCHEM, V199, P93, DOI 10.1023/A:1006934612368; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; White MF, 1998, CURR TOP MICROBIOL, V228, P179; White MF, 1996, PHILOS T ROY SOC B, V351, P181, DOI 10.1098/rstb.1996.0015; Williamson RT, 1901, BRIT MED J, V1901, P760, DOI 10.1136/bmj.1.2100.760; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002	67	201	224	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24944	24950		10.1074/jbc.M300423200	http://dx.doi.org/10.1074/jbc.M300423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714600	hybrid			2022-12-25	WOS:000183824800085
J	Chen, MY; Xie, K; Nouwen, N; Driessen, AJM; Dalbey, RE				Chen, MY; Xie, K; Nouwen, N; Driessen, AJM; Dalbey, RE			Conditional lethal mutations separate the M13 procoat and Pf3 coat functions of YidC - Different YidC structural requirements for membrane protein insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HOMOLOG; TRANSLOCATION; BACTERIA; RESIDUES; SECY	Conditional lethal YidC mutants have been isolated to decipher the role of YidC in the assembly of Sec-dependent and Sec-independent membrane proteins. We now show that the membrane insertion of the Sec-independent M13 procoat-lep protein is inhibited in a short time in a temperature-sensitive mutant when shifted to the nonpermissive temperature. This provides an additional line of evidence that YidC plays a direct role in the insertion of the Sec-independent M13 procoat protein. However, in the temperature-sensitive mutant, the insertion of the Sec-independent Pf3 phage coat protein and the Sec-dependent leader peptidase were not strongly inhibited at the restricted temperatures. Conversely, using a cold-sensitive YidC strain, we find that the membrane insertion of the Sec-independent Pf3 coat protein is blocked, and the Sec-dependent leader peptidase is inhibited at the nonpermissive temperature, whereas the insertion of the M13 procoat protein is nearly normal. These data show that the YidC function for procoat and its function for Pf3 coat and possibly leader peptidase are genetically separable and suggest that the YidC structural requirements are different for the Sec-independent M13 procoat and Pf3 coat phage proteins that insert by different mechanisms.	Ohio State Univ, Dept Chem, Columbus, OH 43210 USA; Ohio State Univ, Biochem Program, Columbus, OH 43210 USA; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Microbiol, NL-9751 NN Haren, Netherlands	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Groningen	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, 120 W 18th Ave, Columbus, OH 43210 USA.		Driessen, Arnold J.M./D-1876-2012	Driessen, Arnold J.M./0000-0001-9258-9104	NIGMS NIH HHS [GM63862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; Chen MY, 2002, BIOL CHEM, V383, P1565, DOI 10.1515/BC.2002.176; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Jiang FL, 2002, J BIOL CHEM, V277, P19281, DOI 10.1074/jbc.M110857200; KUHN A, 1986, EMBO J, V5, P3681, DOI 10.1002/j.1460-2075.1986.tb04699.x; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Miller J. H., 1972, EXPT MOL GENETICS, P431; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529	18	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23295	23300		10.1074/jbc.M301008200	http://dx.doi.org/10.1074/jbc.M301008200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707259	Green Published, hybrid			2022-12-25	WOS:000183638600012
J	Hunger-Glaser, I; Salazar, EP; Sinnett-Smith, J; Rozengurt, E				Hunger-Glaser, I; Salazar, EP; Sinnett-Smith, J; Rozengurt, E			Bombesin, lysophosphatidic acid, and epidermal growth factor rapidly stimulate focal adhesion kinase phosphorylation at Ser-910 - Requirement for ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAXILLIN TYROSINE PHOSPHORYLATION; STRESS FIBER FORMATION; SWISS 3T3 CELLS; ACTIN CYTOSKELETON; SIGNALING PATHWAYS; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; LOOP PHOSPHORYLATION; TERMINAL DOMAIN; FACTOR RECEPTOR	A rapid increase in the tyrosine phosphorylation of focal adhesion kinase (FAK) has been extensively documented in cells stimulated by multiple signaling molecules, but virtually nothing is known about the regulation of FAK phosphorylation at serine residues. Stimulation of Swiss 3T3 cells with bombesin promoted a striking increase (similar to13-fold) in the phosphorylation of FAK at Ser-910, as revealed by site-specific antibodies that recognized the phosphorylated state of this residue. Lysophosphatidic acid and epidermal growth factor (EGF) also stimulated FAK phosphorylation at Ser-910. Direct activation of protein kinase C isoforms with phorbol-12,13-dibutyrate (PDB) also promoted striking phosphorylation of FAK at Ser-910. Treatment with the protein kinase C inhibitor GF I or Ro 31-8220 or chronic exposure to PDB prevented the increase in FAK phosphorylation at Ser-910 induced by bombesin or PDB but not by EGF. Treatment with the ERK inhibitors U0126 and PD98059 prevented FAK phosphorylation at Ser-910 in response to all of the stimuli tested. Furthermore, incubation of activated ERK2 with FAK immunocomplexes leads to FAK phosphorylation at Ser-910 in vitro. Our results demonstrate, for the first time, that stimulation with bombesin, lysophosphatidic acid, PDB, or EGF induces phosphorylation of endogenous FAK at Ser-910 via an ERK-dependent pathway in Swiss 3T3 cells.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.				NCI NIH HHS [P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [DK 56930, DK 17294, DK 55003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, R01DK017294, R37DK017294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charlesworth A, 1996, ONCOGENE, V12, P1337; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hauck CR, 2001, CANCER RES, V61, P7079; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Leopoldt D, 2000, J CELL PHYSIOL, V183, P208, DOI 10.1002/(SICI)1097-4652(200005)183:2<208::AID-JCP7>3.0.CO;2-5; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Ma A, 2001, MOL BIOL CELL, V12, P1; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; ROZENGURT E, 1995, CANCER SURV, V24, P81; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Santiskulvong C, 2001, AM J PHYSIOL-CELL PH, V281, pC886, DOI 10.1152/ajpcell.2001.281.3.C886; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tsuda T, 1997, BIOCHEMISTRY-US, V36, P16328, DOI 10.1021/bi971448o; TURNER CE, 1994, J CELL SCI, V107, P1583; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	95	93	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22631	22643		10.1074/jbc.M210876200	http://dx.doi.org/10.1074/jbc.M210876200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12692126	hybrid			2022-12-25	WOS:000183503900062
J	Reuland, SN; Vlasov, AP; Krupenko, SA				Reuland, SN; Vlasov, AP; Krupenko, SA			Disruption of a calmodulin central helix-like region of 10-formyltetrahydrofolate dehydrogenase impairs its dehydrogenase activity by uncoupling the functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; TERMINAL DOMAIN; PURIFICATION; EXPRESSION	10-Formyltetrahydrofolate dehydrogenase (FDH) is composed of three domains and possesses three catalytic activities but has only two catalytic centers. The amino-terminal domain (residue 1-310) bears 10-formyltetrahydrofolate hydrolase activity, the carboxyl-terminal domain (residue 420-902) bears an aldehyde dehydrogenase activity, and the full-length FDH produces 10-formyltetrahydrofolate dehydrogenase activity. The intermediate linker (residues 311-419) connecting the two catalytic domains does not contribute directly to the enzyme catalytic centers but is crucial for 10-formyltetrahydrofolate dehydrogenase activity. We have identified a region within the intermediate domain ( residues 384-405) that shows sequence similarity to the central helix of calmodulin. Deletion of either the entire putative helix or the central part of the helix or replacement of the six residues within the central part with alanines resulted in total loss of the 10-formyltetrahydrofolate dehydrogenase activity, whereas the full hydrolase and aldehyde dehydrogenase activities were retained. Alanine-scanning mutagenesis revealed that neither of the six residues alone is required for FDH activity. Analysis of the predicted secondary structures and circular dichroic and fluorescence spectroscopy studies of the intermediate domain expressed as a separate protein showed that this region is likely to consist of two alpha-helices connected by a flexible loop. Our results suggest that flexibility within the putative helix is important for FDH function and could be a point for regulation of the enzyme.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	krupenko@musc.edu			NIDDK NIH HHS [DK54388] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054388] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; COOK RJ, 1991, J BIOL CHEM, V266, P4965; FINN BE, 1995, STRUCTURE, V3, P7, DOI 10.1016/S0969-2126(01)00130-7; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; IKURA M, 1991, BIOCHEMISTRY-US, V30, P9216, DOI 10.1021/bi00102a013; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kisliuk RL, 1999, CANC DRUG DISC DEV, P13; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupenko SA, 1997, J BIOL CHEM, V272, P10266; Krupenko SA, 1997, J BIOL CHEM, V272, P10273; Krupenko SA, 1998, PROTEIN EXPRES PURIF, V14, P146, DOI 10.1006/prep.1998.0937; KRUPENKO SA, 1995, BIOCHEM J, V306, P651, DOI 10.1042/bj3060651; KRUPENKO SA, 1995, PROTEIN EXPRES PURIF, V6, P457, DOI 10.1006/prep.1995.1061; KUTZBACH C, 1971, METHODS ENZYMOL B, V18, P793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; Nelson MR, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P17; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; RAO ST, 1993, PROTEIN SCI, V2, P436; RIOSORLANDI EM, 1986, BIOCHIM BIOPHYS ACTA, V871, P24, DOI 10.1016/0167-4838(86)90129-9; SCHIRCH D, 1994, J BIOL CHEM, V269, P24728; SCRUTTON MC, 1979, BIOCHEM J, V177, P833, DOI 10.1042/bj1770833; SMITH GK, 1981, BIOCHEMISTRY-US, V20, P1241, DOI 10.1021/bi00508a029; Tabernero L, 1997, STRUCTURE, V5, P613, DOI 10.1016/S0969-2126(97)00217-7; UDENFRIEND S, 1969, FLUORESCENCE ASSAY B, P261; VANDONSELAAR M, 1994, NAT STRUCT BIOL, V1, P795, DOI 10.1038/nsb1194-795; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Xiao C, 1999, DNA Res, V6, P179, DOI 10.1093/dnares/6.3.179; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	36	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22894	22900		10.1074/jbc.M302948200	http://dx.doi.org/10.1074/jbc.M302948200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684508	hybrid			2022-12-25	WOS:000183503900095
J	Asanuma, K; Tanida, I; Shirato, I; Ueno, T; Takahara, H; Nishitani, T; Kominami, E; Tomino, Y				Asanuma, K; Tanida, I; Shirato, I; Ueno, T; Takahara, H; Nishitani, T; Kominami, E; Tomino, Y			MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis	FASEB JOURNAL			English	Article						processing; puromycin	PUROMYCIN AMINONUCLEOSIDE; GLOMERULOSCLEROSIS; DISSECTION; APOPTOSIS; PROTEINS; HOMOLOG; KIDNEY; INJURY; ENZYME	Microtubule-associated protein 1 light chain 3 (LC3) is a unique modifier protein. LC3-I, the cytosolic form, is modified to LC3-II, the membrane-bound form, by a mechanism similar to ubiquitylation by E1- and E2-like enzymes, Apg7p and Apg3p, respectively. In the present study, we found that LC3-I is processed to LC3-II during the differentiation and recovery from puromycin aminonucleoside-induced nephrosis of podocytes. LC3 is especially expressed in the podocytes of rat kidney as the membrane-bound form LC3-II. Biochemical analysis using a conditionally immortalized mouse podocyte clone (MPC) revealed that LC3-I is processed to LC3-II during the differentiation of cells into mature podocytes and accumulates in the membrane-rich fraction of the cell lysate. LC3-II-localized vesicles, which differ from lysosomes and endosomes, in differentiated MPC cells are morphologically similar to autophagic vacuoles during starvation-induced autophagy. During starvation-induced autophagy, autophagosomes fuses with lysosome and LC3-II on autophagosomes is finally degraded by lysosomal proteases. However, in differentiated MPC cells, little LC3-II on the vesicles is degraded by lysosomal proteases, suggesting that little LC3-II-localized vesicles in differentiated MPC cells fuse with lysosome. Furthermore, the LC3-II level in differentiated MPC cells increases with recovery from damage caused by experimental puromycin aminonucleoside-induced nephrosis. These results suggest that LC3-II-localized vesicles play an important role in the physiological function of podocytes.	Juntendo Univ, Sch Med, Dept Internal Med, Div Nephrol,Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Biochem, Tokyo 113, Japan	Juntendo University; Juntendo University	Tomino, Y (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Nephrol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	yasu@med.juntendo.ac.jp	Tanida, Isei/C-8277-2009; Kominami, Eiki/D-3802-2009	Tanida, Isei/0000-0001-8999-3990				AKASAKI K, 1991, J BIOCHEM-TOKYO, V110, P922, DOI 10.1093/oxfordjournals.jbchem.a123690; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603; BERKENSTAM A, 1983, VIRCHOWS ARCH B, V44, P275, DOI 10.1007/BF02890177; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CAULFIELD JP, 1976, LAB INVEST, V34, P43; COERS W, 1994, EXP NEPHROL, V2, P40; FRIES JWU, 1989, LAB INVEST, V60, P205; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; JOHNSON RJ, 1994, KIDNEY INT, V45, P352, DOI 10.1038/ki.1994.45; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KIHARA I, 1995, PATHOL INT, V45, P625, DOI 10.1111/j.1440-1827.1995.tb03514.x; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDEL P, 1995, ANAT EMBRYOL, V192, P387; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; NOVIKOFF PM, 1985, J CELL BIOL, V101, P339, DOI 10.1083/jcb.101.2.339; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Shirato I, 2000, J AM SOC NEPHROL, V11, P2381, DOI 10.1681/ASN.V11122381; Smoyer WE, 1998, J MOL MED, V76, P172, DOI 10.1007/s001090050206; Striker G E, 1987, Adv Nephrol Necker Hosp, V16, P169; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; TANIDA I, 2002, IN PRESS J BIOL CHEM; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueno T, 1999, J BIOL CHEM, V274, P15222, DOI 10.1074/jbc.274.21.15222	35	169	195	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1165	+		10.1096/fj.02-0580fje	http://dx.doi.org/10.1096/fj.02-0580fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709412				2022-12-25	WOS:000182580100030
J	Chung, HK; Yi, YW; Jung, NC; Kim, D; Suh, JM; Kim, H; Park, KC; Song, JH; Kim, DW; Hwang, ES; Yoon, SH; Bae, YS; Kim, JM; Bae, I; Shong, MH				Chung, HK; Yi, YW; Jung, NC; Kim, D; Suh, JM; Kim, H; Park, KC; Song, JH; Kim, DW; Hwang, ES; Yoon, SH; Bae, YS; Kim, JM; Bae, I; Shong, MH			CR6-interacting factor 1 interacts with Gadd45 family proteins and modulates the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE GROWTH-CONTROL; NUCLEAR ANTIGEN; DNA-DAMAGE; MYD118; PCNA; CHECKPOINT; INDUCTION; IDENTIFICATION; INHIBITION; SEQUENCE	The Gadd45 family of proteins includes Gadd45alpha, MyD118/Gadd45beta, and CR6/OIG37/Gadd45gamma. These proteins play important roles in maintaining genomic stability and in regulating the cell cycle. This study reports the cloning of a novel protein called CR6-interacting factor 1 (CRIF1) which interacts with Gadd45alpha, MyD118/Gadd45beta, and CR6/OIG37/Gadd45gamma. CRIF1 binds specifically to the Gadd45 family proteins, as determined by an in vitro glutathione S-transferase pull-down assay and an in vivo mammalian cell two-hybrid assay along with coimmunoprecipitation assays. CRIF1 mRNA is highly expressed in the thyroid gland, heart, lymph nodes, trachea, and adrenal tissues. CRIF1 localizes exclusively to the nucleus and colocalizes with Gadd45gamma. Recombinant CRIF1 inhibits the histone H1 kinase activity of immunoprecipitated Cdc2-cyclin B1 and Cdk2-cyclin E, and the inhibitory effects were additive with Gadd45 proteins. Overexpression of CRIF1 increases the percentage of cells in G(1), decreases the percentage of cells in S phase, and suppresses growth in NIH3T3 cells. The downregulation of endogenous CRIF1 by the transfection of the small interfering RNA duplexes resulted in the inactivation of Rb by phosphorylation and decreased the G(1) phase cell populations. Expression of CRIF1 is barely detectable in adrenal adenoma and papillary thyroid cancer and much lower than in adjacent normal tissue. The results presented here suggest that CRIF1 is a novel nuclear protein that interacts with Gadd45 and may play a role in negative regulation of cell cycle progression and cell growth.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Chungnam Natl Univ, Sch Med, Dept Pathol, Taejon 301721, South Korea; Chungnam Natl Univ, Sch Med, Dept Internal Med, Natl Res Lab Program,Lab Endocrine Cell Biol, Taejon 301721, South Korea; Samyang Genex Biotech Res Inst, Therapeut Gene Grp, Team 1, Taejon, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Biochem, Taegu 702701, South Korea	Northwell Health; Yeshiva University; Chungnam National University; Chungnam National University; Kyungpook National University	Bae, YS (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, 270-05 76th Ave,Long Isl Campus, New Hyde Pk, NY 11040 USA.		Yi, Yong Weon/AAR-1319-2020; /H-7803-2012	Yi, Yong Weon/0000-0001-6895-0465; KIM, JIN MAN/0000-0003-0905-9730; shong, minho/0000-0002-0247-7115				ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; CHEN IT, 1995, ONCOGENE, V11, P1931; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALL PA, 1995, ONCOGENE, V10, P2427; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Nakayama K, 1999, J BIOL CHEM, V274, P24766, DOI 10.1074/jbc.274.35.24766; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Sherr CJ, 2000, CANCER RES, V60, P3689; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200; Yi YW, 2000, BIOCHEM BIOPH RES CO, V272, P193; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	36	71	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28079	28088		10.1074/jbc.M212835200	http://dx.doi.org/10.1074/jbc.M212835200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12716909	hybrid			2022-12-25	WOS:000184242700094
J	Hays, JL; Watowich, SJ				Hays, JL; Watowich, SJ			Oligomerization-induced modulation of TPR-MET tyrosine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; RECEPTOR; ACTIVATION; AUTOPHOSPHORYLATION; SUSCEPTIBILITY; INHIBITORS; MECHANISM; COMPLEX; BINDING; DOMAIN	Phosphorylation, although necessary, may not be sufficient to fully activate many receptor tyrosine kinases (RTKs). Oligomerization-induced conformational changes may be necessary to modulate the kinetic properties of RTKs and render them fully functional. To investigate this regulatory mechanism, recombinant TPR-MET, a functionally active oncoprotein derivative of the RTK c-MET, has been expressed and purified for quantitative enzymatic analysis. This naturally occurring oncoprotein contains the cytoplasmic domain of c-MET fused to a coiled coil motif from the nuclear pore complex (TPR). cytoMET, the monomeric analog of TPR-MET, has also been expressed and purified for comparative enzymatic analysis. ATP and peptide substrates have been kinetically characterized for both TPR-MET and cytoMET. Significantly, phosphorylated TPR-MET has smaller Km values for ATP ( K-m,K-ATP) and peptide substrates (K-m,K-peptide) and a larger k(cat) relative to phosphorylated cytoMET. This provides the first direct evidence that receptor oligomerization and not simply activation loop phosphorylation modulates RTK enzymatic activity. The ATP dissociation constants (K-d,K-ATP) for the two enzymes also displayed significant differences. In contrast, the K-I values for the ATP competitive inhibitor staurosporin are similar for the two phosphorylated enzymes. These results suggest that much of the oligomerization-induced kinetic changes occur with respect to peptide substrate binding or catalytic efficiency. The possibility that oligomerization-induced conformational changes occur within the cytoplasmic domain of receptor tyrosine kinases has significant implications for structure-based design of RTK inhibitors and the development of a detailed mechanistic model of RTK activation.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Watowich, SJ (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	watowich@bloch.utmb.edu	Hays, John/H-3968-2012		NLM NIH HHS [2T15LM07093] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [T15LM007093] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Bangs PL, 1996, J CELL BIOCHEM, V61, P48, DOI 10.1002/(SICI)1097-4644(19960401)61:1<48::AID-JCB7>3.0.CO;2-2; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Cheng KR, 1996, J BIOL CHEM, V271, P311, DOI 10.1074/jbc.271.1.311; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5766, DOI 10.1021/bi00073a007; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Murray BW, 2001, BIOCHEMISTRY-US, V40, P10243, DOI 10.1021/bi010959e; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Parast CV, 1998, BIOCHEMISTRY-US, V37, P16788, DOI 10.1021/bi981291f; POSNER BI, 1994, J BIOL CHEM, V269, P4596; POSNER I, 1992, J BIOL CHEM, V267, P20638; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Sherrill JM, 1997, BIOCHEMISTRY-US, V36, P5677, DOI 10.1021/bi962447j; Shimizu A, 2001, J BIOL CHEM, V276, P27749, DOI 10.1074/jbc.C100286200; Traxler P, 1999, PHARMACOL THERAPEUT, V82, P195, DOI 10.1016/S0163-7258(98)00044-8; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	28	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27456	27463		10.1074/jbc.M210648200	http://dx.doi.org/10.1074/jbc.M210648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12711601	hybrid			2022-12-25	WOS:000184242700017
J	Xu, W; Chitnis, PR; Valieva, A; van der Est, A; Brettel, K; Guergova-Kuras, M; Pushkar, YN; Zech, SG; Stehlik, D; Shen, GZ; Zybailov, B; Golbeck, JH				Xu, W; Chitnis, PR; Valieva, A; van der Est, A; Brettel, K; Guergova-Kuras, M; Pushkar, YN; Zech, SG; Stehlik, D; Shen, GZ; Zybailov, B; Golbeck, JH			Electron transfer in cyanobacterial photosystem I - II. Determination of forward electron transfer rates of site-directed mutants in a putative electron transfer pathway from A(0) through A(1) to F-x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL REACTION CENTERS; CORRELATED RADICAL PAIRS; IRON-SULFUR CENTERS; SPIN POLARIZATION; TRANSIENT EPR; 3-DIMENSIONAL STRUCTURE; TEMPERATURE-DEPENDENCE; QUANTUM BEATS; VIVO ANALYSIS; ACCEPTOR	The directionality of electron transfer in Photosystem I (PS I) is investigated using site-directed mutations in the phylloquinone (Q(K)) and F-X binding regions of Synnechocystis sp. PCC 6803. The kinetics of forward electron transfer from the secondary acceptor A(1) (phylloquinone) were measured in mutants using time-resolved optical difference spectroscopy and transient EPR spectroscopy. In whole cells and PS I complexes of the wild-type both techniques reveal a major, slow kinetic component of tau approximate to 300 ns while optical data resolve an additional minor kinetic component of tau approximate to 10 ns. Whole cells and PS I complexes from the W697F(PsaA) and S692C(PsaA) mutants show a significant slowing of the slow kinetic component, whereas the W677F(PsaB) and S672C(PsaB) mutants show a less significant slowing of the fast kinetic component. Transient EPR measurements at 260 K show that the slow phase is similar to3 times slower than at room temperature. Simulations of the early time behavior of the spin polarization pattern of P-700 (+)A(1)(-), in which the decay rate of the pattern is assumed to be negligibly small, reproduce the observed EPR spectra at 260 K during the first 100 ns following laser excitation. Thus any spin polarization from P-700 F-+(X)- in this time window is very weak. From this it is concluded that the relative amplitude of the fast phase is negligible at 260 K or its rate is much less temperature-dependent than that of the slow component. Together, the results demonstrate that the slow kinetic phase results from electron transfer from Q(K)-A to F-X and that this accounts for at least 70% of the electrons. Although the assignment of the fast kinetic phase remains uncertain, it is not strongly temperature dependent and it represents a minor fraction of the electrons being transferred. All of the results point toward asymmetry in electron transfer, and indicate that forward transfer in cyanobacterial PS I is predominantly along the PsaA branch.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA, Serv Bioenerget, F-91191 Gif Sur Yvette, France; Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Iowa State University; Brock University; CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Free University of Berlin	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	JHG5@psu.edu	Valieva, Alfia I./ABE-8092-2021	Valieva, Alfia I./0000-0003-2988-6098; Zybailov, Boris/0000-0003-2432-9145; Xu, Wu/0000-0002-2982-3276				Agalarov R, 2003, BBA-BIOENERGETICS, V1604, P7, DOI 10.1016/S0005-2728(03)00024-0; Antonkine ML, 2003, J MOL BIOL, V327, P671, DOI 10.1016/S0022-2836(03)00145-1; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; BIGGINS J, 1988, BIOCHEMISTRY-US, V27, P1494, DOI 10.1021/bi00405a015; BITTL R, 1994, CHEM PHYS LETT, V226, P349, DOI 10.1016/0009-2614(94)00690-3; BOCK CH, 1989, FEBS LETT, V247, P91, DOI 10.1016/0014-5793(89)81247-5; Boudreaux B, 2001, J BIOL CHEM, V276, P37299, DOI 10.1074/jbc.M102327200; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; BRETTEL K, 1986, FEBS LETT, V203, P220, DOI 10.1016/0014-5793(86)80746-3; Brettel K, 2001, BBA-BIOENERGETICS, V1507, P100, DOI 10.1016/S0005-2728(01)00202-X; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; Brettel K, 1998, BBA-BIOENERGETICS, V1363, P175, DOI 10.1016/S0005-2728(98)00010-3; Fromme P, 2001, BBA-BIOENERGETICS, V1507, P5, DOI 10.1016/S0005-2728(01)00195-5; Graige MS, 1998, P NATL ACAD SCI USA, V95, P11679, DOI 10.1073/pnas.95.20.11679; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kandrashkin YE, 1998, APPL MAGN RESON, V15, P417, DOI 10.1007/BF03162027; Kandrashkin YE, 2002, MOL PHYS, V100, P1431, DOI 10.1080/00268970110118240; KANDRASHKIN YE, 2002, RIKEN REV, V44, P124; KOTHE G, 1991, CHEM PHYS LETT, V186, P474, DOI 10.1016/0009-2614(91)90454-H; KRAUSS N, 1993, NATURE, V361, P326, DOI 10.1038/361326a0; MALKIN R, 1986, FEBS LETT, V208, P343, DOI 10.1016/0014-5793(86)81046-8; MATHIS P, 1988, FEBS LETT, V237, P65, DOI 10.1016/0014-5793(88)80173-X; Purton S, 2001, BIOCHEMISTRY-US, V40, P2167, DOI 10.1021/bi0019489; Rigby SEJ, 2001, BBA-BIOENERGETICS, V1507, P247, DOI 10.1016/S0005-2728(01)00211-0; Salikhov KM, 1990, APPL MAGN RESON, V1, P195, DOI 10.1007/BF03166155; Salikhov KM, 2002, MOL PHYS, V100, P1311, DOI 10.1080/00268970110112336; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; van der Est A, 2001, BBA-BIOENERGETICS, V1507, P212, DOI 10.1016/S0005-2728(01)00204-3; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; WEBER S, 1995, P NATL ACAD SCI USA, V92, P7789, DOI 10.1073/pnas.92.17.7789; Xu W, 2003, J BIOL CHEM, V278, P27864, DOI 10.1074/jbc.M302962200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i	35	90	99	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27876	27887		10.1074/jbc.M302965200	http://dx.doi.org/10.1074/jbc.M302965200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12721306	Green Submitted, hybrid			2022-12-25	WOS:000184242700069
J	Chen, CY; Chiu, WC; Liu, JS; Hsu, WH; Wang, WC				Chen, CY; Chiu, WC; Liu, JS; Hsu, WH; Wang, WC			Structural basis for catalysis and substrate specificity of Agrobacterium radiobacter N-carbamoyl-D-amino acid amidohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; MICROBIAL TRANSFORMATION; PROTEIN STRUCTURES; REFINEMENT; PURIFICATION; HYDANTOINS; PROGRAM; CLONING; REVEALS	N-Carbamoyl-D-amino acid amidohydrolase is an industrial biocatalyst to hydrolyze N-carbamoyl-D-amino acids for producing valuable D-amino acids. The crystal structure of N-carbamoyl-D-amino acid amidohydrolase in the unliganded form exhibits a alpha-beta-beta-alpha fold. To investigate the roles of Cys(172), Asn(173), Arg(175), and Arg(176) in catalysis, C172A, C172S, N173A, R175A, R176A, R175K, and R176K mutants were constructed and expressed, respectively. All mutants showed similar CD spectra and had hardly any detectable activity except for R173A that retained 5% of relative activity. N173A had a decreased value in k(cat) or K-m, whereas R175K or R176K showed high Km and very low kcat values. Crystal structures of C172A and C172S in its free form and in complex form with a substrate, along with N173A and R175A, have been determined. Analysis of these structures shows that the overall structure maintains its four-layer architecture and that there is limited conformational change within the binding pocket except for R175A. In the substrate-bound structure, side chains of Glu(47), Lys(127), and C172S cluster together toward the carbamoyl moiety of the substrate, and those of Asn(173), Arg(175), and Arg(176) interact with the carboxyl group. These results collectively suggest that a Cys(172)-Glu(47)-Lys(127) catalytic triad is involved in the hydrolysis of the carbamoyl moiety and that Arg(175) and Arg(176) are crucial in binding to the carboxyl moiety, hence demonstrating substrate specificity. The common (Glu/Asp)-Lys-Cys triad observed among N-carbamoyl-D-amino acid amidohydrolase, Nit-Fhit, and another carbamoylase suggests a conserved and robust platform during evolution, enabling it to catalyze the reactions toward a specific nitrile or amide efficiently.	Natl Chung Hsing Univ, Inst Mol Biol, Taichung 402, Taiwan; Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 30013, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30013, Taiwan	National Chung Hsing University; National Tsing Hua University; National Tsing Hua University	Hsu, WH (corresponding author), Natl Chung Hsing Univ, Inst Mol Biol, Taichung 402, Taiwan.		Wang, Wen-Ching/ABI-2253-2020	Wang, Wen-Ching/0000-0002-7422-3667				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GORDON SA, 1978, ANN CLIN BIOCHEM, V15, P270, DOI 10.1177/000456327801500164; Grifantini R, 1996, J BIOL CHEM, V271, P9326, DOI 10.1074/jbc.271.16.9326; Hsu WH, 1999, ACTA CRYSTALLOGR D, V55, P694, DOI 10.1107/S090744499801525X; Ikenaka Y, 1998, BIOSCI BIOTECH BIOCH, V62, P882, DOI 10.1271/bbb.62.882; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOLLER A, 1988, ENZYME MICROB TECH, V10, P618, DOI 10.1016/0141-0229(88)90109-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X; Nanba H, 1998, BIOSCI BIOTECH BIOCH, V62, P875, DOI 10.1271/bbb.62.875; OGAWA J, 1993, EUR J BIOCHEM, V212, P685, DOI 10.1111/j.1432-1033.1993.tb17706.x; OGAWA J, 1994, J BIOTECHNOL, V38, P11, DOI 10.1016/0168-1656(94)90143-0; OLIVIERI R, 1981, BIOTECHNOL BIOENG, V23, P2173, DOI 10.1002/bit.260231002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; PACE HC, 2001, GENOME BIOL; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROMAO MJ, 1992, J MOL BIOL, V226, P1111, DOI 10.1016/0022-2836(92)91056-U; RUNSER S, 1990, APPL MICROBIOL BIOT, V33, P382; SYLDATK C, 1990, ADV BIOCHEM ENG BIOT, V41, P30; TAKAHASHI S, 1979, J FERMENT TECHNOL, V57, P328; Wang WC, 2001, J MOL BIOL, V306, P251, DOI 10.1006/jmbi.2000.4380; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	30	27	29	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26194	26201		10.1074/jbc.M302384200	http://dx.doi.org/10.1074/jbc.M302384200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12709423	hybrid			2022-12-25	WOS:000183920200118
J	Gu, J; Weng, Y; Zhang, QY; Cui, HD; Behr, M; Wu, L; Yang, WZ; Zhang, L; Ding, XX				Gu, J; Weng, Y; Zhang, QY; Cui, HD; Behr, M; Wu, L; Yang, WZ; Zhang, L; Ding, XX			Liver-specific deletion of the NADPH-cytochrome P450 reductase gene - Impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN RECEPTOR CAR; METABOLIC-ACTIVATION; P450 OXIDOREDUCTASE; PHYSIOLOGICAL-ROLE; P-450 REDUCTASE; MULTIPLE FORMS; MOUSE-LIVER; AH RECEPTOR; EXPRESSION; SYSTEM	A mouse model with liver-specific deletion of the NADPH-cytochrome P450 reductase (Cpr) gene (designated Alb-Cre/Cpr(lox) mice) was generated and characterized in this study. Hepatic microsomal CPR expression was significantly reduced at 3 weeks and was barely detectable at 2 months of age in the Alb-Cre(+/-)/Cpr(lox+/+) (homozygous) mice, with corresponding decreases in liver microsomal cytochrome P450 (CYP) and heme oxygenase (HO) activities, in pentobarbital clearance, and in total plasma cholesterol level. Nevertheless, the homozygous mice are fertile and are normal in gross appearance and growth rate. However, at 2 months, although not at 3 weeks, the homozygotes had significant increases in liver weight, accompanied by hepatic lipidosis and other pathologic changes. Intriguingly, total microsomal CYP content was increased in the homozygotes about 2-fold at 3 weeks and about 3-fold at 2 months of age; at 2 months, there were varying degrees of induction in protein (1-5-fold) and mRNA expression (0-67-fold) for all CYPs examined. There was also an induction of HO-1 protein (nearly 9-fold) but no induction of HO-2. These data indicate the absence of significant alternative redox partners for liver microsomal CYP and HO, provide in vivo evidence for the significance of hepatic CPR-dependent enzymes in cholesterol homeostasis and systemic drug clearance, and reveal novel regulatory pathways of CYP expression associated with altered cellular homeostasis. The Alb-Cre/Cpr(lox) mouse represents a unique model for studying the in vivo function of hepatic HO and microsomal CYP-dependent pathways in the biotransformation of endogenous and xenobiotic compounds.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Ding, XX (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Empire State Plaza,Box 509, Albany, NY 12201 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007462] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07462] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; AIDA K, 1991, BIOCHEMISTRY-US, V30, P8041, DOI 10.1021/bi00246a023; Anandatheerthavarada HK, 1999, J BIOL CHEM, V274, P6617, DOI 10.1074/jbc.274.10.6617; Bhagwat SV, 2000, BIOCHEM PHARMACOL, V59, P573, DOI 10.1016/S0006-2952(99)00362-7; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chemin I, 1996, HEPATOLOGY, V24, P649, DOI 10.1002/hep.510240330; Dalton TP, 2000, BIOCHEM BIOPH RES CO, V267, P184, DOI 10.1006/bbrc.1999.1913; DING XX, 1990, MOL PHARMACOL, V37, P489; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Gonzalez FJ, 2001, MUTAT RES-FUND MOL M, V477, P79, DOI 10.1016/S0027-5107(01)00109-9; Gu J, 1998, J PHARMACOL EXP THER, V285, P1287; Henderson CJ, 2003, J BIOL CHEM, V278, P13480, DOI 10.1074/jbc.M212087200; Hodgson E, 1995, TOXICOL LETT, V82-3, P73, DOI 10.1016/0378-4274(95)03469-2; ILAN Z, 1981, J BIOL CHEM, V256, P66; Jover R, 2000, EUR J BIOCHEM, V267, P7128, DOI 10.1046/j.1432-1327.2000.01815.x; Kawamoto T, 2000, MOL ENDOCRINOL, V14, P1897, DOI 10.1210/me.14.11.1897; Kocarek TA, 2002, MOL PHARMACOL, V62, P1177, DOI 10.1124/mol.62.5.1177; Lamb DC, 1999, FEBS LETT, V462, P283, DOI 10.1016/S0014-5793(99)01548-3; Lewis DFV, 2002, J CHEM TECHNOL BIOT, V77, P1095, DOI 10.1002/jctb.648; Maines MD, 1996, METHOD ENZYMOL, V268, P473; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Maines MD, 2000, CELL MOL BIOL, V46, P573; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; O'Leary KA, 2000, ARCH BIOCHEM BIOPHYS, V379, P97, DOI 10.1006/abbi.2000.1862; OMURA T, 1964, J BIOL CHEM, V239, P2370; ONO T, 1975, J BIOL CHEM, V250, P1571; Pluck A, 1996, INT J EXP PATHOL, V77, P269; POMPON D, 1984, J BIOL CHEM, V259, P5377; Porter TD, 2002, J BIOCHEM MOL TOXIC, V16, P311, DOI 10.1002/jbt.10052; PORTER TD, 1991, J BIOL CHEM, V266, P13469; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Raffalli-Mathieu F, 2002, MOL PHARMACOL, V61, P795, DOI 10.1124/mol.61.4.795; ROBERTS BJ, 1995, J BIOL CHEM, V270, P29632; Robin MA, 2001, J BIOL CHEM, V276, P24680, DOI 10.1074/jbc.M100363200; SALONPAA P, 1995, N-S ARCH PHARMACOL, V351, P446; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Schwarz M, 1998, J LIPID RES, V39, P1833; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Strobel Henry W., 1995, P225; Stromstedt M, 1996, ARCH BIOCHEM BIOPHYS, V329, P73, DOI 10.1006/abbi.1996.0193; Su T, 2000, CANCER RES, V60, P5074; Su T, 1996, DRUG METAB DISPOS, V24, P884; TRUAN G, 1994, GENE, V142, P123, DOI 10.1016/0378-1119(94)90366-2; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VERMILION JL, 1978, J BIOL CHEM, V253, P2694	51	166	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25895	25901		10.1074/jbc.M303125200	http://dx.doi.org/10.1074/jbc.M303125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12697746	hybrid			2022-12-25	WOS:000183920200080
J	Vivo, C; Liu, WH; Broaddus, VC				Vivo, C; Liu, WH; Broaddus, VC			c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; STRESS-INDUCED APOPTOSIS; NH2-TERMINAL KINASE; MEDIATED APOPTOSIS; CANCER-CELLS; PROSTATE CARCINOMA; JNK ACTIVATION; KAPPA-B; PROLIFERATION; EXPRESSION	Apoptotic resistance of cancer cells may be overcome by the combination of treatments that activate the two major apoptotic pathways: (i) the death receptor pathway activated by death ligands and (ii) the DNA damage pathway activated by chemotherapy. We have previously shown that mesothelioma cells, resistant to most treatments, are sensitive to the combination of the death ligand tumor necrosis factor-related apoptosis inducing ligand (TRAIL/Apo2L) plus chemotherapy. We investigated a possible role for c-Jun N-terminal kinase (JNK) in the synergistic effect, knowing that JNK can be activated separately by TRAIL and by DNA damage. We chose to study the M28 and REN human mesothelioma cell lines, which are p53-inactivated, to avoid an interaction between p53 and JNK. We showed that JNK was activated by TRAIL and by etoposide and that the activation was enhanced by the combination of the two treatments. We found this activation to be caspase-independent. To inhibit the JNK pathway, we used either dominant-negative constructs of JNK1 and JNK2 ( compared with dominant-negative caspase 9) or a chemical inhibitor of the JNK pathway (SP600125). In cells treated with TRAIL plus etoposide, JNK inhibition increased cell survival and decreased apoptosis significantly. In transfected M28 cells, the effect of JNK inhibition was as great as that of the dominant-negative caspase 9 construct. We conclude that JNK contributes to the synergistic effect of TRAIL combined with DNA damage by mediating signals independent of p53 leading to apoptosis.	Univ Calif San Francisco, San Francisco Gen Hosp, Lung Biol Ctr, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Broaddus, VC (corresponding author), Univ Calif San Francisco, Lung Biol Ctr, Box 0854, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA095671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008985] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95671] Funding Source: Medline; NIEHS NIH HHS [R01 ES08985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bonavida B, 1999, INT J ONCOL, V15, P793; BOYLAN AM, 1995, J CLIN INVEST, V96, P1987, DOI 10.1172/JCI118246; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Costa-Pereira AP, 2000, BRIT J CANCER, V82, P1827, DOI 10.1054/bjoc.2000.1149; Curtin JF, 2002, BRIT J CANCER, V87, P1188, DOI 10.1038/sj.bjc.6600612; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Herr I, 1999, INT J CANCER, V80, P417, DOI 10.1002/(SICI)1097-0215(19990129)80:3<417::AID-IJC14>3.3.CO;2-2; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hu WH, 1999, J BIOL CHEM, V274, P30603, DOI 10.1074/jbc.274.43.30603; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jarvis WD, 1999, J PHARMACOL EXP THER, V290, P1384; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Levings MK, 1999, BLOOD, V93, P3694, DOI 10.1182/blood.V93.11.3694.411a33_3694_3702; Levresse V, 2002, MOL PHARMACOL, V62, P689, DOI 10.1124/mol.62.3.689; Liu WH, 2001, AM J RESP CELL MOL, V25, P111, DOI 10.1165/ajrcmb.25.1.4472; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mor O, 1997, AM J RESP CELL MOL, V16, P9, DOI 10.1165/ajrcmb.16.1.8998073; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Narasimhan SR, 1998, AM J PHYSIOL-LUNG C, V275, pL165, DOI 10.1152/ajplung.1998.275.1.L165; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 2002, J MOL MED-JMM, V80, P137, DOI 10.1007/s00109-001-0293-3; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walsh PT, 2002, IMMUNOLOGY, V107, P461, DOI 10.1046/j.1365-2567.2002.01525.x; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Yang CT, 2001, CANCER RES, V61, P5959; Yang YM, 2003, CLIN CANCER RES, V9, P391	53	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25461	25467		10.1074/jbc.M302161200	http://dx.doi.org/10.1074/jbc.M302161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12707267	hybrid			2022-12-25	WOS:000183920200026
J	Ciccia, A; Constantinou, A; West, SC				Ciccia, A; Constantinou, A; West, SC			Identification and characterization of the human Mus81-Eme1 endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLLIDAY JUNCTION RESOLUTION; NUCLEOTIDE EXCISION-REPAIR; WERNERS-SYNDROME GENES; SGS1 DNA HELICASE; SACCHAROMYCES-CEREVISIAE; REPLICATION FORKS; PROTEIN COMPLEXES; ESCHERICHIA-COLI; BRANCH MIGRATION; RECQ HELICASES	The faithful and complete replication of DNA is necessary for the maintenance of genome stability. It is known, however, that replication forks stall at lesions in the DNA template and need to be processed so that replication restart can occur. In fission yeast, the Mus81-Eme1 endonuclease complex (Mus81-Mms4 in Saccharomyces cerevisiae) has been implicated in the processing of aberrant replication intermediates. In this report, we identify the human homolog of the Schizosaccharomyces pombe EME1 gene and have purified the human Mus81-Eme1 heterodimer. We show that Mus81-Eme1 is an endonuclease that exhibits a high specificity for synthetic replication fork structures and 3'-flaps in vitro. The nuclease cleaves Holliday junctions inefficiently (similar to75-fold less than flap or fork structures), although cleavage can be increased 6-fold by the presence of homologous sequences previously shown to permit base pair "breathing." We conclude that human Mus81-Eme1 is a flap/fork endonuclease that is likely to play a role in the processing of stalled replication fork intermediates.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk	Constantinou, Angelos/E-5337-2013	West, Stephen/0000-0001-8848-9418; Constantinou, Angelos/0000-0002-2994-8140				BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BENSON FE, 1994, J BIOL CHEM, V269, P5195; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; Cobb JA, 2002, FEBS LETT, V529, P43, DOI 10.1016/S0014-5793(02)03269-6; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; de Laat WL, 1998, NUCLEIC ACIDS RES, V26, P4146, DOI 10.1093/nar/26.18.4146; de Laat WL, 1998, J BIOL CHEM, V273, P7835, DOI 10.1074/jbc.273.14.7835; de los Santos T, 2001, GENETICS, V159, P1511; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Fabre F, 2002, P NATL ACAD SCI USA, V99, P16887, DOI 10.1073/pnas.252652399; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; Mullen JR, 2001, GENETICS, V157, P103; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Postow L, 2001, J BIOL CHEM, V276, P2790, DOI 10.1074/jbc.M006736200; Rothstein R, 2000, GENE DEV, V14, P1; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; SUNG P, 1993, J BIOL CHEM, V268, P26391; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Watt PM, 1996, GENETICS, V144, P935; WEST SC, 1995, NATURE, V373, P27, DOI 10.1038/373027a0; Whitby MC, 2003, J BIOL CHEM, V278, P6928, DOI 10.1074/jbc.M210006200; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465	37	164	167	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25172	25178		10.1074/jbc.M302882200	http://dx.doi.org/10.1074/jbc.M302882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721304	hybrid			2022-12-25	WOS:000183824800112
J	Daltrop, O; Smith, KM; Ferguson, SJ				Daltrop, O; Smith, KM; Ferguson, SJ			Stereoselective in vitro formation of c-type cytochrome variants from Hydrogenobacter thermophilus containing only a single thioether bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME; H-1-NMR; BIOGENESIS; DYNAMICS; FORMS	In vitro formation of Hydrogenobacter thermophilus cytochrome c(552) has previously been demonstrated (Daltrop, O., Allen, J. W. A., Willis, A. C., and Ferguson, S. J. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7872-7876). Now we report that the single cysteine variants of H. thermophilus c552, which bind heme via a single thioether bond, also form in vitro. Furthermore, reaction of the apocytochromes containing either AXXCH or CXXAH in the binding motif with 2-vinyldeuteroheme and 4-vinyldeuteroheme resulted predominantly in covalent attachment between Cys-11 and the 2-vinyl moiety and Cys-14 and the 4-vinyl functionality. This observation shows that the covalent attachment of heme to apocytochrome is stereoselective, indicating that the initial non-covalent complexes between apoprotein and heme have to be in the correct stereochemical orientation for preferential promotion of thioether bond formation. Additionally, the heme derivatives 2-vinyldeuteroheme and 4-vinyldeuteroheme were reacted with wild-type H. thermophilus c(552) to yield another modification of cytochromes containing only one thioether bond. These results show that the formation of the two thioether bonds in typical c-type cytochromes can occur independently from one another. Aspects of rotational isomerism of heme in heme-proteins are discussed.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA	University of Oxford; Louisiana State University System; Louisiana State University	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	stuart.ferguson@bioch.ox.ac.uk	Smith, Kevin M/G-1453-2011	Smith, Kevin M/0000-0002-6736-4779	NHLBI NIH HHS [HL-22252] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022252] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; FISHER WR, 1973, J BIOL CHEM, V248, P3188; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; Hasegawa J, 1998, BIOCHEMISTRY-US, V37, P9641, DOI 10.1021/bi9803067; Kalsbeck WA, 1996, BIOCHEMISTRY-US, V35, P3429, DOI 10.1021/bi952662k; KOJO S, 1989, ANGEW CHEM INT EDIT, V28, P71, DOI 10.1002/anie.198900711; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAR GN, 1984, J AM CHEM SOC, V106, P6395, DOI 10.1021/ja00333a050; MCLACHLAN SJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P274, DOI 10.1016/0167-4838(86)90026-9; McRee DE, 2001, J BIOL CHEM, V276, P6537, DOI 10.1074/jbc.M008421200; Moore G. R., 1990, CYTOCHROMES C EVOLUT; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Pettigrew G.W., 1987, CYTOCHROMES C BIOL A; Rosell FI, 2002, BIOCHEMISTRY-US, V41, P7811, DOI 10.1021/bi016060e; SCOTT RA, 1995, CYTOCHROME C MULTIDI; SMITH KM, 1983, J AM CHEM SOC, V105, P6638, DOI 10.1021/ja00360a015; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Tomlinson EJ, 2000, J BIOL CHEM, V275, P32530, DOI 10.1074/jbc.M004022200; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200; WU JZ, 1991, BIOCHEMISTRY-US, V30, P2156, DOI 10.1021/bi00222a020; YAMAMOTO Y, 1986, BIOCHEMISTRY-US, V25, P5288, DOI 10.1021/bi00366a045	25	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24308	24313		10.1074/jbc.M301967200	http://dx.doi.org/10.1074/jbc.M301967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707264	Green Published, hybrid			2022-12-25	WOS:000183824800011
J	Gouda, MD; Singh, SA; Rao, AGA; Thakur, MS; Karanth, NG				Gouda, MD; Singh, SA; Rao, AGA; Thakur, MS; Karanth, NG			Thermal inactivation of glucose oxidase - Mechanism and stabilization using additives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPEROMETRIC BIOSENSOR; STABILITY; PURIFICATION	Thermal inactivation of glucose oxidase (GOD; beta-D-glucose: oxygen oxidoreductase), from Aspergillus niger, followed first order kinetics both in the absence and presence of additives. Additives such as lysozyme, NaCl, and K2SO4 increased the half-life of the enzyme by 3.5-, 33.4-, and 23.7-fold respectively, from its initial value at 60degreesC. The activation energy increased from 60.3 kcal mol(-1) to 72.9, 76.1, and 88.3 kcal mol(-1), whereas the entropy of activation increased from 104 to 141, 147, and 184 cal.mol(-1).deg(-1) in the presence of 7.1 x 10(-5) M lysozyme, 1 M NaCl, and 0.2 M K2SO4, respectively. The thermal unfolding of GOD in the temperature range of 25-90degreesC was studied using circular dichroism measurements at 222, 274, and 375 nm. Size exclusion chromatography was employed to follow the state of association of enzyme and dissociation of FAD from GOD. The midpoint for thermal inactivation of residual activity and the dissociation of FAD was 59degreesC, whereas the corresponding midpoint for loss of secondary and tertiary structure was 62degreesC. Dissociation of FAD from the holoenzyme was responsible for the thermal inactivation of GOD. The irreversible nature of inactivation was caused by a change in the state of association of apoenzyme. The dissociation of FAD resulted in the loss of secondary and tertiary structure, leading to the unfolding and nonspecific aggregation of the enzyme molecule because of hydrophobic interactions of side chains. This confirmed the critical role of FAD in structure and activity. Cysteine oxidation did not contribute to the nonspecific aggregation. The stabilization of enzyme by NaCl and lysozyme was primarily the result of charge neutralization. K2SO4 enhanced the thermal stability by primarily strengthening the hydrophobic interactions and made the holoenzyme a more compact dimeric structure.	Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570013, Karnataka, India; Cent Food Technol Res Inst, Dept Fermentat Technol & Bioengn, Mysore 570013, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Food Technological Research Institute (CFTRI)	Rao, AGA (corresponding author), Cent Food Technol Res Inst, Dept Prot Chem & Technol, Mysore 570013, Karnataka, India.	appu@cscftri.ren.nic.in	Singh, Sridevi/E-6997-2010; Thakur, M S/B-7765-2011	Singh, Sridevi/0000-0002-0507-6667; 				Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P3819, DOI 10.1021/bi0116700; Appleton B, 1997, SENSOR ACTUAT B-CHEM, V43, P65, DOI 10.1016/S0925-4005(97)00135-4; Baldwin RL, 1996, BIOPHYS J, V71, P2056, DOI 10.1016/S0006-3495(96)79404-3; Bergmeyer H., 1974, METHODS ENZYMATIC AN, V1, P457; COLLINS KD, 1985, Q REV BIOPHYS, V18, P323, DOI 10.1017/S0033583500005369; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; Gouda MD, 1997, BIOTECHNOL TECH, V11, P653, DOI 10.1023/A:1018403225375; Gouda MD, 2001, ELECTROANAL, V13, P849, DOI 10.1002/1521-4109(200106)13:10<849::AID-ELAN849>3.0.CO;2-#; Haouz A, 1998, CHEM PHYS LETT, V294, P197, DOI 10.1016/S0009-2614(98)00852-5; HAYASHI S, 1981, BIOCHIM BIOPHYS ACTA, V657, P40, DOI 10.1016/0005-2744(81)90128-5; JONES MN, 1982, BIOCHEM J, V203, P285, DOI 10.1042/bj2030285; Komineck J., 1983, BIOTECHNOLOGY, V3, P455; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; OMALLEY JJ, 1972, BIOCHEMISTRY-US, V11, P3527, DOI 10.1021/bi00769a006; OMALLEY JJ, 1973, BIOTECHNOL BIOENG, V15, P917, DOI 10.1002/bit.260150509; PAZUR JH, 1964, BIOCHEMISTRY-US, V3, P578, DOI 10.1021/bi00892a018; PRZYBYCIEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1076, P103, DOI 10.1016/0167-4838(91)90226-P; SWOBODA BEP, 1969, BIOCHIM BIOPHYS ACTA, V175, P365, DOI 10.1016/0005-2795(69)90014-2; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; TSUGE H, 1975, J BIOCHEM, V78, P835, DOI 10.1093/oxfordjournals.jbchem.a130974; Turner A. P. F., 1987, BIOSENSORS FUNDAMENT, P770; VOET D, 1995, BIOCHEMISTRY-US, P382; VOET JG, 1981, BIOCHEMISTRY-US, V20, P7182, DOI 10.1021/bi00528a020; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YE WN, 1988, ENZYME MICROB TECH, V10, P498, DOI 10.1016/0141-0229(88)90028-2; YE WN, 1989, BIOCHIM BIOPHYS ACTA, V999, P86, DOI 10.1016/0167-4838(89)90034-4	28	155	184	3	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24324	24333		10.1074/jbc.M208711200	http://dx.doi.org/10.1074/jbc.M208711200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716878	hybrid			2022-12-25	WOS:000183824800013
J	Ji, Y; Li, BL; Reed, TD; Lorenz, JN; Kaetzel, MA; Dedman, JR				Ji, Y; Li, BL; Reed, TD; Lorenz, JN; Kaetzel, MA; Dedman, JR			Targeted inhibition of Ca2+/calmodulin-dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-TRANSPORT; HEART-FAILURE; DILATED CARDIOMYOPATHY; CALMODULIN; EXPRESSION; SITE; CA2+-ATPASE; DYSFUNCTION; HYPERTROPHY; ISOFORM	To investigate the role of Ca2+/calmodulin-dependent kinase II in cardiac sarcoplasmic reticulum function, transgenic mice were designed and generated to target the expression of a Ca2+/calmodulin-dependent kinase II inhibitory peptide in cardiac longitudinal sarcoplasmic reticulum using a truncated phospholamban transmembrane domain. The expressed inhibitory peptide was highly concentrated in cardiac sarcoplasmic reticulum. This resulted in a 59.7 and 73.6% decrease in phospholamban phosphorylation at threonine 17 under basal and beta-adrenergic stimulated conditions without changing phospholamban phosphorylation at serine 16. Sarcoplasmic reticulum Ca2+ uptake assays showed that the V-max was decreased by similar to30% although the apparent affinity for Ca2+ was unchanged in heterozygous hearts. The in vivo measurement of cardiac function showed no significant reductions in positive and negative dP/dt, but a moderate 18% decrease in dP/dt(40), indicative of isovolumic contractility, and a 26.1% increase in the time constant of relaxation (tau) under basal conditions. The changes in these parameters indicate a moderate cardiac dysfunction in transgenic mice. Although the 3- and 4-month-old transgenic mice displayed no overt signs of cardiac disease, when stressed by gestation and parturition, the 7-month-old female mice develop dilated heart failure, suggesting the important role of Ca2+/calmodulin-dependent kinase II pathway in the development of cardiac disease.	Univ Cincinnati, Dept Genome Sci, Coll Med, Cincinnati, OH 45237 USA; Univ Cincinnati, Dept Mol & Cellular Physiol, Coll Med, Cincinnati, OH 45237 USA; Genomatrix Ltd, Cincinnati, OH 45212 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Dedman, JR (corresponding author), Univ Cincinnati, Dept Genome Sci, Coll Med, 2180 E Galbraith Rd, Cincinnati, OH 45237 USA.				NIDDK NIH HHS [R01 DK 46433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; Currie S, 1999, FEBS LETT, V459, P244, DOI 10.1016/S0014-5793(99)01254-5; Hagemann D, 1999, J CELL BIOCHEM, V74, P202; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HI Y, 1999, AM J PHYSIOL, V276, pH89; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Ji Y, 2000, J BIOL CHEM, V275, P38073, DOI 10.1074/jbc.M004804200; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kirchhefer U, 1999, CARDIOVASC RES, V42, P254, DOI 10.1016/S0008-6363(98)00296-X; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LI L, 1998, AM J PHYSIOL, V287, P996; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1; Maier LS, 2002, J MOL CELL CARDIOL, V34, P919, DOI 10.1006/jmcc.2002.2038; MAYER P, 1995, BASIC RES CARDIOL, V90, P372, DOI 10.1007/BF00788498; MORGAN JP, 1991, NEW ENGL J MED, V325, P625; Netticadan T, 1999, AM J PHYSIOL-CELL PH, V277, pC384, DOI 10.1152/ajpcell.1999.277.3.C384; Netticadan T, 2000, CIRC RES, V86, P596, DOI 10.1161/01.RES.86.5.596; Odermatt A, 1996, J BIOL CHEM, V271, P14206, DOI 10.1074/jbc.271.24.14206; Reddy LG, 1996, J BIOL CHEM, V271, P14964, DOI 10.1074/jbc.271.25.14964; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Shannon TR, 2000, BIOPHYS J, V78, P334, DOI 10.1016/S0006-3495(00)76596-9; SIMMERMAN HKB, 1986, J BIOL CHEM, V258, P13587; Stefanadis C, 2001, J HUM HYPERTENS, V15, P635, DOI 10.1038/sj.jhh.1001243; TADA M, 1974, J BIOL CHEM, V249, P6174; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; Wang JH, 1996, AM J PHYSIOL-LUNG C, V271, pL245, DOI 10.1152/ajplung.1996.271.2.L245; Wang YG, 2001, CIRCULATION, V104, P85, DOI 10.1161/01.CIR.104.1.85; WEGENER AD, 1989, J BIOL CHEM, V264, P11469; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; Xu AD, 2000, J BIOL CHEM, V275, P4407, DOI 10.1074/jbc.275.6.4407; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200	46	41	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25063	25071		10.1074/jbc.M302193200	http://dx.doi.org/10.1074/jbc.M302193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12692124	hybrid			2022-12-25	WOS:000183824800100
J	Kitano, J; Nishida, M; Itsukaichi, Y; Minami, I; Ogawa, M; Hirano, T; Mori, Y; Nakanishi, S				Kitano, J; Nishida, M; Itsukaichi, Y; Minami, I; Ogawa, M; Hirano, T; Mori, Y; Nakanishi, S			Direct interaction and functional coupling between metabotropic glutamate receptor subtype 1 and voltage-sensitive Ca(v)2.1 Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; CEREBELLAR PURKINJE-CELLS; BRAIN CALCIUM-CHANNELS; SUBCELLULAR-DISTRIBUTION; MOLECULAR DIVERSITY; SIGNAL-TRANSDUCTION; ALPHA(1A) SUBUNITS; MICE LACKING; G-PROTEIN; RAT	Intracellular Ca2+ concentrations ([Ca2+](i)) are regulated in a spatiotemporal manner via both entry of extracellular Ca2+ and mobilization of Ca2+ from intracellular stores. Metabotropic glutamate receptor subtype 1 (mGluR1) is a G protein-coupled receptor that stimulates the inositol 1,4,5-trisphosphate-Ca2+ signaling cascade, whereas Ca(v)2.1 is a pore-forming channel protein of P/Q-type voltage-sensitive Ca2+ channels. In this investigation, we showed that mGluR1 and Ca(v)2.1 are colocalized at dendrites of cerebellar Purkinje neurons and form the heteromeric assembly in both the brain and heterologously expressing COS-7 cells. This assembly occurs through the direct interaction between their carboxyl-terminal intracellular domains. Calcium imaging and whole-cell recording showed that mGluR1 inhibits Ca(v)2.1-mediated [Ca2+](i) increases and Ba2+ currents in HEK 293 cells expressing Ca(v)2.1 with auxiliary alpha2/delta and beta1 subunits, respectively. This inhibition occurred in a ligand-independent manner and was enhanced by pre-activation of mGluR1 in a ligand-dependent manner. In contrast, simultaneous stimulation of mGluR1 and Ca(v)2.1 induced large [Ca2+](i) increases. Furthermore, the temporally regulated inhibition and stimulation of [Ca2+](i) increases by mGluR1 and Ca(v)2.1 were observed at dendrites but not soma of cultured Purkinje neurons. These data suggest that the assembly of mGluR1 and Ca(v)2.1 provides the mechanism that ensures spatiotemporal regulation of [Ca2+](i) in glutamatergic neurotransmission.	Kyoto Univ, Fac Med, Dept Biol Sci, Kyoto 6068501, Japan; Kyoto Univ, Dept Mol & Syst Biol, Grad Sch Biostudies, Kyoto 6068501, Japan; Okazaki Natl Res Inst, Div Mol & Cellular Physiol, Ctr Integrat Biosci, Okazaki, Aichi 4440864, Japan; Grad Univ Adv Studies, Sch Life Sci, Okazaki, Aichi 4440864, Japan; Kyoto Univ, Dept Biophys, Grad Sch Sci, Kyoto 6068502, Japan	Kyoto University; Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Kyoto University	Nakanishi, S (corresponding author), Kyoto Univ, Fac Med, Dept Biol Sci, Kyoto 6068501, Japan.			Ogawa, Masaaki/0000-0003-4615-8412; Nishida, Motohiro/0000-0002-2587-5458				ABE T, 1992, J BIOL CHEM, V267, P13361; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; Aydar E, 2002, NEURON, V34, P399, DOI 10.1016/S0896-6273(02)00677-3; BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Blackstone C, 1999, CELL CALCIUM, V26, P181, DOI 10.1054/ceca.1999.0071; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bootman MD, 2001, J CELL SCI, V114, P2213; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Choi S, 1996, J NEUROSCI, V16, P36; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; Emptage NJ, 1999, NEURON, V24, P495, DOI 10.1016/S0896-6273(00)81103-4; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GROUL DL, 1996, J NEUROPHYSIOL, V76, P3325; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HILLMAN D, 1991, P NATL ACAD SCI USA, V88, P7076, DOI 10.1073/pnas.88.16.7076; Ishikawa K, 1999, GENES CELLS, V4, P381, DOI 10.1046/j.1365-2443.1999.00269.x; Ito M, 2002, NAT REV NEUROSCI, V3, P896, DOI 10.1038/nrn962; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kitano J, 2003, J BIOL CHEM, V278, P14762, DOI 10.1074/jbc.M300184200; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; McCool BA, 1997, NEUROSCI LETT, V239, P89, DOI 10.1016/S0304-3940(97)00893-8; Minami I, 2003, EUR J NEUROSCI, V17, P1023, DOI 10.1046/j.1460-9568.2003.02499.x; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Mori Y, 2000, J NEUROSCI, V20, P5654, DOI 10.1523/JNEUROSCI.20-15-05654.2000; Nakamura T, 1999, NEURON, V24, P727, DOI 10.1016/S0896-6273(00)81125-3; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Nishida M, 1999, BIOCHEM BIOPH RES CO, V262, P350, DOI 10.1006/bbrc.1999.1218; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Sakurai T, 1996, J CELL BIOL, V134, P511, DOI 10.1083/jcb.134.2.511; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SHIGEMOTO R, 1993, NEUROSCI LETT, V163, P53, DOI 10.1016/0304-3940(93)90227-C; Smitt PS, 2000, NEW ENGL J MED, V342, P21, DOI 10.1056/NEJM200001063420104; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; Stefani A, 1998, SYNAPSE, V30, P424, DOI 10.1002/(SICI)1098-2396(199812)30:4<424::AID-SYN9>3.3.CO;2-0; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; Wada E, 1998, J COMP NEUROL, V393, P493; Wang SSH, 2000, NAT NEUROSCI, V3, P1266, DOI 10.1038/81792; Watanabe D, 1998, CELL, V95, P17, DOI 10.1016/S0092-8674(00)81779-1; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7	59	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25101	25108		10.1074/jbc.M303266200	http://dx.doi.org/10.1074/jbc.M303266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704197	hybrid			2022-12-25	WOS:000183824800104
J	Lebron, F; Vassallo, R; Puri, V; Limper, AH				Lebron, F; Vassallo, R; Puri, V; Limper, AH			Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PATTERN-RECOGNITION RECEPTORS; TNF-ALPHA RELEASE; TRANSCRIPTION FACTOR; PGG-GLUCAN; ALVEOLAR MACROPHAGES; ADJUNCTIVE THERAPY; TOLL; PNEUMONIA	beta-Glucans are major structural components of fungi. We have recently reported that the pathogenic fungus Pneumocystis carinii assembles a beta-glucan-rich cell wall that potently activates alveolar macrophages to release pro-inflammatory cytokines and chemokines. Purified P. carinii beta-glucans predictably induce both cytokine generation and associated neutrophilic lung inflammation. Herein, we demonstrate that P. carinii betaw-glucan-induced macrophage stimulation results from activation of NF-kappaB. Although analogous to macrophage activation induced by bacterial lipopolysaccharide (LPS), P. carinii beta-glucan-induced macrophage NF-kappaB activation exhibits distinctly different kinetics, with slower induction and longer duration compared with LPS stimulation. Macrophage activation in response to P. carinii beta-glucan was also substantially inhibited with the NF-kappaB antagonist pyrrolidine dithiocarbamate. In addition to different kinetics of NF-kappaB activation, P. carinii beta-glucan and LPS also utilize different receptor systems to induce macrophage activation. Macrophages from Toll-like receptor 4-deficient and wild type mice produced equivalent amounts of tumor necrosis factor alpha when stimulated with P. carinii beta-glucan. However, Toll-like receptor 4-deficient macrophages were refractory to stimulation with LPS. In contrast, MyD88-deficient macrophages exhibited a significant ( though partial) blunted response to P. carinii beta-glucan. These data demonstrate that P. carinii beta-glucan acts as potent inducer of macrophage activation through NF-kappaB utilizing cellular receptors and signaling pathways distinct from LPS.	Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Pulm Crit Care & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Limper, AH (corresponding author), Mayo Clin & Mayo Fdn, Thorac Dis Res Unit, 8-24 Stabile Bldg, Rochester, MN 55905 USA.	limper.andrew@mayo.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062150, R01HL055934, R01HL057125] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62150, R01 HL062150, R01-HL55934, R01-HL57125] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEL G, 1992, INT J IMMUNOPHARMACO, V14, P1363, DOI 10.1016/0192-0561(92)90007-8; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Adams DS, 2000, J CELL BIOCHEM, V77, P221, DOI 10.1002/(SICI)1097-4644(20000501)77:2<221::AID-JCB6>3.0.CO;2-V; Adams DS, 1997, J LEUKOCYTE BIOL, V62, P865, DOI 10.1002/jlb.62.6.865; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; BOZZETTE SA, 1990, NEW ENGL J MED, V323, P1451, DOI 10.1056/NEJM199011223232104; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; CASTRO M, 1993, AM J RESP CELL MOL, V9, P73, DOI 10.1165/ajrcmb/9.1.73; Chen F, 1999, CLIN CHEM, V45, P7; CHEN WX, 1992, INFECT IMMUN, V60, P1279, DOI 10.1128/IAI.60.4.1279-1284.1992; DUFFUS JH, 1982, ADV MICROB PHYSIOL, V23, P151, DOI 10.1016/S0065-2911(08)60337-9; ELSADR W, 1986, AIDS RES HUM RETROV, V2, P349, DOI 10.1089/aid.1.1986.2.349; GAGNON S, 1990, NEW ENGL J MED, V323, P1444, DOI 10.1056/NEJM199011223232103; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hahn PY, 2003, J BIOL CHEM, V278, P2043, DOI 10.1074/jbc.M209715200; HOFFMAN OA, 1993, J IMMUNOL, V150, P3932; Hoshino K, 1999, J IMMUNOL, V162, P3749; HUANG ZB, 1993, CHEST, V104, P751, DOI 10.1378/chest.104.3.751; Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KOLLS JK, 1993, AM J RESP CELL MOL, V8, P370, DOI 10.1165/ajrcmb/8.4.370; Kottom TJ, 2000, J BIOL CHEM, V275, P40628, DOI 10.1074/jbc.M002103200; Kougias P, 2001, INFECT IMMUN, V69, P3933, DOI 10.1128/IAI.69.6.3933-3938.2001; Le Cabec V, 2002, J IMMUNOL, V169, P2003, DOI 10.4049/jimmunol.169.4.2003; Limper AH, 1997, J CLIN INVEST, V99, P2110, DOI 10.1172/JCI119384; LIMPER AH, 1989, AM REV RESPIR DIS, V140, P1204, DOI 10.1164/ajrccm/140.5.1204; Limper AH, 1997, AM J RESP CELL MOL, V16, P110, DOI 10.1165/ajrcmb.16.2.9032116; Lowe E, 2001, MICROBES INFECT, V3, P789, DOI 10.1016/S1286-4579(01)01436-8; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Michalek M, 1998, J LEUKOCYTE BIOL, V64, P337, DOI 10.1002/jlb.64.3.337; Modlin RL, 1999, NEW ENGL J MED, V340, P1834, DOI 10.1056/NEJM199906103402312; Mueller A, 2000, GLYCOBIOLOGY, V10, P339, DOI 10.1093/glycob/10.4.339; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NEESE LW, 1994, J IMMUNOL, V152, P4549; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Ozinsky A, 2000, J ENDOTOXIN RES, V6, P393, DOI 10.1179/096805100101532333; Pagano RE, 2000, METHOD ENZYMOL, V312, P523; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Vassallo R, 2001, J EUKARYOT MICROBIOL, p160S; Vassallo R, 1999, J EUKARYOT MICROBIOL, V46, p145S; Vassallo R, 2000, J IMMUNOL, V164, P3755, DOI 10.4049/jimmunol.164.7.3755; Wakshull E, 1999, IMMUNOPHARMACOLOGY, V41, P89, DOI 10.1016/S0162-3109(98)00059-9; Yale SH, 1996, MAYO CLIN PROC, V71, P5, DOI 10.4065/71.1.5; Young SH, 2001, J BIOL CHEM, V276, P20781, DOI 10.1074/jbc.M101111200; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	58	90	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25001	25008		10.1074/jbc.M301426200	http://dx.doi.org/10.1074/jbc.M301426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716885	hybrid			2022-12-25	WOS:000183824800092
J	Mundada, LV; Prorok, M; DeFord, ME; Figuera, M; Castellino, FJ; Fay, WP				Mundada, LV; Prorok, M; DeFord, ME; Figuera, M; Castellino, FJ; Fay, WP			Structure-function analysis of the streptokinase amino terminus (residues 1-59)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN ACTIVATION; ACTIVE-SITE; FIBRIN; EXPRESSION; MECHANISM; FRAGMENTS; PEPTIDES; DELETION; SEQUENCE; AFFINITY	Streptokinase (SK) binds to plasminogen (Pg) to form a complex that converts substrate Pg to plasmin. Residues 1-59 of SK regulate its capacity to induce an active site in bound Pg by a nonproteolytic mechanism and to activate substrate Pg in a fibrin-independent manner. We analyzed 24 SK mutants to better define the functional properties of SK-(1-59). Mutations within the (alpha)beta(1) strand (residues 17-26) of SK completely prevented nonproteolytic active site induction in bound Pg and rendered SK incapable of protecting plasmin from inhibition by alpha(2)-antiplasmin. However, when fibrin-bound, the activities of (alpha)beta(1) strand mutants were similar to that of wild-type (WT) SK and resistant to alpha(2)-antiplasmin. Mutation of Ile(1) of SK also prevented nonproteolytic active site induction in bound Pg. However, unlike (alpha)beta(1) strand mutants, the functional defect of Ile(1) mutants was not relieved by fibrin, and complexes of Ile(1) mutants and plasmin were resistant to alpha(2)-antiplasmin. Plasmin enhanced the activities of (alpha)beta(1) strand and Ile(1) mutants, suggesting that SK- plasmin complexes activated mutant SK.Pg complexes by hydrolyzing the Pg Arg(561)-Val(562) bond. Mutational analysis of Glu(39) of SK suggested that a salt bridge between Glu(39) and Arg(719) of Pg is important, but not essential, for nonproteolytic active site induction in Pg. Deleting residues 1-59 rendered SK dependent on plasmin and fibrin to generate plasminogen activator (PA) activity. However, the PA activity of SK(60-414) in the presence of fibrin was markedly reduced compared with WT SK. Despite its reduced PA activity, the fibrinolytic potency of SK-(60-414) was greater than that of WT SK at higher ( but not lower) SK concentrations due to its capacity to deplete plasma Pg. These studies define mechanisms by which the SK alpha domain regulates rapid active site induction in bound Pg, contributes to the resistance of the SK- plasmin complex to alpha(2)-antiplasmin, and controls fibrin-independent Pg activation.	Univ Michigan, Med Ctr, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Vet Affairs Hosp, Res Serv, Ann Arbor, MI 48109 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Michigan System; University of Michigan; University of Notre Dame	Fay, WP (corresponding author), Univ Michigan, Med Ctr, Sch Med, Dept Internal Med, 1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NHLBI NIH HHS [HL13423, HL 57346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013423, R37HL013423, P01HL057346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; Boyle MDP, 1997, THROMB HAEMOSTASIS, V77, P1; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Fay WP, 1998, THROMB HAEMOSTASIS, V79, P985; JACKSON KW, 1978, THROMB RES, V13, P693, DOI 10.1016/0049-3848(78)90159-7; Kim DM, 2000, THROMB RES, V99, P93, DOI 10.1016/S0049-3848(00)00225-5; Lee AYY, 2001, THROMB HAEMOSTASIS, V85, P502, DOI 10.1055/s-0037-1615612; LEE BR, 1989, BIOCHEM BIOPH RES CO, V165, P1085, DOI 10.1016/0006-291X(89)92713-7; Lee SH, 1997, BIOCHEM MOL BIOL INT, V41, P199; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; Liu L, 2000, J BIOL CHEM, V275, P37686, DOI 10.1074/jbc.M003963200; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Nilsen SL, 1999, PROTEIN EXPRES PURIF, V16, P136, DOI 10.1006/prep.1999.1045; Parrado J, 1996, PROTEIN SCI, V5, P693; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; Reed GL, 1999, P NATL ACAD SCI USA, V96, P8879, DOI 10.1073/pnas.96.16.8879; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.tb20441.x; SHI GY, 1994, BIOCHEM J, V304, P235, DOI 10.1042/bj3040235; TORR SR, 1992, J AM COLL CARDIOL, V19, P1085, DOI 10.1016/0735-1097(92)90300-C; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang SG, 2000, EUR J BIOCHEM, V267, P3994, DOI 10.1046/j.1432-1327.2000.01434.x; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601	28	22	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24421	24427		10.1074/jbc.M301825200	http://dx.doi.org/10.1074/jbc.M301825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704199	hybrid			2022-12-25	WOS:000183824800023
J	Vandeputte-Rutten, L; Bos, MP; Tommassen, J; Gros, P				Vandeputte-Rutten, L; Bos, MP; Tommassen, J; Gros, P			Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CONJUGATE VACCINE; MENINGITIDIS; IMMUNOGENICITY; POLYSACCHARIDE; NEUTROPHILS; DYNAMICS; STRAINS; PEPTIDE	The neisserial surface protein A (NspA) from Neisseria meningitidis is a promising vaccine candidate because it is highly conserved among meningococcal strains and induces bactericidal antibodies. NspA is a homolog of the Opa proteins, which mediate adhesion to host cells. Here, we present the crystal structure of NspA, determined to 2.55-Angstrom resolution. NspA forms an eight-stranded antiparallel beta-barrel. The four loops at the extracellular side of the NspA molecule form a long cleft, which contains mainly hydrophobic residues and harbors a detergent molecule, suggesting that the protein might function in the binding of hydrophobic ligands, such as lipids. In addition, the structure provides a starting point for structure-based vaccine design.	Univ Utrecht, Dept Crystal & Struct Chem, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Dept Mol Microbiol, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	Gros, P (corresponding author), Univ Utrecht, Dept Crystal & Struct Chem, Bijvoet Ctr Biomol Res, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	p.gros@chem.uu.nl	Gros, Piet/AAD-6452-2019; Tommassen, Jan/I-1690-2016; Gros, Piet/I-5569-2016	Gros, Piet/0000-0002-7782-2585; Tommassen, Jan/0000-0001-7633-4945; Gros, Piet/0000-0002-7782-2585				ANDERSON EL, 1994, INFECT IMMUN, V62, P3391, DOI 10.1128/IAI.62.8.3391-3395.1994; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cadieux N, 1999, INFECT IMMUN, V67, P4955, DOI 10.1128/IAI.67.9.4955-4959.1999; Chen T, 1996, P NATL ACAD SCI USA, V93, P14851, DOI 10.1073/pnas.93.25.14851; COSTANTINO P, 1992, VACCINE, V10, P691, DOI 10.1016/0264-410X(92)90091-W; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; DEKKER N, 1995, EUR J BIOCHEM, V232, P214, DOI 10.1111/j.1432-1033.1995.tb20801.x; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOU VC, 2002, 13 INT PATH NEISS C, P127; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koronakis V, 2001, CURR OPIN STRUC BIOL, V11, P403, DOI 10.1016/S0959-440X(00)00224-4; Malorny B, 1998, J BACTERIOL, V180, P1323, DOI 10.1128/JB.180.5.1323-1330.1998; MANDRELL RE, 1982, J IMMUNOL, V129, P2172; Martin D, 1997, J EXP MED, V185, P1173, DOI 10.1084/jem.185.7.1173; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moe GR, 1999, INFECT IMMUN, V67, P5664, DOI 10.1128/IAI.67.11.5664-5675.1999; Moe GR, 2002, INFECT IMMUN, V70, P6021, DOI 10.1128/IAI.70.11.6021-6031.2002; Moe GR, 2001, INFECT IMMUN, V69, P3762, DOI 10.1128/IAI.69.6.3762-3771.2001; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oomen CJ, 2003, J MOL BIOL, V328, P1083, DOI 10.1016/S0022-2836(03)00377-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; Plante M, 1999, INFECT IMMUN, V67, P2855, DOI 10.1128/IAI.67.6.2855-2861.1999; Poolman J, 2001, VACCINE, V20, pS24, DOI 10.1016/S0264-410X(01)00283-3; Prince SM, 2002, P NATL ACAD SCI USA, V99, P3417, DOI 10.1073/pnas.062630899; ROSENQVIST E, 1993, J INFECT DIS, V167, P1065, DOI 10.1093/infdis/167.5.1065; ROSENQVIST E, 1993, MICROB PATHOGENESIS, V15, P197, DOI 10.1006/mpat.1993.1070; SAUKKONEN K, 1987, MICROB PATHOGENESIS, V3, P261, DOI 10.1016/0882-4010(87)90059-3; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; Schulz GE, 2000, CURR OPIN STRUC BIOL, V10, P443, DOI 10.1016/S0959-440X(00)00120-2; Snijder HJ, 2000, BBA-MOL CELL BIOL L, V1488, P91, DOI 10.1016/S1388-1981(00)00113-X; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; Vogt J, 1999, STRUCTURE, V7, P1301, DOI 10.1016/S0969-2126(00)80063-5; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Zeth K, 2000, STRUCTURE, V8, P981, DOI 10.1016/S0969-2126(00)00189-1; ZOLLINGER WD, 1983, INFECT IMMUN, V40, P257, DOI 10.1128/IAI.40.1.257-264.1983	43	94	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24825	24830		10.1074/jbc.M302803200	http://dx.doi.org/10.1074/jbc.M302803200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716881	Green Published, hybrid			2022-12-25	WOS:000183824800070
J	Verdoucq, L; Czjzek, M; Moriniere, J; Bevan, DR; Esen, A				Verdoucq, L; Czjzek, M; Moriniere, J; Bevan, DR; Esen, A			Mutational and structural analysis of aglycone specificity in maize and sorghum beta-glucosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; MECHANISM; CATALYSIS; DHURRIN	Plant beta-glucosidases display varying substrate specificities. The maize beta-glucosidase isozyme Glu1 (ZmGlu1) hydrolyzes a broad spectrum of substrates in addition to its natural substrate DIMBOA-Glc (2-O-beta-D-glucopyranosyl-4-hydroxy-7-methoxy-1,4-benzoxaxin-3-one), whereas the sorghum beta-glucosidase isozyme Dhr1 (SbDhr1) hydrolyzes exclusively its natural substrate dhurrin (p-hydroxy( S)-mandelonitrile-beta-D-glucoside). Structural data from cocrystals of enzyme-substrate and enzyme-aglycone complexes have shown that five amino acid residues (Phe(198), Phe(205), Trp(378), Phe(466), and Ala(467)) are located in the aglycone-binding site of ZmGlu1 and form the basis of aglycone recognition and binding, hence substrate specificity. To study the mechanism of substrate specificity further, mutant beta-glucosidases were generated by replacing Phe(198), Phe(205), Asp(261), Met(263), Phe(377), Phe(466), Ala(467), and Phe(473) of Glu1 by Dhr1 counterparts. The effects of mutations on enzyme activity and substrate specificity were studied using both natural and artificial substrates. The simple mutant replacing Phe(198) by a valine had the most drastic effect on activity, because the capacity of this enzyme to hydrolyze beta-glucosides was almost completely abolished. The analysis of this mutation was completed by a structural study of the double mutant ZmGlu1-E191D, F198V in complex with the natural substrate. The structure reveals that the single mutation F198V causes a cascade of conformational changes, which are unpredictable by standard molecular modeling techniques. Some other mutations led to drastic effects: replacing Asp(261) by an asparagine decreases the catalytic efficiency of this simple mutant by 75% although replacing Tyr(473) by a phenylalanine increase its efficiency by 300% and also provides a new substrate specificity by hydrolyzing dhurrin.	Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France; CNRS, F-13402 Marseille 20, France	Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS)	Esen, A (corresponding author), Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA.	aevatan@vt.edu		Bevan, David/0000-0001-9974-1105				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; BERRIN JG, 2003, IN PRESS BIOCH J; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; Cicek M, 1999, BIOTECHNOL BIOENG, V63, P392, DOI 10.1002/(SICI)1097-0290(19990520)63:4&lt;392::AID-BIT2&gt;3.0.CO;2-M; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; Czjzek M, 2001, BIOCHEM J, V354, P37, DOI 10.1042/0264-6021:3540037; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DHARMAWARDHANA DP, 1995, PLANT PHYSIOL, V107, P331, DOI 10.1104/pp.107.2.331; ESEN A, 1993, ACS SYM SER, V533, P214; FALK A, 1995, PLANT PHYSIOL, V108, P1369, DOI 10.1104/pp.108.4.1369; FOWLER T, 1993, ACS SYM SER, V533, P56; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSEL W, 1987, ARCH BIOCHEM BIOPHYS, V252, P152, DOI 10.1016/0003-9861(87)90019-1; LEAH R, 1995, J BIOL CHEM, V270, P15789, DOI 10.1074/jbc.270.26.15789; Lebbink JHG, 2000, BIOCHEMISTRY-US, V39, P3656, DOI 10.1021/bi991483q; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peracchi A, 2001, TRENDS BIOCHEM SCI, V26, P497, DOI 10.1016/S0968-0004(01)01911-9; POULTON JE, 1990, PLANT PHYSIOL, V94, P401, DOI 10.1104/pp.94.2.401; RAABO E, 1960, SCAND J CLIN LAB INV, V12, P402; SAMBROOK J, 1989, MOL CLONING, V1, P7; SANAPARICIO J, 1998, J MOL BIOL, V275, P491; SINGH A, 1995, J BIOL CHEM, V270, P21928, DOI 10.1074/jbc.270.37.21928; Todd AE, 2002, TRENDS BIOCHEM SCI, V27, P419, DOI 10.1016/S0968-0004(02)02158-8; WANG Q, 1995, BIOCHEMISTRY-US, V34, P14554, DOI 10.1021/bi00044a034; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zouhar J, 2001, PLANT PHYSIOL, V127, P973, DOI 10.1104/pp.010712	32	64	66	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25055	25062		10.1074/jbc.M301978200	http://dx.doi.org/10.1074/jbc.M301978200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12684498	hybrid			2022-12-25	WOS:000183824800099
J	Wansa, KDSA; Harris, JM; Yan, G; Ordentlich, P; Muscat, GEO				Wansa, KDSA; Harris, JM; Yan, G; Ordentlich, P; Muscat, GEO			The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-activation, coactivator recruitment, and activation by the purine anti-metabolite 6-mercaptopurine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-ADRENAL AXIS; LIGAND-BINDING DOMAIN; SERUM GROWTH-FACTORS; T-CELL APOPTOSIS; NGFI-B; MUSCLE DIFFERENTIATION; STEROID-RECEPTOR; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; NURR1/NUR77 SUBFAMILY	NOR-1/NR4A3 is an "orphan member" of the nuclear hormone receptor superfamily. NOR-1 and its close relatives Nurr1 and Nur77 are members of the NR4A subgroup of nuclear receptors. Members of the NR4A subgroup are induced through multiple signal transduction pathways. They have been implicated in cell proliferation, differentiation, T-cell apoptosis, chondrosarcomas, neurological disorders, inflammation, and atherogenesis. However, the mechanism of transcriptional activation, coactivator recruitment, and agonist-mediated activation remain obscure. Hence, we examined the molecular basis of NOR-1-mediated activation. We observed that NOR-1 trans-activates gene expression in a cell- and target-specific manner; moreover, it operates in an activation function (AF)-1-dependent manner. The N-terminal AF-1 domain delimited to between amino acids 1 and 112, preferentially recruits the steroid receptor coactivator (SRC). Furthermore, SRC-2 modulates the activity of the AF-1 domain but not the C-terminal ligand binding domain (LBD). Homology modeling indicated that the NOR-1 LBD was substantially different from that of hRORbeta, a closely related AF-2-dependent receptor. In particular, the hydrophobic cleft characteristic of nuclear receptors was replaced with a very hydrophilic surface with a distinct topology. This observation may account for the inability of this nuclear receptor LBD to efficiently mediate cofactor recruitment and transcriptional activation. In contrast, the N-terminal AF-1 is necessary for cofactor recruitment and can independently conscript coactivators. Finally, we demonstrate that the purine anti-metabolite 6-mercaptopurine, a widely used antineoplastic and anti-inflammatory drug, activates NOR-1 in an AF-1-dependent manner. Additional 6-mercaptopurine analogs all efficiently activated NOR-1, suggesting that the signaling pathways that modulate proliferation via inhibition of de novo purine and/or nucleic acid biosynthesis are involved in the regulation NR4A activity. We hypothesize that the NR4A subgroup mediates the genotoxic stress response and suggest that this subgroup may function as sensors that respond to genotoxicity.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Queensland Univ Technol, Ctr Mol Biotechnol, Brisbane, Qld 4001, Australia; Xceptor Therapeut Inc, San Diego, CA 92121 USA	University of Queensland; Queensland University of Technology (QUT)	Muscat, GEO (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	G.Muscat@imb.uq.edu.au	; Muscat, George/A-6401-2017	Harris, Jonathan/0000-0003-4209-2380; Muscat, George/0000-0002-5829-5695				Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Arnott IDR, 2002, ALIMENT PHARM THER, V16, P857, DOI 10.1046/j.1365-2036.2002.01242.x; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Blake GJ, 2002, J INTERN MED, V252, P283, DOI 10.1046/j.1365-2796.2002.01019.x; Blake GJ, 2002, EUR HEART J, V23, P345, DOI 10.1053/euhj.2001.2905; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; Borghaei RC, 1998, BIOCHEM BIOPH RES CO, V251, P334, DOI 10.1006/bbrc.1998.9477; Buervenich S, 2000, AM J MED GENET, V96, P808, DOI 10.1002/1096-8628(20001204)96:6<808::AID-AJMG23>3.0.CO;2-E; BURCHENAL JH, 1953, BLOOD, V8, P965, DOI 10.1182/blood.V8.11.965.965; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen SL, 2000, GENE DEV, V14, P1209; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chen YH, 2001, AM J MED GENET, V105, P753, DOI 10.1002/ajmg.10036; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; Dowhan DH, 1996, NUCLEIC ACIDS RES, V24, P264, DOI 10.1093/nar/24.2.264; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fernandez PM, 2000, ENDOCRINOLOGY, V141, P2392, DOI 10.1210/en.141.7.2392; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Giverhaug T, 1999, GEN PHARMACOL, V33, P341, DOI 10.1016/S0306-3623(99)00022-1; Glass CK, 2000, GENE DEV, V14, P121; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; Hernandez-Boluda JC, 2001, ANN HEMATOL, V80, P516, DOI 10.1007/s002770100336; HEYMAN R, 2002, 2002 KEYST NUCL REC; Inuzuka H, 2002, FEBS LETT, V522, P88, DOI 10.1016/S0014-5793(02)02890-9; Ishiguro H, 2002, AM J MED GENET, V114, P15, DOI 10.1002/ajmg.1620; Kang HJ, 2000, BIOL PHARM BULL, V23, P815; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIM RW, 1995, BBA-MOL CELL RES, V1266, P91, DOI 10.1016/0167-4889(94)00226-5; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; Maira M, 1999, MOL CELL BIOL, V19, P7549; Maltais A, 2000, DNA CELL BIOL, V19, P121, DOI 10.1089/104454900314636; Maltais A, 2002, CANCER LETT, V183, P87, DOI 10.1016/S0304-3835(02)00104-0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; McEvoy AN, 2002, ANN NY ACAD SCI, V966, P119, DOI 10.1111/j.1749-6632.2002.tb04209.x; McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Monajemi H, 2001, THROMB HAEMOSTASIS, V86, P404; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Murphy EP, 1996, GENE EXPRESSION, V5, P169; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; NAKAI A, 1990, MOL ENDOCRINOL, V4, P1438, DOI 10.1210/mend-4-10-1438; Ohkubo T, 2000, MOL CELL ENDOCRINOL, V162, P151, DOI 10.1016/S0303-7207(00)00222-7; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; Ohkura N, 1998, GENE, V211, P79, DOI 10.1016/S0378-1119(98)00095-X; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Pekarsky Y, 2001, JAMA-J AM MED ASSOC, V286, P2308, DOI 10.1001/jama.286.18.2308; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Renaud JP, 2000, MOL ENDOCRINOL, V14, P700, DOI 10.1210/me.14.5.700; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sacchetti P, 1999, MOL BRAIN RES, V74, P167, DOI 10.1016/S0169-328X(99)00275-2; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Schimmel JJ, 1999, MOL BRAIN RES, V74, P1, DOI 10.1016/S0169-328X(99)00234-X; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Stehlin C, 2001, EMBO J, V20, P5822, DOI 10.1093/emboj/20.21.5822; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Stocco CO, 2000, J BIOL CHEM, V275, P37202, DOI 10.1074/jbc.M006016200; SURLES MC, 1994, PROTEIN SCI, V3, P198; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1993, MOL CELL BIOL, V13, P861, DOI 10.1128/MCB.13.2.861; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Witta J, 2000, MOL BRAIN RES, V84, P67, DOI 10.1016/S0169-328X(00)00211-4; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Young JL, 2002, THROMB HAEMOSTASIS, V88, P554, DOI 10.1055/s-0037-1613256; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087	86	117	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24776	24790		10.1074/jbc.M300088200	http://dx.doi.org/10.1074/jbc.M300088200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709428	Green Published, hybrid			2022-12-25	WOS:000183824800065
J	Zeng, LF; Zhang, YK; Chien, S; Liu, X; Shyy, JYJ				Zeng, LF; Zhang, YK; Chien, S; Liu, X; Shyy, JYJ			The role of p53 deacetylation in p21(Waf1) regulation by laminar flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; C-TERMINAL DOMAIN; DNA-DAMAGE; SHEAR-STRESS; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; CANCER-CELLS; ACTIVATION; APOPTOSIS; HISTONE	Laminar flow arrests vascular endothelial cells at the G(0)/G(1) phase with concurrent increase in p53 and p21(Waf1). We investigated the molecular mechanism by which laminar flow activates p53 and p21(Waf1) in endothelial cells. The application of a laminar flow (12 dyn/cm(2)) increased the deacetylation at Lys-320 and Lys-373 of p53 and the acetylation at Lys-382 in human umbilical vein endothelial cells. Laminar flow increased the activity of histone deacetylase (HDAC) and the association of p53 with HDAC1. Treating human umbilical vein endothelial cells with trichostatin A (TSA), an HDAC inhibitor, abolished the flow-induced p53 deacetylation at Lys-320 and Lys-373. To investigate the role of the HDAC-deacetylated p53 in the flow activation of p21(Waf1), we found that TSA inhibited the activation at both the mRNA and protein levels. Deletion and mutation analyses of the p21(Waf1) promoter revealed that flow activated p21(Waf1) through p53 and TSA abrogated this p53-dependent activation. The expression plasmid encoding the p53 mutant, with Lys-320 and Lys-373 replaced by Arg, increased the activity of the co-transfected p21(Waf1) promoter, which demonstrates that HDAC-deacetylated p53 can transactivate the p21(Waf1) gene. The regulation of the p53-p21(Waf1) pathway by laminar flow was further supported by observations that flow caused an increase of p21(Waf1) level in the wild-type HCT116 (p53(+/+)) cells but not in the p53-null HCT116 cells.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; Univ Calif San Diego, Whitaker Inst Biomed Engn, La Jolla, CA 92093 USA	University of California System; University of California Riverside; University of California System; University of California Riverside; University of California System; University of California San Diego; University of California System; University of California San Diego	Shyy, JYJ (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.				NCI NIH HHS [CA75180] Funding Source: Medline; NHLBI NIH HHS [HL56707, HL60789, HL43026, HL64382, HL19454] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA075180, R01CA075180] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060789, R01HL019454, R01HL064382, R29HL056707, R01HL056707, P01HL043026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto S, 2000, CIRC RES, V86, P185, DOI 10.1161/01.RES.86.2.185; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; LIN SJ, 1989, ARTERIOSCLEROSIS, V9, P230, DOI 10.1161/01.ATV.9.2.230; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scolnick DM, 1997, CANCER RES, V57, P3693; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699	39	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24594	24599		10.1074/jbc.M301955200	http://dx.doi.org/10.1074/jbc.M301955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716906	hybrid			2022-12-25	WOS:000183824800042
J	Bevilacqua, A; Ceriani, MC; Canti, G; Asnaghi, L; Gherzi, R; Brewer, G; Papucci, L; Schiavone, N; Capaccioli, S; Nicolin, A				Bevilacqua, A; Ceriani, MC; Canti, G; Asnaghi, L; Gherzi, R; Brewer, G; Papucci, L; Schiavone, N; Capaccioli, S; Nicolin, A			Bcl-2 protein is required for the adenine/uridine-rich element (ARE)-dependent degradation of its own messenger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; DOWN-REGULATES BCL-2; LYMPHOID-CELL LINES; RNA DEGRADATION; C-MYC; PROTOONCOGENE EXPRESSION; FOLLICULAR LYMPHOMA; BINDING-PROTEINS; APOPTOSIS; LEUKEMIA	We have shown previously that the decay of human bcl-2 mRNA is mediated by an adenine/uridine-rich element (ARE) located in the 3'-untranslated region. Here, we have utilized a non-radioactive cell-free mRNA decay system to investigate the biochemical and functional mechanisms regulating the ARE-dependent degradation of bcl-2 mRNA. Using RNA substrates, mutants, and competitors, we found that decay is specific and ARE-dependent, although maximized by the ARE-flanking regions. In unfractionated extracts from different cell types and in whole cells, the relative enzymatic activity was related to the amount of Bcl-2 protein expressed by the cells at steady state. The degradation activity was lost upon Bcl-2 depletion and was reconstituted by adding recombinant Bcl-2. Ineffective extracts from cells that constitutively do not express Bcl-2 acquire full degradation activity by adding recombinant Bcl-2 protein. We conclude that Bcl-2 is necessary to activate the degradation complex on the relevant RNA target.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; Natl Canc Inst, I-16132 Genoa, Italy; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Milan; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.		Gherzi, Roberto/AAA-7256-2020; Bevilacqua, Annamaria/C-6357-2008	Gherzi, Roberto/0000-0001-8654-0611; Bevilacqua, Annamaria/0000-0002-3136-3424; Schiavone, Nicola/0000-0002-1592-4244; Papucci, Laura/0000-0002-8450-7428				AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BIEDLER JL, 1978, CANCER RES, V38, P3751; Brewer G, 1998, J BIOL CHEM, V273, P34770, DOI 10.1074/jbc.273.52.34770; BROOKS SC, 1973, J BIOL CHEM, V248, P6251; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Campos L, 1999, LEUKEMIA LYMPHOMA, V33, P499, DOI 10.3109/10428199909058454; Capaccioli S, 1996, ONCOGENE, V13, P105; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; DEGLIESPOSTI M, 1999, J BIOL CHEM, V274, P29831; DEMARIA CT, 1997, PROGR MOL SUBCELLULA, P65; Detich N, 2001, J BIOL CHEM, V276, P24881, DOI 10.1074/jbc.M103056200; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; DYER MJS, 1990, BLOOD, V75, P709; GALLAGHER R, 1979, BLOOD, V54, P713; Garland JM, 1998, BLOOD, V92, P1235, DOI 10.1182/blood.V92.4.1235.416k18_1235_1246; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; Hu ZB, 1996, LEUKEMIA, V10, P410; Itano Y, 1996, J NEUROCHEM, V67, P131; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; Konig A, 1997, BLOOD, V90, P4307; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lampert IA, 1999, J CLIN PATHOL-MOL PA, V52, P29, DOI 10.1136/mp.52.1.29; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; Lind EF, 1999, J IMMUNOL, V162, P5374; MINOWADA J, 1972, J NATL CANCER I, V49, P891; Morelli S, 1997, P NATL ACAD SCI USA, V94, P8150, DOI 10.1073/pnas.94.15.8150; Nair APK, 1999, MOL CELL BIOL, V19, P889; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1990, CANCER RES, V50, P6565; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ross J, 1999, METH MOL B, V118, P459; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Siegel DS, 1998, P NATL ACAD SCI USA, V95, P162, DOI 10.1073/pnas.95.1.162; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STEUBE KG, 1995, LEUKEMIA, V9, P1841; TEIXEIRA C, 1995, CANCER RES, V55, P3902; TORIGOE T, 1994, CANCER RES, V54, P4851; van Hoof A, 1999, CELL, V99, P347, DOI 10.1016/S0092-8674(00)81520-2; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Voeltz GK, 1998, MOL CELL BIOL, V18, P7537, DOI 10.1128/MCB.18.12.7537; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	63	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23451	23459		10.1074/jbc.M210620200	http://dx.doi.org/10.1074/jbc.M210620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12702730	hybrid			2022-12-25	WOS:000183638600031
J	Joseph, SM; Buchakjian, MR; Dubyak, GR				Joseph, SM; Buchakjian, MR; Dubyak, GR			Colocalization of ATP release sites and ecto-ATPase activity at the extracellular surface of human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; AORTIC ENDOTHELIAL-CELLS; NUCLEOTIDE PYROPHOSPHATASE; CHLORIDE TRANSPORT; GENE-EXPRESSION; RECEPTORS; ACTIVATION; INVOLVEMENT; METABOLISM; MICE	Extracellular ATP and other nucleotides function as autocrine and paracrine signaling factors in many tissues. Recent studies suggest that P2 nucleotide receptors and ecto-nucleotidases compete for a limited pool of endogenously released nucleotides within cell surface microenvironments that are functionally segregated from the bulk extracellular compartment. To test this hypothesis, we have used luciferase-based methods to continuously record extracellular ATP levels in monolayers of human 1321N1 astrocytoma cells under resting conditions, during stimulation of Ca2+-mobilizing receptors for thrombin or acetylcholine, and during mechanical stimulation by hypotonic stress. Soluble luciferase was utilized as an indicator of ATP levels within the bulk extracellular compartment, whereas a chimeric protein A-luciferase, adsorbed to antibodies against a glycosylphosphatidylinositol-anchored plasma membrane protein, was used as a spatially localized probe of ATP levels at the immediate extracellular surface. Significant accumulation of ATP in the bulk extracellular compartment, under either resting (1-2 nM ATP) or stimulated (10-80 nM ATP) conditions, was observed only when endogenous ecto-ATPase activity was pharmacologically inhibited by the poorly metabolizable analog, betagamma-methylene ATP. In contrast, accumulation of submicromolar ATP in the cell surface microenvironment was readily measured even in the absence of ecto-ATPase inhibition suggesting that the spatially colocalized luciferase could effectively compete with endogenous ecto-ATPases for released ATP. Other experiments revealed a critical role for elevated cytosolic [Ca2+] in the ATP release mechanism triggered by thrombin or muscarinic receptors but not in basal ATP release or release stimulated by hypotonic stress. These observations suggest that ATP release sites are colocalized with ecto-ATPases at the astrocyte cell surface. This colocalization may act to spatially restrict the actions of released ATP as a paracrine or autocrine mediator of cell-to-cell signaling.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Dubyak, GR (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, E565, Cleveland, OH 44106 USA.			Buchakjian, Marisa/0000-0001-8261-1566; Dubyak, George/0000-0001-9720-4226	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018708] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01-HL18708] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbracchio MP, 2003, TRENDS PHARMACOL SCI, V24, P52, DOI 10.1016/S0165-6147(02)00038-X; Aleu J, 2003, J PHYSIOL-LONDON, V547, P209, DOI 10.1113/jphysiol.2002.029660; Arcuino G, 2002, P NATL ACAD SCI USA, V99, P9840, DOI 10.1073/pnas.152588599; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Braet K, 2003, CELL CALCIUM, V33, P37, DOI 10.1016/S0143-4160(02)00180-X; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Ciccarelli R, 2001, INT J DEV NEUROSCI, V19, P395, DOI 10.1016/S0736-5748(00)00084-8; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Contreras JE, 2002, P NATL ACAD SCI USA, V99, P495, DOI 10.1073/pnas.012589799; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Cressman VL, 1999, J BIOL CHEM, V274, P26461, DOI 10.1074/jbc.274.37.26461; DENBURG J L, 1970, Archives of Biochemistry and Biophysics, V141, P668, DOI 10.1016/0003-9861(70)90187-6; DUBYAK GR, 1988, J BIOL CHEM, V263, P18108; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Fabre JE, 1999, NAT MED, V5, P1199, DOI 10.1038/13522; Feranchak AP, 1999, J BIOL CHEM, V274, P30979, DOI 10.1074/jbc.274.43.30979; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hisadome K, 2002, J GEN PHYSIOL, V119, P511, DOI 10.1085/jgp.20028540; Kaiser RA, 2002, CIRC RES, V91, P292, DOI 10.1161/01.RES.0000030711.21521.AC; Kasai Y, 2001, J VET MED SCI, V63, P367, DOI 10.1292/jvms.63.367; Kittel A, 1999, BIOCHEM BIOPH RES CO, V262, P596, DOI 10.1006/bbrc.1999.1254; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Koziak K, 2000, J BIOL CHEM, V275, P2057, DOI 10.1074/jbc.275.3.2057; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Maienschein V, 1999, GLIA, V26, P233, DOI 10.1002/(SICI)1098-1136(199905)26:3<233::AID-GLIA5>3.0.CO;2-2; Majumdar M, 1998, J BIOL CHEM, V273, P10099, DOI 10.1074/jbc.273.17.10099; Maroto R, 2001, J BIOL CHEM, V276, P23867, DOI 10.1074/jbc.M101500200; Matsuoka I, 2002, MOL PHARMACOL, V61, P606, DOI 10.1124/mol.61.3.606; MISUMI Y, 1990, J BIOL CHEM, V265, P2178; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ohkubo S, 2001, J NEUROCHEM, V76, P872, DOI 10.1046/j.1471-4159.2001.00098.x; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Picher M, 2003, J BIOL CHEM, V278, P13468, DOI 10.1074/jbc.M300569200; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Queiroz G, 1999, NEUROSCIENCE, V91, P1171, DOI 10.1016/S0306-4522(98)00644-7; Ralevic V, 1998, PHARMACOL REV, V50, P413; REISIN IL, 1994, J BIOL CHEM, V269, P20584; Robaye B, 2003, MOL PHARMACOL, V63, P777, DOI 10.1124/mol.63.4.777; ROJAS E, 1985, FEBS LETT, V185, P323, DOI 10.1016/0014-5793(85)80931-5; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Scemes E, 2000, J NEUROSCI, V20, P1435; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; UNSWORTH CD, 1990, ANN NY ACAD SCI, V603, P353; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Zhong Y, 2001, EUR J NEUROSCI, V14, P1784, DOI 10.1046/j.0953-816x.2001.01805.x; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6	68	163	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23331	23342		10.1074/jbc.M302680200	http://dx.doi.org/10.1074/jbc.M302680200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684505	hybrid			2022-12-25	WOS:000183638600017
J	Lin, XF; Lee, SS; Sun, GQ				Lin, XF; Lee, SS; Sun, GQ			Functions of the activation loop in Csk protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SRC KINASE; INSULIN-RECEPTOR; CRYSTAL-STRUCTURE; REGULATORY PROPERTIES; CATALYTIC ACTIVITY; PHOSPHORYLATION; DOMAIN; AUTOPHOSPHORYLATION; MECHANISM; SUBSTRATE	Autophosphorylation in the activation loop is a common mechanism regulating the activities of protein-tyrosine kinases (PTKs). PTKs in the Csk family, Csk and Chk, are rare exceptions for lacking Tyr residues in this loop. We probed the function of this loop in Csk by extensive site-specific mutagenesis and kinetic studies using physiological and artificial substrates. These studies led to several surprising conclusions. First, specific residues in Csk activation loop had little discernable functions in phosphorylation of its physiological substrate Src, as Ala scanning and loop replacement mutations decreased Csk activity toward Src less than 40%. Second, some activation loop mutants, such as a single residue deletion or replacing all residues with Gly, exhibited 1-2% of wild type (wt) activity toward artificial substrates, but significantly higher activity toward Src. Third, introduction of a thrombin cleavage site to the activation loop also resulted in loss of 98% of wt activity for poly(E4Y) and loss of 95% of wt activity toward Src, but digestion with thrombin to cut the activation loop, resulted in full recovery of wt activity toward both substrates. This suggested that the catalytic machinery is fully functional without the activation loop, implying an inhibitory role by the activation loop as a regulatory structure. Fourth, Arg(313), although universally conserved in protein kinases, and essential for the activity of other PTKs so far tested, is not important for Csk activity. These findings provide new perspectives for understanding autophosphorylation as a regulatory mechanism and imply key differences in Csk recognition of artificial and physiological substrates.	Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA	University of Rhode Island	Sun, GQ (corresponding author), Univ Rhode Isl, Dept Cell & Mol Biol, 117 Morrill Sci Bldg,45 Lower Coll Rd, Kingston, RI 02881 USA.	gsun@uri.edu			NCI NIH HHS [CA16672] Funding Source: Medline; NCRR NIH HHS [1 P20 RR16457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ablooglu AJ, 2001, J BIOL CHEM, V276, P46933, DOI 10.1074/jbc.M107236200; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Frankel M, 2001, MOL CELL BIOL, V21, P4197, DOI 10.1128/MCB.21.13.4197-4207.2001; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Joukov V, 1997, BIOCHEM J, V322, P927, DOI 10.1042/bj3220927; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; Lee S, 2002, BIOCHEMISTRY-US, V41, P12107, DOI 10.1021/bi026439g; Leon BC, 2001, BIOCHEMISTRY-US, V40, P10078, DOI 10.1021/bi010838e; MACAULEY A, 1993, ONCOGENE, V8, P117; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1991, J BIOL CHEM, V266, P24249; SENFTEN M, 1995, ONCOGENE, V10, P199; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Skamnaki VT, 1999, BIOCHEMISTRY-US, V38, P14718, DOI 10.1021/bi991454f; Skamnaki VT, 2000, J PROTEIN CHEM, V19, P499, DOI 10.1023/A:1026553532289; SMITH JA, 1993, MOL CELL BIOCHEM, V128, P51, DOI 10.1007/BF01076757; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Sondhi D, 1998, BIOCHEMISTRY-US, V37, P165, DOI 10.1021/bi9722960; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; Sun GQ, 1999, ARCH BIOCHEM BIOPHYS, V367, P167, DOI 10.1006/abbi.1999.1253; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; Sun GQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P194, DOI 10.1006/abbi.1997.0156; Szustakowski JD, 2000, PROTEINS, V38, P428, DOI 10.1002/(SICI)1097-0134(20000301)38:4<428::AID-PROT8>3.0.CO;2-N; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	39	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24072	24077		10.1074/jbc.M210596200	http://dx.doi.org/10.1074/jbc.M210596200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12686554	hybrid			2022-12-25	WOS:000183638600110
J	Takada, Y; Aggarwal, BB				Takada, Y; Aggarwal, BB			Genetic deletion of the tumor necrosis factor receptor p60 or p80 sensitizes macrophages to lipopolysaccharide-induced nuclear factor-kappa B, mitogen-activated protein kinases, and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; HUMAN MONOCYTIC CELLS; N-TERMINAL KINASE; FACTOR-ALPHA; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MICE LACKING; LEISHMANIA-MAJOR; TNF-ALPHA	Whether deletion of tumor necrosis factor (TNF) receptor 1 or 2 affects lipopolysaccharide (LPS)-mediated signaling is not understood. In this report, we used macrophages derived from wild type (wt) mice and from mice null for the type 1 receptor (p60(-/-)), the type 2 receptor (p80(-/-)), or both (p60(-/-) p80(-/-)) to investigate the effect of these receptors on LPS-mediated activation of NF-kappaB, mitogen-activated protein kinases, and apoptosis. LPS activated NF-kappaB by 3-4-fold in wt cells but by 9-10-fold in p60(-/-), p80(-/-), and p60(-/-) p80(-/-) macrophages. These results correlated with the IkappaBalpha kinase activation, which is needed for NF-kappaB activation. LPS-induced cyclooxygenase-2 and inducible NO synthase proteins and NO production were maximum in p60(-/-) p80(-/-) macrophages and minimum in wt cells. LPS activated C-Jun N-terminal kinase, p38(MAPK), and extracellular signal-regulated kinase in wt cells, but the levels were much higher in p60(-/-), p80(-/-), and p60(-/-) p80(-/-) cells. LPS-induced cytotoxicity, poly(ADP-ribose) polymerase cleavage, and annexin V staining were also highest in p60(-/-) p80(-/-) cells and lowest in wt cells. The difference in LPS signaling was unrelated to the expression of LPS receptors, CD14, or toll-like receptor 4. Overall, our studies indicate that deletion of either of the TNF receptors sensitizes the macrophages to LPS and provide evidence for cross-talk between TNF and LPS signaling.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Sect, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Deckert-Schluter M, 1998, J IMMUNOL, V160, P3427; DING AH, 1988, J IMMUNOL, V141, P2407; Durando MM, 1998, J LEUKOCYTE BIOL, V64, P259, DOI 10.1002/jlb.64.2.259; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GEPPERT TD, 1994, MOL MED, V1, P93; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hawiger J, 1999, BLOOD, V94, P1711, DOI 10.1182/blood.V94.5.1711.417k20_1711_1716; HAZIOT A, 1988, J IMMUNOL, V141, P547; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hwang D, 2001, FASEB J, V15, P2556, DOI 10.1096/fj.01-0432com; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; LIU MK, 1994, J IMMUNOL, V153, P2642; Majumdar S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/jimmunol.167.5.2911; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, J IMMUNOL, V162, P1510; Marie C, 1999, INFECT IMMUN, V67, P688, DOI 10.1128/IAI.67.2.688-693.1999; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Nashleanas M, 1998, J IMMUNOL, V160, P5506; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Vieira LQ, 1996, J IMMUNOL, V157, P827; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xaus J, 2000, BLOOD, V95, P3823; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yap GS, 1998, J IMMUNOL, V160, P1340	55	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23390	23397		10.1074/jbc.M213237200	http://dx.doi.org/10.1074/jbc.M213237200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695514	hybrid			2022-12-25	WOS:000183638600024
J	Weilbaecher, RG; Awrey, DE; Edwards, AM; Kane, CM				Weilbaecher, RG; Awrey, DE; Edwards, AM; Kane, CM			Intrinsic transcript cleavage in yeast RNA polymerase II elongation complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTE READ-THROUGH; TERNARY COMPLEXES; ESCHERICHIA-COLI; CHAIN ELONGATION; NASCENT RNA; ALPHA-AMANITIN; FACTOR-SII; LARGEST SUBUNIT; FACTOR TFIIS; EXONUCLEASE ACTIVITY	Transcript elongation can be interrupted by a variety of obstacles, including certain DNA sequences, DNA-binding proteins, chromatin, and DNA lesions. Bypass of many of these impediments is facilitated by elongation factor TFIIS through a mechanism that involves cleavage of the nascent transcript by the RNA polymerase II/TFIIS elongation complex. Highly purified yeast RNA polymerase II is able to perform transcript hydrolysis in the absence of TFIIS. The "intrinsic" cleavage activity is greatly stimulated at mildly basic pH and requires divalent cations. Both arrested and stalled complexes can carry out the intrinsic cleavage reaction, although not all stalled complexes are equally efficient at this reaction. Arrested complexes in which the nascent transcript was cleaved in the absence of TFIIS were reactivated to readthrough blocks to elongation. Thus, cleavage of the nascent transcript is sufficient for reactivating some arrested complexes. Small RNA products released following transcript cleavage in stalled ternary complexes differ depending upon whether the cleavage has been induced by TFIIS or has occurred in mildly alkaline conditions. In contrast, both intrinsic and TFIIS-induced small RNA cleavage products are very similar when produced from an arrested ternary complex. Although alpha-amanitin interferes with the transcript cleavage stimulated by TFIIS, it has little effect on the intrinsic cleavage reaction. A mutant RNA polymerase previously shown to be refractory to TFIIS-induced transcript cleavage is essentially identical to the wild type polymerase in all tested aspects of intrinsic cleavage.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Toronto, CH Best Inst, Banting & Best Dept Med Res, Toronto, ON M5W 1L6, Canada	University of California System; University of California Berkeley; University of Toronto	Kane, CM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.			Edwards, Aled/0000-0002-4782-6016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34963, GM54010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHN BY, 1990, MOL CELL BIOL, V10, P5433, DOI 10.1128/MCB.10.10.5433; ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; Chamberlin M J, 1992, Harvey Lect, V88, P1; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chen Y, 1996, J BIOL CHEM, V271, P5993, DOI 10.1074/jbc.271.11.5993; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CIPRESPALACIN G, 1995, BIOCHEMISTRY-US, V34, P15375, DOI 10.1021/bi00046a046; DEMERCOYROL L, 1989, BIOCHEM J, V258, P165, DOI 10.1042/bj2580165; Edwards AM, 1996, METHOD ENZYMOL, V274, P419; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Elmendorf BJ, 2001, J BIOL CHEM, V276, P23109, DOI 10.1074/jbc.M101445200; Erie DA, 2002, BBA-GENE STRUCT EXPR, V1577, P224, DOI 10.1016/S0167-4781(02)00454-2; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Gerlt J. A., 1993, NUCLEASES, P1; Gnatt A, 2002, BBA-GENE STRUCT EXPR, V1577, P175, DOI 10.1016/S0167-4781(02)00451-7; GREENLEAF AL, 1983, J BIOL CHEM, V258, P3403; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HAWLEY DK, 1993, CELL MOL BIOL RES, V39, P339; Hemming SA, 2000, J BIOL CHEM, V275, P2288, DOI 10.1074/jbc.275.4.2288; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANE CM, 1994, TRANSCRIPTION MECH R, V3, pCH16; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; Labhart P, 1997, J BIOL CHEM, V272, P9055; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MILAN S, 1995, THESIS U CALIF, P136; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Powell W, 1996, J BIOL CHEM, V271, P22301, DOI 10.1074/jbc.271.37.22301; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1994, TRANSCRIPTION MECH R, V3, pCH15; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; Rudd MD, 1996, J BIOL CHEM, V271, P21549, DOI 10.1074/jbc.271.35.21549; Schnapp G, 1996, MOL GEN GENET, V252, P412, DOI 10.1007/s004380050245; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; Tschochner H, 1996, P NATL ACAD SCI USA, V93, P12914, DOI 10.1073/pnas.93.23.12914; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; Yoon H, 1998, BIOCHEMISTRY-US, V37, P12104, DOI 10.1021/bi980924n	74	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24189	24199		10.1074/jbc.M211197200	http://dx.doi.org/10.1074/jbc.M211197200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692127	hybrid			2022-12-25	WOS:000183638600125
J	Zhang, H; Andrekopoulos, C; Joseph, J; Chandran, K; Karoui, H; Crow, JP; Kalyanaraman, B				Zhang, H; Andrekopoulos, C; Joseph, J; Chandran, K; Karoui, H; Crow, JP; Kalyanaraman, B			Bicarbonate-dependent peroxidase activity of human Cu, Zn-superoxide dismutase induces covalent aggregation of protein - Intermediacy of tryptophan-derived oxidation products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CARBONATE RADICAL-ANION; CU,ZN-SUPEROXIDE DISMUTASE; HYDROGEN-PEROXIDE; SELF-PEROXIDATION; NITROGEN-DIOXIDE; MOUSE MODEL; PEROXYNITRITE; NITRATION; COPPER	This study addresses the mechanism of covalent aggregation of human Cu,Zn-superoxide dismutase (hSOD1(WT)) induced by bicarbonate (HCO3-)-mediated peroxidase activity. Higher molecular weight species (apparent dimers and trimers) of hSOD1(WT) were formed from incubation mixtures containing hSOD1(WT), H2O2, and HCO3-.HCO3--dependent peroxidase activity and covalent aggregation of hSOD1(WT) were mimicked by UV photolysis of hSOD1-WT in the presence of a [Co(NH3)(5)CO3](+) complex that generates the carbonate radical anion (CO3.-). Human SOD1(WT) has but one aromatic residue, a tryptophan residue (Trp-32) on the surface of the protein. Substitution of Trp-32 with phenylalanine produced a mutant (hSOD1(W32F)) that exhibits HCO3--dependent peroxidase activity similar to wildtype enzyme. However, unlike hSOD1(WT), incubations containing hSOD1(W32F), H2O2, and HCO3- did not result in covalent aggregation of SOD1. These findings indicate that Trp-32 is crucial for CO3.- induced covalent aggregation of hSOD1(WT). Spin-trapping results revealed the formation of the Trp-32 radical from hSOD1(WT), but not from hSOD1(W32F). Spin traps also inhibited the covalent aggregation of hSOD1(WT). Fluorescence experiments revealed that Trp-32 was further oxidized by CO3.- forming kynurenine-type products in the presence of oxygen. Molecular oxygen was needed for HCO3-/H2O2-dependent aggregation of hSOD1(WT), implicating a role for a Trp-32-dependent peroxidative reaction in the covalent aggregation of hSOD1(WT). Taken together, these results indicate that Trp-32 oxidation is crucial for covalent aggregation of hSOD1. Implications of HCO3--dependent SOD1 peroxidase activity in amyotrophic lateral sclerosis disease are discussed.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA; Univ Aix Marseille 1, Lab Struct & React Especes Paramagnet, Marseille, France; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Pharmacol Toxicol, Birmingham, AL 35233 USA	Medical College of Wisconsin; Medical College of Wisconsin; UDICE-French Research Universities; Aix-Marseille Universite; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		KAROUI, HAKIM/ABE-3416-2020		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040819, R01NS040494] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NINDS NIH HHS [NS40494, NS40819] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson LB, 2002, P NATL ACAD SCI USA, V99, P14676, DOI 10.1073/pnas.232591599; Aquilina JA, 1999, BIOCHEMISTRY-US, V38, P11455, DOI 10.1021/bi990458h; Aquilina JA, 2000, BIOCHEMISTRY-US, V39, P16176, DOI 10.1021/bi001230t; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; BASOLO F, 1953, INORG SYN, V4, P171, DOI 10.1002/9780470132357.ch56; Becker DA, 1996, J AM CHEM SOC, V118, P905, DOI 10.1021/ja952895z; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BUETTNER GR, 1978, BIOCHEM BIOPH RES CO, V83, P69, DOI 10.1016/0006-291X(78)90398-4; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; COPE VW, 1973, J AM CHEM SOC, V95, P3116, DOI 10.1021/ja00791a005; Crow JP, 1997, J NEUROCHEM, V69, P1945; Crow JP, 1997, J NEUROCHEM, V69, P1936; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; Hink HU, 2002, ARTERIOSCL THROM VAS, V22, P1402, DOI 10.1161/01.ATV.0000027524.86752.02; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kalyanaraman B, 2001, ADV EXP MED BIOL, V500, P175; Kang JH, 2000, BBA-GEN SUBJECTS, V1524, P162, DOI 10.1016/S0304-4165(00)00153-7; Kim KS, 2002, FREE RADICAL BIO MED, V32, P544, DOI 10.1016/S0891-5849(02)00741-4; KOTAKE Y, 1991, J AM CHEM SOC, V113, P9503, DOI 10.1021/ja00025a013; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOREHOUSE KM, 1988, J BIOL CHEM, V263, P1204; Okado-Matsumoto A, 2000, FREE RADICAL RES, V33, P65, DOI 10.1080/10715760000300621; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Roe JA, 2002, FREE RADICAL BIO MED, V32, P169, DOI 10.1016/S0891-5849(01)00778-X; SATO K, 1992, J BIOL CHEM, V267, P25371; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P12912, DOI 10.1073/pnas.95.22.12912; Stachel SJ, 1996, J AM CHEM SOC, V118, P1225, DOI 10.1021/ja9533297; Timmins GS, 1997, REDOX REP, V3, P125, DOI 10.1080/13510002.1997.11747099; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; Valentine JS, 2002, FREE RADICAL BIO MED, V33, P1314, DOI 10.1016/S0891-5849(02)01080-8; Vazquez S, 2002, J BIOL CHEM, V277, P4867, DOI 10.1074/jbc.M107529200; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Yamakura F, 2001, BBA-PROTEIN STRUCT M, V1548, P38, DOI 10.1016/S0167-4838(01)00212-6; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zhang H, 2000, FEBS LETT, V473, P58, DOI 10.1016/S0014-5793(00)01498-8; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218	48	96	100	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24078	24089		10.1074/jbc.M302051200	http://dx.doi.org/10.1074/jbc.M302051200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12686560	hybrid			2022-12-25	WOS:000183638600111
J	Zheng, CY; Hayes, JJ				Zheng, CY; Hayes, JJ			Intra- and inter-nucleosomal protein-DNA interactions of the core histone tail domains in a model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; RNA-POLYMERASE-II; CHROMATIN FIBER; LINKER DNA; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; IONIC-STRENGTH; IN-VITRO; LYSINE 9; 5S DNA	The core histone tail domains are key regulators of eukaryotic chromatin structure and function and alterations in the tail-directed folding of chromatin fibers and higher order structures are the probable outcome of much of the post-translational modifications occurring in these domains. The functions of the tail domains are likely to involve complex intra- and inter-nucleosomal histone-DNA interactions, yet little is known about either the structures or interactions of these domains. Here we introduce a method for examining inter-nucleosome interactions of the tail domains in a model dinucleosome and determine the propensity of each of the four N-terminal tail domains to mediate such interactions in this system. Using a strong nucleosome "positioning" sequence, we reconstituted a nucleosome containing a single histone site specifically modified with a photoinducible cross-linker within the histone tail domain, and a second nucleosome containing a radiolabeled DNA template. These two nucleosomes were then ligated together and cross-linking induced by brief UV irradiation under various solution conditions. After cross-linking, the two templates were again separated so that cross-linking representing inter-nucleosomal histone-DNA interactions could be unambiguously distinguished from intra- nucleosomal cross-links. Our results show that the N-terminal tails of H2A and H2B, but not of H3 and H4, make internucleosomal histone-DNA interactions within the dinucleosome. The relative extent of intra- to inter-nucleosome interactions was not strongly dependent on ionic strength. Additionally, we find that binding of a linker histone to the dinucleosome increased the association of the H3 and H4 tails with the linker DNA region.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Hayes, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.	jjhs@mail.rochester.edu			NIGMS NIH HHS [R01GM52426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1986, J MOL BIOL, V187, P591, DOI 10.1016/0022-2836(86)90337-2; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Baneres JL, 1997, J MOL BIOL, V273, P503, DOI 10.1006/jmbi.1997.1297; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Butler PJG, 1998, J MOL BIOL, V281, P401, DOI 10.1006/jmbi.1998.1954; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; Davey CA, 2002, P NATL ACAD SCI USA, V99, P11169, DOI 10.1073/pnas.172271399; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; FLETCHER TM, 1994, BIOCHEMISTRY-US, V33, P2226, DOI 10.1021/bi00174a032; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guschin D, 1998, BIOCHEMISTRY-US, V37, P8629, DOI 10.1021/bi9805846; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Harp JM, 2000, ACTA CRYSTALLOGR D, V56, P1513, DOI 10.1107/S0907444900011847; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; HONG L, 1993, J BIOL CHEM, V268, P305; JACKSON V, 1987, BIOCHEMISTRY-US, V26, P2315, DOI 10.1021/bi00382a037; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee KM, 1997, P NATL ACAD SCI USA, V94, P8959, DOI 10.1073/pnas.94.17.8959; Lee KM, 1998, BIOCHEMISTRY-US, V37, P8622, DOI 10.1021/bi980499y; Lee KM, 1999, METHOD ENZYMOL, V304, P231; Luger K, 2002, NAT GENET, V32, P221, DOI 10.1038/ng1000; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MIRZABEKOV AD, 1982, COLD SPRING HARB SYM, V47, P503, DOI 10.1101/SQB.1983.047.01.060; Moore SC, 1997, BIOCHEM BIOPH RES CO, V230, P136, DOI 10.1006/bbrc.1996.5903; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; Polach KJ, 2000, J MOL BIOL, V298, P211, DOI 10.1006/jmbi.2000.3644; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Ren QH, 2001, MOL CELL, V7, P1329, DOI 10.1016/S1097-2765(01)00269-6; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Schwarz PM, 1996, BIOCHEMISTRY-US, V35, P4009, DOI 10.1021/bi9525684; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STEFANOVSKY VY, 1989, NUCLEIC ACIDS RES, V17, P10069, DOI 10.1093/nar/17.23.10069; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suto RK, 2000, NAT STRUCT BIOL, V7, P1121; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; van Holde KE., 1989, SPRINGER SERIES MOL; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vitolo JM, 2000, MOL CELL BIOL, V20, P2167, DOI 10.1128/MCB.20.6.2167-2175.2000; WALKER IO, 1984, BIOCHEMISTRY-US, V23, P5622, DOI 10.1021/bi00318a037; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; YAO J, 1990, P NATL ACAD SCI USA, V87, P7603, DOI 10.1073/pnas.87.19.7603; Zheng CY, 2003, BIOPOLYMERS, V68, P539, DOI 10.1002/bip.10303	76	61	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24217	24224		10.1074/jbc.M302817200	http://dx.doi.org/10.1074/jbc.M302817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697747	hybrid			2022-12-25	WOS:000183638600128
J	Thiel, C; Schwarz, M; Peng, JH; Grzmil, M; Hasilik, M; Braulke, T; Kohlschutter, A; von Figura, K; Lehle, L; Korner, C				Thiel, C; Schwarz, M; Peng, JH; Grzmil, M; Hasilik, M; Braulke, T; Kohlschutter, A; von Figura, K; Lehle, L; Korner, C			A new type of congenital disorders of glycosylation (CDG-Ii) provides new insights into the early steps of dolichol-linked oligosaccharide biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OLIGOSACCHARYLTRANSFERASE COMPLEX; DEFICIENCY; GENE; MUTATIONS; YEAST; DISEASE	Deficiency of GDP- Man: Man(1)GlcNAc(2)- PP- dolichol mannosyltransferase ( hALG2), is the cause of a new type of congenital disorders of glycosylation ( CDG) designated CDG- Ii. The patient presented normal at birth but developed in the 1st year of life a multisystemic disorder with mental retardation, seizures, coloboma of the iris, hypomyelination, hepatomegaly, and coagulation abnormalities. An accumulation of Man1GlcNAc2- PP- dolichol and Man(2)GlcNAc(2)- PP- dolichol was observed in skin fibroblasts of the patient. Incubation of patient fibroblast extracts with Man1GlcNAc2- PP- dolichol and GDP- mannose revealed a severely reduced activity of the mannosyltransferase elongating Man1GlcNAc2- PP dolichol. Because the Saccharomyces cerevisiae mutant alg2- 1 was known to accumulate the same shortened dolichol- linked oligosaccharides as the patient, the yeast ALG2 sequence was used to identify the human ortholog. Genetic analysis revealed that the patient was heterozygous for a single nucleotide deletion and a single nucleotide substitution in the human ortholog of yeast ALG2. Expression of wild type but not of mutant hALG2 cDNA restored the mannosyltransferase activity and the biosynthesis of dolichol-linked oligosaccharides both in patient fibroblasts and in the alg2- 1 yeast cells. hALG2 was shown to act as an alpha1,3- mannosyltransferase. The resulting Manalpha1,3-ManGlcNAc(2)- PP dolichol is further elongated by a yet unknown alpha 1,6- mannosyltransferase.	Univ Gottingen, D-37073 Gottingen, Germany; Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93053 Regensburg, Germany; Univ Hamburg, Dept Pediat, D-20246 Hamburg, Germany	University of Gottingen; University of Regensburg; University of Hamburg	Korner, C (corresponding author), Univ Gottingen, Heinrich Duker Weg 12, D-37073 Gottingen, Germany.	ckoerne@gwdg.de	Braulke, Thomas/AAV-9121-2020; Kohlschütter, Alfried/ABH-5710-2020; Kohlschütter, Alfried/ABE-3495-2021	Braulke, Thomas/0000-0002-2336-8532; Kohlschütter, Alfried/0000-0002-2700-0401; Thiel, Christian/0000-0001-6419-8747; Grzmil, Michal/0000-0002-7866-8145				*1 INT WORKSH CDGS, 1999, GLYCOCONJ J, V16, P669; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; CHAPMAN A, 1979, J BIOL CHEM, V254, P243; De Praeter CM, 2000, AM J HUM GENET, V66, P1744, DOI 10.1086/302948; FREEZE HH, 2001, GLYCOBIOLOGY, V11, P2364; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Grubenmann CE, 2002, HUM MOL GENET, V11, P2331, DOI 10.1093/hmg/11.19.2331; Hansske B, 2002, J CLIN INVEST, V109, P725, DOI 10.1172/JCI200214010; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius J, 2002, SEMIN CELL DEV BIOL, V13, P171, DOI 10.1016/S1084-9521(02)00045-9; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Imbach T, 1999, P NATL ACAD SCI USA, V96, P6982, DOI 10.1073/pnas.96.12.6982; JACKSON BJ, 1993, GLYCOBIOLOGY, V3, P357, DOI 10.1093/glycob/3.4.357; JACKSON BJ, 1989, ARCH BIOCHEM BIOPHYS, V272, P203, DOI 10.1016/0003-9861(89)90211-7; JAEKEN J, 1994, ARCH DIS CHILD, V71, P123, DOI 10.1136/adc.71.2.123; Jaeken J, 2001, CURR OPIN NEUROL, V14, P811, DOI 10.1097/00019052-200112000-00021; Kim S, 2000, J CLIN INVEST, V105, P191, DOI 10.1172/JCI7302; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; Korner C, 1998, GLYCOBIOLOGY, V8, P165, DOI 10.1093/glycob/8.2.165; Korner C, 1999, EMBO J, V18, P6816, DOI 10.1093/emboj/18.23.6816; Korner C, 1998, P NATL ACAD SCI USA, V95, P13200, DOI 10.1073/pnas.95.22.13200; Kranz C, 2001, J CLIN INVEST, V108, P1613, DOI 10.1172/JCI200113635; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; MANIATIS NT, 1989, MOL CLONING LAB MANU; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Oriol R, 2002, MOL BIOL EVOL, V19, P1451, DOI 10.1093/oxfordjournals.molbev.a004208; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; Schenk B, 2001, J CLIN INVEST, V108, P1687, DOI 10.1172/JCI200113419; SHARMA CB, 1982, EUR J BIOCHEM, V126, P319; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Tan J, 1996, AM J HUM GENET, V59, P810; Thiel C, 2002, BIOCHEM J, V367, P195, DOI 10.1042/BJ20020794; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1	39	86	92	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22498	22505		10.1074/jbc.M302850200	http://dx.doi.org/10.1074/jbc.M302850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684507	hybrid			2022-12-25	WOS:000183503900045
J	Goodman, PA; Burkhardt, N; Juran, B; Tibbles, HE; Uckun, FM				Goodman, PA; Burkhardt, N; Juran, B; Tibbles, HE; Uckun, FM			Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia	ONCOGENE			English	Article						CpG island; methylation-specific; PCR; T-lineage leukemia	LYMPHOMA B-CELLS; HUMAN BREAST-CANCER; DNA METHYLATION; CPG ISLANDS; PHOSPHOLIPASE C-GAMMA-2; RECEPTOR STIMULATION; MEDIATED ACTIVATION; INDUCED APOPTOSIS; BINDING PROTEINS; MYELOID-LEUKEMIA	Sequence analysis of the noncoding first exon (exon 1) of the Syk gene demonstrated the presence of a previously cloned CpG island (GenBank #Z 65706). Transient transfection analysis in Daudi cells demonstrated promoter activity (18-fold increase over parental luciferase plasmid) for a 348 bp BstXI-BsrBI fragment containing this island. This region exhibits a high GC content (similar to75%), contains several SP1 binding sites and a potential initiator sequence, but lacks a strong TATA consensus. Bisulfite sequencing and methylation-specific PCR (MSP) of this region demonstrated that the Syk promoter CpG island was largely unmethylated in B-lineage leukemia cell lines, control peripheral blood cells, human thymocytes and CD3(+) T lymphocytes. However, dense methylation was seen in four T-lineage leukemia cell lines, Jurkat, H9, Molt 3 and HUT 78. MSP screening of leukemia cells from six T-lineage acute lymphoblastic leukemia (ALL) patients demonstrated methylation of the Syk promoter CpG island in one T-lineage ALL patient. Promoter methylation was correlated with reduced to absent expression of Syk mRNA and SYK protein in the T-lineage leukemia cell lines. Treatment of the leukemia lines Ha and Molt 3, with the methylation inhibitor, 5-aza-2'-deoxycytidine (5-aza-CdR) resulted in increased Syk mRNA expression. The presence of a methylated promoter sequence in these T-lineage leukemia cell lines and in one T-lineage patient suggests a potential role for SYK as a tumor suppressor in T-ALL.	Parker Hughes Inst, Dept Mol Oncol, St Paul, MN 55113 USA; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Mol Genet, St Paul, MN 55113 USA; Parker Hughes Inst, Dept Biochem, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Parker Hughes Inst, Dept Mol Oncol, 2699 Patton Rd, St Paul, MN 55113 USA.	faith_uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				Akanuma D, 1999, ORAL ONCOL, V35, P476, DOI 10.1016/S1368-8375(99)00020-2; ALCALAY M, 1988, NUCLEIC ACIDS RES, V16, P9527, DOI 10.1093/nar/16.20.9527; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bolen JB, 1997, ANNU REV IMMUNOL, V15, P371, DOI 10.1146/annurev.immunol.15.1.371; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1999, J IMMUNOL, V163, P2610; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Cornall RJ, 2000, P NATL ACAD SCI USA, V97, P1713, DOI 10.1073/pnas.97.4.1713; Craig NL, 1996, CURR TOP MICROBIOL, V204, P27; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Dodge JE, 1998, INT J CANCER, V78, P561, DOI 10.1002/(SICI)1097-0215(19981123)78:5<561::AID-IJC6>3.0.CO;2-R; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLATAU E, 1983, CANCER RES, V43, P4901; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Glavac Damjan, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR193, DOI 10.1007/BF02346334; Goodman PA, 2002, LEUKEMIA LYMPHOMA, V43, P1627, DOI 10.1080/1042819021000002965; Goodman PA, 2001, ONCOGENE, V20, P3969, DOI 10.1038/sj.onc.1204515; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GULBINS E, 1994, J IMMUNOL, V152, P2123; Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JOST JP, 1992, P NATL ACAD SCI USA, V89, P9499, DOI 10.1073/pnas.89.20.9499; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KOEFFLER HP, 1980, BLOOD, V56, P344; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Law CL, 1996, MOL CELL BIOL, V16, P1305; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; LOZZIO BB, 1981, P SOC EXP BIOL MED, V166, P546; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MallickWood CA, 1996, P NATL ACAD SCI USA, V93, P9704, DOI 10.1073/pnas.93.18.9704; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MINOWADA J, 1972, J NATL CANCER I, V49, P891; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Okamura S, 1999, ONCOL RES, V11, P281; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; Qin SF, 1998, FEBS LETT, V427, P139, DOI 10.1016/S0014-5793(98)00383-4; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Stellwagen AE, 1997, EMBO J, V16, P6823, DOI 10.1093/emboj/16.22.6823; STERNBERG NL, 1992, TRENDS GENET, V8, P11, DOI 10.1016/0168-9525(92)90018-Y; Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261; Stirzaker C, 1997, CANCER RES, V57, P2229; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; UCKUN FM, 1989, BLOOD, V73, P1000; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; Uckun FM, 1996, J BIOL CHEM, V271, P6389, DOI 10.1074/jbc.271.11.6389; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; Uckun FM, 1997, BLOOD, V89, P2488; UCKUN FM, 1985, J IMMUNOL, V135, P3817; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Yeivin A, 1993, EXS, V64, P523; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Yuan YF, 2001, CANCER RES, V61, P5558; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810	84	28	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2504	2514		10.1038/sj.onc.1206313	http://dx.doi.org/10.1038/sj.onc.1206313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717427				2022-12-25	WOS:000182383500013
J	Kamiguti, AS; Harris, RJ; Slupsky, JR; Baker, PK; Cawley, JC; Zuzel, M				Kamiguti, AS; Harris, RJ; Slupsky, JR; Baker, PK; Cawley, JC; Zuzel, M			Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways	ONCOGENE			English	Article						cell survival; hairy-cell leukemia; MAPK; PKC; Src	P38 MAP KINASE; GROWTH-FACTOR; RAF-1; APOPTOSIS; LEUKEMIA; PHOSPHORYLATION; ERK; RECEPTORS; STRESS; JNK	The hairy cells (HCs) of hairy-cell leukemia are intrinsically activated mature clonal B cells. The aims of this study were to gain further insights into the nature of this activation and to assess its importance for the prolonged HC survival in this chronic disease. We show that HCs contain phosphorylated/activated p38 MAPK, JNK and ERK1/ERK2 (ERK1/2). PKC inhibitors increased the activation of p38 and JNK, but reduced the phosphorylation of ERK1/2. Moreover, PKC inhibition resulted in cell death; cell death was also observed when the activation of ERK1/2 in HCs was abrogated with an inhibitor of MEK1/2 activation. In addition to PKC, active Src kinase was also shown to be involved in the maintenance of Raf-independent ERK activation in HCs. During cell culture on a nonadherent surface, ERK phosphorylation was sustained, while phosphorylation of p38 and JNK decreased. This decrease was not observed in HCs cultured on vitronectin (VN), indicating that p38/JNK activation is probably a consequence of in vivo HC interaction with VN present in abundance in the red pulp of the spleen. Taken together, these results suggest that active p38/JNK make HCs susceptible to apoptosis, but the cells are effectively rescued by ERK activation involving constitutively active PKC and Src. These findings are relevant for the understanding of the prolonged cell survival of HCs and their selective sensitivity to some chemotherapeutic agents.	Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Liverpool L69 3GA, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Kamiguti, AS (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Haematol, Daulby St, Liverpool L69 3GA, Merseyside, England.	aurakami@liverpool.ac.uk	Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baker PK, 2002, BLOOD, V100, P647, DOI 10.1182/blood.V100.2.647; Bastie JN, 1999, LEUKEMIA LYMPHOMA, V35, P555, DOI 10.1080/10428199909169620; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Birkenkamp KU, 1999, LEUKEMIA, V13, P1037, DOI 10.1038/sj.leu.2401447; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; BURTHEM J, 1994, BLOOD, V84, P873; BURTHEM J, 1996, HAIRY CELL LEUKAEMIA; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CALIGARISCAPPIO F, 1985, BLOOD, V66, P1035; Carlomagno F, 2002, CANCER RES, V62, P1077; CAWLEY JC, 2000, ADV BLOOD DISORD, V5, P9; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen HJ, 1999, BRIT J HAEMATOL, V105, P87; Chen J, 2001, J BIOL CHEM, V276, P47901, DOI 10.1074/jbc.M107574200; Clarke H, 2000, EXP CELL RES, V261, P239, DOI 10.1006/excr.2000.5035; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; CORDINGLEY FT, 1988, LANCET, V1, P969; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREXLER HG, 1989, BLOOD, V74, P1747; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GENOT EM, 1993, J IMMUNOL, V151, P71; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gruber G, 1999, BLOOD, V94, P1077, DOI 10.1182/blood.V94.3.1077.415k06_1077_1085; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Harris RJ, 2000, J IMMUNOL, V164, P3887, DOI 10.4049/jimmunol.164.7.3887; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; Hindley A, 2002, J CELL SCI, V115, P1575; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LYNCH SA, 1993, LEUKEMIA, V7, P1416; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P2; PING P, 1999, AM J PHYSIOL, V276, P468; PIRO LD, 1990, NEW ENGL J MED, V322, P1117, DOI 10.1056/NEJM199004193221605; REUTER CWM, 1992, BLOOD, V96, P655; Savoie L, 2001, Curr Treat Options Oncol, V2, P217, DOI 10.1007/s11864-001-0035-3; SIMONTON SC, 1985, LAB INVEST, V52, pA63; SOUTHERN C, 1995, IMMUNOLOGY, V84, P326; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAM LT, 1971, NEW ENGL J MED, V284, P357, DOI 10.1056/NEJM197102182840704; Zhang Z, 1999, J NEUROCHEM, V73, P1502, DOI 10.1046/j.1471-4159.1999.0731502.x	62	45	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2272	2284		10.1038/sj.onc.1206398	http://dx.doi.org/10.1038/sj.onc.1206398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700663				2022-12-25	WOS:000182231500006
J	Goetze, JP; Christoffersen, C; Perko, M; Arendrup, H; Rehfeld, JF; Kastrup, J; Nielsen, LB				Goetze, JP; Christoffersen, C; Perko, M; Arendrup, H; Rehfeld, JF; Kastrup, J; Nielsen, LB			Increased cardiac BNP expression associated with myocardial ischemia	FASEB JOURNAL			English	Article						heart failure; proBNP; ventricle	BRAIN NATRIURETIC PEPTIDE; ACUTE CORONARY SYNDROMES; INCREASED PLASMA-LEVELS; HEART-FAILURE; UNSTABLE ANGINA; A-TYPE; INFARCTION; DYSFUNCTION; HORMONES; PROTEIN	Congestive heart failure is accompanied by increased cardiac brain natriuretic peptide (BNP) gene expression with elevated plasma concentrations of BNP and its precursor, proBNP. We investigated if myocardial ischemia in the absence of overt heart failure may be another mechanism for increased myocardial BNP expression. The BNP expression was examined in hypoxic myocardium of patients undergoing coronary bypass grafting surgery, in patients with coronary artery disease and normal left ventricular function undergoing percutaneous transluminal intervention therapy, and in heart failure patients without coronary artery disease. BNP mRNA was quantified by real-time PCR, and plasma BNP and proBNP concentrations were measured with radioimmunoassays. Quantitative analysis of BNP mRNA in atrial and ventricular biopsies from coronary bypass grafting patients revealed close associations of plasma BNP and proBNP concentrations to ventricular, but not atrial, BNP mRNA levels. Plasma BNP and proBNP concentrations were markedly increased in patients with coronary artery disease but without concomitant left ventricular dysfunction. These results are compatible with the notion that myocardial ischemia, even in the absence of left ventricular dysfunction, augments cardiac BNP gene expression and increases plasma BNP and proBNP concentrations. Thus, elevated BNP and proBNP concentrations do not necessarily reflect heart failure but may also result from cardiac ischemia.	Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Med B, Cardiac Catheterizat Lab, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem, KB 3011,9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	larsbo@rh.dk		Christoffersen, Christina/0000-0003-3751-5203; Goetze, Jens Peter/0000-0001-6356-3829				Boomsma F, 2001, CARDIOVASC RES, V51, P442, DOI 10.1016/S0008-6363(01)00195-X; Christoffersen C, 2002, HYPERTENSION, V40, P54, DOI 10.1161/01.HYP.0000021780.21830.DD; CHUN YS, 2002, BIOCH J; Clerico A, 2002, CLIN CHEM LAB MED, V40, P371, DOI 10.1515/CCLM.2002.060; Cowie MR, 2002, PROG CARDIOVASC DIS, V44, P293, DOI 10.1053/pcad.2002.24599; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; de Bold AJ, 2001, CAN J PHYSIOL PHARM, V79, P705, DOI 10.1139/cjpp-79-8-705; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Goetze JP, 2002, CLIN CHEM, V48, P1035; Hunt PJ, 1997, CLIN ENDOCRINOL, V47, P287, DOI 10.1046/j.1365-2265.1997.2361058.x; Kikuta K, 1996, AM HEART J, V132, P101, DOI 10.1016/S0002-8703(96)90396-8; Luo YX, 2001, CIRCULATION, V104, P202; Maisel Alan, 2001, Cardiology Clinics, V19, P557, DOI 10.1016/S0733-8651(05)70243-5; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MORITA E, 1993, CIRCULATION, V88, P82, DOI 10.1161/01.CIR.88.1.82; Muders F, 1997, AM HEART J, V134, P442, DOI 10.1016/S0002-8703(97)70079-6; Nagaya N, 1998, AM HEART J, V135, P21, DOI 10.1016/S0002-8703(98)70338-2; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; Talwar S, 2000, HEART, V84, P421, DOI 10.1136/heart.84.4.421; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195	24	289	321	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1105	+		10.1096/fj.02-0796fje	http://dx.doi.org/10.1096/fj.02-0796fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709407				2022-12-25	WOS:000182580100015
J	Kermorgant, S; Zicha, D; Parker, PJ				Kermorgant, S; Zicha, D; Parker, PJ			Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; HORMONE RECEPTOR; DOWN-REGULATION; EGF RECEPTOR; HGF RECEPTOR; MDCK CELLS; PHOSPHORYLATION; ENDOCYTOSIS; ACTIVATION	Upon hepatocyte growth factor stimulation, its receptor c-Met is rapidly internalized via clathrin-coated vesicles and traffics through an early endosomal compartment. We show here that c-Met accumulates progressively in perinuclear compartments, which in part include the Golgi. The c-Met content in the Golgi is principally the newly synthesized precursor form and, to a lesser extent, the internalized, recycling c-Met. By following the trafficking of c-Met inside the cell using a semi-automatic procedure and using inhibition or activation of protein kinase C (PKC) and microtubule depolymerizing agents, we show that PKC positively controls the trans-cytosolic movement of c-Met along microtubules. In parallel to its traffic, internalized c-Met is progressively degraded by a proteasome-sensitive mechanism; the lysosomal pathway does not play a substantial role. Inhibition or promotion of c-Met traffic to the perinuclear compartment does not alter the kinetics of proteasome-dependent c-Met degradation. Thus susceptibility to proteasomal degradation is not a consequence of post-endocytic traffic. The data define a PKC-controlled traffic pathway for c-Met that operates independently of its degradative pathway.	Canc Res UK, Prot Phosphorylat Lab, London Res Inst, Lincolns Inn Fields Labs, London WC2A 3PX, England; Canc Res UK, Prot Phosphorylat Lab, London Res Inst, Light Microscopy Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Kermorgant, S (corresponding author), Canc Res UK, Prot Phosphorylat Lab, London Res Inst, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013; Zicha, Daniel/H-9310-2016; Kermorgant, Stephanie/AAB-4931-2020	Kermorgant, Stephanie/0000-0001-5921-479X; parker, peter/0000-0002-6218-2933; Zicha, Daniel/0000-0002-8808-8064				Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chapell R, 1998, J BIOL CHEM, V273, P32595, DOI 10.1074/jbc.273.49.32595; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; dos Santos CMA, 2001, J BIOL CHEM, V276, P10839, DOI 10.1074/jbc.M003635200; Ferrari SL, 1999, J BIOL CHEM, V274, P29968, DOI 10.1074/jbc.274.42.29968; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GANDINO L, 1994, J BIOL CHEM, V269, P1815; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; Gual P, 2001, ONCOGENE, V20, P156, DOI 10.1038/sj.onc.1204047; HAMMALVAREZ SF, 1994, P NATL ACAD SCI USA, V91, P7812, DOI 10.1073/pnas.91.16.7812; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kabir N, 2001, J CELL BIOL, V152, P1033, DOI 10.1083/jcb.152.5.1033; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lukacs GL, 1997, BIOCHEM J, V328, P353; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Novikoff PM, 1996, J CELL SCI, V109, P21; Park WS, 1999, CANCER RES, V59, P307; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; Sipeki S, 2000, CELL SIGNAL, V12, P549, DOI 10.1016/S0898-6568(00)00105-4; Sonee M, 1998, AM J PHYSIOL-CELL PH, V275, pC1630, DOI 10.1152/ajpcell.1998.275.6.C1630; Taher TEI, 2002, J IMMUNOL, V169, P3793, DOI 10.4049/jimmunol.169.7.3793; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	44	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28921	28929		10.1074/jbc.M302116200	http://dx.doi.org/10.1074/jbc.M302116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12716900	hybrid			2022-12-25	WOS:000184421100071
J	Borroto, A; Ruiz-Paz, S; de la Torre, TV; Borrell-Pages, M; Merlos-Suarez, A; Pandiella, A; Blobel, CP; Baselga, J; Arribas, J				Borroto, A; Ruiz-Paz, S; de la Torre, TV; Borrell-Pages, M; Merlos-Suarez, A; Pandiella, A; Blobel, CP; Baselga, J; Arribas, J			Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH-FACTOR-ALPHA; METALLOPROTEASE-DISINTEGRIN MDC9; INTRACELLULAR MATURATION; PROPROTEIN CONVERTASES; SECRETASE CLEAVAGE; FURIN; FRACTALKINE; RECEPTOR; DISTINCT	Protein ectodomain shedding is a specialized type of regulated proteolysis that releases the extracellular domain of transmembrane proteins. The metalloprotease disintegrin tumor necrosis factor-alpha-converting enzyme (TACE) has been convincingly shown to play a central role in ectodomain shedding, but despite its broad interest, very little is known about the mechanisms that regulate its activity. An analysis of the biosynthesis of TACE in mutant cell lines that have a gross defect in ectodomain shedding (M1 and M2) shows a defective removal of the prodomain that keeps TACE in an inactive form. Using LoVo, a cell line that lacks of active furin, and alpha(1)-Antitrypsin Portland, a protein inhibitor of proprotein convertases, we show that TACE is normally processed by furin and other proprotein convertases. The defect in M1 and M2 cells is due to a blockade of the exit of TACE from the endoplasmic reticulum. The processing of other zinc-dependent metalloproteases, previously suggested to participate in activated ectodomain shedding is normal in the mutant cells, indicating that the component mutated is highly specific for TACE. In summary, the characterization of shedding-defective somatic cell mutants unveils the existence of a specific mechanism that directs the proteolytic activation of TACE through the control of its exit from the ER.	Hosp Univ Vall Hebron, Med Oncol Serv, Lab Recerca Oncol, Barcelona 08035, Spain; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Hospital Universitari Vall d'Hebron; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Memorial Sloan Kettering Cancer Center	Arribas, J (corresponding author), Hosp Univ Vall Hebron, Med Oncol Serv, Lab Recerca Oncol, Psg Vall Hebron 119-129, Barcelona 08035, Spain.		Borrell-Pages, Maria/Q-6307-2019; Pandiella, Atanasio/O-5180-2014; Arribas, Joaquin/M-4482-2014	Borrell-Pages, Maria/0000-0002-1759-9756; Pandiella, Atanasio/0000-0002-4704-8971; Arribas, Joaquin/0000-0002-0504-0664				Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Garton KJ, 2001, J BIOL CHEM, V276, P37993; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	35	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25933	25939		10.1074/jbc.M301673200	http://dx.doi.org/10.1074/jbc.M301673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12714588	hybrid			2022-12-25	WOS:000183920200085
J	Tatara, Y; Lee, BR; Yoshida, T; Takahashi, K; Ichishima, E				Tatara, Y; Lee, BR; Yoshida, T; Takahashi, K; Ichishima, E			Identification of catalytic residues of Ca2+-independent 1,2-alpha-D-mannosidase from Aspergillus saitoi by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I ALPHA-1,2-MANNOSIDASE; NEUTRAL ALPHA-MANNOSIDASE; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PENICILLIUM-CITRINUM; TRICHODERMA-REESEI; GLYCOPROTEIN-BIOSYNTHESIS; CELLOBIOHYDROLASE CEL6A; ENZYMATIC-PROPERTIES	The roles of six conserved active carboxylic acids in the catalytic mechanism of Aspergillus saitoi 1,2-alpha- D-mannosidase were studied by site-directed mutagenesis and kinetic analyses. We estimate that Glu-124 is a catalytic residue based on the drastic decrease of k(cat) values of the E124Q and E124D mutant enzyme. Glu-124 may work as an acid catalyst, since the pH dependence of its mutants affected the basic limb. D269N and E411Q were catalytically inactive, while D269E and E411D showed considerable activity. This indicated that the negative charges at these points are essential for the enzymatic activity and that none of these residues can be a base catalyst in the normal sense. K-m values of E273D, E414D, and E474D mutants were greatly increased to 17-31-fold wild type enzyme, and the kcat values were decreased, suggesting that each of them is a binding site of the substrate. Ca2+, essential for the mammalian and yeast enzymes, is not required for the enzymatic activity of A. saitoi 1,2-alpha-D-mannosidase. EDTA inhibits the Ca2+-free 1,2-alpha-D-mannosidase as a competitive inhibitor, not as a chelator. We deduce that the Glu-124 residue of A. saitoi 1,2-alpha-D-mannosidase is directly involved in the catalytic mechanism as an acid catalyst, whereas no usual catalytic base is directly involved. Ca2+ is not essential for the activity. The catalytic mechanism of 1,2-alpha-D-mannosidase may deviate from that typical glycosyl hydrolase.	Soka Univ, Lab Mol Enzymol, Grad Sch Engn, Tokyo 1928577, Japan; Hirosaki Univ, Dept Biotechnol, Fac Agr & Life Sci, Hirosaki, Aomori 0368561, Japan; Tokyo Univ Agr & Technol, Dept Appl Biol Sci, Tokyo 1838509, Japan	Soka University; Hirosaki University; Tokyo University of Agriculture & Technology	Ichishima, E (corresponding author), Soka Univ, Lab Mol Enzymol, Grad Sch Engn, Tokyo 1928577, Japan.			TATARA, Yota/0000-0001-8114-3289				DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Fujita A, 1997, BIOCHEM BIOPH RES CO, V238, P779, DOI 10.1006/bbrc.1997.7389; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; Hasegawa K, 1999, PROTEIN ENG, V12, P819, DOI 10.1093/protein/12.10.819; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Herscovics A, 1999, BBA-GEN SUBJECTS, V1426, P275, DOI 10.1016/S0304-4165(98)00129-9; ICHISHIMA E, 1981, BIOCHIM BIOPHYS ACTA, V658, P45, DOI 10.1016/0005-2744(81)90248-5; Ichishima E, 1999, BIOCHEM J, V339, P589, DOI 10.1042/0264-6021:3390589; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; Koivula A, 1996, PROTEIN ENG, V9, P691, DOI 10.1093/protein/9.8.691; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipari F, 1999, BIOCHEMISTRY-US, V38, P1111, DOI 10.1021/bi981643i; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; Lobsanov YD, 2002, J BIOL CHEM, V277, P5620, DOI 10.1074/jbc.M110243200; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MacLeod AM, 1996, BIOCHEMISTRY-US, V35, P13165, DOI 10.1021/bi9610616; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Miyake H, 2002, J BIOCHEM, V131, P587, DOI 10.1093/oxfordjournals.jbchem.a003138; Moracci M, 1998, BIOCHEMISTRY-US, V37, P17262, DOI 10.1021/bi981855f; Nelson N, 1944, J BIOL CHEM, V153, P375; OKU H, 1991, J BIOCHEM-TOKYO, V110, P29, DOI 10.1093/oxfordjournals.jbchem.a123538; Richard JP, 1996, BIOCHEMISTRY-US, V35, P12387, DOI 10.1021/bi961029b; Rydberg EH, 2002, BIOCHEMISTRY-US, V41, P4492, DOI 10.1021/bi011821z; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Vallee F, 2000, EMBO J, V19, P581, DOI 10.1093/emboj/19.4.581; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; Viladot JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/bi980586q; WEBB EC, 1992, ENZYME NOMENCLATURE, P349; Yamashiro K, 1997, J BIOCHEM-TOKYO, V122, P1174, DOI 10.1093/oxfordjournals.jbchem.a021878; YAMASHITA K, 1980, BIOCHEM BIOPH RES CO, V96, P1335, DOI 10.1016/0006-291X(80)90097-2; YOSHIDA T, 1993, BIOCHEM J, V290, P349, DOI 10.1042/bj2900349; YOSHIDA T, 1995, BBA-GENE STRUCT EXPR, V1263, P159, DOI 10.1016/0167-4781(95)00101-L; Zechel DL, 2001, CURR OPIN CHEM BIOL, V5, P643, DOI 10.1016/S1367-5931(01)00260-5; Zou JY, 1999, STRUCTURE, V7, P1035, DOI 10.1016/S0969-2126(99)80171-3	39	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25289	25294		10.1074/jbc.M302621200	http://dx.doi.org/10.1074/jbc.M302621200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12702721	hybrid			2022-12-25	WOS:000183920200005
J	Hanssen, E; Reinboth, B; Gibson, MA				Hanssen, E; Reinboth, B; Gibson, MA			Covalent and non-covalent interactions of beta ig-h3 with collagen VI - beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; 5Q31-LINKED CORNEAL DYSTROPHIES; MATRIX PROTEIN BETA-IG-H3; CELL-ADHESION MOLECULE; RGD-CAP BETA-IG-H3; EXTRACELLULAR-MATRIX; TRIPLE-HELIX; IN-VITRO; IDENTIFICATION; INTEGRIN	Transforming growth factor-beta induced gene-h3 (betaig-h3) was found to co-purify with collagen VI microfibrils, extracted from developing fetal ligament, after equilibrium density gradient centrifugation under both non-denaturing and denaturing conditions. Analysis of the collagen VI fraction from the non-denaturing gradient by gel electrophoresis under non-reducing conditions revealed the present of a single high molecular weight band that immunostained for both collagen VI and betaig-h3. When the fraction was analyzed under reducing conditions, collagen VI alpha chains and betaig-h3 were the only species evident. The results indicated that betaig-h3 is associated with collagen VI in tissues by reducible covalent bonding, presumably disulfide bridges. Rotary shadowing and immunogold staining of the collagen VI microfibrils and isolated tetramers indicated that betaig-h3 was specifically and periodically associated with the double-beaded region of many of the microfibrils and that this covalent binding site was located in or near the amino-terminal globular domain of the collagen VI molecule. Using solid phase and co-immunoprecipitation assays, recombinant betaig-h3 was found to bind both native and pepsin-treated collagen VI but not individual pepsin-collagen VI alpha chains. Blocking experiments indicated that the major in vitro betaig-h3 binding site was located in the pepsin-resistant region of collagen VI. In contrast to the tissue situation, the in vitro interaction had the characteristics of a reversible non-covalent interaction, and the K-d was measured as 1.63 x 10(-8) M. Rotary shadowing of immunogold-labeled complexes of recombinant betaig-h3 and pepsin-collagen VI indicated that the in vitro betaig-h3 binding site was located close to the amino-terminal end of the collagen VI triple helix. The evidence indicates that collagen VI may contain distinct covalent and non-covalent binding sites for betaig-h3, although the possibility that both interactions use the same binding region is discussed. Overall the study supports the concept that betaig-h3 is extensively associated with collagen VI in some tissues and that it plays an important modulating role in collagen VI microfibril function.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia	University of Adelaide	Gibson, MA (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.		Hanssen, Eric/A-7217-2013	Hanssen, Eric/0000-0002-4064-1844				Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Billings PC, 2000, J CELL BIOCHEM, V79, P261, DOI 10.1002/1097-4644(20001101)79:2<261::AID-JCB90>3.0.CO;2-#; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Clout NJ, 2003, STRUCTURE, V11, P197, DOI 10.1016/S0969-2126(03)00002-9; Doane KJ, 1998, INVEST OPHTH VIS SCI, V39, P263; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; Finnis ML, 1997, J BIOL CHEM, V272, P22817, DOI 10.1074/jbc.272.36.22817; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; GIBSON MA, 1982, BIOCHEM BIOPH RES CO, V105, P1288, DOI 10.1016/0006-291X(82)90926-3; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1985, J BIOL CHEM, V260, P1149; GIBSON MA, 1986, J BIOL CHEM, V26, P11436; Hashimoto K, 1997, BBA-MOL CELL RES, V1355, P303, DOI 10.1016/S0167-4889(96)00147-4; Hirano K, 1996, CURR EYE RES, V15, P965, DOI 10.3109/02713689609017642; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; Kielty CM, 1998, ANAL BIOCHEM, V255, P108, DOI 10.1006/abio.1997.2442; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kitahama S, 2000, BONE, V27, P61, DOI 10.1016/S8756-3282(00)00292-1; KUO HJ, 1989, BIOCHEMISTRY-US, V28, P3757, DOI 10.1021/bi00435a020; Langenbach KJ, 1999, J BIOL CHEM, V274, P7032, DOI 10.1074/jbc.274.11.7032; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Munier FL, 1997, NAT GENET, V15, P247, DOI 10.1038/ng0397-247; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Ohno S, 2002, BBA-GEN SUBJECTS, V1572, P114, DOI 10.1016/S0304-4165(02)00286-6; PERRIS R, 1993, EXP CELL RES, V209, P103, DOI 10.1006/excr.1993.1290; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3; Reinboth B, 2002, J BIOL CHEM, V277, P3950, DOI 10.1074/jbc.M109540200; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; SPISSINGER T, 1995, MATRIX BIOL, V14, P499, DOI 10.1016/0945-053X(95)90007-1; Streeten BW, 1999, ARCH OPHTHALMOL-CHIC, V117, P67; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200	46	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24334	24341		10.1074/jbc.M303455200	http://dx.doi.org/10.1074/jbc.M303455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12719415	hybrid			2022-12-25	WOS:000183824800014
J	Sengupta, S; Jang, BC; Wu, MT; Paik, JH; Furneaux, H; Hla, T				Sengupta, S; Jang, BC; Wu, MT; Paik, JH; Furneaux, H; Hla, T			The RNA-binding protein HuR regulates the expression of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; 3'-UNTRANSLATED REGION; RICH ELEMENT; POSTTRANSCRIPTIONAL REGULATION; PROSTAGLANDIN SYNTHASE; MAMMALIAN-CELLS; KINASE P38; STABILITY; STABILIZATION; TURNOVER	The cyclooxygenase-2 (COX-2) gene encodes the inducible prostaglandin synthase enzyme implicated in inflammation, cell growth, and tumorigenesis. Regulation of the COX-2 gene expression at the post-transcriptional level is poorly understood. For example, protein factors that regulate the post-transcriptional mRNA metabolism of COX-2 have not been fully characterized. In this study, we demonstrate that the RNA-binding protein HuR binds to COX-2 mRNA and regulates its expression. We show that there are three binding sites for HuR in the 3'-untranslated region of human COX-2. These sites are located at the following positions in the COX-2 3'-untranslated region: 39-84 nucleotides (nt), 1155 1187 nt, and 1244-1256 nt (hereinafter referred to as Sites I, II and III, respectively). Although all three sites are present in the 4.6- kb COX-2 mRNA, only site I is present in the shorter 2.8-kb isoform. HuR in MDA-MB231 cell extracts associated with COX-2 mRNA at the identified sites. Further, HuR location in the cytoplasm was induced by serum withdrawal, a stimulus known to induce COX-2 mRNA. Down-regulation of HuR by two independent methods, namely RNA interference as well as antisense RNA expression, significantly attenuated serum withdrawal-induced increase in COX-2 mRNA ( both the 4.6- and 2.8-kb isoforms) and protein levels. These data suggest that HuR binding to COX-2 is critical for its post-transcriptional mRNA stabilization.	Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, Farmington, CT 06030 USA	University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Physiol, 263 Farmington Ave, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; furneaux, henry/0000-0003-2212-1017	NHLBI NIH HHS [HL49094, HL58510] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094, R01HL058510] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2610, DOI 10.1021/bi00280a003; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Sheng HM, 2001, CANCER RES, V61, P2670; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; WEINER JH, 1975, J BIOL CHEM, V250, P1972; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558	33	136	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25227	25233		10.1074/jbc.M301813200	http://dx.doi.org/10.1074/jbc.M301813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704185	hybrid			2022-12-25	WOS:000183824800117
J	Henderson, JP; Byun, J; Takeshita, J; Heinecke, JW				Henderson, JP; Byun, J; Takeshita, J; Heinecke, JW			Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LUNG-CANCER RISK; MASS-SPECTROMETRIC QUANTIFICATION; HUMAN ATHEROSCLEROTIC INTIMA; HYDROGEN-PEROXIDE; GAS-CHROMATOGRAPHY; HUMAN-NEUTROPHILS; HUMAN EOSINOPHILS; HUMAN-PLASMA; CATALYZED OXIDATION	Oxidative damage to DNA has been implicated in carcinogenesis during chronic inflammation. Epidemiological and biochemical studies suggest that one potential mechanism involves myeloperoxidase, a hemeprotein secreted by human phagocytes. In this study, we demonstrate that human neutrophils use myeloperoxidase to oxidize uracil to 5-chlorouracil in vitro. Uracil chlorination by myeloperoxidase or reagent HOCl exhibited an unusual pH dependence, being minimal at pH similar to5, but increasing markedly under either acidic or mildly basic conditions. This bimodal curve suggests that myeloperoxidase initially produces HOCl, which subsequently chlorinates uracil by acid- or base-catalyzed reactions. Human neutrophils use myeloperoxidase and H2O2 to chlorinate uracil, suggesting that nucleobase halogenation reactions may be physiologically relevant. Using a sensitive and specific mass spectrometric method, we detected two products of myeloperoxidase, 5-chlorouracil and 5-bromouracil, in neutrophil-rich human inflammatory tissue. Myeloperoxidase is the most likely source of 5-chlorouracil in vivo because halogenated uracil is a specific product of the myeloperoxidase system in vitro. In contrast, previous studies have demonstrated that 5-bromouracil could be generated by either eosinophil peroxidase or myeloperoxidase, which preferentially brominates uracil at plasma concentrations of halide and under moderately acidic conditions. These observations indicate that the myeloperoxidase system promotes nucleobase halogenation in vivo. Because 5-chlorouracil and 5-bromouracil can be incorporated into nuclear DNA, and these thymine analogs are well known mutagens, our observations raise the possibility that halogenation reactions initiated by phagocytes provide one pathway for mutagenesis and cytotoxicity at sites of inflammation.	Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Washington University (WUSTL)	Heinecke, JW (corresponding author), Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Box 356426, Seattle, WA 98195 USA.		Henderson, Jeffrey P/D-3337-2015		NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [AG19309, AG021191] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021191, R01AG019309] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Cadet J, 1997, ENVIRON HEALTH PERSP, V105, P1034, DOI 10.2307/3433836; Cascorbi I, 2000, CANCER RES, V60, P644; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Dunford H. B., 1999, HEME PEROXIDASES; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Frost MT, 2000, BIOCHEM J, V345, P453, DOI 10.1042/0264-6021:3450453; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Gaut JP, 2002, ANAL BIOCHEM, V300, P252, DOI 10.1006/abio.2001.5469; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Giese RW, 1996, METHOD ENZYMOL, V271, P504; GOTTO AM, 1969, CANCER RES, V29, P807; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1997, FREE RADICAL BIO MED, V23, P909, DOI 10.1016/S0891-5849(97)00084-1; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Henderson JP, 2001, BIOCHEMISTRY-US, V40, P2052, DOI 10.1021/bi002015f; HUGGINS TG, 1993, J BIOL CHEM, V268, P12341; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KOK RM, 1985, J CHROMATOGR, V343, P59, DOI 10.1016/S0378-4347(00)84568-5; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; London SJ, 1997, CANCER RES, V57, P5001; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MORRIS SM, 1993, MUTAT RES, V297, P39, DOI 10.1016/0165-1110(93)90006-9; MORRIS SM, 1991, MUTAT RES, V258, P161, DOI 10.1016/0165-1110(91)90007-I; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; PAL BC, 1981, MUTAT RES, V91, P395, DOI 10.1016/0165-7992(81)90021-X; PETRECCIA DC, 1987, J LEUKOCYTE BIOL, V41, P283, DOI 10.1002/jlb.41.4.283; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; Reynolds WF, 1997, BLOOD, V90, P2730, DOI 10.1182/blood.V90.7.2730.2730_2730_2737; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Thomas E L, 1986, Methods Enzymol, V132, P569; van der Vliet A, 2000, AM J PHYSIOL-LUNG C, V279, pL537, DOI 10.1152/ajplung.2000.279.3.L537; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Yi DH, 2000, J AM SOC MASS SPECTR, V11, P578, DOI 10.1016/S1044-0305(00)00113-6; YU H, 1993, J BIOL CHEM, V268, P15935	52	129	132	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23522	23528		10.1074/jbc.M303928200	http://dx.doi.org/10.1074/jbc.M303928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707270	hybrid			2022-12-25	WOS:000183638600040
J	Yang, RJ; Newgard, CB				Yang, RJ; Newgard, CB			Hepatic expression of a targeting subunit of protein phosphatase-1 in streptozotocin-diabetic rats reverses hyperglycemia and hyperphagia despite depressed glucokinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLYCOGEN-SYNTHESIS; MAMMALIAN GLUCOKINASE; MAGNETIC-RESONANCE; FOOD-INTAKE; GLUCOSE; OVEREXPRESSION; METABOLISM; LIVER; HEPATOCYTES	Glycogen-targeting subunits of protein phosphatase-1 (PP-1) are scaffolding proteins that facilitate the regulation of key enzymes of glycogen metabolism by PP-1. In the current study, we have tested the effects of hepatic expression of G(M)DeltaC, a truncated version of the muscle-targeting subunit isoform, in rats rendered insulin-deficient via injection of a single moderate dose of streptozotocin (STZ). Three key findings emerged. First, G(M)DeltaC expression in liver was sufficient to fully normalize blood glucose levels (from 335 +/- 31 mg/dl prior to viral injection to 109 +/- 28 mg/dl 6 days after injection) and liver glycogen content in STZ-injected rats. Second, this normalization occurred despite very low levels of liver glucokinase expression in the insulin-deficient STZ-injected rats. Finally, the hyperphagia induced by STZ injection was completely reversed by G(M)DeltaC expression in liver. In contrast to these findings with G(M)DeltaC, overexpression of another targeting subunit, G(L), in STZ-injected rats caused a large increase in liver glycogen stores but only a transient decrease in food intake and blood glucose levels. The surprising demonstration of a glucose-lowering effect of G(M)DeltaC in the background of depressed hepatic glucokinase expression suggests that controlled stimulation of liver glycogen storage may be an effective mechanism for improving glucose homeostasis, even when normal pathways of glucose disposal are impaired.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, DUMC 3813,LSRC 351, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK58398] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Flatt JP, 1996, P NUTR SOC, V55, P449, DOI 10.1079/PNS19960041; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Gasa R, 2002, J BIOL CHEM, V277, P1524, DOI 10.1074/jbc.M107744200; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MAYER J, 1953, NEW ENGL J MED, V249, P13, DOI 10.1056/NEJM195307022490104; MAYER J, 1991, NUTR REV, V49, P46; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; RUSSEK M, 1963, NATURE, V197, P79, DOI 10.1038/197079b0; Russek M, 1971, Neurosci Res (N Y), V4, P213; Sindelar DK, 1999, DIABETES, V48, P1275, DOI 10.2337/diabetes.48.6.1275; TANG PM, 1991, J BIOL CHEM, V266, P15782; TORDOFF MG, 1989, AM J PHYSIOL, V257, pR1474, DOI 10.1152/ajpregu.1989.257.6.R1474; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; Velho G, 1996, J CLIN INVEST, V98, P1755, DOI 10.1172/JCI118974; Yang RJ, 2002, J BIOL CHEM, V277, P1514, DOI 10.1074/jbc.M107001200; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000	32	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23418	23425		10.1074/jbc.M213112200	http://dx.doi.org/10.1074/jbc.M213112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697773	hybrid			2022-12-25	WOS:000183638600027
J	de Bruyn, KMT; Zwartkruis, FJT; de Rooij, J; Akkerman, JWN; Bos, JL				de Bruyn, KMT; Zwartkruis, FJT; de Rooij, J; Akkerman, JWN; Bos, JL			The small GTPase Rap1 is activated by turbulence and is involved in integrin alpha(IIb)beta(3)-mediated cell adhesion in human megakaryocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLATELETS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; MAP KINASE; T-CELL; CYTOSKELETON; RAS; REGULATOR; SIGNAL; LINE	The small GTPase Rap1, which is activated by a large variety of stimuli, functions in the control of integrin-mediated cell adhesion. Here we show that in human megakaryocytes and several other commonly used hematopoietic cell lines such as K562, Jurkat, and THP- 1, stress induced by gentle tumbling of the samples resulted in rapid and strong activation of Rap1. This turbulence-induced activation could not be blocked by inhibitors previously shown to affect Rap1 activation in human platelets, such as the intracellular calcium chelator BAPTA- AM ( 1,2- bis( 2- aminophenoxy) ethane-N, N,N,N',N'- tetraacetic acid) and various protein kinase C inhibitors. Also inhibition of actin cytoskeleton dynamics did not influence this activation of Rap1, suggesting that this activation is mediated by cell surface receptors. Human platelets, however, were refractory to turbulence-induced activation of Rap1. To determine the consequences of Rap1 activation we measured adhesion of megakaryocytes to fibrinogen, which is mediated by the integrin alpha(IIb) beta(3), in the presence of inhibitors of Rap1 signaling. Introduction of both Rap1GAP and RalGDSRBD in the megakaryoblastic cell line DAMI strongly reduced basal adhesion to immobilized fibrinogen. This inhibition was partially rescued by the phorbol ester 12- O- tetradecanoylphorbol- 13- acetate but not by alpha- thrombin. From these results we conclude that in megakaryocytes turbulence induces Rap1 activation that controls alpha(IIb) beta(3)- mediated cell adhesion.	Univ Utrecht, Med Ctr, Thrombosis & Haemostasis Lab, Dept Haematol, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Bos, JL (corresponding author), Univ Utrecht, Med Ctr, Thrombosis & Haemostasis Lab, Dept Haematol, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.		de rooij, johan/C-1325-2019	de rooij, johan/0000-0001-6101-7875				Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; Davies PF, 1997, ANNU REV PHYSIOL, V59, P527, DOI 10.1146/annurev.physiol.59.1.527; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; FUGMAN DA, 1990, BLOOD, V75, P1252; GREENBERG SM, 1988, BLOOD, V72, P1968; Hackeng CM, 2000, BIOCHEM J, V349, P231, DOI 10.1042/0264-6021:3490231; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kraiss LW, 2000, AM J PHYSIOL-HEART C, V278, pH1537, DOI 10.1152/ajpheart.2000.278.5.H1537; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; OGURA M, 1985, BLOOD, V66, P1384; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Romanenko VG, 2002, AM J PHYSIOL-CELL PH, V282, pC708, DOI 10.1152/ajpcell.00247.2001; Sawada Y, 2001, J CELL SCI, V114, P1221; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; White GC, 1998, THROMB HAEMOSTASIS, V79, P832; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	39	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22412	22417		10.1074/jbc.M212036200	http://dx.doi.org/10.1074/jbc.M212036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690117	hybrid			2022-12-25	WOS:000183503900033
J	Deindl, E; Ziegelhoffer, T; Kanse, SM; Fernandez, B; Neubauer, E; Carmeliet, P; Preissner, KT; Schaper, W				Deindl, E; Ziegelhoffer, T; Kanse, SM; Fernandez, B; Neubauer, E; Carmeliet, P; Preissner, KT; Schaper, W			Receptor-independent role of the urokinase-type plasminogen activator during arteriogenesis	FASEB JOURNAL			English	Article						arteriogenesis; plasminogen system; leukocytes	ANGIOGENESIS; GROWTH; CELLS; MEMBRANE; BINDING; MATRIX; STIMULATION; ENHANCEMENT; PROTEOLYSIS; EXPRESSION	To define the role of the plasminogen activators (PAs) urokinase PA (uPA) and tissue PA (tPA) as well as the uPA receptor (uPAR) in arteriogenesis, we investigated their impact in a rabbit and mouse model of adaptive collateral artery growth. Collateral artery growth was induced by occlusion of the femoral artery in rabbit and wild-type (WT) mice and in mice with targeted inactivation of uPA (uPA(-/-)), tPA (tPA(-/-)), or uPAR (uPAR(-/-)). Northern blot results revealed a significant up-regulation of uPA but not uPAR or tPA in the early phase of arteriogenesis in rabbit and WT mice. This up-regulation on RNA level was followed by an increased protein level and enzymatic activity. Impaired perfusion recovery upon femoral artery ligation was observed by laser Doppler analysis in vivo in uPA-deficient mice but not in uPAR or tPA deficiency compared with WT mice. Immunohistochemical studies revealed an association of leukocyte infiltration with arteriogenesis in WT mice that was strongly reduced in uPA(-/-) but not in uPAR- or tPA-deficient mice. We conclude that arteriogenesis is promoted by an uPA-mediated infiltration of leukocytes that is not dependent on uPAR.	Max Planck Inst Physiol & Clin Res, D-6350 Bad Nauheim, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Katholieke Univ Leuven, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Katholieke Univ Leuven VIB, Louvain, Belgium	Max Planck Society; Justus Liebig University Giessen; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Deindl, E (corresponding author), Max Planck Inst, Dept Expt Cardiol, Benekestr 2, D-61231 Bad Nauheim, Germany.	e.deindl@kerckhoff.mpg.de	Carmeliet, Peter/AAQ-5140-2020; Corujo, Francisco Borja Fernández/AAG-8258-2020; Deindl, Elisabeth/A-2511-2013	Carmeliet, Peter/0000-0001-7961-1821; Corujo, Francisco Borja Fernández/0000-0001-9179-910X; Ziegelhoeffer, Tibor/0000-0001-9320-8481; Kanse, Sandip/0000-0003-0782-9957				Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; Cai WJ, 2000, J MOL CELL CARDIOL, V32, P997, DOI 10.1006/jmcc.2000.1137; CAO DR, 1995, J IMMUNOL, V154, P1817; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; CARMELIET P, 1995, TRENDS CARDIOVAS MED, V5, P117, DOI 10.1016/1050-1738(95)00050-J; Carmeliet Peter, 1996, Seminars in Thrombosis and Hemostasis, V22, P525, DOI 10.1055/s-2007-999055; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; COLLEN D, 1991, BLOOD, V78, P3114; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Deindl E, 2001, BIOTECHNIQUES, V31, P1250, DOI 10.2144/01316bm04; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; Fibbi G, 1998, LAB INVEST, V78, P1109; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HARPEL PC, 1990, J BIOL CHEM, V265, P11289; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Ito WD, 1997, AM J PHYSIOL-HEART C, V273, pH1255, DOI 10.1152/ajpheart.1997.273.3.H1255; Ito WD, 1997, CIRC RES, V80, P829; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KNOEPFLER PS, 1995, J MOL CELL CARDIOL, V27, P1317, DOI 10.1016/S0022-2828(05)82394-6; LEE SW, 1992, J BIOL CHEM, V267, P13020; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LOSKUTOFF DJ, 1995, ANN NY ACAD SCI, V748, P177; MARTINEZ J, 1994, EUR J CELL BIOL, V64, P257; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; Min HY, 1996, CANCER RES, V56, P2428; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; OSSOWSKI L, 1996, CURR TOP MICROBIOL I, V213; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; Scholz D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/jmcc.2002.2013; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; SILVERSTEIN RL, 1986, J BIOL CHEM, V261, P9959; Sitrin RG, 1996, J LEUKOCYTE BIOL, V59, P302, DOI 10.1002/jlb.59.2.302; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; STEPHENS RW, 1992, EUR J BIOCHEM, V207, P937, DOI 10.1111/j.1432-1033.1992.tb17127.x; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; Syrovets T, 1997, N-S ARCH PHARMACOL, V355, P312; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wysocki SJ, 1996, CARDIOVASC RES, V31, P28; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	54	42	44	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1174	+		10.1096/fj.02-0800fje	http://dx.doi.org/10.1096/fj.02-0800fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692088				2022-12-25	WOS:000182580100040
J	Seward, DJ; Koh, AS; Boyer, JL; Ballatori, N				Seward, DJ; Koh, AS; Boyer, JL; Ballatori, N			Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OST alpha-OST beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-STRING PROTEIN; MEMBRANE; GLUTATHIONE; FUSION; FAMILY; DRUGS; LIVER	These studies identify an organic solute transporter (OST) that is generated when two novel gene products are co-expressed, namely human OSTalpha and OSTbeta or mouse OSTalpha and OSTbeta. The results also demonstrate that the mammalian proteins are functionally complemented by evolutionarily divergent Ostalpha-Ostbeta proteins recently identified in the little skate, Raja erinacea, even though the latter exhibit only 25-41% predicted amino acid identity with the mammalian proteins. Human, mouse, and skate OSTalpha proteins are predicted to contain seven transmembrane helices, whereas the OSTbeta sequences are predicted to have a single transmembrane helix. Human OSTalpha-OSTbeta and mouse Ostalpha-Ostbeta cDNAs were cloned from liver mRNA, sequenced, expressed in Xenopus laevis oocytes, and tested for their ability to functionally complement the corresponding skate proteins by measuring transport of [(3)H] estrone 3-sulfate. None of the proteins elicited a transport signal when expressed individually in oocytes; however, all nine OSTalpha-OSTbeta combinations (i.e. OSTalpha-OSTbeta pairs from human, mouse, or skate) generated robust estrone 3-sulfate transport activity. Transport was sodium-independent, saturable, and inhibited by other steroids and anionic drugs. Human and mouse OSTalpha-OSTbeta also were able to mediate transport of taurocholate, digoxin, and prostaglandin E(2) but not of estradiol 17beta-D-glucuronide or p-aminohippurate. OSTalpha and OSTbeta were able to reach the oocyte plasma membrane when expressed either individually or in pairs, indicating that co-expression is not required for proper membrane targeting. Interestingly, OSTalpha and OSTbeta mRNAs were highly expressed and widely distributed in human tissues, with the highest levels occurring in the testis, colon, liver, small intestine, kidney, ovary, and adrenal gland.	Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ctr Liver, New Haven, CT 06520 USA	University of Rochester; Mount Desert Island Biological Laboratory; Yale University; Yale University	Ballatori, N (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, Box EHSC,575 Elmwood Ave, Rochester, NY 14642 USA.	Ned_Ballatori@urmc.rochester.edu			NIDDK NIH HHS [DK25636, DK48823] Funding Source: Medline; NIEHS NIH HHS [ES03828, ES06484, ES01247, ES07026] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025636, R01DK048823, R37DK025636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006484, P50ES003828, P30ES003828, P30ES001247] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ballatori N, 1996, AM J PHYSIOL-REG I, V270, pR1156, DOI 10.1152/ajpregu.1996.270.5.R1156; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Cools J, 2001, FEBS LETT, V492, P204, DOI 10.1016/S0014-5793(01)02240-2; DANTZIG AH, 1994, SCIENCE, V264, P430, DOI 10.1126/science.8153632; Edwardes MDD, 1998, STAT SINICA, V8, P393; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Keppler D, 2000, SEMIN LIVER DIS, V20, P265, DOI 10.1055/s-2000-9391; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li LQ, 2000, MOL PHARMACOL, V58, P335, DOI 10.1124/mol.58.2.335; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Linial M, 1997, J NEUROCHEM, V69, P1781; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Saier MH, 2000, MICROBIOL MOL BIOL R, V64, P354, DOI 10.1128/MMBR.64.2.354-411.2000; Suzuki H, 2000, SEMIN LIVER DIS, V20, P251, DOI 10.1055/s-2000-8408; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang W, 2001, P NATL ACAD SCI USA, V98, P9431, DOI 10.1073/pnas.161099898; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	25	137	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27473	27482		10.1074/jbc.M301106200	http://dx.doi.org/10.1074/jbc.M301106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12719432	hybrid			2022-12-25	WOS:000184242700019
J	Xu, W; Chitnis, P; Valieva, A; van der Est, A; Pushkar, YN; Krzystyniak, M; Teutloff, C; Zech, SG; Bittl, R; Stehlik, D; Zybailov, B; Shen, GZ; Golbeck, JH				Xu, W; Chitnis, P; Valieva, A; van der Est, A; Pushkar, YN; Krzystyniak, M; Teutloff, C; Zech, SG; Bittl, R; Stehlik, D; Zybailov, B; Shen, GZ; Golbeck, JH			Electron transfer in cyanobacterial photosystem I - I. Physiological and spectroscopic characterization of site-directed mutants in a putative electron transfer pathway from A(0) through A(1) to F-x	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; PHOTOSYNTHETIC REACTION CENTERS/; STRUCTURAL MODEL; ACCEPTOR A(1); RESOLUTION; BACTERIA; BINDING; ENDOR	The Photosystem I (PS I) reaction center contains two branches of nearly symmetric cofactors bound to the PsaA and PsaB heterodimer. From the x-ray crystal structure it is known that Trp(PsaA)(697) and Trp(PsaB)(677) are pi-stacked with the head group of the phylloquinones and are H-bonded to Ser(692) PsaA and Ser(672) PsaB, whereas Arg(694) (PsaA) and Arg(PsaB)(674) are involved in a H-bonded network of side groups that connects the binding environments of the phylloquinones and F-X. The mutants W697F(PsaA), W677F(PsaB), S692C(PsaA), S672C(PsaB), R694A(PsaA), and R674A(PsaB) were constructed and characterized. All mutants grew photoautotrophically, yet all showed diminished growth rates compared with the wild-type, especially at higher light intensities. EPR and electron nuclear double resonance (ENDOR) studies at both room temperature and in frozen solution showed that the PsaB mutants were virtually identical to the wildtype, whereas significant effects were observed in the PsaA mutants. Spin polarized transient EPR spectra of the P-700 (+)A(1)(-) radical pair show that none of the mutations causes a significant change in the orientation of the measured phylloquinone. Pulsed ENDOR spectra reveal that the W697F(PsaA) mutation leads to about a 5% increase in the hyperfine coupling of the methyl group on the phylloquinone ring, whereas the S692C(PsaA) mutation causes a similar decrease in this coupling. The changes in the methyl hyperfine coupling are also reflected in the transient EPR spectra of P-700 (+)A(1)(-) and the CW EPR spectra of photoaccumulated A(1)(-). We conclude that: (i) the transient EPR spectra at room temperature are predominantly from radical pairs in the PsaA branch of cofactors; (ii) at low temperature the electron cycle involving P-700 and A(1) similarly occurs along the PsaA branch of cofactors; and (iii) mutation of amino acids in close contact with the PsaA side quinone leads to changes in the spin density distribution of the reduced quinone observed by EPR.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada; Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Iowa State University; Brock University; Free University of Berlin	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.		Bittl, Robert/I-8149-2013; Valieva, Alfia I./ABE-8092-2021	Bittl, Robert/0000-0003-4103-3768; Valieva, Alfia I./0000-0003-2988-6098; Xu, Wu/0000-0002-2982-3276; Zybailov, Boris/0000-0003-2432-9145				Boudreaux B, 2001, J BIOL CHEM, V276, P37299, DOI 10.1074/jbc.M102327200; Brettel K, 2001, BBA-BIOENERGETICS, V1507, P100, DOI 10.1016/S0005-2728(01)00202-X; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; Fromme P, 1999, CONCEPTS IN PHOTOBIOLOGY, P181; Fursman CE, 2002, J PHYS CHEM B, V106, P9679, DOI 10.1021/jp0257202; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Hanley J, 1997, BIOCHEMISTRY-US, V36, P11543, DOI 10.1021/bi971360a; Hastings G, 2001, BIOCHEMISTRY-US, V40, P3681, DOI 10.1021/bi0023100; Itoh S, 2001, BBA-BIOENERGETICS, V1507, P115, DOI 10.1016/S0005-2728(01)00199-2; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; KANDRASHKIN YE, 2002, RIKEN REV, V44, P124; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Purton S, 2001, BIOCHEMISTRY-US, V40, P2167, DOI 10.1021/bi0019489; Rigby SEJ, 2001, BBA-BIOENERGETICS, V1507, P247, DOI 10.1016/S0005-2728(01)00211-0; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Shen GZ, 2002, J BIOL CHEM, V277, P20343, DOI 10.1074/jbc.M201103200; van der Est A, 1998, BBA-BIOENERGETICS, V1409, P87, DOI 10.1016/S0005-2728(98)00152-2; van der Est A, 2001, BBA-BIOENERGETICS, V1507, P212, DOI 10.1016/S0005-2728(01)00204-3; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; Xu W, 2003, J BIOL CHEM, V278, P27876, DOI 10.1074/jbc.M302965200; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; Zech SG, 2000, J PHYS CHEM B, V104, P9728, DOI 10.1021/jp002125w	24	68	77	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27864	27875		10.1074/jbc.M302962200	http://dx.doi.org/10.1074/jbc.M302962200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12721305	hybrid			2022-12-25	WOS:000184242700068
J	Bayer, E; Goettsch, S; Mueller, JW; Griewel, B; Guiberman, E; Mayr, LM; Bayer, P				Bayer, E; Goettsch, S; Mueller, JW; Griewel, B; Guiberman, E; Mayr, LM; Bayer, P			Structural analysis of the mitotic regulator hPin1 in solution - Insights into domain architecture and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL ISOMERASE PIN1; DEPENDENT PROLINE ISOMERIZATION; PHOSPHOSERINE-BINDING; PHOSPHORYLATION; MECHANISM; PROTEINS; MITOSIS; P53; RECOGNITION; ENTRY	The peptidyl-prolyl cis/trans isomerase hPin1 is a phosphorylation-dependent regulatory enzyme whose substrates are proteins involved in regulation of cell cycle, transcription, Alzheimer's disease, and cancer pathogenesis. We have determined the solution structure of the two domain protein hPin1-(1-163) and its separately expressed PPIase domain ( 50-163) ( hPin1(PPIase)) with an root mean square deviation of <0.5 &ANGS; over backbone atoms using NMR. Domain organization of hPin1 differs from that observed in structures solved by x-ray crystallography. Whereas PPIase and WW domain are tightly packed onto each other and share a common binding interface in crystals, our NMR-based data revealed only weak interaction of both domains at their interface in solution. Interaction between the two domains of full-length hPin1 is absent when the protein is dissected into the catalytic and the WW domain. It indicates that the flexible linker, connecting both domains, promotes binding. By evaluation of NOESY spectra we can show that the &alpha;1/&beta;1 loop, which was proposed to undergo a large conformational rearrangement in the absence of sulfate and an Ala-Pro peptide, remained in the closed conformation under these conditions. Dissociation constants of 0.4 and 2.0 mM for sulfate and phosphate ions were measured at 12 &DEG;C by fluorescence spectroscopy. Binding of sulfate prevents hPin1 aggregation and changes surface charges across the active center and around the reactive and catalytically essential Cys(113). In the absence of sulfate and/or reducing agent this residue seems to promote aggregation, as observed in hPin1 solutions in vitro.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Interdisciplinary Ctr Magnet Resonance, D-44227 Dortmund, Germany; Novartis Pharma AG, Lead Discovery Ctr, GSO, CH-4002 Basel, Switzerland	Max Planck Society; Novartis	Bayer, P (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.		Mueller, Jonathan Wolf/D-1632-2010; Bayer, Peter/B-8803-2009	Mueller, Jonathan Wolf/0000-0003-1212-189X; Bayer, Peter/0000-0003-0435-7202				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bertini I, 2001, J BIOMOL NMR, V21, P85, DOI 10.1023/A:1012422402545; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Jacobs DM, 2003, J BIOL CHEM, V278, P26174, DOI 10.1074/jbc.M300796200; Jacobs DM, 2002, J BIOMOL NMR, V23, P163, DOI 10.1023/A:1016364324096; Kipping M, 2001, BIOCHEMISTRY-US, V40, P7957, DOI 10.1021/bi010317r; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landrieu I, 2002, J MOL BIOL, V320, P321, DOI 10.1016/S0022-2836(02)00429-1; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; MERITT EA, 1997, METHOD ENZYMOL, V277, P505; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Rippmann JF, 2000, CELL GROWTH DIFFER, V11, P409; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Surmacz TA, 2002, J MOL BIOL, V321, P235, DOI 10.1016/S0022-2836(02)00615-0; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; WILLIAMSON MP, 1993, J MAGN RESON SER B, V101, P63, DOI 10.1006/jmrb.1993.1008; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wintjens R, 2001, J BIOL CHEM, V276, P25150, DOI 10.1074/jbc.M010327200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026	36	111	117	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26183	26193		10.1074/jbc.M300721200	http://dx.doi.org/10.1074/jbc.M300721200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12721297	hybrid			2022-12-25	WOS:000183920200117
J	Lemjabbar, H; Li, DZ; Gallup, M; Sidhu, S; Drori, E; Basbaum, C				Lemjabbar, H; Li, DZ; Gallup, M; Sidhu, S; Drori, E; Basbaum, C			Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR; EGF-RECEPTOR; ENDOTHELIAL-CELLS; CIGARETTE-SMOKE; ACTIVATION; CARCINOGENESIS; INCREASES; OXIDASE	Cells dividing at the time of carcinogen exposure are at particular risk for neoplasia. Tobacco smoke contains numerous carcinogens, and we find that smoke, in the absence of exogenous growth factors, is capable of stimulating cell proliferation. The smoke-triggered mechanism includes the generation of oxygen radicals, which in turn stimulate tumor necrosis factor alpha-converting enzyme (a disintegrin and metalloproteinase (ADAM) 17) to cleave transmembrane amphiregulin, a ligand for the epidermal growth factor receptor (EGFR). The binding of amphiregulin to EGFR then stimulates proliferation of lung epithelial cells. These results shed light on the pathogenesis of lung cancer, suggest novel drug targets for the reduction of cancer risk in smokers, and provide insight into how EGFR integrates responses to diverse noxious stimuli.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Program Biomed Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.			Sidhu, Sukhvinder/0000-0002-2999-4358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043762, P01HL024136] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1 HL43762, P0-1 HL24136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Banzet N, 1999, REDOX REP, V4, P229, DOI 10.1179/135100099101534945; Barsky SH, 1998, JNCI-J NATL CANCER I, V90, P1198, DOI 10.1093/jnci/90.16.1198; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; CARPENTER G, 2000, SCI STKE; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; COFFER PJ, 1995, ONCOGENE, V11, P561; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Gebremichael A, 1996, TOXICOL APPL PHARM, V141, P76; GENSCH E, 1999, P ANN INV M STAT CAL; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Inoue N, 2001, ATHEROSCLEROSIS, V155, P45, DOI 10.1016/S0021-9150(00)00530-X; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Leserer M, 2000, IUBMB LIFE, V49, P405; Obara T, 1999, J Hepatobiliary Pancreat Surg, V6, P229, DOI 10.1007/s005340050112; Peek RM, 1997, JNCI-J NATL CANCER I, V89, P863, DOI 10.1093/jnci/89.12.863; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SEKHON HS, 1994, AM J PHYSIOL-LUNG C, V267, pL557, DOI 10.1152/ajplung.1994.267.5.L557; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Wang YH, 2000, CANCER RES, V60, P6008; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026	31	149	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26202	26207		10.1074/jbc.M207018200	http://dx.doi.org/10.1074/jbc.M207018200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12711607	hybrid			2022-12-25	WOS:000183920200119
J	Bin, LH; Xu, LG; Shu, HB				Bin, LH; Xu, LG; Shu, HB			TIRP, a novel Toll/interleukin-1 receptor (TIR) domain-containing adapter protein involved in TIR signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; IL-1 RECEPTOR; ACCESSORY PROTEIN; MICE LACKING; KINASE IRAK; INTERLEUKIN-1; INNATE; MYD88; ACTIVATION; MOLECULE	The Toll/interleukin-1 receptor (TIR) family members play important roles in host defense. These receptors signal through TIR domain-containing adapter proteins. In this report, we identified a novel TIR domain-containing adapter protein designated as TIRP. Co-immunoprecipitation experiments suggest that TIRP is associated with IL-1 receptors. TIRP also interacts with kinase-inactive mutants of IRAK and IRAK-4, IRAK-2, IRAK-M, and TRAF6. Overexpression of TIRP activates NF-kappaB and potentiates IL-1 receptor-mediated NF-kappaB activation. A dominant negative mutant of TIRP inhibits IL-1- but not tumor necrosis factor-triggered NF-kappaB activation. Moreover, TIRP-mediated NF-kappaB activation is inhibited by dominant negative mutants of IRAK, IRAK-2, TRAF6, and IKKbeta. Our findings suggest that TIRP is involved in IL-1-triggered NF-kappaB activation and functions upstream of IRAK, IRAK-2, TRAF6, and IKKbeta.	Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Peking University	Shu, HB (corresponding author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Immunol, 1400 Jackson St,K516C, Denver, CO 80206 USA.	shuh@njc.org		Xu, Liangguo/0000-0003-1991-2889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049992] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kanakaraj P, 1999, J EXP MED, V189, P1129, DOI 10.1084/jem.189.7.1129; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Martin MU, 2002, BBA-MOL CELL RES, V1592, P265, DOI 10.1016/S0167-4889(02)00320-8; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Thomas JA, 1999, J IMMUNOL, V163, P978; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	34	83	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24526	24532		10.1074/jbc.M303451200	http://dx.doi.org/10.1074/jbc.M303451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721283	hybrid			2022-12-25	WOS:000183824800035
J	Chen, Y; Rice, PA				Chen, Y; Rice, PA			The role of the conserved Trp(330) in Flp-mediated recombination - Functional and structural analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINASE; HUMAN TOPOISOMERASE-I; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; DNA RECOMBINATION; INTEGRASE FAMILY; C-TERMINUS; PROTEIN; CLEAVAGE; BINDING	The active site of Flp contains, in addition to a trans-donated nucleophilic tyrosine, five other residues that are highly conserved within the lambda-integrase family of site-specific recombinases and the type IB topoisomerases. We have used site-directed mutagenesis and x-ray crystallography to investigate the roles of two such residues, Lys(223) and Trp(330). Our findings agree with studies on related enzymes showing the importance of Lys(223) in catalysis but demonstrate that in Flp-mediated recombination the primary role of Trp(330) is architectural rather than catalytic. Eliminating the hydrogen bonding potential of Trp(330) by phenylalanine substitution results in surprisingly small changes in reaction rates, compared with dramatic decreases in the activities of W330A, W330H, and W330Q. The structure of a W330F mutant-DNA complex reveals an active site nearly identical to that of the wild type. The phenylalanine side chain preserves most of the van der Waals interactions Trp(330) forms with the Tyr(343)-containing trans helix, which may be particularly important for the docking of this helix. Our studies of Trp(330) provide the first detailed examination of this conserved residue in the lambda-integrase family, suggesting that the relative importance of active site residues may differ among Flp and related enzymes.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Rice, PA (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.	price@midway.uchicago.edu	Chen, Yu/A-4714-2012		NIGMS NIH HHS [GM58827] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058827] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchholz F, 1998, NAT BIOTECHNOL, V16, P657, DOI 10.1038/nbt0798-657; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Caron P R, 1994, Adv Pharmacol, V29B, P271; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHEN JW, 1992, MOL CELL BIOL, V12, P3757, DOI 10.1128/MCB.12.9.3757; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Conway AB, 2003, J MOL BIOL, V326, P425, DOI 10.1016/S0022-2836(02)01370-0; FRIESEN H, 1992, J MOL BIOL, V225, P313, DOI 10.1016/0022-2836(92)90924-9; GATES CA, 1988, P NATL ACAD SCI USA, V85, P4628, DOI 10.1073/pnas.85.13.4628; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; Grainge I, 2001, J MOL BIOL, V314, P717, DOI 10.1006/jmbi.2001.5194; Grishin NV, 2000, NUCLEIC ACIDS RES, V28, P2229, DOI 10.1093/nar/28.11.2229; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Kazmierczak RA, 2002, NUCLEIC ACIDS RES, V30, P5193, DOI 10.1093/nar/gkf652; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; KULPA J, 1993, J BIOL CHEM, V268, P1101; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee J, 1997, GENE DEV, V11, P2438, DOI 10.1101/gad.11.18.2438; MEYERLEON L, 1987, NUCLEIC ACIDS RES, V15, P6469, DOI 10.1093/nar/15.16.6469; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PAN H, 1991, J BIOL CHEM, V266, P11347; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Prates JAM, 2001, STRUCTURE, V9, P1183, DOI 10.1016/S0969-2126(01)00684-0; Radisky ES, 2002, P NATL ACAD SCI USA, V99, P10316, DOI 10.1073/pnas.112332899; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; SADOWSKI PD, 1995, PROG NUCLEIC ACID RE, V51, P53, DOI 10.1016/S0079-6603(08)60876-4; SERRE MC, 1992, J MOL BIOL, V225, P643, DOI 10.1016/0022-2836(92)90391-V; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tekle M, 2002, J MOL BIOL, V324, P649, DOI 10.1016/S0022-2836(02)01108-7; Van Duyne G.D., 2002, MOBILE DNA, VII, P93; Woods KC, 2001, J MOL BIOL, V313, P49, DOI 10.1006/jmbi.2001.5012; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200	52	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24800	24807		10.1074/jbc.M300853200	http://dx.doi.org/10.1074/jbc.M300853200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716882	hybrid			2022-12-25	WOS:000183824800067
J	Maeno, K; Sada, K; Kyo, S; Miah, SMS; Kawauchi-Kamata, K; Qu, XJ; Shi, YH; Yamamura, H				Maeno, K; Sada, K; Kyo, S; Miah, SMS; Kawauchi-Kamata, K; Qu, XJ; Shi, YH; Yamamura, H			Adaptor protein 3BP2 is a potential ligand of Src homology 2 and 3 domains of Lyn protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; CELL ACTIVATION; C-SRC; SYK; RECEPTOR; PHOSPHORYLATION; IDENTIFICATION; SITE; CD45; AUTOPHOSPHORYLATION	Adaptor protein 3BP2, a c-Abl-Src homology 3 (SH3) domain-binding protein, is known to play a regulatory role in T-cell receptor-mediated transcriptional activation of nuclear factor of activated T cell and activator protein 1 by interacting with Syk/ZAP-70 protein-tyrosine kinase. We have previously demonstrated that aggregation of high affinity IgE receptor (FcRepsilonI) induces tyrosine phosphorylation of 3BP2, and overexpression of the 3BP2-SH2 domain suppresses antigen- induced degranulation in rat basophilic leukemia RBL-2H3 mast cell line. In this report, we attempt to analyze the biological relevance of 3BP2 tyrosine phosphorylation. By using the transient expression system in COS-7 cells, we have demonstrated that 3BP2 was predominantly phosphorylated on Tyr(174), Tyr(183), and Tyr(446) when it was coexpressed with Syk. An in vitro binding study revealed that phosphorylation of Tyr(446) by Syk was likely to create a binding site for the Lyn-SH2 domain in RBL-2H3 cells. In addition, proline-rich region of 3BP2 bound to the Lyn-SH3 domain. Conformational microscopic analysis showed that Lyn and 3BP2 are constitutively colocalized in RBL-2H3 cells. Overexpression of 3BP2 in RBL-2H3 cells resulted in an enhancement of Lyn autophosphorylation. These results suggest that the adaptor protein 3BP2 is a potential regulator of Lyn protein-tyrosine kinase as a ligand of its SH3/SH2 domains in FcepsilonRI-mediated signaling in mast cells.	Kobe Univ, Div Proteom, Dept Genome Sci, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Sada, K (corresponding author), Kobe Univ, Div Proteom, Dept Genome Sci, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	ksada@med.kobe-u.ac.jp	Shi, Yuhong/I-3987-2014; Kawauchi, Keiko/G-4198-2010; Sada, Kiyonao/H-7373-2015	Sada, Kiyonao/0000-0001-6124-3100				Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; Couture C, 1996, J BIOL CHEM, V271, P24294, DOI 10.1074/jbc.271.39.24294; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; EISEMAN E, 1992, NATURE, V355, P78; Foucault I, 2003, J BIOL CHEM, V278, P7146, DOI 10.1074/jbc.M209509200; Furlong MT, 1997, BBA-MOL CELL RES, V1355, P177, DOI 10.1016/S0167-4889(96)00131-0; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; Jevremovic D, 2001, J IMMUNOL, V166, P7219, DOI 10.4049/jimmunol.166.12.7219; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Keshvara LM, 1998, J IMMUNOL, V161, P5276; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Latour S, 1997, MOL CELL BIOL, V17, P4434, DOI 10.1128/MCB.17.8.4434; Mitsui N, 2002, EMBO J, V21, P3274, DOI 10.1093/emboj/cdf328; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sada K, 1997, EUR J BIOCHEM, V248, P827, DOI 10.1111/j.1432-1033.1997.00827.x; Sada K, 2002, BLOOD, V100, P2138, DOI 10.1182/blood-2001-12-0340; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Siraganian RP, 2002, MOL IMMUNOL, V38, P1229, DOI 10.1016/S0161-5890(02)00068-8; Stauffer TP, 1997, BIOCHEMISTRY-US, V36, P9388, DOI 10.1021/bi970781p; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; Yanagi S, 2001, BLOOD, V98, P2869, DOI 10.1182/blood.V98.9.2869; Zhang J, 2000, J BIOL CHEM, V275, P35442, DOI 10.1074/jbc.M004549200; Zhang J, 1999, J IMMUNOL, V163, P2508; Zhang J, 2002, MOL CELL BIOL, V22, P8144, DOI 10.1128/MCB.22.23.8144-8154.2002	39	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24912	24920		10.1074/jbc.M301201200	http://dx.doi.org/10.1074/jbc.M301201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709437	hybrid			2022-12-25	WOS:000183824800081
J	Vella, V; Zhu, JY; Frasca, F; Li, CY; Vigneri, P; Vigneri, R; Wang, JYJ				Vella, V; Zhu, JY; Frasca, F; Li, CY; Vigneri, P; Vigneri, R; Wang, JYJ			Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; RETINOBLASTOMA PROTEIN FUNCTION; TERMINAL REPEATED DOMAIN; P53 HOMOLOG P73; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; BCR SEQUENCES; HUMAN CANCERS	The p73alpha protein is a functional homolog of the p53 tumor suppressor. Although the TP53 gene is frequently mutated in human cancers, the TP73 gene is rarely inactivated. We have found that p73alpha is highly expressed in a significant fraction of anaplastic thyroid cancer, whereas it is not detectable in normal thyroid epithelial cells or in papillary and follicular thyroid cancer cells. Interestingly, the tumor suppression function of p73alpha is actively restrained in anaplastic thyroid cancer cells. We have also found that c-Abl tyrosine kinase, an activator of p73, is excluded from the nucleus of p73alpha-positive thyroid cancer cells; whereas c-Abl undergoes nuclear-cytoplasmic shuttling in normal thyroid and p73-negative thyroid cancer cells. We constructed an AblNuk-FK506-binding protein (FKBP) fusion protein to enforce the nuclear accumulation of an inducible Abl kinase. Activation of this nuclear AblNuk-FKBP by dimerization with AP20187 in anaplastic thyroid cancer cells increased the levels of p73alpha and p21Cip1 and caused p73-dependent apoptosis. These results suggest subcellular segregation of c-Abl from p73 to be a strategy for disrupting the tumor suppression function of p73alpha.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Catania, Inst Med Interna Malattie Endocrine Metab, I-95125 Catania, Italy; Univ Catanzaro Magna Graecia, I-88100 Catanzaro, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Catania; Magna Graecia University of Catanzaro	Wang, JYJ (corresponding author), Univ Calif San Diego, Div Biol Sci, Bonner Hall 3326,9500 Gilman Dr, La Jolla, CA 92093 USA.		Vella, Veronica/N-7977-2018; Frasca, Francesco/J-1332-2018; Vella, Veronica/AAX-5690-2020; Vigneri, Paolo G/K-8504-2016; Vigneri, Riccardo/M-3968-2017	Vella, Veronica/0000-0002-4968-8550; Frasca, Francesco/0000-0002-5556-3201; Vigneri, Paolo G/0000-0002-5943-6066; Vigneri, Riccardo/0000-0002-4401-3140	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, CA43054, R01 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baskaran R, 1999, CELL GROWTH DIFFER, V10, P387; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Han S, 1999, EUR J SURG ONCOL, V25, P194, DOI 10.1053/ejso.1998.0626; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawano S, 1999, BLOOD, V94, P1113; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZH, 2001, EXP THERM FLUID SCI, V25, P447, DOI 10.1016/S0894-1777(01)00101-7; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mihara M, 1999, BRIT J CANCER, V79, P164, DOI 10.1038/sj.bjc.6690027; Nomoto S, 1998, CANCER RES, V58, P1380; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Shishikura T, 1999, INT J CANCER, V84, P321, DOI 10.1002/(SICI)1097-0215(19990621)84:3<321::AID-IJC21>3.0.CO;2-S; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Smith KM, 2001, J BIOL CHEM, V276, P24372, DOI 10.1074/jbc.M100786200; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; WANG JYJ, 1984, CELL, V36, P349; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257	57	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25151	25157		10.1074/jbc.M301962200	http://dx.doi.org/10.1074/jbc.M301962200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716888	hybrid			2022-12-25	WOS:000183824800109
J	Yang, LK; Manithody, C; Olson, ST; Alireza, RR				Yang, LK; Manithody, C; Olson, ST; Alireza, RR			Contribution of basic residues of the autolysis loop to the substrate and inhibitor specificity of factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING EXOSITE; COAGULATION-FACTOR IXA; FACTOR XA SPECIFICITY; ACTIVATED PROTEIN-C; FACTOR-FACTOR VIIA; PRO-TRP INSERTION; FACTOR-VA BINDING; BLOOD-COAGULATION; TISSUE FACTOR; MOLECULAR-BASIS	The autolysis loop (residues 143-154 in chymotrypsinogen numbering) plays a pivotal role in determining the macromolecular substrate and inhibitor specificity of coagulation proteases. This loop in factor IXa (FIXa) has 3 basic residues (Arg(143), Lys(147), and Arg(150)) whose contribution to the protease specificity of factor IXa has not been studied. Here, we substituted these residues individually with Ala in Gla-domainless forms of recombinant factor IX expressed in mammalian cells. All mutants exhibited normal amidolytic activities toward a FIXa-specific chromogenic substrate. However, Arg(143) and Lys(147) mutants showed a similar to3- to 6-fold impairment in FX activation, whereas the Arg(150) mutant activated factor X normally both in the absence and presence of factor VIIIa. By contrast, Arg(143) and Lys(147) mutants reacted normally with antithrombin ( AT) in both the absence and presence of the cofactor, heparin. However, the reactivity of the Arg(150) mutant with AT was impaired 6.6-fold in the absence of heparin and 33- to 70-fold in the presence of pentasaccharide and full-length heparins. These results suggest that Arg(143) and Lys(147) of the autolysis loop are recognition sites for FX independent of factor VIIIa, and Arg(150) is a specific recognition site for AT that can effectively interact with AT only if the serpin is in the heparin-activated conformation.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	Saint Louis University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Alireza, RR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R29HL039888, R37HL039888, R01HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888, HL-62565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEDSTED T, 2003, IN PRESS BIOCHEMISTR; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FUCHS HE, 1984, J CLIN INVEST, V73, P1696, DOI 10.1172/JCI111377; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gale AJ, 2000, BLOOD, V96, P585; HAMAGUCHI N, 1991, J BIOL CHEM, V266, P15213; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; Huntington JA, 1998, BIOCHEMISTRY-US, V37, P3272, DOI 10.1021/bi972182o; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JORDAN RE, 1980, J BIOL CHEM, V255, P81; Kolkman JA, 2000, BIOCHEM J, V350, P701, DOI 10.1042/0264-6021:3500701; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PIETERS J, 1990, BLOOD, V76, P549; Quinsey NS, 2002, J BIOL CHEM, V277, P15971, DOI 10.1074/jbc.M108131200; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2003, THROMB HAEMOSTASIS, V89, P112; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; Schmidt AE, 2003, TRENDS CARDIOVAS MED, V13, P39, DOI 10.1016/S1050-1738(02)00210-4; Shen L, 1999, THROMB HAEMOSTASIS, V82, P1078, DOI 10.1055/s-0037-1614332; Sichler K, 2003, J BIOL CHEM, V278, P4121, DOI 10.1074/jbc.M210722200; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; STENFLO J, 1991, BLOOD, V78, P1637; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Thiec F, 2003, J BIOL CHEM, V278, P10393, DOI 10.1074/jbc.M212144200; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wilkinson FH, 2002, J BIOL CHEM, V277, P5734, DOI 10.1074/jbc.M107753200; Yang LK, 2002, J BIOL CHEM, V277, P50756, DOI 10.1074/jbc.M208485200; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	45	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25032	25038		10.1074/jbc.M302174200	http://dx.doi.org/10.1074/jbc.M302174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721300	hybrid			2022-12-25	WOS:000183824800096
J	Chan, JKL; Sun, LG; Yang, XJ; Zhu, G; Wu, ZG				Chan, JKL; Sun, LG; Yang, XJ; Zhu, G; Wu, ZG			Functional characterization of an amino-terminal region of HDAC4 that possesses MEF2 binding and transcriptional repressive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HISTONE DEACETYLASES; MUSCLE DIFFERENTIATION; DNA-BINDING; ACTIVATION; ASSOCIATION; EXPRESSION; PROTEINS; MYOD; LOCALIZATION; INHIBITION	Like the full-length histone deacetylase (HDAC) 4, its amino terminus (amino acids 1-208) without the carboxyl deacetylase domain is also known to effectively bind and repress myocyte enhancer factor 2 (MEF2). Within this repressive amino terminus, we further show that a stretch of 90 amino acids (119-208) displays MEF2 binding and repressive activity. The same region is also found to associate specifically with HDAC1 which is responsible for the repressive effect. The amino terminus of HDAC4 can associate with the DNA-bound MEF2 in vitro, suggesting that it does not repress MEF2 simply by disrupting the ability of MEF2 to bind DNA. In vivo, MEF2 induces nuclear translocation of both the full-length HDAC4 and HDAC4-(1-208), whereas the nuclear HDAC4 as well as HDAC4-(1-208) in turn specifically sequesters MEF2 to distinct nuclear bodies. In addition, we show that MyoD and HDAC4 functionally antagonize each other to regulate MEF2 activity. Combined with data from others, our data suggest that the full-length HDAC4 can repress MEF2 through multiple independent repressive domains.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; McGill Univ, Mol Oncol Grp, Dept Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada	Hong Kong University of Science & Technology; McGill University	Wu, ZG (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Wu, Zhenguo/B-8144-2013	Wu, Zhenguo/0000-0003-3049-8324				Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Henikoff JG, 1996, METHOD ENZYMOL, V266, P88; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2002, CURR OPIN CELL BIOL, V14, P763, DOI 10.1016/S0955-0674(02)00389-7; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200	41	58	58	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23515	23521		10.1074/jbc.M301922200	http://dx.doi.org/10.1074/jbc.M301922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12709441	hybrid			2022-12-25	WOS:000183638600039
J	Dixon, DP; McEwen, AG; Lapthorn, AJ; Edwards, R				Dixon, DP; McEwen, AG; Lapthorn, AJ; Edwards, R			Forced evolution of a herbicide detoxifying glutathione transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTED DIPHENYLETHER HERBICIDES; S-TRANSFERASE; PHAGE DISPLAY; ACTIVE-SITE; CLONING; PLANTS; IDENTIFICATION; RECOMBINATION; FLUORODIFEN; PEROXIDASES	Plant Tau class glutathione transferases (GSTUs) detoxify diphenylether herbicides such as fluorodifen, determining their selectivity in crops and weeds. Using reconstructive PCR, a series of mutant GSTUs were generated from in vitro recombination and mutagenesis of the maize sequences ZmGSTU1 and ZmGSTU2 ( with the prefix Zm designating Zea mays L.). A screen of 5000 mutant GSTUs identified seven enzymes with enhanced fluorodifen detoxifying activity. The best performing enhanced fluorodifen detoxifying mutant (EFD) had activity 19-fold higher than the parent enzymes, with a single point mutation conferring this enhancement. Further mutagenesis of this residue generated an EFD with a 29-fold higher catalytic efficiency toward fluorodifen as compared with the parents but with unaltered catalysis toward other substrates. When expressed in Arabidopsis thaliana, the optimized EFD, but not the parent enzymes, conferred enhanced tolerance to fluorodifen. Molecular modeling predicts that the serendipitous mutation giving the improvement in detoxification is due to the removal of an unfavorable interaction together with the introduction of a favorable change in conformation of residues 107-119, which contribute to herbicide binding.	Univ Durham, Crop Protect Grp, Sch Biol & Biomed Sci, Durham DH1 3LE, England; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland	Durham University; University of Glasgow	Edwards, R (corresponding author), Univ Durham, Crop Protect Grp, Sch Biol & Biomed Sci, South Rd, Durham DH1 3LE, England.	Robert.Edwards@durham.ac.uk	Dixon, David P/B-5413-2008	Dixon, David P/0000-0003-4644-8399; McEwen, Alastair G./0000-0003-4484-3512; Lapthorn, Adrian/0000-0002-2197-8134; Edwards, Robert/0000-0003-0809-5991				Andrews CJ, 1997, PESTIC SCI, V51, P213, DOI 10.1002/(SICI)1096-9063(199710)51:2&lt;213::AID-PS622&gt;3.0.CO;2-L; Babbitt PC, 2000, P NATL ACAD SCI USA, V97, P10298, DOI 10.1073/pnas.97.19.10298; Broo K, 2002, J MOL BIOL, V318, P59, DOI 10.1016/S0022-2836(02)00032-3; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Cummins I, 1999, PLANT J, V18, P285, DOI 10.1046/j.1365-313X.1999.00452.x; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dixon DP, 1998, PLANT MOL BIOL, V36, P75, DOI 10.1023/A:1005958711207; Dixon DP, 1999, PLANT MOL BIOL, V40, P997, DOI 10.1023/A:1006257305725; Edwards R, 1996, PHYSIOL PLANTARUM, V98, P594, DOI 10.1111/j.1399-3054.1996.tb05716.x; EDWARDS R, 2000, HERBICIDES THEIR MEC, P38; FREAR DS, 1973, PESTIC BIOCHEM PHYS, V3, P473, DOI 10.1016/0048-3575(73)90073-4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULICK AM, 1995, P NATL ACAD SCI USA, V92, P8140, DOI 10.1073/pnas.92.18.8140; Hansson LO, 1999, BIOCHEM J, V344, P93, DOI 10.1042/0264-6021:3440093; Hansson LO, 1997, BIOCHEMISTRY-US, V36, P11252, DOI 10.1021/bi9702952; JEPSON I, 1994, PLANT MOL BIOL, V26, P1855, DOI 10.1007/BF00019498; Lassner M, 2001, CURR OPIN PLANT BIOL, V4, P152, DOI 10.1016/S1369-5266(00)00152-7; McGonigle B, 2000, PLANT PHYSIOL, V124, P1105, DOI 10.1104/pp.124.3.1105; Neuefeind T, 1997, J MOL BIOL, V274, P577, DOI 10.1006/jmbi.1997.1401; Neuefeind T, 1997, J MOL BIOL, V274, P446, DOI 10.1006/jmbi.1997.1402; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; Owen W.J., 2000, METABOLISM AGROCHEMI, P211; SHIMABUKURO RH, 1973, PESTIC BIOCHEM PHYS, V3, P483, DOI 10.1016/0048-3575(73)90074-6; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Thom R, 2002, BIOCHEMISTRY-US, V41, P7008, DOI 10.1021/bi015964x; TOPFER R, 1993, METHOD ENZYMOL, V217, P66; WIDERSTEN M, 1995, J MOL BIOL, V250, P115, DOI 10.1006/jmbi.1995.0362	28	92	102	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23930	23935		10.1074/jbc.M303620200	http://dx.doi.org/10.1074/jbc.M303620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692133	hybrid			2022-12-25	WOS:000183638600091
J	Mizel, SB; West, AP; Hantgan, RR				Mizel, SB; West, AP; Hantgan, RR			Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; TERMINAL REGIONS; CUTTING EDGE; BACTERIAL FLAGELLIN; CD14; TLR4; LIPOPOLYSACCHARIDE; ACTIVATION	Flagellins from Gram-negative bacteria activate inflammatory cells by a toll-like receptor 5 (TLR5)-dependent signaling pathway. We have examined the interaction between flagellin and TLR5 using an in vitro binding assay. Purified recombinant His-tagged flagellin from Salmonella enteritidis bound to TLR5 in detergent lysates from COS-1 cells transiently transfected with a human TLR5 expression plasmid. Flagellins from Salmonella typhimurium and Escherichia coli also bound to TLR5. The specificity of this interaction was demonstrated by its concentration dependence and lack of TLR5 binding to a biologically inactive form of flagellin or to a His-tagged non-flagellar protein. Flagellin bound to the extracellular domain of TLR5 expressed on the surface of COS-1 cells and to a soluble, monomeric form of the extracellular domain ( amino acids 1-636). Although a TLR5 extracellular domain containing amino acids 1-407 retained flagellin binding activity, binding was not evident with a TLR5 peptide encoding residues 1-386. Conversely, a peptide containing amino acid residues 386-636 retained flagellin binding. Thus it is likely that amino acids 386-407 is a binding site for flagellin. This sequence contains a putative leucine-rich repeat. These results support the conclusion that flagellin signaling via TLR5 involves a direct interaction between flagellin and a leucine-rich region in TLR5. We also show that the NH2-terminal 358 amino acids of TLR5 play an important role in its signaling activity. Our results provide, for the first time, a molecular basis for the agonist specificity of a TLR.	Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Mizel, SB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	smizel@wfubmc.edu	West, A. Phillip/A-7867-2009; West, A. Phillip/W-8171-2019	West, A. Phillip/0000-0003-2884-6895	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038670, R01AI038670, R01AI051319] Funding Source: NIH RePORTER; NIAID NIH HHS [AI51319, AI38670] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Ciacci-Woolwine F, 1998, INFECT IMMUN, V66, P1127, DOI 10.1128/IAI.66.3.1127-1134.1998; CiacciWoolwine F, 1997, INFECT IMMUN, V65, P4624, DOI 10.1128/IAI.65.11.4624-4633.1997; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Cunningham MD, 2000, J IMMUNOL, V164, P3255, DOI 10.4049/jimmunol.164.6.3255; Donnelly MA, 2002, J BIOL CHEM, V277, P40456, DOI 10.1074/jbc.M206851200; Eaves-Pyles TD, 2001, J IMMUNOL, V167, P7009, DOI 10.4049/jimmunol.167.12.7009; Frendeus B, 2001, MOL MICROBIOL, V40, P37, DOI 10.1046/j.1365-2958.2001.02361.x; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gugolya Z, 2003, FEBS LETT, V535, P66, DOI 10.1016/S0014-5793(02)03859-0; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hantgan RR, 2001, BBA-MOL CELL RES, V1540, P82, DOI 10.1016/S0167-4889(01)00120-3; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; HOMMA M, 1990, J MOL BIOL, V213, P819, DOI 10.1016/S0022-2836(05)80266-9; Hoshino K, 1999, J IMMUNOL, V162, P3749; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Janeway CA, 1998, SEMIN IMMUNOL, V10, P349, DOI 10.1006/smim.1998.0142; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KOSTYUKOVA AS, 1988, FEBS LETT, V241, P141, DOI 10.1016/0014-5793(88)81047-0; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Ma S, 1998, J BACTERIOL, V180, P956, DOI 10.1128/JB.180.4.956-968.1998; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mizel SB, 2002, J BIOL CHEM, V277, P22414, DOI 10.1074/jbc.M201762200; MIZEL SB, 2003, IN PRESS J IMMUNOL, V170; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; NAMBA K, 1989, NATURE, V342, P648, DOI 10.1038/342648a0; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sebastiani G, 2000, GENOMICS, V64, P230, DOI 10.1006/geno.2000.6115; Shapiro RA, 1997, INFECT IMMUN, V65, P293, DOI 10.1128/IAI.65.1.293-297.1997; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; VONDERVISZT F, 1989, J MOL BIOL, V209, P127, DOI 10.1016/0022-2836(89)90176-9; VONDERVISZT F, 1992, BIOPHYS J, V63, P1672, DOI 10.1016/S0006-3495(92)81751-4	41	110	112	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23624	23629		10.1074/jbc.M303481200	http://dx.doi.org/10.1074/jbc.M303481200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12711596	hybrid			2022-12-25	WOS:000183638600053
J	Rehmann, H; Rueppel, A; Bos, JL; Wittinghofer, A				Rehmann, H; Rueppel, A; Bos, JL; Wittinghofer, A			Communication between the regulatory and the catalytic region of the cAMP-responsive guanine nucleotide exchange factor Epac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CRYSTAL-STRUCTURE; BINDING DOMAINS; RAP1; ACTIVATION; SUBUNIT; FAMILY; RAS; ADHESION; GTPASE	Epac1 is a guanine nucleotide exchange factor (GEF) for the small GTPase Rap1 that is directly activated by cAMP. This protein consists of a regulatory region with a cAMP-binding domain and a catalytic region that mediates the GEF activity. Epac is inhibited by an intramolecular interaction between the cAMP-binding domain and the catalytic region in the absence of cAMP. cAMP binding is proposed to induce a conformational change, which allows a LID, an alpha-helix at the C-terminal end of the cAMP-binding site, to cover the cAMP-binding site (Rehmann, H., Prakash, B., Wolf, E., Rueppel, A., de Rooij, J., Bos, J. L., and Wittinghofer, A. ( 2003) Nat. Struct. Biol. 10, 26-32). Here we show that mutations of conserved residues in the LID region affect cAMP binding only marginally but have a drastic effect on cAMP-induced GEF activity. Surprisingly, some of the mutants have an increased maximal GEF activity compared with wild type. Furthermore, mutation of the conserved VLVLE sequence at the C-terminal end of the LID into five alanine residues makes Epac constitutively active. From these results we conclude that the LID region plays a pivotal role in the communication between the regulatory and catalytic part of Epac.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Max Planck Society; Utrecht University; Utrecht University	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KAUPP UB, 1995, CURR OPIN NEUROBIOL, V5, P434, DOI 10.1016/0959-4388(95)80002-6; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; Vanvooren V, 2001, EUR J ENDOCRINOL, V144, P605, DOI 10.1530/eje.0.1440605; WILD N, 1995, FEBS LETT, V374, P356, DOI 10.1016/0014-5793(95)01146-6	24	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23508	23514		10.1074/jbc.M301680200	http://dx.doi.org/10.1074/jbc.M301680200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707263	hybrid			2022-12-25	WOS:000183638600038
J	Umemura, M; Okamoto, M; Nakayama, K; Sagane, K; Tsukahara, K; Hata, K; Jigami, Y				Umemura, M; Okamoto, M; Nakayama, K; Sagane, K; Tsukahara, K; Hata, K; Jigami, Y			GWT1 gene is required for inositol acylation of glycosylphosphatidylinositol anchors in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GPI ANCHOR; PLASMODIUM-FALCIPARUM; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; 1ST STEP; PIG-L; BIOSYNTHESIS; PROTEINS; PHOSPHATIDYLINOSITOL	Glycosylphosphatidylinositol (GPI) is a conserved posttranslational modification to anchor cell surface proteins to plasma membrane in all eukaryotes. In yeast, GPI mediates cross-linking of cell wall mannoproteins to beta1,6-glucan. We reported previously that the GWT1 gene product is a target of the novel anti-fungal compound, 1-[4-butylbenzyl]isoquinoline, that inhibits cell wall localization of GPI-anchored mannoproteins in Saccharomyces cerevisiae (Tsukahara, K., Hata, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., Yoshimatsu, K., and Nagasu, T. (2003) Mol. Microbiol. 48, 1029-1042). In the present study, to analyze the function of the Gwt1 protein, we isolated temperature-sensitive gwt1 mutants. The gwt1 cells were normal in transport of invertase and carboxypeptidase Y but were delayed in transport of GPI-anchored protein, Gas1p, and were defective in its maturation from the endoplasmic reticulum to the Golgi. The incorporation of inositol into GPI-anchored proteins was reduced in gwt1 mutant, indicating involvement of GWT1 in GPI biosynthesis. We analyzed the early steps of GPI biosynthesis in vitro by using membranes prepared from gwt1 and Deltagwt1 cells. The synthetic activity of GlcN-(acyl)PI from GlcN- PI was defective in these cells, whereas Deltagwt1 cells harboring GWT1 gene restored the activity, indicating that GWT1 is required for acylation of inositol during the GPI synthetic pathway. We further cloned GWT1 homologues in other yeasts, Cryptococcus neoformans and Schizosaccharomyces pombe, and confirmed that the specificity of acyl-CoA in inositol acylation, as reported in studies of endogenous membranes (Franzot, S. P., and Doering, T. L. (1999) Biochem. J. 340, 25-32), is due to the properties of Gwt1p itself and not to other membrane components.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Eisai Co Ltd	Jigami, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba Cent 6,Higashi 1-1-1, Tsukuba, Ibaraki 3058566, Japan.	jigami.yoshi@aist.go.jp		Okamoto, michiyo/0000-0003-4280-6048; Sagane, Koji/0000-0001-5814-3037	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048594, U01AI047087] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI47087, U01 AI48594, AI147079] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F. M., 1999, SHORT PROTOCOLS MOL; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; Delorenzi M, 2002, INFECT IMMUN, V70, P4510, DOI 10.1128/IAI.70.8.4510-4522.2002; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; FANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439, DOI 10.1111/j.1432-1033.1991.tb15723.x; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; Franzot SP, 1999, BIOCHEM J, V340, P25, DOI 10.1042/0264-6021:3400025; Friedmann E, 2002, J BIOL CHEM, V277, P35274, DOI 10.1074/jbc.M201044200; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; Gerold P, 1999, BIOCHEM J, V344, P731, DOI 10.1042/0264-6021:3440731; GEROLD P, 1994, J BIOL CHEM, V269, P2597; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hata K, 1996, ANTIMICROB AGENTS CH, V40, P2237, DOI 10.1128/AAC.40.10.2237; Hiroi Y, 1998, FEBS LETT, V421, P252, DOI 10.1016/S0014-5793(97)01576-7; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Lussier M, 1997, GENETICS, V147, P435; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Maiti T, 2000, GENE, V244, P109, DOI 10.1016/S0378-1119(99)00570-3; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; NAGASU T, 1992, YEAST, V8, P535, DOI 10.1002/yea.320080705; Naik RS, 2003, J BIOL CHEM, V278, P2036, DOI 10.1074/jbc.M208976200; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; PUOTI A, 1992, J BIOL CHEM, V267, P22673; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; Sato K, 2001, J CELL BIOL, V152, P935, DOI 10.1083/jcb.152.5.935; Shahinian S, 2000, MOL MICROBIOL, V35, P477, DOI 10.1046/j.1365-2958.2000.01713.x; SHIMIZU J, 1994, MOL GEN GENET, V242, P641, DOI 10.1007/BF00283417; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; Sutterlin C, 1997, J CELL SCI, V110, P2703; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsukahara K, 2003, MOL MICROBIOL, V48, P1029, DOI 10.1046/j.1365-2958.2003.03481.x; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185; Yan BC, 2001, YEAST, V18, P1383, DOI 10.1002/yea.783	62	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23639	23647		10.1074/jbc.M301044200	http://dx.doi.org/10.1074/jbc.M301044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12714589	hybrid			2022-12-25	WOS:000183638600055
J	Pengal, RA; Ganesan, LP; Fang, HQ; Marsh, CB; Anderson, CL; Tridandapani, S				Pengal, RA; Ganesan, LP; Fang, HQ; Marsh, CB; Anderson, CL; Tridandapani, S			SHIP-2 inositol phosphatase is inducibly expressed in human monocytes and serves to regulate Fc gamma receptor-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-INDUCED SUPPRESSION; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; 5-PHOSPHATASE SHIP2; ACTIVATION MOTIF; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; PHAGOCYTOSIS; TRANSDUCTION; MECHANISMS; CELLS	SHIP-2, a recently identified inositol 5'-phosphatase, shares high level homology with SHIP-1. Although the role of SHIP-1 has been extensively studied, the role of SHIP-2 in myeloid cell functions is not known. Here, we have analyzed the expression patterns, molecular mechanism of activation, and function of SHIP-2 in human myeloid cell Fcgamma receptor (FcgammaR) signaling. We report that SHIP-2 is expressed in transformed myeloid cells and in primary macrophages, but not in peripheral blood monocytes. Treatment of peripheral blood monocytes with bacterial lipopolysaccharide induced expression of SHIP-2 in a dose-dependent manner. FcgammaRIIa clustering in THP-1 cells induced SHIP-2 tyrosine phosphorylation, suggesting a role for SHIP-2 in modulating FcgammaR-mediated function. Consistent with this notion, overexpression of wild-type SHIP-2 (but not catalytically deficient SHIP-2) in THP-1 cells almost completely abrogated NFkappaB-mediated gene transcription in response to FcgammaRIIa clustering. Furthermore, FcgammaRIIa-induced Akt activation was blocked by wild-type SHIP-2, but not by a catalytically deficient mutant of SHIP-2. Additional experiments analyzing the molecular mechanism of SHIP-2 induction by FcgammaRIIa revealed that SHIP-2 associated with the phosphorylated FcgammaRIIa immunoreceptor tyrosine-based activation motif via the SHIP-2 SH2 domain. Thus, an SH2 domain mutant of SHIP-2 failed to associate with FcgammaRIIa or to become tyrosine-phosphorylated upon FcgammaRIIa clustering. Finally, we also demonstrate that SHIP-2 phosphorylation was induced by FcgammaRI clustering in THP-1 cells. These findings unravel a novel level of regulation of FcgammaR-mediated activation of human myeloid cells by the expression and function of the inositol phosphatase SHIP-2.	James Canc Hosp, Dorothy M Davis Heart & Lung Inst, Mol Cellular & Dev Biol Program, Columbus, OH 43210 USA; James Canc Hosp, Dorothy M Davis Heart & Lung Inst, Dept Internal Med, Div Pulm & Crit Care Med, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Tridandapani, S (corresponding author), Ohio State Univ, Dept Internal Med, Rm 405B HLRI,473 W 12th Ave, Columbus, OH 43210 USA.	tridandapani.2@osu.edu	Tridandapani, Susheela/E-4209-2011		NCI NIH HHS [P01 CA095426, P30 CA16058] Funding Source: Medline; NHLBI NIH HHS [HL63800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA095426] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Brauweiler A, 2001, J IMMUNOL, V167, P204, DOI 10.4049/jimmunol.167.1.204; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; Cooney DS, 2001, J IMMUNOL, V167, P844, DOI 10.4049/jimmunol.167.2.844; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; Jacob A, 1999, J BIOL CHEM, V274, P13704, DOI 10.1074/jbc.274.19.13704; Kant AM, 2002, BLOOD, V100, P1852; Kim JS, 2002, BLOOD, V99, P694, DOI 10.1182/blood.V99.2.694; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; Nakamura K, 2002, BLOOD, V100, P3374, DOI 10.1182/blood-2002-03-0787; Ozes ON, 1999, NATURE, V401, P82; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Pesesse X, 2001, J BIOL CHEM, V276, P28348, DOI 10.1074/jbc.M103537200; Prasad N, 2002, J CELL SCI, V115, P3807, DOI 10.1242/jcs.00070; Sanchez-Mejorada G, 1998, J LEUKOCYTE BIOL, V63, P521, DOI 10.1002/jlb.63.5.521; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; SUNDARAM R, 1993, J LEUKOCYTE BIOL, V54, P81, DOI 10.1002/jlb.54.1.81; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tridandapani S, 2002, J IMMUNOL, V169, P4370, DOI 10.4049/jimmunol.169.8.4370; Tridandapani S, 2000, J BIOL CHEM, V275, P20480, DOI 10.1074/jbc.M909462199; Wada T, 2001, MOL CELL BIOL, V21, P1633, DOI 10.1128/MCB.21.5.1633-1646.2001; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Wonderling RS, 1996, IMMUNOPHARM IMMUNOT, V18, P267, DOI 10.3109/08923979609052736	34	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22657	22663		10.1074/jbc.M302907200	http://dx.doi.org/10.1074/jbc.M302907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690104	hybrid			2022-12-25	WOS:000183503900065
J	Yoo, D; Kim, BY; Campo, C; Nance, L; King, A; Maouyo, D; Welling, PA				Yoo, D; Kim, BY; Campo, C; Nance, L; King, A; Maouyo, D; Welling, PA			Cell surface expression of the ROMK (Kir 1.1) channel is regulated by the aldosterone-induced kinase, SGK-1, and protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-INDUCIBLE KINASE; CORTICAL COLLECTING TUBULE; CONDUCTANCE K+ CHANNEL; APICAL MEMBRANE; POTASSIUM SECRETION; TYROSINE KINASE; XENOPUS OOCYTES; DIETARY-K; PHOSPHORYLATION; SERUM	The Kir1.1 (ROMK) subtypes of inward rectifier K+ channels mediate potassium secretion and regulate sodium chloride reabsorption in the kidney. The density of ROMK channels on the cortical collecting duct apical membrane is exquisitely regulated in concert with physiological demands. Although protein kinase A-dependent phosphorylation of one of the three phospho-acceptors in Kir1.1, Ser-44, also a canonical serum-glucocorticoid-regulated kinase (SGK-1) phosphorylation site, controls the number of active channels, it is unknown whether this involves activating dormant channels already residing on the plasma membrane or recruiting new channels to the cell surface. Here we explore the mechanism and test whether SGK-1 phosphorylation of ROMK regulates cell surface expression. Removal of the phosphorylation site by point mutation (Kir1.1, S44A) dramatically attenuated the macroscopic current density in Xenopus oocytes. As measured by antibody binding of external epitope-tagged forms of Kir1.1, surface expression of Kir1.1 S44A was inhibited, paralleling the reduction in macroscopic current. In contrast, surface expression and macroscopic current density was augmented by a phosphorylation mimic mutation, Kir1.1 S44D. In vitro phosphorylation assays revealed that Ser-44 is a substrate of SGK-1 phosphorylation, and expression of SGK-1 with the wild type channel increased channel density to the same level as the phosphorylation mimic mutation. Moreover, the stimulatory effect of SGK-1 was completely abrogated by mutation of the phosphorylation site. In conclusion, SGK-1 phosphorylation of Kir1.1 drives expression on the plasmalemma. Because SGK-1 is an early aldosterone-induced gene, our results suggest a possible molecular mechanism for aldosterone-dependent regulation of the secretory potassium channel in the kidney.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Welling, PA (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.			Alewine, Christine/0000-0003-1661-0957	NIDDK NIH HHS [DK-63049, DK-54231] Funding Source: Medline; NIGMS NIH HHS [T32GM08181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054231, R01DK063049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; Brejon M, 1999, BIOCHEM BIOPH RES CO, V261, P364, DOI 10.1006/bbrc.1999.1016; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Flagg TP, 1999, J GEN PHYSIOL, V114, P685, DOI 10.1085/jgp.114.5.685; Flagg TP, 2002, J PHYSIOL-LONDON, V544, P351, DOI 10.1113/jphysiol.2002.027581; Frindt G, 1998, AM J PHYSIOL-RENAL, V274, pF525, DOI 10.1152/ajprenal.1998.274.3.F525; FRINDT G, 1989, AM J PHYSIOL, V256, pF143, DOI 10.1152/ajprenal.1989.256.1.F143; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; Kamsteeg EJ, 2001, BIOCHEM BIOPH RES CO, V282, P683, DOI 10.1006/bbrc.2001.4629; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; Lang F, 2001, SCI STKE, V2001; Leipziger J, 2000, AM J PHYSIOL-RENAL, V279, pF919, DOI 10.1152/ajprenal.2000.279.5.F919; Lin DH, 2002, AM J PHYSIOL-RENAL, V283, pF671, DOI 10.1152/ajprenal.00160.2002; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Lu M, 2002, J BIOL CHEM, V277, P37881, DOI 10.1074/jbc.M206644200; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; MacGregor GG, 1998, AM J PHYSIOL-RENAL, V275, pF415, DOI 10.1152/ajprenal.1998.275.3.F415; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x; Moral Z, 2001, J BIOL CHEM, V276, P7156, DOI 10.1074/jbc.M008671200; MUTO S, 1988, J CLIN INVEST, V81, P376, DOI 10.1172/JCI113329; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Palmer LG, 1999, AM J PHYSIOL-RENAL, V277, pF805, DOI 10.1152/ajprenal.1999.277.5.F805; PALMER LG, 1994, J GEN PHYSIOL, V104, P693, DOI 10.1085/jgp.104.4.693; Palmer LG, 1999, AM J PHYSIOL-RENAL, V277, pF821, DOI 10.1152/ajprenal.1999.277.6.F821; Palmer LG, 2000, KIDNEY INT, V57, P1324, DOI 10.1046/j.1523-1755.2000.00970.x; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; WANG W, 1998, P NATL ACAD SCI USA, V88, P9722; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; Welling PA, 1997, AM J PHYSIOL-RENAL, V273, pF825, DOI 10.1152/ajprenal.1997.273.5.F825; Woda CB, 2001, AM J PHYSIOL-RENAL, V280, pF786, DOI 10.1152/ajprenal.2001.280.5.F786; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Yun CC, 2002, J AM SOC NEPHROL, V13, P2823, DOI 10.1097/01.ASN.0000035085.54451.81; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	54	127	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23066	23075		10.1074/jbc.M212301200	http://dx.doi.org/10.1074/jbc.M212301200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684516	hybrid			2022-12-25	WOS:000183503900114
J	Chai, JJ; Wu, JW; Yan, N; Massague, J; Pavletich, NP; Shi, YG				Chai, JJ; Wu, JW; Yan, N; Massague, J; Pavletich, NP; Shi, YG			Features of a Smad3 MH1-DNA complex - Roles of water and zinc in DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; MH1 DOMAIN; PROTEIN; RECOGNITION; TRANSCRIPTION; PROMOTER; INSIGHTS; SYSTEM; GROWTH	The Smad family of proteins mediates transforming growth factor-beta signaling from cell membrane to the nucleus. In the nucleus, Smads serve as transcription factors by directly binding to specific DNA sequences and regulating the expression of ligand-response genes. A previous structural analysis, at 2.8-Angstrom resolution, revealed a novel DNA-binding mode for the Smad MH1 domain but did not allow accurate assignment of the fines features of protein-DNA interactions. The crystal structure of a Smad3 MH1 domain bound to a palindromic DNA sequence, determined at 2.4-Angstrom resolution, reveals a surprisingly important role for water molecules. The asymmetric placement of the DNA-binding motif (a conserved 11-residue beta-hairpin) in the major groove of DNA is buttressed by seven well ordered water molecules. These water molecules make specific hydrogen bonds to the DNA bases, the DNA phosphate backbones, and several critical Smad3 residues. In addition, the MH1 domain is found to contain a bound zinc atom using four invariant residues among Smad proteins, three cysteines and one histidine. Removal of the zinc atom results in compromised DNA binding activity. These results define the Smad MH1 domain as a zinc-coordinating module that exhibits unique DNA binding properties.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Princeton University; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.			Shi, Yigong/0000-0003-2030-168X; Chai, Jijie/0000-0001-7591-3873; Massague, Joan/0000-0001-9324-8408	NATIONAL CANCER INSTITUTE [R01CA082171] Funding Source: NIH RePORTER; NCI NIH HHS [CA82171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Grishin NV, 2001, J MOL BIOL, V307, P31, DOI 10.1006/jmbi.2000.4486; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; JOACHIMIAK A, 1994, EMBO J, V13, P367, DOI 10.1002/j.1460-2075.1994.tb06270.x; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SHAKKED Z, 1994, NATURE, V368, P469, DOI 10.1038/368469a0; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	28	60	63	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20327	20331		10.1074/jbc.C300134200	http://dx.doi.org/10.1074/jbc.C300134200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12686552	Green Submitted, hybrid			2022-12-25	WOS:000183078000096
J	Maclaren, A; Clark, W; Black, EJ; Gregory, D; Fujii, H; Gillespie, DAF				Maclaren, A; Clark, W; Black, EJ; Gregory, D; Fujii, H; Gillespie, DAF			v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p2l CIP1	ONCOGENE			English	Article						Jun; p21CIP1; p53	S-PHASE ENTRY; C-JUN; CELL-CYCLE; GROWTH-FACTOR; GENE-EXPRESSION; HUMAN CANCER; DNA-DAMAGE; TRANSFORMATION; PROMOTER; P53	Previous studies have shown that the viral Jun (v-Jun) oncoprotein induces marked alterations in cell cycle control, which are associated with, and may be caused by, increased cdk2 kinase activity. Since p21 CIP1 is an important regulator of cdk2, we investigated whether aberrant expression of this cyclin-dependent kinase inhibitor might contribute to cell cycle deregulation by v-Jun. We find that the basal levels of p21 CIP1 mRNA and protein expression are greatly reduced in chick embryo fibroblasts (CEF) transformed by v-Jun, and that v-Jun blocks the increases in p21 CIP1 expression that normally accompany growth inhibition induced by serum deprivation or confluency in untransformed CEF. Importantly, ectopic expression of p21 CIP1 in v-Juntransformed CEF inhibits both cdk2 kinase activity and cell cycle progression, indicating that these alterations in p21 CIP1 expression are likely to be functionally significant for growth deregulation. We also investigated the mechanism through which v-Jun disturbs p21 CIP1 expression and the possible involvement of a known p21 CIP1 regulator, p53, as an intermediate in this process. This analysis revealed that repression is mediated primarily at the level of p21 CIP1 gene transcription, however the mechanism is complex; both p53-dependent and -independent mechanisms contribute as judged by analysis of p21 CIP1 promoter mutants and other assays of p53 transcriptional activity.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Canc Res UK Dev Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England	Beatson Institute; University of Glasgow; University of Dundee; Cancer Research UK	Maclaren, A (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd,Bearsden, Glasgow G61 1BD, Lanark, Scotland.		Gregory, David/P-2582-2015; Gillespie, David/R-4771-2019	Gregory, David/0000-0001-6534-7150; Gillespie, David/0000-0002-6338-0544				Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Givol I, 1995, ONCOGENE, V11, P2609; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hadman M, 1996, ONCOGENE, V12, P135; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JUVEN T, 1993, ONCOGENE, V8, P3411; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kilbey A, 1996, ONCOGENE, V12, P2409; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MacLaren A, 2000, ONCOGENE, V19, P5906, DOI 10.1038/sj.onc.1203954; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091	41	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2383	2395		10.1038/sj.onc.1206329	http://dx.doi.org/10.1038/sj.onc.1206329			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717415				2022-12-25	WOS:000182383500001
J	Bussolati, B; Deambrosis, I; Russo, S; Deregibus, MC; Camussi, G				Bussolati, B; Deambrosis, I; Russo, S; Deregibus, MC; Camussi, G			Altered angiogenesis and survival in human tumor-derived endothelial cells	FASEB JOURNAL			English	Article						VEGF-D; angiopoietin-1; apoptosis; Akt; PTEN	GROWTH-FACTOR RECEPTOR-3; IN-VITRO; BCL-2 EXPRESSION; KAPOSIS-SARCOMA; UP-REGULATION; SOLID TUMORS; VEGF-C; CANCER; MICROENVIRONMENT; ANGIOPOIETIN-1	Knowledge on the functional properties of tumor-derived endothelial cells (TEC) can be relevant for the development of antiangiogenic therapeutic strategies. In the present study, we obtained and characterized endothelial cell lines from human renal carcinomas. TEC did not undergo senescence and showed constant expression of markers of endothelial activation and angiogenesis. In vitro, TEC, in contrast to normal endothelial cells, were resistant to apoptosis, proadhesive for renal carcinoma cells, and able to grow and organize in the absence of serum in persistent capillary-like structures. In vivo, TEC were able to grow in immunodeficient mice and to form vascular structures connected with the circulation. At a molecular level, gene array analysis showed an increased expression of genes involved in survival and cell adhesion compared with expression in normal microvascular endothelial cells. Moreover, expression of angiopoietin-1 and vascular endothelial growth factor (VEGF)-D and the Akt survival pathway were up-regulated. Inhibition of interaction of VEGFR-2 or VEGFR-3 with VEGF-D but not of Tie-2-angiopoietin-1 interaction with soluble receptors abrogated Akt activation and survival of TEC. These results indicate that at least some of the TEC within a tumor display abnormal characteristics in terms of survival and angiogenic properties and also indicate the presence of a functional autocrine pathway related to VEGF-D.	Univ Turin, Dipartimento Med Interna, Turin, Italy; Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy; Osped San Giovanni Battista Torino, Ctr Ric Med Sperimentale, I-10126 Turin, Italy	University of Turin; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Camussi, G (corresponding author), Osped San Giovanni Battista Torino, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Camussi, Giovanni/J-7624-2016; Bussolati, Benedetta/AAA-9058-2022	Camussi, Giovanni/0000-0003-2795-232X; Bussolati, Benedetta/0000-0002-3663-5134				Achen MG, 2002, GROWTH FACTORS, V20, P99, DOI 10.1080/08977190290031969; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DVORAK HF, 1988, AM J PATHOL, V133, P95; Dye JF, 2001, MICROVASC RES, V62, P94, DOI 10.1006/mvre.2001.2333; Dye JF, 2001, PLACENTA, V22, P32, DOI 10.1053/plac.2000.0579; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Huang HY, 2001, LAB INVEST, V81, P1729, DOI 10.1038/labinvest.3780386; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Ibrahim EC, 2001, CANCER RES, V61, P6838; Ilan N, 1998, J CELL SCI, V111, P3621; Iwahana M, 1998, ANTICANCER RES, V18, P2977; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jung YD, 2000, CANCER METAST REV, V19, P147, DOI 10.1023/A:1026510130114; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; Kubo H, 2000, BLOOD, V96, P546; Kumar S, 1999, CANCER RES, V59, P856; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Le Bouteiller P, 1999, IMMUNOL REV, V167, P233; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; Melder RJ, 2002, NEOPLASIA, V4, P3, DOI 10.1038/sj.neo.7900209; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; St Croix B, 2000, SCIENCE, V289, P1197; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stratmann A, 2001, INT J CANCER, V91, P273, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1054>3.0.CO;2-Q; Wang JH, 2002, CANCER-AM CANCER SOC, V94, P2745, DOI 10.1002/cncr.10520	46	223	232	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1159	+		10.1096/fj.02-0557fje	http://dx.doi.org/10.1096/fj.02-0557fje			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709414				2022-12-25	WOS:000182580100032
J	Seibold, S; Rudroff, C; Weber, M; Galle, J; Wanner, C; Marx, M				Seibold, S; Rudroff, C; Weber, M; Galle, J; Wanner, C; Marx, M			Identification of a new tumor suppressor gene located at chromosome 8p21.3-22	FASEB JOURNAL			English	Article						MTSG1; cancer; tumor progression; D8S254; 3D culture	IN-VITRO ANGIOGENESIS; URINARY-BLADDER CANCER; BREAST CARCINOMAS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; LEUCINE-ZIPPER; TUBE FORMATION; SHORT ARM; GROWTH; LOCALIZATION	Transformation of normal cells into malignant tumor cells, a process termed carcinogenesis, depends on progressive acquisition of genetic alterations. These result in activation of protooncogenes or inactivation of tumor suppressor genes responsible for the loss of proliferative control in tumor cells and the failure to undergo cellular differentiation. The aim of our study was the identification of molecular regulators of carcinogenesis by studying gene expression during induction of cellular differentiation and quiescence in a three-dimensional (3D) cell culture model. Here, we report the discovery of a tumor suppressor gene located at chromosome 8p21.3-22 near marker D8S254. It is ubiquitously expressed in normal tissue and transiently upregulated during initiation of cellular differentiation and quiescence in 3D cell culture. In contrast, mRNA expression was not detectable in tissue from pancreatic tumor and the pancreatic tumor cell line MIA PaCa-2. Recombinant expression in the tumor cell line MIA PaCa-2 inhibited proliferation, as shown by a 30% reduction of BrdU uptake after recombinant expression. Immunocytochemistry and Western blot analysis of subcellular fractions demonstrated a mitochondrial localization for the mature protein. In conclusion, we identified a tumor suppressor gene at chromosome 8p21.3-22, encoding a mitochondrial protein, controlling cellular proliferation.	Univ Med Ctr, Dept Med, D-97080 Wurzburg, Germany; Univ Cologne, Fac Med, Merheim Med Ctr,Cologne Gen Hosp, Dept Internal Med 1, Cologne, Germany; Univ Witten Herdecke, Dept Surg, Wuppertal, Germany	University of Wurzburg; University of Cologne; Witten Herdecke University	Seibold, S (corresponding author), Univ Med Ctr, Dept Med, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	seibold_s@medizin.uni-wuerzburg.de						Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; BARDI G, 1993, BRIT J CANCER, V67, P1106, DOI 10.1038/bjc.1993.203; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Chan KL, 2002, CANCER, V94, P3179, DOI 10.1002/cncr.10612; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUAQUI RF, 1995, CANCER RES, V55, P4995; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; El-Naggar AK, 2001, J MOL DIAGN, V3, P164, DOI 10.1016/S1525-1578(10)60668-X; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gruber H E, 2000, BMC Musculoskelet Disord, V1, P1, DOI 10.1186/1471-2474-1-1; Gustafson CE, 1996, CANCER RES, V56, P5238; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ilan N, 1998, J CELL SCI, V111, P3621; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Kerangueven F, 1997, CANCER RES, V57, P5469; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; Marx M, 1997, KIDNEY INT, V51, P110, DOI 10.1038/ki.1997.14; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ohgaki K, 1999, GENE CHROMOSOME CANC, V25, P1, DOI 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Rudroff C, 2002, CLIN EXP METASTAS, V19, P181, DOI 10.1023/A:1014598904644; Sasiadek M, 2001, INT J ONCOL, V19, P401; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Tsai MH, 2002, HEPATO-GASTROENTEROL, V49, P672; Vocke CD, 1996, CANCER RES, V56, P2411; Wagner U, 1997, AM J PATHOL, V151, P753; Wistuba II, 1999, CANCER RES, V59, P1973; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447	43	84	88	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1180	+		10.1096/fj.02-0934fje	http://dx.doi.org/10.1096/fj.02-0934fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692079				2022-12-25	WOS:000182580100044
J	Henkler, F; Baumann, B; Fortin-Mleczek, M; Weingartner, M; Schwenzer, R; Peters, N; Graness, A; Wirth, T; Scheurich, P; Schmid, JA; Wajant, H				Henkler, F; Baumann, B; Fortin-Mleczek, M; Weingartner, M; Schwenzer, R; Peters, N; Graness, A; Wirth, T; Scheurich, P; Schmid, JA; Wajant, H			Caspase-mediated cleavage converts the tumor necrosis factor (TNF) receptor-associated factor (TRAF)-1 from a selective modulator of TNF receptor signaling to a general inhibitor of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; CYTOPLASMIC DOMAIN; BINDING-SITES; CELL-DEATH; CONTAINS 2; TRAF1; PROTEINS; INDUCTION; APOPTOSIS; IKK	The role of tumor necrosis factor (TNF) receptor-associated factor (TRAF)-1 in NF-kappaB activation by various members of the TNF receptor family is not well understood, and conflicting data have been published. Here, we show that TRAF1 differentially affects TRAF2 recruitment and activation of NF-kappaB by members of the TNF receptor family. Interestingly, a naturally occurring caspase-derived cleavage product of TRAF1 solely comprising its TRAF domain ( TRAF1-(164- 416)) acted as a general inhibitor of NF-kappaB activation. In contrast, a corresponding fragment generated by cleavage of TRAF3 showed no effect in this regard. In accordance with these functional data, TRAF1, but not TRAF3, interacted with the IKK complex via its N-TRAF domain. Endogenous TRAF1 and the overexpressed TRAF domain of TRAF1 were found to be constitutively associated with the IKK complex, whereas endogenous receptor interacting protein was only transiently associated with the IKK complex upon TNF stimulation. Importantly, the caspase-generated TRAF1- fragment, but not TRAF1 itself inhibited IKK activation. Our results suggest that TRAF1 and TRAF1-( 164 - 416) exert their regulatory effects on receptor-induced NF-kappaB activation not only by modulation of TRAF2 receptor interaction but especially TRAF1-( 164 - 416) also by directly targeting the IKK complex.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria	University of Stuttgart; Ulm University; University of Vienna	Wajant, H (corresponding author), Univ Wurzburg, Dept Mol Internal Med, Med Polyclin, Roentgenring 11, D-97070 Wurzburg, Germany.	harald.wajant@mail.uni-wuerzburg.de	Schmid, Johannes A./C-7659-2009; Wajant, Harald/A-3020-2017; Wirth, Thomas/X-7172-2019	Schmid, Johannes A./0000-0002-6586-3507; Wajant, Harald/0000-0002-2005-3949; 				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chung JY, 2002, J CELL SCI, V115, P679; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Krajewska M, 1998, AM J PATHOL, V152, P1549; Lee SY, 1996, J EXP MED, V183, P669, DOI 10.1084/jem.183.2.669; Lee ZH, 2001, J LEUKOCYTE BIOL, V69, P490; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Mack A, 2002, EUR J IMMUNOL, V32, P1986, DOI 10.1002/1521-4141(200207)32:7<1986::AID-IMMU1986>3.0.CO;2-#; Masson R, 1998, MECH DEVELOP, V71, P187, DOI 10.1016/S0925-4773(97)00192-5; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shiels H, 2000, AM J PATHOL, V157, P679, DOI 10.1016/S0002-9440(10)64578-6; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	41	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29216	29230		10.1074/jbc.M211090200	http://dx.doi.org/10.1074/jbc.M211090200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12709429	hybrid			2022-12-25	WOS:000184421100107
J	Schlumberger, MC; Friebel, A; Buchwald, G; Scheffzek, K; Wittinghofer, A; Hardt, WD				Schlumberger, MC; Friebel, A; Buchwald, G; Scheffzek, K; Wittinghofer, A; Hardt, WD			Amino acids of the bacterial toxin SopE involved in G nucleotide exchange on Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL HOMOLOGY DOMAIN; PROTEIN SECRETION SYSTEM; GTP-BINDING PROTEINS; SALMONELLA-TYPHIMURIUM; RHO-GTPASES; HOST-CELL; STRUCTURAL BASIS; IDENTIFICATION; INVASION; FLUORESCENCE	RhoGTPases are central switches in all eukaryotic cells. There are at least two known families of guanine nucleotide exchange factors that can activate RhoGTPases: the Dbl-like eukaryotic G nucleotide exchange factors and the SopE-like toxins of pathogenic bacteria, which are injected into host cells to manipulate signaling. Both families have strikingly different sequences, structures, and catalytic core elements. This suggests that they have emerged by convergent evolution. Nevertheless, both families of G nucleotide exchange factors also share some similarities: ( a) both rearrange the G nucleotide binding site of RhoGTPases into virtually identical conformations, and (b) two SopE residues (Gln-109(SopE) and Asp-124(SopE)) engage Cdc42 in a similar way as equivalent residues of Dbl-like G nucleotide exchange factors (i.e. Asn-810(Dbs) and Glu-639(Dbs)). The functional importance of these observations has remained unclear. Here, we have analyzed the effect of amino acid substitutions at selected SopE residues implicated in catalysis (Asp-124(SopE), Gln-109(SopE), Asp-103(SopE), Lys-198(SopE), and Gly-168(SopE)) on in vitro catalysis of G nucleotide release from Cdc42 and on in vivo activity. Substitutions at Asp124(SopE), Gln-109(SopE), and Gly-168(SopE) severely reduced the SopE activity. Slight defects were observed with Asp-103(SopE) variants, whereas Lys-198(SopE) was not found to be required in vitro or in vivo. Our results demonstrate that G nucleotide exchange by SopE involves both catalytic elements unique to the SopE family (i.e. (166)GAGA(169) loop, Asp-103(SopE)) and amino acid contacts resembling those of key residues of Dbl-like guanine nucleotide exchange factors. Therefore, besides all of the differences, the catalytic mechanisms of the SopE and the Dbl families share some key functional aspects.	ETH, Inst Microbiol, CH-8092 Zurich, Switzerland; Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44227 Dortmund, Germany; European Mol Biol Lab, Struct & Computat Biol Programme, D-69117 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Hardt, WD (corresponding author), ETH, Inst Microbiol, Schmelzbergstr 7, CH-8092 Zurich, Switzerland.			Hardt, Wolf-Dietrich/0000-0002-9892-6420				Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bakshi CS, 2000, J BACTERIOL, V182, P2341, DOI 10.1128/JB.182.8.2341-2344.2000; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Buchwald G, 2002, EMBO J, V21, P3286, DOI 10.1093/emboj/cdf329; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Friebel A, 2000, METHOD ENZYMOL, V325, P82; Friebel A, 2001, J BIOL CHEM, V276, P34035, DOI 10.1074/jbc.M100609200; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hardt WD, 1998, P NATL ACAD SCI USA, V95, P2574, DOI 10.1073/pnas.95.5.2574; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Lesser CF, 2000, TRENDS MICROBIOL, V8, P151, DOI 10.1016/S0966-842X(00)01727-3; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Mirold S, 2001, J BACTERIOL, V183, P2348, DOI 10.1128/JB.183.7.2348-2358.2001; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2002, J BIOL CHEM, V277, P50893, DOI 10.1074/jbc.M208580200; Rudolph MG, 1999, J BIOL CHEM, V274, P30501, DOI 10.1074/jbc.274.43.30501; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Stender S, 2000, MOL MICROBIOL, V36, P1206, DOI 10.1046/j.1365-2958.2000.01933.x; Stevens MP, 2002, MOL MICROBIOL, V46, P649, DOI 10.1046/j.1365-2958.2002.03190.x; Tan YC, 2002, ANAL BIOCHEM, V310, P156, DOI 10.1016/S0003-2697(02)00382-2; Terebiznik MR, 2002, NAT CELL BIOL, V4, P766, DOI 10.1038/ncb854; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wood MW, 1996, MOL MICROBIOL, V22, P327, DOI 10.1046/j.1365-2958.1996.00116.x; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhou DG, 2001, MOL MICROBIOL, V39, P248, DOI 10.1046/j.1365-2958.2001.02230.x; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	43	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27149	27159		10.1074/jbc.M302475200	http://dx.doi.org/10.1074/jbc.M302475200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12719429	hybrid			2022-12-25	WOS:000184155700110
J	Schaefer, L; Beck, KF; Raslik, I; Walpen, S; Mihalik, D; Micegova, M; Macakova, K; Schonherr, E; Seidler, DG; Varga, G; Schaefer, RM; Kresse, H; Pfeilschifter, J				Schaefer, L; Beck, KF; Raslik, I; Walpen, S; Mihalik, D; Micegova, M; Macakova, K; Schonherr, E; Seidler, DG; Varga, G; Schaefer, RM; Kresse, H; Pfeilschifter, J			Biglycan, a nitric oxide-regulated gene, affects adhesion, growth, and survival of mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; EXPERIMENTAL GLOMERULONEPHRITIS; SMALL PROTEOGLYCANS; ENDOTHELIAL-CELLS; DOWN-REGULATION; FACTOR-BETA; DEFICIENT MICE; UP-REGULATION; DECORIN; EXPRESSION	During glomerular inflammation mesangial cells are the major source and target of nitric oxide that profoundly influences proliferation, adhesion, and death of mesangial cells. The effect of nitric oxide on the mRNA expression pattern of cultured rat mesangial cells was therefore investigated by RNA-arbitrarily-primed polymerase chain reaction. Employing this approach, biglycan expression turned out to be down-regulated time- and dose-dependently either by interleukin-1beta-stimulated endogenous nitric oxide production or by direct application of the exogenous nitric oxide donor, diethylenetriamine nitric oxide. There was a corresponding decline in the rate of biglycan biosynthesis and in the steady state level of this proteoglycan. In vivo, in a model of mesangioproliferative glomerulonephritis upregulation of inducible nitric-oxide synthase mRNA was associated with reduced expression of biglycan in isolated glomeruli. Biglycan expression could be normalized, both in vitro and in vivo, by using a specific inhibitor of the inducible nitric-oxide synthase, 1-N-6(1-iminoethyl)-1-lysine dihydrochloride. Further studies showed that biglycan inhibited cell adhesion on type I collagen and fibronectin because of its binding to these substrates. More importantly, biglycan protected mesangial cells from apoptosis by decreasing caspase-3 activity, and it counteracted the proliferative effects of platelet-derived growth factor-BB. These findings indicate a signaling role of biglycan and describe a novel pathomechanism by which nitric oxide modulates the course of renal glomerular disease through regulation of biglycan expression.	Univ Munster, Med Klin & Poliklin D, Dept Med D, D-48149 Munster, Germany; Univ Munster, Dept Physiol Chem, D-48149 Munster, Germany; Univ Munster, Dept Pathobiochem, D-48149 Munster, Germany; Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Goethe Univ Frankfurt, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia	University of Munster; University of Munster; University of Munster; University of Munster; Goethe University Frankfurt; Slovak Academy of Sciences	Schaefer, L (corresponding author), Univ Munster, Med Klin & Poliklin D, Dept Med D, Albert Schweitzer Str 33, D-48149 Munster, Germany.	schaefl@uni-muenster.de	Mihalik, Daniel/AAZ-3712-2020; Varga, Gábor/O-8858-2017	Mihalik, Daniel/0000-0002-3719-8634; Schaefer, Liliana/0000-0002-3318-3005				Ameye L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0848com; Beck KF, 2001, LIFE SCI, V69, P2945, DOI 10.1016/S0024-3205(01)01403-5; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; Chen XD, 2002, J BONE MINER RES, V17, P331, DOI 10.1359/jbmr.2002.17.2.331; COOK HT, 1994, CLIN EXP IMMUNOL, V97, P315; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FLOEGE J, 1993, KIDNEY INT, V43, pS47; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; GOTO S, 1995, AM J PATHOL, V147, P1133; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hugo C, 1997, J CLIN INVEST, V100, P786, DOI 10.1172/JCI119592; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kikuchi A, 2000, J NEUROIMMUNOL, V106, P78, DOI 10.1016/S0165-5728(99)00258-1; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kolb M, 2001, AM J PHYSIOL-LUNG C, V280, pL1327, DOI 10.1152/ajplung.2001.280.6.L1327; Kresse H, 2001, J BIOL CHEM, V276, P13411, DOI 10.1074/jbc.M009321200; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Manderscheid M, 2001, J AM SOC NEPHROL, V12, P1151, DOI 10.1681/ASN.V1261151; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; Morita H, 1996, NEPHRON, V73, P293; Mosley K, 2000, VIRCHOWS ARCH, V436, P567, DOI 10.1007/s004289900167; Muhl H, 1996, EUR J PHARMACOL, V317, P137, DOI 10.1016/S0014-2999(96)00701-7; NARITA I, 1995, LAB INVEST, V72, P17; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; Pfeilschifter J, 2002, KIDNEY INT, V61, P809, DOI 10.1046/j.1523-1755.2002.00225.x; Pfeilschifter J, 2002, NEPHROL DIAL TRANSPL, V17, P347, DOI 10.1093/ndt/17.3.347; Pfeilschifter J, 2001, EUR J PHARMACOL, V429, P279, DOI 10.1016/S0014-2999(01)01326-7; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Prols F, 1999, EXP NEPHROL, V7, P137; RAIJ L, 1993, J AM SOC NEPHROL, V3, P1435; Rupprecht HD, 2000, KIDNEY INT, V57, P70, DOI 10.1046/j.1523-1755.2000.00828.x; Sandau K, 1997, J IMMUNOL, V158, P4938; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schaefer L, 2000, KIDNEY INT, V58, P1557, DOI 10.1046/j.1523-1755.2000.00317.x; Schaefer L, 2002, AM J PATHOL, V160, P1181, DOI 10.1016/S0002-9440(10)64937-1; Schaefer L, 1998, KIDNEY INT, V54, P1529, DOI 10.1046/j.1523-1755.1998.00149.x; Schaefer L, 2001, FASEB J, V15, P559; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Stokes MB, 2000, KIDNEY INT, V57, P487, DOI 10.1046/j.1523-1755.2000.00868.x; TRACHTMAN H, 1995, BIOCHEM BIOPH RES CO, V207, P120, DOI 10.1006/bbrc.1995.1161; Walpen S, 2000, J AM SOC NEPHROL, V11, P468, DOI 10.1681/ASN.V113468; Walpen S, 2001, FASEB J, V15, P571; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746; Yao J, 1998, KIDNEY INT, V53, P598, DOI 10.1046/j.1523-1755.1998.00793.x	56	59	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26227	26237		10.1074/jbc.M210574200	http://dx.doi.org/10.1074/jbc.M210574200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719420	hybrid			2022-12-25	WOS:000183920200122
J	Bird, LE; Ren, J; Wright, A; Leslie, KD; Degreve, B; Balzarini, J; Stammers, DK				Bird, LE; Ren, J; Wright, A; Leslie, KD; Degreve, B; Balzarini, J; Stammers, DK			Crystal structure of varicella zoster virus thymidine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; PYRIMIDINE NUCLEOSIDE ANALOGS; X-RAY CRYSTALLOGRAPHY; DEOXYTHYMIDINE KINASES; SELECTIVE-INHIBITION; ANTIVIRAL ACTIVITY; ADENYLATE KINASE; BINDING-SITE; TYPE-1; GENE	Herpes virus thymidine kinases are responsible for the activation of nucleoside antiviral drugs including (E)-5-(2-bromovinyl)-2'-deoxyuridine. Such viral thymidine kinases (tk), beside having a broader substrate specificity compared with host cell enzymes, also show significant variation in nucleoside phosphorylation among themselves. We have determined the crystal structure of Varicella zoster virus (VZV, human herpes virus 3) thymidine kinase complexed with (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-monophosphate and ADP. Differences in the conformation of a loop region (residues 55-61) and the position of two alpha-helices at the subunit interface of VZV-tk compared with the herpes simplex virus type 1 ( human herpes virus 1) enzyme give rise to changes in the positioning of residues such as tyrosine 66 and glutamine 90, which hydrogen bond to the substrate in the active site. Such changes in combination with the substitution in VZV-tk of two phenylalanine residues ( in place of a tyrosine and methionine), which sandwich the substrate pyrimidine ring, cause an alteration in the positioning of the base. The interaction of the (E)-5-(2-bromovinyl)-2'-deoxyuridine deoxyribose ring with the protein is altered by substitution of tyrosine 21 and phenylalanine 139 (analagous to herpes simplex virus type 1 histidine 58 and tyrosine 172), which may explain some of the differences in nucleoside sugar selectivity between both enzymes. The altered active site architecture may also account for the differences in the substrate activity of ganciclovir for the two thymidine kinases. These data should be of use in the design of novel antiherpes and antitumor drugs.	Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	University of Oxford; Wellcome Centre for Human Genetics; KU Leuven	Stammers, DK (corresponding author), Univ Oxford, Div Struct Biol, Wellcome Trust Ctr Human Genet, Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.		Ren, Jingshan/AAT-7729-2021	Ren, Jingshan/0000-0003-4015-1404; Bird, Louise/0000-0002-9846-5716				Alber F, 1998, PROTEINS, V31, P453, DOI 10.1002/(SICI)1097-0134(19980601)31:4<453::AID-PROT11>3.0.CO;2-E; Andrei G, 2000, ANTIVIR RES, V45, P157, DOI 10.1016/S0166-3542(00)00070-X; Ashida N, 1997, ANTIVIR RES, V35, P167, DOI 10.1016/S0166-3542(97)00026-0; AYISI NK, 1987, MOL PHARMACOL, V31, P422; BALASUBRAMANIAM NK, 1990, J GEN VIROL, V71, P2979, DOI 10.1099/0022-1317-71-12-2979; Balzarini J, 2002, J ANTIMICROB CHEMOTH, V50, P5, DOI 10.1093/jac/dkf037; Bennett MS, 1999, FEBS LETT, V443, P121, DOI 10.1016/S0014-5793(98)01619-6; BEVILACQUA F, 1995, J GEN VIROL, V76, P1927, DOI 10.1099/0022-1317-76-8-1927; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Champness JN, 1998, PROTEINS, V32, P350, DOI 10.1002/(SICI)1097-0134(19980815)32:3<350::AID-PROT10>3.0.CO;2-8; CHEN MS, 1978, J BIOL CHEM, V253, P1325; CHENG YC, 1981, MOL PHARMACOL, V20, P230; Cohen JI, 1999, ANN INTERN MED, V130, P922, DOI 10.7326/0003-4819-130-11-199906010-00017; De Clercq E, 2001, NUCLEOS NUCLEOT NUCL, V20, P271, DOI 10.1081/NCN-100002298; De Clercq E, 2001, REV MED VIROL, V11, P381, DOI 10.1002/rmv.336; Degreve B, 1997, GENE THER, V4, P1107, DOI 10.1038/sj.gt.3300502; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; FYFE JA, 1982, MOL PHARMACOL, V21, P432; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GRIFFIN AM, 1990, J GEN VIROL, V71, P841, DOI 10.1099/0022-1317-71-4-841; GrignetDebrus C, 1997, GENE THER, V4, P560, DOI 10.1038/sj.gt.3300435; HONESS RW, 1989, J GEN VIROL, V70, P3003, DOI 10.1099/0022-1317-70-11-3003; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; Kussmann-Gerber S, 1998, EUR J BIOCHEM, V255, P472, DOI 10.1046/j.1432-1327.1998.2550472.x; McGuigan C, 1999, J MED CHEM, V42, P4479, DOI 10.1021/jm990346o; Naesens L, 2001, Herpes, V8, P12; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pilger BD, 1999, J BIOL CHEM, V274, P31967, DOI 10.1074/jbc.274.45.31967; Prota A, 2000, BIOCHEMISTRY-US, V39, P9597, DOI 10.1021/bi000668q; ROBERTS GB, 1991, J VIROL, V65, P6407, DOI 10.1128/JVI.65.12.6407-6413.1991; SCHULZ GE, 1974, NATURE, V250, P142, DOI 10.1038/250142a0; Sienaert R, 2002, MOL PHARMACOL, V61, P249, DOI 10.1124/mol.61.2.249; SNOECK R, 1994, J MED VIROL, V42, P338, DOI 10.1002/jmv.1890420404; Sulpizi M, 2001, J BIOL CHEM, V276, P21692, DOI 10.1074/jbc.M010223200; SUZUTANI T, 1988, ANTIMICROB AGENTS CH, V32, P1547, DOI 10.1128/AAC.32.10.1547; SUZUTANI T, 1993, J GEN VIROL, V74, P1011, DOI 10.1099/0022-1317-74-6-1011; Vogt J, 2000, PROTEINS, V41, P545, DOI 10.1002/1097-0134(20001201)41:4<545::AID-PROT110>3.0.CO;2-8; WILD K, 1995, FEBS LETT, V368, P289, DOI 10.1016/0014-5793(95)00680-8; Wild K, 1997, PROTEIN SCI, V6, P2097; YOKOTA T, 1989, MOL PHARMACOL, V36, P312	42	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24680	24687		10.1074/jbc.M302025200	http://dx.doi.org/10.1074/jbc.M302025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12686543	hybrid			2022-12-25	WOS:000183824800054
J	Norstrom, EA; Steen, M; Tran, S; Dahlback, B				Norstrom, EA; Steen, M; Tran, S; Dahlback, B			Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-DERIVED MICROPARTICLES; PEPTIDE-BOND CLEAVAGES; COAGULATION-FACTOR VA; BLOOD-COAGULATION; BINDING-SITE; FACTOR-XA; ANTICOAGULANT ACTIVITY; FACTOR VA(R506Q); INACTIVATION; MEMBRANE	The procoagulant function of activated factor V (FVa) is inhibited by activated protein C (APC) through proteolytic cleavages at Arg(306), Arg(506), and Arg(679). The effect of APC is potentiated by negatively charged phospholipid membranes and the APC cofactor protein S. Protein S has been reported to selectively stimulate cleavage at Arg(306), an effect hypothesized to be related to reorientation of the active site of APC closer to the phospholipid membrane. To investigate the importance of protein S and phospholipid in the APC-mediated cleavages of individual sites, recombinant FV variants FV(R306Q/R679Q) and FV(R506Q/R679Q) ( can be cleaved only at Arg(506) and Arg306(,) respectively) were created. The cleavage rate was determined for each cleavage site in the presence of varied protein S concentrations and phospholipid compositions. In contrast to results on record, we found that protein S stimulated both APC cleavages in a phospholipid composition-dependent manner. Thus, on vesicles containing both phosphatidylserine and phosphatidylethanolamine, protein S increased the rate of Arg(306) cleavage 27-fold and that of Arg(506) cleavage 5-fold. Half-maximal stimulation was obtained at similar to30 nM protein S for both cleavages. In conclusion, we demonstrate that APC-mediated cleavages at both Arg(306) and Arg(506) in FVa are stimulated by protein S in a phospholipid composition-dependent manner. These results provide new insights into the mechanism of APC cofactor activity of protein S and the importance of phospholipid composition.	Lund Univ, Dept Lab Med, Div Clin Chem, SE-20502 Malmo, Sweden; Malmo Univ Hosp, Wallenberg Lab, SE-20502 Malmo, Sweden	Lund University; Lund University; Skane University Hospital	Dahlback, B (corresponding author), Lund Univ, Dept Lab Med, Div Clin Chem, SE-20502 Malmo, Sweden.			Dahlback, Bjorn/0000-0003-1546-0328				BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; Butenas S, 2002, BIOCHEMISTRY-MOSCOW+, V67, P3; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; Deguchi H, 2002, J BIOL CHEM, V277, P8861, DOI 10.1074/jbc.M110252200; Esmon CT, 1997, THROMB HAEMOSTASIS, V78, P70; Fernandez JA, 2000, BLOOD CELL MOL DIS, V26, P115, DOI 10.1006/bcmd.2000.0285; FISKE CH, 1925, J BIOL CHEM, V66, P374; Friedrich U, 2001, J BIOL CHEM, V276, P23105, DOI 10.1074/jbc.M103138200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Norstrom E, 2002, BLOOD, V100, P524, DOI 10.1182/blood-2002-02-0343; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Safa O, 2001, J BIOL CHEM, V276, P1829, DOI 10.1074/jbc.M005931200; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; Smeets EF, 1996, THROMB RES, V81, P419, DOI 10.1016/0049-3848(96)00014-X; Smirnov MD, 1999, BIOCHEMISTRY-US, V38, P3591, DOI 10.1021/bi982538b; Smirnov MD, 1999, BLOOD, V94, P3839, DOI 10.1182/blood.V94.11.3839.423k07_3839_3846; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; SOLYMOSS S, 1988, J BIOL CHEM, V263, P14884; Steen M, 2002, J BIOL CHEM, V277, P38424, DOI 10.1074/jbc.M204972200; TANS G, 1991, BLOOD, V77, P2641; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; Yegneswaran S, 1999, J BIOL CHEM, V274, P5462, DOI 10.1074/jbc.274.9.5462	34	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24904	24911		10.1074/jbc.M303829200	http://dx.doi.org/10.1074/jbc.M303829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707283	hybrid			2022-12-25	WOS:000183824800080
J	Picciocchi, A; Douce, R; Alban, C				Picciocchi, A; Douce, R; Alban, C			The plant biotin synthase reaction - Identification and characterization of essential mitochondrial accessory protein components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLUSTER BINDING-SITES; IRON-SULFUR PROTEINS; BIOB GENE-PRODUCT; ACTIVITY IN-VITRO; ESCHERICHIA-COLI; ADRENODOXIN REDUCTASE; FUNCTIONAL-CHARACTERIZATION; CYSTEINE DESULFURASE; ARABIDOPSIS-THALIANA; FERREDOXIN	In plants, the last step of the biotin biosynthetic pathway is localized in mitochondria. This chemically complex reaction is catalyzed by the biotin synthase protein, encoded by the bio2 gene in Arabidopsis thaliana. Unidentified mitochondrial proteins in addition to the bio2 gene product are obligatory for the reaction to occur. In order to identify these additional proteins, potato mitochondrial matrix was fractionated onto different successive chromatographic columns. Combination experiments using purified Bio2 protein and the resulting mitochondrial matrix subfractions together with a genomic based research allowed us to identify mitochondrial adrenodoxin, adrenodoxin reductase, and cysteine desulfurase (Nfs1) proteins as essential components for the plant biotin synthase reaction. Arabidopsis cDNAs encoding these proteins were cloned, and the corresponding proteins were expressed in Escherichia coli cells and purified. Purified recombinant adrenodoxin and adrenodoxin reductase proteins formed in vitro an efficient low potential electron transfer chain that interacted with the bio2 gene product to reconstitute a functional plant biotin synthase complex. Bio2 from Arabidopsis is the first identified protein partner for this specific plant mitochondrial redox chain.	Bayer CropSci, Lab Mixte Rech,CNRS, INRA, UMR 1932, F-69263 Lyon 9, France	Bayer AG; Bayer CropScience; Centre National de la Recherche Scientifique (CNRS); INRAE	Alban, C (corresponding author), Univ Grenoble 1, UMR 5019,CNRS,INRA, Dept Response & Dynam Cellulaires, CEA Grenoble,Lab Physiol Cellulaire Vegetale, 17 Rue Martyrs, F-38054 Grenoble 9, France.	calban@cea.fr	Alban, Claude/ABG-2296-2021	Alban, Claude/0000-0003-3587-6339				Alban C, 2000, ANNU REV PLANT PHYS, V51, P17, DOI 10.1146/annurev.arplant.51.1.17; Baldet P, 1997, FEBS LETT, V419, P206, DOI 10.1016/S0014-5793(97)01458-0; BALDET P, 1996, CR HEBD ACAD SCI, V309, P99; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; Beckert V, 1997, J BIOL CHEM, V272, P4883, DOI 10.1074/jbc.272.8.4883; Birch OM, 2000, J BIOL CHEM, V275, P32277, DOI 10.1074/jbc.M004497200; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P735, DOI 10.1016/0003-9861(92)90749-M; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Bui BTS, 2000, EUR J BIOCHEM, V267, P2688; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; EISENBERG MA, 1987, CELLULAR MOL BIOL, P544; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Gibson KJ, 1999, BIOCHEM BIOPH RES CO, V254, P632, DOI 10.1006/bbrc.1998.9991; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V240, P246, DOI 10.1006/bbrc.1997.7611; Hewitson KS, 2000, FEBS LETT, V466, P372, DOI 10.1016/S0014-5793(00)01101-7; IFUKU O, 1994, EUR J BIOCHEM, V224, P173, DOI 10.1111/j.1432-1033.1994.tb20009.x; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kiyasu T, 2000, J BACTERIOL, V182, P2879, DOI 10.1128/JB.182.10.2879-2885.2000; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Kushnir S, 2001, PLANT CELL, V13, P89, DOI 10.1105/tpc.13.1.89; Lacour T, 1998, J BIOL CHEM, V273, P23984, DOI 10.1074/jbc.273.37.23984; LAMBETH JD, 1977, J BIOL CHEM, V252, P2908; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Marquet A, 2001, VITAM HORM, V61, P51; McIver L, 2000, J BIOL CHEM, V275, P13888, DOI 10.1074/jbc.275.18.13888; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Patton DA, 1998, PLANT PHYSIOL, V116, P935, DOI 10.1104/pp.116.3.935; Picciocchi A, 2001, PLANT PHYSIOL, V127, P1224, DOI 10.1104/pp.010346; SAGARA Y, 1993, BIOL PHARM BULL, V16, P627; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ugulava NB, 2002, J AM CHEM SOC, V124, P9050, DOI 10.1021/ja027004j; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Wan JT, 2002, ARCH BIOCHEM BIOPHYS, V406, P116, DOI 10.1016/S0003-9861(02)00421-6; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	53	63	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24966	24975		10.1074/jbc.M302154200	http://dx.doi.org/10.1074/jbc.M302154200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714594	Green Published, hybrid			2022-12-25	WOS:000183824800088
J	Sato, T; Dohmae, N; Qi, Y; Kakuda, N; Misonoum, H; Mitsumori, R; Maruyama, H; Koo, EH; Haass, C; Takio, K; Morishima-Kawashima, M; Ishiura, S; Ihara, Y				Sato, T; Dohmae, N; Qi, Y; Kakuda, N; Misonoum, H; Mitsumori, R; Maruyama, H; Koo, EH; Haass, C; Takio, K; Morishima-Kawashima, M; Ishiura, S; Ihara, Y			Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; INTRACELLULAR DOMAIN; A-BETA; INTRAMEMBRANE PROTEOLYSIS; ALZHEIMERS-DISEASE; TRANSMEMBRANE ASPARTATES; PRESENILIN-1 MUTATIONS; DISTINCT MECHANISMS; CLEAVAGE; NOTCH	A novel cleavage of beta-amyloid precursor protein (APP), referred to as epsilon-cleavage, occurs downstream of the gamma-cleavage and generates predominantly a C-terminal fragment (CTFgamma) that begins at Val-50, according to amyloid beta-protein (Abeta) numbering. Whether this cleavage occurs independently of, or is coordinated with, gamma-cleavage is unknown. Using a cell-free system, we show here that, although Abeta40 and CTFgamma 50-99 were the predominant species produced by membranes prepared from cells overexpressing wild-type (wt) APP and wt presenilin (PS) 1 or 2, the production of CTFgamma 49-99, which begins at Leu-49, was remarkably enhanced in membranes from cells overexpressing mutant (mt) APP or mtPS1/2 that increases the production of Abeta42. Furthermore, a gamma-secretase inhibitor, which suppresses Abeta40 production and paradoxically enhances Abeta42 production at low concentrations, caused the proportion of CTFgamma 50-99 to decrease and that of CTFgamma 49-99 to increase significantly. These results strongly suggest a link between the production of Abeta42 and CTFgamma 49-99 and provide an important insight into the mechanisms of altered gamma-cleavage caused by mtAPP and mtPS1/2.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; Inst Phys & Chem Res, Biomol Characterizat Div, Characterizat Ctr, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany	University of Tokyo; University of Tokyo; RIKEN; University of California System; University of California San Diego; University of Munich	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Dohmae, Naoshi/C-2040-2011; Kakuda, Nobuto/ABB-5608-2021	Dohmae, Naoshi/0000-0002-5242-9410; Misono, Hiroaki/0000-0001-5892-1804; Kakuda, Nobuto/0000-0001-7011-6891				BURDICK D, 1992, J BIOL CHEM, V267, P546; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1992, NATURE, V359, P325; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Kuo YM, 2000, AM J PATHOL, V156, P797, DOI 10.1016/S0002-9440(10)64947-4; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Qi Y, 2003, BIOCHEMISTRY-US, V42, P1042, DOI 10.1021/bi0267590; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang DM, 2000, NEUROREPORT, V11, P3227, DOI 10.1097/00001756-200009280-00035; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	35	119	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24294	24301		10.1074/jbc.M211161200	http://dx.doi.org/10.1074/jbc.M211161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707272	hybrid			2022-12-25	WOS:000183824800009
J	Szymanski, CM; St Michael, F; Jarrell, HC; Li, JJ; Gilbert, M; Larocque, S; Vinogradov, E; Brisson, JR				Szymanski, CM; St Michael, F; Jarrell, HC; Li, JJ; Gilbert, M; Larocque, S; Vinogradov, E; Brisson, JR			Detection of conserved N-linked glycans and phase-variable lipooligosaccharides and capsules from Campylobacter cells by mass spectrometry and high resolution magic angle spinning NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN GLYCOSYLATION; GUILLAIN-BARRE; NEISSERIA-MENINGITIDIS; LIPO-OLIGOSACCHARIDE; GANGLIOSIDE MIMICS; URINARY-EXCRETION; JEJUNI; POLYSACCHARIDE; IDENTIFICATION; LIPOPOLYSACCHARIDES	Glycomics, the study of microbial polysaccharides and genes responsible for their formation, requires the continuous development of rapid and sensitive methods for the identification of glycan structures. In this study, methods for the direct analysis of sugars from 108 to 1010 cells are outlined using the human gastrointestinal pathogen, Campylobacter jejuni. Using capillary-electrophoresis coupled with sensitive electrospray mass spectrometry, we demonstrate variability in the lipid A component of C. jejuni lipooligosaccharides (LOSs). In addition, these sensitive methods have permitted the detection of phase-variable LOS core structures that were not observed previously. High resolution magic angle spinning (HR-MAS) NMR was used to examine capsular polysaccharides directly from campylobacter cells and showed profiles similar to those observed for purified polysaccharides analyzed by solution NMR. This method also exhibited the feasibility of campylobacter serotyping, mutant verification, and preliminary sugar analysis. HR-MAS NMR examination of growth from individual colonies of C. jejuni NCTC11168 indicated that the capsular glycan modifications are also phase-variable. These variants show different staining patterns on deoxycholate-PAGE and reactivity with immune sera. One of the identified modifications was a novel -OP = O(NH2)OMe phosphoramide, not observed previously in nature. In addition, HR-MAS NMR detected the N-linked glycan, GalNAc-alpha1,4-GalNAc-alpha1,4[Glc-beta1,3-]GalNAc-alpha1,4-GalNAc-alpha1,4-GalNAc-alpha1,3-Bac, where Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose, in C. jejuni and Campylobacter coli. The presence of this common heptasaccharide in multiple campylobacter isolates demonstrates the conservation of the N-linked protein glycosylation pathway in this organism and describes the first report of HR-MAS NMR detection of N-linked glycans on glycoproteins from intact bacterial cells.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Brisson, JR (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	jean-robert.brisson@nrc-cnrc.gc.ca		Li, Jianjun/0000-0002-6531-3687; Vinogradov, Evgeny/0000-0002-5364-1376; Gilbert, Michel/0000-0002-0204-4408				Ahmed IH, 2002, MICROBIOL-SGM, V148, P1203, DOI 10.1099/00221287-148-4-1203; Ang CW, 2002, INFECT IMMUN, V70, P1202, DOI 10.1128/IAI.70.3.1202-1208.2002; ASPINALL GO, 1992, J BACTERIOL, V174, P1324, DOI 10.1128/jb.174.4.1324-1332.1992; Bacon DJ, 2001, MOL MICROBIOL, V40, P769, DOI 10.1046/j.1365-2958.2001.02431.x; BARTON DHR, 1979, COMPREHENSIVE ORGANI, P1270; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; Berry DS, 2002, INFECT IMMUN, V70, P3707, DOI 10.1128/IAI.70.7.3707-3713.2002; Bowes T, 2002, INFECT IMMUN, V70, P5008, DOI 10.1128/IAI.70.9.5008-5018.2002; Breil S, 2001, J PHARMACEUT BIOMED, V25, P669, DOI 10.1016/S0731-7085(00)00582-3; BRISSON JR, 2002, NMR SPECTROSCOPY GLY, P59; Czaja J, 2000, EUR J BIOCHEM, V267, P1672, DOI 10.1046/j.1432-1327.2000.01161.x; Dell A, 2001, SCIENCE, V291, P2351, DOI 10.1126/science.1058890; Dingle KE, 2002, EMERG INFECT DIS, V8, P949; Dorrell N, 2001, GENOME RES, V11, P1706, DOI 10.1101/gr.185801; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; Gallego RG, 2001, J BIOL CHEM, V276, P30834, DOI 10.1074/jbc.M101013200; GILARD V, 1993, CANCER CHEMOTH PHARM, V31, P387, DOI 10.1007/BF00686153; GILARD V, 1994, J MED CHEM, V37, P3986, DOI 10.1021/jm00049a018; Gilard V, 1999, J MED CHEM, V42, P2542, DOI 10.1021/jm980587g; Gilbert M, 2002, J BIOL CHEM, V277, P327, DOI 10.1074/jbc.M108452200; Gilbert M, 2000, J BIOL CHEM, V275, P3896, DOI 10.1074/jbc.275.6.3896; Guerry P, 2002, INFECT IMMUN, V70, P787, DOI 10.1128/IAI.70.2.787-793.2002; Guerry P, 2000, INFECT IMMUN, V68, P6656, DOI 10.1128/IAI.68.12.6656-6662.2000; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hanniffy OM, 1999, CARBOHYD RES, V319, P124, DOI 10.1016/S0008-6215(99)00129-9; Jachymek W, 1999, BIOCHEMISTRY-US, V38, P11788, DOI 10.1021/bi990673y; JACOBS BC, 1995, ANN NEUROL, V37, P260, DOI 10.1002/ana.410370218; Joqueviel C, 1998, DRUG METAB DISPOS, V26, P418; Karlyshev AV, 2000, MOL MICROBIOL, V35, P529, DOI 10.1046/j.1365-2958.2000.01717.x; Kasagami T, 2002, PEST MANAG SCI, V58, P1107, DOI 10.1002/ps.546; Kneidinger B, 2003, J BIOL CHEM, V278, P3615, DOI 10.1074/jbc.M203867200; Krinos CM, 2001, NATURE, V414, P555, DOI 10.1038/35107092; LEE NG, 1995, J BIOL CHEM, V270, P27151, DOI 10.1074/jbc.270.45.27151; Li J, 1998, J CHROMATOGR A, V817, P325, DOI 10.1016/S0021-9673(98)00341-0; Linton D, 2000, MOL MICROBIOL, V37, P501, DOI 10.1046/j.1365-2958.2000.02020.x; Linton D, 2002, MOL MICROBIOL, V43, P497, DOI 10.1046/j.1365-2958.2002.02762.x; Logan SM, 2002, MOL MICROBIOL, V46, P587, DOI 10.1046/j.1365-2958.2002.03185.x; Mackinnon FG, 2002, MOL MICROBIOL, V43, P931, DOI 10.1046/j.1365-2958.2002.02754.x; Manzi AE, 2000, GLYCOBIOLOGY, V10, P669, DOI 10.1093/glycob/10.7.669; MARTINO R, 1992, J PHARMACOL EXP THER, V260, P1133; MEIBOOM S, 1958, REV SCI INSTRUM, V29, P688, DOI 10.1063/1.1716296; MILLS SD, 1991, J MED MICROBIOL, V35, P168, DOI 10.1099/00222615-35-3-168; MORAN AP, 1991, EUR J BIOCHEM, V198, P459, DOI 10.1111/j.1432-1033.1991.tb16036.x; Moran AP, 2001, J AUTOIMMUN, V16, P241, DOI 10.1006/jaut.2000.0490; Moran AP, 1999, J APPL MICROBIOL, V86, P361, DOI 10.1046/j.1365-2672.1999.00713.x; Moran AP, 2000, CAMPYLOBACTER, P241; Nachamkin I, 1998, CLIN MICROBIOL REV, V11, P555, DOI 10.1128/CMR.11.3.555; Parkhill J, 2000, NATURE, V403, P665, DOI 10.1038/35001088; PENNER JL, 1980, J CLIN MICROBIOL, V12, P732, DOI 10.1128/JCM.12.6.732-737.1980; Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370; Shin JEN, 1997, CARBOHYD RES, V305, P223; Shulman-Roskes EM, 1998, J MED CHEM, V41, P515, DOI 10.1021/jm9704659; St Michael F, 2002, EUR J BIOCHEM, V269, P5119, DOI 10.1046/j.1432-1033.2002.03201.x; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Szymanski CM, 2002, INFECT IMMUN, V70, P2242, DOI 10.1128/IAI.70.4.2242-2244.2002; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Uhrin D, 2000, NMR IN MICROBIOLOGY: THEORY AND APPLICATIONS, P165; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; Young NM, 2002, J BIOL CHEM, V277, P42530, DOI 10.1074/jbc.M206114200; YUKI N, 1990, NEUROLOGY, V40, P1900, DOI 10.1212/WNL.40.12.1900	61	157	162	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24509	24520		10.1074/jbc.M301273200	http://dx.doi.org/10.1074/jbc.M301273200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716884	hybrid			2022-12-25	WOS:000183824800033
J	Barrette-Ng, IH; Ng, KKS; Cherney, MM; Pearce, G; Ryan, CA; James, MNG				Barrette-Ng, IH; Ng, KKS; Cherney, MM; Pearce, G; Ryan, CA; James, MNG			Structural basis of inhibition revealed by a 1 : 2 complex of the two-headed tomato inhibitor-II and subtilisin Carlsberg	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; CRYSTAL-STRUCTURE; TRYPSIN-INHIBITOR; TERNARY COMPLEX; BOVINE TRYPSIN; POTATO-TUBERS; REACTIVE-SITE; ACTIVE-SITE; EGLIN-C; PLANTS	Multidomain proteinase inhibitors play critical roles in the defense of plants against predation by a wide range of pests. Despite a wealth of structural information on proteinase-single domain inhibitor interactions, the structural basis of inhibition by multidomain proteinase inhibitors remains poorly understood. Here we report the 2.5-Angstrom resolution crystal structure of the two-headed tomato inhibitor-II (TI-II) in complex with two molecules of subtilisin Carlsberg; it reveals how a multidomain inhibitor from the Potato II family of proteinase inhibitors can bind to and simultaneously inhibit two enzyme molecules within a single ternary complex. The N terminus of TI-II initiates the folding of Domain I (Lys-1 to Cys-15 and Pro-84 to Met-123) and then completes Domain II (Ile-26 to Pro-74) before coming back to complete the rest of Domain I (Pro-84 to Met-123). The two domains of TI-II adopt a similar fold and are arranged in an extended configuration that presents two reactive site loops at the opposite ends of the inhibitor molecule. Each subtilisin molecule interacts with a reactive site loop of TI-II through the standard, canonical binding mode. Remarkably, a significant distortion of the active site of subtilisin is induced by the presence of phenylalanine in the P1 position of reactive site loop II of TI-II. The structure of the TI-II.(subtilisin) 2 complex provides a molecular framework for understanding how multiple inhibitory domains in a single Potato II type proteinase inhibitor molecule from the Potato II family act to inhibit proteolytic enzymes.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA; Stanford Synchrotron Radiat Lab, Natl User Facil, Stanford, CA USA	University of Alberta; University of Calgary; Washington State University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.	michael.james@ualberta.ca		Ng, Kenneth K.S./0000-0001-7280-8445				Antcheva N, 1996, BBA-PROTEIN STRUCT M, V1298, P95, DOI 10.1016/S0167-4838(96)00121-5; Apostoluk W, 1998, PROTEINS, V32, P459, DOI 10.1002/(SICI)1097-0134(19980901)32:4<459::AID-PROT5>3.0.CO;2-B; ATKINSON AH, 1993, PLANT CELL, V5, P203, DOI 10.1105/tpc.5.2.203; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALANDIN T, 1995, PLANT MOL BIOL, V27, P1197, DOI 10.1007/BF00020893; Beekwilder J, 2000, EUR J BIOCHEM, V267, P1975, DOI 10.1046/j.1432-1327.2000.01201.x; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BOULTER D, 1989, BIOTECHNOL ADV, V7, P489, DOI 10.1016/0734-9750(89)90720-9; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; BROADWAY RM, 1986, J INSECT PHYSIOL, V32, P673, DOI 10.1016/0022-1910(86)90108-3; BROWN WE, 1984, BIOCHEMISTRY-US, V23, P3418, DOI 10.1021/bi00310a006; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT J, 1976, BIOCHEMISTRY-US, V15, P3418, DOI 10.1021/bi00661a004; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; DeLano WL, 2002, PYMOL USERS MANUAL; Duan XL, 1996, NAT BIOTECHNOL, V14, P494, DOI 10.1038/nbt0496-494; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GRAHAM JS, 1986, PLANTA, V169, P399, DOI 10.1007/BF00392137; GRAHAM JS, 1985, J BIOL CHEM, V260, P6561; GREEN TR, 1972, SCIENCE, V175, P776, DOI 10.1126/science.175.4023.776; GREENBLATT HM, 1989, J MOL BIOL, V205, P201, DOI 10.1016/0022-2836(89)90376-8; HEATH RL, 1995, EUR J BIOCHEM, V230, P250, DOI 10.1111/j.1432-1033.1995.tb20558.x; HEINZ DW, 1991, J MOL BIOL, V217, P353, DOI 10.1016/0022-2836(91)90549-L; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JANZEN DH, 1979, HERBIVORES THEIR INT, P331; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; Jongsma MA, 1997, J INSECT PHYSIOL, V43, P885, DOI 10.1016/S0022-1910(97)00040-1; KEIL M, 1986, NUCLEIC ACIDS RES, V14, P5641, DOI 10.1093/nar/14.14.5641; Koepke J, 2000, J MOL BIOL, V298, P477, DOI 10.1006/jmbi.2000.3677; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; Lee MCS, 1999, NAT STRUCT BIOL, V6, P526, DOI 10.1038/9293; Li L, 2002, P NATL ACAD SCI USA, V99, P6416, DOI 10.1073/pnas.072072599; LIN GD, 1993, EUR J BIOCHEM, V212, P549, DOI 10.1111/j.1432-1033.1993.tb17692.x; Marchetti S, 2000, THEOR APPL GENET, V101, P519, DOI 10.1007/s001220051511; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NIELSEN KJ, 1994, J MOL BIOL, V242, P231, DOI 10.1006/jmbi.1994.1575; NIELSEN KJ, 1995, BIOCHEMISTRY-US, V34, P14304, DOI 10.1021/bi00044a007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZAWA K, 1966, J BIOL CHEM, V241, P3955; PEARCE G, 1982, ARCH BIOCHEM BIOPHYS, V213, P456, DOI 10.1016/0003-9861(82)90571-9; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARCE G, 1993, PLANT PHYSIOL, V102, P639, DOI 10.1104/pp.102.2.639; PEARCE G, 1988, PLANTA, V175, P527, DOI 10.1007/BF00393075; PLUNKETT G, 1982, ARCH BIOCHEM BIOPHYS, V213, P463, DOI 10.1016/0003-9861(82)90572-0; Raj SSS, 2002, J BIOCHEM, V132, P927, DOI 10.1093/oxfordjournals.jbchem.a003306; RICHARDSON M, 1977, PHYTOCHEMISTRY, V16, P159, DOI 10.1016/S0031-9422(00)86777-1; RICHARDSON M, 1979, FEBS LETT, V104, P322, DOI 10.1016/0014-5793(79)80843-1; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Ryan CA, 2002, P NATL ACAD SCI USA, V99, P6519, DOI 10.1073/pnas.112196499; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scheer JM, 2002, P NATL ACAD SCI USA, V99, P9585, DOI 10.1073/pnas.132266499; STEINMETZ ACU, 1994, BIOCHEMISTRY-US, V33, P10535, DOI 10.1021/bi00200a040; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; TAKEUCHI Y, 1991, PROTEIN ENG, V4, P501, DOI 10.1093/protein/4.5.501; TAYLOR BH, 1993, PLANT MOL BIOL, V23, P1005, DOI 10.1007/BF00021815; THORNBURG RW, 1987, P NATL ACAD SCI USA, V84, P744, DOI 10.1073/pnas.84.3.744; [No title captured]	66	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24062	24071		10.1074/jbc.M302020200	http://dx.doi.org/10.1074/jbc.M302020200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684499	hybrid			2022-12-25	WOS:000183638600109
J	Brown, JR; Fuster, MM; Whisenant, T; Esko, JD				Brown, JR; Fuster, MM; Whisenant, T; Esko, JD			Expression patterns of alpha 2,3-sialyltransferases and alpha 1,3-fucosyltransferases determine the mode of sialyl Lewis X inhibition by disaccharide decoys	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CANCER-CELLS; BENZYL-ALPHA-GALNAC; P-SELECTIN; MOLECULAR-CLONING; INTRACELLULAR TRAFFICKING; OLIGONUCLEOTIDE ARRAYS; CARBOHYDRATE ANTIGEN; ENDOTHELIAL-CELLS; CARCINOMA MUCINS; GASTRIC-CANCER	A variety of human adenocarcinomas express sialylated, fucosylated Lewis blood group antigens on cell surface and secreted mucins. Binding of these antigens to P-selectin on platelets is thought to facilitate formation of platelet-tumor emboli in the circulation, which in turn allows sequestration of the tumor cells in the microvasculature. Here we report a pharmacologic approach for blocking these interactions through metabolic inhibition of sialylation. Peracetylated forms of Galbeta1,4GlcNAcb-O-naphthalenemethanol and GlcNAc-beta1,3Galbeta-O-naphthalenemethanol were taken up by LS180 human colon carcinoma cells, O-deacetylated, and utilized as biosynthetic intermediates, resulting in heterogeneous oligosaccharides. The primed oligosaccharides included sialylated, sulfated, and fucosylated products based on mass spectrometry. Assembly of free oligosaccharides on the glycosides decoyed glycosylation of cellular glycoproteins, as assessed by altered binding of lectins and carbohydrate-specific antibodies. Expression of alpha2,3-sialylated oligosaccharides on the cell surface was diminished specifically, whereas alpha2,6-sialylation and fucosylation were not. In U937 lymphoma cells, the glycosides decreased fucosylation without affecting sialylation. The differential inhibitory activities correlated inversely with fucosyltransferase and sialyltransferase activity based on enzyme assays and microarray analysis. Regardless of the mechanism, the disaccharides blocked the cells from forming selectin ligands and inhibited adhesion to immobilized selectins, suggesting that the glycosides might prove useful for interfering with tumor cell adhesion and metastasis.	Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Pulm Med, San Diego, CA 92103 USA; Scripps Res Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [CA46462] Funding Source: Medline; NIGMS NIH HHS [GM62116, GM61894] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116, R24GM061894] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai XM, 2001, GLYCOBIOLOGY, V11, P621, DOI 10.1093/glycob/11.8.621; Blixt O, 2001, J ORG CHEM, V66, P2442, DOI 10.1021/jo0057809; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; Ellies LG, 2002, BLOOD, V100, P3618, DOI 10.1182/blood-2002-04-1007; Ellies LG, 2002, P NATL ACAD SCI USA, V99, P10042, DOI 10.1073/pnas.142005099; Goss PE, 1995, CLIN CANCER RES, V1, P935; Gouyer V, 2001, J CELL SCI, V114, P1455; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; Granovsky M, 2000, NAT MED, V6, P306; Hartwell DW, 1999, THROMB HAEMOSTASIS, V82, P850, DOI 10.1055/s-0037-1615922; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HUANG J, 1992, ONCOL RES, V4, P507; IZUMI Y, 1995, EXP CELL RES, V216, P215, DOI 10.1006/excr.1995.1027; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; Klopocki AG, 1998, EUR J BIOCHEM, V253, P309, DOI 10.1046/j.1432-1327.1998.2530309.x; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KOJIMA N, 1992, BIOCHEM BIOPH RES CO, V182, P1288, DOI 10.1016/0006-291X(92)91872-N; Kono M, 1998, BIOCHEM BIOPH RES CO, V253, P170, DOI 10.1006/bbrc.1998.9768; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LI C, 2001, GENOME BIOL, V3; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; LOWARY TL, 1994, CARBOHYD RES, V256, P257, DOI 10.1016/0008-6215(94)84212-4; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MANNORI G, 1995, CANCER RES, V55, P4425; MUTCH DM, 2002, BMC BIOINFORMATICS; NAKAMORI S, 1993, CANCER RES, V53, P3632; Nakamori S, 1997, J CLIN ONCOL, V15, P816, DOI 10.1200/JCO.1997.15.2.816; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Ogawa J, 1997, CANCER, V79, P1678, DOI 10.1002/(SICI)1097-0142(19970501)79:9<1678::AID-CNCR7>3.0.CO;2-8; Okajima T, 1999, J BIOL CHEM, V274, P11479, DOI 10.1074/jbc.274.17.11479; ROUX L, 1988, J BIOL CHEM, V263, P8879; Sarkar AK, 1997, J BIOL CHEM, V272, P25608, DOI 10.1074/jbc.272.41.25608; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; Sarkar AK, 2000, CARBOHYD RES, V329, P287, DOI 10.1016/S0008-6215(00)00200-7; SASAKI K, 1994, J BIOL CHEM, V269, P14730; STJOHN JJ, 1994, J IMMUNOL METHODS, V170, P159, DOI 10.1016/0022-1759(94)90391-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Weston BW, 1999, CANCER RES, V59, P2127; WOYNAROWSKA B, 1994, J BIOL CHEM, V269, P22797; Woynarowska B, 1996, GLYCOCONJUGATE J, V13, P663, DOI 10.1007/BF00731455	48	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23352	23359		10.1074/jbc.M303093200	http://dx.doi.org/10.1074/jbc.M303093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12686549	hybrid			2022-12-25	WOS:000183638600019
J	Geerlings, TH; Faber, AW; Bister, MD; Vos, JC; Raue, HA				Geerlings, TH; Faber, AW; Bister, MD; Vos, JC; Raue, HA			Rio2p, an evolutionarily conserved, low abundant protein kinase essential for processing of 20 S Pre-rRNA in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U3 SNORNP; FUNCTIONAL-CHARACTERIZATION; SUBUNIT REQUIRES; FINAL STEP; CYCLE; 5.8S; BIOGENESIS; PESCADILLO; PURIFICATION; MATURATION	Saccharomyces cerevisiae Rio2p ( encoded by open reading frame Ynl207w) is an essential protein of unknown function that displays significant sequence similarity to Rio1p/ Rrp10p. The latter was recently shown to be an evolutionarily conserved, predominantly cytoplasmic serine/ threonine kinase whose presence is required for the final cleavage at site D that converts 20 S pre- rRNA into mature 18 S rRNA. A data base search identified homologs of Rio2p in a wide variety of eukaryotes and Archaea. Detailed sequence comparison and in vitro kinase assays using recombinant protein demonstrated that Rio2p defines a subfamily of protein kinases related to, but both structurally and functionally distinct from, the one defined by Rio1p. Failure to deplete Rio2p in cells containing a GAL- rio2 gene and direct analysis of Rio2p levels by Western blotting indicated the protein to be low abundant. Using a GAL- rio2 gene carrying a point mutation that reduces the kinase activity, we found that depletion of this mutant protein blocked production of 18 S rRNA due to inhibition of the cleavage of cytoplasmic 20 S pre- rRNA at site D. Production of the large subunit rRNAs was not affected. Thus, Rio2p is the second protein kinase that is essential for cleavage at site D and the first in which the processing defect can be linked to its enzymatic activity. Contrary to Rio1p/ Rrp10p, however, Rio2p appears to be localized predominantly in the nucleus.	Free Univ Amsterdam, Sect Biochem & Mol Biol, Inst Mol Biol Wetenschappen, BioCentrum Amsterdam, NL-1081 HV Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam	Raue, HA (corresponding author), Free Univ Amsterdam, Sect Biochem & Mol Biol, Inst Mol Biol Wetenschappen, BioCentrum Amsterdam, Boelelaan 1083, NL-1081 HV Amsterdam, Netherlands.	raue@few.vu.nl		Vos, J. Chris/0000-0003-3737-9942; Bister, Milena D./0000-0001-7590-9321				AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Angermayr M, 2002, FEBS LETT, V524, P31, DOI 10.1016/S0014-5793(02)02993-9; Angermayr M, 2002, MOL MICROBIOL, V44, P309, DOI 10.1046/j.1365-2958.2002.02881.x; Angermayr M, 1997, J BIOL CHEM, V272, P31630, DOI 10.1074/jbc.272.50.31630; BousquetAntonelli C, 1997, EMBO J, V16, P4770, DOI 10.1093/emboj/16.15.4770; Dragon F, 2002, NATURE, V417, P967, DOI 10.1038/nature00769; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Faber AW, 2002, RNA, V8, P1095, DOI 10.1017/S1355838202021027; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geerlings TH, 2000, RNA, V6, P1698, DOI 10.1017/S1355838200001540; Gelperin D, 2001, RNA, V7, P1268, DOI 10.1017/S1355838201013073; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Grandi P, 2002, MOL CELL, V10, P105, DOI 10.1016/S1097-2765(02)00579-8; Harnpicharnchai P, 2001, MOL CELL, V8, P505, DOI 10.1016/S1097-2765(01)00344-6; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Krupa A, 2002, PROTEIN SCI, V11, P1580, DOI 10.1110/ps.3560102; Kufel J, 1999, RNA, V5, P909, DOI 10.1017/S135583829999026X; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; LAFONTAINE D, 1995, GENE DEV, V9, P2470, DOI 10.1101/gad.9.20.2470; LAFONTAINE D, 1994, J MOL BIOL, V241, P492, DOI 10.1006/jmbi.1994.1525; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; Nissan TA, 2002, EMBO J, V21, P5539, DOI 10.1093/emboj/cdf547; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Pestov DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/nar/29.17.3621; RAUE HA, 2003, IN PRESS NUCLEOLUS; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sambrook J, 2001, MOL CLONING LAB MANU; Schafer T, 2003, EMBO J, V22, P1370, DOI 10.1093/emboj/cdg121; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; van Hoof A, 2000, EMBO J, V19, P1357, DOI 10.1093/emboj/19.6.1357; Vanrobays E, 2003, MOL CELL BIOL, V23, P2083, DOI 10.1128/MCB.23.6.2083-2095.2003; Vanrobays E, 2001, EMBO J, V20, P4204, DOI 10.1093/emboj/20.15.4204; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	46	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22537	22545		10.1074/jbc.M300759200	http://dx.doi.org/10.1074/jbc.M300759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690111	hybrid, Green Published			2022-12-25	WOS:000183503900050
J	Lee, DL; Mant, CT; Hodges, RS				Lee, DL; Mant, CT; Hodges, RS			A novel method to measure self-association of small amphipathic molecules - Temperature profiling in reversed-phase chromatography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HELICAL COILED-COILS; PEPTIDE GRAMICIDIN-S; ACID SIDE-CHAINS; INTERACTION/CATION-EXCHANGE CHROMATOGRAPHY; DIFFERENT AQUEOUS ENVIRONMENTS; LIGAND-RECEPTOR INTERFACE; LIPID-BILAYER-MEMBRANES; OLIGOMERIZATION STATE; CYCLIC-PEPTIDES	Biophysical techniques such as size-exclusion chromatography, sedimentation equilibrium analytical ultracentrifugation, and non-denaturing gel electrophoresis are the classical methods for determining the self-association of molecules into dimers, trimers, or other higher order species. However, these techniques usually require high (mg/ml) loading concentrations to detect self-association and also possess a lower size limit that is dependent on the ability of the technique to resolve monomeric from higher order species. Here we describe a novel, sensitive method with no upper or lower molecular size limits that indicates self-association of molecules driven together by the hydrophobic effect under aqueous conditions. "Temperature profiling in reversed-phase chromatography" analyzes the retention behavior of a sample over the temperature range of 5-80degreesC during gradient elution reversed-phase high-performance liquid chromatography. Because this technique greatly increases the effective concentration of analyte upon adsorption to the column, it is extremely sensitive, requiring very small sample quantities (microgram or less). In contrast, the classical techniques mentioned above decrease the effective analyte concentration during analysis, decreasing sensitivity by requiring larger amounts of analyte to detect molecular self-association. We demonstrate the utility of this technique with 14-residue cyclic and linear cationic peptides (<2000 Da) based on the sequence of the de novo-designed cytolytic peptide, GS14. The only requirements for the analyte molecule when using this technique are its ability to be retained on the reversed-phase column and to be subsequently removed from the column during gradient elution.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Alberta	Hodges, RS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [R01 GM61855] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061855] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDEK K, 1993, J CHROMATOGR, V646, P91, DOI 10.1016/S0021-9673(99)87010-1; BLONDELLE SE, 1995, BIOPHYS J, V68, P351, DOI 10.1016/S0006-3495(95)80194-3; Chao HM, 1996, BIOCHEMISTRY-US, V35, P12175, DOI 10.1021/bi9530604; Chen Y, 2002, J PEPT RES, V59, P18, DOI 10.1046/j.1397-002x.2001.10994.x; De Crescenzo G, 2003, BIOCHEMISTRY-US, V42, P1754, DOI 10.1021/bi0268450; Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284; HODGES RS, 1994, J CHROMATOGR A, V676, P3, DOI 10.1016/0021-9673(94)80452-4; INGRAHAM RH, 1985, J CHROMATOGR, V327, P77, DOI 10.1016/S0021-9673(01)81639-3; Jelokhani-Niaraki M, 2000, BIOCHEM J, V349, P747, DOI 10.1042/bj3490747; Jelokhani-Niaraki M, 2002, J PEPT RES, V60, P23, DOI 10.1034/j.1399-3011.2002.21003.x; Jelokhani-Niaraki M, 2001, J PEPT RES, V58, P293, DOI 10.1034/j.1399-3011.2001.00893.x; KATSU T, 1989, BIOCHIM BIOPHYS ACTA, V983, P135, DOI 10.1016/0005-2736(89)90226-5; Kondejewski LH, 1999, J BIOL CHEM, V274, P13181, DOI 10.1074/jbc.274.19.13181; Kondejewski LH, 2002, J BIOL CHEM, V277, P67, DOI 10.1074/jbc.M107825200; Kondejewski LH, 1996, J BIOL CHEM, V271, P25261, DOI 10.1074/jbc.271.41.25261; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lewis RNAH, 1999, BIOCHEMISTRY-US, V38, P15193, DOI 10.1021/bi9912342; Lewis RNAH, 2003, BIOCHEMISTRY-US, V42, P440, DOI 10.1021/bi026707a; Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x; Litowski JR, 2002, J BIOL CHEM, V277, P37272, DOI 10.1074/jbc.M204257200; Mant C.T., 2002, HPLC BIOL MACROMOLEC, P433; Mant CT, 1998, J CHROMATOGR A, V816, P65, DOI 10.1016/S0021-9673(98)00507-X; Mant CT, 1997, J CHROMATOGR A, V791, P85, DOI 10.1016/S0021-9673(97)00767-X; Mant CT, 2002, J CHROMATOGR A, V972, P61, DOI 10.1016/S0021-9673(02)00356-4; Mant CT, 2002, J CHROMATOGR A, V972, P45, DOI 10.1016/S0021-9673(02)00354-0; Mant CT, 1998, J CHROMATOGR A, V816, P79, DOI 10.1016/S0021-9673(98)00508-1; MANT CT, 1987, J CHROMATOGR, V397, P99, DOI 10.1016/S0021-9673(01)84993-1; MANT CT, 1989, J CHROMATOGR, V476, P363, DOI 10.1016/S0021-9673(01)93882-8; MANT CT, 1993, AMPHIPATHIC HELIX, P39; MANT CT, 2003, IN PRESS J CHROMAT A; Mant CT., 1991, HIGH PERFORMANCE LIQ; MANT TC, 2003, IN PRESS J CHROMAT A; McInnes C, 2000, J BIOL CHEM, V275, P14287, DOI 10.1074/jbc.275.19.14287; Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507; Prenner EJ, 1999, BBA-BIOMEMBRANES, V1417, P211, DOI 10.1016/S0005-2736(99)00004-8; Prenner EJ, 1997, BIOCHEMISTRY-US, V36, P7906, DOI 10.1021/bi962785k; Prenner EJ, 1999, BBA-BIOMEMBRANES, V1462, P201, DOI 10.1016/S0005-2736(99)00207-2; PURCELL AW, 1995, PEPTIDE RES, V8, P160; RICHARDS KL, 1994, J CHROMATOGR A, V676, P17, DOI 10.1016/0021-9673(94)00092-1; ROSENFELD R, 1993, J CHROMATOGR, V632, P29, DOI 10.1016/0021-9673(93)80022-Z; Salgado J, 2001, J BIOMOL NMR, V21, P191, DOI 10.1023/A:1012946026231; SEREDA TJ, 1994, J CHROMATOGR A, V676, P139, DOI 10.1016/0021-9673(94)00371-8; Steer DL, 1998, J PEPT RES, V51, P401; STEINER V, 1991, J CHROMATOGR, V586, P43, DOI 10.1016/0021-9673(91)80023-A; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; Wagschal K, 1999, PROTEIN SCI, V8, P2312; Yu YB, 2000, J CHROMATOGR A, V890, P81, DOI 10.1016/S0021-9673(00)00472-6; ZHOU N E, 1990, Peptide Research, V3, P8	51	56	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22918	22927		10.1074/jbc.M301777200	http://dx.doi.org/10.1074/jbc.M301777200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686558	hybrid			2022-12-25	WOS:000183503900098
J	Pelletier, I; Hashidate, T; Urashima, T; Nishi, N; Nakamura, T; Futai, M; Arata, Y; Kasai, K; Hirashima, M; Hirabayashi, J; Sato, S				Pelletier, I; Hashidate, T; Urashima, T; Nishi, N; Nakamura, T; Futai, M; Arata, Y; Kasai, K; Hirashima, M; Hirabayashi, J; Sato, S			Specific recognition of Leishmania major poly-beta-galactosyl epitopes by galectin-9 - Possible implication of galectin-9 in interaction between L-major and host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRONTAL AFFINITY-CHROMATOGRAPHY; NEMATODE CAENORHABDITIS-ELEGANS; RAY CRYSTAL-STRUCTURE; DC-SIGN; EPITHELIAL-CELLS; BINDING LECTINS; SUGAR-BINDING; KINETIC-ANALYSIS; DENDRITIC CELLS; IMMUNE-RESPONSE	Leishmania parasites are the causative agents of leishmaniasis, manifesting itself in a species-specific manner. The glycan epitopes on the parasite are suggested to be involved in the Leishmania pathogenesis. One of such established species-unique glycan structures is the poly-beta-galactosyl epitope (Galbeta1-3)(n) found on L. major, which can develop cutaneous infections with strong inflammatory responses. Interestingly, the polygalactosyl epitope is also suggested to be involved in the development of the parasites in its host vector, sand fly. Thus, the recognition of the galactosyl epitope by lectins expressed in host or sand fly should be implicated in the species-specific manifestations of leishmaniasis and in the parasite life cycle, respectively. We recently reported that one host beta-galactoside-binding protein, galectin-3, can distinguish L. major from the other species through its binding to the poly-beta-galactosyl epitope, proposing a role for galectin-3 as an immunomodulator that could influence the L. major-specific immune responses in leishmaniasis. Here we report that galectin-9 can also recognize L. major by binding to the L. major-specific polygalactosyl epitope. Frontal affinity analysis with different lengths of poly-beta-galactosyl-lactose revealed that the galectin-9 affinity for polygalactose was enhanced in proportion to the number of Galbeta1-3 units present. Even though both galectins have comparable affinities toward the polygalactosyl epitopes, only galectin-9 can promote the interaction between L. major and macrophages, suggesting distinctive roles for the galectins in the L. major-specific development of leishmaniasis in the host.	Univ Laval, Med Ctr, Ctr Hosp Univ Quebec, Res Ctr Infect Dis,Glycobiol Lab, Quebec City, PQ G1V 4G2, Canada; CRCHUL, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Kanagawa 19901, Japan; Obihiro Univ Agr & Vet Med, Dept Bioresource Sci, Obihiro, Hokkaido 0800834, Japan; Kagawa Med Univ, Dept Endocrinol, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Immunol & Immunopathol, Kagawa 7610793, Japan; Osaka Univ, Inst Sci & Ind Res, Osaka 5650047, Japan	Laval University; Laval University; Teikyo University; Obihiro University of Agriculture & Veterinary Medicine; Kagawa University; Kagawa University; Osaka University	Hirabayashi, J (corresponding author), CRCHUL, Ctr Rech Infectiol, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	jun-hirabayashi@aist.go.jp; Sachiko.Sato@crchul.ulaval.ca						AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635; Arata Y, 2001, BIOL PHARM BULL, V24, P14, DOI 10.1248/bpb.24.14; Arata Y, 2001, J BIOL CHEM, V276, P3068, DOI 10.1074/jbc.M008602200; Barboni EAM, 1999, GLYCOCONJUGATE J, V16, P365, DOI 10.1023/A:1007004330048; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; BLACKWELL JM, 1985, J EXP MED, V162, P324, DOI 10.1084/jem.162.1.324; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Chiba A, 1997, J BIOL CHEM, V272, P2156; COLLINS JG, 1981, CARBOHYD RES, V92, P136, DOI 10.1016/S0008-6215(00)85988-1; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dennis JW, 2002, BBA-GEN SUBJECTS, V1573, P414, DOI 10.1016/S0304-4165(02)00411-7; Dietz AB, 2000, BIOCHEM BIOPH RES CO, V275, P731, DOI 10.1006/bbrc.2000.3372; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; Henrick K, 1998, GLYCOBIOLOGY, V8, P45, DOI 10.1093/glycob/8.1.45; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; Hirabayashi J, 2000, J CHROMATOGR A, V890, P261, DOI 10.1016/S0021-9673(00)00545-8; Hirofumi A, 2002, J IMMUNOL, V169, P5912, DOI 10.4049/jimmunol.169.10.5912; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hughes RC, 1997, BIOCHEM SOC T, V25, P1194, DOI 10.1042/bst0251194; John CM, 2002, CELL MICROBIOL, V4, P649, DOI 10.1046/j.1462-5822.2002.00219.x; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; MANDRELL RE, 1994, METHOD ENZYMOL, V236, P231; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Messer M, 2002, TRENDS GLYCOSCI GLYC, V14, P153, DOI 10.4052/tigg.14.153; MESSER M, 1980, CARBOHYD RES, V83, P327, DOI 10.1016/S0008-6215(00)84545-0; MESSER M, 1979, AUST J BIOL SCI, V32, P519, DOI 10.1071/BI9790519; Mey A, 1996, J IMMUNOL, V156, P1572; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MOODY SF, 1993, ACTA TROP, V53, P185, DOI 10.1016/0001-706X(93)90029-B; MOSSER DM, 1985, J IMMUNOL, V135, P2785; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Oka T, 1999, ARCH BIOCHEM BIOPHYS, V361, P195, DOI 10.1006/abbi.1998.0968; Pace KE, 2002, J BIOL CHEM, V277, P13091, DOI 10.1074/jbc.M112105200; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; Rabinovich GA, 1999, BRAZ J MED BIOL RES, V32, P383, DOI 10.1590/S0100-879X1999000400002; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; Sato S, 2002, TRENDS GLYCOSCI GLYC, V14, P285, DOI 10.4052/tigg.14.285; Sato S, 2002, J IMMUNOL, V168, P1813, DOI 10.4049/jimmunol.168.4.1813; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Wang Y, 2001, J BIOL CHEM, V276, P40338, DOI 10.1074/jbc.M107849200	77	94	96	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22223	22230		10.1074/jbc.M302693200	http://dx.doi.org/10.1074/jbc.M302693200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684513	hybrid			2022-12-25	WOS:000183503900007
J	Qahwash, I; Weiland, KL; Lu, YF; Sarver, RW; Kletzien, RF; Yan, RQ				Qahwash, I; Weiland, KL; Lu, YF; Sarver, RW; Kletzien, RF; Yan, RQ			Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN FIBRILLOGENESIS; PAIRED HELICAL FILAMENTS; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; A-BETA; FIBRIL FORMATION; IN-VITRO; NEUROFIBRILLARY TANGLES; SECONDARY STRUCTURE	The amyloid peptide (Abeta), derived from the proteolytic cleavage of the amyloid precursor protein (APP) by beta- and gamma-secretases, undergoes multistage assemblies to fibrillar depositions in the Alzheimer's brains. Abeta protofibrils were previously identified as an intermediate preceding insoluble fibrils. While characterizing a synthetic Abeta variant named EV40 that has mutations in the first two amino acids (D1E/A2V), we discerned unusual aggregation profiles of this variant. In comparison of the fibrillogenesis and cellular toxicity of EV40 to the wild-type Abeta peptide (Abeta(40)), we found that Abeta(40) formed long fibrillar aggregates while EV40 formed only proto-fibrillar aggregates under the same in vitro incubation conditions. Cellular toxicity assays indicated that EV40 was slightly more toxic than Abeta(40) to human neuroblastoma SHEP cells, rat primary cortical, and hippocampal neurons. Like Abeta(40), the neurotoxicity of the protofibrillar EV40 could be partially attributed to apoptosis since multiple caspases such as caspase-9 were activated after SHEP cells were challenged with toxic concentrations of EV40. This suggested that apoptosis-induced neuronal loss might occur before extensive depositions of long amyloid fibrils in AD brains. This study has been the first to show that a mutated Abeta peptide formed only protofibrillar species and mutations of the amyloid peptide at the N-terminal side affect the dynamic amyloid fibrillogenesis. Thus, the identification of EV40 may lead to further understanding of the structural perturbation of Abeta to its fibrillation.	Pharmacia Corp, Dept Cell & Mol Biol, Kalamazoo, MI 49007 USA; Pharmacia Corp, Dept Analyt Chem, Kalamazoo, MI 49007 USA	Pfizer; Pfizer	Yan, RQ (corresponding author), Pharmacia Corp, Dept Cell & Mol Biol, 301 Henrietta St, Kalamazoo, MI 49007 USA.			Yan, Riqiang/0000-0001-7195-7617				Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BURDICK D, 1992, J BIOL CHEM, V267, P546; Cheung NS, 2000, J NEUROCHEM, V74, P1613, DOI 10.1046/j.1471-4159.2000.0741613.x; Choo LP, 1996, BIOPHYS J, V71, P1672, DOI 10.1016/S0006-3495(96)79411-0; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; Demeester N, 2001, EUR J NEUROSCI, V13, P2015, DOI 10.1046/j.0953-816x.2001.01579.x; El-Agnaf OMA, 1998, EUR J BIOCHEM, V256, P560, DOI 10.1046/j.1432-1327.1998.2560560.x; Estus S, 1997, J NEUROSCI, V17, P7736; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Haass C, 1996, CURR OPIN NEUROL, V9, P254, DOI 10.1097/00019052-199608000-00002; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; Hou LM, 2002, J BIOL CHEM, V277, P40173, DOI 10.1074/jbc.C200338200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; IHARA Y, 1986, J BIOCHEM-TOKYO, V99, P1807, DOI 10.1093/oxfordjournals.jbchem.a135662; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lansbury PT, 1997, CURR OPIN CHEM BIOL, V1, P260, DOI 10.1016/S1367-5931(97)80018-X; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.3.CO;2-2; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nichols MR, 2002, BIOCHEMISTRY-US, V41, P6115, DOI 10.1021/bi015985r; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Solomon B, 2000, DRUGS TODAY, V36, P655, DOI 10.1358/dot.2000.36.9.593782; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; Tekirian TL, 1999, J NEUROCHEM, V73, P1584, DOI 10.1046/j.1471-4159.1999.0731584.x; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tomasselli AG, 2003, J NEUROCHEM, V84, P1006, DOI 10.1046/j.1471-4159.2003.01597.x; Troy CM, 2000, J NEUROSCI, V20, P1386; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2001, BIOCHEM J, V355, P869, DOI 10.1042/bj3550869; Watson DJ, 1999, BIOCHEM J, V340, P703, DOI 10.1042/0264-6021:3400703; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	65	38	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23187	23195		10.1074/jbc.M213298200	http://dx.doi.org/10.1074/jbc.M213298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684519	hybrid			2022-12-25	WOS:000183503900127
J	Suzuki, M; Mizuno, A; Kodaira, K; Imai, M				Suzuki, M; Mizuno, A; Kodaira, K; Imai, M			Impaired pressure sensation in mice lacking TRPV4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSELECTIVE CATION CHANNEL; CAPSAICIN-RECEPTOR; HEAT; STIMULI; TOUCH	The sensation of pressure, mechanosensation, in vertebrates remains poorly understood on the molecular level. The ion channel TRPV4 is in the TRP family and is a candidate for a mechanosensitive calcium-permeable channel. It is located in dorsal root ganglia. In the present study, we show that disrupting the Trpv4 gene in mice markedly reduced the sensitivity of the tail to pressure and acidic nociception. The threshold to noxious stimuli and the conduction velocity of myelinated nerve responding to stimuli were also impaired. Activation of unmyelinated nerve was undetected. However, the mouse still retained olfaction, taste sensation, and heat avoidance. The TRPV4 channel expressed in vitro in Chinese hamster ovary cells was opened by low pH, citrate, and inflation but not by heat or capsaicin. These data identify the TRPV4 channel as essential for the normal detection of pressure and as a receptor of the high-threshold mechanosensory complex.	Chugai Pharmaceut Co Ltd, Pharmaceut Technol Lab, Shizuoka 4128513, Japan; Jichi Med Sch, Dept Pharmacol, Minami Kawachi, Tochigi 3290498, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Jichi Medical University	Kodaira, K (corresponding author), Chugai Pharmaceut Co Ltd, Pharmaceut Technol Lab, Shizuoka 4128513, Japan.							BURGESS PR, 1967, J PHYSIOL-LONDON, V190, P541, DOI 10.1113/jphysiol.1967.sp008227; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Delany NS, 2001, PHYSIOL GENOMICS, V4, P165, DOI 10.1152/physiolgenomics.2001.4.3.165; HEATHER AC, 1997, J NEUROSCI, V17, P8259; KRESS M, 1992, J NEUROPHYSIOL, V68, P581, DOI 10.1152/jn.1992.68.2.581; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Lindemann B, 2001, NATURE, V413, P219, DOI 10.1038/35093032; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Schumacher MA, 2000, NEUROSCI LETT, V287, P215, DOI 10.1016/S0304-3940(00)01181-2; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suzuki M, 2002, FEBS LETT, V517, P219, DOI 10.1016/S0014-5793(02)02627-3; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; SUZUKI M, 1999, J AM SOC NEPHROL, V10, P44; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200	22	516	550	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22664	22668		10.1074/jbc.M302561200	http://dx.doi.org/10.1074/jbc.M302561200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12692122	hybrid			2022-12-25	WOS:000183503900066
J	Ko, JK; Lee, MJ; Cho, SH; Cho, JA; Lee, BY; Koh, JS; Lee, SS; Shim, YH; Kim, CW				Ko, JK; Lee, MJ; Cho, SH; Cho, JA; Lee, BY; Koh, JS; Lee, SS; Shim, YH; Kim, CW			Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death	ONCOGENE			English	Article						Bfl-1S; Bcl-2 family; alternative splice; apoptosis; Molt-4; nuclear localization	BCL-2 FAMILY MEMBER; TUMOR-NECROSIS-FACTOR; MEDIATED APOPTOSIS; UP-REGULATION; YEAST-CELLS; B-CELLS; A1; EXPRESSION; HOMOLOG; PROTEIN	Bfl-1 is an antiapoptotic Bcl-2 family member and a mouse A1 homologue. The mouse A1 has been reported to have three isoforms, but little is known about human Bfl-1. By reverse-transcriptase polymerase chain reaction analysis, we have identified Bfl-1S (short form), an alternative splice variant of Bfl-1. The Bfl-1S primary sequence contains four conserved Bcl-2 homology (BH) domains and a positive-charged C-terminus containing KKRK amino acids. The expression of Bfl-1S mRNA was detected predominantly in normal lymph nodes and in B-lymphoid leukemia cells. Confocal microscopic analysis using green fluorescence protein fusion proteins demonstrated that Bfl-1S is localized in the nucleus by its C-terminus as an intrinsic nuclear localization sequence. Bfl-1S acts as an antiapoptotic agent in coexpression experiments with Bax, a proapoptotic molecule. The expression of Bfl-1S provided significant resistance against staurosporine (STS) treatments in Molt-4 human T-leukemia cells. Bfl-1S also significantly inhibited the cleavage of Bid, and of caspases 3 and 8 against STS treatment. These results indicate that Bfl-1S is a novel human Bcl-2 family member that possesses antiapoptotic function.	Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Pathol,Ghongno Gu, Seoul 110799, South Korea; Inst iNtRON Biotechnol, Seoul, South Korea; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Korea Canc Ctr Hosp, Lab Expt Pathol, Seoul, South Korea; Konkuk Univ, Dept Biol Sci, Seoul, South Korea	Seoul National University (SNU); Harvard University; Brigham & Women's Hospital; Harvard Medical School; National Cancer Center - Korea (NCC); Konkuk University	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Inst Canc Res, Dept Pathol,Ghongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.		Kim, Chul-Woo/F-7008-2011; Shim, Yhong-Hee/D-6691-2011	Shim, Yhong-Hee/0000-0002-8660-4176				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Cheung KJ, 2001, EXP CELL RES, V268, P1, DOI 10.1006/excr.2001.5258; CHOI SS, 1995, ONCOGENE, V11, P1693; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; DSaEipper C, 1996, CANCER RES, V56, P3879; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Ha SH, 2002, CANCER RES, V62, P1275; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Hatakeyama S, 1998, INT IMMUNOL, V10, P631, DOI 10.1093/intimm/10.5.631; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holmgreen SP, 1999, CELL DEATH DIFFER, V6, P525, DOI 10.1038/sj.cdd.4400519; Jung-Ha H, 1998, HUM PATHOL, V29, P723, DOI 10.1016/S0046-8177(98)90282-9; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; KEPLER TB, 1993, IMMUNOL TODAY, V14, P412, DOI 10.1016/0167-5699(93)90145-B; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Rao L, 1997, ONCOGENE, V15, P1587, DOI 10.1038/sj.onc.1201323; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Shim YH, 2000, INT J HEMATOL, V72, P484; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; Tomayko MM, 1998, J IMMUNOL, V160, P107; Wang CY, 1999, MOL CELL BIOL, V19, P5923; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	35	32	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2457	2465		10.1038/sj.onc.1206274	http://dx.doi.org/10.1038/sj.onc.1206274			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717423				2022-12-25	WOS:000182383500009
J	Abdulkarim, B; Sabri, S; Zelenika, D; Deutsch, E; Frascogna, V; Klijanienko, J; Vainchenker, W; Joab, I; Bourhis, J				Abdulkarim, B; Sabri, S; Zelenika, D; Deutsch, E; Frascogna, V; Klijanienko, J; Vainchenker, W; Joab, I; Bourhis, J			Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies	ONCOGENE			English	Article						cidofovir; ionizing radiation; EBV-associated cancer; oncoproteins; apoptosis	LATENT MEMBRANE-PROTEIN; LYMPHOMA CELL-LINE; HUMAN-IMMUNODEFICIENCY-VIRUS; IMMEDIATE-EARLY GENES; IMMORTALIZED B-CELLS; NASOPHARYNGEAL CARCINOMA; HUMAN-PAPILLOMAVIRUS; BCL-2 EXPRESSION; BURKITT-LYMPHOMA; KAPPA-B	The Epstein-Barr virus (EBV) is involved in the carcinogenesis of several human cancers such as nasopharyngeal carcinoma (NPC) and Burkitt lymphoma (BL). Given the consistent role of EBV in transformation and maintenance of malignant phenotype, antiviral strategies provide an attractive approach to target EBV-expressing cells. In that aim, we have tested the Cidofovir, which is an acyclic nucleoside phosphonate analog known to exert an antiproliferative activity in some human virus-related tumors. Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells. Using BL cell line BL2 B95-8 (BL2 infected with the B95.8 strain of EBV), we addressed the relation between EBV genome expression and modulation of viral oncoproteins by Cidofovir and/or ionizing radiation (IR). Cidofovir was able to significantly reduce LMP1 and EBNA2 mRNA and protein expression. This effect was associated with inhibition of proliferation, stimulation of apoptosis, and decrease of Bcl-2 expression in BL2 B95.8 cells. In addition, Cidofovir enhanced the radiation-induced apoptosis and the radiosensitivity through the proteolytic cleavage of death effectors caspase-9 and -3, which was specifically induced by combined treatment in EBV-positive cells compared to their negative counterparts. Furthermore, the combined treatment in nude mice led to a complete tumor remission without increasing toxicity in two human EBV-related cancer xenografts (Raji and C15). These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related cancers.	Inst Gustave Roussy, Lab Radiosensibil Tumeurs & Tissus Sains, UPRESEA 27 10, F-94805 Villejuif, France; Inst Curie, Paris, France; Hop St Louis, Inst Mol Genet, Paris, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Bourhis, J (corresponding author), Inst Gustave Roussy, Lab Radiosensibil Tumeurs & Tissus Sains, UPRESEA 27 10, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	bourhis@igr.fr	Sabri, Siham/K-1101-2015	Sabri, Siham/0000-0001-5792-689X; Vainchenker, William/0000-0003-4705-202X; Bourhis, Jean/0000-0001-5162-1171; deutsch, eric/0000-0002-8223-3697				ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Abdulkarim B, 2002, ONCOGENE, V21, P2334, DOI 10.1038/sj.onc.1205006; Abdulkarim B, 2001, LANCET ONCOL, V2, P622, DOI 10.1016/S1470-2045(01)00520-4; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chung YL, 2000, CLIN CANCER RES, V6, P1452; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Fagard R, 2002, ONCOGENE, V21, P4473, DOI 10.1038/sj.onc.1205554; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Griffin B E, 2000, Mutat Res, V462, P395, DOI 10.1016/S1383-5742(00)00028-4; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Johnson JA, 1999, ANTIMICROB AGENTS CH, V43, P1198, DOI 10.1128/AAC.43.5.1198; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kieff E., 1996, FIELDS VIROLOGY, V2, P2343; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Morgan MB, 1999, TUMOR TARGET, V4, P278; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; Neyts J, 1998, CANCER RES, V58, P384; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PRASAD AV, 1995, RADIAT RES, V143, P263, DOI 10.2307/3579212; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SUNG NS, 1991, J VIROL, V65, P2164, DOI 10.1128/JVI.65.5.2164-2169.1991; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; Westphal EM, 2000, CANCER RES, V60, P5781; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	43	36	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2260	2271		10.1038/sj.onc.1206402	http://dx.doi.org/10.1038/sj.onc.1206402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700662				2022-12-25	WOS:000182231500005
J	Uren, A; Merchant, MS; Sun, CJ; Vitolo, MI; Sun, Y; Tsokos, M; Illei, PB; Ladanyi, M; Passaniti, A; Mackall, C; Toretsky, JA				Uren, A; Merchant, MS; Sun, CJ; Vitolo, MI; Sun, Y; Tsokos, M; Illei, PB; Ladanyi, M; Passaniti, A; Mackall, C; Toretsky, JA			Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells	ONCOGENE			English	Article						PDGF; PDGF receptors; Ewing's sarcoma	FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; PDGF-C; TUMORS; LIGAND; TRANSFORMATION; FIBROBLASTS; INHIBITION; EXPRESSION; EWS/FLI-1	The Ewing's sarcoma family of tumors (ESFT) contain a translocation, t(11;22), which results in the novel oncogenic fusion protein EWS/FLI1. Platelet-derived growth factors (PDGF) and their receptors (PDGFR) are involved in the induction and proliferation of numerous solid tumors and are the potential candidates for novel targeted antitumor therapy. Since a relation was reported between PDGF-C and EWS/FLI1, we sought to characterize the PDGF signaling pathway in ESFT. Eight out of nine ESFT cell tines were found to express significant levels of beta-PDGFR. Interestingly, none of the tested cell lines expressed alpha-PDGFR, which is the receptor isotype required for PDGF-C binding. By immunohistochemical staining 47 of 52 (90.4%) archival tumor samples from patients with ESFT were positive for beta-PDGFR. ESFT cell lines were treated with PDGF-AA or PDGF-BB ligands to evaluate downstream signaling. Autophosphorylation of beta-PDGFR and tyrosine phosphorylation of PLC-gamma, PI3Kp85 and She were detected only in PDGF-BB-stimulated cells that express beta-PDGFR. Receptor function was further evaluated using chemotaxis assays that showed TC-32 cell migration towards PDGF-BB. A specific PDGFR kinase inhibitor AG1295 blocked beta-PDGFR activation, downstream signaling, growth in cell culture and chemotaxis of TC-32 cells. AG1295 also delayed tumor formation and prolonged survival in an ESFT animal model. We conclude that ESFT express beta-PDGFR and that this is a functional and potentially crucial signaling pathway. Therefore, beta-PDGFRs may provide a novel therapeutic target in ESFT that can be utilized to design better treatment modalities.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; NIH, Bethesda, MD 20892 USA; Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Georgetown University; National Institutes of Health (NIH) - USA; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Res Bldg,Room W316,3970 Reservoir Rd,NW Box 57146, Washington, DC 20057 USA.		Ladanyi, Marc/AAG-8585-2019	Vitolo, Michele/0000-0001-8055-9645	NCI NIH HHS [R01 CA88004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088004, Z01SC010289, Z01SC009431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BRYCKAERT MC, 1992, EXP CELL RES, V199, P255, DOI 10.1016/0014-4827(92)90432-8; BUCHDUNGER E, 1995, P NATL ACAD SCI USA, V92, P2558, DOI 10.1073/pnas.92.7.2558; Denny CT, 1998, J PEDIAT HEMATOL ONC, V20, P421, DOI 10.1097/00043426-199809000-00002; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grier HE, 1997, PEDIATR CLIN N AM, V44, P991, DOI 10.1016/S0031-3955(05)70541-1; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Kontny HU, 1998, CANCER RES, V58, P5842; KOVALENKO M, 1994, CANCER RES, V54, P6106; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Meyers PA, 2001, J CLIN ONCOL, V19, P2812, DOI 10.1200/JCO.2001.19.11.2812; MISER LS, 1996, P ANN M AM SOC CLIN, pA1472; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Scotlandi K, 1998, CANCER RES, V58, P4127; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; UREN A, 1994, BIOCHEM BIOPH RES CO, V204, P628, DOI 10.1006/bbrc.1994.2505; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	28	67	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2334	2342		10.1038/sj.onc.1206330	http://dx.doi.org/10.1038/sj.onc.1206330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700668				2022-12-25	WOS:000182231500011
J	Blazek, E; Wasmer, S; Kruse, U; Aronheim, A; Aoki, M; Vogt, PK				Blazek, E; Wasmer, S; Kruse, U; Aronheim, A; Aoki, M; Vogt, PK			Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription	ONCOGENE			English	Article						AP-1; JDP2; Jun; repressor; transformation	MAF NUCLEAR ONCOPROTEIN; C-JUN; LEUCINE-ZIPPER; V-JUN; CELL-PROLIFERATION; DELETION MUTANT; AP-1 REPRESSOR; GROWTH-FACTOR; FOS; IDENTIFICATION	Jun dimerization protein 2 (JDP2) was identified as a bZIP protein that forms dimers with Jun proteins. JDP2 represses transcriptional activation of reporter constructs containing 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive elements (TRE) or cyclic AMP responsive elements (CRE). JDP2, overexpressed by the avian retroviral vector RCAS, induces partial oncogenic transformation of chicken embryo fibroblasts. JDP2-expressing cells form multilayered foci in monolayer cultures but do not show anchorage-independent growth. Both the carboxyl and the amino terminus of JDP2 are required for the transforming activity. Chimeric constructs of JDP2 carrying the leucine zipper domain of Fos, GCN4 or EB1 fail to transform CEF. The leucine zipper of Fos mediates only heterodimerization; it cannot homodimerize. In contrast, the leucine zippers of GCN4 and of EB1 exclusively homodimerize and do not form dimers with other bZip proteins. The results with the JDP2 chimeras suggest that the JDP2 homodimer and the JDP2/Jun heterodimer (or other bZip heterodimers formed with the Fos leucine zipper) are nontransforming, leaving as possible transforming combination the JDP2/Fos heterodimer. The unexpected transforming activity of a negative regulator of TRE- and CRE-dependent transcription raises an important question concerning the mechanisms of transformation by the related bZIP proteins Jun and Fos that address the same target sequences.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Technion Israel Inst Technol, IL-31096 Haifa, Israel	Scripps Research Institute; Technion Israel Institute of Technology	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Aronheim, Ami/0000-0002-8575-4092				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HWANG HC, 2002, P NATL ACAD SCI USA, V31, P31; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; Kataoka K, 1996, ONCOGENE, V12, P53; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MORGAN IM, 1992, ONCOGENE, V7, P1119; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	38	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2151	2159		10.1038/sj.onc.1206312	http://dx.doi.org/10.1038/sj.onc.1206312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687017				2022-12-25	WOS:000182066900009
J	Wei, YK; Sun, MH; Nilsson, G; Dwight, T; Xie, YT; Wang, J; Hou, YY; Larsson, O; Larsson, C; Zhu, XZ				Wei, YK; Sun, MH; Nilsson, G; Dwight, T; Xie, YT; Wang, J; Hou, YY; Larsson, O; Larsson, C; Zhu, XZ			Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; translocation; DNA sequence; breakpoints	TOPOISOMERASE-II CLEAVAGE; ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; CLUSTER REGION; DNA-SEQUENCE; ILLEGITIMATE RECOMBINATION; ALVEOLAR RHABDOMYOSARCOMA; BCR GENE; TUMORS; SITES	The SYT-SSXI and SYT-SSX2 fusion genes, derived by reciprocal translocations t(X;18), are acquired genetic events strongly associated with the tumorigenesis of synovial sarcoma. In approaching the mechanisms underlying the formation of these fusion oncogenes, we have analysed the genomic sequences surrounding the SYT-SSX breakpoints in 10 tumors, two expressing SYT-SSXI and eight expressing SYT-SSX2 fusion transcripts. The breakpoints were found to be clustered in the 5' end of intron 10 of SYT, and in two cluster regions within intron 4 of SSX2, whereas the two breakpoints in SSX1 intron 4 were 0.5 kb apart. SYT intron 10 is abundant in repetitive regions with the interspersed repeats occupying 66% of the whole intron. Nine of the 10 breakpoints in intron 10 of SYT and six of the eight breakpoints in intron 4 of SSX2 were at or near repetitive regions. These findings suggest that repetitive regions may contribute to the distribution of genomic breakpoints. Several of the fusion sequences exhibited characteristic signs of nonhomologous end joining, including microhomologies at the end points as well as deletions. Sequences highly homologous (83-94%) to consensus topoisomerase II cleavage sites were identified at or near the breakpoints in all 10 tumors, suggesting a role of this enzyme in creating staggered ends at the breakpoint. Furthermore, sequences highly homologous to consensus Translin binding sequences were found at the breakpoints in two cases, and an Alu-Alu fusion and an insertion of a 206-bp LINE-1 element were found at the breakpoint in one case each. The demonstration of characteristic sequences at the SYT-SSX breakpoint regions is expected to improve our understanding of the molecular genetic mechanisms behind translocations in general, and of the SYT-SSX fusions in synovial sarcoma in particular.	Fudan Univ, Canc Hosp, Dept Pathol, Shanghai 200032, Peoples R China; Karolinska Hosp, CCK R8 04, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Surg Sci, Sect Orthoped, SE-17176 Stockholm, Sweden; Karolinska Hosp, CMM L8 01, Dept Mol Med, SE-17176 Stockholm, Sweden	Fudan University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Zhu, XZ (corresponding author), Fudan Univ, Canc Hosp, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China.			Dwight, Trisha/0000-0003-1943-4514				AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Barr FG, 1998, CANCER GENET CYTOGEN, V102, P32, DOI 10.1016/S0165-4608(97)00287-2; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; BULLOCK P, 1985, SCIENCE, V230, P954, DOI 10.1126/science.2997924; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CHEN SJ, 1989, ONCOGENE, V4, P195; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; Hosaka T, 2000, ONCOGENE, V19, P5821, DOI 10.1038/sj.onc.1203943; Ishida S, 1998, CYTOGENET CELL GENET, V82, P278, DOI 10.1159/000015119; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; Kolomietz E, 2002, GENE CHROMOSOME CANC, V35, P97, DOI 10.1002/gcc.10111; KROWCZYNSKA AM, 1986, NUCLEIC ACIDS RES, V14, P7071; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; Liu J, 1997, GENE CHROMOSOME CANC, V18, P232, DOI 10.1002/(SICI)1098-2264(199703)18:3<232::AID-GCC10>3.0.CO;2-K; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; Nilsson G, 1999, CANCER RES, V59, P3180; Panagopoulos I, 1997, ONCOGENE, V15, P1357, DOI 10.1038/sj.onc.1201281; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SREEKANTAIAH C, 1994, AM J PATHOL, V144, P1121; TOTH G, 1994, GENE, V140, P285, DOI 10.1016/0378-1119(94)90559-2; Villablanca A, 2002, EUR J ENDOCRINOL, V147, P313, DOI 10.1530/eje.0.1470313; WEISS SW, 2001, SOFT TISSUE TUMORS; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	38	23	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2215	2222		10.1038/sj.onc.1206343	http://dx.doi.org/10.1038/sj.onc.1206343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687023				2022-12-25	WOS:000182066900015
J	Anto, RJ; Venkatraman, M; Karunagaran, D				Anto, RJ; Venkatraman, M; Karunagaran, D			Inhibition of NF-kappa B sensitizes A431 cells to epidermal growth factor-induced apoptosis, whereas its activation by ectopic expression of RelA confers resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF RECEPTOR; KINASE-ACTIVITY; TUMOR-CELLS; CANCER; CARCINOMA; PATHWAY; ALPHA; INDUCTION; PROTEIN; GENE	Epidermal growth factor (EGF) is a well known mitogen, but it paradoxically induces apoptosis in cells that overexpress its receptor. We demonstrate for the first time that the EGF-induced apoptosis is accelerated if NF-kappaB is inactivated. To inactivate NF-kappaB, human epidermoid carcinoma cells (A431) that overexpress EGF receptor were stably transfected with an IkappaBalpha double mutant construct. Under the NF-kappaB-inactivated condition, A431 cells were more sensitive to EGF with decreased cell viability and increased externalization of phosphatidylserine on the cell surface, DNA fragmentation, and activation of caspases (3 and 8 but not 9), typical features of apoptosis. These results were further supported by the potentiation of the growth inhibitory effects of EGF by chemical inhibitors of NF-kappaB (curcumin and sodium salicylate) and the protective role of RelA evidenced by the resistance of A431-RelA cells (stably transfected with RelA) to EGF-induced apoptosis. EGF treatment or ectopic expression of RelA in A431 cells induced DNA binding activity of NF-kappaB (p50 and RelA) and the expression of c-IAP1, a downstream target of NF-kappaB. A431-RelA cells exhibited spontaneous phosphorylation of Akt (a downstream target of phosphatidylinositol 3-kinase and regulator of NF-kappaB) and EGF treatment stimulated it further. Blocking this basal Akt phosphorylation with LY294002, an inhibitor of phosphatidylinositol 3-kinase, did not affect their viability but blocking of EGF-induced phosphorylation of Akt sensitized the otherwise resistant A431-RelA cells to EGF-mediated growth inhibition. Our results favor an anti-apoptotic role for NF-kappaB in the regulation of EGF-induced apoptosis.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.	dkarunagaran@hotmail.com	Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947				Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; Bartlett JMS, 1996, BRIT J CANCER, V73, P301, DOI 10.1038/bjc.1996.53; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2003, CANCER RES, V63, P290; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Cao L, 2000, J CELL BIOCHEM, V77, P569, DOI 10.1002/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K; Cenni B, 2001, CANCER CHEMOTH PHARM, V47, P397, DOI 10.1007/s002800000244; CHAJRY N, 1994, BIOCHEM BIOPH RES CO, V203, P984, DOI 10.1006/bbrc.1994.2279; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Conner EA, 1999, CARCINOGENESIS, V20, P583, DOI 10.1093/carcin/20.4.583; Cusack JC, 2001, CANCER RES, V61, P3535; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; De Santis ML, 2000, CELL DEATH DIFFER, V7, P189, DOI 10.1038/sj.cdd.4400588; DONG XF, 1991, ANTICANCER RES, V11, P737; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Genersch E, 1998, INT J CANCER, V75, P205, DOI 10.1002/(SICI)1097-0215(19980119)75:2<205::AID-IJC7>3.0.CO;2-Y; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; HARRIS AL, 1994, BREAST CANCER RES TR, V29, P1, DOI 10.1007/BF00666176; HIRAI M, 1990, CELL SIGNAL, V2, P245, DOI 10.1016/0898-6568(90)90052-C; Hognason T, 2001, FEBS LETT, V491, P9, DOI 10.1016/S0014-5793(01)02166-4; HOMBURG CHE, 1995, BLOOD, V85, P532; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Jakus J, 1996, ONCOGENE, V12, P2369; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KIM HRC, 1995, P NATL ACAD SCI USA, V92, P9500, DOI 10.1073/pnas.92.21.9500; Kottke TJ, 1999, J BIOL CHEM, V274, P15927, DOI 10.1074/jbc.274.22.15927; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; LEE K, 1987, EXP CELL RES, V173, P156, DOI 10.1016/0014-4827(87)90341-7; Lehto VP, 2001, FEBS LETT, V491, P1, DOI 10.1016/S0014-5793(01)02163-9; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; Ohtsubo M, 2000, J CELL PHYSIOL, V184, P131, DOI 10.1002/(SICI)1097-4652(200007)184:1<131::AID-JCP14>3.3.CO;2-N; Ozes ON, 1999, NATURE, V401, P82; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reddy KB, 1999, INT J ONCOL, V15, P301; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Silvy M, 1998, ENDOCRINOLOGY, V139, P2382, DOI 10.1210/en.139.5.2382; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TAYLOR NA, 1996, GENE TRANSCRIPTION R, P96; VAN AD, 1996, SCIENCE, V274, P787; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xi QS, 2000, ACTA BIOCH BIOPH SIN, V32, P601; Yarden Y, 2001, EUR J CANCER, V37, pS3; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328	64	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25490	25498		10.1074/jbc.M301790200	http://dx.doi.org/10.1074/jbc.M301790200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12714587	hybrid			2022-12-25	WOS:000183920200029
J	Le Poul, E; Loison, C; Struyf, S; Springael, JY; Lannoy, V; Decobecq, ME; Brezillon, S; Dupriez, V; Vassart, G; Van Damme, J; Parmentier, M; Detheux, M				Le Poul, E; Loison, C; Struyf, S; Springael, JY; Lannoy, V; Decobecq, ME; Brezillon, S; Dupriez, V; Vassart, G; Van Damme, J; Parmentier, M; Detheux, M			Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; RETRACTED ARTICLE. SEE; PERIPHERAL-BLOOD NEUTROPHILS; CALCIUM MOBILIZATION; ALCOHOL-CONSUMPTION; CHEMOTACTIC-FACTOR; NATURAL LIGANDS; IDENTIFICATION; GENE; SPHINGOSYLPHOSPHORYLCHOLINE	Short chain fatty acids (SCFAs), including acetate, propionate, and butyrate, are produced at high concentration by bacteria in the gut and subsequently released in the bloodstream. Basal acetate concentrations in the blood (about 100 muM) can further increase to millimolar concentrations following alcohol intake. It was known previously that SCFAs can activate leukocytes, particularly neutrophils. In the present work, we have identified two previously orphan G protein-coupled receptors, GPR41 and GPR43, as receptors for SCFAs. Propionate was the most potent agonist for both GPR41 and GPR43. Acetate was more selective for GPR43, whereas butyrate and isobutyrate were more active on GPR41. The two receptors were coupled to inositol 1,4,5-trisphosphate formation, intracellular Ca2+ release, ERK1/2 activation, and inhibition of cAMP accumulation. They exhibited, however, a differential coupling to G proteins; GPR41 coupled exclusively though the Pertussis toxin-sensitive G(i/o) family, whereas GPR43 displayed a dual coupling through G(i/o) and Pertussis toxin-insensitive G(q) protein families. The broad expression profile of GPR41 in a number of tissues does not allow us to infer clear hypotheses regarding its biological functions. In contrast, the highly selective expression of GPR43 in leukocytes, particularly polymorphonuclear cells, suggests a role in the recruitment of these cell populations toward sites of bacterial infection. The pharmacology of GPR43 matches indeed the effects of SCFAs on neutrophils, in terms of intracellular Ca2+ release and chemotaxis. Such a neutrophil-specific SCFA receptor is potentially involved in the development of a variety of diseases characterized by either excessive or inefficient neutrophil recruitment and activation, such as inflammatory bowel diseases or alcoholism-associated immune depression. GPR43 might therefore constitute a target allowing us to modulate immune responses in these pathological situations.	Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Nucl, B-1070 Brussels, Belgium; Euroscreen, B-6041 Gosselies, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Free Univ Brussels, Serv Genet Med, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Parmentier, M (corresponding author), Free Univ Brussels, Inst Rech Interdisciplinaire Biol Humaine & Nucl, Campus Erasme,808 Route Lennik, B-1070 Brussels, Belgium.	mparment@ulb.ac.be	Struyf, Sofie/U-2455-2017	Struyf, Sofie/0000-0003-4558-0769; Parmentier, Marc/0000-0001-8081-4685; Van Damme, Jo/0000-0002-6707-1167; BREZILLON, stephane/0000-0001-7954-8340				Bautista AP, 2002, ALCOHOL, V27, P17, DOI 10.1016/S0741-8329(02)00206-9; Bergman J., 1990, Behav Pharmacol, V1, P355; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brezillon S, 2003, J BIOL CHEM, V278, P776, DOI 10.1074/jbc.M206396200; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; BROWN AJ, 2002, J BIOL CHEM, V278, P9869; BRUNKHORST BA, 1992, INFECT IMMUN, V60, P2957, DOI 10.1128/IAI.60.7.2957-2968.1992; CHADWICK VS, 1990, DIGEST DIS, V8, P253, DOI 10.1159/000171257; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; CORBERAND JX, 1989, ALCOHOL CLIN EXP RES, V13, P542, DOI 10.1111/j.1530-0277.1989.tb00374.x; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; EFTIMIADI C, 1987, J INFECTION, V14, P43, DOI 10.1016/S0163-4453(87)90808-5; FAUCHER N, 1987, J CELL PHYSIOL, V132, P483, DOI 10.1002/jcp.1041320310; FONTERIZ RI, 1991, BIOCHIM BIOPHYS ACTA, V1093, P1, DOI 10.1016/0167-4889(91)90130-P; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; JOLY C, 1995, J NEUROSCI, V15, P3970; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kimura M, 2001, J BIOL CHEM, V276, P26453, DOI 10.1074/jbc.M101289200; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; LAHARRAGUE P, 1985, ANN MED INTERNE, V136, P210; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; NACCACHE PH, 1988, J CELL PHYSIOL, V136, P118, DOI 10.1002/jcp.1041360115; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; Sellin JH, 1999, NEWS PHYSIOL SCI, V14, P58; Senga T, 2003, BLOOD, V101, P1185, DOI 10.1182/blood-2002-06-1881; Shellito JE, 2001, ALCOHOL CLIN EXP RES, V25, P872, DOI 10.1097/00000374-200106000-00013; SHIRATORI Y, 1992, J HEPATOL, V15, P266, DOI 10.1016/0168-8278(92)90048-T; Siler SQ, 1999, AM J CLIN NUTR, V70, P928; Struyf S, 1999, J IMMUNOL, V162, P4903; THOMPSON GN, 1990, METABOLISM, V39, P1133, DOI 10.1016/0026-0495(90)90084-P; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TODOROVIC V, 1994, J STUD ALCOHOL, V55, P239, DOI 10.15288/jsa.1994.55.239; Todorovic V, 1999, INDIAN J MED RES, V109, P105; TRAUNER DA, 1975, NEUROLOGY, V25, P296, DOI 10.1212/WNL.25.3.296; Wolever TMS, 1997, METABOLISM, V46, P805, DOI 10.1016/S0026-0495(97)90127-X; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; YULI I, 1987, SCIENCE, V235, P340, DOI 10.1126/science.3798116; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	42	1029	1065	7	121	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25481	25489		10.1074/jbc.M301403200	http://dx.doi.org/10.1074/jbc.M301403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12711604	hybrid			2022-12-25	WOS:000183920200028
J	Majumder, S; Ghoshal, K; Summers, D; Bai, SM; Datta, J; Jacob, ST				Majumder, S; Ghoshal, K; Summers, D; Bai, SM; Datta, J; Jacob, ST			Chromium(VI) down-regulates heavy metal-induced metallothionein gene transcription by modifying transactivation potential of the key transcription factor, metal-responsive transcription factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MTF-1; CELL-LINE; MOLECULAR MECHANISMS; KNOCKOUT MICE; CROSS-LINKING; LARGE SUBUNIT; C/EBP-ALPHA; I PROMOTER; EXPRESSION; DNA	The robust induction of metallothionein-I and II (MT-I and MT-II) genes by several heavy metals such as zinc and cadmium requires the specific transcription factor metal-responsive transcription factor 1 (MTF1). Chromium (VI), a major environmental carcinogen, not only failed to activate these genes but also inhibited their induction by Zn2+ or Cd2+. The heavy metal-induced expression of another MTF1 target gene, zinc transporter 1 (ZnT-1), was also down-regulated by Cr6+. By contrast, the expression of two MTF1-independent Cd2+-inducible genes, heme oxygenase 1 (HO-1) and HSP-70, was not sensitive to Cr6+. Cr6+ did not also affect the expression of housekeeping genes such as GAPDH or beta-actin. Stable cell lines overexpressing variable levels of MTF1, the key transactivator of the MT genes, demonstrated differential resistance toward the inhibitory effect of Cr6+, indicating MTF1 as a target of chromium toxicity. The basal and inducible binding of MTF1 to metal response elements was not affected by treatment of cells with Cr6+. Transient transfection studies showed that the ability of MTF1 to transactivate the MT-I promoter was significantly compromised by Cr6+. The fusion protein consisting of a Gal-4 DNA binding domain and one or more of the three transactivation domains of MTF1, namely the acidic domain, proline-rich domain, and serine-threonine rich domain, activated the GAL-4-driven luciferase gene to different degrees, but all were sensitive to Cr6+. MTF1 null cells were prone to apoptosis after exposure to Zn2+ or Cd2+ that was augmented in presence Cr6+, whereas the onset of apoptosis was significantly delayed in cells overexpressing MTF1.	Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Ghoshal, K (corresponding author), Ohio State Univ, Coll Med, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	jacob.42@osu.edu	Jacob, Samson/H-3135-2011		NATIONAL CANCER INSTITUTE [R01CA081024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081024-03, R01 CA081024, CA81024, R01 CA081024-04, R01 CA081024-01A2, R01 CA081024-02] Funding Source: Medline; NIEHS NIH HHS [R01 ES010874-04, R01 ES010874-05, R01 ES010874, R01 ES010874-01, R01 ES010874-03, R01 ES010874-02, ES10874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALEXANDER J, 1995, ANALYST, V120, P931, DOI 10.1039/an9952000931; Bevilacqua A, 2000, DEVELOPMENT, V127, P1541; Bredenberg J, 2002, PROTEINS, V49, P24, DOI 10.1002/prot.10195; Burgess-Beusse BL, 1998, MOL CELL BIOL, V18, P7269, DOI 10.1128/MCB.18.12.7269; Casadevall M, 1999, CHEM-BIOL INTERACT, V123, P117, DOI 10.1016/S0009-2797(99)00128-3; Cefalu WT, 2002, J NUTR, V132, P1107, DOI 10.1093/jn/132.6.1107; Chen F, 2002, J BIOL CHEM, V277, P3342, DOI 10.1074/jbc.M101089200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cousins RJ, 2000, J NUTR, V130, p1384S, DOI 10.1093/jn/130.5.1384S; DEFLORA S, 1990, MUTAT RES, V238, P99, DOI 10.1016/0165-1110(90)90007-X; Dillon CT, 1997, CHEM RES TOXICOL, V10, P533, DOI 10.1021/tx970010m; Ding M, 2002, MOL CELL BIOCHEM, V234, P293, DOI 10.1023/A:1015975218920; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; Ghoshal K, 2001, PROG NUCLEIC ACID RE, V66, P357; Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Ghoshal K, 1998, J BIOL CHEM, V273, P27904, DOI 10.1074/jbc.273.43.27904; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Green CJ, 2001, CANCER RES, V61, P2696; Gunes C, 1998, EMBO J, V17, P2846, DOI 10.1093/emboj/17.10.2846; HIDALGO J, 1988, AM J PHYSIOL, V255, pE518, DOI 10.1152/ajpendo.1988.255.4.E518; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; KORTENKAMP A, 1994, ENVIRON HEALTH PERSP, V102, P237, DOI 10.2307/3431793; LaRochelle O, 2001, J BIOL CHEM, V276, P41879, DOI 10.1074/jbc.M108313200; Lichtlen P, 2001, NUCLEIC ACIDS RES, V29, P1514, DOI 10.1093/nar/29.7.1514; Liu KJ, 2001, MOL CELL BIOCHEM, V222, P41, DOI 10.1023/A:1017994720562; Liu KJ, 2001, MOL CELL BIOCHEM, V222, P221, DOI 10.1023/A:1017938918686; Maier A, 2000, MOL CARCINOGEN, V28, P225, DOI 10.1002/1098-2744(200008)28:4<225::AID-MC5>3.0.CO;2-O; Majumder S, 1999, J BIOL CHEM, V274, P28584, DOI 10.1074/jbc.274.40.28584; Majumder S, 2001, GENE EXPRESSION, V9, P203, DOI 10.3727/000000001783992588; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS BW, 1992, AM J CLIN NUTR, V55, P989, DOI 10.1093/ajcn/55.5.989; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; OHNO M, 1991, J IMMUNOL METHODS, V145, P199, DOI 10.1016/0022-1759(91)90327-C; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; Sambrook J, 1989, MOL CLONING LABORATO, V9, P16; Sandstrom B, 2001, BRIT J NUTR, V85, pS181, DOI 10.1079/BJN2000312; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Saydam N, 2002, J BIOL CHEM, V277, P20438, DOI 10.1074/jbc.M110631200; Saydam N, 2001, J BIOL CHEM, V276, P25487, DOI 10.1074/jbc.M009154200; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shi XL, 1999, J TOXICOL ENV HEAL B, V2, P87, DOI 10.1080/109374099281241; Takahashi S, 2002, BIOCHEM J, V367, P641, DOI 10.1042/BJ20020819; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; Truong-Tran AQ, 2001, BIOMETALS, V14, P315, DOI 10.1023/A:1012993017026; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; WEDRYCHOWSKI A, 1985, J BIOL CHEM, V260, P7150; WEDRYCHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P1, DOI 10.1021/bi00349a001; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974	56	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26216	26226		10.1074/jbc.M302887200	http://dx.doi.org/10.1074/jbc.M302887200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716893	Green Accepted, hybrid			2022-12-25	WOS:000183920200121
J	Raussens, V; Slupsky, CM; Sykes, BD; Ryan, RO				Raussens, V; Slupsky, CM; Sykes, BD; Ryan, RO			Lipid-bound structure of an apolipoprotein E-derived peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN SECONDARY STRUCTURE; NUCLEAR-MAGNETIC-RESONANCE; N-TERMINAL DOMAIN; CELL-SURFACE RECEPTORS; LIGAND-BINDING DOMAIN; BACKBONE DYNAMICS; LDL RECEPTOR; DODECYLPHOSPHOCHOLINE MICELLES; CHEMICAL-SHIFTS	Apolipoprotein (apo) E regulates plasma lipid homeostasis through its ability to interact with the low density lipoprotein (LDL) receptor family. Whereas apoE is not a ligand for receptor binding in buffer alone, interaction with lipid confers receptor recognition properties. To investigate the nature of proposed lipid binding-induced conformational changes in apoE, we employed multidimensional heteronuclear NMR spectroscopy to determine the structure of an LDL receptor-active, 58-residue peptide comprising residues 126-183 of apoE in association with the micelle-forming lipid dodecylphosphocholine (DPC). In the presence of 34 mM DPC the peptide forms a continuous amphipathic helix from Glu(131) to Arg(178). NMR relaxation studies of DPC-bound apoE-(126-183), in contrast to apoE-(126-183) in the presence of TFE, are consistent with an isotropically tumbling peptide in solution giving a global correlation time of similar to12.5 ns. These data indicate that the helical peptide is curved and constrained by a lipid micelle consisting of similar to48 DPC molecules. Although the peptide behaves as if it were tumbling isotropically, spectral density analysis reveals that residues 150-183 have more motional freedom than residues 134-149. These molecular and dynamic features are discussed further to provide insight into the structural basis for the interaction between apoE and the ligand binding repeats of the LDL receptor.	Childrens Hosp, Oakland Res Inst, Lipid Biol Hlth & dis Res Grp, Oakland, CA 94609 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Alberta; University of Alberta	Ryan, RO (corresponding author), Childrens Hosp, Oakland Res Inst, Lipid Biol Hlth & dis Res Grp, 747 52nd St, Oakland, CA 94609 USA.				NHLBI NIH HHS [HL64159] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL064159, R01HL064159] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; BAX A, 1994, METHOD ENZYMOL, V239, P79; Beglova N, 2001, BIOCHEMISTRY-US, V40, P2808, DOI 10.1021/bi0027276; Beswick V, 1998, EUR BIOPHYS J BIOPHY, V28, P48, DOI 10.1007/s002490050182; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brutscher B, 1997, BIOCHEMISTRY-US, V36, P13043, DOI 10.1021/bi971538t; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ESSER V, 1988, J BIOL CHEM, V263, P13282; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; KUNTZ ID, 1991, J AM CHEM SOC, V113, P1406, DOI 10.1021/ja00004a050; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; MacRaild CA, 2001, BIOCHEMISTRY-US, V40, P5414, DOI 10.1021/bi002821m; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; North CL, 1999, BIOCHEMISTRY-US, V38, P3926, DOI 10.1021/bi9821622; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Raussens V, 2002, J BIOL CHEM, V277, P29172, DOI 10.1074/jbc.M204043200; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Raussens V, 2000, J BIOL CHEM, V275, P38329, DOI 10.1074/jbc.M005732200; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rozek A, 1999, BIOCHEMISTRY-US, V38, P14475, DOI 10.1021/bi982966h; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; Schellman C., 1980, PROTEIN FOLDING, P53; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Tieleman DP, 2000, J PHYS CHEM B, V104, P6380, DOI 10.1021/jp001268f; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WEISGRABER KH, 1992, HIGH DENSITY LIPOPRO, V3, P175; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042	61	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25998	26006		10.1074/jbc.M301753200	http://dx.doi.org/10.1074/jbc.M301753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12709434	hybrid			2022-12-25	WOS:000183920200095
J	van Grunsven, LA; Michiels, C; Van de Putte, T; Nelles, L; Wuytens, G; Verschueren, K; Huylebroeck, D				van Grunsven, LA; Michiels, C; Van de Putte, T; Nelles, L; Wuytens, G; Verschueren, K; Huylebroeck, D			Interaction between Smad-interacting protein-1 and the corepressor C-terminal binding protein is dispensable for transcriptional repression of E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; HIRSCHSPRUNG-DISEASE; DIFFERENTIAL EXPRESSION; REGULATES BINDING; GROWTH-FACTOR; DNA-BINDING; CTBP; MUTATIONS; SIP1; DELTA-EF1	deltaEF1 and SIP1 (or Zfhx1a and Zfhx1b, respectively) are the only known members of the vertebrate Zfh1 family of homeodomain/zinc finger-containing proteins. Similar to other transcription factors, both Smad-interacting protein-1 (SIP1) and deltaEF1 are capable of repressing E-cadherin transcription through binding to the E2 boxes located in its promoter. In the case of deltaEF1, this repression has been proposed to occur via interaction with the corepressor C-terminal binding protein (CtBP). In this study, we show by coimmunoprecipitation that SIP1 and CtBP interact in vivo and that an isolated CtBP-binding SIP1 fragment depends on CtBP for transcriptional repression. However, and most importantly, full-length SIP1 and deltaEF1 proteins do not depend on their interaction with CtBP to repress transcription from the E-cadherin promoter. Furthermore, in E-cadherin-positive kidney epithelial cells, the conditional synthesis of mutant SIP1 that cannot bind to CtBP abrogates endogenous E-cadherin expression in a similar way as wild-type SIP1. Our results indicate that full-length SIP1 can repress E-cadherin in a CtBP-independent manner.	Katholieke Univ Leuven VIB, Dept Dev Biol, B-3000 Leuven, Belgium; Katholieke Univ Leuven, Mol Biol Lab Celgen, B-3000 Leuven, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven	Verschueren, K (corresponding author), Katholieke Univ Leuven VIB, Dept Dev Biol, Campus Gasthuisberg Bldg O&N,Herestr 49, B-3000 Leuven, Belgium.	Kristin.Verschueren@med.kuleuven.ac.be	van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; Huylebroeck, Danny/0000-0003-4862-1079				Amiel J, 2001, AM J HUM GENET, V69, P1370, DOI 10.1086/324342; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; Cacheux V, 2001, HUM MOL GENET, V10, P1503, DOI 10.1093/hmg/10.14.1503; Chamberlain EM, 1999, MOL CELL BIOL, V19, P3600; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; Dillner NB, 2002, J BIOL CHEM, V277, P33890, DOI 10.1074/jbc.M204399200; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Eisaki A, 2000, BIOCHEM BIOPH RES CO, V271, P151, DOI 10.1006/bbrc.2000.2545; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; FORTINI ME, 1991, MECH DEVELOP, V34, P113, DOI 10.1016/0925-4773(91)90048-B; Fossett N, 2001, P NATL ACAD SCI USA, V98, P7342, DOI 10.1073/pnas.131215798; FUNAHASHI J, 1993, DEVELOPMENT, V119, P433; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Hlubek F, 2001, J BIOCHEM-TOKYO, V129, P635, DOI 10.1093/oxfordjournals.jbchem.a002901; IKEDA K, 1995, EUR J BIOCHEM, V233, P73, DOI 10.1111/j.1432-1033.1995.073_1.x; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Katz SG, 2002, MOL CELL BIOL, V22, P3121, DOI 10.1128/MCB.22.9.3121-3128.2002; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Muraoka O, 2000, DEV BIOL, V228, P29, DOI 10.1006/dbio.2000.9909; Nagaya M, 2002, J PEDIATR SURG, V37, P1117, DOI 10.1053/jpsu.2002.34455; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1997, EMBO J, V16, P3924, DOI 10.1093/emboj/16.13.3924; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sekido R, 1997, GENES CELLS, V2, P771, DOI 10.1046/j.1365-2443.1997.1570355.x; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Strunk B, 2001, DEV BIOL, V239, P229, DOI 10.1006/dbio.2001.0454; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2000, MECH DEVELOP, V94, P189, DOI 10.1016/S0925-4773(00)00318-X; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; Wakamatsu N, 2001, NAT GENET, V27, P369, DOI 10.1038/86860; Yamada K, 2001, AM J HUM GENET, V69, P1178, DOI 10.1086/324343; Zhang QH, 2002, SCIENCE, V295, P1895; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zweier C, 2002, AM J MED GENET, V108, P177, DOI 10.1002/ajmg.10226	53	83	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26135	26145		10.1074/jbc.M300597200	http://dx.doi.org/10.1074/jbc.M300597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12714599	hybrid			2022-12-25	WOS:000183920200112
J	Crosby, D; Poole, AW				Crosby, D; Poole, AW			Physical and functional interaction between protein kinase C delta and Fyn tyrosine kinase in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; SRC FAMILY KINASES; PKC-DELTA; GLYCOPROTEIN-VI; PHOSPHORYLATION SITES; SIGNALING PATHWAY; IN-VITRO; ACTIVATION; CELLS; ASSOCIATION	An increasing number of tyrosine kinases have been shown to associate with isoforms of the protein kinase C (PKC) family. Here, we show evidence for physical and functional interaction between PKCdelta and the Src family kinase Fyn in human platelets activated by alboaggregin-A, a snake venom capable of activating both GPIb-V-IX and GPVI adhesion receptors. This interaction involves phosphorylation of PKCdelta on tyrosine and is specific in that other isoforms of PKC, PKCepsilon and lambda, which also become tyrosine-phosphorylated, do not interact with Fyn. In addition, PKCdelta does not interact with other platelet-expressed tyrosine kinases Syk, Src, or Btk. Stimulation also leads to activation of both Fyn and PKCdelta and to serine phosphorylation of Fyn within a PKC consensus sequence. Alboaggregin-A-dependent activation of Fyn is blocked by bisindolylmaleimide I, suggesting a role for PKC isoforms in regulating Fyn activity. Platelet activation with alboaggregin-A induces translocation of the two kinases from cytoplasm to the plasma membrane of platelets, as observed by confocal immunofluorescence microscopy. Translocation of Fyn and PKCdelta are blocked by PP1 and bisindolylmaleimide I, showing a dependence upon Src and PKC kinase activities. Although PKC activity is required for translocation, it is not required for association between the two kinases, because this was not blocked by bisindolylmaleimide I. Rottlerin, which inhibited PKCdelta activity, did not block translocation of either PKCdelta or Fyn but potentiated platelet aggregation, 5-hydroxytryptamine secretion, and the calcium response induced by alboaggregin-A, indicating that this kinase plays a negative role in the control of these processes.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Poole, AW (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.			Poole, Alastair/0000-0002-0868-297X				Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; GERRARD JM, 1989, BLOOD, V74, P2405; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Ho AK, 1999, MOL CELL ENDOCRINOL, V150, P169, DOI 10.1016/S0303-7207(98)00227-5; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KNIGHT DE, 1984, EUR J BIOCHEM, V143, P437, DOI 10.1111/j.1432-1033.1984.tb08391.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANDGREN E, 1995, ONCOGENE, V10, P2027; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; Leitges M, 2001, LAB INVEST, V81, P1087, DOI 10.1038/labinvest.3780321; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIEBENHOFF U, 1994, CELL MOL BIOL, V40, P645; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; Moussazadeh M, 1998, FEBS LETT, V438, P225, DOI 10.1016/S0014-5793(98)01302-7; Nakai M, 1999, J NEUROCHEM, V72, P1179, DOI 10.1046/j.1471-4159.1999.0721179.x; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Pepio AM, 2001, J BIOL CHEM, V276, P3846, DOI 10.1074/jbc.M006339200; Ping PP, 1999, CIRC RES, V85, P542, DOI 10.1161/01.RES.85.6.542; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; POOLE AW, 1995, BRIT J PHARMACOL, V115, P101, DOI 10.1111/j.1476-5381.1995.tb16326.x; PULCINELLI FM, 1995, FEBS LETT, V364, P87, DOI 10.1016/0014-5793(95)00352-A; RINK TJ, 1983, NATURE, V305, P317, DOI 10.1038/305317a0; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SIESS W, 1988, BIOCHEM J, V255, P309; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Tapia JA, 2002, BBA-MOL CELL RES, V1593, P99, DOI 10.1016/S0167-4889(02)00346-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALKER TR, 1993, BIOCHEM J, V289, P277, DOI 10.1042/bj2890277; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; Wrenn RW, 2001, BIOCHEM BIOPH RES CO, V282, P882, DOI 10.1006/bbrc.2001.4657; Wu Y, 2000, BBA-MOL CELL RES, V1497, P27, DOI 10.1016/S0167-4889(00)00043-4; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836; YAMADA K, 1987, BIOCHEM BIOPH RES CO, V144, P35, DOI 10.1016/S0006-291X(87)80471-0; Yamamoto T, 2000, BIOCHEM BIOPH RES CO, V273, P960, DOI 10.1006/bbrc.2000.3048; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	67	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24533	24541		10.1074/jbc.M301847200	http://dx.doi.org/10.1074/jbc.M301847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721299	hybrid			2022-12-25	WOS:000183824800036
J	Kumagai, I; Nishimiya, Y; Kondo, H; Tsumoto, K				Kumagai, I; Nishimiya, Y; Kondo, H; Tsumoto, K			Structural consequences of target epitope-directed functional alteration of an antibody - The case of anti-hen lysozyme antibody, HyHEL-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; PHAGE DISPLAY; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; INFLUENZA-VIRUS; AFFINITY; SPECIFICITY; CRYSTALLOGRAPHY; RESIDUES; COMPLEX	Decreased affinity of an antibody for a mutated epitope in an antigen can be enhanced and reversed by mutations in certain antibody residues. Here we describe the crystal structures of (a) the complex between a naturally mutated proteinaceous antigen and an antibody that was mutated and selected in vitro, and (b) the complex between the normal antigen and the mutated antibody. The mutated and selected antibody recognizes essentially the same epitope as in the wild-type antibody, indicating successful target site-directed functional alteration of the antibody. In comparing the structure of the mutated antigen-mutant antibody complex with the previously established structure of the wild-type antigen-wild-type antibody complex, we found that the enhanced affinity of the mutated antibody for the mutant antigen originated not from improvements in local complementarity around the mutated sites but from subtle and critical structural changes in nonmutated sites, including an increase in variable domain interactions. Our findings indicate that only a few mutations in the antigen-binding region of an antibody can lead to some structural changes in its paratopes, emphasizing the critical roles of the plasticity of loops in the complementarity-determining region and also the importance of the plasticity of the interaction between the variable regions of immunoglobulin heavy and light chains in determining the specificity of an antibody.	Tohoku Univ, Dept Biomol Engn, Grad Sch Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; Natl Inst Adv Ind Sci & Technol, Sapporo, Hokkaido 0628517, Japan	Tohoku University; National Institute of Advanced Industrial Science & Technology (AIST)	Kumagai, I (corresponding author), Tohoku Univ, Dept Biomol Engn, Grad Sch Engn, Aoba Ku, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	kmiz@mail.cc.tohoku.ac.jp	Kondo, Hidemasa/M-7465-2018; Nishimiya, Yoshiyuki/M-4173-2018	Kondo, Hidemasa/0000-0003-2799-1775; Nishimiya, Yoshiyuki/0000-0002-0701-7775				Baca M, 1997, J BIOL CHEM, V272, P10678; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Bizebard T, 2001, CURR TOP MICROBIOL, V260, P55; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen WN, 1999, FEBS LETT, V453, P237, DOI 10.1016/S0014-5793(99)00704-8; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752; Dall'Acqua W, 1998, CURR OPIN STRUC BIOL, V8, P443, DOI 10.1016/S0959-440X(98)80121-8; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; de Wildt RMT, 1999, J MOL BIOL, V285, P895, DOI 10.1006/jmbi.1998.2396; Diaz M, 2002, CURR OPIN IMMUNOL, V14, P235, DOI 10.1016/S0952-7915(02)00327-8; Fleury D, 1999, NAT STRUCT BIOL, V6, P530, DOI 10.1038/9299; Fleury D, 1998, NAT STRUCT BIOL, V5, P119, DOI 10.1038/nsb0298-119; Holmes MA, 1997, J IMMUNOL, V158, P2192; Holmes MA, 1998, J EXP MED, V187, P479, DOI 10.1084/jem.187.4.479; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Huls G, 2001, CANCER IMMUNOL IMMUN, V50, P163, DOI 10.1007/s002620100182; Huston James S., 2001, Human Antibodies, V10, P127; Kabat E. A., 1991, SEQUENCES PROTEINS I; Klenerman P, 2002, CURR OPIN MICROBIOL, V5, P408, DOI 10.1016/S1369-5274(02)00339-9; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; KNOSSOW M, 1984, NATURE, V311, P678, DOI 10.1038/311678a0; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Ladbury JE, 1996, CHEM BIOL, V3, P973, DOI 10.1016/S1074-5521(96)90164-7; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lo Conte L, 1999, J MOL BIOL, V285, P2177; NAVAZA J, 1994, ACTA CRYSTALLOGR D, V50, P805; Nishimiya Y, 2000, J BIOL CHEM, V275, P12813, DOI 10.1074/jbc.275.17.12813; Ohlin M, 1996, MOL IMMUNOL, V33, P47, DOI 10.1016/0161-5890(95)00123-9; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1995, FASEB J, V9, P133, DOI 10.1096/fasebj.9.1.7821752; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; Saviranta P, 1998, PROTEIN ENG, V11, P143, DOI 10.1093/protein/11.2.143; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shirai H, 1998, J MOL BIOL, V278, P481, DOI 10.1006/jmbi.1998.1698; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Stoop AA, 2000, J MOL BIOL, V301, P1135, DOI 10.1006/jmbi.2000.4035; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TRAMONTANO A, 1990, J MOL BIOL, V215, P175, DOI 10.1016/S0022-2836(05)80102-0; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; Ueda H, 1996, NAT BIOTECHNOL, V14, P1714, DOI 10.1038/nbt1296-1714; Valjakka J, 2002, J BIOL CHEM, V277, P44021, DOI 10.1074/jbc.M208392200; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412	59	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24929	24936		10.1074/jbc.M301149200	http://dx.doi.org/10.1074/jbc.M301149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709438	hybrid			2022-12-25	WOS:000183824800083
J	LaCount, DJ; Gruszynski, AE; Grandgenett, PM; Bangs, JD; Donelson, JE				LaCount, DJ; Gruszynski, AE; Grandgenett, PM; Bangs, JD; Donelson, JE			Expression and function of the Trypanosoma brucei major surface protease (GP63) genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI-CHAGASI; BLOOD-STREAM FORMS; DOUBLE-STRANDED-RNA; AFRICAN TRYPANOSOMES; MEMBRANE GLYCOPROTEIN; PROTEINASE GP63; PROMASTIGOTES; MEXICANA; ATTACHMENT; SITES	The genome of the African trypanosome Trypanosoma brucei (Tb) contains at least three gene families (TbMSP-A, -B, and -C) encoding homologues of the abundant major surface protease (MSP, previously called GP63), which is found in all Leishmania species. TbMSP-B mRNA occurs in both procyclic and bloodstream trypanosomes, whereas TbMSP-A and -C mRNAs are detected only in bloodstream organisms. RNA interference (RNAi)-mediated gene silencing was used to investigate the function of TbMSP-B protein. RNAi directed against TbMSP-B but not TbMSP-A ablated the steady state TbMSP-B mRNA levels in both procyclic and bloodstream cells but had no effect on the kinetics of cultured trypanosome growth in either stage. Procyclic trypanosomes have been shown previously to have an uncharacterized cell surface metalloprotease activity that can release ectopically expressed surface proteins. To determine whether TbMSP-B is responsible for this release, transgenic variant surface glycoprotein 117 (VSG117) was expressed constitutively in T. brucei procyclic TbMSP-RNAi cell lines, and the amount of surface VSG117 was determined using a surface biotinylation assay. Ablation of TbMSP-B but not TbMSP-A mRNA resulted in a marked decrease in VSG release with a concomitant increase in steady state cell-associated VSG117, indicating that TbMSP-B mediates the surface protease activity of procyclic trypanosomes. This finding is consistent with previous pharmacological studies showing that peptidomimetic collagenase inhibitors block release of transgenic VSG from procyclic trypanosomes and are toxic for bloodstream but not procyclic organisms.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Wisconsin, Dept Biol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Donelson, John E/F-5795-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032135, R01AI032135, R29AI035739, T32AI007414, R01AI035739] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI035739, T32 AI007414, AI32135, AI35739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed AA, 1998, SCAND J IMMUNOL, V48, P79; Alarcon CM, 1999, J BIOL CHEM, V274, P16884, DOI 10.1074/jbc.274.24.16884; Ansorge I, 1999, MOL BIOCHEM PARASIT, V101, P81, DOI 10.1016/S0166-6851(99)00060-2; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; Bangs JD, 2001, MOL BIOCHEM PARASIT, V114, P111, DOI 10.1016/S0166-6851(01)00244-4; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; CHAUDHURI G, 1988, MOL BIOCHEM PARASIT, V27, P43, DOI 10.1016/0166-6851(88)90023-0; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; Corradin S, 1999, J BIOL CHEM, V274, P25411, DOI 10.1074/jbc.274.36.25411; ElSayed NMA, 1997, MOL BIOCHEM PARASIT, V84, P167, DOI 10.1016/S0166-6851(96)02792-2; ElSayed NMA, 1997, J BIOL CHEM, V272, P26742, DOI 10.1074/jbc.272.42.26742; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREVERT U, 1990, EUR J CELL BIOL, V52, P264; Garcia MR, 1997, EUR J IMMUNOL, V27, P1005, DOI 10.1002/eji.1830270430; Gruszynski AE, 2003, J BIOL CHEM, V278, P24665, DOI 10.1074/jbc.M301497200; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HIRUMI H, 1980, PARASITOLOGY, V80, P371, DOI 10.1017/S0031182000000822; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; IP HS, 1990, MOL BIOCHEM PARASIT, V40, P163, DOI 10.1016/0166-6851(90)90038-N; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; Kelly BL, 2001, MOL BIOCHEM PARASIT, V116, P101, DOI 10.1016/S0166-6851(01)00307-3; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LaCount DJ, 2002, J BIOL CHEM, V277, P17580, DOI 10.1074/jbc.M200873200; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; Myung KS, 2002, J BIOL CHEM, V277, P16489, DOI 10.1074/jbc.M200174200; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1995, J BIOL CHEM, V270, P8884, DOI 10.1074/jbc.270.15.8884; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; RUSSO DCW, 1994, PARASITOL RES, V80, P487, DOI 10.1007/BF00932695; Schlagenhauf E, 1998, STRUCTURE, V6, P1035, DOI 10.1016/S0969-2126(98)00104-X; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; Seay MB, 1996, INFECT IMMUN, V64, P5129, DOI 10.1128/IAI.64.12.5129-5137.1996; STEINKRAUS HB, 1993, MOL BIOCHEM PARASIT, V62, P173, DOI 10.1016/0166-6851(93)90107-9; TURNER MJ, 1985, BRIT MED BULL, V41, P137, DOI 10.1093/oxfordjournals.bmb.a072040; Voth BR, 1998, MOL BIOCHEM PARASIT, V93, P31, DOI 10.1016/S0166-6851(98)00013-9; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON ME, 1989, J IMMUNOL, V143, P678; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028	56	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24658	24664		10.1074/jbc.M301451200	http://dx.doi.org/10.1074/jbc.M301451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707278	hybrid			2022-12-25	WOS:000183824800051
J	Ostrom, RS; Naugle, JE; Hase, M; Gregorian, C; Swaney, JS; Insel, PA; Brunton, LL; Meszaros, JG				Ostrom, RS; Naugle, JE; Hase, M; Gregorian, C; Swaney, JS; Insel, PA; Brunton, LL; Meszaros, JG			Angiotensin II enhances adenylyl cyclase signaling via Ca2+/calmodulin - G(q-)G(s) cross-talk regulates collagen production in cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE INHIBITS COLLAGEN; SMOOTH-MUSCLE CELLS; HEART-FAILURE; PROTEIN-SYNTHESIS; A(2B) RECEPTORS; NITRIC-OXIDE; VENTRICULAR MYOCYTES; IN-VIVO; CAVEOLAE; PATHWAY	Cardiac fibroblasts regulate formation of extracellular matrix in the heart, playing key roles in cardiac remodeling and hypertrophy. In this study, we sought to characterize cross-talk between G(q) and G(s) signaling pathways and its impact on modulating collagen synthesis by cardiac fibroblasts. Angiotensin II (ANG II) activates cell proliferation and collagen synthesis but also potentiates cyclic AMP ( cAMP) production stimulated by beta-adrenergic receptors (beta-AR). The potentiation of beta-AR-stimulated cAMP production by ANG II is reduced by phospholipase C inhibition and enhanced by overexpression of G(q). Ionomycin and thapsigargin increased intracellular Ca2+ levels and potentiated isoproterenol- and forskolin-stimulated cAMP production, whereas chelation of Ca2+ with 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid/AM inhibited such potentiation. Inhibitors of tyrosine kinases, protein kinase C, or Gbetagamma did not alter this cross-talk. Immunoblot analyses showed prominent expression of adenylyl cyclase 3 (AC3), a Ca2+-activated isoform, along with AC2, AC4, AC5, AC6, and AC7. Of those isoforms, only AC3 and AC5/6 proteins were detected in caveolin-rich fractions. Overexpression of AC6 increased betaAR-stimulated cAMP accumulation but did not alter the size of the ANG II potentiation, suggesting that the cross-talk is AC isoform-specific. Isoproterenol-mediated inhibition of serum-stimulated collagen synthesis increased from 31 to 48% in the presence of ANG II, indicating that betaAR-regulated collagen synthesis increased in the presence of ANG II. These data indicate that ANG II potentiates cAMP formation via Ca2+-dependent activation of AC activity, which in turn attenuates collagen synthesis and demonstrates one functional consequence of crosstalk between G(q) and G(s) signaling pathways in cardiac fibroblasts.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Dept Physiol, Rootstown, OH 44272 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Northeast Ohio Medical University (NEOMED)	Meszaros, JG (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	jgmeszar@neoucom.com		Ostrom, Rennolds/0000-0002-7204-0357	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041307, P01HL066941, P50HL053773, R01HL063885] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66941, HL63885, HL53773, HL 41307] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Asai K, 1999, J CLIN INVEST, V104, P551, DOI 10.1172/JCI7418; Brilla CG, 1995, EUR HEART J, V16, P107, DOI 10.1093/eurheartj/16.suppl_O.107; Brilla CG, 2000, CARDIOVASC RES, V46, P324, DOI 10.1016/S0008-6363(99)00432-0; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Dostal DE, 1996, MOL CELL BIOCHEM, V157, P15; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; Dubey RK, 1999, HYPERTENSION, V33, P190, DOI 10.1161/01.HYP.33.1.190; Dubey RK, 2001, HYPERTENSION, V37, P716, DOI 10.1161/01.HYP.37.2.716; Dubey RK, 1998, HYPERTENSION, V31, P943, DOI 10.1161/01.HYP.31.4.943; Dubey RK, 1997, CIRCULATION, V96, P2656, DOI 10.1161/01.CIR.96.8.2656; EGHBALI M, 1990, MOL CELL BIOCHEM, V96, P1; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; GREEN DA, 1982, J CYCLIC NUCL PROT, V8, P337; GUARDA E, 1993, CARDIOVASC RES, V27, P2130, DOI 10.1093/cvr/27.12.2130; Gustafsson AB, 2000, MOL PHARMACOL, V58, P1470, DOI 10.1124/mol.58.6.1470; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hill J, 2000, CELL SIGNAL, V12, P233, DOI 10.1016/S0898-6568(99)00082-0; Hou M, 2000, ACTA PHYSIOL SCAND, V168, P301; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; LINDENSCHMIDT RC, 1985, J PHARMACOL EXP THER, V232, P346; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; Meszaros JG, 2000, AM J PHYSIOL-CELL PH, V278, pC154, DOI 10.1152/ajpcell.2000.278.1.C154; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Ostrom RS, 2002, MOL PHARMACOL, V62, P983, DOI 10.1124/mol.62.5.983; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Smith KE, 2002, J BIOL CHEM, V277, P6025, DOI 10.1074/jbc.M109615200; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Webb JG, 2001, AM J PHYSIOL-HEART C, V281, pH1545, DOI 10.1152/ajpheart.2001.281.4.H1545; WEBER KT, 1994, J MOL CELL CARDIOL, V26, P279, DOI 10.1006/jmcc.1994.1036; Weber KT, 1997, CIRCULATION, V96, P4065; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Xiang Y, 2002, J BIOL CHEM, V277, P34280, DOI 10.1074/jbc.M201644200; Yu H, 1997, HYPERTENSION, V30, P1047, DOI 10.1161/01.HYP.30.5.1047	40	80	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24461	24468		10.1074/jbc.M212659200	http://dx.doi.org/10.1074/jbc.M212659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12711600	hybrid			2022-12-25	WOS:000183824800027
J	Yang, YF; Meier, UT				Yang, YF; Meier, UT			Genetic interaction between a chaperone of small nucleolar ribonucleoprotein particles and cytosolic serine hydroxymethyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SM-LIKE PROTEINS; CRYSTAL-STRUCTURE; LSM PROTEINS; TRANSFER-RNA; CELL-GROWTH; YEAST; LOCALIZATION; ASSOCIATION; HOMOLOG; NOPP140	Srp40p is a nonessential yeast nucleolar protein proposed to function as a chaperone for over 100 small nucleolar ribonucleoprotein particles that are required for rRNA maturation. To verify and expand on its function, genetic screens were performed for the identification of genes that were lethal when mutated in a SRP40 null background (srp40Delta). Unexpectedly, mutation of both cytosolic serine hydroxymethyltransferase (SHM2) and one-carbon tetrahydrofolate synthase (ADE3) was required to achieve synthetic lethality with srp40Delta. Shm2p and Ade3p are cytoplasmic enzymes producing 5,10-methylene tetrahydrofolate in convergent pathways as the primary source for cellular one-carbon groups. Nonetheless, point mutants of Shm2p that were catalytically inactive (i.e. failed to rescue the methionine auxotrophy of a shm2Delta ade3 strain) complemented the synthetic lethal phenotype, thus revealing a novel metabolism-independent function of Shm2p. The same Shm2p mutants exacerbated a giant cell phenotype observed in the shm2Delta ade3 strain suggesting a catalysis-independent role for Shm2p in cell size control, possibly through regulation of ribosome biogenesis via SRP40. Additionally, we show that the Sm-like protein Lsm5p, which as part of Lsm complexes participates in cytosolic and nuclear RNA processing and degradation pathways, is a multicopy suppressor of the synthetic lethality and of the specific depletion of box H/ACA small nucleolar RNAs from the srp40Delta shm2 ade3 strain. Finally, rat Nopp140 restored growth and stability of box H/ACA snoRNAs after genetic depletion of SRP40 in the synthetic lethal strain indicating that it is indeed the functional homolog of yeast Srp40p.	Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Meier, UT (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	meier@aecom.yu.edu	Yang, Yunfeng/H-9853-2013	Yang, Yunfeng/0000-0001-8274-6196				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BYRNE PC, 1992, BIOCHEM J, V286, P117, DOI 10.1042/bj2860117; Decatur WA, 2002, TRENDS BIOCHEM SCI, V27, P344, DOI 10.1016/S0968-0004(02)02109-6; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; FRATTE SD, 1994, EUR J BIOCHEM, V225, P395, DOI 10.1111/j.1432-1033.1994.00395.x; Fromont-Racine M, 2000, YEAST, V17, P95, DOI 10.1002/1097-0061(20000630)17:2<95::AID-YEA16>3.0.CO;2-H; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; Ikonomova R, 1997, DNA CELL BIOL, V16, P1161, DOI 10.1089/dna.1997.16.1161; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; Kendall A, 2000, P NATL ACAD SCI USA, V97, P13108, DOI 10.1073/pnas.240454997; Kiss T, 2001, EMBO J, V20, P3617, DOI 10.1093/emboj/20.14.3617; Kufel J, 2003, J BIOL CHEM, V278, P2147, DOI 10.1074/jbc.M208856200; Kufel J, 2002, MOL CELL BIOL, V22, P5248, DOI 10.1128/MCB.22.14.5248-5256.2002; Lafontaine DLJ, 2000, MOL CELL BIOL, V20, P2650, DOI 10.1128/MCB.20.8.2650-2659.2000; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; Liu XW, 2000, BIOCHEMISTRY-US, V39, P11523, DOI 10.1021/bi000665d; MARTINI F, 1987, J BIOL CHEM, V262, P5499; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; MCNEIL JB, 1994, J BIOL CHEM, V269, P9155; McNeil JB, 1996, GENETICS, V142, P371; Meier UT, 1996, J BIOL CHEM, V271, P19376; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MEIER UT, 1992, CELL, V70, P127; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; Nigavekar SS, 2002, YEAST, V19, P115, DOI 10.1002/yea.807; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Ogg SC, 2002, J CELL BIOL, V159, P17, DOI 10.1083/jcb.200206111; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Verheggen C, 2002, EMBO J, V21, P2736, DOI 10.1093/emboj/21.11.2736; Verheggen C, 2001, EMBO J, V20, P5480, DOI 10.1093/emboj/20.19.5480; Wang C, 2002, MOL CELL BIOL, V22, P8457, DOI 10.1128/MCB.22.24.8457-8466.2002; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Yang YF, 2000, MOL BIOL CELL, V11, P567, DOI 10.1091/mbc.11.2.567	61	10	11	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23553	23560		10.1074/jbc.M300695200	http://dx.doi.org/10.1074/jbc.M300695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700234	hybrid			2022-12-25	WOS:000183638600044
J	Serysheva, II; Bare, DJ; Ludtke, SJ; Kettlun, CS; Chiu, W; Mignery, GA				Serysheva, II; Bare, DJ; Ludtke, SJ; Kettlun, CS; Chiu, W; Mignery, GA			Structure of the type 1 inositol 1,4,5-trisphosphate receptor revealed by electron cryomicroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHANNEL FUNCTION; LIGAND-BINDING; TRISPHOSPHATE RECEPTOR; OLIGOMERIZATION; RECONSTITUTION	The three- dimensional structure of the type 1 inositol 1,4,5- trisphosphate receptor ( InsP(3)R1) has been determined by electron cryomicroscopy and single- particle reconstruction. The receptor was immunoaffinity- purified and formed functional InsP(3)- and heparin- sensitive channels with a unitary conductance similar to native InsP(3)Rs. The channel structure exhibits the expected 4- fold symmetry and comprises two morphologically distinct regions: a large pinwheel and a smaller square. The pinwheel region has four radial curved spokes interconnected by a central core. The InsP(3)- binding core domain has been localized within each spoke of the pinwheel region by fitting its x- ray structure into our reconstruction. A structural mapping of the amino acid sequences to several functional domains is deduced within the structure of the InsP(3)R1 tetramer.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Baylor Coll Med, Natl Ctr Macromol Imaging, Verna & Mars McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Loyola Univ, Stritch Sch Med, Dept Physiol, Maywood, IL 60153 USA	Baylor College of Medicine; Baylor College of Medicine; Loyola University Chicago	Serysheva, II (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.	irinas@bcm.tmc.edu	Ludtke, Steven/A-4478-2008	Ludtke, Steven/0000-0002-1903-1574	NCRR NIH HHS [P41 RR 02250] Funding Source: Medline; NIMH NIH HHS [MH 53367] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053367, R29MH053367] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; BAUDET S, 1994, METHOD CELL BIOL, V40, P93; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; da Fonseca PCA, 2003, P NATL ACAD SCI USA, V100, P3936, DOI 10.1073/pnas.0536251100; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Galvan DL, 2002, J BIOL CHEM, V277, P48248, DOI 10.1074/jbc.M209990200; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Jiang W, 2001, J MOL BIOL, V308, P1033, DOI 10.1006/jmbi.2001.4633; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Ludtke SJ, 2001, J MOL BIOL, V314, P253, DOI 10.1006/jmbi.2001.5133; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Perez PJ, 1997, J BIOL CHEM, V272, P23961, DOI 10.1074/jbc.272.38.23961; Ramos-Franco J, 2000, BIOPHYS J, V79, P1388, DOI 10.1016/S0006-3495(00)76391-0; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Riley AM, 2002, J BIOL CHEM, V277, P40290, DOI 10.1074/jbc.M206925200; Serysheva II, 2002, P NATL ACAD SCI USA, V99, P10370, DOI 10.1073/pnas.162363499; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	29	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21319	21322		10.1074/jbc.C300148200	http://dx.doi.org/10.1074/jbc.C300148200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12714606	hybrid			2022-12-25	WOS:000183354200002
J	Ghyczy, M; Torday, C; Boros, M				Ghyczy, M; Torday, C; Boros, M			Simultaneous generation of methane, carbon dioxide, and carbon monoxide from choline and ascorbic acid - a defensive mechanism against reductive stress?	FASEB JOURNAL			English	Article						redox balance; mitochondria; electrophilic methyl groups; hydrogen peroxide; iron; oxygen radicals	HYDROGEN-PEROXIDE; PROTECTION	Indirect evidence suggests that an abnormal increase in reducing power (reductive stress) may be associated with abnormal clinical states. We have recently proposed that under such conditions biomolecules with electrophilic methyl groups (EMGs) bound to positively charged nitrogen or sulfur moieties may act as electron acceptors and that this poising mechanism may entail the generation of methane gas. Here we report for the first time the generation of methane by rat liver mitochondria. We also report the formation of methane from choline in the presence of hydrogen peroxide, catalytic iron, and ascorbic acid. In this system, carbon monoxide and carbon dioxide are formed from the ascorbate molecule in parallel with methane generation. In view of these findings, we try to explain the essential role of biomolecules with EMG moiety. We hypothesize that this concerted reaction may be a defensive response to reductive stress and may provide the protection needed against redox imbalance in living systems.	Univ Szeged, Inst Surg Res, H-6701 Szeged, Hungary; Phospholipid GmbH, Cologne, Germany	Szeged University	Boros, M (corresponding author), Univ Szeged, Inst Surg Res, POB 464, H-6701 Szeged, Hungary.	boros@expsur.szote.u-szeged.hu	Boros, Mihály/B-5195-2008					Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Boros M, 1999, SHOCK, V12, P56, DOI 10.1097/00024382-199911001-00174; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANCE B, 1957, FED PROC, V16, P671; Davies M./ B., 1991, VITAMIN C ITS CHEM B; DORMANDY TL, 1966, LANCET, V1, P755; DUAN J, 1990, J CARDIOVASC PHARM, V15, P163, DOI 10.1097/00005344-199001000-00026; DUAN JM, 1990, N-S ARCH PHARMACOL, V342, P342; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Ghyczy M, 2001, BRIT J NUTR, V85, P409, DOI 10.1079/BJN2000274; Gutteridge JMC, 1999, REDOX REP, V4, P129, DOI 10.1179/135100099101534819; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Ido Y, 1997, DIABETOLOGIA, V40, pS115, DOI 10.1007/s001250051422; Ido Y, 2001, FASEB J, V15, P1419, DOI 10.1096/fj.00-0652fje; Kristal BS, 1998, FREE RADICAL BIO MED, V24, P1269, DOI 10.1016/S0891-5849(97)00444-9; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Liochev SI, 2002, REDOX REP, V7, P55, DOI 10.1179/135100002125000190; Lipinski B, 2002, BRIT J NUTR, V87, P93, DOI 10.1079/BJN2001435; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORITA S, 1985, ANESTH ANALG, V64, P343; NIKNAHAD H, 1995, CHEM-BIOL INTERACT, V98, P27, DOI 10.1016/0009-2797(95)03631-U; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Parinandi NL, 1999, ANTIOXID REDOX SIGN, V1, P193, DOI 10.1089/ars.1999.1.2-193; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; Staubli A, 1998, AM J PHYSIOL-GASTR L, V274, pG1031, DOI 10.1152/ajpgi.1998.274.6.G1031; STORM G, 1989, CANCER CHEMOTH PHARM, V24, P341, DOI 10.1007/BF00257439; SWARM RA, 1987, AM J SURG, V153, P48, DOI 10.1016/0002-9610(87)90200-5; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; THOMAS C E, 1985, Journal of Free Radicals in Biology and Medicine, V1, P293; Williamson JR, 1999, DIABETES RES CLIN PR, V45, P81; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	31	51	54	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1124	+		10.1096/fj.02-0918fje	http://dx.doi.org/10.1096/fj.02-0918fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692080				2022-12-25	WOS:000182580100034
J	Unnikrishnan, I; Miller, S; Meinke, M; LaPorte, DC				Unnikrishnan, I; Miller, S; Meinke, M; LaPorte, DC			Multiple positive and negative elements involved in the regulation of expression of GSY1 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESERVE CARBOHYDRATE-METABOLISM; TRANSCRIPTION INITIATION SITES; YEAST GLYCOGEN-SYNTHETASE; SNF1 PROTEIN-KINASE; ESCHERICHIA-COLI; FINGER PROTEINS; GENE-EXPRESSION; MIG1 REPRESSOR; STRESS; PHOSPHORYLATION	GSY1 is one of the two genes encoding glycogen synthase in Saccharomyces cerevisiae. Both the GSY1 message and the protein levels increased as cells approached stationary phase. A combination of deletion analysis and site-directed mutagenesis revealed a complex promoter containing multiple positive and negative regulatory elements. Expression of GSY1 was dependent upon the presence of a TATA box and two stress response elements (STREs). Expression was repressed by Mig1, which mediates responses to glucose, and Rox1, which mediates responses to oxygen. Characterization of the GSY1 promoter also revealed a novel negative element. This element, N1, can repress expression driven by either an STRE or a heterologous element, the UAS of CYC1. Repression by N1 is dependent on the number of these elements that are present, but is independent of their orientation. N1 repressed expression when placed either upstream or downstream of the UAS, although the latter position is more effective. Gel shift analysis detected a factor that appears to bind to the N1 element. The complexity of the GSY1 promoter, which includes two STREs and three distinct negative elements, was surprising. This complexity may allow GSY1 to respond to a wide range of environmental stresses.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	LaPorte, DC (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.	David-L@Lenti.med.umn.edu						AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BECKER JU, 1982, J GEN MICROBIOL, V128, P447; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1111/j.1574-6976.2001.tb00574.x; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; Garreau H, 2000, MICROBIOL-UK, V146, P2113, DOI 10.1099/00221287-146-9-2113; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; Hardie DG, 1999, BIOCHEM SOC SYMP, P13; HUANG KP, 1974, J BIOL CHEM, V249, P3851; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; HWANG PK, 1986, NATURE, V324, P80, DOI 10.1038/324080a0; KENG T, 1992, MOL CELL BIOL, V12, P2616, DOI 10.1128/MCB.12.6.2616; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; LOWRY CV, 1988, MOL CELL BIOL, V8, P4651, DOI 10.1128/MCB.8.11.4651; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; McCartney RR, 2001, J BIOL CHEM, V276, P36460, DOI 10.1074/jbc.M104418200; MEINKE MH, 1993, THESIS U MINNESOTA; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NI HT, 1995, MOL MICROBIOL, V16, P1197, DOI 10.1111/j.1365-2958.1995.tb02342.x; Parrou JL, 1999, YEAST, V15, P191, DOI 10.1002/(SICI)1097-0061(199902)15:3<191::AID-YEA358>3.0.CO;2-O; Parrou JL, 1997, MICROBIOL-UK, V143, P1891, DOI 10.1099/00221287-143-6-1891; Pederson BA, 2000, J BIOL CHEM, V275, P27753; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; ROWEN DW, 1992, THESIS U MINNESOTA; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; SHERMAN F, 1985, METHODS YEAST GENETI; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Sunnarborg SW, 2001, YEAST, V18, P1505; THOMPSONJAEGER S, 1991, GENETICS, V129, P697; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; WILSON HR, 1992, J BACTERIOL, V174, P514, DOI 10.1128/jb.174.2.514-524.1992; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	48	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26450	26457		10.1074/jbc.M211808200	http://dx.doi.org/10.1074/jbc.M211808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12697770	hybrid			2022-12-25	WOS:000184155700022
J	Adir, N; Lerner, N				Adir, N; Lerner, N			The crystal structure of a novel unmethylated form of C-phycocyanin, a possible connector between cores and rods in phycobilisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM MASTIGOCLADUS-LAMINOSUS; 2.2 ANGSTROM RESOLUTION; SPIRULINA-PLATENSIS; ENERGY-TRANSFER; AGMENELLUM-QUADRUPLICATUM; N-METHYLASPARAGINE; R-PHYCOERYTHRIN; LIGHT; ALLOPHYCOCYANIN; REFINEMENT	A novel fraction of c-phycocyanin from the thermophilic cyanobacterium Thermosynechcoccus vulcanus, with an absorption maxima blue-shifted to 612 nm (PC612), has been purified from allophycocyanin and crystallized. The crystals belong to the P6(3) space group with cell dimensions of 153 Angstrom x 153 Angstrom x 59 Angstrom with a single (alphabeta) monomer in the asymmetric unit, resulting in a solvent content of 65%, and diffract to 2.7 Angstrom. The PC612 crystal structure has been determined by molecular replacement and refined to a crystallographic R-factor of 20.9% (R-free = 27.8%). The crystal packing in this form shows that the PC612 form of phycocyanin does not associate into hexamers and that its association with adjacent trimers in the unit cell is very different from that found in a previously determined structure of the normal form of T. vulcanus phycocyanin, which absorbs at 620 nm. Analysis of the PC612 structure shows that the alpha subunits, which typically form the interface between two trimers within a hexamer, have a high degree of flexibility, as indicated by elevated B-factors in portions of helices B, E, and G. Examination of calculated electron density omit maps shows that unlike all other structures of phycobiliproteins determined so far, the Asnbeta(72) residue is not methylated, explaining the blue-shift in its absorption spectra. On the basis of the results presented here, we suggest that this new form of trimeric phycocyanin may constitute a special minor component of the phycobilisome and may form the contact between the phycocyanin rods and the allophycocyanin core.	Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology	Adir, N (corresponding author), Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel.	nadir@tx.technion.ac.il	Adir, Noam/ABE-6990-2020					Adir N, 2002, BBA-BIOENERGETICS, V1556, P168, DOI 10.1016/S0005-2728(02)00359-6; Adir N, 2001, J MOL BIOL, V313, P71, DOI 10.1006/jmbi.2001.5030; Anderson LK, 1998, MOL MICROBIOL, V30, P467, DOI 10.1046/j.1365-2958.1998.01081.x; ANDERSON LK, 1986, J MOL BIOL, V191, P441, DOI 10.1016/0022-2836(86)90139-7; BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT DA, 1981, EUR J BIOCHEM, V119, P415, DOI 10.1111/j.1432-1033.1981.tb05624.x; Chang WR, 1996, J MOL BIOL, V262, P721, DOI 10.1006/jmbi.1996.0547; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; FICNER R, 1992, J MOL BIOL, V228, P935, DOI 10.1016/0022-2836(92)90876-L; GLAUSER M, 1992, EUR J BIOCHEM, V205, P907, DOI 10.1111/j.1432-1033.1992.tb16857.x; GLAZER AN, 1985, ANNU REV BIOPHYS BIO, V14, P47, DOI 10.1146/annurev.biophys.14.1.47; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1983, ANN INST PASTEUR MIC, VB134, P159, DOI 10.1016/S0769-2609(83)80103-3; HUBER R, 1989, EMBO J, V8, P2125, DOI 10.1002/j.1460-2075.1989.tb08337.x; Jiang T, 1999, PROTEINS, V34, P224; Jiang T, 2001, BIOPHYS J, V81, P1171, DOI 10.1016/S0006-3495(01)75774-8; KLOTZ AV, 1986, J BIOL CHEM, V261, P5891; Liu JY, 1999, J BIOL CHEM, V274, P16945, DOI 10.1074/jbc.274.24.16945; MacColl R, 1998, J STRUCT BIOL, V124, P311, DOI 10.1006/jsbi.1998.4062; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAXSON P, 1989, BIOCHIM BIOPHYS ACTA, V977, P40, DOI 10.1016/S0005-2728(89)80007-6; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Padyana AK, 2001, BIOCHEM BIOPH RES CO, V282, P893, DOI 10.1006/bbrc.2001.4663; Reuter W, 1999, P NATL ACAD SCI USA, V96, P1363, DOI 10.1073/pnas.96.4.1363; Ritter S, 1999, J STRUCT BIOL, V126, P86, DOI 10.1006/jsbi.1999.4106; SAUER K, 1988, BIOCHIM BIOPHYS ACTA, V936, P157, DOI 10.1016/0005-2728(88)90232-0; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; Stec B, 1999, BIOPHYS J, V76, P2912, DOI 10.1016/S0006-3495(99)77446-1; SWANSON RV, 1990, J MOL BIOL, V214, P787, DOI 10.1016/0022-2836(90)90293-U; TANDEAUDEMARSAC N, 1977, P NATL ACAD SCI USA, V74, P1635; Wang XQ, 2001, ACTA CRYSTALLOGR D, V57, P784, DOI 10.1107/S0907444901004528; YAMANAKA G, 1982, J BIOL CHEM, V257, P4077; YU MH, 1981, J BIOL CHEM, V256, P3130	37	43	47	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25926	25932		10.1074/jbc.M302838200	http://dx.doi.org/10.1074/jbc.M302838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12709431	hybrid			2022-12-25	WOS:000183920200084
J	Leach, C; Shenolikar, S; Brautigan, DL				Leach, C; Shenolikar, S; Brautigan, DL			Phosphorylation of phosphatase inhibitor-2 at centrosomes during mitosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN PHOSPHATASE; RABBIT SKELETAL-MUSCLE; NIMA-RELATED KINASE; CELL-CYCLE; PHOSPHOPROTEIN PHOSPHATASE; OKADAIC ACID; HELA-CELLS; TYPE-1; GENE; IDENTIFICATION	Inhibitor-2 (I-2) is a regulator of protein phosphatase type-1 (PP1), known to be phosphorylated in vitro by multiple kinases. In particular Thr(72) is a Thr-Pro phosphorylation site conserved from yeast to human, but there is no evidence that this phosphorylation responds to any physiological signals. Here, we used electrophoretic mobility shift and immunoblotting with a site-specific phospho-Thr(72) antibody to establish Thr(72) phosphorylation in HeLa cells and show a 25-fold increase in phosphorylation during mitosis. Mass spectrometry demonstrated I-2 in actively growing HeLa cells was also phosphorylated at three other sites, Ser(120), Ser(121), and an additional Ser located between residues 70 and 90. In vitro kinase assays using recombinant I-2 as a substrate showed that the Thr(72) kinase(s) was activated during mitosis, and sensitivity to kinase inhibitors indicated that the principal I-2 Thr(72) kinase was not GSK3 but instead a member of the cyclin-dependent protein kinase family. Immunocytochemistry confirmed Thr(72) phosphorylation of I-2 during mitosis, with peak intensity at prophase, and revealed subcellular concentration of the phospho-Thr(72) I-2 at centrosomes. Together, the data show dynamic changes in I-2 phosphorylation during mitosis and localization of phosphorylated I-2 at centrosomes, suggesting involvement in mammalian cell division.	Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University of Virginia; Duke University	Brautigan, DL (corresponding author), Univ Virginia, Sch Med, Ctr Cell Signaling, Box 800577-MSB7225, Charlottesville, VA 22908 USA.				NIDDK NIH HHS [DK52054] Funding Source: Medline; NIGMS NIH HHS [GM56362] Funding Source: Medline; NIH HHS [GF-10461] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; DePaoli-Roach A A, 1985, FEBS Lett, V183, P423; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; DOMBRADI V, 1990, FEBS LETT, V275, P39, DOI 10.1016/0014-5793(90)81434-P; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Ghosh S, 1998, EXP CELL RES, V242, P1, DOI 10.1006/excr.1998.4115; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; Hayashi K, 1999, J CELL SCI, V112, P1149; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; HEMMINGS BA, 1982, FEBS LETT, V150, P310; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HOLMES CFB, 1986, BIOCHIM BIOPHYS ACTA, V870, P408, DOI 10.1016/0167-4838(86)90248-7; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; Ishii K, 1996, EMBO J, V15, P6629, DOI 10.1002/j.1460-2075.1996.tb01053.x; LAWRENCE JC, 1988, BIOCHEM BIOPH RES CO, V150, P197, DOI 10.1016/0006-291X(88)90505-0; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PUNTONI F, 1995, BIOCHEM BIOPH RES CO, V207, P732, DOI 10.1006/bbrc.1995.1248; Puntoni F, 1997, ARCH BIOCHEM BIOPHYS, V340, P177, DOI 10.1006/abbi.1997.9889; Tan YSH, 2003, J BIOL CHEM, V278, P147, DOI 10.1074/jbc.M208058200; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; WALKER DH, 1992, MOL BIOL CELL, V3, P687, DOI 10.1091/mbc.3.6.687; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; YANG SD, 1981, J BIOL CHEM, V256, P231	30	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26015	26020		10.1074/jbc.M300782200	http://dx.doi.org/10.1074/jbc.M300782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12697755	hybrid			2022-12-25	WOS:000183920200097
J	Cheng, HC; Abdel-Ghany, M; Pauli, BU				Cheng, HC; Abdel-Ghany, M; Pauli, BU			A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; BREAST-CANCER CELLS; RAT BREAST; EXTRACELLULAR-MATRIX; ADENOSINE-DEAMINASE; BETA(4) INTEGRIN; LUNG METASTASIS; MELANOMA-CELLS; T-CELLS; IN-VIVO	Lung endothelial dipeptidyl peptidase IV (DPPIV/CD26) is a vascular address for cancer cells decorated with cell-surface polymeric fibronectin (poly-FN). Here, we identified the DPPIV-binding sites in FN and examined the effect of binding site peptides on DPPIV/poly-FN adhesion and metastasis. Using proteolytic fragments and maltose-binding protein fusion proteins that together span full-length FN, we found DPPIV-binding sites in type III repeats 13, 14, and 15 (FNIII13, -14, and -15, respectively). DPPIV binding was mediated by the consensus motif T(I/L)TGLX(P/R)G(T/V)X and was confirmed by swapping this motif in FNIII13, -14, and -15 with the corresponding region in FNIII12, which did not bind DPPIV. DPPIV binding was lost in swapped FNIII13, -14, and -15 and gained in swapped FNIII12 ( FNIII12( 14)). Peptides containing the DPPIV-binding domain of FNIII14 blocked DPPIV/poly-FN adhesion and impeded pulmonary metastasis. This study adds to the classes of cell-surface adhesion receptors for FN and will help in the further characterization of the functional implications of the DPPIV/poly-FN adhesion in metastasis and possibly in cell-mediated immunity involving DPPIV-expressing lymphocytes.	Cornell Univ, Canc Biol Labs, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA	Cornell University	Pauli, BU (corresponding author), Cornell Univ, Canc Biol Labs, Dept Mol Med, Coll Vet Med, Ithaca, NY 14853 USA.				NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER; NCI NIH HHS [CA47668] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 1998, INVAS METAST, V18, P35, DOI 10.1159/000024497; Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2019, DOI 10.1093/nar/20.suppl.2019; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Baneyx G, 2001, P NATL ACAD SCI USA, V98, P14464, DOI 10.1073/pnas.251422998; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; Bearz A, 1999, IMMUNOLOGY, V98, P564, DOI 10.1046/j.1365-2567.1999.00917.x; Bozzini S, 1998, J MED VIROL, V54, P44, DOI 10.1002/(SICI)1096-9071(199801)54:1&lt;44::AID-JMV7&gt;3.0.CO;2-P; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Cheng HC, 1999, CLIN EXP METASTAS, V17, P609, DOI 10.1023/A:1006757525190; Cheng HC, 1998, J BIOL CHEM, V273, P24207, DOI 10.1074/jbc.273.37.24207; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Couchman JR, 1999, J CELL SCI, V112, P3415; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; Gines S, 2002, BIOCHEM J, V361, P203, DOI 10.1042/0264-6021:3610203; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; Gorrell MD, 2001, SCAND J IMMUNOL, V54, P249, DOI 10.1046/j.1365-3083.2001.00984.x; Gorrell MD, 2000, ADV EXP MED BIOL, V477, P89; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hamill SJ, 2000, J MOL BIOL, V295, P641, DOI 10.1006/jmbi.1999.3360; HARTELSCHENK S, 1990, HISTOCHEM J, V22, P567, DOI 10.1007/BF01005980; HENIKOFF S, 1995, GENE, V163, P17; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; Ishii T, 2001, P NATL ACAD SCI USA, V98, P12138, DOI 10.1073/pnas.211439098; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JOHNSON RC, 1991, CANCER RES, V51, P394; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; Kato R, 2002, CLIN CANCER RES, V8, P2455; Kim YJ, 1999, CELL IMMUNOL, V192, P13, DOI 10.1006/cimm.1998.1435; KORACH S, 1986, CANCER RES, V46, P3624; Kuhn-Wache K, 2000, ADV EXP MED BIOL, V477, P187; Kurschat P, 2000, CLIN EXP DERMATOL, V25, P482, DOI 10.1046/j.1365-2230.2000.00701.x; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Magnusson MK, 1998, ARTERIOSCL THROM VAS, V18, P1363, DOI 10.1161/01.ATV.18.9.1363; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; Mohri H, 1997, PEPTIDES, V18, P899, DOI 10.1016/S0196-9781(97)00027-2; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; OGATA S, 1989, J BIOL CHEM, V264, P3596; PIAZZA GA, 1989, BIOCHEM J, V262, P327, DOI 10.1042/bj2620327; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; Ruiz P, 1998, CYTOMETRY, V34, P30, DOI 10.1002/(SICI)1097-0320(19980215)34:1<30::AID-CYTO5>3.0.CO;2-I; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Strieter RM, 2002, J CLIN INVEST, V109, P699, DOI 10.1172/JCI200215277; TORIMOTO Y, 1991, J IMMUNOL, V147, P2514; TSUJI E, 1992, BIOCHEMISTRY-US, V31, P11921, DOI 10.1021/bi00162a035; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Woods ML, 2000, EUR J IMMUNOL, V30, P38, DOI 10.1002/1521-4141(200001)30:1<38::AID-IMMU38>3.3.CO;2-2	61	107	111	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24600	24607		10.1074/jbc.M303424200	http://dx.doi.org/10.1074/jbc.M303424200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716896	hybrid			2022-12-25	WOS:000183824800043
J	Couvineau, A; Lacapere, JJ; Tan, YV; Rouyer-Fessard, C; Nicole, P; Laburthe, M				Couvineau, A; Lacapere, JJ; Tan, YV; Rouyer-Fessard, C; Nicole, P; Laburthe, M			Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase - Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; 3RD INTRACELLULAR LOOP; SIGNAL-TRANSDUCTION; CALCITONIN RECEPTOR; FUNCTIONAL EXPRESSION; GLUCAGON RECEPTOR; VPAC(1) RECEPTOR; FAMILY; SECRETIN; VIP	The VPAC1 receptor mediates the action of two neuropeptides, vasoactive intestinal peptide ( VIP) and pituitary adenylate cyclase-activating peptide. It is a class II G protein-coupled receptor-activating adenylyl cyclase (AC). The role of the N-terminal extracellular domain of hVPAC1 receptor for VIP binding is now established (Laburthe, M., Couvineau, A. and Marie, J. C. (2002) Recept. Channels 8, 137-153), but nothing is known regarding the cytoplasmic domains responsible for AC activation. Here, we constructed a large series of mutants by substituting amino acids with alanine in the intracellular loops (IL) 1, 2, and 3 and proximal C-terminal tail of the receptor. The mutation of 40 amino acids followed by expression of mutants in chinese hamster ovary cells showed the following. (i) Mutations IL1 result in the absence of expression of mutants, suggesting a role of this loop in receptor folding. (ii) All residues of IL2 can be mutated without alteration of receptor expression and AC response to VIP. (iii) Mutation of residues IL3 points to the specific role of lysine 322 in the efficacy of the stimulation of AC activity by VIP. This efficacy is reduced by 50% in the K322A mutant. (iv) The proximal C-terminal tail is equipped with another important amino acid since mutation of glutamic acid 394 reduces AC response by 50%. The double mutant K322A/E394A exhibits a drastic reduction of >85% in the efficacy of VIP in stimulating AC activity in membranes and cAMP response in intact cells without alteration of receptor expression or affinity for VIP. These data highlight the role of charged residues in IL3 and the proximal C-terminal tail of hVPAC1 receptor for agonist-induced AC activation. Because these charged residues are absolutely conserved in class II receptors for peptides, which are all mediating AC activation, they may play a general role in coupling of class II receptors with the G(s) protein.	Univ Paris 07, INSERM, U410, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Couvineau, A (corresponding author), Univ Paris 07, INSERM, U410, F-75018 Paris, France.	coucou@bichat.inserm.fr	couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013	couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cao YJ, 2000, FEBS LETT, V469, P142, DOI 10.1016/S0014-5793(00)01269-2; Chan KYY, 2001, ENDOCRINOLOGY, V142, P3926, DOI 10.1210/en.142.9.3926; Cohen DP, 1997, ENDOCRINOLOGY, V138, P1400, DOI 10.1210/en.138.4.1400; Couvineau A, 1996, J BIOL CHEM, V271, P12795, DOI 10.1074/jbc.271.22.12795; COUVINEAU A, 1994, BIOCHEM BIOPH RES CO, V200, P769, DOI 10.1006/bbrc.1994.1517; Cypess AM, 1999, J BIOL CHEM, V274, P19455, DOI 10.1074/jbc.274.27.19455; Du K, 2002, J BIOL CHEM, V277, P37016, DOI 10.1074/jbc.M203049200; FINDLAY DM, 1994, MOL ENDOCRINOL, V8, P1691, DOI 10.1210/me.8.12.1691; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; Greasley PJ, 2001, J BIOL CHEM, V276, P46485, DOI 10.1074/jbc.M105791200; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Huang ZM, 1996, J BIOL CHEM, V271, P33382, DOI 10.1074/jbc.271.52.33382; IidaKlein A, 1997, J BIOL CHEM, V272, P6882, DOI 10.1074/jbc.272.11.6882; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 2002, REGUL PEPTIDES, V108, P165, DOI 10.1016/S0167-0115(02)00099-X; Laburthe M, 1999, CONT ENDOCRINOL, V8, P125; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; Lee NH, 1996, MOL PHARMACOL, V50, P140; Lins L, 2001, J BIOL CHEM, V276, P10153, DOI 10.1074/jbc.M009730200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Lyu RM, 2000, J BIOL CHEM, V275, P36134, DOI 10.1074/jbc.M004612200; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; NABHAN C, 1995, BIOCHEM BIOPH RES CO, V212, P1015, DOI 10.1006/bbrc.1995.2071; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026	47	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24759	24766		10.1074/jbc.M301916200	http://dx.doi.org/10.1074/jbc.M301916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12690118	hybrid			2022-12-25	WOS:000183824800063
J	Denton, CP; Zheng, B; Evans, LA; Xu, SW; Ong, VH; Fisher, I; Lazaridis, K; Abraham, DJ; Black, CM; de Crombrugghe, B				Denton, CP; Zheng, B; Evans, LA; Xu, SW; Ong, VH; Fisher, I; Lazaridis, K; Abraham, DJ; Black, CM; de Crombrugghe, B			Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGF beta) receptor leads to paradoxical activation of TGF beta signaling pathways with fibrosis in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY PULMONARY-HYPERTENSION; DOMINANT-NEGATIVE RECEPTOR; SCLERODERMA FIBROBLASTS; COLLAGEN GENE; GERMLINE MUTATIONS; MESSENGER-RNA; MOUSE; PROTEIN; CELLS; DIFFERENTIATION	To better understand the role of disrupted transforming growth factor beta (TGFbeta) signaling in fibrosis, we have selectively expressed a kinase-deficient human type II TGFbeta receptor (TbetaRIIDeltak) in fibroblasts of transgenic mice, using a lineage-specific expression cassette sub-cloned from the pro-alpha2(I) collagen gene. Surprisingly, despite previous studies that characterized TbetaRIIDeltak as a dominant negative inhibitor of TGFbeta signaling, adult mice expressing this construct demonstrated TGFbeta overactivity and developed dermal and pulmonary fibrosis. Compared with wild type cells, transgenic fibroblasts proliferated more rapidly, produced more extracellular matrix, and showed increased expression of key markers of TGFbeta activation, including plasminogen activator inhibitor-1, connective tissue growth factor, Smad3, Smad4, and Smad7. Smad2/3 phosphorylation was increased in transgenic fibroblasts. Overall, the gene expression profile of explanted transgenic fibroblasts using cDNA microarrays was very similar to that of littermate wild type cells treated with recombinant TGFbeta1. Despite basal up-regulation of TGFbeta signaling pathways, transgenic fibroblasts were relatively refractory to further stimulation with TGFbeta1. Thus, responsiveness of endogenous genes to TGFbeta was reduced, and TGFbeta-regulated promoter-reporter constructs transiently transfected into transgenic fibroblasts showed little activation by recombinant TGFbeta1. Responsiveness was partially restored by overexpression of wild type type II TGFbeta receptors. Activation of MAPK pathways by recombinant TGFbeta1 appeared to be less perturbed than Smad-dependent signaling. Our results show that expression of TbetaRIIDeltak selectively in fibroblasts leads to paradoxical ligand-dependent activation of downstream signaling pathways and causes skin and lung fibrosis. As well as confirming the potential for nonsignaling receptors to regulate TGFbeta activity, these findings support a direct role for perturbed TGFbeta signaling in fibrosis and provide a novel genetically determined animal model of fibrotic disease.	UCL, Ctr Rheumatol, London NW3 2PF, England; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of London; University College London; University of Texas System; UTMD Anderson Cancer Center; University of East Anglia	Denton, CP (corresponding author), UCL, Ctr Rheumatol, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	c.denton@rfc.ucl.ac.uk	Leask, Andrew/G-5217-2015; Ong, Voon/AAB-9836-2020; Lazaridis, Konstantinos/AAB-2761-2022	Lazaridis, Konstantinos/0000-0003-4386-2578	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044888] Funding Source: NIH RePORTER; NIAMS NIH HHS [P50AR44888] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bottinger EP, 1997, KIDNEY INT, V51, P1355, DOI 10.1038/ki.1997.185; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; BRAND T, 1993, J BIOL CHEM, V268, P11500; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Coghlan JG, 2001, CURR OPIN RHEUMATOL, V13, P495, DOI 10.1097/00002281-200111000-00008; Coker RK, 2001, THORAX, V56, P549, DOI 10.1136/thorax.56.7.549; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; de Longh RU, 2001, DEVELOPMENT, V128, P3995; Denton CP, 2001, ARTHRITIS RHEUM-US, V44, P712; Denton CP, 2001, CURR OPIN RHEUMATOL, V13, P505, DOI 10.1097/00002281-200111000-00010; Dong CM, 2002, P NATL ACAD SCI USA, V99, P3908, DOI 10.1073/pnas.062010399; Filvaroff E, 1999, DEVELOPMENT, V126, P4267; Go C, 1999, CANCER RES, V59, P2861; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; Hahm KB, 2000, J CLIN INVEST, V105, P1057, DOI 10.1172/JCI8337; Hahm KB, 2002, ALIMENT PHARM THERAP, V16, P115, DOI 10.1046/j.1365-2036.16.s2.3.x; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; HOGAN B, 1980, MANIPULATING MOUSE E, P497; Ihn H, 2001, ARTHRITIS RHEUM, V44, P474, DOI 10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.3.CO;2-R; Joseph H, 1999, MOL BIOL CELL, V10, P1221, DOI 10.1091/mbc.10.4.1221; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; Kundu SD, 2000, PROSTATE, V43, P118; Kuznetsova N, 1999, J BIOL CHEM, V274, P36083, DOI 10.1074/jbc.274.51.36083; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; Leask A, 2002, ARTHRITIS RHEUM-US, V46, P1857, DOI 10.1002/art.10333; Li YY, 2000, P NATL ACAD SCI USA, V97, P12746, DOI 10.1073/pnas.97.23.12746; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Morrell NW, 2001, CIRCULATION, V104, P790, DOI 10.1161/hc3201.094152; Morse J, 2002, J RHEUMATOL, V29, P2379; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Querfeld C, 1999, J DERMATOL SCI, V21, P13, DOI 10.1016/S0923-1811(99)00008-0; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Rosado E, 2002, BBA-MOL CELL RES, V1590, P1, DOI 10.1016/S0167-4889(02)00194-5; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; SCHMIDT A, 1986, MOL CELL BIOL, V6, P347, DOI 10.1128/MCB.6.2.347; Schramm C, 2003, AM J PHYSIOL-GASTR L, V284, pG525, DOI 10.1152/ajpgi.00286.2002; Serra R, 1997, J CELL BIOL, V139, P541, DOI 10.1083/jcb.139.2.541; Simms RW, 2002, CURR OPIN RHEUMATOL, V14, P717, DOI 10.1097/00002281-200211000-00015; Smith JD, 1999, CIRC RES, V84, P1212, DOI 10.1161/01.RES.84.10.1212; Tew MB, 2002, ARTHRITIS RHEUM-US, V46, P2829, DOI 10.1002/art.10487; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; Yamane K, 2002, ARTHRITIS RHEUM-US, V46, P2421, DOI 10.1002/art.10477; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; Zhang Y, 2002, J IMMUNOL, V168, P3088, DOI 10.4049/jimmunol.168.6.3088; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	61	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25109	25119		10.1074/jbc.M300636200	http://dx.doi.org/10.1074/jbc.M300636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707256	hybrid			2022-12-25	WOS:000183824800105
J	Jemth, P; Smeds, E; Do, AT; Habuchi, H; Kimata, K; Lindahl, U; Kusche-Gullberg, M				Jemth, P; Smeds, E; Do, AT; Habuchi, H; Kimata, K; Lindahl, U; Kusche-Gullberg, M			Oligosaccharide library-based assessment of heparan sulfate 6-O-sulfotransferase substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; HUMAN CDNAS; EXPRESSION; BIOSYNTHESIS; IDENTIFICATION; DIVERSITY; MOUSE	Heparan sulfate mediates numerous complex biological processes. Its action critically depends on the amount and the positions of O-sulfate groups (iduronyl 2-O-sulfates, glucosaminyl 6-O- and 3-O-sulfates) that form binding sites for proteins. The structures and distribution of these protein-binding domains are influenced by the expression and substrate specificity of heparan sulfate biosynthetic enzymes. We describe a general approach to assess substrate specificities of enzymes involved in glycosaminoglycan metabolism, here applied to 6-O- sulfotransferases involved in heparan sulfate biosynthesis. To understand how 2-O-sulfation affects subsequent 6-O- sulfation reactions, the substrate specificity of 6-O- sulfotransferase 3 was probed using substrates from a heparin-based octasaccharide library. Purified H-3-labeled N-sulfated octasaccharides from a library designed to sample 2-O-sulfated motifs were used as sulfate acceptors, 3'-phosphoadenosine 5'-phosphosulfate as sulfate donor, and cell extract from 6-O-sulfotransferase 3-overexpressing 293 cells as enzyme source in the 6-O- sulfotransferase-catalyzed reactions. The first 6-O- sulfate group was preferentially incorporated at the internal glucosamine unit of the octasaccharide substrate. As the reaction proceeded, the octasaccharides acquired three 6-O- sulfate groups. The specificities toward competing octasaccharide substrates, for 6-O-sulfotransferase 2 and 6-O- sulfotransferase 3, were determined using overexpressing 293 cell extracts and purified octasaccharides. Both 6-O- sulfotransferases showed a preference for 2-O-sulfated substrates. The specificity toward substrates with two to three 2-O-sulfate groups was three to five times higher as compared with octasaccharides with no or one 2-O-sulfate group.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Aichi Med Univ, Inst Mol Sci Med, Aichi 4488542, Japan	Uppsala University; Aichi Medical University	Jemth, P (corresponding author), MRC, Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.		Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Crawford BE, 2001, J BIOL CHEM, V276, P21538, DOI 10.1074/jbc.M100880200; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Raman R, 2002, BIOCHEM BIOPH RES CO, V290, P1214, DOI 10.1006/bbrc.2001.6267; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200	34	29	31	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24371	24376		10.1074/jbc.M212155200	http://dx.doi.org/10.1074/jbc.M212155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12702732	hybrid			2022-12-25	WOS:000183824800018
J	Andersen, OM; Yeung, CH; Vorum, H; Wellner, M; Andreassen, TK; Erdmann, B; Mueller, EC; Herz, J; Otto, A; Cooper, TG; Willnow, TE				Andersen, OM; Yeung, CH; Vorum, H; Wellner, M; Andreassen, TK; Erdmann, B; Mueller, EC; Herz, J; Otto, A; Cooper, TG; Willnow, TE			Essential role of the apolipoprotein E receptor-2 in sperm development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA; LIPOPROTEIN RECEPTOR; TYROSINE KINASE; KNOCKOUT MICE; EPITHELIAL-CELLS; PROTEIN IDENTIFICATION; MALE-INFERTILITY; TRANSGENIC MICE; VLDL RECEPTOR	The apolipoprotein (apo) E receptor-2 (apoER2) is a member of the low density lipoprotein receptor gene family and an important regulator of neuronal migration. It acts as a receptor for the signaling factor Reelin and provides positional cues to neurons that migrate to their proper position in the developing brain. Besides brain formation defects, apoER2-deficient mice also exhibit male infertility. The role of the receptor in male reproduction, however, remained unclear. Here we demonstrate that apoER2 is highly expressed in the initial segment of the epididymis, where it affects the functional expression of clusterin and phospholipid hydroperoxide glutathione peroxidase (PHGPx), two proteins required for sperm maturation. Reduced PHGPx expression in apoER2 knockout mice results in the inability of the sperm to regulate the cell volume and in abnormal sperm morphology and immotility. Because insufficient expression of PHGPx is a major cause of infertility in men, these findings not only highlight an important new function for apoER2 that is unrelated to neuronal migration, but they also suggest a possible role for apoER2 in human infertility.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Free Univ Berlin, Fac Med, D-13125 Berlin, Germany; Univ Munster, Inst Reprod Med, D-48149 Munster, Germany; Aarhus Univ, Inst Med Biochem, DK-8000 Aarhus, Denmark; Univ Texas, Dept Mol Genet, SW Med Ctr, Dallas, TX 75390 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; University of Munster; Aarhus University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Willnow, TE (corresponding author), Max Delbruck Ctr Mol Med, Robert Roessle Str 10, D-13125 Berlin, Germany.	willnow@mdc-berlin.de	; Andersen, Olav/N-2777-2017	Willnow, Thomas/0000-0001-9515-7921; Andersen, Olav/0000-0003-4226-3354	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN RJ, 1989, J ANDROL, V10, P214; Aitken RJ, 1998, J REPROD FERTIL, P109; Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Bailey RW, 2002, BIOL REPROD, V66, P1042, DOI 10.1095/biolreprod66.4.1042; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Butler A, 2002, AM J PATHOL, V161, P1061, DOI 10.1016/S0002-9440(10)64267-8; Christova Y, 2002, J ANDROL, V23, P384; Cooke HJ, 2002, NAT REV GENET, V3, P790, DOI 10.1038/nrg911; Cooper TG, 1998, J REPROD FERTIL, P119; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; De Kretser DM, 1999, J CLIN ENDOCR METAB, V84, P3443, DOI 10.1210/jc.84.10.3443; FOLGERO T, 1993, HUM REPROD, V8, P1863, DOI 10.1093/oxfordjournals.humrep.a137950; Foresta C, 2002, BIOL REPROD, V67, P967, DOI 10.1095/biolreprod.102.003822; Garcia CK, 2001, SCIENCE, V292, P1394, DOI 10.1126/science.1060458; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Godeas C, 1997, BIOL REPROD, V57, P1502, DOI 10.1095/biolreprod57.6.1502; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Hermo L, 1999, MOL REPROD DEV, V53, P282, DOI 10.1002/(SICI)1098-2795(199907)53:3&lt;282::AID-MRD4&gt;3.0.CO;2-A; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Huang LS, 1996, P NATL ACAD SCI USA, V93, P10903, DOI 10.1073/pnas.93.20.10903; Imai H, 2001, BIOL REPROD, V64, P674, DOI 10.1095/biolreprod64.2.674; Jones R, 1998, J REPROD FERTIL, P73; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Li YH, 2001, J BIOL CHEM, V276, P18000, DOI 10.1074/jbc.M101589200; LILFORD R, 1994, BMJ-BRIT MED J, V309, P570, DOI 10.1136/bmj.309.6954.570; Morales CR, 1996, BIOL REPROD, V55, P676, DOI 10.1095/biolreprod55.3.676; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; RAO B, 1989, GAMETE RES, V24, P127, DOI 10.1002/mrd.1120240202; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Roveri A, 2001, BIOFACTORS, V14, P213, DOI 10.1002/biof.5520140127; SonnenbergRiethmacher E, 1996, GENE DEV, V10, P1184, DOI 10.1101/gad.10.10.1184; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; TURNER TT, 1995, BIOL REPROD, V52, P1012, DOI 10.1095/biolreprod52.5.1012; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; van Praet O, 2003, MOL REPROD DEV, V64, P129, DOI 10.1002/mrd.10245; Venables JP, 2000, J ENDOCRINOL INVEST, V23, P584, DOI 10.1007/BF03343780; Vorum H, 1998, BBA-PROTEIN STRUCT M, V1386, P121, DOI 10.1016/S0167-4838(98)00089-2; WEINBERG JB, 1995, FERTIL STERIL, V64, P408; Wilund KR, 2002, HUM MOL GENET, V11, P3019, DOI 10.1093/hmg/11.24.3019; Yeung CH, 1999, BIOL REPROD, V61, P1062, DOI 10.1095/biolreprod61.4.1062; Yeung CH, 2000, BIOL REPROD, V63, P612, DOI 10.1095/biolreprod63.2.612; Yeung CH, 2002, BIOL REPROD, V67, P269, DOI 10.1095/biolreprod67.1.269; Yeung CH, 2001, MOL HUM REPROD, V7, P819, DOI 10.1093/molehr/7.9.819; Yeung CH, 1998, J REPROD FERTIL, P137; Zalata AA, 1998, MOL HUM REPROD, V4, P111, DOI 10.1093/molehr/4.2.111	56	82	88	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23989	23995		10.1074/jbc.M302157200	http://dx.doi.org/10.1074/jbc.M302157200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695510	hybrid			2022-12-25	WOS:000183638600099
J	Ghosh, AK; Steele, R; Ray, RB				Ghosh, AK; Steele, R; Ray, RB			Modulation of human luteinizing hormone beta gene transcription by MIP-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC FACTOR-I; SPONDYLOEPIPHYSEAL DYSPLASIA TARDA; GONADOTROPIN-RELEASING-HORMONE; VENTROMEDIAL HYPOTHALAMIC NUCLEUS; ADRENAL HYPOPLASIA CONGENITA; REGULATORY PROTEIN GENE; VIRUS NS5A PROTEIN; TRANSGENIC MICE; PITUITARY HOMEOBOX-1; RECEPTOR SF-1	MIP-2A was recently identified as a MBP-1 interacting cellular protein. We have shown previously that MBP-1 acts as a transcriptional repressor. Functional association between MIP-2A and MBP-1 suggests that MIP-2A can act as a cofactor and relieves MBP-1-mediated transcriptional repression. In this study, we report the tissue-specific expression of MIP-2A and its role in the regulation of gene transcription. RNA dot blot analysis of human multiple tissue expression array suggested that MIP-2A is highly abundant in right cerebellum, pituitary, adrenal, and testis but barely detectable in skeletal muscle. Predominant expression of MIP-2A in pituitary tissue led us to investigate whether MIP-2A can transcriptionally regulate luteinizing hormone beta (LHbeta), a pituitary-specific hormone synthesized and secreted from gonadotropic cells. The LHbeta promoter is regulated by the orphan nuclear receptor SF-1 and homeodomain protein Ptx1. Although each factor enhances the LHbeta promoter, coexpression of both results in a strong synergistic activation. Therefore, we examined whether MIP-2A can modulate SF-1- and Ptx1-mediated transcriptional activation. Our results suggested that MIP-2A expression inhibits SF-1- and Ptx1-mediated transactivation of LHbeta promoter. Subsequent analysis demonstrated that MIP-2A physically interacts with both SF-1 and Ptx1, thereby inhibiting transactivation of the LHbeta promoter. Taken together, our results indicate that MIP-2A preferentially expresses in certain tissues, including the pituitary gland, and negatively regulates the LHbeta gene transcription.	St Louis Univ, Dept Pathol, St Louis, MO 63104 USA; St Louis Univ, Dept Internal Med, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Ray, RB (corresponding author), St Louis Univ, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NATIONAL CANCER INSTITUTE [R29CA052799, R01CA052799] Funding Source: NIH RePORTER; NCI NIH HHS [CA52799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Gecz J, 2000, GENOMICS, V69, P242, DOI 10.1006/geno.2000.6326; Gedeon AK, 1999, NAT GENET, V22, P400, DOI 10.1038/11976; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Ghosh AK, 2003, VIROLOGY, V306, P51, DOI 10.1016/S0042-6822(02)00029-6; Ghosh AK, 2001, MOL CELL BIOL, V21, P655, DOI 10.1128/MCB.21.2.655-662.2001; Halvorson LM, 1996, J BIOL CHEM, V271, P6645, DOI 10.1074/jbc.271.12.6645; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; HATANO O, 1994, DEVELOPMENT, V120, P2787; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1505, DOI 10.1210/me.15.9.1505; Kaiser UB, 2000, MOL ENDOCRINOL, V14, P1235, DOI 10.1210/me.14.8.1235; Keri RA, 1996, J BIOL CHEM, V271, P10782, DOI 10.1074/jbc.271.18.10782; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanctot C, 1999, ENDOCRINOLOGY, V140, P1416, DOI 10.1210/en.140.3.1416; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mumm S, 2001, GENE, V273, P285, DOI 10.1016/S0378-1119(01)00571-6; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; Sadovsky Y, 1998, J SOC GYNECOL INVEST, V5, P6, DOI 10.1016/S1071-5576(97)00096-8; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; Sugawara T, 2000, ENDOCRINOLOGY, V141, P2895, DOI 10.1210/en.141.8.2895; Sugawara T, 2001, ENDOCRINOLOGY, V142, P3570, DOI 10.1210/en.142.8.3570; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Tremblay JJ, 1999, EMBO J, V18, P3431, DOI 10.1093/emboj/18.12.3431; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; Turgeon JL, 1996, MOL ENDOCRINOL, V10, P439, DOI 10.1210/me.10.4.439; Wang ZJ, 2001, P NATL ACAD SCI USA, V98, P7988, DOI 10.1073/pnas.141543298	37	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24033	24038		10.1074/jbc.M211982200	http://dx.doi.org/10.1074/jbc.M211982200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700240	hybrid			2022-12-25	WOS:000183638600105
J	Herring, D; Huang, RQ; Singh, M; Robinson, LC; Dillon, GH; Leidenheimer, NJ				Herring, D; Huang, RQ; Singh, M; Robinson, LC; Dillon, GH; Leidenheimer, NJ			Constitutive GABA(A) receptor endocytosis is dynamin-mediated and dependent on a dileucine AP2 adaptin-binding motif within the beta(2) subunit of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID DOWN-REGULATION; A RECEPTORS; BENZODIAZEPINE RECEPTORS; CYTOPLASMIC DOMAIN; PROTEIN; PHOSPHORYLATION; INTERNALIZATION; SIGNAL; CD4; IDENTIFICATION	Receptor endocytosis is an important mechanism for regulating the synaptic efficacy of neurotransmitters. There is strong evidence that GABA(A) receptor endocytosis is clathrin-dependent; however, this process is not well understood. Here we demonstrate that in HEK 293 cells, endocytosis of GABA(A) receptors composed of either alpha(1)beta(2)gamma(2)L or alpha(1)beta(2) subunits is blocked by the dominant negative dynamin construct K44A. Furthermore, we identify a dileucine AP2 adaptin-binding motif within the receptor beta(2) subunit that is critical for endocytosis. Internalization of GABA(A) receptors lacking this motif is dramatically inhibited, and the receptors appear to accumulate on the cell surface. Patch clamp analysis of receptors lacking the dileucine motif show that there is an increase in the peak amplitude of GABA-gated chloride currents compared with wild-type receptors. Additionally, GABA-gated chloride currents in HEK 293 cells expressing wild-type receptors are increased by introduction of a peptide corresponding to the dileucine motif region of the receptor beta(2) subunit but not by a control peptide containing alanine substitutions for the dileucine motif. In mouse brain cerebral cortical neurons, the dileucine motif peptide increases GABA-gated chloride currents of native GABA(A) receptors. This is the first report to our knowledge that an AP2 adaptin dileucine recognition motif is critical for the endocytosis of ligand-gated ion channels belonging to this superfamily.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Therapeut, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76106 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of North Texas System; University of North Texas Health Science Center	Leidenheimer, NJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Therapeut, 1501 Kings Highway, Shreveport, LA 71130 USA.		Robinson, Lucy C/M-6865-2019	Singh, Meharvan/0000-0002-8072-1769; Robinson, Lucy/0000-0001-6454-040X				ALICKE B, 1995, J NEUROCHEM, V65, P2808; Brunig I, 2001, EUR J NEUROSCI, V13, P1320, DOI 10.1046/j.0953-816x.2001.01506.x; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Cinar H, 2001, BIOCHEMISTRY-US, V40, P14030, DOI 10.1021/bi011025t; Connolly CN, 1999, MOL CELL NEUROSCI, V13, P259, DOI 10.1006/mcne.1999.0746; Connolly CN, 1999, J BIOL CHEM, V274, P36565, DOI 10.1074/jbc.274.51.36565; COVERA S, 1994, J CELL BIOL, V126, P979; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Fabbri M, 1999, EMBO J, V18, P4915, DOI 10.1093/emboj/18.18.4915; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; HARVEY RJ, 1994, J NEUROCHEM, V62, P10; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Huang RQ, 1998, J PHARMACOL EXP THER, V286, P243; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kittler JT, 2000, J NEUROSCI, V20, P7972; Le Borgne R, 1998, CURR OPIN CELL BIOL, V10, P499; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; Santos MS, 2001, J NEUROCHEM, V78, P1104, DOI 10.1046/j.1471-4159.2001.00494.x; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Singh M, 2000, J NEUROSCI, V20, P1694; TEHRANI MHJ, 1993, J NEUROCHEM, V60, P1755; TEHRANI MHJ, 1991, J NEUROCHEM, V57, P1307, DOI 10.1111/j.1471-4159.1991.tb08295.x; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Werbonat Y, 2000, J BIOL CHEM, V275, P21969, DOI 10.1074/jbc.M001736200; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x	31	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24046	24052		10.1074/jbc.M301420200	http://dx.doi.org/10.1074/jbc.M301420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707262	hybrid			2022-12-25	WOS:000183638600107
J	Johnson, DE; Richardson, CC				Johnson, DE; Richardson, CC			A covalent linkage between the gene 5 DNA polymerase of bacteriophage T7 and Escherichia coli thioredoxin, the processivity factor - Fate of thioredoxin during DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION IN-VITRO; DEOXYRIBONUCLEIC-ACID POLYMERASE; EXONUCLEASE ACTIVITIES; CONFERS PROCESSIVITY; T7-DNA POLYMERASE; T7; PROTEIN; MECHANISM; STIMULATION; FORK	Gene 5 protein (gp5) of bacteriophage T7 is a non-processive DNA polymerase, which acquires high processivity by binding to Escherichia coli thioredoxin. The gene 5 protein-thioredoxin complex (gp5/trx) polymerizes thousands of nucleotides before dissociating from a primer-template. We have engineered a disulfide linkage between the gene 5 protein and thioredoxin within the binding surface of the two proteins. The polymerase activity of the covalently linked complex (gp5-S-S-trx) is similar to that of gp5/trx on poly(dA)/oligo(dT). However, gp5-S-S-trx has only one third the polymerase activity of gp5/trx on single-stranded M13 DNA. gp5-S-Strx has difficulty polymerizing nucleotides through sites of secondary structure on M13 DNA and stalls at these sites, resulting in lower processivity. However, gp5-S-Strx has an identical processivity and rate of elongation when E. coli single-stranded DNA-binding protein (SSB protein) is used to remove secondary structure from M13 DNA. Upon completing synthesis on a DNA template lacking secondary structure, both complexes recycle intact, without dissociation of the processivity factor, to initiate synthesis on a new DNA template. However, a complex stalled at secondary structure becomes unstable, and both subunits dissociate from each other as the polymerase prematurely releases from M13 DNA.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	ccr@hms.harvard.edu			NIGMS NIH HHS [GM*54397] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER S, 1979, J BIOL CHEM, V254, P1605; ALDER S, 1983, J BIOL CHEM, V258, P6956; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; Canceill D, 1999, J BIOL CHEM, V274, P27481, DOI 10.1074/jbc.274.39.27481; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; GRIPPO P, 1971, J BIOL CHEM, V246, P6867; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HORI K, 1979, J BIOL CHEM, V254, P1598; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELMAN Z, 1994, CURR OPIN GENET DEV, V4, P185, DOI 10.1016/S0959-437X(05)80044-9; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; KIM YT, 1992, J BIOL CHEM, V267, P15032; KORNBERG A, 1992, DNA REPLICATION, P494; Kumar JK, 2001, J BIOL CHEM, V276, P46151, DOI 10.1074/jbc.M106319200; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MODRICH P, 1975, J BIOL CHEM, V250, P5515; MYERS TW, 1988, J BIOL CHEM, V263, P17006; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; ONRUST R, 1991, J BIOL CHEM, V266, P21681; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599	44	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23762	23772		10.1074/jbc.M301366200	http://dx.doi.org/10.1074/jbc.M301366200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692131	hybrid			2022-12-25	WOS:000183638600071
J	Lloyd-Evans, E; Pelled, D; Riebeling, C; Bodennec, J; de-Morgan, A; Waller, H; Schiffmann, R; Futerman, AH				Lloyd-Evans, E; Pelled, D; Riebeling, C; Bodennec, J; de-Morgan, A; Waller, H; Schiffmann, R; Futerman, AH			Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED SARCOPLASMIC-RETICULUM; INDUCED CA-2+ RELEASE; QUANTAL CA2+ RELEASE; RYANODINE RECEPTOR; GAUCHER-DISEASE; SPHINGOSINE 1-PHOSPHATE; PSYCHOSINE; CHANNEL; GM1; ACTIVATION	We recently demonstrated that elevation of intracellular glucosylceramide (GlcCer) levels results in increased functional Ca2+ stores in cultured neurons, and suggested that this may be due to modulation of ryanodine receptors (RyaRs) by GlcCer (Korkotian, E., Schwarz, A., Pelled, D., Schwarzmann, G., Segal, M. and Futerman, A. H. (1999) J. Biol. Chem. 274, 21673-21678). We now systematically examine the effects of exogenously added GlcCer, other glycosphingolipids (GSLs) and their lyso-derivatives on Ca2+ release from rat brain microsomes. GlcCer had no direct effect on Ca2+ release, but rather augmented agonist-stimulated Ca2+ release via RyaRs, through a mechanism that may involve the redox sensor of the RyaR, but had no effect on Ca2+ release via inositol 1,4,5-trisphosphate receptors. Other GSLs and sphingolipids, including galactosylceramide, lactosylceramide, ceramide, sphingomyelin, sphingosine 1-phosphate, sphinganine 1-phosphate, and sphingosylphosphorylcholine had no effect on Ca2+ mobilization from rat brain microsomes, but both galactosylsphingosine ( psychosine) and glucosylsphingosine stimulated Ca2+ release, although only galactosylsphingosine mediated Ca2+ release via the RyaR. Finally, we demonstrated that GlcCer levels were similar to10-fold higher in microsomes prepared from the temporal lobe of a type 2 Gaucher disease patient compared with a control, and Ca2+ release via the RyaR was significantly elevated, which may be of relevance for explaining the pathophysiology of neuronopathic forms of Gaucher disease.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Riebeling, Christian/0000-0003-1991-0170; Futerman, Anthony/0000-0003-0013-0115	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002984] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ardail D, 2003, BIOCHEM J, V371, P1013, DOI 10.1042/BJ20021834; Baker ML, 2002, P NATL ACAD SCI USA, V99, P12155, DOI 10.1073/pnas.182058899; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Betto R, 1997, BIOCHEM J, V322, P327, DOI 10.1042/bj3220327; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Bodennec J, 2002, FASEB J, V16, P1814, DOI 10.1096/fj.02-0149fje; Bodennec J, 2003, J LIPID RES, V44, P218, DOI 10.1194/jlr.D200026-JLR200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Catalan RE, 1997, BIOCHEM BIOPH RES CO, V238, P347, DOI 10.1006/bbrc.1997.7302; Chini EN, 1996, AM J PHYSIOL-CELL PH, V270, pC530, DOI 10.1152/ajpcell.1996.270.2.C530; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; CONRADI NG, 1984, ACTA NEUROPATHOL, V65, P99, DOI 10.1007/BF00690463; DETTBARN C, 1995, BRAIN RES, V669, P79, DOI 10.1016/0006-8993(94)01234-9; DETTBARN C, 1994, MOL PHARMACOL, V46, P502; Dettbarn C, 1997, MOL PHARMACOL, V52, P1124, DOI 10.1124/mol.52.6.1124; Erikson A, 1997, BAILLIERE CLIN HAEM, V10, P711, DOI 10.1016/S0950-3536(97)80035-2; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; Gravel R. A., 2001, METABOLIC MOL BASES, V3, P3827; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Heringdorf DMZ, 2002, BBA-MOL CELL BIOL L, V1582, P178, DOI 10.1016/S1388-1981(02)00154-3; Himmel HM, 1998, MOL PHARMACOL, V53, P862; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; Ledeen RW, 2002, NEUROCHEM RES, V27, P637, DOI 10.1023/A:1020224016830; Ledeen RW, 1998, ANN NY ACAD SCI, V845, P161, DOI 10.1111/j.1749-6632.1998.tb09669.x; LIU RT, 1995, BIOCHEM BIOPH RES CO, V214, P676, DOI 10.1006/bbrc.1995.2339; Melamed-Book N, 1999, P NATL ACAD SCI USA, V96, P15217, DOI 10.1073/pnas.96.26.15217; Meszaros LG, 1998, CELL CALCIUM, V23, P43, DOI 10.1016/S0143-4160(98)90073-2; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; NILSSON O, 1985, CLIN GENET, V27, P443; Oba T, 2002, AM J PHYSIOL-CELL PH, V282, pC684, DOI 10.1152/ajpcell.01273.2000; OKAJIMA F, 1995, J BIOL CHEM, V270, P26332, DOI 10.1074/jbc.270.44.26332; PADUA RA, 1991, BRAIN RES, V542, P135, DOI 10.1016/0006-8993(91)91007-N; PALADE P, 1987, J BIOL CHEM, V262, P6142; PALADE P, 1987, J BIOL CHEM, V262, P6149; PALADE P, 1989, J BIOENERG BIOMEMBR, V21, P295, DOI 10.1007/BF00812074; PALADE P, 1987, J BIOL CHEM, V262, P6135; PALADE P, 1983, J BIOL CHEM, V258, P8098; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Pelled D, 2000, J INHERIT METAB DIS, V23, P175, DOI 10.1023/A:1005622001239; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; Sakano S, 1996, J BIOL CHEM, V271, P11148, DOI 10.1074/jbc.271.19.11148; Sharma C, 2000, CHEM PHYS LIPIDS, V104, P1, DOI 10.1016/S0009-3084(99)00106-1; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; Suzuki K, 1998, NEUROCHEM RES, V23, P251, DOI 10.1023/A:1022436928925; SVENNERHOLM L, 1980, J LIPID RES, V21, P53; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; Vellodi A, 2001, J INHERIT METAB DIS, V24, P319, DOI 10.1023/A:1010514614570; Venkataraman K, 2001, BBA-MOL CELL BIOL L, V1530, P219, DOI 10.1016/S1388-1981(01)00085-3; VOLPE P, 1983, J BIOL CHEM, V258, P2434; Wang YL, 1999, FEBS LETT, V457, P144, DOI 10.1016/S0014-5793(99)01024-8; Wang YL, 1999, GLYCOCONJUGATE J, V16, P781, DOI 10.1023/A:1007123714104; Wong PW, 1997, MOL PHARMACOL, V51, P693, DOI 10.1124/mol.51.5.693; Xie X, 2002, J NEUROCHEM, V81, P1185, DOI 10.1046/j.1471-4159.2002.00917.x; Young KW, 2001, SEMIN CELL DEV BIOL, V12, P19, DOI 10.1006/scdb.2000.0213; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069; Zucchi R, 1997, PHARMACOL REV, V49, P1	65	120	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23594	23599		10.1074/jbc.M300212200	http://dx.doi.org/10.1074/jbc.M300212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12709427	hybrid			2022-12-25	WOS:000183638600049
J	Fries, DM; Paxinou, E; Themistocleous, M; Swanberg, E; Griendling, KK; Salvemini, D; Slot, JW; Heijnen, HFG; Hazen, SL; Ischiropoulos, H				Fries, DM; Paxinou, E; Themistocleous, M; Swanberg, E; Griendling, KK; Salvemini, D; Slot, JW; Heijnen, HFG; Hazen, SL; Ischiropoulos, H			Expression of inducible nitric-oxide synthase and intracellular protein tyrosine nitration in vascular smooth muscle cells - Role of reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; NECROSIS-FACTOR-ALPHA; IN-VIVO; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; EOSINOPHIL PEROXIDASE; OXIDATIVE DAMAGE; ANGIOTENSIN-II; MYELOPEROXIDASE; PEROXYNITRITE	A significant increase in the induction of inducible nitric-oxide synthase ( iNOS) protein expression and in the levels of nitrite plus nitrate was observed in rat aortic smooth muscle cells (RASMCs) stably transfected with catalase (RASMC-2C2) as compared with empty vector-transfected RASMC-V4 cells after exposure to cytokines and lipopolysaccharide. The increased expression of iNOS protein in the RASMC-2C2 cells was associated with a significant activation of nuclear transcription factor kappaB, one of the transcriptional regulators of iNOS expression. The induction of iNOS was also accompanied by increased protein tyrosine nitration in both cell types as revealed by immunocytochemical staining and high pressure liquid chromatography with on-line electrospray ionization tandem mass spectrometry. Nitrotyrosine formation was inhibited by 1400W, an iNOS inhibitor, by 4-(2-aminoethyl) benzenesulfonyl fluoride, an inhibitor of NADPH oxidase, and by the superoxide dismutase mimetic M40403, but not by the peroxidase inhibitor 4- aminobenzoic hydrazide. Electron microscopy using affinity-purified anti-nitrotyrosine antibodies revealed labeling at the cytosolic side of the rough endoplasmic reticulum membranes, in the nucleus, occasionally in mitochondria, and consistently within the fibrillar layer underneath the plasma membrane. Collectively, the data in this model system indicate that hydrogen peroxide, by inhibiting the activation of nuclear transcription factor kappaB, prevents iNOS expression, whereas superoxide contributes in a precise pattern of intracellular protein tyrosine nitration.	Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30322 USA; MetaPhore Pharmaceut Inc, St Louis, MO 63114 USA; Univ Utrecht, Dept Cell Biol, Utrecht, Netherlands; Univ Med Ctr, Dept Hematol, Utrecht, Netherlands; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Minist Hlth, Sao Paulo, Brazil	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Emory University; Utrecht University; Utrecht University; Utrecht University Medical Center; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, 416D Abramson Res Ctr,34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Hazen, Stanley L/ABD-5845-2021	Griendling, Kathy/0000-0002-9456-8582	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL054926] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54926, HL62526, HL5800] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Aulak KS, 2001, P NATL ACAD SCI USA, V98, P12056, DOI 10.1073/pnas.221269198; Baldus S, 2001, J CLIN INVEST, V108, P1759; Bolan EA, 2000, J NEUROSCI, V20, P4798; Boota A, 1996, AM J PHYSIOL-LUNG C, V271, pL932, DOI 10.1152/ajplung.1996.271.6.L932; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; De Keulenaer GW, 1998, BIOCHEM J, V329, P653; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Diatchuk V, 1997, J BIOL CHEM, V272, P13292, DOI 10.1074/jbc.272.20.13292; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Gole MD, 2000, AM J PHYSIOL-LUNG C, V278, pL961, DOI 10.1152/ajplung.2000.278.5.L961; GOLSTEIN S, 2000, J BIOL CHEM, V275, P3031; Goodwin DC, 1998, J BIOL CHEM, V273, P8903, DOI 10.1074/jbc.273.15.8903; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Griscavage J M, 1995, Adv Pharmacol, V34, P215; Haqqani AS, 2002, J BIOL CHEM, V277, P3614, DOI 10.1074/jbc.M105730200; Hecker M, 1996, FEBS LETT, V380, P224, DOI 10.1016/0014-5793(96)00046-4; Hurst JK, 2002, J CLIN INVEST, V109, P1287, DOI 10.1172/JCI200215816; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Marcondes S, 2001, P NATL ACAD SCI USA, V98, P7146, DOI 10.1073/pnas.141222598; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; RAPOSO G, 1997, WEIRS HDB EXPT IMMUN, P1; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Teng XW, 2002, AM J PHYSIOL-CELL PH, V282, pC144, DOI 10.1152/ajpcell.2002.282.1.C144; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; Zhang HF, 2001, ARTERIOSCL THROM VAS, V21, P529, DOI 10.1161/01.ATV.21.4.529	52	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22901	22907		10.1074/jbc.M210806200	http://dx.doi.org/10.1074/jbc.M210806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690103	hybrid			2022-12-25	WOS:000183503900096
J	Petersen-Mahrt, SK; Neuberger, MS				Petersen-Mahrt, SK; Neuberger, MS			In vitro deamination of cytosine to uracil in single-stranded DNA by apolipoprotein B editing complex catalytic subunit 1 (APOBEC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE DEAMINASE; MESSENGER-RNA; ESCHERICHIA-COLI; AID; HYPERMUTATION; PROTEIN; ENZYME; CELLS; FORM	Apolipoprotein B-editing complex catalytic subunit 1 (APOBEC1) is the catalytic component of an RNA-editing complex that deaminates C-6666 --> U in apolipoprotein B RNA in gastrointestinal tissue, thereby generating a premature stop codon. Whereas RNA is the physiological substrate of APOBEC1, recent experiments have strongly indicated that, when expressed in bacteria, APOBEC1 and some of its homologues can deaminate cytosine in DNA. Indeed, genetic evidence demonstrates that the physiological function of activation-induced deaminase, a B lymphocyte-specific APOBEC1 homologue, is to perform targeted deamination of cytosine within the immunoglobulin locus, thereby triggering antibody gene diversification. However, biochemical evidence of in vitro DNA deamination by members of the APOBEC family is still needed. Here, we show that deamination of cytosine to uracil in DNA can be achieved in vitro using partially purified APOBEC1 from extracts of transformed Escherichia coli. Thus, APOBEC1 can deaminate cytosine in both RNA and DNA. Strikingly, its activity on DNA is specific for single-stranded DNA and exhibits dependence on local sequence context.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Petersen-Mahrt, SK (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COHEN RM, 1971, J BIOL CHEM, V246, P7561; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Kornberg A., 1980, DNA REPLICATION; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483	18	103	106	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19583	19586		10.1074/jbc.C300114200	http://dx.doi.org/10.1074/jbc.C300114200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12697753	hybrid			2022-12-25	WOS:000183078000003
J	Franchitto, A; Pichierri, P; Piergentili, R; Crescenzi, M; Bignami, M; Palitti, F				Franchitto, A; Pichierri, P; Piergentili, R; Crescenzi, M; Bignami, M; Palitti, F			The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase	ONCOGENE			English	Article						MSH2; mismatch repair; cell cycle arrest; DSB repair	STRAND BREAK REPAIR; SACCHAROMYCES-CEREVISIAE MSH2; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; VERTEBRATE CELLS; GENETIC-RECOMBINATION; NUCLEAR FOCI; HISTONE H2AX; IN-VITRO; S-PHASE	In yeast, MSH2 plays an important role in mismatch repair (MMR) and recombination, whereas the function of the mammalian MSH2 protein in recombinational repair is not completely established. We examined the cellular responses of MSH2-deficient mouse cells to X-rays to clarify the role of MSH2 in recombinational repair. Cell survival, checkpoint functions and relocalization of the recombination-related proteins MRE11 and RAD51 were analysed in embryonic fibroblasts derived from MSH2(+/+) and MSH2(-/-) mice, and in MSH2-proficient and deficient mouse colorectal carcinoma cells. Loss of MSH2 function was found to be associated with reduction in cell survival following radiation, absence of either MRE11 or RAD51 relocalization and a higher level of X-ray-induced chromosomal damage specifically in G2-phase cells. Finally, MSH2(-/-) cells showed an inefficient early G2/M checkpoint, being arrested only transiently after irradiation before progressing into mitosis. Consistent with the premature release from the G2-phase arrest, activation of CHK1 was transient and CHK2 was not phosphorylated in synchronized MSH2-null cells. Our data suggest that an active MSH2 is required for a correct response to ionizing radiation-induced DNA damage in the G2 phase of the cell cycle, possibly connecting DSB repair to checkpoint signalling.	Univ Tuscia, DABAC, Lab Citogenet Mol & Mutagenesi, I-01100 Viterbo, Italy; Ist Super Sanita, Tossicol Comparata & Ecotossicol Lab, I-00161 Rome, Italy	Tuscia University; Istituto Superiore di Sanita (ISS)	Palitti, F (corresponding author), Univ Tuscia, DABAC, Lab Citogenet Mol & Mutagenesi, Via S Camillo Lellis, I-01100 Viterbo, Italy.	palitti@unitus.it	Pichierri, Pietro/AAA-5476-2021; Crescenzi, Marco/J-3603-2018; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Crescenzi, Marco/0000-0003-0156-1494; Franchitto, Annapaola/0000-0003-4232-4727				Aebi S, 1996, CANCER RES, V56, P3087; ALANI E, 1994, GENETICS, V137, P19; Anthoney DA, 1996, CANCER RES, V56, P1374; Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Berry SE, 2001, SEMIN RADIAT ONCOL, V11, P300, DOI 10.1053/S1053-4296(01)80067-9; Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO;2-K; BRADLEY MO, 1979, NUCLEIC ACIDS RES, V7, P793, DOI 10.1093/nar/7.3.793; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen WL, 1999, GENETICS, V151, P1299; Chen WL, 1998, MOL CELL BIOL, V18, P6525, DOI 10.1128/MCB.18.11.6525; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; Colussi C, 2002, CURR BIOL, V12, P912, DOI 10.1016/S0960-9822(02)00863-1; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Datta A, 1996, MOL CELL BIOL, V16, P1085; Davis TW, 1998, CANCER RES, V58, P767; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Evans E, 2000, MOL CELL, V5, P789, DOI 10.1016/S1097-2765(00)80319-6; Fiumicino S, 2000, INT J CANCER, V85, P590, DOI 10.1002/(SICI)1097-0215(20000215)85:4<590::AID-IJC23>3.0.CO;2-O; Franchitto A, 1998, MUTAGENESIS, V13, P499, DOI 10.1093/mutage/13.5.499; Fritzell JA, 1997, CANCER RES, V57, P5143; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Palitti F, 1999, INT J RADIAT BIOL, V75, P621, DOI 10.1080/095530099140267; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVAGE JRK, 1976, J MED GENET, V13, P103, DOI 10.1136/jmg.13.2.103; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XXS, 2001, CANCER RES, V61, P3775; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yan T, 2001, CANCER RES, V61, P8290; Zeng M, 2000, CANCER RES, V60, P4889; Zhang H, 2000, CARCINOGENESIS, V21, P1639, DOI 10.1093/carcin/21.9.1639; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	64	79	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2110	2120		10.1038/sj.onc.1206254	http://dx.doi.org/10.1038/sj.onc.1206254			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687013				2022-12-25	WOS:000182066900005
J	Wu, B; Iwakiri, R; Ootani, A; Fujise, T; Tsunada, S; Fujimoto, K				Wu, B; Iwakiri, R; Ootani, A; Fujise, T; Tsunada, S; Fujimoto, K			Platelet activating factor promotes mucosal apoptosis via FasL mediating caspase-9 active pathway in rat small intestine after ischemia-reperfusion	FASEB JOURNAL			English	Article						platelet activating factor acetylhydrolase; platelet endothelial cell adhesion; molecule-1; interleukin-6; Bid; cytochrome c	ENDOTHELIAL CELL-INTERACTIONS; INDUCED LEUKOCYTE ADHERENCE; EPITHELIAL-CELLS; FACTOR RECEPTOR; CYTOCHROME-C; P-SELECTIN; INJURY; PECAM-1; INTERLEUKIN-10; PAF	Platelet activating factor (PAF) is a proinflammatory lipid mediator for inflammatory response. It is unclear whether PAF is involved in the very complex process of ischemia-reperfusion (I/R) induced mucosal apoptosis in small intestine. Intestinal I/R was induced in rats intestine by 60 min occlusion of the superior mesenteric artery, followed by a 60 min reperfusion. I/R induced mucosal apoptosis and PAF activity but inhibited PAF-acetylhydrolase activity. Increases in interleukin-6 (IL-6) and decreases in IL-10 were observed. Western blot analysis showed that I/R induced expressions of platelet endothelial cell adhesion molecule-1 (PECAM-1) and Fas and Fas ligand (FasL) proteins, cleaved Bid, and enhanced the release of cytochrome c from mitochondria to activate caspase-9. Pretreatment of PAF antagonist BN-52021 attenuated these changes, except the increase in Fas. The results showed that I/R-inhibited mucosal PAF-acetylhydrolase activity resulted in an increase of activated PAF. The activated PAF increased the mucosal IL-6 and PECAM-1, enhanced the expression of FasL but not Fas, and led to the cleavage of Bid and the release of cytochrome c from mitochondria to activate caspase-9. This finding suggests that PAF promotes mucosal apoptosis after I/R in the rat small intestine partly through FasL mediating caspase-9 active pathway.	Saga Med Sch, Dept Internal Med & Gastrointestinal Endoscopy, Div Gastroenterol, Saga 8498501, Japan	Saga University	Fujimoto, K (corresponding author), Saga Med Sch, Dept Internal Med & Gastrointestinal Endoscopy, Div Gastroenterol, 5-1-1 Nabeshima, Saga 8498501, Japan.	fujimoto@post.saga-med.ac.jp						Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berdyshev EV, 2001, FASEB J, V15, P2171, DOI 10.1096/fj.01-0181com; Berman ME, 1996, J IMMUNOL, V156, P1515; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Evans PC, 2001, TRANSPLANTATION, V71, P457, DOI 10.1097/00007890-200102150-00020; FERRARIS L, 1993, GUT, V34, P665, DOI 10.1136/gut.34.5.665; Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kogaki S, 1999, CARDIOVASC RES, V43, P968, DOI 10.1016/S0008-6363(99)00140-6; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; Murohisa G, 2002, LIVER, V22, P394, DOI 10.1034/j.1600-0676.2002.01552.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NISHIYAMA R, 1993, TRANSPLANTATION, V55, P1261, DOI 10.1097/00007890-199306000-00010; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Panes J, 1999, HEPATOLOGY, V30, P445, DOI 10.1002/hep.510300214; Panes J, 1998, GASTROENTEROLOGY, V114, P1066, DOI 10.1016/S0016-5085(98)70328-2; Parker MA, 2002, J NEUROSCI RES, V69, P39, DOI 10.1002/jnr.10235; Pender SLF, 1998, GASTROENTEROLOGY, V115, P573, DOI 10.1016/S0016-5085(98)70136-2; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Salter JW, 2001, AM J PHYSIOL-GASTR L, V281, pG1432, DOI 10.1152/ajpgi.2001.281.6.G1432; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; Singbartl K, 2001, FASEB J, V15, P2337, DOI 10.1096/fj.01-0199com; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; Stordeur P, 1998, Int Rev Immunol, V16, P501, DOI 10.3109/08830189809043006; SUEMATSU M, 1993, AM J PHYSIOL, V264, pH881, DOI 10.1152/ajpheart.1993.264.3.H881; Sun Z, 2001, SCAND J GASTROENTERO, V36, P55, DOI 10.1080/00365520150218066; Takahashi H, 2001, NAT MED, V7, P26, DOI 10.1038/83306; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; THOMPSON CB, 1995, SCIENCE, V267, P1455; Turegun M, 1999, PLAST RECONSTR SURG, V104, P1033; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu B, 2002, FREE RADICAL BIO MED, V33, P649, DOI 10.1016/S0891-5849(02)00917-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZIMMERMAN BJ, 1994, AM J PHYSIOL, V266, pH847, DOI 10.1152/ajpheart.1994.266.3.H847; Zingarelli B, 2001, GUT, V48, P610, DOI 10.1136/gut.48.5.610	47	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1156	+		10.1096/fj.02-0499fje	http://dx.doi.org/10.1096/fj.02-0499fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709415				2022-12-25	WOS:000182580100022
J	Boyanovsky, B; Karakashian, A; King, K; Giltiay, N; Nikolova-Karakashian, M				Boyanovsky, B; Karakashian, A; King, K; Giltiay, N; Nikolova-Karakashian, M			Uptake and metabolism of low density lipoproteins with elevated ceramide content by human microvascular endothelial cells - Implications for the regulation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TUMOR-NECROSIS-FACTOR; RECEPTOR-MEDIATED ENDOCYTOSIS; CYTOCHROME-P450 2C11 CYP2C11; SECRETORY SPHINGOMYELINASE; ATHEROGENIC LIPOPROTEINS; SPHINGOSINE KINASE; IN-VIVO; SPHINGOLIPID BIOSYNTHESIS; RAT HEPATOCYTES	Ceramide is a bioactive molecule involved in cellular responses to stress and inflammation. The major pathway for ceramide accumulation is via agonist-induced activation of cellular sphingomyelinases. It has also been shown that the ceramide level in circulating low density lipoprotein (LDL) increases during systemic inflammation, hence it is of importance to understand whether LDL-derived ceramide also contributes to the cellular ceramide homeostasis and affects cell functions. This article provides evidence of uptake of ceramide-enriched LDL by human microvascular endothelial cells in a receptor-mediated fashion. This uptake can be competed by native LDL, indicating that the LDL-binding receptor may be involved. Following uptake, part of the LDL-derived ceramide is converted to sphingosine, but more importantly, part of it accumulates inside the cells ( approximately 1.44 nmol/mg of cell protein). This accumulation of ceramide correlates with an increased incidence of apoptosis. The addition of tumor necrosis factor-alpha further enhances the accumulation of LDL-derived ceramide and the rate of apoptosis. In contrast, inhibitors of receptor-mediated endocytosis block both, the accumulation of LDL-derived ceramide and the concurrent increase in apoptosis. We also show that LDL-delivered ceramide is a more efficient inducer of apoptosis as compared with ethanol-delivered ceramide, the same apoptotic effect being achieved by substantially smaller increases in intracellular ceramide. Taken together, the presented data indicate that increases in lipoprotein ceramide concentration may result in changes in the bioactive properties of circulating lipoproteins such as the enhanced ability to induce apoptosis in the microvascular endothelium.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky	Nikolova-Karakashian, M (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, MS 508, Lexington, KY 40536 USA.		Giltiay, Natalia V./H-8655-2019; Giltiay, Natalia/AAH-2130-2019; Boyanovsky, Boris/AAQ-5194-2021	Giltiay, Natalia/0000-0001-7284-514X; 	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K12DA014040] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 15592] Funding Source: Medline; NIDA NIH HHS [K12 DA14040-03] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Butler P J, 1972, Methods Enzymol, V25, P191, DOI 10.1016/S0076-6879(72)25016-9; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; de Boer OJ, 2000, J PATHOL, V190, P237, DOI 10.1002/(SICI)1096-9896(200002)190:3&lt;237::AID-PATH541&gt;3.0.CO;2-N; Descamps L, 1997, J NEUROIMMUNOL, V74, P173, DOI 10.1016/S0165-5728(96)00226-3; FADOK VA, 1992, J IMMUNOL, V148, P2207; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; LIBBY P, 1985, J CELL PHYSIOL, V124, P1, DOI 10.1002/jcp.1041240102; LIGHTLE S, 2003, IN PRESS ARCH BIOCH; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Memon RA, 1998, ARTERIOSCL THROM VAS, V18, P1257, DOI 10.1161/01.ATV.18.8.1257; MERRILL AH, 1995, J BIOL CHEM, V270, P13834, DOI 10.1074/jbc.270.23.13834; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Oorni K, 1998, J BIOL CHEM, V273, P29127, DOI 10.1074/jbc.273.44.29127; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SCOTTBURDEN T, 1989, J BIOL CHEM, V264, P12582; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBERG D, 1987, CIRCULATION, V76, P508, DOI 10.1161/01.CIR.76.3.508; Subbaiah PV, 1999, J BIOL CHEM, V274, P36409, DOI 10.1074/jbc.274.51.36409; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TABAS I, 1993, J BIOL CHEM, V268, P20419; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; Wong ML, 2000, P NATL ACAD SCI USA, V97, P8681, DOI 10.1073/pnas.150098097; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; XU XX, 1991, J BIOL CHEM, V266, P24849	44	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26992	26999		10.1074/jbc.M301536200	http://dx.doi.org/10.1074/jbc.M301536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12721293	hybrid			2022-12-25	WOS:000184155700090
J	Most, P; Remppis, A; Weber, C; Bernotat, J; Ehlermann, P; Pleger, ST; Kirsch, W; Weber, M; Uttenweiler, D; Smith, GL; Katus, HA; Fink, RHA				Most, P; Remppis, A; Weber, C; Bernotat, J; Ehlermann, P; Pleger, ST; Kirsch, W; Weber, M; Uttenweiler, D; Smith, GL; Katus, HA; Fink, RHA			The C terminus (amino acids 75-94) and the linker region (amino acids 42-54) of the Ca2+-binding protein S100A1 differentially enhance sarcoplasmic Ca2+ release in murine skinned skeletal muscle fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL RYANODINE RECEPTOR; ALPHA-ALPHA PROTEIN; CALCIUM-BINDING; STRIATED MUSCLES; IONS BINDING; RAT; RETICULUM; RABBIT; CONTRACTION; S100-ALPHA	S100A1, a Ca2+-binding protein of the EF-hand type, is most highly expressed in striated muscle and has previously been shown to interact with the skeletal muscle sarcoplasmic reticulum (SR) Ca2+ release channel/ryanodine receptor (RyR1) isoform. However, it was unclear whether S100A1/RyR1 interaction could modulate SR Ca2+ handling and contractile properties in skeletal muscle fibers. Since S100A1 protein is differentially expressed in fast- and slow-twitch skeletal muscle, we used saponin-skinned murine Musculus extensor digitorum longus (EDL) and Musculus soleus (Soleus) fibers to assess the impact of S100A1 protein on SR Ca2+ release and isometric twitch force in functionally intact permeabilized muscle fibers. S100A1 equally enhanced caffeine-induced SR Ca2+ release and Ca2+-induced isometric force transients in both muscle preparations in a dose-dependent manner. Introducing a synthetic S100A1 peptide model (devoid of EF-hand Ca2+-binding sites) allowed identification of the S100A1 C terminus (amino acids 75-94) and hinge region (amino acids 42 54) to differentially enhance SR Ca2+ release with a nearly 3-fold higher activity of the C terminus. These effects were exclusively based on enhanced SR Ca2+ release as S100A1 influenced neither SR Ca2+ uptake nor myofilament Ca2+ sensitivity/cooperativity in our experimental setting. In conclusion, our study shows for the first time that S100A1 augments contractile performance both of fast- and slow-twitch skeletal muscle fibers based on enhanced SR Ca2+ efflux at least mediated by the C terminus of S100A1 protein. Thus, our data suggest that S100A1 may serve as an endogenous enhancer of SR Ca2+ release and might therefore be of physiological relevance in the process of excitation-contraction coupling in skeletal muscle.	Heidelberg Univ, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Heidelberg Univ, Abt Innere Med Kardiol 3, D-69115 Heidelberg, Germany; Univ Glasgow, Inst Biomed Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Glasgow	Fink, RHA (corresponding author), Heidelberg Univ, Inst Physiol & Pathophysiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany.	rainer.fink@agfink.de	Weber, Martin/GPW-6095-2022	Weber, Martin/0000-0001-5039-5010				Adhikari BB, 2001, FEBS LETT, V497, P95, DOI 10.1016/S0014-5793(01)02444-9; AIGNER S, 1993, EUR J BIOCHEM, V211, P367, DOI 10.1111/j.1432-1033.1993.tb19906.x; BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; CHU A, 1988, METHOD ENZYMOL, V157, P36; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Du XJ, 2002, MOL CELL BIOL, V22, P2821, DOI 10.1128/MCB.22.8.2821-2829.2002; Ehlermann P, 2000, J CHROMATOGR B, V737, P39, DOI 10.1016/S0378-4347(99)00366-7; Ehlermann P, 2000, BBA-MOL BASIS DIS, V1500, P249, DOI 10.1016/S0925-4439(99)00106-4; Ehlermann P, 2001, GEN PHYSIOL BIOPHYS, V20, P203; ENDO M, 1980, Journal of Muscle Research and Cell Motility, V1, P89, DOI 10.1007/BF00711927; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FANO G, 1989, FEBS LETT, V255, P381, DOI 10.1016/0014-5793(89)81127-5; FINK RHA, 1987, PFLUG ARCH EUR J PHY, V409, P374, DOI 10.1007/BF00583791; FINK RHA, 1990, J PHYSIOL-LONDON, V420, P337, DOI 10.1113/jphysiol.1990.sp017916; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gonzalez A, 2000, J GEN PHYSIOL, V115, P139, DOI 10.1085/jgp.115.2.139; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Groves P, 1998, FEBS LETT, V421, P175, DOI 10.1016/S0014-5793(97)01535-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIMOTO H, 1987, J NEUROCHEM, V48, P917, DOI 10.1111/j.1471-4159.1987.tb05604.x; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; Herrmann-Frank A, 1999, J MUSCLE RES CELL M, V20, P223, DOI 10.1023/A:1005496708505; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; KATO K, 1986, J NEUROCHEM, V46, P1555, DOI 10.1111/j.1471-4159.1986.tb01776.x; Kunst G, 2000, ANESTHESIOLOGY, V93, P832, DOI 10.1097/00000542-200009000-00034; Lacampagne A, 1998, J GEN PHYSIOL, V111, P207, DOI 10.1085/jgp.111.2.207; LAMB GD, 1991, J PHYSIOL-LONDON, V434, P507, DOI 10.1113/jphysiol.1991.sp018483; Lamb GD, 2001, J PHYSIOL-LONDON, V531, P715, DOI 10.1111/j.1469-7793.2001.0715h.x; Lamb GD, 1999, J PHYSIOL-LONDON, V519, P815, DOI 10.1111/j.1469-7793.1999.0815n.x; Maco B, 1997, GEN PHYSIOL BIOPHYS, V16, P373; Makabe M, 1996, PFLUG ARCH EUR J PHY, V432, P717, DOI 10.1007/s004240050190; Meissner G, 1997, J BIOL CHEM, V272, P1628, DOI 10.1074/jbc.272.3.1628; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Miranda LP, 2001, FEBS LETT, V488, P85, DOI 10.1016/S0014-5793(00)02392-9; Most P, 2001, P NATL ACAD SCI USA, V98, P13889, DOI 10.1073/pnas.241393598; MOST P, 2003, IN PRESS J BIOL CHEM; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; Polyakov AA, 1998, FEBS LETT, V422, P235, DOI 10.1016/S0014-5793(98)00014-3; Remppis A, 1996, BBA-MOL CELL RES, V1313, P253, DOI 10.1016/0167-4889(96)00097-3; REMPPIS A, 2002, BASIC RES CARDIOL, V97, P156; Smith GL, 2000, AM J PHYSIOL-HEART C, V279, pH577, DOI 10.1152/ajpheart.2000.279.2.H577; Smith SP, 1996, BIOCHEMISTRY-US, V35, P8805, DOI 10.1021/bi952698c; Treves S, 1997, BIOCHEMISTRY-US, V36, P11496, DOI 10.1021/bi970160w; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Uttenweiler D, 1998, BIOPHYS J, V74, P1640, DOI 10.1016/S0006-3495(98)77877-4; Wang LC, 2001, J ANAT, V199, P631, DOI 10.1046/j.1469-7580.2001.19960631.x; Wang ZL, 2001, ACTA CRYSTALLOGR D, V57, P882, DOI 10.1107/S0907444901005273; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6; ZIMMER DB, 1991, CELL MOTIL CYTOSKEL, V20, P325, DOI 10.1002/cm.970200408; ZIMMER DB, 1991, BRAIN RES BULL, V27, P157, DOI 10.1016/0361-9230(91)90061-N	54	37	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26356	26364		10.1074/jbc.M303338200	http://dx.doi.org/10.1074/jbc.M303338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12721284	hybrid			2022-12-25	WOS:000184155700011
J	Feltzer, RE; Trent, JO; Gray, RD				Feltzer, RE; Trent, JO; Gray, RD			Alkaline proteinase inhibitor of Pseudomonas aeruginosa - A mutational and molecular dynamics study of the role of N-terminal residues in the inhibition of Pseudomonas alkaline proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MATRIX METALLOPROTEINASES; ERWINIA-CHRYSANTHEMI; SERRATIA-MARCESCENS; TISSUE INHIBITOR; PROTEASE; SPECIFICITY; COMPLEX; TIMP-1; COLLAGENASES	Alkaline proteinase inhibitor of Pseudomonas aeruginosa is a 11.5-kDa, high affinity inhibitor of the serralysin class of zinc-dependent proteinases secreted by several Gram-negative bacteria. X-ray crystallography of the proteinase-inhibitor complex reveals that five N-terminal inhibitor residues occupy the extended substrate binding site of the enzyme and that the catalytic zinc is chelated by the alpha-amino and carbonyl groups of the N-terminal residue of the inhibitor. In this study, we assessed the effect of alteration of inhibitor residues 2-5 on its affinity for Pseudomonas alkaline proteinase (APR) as derived from the ratio of the dissociation and associate rate constants for formation of the enzyme-inhibitor complex. The largest effect was observed at position Ser-2, which occupies the S1' pocket of the enzyme and donates a hydrogen bond to the carboxyl group of the catalytic Glu-177 of the proteinase. Substitution of Asp, Arg, or Trp at this position increased the dissociation constant K-D by 35-, 180-, and 13-fold, respectively. Mutation at positions 3-5 of the trunk also resulted in a reduction in enzyme-inhibitor affinity, with the exception of an I4W mutant, which exhibited a 3-fold increase in affinity. Molecular dynamics simulation of the complex formation between the catalytic domain of APR and the S2D mutant showed that the carboxyl of Asp-2 interacts with the catalytic zinc, thereby partially neutralizing the negative charge that otherwise would clash with the carboxyl group of Glu-177 of APR. Simulation of the interaction between the alkaline proteinase and the I4W mutant revealed a major shift in the loop comprised of residues 189-200 of the enzyme that allowed formation of a stacking interaction between the aromatic rings of Ile-4 of the inhibitor and Tyr-158 of the proteinase. This new interaction could account for the observed increase in enzyme-inhibitor affinity.	Univ Louisville, James Graham Brown Canc Ctr, Sch Med, Dept Med, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA	University of Louisville; University of Louisville; University of Louisville	Gray, RD (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Sch Med, Dept Med, Louisville, KY 40292 USA.			trent, John/0000-0002-7346-4231				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DUONG F, 1992, GENE, V121, P47, DOI 10.1016/0378-1119(92)90160-Q; Feltzer RE, 2000, J BIOL CHEM, V275, P21002, DOI 10.1074/jbc.M002088200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Hamada K, 1996, J BIOCHEM, V119, P844, DOI 10.1093/oxfordjournals.jbchem.a021320; HECK LW, 1986, INFECT IMMUN, V54, P149, DOI 10.1128/IAI.54.1.149-153.1986; Hege T, 2001, J BIOL CHEM, V276, P35087, DOI 10.1074/jbc.M104020200; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P354; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; MOLLA A, 1989, J BIOL CHEM, V264, P10589; MORIHARA K, 1963, BIOCHIM BIOPHYS ACTA, V73, P113; STOCKER W, 1995, PROTEIN SCI, V4, P823; Trent JO, 2001, METHOD ENZYMOL, V340, P290; WEINGARTEN H, 1986, BIOCHEM BIOPH RES CO, V139, P1184, DOI 10.1016/S0006-291X(86)80302-3; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Word JM, 2000, PROTEIN SCI, V9, P2251, DOI 10.1110/ps.9.11.2251	29	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25952	25957		10.1074/jbc.M212691200	http://dx.doi.org/10.1074/jbc.M212691200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12707273	hybrid			2022-12-25	WOS:000183920200088
J	Kamiyama, S; Suda, T; Ueda, R; Suzuki, M; Okubo, R; Kikuchi, N; Chiba, Y; Goto, S; Toyoda, H; Saigo, K; Watanabe, M; Narimatsu, H; Jigami, Y; Nishihara, S				Kamiyama, S; Suda, T; Ueda, R; Suzuki, M; Okubo, R; Kikuchi, N; Chiba, Y; Goto, S; Toyoda, H; Saigo, K; Watanabe, M; Narimatsu, H; Jigami, Y; Nishihara, S			Molecular cloning and identification of 3 '- phosphoadenosine 5 '-phosphosulfate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; N-ACETYLGLUCOSAMINE TRANSPORTER; NUCLEOTIDE SUGAR TRANSPORTERS; KAPPA-B-EPSILON; GOLGI-APPARATUS; HEPARAN-SULFATE; TOUT-VELU; ENDOPLASMIC-RETICULUM; PAPS TRANSLOCASE; ACTIVE SULFATE	Nucleotide sulfate, namely 3'-phosphoadenosine 5'-phosphosulfate (PAPS), is a universal sulfuryl donor for sulfation. Although a specific PAPS transporter is present in Golgi membrane, no study has reported the corresponding gene. We have identified a novel human gene encoding a PAPS transporter, which we have named PAPST1, and the Drosophila melanogaster ortholog, slalom (sll). The amino acid sequence of PAPST1 (432 amino acids) exhibited 48.1% identity with SLL (465 amino acids), and hydropathy analysis predicted the two to be type III transmembrane proteins. The transient expression of PAPST1 in SW480 cells showed a subcellular localization in Golgi membrane. The expression of PAPST1 and SLL in yeast Saccharomyces cerevisiae significantly increased the transport of PAPS into the Golgi membrane fraction. In human tissues, PAPST1 is highly expressed in the placenta and pancreas and present at lower levels in the colon and heart. An RNA interference fly of sll produced with a GAL4-UAS system revealed that the PAPS transporter is essential for viability. It is well known that mutations of some genes related to PAPS synthesis are responsible for human inherited disorders. Our findings provide insights into the significance of PAPS transport and post-translational sulfation.	Soka Univ, Div Cell Biol, Tokyo 1928577, Japan; Seikagaku Corp, Cent Res Labs, Tokyo 2070021, Japan; Tokyo Med Univ, Dept Surg, Shinjuku Ku, Tokyo 1600023, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Natl Inst Genet, Invertebrate Genet Lab, Shizuoka 4418540, Japan; Mitsubishi Kagaku Inst Life Sci, Genet Networks Res Grp, Tokyo 1948511, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058586, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Dept Bioanalyt Chem, Inage Ku, Chiba 2638522, Japan; Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130033, Japan; Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan	Soka University; Seikagaku Corporation; Tokyo Medical University; Japan Science & Technology Agency (JST); Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Mitsubishi Kagaku Institute of Life Sciences (MITILS); National Institute of Advanced Industrial Science & Technology (AIST); Chiba University; University of Tokyo; Keio University	Nishihara, S (corresponding author), Soka Univ, Div Cell Biol, 1-236 Tangi Cho, Tokyo 1928577, Japan.		Chiba, Yasunori/L-7993-2018; Narimatsu, Hisashi/M-4757-2018	Chiba, Yasunori/0000-0002-6401-5071; Narimatsu, Hisashi/0000-0002-8402-133X; Nishihara, Shoko/0000-0002-1668-2603				Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; Binari RC, 1997, DEVELOPMENT, V124, P2623; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; Ishida N, 1996, J BIOCHEM, V120, P1074; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kurima K, 1998, P NATL ACAD SCI USA, V95, P8681, DOI 10.1073/pnas.95.15.8681; LANE N, 1964, J CELL BIOL, V21, P339, DOI 10.1083/jcb.21.3.339; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; LUEDERS F, 2002, 43 ANN DROS RES C SA; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; Muraoka M, 2001, FEBS LETT, V495, P87, DOI 10.1016/S0014-5793(01)02358-4; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3695, DOI 10.1021/bi951303m; Ozeran JD, 1996, BIOCHEMISTRY-US, V35, P3685, DOI 10.1021/bi951302u; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; ROBBINS PW, 1958, J BIOL CHEM, V233, P686; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROBBINS PW, 1957, J BIOL CHEM, V229, P837; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takemae H, 2003, J BIOL CHEM, V278, P15571, DOI 10.1074/jbc.M301123200; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Ueda R, 2001, J NEUROGENET, V15, P193, DOI 10.3109/01677060109167376; UEMURA M, 1992, CANCER RES, V52, P6153; Ul Haque MF, 1998, NAT GENET, V20, P157, DOI 10.1038/2458; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200	44	97	107	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25958	25963		10.1074/jbc.M302439200	http://dx.doi.org/10.1074/jbc.M302439200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716889	hybrid			2022-12-25	WOS:000183920200089
J	Dumont, E; Lallemand, F; Prunier, C; Ferrand, N; Guillouzo, A; Clement, B; Atfi, A; Theret, N				Dumont, E; Lallemand, F; Prunier, C; Ferrand, N; Guillouzo, A; Clement, B; Atfi, A; Theret, N			Evidence for a role of Smad3 and Smad2 in stabilization of the tumor-derived mutant Smad2.Q407R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HEPATOCELLULAR-CARCINOMA; SIGNAL-TRANSDUCTION; SUPPRESSORS SMAD2; GENE MUTATION; II RECEPTOR; DPC4 GENE; DEGRADATION; PROTEINS; CANCER	Transforming growth factor beta (TGF-beta) is a potent inhibitor of cell proliferation and the loss of responsiveness to TGF-beta may contribute to the development of human cancers. In hepatocellular carcinomas, the potential role of TGF-beta signaling as a tumor suppressor pathway can be illustrated by the presence of mutations in genes encoding TGF-beta receptors or downstream components of this signaling such as Smad2. Although Smad2 is mutated in hepatocellular carcinomas, the alteration of TGF-beta signaling with respect to tumor progression remains to be established. Using the HepG2 hepatoma cells, we showed here that expression of Smad2. Q407R, a missense mutation found in human hepatocellular carcinoma, was less effective than expression of wild-type Smad2 in enhancing the ability of TGF-beta to induce transcription from the Mix. 2 promoter. This effect was specifically associated with a decrease in the steady-state level of Smad2. Q407R, presumably because of an enhancement of its ubiquitination and degradation through the proteasome machinery. More importantly, we found that the unstability of Smad2. Q407R was reversed when this mutant undergoes homo-oligomerization with wild-type Smad2 or hetero-oligomerization with Smad3 within the cells. Therefore, our findings allowed us to propose a novel mechanism for suppression of the deleterious effect of a tumor-derived mutation of Smad2, which loss may lead to dysregulated cell proliferation during tumorigenesis.	Univ Rennes 1, U456, INSERM, F-35043 Rennes, France; Hop St Antoine, U482, INSERM, F-75571 Paris 12, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Theret, N (corresponding author), Univ Rennes 1, U456, INSERM, 2 Ave Leon Bernard, F-35043 Rennes, France.		Frottier, Celine Prunier/G-8259-2017; Theret, Nathalie/I-2871-2015; Clement, Bruno/E-5546-2016; theret, nathalie/ABG-6780-2020	Frottier, Celine Prunier/0000-0002-7784-0273; Theret, Nathalie/0000-0002-5857-7828; Clement, Bruno/0000-0001-8827-146X; theret, nathalie/0000-0002-5857-7828				Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Goto D, 1998, FEBS LETT, V430, P201, DOI 10.1016/S0014-5793(98)00658-9; Gressner AM, 1997, J HEPATOL, V26, P1079, DOI 10.1016/S0168-8278(97)80117-1; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawate S, 1999, INT J ONCOL, V14, P127; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lei JY, 1996, ONCOGENE, V13, P2459; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Salvucci M, 1999, ONCOGENE, V18, P181, DOI 10.1038/sj.onc.1202279; Schutte M, 1996, CANCER RES, V56, P2527; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uchida K, 1996, CANCER RES, V56, P5583; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1	40	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24881	24887		10.1074/jbc.M212496200	http://dx.doi.org/10.1074/jbc.M212496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12700238	hybrid			2022-12-25	WOS:000183824800077
J	Nakano, T; Terato, H; Asagoshi, K; Masaoka, A; Mukuta, M; Ohyama, Y; Suzuki, T; Makino, K; Ide, H				Nakano, T; Terato, H; Asagoshi, K; Masaoka, A; Mukuta, M; Ohyama, Y; Suzuki, T; Makino, K; Ide, H			DNA-protein cross-link formation mediated by oxanine - A novel genotoxic mechanism of nitric oxide-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PEROXYNITRITE IN-VITRO; COLI ENDONUCLEASE III; ESCHERICHIA-COLI; NITROUS-ACID; BASE-EXCISION; CHROMATIN STRUCTURE; HYPOCHLOROUS ACID; ENZYMATIC REPAIR; GLYCOSYLASE-II	Chronic inflammation is a risk factor for many human cancers, and nitric oxide ( NO) produced in inflamed tissues has been proposed to cause DNA damage via nitrosation or oxidation of base moieties. Thus, NO-induced DNA damage could be relevant to carcinogenesis associated with chronic inflammation. In this report, we report a novel genotoxic mechanism of NO that involves DNA-protein cross-links (DPCs) induced by oxanine (Oxa), a major NO-induced guanine lesion. When a duplex DNA containing Oxa at the site-specific position was incubated with DNA-binding proteins such as histone, high mobility group (HMG) protein, and DNA glycosylases, DPCs were formed between Oxa and protein. The rate of DPC formation with DNA glycosylases was approximately two orders of magnitude higher than that with histone and HMG protein. Analysis of the reactivity of individual amino acids to Oxa suggested that DPC formation occurred between Oxa and side chains of lysine or arginine in the protein. A HeLa cell extract also gave rise to two major DPCs when incubated with DNA-containing Oxa. These results reveal a dual aspect of Oxa as causal damage of DPC formation and as a suicide substrate of DNA repair enzymes, both of which could pose a threat to the genetic and structural integrity of DNA, hence potentially leading to carcinogenesis.	Hiroshima Univ, Dept Math & Life Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan; Kyoto Univ, Inst Adv Energy, Uji 6110011, Japan	Hiroshima University; Kyoto University	Ide, H (corresponding author), Hiroshima Univ, Dept Math & Life Sci, Grad Sch Sci, Higashihiroshima 7398526, Japan.		Ide, Hiroshi/G-9042-2019	Nakano, Toshiaki/0000-0002-5274-2909; Terato, Hiroaki/0000-0002-7070-5263				Aburatani H, 1997, CANCER RES, V57, P2151; Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Asagoshi K, 2000, J BIOL CHEM, V275, P24781, DOI 10.1074/jbc.M000576200; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Caulfield JL, 1998, J BIOL CHEM, V273, P12689, DOI 10.1074/jbc.273.21.12689; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P8135, DOI 10.1093/nar/14.20.8135; Felley-Bosco E, 1998, CANCER METAST REV, V17, P25, DOI 10.1023/A:1005948420548; FRANKEL AD, 1980, J BACTERIOL, V142, P335, DOI 10.1128/JB.142.1.335-338.1980; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; HARTMAN Z, 1994, ENVIRON MOL MUTAGEN, V24, P168, DOI 10.1002/em.2850240305; Hashimoto M, 2001, J AM CHEM SOC, V123, P3161, DOI 10.1021/ja003354z; Hazra TK, 2000, J BIOL CHEM, V275, P27762; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; KAMIYA H, 1992, NUCLEOS NUCLEOT, V11, P247, DOI 10.1080/07328319208021700; Kennedy LJ, 1997, CHEM RES TOXICOL, V10, P386, DOI 10.1021/tx960102w; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; KORNBERG RD, 1974, SCIENCE, V184, P865, DOI 10.1126/science.184.4139.865; Kroeger KM, 2003, BIOCHEMISTRY-US, V42, P2449, DOI 10.1021/bi027168c; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; Kulcharyk PA, 2001, BIOCHEMISTRY-US, V40, P3648, DOI 10.1021/bi001962l; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Kurtz AJ, 2003, J BIOL CHEM, V278, P5970, DOI 10.1074/jbc.M212012200; Kuznetsov SV, 2001, BIOCHEM BIOPH RES CO, V288, P121, DOI 10.1006/bbrc.2001.5732; Lucas LT, 1999, J BIOL CHEM, V274, P18319, DOI 10.1074/jbc.274.26.18319; Lucas LT, 2001, CHEM RES TOXICOL, V14, P158, DOI 10.1021/tx000179r; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masaoka A, 1999, J BIOL CHEM, V274, P25136, DOI 10.1074/jbc.274.35.25136; Mattagajasingh SN, 1996, J BIOL CHEM, V271, P33550, DOI 10.1074/jbc.271.52.33550; Minko IG, 2002, P NATL ACAD SCI USA, V99, P1905, DOI 10.1073/pnas.042700399; Monden Y, 1999, BIOCHEM BIOPH RES CO, V258, P605, DOI 10.1006/bbrc.1999.0649; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; PERMANA PA, 1994, CARCINOGENESIS, V15, P1031, DOI 10.1093/carcin/15.5.1031; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Routledge MN, 2000, MUTAT RES-FUND MOL M, V450, P95, DOI 10.1016/S0027-5107(00)00018-X; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; Roy R, 1996, CARCINOGENESIS, V17, P2177, DOI 10.1093/carcin/17.10.2177; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Sidorkina O, 1997, MUTAGENESIS, V12, P23, DOI 10.1093/mutage/12.1.23; Spek EJ, 2001, J BACTERIOL, V183, P131, DOI 10.1128/JB.183.1.131-138.2001; Suzuki T, 2000, CHEM RES TOXICOL, V13, P227, DOI 10.1021/tx990164x; Suzuki T, 1998, BIOCHEMISTRY-US, V37, P11592, DOI 10.1021/bi980971f; Suzuki T, 1999, BIOCHEMISTRY-US, V38, P7151, DOI 10.1021/bi982803t; Suzuki T, 2000, NUCLEIC ACIDS RES, V28, P544, DOI 10.1093/nar/28.2.544; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P8013, DOI 10.1021/bi970166l; Suzuki T, 2000, CHEM RES TOXICOL, V13, P1223, DOI 10.1021/tx0001528; Suzuki T, 1996, J AM CHEM SOC, V118, P2515, DOI 10.1021/ja952550g; Tamir S, 1996, CHEM RES TOXICOL, V9, P821, DOI 10.1021/tx9600311; TAMIR S, 1996, BIOCHIM BIOPHYS ACTA, V1288, P31; Terato H, 1999, J BIOL CHEM, V274, P25144, DOI 10.1074/jbc.274.35.25144; Terato H, 2002, NUCLEIC ACIDS RES, V30, P4975, DOI 10.1093/nar/gkf630; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; VANHOUTEN B, 1993, BIOCHEMISTRY-US, V32, P11794, DOI 10.1021/bi00095a007; Wang Y, 1995, Adv Pharmacol, V34, P71; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Xu YJ, 2003, DNA REPAIR, V2, P175, DOI 10.1016/S1568-7864(02)00194-5; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6; YERMILOV V, 1995, CARCINOGENESIS, V16, P2045, DOI 10.1093/carcin/16.9.2045; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	66	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25264	25272		10.1074/jbc.M212847200	http://dx.doi.org/10.1074/jbc.M212847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12719419	hybrid			2022-12-25	WOS:000183824800121
J	Oakley, F; Mann, J; Ruddell, RG; Pickford, J; Weinmaster, G; Mann, DA				Oakley, F; Mann, J; Ruddell, RG; Pickford, J; Weinmaster, G; Mann, DA			Basal expression of I kappa B alpha is controlled by the mammalian transcriptional repressor RBP-J (CBF1) and its activator notch1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; PERSISTENT ACTIVATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; STERNBERG CELLS; DNA-BINDING; RAT-BRAIN; PROMOTER; PROTEINS; PATHWAY	By using the hepatic stellate cell (HSC) as a paradigm for cells that undergo long term re-programming of NF-kappaB-dependent transcription, we have determined a novel mechanism by which mammalian cells establish their basal NF-kappaB activity. Elevation of NF-kappaB activity during HSC activation is accompanied by induction of CBF1 expression and DNA binding activity. We show that the transcriptional repressor CBF1 interacts with a dual NF-kappaB/CBF1-binding site (kappaB2) in the IkappaBalpha promoter. Nucleotide substitutions that disrupt CBF1 binding to the kappaB2 site result in an elevation of IkappaBalpha promoter activity and loss of responsiveness of the promoter to a transfected CBF1 reporter vector. Overexpression of CBF1 in COS1 cells was associated with markedly reduced IkappaBalpha protein expression and elevated NF-kappaB DNA binding activity. CBF1-induced repression of IkappaBalpha promoter activity was reversed in HSC transfected with the Notch1 intracellular domain (NICD). The ability of NICD to enhance IkappaBalpha gene transcription was confirmed in COS1 cells and was found to be dependent on an intact RAM domain of NICD that has been shown previously to help mediate the interaction of NICD with CBF1. One of the mechanisms by which NICD is thought to convert CBF1 into an activator of transcription is via the recruitment of transcriptional co-activators/histone acetylases to gene promoters. Co-transfection of HSC with NICD and p53 caused a diminution of IkappaBalpha promoter activity, by contrast overexpression of p300 enhanced IkappaBalpha promoter function. Taken together, these data suggest that basal IkappaBalpha expression (and as a consequence NF-kappaB activity) is under the control of the various components of the CBF1/Notch signal transduction pathway.	Univ Southampton, Liver Grp, Div Infect Inflammat & Repair, Southampton Gen Hosp, Southampton S016 6YD, Hants, England; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of Southampton; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mann, DA (corresponding author), Univ Southampton, Liver Grp, Div Infect Inflammat & Repair, Southampton Gen Hosp, Level D, Southampton S016 6YD, Hants, England.	dam2@soton.ac.uk		Oakley, Fiona/0000-0001-8692-1836; Mann, Derek/0000-0003-0950-243X				Acarin L, 2000, NEUROSCI LETT, V288, P41, DOI 10.1016/S0304-3940(00)01202-7; Algarte M, 1999, MOL CELL BIOL, V19, P6140; Ammon C, 2000, BIOCHEM BIOPH RES CO, V268, P99, DOI 10.1006/bbrc.1999.2083; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENNERIAH Y, 2000, NAT IMMUN, V3, P20; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Feuillard J, 2000, INT IMMUNOL, V12, P613, DOI 10.1093/intimm/12.5.613; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kadesch T, 2000, EXP CELL RES, V260, P1, DOI 10.1006/excr.2000.4921; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kato H, 1997, DEVELOPMENT, V124, P4133; Kolenko V, 1999, J IMMUNOL, V163, P590; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lang A, 2000, J HEPATOL, V33, P49, DOI 10.1016/S0168-8278(00)80159-2; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Lee SH, 2000, NUCLEIC ACIDS RES, V28, P2091, DOI 10.1093/nar/28.10.2091; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Maher JJ, 2001, SEMIN LIVER DIS, V21, P417, DOI 10.1055/s-2001-17555; Mann DA, 2002, GUT, V50, P891, DOI 10.1136/gut.50.6.891; Morel V, 2000, GENE DEV, V14, P377; Nijjar SS, 2002, AM J PATHOL, V160, P1695, DOI 10.1016/S0002-9440(10)61116-9; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Nomaguchi K, 2001, EXP HEMATOL, V29, P850, DOI 10.1016/S0301-472X(01)00657-9; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palmieri M, 1999, NUCLEIC ACIDS RES, V27, P2785, DOI 10.1093/nar/27.13.2785; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Shin WS, 1996, J BIOL CHEM, V271, P11317, DOI 10.1074/jbc.271.19.11317; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Wright MC, 2001, GASTROENTEROLOGY, V121, P685, DOI 10.1053/gast.2001.27188; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	69	74	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24359	24370		10.1074/jbc.M211051200	http://dx.doi.org/10.1074/jbc.M211051200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12700242	hybrid			2022-12-25	WOS:000183824800017
J	Tryoen-Toth, P; Richert, S; Sohm, B; Mine, M; Marsac, C; Van Dorsselaer, A; Leize, E; Florentz, C				Tryoen-Toth, P; Richert, S; Sohm, B; Mine, M; Marsac, C; Van Dorsselaer, A; Leize, E; Florentz, C			Proteomic consequences of a human mitochondrial tRNA mutation beyond the frame of mitochondrial translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; PYRUVATE-DEHYDROGENASE ACTIVITY; CULTURED HUMAN-CELLS; GENE-EXPRESSION; DNA MUTATIONS; 2-DIMENSIONAL ELECTROPHORESIS; MYOCLONIC EPILEPSY; MASS-SPECTROMETRY; PROTEIN-SYNTHESIS; ENCODED SUBUNITS	Numerous severe neurodegenerative and neuromuscular disorders, characterized biochemically by strong perturbations in energy metabolism, are correlated with single point mutations in mitochondrial genes coding for transfer RNAs. Initial comparative proteomics performed on wild-type and Myoclonic Epilepsy and Ragged Red Fibers (MERRF) mitochondria from sibling human cybrid cell lines revealed the potential of this approach. Here a quantitative analysis of several hundred silver-stained spots separated by two-dimensional gel electrophoresis was performed in the specific case of a couple of mitochondria, containing or not mutation A8344G in the gene for mitochondrial tRNALys, correlated with MERRF syndrome. Computer-assisted analysis allowed us to detect 38 spots with significant quantitative variations, of which 20 could be assigned by mass spectrometry. These include nuclear encoded proteins located in mitochondria such as respiratory chain subunits, metabolic enzymes, a protein of the mitochondrial translation machinery, and cytosolic contaminants. Furthermore, Western blotting combined with mass spectrometry revealed the occurrence of numerous isoforms of pyruvate dehydrogenase subunits, with subtle changes in post-translational modifications. This comparative proteomic approach gives the first insight for nuclear encoded proteins that undergo the largest quantitative changes, and pinpoints new potential molecular partners involved in the cascade of events that connect genotype to phenotype.	CNRS, UPR 9002, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Ecole Chim Polymeres, Lab Spectrometrie Masse Bioorgan, F-67087 Strasbourg 2, France; Fac Necker, Lab CERTO, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universite Paris Cite	Florentz, C (corresponding author), CNRS, UPR 9002, Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.		SOHM, Bénédicte/C-1339-2012	SOHM, Benedicte/0000-0002-7204-5414; Mine, Manuele/0000-0001-8682-6660; Toth, Petra/0000-0003-4573-4705				Antonicka H, 1999, BIOCHEM J, V342, P537, DOI 10.1042/0264-6021:3420537; Arden SD, 1996, J CLIN INVEST, V97, P551, DOI 10.1172/JCI118448; Asoh S, 1996, J BIOCHEM-TOKYO, V120, P600; Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BENTLAGE HACM, 1995, BBA-BIOMEMBRANES, V1234, P63, DOI 10.1016/0005-2736(94)00288-Z; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Celis JE, 2000, FEBS LETT, V480, P2, DOI 10.1016/S0014-5793(00)01771-3; Chambers G, 2000, J PATHOL, V192, P280, DOI 10.1002/1096-9896(200011)192:3<280::AID-PATH748>3.0.CO;2-L; Chinnery PF, 2000, MOL MED TODAY, V6, P425, DOI 10.1016/S1357-4310(00)01805-0; Chomyn A, 1998, AM J HUM GENET, V62, P745, DOI 10.1086/301813; Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961; CLOT JP, 1992, J CLIN ENDOCR METAB, V74, P1258, DOI 10.1210/jc.74.6.1258; Coenen MJH, 2001, CURR OPIN NEUROL, V14, P777, DOI 10.1097/00019052-200112000-00016; DiMauro S, 2000, BRAIN PATHOL, V10, P431; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165; FLORENTZ C, 2003, IN PRESS TRANSLATION; Fountoulakis M, 2002, ELECTROPHORESIS, V23, P311, DOI 10.1002/1522-2683(200202)23:2<311::AID-ELPS311>3.0.CO;2-0; Garesse R, 2001, GENE, V263, P1, DOI 10.1016/S0378-1119(00)00582-5; Gygi SP, 2000, CURR OPIN BIOTECH, V11, P396, DOI 10.1016/S0958-1669(00)00116-6; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463; Jacobs HT, 2001, TRENDS GENET, V17, P653, DOI 10.1016/S0168-9525(01)02480-5; Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2001, J BIOL CHEM, V276, P19363, DOI 10.1074/jbc.M100727200; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Lopez MF, 2002, CIRC RES, V90, P380, DOI 10.1161/hh0402.105757; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; Mitsumoto A, 2002, FREE RADICAL BIO MED, V32, P22, DOI 10.1016/S0891-5849(01)00755-9; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; Pflieger D, 2002, ANAL CHEM, V74, P2400, DOI 10.1021/ac011295h; Rabilloud T, 2002, BIOCHEMISTRY-US, V41, P144, DOI 10.1021/bi0114776; Rabilloud T, 1998, ELECTROPHORESIS, V19, P1006, DOI 10.1002/elps.1150190616; Scheffler IE, 1999, MITOCHONDRIA; Scheffler NK, 2001, MITOCHONDRION, V1, P161, DOI 10.1016/S1567-7249(01)00007-1; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Silva JP, 2002, BBA-BIOENERGETICS, V1555, P106, DOI 10.1016/S0005-2728(02)00263-3; Smolka M, 2002, MOL CELL PROTEOMICS, V1, P19, DOI 10.1074/mcp.M100013-MCP200; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; Tan S, 2002, INT J CANCER, V98, P523, DOI 10.1002/ijc.10236; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WONG PTH, 1982, BRAIN RES, V231, P466, DOI 10.1016/0006-8993(82)90385-7	58	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24314	24323		10.1074/jbc.M301530200	http://dx.doi.org/10.1074/jbc.M301530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714596	Green Published, hybrid			2022-12-25	WOS:000183824800012
J	Coghill, ID; Brown, S; Cottle, DL; McGrath, MJ; Robinson, PA; Nandurkar, HH; Dyson, JM; Mitchell, CA				Coghill, ID; Brown, S; Cottle, DL; McGrath, MJ; Robinson, PA; Nandurkar, HH; Dyson, JM; Mitchell, CA			FHL3 is an actin-binding protein that regulates alpha-actinin-mediated actin bundling - FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-ONLY PROTEIN; SKELETAL-MUSCLE; NUCLEAR EXPORT; MOLECULAR-CLONING; Z-DISC; ADHESION; DOMAIN; EXPRESSION; FAMILY; ACTIVATION	Four and a half LIM domain (FHL) proteins are members of the LIM protein superfamily. Several FHL proteins function as co-activators of CREM/CREB transcription factors and the androgen receptor. FHL3 is highly expressed in skeletal muscle, but its function is unknown. FHL3 localized to the nucleus in C2C12 myoblasts and, following integrin engagement, exited the nucleus and localized to actin stress fibers and focal adhesions. In mature skeletal muscle FHL3 was found at the Z-line. Actin was identified as a potential FHL3 binding partner in yeast two-hybrid screening of a skeletal muscle library. FHL3 complexed with actin both in vitro and in vivo as shown by glutathione S-transferase pull-down assays and co-immunoprecipitation of recombinant and endogenous proteins. FHL3 promoted cell spreading and when overexpressed in spread C2C12 cells disrupted actin stress fibers. Increased FHL3 expression was detected in highly motile cells migrating into an artificial wound, compared with non-motile cells. The molecular mechanism by which FHL3 induced actin stress fiber disassembly was demonstrated by low speed actin co-sedimentation assays and electron microscopy. FHL3 inhibited alpha-actinin-mediated actin bundling. These studies reveal FHL3 as a significant regulator of actin cytoskeletal dynamics in skeletal myoblasts.	Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia	Monash University	Mitchell, CA (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3800, Australia.	christina.mitchell@med.monash.edu.au	Cottle, Denny/AAN-1574-2020; Nandurkar, Harshal/AAO-7443-2020; Cottle, Denny/G-4278-2013	Cottle, Denny/0000-0001-5047-6515; McGrath, Meagan/0000-0002-9414-6558; Mitchell, Christina A/0000-0001-9372-3192; Nandurkar, Harshal/0000-0002-8767-116X				Akiyama S K, 1996, Hum Cell, V9, P181; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Aplin AE, 2002, J CELL SCI, V115, P2781; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Canobbio I, 2002, THROMB HAEMOSTASIS, V87, P509, DOI 10.1055/s-0037-1613032; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486; Du XJ, 2002, BBA-GENE STRUCT EXPR, V1577, P93, DOI 10.1016/S0167-4781(02)00414-1; Faulkner G, 2001, IUBMB LIFE, V51, P275, DOI 10.1080/152165401317190761; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Flick MJ, 2000, J CELL SCI, V113, P1553; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GODDETTE DW, 1986, J BIOL CHEM, V261, P5974; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Gullberg Donald, 1998, Frontiers in Bioscience, V3, pD1039; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; JOCKUSCH H, 1980, DEV BIOL, V75, P231, DOI 10.1016/0012-1606(80)90158-X; Khurana T, 2002, PROTOPLASMA, V219, P1, DOI 10.1007/s007090200000; Kong YF, 2001, CIRCULATION, V103, P2731; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lange S, 2002, J CELL SCI, V115, P4925, DOI 10.1242/jcs.00181; Lee SMY, 1998, SOMAT CELL MOLEC GEN, V24, P197, DOI 10.1023/B:SCAM.0000007122.03392.4b; Lee SMY, 1998, GENE, V216, P163, DOI 10.1016/S0378-1119(98)00302-3; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Lim DS, 2001, J AM COLL CARDIOL, V38, P1175, DOI 10.1016/S0735-1097(01)01509-1; Littlefield R, 1998, ANNU REV CELL DEV BI, V14, P487, DOI 10.1146/annurev.cellbio.14.1.487; Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330; Loughna P. T., 2000, Molecular Cell Biology Research Communications, V3, P136, DOI 10.1006/mcbr.2000.0206; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morgan MJ, 2000, BIOCHEM BIOPH RES CO, V273, P776, DOI 10.1006/bbrc.2000.3006; Morgan MJ, 1999, BIOCHEM BIOPH RES CO, V255, P251, DOI 10.1006/bbrc.1999.0180; Morgan MJ, 1996, BIOCHEM BIOPH RES CO, V225, P632, DOI 10.1006/bbrc.1996.1222; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nakata T, 2001, BIOCHEM BIOPH RES CO, V286, P156, DOI 10.1006/bbrc.2001.5353; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Pashmforoush M, 2001, NAT MED, V7, P591, DOI 10.1038/87920; Reddy KB, 2001, J BIOL CHEM, V276, P28300, DOI 10.1074/jbc.M102794200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Robinson PA, 2003, AM J PHYSIOL-CELL PH, V284, pC681, DOI 10.1152/ajpcell.00370.2002; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sasaki Y, 1996, J NEUROCHEM, V66, P980; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Tanaka K, 1998, J STRUCT BIOL, V124, P13, DOI 10.1006/jsbi.1998.4051; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Taylor KA, 2000, J CELL BIOL, V149, P635, DOI 10.1083/jcb.149.3.635; TSKHOVREBOVA LA, 1991, J MUSCLE RES CELL M, V12, P425, DOI 10.1007/BF01738327; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Wang YG, 2000, J PHYSIOL-LONDON, V526, P57, DOI 10.1111/j.1469-7793.2000.t01-1-00057.x; Wang YG, 2000, J PHYSIOL-LONDON, V527, P3, DOI 10.1111/j.1469-7793.2000.t01-2-00003.x; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yang JC, 2000, CIRCULATION, V102, P3046	81	69	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24139	24152		10.1074/jbc.M213259200	http://dx.doi.org/10.1074/jbc.M213259200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704194	hybrid			2022-12-25	WOS:000183638600120
J	Hilairet, S; Bouaboula, M; Carriere, D; Le Fur, G; Casellas, P				Hilairet, S; Bouaboula, M; Carriere, D; Le Fur, G; Casellas, P			Hypersensitization of the orexin 1 receptor by the CB1 receptor - Evidence for cross-talk blocked by the specific CB1 antagonist, SR141716	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CANNABINOID RECEPTOR; INVERSE AGONIST; FOOD-INTAKE; SELECTIVE ANTAGONIST; BODY-WEIGHT; RAT-BRAIN; SR 141716; ACTIVATION; EXPRESSION	In the present study, we observed evidence of crosstalk between the cannabinoid receptor CB1 and the orexin 1 receptor (OX1R) using a heterologous system. When the two receptors are co-expressed, we observed a major CB1-dependent enhancement of the orexin A potency to activate the mitogen-activated protein kinase pathway; dose-responses curves indicated a 100-fold increase in the potency of orexin-mediated mitogen-activated protein kinase activation. This effect required a functional CB1 receptor as evidenced by the blockade of the orexin response by the specific CB1 antagonist, N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716), but also by pertussis toxin, suggesting that this potentiation is G(i)-mediated. In contrast to OX1R, the potency of direct activation of CB1 was not affected by co-expression with OX1R. In addition, electron microscopy experiments revealed that CB1 and OX1R are closely apposed at the plasma membrane level; they are close enough to form hetero-oligomers. Altogether, for the first time our data provide evidence that CB1 is able to potentiate an orexigenic receptor. Considering the anti-obesity effect of SR141716, these results open new avenues to understand the mechanism by which the molecule may prevent weight gain through functional interaction between CB1 and other receptors involved in the control of appetite.	Sanofi Synthelabo Rech, Immunol Oncol Dept, F-34184 Montpellier 04, France; Sanofi Synthelabo Rech, F-75635 Paris 13, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Casellas, P (corresponding author), Sanofi Synthelabo Rech, Immunol Oncol Dept, 371 Rue Professeur J Blayac, F-34184 Montpellier 04, France.	pierre.casellas@sanofi-synthelabo.com						AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Arnone M, 1997, PSYCHOPHARMACOLOGY, V132, P104, DOI 10.1007/s002130050326; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; Beuckmann CT, 2002, J MOL MED, V80, P329, DOI 10.1007/s00109-002-0322-x; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; BOUABOULA M, 1995, J BIOL CHEM, V270, P13973, DOI 10.1074/jbc.270.23.13973; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Breivogel CS, 1997, J PHARMACOL EXP THER, V282, P1632; Cabrele C, 2000, J BIOL CHEM, V275, P36043, DOI 10.1074/jbc.M000626200; Chiesi M, 2001, TRENDS PHARMACOL SCI, V22, P247, DOI 10.1016/S0165-6147(00)01664-3; Colombo G, 1998, LIFE SCI, V63, pPL113, DOI 10.1016/S0024-3205(98)00322-1; COMPTON DR, 1996, J PHARMACOL EXP THER, V344, P67; Coutts AA, 2000, BRIT J PHARMACOL, V129, P645, DOI 10.1038/sj.bjp.0703094; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; de Ligt RAF, 2000, BRIT J PHARMACOL, V130, P1, DOI 10.1038/sj.bjp.0703311; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Devlin MG, 2002, J NEUROCHEM, V80, P1095, DOI 10.1046/j.0022-3042.2002.00797.x; DEWEY WL, 1986, PHARMACOL REV, V38, P151; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; FOLTIN RW, 1988, APPETITE, V11, P1, DOI 10.1016/S0195-6663(88)80017-5; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Hervieu GJ, 2001, NEUROSCIENCE, V103, P777, DOI 10.1016/S0306-4522(01)00033-1; HOLLISTER LE, 1986, PHARMACOL REV, V38, P1; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; MACEWAN DJ, 1995, MOL PHARMACOL, V48, P316; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; Meschler JP, 2000, BIOCHEM PHARMACOL, V60, P1315, DOI 10.1016/S0006-2952(00)00447-0; Meschler JP, 2001, NEUROPHARMACOLOGY, V40, P918, DOI 10.1016/S0028-3908(01)00012-0; Mukhopadhyay S, 2000, MOL PHARMACOL, V57, P162; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Pietras TA, 2002, EUR J PHARMACOL, V442, P237, DOI 10.1016/S0014-2999(02)01551-0; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V287, P1038; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RIVINETTRILLOU C, 2003, AM J PHYSIOL, V284, pR345; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sim-Selley LJ, 2001, EUR J PHARMACOL, V414, P135, DOI 10.1016/S0014-2999(01)00784-1; Simiand J, 1998, BEHAV PHARMACOL, V9, P179; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Williams CM, 1999, PSYCHOPHARMACOLOGY, V143, P315, DOI 10.1007/s002130050953; Williams CM, 1998, PHYSIOL BEHAV, V65, P343, DOI 10.1016/S0031-9384(98)00170-X; Williams CM, 2002, PHARMACOL BIOCHEM BE, V71, P333, DOI 10.1016/S0091-3057(01)00694-3; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098	56	142	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23731	23737		10.1074/jbc.M212369200	http://dx.doi.org/10.1074/jbc.M212369200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12690115	hybrid			2022-12-25	WOS:000183638600067
J	Plisson, C; Drucker, M; Blanc, S; German-Retana, S; Le Gall, O; Thomas, D; Bron, P				Plisson, C; Drucker, M; Blanc, S; German-Retana, S; Le Gall, O; Thomas, D; Bron, P			Structural characterization of HC-Pro, a plant virus multifunctional protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELPER COMPONENT-PROTEINASE; SECONDARY STRUCTURE PREDICTION; LONG-DISTANCE MOVEMENT; 2-DIMENSIONAL CRYSTALLIZATION; PROJECTION STRUCTURE; ELECTRON-MICROSCOPY; APHID TRANSMISSION; CAPSID PROTEIN; POTYVIRUS; POTATO	The helper component proteinase (HC-Pro) is a key protein encoded by plant viruses of the genus Potyvirus. HC-Pro is involved in different steps of the viral cycle, aphid transmission, replication, and virus cell-to-cell and systemic movement and is a suppressor of posttranscriptional gene silencing. Structural knowledge of HC-Pro is required to better understand its multiple functions. To this aim, we purified His-tagged wild-type HC-Pro and a N-terminal deletion mutant (DeltaHC-Pro) from plants infected with recombinant potyviruses. Biochemical analysis of the recombinant proteins confirmed that HC-Pro is a dimer in solution, that the N terminus is not essential for self-interaction, and that a large C-terminal domain is highly resistant to proteolysis. Two-dimensional crystals of the recombinant proteins were successfully grown on Ni2+-chelating lipid monolayers. Comparison of projection maps of negatively stained crystals revealed that HC-Pro is composed of two domains separated by a flexible constriction. Cryo-electron crystallography of DeltaHC-Pro allowed us to calculate a projection map at 9-Angstrom resolution. Our data from electron microscopy, biochemical analysis, and secondary structure predictions lead us to suggest a model for structure/function relationships in the HC-Pro protein.	Univ Montpellier 2, CNRS,Unite Mixte Rech 5087, INRA, Stn Rech Pathol Comparee, F-30380 St Christol Les Ales, France; Univ Rennes 1, CNRS, Unite Mixte Rech 6026, F-35042 Rennes, France; INRA, Inst Biol Vegetale Mol, F-33883 Villenave Dornon, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; INRAE	Bron, P (corresponding author), Univ Montpellier 2, CNRS,Unite Mixte Rech 5087, INRA, Stn Rech Pathol Comparee, F-30380 St Christol Les Ales, France.	patrick.bron@univ-rennes1.fr	Plisson-Chastang, Celia/AAB-3629-2019; Blanc, Stéphane/F-5873-2011; THOMAS, Danniel/AAJ-5033-2020; Le Gall, Olivier/C-4820-2011; Drucker, Martin/S-6832-2019	Blanc, Stéphane/0000-0002-3412-0989; THOMAS, Danniel/0000-0002-9650-0434; Le Gall, Olivier/0000-0002-8547-6061; bron, patrick/0000-0002-3354-9513; Plisson-Chastang, Celia/0000-0002-8439-8428				Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanc S, 1998, J GEN VIROL, V79, P3119, DOI 10.1099/0022-1317-79-12-3119; Blanc S, 1997, VIROLOGY, V231, P141, DOI 10.1006/viro.1997.8521; Brisson A, 1999, J CRYST GROWTH, V196, P456, DOI 10.1016/S0022-0248(98)00834-3; Bron P, 1999, J MOL BIOL, V287, P117, DOI 10.1006/jmbi.1999.2604; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CRONIN S, 1995, PLANT CELL, V7, P549, DOI 10.1105/tpc.7.5.549; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; DOLJA VV, 1993, J VIROL, V67, P5968, DOI 10.1128/JVI.67.10.5968-5975.1993; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; German-Retana S, 2000, MOL PLANT MICROBE IN, V13, P316, DOI 10.1094/MPMI.2000.13.3.316; GOVIER DA, 1977, VIROLOGY, V78, P306, DOI 10.1016/0042-6822(77)90101-5; Guo DY, 1999, J GEN VIROL, V80, P1127, DOI 10.1099/0022-1317-80-5-1127; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Kasschau KD, 1997, VIROLOGY, V228, P251, DOI 10.1006/viro.1996.8368; Kasschau KD, 2001, VIROLOGY, V285, P71, DOI 10.1006/viro.2001.0901; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Kornberg RD, 1991, CURR OPIN STRUC BIOL, V1, P642, DOI 10.1016/S0959-440X(05)80090-9; Levy D, 1999, J STRUCT BIOL, V127, P44, DOI 10.1006/jsbi.1999.4155; Maia IG, 1996, J GEN VIROL, V77, P869, DOI 10.1099/0022-1317-77-5-869; Mallory AC, 2001, PLANT CELL, V13, P571, DOI 10.1105/tpc.13.3.571; MCCLELLAND JL, 1988, EXPLORATIONS PARALLE, V3, P318; OH CS, 1989, VIROLOGY, V173, P692, DOI 10.1016/0042-6822(89)90582-5; Peng YH, 1998, J GEN VIROL, V79, P897, DOI 10.1099/0022-1317-79-4-897; Raccah Benjamin, 2001, P181, DOI 10.1016/B978-012327681-0/50013-3; ROBAGLIA C, 1989, J GEN VIROL, V70, P935, DOI 10.1099/0022-1317-70-4-935; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Roudet-Tavert G, 2002, J GEN VIROL, V83, P1765, DOI 10.1099/0022-1317-83-7-1765; THORNBURY DW, 1985, VIROLOGY, V144, P260, DOI 10.1016/0042-6822(85)90322-8; Urcuqui-Inchima S, 1999, J GEN VIROL, V80, P2809, DOI 10.1099/0022-1317-80-11-2809; Urcuqui-Inchima S, 2000, VIROLOGY, V268, P104, DOI 10.1006/viro.1999.0156; Urcuqui-Inchima S, 1999, VIROLOGY, V258, P95, DOI 10.1006/viro.1999.9725; Urcuqui-Inchima S, 2001, VIRUS RES, V74, P157, DOI 10.1016/S0168-1702(01)00220-9; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Venien-Bryan C, 1997, J MOL BIOL, V274, P687, DOI 10.1006/jmbi.1997.1431; Venien-Bryan C, 2000, J MOL BIOL, V296, P863, DOI 10.1006/jmbi.1999.3480; Voinnet O, 2001, TRENDS GENET, V17, P449, DOI 10.1016/S0168-9525(01)02367-8; WAN XL, 2001, CURR OPIN BIOTECH, V12, P150; Wang RY, 1999, PHYTOPATHOLOGY, V89, P564, DOI 10.1094/PHYTO.1999.89.7.564; Yang SJ, 1998, ARCH VIROL, V143, P2443, DOI 10.1007/s007050050474	47	117	140	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23753	23761		10.1074/jbc.M302512200	http://dx.doi.org/10.1074/jbc.M302512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684502	Green Published, hybrid			2022-12-25	WOS:000183638600070
J	Ganga, M; Espinoza, HM; Cox, CJ; Morton, L; Hjalt, TA; Lee, Y; Amendt, BA				Ganga, M; Espinoza, HM; Cox, CJ; Morton, L; Hjalt, TA; Lee, Y; Amendt, BA			PITX2 isoform-specific regulation of atrial natriuretic factor expression - Synergism and repression with Nkx2.5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-RIGHT ASYMMETRY; LYSYL HYDROXYLASE GENE; EHLERS-DANLOS-SYNDROME; HORMONE BETA-GENE; RIEGER-SYNDROME; HOMEOBOX GENES; CRYSTAL-STRUCTURE; SIGNALING PATHWAY; HEART DEVELOPMENT; BINDING-SITE	PITX2 and Nkx2.5 are two of the earliest known transcriptional markers of vertebrate heart development. Pitx2(-/-) mice present with severe cardiac malformations and embryonic lethality, demonstrating a role for PITX2 in heart development. However, little is known about the downstream targets of PITX2 in cardiogenesis. We report here that the atrial natriuretic factor ( ANF) promoter is a target of PITX2. PITX2A, PITX2B, and PITX2C isoforms differentially activate the ANF promoter. However, only PITX2C can synergistically activate the ANF promoter in the presence of Nkx2.5. We further demonstrate that the procollagen lysyl hydroxylase ( PLOD1) promoter is regulated by Nkx2.5. Mechanistically, PITX2C and Nkx2.5 synergistically regulate ANF and PLOD1 expression through binding to their respective DNA elements. Surprisingly, PITX2A activation of the ANF and PLOD1 promoters is repressed by co- transfection of Nkx2.5 in the C3H10T1/ 2 embryonic fibroblast cell line. Pitx2a and Pitx2c are endogenously expressed in C3H10T1/ 2 cells, and these cells express factors that differentially regulate PITX2 isoform activities. We provide a new mechanism for the regulation of heart development by PITX2 isoforms through the regulation of ANF and PLOD1 gene expression and Nkx2.5 transcriptional activity.	Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA; Lund Univ, Dept Cell & Mol Biol, SE-22184 Lund, Sweden; Univ Wisconsin, Dept Anat, Madison, WI 53706 USA	University of Tulsa; Lund University; University of Wisconsin System; University of Wisconsin Madison	Amendt, BA (corresponding author), Univ Tulsa, Dept Biol Sci, 600 S College Ave, Tulsa, OK 74104 USA.		Ganga, Maria Angelica/S-8176-2019	Amendt, Brad A./0000-0001-6524-1006	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013941] Funding Source: NIH RePORTER; NIDCR NIH HHS [1 R01 DE13941] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Amendt BA, 1999, J BIOL CHEM, V274, P11635, DOI 10.1074/jbc.274.17.11635; Amendt BA, 1999, MOL CELL BIOL, V19, P7001; Amendt BA, 1998, J BIOL CHEM, V273, P20066, DOI 10.1074/jbc.273.32.20066; Amendt BA, 2000, CELL MOL LIFE SCI, V57, P1652, DOI 10.1007/PL00000647; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BODMER R, 1993, DEVELOPMENT, V118, P719; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Cox CJ, 2002, J BIOL CHEM, V277, P25001, DOI 10.1074/jbc.M201737200; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Cunningham ET, 1998, ARCH OPHTHALMOL-CHIC, V116, P78, DOI 10.1001/archopht.116.1.78; Dorn C, 1999, J BIOL CHEM, V274, P13870, DOI 10.1074/jbc.274.20.13870; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Essner JJ, 2000, DEVELOPMENT, V127, P1081; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Fossett N, 2000, P NATL ACAD SCI USA, V97, P7348, DOI 10.1073/pnas.97.13.7348; Galliot B, 1999, DEV GENES EVOL, V209, P186, DOI 10.1007/s004270050243; Goldmuntz E, 2001, CIRCULATION, V104, P2565, DOI 10.1161/hc4601.098427; Green PD, 2001, GENE EXPRESSION, V9, P265, DOI 10.3727/000000001783992515; Habets PEMH, 2002, GENE DEV, V16, P1234, DOI 10.1101/gad.222902; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Heikkinen J, 1997, AM J HUM GENET, V60, P48; Hjalt TA, 2000, DEV DYNAM, V218, P195, DOI 10.1002/(SICI)1097-0177(200005)218:1<195::AID-DVDY17>3.0.CO;2-C; Hjalt TA, 2001, J CELL BIOL, V152, P545, DOI 10.1083/jcb.152.3.545; HYLAND J, 1992, NAT GENET, V2, P228, DOI 10.1038/ng1192-228; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Liu CY, 2001, DEVELOPMENT, V128, P2039; Mammi I, 1998, ACTA OPHTHALMOL SCAN, V76, P509, DOI 10.1034/j.1600-0420.1998.760424.x; Melamed P, 2002, J BIOL CHEM, V277, P26200, DOI 10.1074/jbc.M201605200; Quirk CC, 2001, MOL ENDOCRINOL, V15, P734, DOI 10.1210/me.15.5.734; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; RIEGER H, 1935, GRAEFE ARCH OPHTHALM, V133, P602; RINKWITZBRANDT S, 1995, MECH DEVELOP, V52, P371, DOI 10.1016/0925-4773(95)00414-V; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Schweickert A, 2000, MECH DEVELOP, V90, P41, DOI 10.1016/S0925-4773(99)00227-0; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Semina EV, 1998, HUM MOL GENET, V7, P415, DOI 10.1093/hmg/7.3.415; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; St Amand TR, 1998, BIOCHEM BIOPH RES CO, V247, P100; STADLER HS, 1994, DEV BIOL, V161, P251, DOI 10.1006/dbio.1994.1025; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; TSAI JC, 1994, AM J OPHTHALMOL, V118, P255, DOI 10.1016/S0002-9394(14)72910-1; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yamagishi H, 2001, DEV BIOL, V239, P190, DOI 10.1006/dbio.2001.0417; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Yu XY, 2001, DEVELOPMENT, V128, P1005	52	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22437	22445		10.1074/jbc.M210163200	http://dx.doi.org/10.1074/jbc.M210163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12692125	hybrid			2022-12-25	WOS:000183503900037
J	Goto, M; Omi, R; Miyahara, I; Sugahara, M; Hirotsu, K				Goto, M; Omi, R; Miyahara, I; Sugahara, M; Hirotsu, K			Structures of argininosuccinate synthetase in enzyme-ATP substrates and enzyme-AMP product forms - Stereochemistry of the catalytic reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH3-DEPENDENT NAD(+) SYNTHETASE; TRANSFER-RNA SYNTHETASE; CRYSTAL-STRUCTURE; ASPARAGINE SYNTHETASE; MECHANISM; BIOSYNTHESIS; ARCHAEON; UREA; BACTERIUM; MOLSCRIPT	Argininosuccinate synthetase reversibly catalyzes the ATP-dependent condensation of a citrulline with an aspartate to give argininosuccinate. The structures of the enzyme from Thermus thermophilus HB8 complexed with intact ATP and substrates (citrulline and aspartate) and with AMP and product (argininosuccinate) have been determined at 2.1- and 2.0-Angstrom resolution, respectively. The enzyme does not show the ATP-induced domain rotation observed in the enzyme from Escherichia coli. In the enzyme-substrate complex, the reaction sites of ATP and the bound substrates are adjacent and are sufficiently close for the reaction to proceed without the large conformational change at the domain level. The mobility of the triphosphate group in ATP and the side chain of citrulline play an important role in the catalytic action. The protonated amino group of the bound aspartate interacts with the alpha-phosphate of ATP and the ureido group of citrulline, thus stimulating the adenylation of citrulline. The enzyme-product complex explains how the citrullyl-AMP intermediate is bound to the active site. The stereochemistry of the catalysis of the enzyme is clarified on the basis of the structures of tAsS (argininosuccinate synthetase from T. thermophilus HB8) complexes.	Osaka City Univ, Dept Chem, Grad Sch Sci, Osaka 5588585, Japan; SPring 8, Harima Inst, Inst Phys & Chem Res, RIKEN, Sayo, Hyogo 6795148, Japan	Osaka Metropolitan University; Japan Synchrotron Radiation Research Institute; RIKEN	Hirotsu, K (corresponding author), Osaka City Univ, Dept Chem, Grad Sch Sci, Osaka 5588585, Japan.	hirotsu@sci.osaka-cu.ac.jp						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORK P, 1994, PROTEINS, V20, P347, DOI 10.1002/prot.340200407; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN TL, 1986, BIOCHEMISTRY-US, V25, P4739, DOI 10.1021/bi00365a003; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; Devedjiev Y, 2001, ACTA CRYSTALLOGR D, V57, P806, DOI 10.1107/S0907444901003523; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; GHOSE C, 1985, BIOCHEMISTRY-US, V24, P5894, DOI 10.1021/bi00342a031; Goto M, 2002, J BIOL CHEM, V277, P15890, DOI 10.1074/jbc.M112430200; HILGER F, 1979, EUR J BIOCHEM, V94, P153, DOI 10.1111/j.1432-1033.1979.tb12882.x; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lebbink JHG, 1995, PROTEIN ENG, V8, P1287, DOI 10.1093/protein/8.12.1287; Lemke CT, 2002, J BIOL CHEM, V277, P13074, DOI 10.1074/jbc.M112436200; Lemke CT, 2001, STRUCTURE, V9, P1153, DOI 10.1016/S0969-2126(01)00683-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nakatsu T, 1998, NAT STRUCT BIOL, V5, P15, DOI 10.1038/nsb0198-15; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAUSHEL FM, 1983, ARCH BIOCHEM BIOPHYS, V225, P979, DOI 10.1016/0003-9861(83)90114-5; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Rizzi M, 1998, STRUCTURE, V6, P1129, DOI 10.1016/S0969-2126(98)00114-2; ROCHOVAN.O, 1967, J BIOL CHEM, V242, P3839; ROCHOVANSKY O, 1961, J BIOL CHEM, V236, P2254; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; RUSSELL RJM, 1994, STRUCTURE, V2, P1157, DOI 10.1016/S0969-2126(94)00118-9; Sauter C, 2000, J MOL BIOL, V299, P1313, DOI 10.1006/jmbi.2000.3791; Scandurra R, 1998, BIOCHIMIE, V80, P933, DOI 10.1016/S0300-9084(00)88890-2; Schmitt E, 1998, EMBO J, V17, P5227, DOI 10.1093/emboj/17.17.5227; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ura H, 2001, J BIOCHEM, V129, P173, DOI 10.1093/oxfordjournals.jbchem.a002829	40	11	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22964	22971		10.1074/jbc.M213198200	http://dx.doi.org/10.1074/jbc.M213198200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684518	hybrid			2022-12-25	WOS:000183503900103
J	Shibata, N; Nakanishi, Y; Fukuoka, M; Yamanishi, M; Yasuoka, N; Toraya, T				Shibata, N; Nakanishi, Y; Fukuoka, M; Yamanishi, M; Yasuoka, N; Toraya, T			Structural rationalization for the lack of stereospecificity in coenzyme B-12-dependent diol dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYLCOBALAMIN-DEPENDENT ENZYME; ETHANOLAMINE AMMONIA-LYASE; ELECTRON-SPIN RESONANCE; X-RAY STRUCTURE; CRYSTAL-STRUCTURE; KLEBSIELLA-OXYTOCA; COBAMIDE COENZYME; HYDROGEN TRANSFER; B12 COENZYME; DIOLDEHYDRASE REACTION	Adenosylcobalamin- dependent diol dehydratase of Klebsiella oxytoca is apparently not stereospecific and catalyzes the conversion of both ( R)- and ( S)- 1,2- propanediol to propionaldehyde. To explain this unusual property of the enzyme, we analyzed the crystal structures of diol dehydratase in complexes with cyanocobalamin and ( R)- or ( S)- 1,2- propanediol. ( R)- and ( S)- isomers are bound in a symmetrical manner, although the hydrogen- bonding interactions between the substrate and the active- site residues are the same. From the position of the adenosyl radical in the modeled " distal" conformation, it is reasonable for the radical to abstract the pro- R and pro- S hydrogens from ( R)- and ( S)- isomers, respectively. The hydroxyl groups in the substrate radicals would migrates from C( 2) to C( 1) by a suprafacial shift, resulting in the stereochemical inversion at C(1). This causes 60degrees clockwise and 70degrees counterclockwise rotations of the C( 1) - C( 2) bond of the ( R)- and ( S)- isomers, respectively, if viewed from K+. A modeling study of 1,1- gem- diol intermediates indicated that new radical center C( 2) becomes close to the methyl group of 5'-deoxyadenosine. Thus, the hydrogen back- abstraction ( recombination) from 5'- deoxyadenosine by the product radical is structurally feasible. It was also predictable that the substitution of the migrating hydroxyl group by a hydrogen atom from 5'- deoxyadenosine takes place with the inversion of the configuration at C( 2) of the substrate. Stereospecific dehydration of the 1,1- gem- diol intermediates can also be rationalized by assuming that Asp-alpha335 and Glu-alpha170 function as base catalysts in the dehydration of the ( R)- and ( S)- isomers, respectively. The structure- based mechanism and stereochemical courses of the reaction are proposed.	Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan; Himeji Inst Technol, Grad Sch Sci, Dept Life Sci, Kamigori, Hyogo 6781297, Japan	Okayama University; University of Hyogo	Toraya, T (corresponding author), Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan.		Shibata, Naoki/AFK-9971-2022	Shibata, Naoki/0000-0002-5096-1104				Abeles R. H., 1979, Vitamin B12, P373; ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P114, DOI 10.1021/ar50099a006; ABELES RH, 1966, J BIOL CHEM, V241, P1245; ABELES RH, 1964, ANN NY ACAD SCI, V112, P695, DOI 10.1111/j.1749-6632.1964.tb45046.x; Arigoni D., 1979, VITAMIN B12, P389; BACHOVCHIN WW, 1977, BIOCHEMISTRY-US, V16, P1082, DOI 10.1021/bi00625a009; Banerjee R., 1999, CHEM BIOCH B 12; BROWNSTEIN A, 1961, J BIOL CHEM, V236, P1199; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COCKLE SA, 1972, J AM CHEM SOC, V94, P275, DOI 10.1021/ja00756a050; DIZIOL P, 1980, EUR J BIOCHEM, V106, P211; Dolphin D., 1982, B12, V2; Eda M, 2002, B CHEM SOC JPN, V75, P1469, DOI 10.1246/bcsj.75.1469; ESSENBERG MK, 1971, J AM CHEM SOC, V93, P1242; FINLAY TH, 1973, J BIOL CHEM, V248, P1285; FREY PA, 1967, J BIOL CHEM, V242, P5369; FREY PA, 1970, J AM CHEM SOC, V92, P4488, DOI 10.1021/ja00717a074; FREY PA, 1967, BIOCHEM BIOPH RES CO, V29, P873, DOI 10.1016/0006-291X(67)90301-4; FREY PA, 1966, J BIOL CHEM, V241, P2732; GOLDING BT, 1976, J AM CHEM SOC, V98, P6331, DOI 10.1021/ja00436a044; JENSEN FR, 1975, BIOCHEM BIOPH RES CO, V62, P816, DOI 10.1016/0006-291X(75)90395-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE HA, 1963, J BIOL CHEM, V238, P2367; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Masuda J, 2000, STRUCTURE, V8, P775, DOI 10.1016/S0969-2126(00)00164-7; Masuda J, 1999, ACTA CRYSTALLOGR D, V55, P907, DOI 10.1107/S0907444998018356; MCREE DE, 1993, PRACTICAL PROTEIN; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; RETEY J, 1974, J BIOL CHEM, V249, P6359; RETEY J, 1966, EXPERIENTIA, V22, P502, DOI 10.1007/BF01898652; RETEY J, 1966, EXPERIENTIA, V22, P72, DOI 10.1007/BF01900153; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Shibata N, 2002, BIOCHEMISTRY-US, V41, P12607, DOI 10.1021/bi026104z; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Smith DM, 1999, J AM CHEM SOC, V121, P5700, DOI 10.1021/ja990209g; Smith DM, 2001, J AM CHEM SOC, V123, P1664, DOI 10.1021/ja001454z; Tobimatsu T, 1997, ARCH BIOCHEM BIOPHYS, V347, P132, DOI 10.1006/abbi.1997.0325; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TORAYA T, 1977, J BIOL CHEM, V252, P963; Toraya T, 2001, J BIOCHEM-TOKYO, V130, P865, DOI 10.1093/oxfordjournals.jbchem.a003059; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; Toraya T, 1999, J BIOCHEM, V126, P650, DOI 10.1093/oxfordjournals.jbchem.a022498; Toraya T, 2000, CELL MOL LIFE SCI, V57, P106, DOI 10.1007/s000180050502; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; Toraya T., 1982, B12, P233; VALINSKY JE, 1974, J AM CHEM SOC, V96, P4709, DOI 10.1021/ja00821a077; YAMANE T, 1966, ARCH BIOCHEM BIOPHYS, V113, P362, DOI 10.1016/0003-9861(66)90198-6; Yamanishi M, 2002, EUR J BIOCHEM, V269, P4484, DOI 10.1046/j.1432-1033.2002.03151.x; ZAGALAK B, 1966, J BIOL CHEM, V241, P3028	51	39	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22717	22725		10.1074/jbc.M301513200	http://dx.doi.org/10.1074/jbc.M301513200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684496	hybrid			2022-12-25	WOS:000183503900073
J	Weiergraber, OH; Senin, II; Philippov, PP; Granzin, J; Koch, KW				Weiergraber, OH; Senin, II; Philippov, PP; Granzin, J; Koch, KW			Impact of N-terminal myristoylation on the Ca2+-dependent conformational transition in recoverin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM SENSOR PROTEINS; RHODOPSIN KINASE; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; BINDING; SYSTEM; FAMILY; SWITCH; PHOSPHORYLATION; INHIBITION	Recoverin is a Ca2+-regulated signal transduction modulator found in vertebrate retina that has been shown to undergo dramatic conformational changes upon Ca2+ binding to its two functional EF-hand motifs. To elucidate the differential impact of the N-terminal myristoylation as well as occupation of the two Ca2+ binding sites on recoverin structure and function, we have investigated a non-myristoylated E85Q mutant exhibiting virtually no Ca2+ binding to EF-2. Crystal structures of the mutant protein as well as the non-myristoylated wild-type have been determined. Although the non-myristoylated E85Q mutant does not display any functional activity, its three-dimensional structure in the presence of Ca2+ resembles the myristoylated wildtype with two Ca2+ but is quite dissimilar from the myristoylated E85Q mutant. We conclude that the N-terminal myristoyl modification significantly stabilizes the conformation of the Ca2+-free protein (i.e. the T conformation) during the stepwise transition toward the fully Ca2+-occupied state. On the basis of these observations, a refined model for the role of the myristoyl group as an intrinsic allosteric modulator is proposed.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung IBI 1, D-52425 Julich, Germany; Forschungszentrum Julich, Inst Biol Informat Verarbeitung IBI 2, D-52425 Julich, Germany; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia	Helmholtz Association; Research Center Julich; Helmholtz Association; Research Center Julich; Lomonosov Moscow State University	Koch, KW (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung IBI 1, Postfach 1913, D-52425 Julich, Germany.	k.w.koch@fz-juelich.de	Granzin, Joachim/G-8937-2013; Weiergräber, Oliver H./G-8940-2013; Philippov, Pavel P/A-8939-2012; Senin, Ivan I/D-9163-2012; Koch, Karl-Wilhelm/C-9551-2015	Granzin, Joachim/0000-0001-6604-950X; Weiergräber, Oliver H./0000-0002-2410-3691; Koch, Karl-Wilhelm/0000-0003-1501-0044				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1996, CURR OPIN STRUC BIOL, V6, P432, DOI 10.1016/S0959-440X(96)80106-0; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Braunewell KH, 1999, CELL TISSUE RES, V295, P1, DOI 10.1007/s004410051207; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; Dean KR, 1996, BIOCHEMISTRY-US, V35, P6164, DOI 10.1021/bi952480q; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GORODOVIKOVA EN, 1994, FEBS LETT, V353, P171, DOI 10.1016/0014-5793(94)01030-7; GORODOVIKOVA EN, 1994, FEBS LETT, V349, P187, DOI 10.1016/0014-5793(94)00661-X; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hwang JY, 2002, BIOCHEMISTRY-US, V41, P13021, DOI 10.1021/bi026618y; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATAOKA M, 1993, J BIOCHEM-TOKYO, V114, P535, DOI 10.1093/oxfordjournals.jbchem.a124212; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; Kawasaki H, 1998, BIOMETALS, V11, P277, DOI 10.1023/A:1009282307967; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; Matsuda S, 1999, BIOCHEMISTRY-US, V38, P1310, DOI 10.1021/bi982117u; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Neubert TA, 1997, PROTEIN SCI, V6, P843; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; Permyakov SE, 2000, PROTEIN ENG, V13, P783, DOI 10.1093/protein/13.11.783; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; SENIN II, 1995, FEBS LETT, V376, P87, DOI 10.1016/0014-5793(95)01187-2; Senin II, 2002, J BIOL CHEM, V277, P50365, DOI 10.1074/jbc.M204338200; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; Tachibanaki S, 2000, J BIOL CHEM, V275, P3313, DOI 10.1074/jbc.275.5.3313; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	50	38	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22972	22979		10.1074/jbc.M300447200	http://dx.doi.org/10.1074/jbc.M300447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686556	hybrid, Green Published			2022-12-25	WOS:000183503900104
J	Zhu, L; Tamvakopoulos, C; Xie, D; Dragovic, J; Shen, XL; Fenyk-Melody, JE; Schmidt, K; Bagchi, A; Griffin, PR; Thornberry, NA; Roy, RS				Zhu, L; Tamvakopoulos, C; Xie, D; Dragovic, J; Shen, XL; Fenyk-Melody, JE; Schmidt, K; Bagchi, A; Griffin, PR; Thornberry, NA; Roy, RS			The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides - In vivo metabolism of pituitary adenylate cyclase-activating polypeptide-(1-38)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPROVED GLUCOSE-TOLERANCE; HORMONE-RELEASING FACTOR; HUMAN GROWTH-HORMONE; MASS-SPECTROMETRY; INSULIN-SECRETION; HUMAN PLASMA; MICE; DEGRADATION; INHIBITION; RATS	Dipeptidyl peptidase IV ( DP- IV) is a cell surface serine dipeptidase that is involved in the regulation of the incretin hormones, glucagon- like peptide ( GLP- 1) and glucose- dependent insulinotropic polypeptide ( GIP). There is accumulating evidence that other members of the glucagon family of peptides are also endogenous substrates for this enzyme. To identify candidate substrates for DP- IV, a mass spectrometry- based protease assay was developed that measures cleavage efficiencies (k(cat)/K-m) of polypeptides in a mixture, using only a few picomoles of each substrate and physiological amounts of enzyme in a single kinetic experiment. Oxyntomodulin and the growth hormone-( 1 - 43) fragment were identified as new candidate in vivo substrates. Pituitary adenylate cyclase- activating polypeptide-( 1 - 38) ( PACAP38), a critical mediator of lipid and carbohydrate metabolism, was also determined to be efficiently processed by DP- IV in vitro. The catabolism of exogenously administered PACAP38 in wild type and DP- IV-deficient C57Bl/ 6 mice was monitored by tandem mass spectrometry. Animals lacking DP- IV exhibited a significantly slower clearance of the circulating peptide with virtually complete suppression of the inactive DP- IV metabolite, PACAP-( 3 - 38). These in vivo results suggest that DP- IV plays a major role in the degradation of circulating PACAP38.	Merck Res Labs, Dept Metabol Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Comparat Med, Rahway, NJ 07065 USA; Merck Res Labs, Dept Comp Sci & Appl Math, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company	Roy, RS (corresponding author), Merck Res Labs, Dept Metabol Disorders, Mail Code RY50G-241, Rahway, NJ 07065 USA.			Tamvakopoulos, Constantin/0000-0001-9627-4812				Ahren B, 2000, EUR J PHARMACOL, V404, P239, DOI 10.1016/S0014-2999(00)00600-2; Ahren B, 2002, DIABETES CARE, V25, P869, DOI 10.2337/diacare.25.5.869; Balkan B, 1999, DIABETOLOGIA, V42, P1324, DOI 10.1007/s001250051445; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; Dakin CL, 2001, ENDOCRINOLOGY, V142, P4244, DOI 10.1210/en.142.10.4244; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; DOW RC, 1994, J ENDOCRINOL, V142, pR1, DOI 10.1677/joe.0.142R001; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; GOURLET P, 1991, EUR J BIOCHEM, V195, P535, DOI 10.1111/j.1432-1033.1991.tb15734.x; Gray SL, 2002, ENDOCRINOLOGY, V143, P3946, DOI 10.1210/en.2002-220401; Gray SL, 2001, MOL ENDOCRINOL, V15, P1739, DOI 10.1210/me.15.10.1739; Gruninger-Leitch F, 2000, NAT BIOTECHNOL, V18, P66, DOI 10.1038/71944; Hamelink C, 2002, P NATL ACAD SCI USA, V99, P461, DOI 10.1073/pnas.012608999; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Jamen F, 2000, J CLIN INVEST, V105, P1307, DOI 10.1172/JCI9387; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KEIFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585; Knudsen LB, 1996, EUR J PHARMACOL, V318, P429, DOI 10.1016/S0014-2999(96)00795-9; Lambeir AM, 2002, BIOCHEM PHARMACOL, V64, P1753, DOI 10.1016/S0006-2952(02)01415-6; Lambeir AM, 2001, FEBS LETT, V507, P327, DOI 10.1016/S0014-5793(01)02982-9; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; MARTIN RA, 1993, BIOCHIM BIOPHYS ACTA, V1164, P252, DOI 10.1016/0167-4838(93)90256-Q; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Meyer-Almes FJ, 2000, BIOCHEMISTRY-US, V39, P13261, DOI 10.1021/bi000057y; *NAT RES COUNC, 1996, GUID CAR US LAB; Nauck MA, 1997, EXP CLIN ENDOCR DIAB, V105, P187, DOI 10.1055/s-0029-1211750; NAUSCH I, 1990, BIOL CHEM H-S, V371, P1113, DOI 10.1515/bchm3.1990.371.2.1113; Pauly RP, 1996, J BIOL CHEM, V271, P23222, DOI 10.1074/jbc.271.38.23222; POPISILIK JA, 2002, DIABETES, V51, P943; Pospisilik JA, 2001, REGUL PEPTIDES, V96, P133, DOI 10.1016/S0167-0115(00)00170-1; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Reimer MK, 2002, EUR J ENDOCRINOL, V146, P717, DOI 10.1530/eje.0.1460717; ROBBERECHT P, 1992, MOL PHARMACOL, V42, P347; RUIZGRANDE C, 1993, HORM METAB RES, V25, P612, DOI 10.1055/s-2007-1002190; SALEM MAM, 1989, P SOC EXP BIOL MED, V191, P408; SALEM MAM, 1988, ENDOCRINOLOGY, V123, P1565, DOI 10.1210/endo-123-3-1565; Sudre B, 2002, DIABETES, V51, P1461, DOI 10.2337/diabetes.51.5.1461; Tams JW, 1999, BIOCHEM J, V341, P271, DOI 10.1042/0264-6021:3410271; ULMER AJ, 1990, SCAND J IMMUNOL, V31, P429, DOI 10.1111/j.1365-3083.1990.tb02789.x; Vaudry D, 2000, PHARMACOL REV, V52, P269; Yasuda N, 2002, LIFE SCI, V71, P227, DOI 10.1016/S0024-3205(02)01637-5	47	195	217	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22418	22423		10.1074/jbc.M212355200	http://dx.doi.org/10.1074/jbc.M212355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690116	hybrid			2022-12-25	WOS:000183503900034
J	Parker, LL; Backstrom, JR; Sanders-Bush, E; Shieh, BH				Parker, LL; Backstrom, JR; Sanders-Bush, E; Shieh, BH			Agonist-induced phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple PDZ protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEINS; PLEXUS EPITHELIAL-CELLS; LONG-TERM DEPRESSION; CHOROID-PLEXUS; AMPA RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; POSTSYNAPTIC DENSITY-95; SIGNALING COMPLEXES; CRYSTAL-STRUCTURE; 2C RECEPTORS	Multiple PDZ domain protein 1 (MUPP1), a putative scaffolding protein containing 13 PSD-95, Dlg, ZO-1 ( PDZ) domains, was identified by a yeast two-hybrid screen as a serotonin(2C) receptor (5-HT2C R)- interacting protein (Ullmer, C., Schmuck, K., Figge, A., and Lubbert, H. (1998) FEBS Lett. 424, 63 - 68). MUPP1 PDZ domain 10 ( PDZ 10) associates with Ser(458)-Ser-Val at the carboxylterminal tail of the 5-HT2C R. Both Ser(458) and Ser(459) are phosphorylated upon serotonin stimulation of the receptor (Backstrom, J. R., Price, R. D., Reasoner, D. T., and Sanders-Bush, E. (2000) J. Biol. Chem. 275, 23620 23626). To investigate whether phosphorylation of these serines in the receptor regulates MUPP1 interaction, we used several approaches. First, we substituted the serines in the receptor carboxyl tail with aspartates to mimic phosphorylation ((SD)-D-458, (SD)-D-459, or (SD)-D-458/(SD)-D-459). Pull-down assays demonstrated that Asp mutations at Ser(458) significantly decreased receptor tail interaction with PDZ 10. Next, serotonin treatment of 5-HT2C R/3T3 cells resulted in a dose-dependent reduction of receptor interaction with PDZ 10. Effects of serotonin on receptor-PDZ 10 binding could be blocked by pretreatment with a receptor antagonist. Alkaline phosphatase treatment reverses the effect of serotonin, indicating that agonist-induced phosphorylation at Ser(458) resulted in a loss of MUPP1 association and also revealed a significant amount of basal phosphorylation of the receptor. We conclude that 5-HT2C R interaction with MUPP1 is dynamically regulated by phosphorylation at Ser(458).	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol & Cellular Neurosciol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Shieh, BH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, 402 Robinson Res Bldg,23rd Ave & Pierce, Nashville, TN 37232 USA.	Bih-Hwa.Shieh@vanderbilt.edu			NEI NIH HHS [EY 09743] Funding Source: Medline; NIGMS NIH HHS [F31 GM 20275] Funding Source: Medline; NIMH NIH HHS [MH 34007] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH034007, R01MH034007] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; Backstrom JR, 1997, J NEUROSCI METH, V77, P109, DOI 10.1016/S0165-0270(97)00102-7; Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; BARKER EL, 1993, MOL PHARMACOL, V44, P725; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; BURRIS KD, 1991, J PHARMACOL EXP THER, V258, P891; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Chung HJ, 2000, J NEUROSCI, V20, P7258; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CONN PJ, 1986, J NEUROCHEM, V47, P1754, DOI 10.1111/j.1471-4159.1986.tb13085.x; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; De Vry J, 2000, NEUROSCI BIOBEHAV R, V24, P341, DOI 10.1016/S0149-7634(99)00083-4; Dev KK, 2000, J NEUROSCI, V20, P7252; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; FIORELLA D, 1995, PSYCHOPHARMACOLOGY, V121, P364, DOI 10.1007/BF02246076; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Huber A, 2001, EUR J NEUROSCI, V14, P769, DOI 10.1046/j.0953-816x.2001.01704.x; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; KAUFMAN MJ, 1995, J NEUROCHEM, V64, P199; Kim CH, 2001, P NATL ACAD SCI USA, V98, P11725, DOI 10.1073/pnas.211132798; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Leonoudakis D, 2001, J CELL SCI, V114, P987; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Matsuda S, 1999, J NEUROCHEM, V73, P1765, DOI 10.1046/j.1471-4159.1999.731765.x; MAYER SE, 1994, MOL PHARMACOL, V45, P991; McGrew L, 2002, MOL PHARMACOL, V62, P1339, DOI 10.1124/mol.62.6.1339; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shieh BH, 1997, P NATL ACAD SCI USA, V94, P12682, DOI 10.1073/pnas.94.23.12682; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Vaccaro P, 2001, J BIOL CHEM, V276, P42122, DOI 10.1074/jbc.M104208200; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8	58	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21576	21583		10.1074/jbc.M210973200	http://dx.doi.org/10.1074/jbc.M210973200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682077	hybrid			2022-12-25	WOS:000183354200034
J	Ahonen, M; Poukkula, M; Baker, AH; Kashiwagi, M; Nagase, H; Eriksson, JE; Kahari, VM				Ahonen, M; Poukkula, M; Baker, AH; Kashiwagi, M; Nagase, H; Eriksson, JE; Kahari, VM			Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors	ONCOGENE			English	Article						TIMP-3; death receptor; apoptosis; caspase; melanoma	FAS-LIGAND EXPRESSION; MATRIX-METALLOPROTEINASE; TNF RECEPTOR; IN-VITRO; TIMP-3; GENE; INVASION; PROTEASE; CANCER; DOMAIN	Tissue inhibitors of metalloproteinases (TIMPs) are important regulators of matrix metalloproteinase (MMP) and adamalysin (ADAM) activity. We have previously shown that adenovirally expressed tissue inhibitor of metalloproteinases-3 (TIMP-3) induces apoptosis in melanoma cells and inhibits growth of human melanoma xenografts. Here, we have studied the role of death receptors in apoptosis of melanoma cells induced by TIMP-3. Our results show, that the exposure of three metastatic melanoma cell lines (A2058, SK-Mel-5, and WM-266-4) to recombinant TIMP-3, N-terminal MMP inhibitory domain of TIMP-3, as well as to adenovirally expressed TIMP-3 results in stabilization of tumor necrosis factor receptor-1 (TNF-RI), FAS, and TNF-related apoptosis inducing ligand receptor-1 (TRAIL-RI) on melanoma cell surface and sensitizes these cells to apoptosis induced by TNF-alpha, anti-Fas-antibody and TRAIL. Stabilization of death receptors by TIMP-3 results in activation of caspase-8 and caspase-3, and subsequent apoptosis is blocked by specific caspase-8 inhibitor (Z-IETD-FMK) and by pan-caspase inhibitor (Z-DEVD-FMK). Adenovirus-mediated expression of TIMP-3 in human melanoma xenografts in vivo resulted in increased immunostaining for TNF-RI, FAS, and cleaved caspase-3, and in apoptosis of melanoma cells. Taken together, these results show that TIMP-3 promotes apoptosis in melanoma cells through stabilization of three distinct death receptors and activation of their apoptotic signaling cascade through caspase-8.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Dept Biol, FIN-20014 Turku, Finland; Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Turku; University of Glasgow; Imperial College London; University of Oxford	Kahari, VM (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Baker, Andy/AAO-5250-2021; Kahari, Veli-Matti/E-5144-2011	Baker, Andy/0000-0003-1441-5576; Poukkula, Minna Karoliina/0000-0003-4192-2899; Kahari, Veli-Matti/0000-0003-2421-9368	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bachman KE, 1999, CANCER RES, V59, P798; Baker AH, 1996, MATRIX BIOL, V15, P383, DOI 10.1016/S0945-053X(96)90158-4; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bond M, 2002, J BIOL CHEM, V277, P13787, DOI 10.1074/jbc.M111507200; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHIRIVI RGS, 1994, INT J CANCER, V58, P460, DOI 10.1002/ijc.2910580326; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Ekmekcioglu S, 1999, MELANOMA RES, V9, P261, DOI 10.1097/00008390-199906000-00008; Fariss RN, 1997, AM J PATHOL, V150, P323; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; Killar L, 1999, ANN NY ACAD SCI, V878, P442, DOI 10.1111/j.1749-6632.1999.tb07701.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Mitsiades N, 2001, CANCER RES, V61, P577; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; Pennie WD, 1999, CELL GROWTH DIFFER, V10, P279; Schlondorff J, 1999, J CELL SCI, V112, P3603; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Solomon KA, 1999, J IMMUNOL, V163, P4105; Soubrane C, 2000, BRIT J DERMATOL, V143, P307, DOI 10.1046/j.1365-2133.2000.03655.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Terheyden P, 1999, J INVEST DERMATOL, V112, P899, DOI 10.1046/j.1523-1747.1999.00607.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ueki T, 2000, CANCER RES, V60, P1835; UGUREL S, 2001, CLIN CANCER RES, V7, P1108; Wehrli P, 2000, J INVEST DERMATOL, V115, P141, DOI 10.1046/j.1523-1747.2000.00037.x; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	54	152	168	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2121	2134		10.1038/sj.onc.1206292	http://dx.doi.org/10.1038/sj.onc.1206292			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687014				2022-12-25	WOS:000182066900006
J	Kikuchi, T; Daigo, Y; Katagiri, T; Tsunoda, T; Okada, K; Kakiuchi, S; Zembutsu, H; Furukawa, Y; Kawamura, M; Kobayashi, K; Imai, K; Nakamura, Y				Kikuchi, T; Daigo, Y; Katagiri, T; Tsunoda, T; Okada, K; Kakiuchi, S; Zembutsu, H; Furukawa, Y; Kawamura, M; Kobayashi, K; Imai, K; Nakamura, Y			Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs	ONCOGENE			English	Article						non-small cell lung cancer; gene-expression profile; chemosensitivity; lymph-node metastasis	LASER-CAPTURE MICRODISSECTION; COLORECTAL TUMORS; CARCINOMAS; CLASSIFICATION; ADENOCARCINOMA; CARCINOGENESIS; RESISTANCE; ADHESION; P53	To investigate genes involved in pulmonary carcinogenesis and those related to sensitivity of nonsmall cell lung cancers (NSCLCs) to therapeutic drugs, we performed cDNA microarray analysis of 37 NSCLCs after laser-capture microdissection of cancer cells from primary tumors. A clustering algorithm applied to the expression data easily distinguished two major histological types of non-small cell lung cancer, adenocarcinoma and squamous cell carcinoma. Subsequent analysis of the 18 adenocarcinomas identified 40 genes whose expression levels could separate cases with lymph-node metastasis from those without metastasis. In addition, we compared the expression data with measurements of the sensitivity of surgically dissected NSCLC specimens to six anti-cancer drugs (docetaxel, paclitaxel, irinotecan, cisplatin, gemcitabine, and vinorelbine), as measured by the CD-DST (collagen gel droplet embedded culture-drug sensitivity test) method. We found significant associations between expression levels of dozens of genes and chemosensitivity of NSCLCs. Our results provide valuable information for eventually identifying predictive markers and novel therapeutic target molecules for this type of cancer.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Med Informat, Kanagawa 2300045, Japan; Keio Univ, Sch Med, Dept Surg, Div Gen Thorac Surg, Tokyo 1608582, Japan	University of Tokyo; Sapporo Medical University; RIKEN; Keio University	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tsunoda, Tatsuhiko/K-2061-2014	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Daigo, Yataro/0000-0002-0915-3025				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FRANKLIN WA, 1994, INT J CANCER, P89; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Furuhata T, 1996, ONCOGENE, V13, P1965; FURUKAWA T, 1995, CLIN CANCER RES, V1, P305; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Ichigotani Y, 2002, CANCER RES, V62, P2215; Kawano N, 1997, HUM PATHOL, V28, P613, DOI 10.1016/S0046-8177(97)90085-X; Kitahara O, 2001, CANCER RES, V61, P3544; Kondoh N, 2001, ANTICANCER RES, V21, P2429; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Makino K, 2001, ONCOGENE, V20, P2537, DOI 10.1038/sj.onc.1204366; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Meyaard L, 2001, J EXP MED, V194, P107, DOI 10.1084/jem.194.1.107; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; Niklinski J, 2001, LUNG CANCER, V34, pS53, DOI 10.1016/S0169-5002(01)00345-2; Okabe H, 2001, CANCER RES, V61, P2129; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Sozzi G, 2001, EUR J CANCER, V37, pS63; Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235; UEDA K, 1987, J BIOL CHEM, V262, P505; VAMVAKOPOULOS NC, 1995, CYTOGENET CELL GENET, V68, P8, DOI 10.1159/000133878; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Watine J, 2000, BRIT MED J, V320, P379; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Yanagawa R, 2001, NEOPLASIA, V3, P395, DOI 10.1038/sj.neo.7900185; Zembutsu H, 2002, CANCER RES, V62, P518	33	273	314	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2192	2205		10.1038/sj.onc.1206288	http://dx.doi.org/10.1038/sj.onc.1206288			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687021				2022-12-25	WOS:000182066900013
J	Laiho, P; Hienonen, T; Karhu, A; Lipton, L; Aalto, Y; Thomas, HJW; Birkenkamp-Demtroder, K; Hodgson, S; Salovaara, R; Mecklin, JP; Jarvinen, H; Knuutila, S; Halford, S; Orntoft, TF; Tomlinson, I; Launonen, V; Houlston, R; Aaltonen, LA				Laiho, P; Hienonen, T; Karhu, A; Lipton, L; Aalto, Y; Thomas, HJW; Birkenkamp-Demtroder, K; Hodgson, S; Salovaara, R; Mecklin, JP; Jarvinen, H; Knuutila, S; Halford, S; Orntoft, TF; Tomlinson, I; Launonen, V; Houlston, R; Aaltonen, LA			Genome-wide allelotyping of 104 Finnish colorectal cancers reveals an excess of allelic imbalance in chromosome 20q in familial cases	ONCOGENE			English	Article						colorectal cancer; familial; hereditary; allelic imbalance; loss of heterozygosity	HERITABLE FACTORS; HETEROZYGOSITY; HYBRIDIZATION; GAINS; SUSCEPTIBILITY; CARCINOMAS; LOSSES; SWEDEN; GENES	We have allelotyped a series of 104 Finnish colorectal cancers (CRCs) using 372 polymorphic markers spaced, on average, at 10 cM intervals, and have made a comparison of the differences in the frequency of allelic imbalance (AI) between familial and sporadic cases. Differences in the frequency of allelic imbalance (loss of heterozygosity or amplification) at a number of loci were detected and these were evaluated through analysis of additional series of cancers using specific markers. The most consistent difference was observed at chromosome 20q13.1-13.3 characterized by a two fold difference between familial and nonfamilial disease in a total of 99 familial and 186 sporadic Finnish cases. This difference was not observed in a UK set of 67 familial and 96 sporadic CRCs. The genome-wide effort resulted in a large data set giving clues to the location of putative CRC predisposition genes in the genome. The approach provides an alternative strategy for detecting cancer predisposition genes solely reliant on the molecular analysis of single cases obviating the requirement to collect multiple samples from families.	Univ Helsinki, Biomedicum, Dept Med Genet, FIN-00014 Helsinki, Finland; Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; St Marks Hosp, Cancres Res UK, Colorectal Unit, Harrow HA1 3UJ, Middx, England; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00029 Helsinki, Finland; Aarhus Univ Hosp, Dept Clin Biochem, Mol Diagnost Lab, DK-8200 Aarhus, N Skejby, Denmark; Guys Hosp, Dept Clin Genet, Canc Res UK, London SE1 9RT, England; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Cent Hosp Jyvaskyla, Dept Surg, FIN-40620 Jyvaskyla, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00029 Helsinki, Finland; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland	University of Helsinki; Cancer Research UK; Imperial College London; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aarhus University; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of Helsinki; Central Finland Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of London; Institute of Cancer Research - UK; University of Helsinki; Helsinki University Central Hospital	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum, Dept Med Genet, POB 63, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Mecklin, Jukka-Pekka/AAB-5378-2020; Birkenkamp-Demtröder, Karin/C-1981-2017; Aaltonen, Lauri/A-5375-2010; Birkenkamp-Demtröder, Karin/AAN-1764-2021	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen, Lauri/0000-0001-6839-4286; Birkenkamp-Demtröder, Karin/0000-0001-8057-6277; Houlston, Richard/0000-0002-5268-0242; Karhu, Auli/0000-0002-7927-0796				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Aust DE, 2000, HUM PATHOL, V31, P109, DOI 10.1016/S0046-8177(00)80206-3; Bonaiti-Pellie C, 1999, EUR J CANCER PREV, V8, pS27; BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655; Canzian F, 1996, CANCER RES, V56, P3331; CUZICK J, 1999, METABOLIC POLYMORPHI, P109; De Angelis PM, 1999, BRIT J CANCER, V80, P526; De Angelis PM, 2001, INT J COLORECTAL DIS, V16, P38, DOI 10.1007/s003840000275; Dong C, 2001, INT J CANCER, V93, P155, DOI 10.1002/ijc.1317; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; Ginzinger DG, 2000, CANCER RES, V60, P5405; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Lewis CM, 1996, CANCER RES, V56, P1382; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; Mertens F, 1997, CANCER RES, V57, P2765; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Peto J, 2001, EUR J CANCER, V37, pS88; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Teh BT, 1998, AM J HUM GENET, V63, P1544, DOI 10.1086/302097; THORLACIUS S, 1991, ANTICANCER RES, V11, P1501; Tomlinson I, 1999, GASTROENTEROLOGY, V116, P789, DOI 10.1016/S0016-5085(99)70061-2; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; Weber TK, 1999, CYTOGENET CELL GENET, V86, P142, DOI 10.1159/000015368	27	13	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2206	2214		10.1038/sj.onc.1206294	http://dx.doi.org/10.1038/sj.onc.1206294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687022				2022-12-25	WOS:000182066900014
J	Wang, HM; Chakrabarty, S				Wang, HM; Chakrabarty, S			Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells	ONCOGENE			English	Article						PAF; colon; carcinomas	METHOXY HEXADECYL GLYCEROL; EPIDERMAL GROWTH-FACTOR; FACTOR-RECEPTOR; C-ALPHA; EXPRESSION; PAF; SECRETION	Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid modulator of allergic and inflammatory reactions, is diverse and functions as a modulator of a variety of physiological and pathological events in many cell types and tissues. Its role (if any) in modulating the proliferation, transformation and/or differentiation of epithelial colonic cells, however, is not known. In this study, we showed that PAF is biologically active in epithelial-derived human colon carcinoma cells with different phenotypic properties. These cells expressed the PAF receptor. PAF activated three prominent mitogen-activated protein kinase modules (ERK, p38MAPK and Jun N-terminal kinases) in these cells, inhibited proliferation and induced differentiation (measured by the induction of Waf1/p21 and the induction of the differentiation-related marker CEA). The net effect of PAF treatment was the suppression of malignant cell behavior (measured by anchorage-independent growth and cellular invasion). It is concluded that PAF is a modulator of proliferation and differentiation in human epithelial-derived colon carcinoma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, DIv Pathol & Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chakrabarty, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, DIv Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Bazan HEP, 1997, J OCUL PHARMACOL TH, V13, P277, DOI 10.1089/jop.1997.13.277; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Chakrabarty S, 1998, LAB INVEST, V78, P413; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; GUADAGNI F, 1990, CANCER RES, V50, P6248; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mukherjee PK, 1999, J BIOL CHEM, V274, P6493, DOI 10.1074/jbc.274.10.6493; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Reynolds S, 1998, CANCER LETT, V134, P53, DOI 10.1016/S0304-3835(98)00242-0; Reynolds S, 2000, CLIN EXP METASTAS, V18, P309, DOI 10.1023/A:1011071907047; SAITO H, 1992, J LIPID MEDIATOR, V5, P135; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123; Sperber K, 1998, INFLAMM BOWEL DIS, V4, P12, DOI 10.1097/00054725-199802000-00003; STOLL LL, 1991, J CELL SCI, V100, P145; Sugano T, 2001, MOL HUM REPROD, V7, P475, DOI 10.1093/molehr/7.5.475; Tokutomi T, 2001, NEUROL RES, V23, P605, DOI 10.1179/016164101101199081; Wang H, 1999, J CELL PHYSIOL, V178, P173, DOI 10.1002/(SICI)1097-4652(199902)178:2<173::AID-JCP6>3.3.CO;2-H; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068	26	24	25	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2186	2191		10.1038/sj.onc.1206348	http://dx.doi.org/10.1038/sj.onc.1206348			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687020				2022-12-25	WOS:000182066900012
J	Murphy, MP; Das, P; Nyborg, AC; Rochette, MJ; Dodson, MW; Loosbrock, NM; Souder, TM; McLendon, C; Merit, SL; Piper, SC; Jansen, KR; Golde, TE				Murphy, MP; Das, P; Nyborg, AC; Rochette, MJ; Dodson, MW; Loosbrock, NM; Souder, TM; McLendon, C; Merit, SL; Piper, SC; Jansen, KR; Golde, TE			Overexpression of nicastrin increases A beta production	FASEB JOURNAL			English	Article						amyloid beta-peptide; presenilin; gamma-secretase	GAMMA-SECRETASE CLEAVAGE; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; TRANSMEMBRANE DOMAIN; PRESENILIN; NOTCH; MUTATIONS; DROSOPHILA; COMPLEX	gamma-Secretase cleavage is the final proteolytic step that releases the amyloid beta-peptide (Abeta) from the amyloid beta-protein precursor (APP). Significant evidence indicates that the presenilins (PS) are catalytic components of a high molecular weight gamma-secretase complex. The glycoprotein nicastrin was recently identified as a functional unit of this complex based on 1) binding to PS and 2) the ability to modulate Abeta production following mutation of a conserved DYIGS region. In contrast to the initial report, we find that overexpression of wild-type (WT) nicastrin increases Abeta production, whereas DYIGS mutations (MT) have little or no effect. The increase in Abeta production is associated with an increase in gamma-secretase activity but not with a detectable increase in PS1 levels. Subcellular fractionation studies show that WT but not MT nicastrin matures into buoyant membrane fractions enriched in gamma-secretase activity. These data support the hypothesis that nicastrin is an essential component of the gamma-secretase complex. The finding that WT nicastrin overexpression can increase gamma-secretase activity without altering levels of the presumed catalytic component (PS) of the enzyme may point to a role for nicastrin in facilitating cleavage by regulating substrate interactions with the gamma-secretase complex.	Mayo Clin Jacksonville, Dept Neurosci, Mol Neurobiol Lab, Jacksonville, FL 32224 USA	Mayo Clinic	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, Mol Neurobiol Lab, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu						Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; De Jonghe C, 1998, NEUROBIOL DIS, V5, P281, DOI 10.1006/nbdi.1998.0202; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dermaut B, 2002, AM J HUM GENET, V70, P1568, DOI 10.1086/340732; Desforges M, 2002, VIROLOGY, V295, P63, DOI 10.1006/viro.2001.1329; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Goutte C, 2000, DEVELOPMENT, V127, P2481; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McLendon C, 2000, FASEB J, V14, P2383; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 2002, BBA-MOL BASIS DIS, V1586, P199, DOI 10.1016/S0925-4439(01)00098-9; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	53	31	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1138	+		10.1096/fj.02-1050fje	http://dx.doi.org/10.1096/fj.02-1050fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692078				2022-12-25	WOS:000182580100036
J	Silva, AP; Pinheiro, PS; Carvalho, AP; Carvalho, CM; Jakobsen, B; Zimmer, J; Malva, JO				Silva, AP; Pinheiro, PS; Carvalho, AP; Carvalho, CM; Jakobsen, B; Zimmer, J; Malva, JO			Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures	FASEB JOURNAL			English	Article						NPY; AMPA; kainate; neuroprotection; neurodegeneration	SUPPRESSES EPILEPTIFORM ACTIVITY; RAT HIPPOCAMPUS; DENTATE GYRUS; IN-VITRO; KAINATE RECEPTORS; GLUTAMATE RELEASE; AMPA RECEPTORS; CELL-DEATH; NEURONS; EXPRESSION	Glutamate and NPY have been implicated in hippocampal neuropathology in temporal lobe epilepsy. Thus, we investigated the involvement of NPY receptors in mediating neuroprotection against excitotoxic insults in organotypic cultures of rat hippocampal slices. Exposure of hippocampal slice cultures to 2 muM AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate) induced neuronal degeneration, monitored by propidium iodide uptake, of granule cells and CA1 pyramidal cells. For dentate granule cells, selective activation of Y1, Y2, or Y5 receptors with 1 muM [Leu(31), Pro(34)]NPY, 300 nM NPY13-36 or 1 muM 500 nM NPY(19-23)-(Gly(1), Ser(3), Gln(4), Thr(6), Ala(31), Aib(32), Gln(34))-PP, respectively, had a neuroprotective effect against AMPA, whereas only the activation of Y2 receptors was effective for CA1 pyramidal cells. When the slice cultures were exposed to 6 muM kainate, the CA3 pyramidal cells displayed significant degeneration, and in this case the activation of Y1, Y2, and Y5 receptors was neuroprotective. For the kainic acid-induced degeneration of CA1 pyramidal cells, it was again found that only the Y2 receptor activation was effective. Based on the present findings, it was concluded that Y1, Y2, and Y5 receptors effectively can modify glutamate receptor-mediated neurodegeneration in the hippocampus.	Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal; Univ Coimbra, Dept Zool, Ctr Neurosci Coimbra, P-3004517 Coimbra, Portugal; Univ So Denmark, Dept Anat & Neurobiol, DK-5000 Odense, Denmark	Universidade de Coimbra; Universidade de Coimbra; University of Southern Denmark	Malva, JO (corresponding author), Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal.	jomalva@cnc.cj.uc.pt	Pinheiro, Paulo/O-8765-2017; Silva, Ana Paula/L-4184-2014; Malva, Joao/L-3557-2014	Pinheiro, Paulo/0000-0002-9024-1021; Silva, Ana Paula/0000-0002-7802-8690; Malva, Joao/0000-0002-5438-4447				Ambrosio AF, 2000, EUR J NEUROSCI, V12, P2021, DOI 10.1046/j.1460-9568.2000.00091.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bacci A, 2002, P NATL ACAD SCI USA, V99, P17125, DOI 10.1073/pnas.012481899; Balasubramaniam A, 1997, PEPTIDES, V18, P445, DOI 10.1016/S0196-9781(96)00347-6; Baraban SC, 1997, J NEUROSCI, V17, P8927, DOI 10.1523/jneurosci.17-23-08927.1997; Bijak M, 1999, NEUROSCI LETT, V268, P115, DOI 10.1016/S0304-3940(99)00381-X; BONNEFIL PC, 1993, NEUROSCI LETT, V154, P5; Cabrele C, 2000, J BIOL CHEM, V275, P36043, DOI 10.1074/jbc.M000626200; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Doods H, 1999, EUR J PHARMACOL, V384, pR3, DOI 10.1016/S0014-2999(99)00650-0; Dumont Y, 1998, J NEUROSCI, V18, P5565; Fujikawa DG, 2000, NEUROSCIENCE, V98, P41, DOI 10.1016/S0306-4522(00)00085-3; Furtinger S, 2001, J NEUROSCI, V21, P5804, DOI 10.1523/JNEUROSCI.21-15-05804.2001; Grove KL, 2000, NEUROSCIENCE, V100, P731, DOI 10.1016/S0306-4522(00)00308-0; Ho MWY, 2000, J NEUROPHYSIOL, V83, P723, DOI 10.1152/jn.2000.83.2.723; HSU SSF, 1994, NEUROSCI LETT, V178, P189, DOI 10.1016/0304-3940(94)90756-0; JACQUES D, 1997, NEUROSCIENCE, V79, P5804; Kanatani A, 2000, BIOCHEM BIOPH RES CO, V272, P169, DOI 10.1006/bbrc.2000.2696; Klapstein GJ, 1997, J NEUROPHYSIOL, V78, P1651, DOI 10.1152/jn.1997.78.3.1651; Kristensen BW, 1999, BRAIN RES, V841, P143, DOI 10.1016/S0006-8993(99)01833-8; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Larm JA, 1997, J NEUROCHEM, V69, P617; Lee CC, 1998, REGUL PEPTIDES, V75-6, P71, DOI 10.1016/S0167-0115(98)00054-8; LEES GJ, 1993, BRAIN RES, V628, P1, DOI 10.1016/0006-8993(93)90930-L; Malva JO, 1998, NEUROCHEM INT, V32, P1, DOI 10.1016/S0197-0186(97)00046-6; Marsh DJ, 1999, P NATL ACAD SCI USA, V96, P13518, DOI 10.1073/pnas.96.23.13518; McCullough LA, 1998, REGUL PEPTIDES, V75-6, P101, DOI 10.1016/S0167-0115(98)00058-5; McQuiston AR, 1996, J NEUROPHYSIOL, V76, P3159, DOI 10.1152/jn.1996.76.5.3159; Michel MC, 1998, PHARMACOL REV, V50, P143; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Patrylo PR, 1999, J NEUROPHYSIOL, V82, P478, DOI 10.1152/jn.1999.82.1.478; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Schwarzer C, 1996, BRAIN RES REV, V22, P27; Silva AP, 2001, J NEUROCHEM, V79, P286, DOI 10.1046/j.1471-4159.2001.00560.x; Silva AP, 2001, J NEUROSCI RES, V65, P378, DOI 10.1002/jnr.1164; Statnick MA, 1998, BRAIN RES, V810, P16, DOI 10.1016/S0006-8993(98)00855-5; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Takahashi Y, 2000, NEUROSCI LETT, V287, P105, DOI 10.1016/S0304-3940(00)01133-2; vandenPol AN, 1996, J NEUROSCI, V16, P5883; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; VITALE M, 1993, HISTOCHEMISTRY, V100, P223, DOI 10.1007/BF00269095; WAN CP, 1995, LIFE SCI, V56, P1055, DOI 10.1016/0024-3205(95)00041-4; WETTSTEIN JG, 1995, PHARMACOL THERAPEUT, V65, P397, DOI 10.1016/0163-7258(95)98598-K; Whittaker E, 1999, BRAIN RES, V827, P229, DOI 10.1016/S0006-8993(99)01302-5; WIELAND HA, 1995, PEPTIDES, V16, P1389, DOI 10.1016/0196-9781(95)02028-4; Woldbye DPD, 1997, NAT MED, V3, P761, DOI 10.1038/nm0797-761	49	76	79	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1118	+		10.1096/fj.02-0885fje	http://dx.doi.org/10.1096/fj.02-0885fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692082	Green Submitted			2022-12-25	WOS:000182580100045
J	Li, JH; Huang, XR; Zhu, HJ; Oldfield, M; Cooper, M; Truong, LD; Johnson, RJ; Lan, HY				Li, JH; Huang, XR; Zhu, HJ; Oldfield, M; Cooper, M; Truong, LD; Johnson, RJ; Lan, HY			Advanced glycation end products activate Smad signaling via TGF-beta-dependent and -independent mechanisms: implications for diabetic renal and vascular disease	FASEB JOURNAL			English	Article						TGF-beta/Smad signaling; Smad7; AGEs and RAGE; diabetic nephropathy and vasculopathy	GROWTH-FACTOR-BETA; MATRIX GENE-EXPRESSION; EMBRYONIC LUNG MORPHOGENESIS; RECEPTOR COMPLEX; EPITHELIAL-CELLS; MESANGIAL CELLS; OXIDANT STRESS; CROSS-TALK; IN-VIVO; KAPPA-B	While it is thought that advanced glycation end products (AGEs) act by stimulating transforming growth factor (TGF)-beta to mediate diabetic injury, we report that AGEs can activate TGF-beta signaling, Smads, and mediate diabetic scarring directly and independently of TGF-beta. AGEs activate Smad2/3 in renal and vascular cells at 5 min, peaking over 15.30 min before TGF-beta synthesis at 24 h and occurs in TGF-beta receptor I and II mutant cells. This is mediated by RAGE and ERK/p38 mitogen-activated protein kinases (MAPKs). In addition, AGEs also activate Smads at 24 h via the classic TGF-beta-dependent pathway. A substantial inhibition of AGE-induced Smad activation and collagen synthesis by ERK/p38 MAPK inhibitors, but not by TGF-beta blockade, suggests that the MAPK-Smad signaling crosstalk pathway is a key mechanism in diabetic scarring. Prevention of AGE-induced Smad activation and collagen synthesis by overexpression of Smad7 indicates that Smad signaling may play a critical role in diabetic complications. This is further supported by the findings that activation of Smad2/3 in human diabetic nephropathy and vasculopathy is associated with local deposition of AGEs and upregulation of RAGE. Thus, AGEs act by activating Smad signaling to mediate diabetic complications via both TGF-beta-dependent and -independent pathways, shedding new light on the pathogenesis of diabetic organ injury.	Baylor Coll Med, Dept Med Nephrol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Melbourne, Vic, Australia	Baylor College of Medicine; Baylor College of Medicine; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Lan, HY (corresponding author), Baylor Coll Med, Dept Med Nephrol, 1 Baylor Plaza,Alkek N520, Houston, TX 77030 USA.	hlan@bcm.tmc.edu	Li, Jinhua/I-2741-2014; Lan, Hui Yao/C-9734-2015	Lan, Hui Yao/0000-0003-4283-9755; Li, Jinhua/0000-0003-4039-5759; Zhu, Hong-Jian/0000-0002-1478-995X	Juvenile Diabetes Research Foundation (JDRF) [1-2001-596, 4-1999-821]; Texas Advanced Technology Program [004949-0005-2001]; National Health & Medical Research Council [164812]	Juvenile Diabetes Research Foundation (JDRF)(Juvenile Diabetes Research Foundation); Texas Advanced Technology Program; National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-596 and 4-1999-821), Texas Advanced Technology Program (004949-0005-2001), and from the National Health & Medical Research Council (164812).	Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Border WA, 1996, DIABETES METAB REV, V12, P309; Bucala R, 1995, AM J KIDNEY DIS, V26, P875, DOI 10.1016/0272-6386(95)90051-9; Chen RH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134887; Cooper ME, 2001, AM J HYPERTENS, V14, P475, DOI 10.1016/S0895-7061(00)01323-6; Forbes JM, 2001, DIABETOLOGIA, V44, P108, DOI 10.1007/s001250051587; Han DC, 2000, AM J PHYSIOL-RENAL, V278, pF628, DOI 10.1152/ajprenal.2000.278.4.F628; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Hong SW, 2001, AM J PATHOL, V158, P1653; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JH, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014252.37680.E4; Massague J, 2000, GENE DEV, V14, P627; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Reeves WB, 2000, P NATL ACAD SCI USA, V97, P7667, DOI 10.1073/pnas.97.14.7667; Rumble JR, 1997, J CLIN INVEST, V99, P1016, DOI 10.1172/JCI119229; Schmidt AM, 2000, TRENDS ENDOCRIN MET, V11, P368, DOI 10.1016/S1043-2760(00)00311-8; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; Striker LJ, 1996, NEPHROL DIAL TRANSPL, V11, P62; THROCKMORTON DC, 1995, KIDNEY INT, V48, P111, DOI 10.1038/ki.1995.274; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200; Zhao JS, 2000, MECH DEVELOP, V93, P71, DOI 10.1016/S0925-4773(00)00281-1; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	43	210	231	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					176	178		10.1096/fj.02-1117fje	http://dx.doi.org/10.1096/fj.02-1117fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	12709399				2022-12-25	WOS:000188829300055
J	Doucey, MA; Legler, DF; Faroudi, M; Boucheron, N; Baumgaertner, P; Naeher, D; Cebecauer, M; Hudrisier, D; Ruegg, C; Palmer, E; Valitutti, S; Bron, C; Luescher, IF				Doucey, MA; Legler, DF; Faroudi, M; Boucheron, N; Baumgaertner, P; Naeher, D; Cebecauer, M; Hudrisier, D; Ruegg, C; Palmer, E; Valitutti, S; Bron, C; Luescher, IF			The beta(1) and beta(3) integrins promote T cell receptor-mediated cytotoxic T lymphocyte activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; FUNCTION-ASSOCIATED ANTIGEN-1; CD8 CORECEPTOR FUNCTION; IMMUNOLOGICAL SYNAPSE; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; LIGAND INTERACTIONS; CROSS-LINKING; LIPID RAFTS; TCR	Recognition by CD8(+) cytotoxic T lymphocytes (CTLs) of antigenic peptides bound to major histocompatibility class (MHC) I molecules on target cells leads to sustained calcium mobilization and CTL degranulation resulting in perforin-dependent killing. We report that beta(1) and beta(3) integrin-mediated adhesion to extracellular matrix proteins on target cells and/or surfaces dramatically promotes CTL degranulation. CTLs, when adhered to fibronectin but not CTL in suspension, efficiently degranulate upon exposure to soluble MHC . peptide complexes, even monomeric ones. This adhesion induces recruitment and activation of the focal adhesion kinase Pyk2, the cytoskeleton linker paxillin, and the Src kinases Lck and Fyn in the contact site. The T cell receptor, by association with Pyk2, becomes part of this adhesion-induced activation cluster, which greatly increases its signaling.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland; CHU Purpan, INSERM, U563, F-31059 Toulouse, France; Univ Basel, Kantonsspital, CH-4031 Basel, Switzerland; Univ Lausanne, Sch Med, Ctr Pluridisciplinaire Oncol, CH-1066 Epalinges, Switzerland	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Kantonsspital Aarau AG (KSA); University of Basel; University of Lausanne	Doucey, MA (corresponding author), Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland.		Cebecauer, Marek/F-5169-2014; Valitutti, Salvatore/M-2999-2014	Cebecauer, Marek/0000-0002-4606-1218; Valitutti, Salvatore/0000-0002-6432-4421; Boucheron, Nicole/0000-0002-4979-8311; Hudrisier, Denis/0000-0002-3631-9561; Legler, Daniel F./0000-0001-8610-4764				ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ANICHINI A, 1992, J IMMUNOTHER, V12, P183, DOI 10.1097/00002371-199210000-00008; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Bearz A, 1999, IMMUNOLOGY, V98, P564, DOI 10.1046/j.1365-2567.1999.00917.x; Berg NN, 1997, J IMMUNOL, V159, P1753; Block MS, 2001, J IMMUNOL, V167, P821, DOI 10.4049/jimmunol.167.2.821; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Burack WR, 2002, J IMMUNOL, V169, P2837, DOI 10.4049/jimmunol.169.6.2837; Cawthon AG, 2002, J IMMUNOL, V169, P3492, DOI 10.4049/jimmunol.169.7.3492; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Daniels MA, 2000, J EXP MED, V191, P335, DOI 10.1084/jem.191.2.335; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Delon J, 1998, IMMUNITY, V9, P467, DOI 10.1016/S1074-7613(00)80630-5; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Doucey MA, 2001, EUR J IMMUNOL, V31, P1561, DOI 10.1002/1521-4141(200105)31:5&lt;1561::AID-IMMU1561&gt;3.0.CO;2-W; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Dustin ML, 2001, CURR OPIN IMMUNOL, V13, P286, DOI 10.1016/S0952-7915(00)00217-X; Epler JA, 2000, J IMMUNOL, V165, P4941, DOI 10.4049/jimmunol.165.9.4941; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Freiberg BA, 2002, NAT IMMUNOL, V3, P911, DOI 10.1038/ni836; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ge Q, 2002, P NATL ACAD SCI USA, V99, P13729, DOI 10.1073/pnas.212515299; Gismondi A, 2000, J IMMUNOL, V164, P2272, DOI 10.4049/jimmunol.164.5.2272; Gismondi A, 1997, J IMMUNOL, V159, P4729; Griffiths EK, 2002, CURR OPIN IMMUNOL, V14, P317, DOI 10.1016/S0952-7915(02)00334-5; Griffiths EK, 2001, SCIENCE, V293, P2260, DOI 10.1126/science.1063397; Iwata S, 2000, J DERMATOL SCI, V23, P75, DOI 10.1016/S0923-1811(99)00096-1; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kessler B, 1997, J EXP MED, V186, P2033, DOI 10.1084/jem.186.12.2033; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Lanzavecchia A, 2001, NAT IMMUNOL, V2, P487, DOI 10.1038/88678; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Legler DF, 2001, J CELL SCI, V114, P1545; Legler DF, 2001, FASEB J, V15, P1601, DOI 10.1096/fj.00-0841fje; Leupin O, 2000, CURR BIOL, V10, P277, DOI 10.1016/S0960-9822(00)00362-6; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; LUESCHER IF, 1995, IMMUNITY, V3, P51, DOI 10.1016/1074-7613(95)90158-2; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; McGavern DB, 2002, NAT IMMUNOL, V3, P918, DOI 10.1038/ni843; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Peterson EJ, 2001, SCIENCE, V293, P2263, DOI 10.1126/science.1063486; Potter TA, 2001, P NATL ACAD SCI USA, V98, P12624, DOI 10.1073/pnas.221458898; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Rao WH, 2000, J IMMUNOL, V165, P4935, DOI 10.4049/jimmunol.165.9.4935; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Sancho D, 2000, J CELL BIOL, V149, P1249, DOI 10.1083/jcb.149.6.1249; Sancho D, 2002, J IMMUNOL, V169, P292, DOI 10.4049/jimmunol.169.1.292; Schmits R, 1996, J EXP MED, V183, P1415, DOI 10.1084/jem.183.4.1415; Schott E, 2002, P NATL ACAD SCI USA, V99, P13735, DOI 10.1073/pnas.212515399; SHIMONKEVITZ R, 1985, J IMMUNOL, V135, P1555; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Ybarrondo B, 1997, IMMUNOLOGY, V91, P186, DOI 10.1046/j.1365-2567.1997.00237.x; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	69	57	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26983	26991		10.1074/jbc.M302709200	http://dx.doi.org/10.1074/jbc.M302709200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12690105	hybrid			2022-12-25	WOS:000184155700089
J	Ishimi, Y; Komamura-Kohno, Y; Kwon, HJ; Yamada, K; Nakanishi, M				Ishimi, Y; Komamura-Kohno, Y; Kwon, HJ; Yamada, K; Nakanishi, M			Identification of MCM4 as a target of the DNA replication block checkpoint system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; CELL-CYCLE; HELICASE ACTIVITY; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DAMAGE CHECKPOINT; FORK PROGRESSION; HUMAN CHK1; PHOSPHORYLATION	Inhibition of the progression of DNA replication prevents further initiation of DNA replication and allows cells to maintain arrested replication forks, but the proteins that are targets of the replication checkpoint system remain to be identified. We report here that human MCM4, a subunit of the putative DNA replicative helicase, is extensively phosphorylated in HeLa cells when they are incubated in the presence of inhibitors of DNA synthesis or are exposed to UV irradiation. The data presented here indicate that the consecutive actions of ATR-CHK1 and CDK2 kinases are involved in this phosphorylation in the presence of hydroxyurea. The phosphorylation sites in MCM4 were identified using specific anti-phosphoantibodies. Based on results that showed that the DNA helicase activity of the MCM4-6-7 complex is negatively regulated by CDK2 phosphorylation, we suggest that the phosphorylation of MCM4 in the checkpoint control inhibits DNA replication, which includes blockage of DNA fork progression, through inactivation of the MCM complex.	Mitsubishi Kagaku Inst Life Sci, Biomol & Technol Dept, Tokyo 1948511, Japan; Natl Inst Hlth & Nutr, Shinjuku Ku, Tokyo 1628636, Japan; Nagoya City Univ, Dept Biochem & Cell Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); National Institute of Health & Nutrition - Japan; Nagoya City University	Ishimi, Y (corresponding author), Mitsubishi Kagaku Inst Life Sci, Biomol & Technol Dept, 11 Minamiooya, Tokyo 1948511, Japan.		권, 호정/AAS-3642-2021					Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Donaldson AD, 2001, CURR BIOL, V11, pR979, DOI 10.1016/S0960-9822(01)00579-6; Eapen AK, 2001, MOL CELL BIOL, V21, P6113, DOI 10.1128/MCB.21.18.6113-6121.2001; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kihara M, 2000, J BIOL CHEM, V275, P35051, DOI 10.1074/jbc.M003491200; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; Kohn EA, 2003, CANCER RES, V63, P31; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Liberi G, 2000, EMBO J, V19, P5027, DOI 10.1093/emboj/19.18.5027; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marchetti MA, 2002, P NATL ACAD SCI USA, V99, P7472, DOI 10.1073/pnas.112702399; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Rhind N, 2000, J CELL SCI, V113, P3889; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	44	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24644	24650		10.1074/jbc.M213252200	http://dx.doi.org/10.1074/jbc.M213252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714602	hybrid			2022-12-25	WOS:000183824800049
J	Ordentlich, P; Yan, YZ; Zhou, SH; Heyman, RA				Ordentlich, P; Yan, YZ; Zhou, SH; Heyman, RA			Identification of the antineoplastic agent 6-mercaptopurine as an activator of the orphan nuclear hormone receptor Nurr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GANGLION-CELLS; NGFI-B; 6-METHYLMERCAPTOPURINE RIBOSIDE; TYROSINE-HYDROXYLASE; NUR77; GENE; APOPTOSIS; MECHANISM; KINASE; HETERODIMERIZATION	The purine anti-metabolite 6-mercaptopurine is one of the most widely used drugs for the treatment of acute childhood leukemia and chronic myelocytic leukemia. Developed in the 1950s, the drug is also being used as a treatment for inflammatory diseases such as Crohn's disease. The antiproliferative mechanism of action of this drug and other purine anti-metabolites has been demonstrated to be through inhibition of de novo purine synthesis and incorporation into nucleic acids. Despite the extensive clinical use and study of 6-mercaptopurine and other purine analogues, the cellular effects of these compounds remain relatively unknown. More recently, purine anti-metabolites have been shown to function as protein kinase inhibitors and to regulate gene expression. In an attempt to find small molecule regulators of the orphan nuclear receptor Nurr1, interestingly, we identified 6-mercaptopurine as a specific activator of this receptor. A detailed analysis of 6-mercaptopurine regulation of Nurr1 demonstrates that 6-mercaptopurine regulates Nurr1 through a region in the amino terminus. This activity can be inhibited by components of the purine biosynthesis pathway. These findings indicate that Nurr1 may play a role in mediating some of the antiproliferative effects of 6-mercaptopurine and potentially implicate Nurr1 as a molecular target for treatment of leukemias.	XCeptor Therapeut Inc, San Diego, CA 92121 USA		Ordentlich, P (corresponding author), XCeptor Therapeut Inc, 4757 Nexus Ctr Dr, San Diego, CA 92121 USA.							Benowitz LI, 1998, J BIOL CHEM, V273, P29626, DOI 10.1074/jbc.273.45.29626; Castillo SO, 1998, MOL CELL NEUROSCI, V11, P36, DOI 10.1006/mcne.1998.0673; CHABNER BA, 1996, GOODMAN GILMANS PHAR, P1252; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; ELION GB, 1952, J AM CHEM SOC, V74, P411, DOI 10.1021/ja01122a037; ELION GB, 1967, FED PROC, V26, P898; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; HIRATA Y, 1995, J NEUROCHEM, V65, P1780; HOKI H, 1990, Mie Medical Journal, V40, P99; Hortelano S, 1997, MOL PHARMACOL, V51, P414; Iwawaki T, 2000, BIOCHEM BIOPH RES CO, V274, P590, DOI 10.1006/bbrc.2000.3204; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maira M, 1999, MOL CELL BIOL, V19, P7549; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maruyama K, 1998, INT J ONCOL, V12, P1237; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Petrausch B, 2000, J NEUROSCI, V20, P8031; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Presta M, 1999, CANCER RES, V59, P2417; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; STET EH, 1995, BIOCHEM PHARMACOL, V49, P49, DOI 10.1016/0006-2952(94)00387-2; Tendian SW, 2000, MOL PHARMACOL, V57, P695, DOI 10.1124/mol.57.4.695; TIDD DM, 1974, CANCER RES, V34, P738; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VOGT MHJ, 1993, BIOCHIM BIOPHYS ACTA, V1181, P189, DOI 10.1016/0925-4439(93)90110-M; VOLONTE C, 1993, MOL BIOL CELL, V4, P71, DOI 10.1091/mbc.4.1.71; VOLONTE C, 1992, J NEUROCHEM, V58, P700, DOI 10.1111/j.1471-4159.1992.tb09774.x; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	45	89	97	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24791	24799		10.1074/jbc.M302167200	http://dx.doi.org/10.1074/jbc.M302167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709433	hybrid			2022-12-25	WOS:000183824800066
J	Choi, MG; Park, TS; Carman, GM				Choi, MG; Park, TS; Carman, GM			Phosphorylation of Saccharomyces cerevisiae CTP synthetase at Ser(424) by protein kinases A and C regulates phosphatidylcholine synthesis by the CDP-choline pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE TRIPHOSPHATE SYNTHETASE; CYTOSINE INDUCES APOPTOSIS; HAMSTER OVARY CELLS; PHOSPHOLIPID BIOSYNTHESIS; LYMPHOBLASTIC-LEUKEMIA; ALLOSTERIC EFFECTOR; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; URA7 GENE; YEAST	The Saccharomyces cerevisiae URA7-encoded CTP synthetase is phosphorylated and stimulated by protein kinases A and C. Previous studies have revealed that Ser(424) is the target site for protein kinase A. Using a purified S424A mutant CTP synthetase enzyme, we examined the effect of Ser(424) phosphorylation on protein kinase C phosphorylation. The S424A mutation in CTP synthetase caused a 50% decrease in the phosphorylation of the enzyme by protein kinase C and an 80% decrease in the stimulatory effect on CTP synthetase activity by protein kinase C. The S424A mutation caused increases in the apparent Km values of CTP synthetase and ATP of 20- and 2-fold, respectively, in the protein kinase C reaction. The effect of the S424A mutation on the phosphorylation reaction was dependent on time and protein kinase C concentration. A CTP synthetase synthetic peptide (SLGRKDSHSA) containing Ser(424) was a substrate for protein kinase C. Comparison of phosphopeptide maps of the wild type and S424A mutant CTP synthetase enzymes phosphorylated by protein kinases A and C indicated that Ser(424) was also a target site for protein kinase C. Phosphorylation of Ser(424) accounted for 10% of the total phosphorylation of CTP synthetase by protein kinase C. The incorporation of [methyl-H-3] choline into phosphocholine, CDP-choline, and phosphatidylcholine in cells carrying the S424A mutant CTP synthetase enzyme was reduced by 48, 32, and 46%, respectively, when compared with control cells. These data indicated that phosphorylation of Ser(424) by protein kinase A or by protein kinase C was required for maximum phosphorylation and stimulation of CTP synthetase and that the phosphorylation of this site played a role in the regulation of phosphatidylcholine synthesis by the CDP-choline pathway.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, 65 Dudley Rd, New Brunswick, NJ 08901 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1987, J BIOL CHEM, V262, P5106; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bearne SL, 2001, BIOCHEM J, V356, P223, DOI 10.1042/0264-6021:3560223; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; ESKO JD, 1980, J BIOL CHEM, V255, P4474; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hatch GM, 1996, J BIOL CHEM, V271, P25810, DOI 10.1074/jbc.271.42.25810; Hendriks EF, 1998, BBA-GENE STRUCT EXPR, V1399, P213, DOI 10.1016/S0167-4781(98)00108-0; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mahony TJ, 1998, FEMS MICROBIOL LETT, V165, P153; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Park TS, 2003, J BIOL CHEM, V278, P20785, DOI 10.1074/jbc.M301394200; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 2002, MOL CLONING LAB MANU; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; Van Kuilenburg ABP, 1998, ADV EXP MED BIOL, V431, P255; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P257; van Kuilenburg ABP, 2000, BBA-GENE STRUCT EXPR, V1492, P548, DOI 10.1016/S0167-4781(00)00141-X; VANDENBERG AA, 1995, EUR J CANCER, V31A, P108, DOI 10.1016/0959-8049(94)00442-8; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; Verschuur AC, 1998, ADV EXP MED BIOL, V431, P667; Verschuur AC, 2000, ADV EXP MED BIOL, V486, P319; Verschuur AC, 2001, LEUKEMIA RES, V25, P891, DOI 10.1016/S0145-2126(01)00047-9; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; Willemoes M, 2003, J BIOL CHEM, V278, P9407, DOI 10.1074/jbc.M212995200; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	74	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23610	23616		10.1074/jbc.M303337200	http://dx.doi.org/10.1074/jbc.M303337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12709422	Green Submitted, hybrid			2022-12-25	WOS:000183638600051
J	Shikamoto, Y; Morita, T; Fujimoto, Z; Mizuno, H				Shikamoto, Y; Morita, T; Fujimoto, Z; Mizuno, H			Crystal structure of Mg2+- and Ca2+-bound Gla domain of factor IX complexed with binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-IX; GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-X ACTIVATION; TISSUE FACTOR PATHWAY; K-DEPENDENT PROTEINS; GROWTH-FACTOR DOMAIN; VITAMIN-K; BLOOD-COAGULATION; TRIMERESURUS-FLAVOVIRIDIS; MONOCLONAL-ANTIBODY	Factor IX is an indispensable protein required in the blood coagulation cascade. It binds to the surface of phospholipid membrane by means of a gamma-carboxyglutamic acid (Gla) domain situated at the N terminus. Recently, we showed that physiological concentrations of Mg2+ ions affect the native conformation of the Gla domain and in doing so augment the biological activity of factor IXa and binding affinity with its binding protein even in the presence of Ca2+ ions. Here we report on the crystal structures of the Mg2+/Ca2+-bound and Ca2+-bound (Mg2+-free) factor IX Gla domain (IXGD1-46) in complex with its binding protein (IX-bp) at 1.55 and 1.80 Angstrom resolutions, respectively. Three Mg2+ and five Ca2+ ions were bound in the Mg2+/Ca2+-bound IXGD1-46, and the Mg2+ ions were replaced by Ca2+ ions in Mg2+-free IXGD1-46. Comparison of Mg2+/Ca2+-bound with Ca2+-bound structures of the complexes showed that Mg2+ ion, which formed a bridge between IXGD1-46 and IX-bp, forced IXGD1-46 to rotate 4degrees relative to IX-bp and hence might be the cause of a more tight interaction between the molecules than in the case of the Mg2+-free structure. The results clearly suggest that Mg2+ ions are required to maintain native conformation and in vivo function of factor IX Gla domain during blood coagulation.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	National Institute of Agrobiological Sciences - Japan; Meiji Pharmaceutical University	Mizuno, H (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, Kannondai 2-1-2, Tsukuba, Ibaraki 3058602, Japan.	mizuno@affrc.go.jp		Fujimoto, Zui/0000-0002-3551-6854				AHMAD SS, 1992, J BIOL CHEM, V267, P8571; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ATODA H, 1995, J BIOCHEM-TOKYO, V118, P965, DOI 10.1093/jb/118.5.965; ATODA H, 1991, J BIOL CHEM, V266, P14903; ATODA H, 1989, J BIOCHEM, V106, P808, DOI 10.1093/oxfordjournals.jbchem.a122935; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; Falls LA, 2001, J BIOL CHEM, V276, P23895, DOI 10.1074/jbc.M008332200; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1992, NEW ENGL J MED, V326, P800; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; HASHIMOTO N, 1985, J BIOCHEM, V97, P1347, DOI 10.1093/oxfordjournals.jbchem.a135187; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; JONES KC, 1994, J BIOL CHEM, V269, P23367; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LIN SW, 1990, J BIOL CHEM, V265, P144; MANN KG, 1990, BLOOD, V76, P1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizuno H, 1999, J MOL BIOL, V289, P103, DOI 10.1006/jmbi.1999.2756; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; Nelsestuen GL, 1999, CURR OPIN STRUC BIOL, V9, P433, DOI 10.1016/S0959-440X(99)80060-8; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATERSON CR, 1983, ESSENTIALS HUMAN BIO, P237; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Persson KEM, 2002, J BIOL CHEM, V277, P35616, DOI 10.1074/jbc.M205930200; Sekiya F, 1996, FEBS LETT, V392, P205, DOI 10.1016/0014-5793(96)00813-7; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; Sekiya F, 1996, J BIOL CHEM, V271, P8541, DOI 10.1074/jbc.271.15.8541; SORIANOGARCIA M, 1989, BIOCHEMISTRY-US, V28, P6805, DOI 10.1021/bi00443a004; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; THOMPSON AR, 1986, BLOOD, V67, P565	42	73	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24090	24094		10.1074/jbc.M300650200	http://dx.doi.org/10.1074/jbc.M300650200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695512	hybrid			2022-12-25	WOS:000183638600112
J	D'Alessio, C; Trombetta, ES; Parodi, AJ				D'Alessio, C; Trombetta, ES; Parodi, AJ			Nucleoside diphosphatase and glycosyltransferase activities can localize to different subcellular compartments in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLC-GLYCOPROTEIN GLUCOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; CARRIER-MEDIATED TRANSPORT; SACCHAROMYCES-CEREVISIAE; GUANOSINE DIPHOSPHATASE; TRYPANOSOMATID PROTOZOA; LINKED OLIGOSACCHARIDES; GOLGI-APPARATUS; GLUCOSIDASE-II; RAT-LIVER	Nucleoside diphosphates generated by glycosyltransferases in the fungal, plant, and mammalian cell secretory pathways are converted into monophosphates to relieve inhibition of the transferring enzymes and provide substrates for antiport transport systems by which the entrance of nucleotide sugars from the cytosol into the secretory pathway lumen is coupled to the exit of nucleoside monophosphates. Analysis of the yeast Schizosaccharomyces pombe genome revealed that it encodes two enzymes with potential nucleoside diphosphatase activity, Spgda1p and Spynd1p. Characterization of the overexpressed enzymes showed that Spgda1p is a GDPase/ UDPase, whereas Spynd1p is an apyrase because it hydrolyzed both nucleoside tri and diphosphates. Subcellular fractionation showed that both activities localize to the Golgi. Individual disruption of their encoding genes did not affect cell viability, but disruption of both genes was synthetically lethal. Disruption of Spgda1(+) did not affect Golgi N- or O- glycosylation, whereas disruption of Spynd1(+) affected Golgi N- mannosylation but not O- mannosylation. Although no nucleoside diphosphatase activity was detected in the endoplasmic reticulum ( ER), N- glycosylation mediated by the UDP- Glc: glycoprotein glucosyltransferase ( GT) was not severely impaired in mutants because first, no ER accumulation of misfolded glycoproteins occurred as revealed by the absence of induction of BiP mRNA, and second, in vivo GT- dependent glucosylation monitored by incorporation of labeled Glc into folding glycoproteins showed a partial ( 35 - 50%) decrease in Spgda1 but was not affected in Spynd1 mutants. Results show that, contrary to what has been assumed to date for eukaryotic cells, in S. pombe nucleoside diphosphatase and glycosyltransferase activities can localize to different subcellular compartments. It is tentatively suggested that ER- Golgi vesicle transport might be involved in nucleoside diphosphate hydrolysis.	Univ San Martin, Biotechnol Res Inst, RA-1650 San Martin, Argentina; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University	Parodi, AJ (corresponding author), Fdn Inst Leloir, Avda Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.	aparodi@leloir.org.ar		D'Alessio, Cecilia/0000-0001-7371-5080	NIGMS NIH HHS [GM 44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Alfa C., 1993, EXPT FISSION YEAST L, P133; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BOSCH M, 1988, J BIOL CHEM, V263, P17360; Bossuyt X, 1997, BIOCHEM J, V323, P645, DOI 10.1042/bj3230645; BOSSUYT X, 1994, BIOCHEM J, V302, P261, DOI 10.1042/bj3020261; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; Failer BU, 2002, J BIOL CHEM, V277, P36978, DOI 10.1074/jbc.M201656200; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; Fernandez F, 1998, EMBO J, V17, P5877, DOI 10.1093/emboj/17.20.5877; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gemmill TR, 1999, GLYCOBIOLOGY, V9, P507, DOI 10.1093/glycob/9.5.507; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; JANNATIPOUR M, 1995, J BIOL CHEM, V270, P4845, DOI 10.1074/jbc.270.9.4845; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PIDOUX AL, 1992, EMBO J, V11, P1583, DOI 10.1002/j.1460-2075.1992.tb05203.x; SIMEON A, 1995, YEAST, V11, P271, DOI 10.1002/yea.320110309; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	36	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22379	22387		10.1074/jbc.M300892200	http://dx.doi.org/10.1074/jbc.M300892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686557	hybrid			2022-12-25	WOS:000183503900029
J	Nyberg, P; Heikkila, P; Sorsa, T; Luostarinen, J; Heljasvaara, R; Stenman, UH; Pihlajaniemi, T; Salo, T				Nyberg, P; Heikkila, P; Sorsa, T; Luostarinen, J; Heljasvaara, R; Stenman, UH; Pihlajaniemi, T; Salo, T			Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2,-9, and-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-ASSOCIATED TRYPSIN; PLASMINOGEN-ACTIVATOR; NC1/ENDOSTATIN DOMAIN; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; CANCER PATIENTS; IV COLLAGENASE; XVIII COLLAGEN; ORAL CAVITY; CYST FLUID	Endostatin, a 20- kDa collagen XVIII fragment, inhibits angiogenesis and tumor growth in vivo, but the mechanisms are still unclear. Matrix metalloproteases ( MMPs), a family of extracellular and membrane- associated endopeptidases, collectively digest almost all extracellular matrix and basement membrane components, and thus play an important role in tumor progression. We studied the effects of recombinant human endostatin on human MMP- 2, - 9, - 8, and - 13. We found that endostatin inhibited the activation and catalytic activity of pro- MMP- 9 and - 13 as well as recombinant pro- MMP- 2. It prevented the fragmentation of pro- MMP- 2 that was associated with reduction of catalytic activity. Endostatin had no effect on MMP- 8 as shown by collagenase activity assays. An in vitro migration assay and an in vivo chicken chorioallantoic membrane intravasation assay with the human tongue squamous cell carcinoma cell line HSC- 3 revealed the biphasic nature of endostatin; low endostatin concentrations inhibited intravasation and migration of these cells in a dose- dependent manner, but at increased concentrations, the inhibitory effect was far less efficient. The results show that endostatin blocks the activation and activities of certain tumor-associated pro- MMPs, such as pro- MMP- 2, - 9, and - 13, which may explain, at least in part, the antitumor effect of endostatin. Our results also suggest that endostatin inhibits tumor progression by directly affecting the tumor cells and not just acting via endothelial cells and blockage of angiogenesis.	Oulu Univ, Dept Diagnost & Oral Med, Inst Dent, FIN-90014 Oulu, Finland; Univ Helsinki, Dept Oral & Maxillofacial Dis, Cent Hosp, Inst Dent,Orton Res Inst, FIN-00014 Helsinki, Finland; Orthoped Hosp Invalid Fdn, FIN-00014 Helsinki, Finland; Oulu Univ, Collagen Res Unit, Bioctr, FIN-90014 Oulu, Finland; Oulu Univ, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; Univ Helsinki, Cent Hosp, Dept Clin Chem, FIN-00029 Helsinki, Finland; Univ Helsinki, Inst Dent, FIN-00014 Helsinki, Finland; Univ Helsinki, Dent Clin, FIN-00014 Helsinki, Finland	University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki	Salo, T (corresponding author), Oulu Univ, Dept Diagnost & Oral Med, Inst Dent, POB 5281, FIN-90014 Oulu, Finland.	tuula.salo@oulu.fi	, tuula/ABG-2051-2021	Heljasvaara, Ritva/0000-0003-4763-3844; Pihlajaniemi, Taina/0000-0002-1664-9045				Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Croce MV, 2001, INT J ONCOL, V18, P729; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Heikkila P, 2002, ANTI-CANCER DRUG, V13, P245, DOI 10.1097/00001813-200203000-00006; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kawamata H, 1998, INT J ONCOL, V13, P699; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200; Kim YM, 2000, CANCER RES, V60, P5410; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1990, CANCER RES, V50, P2375; KOIVUNEN E, 1989, J BIOL CHEM, V264, P14095; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; KOIVUNEN E, 1991, CANCER RES, V51, P2107; Kranenburg O, 2002, CURR BIOL, V12, P1833, DOI 10.1016/S0960-9822(02)01224-1; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Lee SJ, 2002, FEBS LETT, V519, P147, DOI 10.1016/S0014-5793(02)02742-4; MAKELA M, 1994, J DENT RES, V73, P1397, DOI 10.1177/00220345940730080201; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Miyata S, 1998, CLIN EXP METASTAS, V16, P613, DOI 10.1023/A:1006576313979; Nyberg P, 2002, J DENT RES, V81, P831, DOI 10.1177/154405910208101207; OGRADY RL, 1984, ANAL BIOCHEM, V140, P490, DOI 10.1016/0003-2697(84)90199-4; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; Olsen BR, 2002, MATRIX BIOL, V21, P309; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Paju A, 2001, BRIT J CANCER, V84, P1363, DOI 10.1054/bjoc.2001.1806; REHN M, 1994, J BIOL CHEM, V269, P13929; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; RISTELI L, 1987, METHOD ENZYMOL, V145, P391; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; SORSA T, 1994, ANN NY ACAD SCI, V732, P112, DOI 10.1111/j.1749-6632.1994.tb24729.x; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; Wickstrom SA, 2001, CANCER RES, V61, P6511; Xue H, 2001, BIOCHEM BIOPH RES CO, V288, P610, DOI 10.1006/bbrc.2001.5813; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	55	119	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22404	22411		10.1074/jbc.M210325200	http://dx.doi.org/10.1074/jbc.M210325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690120	hybrid			2022-12-25	WOS:000183503900032
J	Chan, SL; Lee, MC; Tan, KO; Yang, LK; Lee, ASY; Flotow, H; Fu, NY; Butler, MS; Soejarto, DD; Buss, AD; Yu, VC				Chan, SL; Lee, MC; Tan, KO; Yang, LK; Lee, ASY; Flotow, H; Fu, NY; Butler, MS; Soejarto, DD; Buss, AD; Yu, VC			Identification of chelerythrine as an inhibitor of BclXL function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-MOLECULE INHIBITORS; SEX-DETERMINING PROTEIN; CYTOCHROME-C RELEASE; CELL-DEATH; BCL-2 FAMILY; BH3 DOMAIN; KINASE-C; APOPTOSIS; BAX; MITOCHONDRIA	The identification of small molecule inhibitors of antiapoptotic Bcl-2 family members has opened up new therapeutic opportunities, while the vast diversity of chemical structures and biological activities of natural products are yet to be systematically exploited. Here we report the identification of chelerythrine as an inhibitor of BclXL-Bak Bcl-2 homology 3 (BH3) domain binding through a high throughput screening of 107,423 extracts derived from natural products. Chelerythrine inhibited the BclXL-Bak BH3 peptide binding with IC50 of 1.5 muM and displaced Bax, a BH3-containing protein, from BclXL. Mammalian cells treated with chelerythrine underwent apoptosis with characteristic features that suggest involvement of the mitochondrial pathway. While staurosporine, H7, etoposide, and chelerythrine released cytochrome c from mitochondria in intact cells, only chelerythrine released cytochrome c from isolated mitochondria. Furthermore BclXL-overexpressing cells that were completely resistant to apoptotic stimuli used in this study remained sensitive to chelerythrine. Although chelerythrine is widely known as a protein kinase C inhibitor, the mechanism by which it mediates apoptosis remain controversial. Our data suggest that chelerythrine triggers apoptosis through a mechanism that involves direct targeting of Bcl-2 family proteins.	Inst Mol & Cell Biol, Singapore 117609, Singapore; MerLion Pharmaceut Pte Ltd, Fleming, Singapore 118240, Singapore; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Yu, VC (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Butler, Mark S./D-9973-2011; Lee, Andrew/GVU-2817-2022; Chan, S.L./X-4154-2018; Yu, Victor/A-7899-2015	Butler, Mark S./0000-0001-6689-4236; Chan, S.L./0000-0002-3270-0525; Yu, Victor/0000-0003-3270-4734; Tan, Kuan/0000-0002-0947-7337; FU, Naiyang/0000-0001-5457-4323; Lee, Mei Chin/0000-0001-7689-6446				Baell JB, 2002, BIOCHEM PHARMACOL, V64, P851, DOI 10.1016/S0006-2952(02)01148-6; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Chmura SJ, 2000, CLIN CANCER RES, V6, P737; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANAOKA M, 1986, J CHEM SOC PERK T 1, P2253, DOI 10.1039/p19860002253; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nielsen J, 2002, CURR OPIN CHEM BIOL, V6, P297, DOI 10.1016/S1367-5931(02)00330-7; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PETTIT GR, 1985, TETRAHEDRON, V41, P985, DOI 10.1016/S0040-4020(01)96466-X; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559	29	145	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20453	20456		10.1074/jbc.C300138200	http://dx.doi.org/10.1074/jbc.C300138200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12702731	hybrid			2022-12-25	WOS:000183230500003
J	Bhattacharya, S; Garriga, J; Calbo, J; Yong, T; Haines, DS; Grana, X				Bhattacharya, S; Garriga, J; Calbo, J; Yong, T; Haines, DS; Grana, X			SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells	ONCOGENE			English	Article						adenoviruses; cyclin D1; cyclin E; CDK; E2F1	DEPENDENT KINASE INHIBITORS; HUMAN PROSTATE-CANCER; LIGASE SUBUNIT SKP2; BOX PROTEIN SKP2; RETINOBLASTOMA PROTEIN; S-PHASE; ADIPOCYTE DIFFERENTIATION; CYCLIN-E; PHOSPHORYLATION; P107	p130 is a member of the retinoblastoma family of pocket proteins, which includes pRB and p107. Unlike pRB and p107, p130 protein levels decrease dramatically following its hyperphosphorylation starting in the mid-G1 phase of the cell cycle. However, the mechanism leading to p130 downregulation is unknown. We have found that the proteasome inhibitor, lactacystin, inhibited p130 downregulation in T98G cells progressing through the G1/S transition and S phase and that p130 is multiubiquitylated in 293 cells. We have previously shown that ectopic expression of both cyclin D and E induces phosphorylation and downregulation of p130. Since the SKP1/Cul1/SKP2 E3 ubiquitin ligase complex mediates ubiquitylation of substrates previously phosphorylated by cyclin-dependent kinases, we investigated the potential role of this ubiquitin ligase in mediating p130 downregulation. We found that p130 interacts with SKP1, Cul-1 and SKP2 in human 293 cells. We also found that ectopic coexpression of SKP2 and p130 leads to dose-dependent downregulation of p130, reduces p130 protein half-life and induces p130 ubiquitylation in these cells. Moreover, adenoviral-mediated expression of SKP2 accelerates downregulation of endogenous hyperphosphorylated p130 in mitogen-stimulated T98G cells and primary W138 fibroblasts. We conclude that p130 is a substrate of the SCFSKP2 ubiquitin ligase and this E3 ligase regulates p130 abundance during the cell cycle.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Barcelona	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, AHP Bldg,Room 308,3307 N Broad St, Philadelphia, PA 19140 USA.			Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [R24CA088261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045450, K02AI001823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88261-01] Funding Source: Medline; NIAID NIH HHS [R01 AI45450, K02 AI01823] Funding Source: Medline; NIGMS NIH HHS [R29 GM54894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GRANA X, 1995, ONCOGENE, V11, P211; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Masuda T, 2002, CANCER RES, V62, P3819; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; Parreno M, 2001, ONCOGENE, V20, P4793, DOI 10.1038/sj.onc.1204644; Penin RM, 2002, MODERN PATHOL, V15, P1227, DOI 10.1097/01.MP.0000036589.99516.D6; Prince AM, 2002, BIOCHEM BIOPH RES CO, V290, P1066, DOI 10.1006/bbrc.2001.6291; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	43	85	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2443	2451		10.1038/sj.onc.1206339	http://dx.doi.org/10.1038/sj.onc.1206339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717421				2022-12-25	WOS:000182383500007
J	Lu, KP; Ramos, KS				Lu, KP; Ramos, KS			Redox regulation of a novel L1Md-A2 retrotransposon in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE L1 ELEMENTS; C-HA-RAS; ANTIOXIDANT/ELECTROPHILE RESPONSE ELEMENT; TRANSPOSABLE ELEMENTS; CHEMICAL ATHEROGENESIS; REVERSE TRANSCRIPTION; BREAST-CANCER; SPASTIC MOUSE; 5' END; GENE	Activation and reintegration of retrotransposons into the genome is linked to several diseases in human and rodents, but mechanisms of gene activation remain largely unknown. Here we identify a novel gene of L1Md-A2 lineage in vascular smooth muscle cells and show that environmental hydrocarbons enhance gene expression and activate monomer-driven transcription via a redox-sensitive mechanism. Site-directed mutagenesis and progressive deletion analyses identified two antioxidant/electrophile response-like elements (5'-GTGACTCGAGC-3') within the A2/3 and A3 region. These elements mediated activation, with the A3 monomer playing an essential role in transactivation. This signaling pathway may contribute to gene instability during the course of atherogenesis.	Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Ramos, KS (corresponding author), Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.				NIEHS NIH HHS [ES 04849, ES 09106] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004849, P30ES009106] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADEY NB, 1994, MOL BIOL EVOL, V11, P778; Bieche I, 1998, INT J CANCER, V78, P661, DOI 10.1002/(SICI)1097-0215(19981123)78:5<661::AID-IJC22>3.3.CO;2-9; BRATTHAUER GL, 1994, CANCER, V73, P2333, DOI 10.1002/1097-0142(19940501)73:9<2333::AID-CNCR2820730915>3.0.CO;2-4; BURR B, 1988, PLANT TRANSPOSABLE E, P317; Chen YH, 2000, J BIOL CHEM, V275, P27366; DAWSON A, 1997, EMBO J, V12, P2773; DeBerardinis RJ, 1999, GENOMICS, V56, P317, DOI 10.1006/geno.1998.5729; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; EVANS JP, 1991, P NATL ACAD SCI USA, V88, P8792, DOI 10.1073/pnas.88.19.8792; FANNING TG, 1983, NUCLEIC ACIDS RES, V20, P288; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Finnegan DJ, 1997, CURR BIOL, V7, pR245, DOI 10.1016/S0960-9822(06)00112-6; GEORGIEV PG, 1990, MOL GEN GENET, V220, P229; Giesen K, 1997, DEVELOPMENT, V124, P2307; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; GILMAN JG, 1987, BRIT J HAEMATOL, V67, P369, DOI 10.1111/j.1365-2141.1987.tb02360.x; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; GUO M, 1995, NEURON, V14, P913, DOI 10.1016/0896-6273(95)90330-5; Holderman MT, 2002, MOL PHARMACOL, V61, P1174, DOI 10.1124/mol.61.5.1174; Ikeda K, 2001, MOL GENET GENOMICS, V266, P318, DOI 10.1007/s004380100560; Ishihara H, 1997, FEBS LETT, V418, P205, DOI 10.1016/S0014-5793(97)01383-5; Ishihara H, 2000, RADIAT RES, V153, P392, DOI 10.1667/0033-7587(2000)153[0392:IEOIAP]2.0.CO;2; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Kerzee JK, 2000, MOL PHARMACOL, V58, P152, DOI 10.1124/mol.58.1.152; Kidwell MG, 1997, P NATL ACAD SCI USA, V94, P7704, DOI 10.1073/pnas.94.15.7704; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; KOLOSHA VO, 1995, J BIOL CHEM, V270, P2868, DOI 10.1074/jbc.270.6.2868; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; Kurth R, 1995, ANN NY ACAD SCI, V772, P140, DOI 10.1111/j.1749-6632.1995.tb44739.x; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; Lu KP, 2000, MUTAT RES-FUND MOL M, V454, P35, DOI 10.1016/S0027-5107(00)00095-6; Lu KP, 1998, BIOCHEM BIOPH RES CO, V253, P828, DOI 10.1006/bbrc.1998.9866; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Martell M, 1999, J CLIN MICROBIOL, V37, P327, DOI 10.1128/JCM.37.2.327-332.1999; Martin SL, 1998, GENE, V215, P69, DOI 10.1016/S0378-1119(98)00252-2; Mears ML, 2001, J MOL EVOL, V52, P51, DOI 10.1007/s002390010133; Mhiri C, 1997, PLANT MOL BIOL, V33, P257, DOI 10.1023/A:1005727132202; MIKI Y, 1992, CANCER RES, V52, P643; Miller KP, 2000, BIOCHEM PHARMACOL, V60, P1285, DOI 10.1016/S0006-2952(00)00439-1; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; Okada N, 1997, GENE, V205, P229, DOI 10.1016/S0378-1119(97)00409-5; Perou CM, 1997, GENOMICS, V42, P366, DOI 10.1006/geno.1997.4740; Ramos KS, 1999, ANNU REV PHARMACOL, V39, P243, DOI 10.1146/annurev.pharmtox.39.1.243; SHEHEE WR, 1987, J MOL BIOL, V196, P757, DOI 10.1016/0022-2836(87)90402-5; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; Speek M, 2001, MOL CELL BIOL, V21, P1973, DOI 10.1128/MCB.21.6.1973-1985.2001; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Takahara T, 1996, HUM MOL GENET, V5, P989, DOI 10.1093/hmg/5.7.989; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; VERONIQUE JM, 1992, MOL BIOL EVOL, V9, P41; VOLIVA CF, 1983, NUCLEIC ACIDS RES, V11, P8847, DOI 10.1093/nar/11.24.8847; Whitelaw E, 2001, NAT GENET, V27, P361, DOI 10.1038/86850; [No title captured]	59	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					28201	28209		10.1074/jbc.M303888200	http://dx.doi.org/10.1074/jbc.M303888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12714586	hybrid			2022-12-25	WOS:000184242700109
J	Chattopadhyay, R; Rathore, D; Fujioka, H; Kumar, S; de la Vega, P; Haynes, D; Moch, K; Fryauff, D; Wang, RB; Carucci, DJ; Hoffman, SL				Chattopadhyay, R; Rathore, D; Fujioka, H; Kumar, S; de la Vega, P; Haynes, D; Moch, K; Fryauff, D; Wang, RB; Carucci, DJ; Hoffman, SL			PfSPATR, a Plasmodium falciparum protein containing an altered thrombospondin type I repeat domain is expressed at several stages of the parasite life cycle and is the target of inhibitory antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCUMSPOROZOITE PROTEIN; MALARIA PARASITE; GENE; VACCINE; SPOROZOITES; SEQUENCE; IMMUNOGENICITY; SAFETY; GLYCOPROTEIN; GENOMICS	The annotated sequence of chromosome 2 of Plasmodium falciparum was examined for genes encoding proteins that may be of interest for vaccine development. We describe here the characterization of a protein with an altered thrombospondin Type I repeat domain (PfSPATR) that is expressed in the sporozoite, asexual, and sexual erythrocytic stages of the parasite life cycle. Immunoelectron microscopy indicated that this protein was expressed on the surface of the sporozoites and around the rhoptries in the asexual erythrocytic stage. An Escherichia coli-produced recombinant form of the protein bound to HepG2 cells in a dose-dependent manner and antibodies raised against this protein blocked the invasion of sporozoites into a transformed hepatoma cell line. Sera from Ghanaian adults and from a volunteer who had been immunized with radiation-attenuated P. falciparum sporozoites specifically recognized the expression of this protein on transfected COS-7 cells. These data support the evaluation of this protein as a vaccine candidate.	USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Case Western Reserve University	Hoffman, SL (corresponding author), Sanaria, 308 Argosy Dr, Gaithersburg, MD 20878 USA.	SLHoffman@sanaria.com						AMADOR R, 1992, VACCINE, V10, P179, DOI 10.1016/0264-410X(92)90009-9; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Black CG, 2001, MOL BIOCHEM PARASIT, V114, P217, DOI 10.1016/S0166-6851(01)00265-1; Carlton JMR, 1998, MOL BIOCHEM PARASIT, V93, P285, DOI 10.1016/S0166-6851(98)00043-7; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; CHAROENVIT Y, 1991, J IMMUNOL, V146, P1020; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; DAVIS C G, 1990, New Biologist, V2, P410; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; HOFFMAN SL, 1994, AM J TROP MED HYG, V51, P603, DOI 10.4269/ajtmh.1994.51.603; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; Hutter H, 2000, SCIENCE, V287, P989, DOI 10.1126/science.287.5455.989; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Long CA, 2002, SCIENCE, V297, P345, DOI 10.1126/science.1074484; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Naitza S, 1998, PARASITOL TODAY, V14, P479, DOI 10.1016/S0169-4758(98)01346-5; Nardin EH, 2000, J INFECT DIS, V182, P1486, DOI 10.1086/315871; Nguyen TV, 2001, J BIOL CHEM, V276, P26724, DOI 10.1074/jbc.M103375200; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; PACHECO ND, 1979, J PARASITOL, V65, P414, DOI 10.2307/3280286; Rathore D, 2000, INFECT IMMUN, V68, P740, DOI 10.1128/IAI.68.2.740-743.2000; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Templeton TJ, 2000, MOL MICROBIOL, V36, P1, DOI 10.1046/j.1365-2958.2000.01821.x; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; Wang L, 1999, INFECT IMMUN, V67, P2193, DOI 10.1128/IAI.67.5.2193-2200.1999; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Wu TQ, 1999, MOL BIOCHEM PARASIT, V103, P243, DOI 10.1016/S0166-6851(99)00134-6	37	44	44	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25977	25981		10.1074/jbc.M300865200	http://dx.doi.org/10.1074/jbc.M300865200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716913	hybrid			2022-12-25	WOS:000183920200092
J	Howitt, J; Bewley, MC; Graziano, V; Flanagan, JM; Freimuth, P				Howitt, J; Bewley, MC; Graziano, V; Flanagan, JM; Freimuth, P			Structural basis for variation in adenovirus affinity for the cellular coxsackievirus and adenovirus receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-5 FIBER PROTEIN; IMMUNOGLOBULIN SUPERFAMILY; 1.7-ANGSTROM RESOLUTION; SURFACE-RECEPTORS; SEROTYPE-2 FIBER; AIRWAY EPITHELIA; BINDING DOMAIN; HEAD DOMAIN; SUBGROUP-C; B VIRUSES	The majority of adenovirus serotypes can bind to the coxsackievirus and adenovirus receptor (CAR) on human cells despite only limited conservation of the amino acid residues that comprise the receptor-binding sites of these viruses. Using a fluorescence anisotropy-based assay, we determined that the recombinant knob domain of the fiber protein from adenovirus serotype (Ad) 2 binds the soluble, N-terminal domain (domain 1 (D1)) of CAR with 8-fold greater affinity than does the recombinant knob domain from Ad12. Homology modeling predicted that the increased affinity of Ad2 knob for CAR D1 could result from additional contacts within the binding interface contributed by two residues, Ser(408) and Tyr(477), which are not conserved in the Ad12 knob. Consistent with this structural model, substitution of serine and tyrosine for the corresponding residues in the Ad12 knob (P417S and S489Y) increased the binding affinity by 4- and 8-fold, respectively, whereas the double mutation increased binding affinity 10-fold. X-ray structure analysis of Ad12 knob mutants P417S and S489Y indicated that both substituted residues potentially could form additional hydrogen bonds across the knob-CAR interface. Structural changes resulting from these mutations were highly localized, implying that the high tolerance for surface variation conferred by the stable knob scaffold can minimize the impact of antigenic drift on binding specificity and affinity during evolution of virus serotypes. Our results suggest that the interaction of knob domains from different adenovirus serotypes with CAR D1 can be accurately modeled using the Ad12 knob-CAR D1 crystal structure as a template.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Freimuth, P (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.			bewley, maria/0000-0001-7097-0123; Howitt, Jason/0000-0001-9922-7931	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036251] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI36251] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baranowski E, 2001, SCIENCE, V292, P1102, DOI 10.1126/science.1058613; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; Durmort C, 2001, VIROLOGY, V285, P302, DOI 10.1006/viro.2001.0967; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; Hong JS, 1996, J VIROL, V70, P7071, DOI 10.1128/JVI.70.10.7071-7078.1996; HUFF S, 1994, J BIOL CHEM, V269, P15563; Kirby I, 2000, J VIROL, V74, P2804, DOI 10.1128/JVI.74.6.2804-2813.2000; Kirby I, 1999, J VIROL, V73, P9508, DOI 10.1128/JVI.73.11.9508-9514.1999; Kirby I, 2001, J VIROL, V75, P7210, DOI 10.1128/JVI.75.15.7210-7214.2001; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEVINE A. J., 1967, J VIROL, V1, P747; Lortat-Jacob H, 2001, J BIOL CHEM, V276, P9009, DOI 10.1074/jbc.M009304200; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patten PA, 1997, CURR OPIN BIOTECH, V8, P724, DOI 10.1016/S0958-1669(97)80127-9; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; Spear PG, 2002, DEV CELL, V3, P462, DOI 10.1016/S1534-5807(02)00298-8; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; van Raaij MJ, 1999, VIROLOGY, V262, P333, DOI 10.1006/viro.1999.9849; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; Walters RW, 1999, J BIOL CHEM, V274, P10219, DOI 10.1074/jbc.274.15.10219; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Wang JH, 2002, TRENDS BIOCHEM SCI, V27, P122, DOI 10.1016/S0968-0004(01)02038-2; Wang XH, 1999, J VIROL, V73, P2559, DOI 10.1128/JVI.73.3.2559-2562.1999; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wu E, 2001, VIROLOGY, V279, P78, DOI 10.1006/viro.2000.0703; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625	42	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26208	26215		10.1074/jbc.M301492200	http://dx.doi.org/10.1074/jbc.M301492200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716886	hybrid			2022-12-25	WOS:000183920200120
J	Calabrese, C; Frank, A; Maclean, K; Gilbertson, R				Calabrese, C; Frank, A; Maclean, K; Gilbertson, R			Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CANCER CELL-LINE; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PROSTATE-CANCER; PROGNOSTIC-SIGNIFICANCE; NIH 3T3-CELLS; MAP KINASE; GELDANAMYCIN; EXPRESSION	ERBB2 increases the sensitivity of breast cancer cells to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG). This has been attributed to the disruption of ERBB3/ERBB2 heterodimers that maintain a crucial cell survival signal via phosphatidylinositol 3-kinase/AKT. ERBB2 confers a poor clinical outcome in medulloblastoma, the most common malignant pediatric brain tumor. Here, we show that medulloblastoma cell sensitivity to 17-AAG is directly related to ERBB2 expression level. Furthermore, overexpression of exogenous ERBB2 in these cells induces spontaneous homodimerization, further enhancing cell sensitivity to 17-AAG. In contrast to breast cancer cells, this increased sensitivity to 17-AAG does not result from cell dependence on AKT1 activity. Rather, we show that 17-AAG generates a dose- and time-dependent increase in MEK/ERK signaling that is required for the drug to inhibit the proliferation of medulloblastoma cells and that ERBB2 sensitizes medulloblastoma cells to 17-AAG by up-regulating basal MEK/ERK signaling. We further show that down-regulation of MEK1 activity markedly reduces the sensitivity of medulloblastoma, breast, and ovarian cancer cells to 17-AAG, whereas expression of a constitutively active MEK1 potentiates the activity of 17-AAG against these cells. Therefore, intact MEK/ERK signaling may be required for optimal 17AAG activity against a variety of tumor cell types. These data identify a new mechanism by which 17-AAG inhibits the proliferation of cancer cells. Defining the precise mode of action of these agents within specific tumor cell types will be crucial if this class of drugs is to be efficiently developed in the clinic.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	Gilbertson, R (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale, Memphis, TN 38105 USA.	Richard.Gilbertson@stjude.org	Gilbertson, Richard James/ABE-1346-2021	Gilbertson, Richard James/0000-0001-7539-9472	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; An WG, 2000, CELL GROWTH DIFFER, V11, P355; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Duesbery NS, 1999, NAT MED, V5, P736, DOI 10.1038/10457; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; Gilbertson R, 2001, BRIT J CANCER, V85, P705, DOI 10.1054/bjoc.2001.1987; Gilbertson RJ, 1998, CANCER RES, V58, P3932; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Gilbertson RJ, 1997, EUR J CANCER, V33, P609, DOI 10.1016/S0959-8049(96)00516-3; Gilbertson RJ, 2002, CLIN CANCER RES, V8, P3054; GILBERTSON RJ, 1995, BRIT J CANCER, V71, P473, DOI 10.1038/bjc.1995.96; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hernan R, 2003, CANCER RES, V63, P140; Hostein I, 2001, CANCER RES, V61, P4003; Kelland LR, 1999, J NATL CANCER I, V91, P1940, DOI 10.1093/jnci/91.22.1940; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lopez-Maderuelo MD, 2001, FEBS LETT, V490, P23, DOI 10.1016/S0014-5793(01)02130-5; Munster PN, 2002, CANCER RES, V62, P3132; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neckers L, 2002, CLIN CANCER RES, V8, P962; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Packer RJ, 1999, BRAIN DEV-JPN, V21, P75, DOI 10.1016/S0387-7604(98)00085-0; Perunovic B, 2002, HUM PATHOL, V33, P703, DOI 10.1053/hupa.2002.125377; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Piatelli MJ, 2002, J BIOL CHEM, V277, P12144, DOI 10.1074/jbc.M200102200; PIETSCH T, 1994, CANCER RES, V54, P3278; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; Robinson CJM, 1996, BIOCHEM J, V320, P123, DOI 10.1042/bj3200123; Sausville EA, 2003, ANNU REV PHARMACOL, V43, P199, DOI 10.1146/annurev.pharmtox.43.100901.135813; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P67, DOI 10.1053/sonc.2001.28557; Smith V, 2002, ANTICANCER RES, V22, P1993; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stefanelli C, 2002, FEBS LETT, V527, P223, DOI 10.1016/S0014-5793(02)03242-8; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Verlhac MH, 2000, EMBO J, V19, P6065, DOI 10.1093/emboj/19.22.6065; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Xiao D, 2002, CANCER RES, V62, P3615; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zeltzer PM, 1999, J CLIN ONCOL, V17, P832, DOI 10.1200/JCO.1999.17.3.832; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	55	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24951	24959		10.1074/jbc.M211600200	http://dx.doi.org/10.1074/jbc.M211600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709419	hybrid			2022-12-25	WOS:000183824800086
J	Kadyrov, FA; Drake, JW				Kadyrov, FA; Drake, JW			Properties of bacteriophage T4 proteins deficient in replication repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA BINDING-PROTEIN; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; RECOMBINATION; HELICASE; DAMAGE; GENE-41; MUTANTS; PATHWAY; BYPASS	An epistasis group of mutations engendering increased sensitivity to diverse DNA-damaging agents was described previously in bacteriophage T4. These mutations are alleles of genes 32 and 41, which, respectively, encode a single-stranded DNA-binding protein (gp32) and the replicative DNA helicase (gp41). The mechanism by which the lethality of DNA damage is mitigated is unknown but seems not to involve the direct reversal of damage, excision repair, conventional recombination repair, or translesion synthesis. Here we explore the hypothesis that the mechanism involves a switch in DNA primer extension from the cognate template to an alternative template, the just-synthesized daughter strand of the other parental strand. The activities of the mutant proteins are reduced about 2-fold (for gp32) or 4-fold (for gp41) in replication complexes catalyzing coordinated synthesis of leading and lagging strands, in binding single-stranded DNA, promoting DNA annealing, and promoting branch migration. In striking contrast, the mutant proteins are strongly impaired in promoting template switching, thus supporting the hypothesis of survival by template switching.	NIEHS, Lab Mol Genet E3 01, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Drake, JW (corresponding author), NIEHS, Lab Mol Genet E3 01, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061055, ZIAES061055] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; Bleuit JS, 2001, P NATL ACAD SCI USA, V98, P8298, DOI 10.1073/pnas.131007498; BROOMFIELD S, 2001, MUTAT RES, V486, P176; CUPIDO M, 1980, MUTAT RES, V70, P131, DOI 10.1016/0027-5107(80)90152-9; CUPIDO M, 1983, MUTAT RES, V109, P1, DOI 10.1016/0027-5107(83)90089-1; EBISUZAKI K, 1975, VIROLOGY, V64, P330, DOI 10.1016/0042-6822(75)90109-9; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FUJIWARA Y, 1976, MUTAT RES, V37, P91, DOI 10.1016/0027-5107(76)90058-0; GAUSS P, 1987, P NATL ACAD SCI USA, V84, P8515, DOI 10.1073/pnas.84.23.8515; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; HINTON DM, 1986, J BIOL CHEM, V261, P5663; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kuroki E, 1999, MOL GEN GENET, V262, P525, DOI 10.1007/s004380051114; Li ZQ, 2002, P NATL ACAD SCI USA, V99, P4459, DOI 10.1073/pnas.062047799; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; VANMINDERHOUT L, 1976, MUTAT RES, V35, P161, DOI 10.1016/0027-5107(76)90178-0; VANMINDERHOUT L, 1978, MUTAT RES, V52, P313, DOI 10.1016/0027-5107(78)90170-7; WACHSMAN JT, 1987, GENETICS, V115, P405; YONESAKI T, 1994, GENETICS, V138, P247	27	12	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25247	25255		10.1074/jbc.M302564200	http://dx.doi.org/10.1074/jbc.M302564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12697750	hybrid			2022-12-25	WOS:000183824800119
J	Konig, J; Lotte, K; Plessow, R; Brockhinke, A; Baier, M; Dietz, KJ				Konig, J; Lotte, K; Plessow, R; Brockhinke, A; Baier, M; Dietz, KJ			Reaction mechanism of plant 2-Cys peroxiredoxin - Role of the C terminus and the quaternary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASES; THIOL-SPECIFIC ANTIOXIDANT; CRYSTAL-STRUCTURE; TRYPAREDOXIN PEROXIDASE; MYCOBACTERIUM-TUBERCULOSIS; CRITHIDIA-FASCICULATA; ANGSTROM RESOLUTION; OXIDATIVE STRESS; SITE CYSTEINE; ACTIVE-SITE	Barley 2-cysteine peroxiredoxin (2-Cys Prx) was analyzed for peroxide reduction, quaternary structure, thylakoid attachment, and function as well as in vivo occurrence of the inactivated form, with emphasis on the role of specific amino acid residues. Data presented show the following. 1) 2-Cys Prx has a broad substrate specificity and reduces even complex lipid peroxides such as phosphatidylcholine dilineoyl hydroperoxide, although at low rates. 2) 2-Cys Prx partly becomes irreversibly oxidized by peroxide substrates during the catalytic cycle in a concentration-dependent manner, particularly by bulky hydroperoxides. 3) Using dithiothreitol and thioredoxin (Trx) as reductants, amino acids were identified that are important for peroxide reduction (Cys(64), Arg(140), and Arg(163)), regeneration by Trx (Cys(185)), and conformation changes from dimer to oligomer (Thr(66), Trp(99), and Trp(189)). 4) Oligomerization decreased the rate of Trx-dependent peroxide detoxification. 5) Comparison of Prx(WT), W99L, and W189L using static and time-resolved LIF techniques demonstrated the contributions of the tryptophan residues and yielded information about their local environment. Data indicated protein dynamics in the catalytic site and the carboxyl terminus during the reduction-oxidation cycle. 6) Reduced and inactivated barley 2-Cys Prx oligomerized and attached to the thylakoid membrane in isolated chloroplasts. The in vivo relevance of inactivation was shown in leaves subjected to cold and wilting stress and during senescence. Based on these results, it is hypothesized that in addition to its function in peroxide detoxification, 2-Cys Prx may play a role as a structural redox sensor in chloroplasts.	Univ Bielefeld, D-33501 Bielefeld, Germany	University of Bielefeld	Dietz, KJ (corresponding author), Univ Bielefeld, D-33501 Bielefeld, Germany.		Dietz, Karl-Josef/B-6029-2009	Dietz, Karl-Josef/0000-0003-0311-2182				Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Baier M, 2000, PLANT PHYSIOL, V124, P823, DOI 10.1104/pp.124.2.823; Baier M, 1999, TRENDS PLANT SCI, V4, P166, DOI 10.1016/S1360-1385(99)01398-9; Baier M, 1996, PLANT MOL BIOL, V31, P553, DOI 10.1007/BF00042228; Baier M, 1999, PLANT PHYSIOL, V119, P1407, DOI 10.1104/pp.119.4.1407; Baier M, 1997, PLANT J, V12, P179, DOI 10.1046/j.1365-313X.1997.12010179.x; Brockhinke A, 2000, APPL PHYS B-LASERS O, V71, P755, DOI 10.1007/s003400000384; Broin M, 2002, PLANT CELL, V14, P1417, DOI 10.1105/tpc.001644; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chauhan R, 2001, BIOCHEM J, V354, P209, DOI 10.1042/0264-6021:3540209; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; Dietz KJ, 2002, J EXP BOT, V53, P1321, DOI 10.1093/jexbot/53.372.1321; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1993, BIOCHEMISTRY-US, V32, P9189, DOI 10.1021/bi00086a026; Feussner I, 2001, TRENDS PLANT SCI, V6, P268, DOI 10.1016/S1360-1385(01)01950-1; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; Horling F, 2003, PLANT PHYSIOL, V131, P317, DOI 10.1104/pp.010017; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; Montemartini M, 1999, EUR J BIOCHEM, V264, P516, DOI 10.1046/j.1432-1327.1999.00656.x; Motohashi K, 2001, P NATL ACAD SCI USA, V98, P11224, DOI 10.1073/pnas.191282098; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; Plessow R, 2000, J PHYS CHEM B, V104, P3695, DOI 10.1021/jp994132u; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; TSUJI K, 1995, BIOCHEM J, V307, P377, DOI 10.1042/bj3070377; Wasylewski Z, 1996, J PROTEIN CHEM, V15, P45, DOI 10.1007/BF01886810; WELLS TA, 1994, BIOCHEMISTRY-US, V33, P708, DOI 10.1021/bi00169a012; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Yamamoto H, 1999, FEBS LETT, V447, P269, DOI 10.1016/S0014-5793(99)00309-9; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Yi-Brunozzi HY, 2001, J BIOL CHEM, V276, P37827	48	147	155	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24409	24420		10.1074/jbc.M301145200	http://dx.doi.org/10.1074/jbc.M301145200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12702727	hybrid			2022-12-25	WOS:000183824800022
J	Rees, MI; Harvey, K; Ward, H; White, JH; Evans, L; Duguid, IC; Hsu, CCH; Coleman, SL; Miller, J; Baer, K; Waldvogel, HJ; Gibbon, F; Smart, TG; Owen, MJ; Harvey, RJ; Snell, RG				Rees, MI; Harvey, K; Ward, H; White, JH; Evans, L; Duguid, IC; Hsu, CCH; Coleman, SL; Miller, J; Baer, K; Waldvogel, HJ; Gibbon, F; Smart, TG; Owen, MJ; Harvey, RJ; Snell, RG			Isoform heterogeneity of the human gephyrin gene (GPHN), binding domains to the glycine receptor, and mutation analysis in hyperekplexia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; PROTEIN GEPHYRIN; SPLICE VARIANTS; STARTLE DISEASE; SPINAL-CORD; BRAIN; SEQUENCE; EXPRESSION; TUBULIN; CELLS	Gephyrin (GPHN) is an organizational protein that clusters and localizes the inhibitory glycine (GlyR) and GABA(A) receptors to the microtubular matrix of the neuronal postsynaptic membrane. Mice deficient in gephyrin develop a hereditary molybdenum cofactor deficiency and a neurological phenotype that mimics startle disease (hyperekplexia). This neuromotor disorder is associated with mutations in the GlyR alpha(1) and beta subunit genes (GLRA1 and GLRB). Further genetic heterogeneity is suspected, and we hypothesized that patients lacking mutations in GLRA1 and GLRB might have mutations in the gephyrin gene (GPHN). In addition, we adopted a yeast two-hybrid screen, using the GlyR beta subunit intracellular loop as bait, in an attempt to identify further GlyR-interacting proteins implicated in hyperekplexia. Gephyrin cDNAs were isolated, and subsequent RT-PCR analysis from human tissues demonstrated the presence of five alternatively spliced GPHN exons concentrated in the central linker region of the gene. This region generated 11 distinct GPHN transcript isoforms, with 10 being specific to neuronal tissue. Mutation analysis of GPHN exons in hyperekplexia patients revealed a missense mutation (A28T) in one patient causing an amino acid substitution (N10Y). Functional testing demonstrated that GPHN(N10Y) does not disrupt GlyR-gephyrin interactions or collybistin-induced cell-surface clustering. We provide evidence that GlyR-gephyrin binding is dependent on the presence of an intact C-terminal MoeA homology domain. Therefore, the N10Y mutation and alternative splicing of GPHN transcripts do not affect interactions with GlyRs but may affect other interactions with the cytoskeleton or gephyrin accessory proteins.	Univ Auckland, Dept Mol Med, Fac Med & Hlth Sci, Auckland 1, New Zealand; Univ Auckland, Dept Anat, Fac Med & Hlth Sci, Auckland 1, New Zealand; Univ London, Sch Pharm, Dept Pharmacol, London WC1N 1AX, England; GlaxoSmithKline, Med Res Ctr, Pathway Discovery, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Med Res Ctr, Genom & Proteom Sci, Stevenage SG1 2NY, Herts, England; Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England; Cardiff Univ, Dept Psychol Med, Cardiff CF14 4XN, S Glam, Wales; Univ Wales Hosp, Dept Paediat Neurol, Cardiff CF14 4XN, S Glam, Wales	University of Auckland; University of Auckland; University of London; University College London; University of London School of Pharmacy; GlaxoSmithKline; GlaxoSmithKline; University of Birmingham; Cardiff University; Cardiff University	Rees, MI (corresponding author), Univ Auckland, Dept Mol Med, Fac Med & Hlth Sci, Private Bag 92019, Auckland 1, New Zealand.	m.rees@auckland.ac.nz	Harvey, Robert/D-3994-2016; Rees, Mark I/J-3129-2012; Waldvogel, Henry/D-6691-2012	Harvey, Robert/0000-0001-5956-6664; Rees, Mark I/0000-0003-3570-5986; Duguid, Ian/0000-0001-6966-2641; Waldvogel, Henry/0000-0003-2165-8568; Snell, Russell/0000-0002-8166-4014				ANDERMANN F, 1980, BRAIN, V103, P985, DOI 10.1093/brain/103.4.985; Baer K, 1999, P NATL ACAD SCI USA, V96, P12860, DOI 10.1073/pnas.96.22.12860; BETZ H, 1991, TRENDS NEUROSCI, V14, P458, DOI 10.1016/0166-2236(91)90045-V; Brown P, 2002, ADV NEUROL, V89, P153; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; Butler MH, 2000, NEURON, V26, P307, DOI 10.1016/S0896-6273(00)81165-4; David-Watine B, 2001, GENE, V271, P239, DOI 10.1016/S0378-1119(01)00511-X; Dunne EL, 2002, BRIT J PHARMACOL, V137, P29, DOI 10.1038/sj.bjp.0704835; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Fuller KJ, 1998, BIOTECHNIQUES, V25, P85, DOI 10.2144/98251st04; GRAHAM D, 1985, BIOCHEMISTRY-US, V24, P990, DOI 10.1021/bi00325a027; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; Handford CA, 1996, MOL BRAIN RES, V35, P211; HARVEY RJ, 1991, EMBO J, V10, P3239, DOI 10.1002/j.1460-2075.1991.tb04887.x; Heck S, 1997, DEV BRAIN RES, V98, P211, DOI 10.1016/S0165-3806(96)00181-2; Kannenberg K, 1997, J NEUROCHEM, V68, P1352; Kawasaki BT, 1997, J NEUROSCI RES, V49, P381, DOI 10.1002/(SICI)1097-4547(19970801)49:3<381::AID-JNR13>3.0.CO;2-2; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; KIRSCH J, 1993, EUR J NEUROSCI, V5, P1109, DOI 10.1111/j.1460-9568.1993.tb00965.x; Kirsch J, 1996, MOL CELL NEUROSCI, V8, P93, DOI 10.1006/mcne.1996.0048; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, NATURE, V366, P745, DOI 10.1038/366745a0; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 1999, J NEUROCHEM, V72, P1323, DOI 10.1046/j.1471-4159.1999.0721323.x; Kneussel M, 2000, J PHYSIOL-LONDON, V525, P1, DOI 10.1111/j.1469-7793.2000.t01-4-00001.x; KRAUSS S, 1990, GENE, V86, P241, DOI 10.1016/0378-1119(90)90285-Y; Krisch J, 1999, CURR OPIN NEUROBIOL, V9, P329, DOI 10.1016/S0959-4388(99)80048-8; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; LANGOSCH D, 1992, FEBS LETT, V298, P113, DOI 10.1016/0014-5793(92)80034-E; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Liu Q, 1996, HUM MOL GENET, V5, P107, DOI 10.1093/hmg/5.1.107; Mammoto A, 1998, BIOCHEM BIOPH RES CO, V243, P86, DOI 10.1006/bbrc.1997.8068; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; REES MI, 1994, HUM MOL GENET, V3, P2175, DOI 10.1093/hmg/3.12.2175; Rees MI, 2002, HUM MOL GENET, V11, P853, DOI 10.1093/hmg/11.7.853; Rees MI, 2001, AM J HUM GENET, V69, P627; Rees MI, 2001, HUM GENET, V109, P267, DOI 10.1007/s004390100569; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; SAENZLOPE E, 1984, ANN NEUROL, V15, P36, DOI 10.1002/ana.410150107; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sassoe-Pognetto M, 2000, J COMP NEUROL, V420, P481, DOI 10.1002/(SICI)1096-9861(20000515)420:4<481::AID-CNE6>3.0.CO;2-5; SASSOEPOGNETTO M, 1995, J COMP NEUROL, V357, P1, DOI 10.1002/cne.903570102; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333	55	88	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24688	24696		10.1074/jbc.M301070200	http://dx.doi.org/10.1074/jbc.M301070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12684523	hybrid, Green Published			2022-12-25	WOS:000183824800055
J	Fraley, TS; Tran, TC; Corgan, AM; Nash, CA; Hao, J; Critchley, DR; Greenwood, JA				Fraley, TS; Tran, TC; Corgan, AM; Nash, CA; Hao, J; Critchley, DR; Greenwood, JA			Phosphoinositide binding inhibits alpha-actinin bundling activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESIONS; STRESS FIBERS; SMOOTH-MUSCLE; CRYSTAL-STRUCTURE; VINCULIN-BINDING; MOLECULAR-BASIS; LIPID BILAYERS; PROTEIN; CELLS; LOCALIZATION	alpha-Actinin is an abundant actin-bundling and adhesion protein that directly links actin filaments to integrin receptors. Previously, in platelet-derived growth factor-treated fibroblasts, we demonstrated that phosphoinositides bind to alpha-actinin, regulating its localization (Greenwood, J. A., Theibert, A. B., Prestwich, G. D., and Murphy-Ullrich, J. E. (2000) J. Cell Biol. 150, 627-642). In this study, phosphoinositide binding and regulation of alpha-actinin function is further characterized. Phosphoinositide binding specificity, determined using a protein-lipid overlay procedure, suggests that alpha-actinin interacts with phosphates on the 4th and 5th position of the inositol head group. Binding assays and mutational analyses demonstrate that phosphoinositides bind to the calponin homology domain 2 of alpha-actinin. Phosphoinositide binding inhibited the bundling activity of alpha-actinin by blocking the interaction of the actin-binding domain with actin filaments. Consistent with these results, excessive bundling of actin filaments was observed in fibroblasts expressing an alpha-actinin mutant with decreased phosphoinositide affinity. We conclude that the interaction of alpha-actinin with phosphoinositides regulates actin stress fibers in the cell by controlling the extent to which microfilaments are bundled.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	Oregon State University; University of Leicester	Greenwood, JA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, ALS 2011, Corvallis, OR 97331 USA.			Greenwood, Juliet/0000-0001-6438-964X	NIEHS NIH HHS [P30 ES00210] Funding Source: Medline; NIGMS NIH HHS [GM63711] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063711] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen RY, 2002, J HISTOCHEM CYTOCHEM, V50, P697, DOI 10.1177/002215540205000511; Ching TT, 2001, J BIOL CHEM, V276, P43932, DOI 10.1074/jbc.M105159200; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; FURUHASHI K, 1992, BIOCHEM BIOPH RES CO, V184, P1261, DOI 10.1016/S0006-291X(05)80018-X; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GLUCK U, 1994, J CELL SCI, V107, P1773; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Goldmann WH, 1999, BIOCHEM BIOPH RES CO, V264, P225, DOI 10.1006/bbrc.1999.1495; Greenwood JA, 2000, J CELL BIOL, V150, P627, DOI 10.1083/jcb.150.3.627; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Han X, 1998, BIOCHEMISTRY-US, V37, P10730, DOI 10.1021/bi9800451; Han X, 1997, BIOCHEMISTRY-US, V36, P10364, DOI 10.1021/bi962929v; Keep NH, 1999, STRUCTURE, V7, P1539, DOI 10.1016/S0969-2126(00)88344-6; LANGANGER G, 1986, J CELL BIOL, V102, P200, DOI 10.1083/jcb.102.1.200; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; MCGREGOR A, 1994, BIOCHEM J, V301, P225, DOI 10.1042/bj3010225; MEJEAN C, 1995, BIOCHEM BIOPH RES CO, V210, P152, DOI 10.1006/bbrc.1995.1640; Norwood FLM, 2000, STRUCTURE, V8, P481, DOI 10.1016/S0969-2126(00)00132-5; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1991, BIOCHEM SOC T, V19, P1065, DOI 10.1042/bst0191065; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; Rajfur Z, 2002, NAT CELL BIOL, V4, P286, DOI 10.1038/ncb772; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Tang JH, 2001, J MOL BIOL, V310, P845, DOI 10.1006/jmbi.2001.4789; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; Ylanne J, 2001, STRUCTURE, V9, P597, DOI 10.1016/S0969-2126(01)00619-0	42	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24039	24045		10.1074/jbc.M213288200	http://dx.doi.org/10.1074/jbc.M213288200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12716899	hybrid			2022-12-25	WOS:000183638600106
J	Hendriks, BS; Opresko, LK; Wiley, HS; Lauffenburger, D				Hendriks, BS; Opresko, LK; Wiley, HS; Lauffenburger, D			Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis - Distribution of homo- and heterodimers depends on relative HER2 levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; ERBB SIGNALING NETWORK; HUMAN-BREAST-CANCER; TYROSINE KINASES; MONOCLONAL-ANTIBODIES; DOWN-REGULATION; EGF RECEPTORS; INTERNALIZATION; DIMERIZATION; NEU	Endocytic trafficking plays an important role in the regulation of the epidermal growth factor receptor ( EGFR) family. Many cell types express multiple EGFR family members (including EGFR, HER2, HER3, and/or HER4) that interact to form an array of homo- and heterodimers. Differential trafficking of these receptors should strongly affect signaling through this system by changing substrate access and heterodimerization efficiency. Because of the complexity of these dynamic processes, we used a quantitative and computational model to understand their integrated operation. Parameters characterizing EGFR and HER2 interactions were determined using experimental data obtained from mammary epithelial cells constructed to express different levels of HER2, enabling us to estimate receptor-specific internalization rate constants and dimer uncoupling rate constants. Significant novel results obtained from this work are as follows: first, that EGFR homodimerization and EGFR/HER2 heterodimerization occur with comparable affinities; second, that EGFR/HER2 heterodimers traffic as single entities. Furthermore, model predictions of the relationship of HER2 expression levels to consequent distribution of EGFR homodimers and EGFR/HER2 heterodimers suggest that the levels of HER2 found on normal cells are barely at the threshold necessary to drive efficient heterodimerization. Thus, altering HER2 concentrations, either overall or local, could provide an effective mechanism for regulating EGFR/HER2 heterodimerization and may explain why HER2 overexpression found in some cancers has such a profound effect on cell physiology.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Pacific NW Natl Lab, Div Biol Sci, Richland, WA 99352 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Pacific Northwest National Laboratory	Lauffenburger, D (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.			Wiley, Steven/0000-0003-0232-6867; Hendriks, Bart/0000-0002-4219-4945				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baulida J, 1996, J BIOL CHEM, V271, P5251; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; Burke PM, 1999, J CELL PHYSIOL, V180, P448, DOI 10.1002/(SICI)1097-4652(199909)180:3<448::AID-JCP16>3.0.CO;2-8; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DSOUZA B, 1993, ONCOGENE, V8, P1797; FENDLY BM, 1990, CANCER RES, V50, P1550; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Hendriks BS, 2003, CANCER RES, V63, P1130; Kholodenko BN, 1999, J BIOL CHEM, V274, P30169, DOI 10.1074/jbc.274.42.30169; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P73; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAHAMA PA, 1994, BIOPHYS J, V67, P1345, DOI 10.1016/S0006-3495(94)80606-X; Meier T, 1997, J NEUROSCI, V17, P6534; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Shea LD, 1997, BIOPHYS J, V73, P2949, DOI 10.1016/S0006-3495(97)78323-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	52	136	140	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23343	23351		10.1074/jbc.M300477200	http://dx.doi.org/10.1074/jbc.M300477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12686539	hybrid			2022-12-25	WOS:000183638600018
J	Paredes, N; Wang, AM; Berry, LR; Smith, LJ; Stafford, AR; Weitz, JI; Chan, AKC				Paredes, N; Wang, AM; Berry, LR; Smith, LJ; Stafford, AR; Weitz, JI; Chan, AKC			Mechanisms responsible for catalysis of the inhibition of factor Xa or thrombin by antithrombin using a covalent antithrombin-heparin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANTI-THROMBIN; BINDING-SITE; POLYACRYLAMIDE-GELS; ALCIAN BLUE; GLYCOSAMINOGLYCANS; ACTIVATION; PENTASACCHARIDE; IDENTIFICATION; PROTEOGLYCANS	Covalent antithrombin-heparin (ATH) complexes, formed spontaneously between antithrombin (AT) and unfractionated standard heparin (H), have a potent ability to catalyze the inhibition of factor Xa (or thrombin) by added AT. Although approximate to30% of ATH molecules contain two AT-binding sites on their heparin chains, the secondary site does not solely account for the increased activity of ATH. We studied the possibility that all pentasaccharide AT-binding sequences in ATH may catalyze factor Xa inhibition. Chromatography of ATH on Sepharose-AT resulted in >80% binding of the load. Similar chromatographies of non-covalent AT + H mixtures lead to a lack of binding for AT and fractionation of H into unbound (separate from AT) or bound material. Gradient elution of ATH from Sepharose-AT gave 2 peaks, a peak containing higher affinity material that had greater anti-factor Xa catalytic activity (708 units/mg heparin) compared with the peak containing lower affinity material (112 units/mg). Sepharose-AT chromatography of the ATH component with short heparin chains (less than or equal to12 monosaccharides) resulted in active unbound (40%) and bound fractions (190 and 560 units/mg, respectively). Factor Xa-ATH or thrombin-ATH inhibitor complexes gave chromatograms on Sepharose-AT with more unbound material compared with that of free ATH. Also, ATH did not bind to Sepharose-heparin, and the intrinsic fluorescence due to activation of AT in ATH by its heparin chain was reversed at higher [NaCl] than that required to dissociate non-covalent AT.H complexes. Thus, exogenous AT can compete with the AT moiety of ATH for binding to the covalently linked heparin chain, leading to catalytic inhibition of factor Xa or thrombin. These data may suggest that access to pentasaccharide units in non-covalent AT.H complexes by free AT may be facile.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8S 4L8, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA	McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Cleveland Clinic Foundation	Chan, AKC (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019; Chan, Anthony K. C./AAR-8892-2021	Weitz, Jeffrey/0000-0002-1092-7550; Chan, Anthony K. C./0000-0003-1551-3995				ANDERSSON LO, 1979, THROMB RES, V15, P531, DOI 10.1016/0049-3848(79)90159-2; BARTOLD PM, 1985, ANAL BIOCHEM, V150, P320, DOI 10.1016/0003-2697(85)90517-2; Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; Belzar KJ, 2000, J BIOL CHEM, V275, P8733, DOI 10.1074/jbc.275.12.8733; Berry L, 1998, J BIOL CHEM, V273, P34730, DOI 10.1074/jbc.273.52.34730; Berry L, 1998, J BIOCHEM-TOKYO, V124, P434, DOI 10.1093/oxfordjournals.jbchem.a022131; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BLACKBURN MN, 1984, J BIOL CHEM, V259, P939; BREEN M, 1970, ANAL BIOCHEM, V35, P146, DOI 10.1016/0003-2697(70)90020-5; Byun Y, 1996, J BIOMED MATER RES, V30, P423, DOI 10.1002/jbm.820300403; Calabro A, 2001, OSTEOARTHR CARTILAGE, V9, pS16, DOI 10.1053/joca.2001.0439; Chan A, 1997, J BIOL CHEM, V272, P22111, DOI 10.1074/jbc.272.35.22111; Chan AKC, 1998, AM J PHYSIOL-LUNG C, V274, pL914, DOI 10.1152/ajplung.1998.274.6.L914; Chan AKC, 1998, BLOOD COAGUL FIBRIN, V9, P587, DOI 10.1097/00001721-199810000-00004; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; Desai U, 2000, J BIOL CHEM, V275, P18976, DOI 10.1074/jbc.M001340200; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GOLD EW, 1979, ANAL BIOCHEM, V99, P183, DOI 10.1016/0003-2697(79)90061-7; GRANT AC, 1984, ANAL BIOCHEM, V137, P25, DOI 10.1016/0003-2697(84)90341-5; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; HATTON MWC, 1983, THROMB HAEMOSTASIS, V50, P873; HATTON MWC, 1979, CAN J BIOCHEM CELL B, V57, P1183, DOI 10.1139/o79-154; HATTON MWC, 1978, THROMB RES, V13, P655, DOI 10.1016/0049-3848(78)90155-X; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; JACOBSSON KG, 1986, BIOCHEM J, V240, P625, DOI 10.1042/bj2400625; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; Manson H E, 1989, Transfus Med Rev, V3, P264, DOI 10.1016/S0887-7963(89)70087-0; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OKAJIMA K, 1989, THROMB HAEMOSTASIS, V61, P20; OKAJIMA K, 1993, BLOOD, V81, P1300; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OWEN MC, 1987, BLOOD, V69, P1275; PETERSEN LC, 1983, BIOCHEM J, V211, P91, DOI 10.1042/bj2110091; Petitou M, 1997, GLYCOBIOLOGY, V7, P323, DOI 10.1093/glycob/7.3.323-e; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSENBERG RD, 1979, BIOCHEM BIOPH RES CO, V86, P1319, DOI 10.1016/0006-291X(79)90260-2; SMITH JW, 1987, J BIOL CHEM, V262, P11964; VOLPI N, 1995, BBA-GEN SUBJECTS, V1243, P49, DOI 10.1016/0304-4165(94)00123-F	47	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23398	23409		10.1074/jbc.M302895200	http://dx.doi.org/10.1074/jbc.M302895200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695507	hybrid			2022-12-25	WOS:000183638600025
J	So, H; Rho, J; Jeong, D; Park, R; Fisher, DE; Ostrowski, MC; Choi, Y; Kim, N				So, H; Rho, J; Jeong, D; Park, R; Fisher, DE; Ostrowski, MC; Choi, Y; Kim, N			Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF FAMILY-MEMBER; DIFFERENTIATION FACTOR; OSTEOPETROSIS; LIGAND; ACTIVATION; MOUSE; TRANCE; MICE; PROTEIN; CELLS	We have recently reported the identification of a novel member of the leukocyte receptor family, osteoclast-associated receptor (OSCAR), which has two Ig-like domains and functions as a bone-specific regulator of osteoclast differentiation. Here, we have cloned the OSCAR promoter region to examine its regulation by transcription factors. The 1.7-kb promoter region of the mouse OSCAR gene contains two potential E-box elements for microphthalmia transcription factor (MITF) and three putative PU.1 sites. MITF or PU.1 alone activates the OSCAR reporter construct 5-6-fold, and the combination of MITF and PU.1 synergistically activates the OSCAR reporter activity up to 110-fold. The mRNA expression patterns of MITF, PU.1, and OSCAR in TRANCE-treated (RAW 264.7) or TRANCE/M-CSF-treated cells (primary osteoclasts) reveal that MITF mRNA expression is induced at a much earlier time point than OSCAR gene expression. In contrast to MITF, PU.1 mRNA levels remain relatively constant at all time points, suggesting that TRANCE-induced MITF, not PU.1 expression, is one of the critical regulatory mechanisms for optimal OSCAR expression during osteoclastogenesis. In addition, we have shown that the combination of MITF and constitutively active MKK6-expressing plasmids synergistically activates OSCAR reporter activity. Taken together, our results strongly suggest that PU.1 and MITF transcription factors synergistically activate OSCAR gene expression. Moreover, the activation of OSCAR gene expression by PU.1/MITF is further enhanced by the TRANCE-induced MKK6/p38 signaling cascade.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Wonkwang Univ, Sch Med, Vestibulorcochlear Res Ctr, Chonbuk 570749, South Korea; Chungnam Natl Univ, Dept Microbiol, Taejon 305764, South Korea; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Pennsylvania; Pennsylvania Medicine; Wonkwang University; Chungnam National University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Kim, N (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Rm 351 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		; Ostrowski, Michael/H-3108-2011	Rho, Jaerang/0000-0002-0019-4939; Ostrowski, Michael/0000-0003-2948-6297	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045662, R03AR048251, R01AR044719] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR48251, AR045662, R01-AR44719] Funding Source: Medline; PHS HHS [R13-2002-055-00020] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Chambers TJ, 2000, J PATHOL, V192, P4; Fox SW, 2000, J IMMUNOL, V165, P4957, DOI 10.4049/jimmunol.165.9.4957; Galvin RJS, 1999, BIOCHEM BIOPH RES CO, V265, P233, DOI 10.1006/bbrc.1999.1632; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hayman AR, 1996, DEVELOPMENT, V122, P3151; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HOLTROP ME, 1981, METAB BONE DIS RELAT, V3, P123, DOI 10.1016/0221-8747(81)90030-8; Jimi S, 1998, ONCOL RES, V10, P7; Kim N, 2000, P NATL ACAD SCI USA, V97, P10905, DOI 10.1073/pnas.200294797; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; MARKS SC, 1976, J HERED, V67, P11, DOI 10.1093/oxfordjournals.jhered.a108657; Massey HM, 2001, BONE, V28, P577, DOI 10.1016/S8756-3282(01)00432-X; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Simon MC, 1998, SEMIN IMMUNOL, V10, P111, DOI 10.1006/smim.1998.0112; Singh H, 1999, COLD SPRING HARB SYM, V64, P13, DOI 10.1101/sqb.1999.64.13; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2000, ARTHRITIS RHEUM-US, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; THESINGH CW, 1985, BONE, V6, P43, DOI 10.1016/8756-3282(85)90406-5; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yang XL, 2002, TRENDS MOL MED, V8, P340, DOI 10.1016/S1471-4914(02)02340-7; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	40	78	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24209	24216		10.1074/jbc.M302940200	http://dx.doi.org/10.1074/jbc.M302940200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695521	hybrid			2022-12-25	WOS:000183638600127
J	Dasgupta, S; Jana, M; Liu, XJ; Pahan, K				Dasgupta, S; Jana, M; Liu, XJ; Pahan, K			Role of very-late antigen-4 (VLA-4) in myelin basic protein-primed T cell contact-induced expression of proinflammatory cytokines in microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; LIPOPOLYSACCHARIDE INDUCTION; INTERFERON BETA-1B; MACROPHAGES; ACTIVATION	The presence of neuroantigen- primed T cells recognizing self- myelin antigens within the CNS is necessary for the development of demyelinating autoimmune disease like multiple sclerosis. This study was undertaken to investigate the role of myelin basic protein ( MBP)primed T cells in the expression of proinflammatory cytokines in microglial cells. MBP- primed T cells alone induced specifically the microglial expression of interleukin (IL)-1beta, IL-1alpha tumor necrosis factor alpha, and IL- 6, proinflammatory cytokines that are primarily involved in the pathogenesis of MS. This induction was primarily dependent on the contact between MBP- primed T cells and microglia. The activation of microglial NF-kappaB and CCAAT/ enhancer- binding protein beta ( C/ EBPbeta) by MBP-primed T cell contact and inhibition of contact- mediated microglial expression of proinflammatory cytokines by dominant- negative mutants of p65 and C/ EBPbeta suggest that MBP- primed T cells induce microglial expression of cytokines through the activation of NF- kappaB and C/EBPbeta. In addition, we show that MBP- primed T cells express very late antigen- 4 ( VLA- 4), and functional blocking antibodies to alpha(4) chain of VLA- 4 ( CD49d) inhibited the ability of MBP- primed T cells to induce microglial proinflammatory cytokines. Interestingly, the blocking of VLA- 4 impaired the ability of MBP- primed T cells to induce microglial activation of only C/ EBPbeta but not that of NF-kappaB. This study illustrates a novel role of VLA- 4 in regulating neuroantigen- primed T cell- induced activation of microglia through C/ EBPbeta.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG019487] Funding Source: NIH RePORTER; NIA NIH HHS [R03 AG019487-01] Funding Source: Medline; NINDS NIH HHS [R01 NS039940-02, R01 NS039940, NS39940] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chabot S, 2000, NEUROLOGY, V55, P1497, DOI 10.1212/WNL.55.10.1497; Chabot S, 1997, J CLIN INVEST, V100, P604, DOI 10.1172/JCI119571; CROSS AH, 1993, NEUROLOGY, V43, P1028, DOI 10.1212/WNL.43.5.1028; Dasgupta S, 2002, J BIOL CHEM, V277, P39327, DOI 10.1074/jbc.M111841200; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DSouza SD, 1996, J EXP MED, V184, P2361, DOI 10.1084/jem.184.6.2361; ESIRI MM, 1997, MULTIPLE SCLEROSIS C, P173; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111; Jana M, 2002, J NEUROCHEM, V80, P197, DOI 10.1046/j.0022-3042.2001.00691.x; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Liu HB, 2001, J NEUROIMMUNOL, V116, P83, DOI 10.1016/S0165-5728(01)00284-3; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; Pahan K, 2002, J BIOL CHEM, V277, P45984, DOI 10.1074/jbc.M200250200; RUDDLE NH, 1990, J EXP MED, V172, P1193, DOI 10.1084/jem.172.4.1193; Samoilova EB, 1998, J IMMUNOL, V161, P6480; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; Tan J, 1999, J NEUROIMMUNOL, V97, P77, DOI 10.1016/S0165-5728(99)00053-3; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; UTZ U, 1994, J NEUROPATH EXP NEUR, V53, P351, DOI 10.1097/00005072-199407000-00005; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	40	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22424	22431		10.1074/jbc.M301789200	http://dx.doi.org/10.1074/jbc.M301789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690109	Green Accepted, hybrid			2022-12-25	WOS:000183503900035
J	Fitch, CD; Chen, YF; Cai, GZ				Fitch, CD; Chen, YF; Cai, GZ			Chloroquine-induced masking of a lipid that promotes ferriprotoporphyrin IX dimerization in malaria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-BERGHEI; HEME POLYMERASE; BETA-HEMATIN; PIGMENT; ERYTHROCYTES; TROPHOZOITES; HEMOGLOBIN; FALCIPARUM; PARASITES	Mice infected with the NYU-2 strain of Plasmodium berghei were used to study the effect of chloroquine on masking of a lipid that promotes ferriprotoporphyrin IX dimerization. More than 40% of this lipid was masked and unable to promote dimerization in membrane ghosts from erythrocytes of untreated, infected mice. Thus, preparations of membrane ghosts dimerized 57 +/- 6 nmol of ferriprotoporphyrin IX during a 2-h incubation, whereas the lipids extracted from these preparations dimerized 101 +/- 11 nmol of ferriprotoporphyrin IX (means +/- S. D. for four experiments). Exposure of membrane ghosts to sonication or cold significantly increased the extent of masking. In addition, chloroquine treatment of infected mice increased the extent of masking to similar to90%. The lipid could be unmasked by extracting it into acetone or by aging erythrocyte membrane ghosts from untreated or chloroquine-treated, infected mice for 24 h at pH 7.4 and 25 degreesC. These findings indicate that masking and unmasking of a lipid is central to the regulation of ferriprotoporphyrin IX dimerization in malaria parasites. They also indicate that chloroquine impairs the function of this regulatory process.	St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA	Saint Louis University	Fitch, CD (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, 1402 S Grand Blvd, St Louis, MO 63104 USA.							AIKAWA M, 1980, MALARIA, V1, P285; ASAKURA T, 1977, J CLIN INVEST, V59, P633, DOI 10.1172/JCI108681; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; CHOU AC, 1993, BIOCHEM BIOPH RES CO, V195, P422, DOI 10.1006/bbrc.1993.2060; CHOU AC, 1992, LIFE SCI, V51, P2073, DOI 10.1016/0024-3205(92)90158-L; EINHEBER A, 1976, EXP PARASITOL, V40, P52, DOI 10.1016/0014-4894(76)90063-1; Fitch CD, 1997, ANTIMICROB AGENTS CH, V41, P2461, DOI 10.1128/AAC.41.11.2461; Fitch CD, 1999, BBA-MOL BASIS DIS, V1454, P31, DOI 10.1016/S0925-4439(99)00017-4; FITCH CD, 1987, J BIOL CHEM, V262, P15552; FITCH CD, 1986, PARASITOL TODAY, V2, P330, DOI 10.1016/0169-4758(86)90051-7; Fitch CD, 2000, BBA-MOL BASIS DIS, V1535, P45, DOI 10.1016/S0925-4439(00)00081-8; Fitch CD, 1996, MOL BIOCHEM PARASIT, V82, P261, DOI 10.1016/0166-6851(96)02744-2; Hempelmann E, 2003, TRENDS PARASITOL, V19, P23, DOI 10.1016/S1471-4922(02)00011-9; MACOMBER PB, 1967, NATURE, V214, P937, DOI 10.1038/214937a0; Orjih AU, 2001, EXP BIOL MED, V226, P746, DOI 10.1177/153537020222600806; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; RUDZINSKA MA, 1965, J PROTOZOOL, V12, P563, DOI 10.1111/j.1550-7408.1965.tb03256.x; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLOMIANNY C, 1985, PARASITOLOGY, V90, P579, DOI 10.1017/S0031182000055578; WARHURST DC, 1967, NATURE, V214, P935, DOI 10.1038/214935a0	20	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22596	22599		10.1074/jbc.M301407200	http://dx.doi.org/10.1074/jbc.M301407200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12697766	hybrid			2022-12-25	WOS:000183503900057
J	Hertz, R; Ben-Haim, N; Petrescu, AD; Kalderon, B; Berman, I; Eldad, N; Schroeder, F; Bar-Tana, J				Hertz, R; Ben-Haim, N; Petrescu, AD; Kalderon, B; Berman, I; Eldad, N; Schroeder, F; Bar-Tana, J			Rescue of MODY-1 by agonist ligands of hepatocyte nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HNF4-ALPHA GENE IMPAIR; ACYL-COA THIOESTERS; RETINOID-X-RECEPTOR; TRANSCRIPTION FACTOR; DOCOSAHEXAENOIC ACID; MISSENSE MUTATION; CRYSTAL-STRUCTURE; ALPHA-GENE; YOUNG; EXPRESSION	Missense mutations of the ligand binding domain of hepatocyte nuclear factor (HNF)-4alpha result in maturity onset diabetes of the young (MODY)-1. We show here that MODY-1 as well as Gln-185 missense mutants of the ligand binding domain of HNF-4alpha fail to transactivate transcription of HNF-4alpha-responsive genes. Defective transactivation by these mutants is accounted for by their reduced binding affinities for fatty acyl agonist ligands of HNF-4alpha. These mutants may be rescued by exogenous fatty acid agonist ligands of HNF-4alpha, yielding transcriptional activities in the wild type range. The effect of added ligands is synergistic with that of transcriptional coactivators of HNF-4alpha. These findings may indicate the means for treating selected MODY-1 subjects with HNF-4alpha agonist nutrients and drugs.	Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel; Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA	Hebrew University of Jerusalem; Texas A&M University System; Texas A&M University College Station	Bar-Tana, J (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel.	bartanaj@cc.huji.ac.il						Bartoov-Shifman R, 2002, J BIOL CHEM, V277, P25914, DOI 10.1074/jbc.M201582200; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Bulman MP, 1997, DIABETOLOGIA, V40, P859, DOI 10.1007/s001250050760; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; DORIA A, 2000, CURR OPIN ENDOCRINOL, V7, P203; Duncan SA, 1997, DEVELOPMENT, V124, P279; Eeckhoute J, 2001, MOL ENDOCRINOL, V15, P1200, DOI 10.1210/me.15.7.1200; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Gardezi SA, 2001, J BIOL CHEM, V276, P29148, DOI 10.1074/jbc.M100898200; Hani E, 1998, J CLIN INVEST, V101, P521, DOI 10.1172/JCI1403; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Kistanova E, 2001, BIOCHEM J, V356, P635, DOI 10.1042/0264-6021:3560635; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laine B, 2000, FEBS LETT, V479, P41, DOI 10.1016/S0014-5793(00)01864-0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Li JX, 2000, GENE DEV, V14, P464; Moller AM, 1997, DIABETOLOGIA, V40, P980, DOI 10.1007/s001250050778; Navas MA, 1999, DIABETES, V48, P1459, DOI 10.2337/diabetes.48.7.1459; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Radominska-Pandya A, 2002, BIOCHEMISTRY-US, V41, P4883, DOI 10.1021/bi0121151; Rajas F, 2002, J BIOL CHEM, V277, P15736, DOI 10.1074/jbc.M200971200; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SEGEL IH, 1981, ENZYME KINETICS, P365; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Suaud L, 1999, DIABETES, V48, P1162, DOI 10.2337/diabetes.48.5.1162; TAKEDA T, 1995, J CLIN ENDOCR METAB, V80, P2033, DOI 10.1210/jc.80.7.2033; Vivat V, 1997, EMBO J, V16, P5697, DOI 10.1093/emboj/16.18.5697; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yang Q, 2000, DIABETOLOGIA, V43, P520, DOI 10.1007/s001250051338; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis	43	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22578	22585		10.1074/jbc.M212138200	http://dx.doi.org/10.1074/jbc.M212138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12697772	hybrid			2022-12-25	WOS:000183503900055
J	Seck, T; Baron, R; Horne, WC				Seck, T; Baron, R; Horne, WC			The alternatively spliced Delta e13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; METABOTROPIC GLUTAMATE-RECEPTOR; 7TH TRANSMEMBRANE DOMAIN; TYROSINE PHOSPHORYLATION; INTERNATIONAL UNION; GABA(B) RECEPTOR; HORMONE-RECEPTOR; HIV-1 INFECTION; CELL-SURFACE	Numerous alternatively spliced transcripts are generated from the gene for the G protein-coupled calcitonin receptor, and some of the splice variants show differences in receptor-mediated signaling events. This study showed that the Deltae13 splice variant of the rabbit calcitonin receptor is expressed together with the more common C1a in osteoclast-like cells. Since other G protein-coupled receptors form homo- or heterodimers, we examined whether heterodimerization of the calcitonin receptor splice variants occurs and, if so, whether it affects the function of the receptor. Homodimers of both isoforms and Deltae13/C1a heterodimers were detected by co-immunoprecipitation and fluorescence resonance energy transfer analysis. In contrast to the C1a isoform, the Deltae13 isoform was not efficiently transported to the cell surface. When co-expressed with the C1a splice variant, the Deltae13 isoform colocalized with the C1a isoform within the cell but not at the cell surface. Furthermore, the overexpression of the Deltae13 variant led to a significant reduction of the C1a surface expression and consequently a reduction of the cAMP response and Erk phosphorylation after ligand stimulation. We therefore suggest that the Deltae13 variant of the rabbit calcitonin receptor acts to regulate the surface expression of the C1a isoform.	Ruhr Univ Bochum, Berufsgenossenschaftliche Kliniken Bergmannsheil, Dept Internal Med, D-44789 Bochum, Germany; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06510 USA	Ruhr University Bochum; Yale University; Yale University	Seck, T (corresponding author), Ruhr Univ Bochum, Berufsgenossenschaftliche Kliniken Bergmannsheil, Dept Internal Med, D-44789 Bochum, Germany.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE-04724] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBRANDT K, 1993, FEBS LETT, V325, P225, DOI 10.1016/0014-5793(93)81078-E; AZRIA M, 1989, CALCITONINS PHYSL PH, P43; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAKRABORTY M, 1991, SCIENCE, V251, P1078, DOI 10.1126/science.1847755; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; COPP DH, 1969, ANNU REV PHARMACOLOG, V9, P327, DOI 10.1146/annurev.pa.09.040169.001551; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; David JP, 1998, J BONE MINER RES, V13, P1730, DOI 10.1359/jbmr.1998.13.11.1730; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DING C, 1995, J BONE MINER RES, V10, pS484; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Grammatopoulos DK, 1999, MOL ENDOCRINOL, V13, P2189, DOI 10.1210/me.13.12.2189; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LIN HY, 1991, T ASSOC AM PHYSICIAN, V104, P265; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; PEREZ M, 1997, J BONE MINER RES, V12, pS323; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Santhanagopal A, 2001, ENDOCRINOLOGY, V142, P4401, DOI 10.1210/en.142.10.4401; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; SEXTON PM, 1993, MOL ENDOCRINOL, V7, P815, DOI 10.1210/me.7.6.815; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; Shyu JF, 1999, EUR J BIOCHEM, V262, P95, DOI 10.1046/j.1432-1327.1999.00346.x; Spedding M, 2002, PHARMACOL REV, V54, P231, DOI 10.1124/pr.54.2.231; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; YAMIN M, 1994, ENDOCRINOLOGY, V135, P2635, DOI 10.1210/en.135.6.2635; ZAIDI M, 1990, CRIT REV CL LAB SCI, V28, P109, DOI 10.3109/10408369009105900; Zhang ZY, 1999, J BIOL CHEM, V274, P25093, DOI 10.1074/jbc.274.35.25093; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	45	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23085	23093		10.1074/jbc.M211280200	http://dx.doi.org/10.1074/jbc.M211280200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686555	hybrid			2022-12-25	WOS:000183503900116
J	Sun, CH; McCaffery, JM; Reiner, DS; Gillin, FD				Sun, CH; McCaffery, JM; Reiner, DS; Gillin, FD			Mining the Giardia lamblia genome for new cyst wall proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEATS; REGULATED SECRETORY PATHWAY; GREEN FLUORESCENT PROTEIN; FIELD-EMISSION SEM; PRIMITIVE EUKARYOTE; ENDOPLASMIC-RETICULUM; GENE PROMOTER; ENCYSTATION; IDENTIFICATION; EXCYSTATION	The Giardia lamblia cyst wall ( CW), which is required for survival outside the host and infection, is a primitive extracellular matrix. Because of the importance of the CW, we queried the Giardia Genome Project Database with the coding sequences of the only two known CW proteins, which are cysteine- rich and contain leucine-rich repeats ( LRRs). We identified five new LRR- containing proteins, of which only one ( CWP3) is up- regulated during encystation and incorporated into the cyst wall. Sequence comparison with CWP1 and - 2 revealed conservation within the LRRs and the 44- amino- acid N- flanking region, although CWP3 is more divergent. Interestingly, all 14 cysteine residues of CWP3 are positionally conserved with CWP1 and - 2. During encystation, C- terminal epitope- tagged CWP3 was transported to the wall of water- resistant cysts via the novel regulated secretory pathway in encystation- secretory vesicles ( ESVs). Deletion analysis revealed that the four LRRs are each essential to target CWP3 to the ESVs and cyst wall. In a deletion of the most C- terminal region, fewer ESVs were stained in encysting cells, and there was no staining in cysts. In contrast, deletion of the 44 amino acids between the signal sequence and the LRRs or the region just C- terminal to the LRRs only decreased the number of cells with CWP3 targeting to ESVs and cyst wall by similar to 50%. Our studies indicate that virtually every portion of the CWP3 protein is needed for efficient targeting to the regulated secretory pathway and incorporation into the cyst wall. Further, these data demonstrate the power of genomics in combination with rigorous functional analyses to verify annotation.	Univ Calif San Diego, Sch Med, Dept Pathol, San Diego, CA 92103 USA; Johns Hopkins Univ, Dept Biol, Integrated Imaging Ctr, Baltimore, MD 21218 USA	University of California System; University of California San Diego; Johns Hopkins University	Gillin, FD (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 214 Dickinson St,8416, San Diego, CA 92103 USA.		Shin, Jerry/AAO-2515-2021; Reiner, David S./F-6106-2012	Reiner, David S./0000-0002-8289-7311; SUN, CHIN-HUNG/0000-0002-8604-8085	NIAID NIH HHS [AI 51687, AI 42488] Funding Source: Medline; NIDDK NIH HHS [DK 35108] Funding Source: Medline; NIGMS NIH HHS [GM 61896] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042488, R01AI051687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061896] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel ES, 2001, J BIOL CHEM, V276, P10320, DOI 10.1074/jbc.M006589200; ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; ALBERTS B, 2002, MOL BIOL CELL, P551; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BINGHAM AK, 1979, NATURE, V277, P301, DOI 10.1038/277301a0; Blazquez M, 2000, BIOCHEM CELL BIOL, V78, P181, DOI 10.1139/bcb-78-3-181; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; Bowman GR, 2001, GENETICS, V159, P1605; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Despommier D.D., 1987, PARASITE LIFE CYCLES; Eichinger D, 2001, CURR OPIN MICROBIOL, V4, P421, DOI 10.1016/S1369-5274(00)00229-0; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; Erlandsen SL, 1996, J EUKARYOT MICROBIOL, V43, P416, DOI 10.1111/j.1550-7408.1996.tb05053.x; ERLANDSEN SL, 1989, J PARASITOL, V75, P787, DOI 10.2307/3283065; ERLANDSEN SL, 1990, J HISTOCHEM CYTOCHEM, V38, P625, DOI 10.1177/38.5.2332623; Farthing Michael J. G., 1995, P1081; FAUBERT G, 1991, EXP PARASITOL, V72, P345, DOI 10.1016/0014-4894(91)90080-G; Gerwig GJ, 2002, GLYCOBIOLOGY, V12, P499, DOI 10.1093/glycob/cwf059; GILLIN FD, 1987, SCIENCE, V235, P1040, DOI 10.1126/science.3547646; GILLIN FD, 1981, EXP PARASITOL, V52, P9, DOI 10.1016/0014-4894(81)90055-2; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; GUPTA RS, 1994, P NATL ACAD SCI USA, V91, P2895, DOI 10.1073/pnas.91.8.2895; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hetsko ML, 1998, EXP PARASITOL, V88, P172, DOI 10.1006/expr.1998.4246; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jarroll EL, 2001, J EUKARYOT MICROBIOL, V48, P22, DOI 10.1111/j.1550-7408.2001.tb00412.x; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Knodler LA, 1999, MOL MICROBIOL, V34, P327, DOI 10.1046/j.1365-2958.1999.01602.x; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; Marino M, 2000, P NATL ACAD SCI USA, V97, P8784, DOI 10.1073/pnas.97.16.8784; Marshall MM, 1997, CLIN MICROBIOL REV, V10, P67, DOI 10.1128/CMR.10.1.67; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P220, DOI 10.1006/expr.1994.1086; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; PUGSLEY AP, 1989, PROTEIN TARGETING, P126; Que XC, 1996, MOL BIOCHEM PARASIT, V81, P101, DOI 10.1016/0166-6851(96)02698-9; REINER DS, 1990, EUR J CELL BIOL, V53, P142; REINER DS, 1989, INFECT IMMUN, V57, P963, DOI 10.1128/IAI.57.3.963-968.1989; Reiner DS, 2001, CELL MICROBIOL, V3, P459, DOI 10.1046/j.1462-5822.2001.00129.x; RICE EW, 1981, J CLIN MICROBIOL, V14, P709, DOI 10.1128/JCM.14.6.709-710.1981; Sambrook J., 2002, MOL CLONING LAB MANU; Singer SM, 1998, MOL BIOCHEM PARASIT, V92, P59, DOI 10.1016/S0166-6851(97)00225-9; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Sun CH, 1999, J BIOL CHEM, V274, P19699, DOI 10.1074/jbc.274.28.19699; Sun CH, 2002, MOL MICROBIOL, V46, P971, DOI 10.1046/j.1365-2958.2002.03233.x; Sun CH, 1998, MOL BIOCHEM PARASIT, V92, P123, DOI 10.1016/S0166-6851(97)00239-9; Svard SG, 1998, MOL MICROBIOL, V30, P979, DOI 10.1046/j.1365-2958.1998.01125.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; TOUZ MC, 2002, J BIOL CHEM; Yee J, 2000, J BIOL CHEM, V275, P11432, DOI 10.1074/jbc.275.15.11432	62	86	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21701	21708		10.1074/jbc.M302023200	http://dx.doi.org/10.1074/jbc.M302023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12686559	hybrid			2022-12-25	WOS:000183354200050
J	Zhang, XC; Shan, PY; Alam, J; Davis, RJ; Flavell, RA; Lee, PJ				Zhang, XC; Shan, PY; Alam, J; Davis, RJ; Flavell, RA; Lee, PJ			Carbon monoxide modulates Fas/Fas ligand, caspases, and Bcl-2 family proteins via the p38 alpha mitogen-activated protein kinase pathway during ischemia-reperfusion lung injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; HEME OXYGENASE-1 SUPPRESSES; SIGNALING PATHWAY; TRANSCRIPTION FACTOR; MEDIATED APOPTOSIS; MAJOR ACTIVATOR; CELLS; ISCHEMIA/REPERFUSION; EXPRESSION; DEATH	Carbon monoxide is protective in ischemia-reperfusion organ injury, but the precise mechanisms remain elusive. We have recently shown that low levels of exogenous carbon monoxide (CO) utilize p38 MAPK and attenuate caspase 3 activity to exert an antiapoptotic effect during lung ischemia-reperfusion injury. Our current data demonstrate that CO activates the p38alpha MAPK isoform and the upstream MAPK kinase MKK3 to modulate Fas/Fas ligand expression; caspases 3, 8, and 9; mitochondrial cytochrome c release; Bcl-2 proteins; and poly(ADP-ribose) polymerase cleavage. We correlate our in vitro findings with in vivo studies using MKK3-deficient and Fas-deficient mice. Taken together, our data are the first to demonstrate that CO has an antiapoptotic effect by inhibiting Fas/Fas ligand, caspases, proapoptotic Bcl-2 proteins, and cytochrome c release via the MKK3/p38alpha MAPK pathway.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA	Yale University; Yale University; Ochsner Health System; University of Massachusetts System; University of Massachusetts Worcester	Lee, PJ (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St,POB 208057, New Haven, CT 06520 USA.		zhang, xu/GYE-3558-2022; Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X; Zhang, Xuchen/0000-0002-1484-4672	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43135] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Cao GD, 2002, J NEUROSCI, V22, P5423; Coito AJ, 2002, TRANSPLANTATION, V74, P96, DOI 10.1097/00007890-200207150-00017; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Cursio R, 2000, Transpl Int, V13 Suppl 1, pS568, DOI 10.1111/j.1432-2277.2000.tb02108.x; Daemen MARC, 2002, TRANSPLANTATION, V73, P1693; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Gottlieb RA, 1999, ANN NY ACAD SCI, V874, P412, DOI 10.1111/j.1749-6632.1999.tb09255.x; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Ke BB, 2002, HUM GENE THER, V13, P1189, DOI 10.1089/104303402320138970; Kitamura Y, 2001, AM J RESP CRIT CARE, V163, P762, DOI 10.1164/ajrccm.163.3.2003065; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Singh R, 2002, J BIOL CHEM, V277, P37630, DOI 10.1074/jbc.M203648200; Stammberger U, 2000, ANN THORAC SURG, V69, P1532, DOI 10.1016/S0003-4975(00)01228-5; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tulis DA, 2001, CIRCULATION, V104, P2710, DOI 10.1161/hc4701.099585; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yue TL, 1998, CIRC RES, V82, P166; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhang XC, 2002, AM J PHYSIOL-LUNG C, V283, pL815, DOI 10.1152/ajplung.00485.2001	37	135	150	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22061	22070		10.1074/jbc.M301858200	http://dx.doi.org/10.1074/jbc.M301858200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12690100	hybrid			2022-12-25	WOS:000183354200094
J	She, QB; Ma, WY; Wang, MF; Kaji, A; Ho, CT; Dong, ZG				She, QB; Ma, WY; Wang, MF; Kaji, A; Ho, CT; Dong, ZG			Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved	ONCOGENE			English	Article						resveratrol; resveratrol derivatives; cell transformation; p53; PI-3K/Akt; chemoprevention	ACTIVATOR PROTEIN-1 ACTIVATION; PHOSPHATIDYLINOSITOL KINASE; APOPTOSIS; GROWTH; CHEMOPREVENTION; P53; PRODUCT; PATHWAY; ARREST; PHOSPHORYLATION	Resveratrol, a constituent of grapes and other foods, has been reported to be a potential cancer chemopreventive agent. Our previous study showed that the antitumor activity of resveratrol occurs through mitogen-activated protein kinases-mediated p53 activation and induction of apoptosis. To develop more effective agents with fewer side effects for the chemoprevention of cancer, we investigated the effect of resveratrol and its structurally related derivatives on epidermal growth factor (EGF)-induced cell transformation. Our results provided the first evidence that one of the resveratrol derivatives exerted a more potent inhibitory effect than resveratrol on EGF-induced cell transformation, but had less cytotoxic effects on normal nontransformed cells. Compared to resveratrol, this compound also caused cell cycle arrest in the G1 phase, but did not induce p53 activation and apoptosis. Furthermore, this compound, but not resveratrol, markedly inhibited EGF-induced phosphatidylinositol-3 kinase (PI-3K) and Akt activation. Collectively, these data suggested that the higher antitumor effect of the compound compared to resveratrol, may act through a different mechanism by mainly targeting PI-3K/Akt signaling pathways.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA	University of Minnesota System; Rutgers State University New Brunswick	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Wang, Mingfu/AAT-3292-2021	Wang, Mingfu/0000-0003-1469-3963; She, Qing-Bai/0000-0002-7207-0599	NATIONAL CANCER INSTITUTE [R01CA077646, R37CA081064, R01CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2001, BIOCHEM BIOPH RES CO, V288, P579, DOI 10.1006/bbrc.2001.5819; Ahmad N, 2001, CLIN CANCER RES, V7, P1466; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Clement MV, 1998, BLOOD, V92, P996; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong ZG, 1999, ANTICANCER RES, V19, P3743; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Huang CS, 1997, CANCER RES, V57, P2873; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kelloff GJ, 2000, J NUTR, V130, p467S, DOI 10.1093/jn/130.2.467S; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; Prives C, 1999, J PATHOL, V187, P112; SERUNIAN LA, 1990, J VIROL, V64, P4718, DOI 10.1128/JVI.64.10.4718-4725.1990; She QB, 2000, FEBS LETT, V469, P163, DOI 10.1016/S0014-5793(00)01273-4; She QB, 2002, MOL CARCINOGEN, V33, P244, DOI 10.1002/mc.10041; She QB, 2001, CANCER RES, V61, P1604; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang MF, 1999, J AGR FOOD CHEM, V47, P3974, DOI 10.1021/jf990382w; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	38	49	53	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2143	2150		10.1038/sj.onc.1206370	http://dx.doi.org/10.1038/sj.onc.1206370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687016				2022-12-25	WOS:000182066900008
J	Rosenkranz, AA; Lunin, VG; Gulak, PV; Sergienko, OV; Shumiantseva, MA; Voronina, OL; Gilyazova, DG; John, AP; Kofner, AA; Mironov, AF; Jans, DA; Sobolev, AS				Rosenkranz, AA; Lunin, VG; Gulak, PV; Sergienko, OV; Shumiantseva, MA; Voronina, OL; Gilyazova, DG; John, AP; Kofner, AA; Mironov, AF; Jans, DA; Sobolev, AS			Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity	FASEB JOURNAL			English	Article						targeted drug delivery; intracellular transport; nucleo-cytoplasmic transport; cancer; melanoma	TARGETED INTRACELLULAR DELIVERY; VIVO PROTEIN TRANSDUCTION; GENE-TRANSFER; PHOTODYNAMIC ACTIVITY; IN-VITRO; RECEPTOR; HORMONE; FUSION; TOXIN; PEPTIDES	The search for new pharmaceuticals that are specific for diseased rather than normal cells in the case of cancer and viral disease has raised interest in locally acting drugs that act over short distances within the cell and for which different cell compartments have distinct sensitivities. Thus, photo sensitizers (PSs) used in anti-cancer therapy should ideally be transported to the most sensitive subcellular compartments in order for their action to be most pronounced. Here we describe the design, production, and characterization of the effects of bacterially expressed modular recombinant transporters for PSs comprising 1) a-melanocyte-stimulating hormone as an internalizable, cell-specific ligand; 2) an optimized nuclear localization sequence of the SV40 large T-antigen; 3) an Escherichia coli hemoglobin-like protein as a carrier; and 4) an endosomolytic amphipathic polypeptide, the translocation domain of diphtheria toxin. These modular transporters delivered PSs into the nuclei, the most vulnerable sites for the action of PSs, of murine melanoma cells, but not non-MSH receptor-overexpressing cells, to result in cytotoxic effects several orders of magnitude greater than those of nonmodified PSs. The modular fusion proteins described here for the first time, capable of cell-specific targeting to particular subcellular compartments to increase drug efficacy, represent new pharmaceuticals with general application.	Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, Moscow 119334, Russia; Moscow MV Lomonosov State Univ, Fac Biol, Dept Biophys, Moscow 119899, Russia; Russian Acad Agr Sci, All Russia Inst Agr Biotechnol, Lab Mol Diagnost & Gene Engn Constructs, Moscow 127550, Russia; Russian Acad Sci, Bach Inst Biochem, Lab Enzyme Syst, Moscow 119071, Russia; Australian Natl Univ, John Curtin Sch Med Res, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Moscow Acad Fine Chem Technol, Dept Chem & Technol Fine Organ Chem, Moscow 117571, Russia; Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Research Center of Biotechnology RAS; Russian Academy of Sciences; Australian National University; John Curtin School of Medical Research; Monash University	Sobolev, AS (corresponding author), Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, 34-5 Vavilov St, Moscow 119334, Russia.	asobol@l.biophys.bio.msu.ru	Voronina, Olga L/F-4959-2018; Mironov, Andrey/ABB-3245-2021; Sobolev, Alexander S./P-6302-2015; Rosenkranz, Andrey A/J-3514-2015	Voronina, Olga L/0000-0001-7206-3594; Sobolev, Alexander S./0000-0001-8315-7764; Rosenkranz, Andrey A/0000-0001-9941-6118; Jans, David/0000-0001-5115-4745; Mironov, Andrey F./0000-0001-8353-1904				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1990, B EXP BIOL MED+, V109, P183, DOI 10.1007/BF00841665; Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; Akhlynina TV, 1999, INT J CANCER, V81, P734, DOI 10.1002/(SICI)1097-0215(19990531)81:5<734::AID-IJC12>3.3.CO;2-A; Atkins JH, 2002, NAT REV DRUG DISCOV, V1, P491, DOI 10.1038/nrd842; Barati S, 2002, EXP NEUROL, V177, P75, DOI 10.1006/exnr.2002.7999; Bisland SK, 1999, BIOCONJUGATE CHEM, V10, P982, DOI 10.1021/bc990020u; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chan CK, 2001, GENE THER, V8, P166, DOI 10.1038/sj.gt.3301366; Chenal A, 2002, PROTEIN ENG, V15, P383, DOI 10.1093/protein/15.5.383; de Jong M, 2002, SEMIN NUCL MED, V32, P133, DOI 10.1053/snuc.2002.31027; FINLAY GJ, 1984, ANAL BIOCHEM, V139, P272, DOI 10.1016/0003-2697(84)90002-2; Frankel AE, 2002, CLIN CANCER RES, V8, P1004; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Hamblin MR, 2000, PHOTOCHEM PHOTOBIOL, V72, P533, DOI 10.1562/0031-8655(2000)072<0533:SRTPT>2.0.CO;2; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jiang J, 1996, Exp Dermatol, V5, P325, DOI 10.1111/j.1600-0625.1996.tb00136.x; Kwekkeboom DJ, 2002, SEMIN NUCL MED, V32, P84, DOI 10.1053/snuc.2002.31022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273; Liang H, 2000, LASER MED SCI, V15, P109, DOI 10.1007/s101030050056; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mironov A. F., 1992, P SOC PHOTO-OPT INS, V1922, P204; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; O'Hare KB, 1993, J DRUG TARGET, V1, P217, DOI 10.3109/10611869308996079; PLANK C, 1994, J BIOL CHEM, V269, P12918; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; *QIAGEN, 2001, QIAEXPR; Ramage JG, 2003, LEUKEMIA RES, V27, P79, DOI 10.1016/S0145-2126(02)00077-2; Rosenkranz AA, 1997, BIOCHEM BIOPH RES CO, V236, P750, DOI 10.1006/bbrc.1997.7040; Rosenkranz AA, 2000, IMMUNOL CELL BIOL, V78, P452, DOI 10.1046/j.1440-1711.2000.00925.x; SAHM UG, 1994, PEPTIDES, V15, P441, DOI 10.1016/0196-9781(94)90202-X; Salazar-Onfray F, 2002, BRIT J CANCER, V87, P414, DOI 10.1038/sj.bjc.6600441; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; Silver RB, 1998, METHOD CELL BIOL, V56, P237, DOI 10.1016/S0091-679X(08)60429-X; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Sobolev AS, 2000, PROG BIOPHYS MOL BIO, V73, P51, DOI 10.1016/S0079-6107(00)00002-X; Trail PA, 1999, CURR OPIN IMMUNOL, V11, P584, DOI 10.1016/S0952-7915(99)00012-6; Uherek C, 1998, J BIOL CHEM, V273, P8835, DOI 10.1074/jbc.273.15.8835; WEN ZL, 1991, J BIOL CHEM, V266, P12289; Wikberg JES, 2000, PHARMACOL RES, V42, P393, DOI 10.1006/phrs.2000.0725; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wong WS, 1996, INT J BIOCHEM CELL B, V28, P1223, DOI 10.1016/S1357-2725(96)00074-X	48	50	58	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1121	+		10.1096/fj.02-0888fje	http://dx.doi.org/10.1096/fj.02-0888fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692081				2022-12-25	WOS:000182580100041
J	Ahonen, TJ; Xie, JW; LeBaron, MJ; Zhu, JQ; Nurmi, M; Alanen, K; Rui, H; Nevalainen, MT				Ahonen, TJ; Xie, JW; LeBaron, MJ; Zhu, JQ; Nurmi, M; Alanen, K; Rui, H; Nevalainen, MT			Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGAN-CULTURE; SIGNAL-TRANSDUCTION; LATERAL PROSTATE; RAT DORSAL; PROLACTIN RECEPTORS; HORMONE REGULATION; TRANSGENIC MICE; GENE; ACTIVATION; EXPRESSION	Identifying regulators of prostate cancer cell survival may lead to new therapeutic strategies for prostate cancer. We now report prevalent activation of transcription factor Stat5 in human prostate cancer and provide novel evidence that blocking activation of Stat5 in human prostate cancer cells leads to extensive cell death. Specifically, Stat5 was activated in 65% of human prostate cancer specimens examined based on nuclear location of tyrosine phosphorylated Stat5. Adenoviral gene delivery of a dominant-negative Stat5 mutant (DNStat5), but not wild-type Stat5, induced cell death of both the androgen-independent human prostate cancer cell line CWR22Rv and the androgen-sensitive LnCap cell line. Endogenous Stat5 was active in both CWR22Rv and LnCap cells. In contrast, only low levels of inactive Stat5 proteins were detected in the PC-3 cell line, which correlated with resistance to DNStat5-induced cell death. In CWR22Rv and LnCap cells, inhibition of Stat5 by expression of DNStat5 induced apoptotic cell death as judged from morphological changes, DNA fragmentation, and caspase-3 activation with evidence of a caspase-9-dependent mechanism. We propose that blocking Stat5 function may represent a novel therapeutic approach for prostate cancer.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA; Univ Turku, Inst Biomed, Dept Anat & Cell Biol, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Surg, FIN-20520 Turku, Finland; Univ Turku, Inst Biomed, Dept Pathol, FIN-20520 Turku, Finland	Georgetown University; University of Turku; University of Turku; University of Turku	Nevalainen, MT (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Res Bldg E508,3970 Reservoir Rd NW, Washington, DC 20057 USA.				NATIONAL CANCER INSTITUTE [R01CA083813] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83813] Funding Source: Medline; NIDDK NIH HHS [DK52013] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahonen TJ, 2002, ENDOCRINOLOGY, V143, P228, DOI 10.1210/en.143.1.228; Ahonen TJ, 1999, ENDOCRINOLOGY, V140, P5412, DOI 10.1210/en.140.11.5412; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Kindblom J, 2002, PROSTATE, V53, P24, DOI 10.1002/pros.10113; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Mah C, 2002, CLIN PHARMACOKINET, V41, P901, DOI 10.2165/00003088-200241120-00001; Nevalainen MT, 1997, J CLIN INVEST, V99, P618, DOI 10.1172/JCI119204; Nevalainen MT, 1996, ENDOCRINOLOGY, V137, P3078, DOI 10.1210/en.137.7.3078; NEVALAINEN MT, 1991, ENDOCRINOLOGY, V129, P612, DOI 10.1210/endo-129-2-612; Nevalainen MT, 1997, FASEB J, V11, P1297, DOI 10.1096/fasebj.11.14.9409549; Nevalainen MT, 2002, MOL ENDOCRINOL, V16, P1108, DOI 10.1210/mend.16.5.0839; Nevalainen MT, 2000, LAB INVEST, V80, P993, DOI 10.1038/labinvest.3780105; NEVALAINEN MT, 1993, CANCER RES, V53, P5199; Ni ZY, 2002, J UROLOGY, V167, P1859, DOI 10.1016/S0022-5347(05)65249-4; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; RUI H, 1994, J BIOL CHEM, V269, P5364; Steger RW, 1998, ENDOCRINOLOGY, V139, P3691, DOI 10.1210/en.139.9.3691; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Yamashita H, 2003, ONCOGENE, V22, P1638, DOI 10.1038/sj.onc.1206277	24	107	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27287	27292		10.1074/jbc.M304307200	http://dx.doi.org/10.1074/jbc.M304307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12719422	hybrid			2022-12-25	WOS:000184155700125
J	Mak, KKL; Chan, SY				Mak, KKL; Chan, SY			Epidermal growth factor as a biologic switch in hair growth cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; EGF RECEPTOR; FOLLICLE DEVELOPMENT; COMPREHENSIVE GUIDE; HEPARIN-BINDING; MICE LACKING; SKIN; MUTATION; CLASSIFICATION; MORPHOGENESIS	The hair growth cycle consists of three stages known as the anagen (growing), catagen (involution), and telogen (resting) phases. This cyclical growth of hair is regulated by a diversity of growth factors. Although normal expression of both epidermal growth factor and its receptor (EGFR) in the outer root sheath is down-regulated with the completion of follicular growth, here we show that continuous expression of epidermal growth factor in hair follicles of transgenic mice arrested follicular development at the final stage of morphogenesis. Data from immunoprecipitation and immunoblotting showed that epidermal growth factor signals through EGFR/ErbB2 heterodimers in skin. Furthermore, topical application of tyrphostin AG1478 or AG825, specific inhibitors of EGFR and ErbB2, respectively, completely inhibited new hair growth in wild type mice but not in transgenic mice. When the transgenic mice were crossed with waved-2 mice, which possess a lower kinase activity of EGFR, the hair phenotype was rescued in the offspring. Taken together, these data suggest that EGFR signaling is indispensable for the initiation of hair growth. On the other hand, continuous expression of epidermal growth factor prevents entry into the catagen phase. We propose that epidermal growth factor functions as a biologic switch that is turned on and off in hair follicles at the beginning and end of the anagen phase of the hair cycle, guarding the entry to and exit from the anagen phase.	Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Dept Paediat & Adolescent Med, Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.			Mak, Kingston King-Lun/0000-0002-4733-9146; Chan, Siu Yuen/0000-0001-7262-1293				COHEN S, 1986, BIOSCIENCE REP, V6, P1017, DOI 10.1007/BF01141022; Downing MT, 1997, HISTOCHEM J, V29, P735, DOI 10.1023/A:1026417202351; DUCROS DL, 1992, J INVEST DERMATOL, V98, P109, DOI 10.1111/1523-1747.ep12496010; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Hansen LA, 1997, AM J PATHOL, V150, P1959; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HOGAN B, 1994, MANIPULATING MOUSE E, P232; HOLLIS DE, 1987, J INVEST DERMATOL, V88, P455; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MOORE GPM, 1985, J INVEST DERMATOL, V84, P172, DOI 10.1111/1523-1747.ep12264699; MOORE GPM, 1983, ANAT RECORD, V205, P47, DOI 10.1002/ar.1092050107; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; NIXON AJ, 1996, J HISTOCHEM CYTOCHEM, V44, P337; Ogawa H, 1983, Curr Probl Dermatol, V11, P159; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P186, DOI 10.1111/1523-1747.ep12371760; PIEPKORN M, 1995, J INVEST DERMATOL, V105, P802, DOI 10.1111/1523-1747.ep12326567; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; ZSCHIESCHE W, 1988, EXPERIENTIA, V44, P249, DOI 10.1007/BF01941725	35	68	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26120	26126		10.1074/jbc.M212082200	http://dx.doi.org/10.1074/jbc.M212082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12714603	hybrid			2022-12-25	WOS:000183920200110
J	Ruehr, ML; Russell, MA; Ferguson, DG; Bhat, M; Ma, JJ; Damron, DS; Scott, JD; Bond, M				Ruehr, ML; Russell, MA; Ferguson, DG; Bhat, M; Ma, JJ; Damron, DS; Scott, JD; Bond, M			Targeting of protein kinase A by muscle a kinase-anchoring protein (mAKAP) regulates phosphorylation and function of the skeletal muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; GREEN FLUORESCENT PROTEIN; RAT VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; DIHYDROPYRIDINE RECEPTOR; DEFECTIVE REGULATION; DEPENDENT REGULATION; MEMBRANE; CELLS; PKA	Protein kinase A anchoring proteins (AKAPs) tether cAMP-dependent protein kinase (PKA) to specific subcellular locations. The muscle AKAP, mAKAP, co-localizes with the sarcoplasmic reticulum Ca2+ release channel or ryanodine receptor (RyR). The purpose of this study was to determine whether anchoring of PKA by mAKAP regulates RyR function. Either mAKAP or mAKAP-P, which is unable to anchor PKA, was expressed in CHO cells stably expressing the skeletal muscle isoform of RyR (CHO-RyR1). Immunoelectron microscopy showed that mAKAP co-localized with RyR1 in disrupted skeletal muscle. Following the addition of 10 muM forskolin to activate adenylyl cyclase, RyR1 phosphorylation in CHO-RyR1 cells expressing mAKAP increased by 42.4 +/- 6.6% (n = 4) compared with cells expressing mAKAP-P. Forskolin treatment alone did not increase the amplitude of the cytosolic Ca2+ transient in CHO-RyR1 cells expressing mAKAP or mAKAP-P; however, forskolin plus 10 mM caffeine elicited a cytosolic Ca2+ transient, the amplitude of which increased by 22% (p < 0.05) in RyR1/mAKAP- expressing cells compared with RyR1/mAKAP-P-expressing cells. Therefore, localization of PKA by mAKAP at RyR1 increases both PKA-dependent RyR phosphorylation as well as efflux of Ca2+ through the RyR. Therefore, RyR1 function is regulated by mAKAP targeting of PKA, implying an important functional role for PKA phosphorylation of RyR in skeletal muscle.	Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Anesthesiol Res, Cleveland, OH 44195 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Oregon Hlth & Sci Univ, Howard Hughes Med Inst, Vollum Inst, Portland, OR 97201 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Anat, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Oregon Health & Science University; Case Western Reserve University; Case Western Reserve University	Bond, M (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol, Lerner Res Inst, 9500 Euclid Ave,NB50, Cleveland, OH 44195 USA.	bondm@ccf.org		Russell, Mary A/0000-0001-5677-8194	NHLBI NIH HHS [HL065701, HL10273, HL56256, HL69000] Funding Source: Medline; NIA NIH HHS [AG15556, AG16613] Funding Source: Medline; NIDDK NIH HHS [DK54441] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069000, R01HL056256, R01HL065701, F32HL010273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556, R01AG016613] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bhat MB, 1999, BIOPHYS J, V77, P808, DOI 10.1016/S0006-3495(99)76933-X; Bhat MB, 1997, BIOPHYS J, V73, P1320, DOI 10.1016/S0006-3495(97)78165-7; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Bhat MB, 2002, J BIOL CHEM, V277, P8597, DOI 10.1074/jbc.M107609200; Blazev R, 2001, J MUSCLE RES CELL M, V22, P277, DOI 10.1023/A:1012289526618; CAIRNS SP, 1993, MUSCLE NERVE, V16, P1317, DOI 10.1002/mus.880161208; CARR DW, 1992, J BIOL CHEM, V267, P13376; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Dulhunty AF, 2002, PROG BIOPHYS MOL BIO, V79, P45, DOI 10.1016/S0079-6107(02)00013-5; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Gray PC, 1997, J BIOL CHEM, V272, P6297, DOI 10.1074/jbc.272.10.6297; HAIN J, 1994, BIOPHYS J, V67, P1823, DOI 10.1016/S0006-3495(94)80664-2; Hamada H, 1997, CIRC RES, V81, P812; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; JONES LR, 1981, BIOCHIM BIOPHYS ACTA, V641, P242, DOI 10.1016/0005-2736(81)90588-5; Kapiloff MS, 1999, J CELL SCI, V112, P2725; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Liu YW, 1997, AM J PHYSIOL-CELL PH, V273, pC1915, DOI 10.1152/ajpcell.1997.273.6.C1915; Lorenzon NM, 2001, ARCH BIOCHEM BIOPHYS, V388, P13, DOI 10.1006/abbi.2000.2263; LU XY, 1995, J BIOL CHEM, V270, P18459, DOI 10.1074/jbc.270.31.18459; LU XY, 1994, J BIOL CHEM, V269, P6511; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MCCARTNEY S, 1995, J BIOL CHEM, V270, P9327, DOI 10.1074/jbc.270.16.9327; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Ruehr ML, 1999, J BIOL CHEM, V274, P33092, DOI 10.1074/jbc.274.46.33092; Sacchetto R, 2001, J MUSCLE RES CELL M, V22, P545, DOI 10.1023/A:1015010914328; Scriven DRL, 2000, BIOPHYS J, V79, P2682, DOI 10.1016/S0006-3495(00)76506-4; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; Stern MD, 1997, J GEN PHYSIOL, V110, P415, DOI 10.1085/jgp.110.4.415; STRAND MA, 1993, BIOCHIM BIOPHYS ACTA, V1175, P319, DOI 10.1016/0167-4889(93)90224-D; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Tang W, 2002, FRONT BIOSCI, V7, pD1583, DOI 10.2741/tang; TRAFFORD AW, 1995, J PHYSIOL-LONDON, V488, P577, DOI 10.1113/jphysiol.1995.sp020991; Uehara A, 2002, PFLUG ARCH EUR J PHY, V444, P202, DOI 10.1007/s00424-002-0791-3; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735; Zakhary DR, 2000, J BIOL CHEM, V275, P41389, DOI 10.1074/jbc.M004212200	56	52	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24831	24836		10.1074/jbc.M213279200	http://dx.doi.org/10.1074/jbc.M213279200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709444	hybrid			2022-12-25	WOS:000183824800071
J	Jeon, SJ; Ishikawa, K				Jeon, SJ; Ishikawa, K			Characterization of novel hexadecameric thioredoxin peroxidase from Aeropyrum pernix K1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC HYPERTHERMOPHILIC ARCHAEON; ALKYL HYDROPEROXIDE REDUCTASE; ONE-CONSERVED CYSTEINE; GENOME SEQUENCE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN PEROXIREDOXIN; SALMONELLA-TYPHIMURIUM; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; ANTIOXIDANT	A gene (APE2278) encoding the peroxiredoxin (Prx) homologous protein of yeast and human was identified in the genome data base of the aerobic hyperthermophilic archaeon Aeropyrum pernix. We cloned the gene and produced the encoded protein in Escherichia coli cells. The isolated recombinant protein showed peroxidase activity in vitro and used the thioredoxin system of A. pernix as an electron donor. These results indicate that the recombinant protein is in fact thioredoxin peroxidase (ApTPx) of A. pernix. Immunoblot analysis revealed that the expression of ApTPx was induced as a cellular adaptation in response to the addition of exogenous H2O2 and may exert an antioxidant activity in vivo. An analysis of the ApTPx oligomers by high pressure liquid chromatography and electron microscopic studies showed that ApTPx exhibited the hexadecameric protein forming 2-fold toroid-shaped structure with outer and inner diameters of 14 and 6 nm, respectively. These results indicated that ApTPx is a novel hexadecameric protein composed of two identical octamers. Although oligomerization of individual subunits does not take place through an intersubunit-disulfide linkage involving Cys(50) and Cys(213), Cys(50) is essential for the formation of the hexadecamer. Mutagenesis studies suggest that the sulfhydryl group of Cys(50) is the site of oxidation by peroxide and that oxidized Cys(50) reacts with the sulfhydryl group of Cys(213) of another subunit to form an intermolecular disulfide bond. The resulting disulfide can then be reduced by thioredoxin. In support of this hypothesis, ApTPx mutants lacking either Cys(50) or Cys(213) showed no TPx activity, whereas the mutant lacking Cys(207) had a TPx activity. This is the first report on the biochemical and structural features of a novel hexadecameric thioredoxin peroxidase from the archaea.	Natl Inst AIST Kansai, Special Div Human Life Technol, Osaka 5638577, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Ishikawa, K (corresponding author), Natl Inst AIST Kansai, Special Div Human Life Technol, 1-8-31 Midorigaoka, Osaka 5638577, Japan.							CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chauhan R, 2002, BIOCHEM J, V367, P255, DOI 10.1042/BJ20020545; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Halliwell B, 1989, FREE RADICAL BIO MED, P299; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Jeon SJ, 2002, EUR J BIOCHEM, V269, P5423, DOI 10.1046/j.1432-1033.2002.03231.x; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawashima T, 2000, P NATL ACAD SCI USA, V97, P14257, DOI 10.1073/pnas.97.26.14257; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM K, 1985, J BIOL CHEM, V260, P5394; KIM KW, 1988, J BIOL CHEM, V263, P4704; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Sako Y, 1996, INT J SYST BACTERIOL, V46, P1070, DOI 10.1099/00207713-46-4-1070; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Schroder E, 1998, PROTEIN SCI, V7, P2465, DOI 10.1002/pro.5560071125; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; STORZ G, 1987, P NATL ACAD SCI USA, V84, P8917, DOI 10.1073/pnas.84.24.8917; Teller D C, 1973, Methods Enzymol, V27, P346; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Yamano S, 1999, J BIOCHEM-TOKYO, V126, P218, DOI 10.1093/oxfordjournals.jbchem.a022426	30	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24174	24180		10.1074/jbc.M300618200	http://dx.doi.org/10.1074/jbc.M300618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707274	hybrid			2022-12-25	WOS:000183638600123
J	Kitagawa, H; Izumikawa, T; Uyama, T; Sugahara, K				Kitagawa, H; Izumikawa, T; Uyama, T; Sugahara, K			Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE-REGION; N-ACETYLGALACTOSAMINYLTRANSFERASE; GLUCURONIC-ACID; CORE PROTEIN; SULFATE; EXPRESSION; TETRASACCHARIDE; ELONGATION; INITIATION; GLUCURONOSYLTRANSFERASE	We recently cloned human chondroitin synthase (ChSy) exhibiting the glucuronyltransferase-II (GlcAT-II) and N-acetylgalactosaminyltransferase-II (GalNAcT-II) activities responsible for the biosynthesis of repeating disaccharide units of chondroitin sulfate, but chondroitin polymerization was not demonstrated in vitro using the recombinant ChSy. We report here that the chondroitin polymerizing activity requires concomitant expression of a novel protein designated chondroitin polymerizing factor (ChPF) with ChSy. The human ChPF consists of 775 amino acids with a type II transmembrane protein topology. The amino acid sequence displayed 23% identity to that of human ChSy. The expression of a soluble recombinant form of the protein in COS-1 cells produced a protein with little GlcAT-II or GalNAcT-II activity. In contrast, coexpression of the ChPF and ChSy yielded markedly augmented glycosyltransferase activities, whereas simple mixing of the two separately expressed proteins did not. Moreover, using both UDP-glucuronic acid (GlcUA) and UDP-N-acetylgalactosamine (GalNAc) as sugar donors, chondroitin polymerization was demonstrated on the so-called glycosaminoglycan-protein linkage region tetrasaccharide sequence of alpha-thrombomodulin. These results suggested that the ChPF acts as a specific activating factor for ChSy in chondroitin polymerization. The coding region of the ChPF was divided into four discrete exons and localized to chromosome 2q35-q36. Northern blot analysis revealed that the ChPF gene exhibited a markedly different expression pattern among various human tissues, which was similar to that of ChSy. Thus, the ChPF is required for chondroitin polymerizing activity of mammalian ChSy.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Fernandez CJ, 1998, J BIOL CHEM, V273, P19030, DOI 10.1074/jbc.273.30.19030; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; HOVINGH P, 1977, BIOCHEM J, V165, P287, DOI 10.1042/bj1650287; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Sakaguchi H, 2001, J BIOCHEM-TOKYO, V129, P107, DOI 10.1093/oxfordjournals.jbchem.a002820; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Tamura J, 1996, LIEBIGS ANN, P1239; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	30	134	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23666	23671		10.1074/jbc.M302493200	http://dx.doi.org/10.1074/jbc.M302493200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12716890	hybrid			2022-12-25	WOS:000183638600058
J	Onda, M; Hirose, M				Onda, M; Hirose, M			Refolding mechanism of ovalbumin - Investigation by using a starting urea-denatured disulfide isomer with mispaired Cys(367)-Cys(382)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; TERMINAL HALF-MOLECULE; PARTIALLY FOLDED STATE; BETA-LACTOGLOBULIN; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; REVERSIBLE DENATURATION; CONFORMATIONAL DISEASE; SECONDARY STRUCTURE; REDUCED OVALBUMIN	Ovalbumin, a member of the serpin superfamily, contains one cystine disulfide (Cys(73)-Cys(120)) and four cysteine sulfhydryls (Cys(11), Cys(30), Cys(367), and Cys(382)) in the native state. To investigate the folding mechanism of ovalbumin, a urea-denatured disulfide isomer with a mispaired disulfide Cys(367)-Cys(382) (D[367-382]) and its derivative (D[367-382/CM-73]) in which a native cystine counterpart of Cys(73) is blocked by carboxymethylation were produced. Both the denatured isomers refolded within an instrumental dead time of 4 ms into an initial burst intermediate I-N with partially folded conformation. After the initial burst phase, most of the D[367-382] molecules further refolded into the native form. In contrast, upon dilution of D[367-382/CM-73] with the refolding buffer, the protein stayed in the I-N state as a stable form, which displayed a partial regain of the native secondary structure and a compact conformation with a similar Stokes radius to the native form. The structural characteristics of I-N were clearly differentiated from those of an equilibrium intermediate I-A that was produced by dilution with an acidic buffer of urea-denatured ovalbumin; I-A showed much more hydrophobic dye binding and a larger Stokes radius than the I-N state, despite their indistinguishable far-UV circular dichroic spectra. The non-productive nature of I-A highlighted the importance of a compact conformation of the I-N state for subsequent native refolding. These observations were consistent with a refolding model of ovalbumin that includes the regain of the partial secondary structure and of the compactness of overall conformation in an initial burst phase before the subsequent native refolding.	Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Kyoto 6110011, Japan; Osaka Womens Univ, Dept Environm Sci, Fac Sci, Osaka 5900035, Japan	Kyoto University; Osaka Metropolitan University	Hirose, M (corresponding author), Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Kyoto 6110011, Japan.	hirose@kais.kyoto-u.ac.jp		Hirose, Masaaki/0000-0003-2672-4384				Arai M, 1998, J MOL BIOL, V275, P149, DOI 10.1006/jmbi.1997.1456; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; COBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888; DAGGETT V, 2000, MECH PROTEIN FOLDING, P175; DARBY NJ, 1991, FEBS LETT, V279, P61, DOI 10.1016/0014-5793(91)80251-W; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 2001, BIOCHEM SOC SYMP, V68, P1; FRECH C, 1995, J MOL BIOL, V251, P135, DOI 10.1006/jmbi.1995.0421; Fujiwara K, 1999, BIOCHEMISTRY-US, V38, P4455, DOI 10.1021/bi982683p; GALAT A, 1981, BIOCHEMISTRY-US, V20, P594, DOI 10.1021/bi00506a023; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; Hamada D, 1996, NAT STRUCT BIOL, V3, P868, DOI 10.1038/nsb1096-868; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; KOSEN PA, 1983, BIOCHEMISTRY-US, V22, P2433, DOI 10.1021/bi00279a020; Kuwata K, 2001, NAT STRUCT BIOL, V8, P151, DOI 10.1038/84145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JY, 1992, J BIOL CHEM, V267, P14753; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; Onda M, 1997, J BIOCHEM-TOKYO, V122, P83; Onda M, 1997, J BIOL CHEM, V272, P3973, DOI 10.1074/jbc.272.7.3973; SEETHARAMA A, 1982, MOL CELL BIOCHEM, V44, P129; SOENSEN SPL, 1915, COMP REND TRAV LAB C, V29, P12; Soto C, 2001, FEBS LETT, V498, P204, DOI 10.1016/S0014-5793(01)02486-3; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; Tatsumi E, 1997, J BIOCHEM, V122, P300; Tatsumi E, 1998, BIOCHEMISTRY-US, V37, P12351, DOI 10.1021/bi980353z; Tatsumi E, 1999, BIOSCI BIOTECH BIOCH, V63, P1285, DOI 10.1271/bbb.63.1285; TATSUMI E, 1994, J BIOL CHEM, V269, P28062; THOMPSON EOP, 1978, AUST J BIOL SCI, V31, P433, DOI 10.1071/BI9780433; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; WEISSMAN JS, 1995, NAT STRUCT BIOL, V2, P1123, DOI 10.1038/nsb1295-1123; WHITE FH, 1982, BIOCHEMISTRY-US, V21, P967, DOI 10.1021/bi00534a023; WRIGHT HT, 1990, J MOL BIOL, V213, P513; WRIGHT HT, 1984, J BIOL CHEM, V259, P4335; WRIGHT PE, 2000, MECH PROTEIN FOLDING, P309; Yamasaki M, 2002, J MOL BIOL, V315, P113, DOI 10.1006/jmbi.2001.5056; YAMASHITA H, 1993, J BIOL CHEM, V268, P19062; Zerovnik E, 2002, EUR J BIOCHEM, V269, P3362, DOI 10.1046/j.1432-1033.2002.03024.x	50	16	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23600	23609		10.1074/jbc.M300295200	http://dx.doi.org/10.1074/jbc.M300295200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12711610	hybrid			2022-12-25	WOS:000183638600050
J	Pikkarainen, S; Tokola, H; Majalahti-Palviainen, T; Kerkela, R; Hautala, N; Bhalla, SS; Charron, F; Nemer, M; Vuolteenaho, O; Ruskoaho, H				Pikkarainen, S; Tokola, H; Majalahti-Palviainen, T; Kerkela, R; Hautala, N; Bhalla, SS; Charron, F; Nemer, M; Vuolteenaho, O; Ruskoaho, H			GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE GENE; RAT CARDIAC MYOCYTES; TRANSCRIPTION FACTORS CSX/NKX-2.5; LEFT-VENTRICULAR HYPERTROPHY; BONE MORPHOGENETIC PROTEINS; SERUM RESPONSE FACTOR; CARDIOMYOCYTE HYPERTROPHY; PRESSURE-OVERLOAD; KINASE-C; IN-VITRO	In overloaded heart the cardiomyocytes adapt to increased mechanical and neurohumoral stress by activation of hypertrophic program, resulting in morphological changes of individual cells and specific changes in gene expression. Accumulating evidence suggests an important role for the zinc finger transcription factor GATA-4 in hypertrophic agonist-induced cardiac hypertrophy. However, its role in stretch-induced cardiomyocyte hypertrophy is not known. We employed an in vitro mechanical stretch model of cultured cardiomyocytes and used rat B-type natriuretic peptide promoter as stretch-sensitive reporter gene. Stretch transiently increased GATA-4 DNA binding activity and transcript levels, which was followed by increases in the expression of B-type natriuretic peptide as well as atrial natriuretic peptide and skeletal alpha-actin genes. The stretch inducibility mapped primarily to the proximal 520 bp of the B-type natriuretic peptide promoter. Mutational studies showed that the tandem GATA consensus sites of the proximal promoter in combination with an Nkx-2.5 binding element are critical for stretch-activated B-type natriuretic peptide transcription. Inhibition of GATA-4 protein production by adenovirus-mediated transfer of GATA-4 antisense cDNA blocked stretch-induced increases in B-type natriuretic peptide transcript levels and the sarcomere reorganization. The proportion of myocytes with assembled sarcomeres in control adenovirus-infected cultures increased from 14 to 59% in response to stretch, whereas the values for GATA-4 antisense-treated cells were 6 and 13%, respectively. These results show that activation of GATA-4, in cooperation with a factor binding on Nkx-2.5 binding element, is essential for mechanical stretch-induced cardiomyocyte hypertrophy.	Univ Oulu, Bioctr Oulu, Fac Med, Dept Pharmacol & Toxicol, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, Dept Physiol, FIN-90014 Oulu, Finland; Univ Montreal, Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	University of Oulu; University of Oulu; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Ruskoaho, H (corresponding author), Univ Oulu, Bioctr Oulu, Fac Med, Dept Pharmacol & Toxicol, POB 5000,Aapistie 5, FIN-90014 Oulu, Finland.	heikki.ruskoaho@oulu.fi	Charron, Frederic/O-8017-2019	Charron, Frederic/0000-0003-3483-8672				Aikawa R, 2001, BIOCHEM BIOPH RES CO, V289, P901, DOI 10.1006/bbrc.2001.6068; Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dai YS, 2002, J BIOL CHEM, V277, P24390, DOI 10.1074/jbc.M202490200; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; FRENCH BA, 1994, CIRCULATION, V90, P2402, DOI 10.1161/01.CIR.90.5.2402; GARDNER DG, 1992, AM J PHYSIOL, V263, pE239, DOI 10.1152/ajpendo.1992.263.2.E239; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hautala N, 2001, CIRCULATION, V103, P730; He Q, 2002, AM J PHYSIOL-ENDOC M, V283, pE50, DOI 10.1152/ajpendo.00274.2001; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; Kim MK, 2002, INT J ARTIF ORGANS, V25, P33, DOI 10.1177/039139880202500106; KOMURO I, 1991, J BIOL CHEM, V266, P1265; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Liang FQ, 1998, J BIOL CHEM, V273, P14612, DOI 10.1074/jbc.273.23.14612; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Lorell BH, 2000, CIRCULATION, V102, P470; MAGGA J, 1994, ENDOCRINOLOGY, V134, P2505, DOI 10.1210/en.134.6.2505; Magga J, 1997, CIRCULATION, V96, P3053, DOI 10.1161/01.CIR.96.9.3053; Marttila M, 2001, ENDOCRINOLOGY, V142, P4693, DOI 10.1210/en.142.11.4693; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Morimoto T, 2001, J BIOL CHEM, V276, P34983, DOI 10.1074/jbc.M005498200; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Pikkarainen S, 2003, J BIOL CHEM, V278, P3969, DOI 10.1074/jbc.M205616200; Pikkarainen S, 2002, J MOL MED, V80, P51, DOI 10.1007/s001090100278; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; TOKOLA H, 1994, EUR J PHARM-MOLEC PH, V267, P195, DOI 10.1016/0922-4106(94)90171-6; VUOLTEENAHO O, 1985, BIOCHEM BIOPH RES CO, V129, P82, DOI 10.1016/0006-291X(85)91406-8; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054	58	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23807	23816		10.1074/jbc.M302719200	http://dx.doi.org/10.1074/jbc.M302719200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704188	hybrid			2022-12-25	WOS:000183638600075
J	Tigges, U; Koch, B; Wissing, J; Jockusch, BM; Ziegler, WH				Tigges, U; Koch, B; Wissing, J; Jockusch, BM; Ziegler, WH			The F-actin cross-linking and focal adhesion protein filamin A is a ligand and in vivo substrate for protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR ACTIVATION; BINDING PROTEIN; CELL-ADHESION; TARGETS FILAMIN; DOWN-REGULATION; SMOOTH-MUSCLE; PHOSPHORYLATION; VINCULIN; DOMAIN; BETA	Filamin A is an established structural component of cell-matrix adhesion sites. In addition, it serves as a scaffold for the subcellular targeting of different signaling molecules. Protein kinase C (PKC) has been found associated with filamin; however, details about this interaction and its significance for cell-matrix adhesion-dependent signaling have remained elusive. We performed a yeast two-hybrid analysis using protein kinase Calpha as a bait and identified filamin as a direct binding partner. The interaction was confirmed in transfected HeLa cells, and serial truncation fragments of filamin A were employed to identify two binding sites on filamin. In vitro ligand binding assays revealed a Ca2+ and phospholipid-dependent association of the regulatory domain of protein kinase C with these sites. Phosphorylation of filamin was found to be isoform-restricted, leading to phosphate incorporation in the C termini of filamin A and C, but not B. PKC-dependent phosphorylation of filamin was also detected in cells. Our data suggest an intimate interaction between filamin and PKC in cell signaling.	Tech Univ Braunschweig, Dept Cell Biol, Inst Zool, D-38092 Braunschweig, Germany; Tech Univ Braunschweig, Dept Biochem, Inst Biochem & Biotechnol, D-38092 Braunschweig, Germany	Braunschweig University of Technology; Braunschweig University of Technology	Ziegler, WH (corresponding author), Tech Univ Braunschweig, Dept Cell Biol, Inst Zool, D-38092 Braunschweig, Germany.	w.ziegler@tu-bs.de		Ziegler, Wolfgang H./0000-0003-4529-1916				Banci L, 2002, J BIOL CHEM, V277, P12988, DOI 10.1074/jbc.M106875200; BASU A, 1992, BIOCHEMISTRY-US, V31, P3824, DOI 10.1021/bi00130a013; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; CHEN M, 1989, J BIOL CHEM, V264, P14282; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; Couchman JR, 1999, J CELL SCI, V112, P3415; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FURUHASHI K, 1992, BIOCHEM BIOPH RES CO, V184, P1261, DOI 10.1016/S0006-291X(05)80018-X; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; Goldmann WH, 1999, BIOCHEM BIOPH RES CO, V259, P108, DOI 10.1006/bbrc.1999.0735; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Haller H, 1996, ARTERIOSCL THROM VAS, V16, P678, DOI 10.1161/01.ATV.16.5.678; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Huttelmaier S, 1997, EUR J BIOCHEM, V247, P1136, DOI 10.1111/j.1432-1033.1997.01136.x; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Leinweber B, 2000, J BIOL CHEM, V275, P40329, DOI 10.1074/jbc.M008257200; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nikki M, 2002, J BIOL CHEM, V277, P11432, DOI 10.1074/jbc.M111753200; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHNO S, 1990, J BIOL CHEM, V265, P6296; Ohta Y, 1996, J BIOL CHEM, V271, P11858, DOI 10.1074/jbc.271.20.11858; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Parsons M, 2002, MOL CELL BIOL, V22, P5897, DOI 10.1128/MCB.22.16.5897-5911.2002; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Rudiger M, 1997, BIOTECHNIQUES, V23, P96, DOI 10.2144/97231bm20; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; TURNER CE, 1989, J BIOL CHEM, V264, P11938; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020; Zamir E, 2001, J CELL SCI, V114, P3583; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Ziegler WH, 2002, J BIOL CHEM, V277, P7396, DOI 10.1074/jbc.M110008200	60	68	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23561	23569		10.1074/jbc.M302302200	http://dx.doi.org/10.1074/jbc.M302302200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704190	hybrid			2022-12-25	WOS:000183638600045
J	Barends, TRM; Polderman-Tijmes, JJ; Jekel, PA; Hensgens, CMH; de Vries, EJ; Janssen, DB; Dijkstra, BW				Barends, TRM; Polderman-Tijmes, JJ; Jekel, PA; Hensgens, CMH; de Vries, EJ; Janssen, DB; Dijkstra, BW			The sequence and crystal structure of the alpha-amino acid ester hydrolase from Xanthomonas citri define a new family of beta-lactam antibiotic acylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; ENZYMATIC-SYNTHESIS; ESCHERICHIA-COLI; BINDING-SITE; CLONING; GENE; SPECIFICITY; EXPRESSION; CATALYSIS; KINETICS	alpha-Amino acid ester hydrolases (AEHs) catalyze the hydrolysis and synthesis of esters and amides with an alpha-amino group. As such, they can synthesize beta-lactam antibiotics from acyl compounds and beta-lactam nuclei obtained from the hydrolysis of natural antibiotics. This article describes the gene sequence and the 1.9-Angstrom resolution crystal structure of the AEH from Xanthomonas citri. The enzyme consists of an alpha/beta-hydrolase fold domain, a helical cap domain, and a jellyroll beta-domain. Structural homology was observed to the Rhodococcus cocaine esterase, indicating that both enzymes belong to the same class of bacterial hydrolases. Docking of a beta-lactam antibiotic in the active site explains the substrate specificity, specifically the necessity of an alpha-amino group on the substrate, and explains the low specificity toward the beta-lactam nucleus.	Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	B.W.Dijkstra@chem.rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586				Alkema WBL, 2000, PROTEIN ENG, V13, P857, DOI 10.1093/protein/13.12.857; Alkema WBL, 1999, ANAL BIOCHEM, V275, P47, DOI 10.1006/abio.1999.4300; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARAMORI I, 1991, J BACTERIOL, V173, P7848, DOI 10.1128/jb.173.24.7848-7855.1991; Barends TRM, 2003, ACTA CRYSTALLOGR D, V59, P158, DOI 10.1107/S090744490201836X; BLINKOVSKY AM, 1993, ENZYME MICROB TECH, V15, P965, DOI 10.1016/0141-0229(93)90173-Y; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Bresler MM, 2000, APPL ENVIRON MICROB, V66, P904, DOI 10.1128/AEM.66.3.904-908.2000; Bruggink A, 2001, SYNTHESIS OF BETA-LACTAM ANTIBIOTICS: CHEMISTRY, BIOCATALYSIS & PROCESS INTEGRATION, P12; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fernandez-Lafuente R, 2001, J MOL CATAL B-ENZYM, V11, P633, DOI 10.1016/S1381-1177(00)00065-5; Fulop V, 1998, CELL, V94, P161, DOI 10.1016/S0092-8674(00)81416-6; Howell PL, 2000, ACTA CRYSTALLOGR D, V56, P604, DOI 10.1107/S0907444900002936; HYUN CK, 1993, BIOTECHNOL BIOENG, V41, P654, DOI 10.1002/bit.260410608; HYUN CK, 1993, BIOTECHNOL BIOENG, V42, P800, DOI 10.1002/bit.260420703; JANSSEN DB, 1984, INNOVATIONS BIOTECHN; KATO K, 1980, AGR BIOL CHEM TOKYO, V44, P1083, DOI 10.1080/00021369.1980.10864077; KATO K, 1980, AGR BIOL CHEM TOKYO, V44, P1075, DOI 10.1080/00021369.1980.10864076; KATO K, 1980, AGR BIOL CHEM TOKYO, V44, P1069, DOI 10.1080/00021369.1980.10864075; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; Larsen NA, 2002, NAT STRUCT BIOL, V9, P17, DOI 10.1038/nsb742; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAM DH, 1985, BIOTECHNOL BIOENG, V27, P953, DOI 10.1002/bit.260270705; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Polderman-Tijmes JJ, 2002, APPL ENVIRON MICROB, V68, P211, DOI 10.1128/AEM.68.1.211-218.2002; POLDERMANTIJMES JJ, 2002, J BIOL CHEM; RHEE DK, 1980, BIOTECHNOL BIOENG, V22, P1237, DOI 10.1002/bit.260220610; Rigolet P, 2002, STRUCTURE, V10, P1383, DOI 10.1016/S0969-2126(02)00851-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith GD, 1998, ACTA CRYSTALLOGR D, V54, P799, DOI 10.1107/S0907444997018805; Szeltner Z, 2000, PROTEIN SCI, V9, P353; TAKAHASHI T, 1972, J AM CHEM SOC, V94, P4035, DOI 10.1021/ja00766a076; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Turner JM, 2002, BIOCHEMISTRY-US, V41, P12297, DOI 10.1021/bi026131p; van Asselt EJ, 1998, ACTA CRYSTALLOGR D, V54, P58, DOI 10.1107/S0907444997010330	47	35	44	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23076	23084		10.1074/jbc.M302246200	http://dx.doi.org/10.1074/jbc.M302246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684501	hybrid, Green Published			2022-12-25	WOS:000183503900115
J	Troussard, AA; Mawji, NM; Ong, C; Mui, A; St Arnaud, R; Dedhar, S				Troussard, AA; Mawji, NM; Ong, C; Mui, A; St Arnaud, R; Dedhar, S			Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; SIGNALING PATHWAY; CANCER CELLS; PHOSPHORYLATION; ILK; PDK1; IDENTIFICATION; CYTOSKELETON; INHIBITION; ADHESION	Protein kinase B ( PKB/ Akt) plays a pivotal role in signaling pathways downstream of phosphatidylinositol 3- kinase, regulating fundamental processes such as cell survival, cell proliferation, differentiation, and metabolism. PKB/ Akt activation is regulated by phosphoinositide phospholipid- mediated plasma membrane anchoring and by phosphorylation on Thr- 308 and Ser- 473. Whereas the Thr- 308 site is phosphorylated by PDK- 1, the identity of the Ser- 473 kinase has remained unclear and controversial. The integrin- linked kinase ( ILK) is a potential regulator of phosphorylation of PKB/ Akt on Ser- 473. Utilizing double- stranded RNA interference ( siRNA) as well as conditional knock- out of ILK using the Cre- Lox system, we now demonstrate that ILK is essential for the regulation of PKB/ Akt activity. ILK knock- out had no effect on phosphorylation of PKB/ Akt on Thr- 308 but resulted in almost complete inhibition of phosphorylation on Ser- 473 and significant inhibition of PKB/ Akt activity, accompanied by significant stimulation of apoptosis. The inhibition of PKB/ Akt Ser- 473 phosphorylation was rescued by kinase- active ILK but not by a kinase- deficient mutant of ILK, suggesting a role for the kinase activity of ILK in the stimulation of PKB/ Akt phosphorylation. ILK knock- out also resulted in the suppression of phosphorylation of GSK- 3 beta on Ser- 9 and cyclin D1 expression. These data establish ILK as an essential upstream regulator of PKB/ Akt activation.	Univ British Columbia, Dept Biochem, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Vancouver Hosp, Hlth Sci Ctr, Prostate Ctr, Vancouver, BC V6H 3Z5, Canada; Univ British Columbia, Dept Surg, Vancouver, BC V6H 3Z5, Canada; Shriners Hosp Crippled Children, Montreal, PQ H3G 1A6, Canada; McGill Univ, Montreal, PQ H3G 1A6, Canada	University of British Columbia; British Columbia Cancer Agency; University of British Columbia; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of British Columbia; McGill University; McGill University	Dedhar, S (corresponding author), Univ British Columbia, Dept Biochem, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.			Dedhar, Shoukat/0000-0003-4355-1657				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deng JT, 2002, BIOCHEM J, V367, P517, DOI 10.1042/BJ20020522; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Kaartinen V, 2001, GENESIS, V31, P126, DOI 10.1002/gene.10015; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007	28	239	262	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22374	22378		10.1074/jbc.M303083200	http://dx.doi.org/10.1074/jbc.M303083200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686550	hybrid			2022-12-25	WOS:000183503900028
J	Mosesson, Y; Shtiegman, K; Katz, M; Zwang, Y; Vereb, G; Szollosi, J; Yarden, Y				Mosesson, Y; Shtiegman, K; Katz, M; Zwang, Y; Vereb, G; Szollosi, J; Yarden, Y			Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RING FINGER; UBIQUITIN; PROTEINS; UBIQUITYLATION; SIGNAL; PHOSPHORYLATION; DEGRADATION; RECOGNITION; COMPLEX	Growth factors stimulate specific receptor tyrosine kinases, but subsequent receptor endocytosis terminates signaling. The ubiquitin ligase c- Cbl targets epidermal growth factor receptors ( EGFRs) to endocytosis by tagging them with multiple ubiquitin molecules. However, the type of ubiquitylation is unknown; whereas polyubiquitin chains signal proteasomal degradation, ubiquitin monomers control other processes. We report that in isolation c- Cbl mediates monoubiquitylation rather than polyubiquitylation of EGFRs. Consistent with the sufficiency of monoubiquitylation, when fused to the tail of EGFR, a single ubiquitin induces receptor endocytosis and degradation in cells. By using receptor and ubiquitin mutants, we infer that c- Cbl attaches a founder monoubiquitin to the kinase domain of EGFR and this is complemented by the conjugation of additional monoubiquitins. Hence, receptor tyrosine kinases are desensitized through conjugation of multiple monoubiquitins, which is distinct from polyubiquitin- dependent proteasomal degradation.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Univ Debrecen, Dept Biophys & Cell Biol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary	Weizmann Institute of Science; University of Debrecen	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.		YARDEN, YOSEF/K-1467-2012; Vereb, György/A-4241-2008	Vereb, György/0000-0003-2157-3265	NATIONAL CANCER INSTITUTE [R37CA072981, R01CA072981] Funding Source: NIH RePORTER; NCI NIH HHS [CA 72981] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Wang Y, 1999, J CELL BIOCHEM, V72, P119; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	22	270	277	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21323	21326		10.1074/jbc.C300096200	http://dx.doi.org/10.1074/jbc.C300096200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12719435	hybrid			2022-12-25	WOS:000183354200003
J	Partridge, AW; Melnyk, RA; Yang, D; Bowie, JU; Deber, CM				Partridge, AW; Melnyk, RA; Yang, D; Bowie, JU; Deber, CM			A transmembrane segment mimic derived from Escherichia coli diacylglycerol kinase inhibits protein activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-HELIX PACKING; M13 COAT PROTEIN; MEMBRANE-PROTEIN; ALPHA-HELICES; CROSS-LINKING; GLYCOPHORIN-A; ION-CHANNEL; DOMAIN; RECEPTOR; OLIGOMERIZATION	The function of membrane proteins is inextricably linked to the proper packing and assembly of their independently helical transmembrane (TM) segments. Here we examined whether an externally added TM peptide analogue could specifically inhibit the function of the membrane protein from which it is derived by competing for native TM helix packing sites, thereby producing a non-functional peptide-protein complex. This hypothesis was tested using Lys-tagged peptides synthesized with sequences corresponding to the three TM segments of the homotrimeric Escherichia coli diacylglycerol kinase (DGK). The peptide corresponding to wild-type DGK TM-2 inhibited the protein's enzymatic activity in a dose-dependent manner through formation of an inactive pseudo-complex, whereas peptides derived from TM-1 and TM-3 were benign toward DGK structure/function. Also, substitution of a conserved residue (Glu-69) within the TM-2 peptide abolished these effects, demonstrating the strict sequence requirements for TM-2-mediated association. This strategy, coupled with the practical advantages of the water solubility of Lys-tagged TM peptides, may constitute an attractive approach for the design of therapeutic membrane protein modulators even in the absence of a high resolution structure.	Hosp Sick Children, Res Inst, Div Stuct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Calif Los Angeles, Dept Chem & Biochem, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of California System; University of California Los Angeles	Deber, CM (corresponding author), Hosp Sick Children, Res Inst, Div Stuct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Melnyk, Roman/GQA-9908-2022					ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Badola P, 1997, J BIOL CHEM, V272, P24176, DOI 10.1074/jbc.272.39.24176; Bauer CM, 1999, VIROLOGY, V254, P196, DOI 10.1006/viro.1998.9552; DEBER CM, 1993, P NATL ACAD SCI USA, V90, P11648, DOI 10.1073/pnas.90.24.11648; Deber CM, 2001, PROTEIN SCI, V10, P212, DOI 10.1110/ps.30301; Ding FX, 2001, BIOCHEMISTRY-US, V40, P8945, DOI 10.1021/bi010394m; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; Gerber D, 2001, J BIOL CHEM, V276, P31229, DOI 10.1074/jbc.M101889200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Lau FW, 1999, J MOL BIOL, V290, P559, DOI 10.1006/jmbi.1999.2905; Lau FW, 1997, BIOCHEMISTRY-US, V36, P5884, DOI 10.1021/bi963095j; Lau FW, 1999, BIOCHEMISTRY-US, V38, P5521, DOI 10.1021/bi982763t; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; Liu LP, 1997, BIOCHEMISTRY-US, V36, P5476, DOI 10.1021/bi970030n; Melnyk RA, 2002, J MOL BIOL, V315, P63, DOI 10.1006/jmbi.2001.5214; Melnyk RA, 2001, BIOCHEMISTRY-US, V40, P11106, DOI 10.1021/bi010642e; Mingarro I, 1997, J MOL BIOL, V272, P633, DOI 10.1006/jmbi.1997.1276; Nagy JK, 2000, BIOCHEMISTRY-US, V39, P4154, DOI 10.1021/bi991781n; Partridge AW, 2002, BIOCHEMISTRY-US, V41, P3647, DOI 10.1021/bi0120502; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; Sanders CR, 1996, BIOCHEMISTRY-US, V35, P8610, DOI 10.1021/bi9604892; SMITH RL, 1994, J BACTERIOL, V176, P5459, DOI 10.1128/JB.176.17.5459-5465.1994; Tarasova NI, 1999, J BIOL CHEM, V274, P34911, DOI 10.1074/jbc.274.49.34911; Vinogradova O, 1997, BIOPHYS J, V72, P2688, DOI 10.1016/S0006-3495(97)78912-4; Wang C, 2000, J BIOL CHEM, V275, P16155, DOI 10.1074/jbc.M000723200; Zhou YF, 1997, NAT STRUCT BIOL, V4, P986, DOI 10.1038/nsb1297-986	27	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22056	22060		10.1074/jbc.M210685200	http://dx.doi.org/10.1074/jbc.M210685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12686537	hybrid			2022-12-25	WOS:000183354200093
J	Reddy, SPM; Vuong, H; Adiseshaiah, P				Reddy, SPM; Vuong, H; Adiseshaiah, P			Interplay between proximal and distal promoter elements is required for squamous differentiation marker induction in the bronchial epithelium - Role for ESE-1, Sp1, and AP-1 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTOR; KERATINOCYTE TERMINAL DIFFERENTIATION; GENOMIC ORGANIZATION; SPR1 EXPRESSION; GENE-EXPRESSION; BREAST-CANCER; FACTOR FAMILY; CELLS; GROWTH; MEMBER	Overexpression of SPRR1B in bronchial epithelial cells is a marker for early metaplastic changes induced by various toxicants/ carcinogens. Previously, we have shown that the transcriptional stimulation of SPRR1B expression by phorbol 12- myristate 13- acetate ( PMA) is mainly mediated by a - 150/ - 94 bp enhancer harboring two critical 12- O- tetradecanoylphorbol- 13- acetate-responsive elements ( TREs) and by Jun . Fra- 1 dimers. Here, we show that a region between - 54 and - 39 bp containing an ETS- binding site ( EBS) and a GC box is essential for both basal and PMA- inducible SPRR1B transcription. In vivo footprinting demonstrated binding of transcription factors to these elements. However, unlike enhancer TREs, exposure of cells to PMA did not significantly alter the footprinting pattern at these elements. Mutations that crippled both the EBS and GC box suppressed both basal and PMA- inducible SPRR1B transcription. Consistent with this, overexpression of EBS- binding proteins ESE- 1 and ESE- 3 significantly stimulated SPRR1B promoter activity. Furthermore, preceding SPRR1B transcription, PMA up- regulated mRNA expression of ETS family members such as ESE- 1 and ESE- 3. Although ESE- 1 synergistically activated c- Jun- and PMA- enhanced SPRR1B transcription, coexpression of Sp1 and ESE- 1 showed no synergistic or additive effect on promoter activity, indicating an obligatory role for AP- 1 proteins in such regulation. In support of this notion, deletion or mutation of two functional TREs inhibited ESE- 1- and Sp1- enhanced promoter activation. Thus, the interaction between ESE- 1 and Sp1, and AP- 1 proteins that bind to the proximal and distal promoter regions, respectively, play a critical role in the induction of squamous differentiation marker expression in bronchial epithelial cells.	Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Reddy, SPM (corresponding author), Johns Hopkins Univ, Dept Environm Hlth Sci, Div Physiol, Rm W7006,615 N Wolfe St, Baltimore, MD 21205 USA.	sreddy@jhsph.edu	Adiseshaiah, Pavan/R-3917-2018		NHLBI NIH HHS [HL 66109, HL 58122] Funding Source: Medline; NIEHS NIH HHS [ES 011863] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058122, R01HL066109, R01HL058122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011863] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Brembeck FH, 2000, ONCOGENE, V19, P1941, DOI 10.1038/sj.onc.1203441; Cabral A, 2001, J CELL SCI, V114, P3837; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P25, DOI 10.1165/ajrcmb.19.1.3078; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Jetten Anton M., 1997, Journal of Dermatology (Tokyo), V24, P711; Kas K, 2000, J BIOL CHEM, V275, P2986, DOI 10.1074/jbc.275.4.2986; Lee JH, 1996, J BIOL CHEM, V271, P4561; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Nacht M, 1999, CANCER RES, V59, P5464; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, GENOMICS, V55, P358, DOI 10.1006/geno.1998.5681; PAPAS TS, 1990, AM J MED GENET, P251; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; PFEIFER AMA, 1989, ENVIRON HEALTH PERSP, V80, P209, DOI 10.2307/3430746; Reddy SP, 1997, FASEB J, V11, pA942; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Tesfaigzi J, 1996, AM J RESP CELL MOL, V14, P478, DOI 10.1165/ajrcmb.14.5.8624253; Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069; Tugores A, 2001, J BIOL CHEM, V276, P20397, DOI 10.1074/jbc.M010930200; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Vuong H, 2002, AM J PHYSIOL-LUNG C, V282, pL215, DOI 10.1152/ajplung.00125.2001; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398	38	30	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21378	21387		10.1074/jbc.M212258200	http://dx.doi.org/10.1074/jbc.M212258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682075	hybrid			2022-12-25	WOS:000183354200011
J	Coltella, N; Manara, MC; Cerisano, V; Trusolino, L; Di Renzo, MF; Scotlandi, K; Ferracini, R				Coltella, N; Manara, MC; Cerisano, V; Trusolino, L; Di Renzo, MF; Scotlandi, K; Ferracini, R			Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma	FASEB JOURNAL			English	Article						signal transduction; MAPK; PKB/AKT; invasion; tumor growth	HEPATOCYTE GROWTH-FACTOR; FACTOR SIGNAL-TRANSDUCTION; FACTOR SCATTER FACTOR; TYROSINE KINASE; MET PROTOONCOGENE; MUSCULOSKELETAL TUMORS; OSTEO-SARCOMA; MAP KINASE; NEUROTROPHIN RECEPTORS; PLASMINOGEN-ACTIVATOR	Signal transduction downstream HGF receptor (MET) activation involves multiple pathways that account for mitogenesis, motility and morphogenesis in a cell type-dependent fashion. MET receptor is aberrantly expressed in almost 100% of human osteosarcomas. We analyzed the effect of the MET receptor activation in five human osteosarcoma cell lines evaluating the levels of HGF-dependent activation of MAPK and PKB/AKT as biochemical readouts of mitogenic and invasive responses, respectively. All the cell lines tested expressed high levels of the MET proto-oncogene. Four cell lines showed activation of the MAPK cascade upon HGF stimulation, suggesting that this growth factor serves a common proliferative function in osteosarcomas. Two lines showed activation of PKB/AKT, that is known to be involved in migration mediated by HGF receptor. Accordingly, cell lines where MAPK cascade was activated responded to HGF with increased proliferation, while induction and inhibition of PKB/AKT activity corresponded to acquisition or block of the invasive-motile response to HGF, respectively. Both the HGF dependent responses were reverted by the specific MET inhibitor K252a. These data show that HGF activates both the mitogen and motogen machinery in osteosarcoma cells and suggest that HGF might promote their malignant behavior by concomitant activation of different pathways and biological functions.	Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Lab Canc Genet,Div Mol Oncol, I-10060 Candiolo, To, Italy; Ist Ortoped Rizzoli, Oncol Res Lab, Bologna, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Istituto Ortopedico Rizzoli	Coltella, N (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Lab Canc Genet,Div Mol Oncol, Strada Prov 141,Km 3-95, I-10060 Candiolo, To, Italy.	nadia.coltella@ircc.it	Ferracini, Riccardo/AAL-4622-2020; Manara, Maria Cristina/K-3366-2018; Coltella, Nadia/AAO-3671-2020; Trusolino, Livio/A-3896-2011; Scotlandi, Katia/J-9009-2016; DI RENZO, Maria Flavia/B-6091-2012	Manara, Maria Cristina/0000-0001-5686-720X; Scotlandi, Katia/0000-0001-6114-9499; DI RENZO, Maria Flavia/0000-0002-5093-3373; Trusolino, Livio/0000-0002-6379-3365				AHN NG, 1991, J BIOL CHEM, V266, P4220; Albini A, 1998, Pathol Oncol Res, V4, P230; BACCI G, 1988, TUMORI J, V74, P421, DOI 10.1177/030089168807400408; Bacci G, 2001, CLIN ORTHOP RELAT R, P186; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Chin LS, 1997, CLIN CANCER RES, V3, P771; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAHLIN DC, 1967, J BONE JOINT SURG AM, VA 49, P101, DOI 10.2106/00004623-196749010-00008; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; Ferracini R, 2000, J CELL PHYSIOL, V184, P191, DOI 10.1002/1097-4652(200008)184:2<191::AID-JCP6>3.0.CO;2-B; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GOORIN AM, 1981, SURG CLIN N AM, V61, P1379; HALABAN R, 1992, ONCOGENE, V7, P2195; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KOBAYASHI H, 1992, CANCER RES, V52, P3610; MALAWER MM, 1983, J SURG ONCOL, V22, P236, DOI 10.1002/jso.2930220406; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; Oda Y, 2000, HUM PATHOL, V31, P709, DOI 10.1053/hupa.2000.8230; Oda Yoshinao, 1995, General and Diagnostic Pathology, V141, P97; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Porte H, 1998, CLIN CANCER RES, V4, P1375; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SCOTLANDI K, 1992, ANN ONCOL, V3, pS29, DOI 10.1093/annonc/3.suppl_2.S29; SERRA M, 1993, ANTICANCER RES, V13, P323; SERRA M, 1992, HUM PATHOL, V23, P1326, DOI 10.1016/0046-8177(92)90050-D; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Stefanou DG, 1998, ANTICANCER RES, V18, P4673; TAPLEY P, 1992, ONCOGENE, V7, P371; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wallenius V, 2000, AM J PATHOL, V156, P821, DOI 10.1016/S0002-9440(10)64950-4; WUISMAN P, 1990, J BONE JOINT SURG AM, V72A, P60, DOI 10.2106/00004623-199072010-00010; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	59	68	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1162	+		10.1096/fj.02-0576fje	http://dx.doi.org/10.1096/fj.02-0576fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709413				2022-12-25	WOS:000182580100023
J	Fiorucci, S; Distrutti, E; de Lima, OM; Romano, M; Mencarelli, A; Barbanti, M; Palazzini, E; Morelli, A; Wallace, JL				Fiorucci, S; Distrutti, E; de Lima, OM; Romano, M; Mencarelli, A; Barbanti, M; Palazzini, E; Morelli, A; Wallace, JL			Relative contribution of acetylated cyclooxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin	FASEB JOURNAL			English	Article						gastric adaptation; cyclooxygenase 1; ATL; aspirin-triggered lipoxin; licofelone	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRIGGERED 15-EPI-LIPOXIN A(4); STABLE ANALOGS; RAT STOMACH; INHIBITION; DAMAGE; 5-LIPOXYGENASE; INFLAMMATION; LEUKOTRIENES; EXPRESSION	In addition to inhibiting formation of prothrombotic eicosanoids, aspirin causes the acetylation of cyclooxygenase (COX)-2. The acetylated COX-2 remains active, and upon cell activation, initiates the generation of 15R-HETE, a lipid substrate for 5-lipoxygenase (LOX) leading to the formation of 15-epi-LXA(4) (also termed "aspirin-triggered lipoxin," or ATL). Because ATL potently inhibits polymorphonuclear cell (PMN) function, we assessed the relative contribution of this lipid mediator in conjunction with another 5-LOX product, the leukotriene (LT)B-4, to the pathogenesis of acute damage and gastric adaptation to aspirin. Data presented herein indicate that acute injury and gastric adaptation to aspirin is associated with ATL generation. Administration of COX inhibitors (celecoxib, indomethacin, ketoprofen) to aspirin-treated rats exacerbated acute injury and abolished adaptation to aspirin. Moreover, it inhibited ATL formation and caused a four- to fivefold increase in LTB4 synthesis. In contrast, licofelone, a COX/5-LOX inhibitor, did not exacerbate acute gastric injury nor did it interfere with gastric adaptation to aspirin. Although licofelone blocked ATL and LTB4 formation in aspirin-treated rats, it attenuated aspirin-induced gastric PMN margination. These findings indicate that the balance between the production of LTB4 and ATL modulates PMN recruitment/function and gastric mucosal responses to aspirin.	Univ Perugia, Dipartimento Med Clin & Sperimentale, Clin Gastroenterol & Epatol, I-06100 Perugia, Italy; Univ Calgary, Dept Pharmacol, Calgary, AB, Canada; Univ G DAnnunzio, Dipartimento Sci Biomediche, Chieti, Italy; Alfa Wassermann, Bologna, Italy	University of Perugia; University of Calgary; G d'Annunzio University of Chieti-Pescara	Fiorucci, S (corresponding author), Digest Policlin, Clin Gastroenterol & Endoscopia, I-06100 Perugia, Italy.	fiorucci@unipg.it	Wallace, John/AAL-3763-2021; Fiorucci, Stefano/I-1251-2012; Romano, Mario/I-7986-2012	Romano, Mario/0000-0001-8512-1458				ANDREWS FJ, 1994, AM J PHYSIOL, V266, pG657, DOI 10.1152/ajpgi.1994.266.4.G657; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Davies NM, 1997, ALIMENT PHARM THERAP, V11, P1101, DOI 10.1046/j.1365-2036.1997.00247.x; Ferraz JGP, 1997, GASTROENTEROLOGY, V113, P195, DOI 10.1016/S0016-5085(97)70095-7; Fiorucci S, 2000, J IMMUNOL, V165, P5245, DOI 10.4049/jimmunol.165.9.5245; Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0; FIORUCCI S, IN PRESS GASTROENTER; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Gyomber E, 1996, J GASTROEN HEPATOL, V11, P922; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAUFER SA, 1994, J MED CHEM, V37, P1894, DOI 10.1021/jm00038a021; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEE M, 1992, DIGEST DIS SCI, V37, P1282, DOI 10.1007/BF01296573; Mancini JA, 1997, MOL PHARMACOL, V51, P52, DOI 10.1124/mol.51.1.52; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; ROMANO M, 1992, BIOCHEMISTRY-US, V31, P8269, DOI 10.1021/bi00150a021; ROMANO M, IN PRESS LAB INVEST; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1990, GASTROENTEROLOGY, V98, P1178, DOI 10.1016/0016-5085(90)90331-T; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; WALLACE JL, J LIPID MEDIAT, V7, P183; Wenzel SE, 1996, ANN PHARMACOTHER, V30, P858, DOI 10.1177/106002809603000725	32	58	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1171	+		10.1096/fj.02-0777fje	http://dx.doi.org/10.1096/fj.02-0777fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709408				2022-12-25	WOS:000182580100019
J	Jiang, Y; Luo, L; Gustafson, EL; Yadav, D; Laverty, M; Murgolo, N; Vassileva, G; Zeng, M; Laz, TM; Behan, J; Qiu, P; Wang, LQ; Wang, SK; Bayae, M; Greene, J; Monsma, F; Zhang, FL				Jiang, Y; Luo, L; Gustafson, EL; Yadav, D; Laverty, M; Murgolo, N; Vassileva, G; Zeng, M; Laz, TM; Behan, J; Qiu, P; Wang, LQ; Wang, SK; Bayae, M; Greene, J; Monsma, F; Zhang, FL			Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; NEUROPEPTIDE GENE; ADP RECEPTOR; FAMILY; DISCOVERY	Orphan G-protein-coupled receptors are a large class of receptors whose cognate ligands are unknown. SP9155 (also referred to as AQ27 and GPR103) is an orphan G-protein-coupled receptor originally cloned from a human brain cDNA library. SP9155 was found to be predominantly expressed in brain, heart, kidney, retina, and testis. Phylogenetic analysis shows that SP9155 shares high homology with Orexin, NPFF, and cholecystokinin (CCK) receptors, but identification of the endogenous ligand for SP9155 has not been reported. In this study, we have used a novel method to predict peptides from genome data bases. From these predicted peptides, a novel RF-amide peptide, P52 was shown to selectively activate SP9155-transfected cells. We subsequently cloned the precursor gene of the P52 ligand and characterized the activity of other possible peptides encoded by the precursor. This revealed an extended peptide, P518, which exhibited high affinity for SP9155 (EC50 = 7 nM). mRNA expression analysis revealed that the peptide P518 precursor gene is predominantly expressed in various brain regions, coronary arteries, thyroid and parathyroid glands, large intestine, colon, bladder, testes, and prostate. These results indicate the existence of a novel RF-amide neuroendocrine peptide system, and suggest that SP9155 is likely the relevant G-protein-coupled receptor for this peptide.	Schering Plough Res Inst, Dept Discovery Technol, Kenilworth, NJ 07033 USA	Merck & Company; Schering-Plough Research Institute	Zhang, FL (corresponding author), Schering Plough Res Inst, Dept Discovery Technol, K-15-1-1945, Kenilworth, NJ 07033 USA.		Vassileva, Galya/A-6807-2009	Monsma, Frederick/0000-0002-5711-5883				Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHARMERS J, 1999, NATURE, V400, P261; Civelli O, 2001, TRENDS NEUROSCI, V24, P230, DOI 10.1016/S0166-2236(00)01763-X; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Howard AD, 2001, TRENDS PHARMACOL SCI, V22, P132, DOI 10.1016/S0165-6147(00)01636-9; Jiang Y, 2003, MAMM GENOME, V14, P341, DOI 10.1007/s00335-002-3061-y; JOOST P, 2002, GENOME BIOL, V3; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; Li C, 1999, BRAIN RES, V848, P26, DOI 10.1016/S0006-8993(99)01972-1; Nelson LS, 1998, SCIENCE, V281, P1686, DOI 10.1126/science.281.5383.1686; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shan LX, 2000, J BIOL CHEM, V275, P39482, DOI 10.1074/jbc.C000522200; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238; Zhang FL, 2002, J PHARMACOL EXP THER, V301, P705, DOI 10.1124/jpet.301.2.705; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200	23	141	154	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27652	27657		10.1074/jbc.M302945200	http://dx.doi.org/10.1074/jbc.M302945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12714592	hybrid			2022-12-25	WOS:000184242700041
J	Jurchott, K; Bergmann, S; Stein, U; Walther, W; Janz, M; Manni, I; Piaggio, G; Fietze, E; Dietel, M; Royer, HD				Jurchott, K; Bergmann, S; Stein, U; Walther, W; Janz, M; Manni, I; Piaggio, G; Fietze, E; Dietel, M; Royer, HD			YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							Y-BOX PROTEINS; CCAAT-BINDING-PROTEIN; COLD-SHOCK DOMAIN; MATERNAL MESSENGER-RNA; NUCLEAR EXPRESSION; S-PHASE; NF-Y; DNA-REPLICATION; DOWN-REGULATION; BREAST-CANCER	Expression of the Y-box protein YB-1 is increased in proliferating normal and cancer cells, but its role in cell proliferation and cell cycle progression is unclear. We have identified a cell cycle-dependent relocalization of YB-1 from the cytoplasm to the nucleus at the G(1)/S phase transition and demonstrate that both the charged zipper and the cold shock domain are involved in regulating this process. Using cell lines that constitutively overexpress YB-1, we show that nuclear accumulation of YB-1 is associated with increased cyclin A and cyclin B1 mRNA and protein expression. We provide evidence that deregulated YB-1 expression is linked to adhesion-independent cell proliferation through the induction of cyclin A. Thus, we have identified YB-1 as a cell cycle stage-specific transcription factor important for cell proliferation.	Humboldt Univ, Univ Klinikum Charite, Inst Pathol, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, D-13125 Berlin, Germany; CAESAR, D-53175 Bonn, Germany; Inst Human Genet & Anthropol, D-40001 Dusseldorf, Germany; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Center of Advanced European Studies & Research (CAESAR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Jurchott, K (corresponding author), Humboldt Univ, Univ Klinikum Charite, Inst Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	karsten.juerchott@charite.de	Manni, Isabella/ABH-6460-2020; Royer, Hans-dieter/AAH-6293-2019; Piaggio, Giulia/AAD-7336-2022; Piaggio, Giulia/J-7214-2018	Manni, Isabella/0000-0003-4823-0596; Piaggio, Giulia/0000-0003-2114-1892; Jurchott, Karsten/0000-0003-1589-0037; Stein, Ulrike/0000-0001-7006-282X; Walther, Wolfgang/0000-0003-2360-1370; Janz, Martin/0000-0002-1127-0044				Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Chen CY, 2000, GENE DEV, V14, P1236; Deng CX, 2000, BIOESSAYS, V22, P728; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Farina A, 1996, ONCOGENE, V13, P1287; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hipfel R, 2000, BRIT J CANCER, V82, P1149; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Janz M, 2002, INT J CANCER, V97, P278, DOI 10.1002/ijc.1610; JANZ M, 2000, GENE FUNCT DIS, V1, P57; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1991, CANCER RES, V51, P3602; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kramer A, 1997, CANCER RES, V57, P5117; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; KWON YK, 1993, DEV BIOL, V158, P90, DOI 10.1006/dbio.1993.1170; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Martin J, 1999, MOL CELL BIOL, V19, P5548; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Michalides R, 2002, BRIT J CANCER, V86, P402, DOI 10.1038/sj.bjc.6600072; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROYER HD, 1991, NUCLEIC ACIDS RES, V19, P2363, DOI 10.1093/nar/19.9.2363; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shibahara K, 2001, CLIN CANCER RES, V7, P3151; Shibao K, 1999, INT J CANCER, V83, P732; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stenina OI, 2001, P NATL ACAD SCI USA, V98, P7277, DOI 10.1073/pnas.121592298; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	62	173	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27988	27996		10.1074/jbc.M212966200	http://dx.doi.org/10.1074/jbc.M212966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12695516	hybrid			2022-12-25	WOS:000184242700083
J	Li, SQ; Covino, ND; Stein, EG; Till, JH; Hubbard, SR				Li, SQ; Covino, ND; Stein, EG; Till, JH; Hubbard, SR			Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; KINASE DOMAIN; SMALL-MOLECULE; ACTIVATION LOOP; ANTIDIABETIC ACTIVITY; AUTOPHOSPHORYLATION; SRC; AUTOREGULATION; INHIBITION; MECHANISM	Tyrosine 984 in the juxtamembrane region of the insulin receptor, between the transmembrane helix and the cytoplasmic tyrosine kinase domain, is conserved among all insulin receptor-like proteins from hydra to humans. Crystallographic studies of the tyrosine kinase domain and proximal juxtamembrane region reveal that Tyr-984 interacts with several other conserved residues in the N-terminal lobe of the kinase domain, stabilizing a catalytically nonproductive position of alpha-helix C. Steady-state kinetics measurements on the soluble kinase domain demonstrate that replacement of Tyr-984 with phenylalanine results in a 4-fold increase in k(cat) in the unphosphorylated (basal state) enzyme. Moreover, mutation of Tyr-984 in the full-length insulin receptor results in significantly elevated receptor phosphorylation levels in cells, both in the absence of insulin and following insulin stimulation. These data demonstrate that Tyr-984 plays an important structural role in maintaining the quiescent, basal state of the insulin receptor. In addition, the structural studies suggest a possible target site for small molecule activators of the insulin receptor, with potential use in the treatment of noninsulin-dependent diabetes mellitus.	NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University; New York University	Hubbard, SR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, 540 1st Ave, New York, NY 10016 USA.			Hubbard, Stevan/0000-0002-2707-9383	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052916] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52916] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ablooglu AJ, 2001, J BIOL CHEM, V276, P46933, DOI 10.1074/jbc.M107236200; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cann AD, 1997, BIOCHEMISTRY-US, V36, P7681, DOI 10.1021/bi970170x; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Frankel M, 2001, MOL CELL BIOL, V21, P4197, DOI 10.1128/MCB.21.13.4197-4207.2001; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; GRUPPUSO PA, 1992, BIOCHEM BIOPH RES CO, V189, P1457, DOI 10.1016/0006-291X(92)90238-G; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hubbard SR, 2002, CURR OPIN STRUC BIOL, V12, P735, DOI 10.1016/S0959-440X(02)00383-4; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; Li M, 2001, DIABETES, V50, P2323, DOI 10.2337/diabetes.50.10.2323; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Manchem VP, 2001, DIABETES, V50, P824, DOI 10.2337/diabetes.50.4.824; McTigue MA, 1999, STRUCT FOLD DES, V7, P319, DOI 10.1016/S0969-2126(99)80042-2; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Munshi S, 2002, J BIOL CHEM, V277, P38797, DOI 10.1074/jbc.M205580200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Qureshi SA, 2000, J BIOL CHEM, V275, P36590, DOI 10.1074/jbc.M006287200; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; Till JH, 2001, J BIOL CHEM, V276, P10049, DOI 10.1074/jbc.M010161200; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974	41	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26007	26014		10.1074/jbc.M302425200	http://dx.doi.org/10.1074/jbc.M302425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12707268	hybrid			2022-12-25	WOS:000183920200096
J	Buhusi, M; Midkiff, BR; Gates, AM; Richter, M; Schachner, M; Maness, PF				Buhusi, M; Midkiff, BR; Gates, AM; Richter, M; Schachner, M; Maness, PF			Close homolog of L1 is an enhancer of integrin-mediated cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE L1; NEURITE OUTGROWTH; NERVOUS-SYSTEM; CYTOPLASMIC DOMAIN; PROTEIN-KINASE; ALPHA(V)BETA(3) INTEGRIN; PERIPHERAL-NERVE; ANKYRIN BINDING; MESSENGER-RNA; SCIATIC-NERVE	Close homolog of L1 (CHL1) is a member of the L1 family of cell adhesion molecules expressed by subpopulations of neurons and glia in the central and peripheral nervous system. It promotes neurite outgrowth and neuronal survival in vitro. This study describes a novel function for CHL1 in potentiating integrin-dependent cell migration toward extracellular matrix proteins. Expression of CHL1 in HEK293 cells stimulated their haptotactic migration toward collagen I, fibronectin, laminin, and vitronectin substrates in Transwell assays. CHL1-potentiated cell migration to collagen I was dependent on alpha(1)beta(1) and alpha(2)beta(1) integrins, as shown with function blocking antibodies. Potentiated migration relied on the early integrin signaling intermediates c-Src, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase. Enhancement of migration was disrupted by mutation of a potential integrin interaction motif Asp-Gly-Glu-Ala ( DGEA) in the sixth immunoglobulin domain of CHL1, suggesting that CHL1 functionally interacts with beta(1) integrins through this domain. CHL1 was shown to associate with beta(1) integrins on the cell surface by antibody-induced co-capping. Through a cytoplasmic domain sequence containing a conserved tyrosine residue (Phe-Ile-Gly-Ala-Tyr), CHL1 recruited the actin cytoskeletal adapter protein ankyrin to the plasma membrane, and this sequence was necessary for promoting integrin-dependent migration to extracellular matrix proteins. These results support a role for CHL1 in integrin-dependent cell migration that may be physiologically important in regulating cell migration in nerve regeneration and cortical development.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Hamburg, Klin Eppendorf, Zentrum Mol Neurobiol, Inst Biosynthese Neuraler Strukturen, D-20246 Hamburg, Germany	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Hamburg; University Medical Center Hamburg-Eppendorf	Maness, PF (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, 505 Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.			Richter, Melanie/0000-0003-0575-9625	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER; NIMH NIH HHS [MH064056] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angeloni D, 1999, AM J MED GENET, V86, P482, DOI 10.1002/(SICI)1096-8628(19991029)86:5<482::AID-AJMG15>3.0.CO;2-L; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bennett V, 2001, CURR OPIN CELL BIOL, V13, P61, DOI 10.1016/S0955-0674(00)00175-7; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; BODARY SC, 1990, J BIOL CHEM, V265, P5938; Brummendorf T, 2001, CURR OPIN CELL BIOL, V13, P611, DOI 10.1016/S0955-0674(00)00259-3; Chaisuksunt V, 2000, J COMP NEUROL, V425, P382, DOI 10.1002/1096-9861(20000925)425:3<382::AID-CNE4>3.0.CO;2-N; Chen LS, 2001, J CELL BIOL, V154, P841, DOI 10.1083/jcb.200009004; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COHEN NR, 1997, CURR BIOL, V8, P26; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Demyanenko GP, 1999, J NEUROSCI, V19, P4907; Demyanenko GP, 2001, DEV BRAIN RES, V126, P21, DOI 10.1016/S0165-3806(00)00129-2; Dickson TC, 2002, J CELL BIOL, V157, P1105, DOI 10.1083/jcb.200111076; Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRANSEN E, 1995, EUR J HUM GENET, V3, P273; Fransen E, 1997, HUM MOL GENET, V6, P1625, DOI 10.1093/hmg/6.10.1625; Freigang J, 2000, CELL, V101, P425, DOI 10.1016/S0092-8674(00)80852-1; FRINTS SGM, 2003, IN PRESS J HUM GENET; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hillenbrand R, 1999, EUR J NEUROSCI, V11, P813, DOI 10.1046/j.1460-9568.1999.00496.x; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Jenkins SM, 2001, J CELL SCI, V114, P3823; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 1997, J NEUROSCI RES, V49, P1, DOI 10.1002/(SICI)1097-4547(19970701)49:1<1::AID-JNR1>3.0.CO;2-H; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; Kizhatil K, 2002, J NEUROSCI, V22, P7948; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kunz B, 2002, J BIOL CHEM, V277, P4551, DOI 10.1074/jbc.M109779200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEFCORT F, 1992, DEVELOPMENT, V116, P767; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Liu Q, 2000, J NEUROSCI, V20, P7682; Long KE, 2000, J NEUROBIOL, V44, P230, DOI 10.1002/1097-4695(200008)44:2<230::AID-NEU12>3.0.CO;2-W; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Montag-Sallaz M, 2002, MOL CELL BIOL, V22, P7967, DOI 10.1128/MCB.22.22.7967-7981.2002; Montgomery AMP, 1996, J CELL BIOL, V132, P475, DOI 10.1083/jcb.132.3.475; Nakai Y, 2002, J CELL BIOL, V159, P1097, DOI 10.1083/jcb.200209077; Needham LK, 2001, J NEUROSCI, V21, P1490, DOI 10.1523/JNEUROSCI.21-05-01490.2001; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Ni HY, 1998, CELL ADHES COMMUN, V5, P257, DOI 10.3109/15419069809040296; Previtali SC, 2001, PROG NEUROBIOL, V64, P35, DOI 10.1016/S0301-0082(00)00045-9; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; Sakurai K, 2002, MOL PSYCHIATR, V7, P412, DOI 10.1038/sj.mp.4000973; Schmid RS, 2000, J NEUROSCI, V20, P4177; Schmid RS, 2003, CEREB CORTEX, V13, P219, DOI 10.1093/cercor/13.3.219; Schmid RS, 2001, HANDBOOK OF BRAIN AND BEHAVIOUR IN HUMAN DEVELOPMENT, P199; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; Scotland P, 1998, J CELL BIOL, V143, P1305, DOI 10.1083/jcb.143.5.1305; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; SIIRONEN J, 1992, LAB INVEST, V67, P80; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Sobeih MM, 2002, INT J DEV NEUROSCI, V20, P349, DOI 10.1016/S0736-5748(02)00040-0; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; Thelen K, 2002, J NEUROSCI, V22, P4918, DOI 10.1523/JNEUROSCI.22-12-04918.2002; Treubert U, 1998, J NEUROSCI, V18, P1795; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wei MH, 1998, HUM GENET, V103, P355, DOI 10.1007/s004390050829; Wong CWY, 2000, MOL BIOL CELL, V11, P3109, DOI 10.1091/mbc.11.9.3109; Wong EV, 1996, J NEUROCHEM, V66, P779; Wong EV, 1996, J BIOL CHEM, V271, P18217, DOI 10.1074/jbc.271.30.18217; Yip PM, 1998, MOL BIOL CELL, V9, P277, DOI 10.1091/mbc.9.2.277; Zhang X, 1998, J CELL BIOL, V142, P1571, DOI 10.1083/jcb.142.6.1571; Zhang Y, 2000, MOL CELL NEUROSCI, V16, P71, DOI 10.1006/mcne.2000.0852	80	77	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25024	25031		10.1074/jbc.M303084200	http://dx.doi.org/10.1074/jbc.M303084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721290	hybrid, Green Published			2022-12-25	WOS:000183824800095
J	Cai, ML; Williams, DC; Wang, GS; Lee, BR; Peterkofsky, A; Clore, GM				Cai, ML; Williams, DC; Wang, GS; Lee, BR; Peterkofsky, A; Clore, GM			Solution structure of the phosphoryl transfer complex between the signal-transducing protein IIA(Glucose) and the cytoplasmic domain of the glucose transporter IICBGlucose of the Escherichia coli glucose phosphotransferase system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESIDUAL DIPOLAR COUPLINGS; N-TERMINAL DOMAIN; GLOBAL REPRESSOR MLC; TYROSINE-PHOSPHATASE; BACTERIAL PHOSPHOENOLPYRUVATE; PHOSPHOCARRIER PROTEIN; STRUCTURE REFINEMENT; NMR STRUCTURES; ENZYME-I; CARBOHYDRATE TRANSPORTERS	The solution structure of the final phosphoryl transfer complex in the glucose-specific arm of the Escherichia coli phosphotransferase system, between enzyme IIA(Glucose) (IIA(Glc)) and the cytoplasmic B domain (IIBGlc) of the glucose transporter IICBGlc, has been solved by NMR. The interface (similar to1200-Angstrom(2) buried surface) is formed by the interaction of a concave depression on IIA(Glc) with a convex protrusion on IIBGlc. The phosphoryl donor and acceptor residues, His-90 of IIA(Glc) and Cys-35 of IIBGlc ( residues of IIBGlc are denoted in italics) are in close proximity and buried at the center of the interface. Cys-35 is primed for nucleophilic attack on the phosphorus atom by stabilization of the thiolate anion (pK(a) similar to6.5) through intramolecular hydrogen bonding interactions with several adjacent backbone amide groups. Hydrophobic intermolecular contacts are supplemented by peripheral electrostatic interactions involving an alternating distribution of positively and negatively charged residues on the interaction surfaces of both proteins. Salt bridges between the Asp-38/Asp-94 pair of IIA(Glc) and the Arg-38/Arg-40 pair of IIBGlc neutralize the accumulation of negative charge in the vicinity of both the Sgamma atom of Cys-35 and the phosphoryl group in the complex. A pentacoordinate phosphoryl transition state is readily accommodated without any change in backbone conformation, and the structure of the complex accounts for the preferred directionality of phosphoryl transfer between IIA(Glc) and IIBGlc. The structures of IIA(Glc).IIBGlc and the two upstream complexes of the glucose phosphotransferase system (EI.HPr and IIA(Glc).HPr) reveal a cascade in which highly overlapping binding sites on HPr and IIA(Glc) recognize structurally diverse proteins.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg ,Rm B1-30I, Bethesda, MD 20892 USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029023, ZIADK029023] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; BEGLEY GS, 1982, BIOCHEMISTRY-US, V21, P5552, DOI 10.1021/bi00265a026; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; Cai ML, 1998, J BIOMOL NMR, V11, P97, DOI 10.1023/A:1008222131470; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k; Clore GM, 2002, J AM CHEM SOC, V124, P2866, DOI 10.1021/ja017712p; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f; Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 2002, J BIOL CHEM, V277, P42289, DOI 10.1074/jbc.M207314200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ding KY, 2002, J MAGN RESON, V158, P173, DOI 10.1016/S1090-7807(02)00024-1; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; Feese MD, 1997, BIOCHEMISTRY-US, V36, P16087, DOI 10.1021/bi971999e; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P156; FOUET A, 1987, P NATL ACAD SCI USA, V84, P8773, DOI 10.1073/pnas.84.24.8773; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Garrett DS, 1999, NAT STRUCT BIOL, V6, P166; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; Hansen MR, 1998, J AM CHEM SOC, V120, P11210, DOI 10.1021/ja9829665; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; Kuszewski J, 1999, J AM CHEM SOC, V121, P2337, DOI 10.1021/ja9843730; KUSZEWSKI J, 1997, J MAGN RESON SER B, V105, P92; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LUX R, 1995, P NATL ACAD SCI USA, V92, P11583, DOI 10.1073/pnas.92.25.11583; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1986, J BIOL CHEM, V261, P13505; MEINS M, 1993, J BIOL CHEM, V268, P11604; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Ni JP, 1999, NAT STRUCT BIOL, V6, P427; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NOVOTNY MJ, 1985, J BACTERIOL, V162, P810, DOI 10.1128/JB.162.2.810-816.1985; NUOEFFER C, 1988, J BIOL CHEM, V263, P6647; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1993, PROTEIN SCI, V2, P543; PETERKOFSKY A, 1993, PROG NUCLEIC ACID RE, V44, P31, DOI 10.1016/S0079-6603(08)60216-0; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; REIZER J, 1992, J BIOL CHEM, V267, P9158; Robillard GT, 1999, BBA-REV BIOMEMBRANES, V1422, P73, DOI 10.1016/S0304-4157(99)00002-7; Rognan D, 2001, J COMPUT AID MOL DES, V15, P103, DOI 10.1023/A:1008145813315; Rohwer JM, 2000, J BIOL CHEM, V275, P34909, DOI 10.1074/jbc.M002461200; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Schwieters CD, 2002, J BIOMOL NMR, V23, P221, DOI 10.1023/A:1019875223132; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300; Seitz S, 2003, J BIOL CHEM, V278, P10744, DOI 10.1074/jbc.M212066200; Seok YJ, 1997, J BIOL CHEM, V272, P26511, DOI 10.1074/jbc.272.42.26511; Siebold C, 2001, FEBS LETT, V504, P104, DOI 10.1016/S0014-5793(01)02705-3; Sondej M, 2000, BIOCHEMISTRY-US, V39, P2931, DOI 10.1021/bi9919596; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; VanDuyne GD, 1996, J MOL BIOL, V256, P377, DOI 10.1006/jmbi.1996.0093; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang GS, 2000, J BIOL CHEM, V275, P16401, DOI 10.1074/jbc.C000167200; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012	79	60	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25191	25206		10.1074/jbc.M302677200	http://dx.doi.org/10.1074/jbc.M302677200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716891	hybrid			2022-12-25	WOS:000183824800114
J	Johnson, MA; Jaseja, M; Zou, W; Jennings, HJ; Copie, V; Pinto, BM; Pincus, SH				Johnson, MA; Jaseja, M; Zou, W; Jennings, HJ; Copie, V; Pinto, BM; Pincus, SH			NMR studies of carbohydrates and carbohydrate-mimetic peptides recognized by an anti-group B Streptococcus antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-DIFFERENCE NMR; CAPSULAR POLYSACCHARIDE; CONFORMATIONAL EPITOPE; WATER SOLUTION; CRYPTOCOCCUS-NEOFORMANS; NEISSERIA-MENINGITIDIS; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; VACCINE DESIGN; LIGAND-BINDING	As part of a program to investigate the origins of peptide-carbohydrate mimicry, the conformational preferences of peptides that mimic the group B streptococcal type III capsular polysaccharide have been investigated by NMR spectroscopy. Detailed studies of a dodecapeptide, FDTGAFDPDWPA, a molecular mimic of the polysaccharide antigen, and two new analogs, indicated a propensity for beta-turn formation. Different beta-turn types were found to be present in the trans and cis (Trp-10 Pro-11) isomers of the peptide: the trans isomer favored a type I beta-turn from residues Asp-7-Trp-10, whereas the cis isomer exhibited a type VI beta-turn from residues Asp-9-Ala-12. The interaction of the dodecapeptide FDTGAFDPDWPA with a protective anti-group B Streptococcus monoclonal antibody has also been investigated, by transferred nuclear Overhauser effect NMR spectroscopy and saturation-transfer difference NMR spectroscopy (STD-NMR). The peptide was found to adopt a type I beta-turn conformation on binding to the antibody; the peptide residues (Asp-7-Trp-10) forming this turn are recognized by the antibody, as demonstrated by STD-NMR experiments. STD-NMR studies of the interactions of oligosaccharide fragments of the capsular polysaccharide have also been performed and provide evidence for the existence of a conformational epitope.	Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; N Dakota State Univ, Dept Chem, Ctr Protease Res, Fargo, ND 58102 USA; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Louisiana State Hlth Sci Ctr, Res Inst Children, New Orleans, LA 70118 USA; Louisiana State Hlth Sci Ctr, Dept Pediat, New Orleans, LA 70118 USA	Simon Fraser University; Simon Fraser University; Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; North Dakota State University Fargo; National Research Council Canada; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Pinto, BM (corresponding author), Simon Fraser Univ, Dept Chem, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	bpinto@sfu.ca; spincus@chnola-research.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042184, R01AI042184] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42184] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRAND JP, 1979, INT J BIOL MACROMOL, V1, P37, DOI 10.1016/0141-8130(79)90008-4; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; BAKER CJ, 1988, ANN NY ACAD SCI, V549, P193, DOI 10.1111/j.1749-6632.1988.tb23972.x; BALARAM P, 1972, J AM CHEM SOC, V94, P4017, DOI 10.1021/ja00766a064; BALARAM P, 1972, J AM CHEM SOC, V94, P4015, DOI 10.1021/ja00766a063; BALEJA JD, 1990, J MAGN RESON, V87, P375, DOI 10.1016/0022-2364(90)90015-2; Beenhouwer DO, 2002, J IMMUNOL, V169, P6992, DOI 10.4049/jimmunol.169.12.6992; Berner R, 2002, CURR OPIN INFECT DIS, V15, P307, DOI 10.1097/00001432-200206000-00015; BRAUN DG, 1980, STREPTOCOCCAL DISEAS, P317; Brisson JR, 1997, BIOCHEMISTRY-US, V36, P3278, DOI 10.1021/bi961819l; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Campbell AP, 1995, BIOCHEMISTRY-US, V34, P16255, DOI 10.1021/bi00050a005; Campbell AP, 2000, BIOCHEMISTRY-US, V39, P14847, DOI 10.1021/bi0016568; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; DELORIMIER R, 1994, BIOCHEMISTRY-US, V33, P2055, DOI 10.1021/bi00174a011; Derrick JP, 1999, J MOL BIOL, V293, P81, DOI 10.1006/jmbi.1999.3144; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EVANS SV, 1995, BIOCHEMISTRY-US, V34, P6737, DOI 10.1021/bi00020a019; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; Haselhorst T, 2001, J AM CHEM SOC, V123, P10705, DOI 10.1021/ja011156h; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; JENNINGS HJ, 1984, PURE APPL CHEM, V56, P893, DOI 10.1351/pac198456070893; JENNINGS HJ, 1983, ADV CARBOHYD CHEM BI, V41, P155, DOI 10.1016/S0065-2318(08)60058-X; Johnson MA, 2002, AUST J CHEM, V55, P13, DOI 10.1071/CH02047; Johnson MA, 2002, J AM CHEM SOC, V124, P15368, DOI 10.1021/ja020983v; Kieber-Emmons T, 1999, NAT BIOTECHNOL, V17, P660, DOI 10.1038/10870; Klein J, 1999, J AM CHEM SOC, V121, P5336, DOI 10.1021/ja990706x; Kooistra O, 2002, EUR J BIOCHEM, V269, P573, DOI 10.1046/j.0014-2956.2001.02684.x; LANCEFIELD RC, 1966, J HYG-CAMB, V64, P191, DOI 10.1017/S0022172400040456; Maaheimo H, 2000, BIOCHEMISTRY-US, V39, P12778, DOI 10.1021/bi000780o; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meinecke R, 2001, J MED CHEM, V44, P3059, DOI 10.1021/jm0109154; Moller H, 2002, EUR J BIOCHEM, V269, P1444, DOI 10.1046/j.1432-1033.2002.02787.x; Monzavi-Karbassi B, 2001, BIOLOGICALS, V29, P249, DOI 10.1006/biol.2001.0307; PETERS T, 2001, Patent No. 6214561; PETERS T, 1998, Patent No. 19649359; PETERS T, 1998, Patent No. 2321104; PETERS T, 2000, Patent No. 690695; Pincus SH, 1998, J IMMUNOL, V160, P293; PINCUS SH, 1988, J IMMUNOL, V140, P2779; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pon RA, 1997, J EXP MED, V185, P1929, DOI 10.1084/jem.185.11.1929; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Vogtherr M, 2000, J AM CHEM SOC, V122, P6093, DOI 10.1021/ja0001916; Weimar T, 2000, J BIOL CHEM, V275, P37006, DOI 10.1074/jbc.M005092200; WESSELS MR, 1989, J EXP MED, V169, P2121, DOI 10.1084/jem.169.6.2121; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAO J, 1994, J MOL BIOL, V243, P754, DOI 10.1016/0022-2836(94)90045-0; YAO J, 1994, J MOL BIOL, V243, P736, DOI 10.1016/0022-2836(94)90044-2; YIP PF, 1990, J MAGN RESON, V90, P382, DOI 10.1016/0022-2364(90)90146-Z; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407; Zou W, 1999, J IMMUNOL, V163, P820; Zou W, 1996, CARBOHYD RES, V295, P209, DOI 10.1016/S0008-6215(96)90144-5	61	25	26	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24740	24752		10.1074/jbc.M301846200	http://dx.doi.org/10.1074/jbc.M301846200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12700231	hybrid			2022-12-25	WOS:000183824800061
J	Castelli, ME; Cauerhff, A; Amongero, M; Soncini, FC; Vescovi, EG				Castelli, ME; Cauerhff, A; Amongero, M; Soncini, FC; Vescovi, EG			The H box-harboring domain is key to the function of the Salmonella enterica PhoQ Mg2+-sensor in the recognition of its partner PhoP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; PHOSPHORELAY SIGNAL-TRANSDUCTION; HISTIDINE KINASE DOMAIN; ESCHERICHIA-COLI; RESPONSE REGULATOR; CRYSTAL-STRUCTURE; INTERMOLECULAR COMPLEMENTATION; PSEUDOMONAS-AERUGINOSA; MOLECULAR RECOGNITION; BACTERIAL CHEMOTAXIS	In two-component signaling systems, the transduction strategy relies on a conserved His-Asp phosphoryl exchange between the sensor histidine kinase and its cognate response-regulator, and structural and functional consensus motifs are found when comparing either the diverse histidine kinases or response regulators present in a single cell. Therefore, the mechanism that guarantees the specific recognition between partners of an individual pair is essential to unequivocally generate the appropriate adaptive response. Based on sequence alignments with other histidine kinases, we dissected the Salmonella enterica Mg2+-sensor PhoQ in different subdomains and examined by in vivo and in vitro assays its interaction with the associated response regulator PhoP. This signal transduction system allows Salmonella to withstand environmental Mg2+ limitation by triggering gene expression that is vital throughout the infective cycle in the host. Using resonant mirror biosensor technology, we calculated the kinetic and equilibrium binding constants and determined that the His-phosphotransfer domain is essential for the PhoQ specific recognition and interaction with PhoP. Additionally, we show the role of this domain in the bimolecular transphosphorylation and provide evidence that this region undergoes dimerization.	Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, Dept Microbiol,Fac Ciencias Bioquim & Farmaceut, RA-2000 Rosario, Argentina; Univ Buenos Aires, Consejo Nacl Invest Cient & Tecn, Laboratorio Inmunol Estructural, Fdn Inst Leloir, Rosario, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires	Vescovi, EG (corresponding author), Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, Dept Microbiol,Fac Ciencias Bioquim & Farmaceut, S2002-LRK, RA-2000 Rosario, Argentina.	pat-bact@citynet.net.ar		Garcia Vescovi, Eleonora/0000-0002-4431-8606; Cauerhff, Ana/0000-0001-9686-9883; Soncini, Fernando/0000-0002-8925-7763; Castelli, Maria Eugenia/0000-0002-9449-9177				Baikalov I, 1996, BIOCHEMISTRY-US, V35, P11053, DOI 10.1021/bi960919o; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Carmany DO, 2003, J BACTERIOL, V185, P1112, DOI 10.1128/JB.185.3.1112-1115.2003; Castelli ME, 2000, J BIOL CHEM, V275, P22948, DOI 10.1074/jbc.M909335199; Chamnongpol S, 2003, J MOL BIOL, V325, P795, DOI 10.1016/S0022-2836(02)01268-8; Dutta R, 1999, MOL MICROBIOL, V34, P633, DOI 10.1046/j.1365-2958.1999.01646.x; Fabret C, 1999, J BACTERIOL, V181, P1975, DOI 10.1128/JB.181.7.1975-1983.1999; Fisher SL, 1996, BIOCHEMISTRY-US, V35, P4732, DOI 10.1021/bi9525435; GARCIAVESCOVI E, 1997, J BIOL CHEM, V272, P1440; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Hoch JA, 2000, CURR OPIN MICROBIOL, V3, P165, DOI 10.1016/S1369-5274(00)00070-9; Hoch JA, 2001, J BACTERIOL, V183, P4941, DOI 10.1128/JB.183.17.4941-4949.2001; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; Kramer G, 1999, P NATL ACAD SCI USA, V96, P604, DOI 10.1073/pnas.96.2.604; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lesley JA, 2001, J BIOL CHEM, V276, P30827, DOI 10.1074/jbc.M104262200; LI JY, 1995, BIOCHEMISTRY-US, V34, P14626, DOI 10.1021/bi00045a003; Madhusudan, 1996, STRUCTURE, V4, P679, DOI 10.1016/S0969-2126(96)00074-3; Marina A, 2001, J BIOL CHEM, V276, P41182, DOI 10.1074/jbc.M106080200; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; Mattison K, 2002, J BIOL CHEM, V277, P11143, DOI 10.1074/jbc.M111128200; McEvoy MM, 1998, P NATL ACAD SCI USA, V95, P7333, DOI 10.1073/pnas.95.13.7333; Montagne M, 2001, J BACTERIOL, V183, P1787, DOI 10.1128/JB.183.5.1787-1791.2001; MORRISON TB, 1994, P NATL ACAD SCI USA, V91, P5485, DOI 10.1073/pnas.91.12.5485; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; Oshima T, 2002, MOL MICROBIOL, V46, P281, DOI 10.1046/j.1365-2958.2002.03170.x; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; Perraud AL, 2000, BBA-PROTEIN STRUCT M, V1478, P341, DOI 10.1016/S0167-4838(00)00052-2; Regelmann AG, 2002, J BACTERIOL, V184, P5468, DOI 10.1128/JB.184.19.5468-5478.2002; Rodrigue A, 2000, TRENDS MICROBIOL, V8, P498, DOI 10.1016/S0966-842X(00)01833-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Schuster M, 2001, P NATL ACAD SCI USA, V98, P6003, DOI 10.1073/pnas.101571298; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; Stock J, 1999, CURR BIOL, V9, pR364, DOI 10.1016/S0960-9822(99)80228-0; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; Tanabe H, 1998, BIOSCI BIOTECH BIOCH, V62, P78, DOI 10.1271/bbb.62.78; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; Varughese KL, 2002, CURR OPIN MICROBIOL, V5, P142, DOI 10.1016/S1369-5274(02)00305-3; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; Wang L, 2001, J BACTERIOL, V183, P2795, DOI 10.1128/JB.183.9.2795-2802.2001; Wright JS, 2000, J BACTERIOL, V182, P6279, DOI 10.1128/JB.182.22.6279-6286.2000; Wright JS, 2001, J BACTERIOL, V183, P3149, DOI 10.1128/JB.183.10.3149-3159.2001; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; Yoshida T, 2002, MOL MICROBIOL, V46, P1283, DOI 10.1046/j.1365-2958.2002.03240.x; Zapf J, 2000, STRUCTURE, V8, P851, DOI 10.1016/S0969-2126(00)00174-X; Zhu XY, 1997, J BIOL CHEM, V272, P23758, DOI 10.1074/jbc.272.38.23758	59	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23579	23585		10.1074/jbc.M303042200	http://dx.doi.org/10.1074/jbc.M303042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12702718	hybrid			2022-12-25	WOS:000183638600047
J	Qian, P; Addlesee, HA; Ruban, AV; Wang, PY; Bullough, PA; Hunter, CN				Qian, P; Addlesee, HA; Ruban, AV; Wang, PY; Bullough, PA; Hunter, CN			A reaction center-light-harvesting 1 complex (RC-LH1) from a Rhodospirillum rubrum mutant with altered esterifying pigments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; PHOTOSYNTHETIC REACTION CENTER; RHODOBACTER-SPHAEROIDES; ANTENNA COMPLEX; FUNCTIONAL ASSIGNMENT; BACTERIOCHLOROPHYLL BINDING; RHODOPSEUDOMONAS-SPHEROIDES; ENERGY-TRANSFER; GENE-CLUSTER; BIOSYNTHESIS	Introduction of the bchP gene from Rhodobacter sphaeroides encoding geranylgeranyl reductase into Rhodospirillum rubrum alters the esterification of the bacteriochlorophylls so that phytol is used instead of geranylgeraniol. The resulting transconjugant strain of Rs. rubrum grows photosynthetically, showing that phytolated Bchla can substitute for the native pigment in both the reaction center (RC) and the light-harvesting 1 (LH1) complexes. This genetic manipulation perturbs the native carotenoid biosynthetic pathway; several biosynthetic intermediates are assembled into the core complex and are capable of energy transfer to the bacteriochlorophylls. RC-LH1 complexes containing phytolated Bchla were analyzed by low temperature absorption and fluorescence spectroscopy and circular dichroism. These show that phytolated Bchls can assemble in vivo into the photosynthetic apparatus of Rs. rubrum and that the newly introduced phytol tail provokes small perturbations to the Bchls within their binding sites in the LH1 complex. The RC-LH1 core complex was purified from membranes and reconstituted into well ordered two-dimensional crystals with a p42(1)2 space group. A projection map calculated to 9 Angstrom shows clearly that the LH1 ring from the mutant is composed of 16 subunits that surround the reaction center and that the diameter of this complex is in close agreement with that of the wild-type LH1 complex.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Hunter, CN (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Qian, Pu/GZM-2400-2022	Bullough, Per/0000-0001-8147-1127				Addlesee HA, 1999, J BACTERIOL, V181, P7248, DOI 10.1128/JB.181.23.7248-7255.1999; Addlesee HA, 1996, FEBS LETT, V389, P126, DOI 10.1016/0014-5793(96)00549-2; Addlesee HA, 2000, J BACTERIOL, V182, P3175, DOI 10.1128/JB.182.11.3175-3182.2000; Addlesee HA, 2002, J BACTERIOL, V184, P1578, DOI 10.1128/JB.184.6.1578-1586.2002; Aklujkar M, 2000, J BACTERIOL, V182, P5440, DOI 10.1128/JB.182.19.5440-5447.2000; Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; BOLLIVAR DW, 1994, BIOCHEMISTRY-US, V33, P12763, DOI 10.1021/bi00209a006; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; BRITTON G, 1995, CAROTENOIDS, V1, P227; BROWN AE, 1972, PLANT PHYSIOL, V50, P747, DOI 10.1104/pp.50.6.747; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Davis CM, 1996, BIOCHEMISTRY-US, V35, P3072, DOI 10.1021/bi951777l; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Desamero RZB, 1998, J PHYS CHEM B, V102, P8151, DOI 10.1021/jp980911j; DUYSENS LNM, 1952, THESIS U UTRECHT; Freer A, 1996, STRUCTURE, V4, P449, DOI 10.1016/S0969-2126(96)00050-0; Georgakopoulou S, 2002, BIOPHYS J, V82, P2184, DOI 10.1016/S0006-3495(02)75565-3; Gradinaru CC, 2001, P NATL ACAD SCI USA, V98, P2364, DOI 10.1073/pnas.051501298; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Jamieson SJ, 2002, EMBO J, V21, P3927, DOI 10.1093/emboj/cdf410; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; KATZ JJ, 1972, J AM CHEM SOC, V94, P7938, DOI 10.1021/ja00777a054; Keller Y, 1998, EUR J BIOCHEM, V251, P413, DOI 10.1046/j.1432-1327.1998.2510413.x; Kessi J, 1995, PHOTOSYNTH RES, V46, P353, DOI 10.1007/BF00020451; Komori M, 1998, BIOCHEMISTRY-US, V37, P8987, DOI 10.1021/bi9730947; Koolhaas MHC, 1997, J PHYS CHEM B, V101, P7262, DOI 10.1021/jp963368k; Koolhaas MHC, 1997, BIOPHYS J, V72, P1828, DOI 10.1016/S0006-3495(97)78829-5; LASCELLE.J, 1967, ARCH MIKROBIOL, V59, P204, DOI 10.1007/BF00406333; Naylor GW, 1999, PHOTOSYNTH RES, V62, P121, DOI 10.1023/A:1006350405674; OLSEN JD, 1994, P NATL ACAD SCI USA, V91, P7124, DOI 10.1073/pnas.91.15.7124; Oster U, 1997, J BIOL CHEM, V272, P9671; PANDIT A, 2003, IN PRESS PHOTOSYNTH; PARKESLOACH PS, 1990, BIOCHEMISTRY-US, V29, P2951, DOI 10.1021/bi00464a010; RUDIGER W, 1991, CHLOROPHYLLS, P451; Scheer H., 1991, CHLOROPHYLLS, P3; SCHOCH S, 1978, Z NATURFORSCH C, V33, P712; TAKUMI N, 1990, BIOCHIM BIOPHYS ACTA, V1017, P280; Walz T, 1998, J MOL BIOL, V282, P833, DOI 10.1006/jmbi.1998.2050; Walz T, 1997, J MOL BIOL, V265, P107, DOI 10.1006/jmbi.1996.0714; Westerhuis WHJ, 2002, BIOCHEMISTRY-US, V41, P8698, DOI 10.1021/bi011663b; Young CS, 1998, J BACTERIOL, V180, P4742, DOI 10.1128/JB.180.17.4742-4745.1998; Young CS, 1998, J BACTERIOL, V180, P1759, DOI 10.1128/JB.180.7.1759-1765.1998	45	21	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23678	23685		10.1074/jbc.M302753200	http://dx.doi.org/10.1074/jbc.M302753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12719425	hybrid			2022-12-25	WOS:000183638600060
J	Shimono, K; Hayashi, T; Ikeura, Y; Sudo, Y; Iwamoto, M; Kamo, N				Shimono, K; Hayashi, T; Ikeura, Y; Sudo, Y; Iwamoto, M; Kamo, N			Importance of the broad regional interaction for spectral tuning in Natronobacterium pharaonis phoborhodopsin (sensory rhodopsin II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL BINDING-SITE; VISUAL PIGMENTS; OPSIN SHIFT; WAVELENGTH REGULATION; MOLECULAR-MECHANISM; ESCHERICHIA-COLI; PROTON TRANSPORT; BACTERIORHODOPSIN; CHROMOPHORE; ABSORPTION	Natronobacterium pharaonis phoborhodopsin (ppR; also called N. pharaonis sensory rhodopsin II, NpsRII) is a photophobic sensor in N. pharaonis, and has a shorter absorption maximum (lambdamax, 500 nm) than those of other archaeal retinal proteins (lambdamax, 560-590 nm) such as bacteriorhodopsin (bR). We constructed chimeric proteins between bR and ppR to investigate the long range interactions effecting the color regulation among archaeal retinal proteins. The lambdamax of B-DEFG/P-ABC was 545 nm, similar to that of bR expressed in Escherichia coli (lambdamax, 550 nm). B-DEFG/P-ABC means a chimera composed of helices D, E, F, and G of bR and helices A, B, and C of ppR. This indicates that the major factor(s) determining the difference in lambdamax between bR and ppR exist in helices DEFG. To specify the more minute regions for the color determination between bR and ppR, we constructed 15 chimeric proteins containing helices D, E, F, and G of bR. According to the absorption spectra of the various chimeric proteins, the interaction between helices D and E as well as the effect of the hydroxyl group around protonated Schiff base on helix G (Thr-204 for ppR and Ala-215 for bR) are the main factors for spectral tuning between bR and ppR.	Hokkaido Univ, Biophys Chem Lab, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Shimono, K (corresponding author), Hokkaido Univ, Biophys Chem Lab, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan.		Sudo, Yuki/AGY-0493-2022	Sudo, Yuki/0000-0001-8155-9356; Iwamoto, Masayuki/0000-0001-9505-2652; Shimono, Kazumi/0000-0001-9752-5329				Arakawa T, 2003, FEBS LETT, V536, P237, DOI 10.1016/S0014-5793(03)00065-6; Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; CHARLEBOIS RL, 1989, CAN J MICROBIOL, V35, P21, DOI 10.1139/m89-004; Chizhov I, 1998, BIOPHYS J, V75, P999, DOI 10.1016/S0006-3495(98)77588-5; Essen LO, 2002, CURR OPIN STRUC BIOL, V12, P516, DOI 10.1016/S0959-440X(02)00356-1; Gordeliy VI, 2002, NATURE, V419, P484, DOI 10.1038/nature01109; GREENHALGH DA, 1993, J BIOL CHEM, V268, P20305; Hayashi S, 2001, J PHYS CHEM B, V105, P10124, DOI 10.1021/jp011362b; HIRAYAMA J, 1992, BIOCHEMISTRY-US, V31, P2093, DOI 10.1021/bi00122a029; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Hohenfeld IP, 1999, FEBS LETT, V442, P198, DOI 10.1016/S0014-5793(98)01659-7; HONIG B, 1979, J AM CHEM SOC, V101, P7084, DOI 10.1021/ja00517a060; Houjou H, 2001, J PHYS CHEM B, V105, P867, DOI 10.1021/jp0032863; HU JG, 1994, P NATL ACAD SCI USA, V91, P8880, DOI 10.1073/pnas.91.19.8880; Ihara K, 1999, J MOL BIOL, V285, P163, DOI 10.1006/jmbi.1998.2286; IMAMOTO Y, 1992, BIOCHEMISTRY-US, V31, P2523, DOI 10.1021/bi00124a012; Kamo N, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1277, DOI 10.1023/A:1013187403599; Kandori H, 2001, BIOCHEMISTRY-US, V40, P15693, DOI 10.1021/bi011621n; Kandori H, 2001, BIOCHEMISTRY-US, V40, P9238, DOI 10.1021/bi0103819; Klare JP, 2002, BIOPHYS J, V82, P2156, DOI 10.1016/S0006-3495(02)75562-8; Kochendoerfer GG, 1999, TRENDS BIOCHEM SCI, V24, P300, DOI 10.1016/S0968-0004(99)01432-2; Lanyi JK, 2001, CURR OPIN STRUC BIOL, V11, P415, DOI 10.1016/S0959-440X(00)00226-8; Lin SW, 1998, J BIOL CHEM, V273, P24583, DOI 10.1074/jbc.273.38.24583; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; METZLER DE, 1978, VISION RES, V18, P1417, DOI 10.1016/0042-6989(78)90235-3; MIYAZAKI M, 1992, BIOCHIM BIOPHYS ACTA, V1140, P22, DOI 10.1016/0005-2728(92)90015-T; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; Pebay-Peyroula E, 2002, BBA-BIOMEMBRANES, V1565, P196, DOI 10.1016/S0005-2736(02)00569-2; Rajamani R, 2002, J COMPUT CHEM, V23, P96, DOI 10.1002/jcc.1159; Ren L, 2001, BIOCHEMISTRY-US, V40, P13906, DOI 10.1021/bi0116487; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Sasaki J, 2000, BBA-BIOENERGETICS, V1460, P230, DOI 10.1016/S0005-2728(00)00142-0; Shi YS, 2001, P NATL ACAD SCI USA, V98, P11731, DOI 10.1073/pnas.201257398; Shimono K, 2000, BIOPHYS CHEM, V87, P225, DOI 10.1016/S0301-4622(00)00195-2; Shimono K, 1998, J BIOCHEM, V124, P404, DOI 10.1093/oxfordjournals.jbchem.a022126; Shimono K, 2002, BIOCHEMISTRY-US, V41, P6504, DOI 10.1021/bi025636c; Shimono K, 1997, FEBS LETT, V420, P54, DOI 10.1016/S0014-5793(97)01487-7; Shimono K, 2001, BBA-BIOMEMBRANES, V1515, P92, DOI 10.1016/S0005-2736(01)00394-7; Shimono K, 2000, PHOTOCHEM PHOTOBIOL, V72, P141; SHIMONO K, 2002, J PHOTOSCI, V9, P302; Spudich J, 2002, NAT STRUCT BIOL, V9, P797, DOI 10.1038/nsb1102-797; Spudich JL, 2002, CURR OPIN STRUC BIOL, V12, P540, DOI 10.1016/S0959-440X(02)00359-7; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; TAKAHASHI T, 1990, BIOCHEMISTRY-US, V29, P8467, DOI 10.1021/bi00488a038; TOMIOKA H, 1986, BIOCHEM BIOPH RES CO, V139, P389, DOI 10.1016/S0006-291X(86)80003-1; Varo G, 2000, BBA-BIOENERGETICS, V1460, P220, DOI 10.1016/S0005-2728(00)00141-9; YAN B, 1995, J BIOL CHEM, V270, P29668; Yokoyama S, 2000, PROG RETIN EYE RES, V19, P385, DOI 10.1016/S1350-9462(00)00002-1	50	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23882	23889		10.1074/jbc.M301200200	http://dx.doi.org/10.1074/jbc.M301200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12690098	hybrid			2022-12-25	WOS:000183638600085
J	Lai, MT; Chen, E; Crouthamel, MC; DiMuzio-Mower, J; Xu, M; Huang, Q; Price, E; Register, RB; Shi, XP; Donoviel, DB; Bernstein, A; Hazuda, D; Gardell, SJ; Li, YM				Lai, MT; Chen, E; Crouthamel, MC; DiMuzio-Mower, J; Xu, M; Huang, Q; Price, E; Register, RB; Shi, XP; Donoviel, DB; Bernstein, A; Hazuda, D; Gardell, SJ; Li, YM			Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BETA-APP; CAENORHABDITIS-ELEGANS; THYMOCYTE DEVELOPMENT; SIGNAL-TRANSDUCTION; CLEAVAGE; NOTCH; INHIBITORS; DEFICIENCY; STATE	Presenilin- 1 ( PS1) and presenilin 2 ( PS2) are proposed to be transmembrane aspartyl proteases that cleave amyloid precursor protein and Notch. PS1- and PS2- mediated activities were individually characterized using blastocyst-derived ( BD) cells and membranes from PS1(+/-) - PS2(-/-) and PS1(-/-) PS2(+/+) mice, respectively. The relative amounts of PS1 and PS2 in the various BD cells were determined from the intensities of the anti- PS1 and anti-PS2 immunoblot signals by comparison with standard curves using radiolabeled PS1 and PS2 standards produced by in vitro transcription and translation. Cellular membranes from wild type, PS1(+/-) - PS2(-/-), and PS1(-/-)PS2(+/+) but not PS1(-/-) PS2(-/-) BD cells generated the Abeta40 and Abeta42 products from the C100FLAG substrate. PS1-associated gamma- secretase displays considerably higher specific activity than PS2- associated gamma- secretase. Moreover, the PS1(+/-) - PS2(-/-) BD cells and corresponding membranes exhibited much higher gamma- secretase activity as compared with other BD cells and membranes. The PS1- mediated gamma-secretase activity correlated better with the amount of PS1 that is modifiable by a photoactivated active site-directed gamma-secretase inhibitor rather than total PS1; hence, only a small portion (< 14%) of the PS1 in wild- type membranes appears to be engaged in an active &gamma;-secretase complex. This finding suggests that PS1 may serve other biological functions in addition to that associated with its &gamma;-secretase activity. Furthermore, the PS1 &gamma;-secretase complex and the PS2 &gamma;-secretase complex activities can be discriminated on the basis of their susceptibility to inhibition by a potent &gamma;-secretase inhibitor. The distinct yet overlapping enzymatic properties of the PS1 &gamma;-secretase complex and the PS2 &gamma;-secretase complex imply that these two putative aspartyl class proteases may contribute to different biological processes.	Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Merck & Company; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Lai, MT (corresponding author), Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA.							Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Handler M, 2000, DEVELOPMENT, V127, P2593; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; LAHAD EL, 1995, SCIENCE, V269, P973; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Li Y M, 2001, Mol Interv, V1, P198; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Wen PH, 2002, NEUROSCI LETT, V318, P53, DOI 10.1016/S0304-3940(01)02485-5; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	33	135	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22475	22481		10.1074/jbc.M300974200	http://dx.doi.org/10.1074/jbc.M300974200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684521	hybrid			2022-12-25	WOS:000183503900042
J	Malek, S; Huang, DB; Huxford, T; Ghosh, S; Ghosh, G				Malek, S; Huang, DB; Huxford, T; Ghosh, S; Ghosh, G			X-ray crystal structure of an I kappa B beta center dot NF-kappa B p65 homodimer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; DEPENDENT KINASE CDK6; ANKYRIN REPEAT DOMAIN; DNA-BINDING; ONCOPROTEIN BCL-3; REL PROTEINS; ALPHA; LOCALIZATION; ACTIVATION; INHIBITOR	We report the crystal structure of a murine IkappaBbeta.NF-kappaB p65 homodimer complex. Crystallographic models were determined for two triclinic crystalline systems and refined against data at 2.5 and 2.1 Angstrom. The overall complex structure is similar to that of the IkappaBalpha.NF-kappaB p50/p65 heterodimer complex. One NF-kappaB p65 subunit nuclear localization signal clearly contacts IkappaBbeta, whereas a homologous segment from the second subunit of the homodimer is mostly solvent-exposed. The unique 47-amino acid insertion between ankyrin repeats three and four of IkappaBbeta is mostly disordered in the structure. Primary sequence analysis and differences in the mode of binding at the IkappaBbeta sixth ankyrin repeat and NF-kappaB p65 homodimer suggest a model for nuclear IkappaBbeta.NF-kappaB.DNA ternary complex formation. These unique structural features of IkappaBbeta may contribute to its ability to mediate persistent NF-kappaB activation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr,MC 0359, La Jolla, CA 92093 USA.	gghosh@chem.ucsd.edu		Malek, Shiva/0000-0002-9526-7968; Huxford, Tom/0000-0002-1939-7373	NATIONAL CANCER INSTITUTE [R01CA078749] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; BRUNGER AT, 1998, ACTA CRYSTALLOGR D, V10, P25; Bundy DL, 1997, J BIOL CHEM, V272, P33132, DOI 10.1074/jbc.272.52.33132; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; Chen Y, 2003, J BIOL CHEM, V278, P23101, DOI 10.1074/jbc.M301021200; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Cramer P, 1999, STRUCT FOLD DES, V7, pR1, DOI 10.1016/S0969-2126(99)80002-1; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Huxford T, 2000, J BIOL CHEM, V275, P32800, DOI 10.1074/jbc.M006037200; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Huxford T, 2002, J MOL BIOL, V324, P587, DOI 10.1016/S0022-2836(02)01149-X; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phillips RJ, 1997, MOL CELL BIOL, V17, P4390, DOI 10.1128/MCB.17.8.4390; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yang YW, 1998, STRUCTURE, V6, P619, DOI 10.1016/S0969-2126(98)00063-X	55	92	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23094	23100		10.1074/jbc.M301022200	http://dx.doi.org/10.1074/jbc.M301022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686541	hybrid			2022-12-25	WOS:000183503900117
J	Palfey, BA; Murthy, YVSN; Massey, V				Palfey, BA; Murthy, YVSN; Massey, V			Altered balance of half-reactions in p-hydroxybenzoate hydroxylase caused by substituting the 2 '-carbon of FAD with fluorine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBITYL SIDE-CHAIN; CRYSTAL-STRUCTURE; REACTION-MECHANISM; ACTIVE-SITE; FLAVIN; OXYGEN; SUBSTRATE; PROTON; MUTANT; DIHYDROFLAVINS	Apo-p-hydroxybenzoate hydroxylase was reconstituted using 2'-fluoro-2'-deoxy-arabino-FAD, a synthetic flavin in which the hydroxyl of the 2'-center of the ribityl chain was replaced with fluorine in an inverted configuration. The absorbance spectral changes caused by the binding of either p-hydroxybenzoate (pOHB) or 2,4-dihydroxybenzoate (2,4-diOHB) indicated that the isoalloxazine of the artificial flavin adopts the more solvent-exposed "out" conformation rather than the partially buried "in" conformation near the aromatic substrate. In contrast, the flavin of the natural enzyme adopts the in conformation when pOHB is bound. Much of the behavior of the artificial enzyme can be rationalized in light of the preference of the flavin for the out conformation, including the weaker binding of pOHB, the tighter binding of 2,4-diOHB, and the slower reactions involved in the hydroxylation of pOHB and 2,4-diOHB. Particularly noteworthy is the enhancement of the reduction of the flavin by NADPH when pOHB is bound to the active site, consistent with the recent finding that the reaction occurs when the flavin adopts the out conformation ( Palfey, B. A., Moran, G. R., Entsch, B., Ballou, D. P., and Massey, V. ( 1999) Biochemistry 38, 1153 - 1158). Thus, whereas the change that induces the out conformation is detrimental to the oxidative half-reaction, it improves the reductive half-reaction, showing that the control of the flavin position in p-hydroxybenzoate hydroxylase represents a compromise between the conflicting needs of two chemically disparate half-reactions, and demonstrating that the 2'-hydroxyl of FAD can serve as a critical control element in flavoenzyme catalysis.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Palfey, BA (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Palfey, Bruce/0000-0001-5098-259X	NIGMS NIH HHS [GM20877, GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R37GM020877, R01GM011106, R01GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; EBERLEIN G, 1983, J AM CHEM SOC, V105, P6685, DOI 10.1021/ja00360a024; Engst S, 1999, BIOCHEMISTRY-US, V38, P257, DOI 10.1021/bi9815041; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; Frederick KK, 2001, BIOCHEMISTRY-US, V40, P3891, DOI 10.1021/bi001851m; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; Ghisla S, 1994, FLAVINS AND FLAVOPROTEINS 1993, P283; GHISLA S, 1986, BIOCHEM J, V239, P1; HUSSAIN M, 1979, J BIOL CHEM, V254, P6657; KEMAL C, 1977, J AM CHEM SOC, V99, P7272, DOI 10.1021/ja00464a030; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MAEDAYORITA K, 1993, J BIOL CHEM, V268, P4134; MASSEY, 1990, FLAVINS FLAVOPROTEIN, P59; Massey V., 1973, OXIDASES RELATED RED, P25; MILLER SM, 1995, BIOCHEMISTRY-US, V34, P13066, DOI 10.1021/bi00040a018; MORAN GR, 1995, PROTEIN EXPRES PURIF, V6, P164, DOI 10.1006/prep.1995.1020; Murthy YVSN, 1996, J BIOL CHEM, V271, P19915, DOI 10.1074/jbc.271.33.19915; MURTHY YVSN, 1995, J BIOL CHEM, V270, P28586, DOI 10.1074/jbc.270.48.28586; Palfey BA, 1999, BIOCHEMISTRY-US, V38, P1153, DOI 10.1021/bi9826613; Palfey BA, 2002, BIOCHEMISTRY-US, V41, P8438, DOI 10.1021/bi012073g; PALFEY BA, 1994, BIOCHEMISTRY-US, V33, P1545, DOI 10.1021/bi00172a035; SCHOPFER LM, 1991, J BIOL CHEM, V266, P13080; SCHREUDER HA, 1994, BIOCHEMISTRY-US, V33, P10161, DOI 10.1021/bi00199a044; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1992, PROTEINS, V14, P178, DOI 10.1002/prot.340140205; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; WESSIAK A, 1984, J BIOL CHEM, V259, P2547	31	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22210	22216		10.1074/jbc.M301830200	http://dx.doi.org/10.1074/jbc.M301830200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684497	hybrid			2022-12-25	WOS:000183503900005
J	Zada, AAP; Singh, SM; Reddy, VA; Elsasser, A; Meisel, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G				Zada, AAP; Singh, SM; Reddy, VA; Elsasser, A; Meisel, A; Haferlach, T; Tenen, DG; Hiddemann, W; Behre, G			Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation	ONCOGENE			English	Article						CD44; c-Jun; AML; differentiation; proliferation; cell cycle	TRANS-RETINOIC ACID; ADHESION MOLECULE; C/EBP-ALPHA; TRANSCRIPTIONAL ACTIVITY; RETINOBLASTOMA PROTEIN; KINASE-ACTIVITY; DIFFERENTIATION; PHOSPHORYLATION; AP-1; P21	In the present study, we investigated the mechanism of CD44 ligation with the anti-CD44 monoclonal antibody A3D8 to inhibit the proliferation of human acute myeloid leukemia (AML) cells. The effects of A3D8 on myeloid cells were associated with specific disruption of cell cycle events and induction of G0/G1 arrest. Induction of G0/G1 arrest was accompanied by an increase in the expression of p21, attenuation of pRb phosphorylation and associated with decreased Cdk2 and Cdk4 kinase activities. Since c-Jun is an important regulator of proliferation and cell cycle progression, we analysed its role in A3D8-mediated growth arrest. We observed that A3D8 treatment of AML patient blasts and HL60/U937 cells led to the down-regulation of c-Jun expression at mRNA and protein level. Transient transfection studies showed the inhibition of c-jun promoter activity by A3D8, involving both AP-1 sites. Furthermore, A3D8 treatment caused a decrease in JNK protein expression and a decrease in the level of phosphorylated c-Jun. Ectopic overexpression of c-Jun in HL60 cells was able to induce proliferation and prevent the antiproliferative effects of A3D8. In summary, these data identify an important functional role of c-Jun in the induction of cell cycle arrest and proliferation arrest of myeloid leukemia cells because of the ligation of the cell surface adhesion receptor CD44 by anti-CD44 antibody. Moreover, targeting of G1 regulatory proteins and the resulting induction of G I arrest by A3D8 may provide new insights into antiproliferative and differentiation therapy of AML.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; GSF Munich, Hematologikum, D-81377 Munich, Germany; Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School	Behre, G (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	gerdbehre@aol.com		Tenen, Daniel/0000-0002-6423-3888				Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BATES S, 1994, ONCOGENE, V9, P1633; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Behre G, 1999, BIOTECHNIQUES, V26, P24, DOI 10.2144/99261bm03; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; CHOU SY, 1992, MOL BIOL CELL, V3, P1117, DOI 10.1091/mbc.3.10.1117; DANOVA M, 1990, LEUKEMIA RES, V14, P417, DOI 10.1016/0145-2126(90)90027-7; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; ELSASSER A, 2002, ASH, V100, P200; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Gitig DM, 2000, METH MOL B, V142, P109; HARPER JW, 1993, CELL, V75, P805; HILBERG F, 1992, ONCOGENE, V7, P2371; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kantarjian H, 1999, SEMIN HEMATOL, V36, P16; Kiaris H, 1999, ONCOGENE, V18, P7168, DOI 10.1038/sj.onc.1203213; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUHN LC, 1994, BAILLIERE CLIN HAEM, V7, P763, DOI 10.1016/S0950-3536(05)80123-4; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIESVELD JL, 1994, LEUKEMIA LYMPHOMA, V14, P19, DOI 10.3109/10428199409049647; Lowell CA, 1999, J LEUKOCYTE BIOL, V65, P313, DOI 10.1002/jlb.65.3.313; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; Moll J, 1998, J CLIN INVEST, V102, P1024, DOI 10.1172/JCI2494; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Patel R, 1998, J CELL SCI, V111, P2247; Pisani F, 1997, ANN HEMATOL, V75, P145, DOI 10.1007/s002770050332; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; REUSSBORST MA, 1992, ANN HEMATOL, V65, P169, DOI 10.1007/BF01703110; SANFORD JS, 1998, BLOOD, V91, P2645; SAVATIER P, 1994, ONCOGENE, V9, P809; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1994, STEM CELLS, V12, P47; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sievers EL, 2000, CURR OPIN ONCOL, V12, P30, DOI 10.1097/00001622-200001000-00005; SLACK RS, 1993, ONCOGENE, V8, P1585; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MJ, 1992, BLOOD, V79, P2107; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; THEIL EC, 1990, J BIOL CHEM, V265, P4771; Trayner ID, 1998, LEUKEMIA RES, V22, P537, DOI 10.1016/S0145-2126(98)00041-1; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714; Wei P, 1998, MOL ENDOCRINOL, V12, P1322, DOI 10.1210/me.12.9.1322; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188	67	37	47	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2296	2308		10.1038/sj.onc.1206330	http://dx.doi.org/10.1038/sj.onc.1206330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700665				2022-12-25	WOS:000182231500008
J	Falahatpisheh, MH; Ramos, KS				Falahatpisheh, MH; Ramos, KS			Ligand-activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing	ONCOGENE			English	Article						Ahr; WT1 splicing; nephrogenesis	ARYL-HYDROCARBON RECEPTOR; GENE-EXPRESSION; EMBRYONAL CARCINOMA; KIDNEY DEVELOPMENT; DEFICIENT MICE; WT1 GENE; GROWTH; CELLS; TRANSCRIPTION; INVOLVEMENT	The aryl hydrocarbon receptor (Ahr), a member of the large basic helix-loop-helix (bHLH) and PAS homology domain superfamily, is a highly conserved transcriptional regulator involved in mammalian development. In the present study, a murine metanephros organ culture system was employed to evaluate the role of the Ahr signaling in nephrogenesis in vitro. Ahr and Wilms' tumor suppressor (wt1) mRNAs were detected by in situ hybridization and RT-PCR during the course of renal development. Treatment with 3 pm BaP, a hydrocarbon ligand of Ahr, inhibited glomerulogenesis and branching morphogenesis of metanephric kidneys. Deficits in the epithelialization of mesenchymal cells were evidenced by inhibition of the formation of podocyte foot processes and glomerular basement membranes. Hydrocarbon treatment markedly induced -KTS wt1 splice variants, although total wt1 mRNA levels remained unchanged. A significant decrease in total WT1 protein was observed by both immunocytochemistry and Western analysis in cultures challenged with BaP compared to controls. Comparison of metanephric cultures from Ahr+/+ and Ahr-/- mice showed that Ahr is involved in kidney development, and required for BaP-induced deficits in nephrogenesis. These results indicate that ligand activation of Ahr signaling disrupts nephrogenesis in vitro, and that this response involves modulation of wt1 alternative splicing and post-transcriptional control.	Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Ramos, KS (corresponding author), Texas A&M Univ, Ctr Environm & Rural Hlth, College Stn, TX 77843 USA.				NIEHS NIH HHS [ES09106, ES04917] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, P42ES004917] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott BD, 1995, TOXICOLOGY, V105, P365, DOI 10.1016/0300-483X(95)03234-7; ASWIN M, 1998, KIDNEY INT, V53, P1512; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; AVNER ED, 1993, SEMIN NEPHROL, V13, P427; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bowes RC, 1996, BIOCHEM PHARMACOL, V52, P587, DOI 10.1016/0006-2952(96)00310-3; BOWES RC, 1994, TOXICOL IN VITRO, V8, P1151, DOI 10.1016/0887-2333(94)90104-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Cantrell SM, 1998, TOXICOL APPL PHARM, V148, P24, DOI 10.1006/taap.1997.8309; Carver LA, 1997, J BIOL CHEM, V272, P11452; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Dressler G R, 1997, Adv Nephrol Necker Hosp, V26, P1; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; Gutierrez A, 1997, MOL BRAIN RES, V45, P59, DOI 10.1016/S0169-328X(96)00237-9; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HABIB R, 1985, CLIN NEPHROL, V24, P269; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hewitt SM, 1996, ANTICANCER RES, V16, P621; Hida M, 2002, KIDNEY INT, V61, P1252, DOI 10.1046/j.1523-1755.2002.00273.x; Hundeiker C, 1999, INT J IMMUNOPHARMACO, V21, P841, DOI 10.1016/S0192-0561(99)00053-3; Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508; KAFAFI SA, 1993, CHEM RES TOXICOL, V6, P328, DOI 10.1021/tx00033a012; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kudoh T, 1996, ONCOGENE, V13, P1431; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; Laity JH, 2000, BIOCHEMISTRY-US, V39, P5341, DOI 10.1021/bi9926678; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; RYAN G, 1995, DEVELOPMENT, V121, P867; SAXON L, 1987, ORGANOGENESIS KIDNEY; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; Toth T, 1996, NEPHRON, V74, P64, DOI 10.1159/000189283; WALKER C, 1994, CANCER RES, V54, P3101; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Yeger H, 1996, IN VITRO CELL DEV-AN, V32, P496; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	47	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2160	2171		10.1038/sj.onc.1206238	http://dx.doi.org/10.1038/sj.onc.1206238			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687018	Bronze			2022-12-25	WOS:000182066900010
J	de Cavanagh, EMV; Piotrkowski, B; Basso, N; Stella, I; Inserra, F; Ferder, L; Fraga, CG				de Cavanagh, EMV; Piotrkowski, B; Basso, N; Stella, I; Inserra, F; Ferder, L; Fraga, CG			Enalapril and losartan attenuate mitochondrial dysfunction in aged rats	FASEB JOURNAL			English	Article						renin-angiotensin system; aging; nitric oxide; glutathione; oxidant damage	NITRIC-OXIDE; ANGIOTENSIN; INHIBITION; OXYGEN; SUPEROXIDE; KIDNEY	Renin-angiotensin system (RAS) inhibition can attenuate the effects of aging on renal function and structure; however, its effect on mitochondrial aging is unknown. To investigate whether an angiotensin-converting enzyme inhibitor (enalapril) or an angiotensin II receptor blocker (losartan) could mitigate age-associated changes in kidney mitochondria, male Wistar rats (14 mo old) received during 8 mo water containing either enalapril (10 mg/kg/day) (Enal), or losartan (30 mg/kg/day) (Los), or no additions (Old). Four-month-old untreated rats (Young) were also studied. In Old rats mitochondrial respiratory control, ADP/O, nitric oxide synthase activity, and uncoupling protein 2 levels were lower (46, 42, 27, and 76%, respectively), and Mn-SOD activity was higher (70%) than in Young, Enal, and Los rats. In Old rats mitochondrial hydrogen peroxide production was higher than in both Young (197%) and Enal or Los (40%) rats. In Old rats, kidney GSH/GSSG was lower than in both Young (80%) and Enal (57%) or Los (68%) rats. In Old rats electron microscopy showed effacement of microvilli in tubular epithelial cells, ill-defined mitochondrial cristae, lower mitochondrial numbers, and enhanced number of osmiophilic bodies relative to Young, Enal, or Los rats. In conclusion, enalapril and losartan can protect against both age-related mitochondrial dysfunction and ultrastructural alterations, underscoring the role of RAS in the aging process. An association with oxidative stress modulation is suggested.	Univ Buenos Aires, Sch Pharm & Biochem, Phys Chem PRALIB, Buenos Aires, DF, Argentina; Inst Cardiovasc Res ININCA, Buenos Aires, DF, Argentina	University of Buenos Aires	Fraga, CG (corresponding author), Junin 956, RA-1113 Buenos Aires, DF, Argentina.	cfraga@huemul.ffyb.uba.ar	Fraga, Cesar/Q-8161-2019					AEBI H, 1984, METHOD ENZYMOL, V105, P121; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; Baylis C, 1998, J AM SOC NEPHROL, V9, P699; Bosc LVG, 2001, J HYPERTENS, V19, P1403, DOI 10.1097/00004872-200108000-00008; BOVERIS A, 1999, OXIDAT STRESS DIS, V2, P1; BOVERIS A, 2000, NITRIC OXIDE BIOL PA, P355; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CARLBERG I, 1997, METHOD ENZYMOL, V133, P485; CAVANAGH EM, 1997, AM J PHYSIOL, V272, pR514; De Cavanagh EMV, 2000, AM J PHYSIOL-REG I, V278, pR572, DOI 10.1152/ajpregu.2000.278.3.R572; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; Dzau VJ, 2001, HYPERTENSION, V37, P1047, DOI 10.1161/01.HYP.37.4.1047; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FERDER L, 1994, J AM SOC NEPHROL, V5, P1147; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GUNZLER WA, 1974, Z KLIN CHEM KLIN BIO, V12, P444; HEUDES D, 1994, AM J PHYSIOL, V266, pR1038, DOI 10.1152/ajpregu.1994.266.3.R1038; Inoue K, 2000, J Renin Angiotensin Aldosterone Syst, V1, P180, DOI 10.3317/jraas.2000.023; JONES OTG, 1994, METHOD ENZYMOL, V233, P222; Knowles RG, 1998, METH MOL B, V100, P67; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; Ma LJ, 2000, KIDNEY INT, V58, P2425, DOI 10.1046/j.1523-1755.2000.00426.x; Meister A., 1995, BIOTHIOLS HLTH DIS, P165; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1; SIES H, 1984, METHOD ENZYMOL, V105, P445; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; Yusuf S, 2000, NEW ENGL J MED, V342, P145	34	144	150	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1096	+		10.1096/fj.02-0063fje	http://dx.doi.org/10.1096/fj.02-0063fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709417				2022-12-25	WOS:000182580100027
J	Negroiu, G; Dwek, RA; Petrescu, SM				Negroiu, G; Dwek, RA; Petrescu, SM			The inhibition of early N-glycan processing targets TRP-2 to degradation in B16 melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINASE-RELATED PROTEIN-2; DISULFIDE BOND FORMATION; ENDOPLASMIC-RETICULUM; DOPACHROME TAUTOMERASE; HUMAN MELANOCYTES; MISFOLDED GLYCOPROTEINS; MELANOSOMAL PROTEINS; DENDRITIC CELLS; QUALITY-CONTROL; MYOSIN-VA	Tyrosinase-related protein-2 (TRP-2) is a DOPAchrome tautomerase catalyzing a distal step in the melanin synthesis pathway. Similar to the other two melanogenic enzymes belonging to the TRP gene family, tyrosinase and TRP-1, TRP-2 is expressed in melanocytes and melanoma cells. Despite the increasing evidence of its efficiency as a melanoma antigen, little is known about the maturation and intracellular trafficking of TRP-2. Here we show that TRP-2 is mainly distributed in the TGN of melanoma cells instead of being confined solely to melanosomes. This, together with the plasma membrane occasional localization observed by immunofluorescence, suggest the TRP-2 participation in a recycling pathway, which could include or not the melanosomes. Using pulse-chase experiments we show that the TRP-2 polypeptide folds in the endoplasmic reticulum ( ER) in the presence of calnexin, until it reaches a dithiothreitol-resistant conformation enabling its ER exit to the Golgi. If N-glycosylation inhibitors prevent the association with calnexin, the TRP-2 nascent chain undergoes an accelerated degradation process. This process is delayed in the presence of proteasomal inhibitors, indicating that the misfolded chain is retro-translocated from the ER into the cytosol and degraded in proteasomes. This is a rare example in which calnexin although indispensable for the nascent chain folding is not required for its targeting to degradation. Therefore TRP-2 may prove to be a good model to document the calnexin-independent retro-translocation process of proteasomally degraded proteins. Clearly, TRP-2 has a distinct maturation pathway from tyrosinase and TRP-1 and possibly a second regulatory function within the cell.	Romanian Acad, Inst Biochem, Bucharest 77700, Romania; Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England	Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Oxford	Petrescu, SM (corresponding author), Romanian Acad, Inst Biochem, Splaiul Independentei 296, Bucharest 77700, Romania.		Negroiu, Gabriela/AAO-3980-2020; Negroiu, Gabriela/G-4649-2016; Petrescu, Stefana M/I-9240-2012; Petrescu, Stefana/AAJ-9505-2021	Petrescu, Stefana M/0000-0002-4047-0811; Petrescu, Stefana/0000-0002-4047-0811; Negroiu, Gabriela/0000-0003-3712-7681				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Branza-Nichita N, 1999, BIOCHEM BIOPH RES CO, V261, P720, DOI 10.1006/bbrc.1999.1030; Bronte V, 2000, CANCER RES, V60, P253; Chen D, 1997, BIOCHEM MOL MED, V60, P27, DOI 10.1006/bmme.1996.2559; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; De Maziere AM, 2002, TRAFFIC, V3, P678, DOI 10.1034/j.1600-0854.2002.30909.x; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Furumura M, 1998, BIOCHEM BIOPH RES CO, V242, P579, DOI 10.1006/bbrc.1997.8007; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEARING VJ, 1993, PIGMENTATION PIGMENT, P3; Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; Liu TF, 2001, J BIOL CHEM, V276, P35768, DOI 10.1074/jbc.M103585200; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Metharom P, 2001, HUM GENE THER, V12, P2203, DOI 10.1089/10430340152710540; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Negroiu G, 1999, BIOCHEM J, V344, P659, DOI 10.1042/0264-6021:3440659; Negroiu G, 2000, J BIOL CHEM, V275, P32200, DOI 10.1074/jbc.M005186200; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Okamoto T, 1998, J INVEST DERMATOL, V111, P1034, DOI 10.1046/j.1523-1747.1998.00411.x; ORLOW SJ, 1995, P NATL ACAD SCI USA, V92, P10152, DOI 10.1073/pnas.92.22.10152; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; PAWELEK JM, 1986, CANCER RES, V46, P493; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Solano F, 1996, BIOCHEM J, V313, P447, DOI 10.1042/bj3130447; SOLANO F, 1994, BIOCHEM BIOPH RES CO, V204, P1243, DOI 10.1006/bbrc.1994.2596; Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104; Steitz J, 2002, GENE THER, V9, P208, DOI 10.1038/sj.gt.3301634; Sun YS, 2000, INT J CANCER, V87, P399, DOI 10.1002/1097-0215(20000801)87:3<399::AID-IJC14>3.0.CO;2-9; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Visser M, 2001, METH MOLEC MED, V61, P31, DOI 10.1385/1-59259-145-0:31; Wang RF, 1998, J IMMUNOL, V160, P890; Wang RF, 2002, NAT BIOTECHNOL, V20, P149, DOI 10.1038/nbt0202-149; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; Wu XF, 2002, MOL BIOL CELL, V13, P1735, DOI 10.1091/mbc.01-12-0595; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Xu YQ, 2001, EXP CELL RES, V267, P115, DOI 10.1006/excr.2001.5232; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	54	27	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27035	27042		10.1074/jbc.M303167200	http://dx.doi.org/10.1074/jbc.M303167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12719423	hybrid			2022-12-25	WOS:000184155700095
J	Muller-Loennies, S; Brade, L; MacKenzie, CR; Di Padova, FE; Brade, H				Muller-Loennies, S; Brade, L; MacKenzie, CR; Di Padova, FE; Brade, H			Identification of a cross-reactive epitope widely present in lipopolysaccharide from enterobacteria and recognized by the cross-protective monoclonal antibody WN1 222-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STRUCTURAL-ANALYSIS; CORE REGION; ARTIFICIAL GLYCOCONJUGATE; CHEMICAL-STRUCTURE; LIPID-A; SALMONELLA; VACCINES; BINDING	Septic shock due to infections with Gram-negative bacteria is a severe disease with a high mortality rate. We report the identification of the antigenic determinants of an epitope that is present in enterobacterial lipopolysaccharide (LPS) and recognized by a cross-reactive monoclonal antibody (mAb WN1 222-5) regarded as a potential means of treatment. Using whole LPS and a panel of neoglycoconjugates containing purified LPS oligosaccharides obtained from Escherichia coli core types R1, R2, R3, and R4, Salmonella enterica, and the mutant strain E. coli J-5, we showed that mAb WN1 222-5 binds to the distal part of the inner core region and recognizes the structural element R-1-alpha-D-Glcp-(1-->3)-[L-alpha-D-Hepp-(1-->7)]-L-alpha-D-Hepp 4P-(1-->3)-R-2 (where R1 represents additional sugars of the outer core and R2 represents additional sugars of the inner core), which is common to LPS from all E. coli, Salmonella, and Shigella. WN1 222-5 binds poorly to molecules that lack the side chain heptose or lack phosphate at the branched heptose. Also molecules that are substituted with GlcpN at the side chain heptose are poorly bound. Thus, the side chain heptose and the 4-phosphate on the branched heptose are main determinants of the epitope. We have determined the binding kinetics and affinities (K-D values) of the monovalent interaction of E. coli core oligosaccharides with WN1 222-5 by surface plasmon resonance and isothermal titration microcalorimetry. Affinity constants (K-D values) determined by SPR were in the range of 3.6 x 10(-5) to 3.2 x 10(-8) M, with the highest affinity being observed for the core oligosaccharide from E. coli F576 (R2 core type) and the lowest K-D values for those from E. coli J-5. Affinities of E. coli R1, R3, and R4 oligosaccharides were 5-10-fold lower, and values from the E. coli J-5 mutant were 29-fold lower than the R2 core oligosaccharide. Thus, the outer core sugars had a positive effect on binding.	Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Novartis Pharma AG, CH-4002 Basel, Switzerland	Forschungszentrum Borstel; National Research Council Canada; Novartis	Muller-Loennies, S (corresponding author), Ctr Med & Biosci, Res Ctr Borstel, Pk Allee 22, D-23845 Borstel, Germany.	sml@fz-borstel.de						Bailat S, 1997, INFECT IMMUN, V65, P811, DOI 10.1128/IAI.65.2.811-814.1997; Baumgartner LD, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P865; Boutonnier A, 2001, INFECT IMMUN, V69, P3488, DOI 10.1128/IAI.69.5.3488-3493.2001; BRADE L, 1993, INFECT IMMUN, V61, P4514, DOI 10.1128/IAI.61.10.4514-4517.1993; BRADE L, 1994, FEMS IMMUNOL MED MIC, V8, P27, DOI 10.1111/j.1574-695X.1994.tb00422.x; BRAUDE AI, 1972, J IMMUNOL, V108, P505; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DIPADOVA FE, 1993, INFECT IMMUN, V61, P3863, DOI 10.1128/IAI.61.9.3863-3872.1993; ELBEIN AD, 1965, J BIOL CHEM, V240, P1919; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; HOLST O, 1993, EUR J BIOCHEM, V214, P695, DOI 10.1111/j.1432-1033.1993.tb17970.x; Holst O, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P115; HOLST O, 1991, CARBOHYD RES, V219, P247, DOI 10.1016/0008-6215(91)89058-N; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; KASTOWSKY M, 1992, J BACTERIOL, V174, P4798, DOI 10.1128/JB.174.14.4798-4806.1992; Levy O., 2001, Current Infectious Disease Reports, V3, P407, DOI 10.1007/BF03160475; Makela PH, 2000, FEMS MICROBIOL REV, V24, P9, DOI 10.1111/j.1574-6976.2000.tb00530.x; Meyer B, 1997, EUR J BIOCHEM, V246, P705, DOI 10.1111/j.1432-1033.1997.t01-1-00705.x; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P5982, DOI 10.1046/j.1432-1033.2002.03322.x; Muller-Loennies S, 2002, J ENDOTOXIN RES, V8, P295, DOI 10.1179/096805102125000506; Muller-Loennies S, 2002, EUR J BIOCHEM, V269, P1237, DOI 10.1046/j.1432-1033.2002.02763.x; Muller-Loennies S, 1999, EUR J BIOCHEM, V260, P235, DOI 10.1046/j.1432-1327.1999.00134.x; Muller-Loennies S, 2000, FIGHTING INFECT 21 C, P143; Olsthoorn MMA, 1998, J BIOL CHEM, V273, P3817, DOI 10.1074/jbc.273.7.3817; POLLACK M, 1999, PATHOLOGY SEPSIS SEP, P275; Tan TQ, 2000, CURR OPIN MICROBIOL, V3, P502, DOI 10.1016/S1369-5274(00)00130-2; Vaara M, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P31; Vinogradov E, 2001, EUR J BIOCHEM, V268, P1722; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x	30	35	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25618	25627		10.1074/jbc.M302904200	http://dx.doi.org/10.1074/jbc.M302904200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716894	hybrid			2022-12-25	WOS:000183920200044
J	Sasai, K; Ikeda, Y; Ihara, H; Honke, K; Taniguchi, N				Sasai, K; Ikeda, Y; Ihara, H; Honke, K; Taniguchi, N			Caveolin-1 regulates the functional localization of N-acetylglucosaminyltransferase III within the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-SYNTHESIS; IN-VIVO; GENE TRANSFECTION; DOWN-REGULATION; HEN OVIDUCT; GNT-III; MEMBRANE; DOMAINS; OLIGOSACCHARIDES; BIOSYNTHESIS	In an investigation of the mechanism underlying the functional sublocalization of glycosyltransferases within the Golgi apparatus, caveolin-1 was identified as a possible cellular factor. Caveolin-1 appears to regulate the localization of N-acetylglucosaminyltransferase III (GnT-III) in the intra-Golgi subcompartment. Structural analyses of total cellular N-glycans indicated that the overexpression of GnT-III in human hepatoma cells, in which caveolin-1 is not expressed, failed to reduce branch formation, whereas expression of caveolin-1 led to a dramatic decrease in the extent of branching with no enhancement in GnT-III activity. Because the addition of a bisecting GlcNAc by GnT-III to the core beta-Man in N-glycans prevents the action of GnT-IV and GnT-V, both of which are involved in branch formation, this result suggests that caveolin-1 facilitates the prior action of GnT-III, relative to the other GnTs, on the nascent sugar chains in the Golgi apparatus and that GnT-III is redistributed in the earlier Golgi subcompartment by caveolin-1. Indeed, when caveolin-1 was expressed in human hepatoma cells, it was found to be co-localized with GnT-III, as evidenced by the fractionation of Triton X-100-insoluble cellular membranes by density gradient ultracentrifugation. Caveolin-1 may modify the biosynthetic pathway of sugar chains via the regulation of the intra-Golgi subcompartment localization of this key glycosyltransferase.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				BENDIAK B, 1987, J BIOL CHEM, V262, P5784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKHAUSEN I, 1988, BIOCHEM CELL BIOL, V66, P1134, DOI 10.1139/o88-131; BURKE J, 1994, J BIOL CHEM, V269, P12049; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; Fujimoto T, 2000, J CELL SCI, V113, P3509; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Ihara H, 2002, EUR J BIOCHEM, V269, P193, DOI 10.1046/j.0014-2956.2001.02640.x; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; Kano F, 2000, J CELL BIOL, V149, P357, DOI 10.1083/jcb.149.2.357; Koyota S, 2001, J BIOL CHEM, V276, P32867, DOI 10.1074/jbc.M102371200; KURAYA N, 1992, J BIOCHEM, V112, P122, DOI 10.1093/oxfordjournals.jbchem.a123850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; NARASIMHAN S, 1982, J BIOL CHEM, V257, P235; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oguri S, 1997, J BIOL CHEM, V272, P22721, DOI 10.1074/jbc.272.36.22721; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sasai K, 2002, FEBS LETT, V522, P151, DOI 10.1016/S0014-5793(02)02916-2; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tanemura M, 1997, BIOCHEM BIOPH RES CO, V235, P359, DOI 10.1006/bbrc.1997.6784; TANIGUCHI N, 1989, METHOD ENZYMOL, V179, P397; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	36	26	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25295	25301		10.1074/jbc.M301913200	http://dx.doi.org/10.1074/jbc.M301913200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716887	hybrid			2022-12-25	WOS:000183920200006
J	Bhatia, B; Maldonado, CJ; Tang, SH; Chandra, D; Klein, RD; Chopra, D; Shappell, SB; Yang, PY; Newman, RA; Tang, DG				Bhatia, B; Maldonado, CJ; Tang, SH; Chandra, D; Klein, RD; Chopra, D; Shappell, SB; Yang, PY; Newman, RA; Tang, DG			Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PROSTATE-CANCER CELLS; NUCLEAR-LOCALIZATION; EPITHELIAL-CELLS; HYDROXAMIC ACID; CYCLIN D1; 5-LIPOXYGENASE; EXPRESSION; APOPTOSIS; PROTEINS	15-Lipoxygenase 2 (15-LOX2), the most abundant arachidonate (AA)-metabolizing enzyme expressed in adult human prostate, is a negative cell-cycle regulator in normal human prostate epithelial cells. Here we study the subcellular distribution of 15-LOX2 and report its tumor-suppressive functions. Immunocytochemistry and biochemical fractionation reveal that 15-LOX2 is expressed at multiple subcellular locations, including cytoplasm, cytoskeleton, cell-cell border, and nucleus. Surprisingly, the three splice variants of 15-LOX2 we previously cloned, i.e. 15-LOX2sv-a/b/c, are mostly excluded from the nucleus. A potential bi-partite nuclear localization signal (NLS), (203)RKGLWRSLNEMKRIFN-FRR221, is identified in the N terminus of 15-LOX2, which is retained in all splice variants. Site-directed mutagenesis reveals that this putative NLS is only partially involved in the nuclear import of 15-LOX2. To elucidate the relationship between nuclear localization, enzymatic activity, and tumor suppressive functions, we established PCa cell clones stably expressing 15-LOX2 or 15-LOX2sv-b. The 15-LOX2 clones express 15-LOX2 in the nuclei and possess robust enzymatic activity, whereas 15-LOX2sv-b clones show neither nuclear protein localization nor AA-metabolizing activity. To our surprise, both 15-LOX2- and 15-LOX2sv-b-stable clones proliferate much slower in vitro when compared with control clones. More importantly, when orthotopically implanted in nude mouse prostate, both 15- LOX2 and 15-LOX2sv-b suppress PC3 tumor growth in vivo. Together, these results suggest that both 15- LOX2 and 15-LOX2sv-b suppress prostate tumor development, and the tumor-suppressive functions apparently do not necessarily depend on AA-metabolizing activity and nuclear localization.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Wayne State Univ, Inst Chem Toxicol, Detroit, MI 48226 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37221 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Wayne State University; Vanderbilt University; University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Pk Rd 1C, Smithville, TX 78957 USA.		Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NCI NIH HHS [CA-90297, T32 CA09480-16] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009480, R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alberts B., 2002, MOL BIOL CELL, P1065; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Chopra DP, 1997, CANCER RES, V57, P3688; Chopra DP, 1996, J CELL PHYSIOL, V169, P269, DOI 10.1002/(SICI)1097-4652(199611)169:2<269::AID-JCP6>3.0.CO;2-M; Christmas P, 1999, J BIOL CHEM, V274, P25594, DOI 10.1074/jbc.274.36.25594; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVANS WH, 1992, PREPARATIVE CENTRIFU, P233; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; Joshi B, 1999, CANCER RES, V59, P4343; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Kitamura S, 2001, INT J CANCER, V94, P335, DOI 10.1002/ijc.1470; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Li L, 1999, ANTICANCER RES, V19, P61; Liu JW, 2002, CANCER RES, V62, P2976; SCHEFFLER IE, 1999, MITOCHONDRIA, P26; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, NEOPLASIA, V3, P287, DOI 10.1038/sj.neo.7900166; Shappell SB, 2001, CANCER RES, V61, P497; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANG DG, 1993, EXP CELL RES, V207, P361, DOI 10.1006/excr.1993.1203; TANG DG, 1993, J CELL BIOL, V121, P689, DOI 10.1083/jcb.121.3.689; Tang DG, 1998, CANCER RES, V58, P3466; Tang KQ, 2000, BIOCHEMISTRY-US, V39, P3185, DOI 10.1021/bi992664v; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Timar J, 2000, INT J CANCER, V87, P37, DOI 10.1002/1097-0215(20000701)87:1<37::AID-IJC6>3.0.CO;2-L; UMBAS R, 1992, CANCER RES, V52, P5104; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001	44	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25091	25100		10.1074/jbc.M301920200	http://dx.doi.org/10.1074/jbc.M301920200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704195	hybrid			2022-12-25	WOS:000183824800103
J	Dagda, RK; Zaucha, JA; Wadzinski, BE; Strack, S				Dagda, RK; Zaucha, JA; Wadzinski, BE; Strack, S			A developmentally regulated, neuron-specific splice variant of the variable subunit B beta targets protein phosphatase 2A to mitochondria and modulates apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; CELL-DEATH; A-SUBUNIT; EXPRESSION; PP2A; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; HOLOENZYME; CLONING	Heterotrimeric protein phosphatase 2A (PP2A) is a major Ser/Thr phosphatase composed of catalytic, structural, and regulatory subunits. Here, we characterize Bbeta2, a novel splice variant of the neuronal Bbeta regulatory subunit with a unique N-terminal tail. Bbeta2 is expressed predominantly in forebrain areas, and PP2A holoenzymes containing Bbeta2 are about 10-fold less abundant than those containing the Bbeta1 ( previously Bbeta) isoform. Bbeta2 mRNA is dramatically induced postnatally and in response to neuronal differentiation of a hippocampal progenitor cell line. The divergent N terminus of Bbeta2 does not affect phosphatase activity but encodes a subcellular targeting signal. Bbeta2, but not Bbeta1 or an N-terminal truncation mutant, colocalizes with mitochondria in neuronal PC12 cells. Moreover, the Bbeta2 N-terminal tail is sufficient to target green fluorescent protein to this organelle. Inducible or transient expression of Bbeta2, but neither Bbeta1, Bgamma, nor a Bbeta2 mutant defective in holoenzyme formation, accelerates apoptosis in response to growth factor deprivation. Thus, alternative splicing of a mitochondrial localization signal generates a PP2A holoenzyme involved in neuronal survival signaling.	Univ Iowa, Dept Pharmacol, Carver Coll Med, Iowa City, IA 52242 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN USA	University of Iowa; Vanderbilt University	Strack, S (corresponding author), Univ Iowa, Dept Pharmacol, Carver Coll Med, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu		Strack, Stefan/0000-0002-6175-7280; Dagda, Ruben/0000-0002-9946-9591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051366, R56GM051366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043254] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51366] Funding Source: Medline; NINDS NIH HHS [NS43254] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Berger F, 1998, J NEUROSCI, V18, P6871; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HATANO Y, 1993, FEBS LETT, V324, P71, DOI 10.1016/0014-5793(93)81535-8; Hatch GM, 1998, INT J MOL MED, V1, P33; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McEwen BS, 2002, NEUROBIOL AGING, V23, P921, DOI 10.1016/S0197-4580(02)00027-1; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Schmidt K, 2002, EUR J NEUROSCI, V16, P2039, DOI 10.1046/j.1460-9568.2002.02274.x; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Srivastava AK, 2001, ANN NEUROL, V50, P796, DOI 10.1002/ana.10048; Strack S, 1999, FEBS LETT, V460, P462, DOI 10.1016/S0014-5793(99)01377-0; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Strack S, 1998, J COMP NEUROL, V392, P515; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Wang XD, 2001, GENE DEV, V15, P2922; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Zaucha JA, 1998, METH MOL B, V93, P279	48	60	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24976	24985		10.1074/jbc.M302832200	http://dx.doi.org/10.1074/jbc.M302832200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716901	hybrid			2022-12-25	WOS:000183824800089
J	Hori, H; Kubota, S; Watanabe, K; Kim, JM; Ogasawara, T; Sawasaki, T; Endo, Y				Hori, H; Kubota, S; Watanabe, K; Kim, JM; Ogasawara, T; Sawasaki, T; Endo, Y			Aquifex aeolicus tRNA (Gm18) methyltransferase has unique substrate specificity - tRNA recognition mechanism of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS HB27; YEAST SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GUANINE TRANSGLYCOSYLASE; ANTICODON LOOP; PSEUDOURIDINE SYNTHASE; EXTREME THERMOPHILE; CRYSTAL-STRUCTURE; MODIFICATION-DATABASE; BINDING PROTEIN	Transfer RNA (guanosine-2')-methyltransferase (Gm-methylase) catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to 2'-OH of G18 in the D-loop of tRNA. Based on their mode of tRNA recognition, Gm-methylases can be divided into the following two types: type I having broad specificity toward the substrate tRNA, and type II that methylates only limited tRNA species. Protein synthesized by in vitro cell-free translation revealed that Gm-methylase encoded in the Aquifex aeolicus genome is a novel type II enzyme. Experiments with chimeric tRNAs and mini- and micro-helix RNAs showed that the recognition region of this enzyme is included within the D-arm structure of tRNA(Leu) and that a bulge is essentially required. Variants of tRNA(Leu), tRNA(Ser), and tRNA(Phe) revealed that a combination of certain base pairs in the D-stem is strongly recognized by the enzyme, that 4 bp in the D-stem enhance methyl acceptance activity, and that the Py16Py17G18G19 sequence is important for efficient methyl transfer. The methyl acceptance activities of all the A. aeolicus tRNA genes, which can be classified into 14 categories on the basis of their D-arm structure, were tested. The results clearly showed that the substrate recognition mechanism elucidated by the variant experiments was applicable to their native substrates.	Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan	Ehime University	Hori, H (corresponding author), Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan.		Kim, Jong-Myong/C-8154-2017; Watanabe, Kazunori/G-6671-2012; Hori, Hiroyuki/AAB-3911-2021	Kim, Jong-Myong/0000-0003-0017-2577; Watanabe, Kazunori/0000-0003-3678-636X; Sawasaki, Tatsuya/0000-0002-7952-0556				Ansmant I, 2001, J BIOL CHEM, V276, P34934, DOI 10.1074/jbc.M103131200; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Benne R., 1998, MODIFICATION EDITING, P543; Bjork Glenn R., 1995, P165; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P353; CARBON P, 1983, EMBO J, V2, P1093, DOI 10.1002/j.1460-2075.1983.tb01551.x; Cavaille J, 1999, RNA, V5, P66, DOI 10.1017/S1355838299981475; Constantinesco F, 1999, J MOL BIOL, V291, P375, DOI 10.1006/jmbi.1999.2976; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dirheimer G., 1995, P93; DROOGMANS L, 1986, EMBO J, V5, P1105, DOI 10.1002/j.1460-2075.1986.tb04329.x; EDQVIST J, 1993, NUCLEIC ACIDS RES, V21, P413, DOI 10.1093/nar/21.3.413; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; Foster PG, 2000, NAT STRUCT BIOL, V7, P23; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GU XG, 1994, BIOCHEMISTRY-US, V33, P2255, DOI 10.1021/bi00174a036; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; Hori H, 2002, GENES CELLS, V7, P259, DOI 10.1046/j.1365-2443.2002.00520.x; Hori H, 1998, J BIOL CHEM, V273, P25721, DOI 10.1074/jbc.273.40.25721; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; Ishitani R, 2002, J MOL BIOL, V318, P665, DOI 10.1016/S0022-2836(02)00090-6; KAWAI G, 1992, BIOCHEMISTRY-US, V31, P1040, DOI 10.1021/bi00119a012; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; Kung FL, 2000, RNA, V6, P233, DOI 10.1017/S135583820099191X; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; Li JN, 1999, RNA, V5, P395, DOI 10.1017/S1355838299980834; Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559; MARECHALDROUARD L, 1990, FEBS LETT, V262, P170, DOI 10.1016/0014-5793(90)80181-H; MATSUMOTO T, 1990, J BIOCHEM-TOKYO, V107, P331, DOI 10.1093/oxfordjournals.jbchem.a123047; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; MURAMATSU T, 1988, J BIOL CHEM, V263, P9261; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; Persson BC, 1997, NUCLEIC ACIDS RES, V25, P4093, DOI 10.1093/nar/25.20.4093; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; Redlak M, 1997, BIOCHEMISTRY-US, V36, P8699, DOI 10.1021/bi9701538; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Soderberg T, 2000, BIOCHEMISTRY-US, V39, P6546, DOI 10.1021/bi992775u; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Swairjo MA, 2000, EMBO J, V19, P6287, DOI 10.1093/emboj/19.23.6287; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200	55	32	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25081	25090		10.1074/jbc.M212577200	http://dx.doi.org/10.1074/jbc.M212577200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704200	hybrid			2022-12-25	WOS:000183824800102
J	Marti, M; Regos, A; Li, YJ; Schraner, EM; Wild, P; Muller, N; Knopf, LG; Hehl, AB				Marti, M; Regos, A; Li, YJ; Schraner, EM; Wild, P; Muller, N; Knopf, LG; Hehl, AB			An ancestral secretory apparatus in the protozoan parasite Giardia intestinalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL PROTEIN; PRIMITIVE EUKARYOTE; SACCHAROMYCES-CEREVISIAE; TRYPANOSOMA-BRUCEI; TRICHOMONAS-VAGINALIS; ENDOPLASMIC-RETICULUM; BINDING PROTEINS; GOLGI STRUCTURE; LAMBLIA; COMPLEX	The protozoan parasite Giardia intestinalis belongs to one of the earliest diverged eukaryotic lineages. This is also reflected in a simple intracellular organization, as Giardia lacks common subcellular compartments such as mitochondria, peroxisomes, and apparently also a Golgi apparatus. During encystation, developmentally regulated formation of large secretory compartments containing cyst wall material occurs. Despite the lack of any morphological similarities, these encystation-specific vesicles (ESVs) show several biochemical characteristics of maturing Golgi cisternae. Previous studies suggested that Golgi structure and function are induced only during encystation in Giardia, giving rise to the hypothesis that ESVs, as a Giardia Golgi equivalent, are generated de novo. Alternatively, ESV compartments could be built on the template structure of a cryptic Golgi in trophozoites in response to ER export of cyst wall material during encystation. We addressed this question by defining the molecular framework of the Giardia secretory apparatus using a comparative genomic approach. Analysis of the corresponding transcriptome during growth and encystation revealed surprisingly little stage-specific regulation. A panel of antibodies was generated against selected marker proteins to investigate the developmental dynamics of the endomembrane system. We show evidence that Giardia accommodates the export of large amounts of cyst wall material through re-organization of membrane compartment(s) in trophozoites with biochemical similarities to ESVs. This suggests that ESVs are selectively stabilized Golgi-like compartments in a unique and archetypical secretory system, which arise from a structural template in trophozoites rather than being generated de novo.	Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland; Univ Zurich, Electron Microscopy Unit, Inst Vet Anat, CH-8057 Zurich, Switzerland; Univ Zurich, Electron Microscopy Unit, Inst Virol, CH-8057 Zurich, Switzerland; Univ Bern, Inst Parasitol, CH-3012 Bern, Switzerland	University of Zurich; University of Zurich; University of Zurich; University of Bern	Hehl, AB (corresponding author), Univ Zurich, Inst Parasitol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.	ahehl@vetparas.unizh.ch		Knopf, Lea/0000-0001-5927-5285; Hehl, Adrian/0000-0002-2110-4445				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; Benchimol M, 2001, EUR J CELL BIOL, V80, P593, DOI 10.1078/0171-9335-00191; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; BONIFACINO JS, 2001, CURRENT PROTOCOLS CE; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; BRUGEROLLE G, 1980, Z PARASITENKD, V62, P47, DOI 10.1007/BF00925366; BRUGEROLLE G, 1974, Protistologica, V10, P83; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Dacks JB, 2001, CELL, V107, P419, DOI 10.1016/S0092-8674(01)00584-0; Das S, 1996, EXP PARASITOL, V83, P19, DOI 10.1006/expr.1996.0045; EYDEN BP, 1975, J PROTOZOOL, V22, P54, DOI 10.1111/j.1550-7408.1975.tb00944.x; Hashimoto T, 1998, P NATL ACAD SCI USA, V95, P6860, DOI 10.1073/pnas.95.12.6860; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; Horner DS, 2001, MOL BIOL EVOL, V18, P1970, DOI 10.1093/oxfordjournals.molbev.a003737; Jeffries TR, 2002, MOL BIOCHEM PARASIT, V121, P63, DOI 10.1016/S0166-6851(02)00023-3; Jeffries TR, 2001, J CELL SCI, V114, P2617; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; Lanfredi-Rangel A, 1998, J STRUCT BIOL, V123, P225, DOI 10.1006/jsbi.1998.4035; Lanfredi-Rangel A, 1999, FEMS MICROBIOL LETT, V181, P245, DOI [10.1016/S0378-1097(99)00546-7, 10.1111/j.1574-6968.1999.tb08851.x]; Langford TD, 2002, EXP PARASITOL, V101, P13, DOI 10.1016/S0014-4894(02)00037-1; LEE FJS, 1992, J BIOL CHEM, V267, P24441; LEIPE DD, 1993, MOL BIOCHEM PARASIT, V59, P41, DOI 10.1016/0166-6851(93)90005-I; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; Marti M, 2002, INFECT IMMUN, V70, P1014, DOI 10.1128/IAI.70.2.1014-1016.2002; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P220, DOI 10.1006/expr.1994.1086; MCCAFFERY JM, 1994, EXP PARASITOL, V79, P236, DOI 10.1006/expr.1994.1087; Morgado-Diaz JA, 2001, PARASITOLOGY, V123, P33, DOI 10.1017/S0031182001007946; Morgan GW, 2001, J CELL SCI, V114, P2605; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; REINER DS, 1990, EUR J CELL BIOL, V53, P142; Roger AJ, 1998, P NATL ACAD SCI USA, V95, P229, DOI 10.1073/pnas.95.1.229; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Schledzewski K, 1999, J MOL EVOL, V48, P770, DOI 10.1007/PL00006521; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Tellam JT, 1997, J BIOL CHEM, V272, P6187, DOI 10.1074/jbc.272.10.6187; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Ungar D, 2002, J CELL BIOL, V157, P405, DOI 10.1083/jcb.200202016; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; Whyte JRC, 2002, J CELL SCI, V115, P2627; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wild P, 2001, MICROSC RES TECHNIQ, V53, P313, DOI 10.1002/jemt.1098; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	54	89	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24837	24848		10.1074/jbc.M302082200	http://dx.doi.org/10.1074/jbc.M302082200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12711599	hybrid			2022-12-25	WOS:000183824800072
J	Friedler, A; Veprintsev, DB; Hansson, LO; Fersht, AR				Friedler, A; Veprintsev, DB; Hansson, LO; Fersht, AR			Kinetic instability of p53 core domain mutants - Implications for rescue by small molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; CANCER; MUTATIONS; PATHWAY	Oncogenic mutations in the tumor suppressor protein p53 are found mainly in its DNA-binding core domain. Many of these mutants are thermodynamically unstable at body temperature. Here we show that these mutants also denature within minutes at 37 degreesC. The half-life (t(1/2)) of the unfolding of wild-type p53 core domain was 9 min. Hot spot mutants denatured more rapidly with increasing thermodynamic instability. The highly destabilized mutant I195T had a t(1/2) of less than 1 min. The wild-type p53-(94-360) construct, containing the core and tetramerization domains, was more stable, with t(1/2) = 37 min at 37 degreesC, similar to full-length p53. After unfolding, the denatured proteins aggregated, the rate increasing with higher concentrations of protein. A derivative of the p53-stabilizing peptide CDB3 significantly slowed down the unfolding rate of the p53 core domain. Drugs such as CDB3, which rescue the conformation of unstable mutants of p53, have to act during or immediately after biosynthesis. They should maintain the mutant protein in a folded conformation and prevent its aggregation, allowing it enough time to reach the nucleus and bind its sequence-specific target DNA or the p53 binding proteins that will stabilize it.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; Cambridge Ctr Prot Engn, MRC Ctr, Cambridge CB2 2QH, England	University of Cambridge; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hills Rd, Cambridge CB2 2QH, England.		Veprintsev, Dmitry B/H-2228-2012; Fersht, Alan R/B-2189-2008	Veprintsev, Dmitry B/0000-0002-3583-5409; , Lars Olof/0000-0002-4413-628X				Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; PARKER TG, 1977, BIOPOLYMERS, V16, P2533, DOI 10.1002/bip.1977.360161115; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7	16	110	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24108	24112		10.1074/jbc.M302458200	http://dx.doi.org/10.1074/jbc.M302458200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700230	hybrid			2022-12-25	WOS:000183638600115
J	Steen, A; Buist, G; Leenhouts, KJ; El Khattabi, M; Grijpstra, F; Zomer, AL; Venema, G; Kuipers, OP; Kok, J				Steen, A; Buist, G; Leenhouts, KJ; El Khattabi, M; Grijpstra, F; Zomer, AL; Venema, G; Kuipers, OP; Kok, J			Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIS SUBSP LACTIS; BACILLUS-SUBTILIS; LACTOCOCCUS-LACTIS; STREPTOCOCCUS-CREMORIS; ESCHERICHIA-COLI; GENE-EXPRESSION; MODULAR DESIGN; PROTEIN; HYDROLASE; CLONING	The C-terminal region (cA) of the major autolysin AcmA of Lactococcus lactis contains three highly similar repeated regions of 45 amino acid residues (LysM domains), which are separated by nonhomologous sequences. The cA domain could be deleted without destroying the cell wall-hydrolyzing activity of the enzyme in vitro. This AcmA derivative was capable neither of binding to lactococcal cells nor of lysing these cells while separation of the producer cells was incomplete. The cA domain and a chimeric protein consisting of cA fused to the C terminus of MSA2, a malaria parasite surface antigen, bound to lactococcal cells specifically via cA. The fusion protein also bound to many other Gram-positive bacteria. By chemical treatment of purified cell walls of L. lactis and Bacillus subtilis, peptidoglycan was identified as the cell wall component interacting with cA. Immunofluorescence studies showed that binding is on specific locations on the surface of L. lactis, Enterococcus faecalis, Streptococcus thermophilus, B. subtilis, Lactobacillus sake, and Lactobacillus casei cells. Based on these studies, we propose that LysM-type repeats bind to peptidoglycan and that binding is hindered by other cell wall constituents, resulting in localized binding of AcmA. Lipoteichoic acid is a candidate hindering component. For L. lactis SK110, it is shown that lipoteichoic acids are not uniformly distributed over the cell surface and are mainly present at sites where no MSA2cA binding is observed.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; BioMaDe Technol Fdn, NL-9747 AG Groningen, Netherlands	University of Groningen	Buist, G (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	g.buist@biol.rug.nl	Kok, Jan/C-9972-2012; Zomer, Aldert/B-3172-2010; Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735; Zomer, Aldert/0000-0002-0758-5190				Baba T, 1998, EMBO J, V17, P4639, DOI 10.1093/emboj/17.16.4639; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; BELIVEAU C, 1991, J BACTERIOL, V173, P5619, DOI 10.1128/jb.173.18.5619-5623.1991; BIRKELAND NK, 1994, CAN J MICROBIOL, V40, P658, DOI 10.1139/m94-104; Buist G, 1997, APPL ENVIRON MICROB, V63, P2722, DOI 10.1128/AEM.63.7.2722-2728.1997; BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; Buist G, 1998, J BACTERIOL, V180, P5947, DOI 10.1128/JB.180.22.5947-5953.1998; BUIST G, 1997, THESIS U GRONINGEN G; Cibik R, 2001, APPL ENVIRON MICROB, V67, P858, DOI 10.1128/AEM.67.2.858-864.2001; DE MAN J. C., 1960, JOUR APPL BACT, V23, P130, DOI 10.1111/j.1365-2672.1960.tb00188.x; DIAZ E, 1991, J BIOL CHEM, V266, P5464; GASSON MJ, 1983, J BACTERIOL, V154, P1; Gopal PK, 1995, INT DAIRY J, V5, P1095, DOI 10.1016/0958-6946(95)00046-1; HOURDOU ML, 1993, BIOCHEM J, V292, P563, DOI 10.1042/bj2920563; Husson-Kao C, 2000, FEMS MICROBIOL LETT, V187, P69, DOI 10.1111/j.1574-6968.2000.tb09139.x; Ishikawa S, 1998, J BACTERIOL, V180, P2549, DOI 10.1128/JB.180.9.2549-2555.1998; JORIS B, 1992, FEMS MICROBIOL LETT, V91, P257; KARIYAMA R, 1992, J BACTERIOL, V174, P3236, DOI 10.1128/jb.174.10.3236-3241.1992; KNOWLES J, 1987, TRENDS BIOTECHNOL, V5, P255, DOI 10.1016/0167-7799(87)90102-8; Kodama T, 1999, J BACTERIOL, V181, P4584, DOI 10.1128/JB.181.15.4584-4591.1999; Kodama T, 2000, J BIOCHEM, V128, P655, DOI 10.1093/oxfordjournals.jbchem.a022798; KOK J, 1991, GENETICS AND MOLECULAR BIOLOGY OF STREPTOCOCCI, LACTOCOCCI, AND ENTEROCOCCI, P97; KOK J, 1985, APPL ENVIRON MICROB, V50, P94, DOI 10.1128/AEM.50.1.94-101.1985; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Leenhouts K., 1992, Mededelingen van de Faculteit Landbouwwetenschappen Universiteit Gent, V57, P2031; LONGCHAMP PF, 1994, MICROBIOL-UK, V140, P1855, DOI 10.1099/13500872-140-8-1855; Margot P, 1998, J BACTERIOL, V180, P749, DOI 10.1128/JB.180.3.749-752.1998; Margot P, 1999, MICROBIOL-SGM, V145, P57, DOI 10.1099/13500872-145-1-57; MOU L, 1976, J DAIRY RES, V43, P275, DOI 10.1017/S0022029900015831; Ohnishi R, 1999, J BACTERIOL, V181, P3178, DOI 10.1128/JB.181.10.3178-3184.1999; Ozin AJ, 2000, J BACTERIOL, V182, P1828, DOI 10.1128/JB.182.7.1828-1833.2000; Poquet I, 2000, MOL MICROBIOL, V35, P1042, DOI 10.1046/j.1365-2958.2000.01757.x; Ramasamy R, 1999, PARASITE IMMUNOL, V21, P397, DOI 10.1046/j.1365-3024.1999.00239.x; RUHLAND GJ, 1993, J GEN MICROBIOL, V139, P609, DOI 10.1099/00221287-139-3-609; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAUVE DM, 1995, ANAL BIOCHEM, V226, P382, DOI 10.1006/abio.1995.1242; SCHAFER A, 1991, FEMS MICROBIOL LETT, V78, P69, DOI [10.1016/S0378-1097(99)00347-X, 10.1016/0378-1097(91)90257-B]; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SEEGERS JFML, 1994, MICROBIOL-UK, V140, P1291, DOI 10.1099/00221287-140-6-1291; SIJTSMA L, 1990, J BACTERIOL, V172, P7126, DOI 10.1128/jb.172.12.7126-7130.1990; Smit E, 2001, J MOL BIOL, V305, P245, DOI 10.1006/jmbi.2000.4258; Towbin H, 1992, Biotechnology, V24, P145; VANASSELDONK M, 1990, GENE, V95, P155, DOI 10.1016/0378-1119(90)90428-T; VANDEGUCHTE M, 1990, APPL ENVIRON MICROB, V56, P2606, DOI 10.1128/AEM.56.9.2606-2611.1990; Ventura M, 2000, FEMS MICROBIOL LETT, V189, P275, DOI 10.1111/j.1574-6968.2000.tb09243.x; ZABAROVSKY ER, 1990, NUCLEIC ACIDS RES, V18, P5912	48	181	198	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23874	23881		10.1074/jbc.M211055200	http://dx.doi.org/10.1074/jbc.M211055200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684515	Green Published, hybrid			2022-12-25	WOS:000183638600084
J	Zheng, YL; Li, BS; Veeranna; Pant, HC				Zheng, YL; Li, BS; Veeranna; Pant, HC			Phosphorylation of the head domain of neurofilament protein (NF-M) - A factor regulating topographic phosphorylation of NF-M tail domain KSP sites in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; C-TERMINAL PHOSPHORYLATION; UNDERGO AXONAL-TRANSPORT; INTERMEDIATE-FILAMENTS; PKA PHOSPHORYLATION; CDC2-LIKE KINASE; SUBUNIT; INHIBITION; GROWTH; DIFFERENTIATION	In neurons the phosphorylation of neurofilament (NF) proteins NF-M and NF-H is topographically regulated. Although kinases and NF subunits are synthesized in cell bodies, extensive phosphorylation of the KSP repeats in tail domains of NF-M and NF-H occurs primarily in axons. The nature of this regulation, however, is not understood. As obligate heteropolymers, NF assembly requires interactions between the core NF-L with NF-M or NF-H subunits, a process inhibited by NF head domain phosphorylation. Phosphorylation of head domains at protein kinase A (PKA)-specific sites seems to occur transiently in cell bodies after NF subunit synthesis. We have proposed that transient phosphorylation of head domains prevents NF assembly in the soma and inhibits tail domain phosphorylation; i.e. assembly and KSP phosphorylation in axons depends on prior dephosphorylation of head domain sites. Deregulation of this process leads to pathological accumulations of phosphorylated NFs in the soma as seen in some neurodegenerative disorders. To test this hypothesis, we studied the effect of PKA phosphorylation of the NF-M head domain on phosphorylation of tail domain KSP sites. In rat cortical neurons we showed that head domain phosphorylation of endogenous NF-M by forskolin-activated PKA inhibits NF-M tail domain phosphorylation. To demonstrate the site specificity of PKA phosphorylation and its effect on tail domain phosphorylation, we transfected NIH3T3 cells with NF-M mutated at PKA-specific head domain serine residues. Epidermal growth factor stimulation of cells with mutant NF-M in the presence of forskolin exhibited no inhibition of NF-tail domain phosphorylation compared with the wild type NF-M-transfected cells. This is consistent with our hypothesis that transient phosphorylation of NF-M head domains inhibits tail domain phosphorylation and suggests this as one of several mechanisms underlying topographic regulation.	NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Pant, HC (corresponding author), NINDS, Neurochem Lab, NIH, Bldg 36,Rm 4D04,9000 Rockville Pike, Bethesda, MD 20892 USA.	panth@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002725, Z01NS002725] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Ching GY, 1999, J CELL SCI, V112, P2233; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Cleverley KE, 1998, BIOCHEMISTRY-US, V37, P3917, DOI 10.1021/bi9724523; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DOSEMECI A, 1992, BIOCHEM J, V282, P477, DOI 10.1042/bj2820477; FLOYD CC, 1991, J BIOL CHEM, V266, P4987; Gibb BJM, 1998, J NEUROCHEM, V70, P492; Grant P, 1999, J NEUROBIOL, V40, P89, DOI 10.1002/(SICI)1097-4695(199907)40:1<89::AID-NEU8>3.0.CO;2-R; Grant P, 2000, J NEUROCYTOL, V29, P843, DOI 10.1023/A:1010999509251; Guidato S, 1996, NEUROSCI LETT, V217, P157, DOI 10.1016/0304-3940(96)13098-6; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HISANAGA S, 1994, MOL BIOL CELL, V5, P161, DOI 10.1091/mbc.5.2.161; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Jung C, 2000, CELL MOTIL CYTOSKEL, V47, P120, DOI 10.1002/1097-0169(200010)47:2<120::AID-CM3>3.0.CO;2-6; Jung C, 2000, BRAIN RES, V856, P12, DOI 10.1016/S0006-8993(99)02314-8; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; Li BS, 1999, EUR J BIOCHEM, V262, P211, DOI 10.1046/j.1432-1327.1999.00372.x; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; MANETTO V, 1988, J NEUROPATH EXP NEUR, V47, P642, DOI 10.1097/00005072-198811000-00007; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; Nakamura Y, 2000, J NEUROCHEM, V74, P949, DOI 10.1046/j.1471-4159.2000.0740949.x; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Rao MV, 2002, J CELL BIOL, V158, P681, DOI 10.1083/jcb.200202037; Rao MV, 1998, J CELL BIOL, V143, P171, DOI 10.1083/jcb.143.1.171; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; Shea TB, 2000, J NEUROCYTOL, V29, P873, DOI 10.1023/A:1010951626090; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Sidovar MF, 2000, J BIOL CHEM, V275, P28688, DOI 10.1074/jbc.M909351199; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1991, J BIOL CHEM, V266, P18861; Sihag RK, 1999, J NEUROCHEM, V72, P491, DOI 10.1046/j.1471-4159.1999.0720491.x; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SOBUE G, 1990, ACTA NEUROPATHOL, V79, P402, DOI 10.1007/BF00308716; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Svensson B, 1998, J NEUROSCI RES, V52, P453, DOI 10.1002/(SICI)1097-4547(19980515)52:4<453::AID-JNR9>3.0.CO;2-8; TAKAHASHI M, 1995, J NEUROSCI, V15, P6222; Veeranna, 1998, J NEUROSCI, V18, P4008; Veeranna, 1996, NEUROCHEM RES, V21, P629, DOI 10.1007/BF02527763; Veeranna GJ, 2000, MOL BRAIN RES, V76, P229, DOI 10.1016/S0169-328X(00)00003-6; Weisenhorn DMV, 2001, EXP NEUROL, V169, P44, DOI 10.1006/exnr.2001.7651; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yabe JT, 2001, J NEUROSCI, V21, P2195; Yabe JT, 2001, CELL MOTIL CYTOSKEL, V48, P61, DOI 10.1002/1097-0169(200101)48:1<61::AID-CM6>3.0.CO;2-S; Yin XH, 1998, J NEUROSCI, V18, P1953, DOI 10.1523/jneurosci.18-06-01953.1998; Zheng YL, 2002, EUR J BIOCHEM, V269, P4427, DOI 10.1046/j.1432-1033.2002.03133.x	59	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24026	24032		10.1074/jbc.M303079200	http://dx.doi.org/10.1074/jbc.M303079200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695506	hybrid			2022-12-25	WOS:000183638600104
J	Avila, G; Lee, EH; Perez, CF; Allen, PD; Dirksen, RT				Avila, G; Lee, EH; Perez, CF; Allen, PD; Dirksen, RT			FKBP12 binding to RyR1 modulates excitation-contraction coupling in mouse skeletal myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR FUNCTION; II-III LOOP; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; DEFECTIVE REGULATION; MUSCLE FIBERS; PROTEIN; FK506; RAPAMYCIN	The skeletal muscle sarcoplasmic reticulum (SR) Ca2+ release channel or ryanodine receptor (RyR1) binds four molecules of FKBP12, and the interaction of FKBP12 with RyR1 regulates both unitary and coupled gating of the channel. We have characterized the physiologic effects of previously identified mutations in RyR1 that disrupt FKBP12 binding (V2461G and V2461I) on excitation-contraction (EC) coupling and intracellular Ca2+ homeostasis following their expression in skeletal myotubes derived from RyR1-knockout (dyspedic) mice. Wild-type RyR1-, V246I-, and V2461G-expressing myotubes exhibited similar resting Ca2+ levels and maximal responses to caffeine (10 mM) and cyclopiazonic acid (30 muM). However, maximal voltage-gated Ca2+ release in V2461G-expressing myotubes was reduced by similar to50% compared with that attributable to wild-type RyR1 (DeltaF/F-max = 1.6 +/- 0.2 and 3.1 +/- 0.4, respectively). Dyspedic myotubes expressing the V2461I mutant protein, that binds FKBP12.6 but not FKBP12, exhibited a comparable reduction in voltage- gated SR Ca2+ release (DeltaF/F-max = 1.0 +/- 0.1). However, voltage- gated Ca2+ release in V2461I-expressing myotubes was restored to a normal level (DeltaF/F-max = 2.9 +/- 0.6) following co-expression of FKBP12.6. None of the mutations that disrupted FKBP binding to RyR1 significantly affected RyR1- mediated enhancement of L-type Ca2+ channel activity (retrograde coupling). These data demonstrate that FKBP12 binding to RyR1 enhances the gain of skeletal muscle EC coupling.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Inst Politecn Nacl, CINVESTAV, Dept Biochem, Mexico City 07000, DF, Mexico; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesia Pain & Perioperat Med, Boston, MA 02115 USA	University of Rochester; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Gwangju Institute of Science & Technology (GIST); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dirksen, RT (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	RobertDirksen@URMC.rochester.edu	Avila, Guillermo/B-5782-2013	Avila, Guillermo/0000-0001-7615-8945; Lee, Eun Hui/0000-0003-4555-1730	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044657, R01AR044657, P01AR044750] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44750, AR44657] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahern CA, 2001, P NATL ACAD SCI USA, V98, P6935, DOI 10.1073/pnas.111001898; Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Avila G, 2001, P NATL ACAD SCI USA, V98, P4215, DOI 10.1073/pnas.071048198; Avila G, 2001, J GEN PHYSIOL, V118, P277, DOI 10.1085/jgp.118.3.277; Avila G, 2001, J BIOL CHEM, V276, P17732, DOI 10.1074/jbc.M009685200; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; Dirksen RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD659, DOI 10.2741/dirksen; duBell WH, 1997, J PHYSIOL-LONDON, V501, P509, DOI 10.1111/j.1469-7793.1997.509bm.x; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; Estrada M, 2001, J BIOL CHEM, V276, P22868, DOI 10.1074/jbc.M100118200; Fessenden JD, 2000, BIOPHYS J, V79, P2509, DOI 10.1016/S0006-3495(00)76492-7; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Gaburjakova M, 2001, J BIOL CHEM, V276, P16931, DOI 10.1074/jbc.M100856200; HARKINS AB, 1993, BIOPHYS J, V65, P865, DOI 10.1016/S0006-3495(93)81112-3; HIDALGO C, 1993, J BIOL CHEM, V268, P15111; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Masumiya H, 2003, J BIOL CHEM, V278, P3786, DOI 10.1074/jbc.M210962200; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; ONEILL SC, 1990, J PHYSIOL-LONDON, V425, P55, DOI 10.1113/jphysiol.1990.sp018092; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; Zissimopoulos S, 2002, BIOPHYS J, V82, p59A	39	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22600	22608		10.1074/jbc.M205866200	http://dx.doi.org/10.1074/jbc.M205866200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12704193	hybrid			2022-12-25	WOS:000183503900058
J	Yeo, SJ; Gravis, D; Yoon, JG; Yi, AK				Yeo, SJ; Gravis, D; Yoon, JG; Yi, AK			Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA - Role of NF-kappa B and p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE-2 GENE; RECEPTOR-ASSOCIATED KINASE; ELEMENT-BINDING PROTEIN; VASCULAR ENDOTHELIAL-CELLS; CAMP-RESPONSE ELEMENT; TOLL-LIKE RECEPTORS; BACTERIAL-DNA; C/EBP-BETA; REACTIVE ARTHRITIS; DENDRITIC CELLS	CpG DNA induces macrophage cyclooxgenase- 2 ( Cox- 2) production. In this study, we have investigated a biochemical signaling pathway and transcription factors responsible for transcriptional regulation of the Cox- 2 gene expression induced by CpG DNA. CpG DNAinduced Cox- 2 promoter activity was completely inhibited by an endosomal acidification inhibitor ( chloroquine), a TLR9 antagonist inhibitory CpG DNA, or overexpression of a dominant negative ( DN) form of MyD88. In contrast, overexpression of DN- IRAK1 or DN-TRAF6 only partially inhibited CpG DNA- induced Cox- 2 promoter activity and NF-kappaB activation, indicating the presence of additional signaling modulators downstream of MyD88. CpG DNA- induced Cox- 2 promoter activity was substantially suppressed in cells overexpressing super- suppressive IkappaB (IkappaB- arachidonic acid), DN-p38, or DN- CREB. In addition, Cox- 2 promoter- luciferase reporters with alterations in predicted cis- acting transcriptional regulatory elements revealed that C/ EBP, Ets- 1, NF-kappaB, and CREB- binding sites are essential for optimal Cox- 2 expression in response to CpG DNA. Conclusively, these results demonstrate that endosomal DNA processing and TLR9/ MyD88- dependent activation of NF-kappaB and p38 are required for transcriptional regulation of Cox- 2 expression induced by CpG DNA, and suggest that interleukin- 1 receptor- associated kinase and/ or TRAF6 may be a diverging point for NF-kappaB activation in response to CpG DNA in RAW264.7 cells.	Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr,Dept Pediat, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Yi, AK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Le Bonheur Childrens Med Ctr, Childrens Fdn Res Ctr,Dept Pediat, 50 N Dunlap St,WPT 315, Memphis, TN 38103 USA.	ayi@utmem.edu			NIAMS NIH HHS [1R03AR47757] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR047757] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; BAS S, 1995, ARTHRITIS RHEUM, V38, P1005, DOI 10.1002/art.1780380718; Berg DJ, 2001, J IMMUNOL, V166, P2674, DOI 10.4049/jimmunol.166.4.2674; Billack B, 2002, AM J PHYSIOL-CELL PH, V283, pC1267, DOI 10.1152/ajpcell.00609.2001; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cernanec J, 2002, ARTHRITIS RHEUM-US, V46, P968, DOI 10.1002/art.10213; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Cieslik K, 2002, J BIOL CHEM, V277, P49304, DOI 10.1074/jbc.M205030200; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Cowdery J, 1996, J IMMUNOL, V156, P4570; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Ghosh DK, 2001, INFECT IMMUN, V69, P7703, DOI 10.1128/IAI.69.12.7703-7710.2001; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; Granfors K, 1998, ARTHRITIS RHEUM, V41, P855, DOI 10.1002/1529-0131(199805)41:5<855::AID-ART12>3.0.CO;2-J; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jakob T, 1998, J IMMUNOL, V161, P3042; Janelle ME, 2002, J BIOL CHEM, V277, P30665, DOI 10.1074/jbc.M203041200; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kojima F, 2002, J RHEUMATOL, V29, P1836; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lenert P, 2001, ANTISENSE NUCLEIC A, V11, P247, DOI 10.1089/108729001317022241; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lin CH, 2001, BRIT J PHARMACOL, V134, P543, DOI 10.1038/sj.bjp.0704290; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Naraba H, 1998, J IMMUNOL, V160, P2974; Ogasawara A, 2001, J BIOL CHEM, V276, P7048, DOI 10.1074/jbc.M008070200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schroer K, 2002, CIRCULATION, V105, P2760, DOI 10.1161/01.CIR.0000018127.10968.34; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stunz LL, 2002, EUR J IMMUNOL, V32, P1212, DOI 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D; Subbaramaiah K, 2002, CANCER RES, V62, P2522; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeshita S, 2000, CELL IMMUNOL, V206, P101, DOI 10.1006/cimm.2000.1735; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Thomas JA, 1999, J IMMUNOL, V163, P978; van der Heijden IM, 2000, ARTHRITIS RHEUM-US, V43, P593, DOI 10.1002/1529-0131(200003)43:3<593::AID-ANR16>3.0.CO;2-1; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wardlaw SA, 2002, MOL PHARMACOL, V62, P326, DOI 10.1124/mol.62.2.326; Warren T L, 2000, Clin Lymphoma, V1, P57, DOI 10.3816/CLM.2000.n.005; Warren TL, 2000, J IMMUNOL, V165, P6244, DOI 10.4049/jimmunol.165.11.6244; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wilbrink B, 1998, ARTHRITIS RHEUM-US, V41, P535, DOI 10.1002/1529-0131(199803)41:3<535::AID-ART20>3.0.CO;2-4; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	75	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22563	22573		10.1074/jbc.M302076200	http://dx.doi.org/10.1074/jbc.M302076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12695520	hybrid			2022-12-25	WOS:000183503900053
J	Glassford, J; Soeiro, I; Skarell, SM; Banerji, L; Holman, M; Klaus, GGB; Kadowaki, T; Koyasu, S; Lam, EWF				Glassford, J; Soeiro, I; Skarell, SM; Banerji, L; Holman, M; Klaus, GGB; Kadowaki, T; Koyasu, S; Lam, EWF			BCR targets cyclin D2 via Btk and the p85 alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells	ONCOGENE			English	Article						BCR; Btk; p85 alpha; cyclin D2; PKC beta; Ca2+ flux; cell cycle	BRUTONS-TYROSINE-KINASE; XID-LIKE IMMUNODEFICIENCY; FACTOR-KAPPA-B; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-2; T-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED PROLIFERATION; ADAPTER PROTEIN; ACTIVATION	The p85alpha subunit of PI3-K and Btk are two crucial components of the B-cell receptor (BCR) signalling pathway. In the present study, we showed that primary splenic B cells from p85alpha null and xid (Btk-deficient) mice fail to induce cyclin D2 expression and enter early G1, but not S phase of the cell cycle in response to BCR engagement. Furthermore, these Btk or p85alpha null B cells displayed increased cell death compared with wild type following BCR engagement. These findings are further confirmed by studies showing that specific pharmacological inhibitors of Btk (LFM-A13), PI3-K (LY294002 and Wortmannin) and PLCgamma (U73122) also block cyclin D2 expression and S phase entry following BCR stimulation, as well as triggering apoptosis. Collectively, these data provide evidence for the concept that the B-cell signalosome (p85alpha, Btk, BLNK and PLCgamma) is involved in regulating cyclin D2 expression in response to BCR engagement. PKC and intracellular calcium are two major downstream effectors of the B-cell signalosome and can be activated by PMA and ionomycin, respectively. In small resting (GO) B cells, costimulation with PMA and ionomycin, but not PMA or ionomycin alone, induces cyclin D2 expression and cell-cycle progression. Consistent with this, we also showed that the BCR-mediated cyclin D2 induction could be abolished by pretreatment of resting B cells with specific inhibitors of capacitative Ca2+ entry (SK&F 96365) or PKC (Go6850). Our present results lead us to propose a model in which the B-cell signalosome targets cyclin D2 via the Ca2+ and PKC-dependent signalling cascades to mediate cell-cycle progression in response to BCR engagement.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Canc Re UK Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Sect Canc Cell Biol,Dept Canc Med, London W12 0NN, England; Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Imperial College London; Imperial College London; MRC National Institute for Medical Research; University of Tokyo; Keio University; Japan Science & Technology Agency (JST)	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Canc Re UK Labs, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Lam, Eric W-F/AAW-8566-2020; Koyasu, Shigeo/J-5583-2015	Lam, Eric W-F/0000-0003-1274-3576; Koyasu, Shigeo/0000-0001-9585-3038				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Brorson K, 1997, J IMMUNOL, V159, P135; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cariappa A, 2002, CURR OPIN IMMUNOL, V14, P241, DOI 10.1016/S0952-7915(02)00328-X; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fu C, 1997, J BIOL CHEM, V272, P27362, DOI 10.1074/jbc.272.43.27362; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gulbranson-Judge A, 1999, EUR J IMMUNOL, V29, P477, DOI 10.1002/(SICI)1521-4141(199902)29:02&lt;477::AID-IMMU477&gt;3.0.CO;2-V; HAHNER L, 1991, FASEB J, V5, P2466, DOI 10.1096/fasebj.5.10.1648524; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Johnson-Leger C, 1998, J IMMUNOL, V161, P4618; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King LB, 1999, J IMMUNOL, V162, P2655; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; Klaus GGB, 1997, EUR J IMMUNOL, V27, P2749, DOI 10.1002/eji.1830271102; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lam EWF, 1999, EUR J IMMUNOL, V29, P3380, DOI 10.1002/(SICI)1521-4141(199910)29:10<3380::AID-IMMU3380>3.0.CO;2-C; Lam EWF, 1998, J BIOL CHEM, V273, P10051, DOI 10.1074/jbc.273.16.10051; Lam EWF, 2000, J BIOL CHEM, V275, P3479, DOI 10.1074/jbc.275.5.3479; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Mahajan S, 1999, J BIOL CHEM, V274, P9587, DOI 10.1074/jbc.274.14.9587; Mahajan S, 2001, J BIOL CHEM, V276, P31216, DOI 10.1074/jbc.M104874200; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MUTHUKKUMAR S, 1993, EUR J IMMUNOL, V23, P2419, DOI 10.1002/eji.1830231007; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Okkenhaug K, 2002, SCIENCE, V297, P1031; Petro JB, 2002, FEBS LETT, V532, P57, DOI 10.1016/S0014-5793(02)03623-2; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; Tsukada S, 2001, ADV IMMUNOL, V77, P123, DOI 10.1016/S0065-2776(01)77016-2; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; Vihinen M, 1997, NUCLEIC ACIDS RES, V25, P166, DOI 10.1093/nar/25.1.166; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Williams CD, 1997, BLOOD, V90, P194; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	71	54	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2248	2259		10.1038/sj.onc.1206425	http://dx.doi.org/10.1038/sj.onc.1206425			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700661				2022-12-25	WOS:000182231500004
J	Shimokawa, I; Higami, Y; Tsuchiya, T; Otani, H; Komatsu, T; Chiba, T; Yamaza, H				Shimokawa, I; Higami, Y; Tsuchiya, T; Otani, H; Komatsu, T; Chiba, T; Yamaza, H			Lifespan extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction	FASEB JOURNAL			English	Article						longevity; transgenic rat; dwarf; pathology	DIETARY RESTRICTION; GENE-EXPRESSION; SPAN EXTENSION; DWARF MICE; LONGEVITY; RATS	A reduced growth hormone (GH)-insulin-like growth factor (IGF)-1 axis is associated with an extension of lifespan in laboratory rodents. Several phenotypes of such animal models resemble those induced by caloric restriction (CR). Using a transgenic male Wistar rat model whose GH-IGF-1 axis was moderately suppressed by overexpression of the antisense GH transgene (tg), we elucidated a relationship between the effects of a reduced GH-IGF-1 axis and CR for some biomarkers of aging, lifespan, and pathologies. Heterozygous (tg/-) rats fed ad libitum (AL) had a dwarf phenotype similar to that of control nontransgenic (-/-) rats subjected to 30% CR from 6 wk of age. Both the reduced GH-IGF-1 axis and CR extended lifespan to a similar extent, although the effect of CR seemed to be greater. There was an additive effect of CR to lifespan extension when tg/- rats were subjected to CR. Pathologic analyses indicated that the preventive effect of CR on selected diseases was greater than that of the reduced GH-IGF-1 axis. The present study suggests that CR affects aging and longevity by mechanisms other than suppression of the GH-IGF-1 axis, although CR might exhibit its effects partly through the reduced GH-IGF-1 axis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol & Gerontol, Nagasaki 8528523, Japan	Nagasaki University	Shimokawa, I (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol & Gerontol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	shimo@net.nagasaki-u.ac.jp	Yamaza, Haruyoshi/AAD-4011-2019	Yamaza, Haruyoshi/0000-0003-1138-3943; Higami, Yoshikazu/0000-0003-1381-0777; Tsuchiya, Tomoshi/0000-0002-8419-1478				Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; BIELSCHOWSKY F, 1961, BRIT J CANCER, V15, P257, DOI 10.1038/bjc.1961.32; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; CHEN HW, 1972, JNCI-J NATL CANCER I, V49, P1145; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Hsieh CC, 2002, MECH AGEING DEV, V123, P1229, DOI 10.1016/S0047-6374(02)00036-2; MAEDA H, 1985, J GERONTOL, V40, P671, DOI 10.1093/geronj/40.6.671; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; MATSUMOTO K, 1993, MOL REPROD DEV, V36, P53, DOI 10.1002/mrd.1080360109; Mattison JA, 2000, J AM AGING ASSOC, V23, P9, DOI 10.1007/s11357-000-0002-0; OOKA H, 1983, MECH AGEING DEV, V22, P113, DOI 10.1016/0047-6374(83)90104-5; RENNELS EG, 1965, TEX REP BIOL MED, V23, P776; Shimokawa I, 2002, AM J PATHOL, V160, P2259, DOI 10.1016/S0002-9440(10)61173-X; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; WEINDRUCH R, 1988, RETARDATION AGING DI	20	94	99	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1108	+		10.1096/fj.02-0819fje	http://dx.doi.org/10.1096/fj.02-0819fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692087				2022-12-25	WOS:000182580100033
J	Tadokoro, T; Kobayashi, N; Zmudzka, BZ; Ito, S; Wakamatsu, K; Yamaguchi, Y; Korossy, KS; Miller, SA; Beer, JZ; Hearing, VJ				Tadokoro, T; Kobayashi, N; Zmudzka, BZ; Ito, S; Wakamatsu, K; Yamaguchi, Y; Korossy, KS; Miller, SA; Beer, JZ; Hearing, VJ			UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin	FASEB JOURNAL			English	Article						melanocytes; skin color; photocarcinogenesis; cyclobutane pyrimidine dimers	CYCLOBUTANE PYRIMIDINE DIMERS; HUMAN MELANOCYTES; 6-4 PHOTOPRODUCTS; ULTRAVIOLET-B; P53 GENE; INDUCTION; CANCER; REPAIR; RADIATION; RESPONSES	DNA damage induced by UV radiation is a critical event in skin photocarcinogenesis. However, the role of racial/ethnic origin in determining individual UV sensitivity remains unclear. In this study, we examined the relationships between melanin content and DNA damage induced by UV exposure in situ in normal human skin of different racial/ethnic groups, phototypes, and UV sensitivities. The minimal erythema dose (MED) was established for each subject exposed to UVA/UVB radiation, and skin was biopsied before as well as 7 min, 1 day, and 1 wk after UV exposure. There was great variation among individuals in the amount of DNA damage incurred and rates of its removal. The results show that after exposure to 1 MED of UV, the skin of subjects from all groups suffered significant DNA damage, and that increasing content of constitutive melanin inversely correlated with the amount of DNA damage. It is clear from these results that measured erythemal UV sensitivity of the skin (MED) is a more useful predictor of DNA photodamage than is racial/ethnic origin or skin phototype and that rates of DNA damage removal following UV radiation may be the critical determinant of the UV sensitivity (including predisposition to cancer) of the skin.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20852 USA; Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Aichi 4701192, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Fujita Health University	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Yamaguchi, Yuji/X-6681-2019; Wakamatsu, Kazumasa/AAZ-5877-2020; Yamaguchi, Yuji/B-9312-2008	Wakamatsu, Kazumasa/0000-0003-1748-9001; Ito, Shosuke/0000-0001-9182-5144; Yamaguchi, Yuji/0000-0003-4338-2662	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Malek Z, 2000, PIGM CELL RES, V13, P156, DOI 10.1034/j.1600-0749.13.s8.28.x; Bancroft J.D., 1996, THEORY PRACTICE HIST, VVolume 6; BARKER D, 1995, CANCER RES, V55, P4041; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Bykov VJ, 2000, J INVEST DERMATOL, V114, P40, DOI 10.1046/j.1523-1747.2000.00821.x; Bykov VJ, 1999, J INVEST DERMATOL, V112, P326, DOI 10.1046/j.1523-1747.1999.00523.x; CARSBERG CJ, 1994, J CELL SCI, V107, P2591; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; De Leeuw SM, 2001, J PHOTOCH PHOTOBIO B, V61, P106, DOI 10.1016/S1011-1344(01)00168-3; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; Duval C, 2001, PIGM CELL RES, V14, P348, DOI 10.1034/j.1600-0749.2001.140506.x; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Funasaka Y, 1998, BRIT J DERMATOL, V139, P216; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; HALABAN R, 1993, MELANOTROPIC PEPTIDE, P290; HALDER RM, 1995, CANCER, V75, P667, DOI 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I; Hearing VJ, 2000, PIGM CELL RES, V13, P23, DOI 10.1034/j.1600-0749.13.s8.7.x; Hemminki K, 2002, CARCINOGENESIS, V23, P605, DOI 10.1093/carcin/23.4.605; ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; KOBAYASHI N, 1993, J INVEST DERMATOL, V101, P685, DOI 10.1111/1523-1747.ep12371676; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Langley RGB, 1997, CANCER INVEST, V15, P561, DOI 10.3109/07357909709047598; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; Miller SA, 2002, BIOLOGIC EFFECTS OF LIGHT 2001, P113; MONTAGNA W, 1972, PIGMENTATION ITS GEN, P1; MURAMATSU T, 1992, ARCH DERMATOL RES, V284, P232, DOI 10.1007/BF00375800; Nordlund J.J., 1998, PIGMENTARY SYSTEM PH, V1st; PATHAK MA, 1971, BIOL NORMAL ABNORMAL, P149; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Prota G, 1997, PIGM CELL RES, V10, P5, DOI 10.1111/j.1600-0749.1997.tb00460.x; Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Smit NPM, 2001, PHOTOCHEM PHOTOBIOL, V74, P424, DOI 10.1562/0031-8655(2001)074<0424:MOPAIO>2.0.CO;2; STRICKLAND PT, 1988, PHOTODERMATOLOGY, V5, P166; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; TADOKORO T, 2002, UV INDUCED MELANOGEN, P67; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; VITASA BC, 1990, CANCER, V65, P2811, DOI 10.1002/1097-0142(19900615)65:12<2811::AID-CNCR2820651234>3.0.CO;2-U; Wakamatsu K, 2002, PIGM CELL RES, V15, P174, DOI 10.1034/j.1600-0749.2002.02017.x; Wakamatsu K, 2002, PIGM CELL RES, V15, P225, DOI 10.1034/j.1600-0749.2002.02009.x; YOUNG AR, 1991, J INVEST DERMATOL, V97, P942, DOI 10.1111/1523-1747.ep12491807; Zeise L, 1995, MELANIN: ITS ROLE IN HUMAN PHOTOPROTECTION, P65; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	48	237	248	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1177	+		10.1096/fj.02-0865fje	http://dx.doi.org/10.1096/fj.02-0865fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692083				2022-12-25	WOS:000182580100042
J	Tian, GC; Ghanekar, SV; Aharony, D; Shenvi, AB; Jacobs, RT; Liu, XD; Greenberg, BD				Tian, GC; Ghanekar, SV; Aharony, D; Shenvi, AB; Jacobs, RT; Liu, XD; Greenberg, BD			The mechanism of gamma-secretase - Multiple inhibitor binding sites for transition state analogs and small molecule inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; BETA-APP; PRESENILIN; CLEAVAGE; NICASTRIN; COMPLEX; PEPSTATIN; COMPONENT	Transition state analogs pepstatin methylester (PME) and L685458 have been shown to inhibit gamma-secretase non-competitively (Tian, G., Sobotka-Briner, C., Zysk, J., Liu, X., Birr, C., Sylvester, M. A., Edwards, P. D., Scott, C. W., and Greenberg, B. D. (2002) J. Biol. Chem. 277, 31499-31505). This unusual kinetics suggests physical separation of the sites for substrate binding and catalysis with binding of the transition state analogs to the catalytic site and not to the substrate binding site. Methods of inhibitor cross-competition kinetics and competition ligand binding were utilized to address whether nontransition state small molecule inhibitors, which also display non-competitive inhibition of gamma-secretase, inhibit the enzyme by binding to the catalytic site as well. Inhibitor cross-competition kinetics indicated competitive binding between the transition state analogs PME and L685458 and between small molecules arylsulfonamides and benzodiazepines, but non-competitive binding between the transition state analogs and the small molecule inhibitors. These results were indicative of two inhibitor binding sites, one for transition state analogs and the other for non-transition state small molecule inhibitors. The presence of two inhibitor binding sites for two different classes of inhibitors was corroborated by results from competition ligand binding using [H-3]L685458 as the radioligand. Although L685458 and PME displaced the radioligand at the same concentrations as for enzyme inhibition, arylsulfonamides and benzodiazepines did not displace the radioligand at their K-i values, a result consistent with the presence of two inhibitor binding sites. These findings provide useful insights into the catalytic and regulatory mechanisms of gamma-secretase that may facilitate the design of novel gamma-secretase inhibitors.	AstrraZeneca Pharmaceut, Dept Lead Discovery, Wilmington, DE 19850 USA; AstrraZeneca Pharmaceut, Dept Neurosci, Wilmington, DE 19850 USA; AstrraZeneca Pharmaceut, Dept Mol Sci, Wilmington, DE 19850 USA; AstrraZeneca Pharmaceut, Dept Chem, Wilmington, DE 19850 USA		Tian, GC (corresponding author), AstrraZeneca Pharmaceut, Dept Lead Discovery, 1800 Concord Pike, Wilmington, DE 19850 USA.	gaochao.tian@astrazeneca.com						Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LIU XF, 2002, SOC NEUR 32 ANN M OR; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; TEALL MR, 2002, Patent No. 20020013315; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	39	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28968	28975		10.1074/jbc.M300905200	http://dx.doi.org/10.1074/jbc.M300905200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12719412	hybrid			2022-12-25	WOS:000184421100077
J	Herlan, M; Vogel, F; Bornhovd, C; Neupert, W; Reichert, AS				Herlan, M; Vogel, F; Bornhovd, C; Neupert, W; Reichert, AS			Processing of Mgm1 by the rhomboid-type protease Pcp1 is required for maintenance of mitochondrial morphology and of mitochondrial DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; CYTOCHROME-C PEROXIDASE; INNER MEMBRANE; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; YEAST REQUIRES; IMPORT; FISSION; FUSION; GTPASE	The structure of mitochondria is highly dynamic and depends on the balance of fusion and fission processes. Deletion of the mitochondrial dynamin-like protein Mgm1 in yeast leads to extensive fragmentation of mitochondria and loss of mitochondrial DNA. Mgm1 and its human ortholog OPA1, associated with optic atrophy type I in humans, were proposed to be involved in fission or fusion of mitochondria or, alternatively, in remodeling of the mitochondrial inner membrane and cristae formation (Wong, E. D., Wagner, J. A., Gorsich, S. W., McCaffery, J. M., Shaw, J. M., and Nunnari, J. (2000) J. Cell Biol. 151, 341-352; Wong, E. D., Wagner, J. A., Scott, S. V., Okreglak, V., Holewinske, T. J., Cassidy-Stone, A., and Nunnari, J. (2003) J. Cell Biol. 160, 303-311; Sesaki, H., Southard, S. M., Yaffe, M. P., and Jensen, R. E. (2003) Mol. Biol. Cell, in press). Mgm1 and its orthologs exist in two forms of different lengths. To obtain new insights into their biogenesis and function, we have characterized these isoforms. The large isoform (L-Mgm1) contains an N-terminal putative transmembrane segment that is absent in the short isoform (s-Mgm1). The large isoform is an integral inner membrane protein facing the intermembrane space. Furthermore, the conversion of l-Mgm1 into s-Mgm1 was found to be dependent on Pcp1 (Mdm37/YGR101w) a recently identified component essential for wild type mitochondrial morphology. Pcp1 is a homolog of Rhomboid, a serine protease known to be involved in intercellular signaling in Drosophila melanogaster, suggesting a function of Pcp1 in the proteolytic maturation process of Mgm1. Expression of s-Mgm1 can partially complement the Deltapcp1 phenotype. Expression of both isoforms but not of either isoform alone was able to partially complement the Deltamgm1 phenotype. Therefore, processing of l-Mgm1 by Pcp1 and the presence of both isoforms of Mgm1 appear crucial for wild type mitochondrial morphology and maintenance of mitochondrial DNA.	Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reichert, AS (corresponding author), Univ Munich, Adolf Butenandt Inst Physiol Chem, Butenandtstr 5, D-81377 Munich, Germany.		Reichert, Andreas/A-4090-2012	Reichert, Andreas/0000-0001-9340-3113				[Anonymous], 1991, Methods Enzymol, V194, P1; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; DAUM G, 1982, J BIOL CHEM, V257, P3028; Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Esser K, 2002, J MOL BIOL, V323, P835, DOI 10.1016/S0022-2836(02)01000-8; Fritz S, 2001, J CELL BIOL, V152, P683, DOI 10.1083/jcb.152.4.683; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; Misaka T, 2002, J BIOL CHEM, V277, P15834, DOI 10.1074/jbc.M109260200; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Pelloquin L, 1999, J CELL SCI, V112, P4151; Pelloquin L, 1998, BIOCHEM BIOPH RES CO, V251, P720, DOI 10.1006/bbrc.1998.9539; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Prokisch H, 2000, MOL BIOL CELL, V11, P2961, DOI 10.1091/mbc.11.9.2961; Reichert AS, 2002, BBA-MOL CELL RES, V1592, P41, DOI 10.1016/S0167-4889(02)00263-X; REID GA, 1982, J BIOL CHEM, V257, P3068; Rojo EE, 1998, J BIOL CHEM, V273, P8040, DOI 10.1074/jbc.273.14.8040; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; SESAKI H, 2003, IN PRESS MOL BIOL CE; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Sherman F., 1986, METHODS YEAST GENETI; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Urban S, 2002, CURR BIOL, V12, P1507, DOI 10.1016/S0960-9822(02)01092-8; Wasserman JD, 2000, GENE DEV, V14, P1651; Westermann B, 2000, YEAST, V16, P1421, DOI 10.1002/1097-0061(200011)16:15<1421::AID-YEA624>3.3.CO;2-L; Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341	38	293	302	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27781	27788		10.1074/jbc.M211311200	http://dx.doi.org/10.1074/jbc.M211311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12707284	hybrid			2022-12-25	WOS:000184242700058
J	Ishii, T; Furuoka, H; Muroi, Y; Nishimura, M				Ishii, T; Furuoka, H; Muroi, Y; Nishimura, M			Inactivation of integrin-linked kinase induces aberrant tau phosphorylation via sustained activation of glycogen synthase kinase 3 beta in N1E-115 neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; PROTEIN; HYPERPHOSPHORYLATION; KINASE-3-BETA; ACCUMULATION; ROLES	Integrin-linked kinase (ILK) is a focal adhesion serine/ threonine protein kinase with an important role in integrin and growth factor signaling pathways. Recently, we demonstrated that ILK is expressed in N1E-115 neuroblastoma cells and controls integrin-dependent neurite outgrowth in serum-starved cells grown on laminin (Ishii, T., Satoh, E., and Nishimura, M. ( 2001) J. Biol. Chem. 276, 42994 - 43003). Here we report that ILK controls tau phosphorylation via regulation of glycogen synthase kinase-3beta (GSK-3beta) activity in N1E-115 cells. Stable transfection of a kinase-deficient ILK mutant (DN-ILK) resulted in aberrant tau phosphorylation in N1E-115 cells at sites recognized by the Tau-1 antibody that are identical to some of the phosphorylation sites in paired helical filaments, PHF-tau, in brains of patients with Alzheimer's disease. The tau phosphorylation levels in the DN-ILK-expressing cells are constant under normal and differentiating conditions. On the other hand, aberrant tau phosphorylation was not observed in the parental control cells. ILK inactivation resulted in an increase in the active form but a decrease in the inactive form of GSK-3beta, which is a candidate kinase involved in PHF-tau formation. Moreover, inhibition of GSK-3beta with lithium prevented aberrant tau phosphorylation in the DN-ILK-expressing cells. These results suggest that ILK inactivation results in aberrant tau phosphorylation via sustained activation of GSK-3beta in N1E-115 Cells. ILK directly phosphorylates GSK-3beta and inhibits its activity. Therefore, endogenous ILK protects against GSK-3beta-induced aberrant tau phosphorylation via inhibition of GSK-3beta activity in N1E-115 cells.	Obihiro Univ Agr & Vet Med, Dept Pathol Sci, Obihiro, Hokkaido 0808555, Japan	Obihiro University of Agriculture & Veterinary Medicine	Ishii, T (corresponding author), Obihiro Univ Agr & Vet Med, Dept Pathol Sci, Obihiro, Hokkaido 0808555, Japan.	ishii@obihiro.ac.jp						BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Burack MA, 1996, NEUROSCIENCE, V72, P167, DOI 10.1016/0306-4522(95)00546-3; CRESSMAN CM, 1995, J NEUROSCI RES, V42, P648, DOI 10.1002/jnr.490420507; Cross D, 2000, METH MOL B, V124, P147; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Huang Y, 1999, INT J MOL MED, V3, P563; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ishii T, 2001, J BIOL CHEM, V276, P42994, DOI 10.1074/jbc.M105198200; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Liu F, 2002, FEBS LETT, V530, P209, DOI 10.1016/S0014-5793(02)03487-7; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MalchiodiAlbedi F, 1997, J NEUROSCI RES, V48, P425, DOI 10.1002/(SICI)1097-4547(19970601)48:5<425::AID-JNR4>3.0.CO;2-G; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Mills J, 2003, J NEUROSCI, V23, P1638; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wagner U, 1996, J CELL SCI, V109, P1537; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871	33	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26970	26975		10.1074/jbc.M304113200	http://dx.doi.org/10.1074/jbc.M304113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12714590	hybrid			2022-12-25	WOS:000184155700087
J	Yamada, R; Sonobe, H				Yamada, R; Sonobe, H			Purification, kinetic characterization, and molecular cloning of a novel enzyme ecdysteroid-phosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI; EMBRYONIC DIAPAUSE; NONDIAPAUSE EGGS; ACID-PHOSPHATASE; PND MUTANT; SILKWORM; METABOLISM; 20-HYDROXYECDYSONE; IDENTIFICATION; INVOLVEMENT	From eggs of the silkworm Bombyx mori, we isolated a novel enzyme that is involved in the conversion of physiologically inactive conjugated ecdysteroids, such as ecdysone 22-phosphate and 20-hydroxyecdysone 22-phosphate, to active free ecdysteroids. This enzyme, called ecdysteroid-phosphate phosphatase (EPPase), was located in the cytosol fraction and differed from nonspecific lysosomal acid phosphatases in various enzymic properties. EPPase was purified about 3,000-fold to homogeneity by seven steps of column chromatography. The cDNA clone encoding EPPase was isolated by reverse transcription polymerase chain reaction using degenerate primers on the basis of the partial amino acid sequence obtained from purified EPPase and by subsequent 3'- and 5'-rapid amplification of cDNA ends. The full-length cDNA of EPPase was found to be composed of 1620 bp with an open reading frame encoding a protein of 331 amino acid residues. A data base search showed that there was no functional protein with the amino acid sequence identical to that of EPPase. Northern blot analysis revealed that EPPase mRNA was expressed predominantly during gastrulation and organogenesis in nondiapause eggs but was not detected in diapause eggs whose development was arrested at the late gastrula stage. In nondiapause eggs, the developmental changes in the expression pattern of EPPase mRNA corresponded closely to changes in the enzyme activity and in the amounts of free ecdysteroids in eggs.	Konan Univ, Fac Sci & Engn, Dept Biol, Kobe, Hyogo 6588501, Japan; Konan Univ, Grad Sch Nat Sci, Dept Life & Funct Mat Sci, Kobe, Hyogo 6588501, Japan	Konan University; Konan University	Sonobe, H (corresponding author), Konan Univ, Fac Sci & Engn, Dept Biol, Kobe, Hyogo 6588501, Japan.	sonobe@konan-u.ac.jp						ATTWOOD PV, 1988, BIOCHEM J, V253, P387, DOI 10.1042/bj2530387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLIERE D, 1979, ROUX ARCH DEV BIOL, V186, P103, DOI 10.1007/BF00848172; CHINO H, 1963, ARCH BIOCHEM BIOPHYS, V102, P400, DOI 10.1016/0003-9861(63)90248-0; CHINO H, 1961, J INSECT PHYSIOL, V6, P231, DOI 10.1016/0022-1910(61)90067-1; DINAN L, 1983, INSECT BIOCHEM, V13, P411, DOI 10.1016/0020-1790(83)90025-2; GHARIB B, 1981, J INSECT PHYSIOL, V27, P711, DOI 10.1016/0022-1910(81)90008-1; GHARIB B, 1981, EXPERIENTIA, V37, P1107, DOI 10.1007/BF02085039; Hoffmann J.A., 1985, P435; Horike N, 1999, ARCH INSECT BIOCHEM, V41, P9, DOI 10.1002/(SICI)1520-6327(1999)41:1&lt;9::AID-ARCH3&gt;3.0.CO;2-G; Horike N, 2000, EUR J BIOCHEM, V267, P6914, DOI 10.1046/j.1432-1033.2000.01796.x; ISSAC RE, 1983, BIOCHEM SOC T, V11, P379; KABBOUH M, 1991, INSECT BIOCHEM, V21, P57, DOI 10.1016/0020-1790(91)90064-L; KABBOUH M, 1993, INSECT BIOCHEM MOLEC, V23, P73, DOI 10.1016/0965-1748(93)90084-6; KAMBA M, 1994, INSECT BIOCHEM MOLEC, V24, P395, DOI 10.1016/0965-1748(94)90032-9; KOOLMAN J, 1990, ZOOL SCI, V7, P563; LAFONT R, 1995, RECENT ADV INSECT BI, P45; LAGUEUX M, 1979, J INSECT PHYSIOL, V25, P709, DOI 10.1016/0022-1910(79)90123-9; LAWRENCE GL, 1981, ARCH BIOCHEM BIOPHYS, V206, P122, DOI 10.1016/0003-9861(81)90073-4; LOWRY OH, 1954, J BIOL CHEM, V207, P19; Makka T, 2000, ZOOL SCI, V17, P89, DOI 10.2108/zsj.17.89; Makka T, 2002, ARCH INSECT BIOCHEM, V51, P111, DOI 10.1002/arch.10055; OHNISHI E, 1989, INSECT BIOCHEM, V19, P95, DOI 10.1016/0020-1790(89)90014-0; Ohnishi E., 1990, P121; Rees H.H., 1984, P181; SCALIA S, 1987, INSECT BIOCHEM, V17, P227, DOI 10.1016/0020-1790(87)90164-8; SONOBE H, 1991, EXPERIENTIA, V47, P948, DOI 10.1007/BF01929889; SONOBE H, 1986, ROUX ARCH DEV BIOL, V195, P229, DOI 10.1007/BF02438955; Sonobe H, 1999, ZOOL SCI, V16, P935, DOI 10.2108/zsj.16.935; SONOBE H, 1986, J INSECT PHYSIOL, V32, P215, DOI 10.1016/0022-1910(86)90061-2; TAGA EM, 1982, ARCH BIOCHEM BIOPHYS, V214, P505, DOI 10.1016/0003-9861(82)90054-6; TAKAHASHI SY, 1992, ZOOL SCI, V9, P169; TAKAI A, 1991, BIOCHEM J, V275, P233, DOI 10.1042/bj2750233; Tawfik AI, 2002, J INSECT PHYSIOL, V48, P743, DOI 10.1016/S0022-1910(02)00099-9; VERMA AK, 1984, BIOCHEMISTRY-US, V23, P5010, DOI 10.1021/bi00316a028; WARREN JT, 1986, J LIQ CHROMATOGR, V9, P1759, DOI 10.1080/01483918608076716; Yamada R, 2002, PROCEEDINGS OF THE 21ST CONFERENCE OF EUROPEAN COMPARATIVE ENDOCRINOLOGISTS, P179	37	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26365	26373		10.1074/jbc.M304158200	http://dx.doi.org/10.1074/jbc.M304158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12721294	hybrid			2022-12-25	WOS:000184155700012
J	Esposito, G; Garcia, J; Mangione, P; Giorgetti, S; Corazza, A; Viglino, P; Chiti, F; Andreola, A; Dumy, P; Booth, D; Hawkins, PN; Bellotti, V				Esposito, G; Garcia, J; Mangione, P; Giorgetti, S; Corazza, A; Viglino, P; Chiti, F; Andreola, A; Dumy, P; Booth, D; Hawkins, PN; Bellotti, V			Structural and folding dynamic properties of the T70N variant of human lysozyme*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRIL FORMATION; PULSED-FIELD GRADIENTS; CONFORMATIONAL STABILITY; DISEASE; SPECTROSCOPY; PROTEIN; COOPERATIVITY; NETWORKS; PROGRAM; PHASE	Definition of the transition mechanism from the native globular protein into fibrillar polymer was greatly improved by the biochemical and biophysical studies carried out on the two amyloidogenic variants of human lysozyme, I56T and D67H. Here we report thermodynamic and kinetic data on folding as well as structural features of a naturally occurring variant of human lysozyme, T70N, which is present in the British population at an allele frequency of 5% and, according to clinical and histopathological data, is not amyloidogenic. This variant is less stable than the wild-type protein by 3.7 kcal/mol, but more stable than the pathological, amyloidogenic variants. Unfolding kinetics in guanidine are six times faster than in the wild-type, but three and twenty times slower than in the amyloidogenic variants. Enzyme catalytic parameters, such as maximal velocity and affinity, are reduced in comparison to the wild-type. The solution structure, determined by H-1 NMR and modeling calculations, exhibits a more compact arrangement at the interface between the beta-sheet domain and the subsequent loop on one side and part of the alpha domain on the other side, compared with the wild-type protein. This is the opposite of the conformational variation shown by the amyloidogenic variant D67H, but it accounts for the reduced stability and catalytic performance of T70N.	Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Univ Grenoble 1, Etud Dynam & Struct Select Lab, F-38041 Grenoble 9, France; Univ Florence, Dipartimento Sci Biochim, I-55100 Florence, Italy; UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Amyloidosis & Acute Phase Prot, London NW3 2PF, England; Univ Pavia, Policlin San Matteo Pavia,Dipartimento Biochim, Ctr Interdipartimentale Biol Applicata, Lab Biotecnol,Ist Ricovero & Cura Carattere Sci, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Florence; University of London; University College London; UCL Medical School; IRCCS Fondazione San Matteo; University of Pavia	Bellotti, V (corresponding author), Univ Pavia, Policlin San Matteo Pavia,Dipartimento Biochim, Ctr Interdipartimentale Biol Applicata, Lab Biotecnol,Ist Ricovero & Cura Carattere Sci, Via Taramelli 3-B, I-27100 Pavia, Italy.	vbellot@unipv.it	Giorgetti, Sofia/AAD-4341-2019; dumy, pascal/C-4863-2008; Bellotti, Vittorio/A-6201-2014; Corazza, Alessandra/AGB-1457-2022; Hawkins, Philip N/C-5573-2008	Giorgetti, Sofia/0000-0001-9438-6511; dumy, pascal/0000-0002-7660-763X; Bellotti, Vittorio/0000-0001-8678-662X; Corazza, Alessandra/0000-0003-2272-1928; Mangione, Palma/0000-0003-0260-1400	Telethon [GP0186Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Booth D R, 2000, Hum Mutat, V16, P180, DOI 10.1002/1098-1004(200008)16:2<180::AID-HUMU20>3.0.CO;2-#; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Canet D, 1999, BIOCHEMISTRY-US, V38, P6419, DOI 10.1021/bi983037t; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Chamberlain AK, 2001, PROTEIN SCI, V10, P2525, DOI 10.1110/ps.ps.28101; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Funahashi J, 2002, J BIOL CHEM, V277, P21792, DOI 10.1074/jbc.M110728200; Gillmore JD, 1999, NEPHROL DIAL TRANSPL, V14, P2639, DOI 10.1093/ndt/14.11.2639; Hooft RWW, 1996, PROTEINS, V26, P363; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KEELER J, 1994, METHOD ENZYMOL, V239, P145; Luque I, 2002, ANNU REV BIOPH BIOM, V31, P235, DOI 10.1146/annurev.biophys.31.082901.134215; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; MURAKI M, 1992, BIOCHEMISTRY-US, V31, P9212, DOI 10.1021/bi00153a014; NANJO F, 1988, J BIOCHEM-TOKYO, V104, P255, DOI 10.1093/oxfordjournals.jbchem.a122453; Peterson SA, 1998, P NATL ACAD SCI USA, V95, P12956, DOI 10.1073/pnas.95.22.12956; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; REDFIELD C, 1990, BIOCHEMISTRY-US, V29, P7201, DOI 10.1021/bi00483a007; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Takano K, 1999, BIOCHEMISTRY-US, V38, P12698, DOI 10.1021/bi9910169; Takano K, 2001, EUR J BIOCHEM, V268, P155, DOI 10.1046/j.1432-1327.2001.01863.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WUTHRICH K, 1986, NMR SPECTROSCOPY PRO	38	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25910	25918		10.1074/jbc.M211000200	http://dx.doi.org/10.1074/jbc.M211000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12709420	hybrid			2022-12-25	WOS:000183920200082
J	Chang, HC; Chang, GG				Chang, HC; Chang, GG			Involvement of single residue tryptophan 548 in the quaternary structural stability of pigeon cytosolic malic enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIZE-DISTRIBUTION ANALYSIS; ANALYTICAL ULTRACENTRIFUGATION; CRYSTAL-STRUCTURE; ACTIVE SUBUNITS; LAMM EQUATION; EQUILIBRIUM; MECHANISM; MACROMOLECULES; DENATURATION; RESOLUTION	Pigeon cytosolic malic enzyme has a double dimer quaternary structure with three tryptophanyl residues in each monomer distributed in different structural domains. The enzyme showed a three-state unfolding phenomenon upon increasing the urea concentration (Chang, H. C., Chou, W. Y., and Chang, G. G. (2002) J. Biol. Chem. 277, 4663-4671). At urea concentration of 4-4.5 M, where the intermediate form was detected, the enzyme existed as partially unfolded dimers, which were easily polymerized. Mn2+ provided full protection against the polymerization. To further characterize this phenomenon, three mutants of the enzyme (W129, W321, and W548), each with only one tryptophanyl residue left, were constructed. All these mutants were successfully overexpressed in Escherichia coli cells and purified to homogeneity. Changes in the circular dichroism spectra of all mutants revealed a three-state urea-unfolding process in the absence of Mn2+. In the presence of 4 mM Mn2+, W548 and wild type (WT) enzymes shifted to monophasic, while W129 and W321 were still biphasic. Similar results were obtained from the fluorescence spectral changes, except for W321, which showed monophasic denaturation curve with or without Mn2+. Analytical ultracentrifugation analysis indicated that the mutant enzymes were polymerized at 4.5 M urea, and Mn2+ provided protective effect on W548 and WT enzymes only. Other mutants with mutated Trp-548 polymerized at 4.5 M urea in the absence or presence of 4 mM Mn2+. The above results indicate that a single residue, Trp-548, in the subunit interface region, is responsible for the integrity of the quaternary structure of the pigeon cytosolic malic enzyme.	Natl Yang Ming Univ, Fac Life Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chang, GG (corresponding author), Natl Yang Ming Univ, Fac Life Sci, Taipei 112, Taiwan.							BEASTY AM, 1986, BIOCHEMISTRY-US, V25, P2965, DOI 10.1021/bi00358a035; BERSTEIN HJ, 2000, TRENDS BIOCHEM SCI, V25, P453; CHANG GG, 1992, ARCH BIOCHEM BIOPHYS, V296, P468, DOI 10.1016/0003-9861(92)90599-R; CHANG GG, 1988, BIOCHEM J, V254, P123, DOI 10.1042/bj2540123; CHANG GG, 1993, EUR J BIOCHEM, V213, P1159, DOI 10.1111/j.1432-1033.1993.tb17866.x; Chang HC, 2002, J BIOL CHEM, V277, P4663, DOI 10.1074/jbc.M111156200; Chou WY, 1997, PROTEIN ENG, V10, P1205, DOI 10.1093/protein/10.10.1205; Coleman DE, 2002, BIOCHEMISTRY-US, V41, P6928, DOI 10.1021/bi0255120; delPino MMS, 1997, BIOCHEMISTRY-US, V36, P5560, DOI 10.1021/bi963133z; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; Hammarstrom P, 2001, J BIOL CHEM, V276, P21765, DOI 10.1074/jbc.M010858200; HUANG TM, 1992, BIOCHEMISTRY-US, V31, P12658, DOI 10.1021/bi00165a016; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lakowitcz J.R, 1999, PRINCIPLES FLUORESCE, P237, DOI DOI 10.1007/978-1-4757-3061-6_8; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NEVALDINE BH, 1974, BIOCHIM BIOPHYS ACTA, V336, P283; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; Rudyak SG, 2001, BIOCHEMISTRY-US, V40, P9317, DOI 10.1021/bi0102508; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2000, BIOCHEM BIOPH RES CO, V274, P440, DOI 10.1006/bbrc.2000.3163; Yang ZR, 2000, NAT STRUCT BIOL, V7, P251; Yang ZR, 2002, PROTEIN SCI, V11, P332, DOI 10.1110/ps.38002	33	16	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23996	24002		10.1074/jbc.M213242200	http://dx.doi.org/10.1074/jbc.M213242200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12711612	hybrid			2022-12-25	WOS:000183638600100
J	Foucaud, B; Laube, B; Schemm, R; Kreimeyer, A; Goeldner, M; Betz, H				Foucaud, B; Laube, B; Schemm, R; Kreimeyer, A; Goeldner, M; Betz, H			Structural model of the N-methyl-D-aspartate receptor glycine site probed by site-directed chemical coupling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING CORE; NMDA RECEPTOR; NR1 SUBUNIT; GLUTAMATE-RECEPTOR; ACTIVE ANTAGONISTS; CYSTEINE MUTANTS; M3-M4 LOOP; ACTIVATION; POCKET; POTENT	The N-methyl-D-aspartate (NMDA) receptor is a ligand-gated ion channel that requires both glutamate and glycine for efficient activation. Here, a strategy combining cysteine scanning mutagenesis and affinity labeling was used to investigate the glycine binding site located on the NR1 subunit. Based on homology modeling to the crystal structure of the glutamate binding site of the 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)-propionic acid receptor GluR2, cysteines were introduced into the NR1 subunit as chemical sensors for three thiol-reactive derivatives of the competitive antagonist L-701,324. After coexpressing the mutant NR1 with wildtype NR2B subunits in Xenopus oocytes, agonist-induced currents were recorded to monitor irreversible receptor inactivation by the reactive antagonists. For each derivative, glycine site-specific inactivations were observed with a distinct subset of cysteine-substituted receptors. Together these inactivating substitutions identified seven NR1 residues (Ile-385, Gln-387, Glu-388, Thr-500, Asn-502, Ala-696, and Val-717) that undergo proximity-induced covalent coupling with specific regions of the bound antagonist and disclose its mode of docking in the glycine binding pocket of the NMDA receptor. Our approach may help to unravel the structural basis of distinct NMDA receptor subtype pharmacologies.	Univ Louis Pasteur Strasbourg 1, Chim Bioorgan Lab, CNRS UMR 7514, Fac Pharm, F-67401 Illkirch Graffenstaden, France; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Max Planck Society	Foucaud, B (corresponding author), Univ Louis Pasteur Strasbourg 1, Chim Bioorgan Lab, CNRS UMR 7514, Fac Pharm, 74 Rte Rhin, F-67401 Illkirch Graffenstaden, France.							Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Auberson YP, 1998, BIOORG MED CHEM LETT, V8, P71, DOI 10.1016/S0960-894X(97)10187-1; BULLER AL, 1994, J NEUROSCI, V14, P5471; Cai SX, 1997, J MED CHEM, V40, P730, DOI 10.1021/jm960654b; Cai SX, 1996, J MED CHEM, V39, P3248, DOI 10.1021/jm960214k; Chatterton JE, 2002, NATURE, V415, P793, DOI 10.1038/nature715; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Danysz W, 1998, PHARMACOL REV, V50, P597; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fern R, 1996, NEUROREPORT, V7, P1953, DOI 10.1097/00001756-199608120-00018; Foucaud B, 2001, TRENDS PHARMACOL SCI, V22, P170, DOI 10.1016/S0165-6147(00)01674-6; GRIMWOOD S, 1995, J NEUROCHEM, V64, P525; GRIMWOOD S, 1995, EUR J PHARM-MOLEC PH, V290, P221, DOI 10.1016/0922-4106(95)00081-X; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; Ivanovic A, 1998, J BIOL CHEM, V273, P19933, DOI 10.1074/jbc.273.32.19933; JIMONET P, 1994, BIOORG MED CHEM LETT, V4, P2735, DOI 10.1016/S0960-894X(01)80586-2; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Kreimeyer A, 1999, J MED CHEM, V42, P4394, DOI 10.1021/jm9910730; KULAGOWSKI JJ, 1994, J MED CHEM, V37, P1402, DOI 10.1021/jm00036a002; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LEESON PD, 1994, J MED CHEM, V37, P4053, DOI 10.1021/jm00050a001; LEESON PD, 1991, J MED CHEM, V34, P1343; Louvel E, 1997, TRENDS PHARMACOL SCI, V18, P196, DOI 10.1016/S0165-6147(97)90623-4; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OH BH, 1993, J BIOL CHEM, V268, P11348; Perret P, 1999, J BIOL CHEM, V274, P25350, DOI 10.1074/jbc.274.36.25350; ROGERS M, 1995, BIOPHYS J, V68, P501, DOI 10.1016/S0006-3495(95)80211-0; Uchino S, 1997, NEUROREPORT, V8, P445, DOI 10.1097/00001756-199701200-00014; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Williams K, 1996, MOL PHARMACOL, V50, P701; Wittekindt B, 2001, NEUROPHARMACOLOGY, V41, P753, DOI 10.1016/S0028-3908(01)00112-5; Wood MW, 1997, J BIOL CHEM, V272, P3532, DOI 10.1074/jbc.272.6.3532; Wood MW, 1999, MOL BRAIN RES, V73, P189, DOI 10.1016/S0169-328X(99)00247-8	42	28	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24011	24017		10.1074/jbc.M300219200	http://dx.doi.org/10.1074/jbc.M300219200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697759	hybrid			2022-12-25	WOS:000183638600102
J	Luque, A; Carpizo, DR; Iruela-Arispe, ML				Luque, A; Carpizo, DR; Iruela-Arispe, ML			ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF(165)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; GROWTH-FACTOR VEGF; EXTRACELLULAR-MATRIX; TUMOR-ANGIOGENESIS; FACTOR RECEPTORS; MATERNAL SERUM; BREAST-CANCER; FACTOR-BETA; THROMBOSPONDIN-1; ADAMTS-1	ADAMTS1 is a metalloprotease previously shown to inhibit angiogenesis in a variety of in vitro and in vivo assays. In the present study, we demonstrate that ADAMTS1 significantly blocks VEGFR2 phosphorylation with consequent suppression of endothelial cell proliferation. The effect on VEGFR2 function was due to direct binding and sequestration of VEGF(165) by ADAMTS1. Binding was confirmed by co-immunoprecipitation and cross-linking analysis. Inhibition of VEGF function was reversible, as active VEGF could be recovered from the complex. The interaction required the heparin-binding domain of the growth factor, because VEGF(121) failed to bind to ADAMTS1. Structure/function analysis with independent ADAMTS1 domains indicated that binding to VEGF(165) was mediated by the carboxyl-terminal (CT) region. ADAMTS1 and VEGF(165) were also found in association in tumor extracts. These findings provide a mechanism for the anti-angiogenic activity of ADAMTS1 and describe a novel modulator of VEGF bioavailability.	Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Iruela-Arispe, ML (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Cell & Dev Biol, 611 Charles Young Dr E, Los Angeles, CA 90095 USA.	arispe@mbi.ucla.edu	Luque, Alfonso/C-5846-2018; Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168	NCI NIH HHS [R01CA77420] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anthony FW, 1997, ANN CLIN BIOCHEM, V34, P276, DOI 10.1177/000456329703400309; Barillari G, 1998, AM J PATHOL, V152, P1161; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Brekken Rolf A., 2001, Matrix Biology, V19, P816; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; CRISCUOLO GR, 1988, J NEUROSURG, V69, P254, DOI 10.3171/jns.1988.69.2.0254; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fong TAT, 1999, CANCER RES, V59, P99; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Goldbrunner RH, 1999, J NEUROSCI RES, V55, P486, DOI 10.1002/(SICI)1097-4547(19990215)55:4<486::AID-JNR8>3.0.CO;2-A; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hogg PJ, 1997, BIOCHEM J, V326, P709, DOI 10.1042/bj3260709; Ikuta T, 2000, GENES CELLS, V5, P913, DOI 10.1046/j.1365-2443.2000.00376.x; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Miralem T, 2001, ONCOGENE, V20, P5511, DOI 10.1038/sj.onc.1204753; Mukhopadhyay D, 1996, BIOCHEM BIOPH RES CO, V229, P733, DOI 10.1006/bbrc.1996.1873; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Prewett M, 1999, CANCER RES, V59, P5209; Robinson CJ, 2001, J CELL SCI, V114, P853; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Sahni A, 2000, BLOOD, V96, P3772, DOI 10.1182/blood.V96.12.3772.h8003772_3772_3778; Sasaki H, 2000, TOXICOLOGY, V155, P27, DOI 10.1016/S0300-483X(00)00274-2; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SOKER S, 1993, J BIOL CHEM, V268, P7685; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Taraboletti G, 1997, CELL GROWTH DIFFER, V8, P471; Tian XJ, 2001, BIOCHEM BIOPH RES CO, V286, P505, DOI 10.1006/bbrc.2001.5409; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Veikkola T, 2000, CANCER RES, V60, P203; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Vuorela-Vepsalainen P, 1999, HUM REPROD, V14, P1346, DOI 10.1093/humrep/14.5.1346; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Zhu ZP, 1998, CANCER RES, V58, P3209	63	203	217	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23656	23665		10.1074/jbc.M212964200	http://dx.doi.org/10.1074/jbc.M212964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12716911	hybrid			2022-12-25	WOS:000183638600057
J	Saito, H; Dhanasekaran, P; Nguyen, D; Holvoet, P; Lund-Katz, S; Phillips, MC				Saito, H; Dhanasekaran, P; Nguyen, D; Holvoet, P; Lund-Katz, S; Phillips, MC			Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHIPATHIC ALPHA-HELIX; N-TERMINAL DOMAIN; EXCHANGEABLE APOLIPOPROTEIN; E ISOFORMS; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; APOLIPOPHORIN-III; BINDING; CONFORMATION; STABILITY	Detailed structural information on human exchangeable apolipoproteins (apo) is required to understand their functions in lipid transport. Using a series of deletion mutants that progressively lacked different regions along the molecule, we probed the structural organization of lipid-free human apoA-I and the role of different domains in lipid binding, making comparisons to apoE, which is a member of the same gene family and known to have two structural domains. Measurements of alpha-helix content by CD in conjunction with tryptophan and 8-anilino-1-naphthalenesulfonic acid fluorescence data demonstrated that deletion of the amino-terminal or central regions disrupts the tertiary organization, whereas deletion of the carboxyl terminus has no effect on stability and induces a more cooperative structure. These data are consistent with the lipid-free apoA-I molecule being organized into two structural domains similar to apoE; the amino-terminal and central parts form a helix bundle, whereas the carboxyl-terminal alpha-helices form a separate, less organized structure. The binding of the apoA-I variants to lipid emulsions is modulated by reorganization of the helix bundle structure, because the rate of release of heat on binding is inversely correlated with the stability of the helix bundle. Based on these observations, we propose that there is a two-step mechanism for lipid binding of apoA-I: apoA-I initially binds to a lipid surface through amphipathic alpha-helices in the carboxyl-terminal domain, followed by opening of the helix bundle in the amino-terminal domain. Because apoE behaves similarly, this mechanism is probably a general feature for lipid interaction of other exchangeable apolipoproteins, such as apoA-IV.	Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Sch Med, Abramson Res Ctr, Philadelphia, PA 19104 USA; Natl Inst Hlth Sci, Osaka Branch, Osaka 5400006, Japan; Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, B-3000 Louvain, Belgium	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institute of Health Sciences - Japan; KU Leuven	Phillips, MC (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst,Sch Med, Abramson Res Ctr, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.		HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633, R01HL056083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56083, HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acharya P, 2002, BBA-MOL CELL BIOL L, V1584, P9, DOI 10.1016/S1388-1981(02)00263-9; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Brouillette CG, 2001, BBA-MOL CELL BIOL L, V1531, P4, DOI 10.1016/S1388-1981(01)00081-6; Davidson WS, 1999, BIOCHEMISTRY-US, V38, P14387, DOI 10.1021/bi991428h; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; de Beer MC, 2001, J LIPID RES, V42, P309; Derksen A, 1996, BIOPHYS J, V70, P330, DOI 10.1016/S0006-3495(96)79574-7; Frank PG, 2000, J LIPID RES, V41, P853; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gorshkova IN, 2002, BIOCHEMISTRY-US, V41, P10529, DOI 10.1021/bi025807d; Gorshkova IN, 2000, BIOCHEMISTRY-US, V39, P15910, DOI 10.1021/bi0014406; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; LI WH, 1988, J LIPID RES, V29, P245; Morrow JA, 2000, BIOCHEMISTRY-US, V39, P11657, DOI 10.1021/bi000099m; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; REIJNGOUD DJ, 1982, BIOCHEMISTRY-US, V21, P2969, DOI 10.1021/bi00541a026; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P11714, DOI 10.1021/bi973112k; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; Segall ML, 2002, J LIPID RES, V43, P1688, DOI 10.1194/jlr.M200157-JLR200; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Tricerri MA, 2000, BIOCHEMISTRY-US, V39, P14682, DOI 10.1021/bi0014251; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	39	162	169	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23227	23232		10.1074/jbc.M303365200	http://dx.doi.org/10.1074/jbc.M303365200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12709430	hybrid			2022-12-25	WOS:000183638600004
J	Song, DH; Dominguez, I; Mizuno, J; Kaut, M; Mohr, SC; Seldin, DC				Song, DH; Dominguez, I; Mizuno, J; Kaut, M; Mohr, SC; Seldin, DC			CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; KAPPA-B-ALPHA; PROTEIN PHOSPHATASE 2A; EARLY XENOPUS-EMBRYOS; AXIS FORMATION; FUNCTIONAL INTERACTION; MEDIATED DEGRADATION; NUCLEAR-LOCALIZATION; CONSENSUS SEQUENCES; NEGATIVE REGULATOR	Protein kinase CK2 is a ubiquitous serine/threonine kinase involved in many biological processes. It is overexpressed in many malignancies including rodent and human breast cancer, and is up-regulated in Wnt-transfected mammary epithelial cells, where it can be found in a complex with dishevelled and beta-catenin. beta-Catenin is a substrate for CK2 and inhibition of CK2 reduces levels of beta-catenin and dishevelled. Here we report that inhibition of CK2 using pharmacologic agents or expression of kinase inactive subunits reduces beta-catenin-dependent transcription and protein levels in a proteasome-dependent fashion. The major region of phosphorylation of beta-catenin by CK2 is the central armadillo repeat domain, where carrier proteins like axin and the adenomatous polyposis coli gene product APC interact with beta-catenin. The major CK2 phosphorylation site in this domain is Thr(393), a solvent-accessible residue in a key hinge region of the molecule. Mutation of this single amino acid reduces beta-catenin phosphorylation, co-transcriptional activity, and stability. Thus, CK2 is a positive regulator of Wnt signaling through phosphorylation of beta-catenin at Thr(393), leading to proteasome resistance and increased protein and co-transcriptional activity.	Boston Univ, Med Ctr, Dept Med, Boston, MA 02118 USA; Boston Univ, Dept Chem, Boston, MA 02118 USA	Boston University; Boston University	Seldin, DC (corresponding author), Boston Univ, Med Ctr, Dept Med, 650 Albany St, Boston, MA 02118 USA.			Seldin, David C/0000-0003-0168-2333; /0000-0001-9617-4141	NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011624] Funding Source: NIH RePORTER; NCI NIH HHS [CA71796] Funding Source: Medline; NIEHS NIH HHS [ES11624] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Battistutta R, 2000, EUR J BIOCHEM, V267, P5184, DOI 10.1046/j.1432-1327.2000.01587.x; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; CHAUDHRY PS, 1989, ARCH BIOCHEM BIOPHYS, V271, P98, DOI 10.1016/0003-9861(89)90259-2; COCHET C, 1983, J BIOL CHEM, V258, P1403; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dominguez I, 2000, DEVELOPMENT, V127, P861; Dotan I, 2001, BIOCHEM BIOPH RES CO, V288, P603, DOI 10.1006/bbrc.2001.5804; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GLOVER CVC, 1994, CELL MOL BIOL RES, V40, P481; Gradl D, 1999, MECH DEVELOP, V86, P3, DOI 10.1016/S0925-4773(99)00129-X; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Kim MS, 1998, MOL CELLS, V8, P43; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; LEROY D, 1994, CELL MOL BIOL RES, V40, P441; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Sokol SY, 1999, CURR OPIN GENET DEV, V9, P405, DOI 10.1016/S0959-437X(99)80061-6; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	70	130	137	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24018	24025		10.1074/jbc.M212260200	http://dx.doi.org/10.1074/jbc.M212260200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700239	hybrid			2022-12-25	WOS:000183638600103
J	Brindley, AA; Raux, E; Leech, HK; Schubert, HL; Warren, MJ				Brindley, AA; Raux, E; Leech, HK; Schubert, HL; Warren, MJ			A story of chelatase evolution - Identification and characterization of a small 13-15-kda "ancestral" cobaltochelatase (CbiX(s)) in the archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN VITAMIN-B-12 BIOSYNTHESIS; BACILLUS-MEGATERIUM; SIROHAEM; FERROCHELATASE; INSERTION; ENZYME; HEME; GENE	The cobaltochelatase required for the synthesis of vitamin B-12 ( cobalamin) in the archaeal kingdom has been identified as CbiX through similarity searching with the CbiX from Bacillus megaterium. However, the CbiX proteins in the archaea are much shorter than the CbiX proteins found in eubacteria, typically containing less than half the number of amino acids in their primary structure. For this reason the shorter CbiX proteins have been termed CbiX(S) and the longer versions CbiX(L). The CbiX(S) proteins from Methanosarcina barkeri and Methanobacter thermoautotrophicum were overproduced in Escherichia coli as recombinant proteins and characterized. Through complementation studies of a defined chelatase- deficient strain of E. coli and by direct in vitro assays the function of CbiX(S) as a sirohydrochlorin cobaltochelatase has been demonstrated. On the basis of sequence alignments and conserved active site residues we suggest that CbiX(S) may represent a primordial chelatase, giving rise to larger chelatases such as CbiX(L), SirB, CbiK, and HemH through gene duplication and subsequent variation and selection. A classification scheme for chelatases is proposed.	Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	University of London; Queen Mary University London; Utah System of Higher Education; University of Utah	Warren, MJ (corresponding author), Queen Mary Univ London, Sch Biol Sci, Mile End Rd, London E1 4NS, England.	m.j.warren@qmul.ac.uk		Warren, Martin/0000-0002-6028-6456				Al-Karadaghi S, 1997, STRUCTURE, V5, P1501, DOI 10.1016/S0969-2126(97)00299-2; Battersby AR, 2000, NAT PROD REP, V17, P507, DOI 10.1039/b002635m; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; Fodje MN, 2001, J MOL BIOL, V311, P111, DOI 10.1006/jmbi.2001.4834; GRIFFITHS L, 1987, ARCH MICROBIOL, V147, P364, DOI 10.1007/BF00406134; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Leech HK, 2002, BIOCHEM SOC T, V30, P610, DOI 10.1042/bst0300610; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; Raux E, 2000, CELL MOL LIFE SCI, V57, P1880, DOI 10.1007/PL00000670; Raux E, 1999, BIOCHEM J, V338, P701, DOI 10.1042/0264-6021:3380701; Raux E, 1999, BIOORG CHEM, V27, P100, DOI 10.1006/bioo.1998.1125; Roper JM, 2000, J BIOL CHEM, V275, P40316, DOI 10.1074/jbc.M007146200; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Schubert HL, 2002, EMBO J, V21, P2068, DOI 10.1093/emboj/21.9.2068; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; Walker CJ, 1997, BIOCHEM J, V327, P321; WARREN MJ, 1994, BIOCHEM J, V302, P837, DOI 10.1042/bj3020837; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P486, DOI 10.1016/0968-0004(90)90304-T	22	69	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22388	22395		10.1074/jbc.M302468200	http://dx.doi.org/10.1074/jbc.M302468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686546	hybrid			2022-12-25	WOS:000183503900030
J	Ray, A; Ray, P; Guthrie, N; Shakya, A; Kumar, D; Ray, BK				Ray, A; Ray, P; Guthrie, N; Shakya, A; Kumar, D; Ray, BK			Protein kinase A signaling pathway regulates transcriptional activity of SAF-1 by unmasking its DNA-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; GENE-EXPRESSION; CATALYTIC SUBUNIT; ACTIVATING FACTOR; ETS-DOMAIN; PROMOTER; SP1; CAMP; SITE; MAZ	Serum amyloid A (SAA) activating factor-1 (SAF-1) is an inducible transcription factor that plays a key role in the regulation of several inflammation-responsive genes including SAA and matrix metalloproteinase-1. Increased synthesis of SAA and matrix metalloproteinase-1 is associated with pathogenesis of several diseases including amyloidosis, arthritis, and atherosclerosis. Previously, we showed in vivo interaction of SAF-1 and protein kinase A (PKA) and presented evidence for induction of SAF-1-regulated genes by a PKA signaling pathway. Here we demonstrate a mechanism by which PKA increases functional activities of SAF-1. Site-directed mutagenesis and phosphorylation analyses revealed two sites in the SAF-1 protein, serine 187 and threonine 386, as the target of PKA. Interestingly, mutation of both PKA phosphorylation sites created a highly active SAF-1 protein with high DNA-binding ability. Furthermore, we found that terminal deletion of SAF-1 protein from either end creates SAF-1 isoforms that are highly transcriptionally active. Partial proteolysis experiments indicated that unphosphorylated and phosphorylated SAF-1 proteins are structurally distinct. Together these results suggest that under native condition, N and C termini of SAF-1 are engaged in an inhibitory intramolecular interaction. PKA-mediated phosphorylation increases transcriptional activity of SAF-1 by unmasking the DNA-binding domain.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, A (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.			Shakya, Arvind/0000-0001-7993-6159	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK049205, R01DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Barik S, 1997, Methods Mol Biol, V67, P173; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KERLAVAGE AR, 1982, J BIOL CHEM, V257, P1749; Kolomytkin OV, 1999, AM J PHYSIOL-CELL PH, V276, pC9, DOI 10.1152/ajpcell.1999.276.1.C9; LALLI E, 1994, J BIOL CHEM, V269, P17359; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2003, ARTHRITIS RHEUM, V48, P134, DOI 10.1002/art.10706; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Ray A, 2002, DNA CELL BIOL, V21, P31, DOI 10.1089/10445490252810294; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 1997, DNA CELL BIOL, V16, P1, DOI 10.1089/dna.1997.16.1; RAY BK, 1991, BIOCHEM BIOPH RES CO, V180, P1258, DOI 10.1016/S0006-291X(05)81331-2; Ray BK, 2001, J IMMUNOL, V167, P2343, DOI 10.4049/jimmunol.167.4.2343; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Sambrook J., 1989, MOL CLONING LAB MODE, V2; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666	37	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22586	22595		10.1074/jbc.M300705200	http://dx.doi.org/10.1074/jbc.M300705200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12697757	hybrid			2022-12-25	WOS:000183503900056
J	Zhao, RX; Fu, XQ; Li, QS; Krantz, SB; Zhao, ZZJ				Zhao, RX; Fu, XQ; Li, QS; Krantz, SB; Zhao, ZZJ			Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PX DOMAINS; HOMOLOGY; BINDING; RECEPTOR; CELLS; PHOSPHOLIPIDS; LOCALIZATION; PURIFICATION; CLEARANCE; MEMBRANES	Protein tyrosine phosphatase (PTP)-MEG2 is an intracellular tyrosine phosphatase that contains a Sec14 homology domain. We have purified the full-length and truncated forms of the enzyme from recombinant adenovirus-infected human 293 cells. By using lipid-membrane overlay and liposome binding assays, we demonstrated that PTP-MEG2 specifically binds phosphatidylserine among over 20 lipid compounds tested. The binding is mediated by its N-terminal Sec14 domain. In intact cells, the Sec14 domain is responsible for localization of PTP-MEG2 to the perinuclear region, and uploading of PS into the cell membrane causes translocation of PTP-MEG2 to the plasma membrane. Phosphatidylserine is a relatively abundant cell membrane phospholipid non-symmetrically distributed in the outer layer and inner layer of cell membranes. It has recently been defined as an important ligand for clearance of apoptotic cells. By specifically binding phosphatidylserine, PTP-MEG2 may play an important role in regulating signaling processes associated with phagocytosis of apoptotic cells.	Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Jilin Univ, Coll Life Sci, Changchun 130023, Peoples R China	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Jilin University	Zhao, ZZJ (corresponding author), 777,PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	joe.zhao@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485, R01CA075218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015555] Funding Source: NIH RePORTER; NCI NIH HHS [CA75218, CA-68485] Funding Source: Medline; NIDDK NIH HHS [DK-15555] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1999, J MAMMARY GLAND BIOL, V4, P203, DOI 10.1023/A:1011384009787; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kruger JM, 2002, J BIOL CHEM, V277, P2620, DOI 10.1074/jbc.M104550200; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Qi Y, 2002, J CELL BIOCHEM, V86, P79, DOI 10.1002/jcb.10195; SATO Y, 1993, J BIOL CHEM, V268, P17705; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 2002, J BIOL CHEM, V277, P27412, DOI 10.1074/jbc.M109672200; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Wang XD, 2002, J IMMUNOL, V168, P4612, DOI 10.4049/jimmunol.168.9.4612; WOLF G, 1991, NUTR REV, V49, P1, DOI 10.1111/j.1753-4887.1991.tb07349.x; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780	34	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22609	22614		10.1074/jbc.M301560200	http://dx.doi.org/10.1074/jbc.M301560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12702726	hybrid			2022-12-25	WOS:000183503900059
J	Kiss, RS; Weers, PMM; Narayanaswami, V; Cohen, J; Kay, CM; Ryan, RO				Kiss, RS; Weers, PMM; Narayanaswami, V; Cohen, J; Kay, CM; Ryan, RO			Structure-guided protein engineering modulates helix bundle exchangeable apolipoprotein properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-BINDING DOMAIN; N-TERMINAL DOMAIN; MIGRATORIA APOLIPOPHORIN-III; A AMPHIPATHIC HELIX; LIPID-BINDING; LDL RECEPTOR; PHOSPHOLIPID-VESICLES; SECONDARY STRUCTURE; TRANSPORT PROTEIN	Apolipoprotein (apo) E plays a major role in lipid metabolism by mediating cellular uptake of lipoprotein particles through interaction with members of the low density lipoprotein (LDL) receptor family. The primary region of apoE responsible for receptor binding has been limited to a cluster of basic amino acids between residues 134 and 150, located in the fourth helix of the N-terminal domain globular helix bundle structure. To investigate structural and functional requirements of this "receptor binding region" we engineered an apolipoprotein chimera wherein residues 131-151 of human apoE were substituted for residues 146-166 ( helix 5) of Manduca sexta apolipophorin III (apoLp-III). Recombinant hybrid apolipoprotein was expressed in Escherichia coli, isolated, and characterized. Hybrid apolipoprotein and apoE3-N-terminal, but not apoLp-III, bound to heparin-Sepharose. Far UV circular dichroism spectroscopy revealed the presence of predominantly alpha-helix secondary structure, and stability studies revealed a urea denaturation midpoint of 1.05 M, similar to wild-type apoLp-III. Hybrid apolipoprotein-induced dimyristoylphosphatidylcholine ( DMPC) bilayer vesicle solubilization activity was significantly enhanced compared with either parent protein, consistent with detection of solvent-exposed hydrophobic regions on the protein in fluorescent dye binding experiments. Unlike wild-type apoLp-III.DMPC complexes, disc particles bearing the hybrid apolipoprotein competed with I-125-LDL for binding to the LDL receptor on cultured human skin fibroblasts. We conclude that a hybrid apolipoprotein containing a key receptor recognition element of apoE preserves the structural integrity of the parent protein while conferring a new biological activity, illustrating the potential of helix swapping to introduce desirable biological properties into unrelated or engineered apolipoproteins.	Childrens Hosp Oakland, Res Inst, Lipid Biol Hlth & Dis Res Grp, Oakland, CA 94609 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Prot Engn Network Ctr Excellencee, Edmonton, AB T6G 2S2, Canada	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Alberta; University of Alberta	Ryan, RO (corresponding author), Childrens Hosp Oakland, Res Inst, Lipid Biol Hlth & Dis Res Grp, 5700 MLK Jr Way, Oakland, CA 94609 USA.			Narayanaswami, Vasanthy/0000-0001-7088-4057	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL064159, R01HL064159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 64159] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; Chao HM, 1996, BIOCHEMISTRY-US, V35, P12175, DOI 10.1021/bi9530604; Clayton D, 1999, PROTEIN SCI, V8, P1797, DOI 10.1110/ps.8.9.1797; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; Datta G, 2001, J LIPID RES, V42, P959; Datta G, 2000, BIOCHEMISTRY-US, V39, P213, DOI 10.1021/bi991209w; Dhoest A, 1997, J BIOL CHEM, V272, P15967, DOI 10.1074/jbc.272.25.15967; DYER CA, 1991, J BIOL CHEM, V266, P22803; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; Fisher CA, 1997, BIOCHEM CELL BIOL, V75, P45, DOI 10.1139/bcb-75-1-45; Garda H. A., 2002, J BIOL CHEM, V262, P11794; HODGES R S, 1988, Peptide Research, V1, P19; Holvoet P, 2001, ARTERIOSCL THROM VAS, V21, P1977, DOI 10.1161/hq1201.100221; Holvoet P, 1996, J BIOL CHEM, V271, P19395, DOI 10.1074/jbc.271.32.19395; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KAWOOYA JK, 1984, J BIOL CHEM, V259, P733; Kiss RS, 1999, BIOCHEMISTRY-US, V38, P4327, DOI 10.1021/bi982597p; KISS RS, 1993, BIOCHEMISTRY-US, V32, P7872, DOI 10.1021/bi00082a006; LANGER T, 1972, J CLIN INVEST, V51, P1528, DOI 10.1172/JCI106949; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Laue T. M., 1991, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MIMS MP, 1994, J BIOL CHEM, V269, P20539; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Morrow JA, 2000, J BIOL CHEM, V275, P2576, DOI 10.1074/jbc.275.4.2576; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RAFFAI R, 1995, J LIPID RES, V36, P1905; Raussens V, 1998, J BIOL CHEM, V273, P25825, DOI 10.1074/jbc.273.40.25825; Raussens V, 2000, J BIOL CHEM, V275, P38329, DOI 10.1074/jbc.M005732200; Reschly EJ, 2002, J BIOL CHEM, V277, P9645, DOI 10.1074/jbc.M107883200; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; RYAN RO, 1995, J LIPID RES, V36, P1066; RYAN RO, 1993, J BIOL CHEM, V268, P1525; Sahoo D, 2002, J MOL BIOL, V321, P201, DOI 10.1016/S0022-2836(02)00618-6; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1992, J LIPID RES, V33, P141; Soulages JL, 1998, BIOCHEMISTRY-US, V37, P10203, DOI 10.1021/bi980622l; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; Weers PMM, 2000, J LIPID RES, V41, P416; Weers PMM, 2003, BIOPHYS CHEM, V100, P481, DOI 10.1016/S0301-4622(02)00300-9; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; Weers PMM, 2001, EUR J BIOCHEM, V268, P3728, DOI 10.1046/j.1432-1327.2001.02282.x; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Zaiou M, 2000, J LIPID RES, V41, P1087; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	63	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21952	21959		10.1074/jbc.M302676200	http://dx.doi.org/10.1074/jbc.M302676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12684504	hybrid			2022-12-25	WOS:000183354200081
J	Zhang, XW; Chen, Z; Chen, YL; Tong, TJ				Zhang, XW; Chen, Z; Chen, YL; Tong, TJ			Delivering antisense telomerase RNA by a hybrid adenovirus/adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells	ONCOGENE			English	Article						telomerase RNA; antisense; adenovirus; adeno-associated virus; gene therapy; breast cancer	SITE-SPECIFIC INTEGRATION; CATALYTIC SUBUNIT; IMMORTAL CELLS; HIGH-CAPACITY; GENE-TRANSFER; TUMOR-CELLS; DNA; INDUCTION; VECTORS; INHIBITION	Activated tetomerase is frequently detected in cancer cells and is able to maintain and stabilize the integrity of telomeres; it also contributes to unlimited divisions in cancer cells. Recently, a new generation of selective anticancer strategies is under development targeting the blockage of telomerase activity either at the protein level or telomerase RNA. Here, we report suppression of the malignant phenotype by the expression of the full-length antisense human telomerase RNA (hTR) delivered by a novel hybrid vector recombining adenovirus and adenoassociated virus (vAd-AAV). The hybrid vector vAd-AAV retained the unique traits from two parental viruses, such as high efficiency of gene transfer in mammalian cells and the ability to integrate into the genomic DNA of host cells. The stable expression of antisense hTR in MCF-7, cells significantly suppressed telomerase activity and progressively shortened telomere length for 30 population doublings (PD30). Expression of antisense hTR leads to a telomere-based growth arrest and the induction of spontaneous apoptosis. Antisense hTR decreased soft agar colony formation and reduced the cell proliferation, leading to exit from the cell cycle at G1 at PD15. The expression of antisense hTR also sensitized MCF-7 cells to apoptosis induced by sodium butyrate or serum starvation. Our study demonstrates that delivering antisense hTR by the hybrid Ad/AAV vector is an effective antineoplastic gene therapeutic strategy, which significantly suppresses the malignant phenotype and enhances apoptosis of human breast cancer cells.	Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China; Natl Inst Deafness & Commun Disorders, Head & Neck Surg Branch, Tumor Biol Sect, NIH, Bethesda, MD 20892 USA	Peking University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Tong, TJ (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.							ALI M, 1994, GENE THER, V1, P367; ANDREW NS, 1994, CANCER GENE THER, V1, P165; Avilion AA, 1996, CANCER RES, V56, P645; BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Campisi J, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P348; Campisi Judith, 1996, P121; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOUGLAS J, 1994, CANCER GENE THER, V1, P51; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Elenitoba-Johnson KSJ, 2001, AM J PATHOL, V159, P405, DOI 10.1016/S0002-9440(10)61710-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; GUILBAUD NF, 1990, J CELL PHYSIOL, V145, P162, DOI 10.1002/jcp.1041450122; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2001, CLIN CANCER RES, V7, P2953; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; Hsiao RS, 1997, ANTICANCER RES, V17, P827; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; KOTIN RM, 1992, EMBO J, V11, P5071, DOI 10.1002/j.1460-2075.1992.tb05614.x; Kyo S, 1997, CANCER RES, V57, P610; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li ZD, 2000, ACTA BIOCH BIOPH SIN, V32, P383; Lieber A, 1999, J VIROL, V73, P9314, DOI 10.1128/JVI.73.11.9314-9324.1999; Lu MS, 1996, J VIROL, V70, P8850, DOI 10.1128/JVI.70.12.8850-8857.1996; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Philpott NJ, 2002, J VIROL, V76, P5411, DOI 10.1128/JVI.76.11.5411-5421.2002; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Recchia A, 1999, P NATL ACAD SCI USA, V96, P2615, DOI 10.1073/pnas.96.6.2615; RICHARD JS, 1989, J VIROL, V63, P3822; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Schulick AH, 1997, J CLIN INVEST, V99, P209, DOI 10.1172/JCI119149; Shay J W, 2001, Novartis Found Symp, V235, P116; Shayakhmetov DM, 2002, J VIROL, V76, P1135, DOI 10.1128/JVI.76.3.1135-1143.2002; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Smith R. H., 2002, MOBILE DNA, P905; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; Strahl C, 1996, MOL CELL BIOL, V16, P53; Tsao JI, 1997, CLIN CANCER RES, V3, P627; WANG FS, 1997, J BEIJING MED U, V29, P295; WANG WG, 1999, CHIN J BIOCH MOL BIO, V15, P655; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wright Woodring E., 1996, V16, P153; Yamamoto I, 1996, J BIOCHEM-TOKYO, V119, P1056; 王文恭, 1997, 北京医科大学学报, V29, P490; 张新庆, 2001, 中华神经外科杂志, V17, P395	70	27	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2405	2416		10.1038/sj.onc.1206317	http://dx.doi.org/10.1038/sj.onc.1206317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717417				2022-12-25	WOS:000182383500003
J	Thompson, HGR; Harris, JW; Wold, BJ; Lin, F; Brody, JP				Thompson, HGR; Harris, JW; Wold, BJ; Lin, F; Brody, JP			p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells	ONCOGENE			English	Article						breast cancer; P62; PDEF; promoter; proteasome inhibitor; SQSTM1	PHOSPHOTYROSINE-INDEPENDENT LIGAND; CHAIN BINDING-PROTEIN; KAPPA-B ACTIVATION; TRANSCRIPTION FACTOR; DNA-BINDING; SH2 DOMAIN; GENE; PEA3; PROTEASOME; EXPRESSION	p62 is a multifunctional cytoplasmic protein able to noncovalently bind ubiquitin and several signaling proteins, suggesting a regulatory role connected to the ubiquitin-proteasome pathway. No studies to date have linked p62 protein expression with pathological states. Here we demonstrate the overabundance of p62 protein in malignant breast tissue relative to normal breast tissue. The proteasome inhibitor PSI increased p62 mRNA and protein; however, PSI treatment of breast epithelial cells transfected with the p62 promoter did not affect promoter activity. High levels of prostate-derived Ets factor (PDEF) mRNA have been identified in breast cancer compared to normal breast. Only the PSA and maspin promoters have been identified as targets of this transcription factor. Here we show that PDEF stimulates the p62 promoter through at least two sites, and likely acts as a coactivator. PSI treatment abrogates the PDEF-stimulated increase of p62 promoter activity by 50%. Thus, multiple mechanisms for the induction of p62 exist. We conclude that (1) p62 protein is overexpressed in breast cancer; (2) p62 mRNA and protein increase in response to PSI, with no change of basal promoter activity; (3) PDEF upregulates p62 promoter activity through at least two sites; and (4) PSI downregulates PDEF-induced p62 promoter activation through one of these sites.	Univ Calif Irvine, Dept Biomed Engn, Rockwell Engn Ctr 204, Irvine, CA 92697 USA; CALTECH, Dept Biol, Pasadena, CA 91125 USA; Univ Calif Irvine, Irvine Med Ctr, Orange, CA 92868 USA	University of California System; University of California Irvine; California Institute of Technology; University of California System; University of California Irvine	Brody, JP (corresponding author), Univ Calif Irvine, Dept Biomed Engn, Rockwell Engn Ctr 204, Irvine, CA 92697 USA.			Brody, James/0000-0002-7995-5197	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K22HG000047] Funding Source: NIH RePORTER; NHGRI NIH HHS [1K22HG00047-01, K22 HG000047, K22 HG000047-01, K22 HG000047-03, K22 HG000047-02] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Adams J, 2001, SEMIN ONCOL, V28, P613, DOI 10.1053/sonc.2001.28609; Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen H, 2002, CANCER RES, V62, P338; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Fan XM, 2001, INT J CANCER, V93, P481, DOI 10.1002/ijc.1373; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hiroumi H, 2001, INT J CANCER, V93, P786, DOI 10.1002/ijc.1410; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Lee YH, 1998, FEBS LETT, V438, P297, DOI 10.1016/S0014-5793(98)01323-4; Nagamura-Inoue T, 2001, Int Rev Immunol, V20, P83, DOI 10.3109/08830180109056724; Nozawa M, 2000, CANCER RES, V60, P1348; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pasquini LA, 2000, J NEUROSCI RES, V59, P601, DOI 10.1002/(SICI)1097-4547(20000301)59:5<601::AID-JNR3>3.0.CO;2-1; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Sudo T, 2000, BIOCHEM BIOPH RES CO, V269, P521, DOI 10.1006/bbrc.2000.2333; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Vadlamudi RK, 1998, FEBS LETT, V435, P138, DOI 10.1016/S0014-5793(98)01021-7; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300	44	142	148	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2322	2333		10.1038/sj.onc.1206325	http://dx.doi.org/10.1038/sj.onc.1206325			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700667				2022-12-25	WOS:000182231500010
J	Zhang, H; Morisaki, T; Nakahara, C; Matsunaga, H; Sato, N; Nagumo, F; Tadano, J; Katano, M				Zhang, H; Morisaki, T; Nakahara, C; Matsunaga, H; Sato, N; Nagumo, F; Tadano, J; Katano, M			PSK-mediated NF-kappa B inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1	ONCOGENE			English	Article						pancreatic cancer; docetaxel; PSK; apoptosis; NF-kappa B	PHASE-II; TUMOR-CELLS; ACTIVATION; CHEMOTHERAPY; AGENTS; LINE; PHOSPHORYLATION; SUPPRESSION; EXPERIENCE; EXPRESSION	Docetaxel, a member of the taxane family, has been shown to induce apoptosis in a variety of cancer cells. However, toxicity at therapeutic doses has precluded the use of docetaxel alone for the management of cancer patients. PSK, a protein-bound polysaccharide, is widely used in Japan as an immunopotentiating biological response modifier for cancer patients. Our previous study showed that PSK induced downregulation of several invasion-related factors, suggesting an interaction of PSK with transcriptional factors. In this study, we showed that PSK dose dependently enhanced apoptosis induced by 1 nM of docetaxel in a human pancreatic cancer cell line NOR-P1. Furthermore, PSK inhibited docetaxel-induced nuclear factor kappa B (NF-kappaB) activation. Moreover, the expression of cellular inhibitor of apoptosis protein (cIAP-1), which is transcriptionally regulated by NF-kappaB and functions as an antiapoptotic molecule through interrupting the caspase pathway, was also inhibited by treatment with PSK plus docetaxel. As a result, PSK enhanced the docetaxel-induced caspase-3 activation. In addition, treatment by transfection of NF-kappaB decoy oligodeoxynucleotides (ODNs), but not scramble ones, inhibited the expression of cIAP-1 in NOR-P1 cells and induced a significant increase in docetaxel-induced apoptosis. Our data indicate that PSK suppresses the docetaxel-induced NF-kappaB activation pathway. Combination of PSK with a low dose of docetaxel may be a new therapeutic strategy to treat patients with pancreatic cancer.	Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Saga Med Sch, Dept Hosp Clin Lab, Saga 8498501, Japan; Saga Med Sch, Dept Hosp Pharm, Saga 8498501, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Oncol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Saga University; Saga University; Kyushu University	Morisaki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ANAI H, 1991, ANTI-CANCER DRUG, V2, P275; Aota K, 2000, BIOCHEM BIOPH RES CO, V273, P1168, DOI 10.1006/bbrc.2000.3072; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BISSERY MC, 1995, ANTI-CANCER DRUG, V6, P339, DOI 10.1097/00001813-199506000-00001; Cascinu S, 1999, ANN ONCOL, V10, P1377, DOI 10.1023/A:1008394111533; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CORTES JE, 1995, J CLIN ONCOL, V13, P2643, DOI 10.1200/JCO.1995.13.10.2643; Cui XF, 2000, BBA-GEN SUBJECTS, V1524, P178, DOI 10.1016/S0304-4165(00)00155-0; EBINA T, 1992, JPN J CANCER RES, V83, P775, DOI 10.1111/j.1349-7006.1992.tb01979.x; Fisher M, 2002, ANTICANCER RES, V22, P1737; Fukushima M, 1996, SEMIN ONCOL, V23, P369; Haldar S, 1997, CANCER RES, V57, P229; Huang Y, 2000, CANCER RES, V60, P4426; IINO Y, 1992, ANTICANCER RES, V12, P2101; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; IWAGUCHI T, 1989, J BIOCHEM BIOPH METH, V18, P157, DOI 10.1016/0165-022X(89)90077-8; KAYE SB, 1995, SEMIN ONCOL, V22, P30; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kolfschoten GM, 2002, BIOCHEM PHARMACOL, V63, P733, DOI 10.1016/S0006-2952(01)00895-4; Lenzi R, 2002, CANCER INVEST, V20, P464, DOI 10.1081/CNV-120002146; MORI H, 1987, INT J IMMUNOPHARMACO, V9, P881, DOI 10.1016/0192-0561(87)90004-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okada S, 1999, BRIT J CANCER, V80, P438, DOI 10.1038/sj.bjc.6690375; Rougier P, 2000, EUR J CANCER, V36, P1016, DOI 10.1016/S0959-8049(00)00072-1; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sato N, 2000, CANCER LETT, V155, P153, DOI 10.1016/S0304-3835(00)00421-3; Shibata M, 2002, CANCER INVEST, V20, P166, DOI 10.1081/CNV-120001142; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; Stathopoulos GP, 2001, ANN ONCOL, V12, P101, DOI 10.1023/A:1008310106171; Takahashi Y, 2001, Gan To Kagaku Ryoho, V28, P531; TSUKAGOSHI S, 1984, CANCER TREAT REV, V11, P131, DOI 10.1016/0305-7372(84)90005-7; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1; Zhang H, 2000, CLIN EXP METASTAS, V18, P343	38	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2088	2096		10.1038/sj.onc.1206310	http://dx.doi.org/10.1038/sj.onc.1206310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687011				2022-12-25	WOS:000182066900003
J	Hutchings, H; Ortega, N; Plouet, J				Hutchings, H; Ortega, N; Plouet, J			Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation	FASEB JOURNAL			English	Article						angiogenesis; VEGF; tumstatin	ALPHA(V)BETA(3) INTEGRIN; TYROSINE KINASE; FACTOR VEGF; RECEPTOR; ACTIVATION; ISOFORM; IDENTIFICATION; ANGIOGENESIS; MECHANISM; SEQUENCE	Vascular endothelial growth factor (VEGF), a major factor mediating endothelial cell survival, migration, and proliferation during angiogenesis, is expressed as five splice variants (121, 145, 165, 189, and 206 aminoacids) encoded by a single gene. Although the three shorter isoforms are mainly diffusible, the two longer ones are sequestered in cell membranes after secretion. However, their potential role as true components of the extracellular matrix has not been investigated. We determined that endothelial cells could adhere and spread on VEGF(189) and VEGF(165), but not on VEGF(121). Adhesion was mediated by the alpha3beta1 and alphavbeta3 integrins and other alphav integrins but not by the cognate VEGF receptors. Cells migrated on VEGF(165) and VEGF(189) and displayed a stellate morphology with numerous lamellopodia and FAK staining but no actin stress fibers. Tumstatin, an antiangiogenic peptide that interacts with the alphavbeta3 integrin, could inhibit adhesion on VEGF, and this effect was potentiated by anti-alphavbeta3 blocking antibody. Immobilized VEGF almost totally abolished endothelial cell apoptosis through interactions with integrins. The inhibition of alphavbeta3 engagement with immobilized VEGF by tumstatin inhibited most of its survival activity. We have thus determined a new VEGF receptor-independent role for immobilized VEGF in supporting cell adhesion and survival through interactions with integrins.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Plouet, J (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	jean.plouet@ipbs.fr	Ortega, Nathalie/C-3382-2019					Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BENSAID M, 1989, EXP EYE RES, V48, P801, DOI 10.1016/0014-4835(89)90065-1; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Dallabrida SM, 2000, BLOOD, V95, P2586, DOI 10.1182/blood.V95.8.2586.008k04_2586_2592; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P29922; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Moore A, 1998, METHOD CELL BIOL, V57, P265; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Okamoto K, 1999, ONCOL REP, V6, P1201; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Pufe T, 2001, ARTHRITIS RHEUM, V44, P1082, DOI 10.1002/1529-0131(200105)44:5<1082::AID-ANR188>3.0.CO;2-X; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yuan A, 2001, J CLIN ONCOL, V19, P432, DOI 10.1200/JCO.2001.19.2.432	40	169	180	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1520	+		10.1096/fj.02-0691fje	http://dx.doi.org/10.1096/fj.02-0691fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709411				2022-12-25	WOS:000182580100024
J	Arien, H; Wiser, O; Arkin, IT; Leonov, H; Atlas, D				Arien, H; Wiser, O; Arkin, IT; Leonov, H; Atlas, D			Syntaxin 1A modulates the voltage-gated L-type calcium channel (Ca(v)1.2) in a cooperative manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE STRING PROTEINS; N-TYPE; CA2+ CHANNEL; TRANSMEMBRANE DOMAIN; MOLECULAR DETERMINANTS; FUNCTIONAL INTERACTION; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; SNARE PROTEINS; BETA-SUBUNITS	Syntaxin 1A (Sx1A) modifies the activity of voltage-gated Ca2+ channels acting via the cytosolic and the two vicinal cysteines ( 271 and 272) at the transmembrane domain. Here we show that Sx1A modulates the Lc-type Ca2+ channel, Ca(v)1.2, in a cooperative manner, and we explore whether channel clustering or the Sx1A homodimer is responsible for this activity. Sx1A formed homodimers but, when mutated at the two vicinal transmembrane domain cysteines, was unable to either dimerize or modify the channel activity suggesting disulfide bond formation. Moreover, applying global molecular dynamic search established a theoretical prospect of generating a disulfide bond between two Sx1A transmembrane helices. Nevertheless, Sx1A activity was not correlated with Sx1A homodimer. Application of a vicinal thiol reagent, phenylarsine oxide, abolished Sx1A action indicating the accessibility of Cys-271,272 thiols. Sx1A inhibition of channel activity was restored by phenylarsine oxide antidote, 2,3-dimercaptopropanol, consistent with thiol interaction of Sx1A. In addition, the supralinear mode of channel inhibition was correlated to the monomeric form of Sx1A and was apparent only when the three channel subunits alpha(1)1.2/alpha(2) delta1/ beta2a were present. This functional demonstration of cooperativity suggests that the three-subunit channel responds as a cluster, and Sx1A monomers associate with a dimer ( or more) of a three-subunit Ca2+ channel. Consistent with channel cluster linked to Sx1A, a conformational change driven by membrane depolarization and Ca2+ entry would rapidly be transduced to the exocytotic machinery. As shown herein, the supralinear relationship between Sx1A and the voltage-gated Ca2+ channel within the cluster could convey the cooperativity that distinguishes the process of neurotransmitter release.	Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Atlas, D (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Inst Life Sci, IL-91904 Jerusalem, Israel.	datlas@vms.huji.ac.il	Arkin, Isaiah/GQA-4328-2022	Arkin, Isaiah/0000-0002-7659-1746				ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; Atlas D, 2001, CELL MOL NEUROBIOL, V21, P717, DOI 10.1023/A:1015104105262; Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Bezprozvanny I, 2000, P NATL ACAD SCI USA, V97, P13943, DOI 10.1073/pnas.220389697; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bowen ME, 2002, BIOCHEMISTRY-US, V41, P15861, DOI 10.1021/bi0269411; Brice NL, 1999, J PHYSIOL-LONDON, V515, P685, DOI 10.1111/j.1469-7793.1999.685ab.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulbarelli A, 2002, J CELL SCI, V115, P1689; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cohen R, 2003, J BIOL CHEM, V278, P9258, DOI 10.1074/jbc.M210270200; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; Frank K, 2000, ANN MED, V32, P572, DOI 10.3109/07853890008998837; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Laage R, 2000, J BIOL CHEM, V275, P17481, DOI 10.1074/jbc.M910092199; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; Lewis JL, 2001, J BIOL CHEM, V276, P15458, DOI 10.1074/jbc.M011687200; Margittai M, 1999, FEBS LETT, V446, P40, DOI 10.1016/S0014-5793(99)00028-9; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; Mirotznik RR, 2000, J NEUROSCI, V20, P7614; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; Trus M, 2001, NEUROSCIENCE, V104, P599, DOI 10.1016/S0306-4522(01)00083-5; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wang MC, 2002, J MOL BIOL, V323, P85, DOI 10.1016/S0022-2836(02)00890-2; Wiser O, 1997, FEBS LETT, V404, P203, DOI 10.1016/S0014-5793(97)00130-0; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 2002, P NATL ACAD SCI USA, V99, P3968, DOI 10.1073/pnas.052017299; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Wyatt CN, 1998, J PHYSIOL-LONDON, V510, P347, DOI 10.1111/j.1469-7793.1998.347bk.x; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348	53	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29231	29239		10.1074/jbc.M301401200	http://dx.doi.org/10.1074/jbc.M301401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12721298	hybrid			2022-12-25	WOS:000184421100108
J	Rao, KS; Albro, M; Vockley, J; Frerman, FE				Rao, KS; Albro, M; Vockley, J; Frerman, FE			Mechanism-based inactivation of human glutaryl-CoA dehydrogenase by 2-pentynoyl-CoA - Rationale for enhanced reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; PIG-KIDNEY; SUBSTRATE; LIVER; DECARBOXYLATION; IDENTIFICATION; FLAVOPROTEIN; CARBOXYLATE; ACTIVATION; RESOLUTION	2-Pentynoyl-CoA inactivates glutaryl-CoA dehydrogenase at a rate that considerably exceeds the rates of inactivation of short chain and medium chain acyl-CoA dehydrogenases by this inhibitor and related 2-alkynoyl-CoAs. To determine the rate of inactivation by 2-pentynoyl-CoA, we investigated the inactivation in the presence of a non-oxidizable analog, 3-thiaglutaryl-CoA, which competes for the binding site. The enhanced rate of inactivation does not reflect an alteration in specificity for the acyl group, nor does it reflect the covalent modification of a residue other than the active site glutamate. In addition to determining the inactivation of catalytic activity a spectral intermediate was detected by stopped-flow spectrophotometry, and the rate constants of formation and decay of this charge transfer complex (lambda(max) approximate to 790 nm) were determined by global analysis. Although the rate-limiting step in the inactivation of the other acyl-CoA dehydrogenases can involve the abstraction of a proton at C-4, this is not the case with glutaryl-CoA dehydrogenase. Glutaryl-CoA dehydrogenase is also differentiated from other acyl-CoA dehydrogenases in that the catalytic base must access both C-2 and C-4 in the normal catalytic pathway. Access to C-4 is not obligatory for the other dehydrogenases. Analysis of the distance from the closest carboxylate oxygen of the glutamate base catalyst to C-4 of a bound acyl-CoA ligand for medium chain, short chain, and isovaleryl-CoA dehydrogenases suggests that the increased rate of inactivation reflects the carboxylate oxygen to ligand C-4 distance in the binary complexes. This distance for wild type glutaryl-CoA dehydrogenase is not known. Comparison of the rate constants of inactivation and formation of a spectral species between wild type glutaryl-CoA dehydrogenase and a E370D mutant are consistent with the idea that this distance in glutaryl-CoA dehydrogenase contributes to the enhanced rate of inactivation and the 1,3-prototropic shift catalyzed by the enzyme.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Denver, CO 80262 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Mayo Clinic; Mayo Clinic	Frerman, FE (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, 4200 E 9th Ave,Box C-233, Denver, CO 80262 USA.	Frank.Frerman@UCHSC.edu	Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039339] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39339] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bach RD, 2002, J PHYS CHEM B, V106, P4325, DOI 10.1021/jp020029k; Battaile KP, 2002, J BIOL CHEM, V277, P12200, DOI 10.1074/jbc.M111296200; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; CHARBONNEAU H, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P15; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; Dwyer TM, 2000, BIOCHEMISTRY-US, V39, P11488, DOI 10.1021/bi000700g; Dwyer TM, 2001, J BIOL CHEM, V276, P133, DOI 10.1074/jbc.M007672200; FENDRICH G, 1982, BIOCHEMISTRY-US, V21, P6685, DOI 10.1021/bi00269a011; FREUND K, 1985, BIOCHEMISTRY-US, V24, P5996, DOI 10.1021/bi00342a046; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GOMES B, 1981, BIOCHEMISTRY-US, V20, P1481, DOI 10.1021/bi00509a012; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Griffin KJ, 1998, EUR J BIOCHEM, V255, P125, DOI 10.1046/j.1432-1327.1998.2550125.x; Jogl G, 2003, P NATL ACAD SCI USA, V100, P50, DOI 10.1073/pnas.0233793100; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KIM JJP, 1999, FLAVINS FLAVOPROTEIN, P539; KIM JJP, 1999, FLAVINS FLAVOPROTEIN, P491; Leatherbarrow R. J., 1998, GRAFIT VERSION 4 0; LUNDBERG NN, 1993, ARCH BIOCHEM BIOPHYS, V305, P454, DOI 10.1006/abbi.1993.1446; Mohsen AWA, 2001, MOL GENET METAB, V73, P126, DOI 10.1006/mgme.2001.3183; Peterson KL, 1998, BIOCHEMISTRY-US, V37, P1697, DOI 10.1021/bi972590s; POWELL PJ, 1988, BIOCHEMISTRY-US, V27, P8022, DOI 10.1021/bi00421a008; Rando R R, 1977, Methods Enzymol, V46, P158; Rao KS, 2002, BIOCHEMISTRY-US, V41, P1274, DOI 10.1021/bi015617n; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Schaller RA, 1997, BIOCHEMISTRY-US, V36, P7761, DOI 10.1021/bi970095q; Scheiner S, 2001, J BIOL CHEM, V276, P9832, DOI 10.1074/jbc.M010770200; SILVERMAN RB, 1995, METHOD ENZYMOL, V249, P240; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; Tamaoki H, 1999, J BIOCHEM, V125, P285, DOI 10.1093/oxfordjournals.jbchem.a022285; Telford EAR, 1999, BBA-GENE STRUCT EXPR, V1446, P371, DOI 10.1016/S0167-4781(99)00102-5; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; TIPTON KF, 1980, ENZYME INHIBITORS DR, P1; Westover JB, 2001, BIOCHEMISTRY-US, V40, P14106, DOI 10.1021/bi015637p; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415	38	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26342	26350		10.1074/jbc.M210781200	http://dx.doi.org/10.1074/jbc.M210781200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12716879	hybrid			2022-12-25	WOS:000184155700009
J	Bykova, NV; Stensballe, A; Egsgaard, H; Jensen, ON; Moller, IM				Bykova, NV; Stensballe, A; Egsgaard, H; Jensen, ON; Moller, IM			Phosphorylation of formate dehydrogenase in potato tuber mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS PROTEIN-PHOSPHORYLATION; POLYACRYLAMIDE-GEL ELECTROPHORESIS; NUCLEOSIDE-DIPHOSPHATE KINASE; PLANT-MITOCHONDRIA; MASS-SPECTROMETRY; PHOSPHOPROTEINS; MEMBRANE; IDENTIFICATION; DEAMIDATION; COMPLEXES	Two highly phosphorylated proteins were detected after two-dimensional (blue native/SDS-PAGE) gel electrophoretic separation of the matrix fraction isolated from potato tuber mitochondria. These two phosphoproteins were identified by mass spectrometry as formate dehydrogenase (FDH) and the E1alpha-subunit of pyruvate dehydrogenase (PDH). Isoelectric focusing/SDS-PAGE two-dimensional gels separated FDH and PDH and resolved several different phosphorylated forms of FDH. By using combinations of matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization tandem mass spectrometry, several phosphorylation sites were identified for the first time in FDH and PDH. FDH was phosphorylated on Thr(76) and Thr(333), whereas PDH was phosphorylated on Ser(294). Both Thr(76) and Thr(333) in FDH were accessible to protein kinases, as demonstrated by protein structure homology modeling. The extent of phosphorylation of both FDH and PDH was strongly decreased by NAD(+), formate, and pyruvate, indicating that reversible phosphorylation of FDH and PDHs was regulated in a similar fashion. At low oxygen concentrations inside the intact potato tubers, FDH activity was strongly increased relative to cytochrome c oxidase activity pointing to a possible involvement of FDH in hypoxic metabolism. Computational sequence analysis indicated that a conserved local sequence motif of pyruvate formate-lyase is found in the Arabidopsis thaliana genome, and this enzyme might be the source of formate for FDH in plants.	Riso Natl Lab, Plant Res Dept, DK-4000 Roskilde, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	Technical University of Denmark; University of Southern Denmark	Moller, IM (corresponding author), Riso Natl Lab, Plant Res Dept, Bldg 301,POB 49, DK-4000 Roskilde, Denmark.	ian.max.moller@risoe.dk	Jensen, Ole N/J-1763-2012; Stensballe, Allan/K-6756-2019	Jensen, Ole N/0000-0003-1862-8528; Stensballe, Allan/0000-0002-9888-1955				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Becker A, 1999, NAT STRUCT BIOL, V6, P969; BERKELMAN T, 1998, 2 D ELECTROPHORESIS, P100; Bykova NV, 2003, FEBS LETT, V540, P141, DOI 10.1016/S0014-5793(03)00250-3; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Corso M, 2001, PLACENTA, V22, P432, DOI 10.1053/plac.2001.0672; DESFRANCSSMALL CC, 1993, PLANT PHYSIOL, V102, P1171, DOI 10.1104/pp.102.4.1171; Exner T, 1999, P NATL ACAD SCI USA, V96, P1327, DOI 10.1073/pnas.96.4.1327; Gaut JR, 1997, CELL STRESS CHAPERON, V2, P252, DOI 10.1379/1466-1268(1997)002<0252:IVTPOI>2.3.CO;2; Geigenberger P, 2000, BIOL CHEM, V381, P723, DOI 10.1515/BC.2000.093; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARRIS RA, 1997, ADV ENZYME REGUL, V3, P271; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hourton-Cabassa C, 1998, PLANT PHYSIOL, V116, P627, DOI 10.1104/pp.116.2.627; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Igamberdiev AU, 1999, PLANT PHYSIOL BIOCH, V37, P503, DOI 10.1016/S0981-9428(99)00152-7; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Jensen ON, 1998, PROTEINS, P74; Kruft V, 2001, PLANT PHYSIOL, V127, P1694, DOI 10.1104/pp.010474; Lambeth DO, 1997, J BIOL CHEM, V272, P24604, DOI 10.1074/jbc.272.39.24604; LAMZIN VS, 1992, EUR J BIOCHEM, V206, P441, DOI 10.1111/j.1432-1033.1992.tb16945.x; LAMZIN VS, 1994, J MOL BIOL, V236, P759, DOI 10.1006/jmbi.1994.1188; Lund AA, 2001, J BIOL CHEM, V276, P29924, DOI 10.1074/jbc.M103373200; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Marchler-Bauer A, 2002, NUCLEIC ACIDS RES, V30, P281, DOI 10.1093/nar/30.1.281; MIERNYK JA, 1992, PLANT PHYSIOL, V100, P965, DOI 10.1104/pp.100.2.965; MOLLER IM, 1987, METHOD ENZYMOL, V148, P442; Mooney BP, 2002, ANNU REV PLANT BIOL, V53, P357, DOI 10.1146/annurev.arplant.53.100301.135251; PETIT PX, 1990, PHYSIOL PLANTARUM, V80, P493, DOI 10.1111/j.1399-3054.1990.tb05669.x; PICAL C, 1993, FEBS LETT, V336, P347, DOI 10.1016/0014-5793(93)80835-I; RASMUSSON AG, 1990, PLANT PHYSIOL, V94, P1012, DOI 10.1104/pp.94.3.1012; Sarioglu H, 2000, ELECTROPHORESIS, V21, P2209, DOI 10.1002/1522-2683(20000601)21:11<2209::AID-ELPS2209>3.0.CO;2-T; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Signorile A, 2002, FEBS LETT, V512, P91, DOI 10.1016/S0014-5793(02)02226-3; Snyder A.P., 2000, INTERPRETING PROTEIN, P265; SOMMARIN M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P195, DOI 10.1016/0167-4889(90)90076-P; Steen H, 2001, J AM SOC MASS SPECTR, V12, P228, DOI 10.1016/S1044-0305(00)00219-1; Stensballe A, 2001, PROTEOMICS, V1, P207, DOI 10.1002/1615-9861(200102)1:2<207::AID-PROT207>3.3.CO;2-V; Struglics A, 1999, EUR J BIOCHEM, V262, P765, DOI 10.1046/j.1432-1327.1999.00432.x; Struglics A, 1999, PLANT CELL PHYSIOL, V40, P1271, DOI 10.1093/oxfordjournals.pcp.a029515; Struglics A, 1998, BIOCHEM BIOPH RES CO, V243, P664, DOI 10.1006/bbrc.1998.8151; Struglics A, 2000, FEBS LETT, V475, P213, DOI 10.1016/S0014-5793(00)01680-X; Suzuki K, 1998, PLANT PHYSIOL, V116, P725, DOI 10.1104/pp.116.2.725; Takemoto L, 2000, MOL VIS, V6, P164; Takemoto L, 1998, BIOCHEMISTRY-US, V37, P13681, DOI 10.1021/bi981542k; TECHNIKOVADOBROVA Z, 1993, FEBS LETT, V322, P51, DOI 10.1016/0014-5793(93)81109-D; TRUESDALE GA, 1955, J APPL CHEM-USSR, V5, P153; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	53	59	67	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26021	26030		10.1074/jbc.M300245200	http://dx.doi.org/10.1074/jbc.M300245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12714601	hybrid			2022-12-25	WOS:000183920200098
J	Hoekstra, M; Kruijt, J; Van Eck, M; van Berkel, TJC				Hoekstra, M; Kruijt, J; Van Eck, M; van Berkel, TJC			Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE CHOLESTEROL TRANSPORT; DENSITY-LIPOPROTEIN RECEPTOR; SALT EXPORT PUMP; SCAVENGER RECEPTOR; STEROL 27-HYDROXYLASE; DIETARY-CHOLESTEROL; X-RECEPTOR; LXR-ALPHA; CLASS-B; ABCG5	Hepatic cholesterol(ester) uptake from serum coupled to intracellular processing and biliary excretion are important features in the removal of excess cholesterol from the body. ATP-binding cassette (ABC) transporters play an important role in hepatic cholesterol transport. The liver consists of different cell types, and ABC transporters may exert different physiological functions dependent on the individual cell type. Therefore, in the current study, using real time PCR we compared the mRNA expression of ABC transporters and genes involved in the regulation of cholesterol metabolism in liver parenchymal, endothelial, and Kupffer cells. It appears that liver parenchymal cells contain high expression levels compared with endothelial and Kupffer cells of scavenger receptor class BI (similar to3-fold), peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma (8 -20-fold), cholesterol 7alpha-hydroxylase A1 (> 100-fold), and ABCG5/G8 (similar to5-fold). Liver endothelial cells show a high expression of cholesterol 27-hydroxylase, liver X receptor (LXR) beta, PPARdelta, and ABCG1, suggesting a novel specific role for these genes in endothelial cells. In Kupffer cells, the expression level of LXRalpha, ABCA1, and in particular ABCG1 is high, leading to an ABCG1 mRNA expression level that is 70-fold higher than in parenchymal cells. It can be calculated that 51% of the total liver ABCG1 expression resides in Kupffer cells and 24% in endothelial cells, suggesting an intrahepatic-specific role for ABCG1 in Kupffer and endothelial cells. Because of a specific stimulation of ABCG1 in parenchymal cells by a high cholesterol diet, the contribution of parenchymal cells to the total liver increased from 25 to 60%. Our data indicate that for studies of the role of ABC transporters and their regulation in liver, their cellular localization should be taken into account, allowing proper interpretation of metabolic changes, which are directly related to their ( intra) cellular expression level.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Hoekstra, M (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9502, NL-2300 RA Leiden, Netherlands.	Hoekstra@LACDR.Leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021	van Eck, Miranda/0000-0003-3936-3194; Hoekstra, Menno/0000-0001-7463-2893				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; Argmann CA, 2001, ARTERIOSCL THROM VAS, V21, P2011, DOI 10.1161/hq1201.099426; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; DERIJKE YB, 1992, ARTERIOSCLER THROMB, V12, P41, DOI 10.1161/01.ATV.12.1.41; Fitzgerald ML, 2002, J MOL MED, V80, P271, DOI 10.1007/s00109-001-0318-y; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Glomset J A, 1980, Adv Intern Med, V25, P91; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Haghpassand M, 2001, J CLIN INVEST, V108, P1315, DOI 10.1172/JCI200112810; Heimerl Susanne, 2002, Human Mutation, V20, P151, DOI 10.1002/humu.9047; Hunt MC, 2000, J BIOL CHEM, V275, P28947, DOI 10.1074/jbc.M002782200; Jansen PLM, 1999, GASTROENTEROLOGY, V117, P1370, DOI 10.1016/S0016-5085(99)70287-8; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Laffitte Bryan A, 2002, Curr Atheroscler Rep, V4, P213; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Lu KM, 2001, AM J HUM GENET, V69, P278, DOI 10.1086/321294; Malerod L, 2002, BIOCHEM BIOPH RES CO, V299, P916, DOI 10.1016/S0006-291X(02)02760-2; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Neufeld EB, 2002, BIOCHEM BIOPH RES CO, V297, P974, DOI 10.1016/S0006-291X(02)02274-X; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; PIETERS MN, 1994, HEPATOLOGY, V19, P1459, DOI 10.1016/0270-9139(94)90243-7; REISS AB, 1994, J LIPID RES, V35, P1026; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Tall AR, 2001, J CLIN INVEST, V108, P1273; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	38	153	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25448	25453		10.1074/jbc.M301189200	http://dx.doi.org/10.1074/jbc.M301189200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12704191	Green Published, hybrid			2022-12-25	WOS:000183920200024
J	Sedarous, M; Keramaris, E; O'Hare, M; Melloni, E; Slack, RS; Elce, JS; Greer, PA; Park, DS				Sedarous, M; Keramaris, E; O'Hare, M; Melloni, E; Slack, RS; Elce, JS; Greer, PA; Park, DS			Calpains mediate p53 activation and neuronal death evoked by DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; KILLS POSTMITOTIC NEURONS; INDUCED CELL-DEATH; SMALL-SUBUNIT GENE; FACTOR-KAPPA-B; CYTOSINE-ARABINOSIDE; INDUCED APOPTOSIS; IONIZING-RADIATION; CORTICAL-NEURONS; INHIBITOR	DNA damage is an initiator of neuronal death implicated in neuropathological conditions such as stroke. Previous evidence has shown that apoptotic death of embryonic cortical neurons treated with the DNA damaging agent camptothecin is dependent upon the tumor suppressor p53, an upstream death mediator, and more distal death effectors such as caspases. We show here that the calcium-regulated cysteine proteases, calpains, are activated during DNA damage induced by camptothecin treatment. Moreover, calpain deficiency, calpastatin expression, or pharmacological calpain inhibitors prevent the death of embryonic cortical neurons, indicating the important role of calpain in DNA damage-induced death. Calpain inhibition also significantly reduced and delayed the induction of p53. Consistent with the actions of calpains upstream of p53 and the proximal nature of p53 death signaling, calpain inhibition inhibited cytochrome c release and DEVD-AFC cleavage activity. Taken together, our results indicate that calpains are a key mediator of p53 induction and consequent caspase-dependent neuronal death due to DNA damage.	Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Grp, Ottawa, ON K1H 8M5, Canada; Univ Genoa, Dept Expt Med, Genoa, Italy; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Genoa; Queens University - Canada; Queens University - Canada	Park, DS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Grp, Ottawa, ON K1H 8M5, Canada.	dpark@uottawa.ca		Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784				Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Atencio IA, 2000, CELL GROWTH DIFFER, V11, P247; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chakrabarti AK, 1996, J NEUROSCI RES, V44, P374; Chen J, 1997, J NEUROCHEM, V69, P232; Chua BT, 2000, J BIOL CHEM, V275, P5131, DOI 10.1074/jbc.275.7.5131; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Enokido Y, 1996, NEUROSCI LETT, V203, P1, DOI 10.1016/0304-3940(95)12247-8; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Grynspan F, 1997, J NEUROSCI RES, V48, P181; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Johnson MD, 1998, J NEUROSCI RES, V54, P721, DOI 10.1002/(SICI)1097-4547(19981215)54:6<721::AID-JNR1>3.0.CO;2-1; Jordan J, 1997, J NEUROCHEM, V68, P1612; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MARTIN DP, 1990, J NEUROSCI, V10, P184; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Melloni E, 1998, FEBS LETT, V431, P55, DOI 10.1016/S0014-5793(98)00724-8; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; NAKAJIMA M, 1994, BRAIN RES, V641, P350, DOI 10.1016/0006-8993(94)90165-1; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Park DS, 1998, J NEUROSCI, V18, P830; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shieh SY, 2000, GENE DEV, V14, P289; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Stefanis L, 1997, CURR OPIN NEUROL, V10, P299, DOI 10.1097/00019052-199708000-00004; Stefanis L, 1999, J NEUROSCI, V19, P6235; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TOMKINS CE, 1994, J CELL SCI, V107, P1499; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; WALLACE TL, 1989, J NEUROSCI, V9, P115; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WINKELMAN MD, 1983, ANN NEUROL, V14, P520, DOI 10.1002/ana.410140505; WU HY, 1994, J BIOL CHEM, V269, P20067; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Zhu DM, 2000, CLIN CANCER RES, V6, P2456; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	71	77	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26031	26038		10.1074/jbc.M302833200	http://dx.doi.org/10.1074/jbc.M302833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12721303	hybrid			2022-12-25	WOS:000183920200099
J	Xu, Z; Lai, KO; Zhou, HM; Lin, SC; Ip, NY				Xu, Z; Lai, KO; Zhou, HM; Lin, SC; Ip, NY			Ephrin-B1 reverse signaling activates JNK through a novel mechanism that is independent of tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATES INTEGRIN ACTIVITY; EPH RECEPTORS; PROTEIN-KINASE; TRANSMEMBRANE LIGANDS; ADAPTER PROTEINS; CELL-ADHESION; PATHWAYS; DOMAINS; EMBRYOGENESIS; MANNER	Eph receptors and their cognate ligand ephrins play important roles in various biological processes such as cell migration, axon guidance, and synaptic plasticity. One characteristic feature of the Eph-ephrin signal transduction is that, upon interaction with the receptor, the transmembrane B-class ephrins become tyrosine-phosphorylated and transduce intracellular signals that lead to reorganization of the cytoskeleton. Although in vitro and genetic studies have demonstrated unequivocally the significance of this reverse signaling, the underlying mechanism remains unclear. We report here that transfection of ephrin-B1 into 293 cells resulted in robust increase in JNK activity, whereas expression of truncated ephrin-B1 lacking the cytoplasmic domain had a negligible effect, indicating that the induction of JNK activity was attributed mainly to the reverse signaling. The ephrin-B1-mediated JNK activation was reduced significantly by dominant-negative TAK1, MKK4, or MKK7. Ephrin-B1 over-expressing 293 cells became rounded in morphology. Surprisingly, ephrin-B1 that lacked all six intracellular tyrosine residues still triggered JNK activation and rounding morphology of the transfected cells. Consistent with these observations, activation of JNK and the resulting morphological changes mediated by ephrin-B1 could be abolished by the JNK inhibitor SP600125 but not the Src inhibitor PP2. Taken together, our findings have identified a novel reverse signaling pathway transduced by ephrin-B1, which is independent of tyrosine phosphorylation but involves the activation of JNK through TAK1 and MKK4/MKK7 and leads to changes in cell morphology.	Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Tsinghua University	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China.	linsc@ust.hk; boip@ust.hk	Lai, Kwok On/ABC-8046-2021; Lai, Kwok-On/E-5182-2011; Lai, Kwok-On/L-7468-2019; Lin, SC/G-4666-2010; Xu, Zhen/P-3029-2014	Lai, Kwok-On/0000-0002-4069-054X; Xu, Zhen/0000-0002-2190-3861; Ip, Nancy Yuk-Yu/0000-0002-2763-8907				Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Birgbauer E, 2001, DEVELOPMENT, V128, P3041; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Cheyette BNR, 2002, DEV CELL, V2, P449, DOI 10.1016/S1534-5807(02)00140-5; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Gu C, 2001, MOL CELL BIOL, V21, P4579, DOI 10.1128/MCB.21.14.4579-4597.2001; Han DC, 2002, J BIOL CHEM, V277, P45655, DOI 10.1074/jbc.M203165200; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Huynh-Do U, 1999, EMBO J, V18, P2165, DOI 10.1093/emboj/18.8.2165; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jones TL, 1998, P NATL ACAD SCI USA, V95, P576, DOI 10.1073/pnas.95.2.576; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lai KO, 1999, FEBS LETT, V458, P265, DOI 10.1016/S0014-5793(99)01159-X; Lai KO, 2001, MOL CELL NEUROSCI, V17, P1034, DOI 10.1006/mcne.2001.0997; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tong JF, 2003, J BIOL CHEM, V278, P6111, DOI 10.1074/jbc.M208972200; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Toth J, 2001, DEV CELL, V1, P83, DOI 10.1016/S1534-5807(01)00002-8; Uyen HD, 2002, J CELL SCI, V115, P3073; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	52	42	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24767	24775		10.1074/jbc.M302454200	http://dx.doi.org/10.1074/jbc.M302454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709432	hybrid			2022-12-25	WOS:000183824800064
J	Burchmore, RJS; Wallace, LJM; Candlish, D; Al-Salabi, MI; Beal, PR; Barrett, MP; Baldwin, SA; de Koning, HP				Burchmore, RJS; Wallace, LJM; Candlish, D; Al-Salabi, MI; Beal, PR; Barrett, MP; Baldwin, SA; de Koning, HP			Cloning, heterologous expression, and in situ characterization of the first high affinity nucleobase transporter from a protozoan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI-BRUCEI; SUBSTRATE RECOGNITION MOTIFS; BLOOD-STREAM FORMS; NUCLEOSIDE TRANSPORTER; FUNCTIONAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; ASPERGILLUS-NIDULANS; PURINE; FAMILY; GENE	While multiple nucleoside transporters, some of which can also transport nucleobases, have been cloned in recent years from many different organisms, no sequence information is available for the high affinity, nucleobase-selective transporters of metazoa, parazoa, or protozoa. We have identified a gene, TbNBT1, from Trypanosoma brucei brucei that encodes a 435-residue protein of the equilibrative nucleoside transporter superfamily. The gene was expressed in both the procyclic and bloodstream forms of the organism. Expression of TbNBT1 in a Saccharomyces cerevisiae strain lacking an endogenous purine transporter allowed growth on adenine as sole purine source and introduced a high affinity transport activity for adenine and hypoxanthine, with K-m values of 2.1 +/- 0.6 and 0.66 +/- 0.22 muM, respectively, as well as high affinity for xanthine, guanine, guanosine, and allopurinol and moderate affinity for inosine. A transporter with an indistinguishable kinetic profile was identified in T. b. brucei procyclics and designated H4. RNA interference of TbNBT1 in procyclics reduced cognate mRNA levels by similar to80% and H4 transport activity by similar to90%. Expression of TbNBT1 in Xenopus oocytes further confirmed that this gene encodes the first high affinity nucleobase transporter from protozoa or animals to be identified at the molecular level.	Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Glasgow; University of Leeds	de Koning, HP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	H.de-Koning@bio.gla.ac.uk	Burchmore, Richard/A-1896-2011	Burchmore, Richard/0000-0003-1663-9004; Barrett, Mike/0000-0001-9447-3519; De Koning, Harry/0000-0002-9963-1827				Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; Al-Salabi MI, 2003, MOL PHARMACOL, V63, P814, DOI 10.1124/mol.63.4.814; Argyrou E, 2001, PLANT CELL, V13, P953, DOI 10.1105/tpc.13.4.953; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Carter NS, 2000, J BIOL CHEM, V275, P20935, DOI 10.1074/jbc.M002418200; Carter NS, 2000, J BIOL CHEM, V275, P10683, DOI 10.1074/jbc.275.14.10683; Cheson BD, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.34878; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; De Koning HP, 1999, MOL PHARMACOL, V56, P1162, DOI 10.1124/mol.56.6.1162; de Koning HP, 1998, BIOCHEM CELL BIOL, V76, P853, DOI 10.1139/bcb-76-5-853; de Koning HP, 2000, MOL BIOCHEM PARASIT, V106, P93, DOI 10.1016/S0166-6851(99)00203-0; de Koning HP, 1998, J BIOL CHEM, V273, P9486, DOI 10.1074/jbc.273.16.9486; de Koning HP, 2001, INT J PARASITOL, V31, P512, DOI 10.1016/S0020-7519(01)00167-9; DeKoning HP, 1997, EUR J BIOCHEM, V247, P1102, DOI 10.1111/j.1432-1033.1997.01102.x; deKoning HP, 1997, MOL BIOCHEM PARASIT, V89, P245, DOI 10.1016/S0166-6851(97)00129-1; DEKONING HP, 2003, IN PRESS INT J PARAS; DIALLINAS G, 1995, J BIOL CHEM, V270, P8610; DIALLINAS G, 1989, GENETICS, V122, P341; Gillissen B, 2000, PLANT CELL, V12, P291, DOI 10.1105/tpc.12.2.291; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Hofmann K, 1993, TMBASE DATABASE MEMB; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; Kolb V M, 1997, Prog Drug Res, V48, P195; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Parker MD, 2000, BIOCHEM J, V349, P67, DOI 10.1042/0264-6021:3490067; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Rajan DP, 1999, BIOCHEM BIOPH RES CO, V262, P762, DOI 10.1006/bbrc.1999.1272; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Sanchez MA, 1999, J BIOL CHEM, V274, P30244, DOI 10.1074/jbc.274.42.30244; Sanchez MA, 2002, J BIOL CHEM, V277, P21499, DOI 10.1074/jbc.M202319200; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Wallace LJM, 2002, J BIOL CHEM, V277, P26149, DOI 10.1074/jbc.M202835200; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200	43	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23502	23507		10.1074/jbc.M301252200	http://dx.doi.org/10.1074/jbc.M301252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707261	hybrid			2022-12-25	WOS:000183638600037
J	Colin, C; Leblanc, C; Wagner, E; Delage, L; Leize-Wagner, E; Van Dorsselaer, A; Kloareg, B; Potin, P				Colin, C; Leblanc, C; Wagner, E; Delage, L; Leize-Wagner, E; Van Dorsselaer, A; Kloareg, B; Potin, P			The brown algal kelp Laminaria digitata features distinct bromoperoxidase and iodoperoxidase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANADIUM-DEPENDENT BROMOPEROXIDASE; FUNGUS CURVULARIA-INAEQUALIS; MARINE MACRO-ALGA; X-RAY-STRUCTURE; CORALLINA-PILULIFERA; ASCOPHYLLUM-NODOSUM; ANIONIC MUCILAGES; L-SACCHARINA; CHLOROPEROXIDASE; HALOPEROXIDASES	Different haloperoxidases, one specific for the oxidation of iodide and another that can oxidize both iodide and bromide, were separated from the sporophytes of the brown alga Laminaria digitata and purified to electrophoretic homogeneity. The iodoperoxidase activity was approximately seven times more efficient than the bromoperoxidase fraction in the oxidation of iodide. The two enzymes were markedly different in their molecular masses, trypsin digestion profiles, and immunological characteristics. Also, in contrast to the iodoperoxidase, bromoperoxidases were present in the form of multimeric aggregates of near-identical proteins. Two full-length haloperoxidase cDNAs were isolated from L. digitata, using haloperoxidase partial cDNAs that had been identified previously in an Expressed Sequence Tag analysis of the life cycle of this species ( 1). Sequence comparisons, mass spectrometry, and immunological analyses of the purified bromoperoxidase, as well as the activity of the protein expressed in Escherichia coli, all indicate that these almost identical cDNAs encode bromoperoxidases. Haloperoxidases form a large multigenic family in L. digitata, and the potential functions of haloperoxidases in this kelp are discussed.	CNRS, UMR 1931, Labs Goemar, Biol Stn, F-29682 Roscoff, France; Univ Strasbourg, Lab Spectrometrie Masse Bioorgan, UMR 7509, CNRS, F-67087 Strasbourg 2, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Leblanc, C (corresponding author), CNRS, UMR 1931, Labs Goemar, Biol Stn, BP 74, F-29682 Roscoff, France.	leblanc@sb-roscoff.fr		POTIN, Philippe/0000-0001-7358-6282				Almeida M, 2001, PHYTOCHEMISTRY, V57, P633, DOI 10.1016/S0031-9422(01)00094-2; Almeida M, 1998, PHYTOCHEMISTRY, V48, P229, DOI 10.1016/S0031-9422(98)00003-X; Almeida M., 1996, PLANT PEROXIDASES BI, P146; APT KE, 1995, MOL GEN GENET, V246, P455, DOI 10.1007/BF00290449; Barnett P, 1998, J BIOL CHEM, V273, P23381, DOI 10.1074/jbc.273.36.23381; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brochardt SA, 2001, APPL ENVIRON MICROB, V67, P3174, DOI 10.1128/AEM.67.7.3174-3179.2001; Butler A, 1998, CURR OPIN CHEM BIOL, V2, P279, DOI 10.1016/S1367-5931(98)80070-7; Butler A, 2001, HANDBOOK ON METALLOPROTEINS, P153; Carpenter LJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P1191, DOI 10.1029/2000GB001257; Carter JN, 2002, J INORG BIOCHEM, V91, P59, DOI 10.1016/S0162-0134(02)00400-2; Crepineau F, 2000, PLANT MOL BIOL, V43, P503, DOI 10.1023/A:1006489920808; DEBOER E, 1986, BIOCHIM BIOPHYS ACTA, V872, P104, DOI 10.1016/0167-4838(86)90153-6; Gall EA, 1996, EUR J PHYCOL, V31, P369, DOI 10.1080/09670269600651601; HAGER LP, 1966, J BIOL CHEM, V241, P1769; Hara I, 1998, J INORG BIOCHEM, V72, P23, DOI 10.1016/S0162-0134(98)10055-7; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Isupov MN, 2000, J MOL BIOL, V299, P1035, DOI 10.1006/jmbi.2000.3806; JORDAN P, 1991, BIOCHIM BIOPHYS ACTA, V1073, P98, DOI 10.1016/0304-4165(91)90188-M; JORDAN P, 1990, ELECTROPHORESIS, V11, P653, DOI 10.1002/elps.1150110814; JORDAN P, 1991, J PLANT PHYSIOL, V137, P520, DOI 10.1016/S0176-1617(11)80692-9; Kupper FC, 1998, PLANTA, V207, P163, DOI 10.1007/s004250050469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; O'Dowd CD, 2002, NATURE, V417, P632, DOI 10.1038/nature00775; Ohsawa N, 2001, PHYTOCHEMISTRY, V58, P683, DOI 10.1016/S0031-9422(01)00259-X; Ohshiro T, 2002, PHYTOCHEMISTRY, V60, P595, DOI 10.1016/S0031-9422(02)00160-7; Pedersen M, 1996, SCI MAR, V60, P257; Potin P, 2002, CURR OPIN PLANT BIOL, V5, P308, DOI 10.1016/S1369-5266(02)00273-X; Rabilloud T, 2001, PROTEOMICS, V1, P699, DOI 10.1002/1615-9861(200104)1:5<699::AID-PROT699>3.3.CO;2-3; SAENKO GN, 1978, MAR BIOL, V47, P243, DOI 10.1007/BF00541002; SAUBER C, 2002, AGILENT TECHNOLOGIES; Shimonishi M, 1998, FEBS LETT, V428, P105, DOI 10.1016/S0014-5793(98)00500-6; SIMONS BH, 1995, EUR J BIOCHEM, V229, P566, DOI 10.1111/j.1432-1033.1995.tb20499.x; SOEDJAK HS, 1990, BIOCHEMISTRY-US, V29, P7974, DOI 10.1021/bi00486a028; Thomas JG, 1997, PROTEIN EXPRES PURIF, V11, P289, DOI 10.1006/prep.1997.0796; VILTER H, 1995, MET IONS BIOL SYST, V31, P325; VILTER H, 1984, PHYTOCHEMISTRY, V23, P1387, DOI 10.1016/S0031-9422(00)80471-9; VILTER H, 1994, METHOD ENZYMOL, V228, P665; Vreeland V, 1998, MOL BIOL CELL, V9, p180A; WEVER R, 1991, ENVIRON SCI TECHNOL, V25, P446, DOI 10.1021/es00015a010; Weyand M, 1999, J MOL BIOL, V293, P595, DOI 10.1006/jmbi.1999.3179	42	73	78	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23545	23552		10.1074/jbc.M300247200	http://dx.doi.org/10.1074/jbc.M300247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697758	hybrid			2022-12-25	WOS:000183638600043
J	Hancock, MA; Boffa, MB; Marcovina, SM; Nesheim, ME; Koschinsky, ML				Hancock, MA; Boffa, MB; Marcovina, SM; Nesheim, ME; Koschinsky, ML			Inhibition of plasminogen activation by lipoprotein(a) - Critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; IN-VITRO; RECOMBINANT APOLIPOPROTEIN(A); NONHUMAN-PRIMATES; KINETIC-ANALYSIS; MAMMALIAN-CELLS; GLU-PLASMINOGEN; LYS-PLASMINOGEN; BINDING SITES; RHESUS-MONKEY	Similarity between the apolipoprotein(a) (apo(a)) moiety of lipoprotein(a) (Lp(a)) and plasminogen suggests a potentially important link between atherosclerosis and thrombosis. Lp(a) may interfere with tissue plasminogen activator (tPA)-mediated plasminogen activation in fibrinolysis, thereby generating a hypercoagulable state in vivo. A fluorescence-based system was employed to study the effect of apo(a) on plasminogen activation in the presence of native fibrin and degraded fibrin cofactors and in the absence of positive feedback reactions catalyzed by plasmin. Human Lp(a) and a physiologically relevant, 17-kringle recombinant apo(a) species exhibited strong inhibition with both cofactors. A variant lacking the protease domain also exhibited strong inhibition, indicating that the apo(a)-plasminogen binding interaction mediated by the apo(a) protease domain does not ultimately inhibit plasminogen activation. A variant in which the strong lysine-binding site in kringle IV type 10 had been abolished exhibited substantially reduced inhibition whereas another lacking the kringle V domain showed no inhibition. Amino-terminal truncation mutants of apo(a) also revealed that additional sequences within kringle IV types 1-4 are required for maximal inhibition. To investigate the inhibition mechanism, the concentrations of plasminogen, cofactor, and a 12-kringle recombinant apo(a) species were systematically varied. Kinetics for both cofactors conformed to a single, equilibrium template model in which apo(a) can interact with all three fibrinolytic components and predicts the formation of ternary (cofactor, tPA, and plasminogen) and quaternary (cofactor, tPA, plasminogen, and apo(a)) catalytic complexes. The latter complex exhibits a reduced turnover number, thereby accounting for inhibition of plasminogen activation in the presence of apo(a)/Lp(a).	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Washington, Dept Med, NW Lipid Res Labs, Seattle, WA 98103 USA	Queens University - Canada; Queens University - Canada; University of Washington; University of Washington Seattle	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Angles-Cano E, 2001, ANN NY ACAD SCI, V936, P261; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Belczewski AR, 1996, GENE, V171, P271, DOI 10.1016/0378-1119(96)00011-X; Berg K, 1963, ACTA PATHOL MIC SC, V59, P362; Biemond BJ, 1997, CIRCULATION, V96, P1612, DOI 10.1161/01.CIR.96.5.1612; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; DELLENBACK RJ, 1970, P SOC EXP BIOL MED, V134, P353; EDELBERG JM, 1990, THROMB RES, V57, P155, DOI 10.1016/0049-3848(90)90203-O; Edelstein C, 2001, ANAL BIOCHEM, V288, P201, DOI 10.1006/abio.2000.4904; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; Falco C, 1998, THROMB HAEMOSTASIS, V79, P818, DOI 10.1055/s-0037-1615071; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GABEL BR, 1995, BIOCHEMISTRY-US, V34, P15777, DOI 10.1021/bi00048a023; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; Gabel BR, 1998, BIOCHEMISTRY-US, V37, P7892, DOI 10.1021/bi973186w; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HOLM B, 1985, THROMB RES, V37, P165, DOI 10.1016/0049-3848(85)90043-X; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2183; Horrevoets AJG, 1997, J BIOL CHEM, V272, P2176; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Kang C, 2002, ARTERIOSCL THROM VAS, V22, P1232, DOI 10.1161/01.ATV.0000021144.87870.C8; Keesler GA, 1996, J BIOL CHEM, V271, P32096, DOI 10.1074/jbc.271.50.32096; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; KOSCHINSKY ML, 1991, BIOCHEMISTRY-US, V30, P5044, DOI 10.1021/bi00234a029; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KUSUMI Y, 1993, ATHEROSCLEROSIS, V99, P165, DOI 10.1016/0021-9150(93)90019-Q; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LEERINK CB, 1991, FIBRINOLYSIS, V5, P233, DOI 10.1016/0268-9499(91)90005-O; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MAO SJT, 1990, FEBS LETT, V267, P131, DOI 10.1016/0014-5793(90)80306-4; Marcovina Santica M, 2002, Semin Vasc Med, V2, P335, DOI 10.1055/s-2002-35404; Marcovina SM, 1996, CLIN CHEM, V42, P436; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; NACHMAN RL, 1991, ARTERIOSCLER THROMB, V11, P32, DOI 10.1161/01.ATV.11.1.32; Nesheim M, 2001, ANN NY ACAD SCI, V936, P247; OLEXA SA, 1979, BIOCHEMISTRY-US, V18, P991, DOI 10.1021/bi00573a009; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256; SANGRAR W, 1994, PROTEIN ENG, V7, P723, DOI 10.1093/protein/7.5.723; Sangrar W, 2000, BIOCHEM CELL BIOL, V78, P519, DOI 10.1139/bcb-78-4-519; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; SANGRAR W, 1995, BIOCHEMISTRY-US, V34, P5151, DOI 10.1021/bi00015a028; Scanu AM, 1997, CLIN GENET, V52, P367; SIMON DI, 1991, BIOCHEMISTRY-US, V30, P6671, DOI 10.1021/bi00241a006; Stewart RJ, 2000, J BIOL CHEM, V275, P36612, DOI 10.1074/jbc.M005483200; STRAUGHN W, 1966, THROMB DIATH HAEMOST, V16, P198, DOI 10.1055/s-0038-1655637; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; TAYLOR CB, 1963, ARCH PATHOL, V76, P239; THORSEN S, 1992, ANN NY ACAD SCI, V667, P52, DOI 10.1111/j.1749-6632.1992.tb51597.x; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; VANDERHOEK YY, 1993, HUM MOL GENET, V2, P361, DOI 10.1093/hmg/2.4.361; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; Wissler R.W., 1977, Advances in Veterinary Science and Comparative Medicine, V21, P351; Xue S, 2001, THROMB HAEMOSTASIS, V86, P1229, DOI 10.1055/s-0037-1616056	54	78	83	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23260	23269		10.1074/jbc.M302780200	http://dx.doi.org/10.1074/jbc.M302780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697748	hybrid			2022-12-25	WOS:000183638600008
J	Kauppi, B; Jakob, C; Farnegardh, M; Yang, J; Ahola, H; Alarcon, M; Calles, K; Engstrom, O; Harlan, J; Muchmore, S; Ramqvist, AK; Thorell, S; Ohman, L; Greer, J; Gustafsson, JA; Carlstedt-Duke, J; Carlquist, M				Kauppi, B; Jakob, C; Farnegardh, M; Yang, J; Ahola, H; Alarcon, M; Calles, K; Engstrom, O; Harlan, J; Muchmore, S; Ramqvist, AK; Thorell, S; Ohman, L; Greer, J; Gustafsson, JA; Carlstedt-Duke, J; Carlquist, M			The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain - RU-486 induces a transconformation that leads to active antagonism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-BINDING; IN-VITRO; IDENTIFICATION; SPECIFICITY; ESTROGEN; RU486; GENE; DIMERIZATION; SITES	Here we describe the three- dimensional crystal structures of human glucocorticoid receptor ligand- binding domain ( GR- LBD) in complex with the antagonist RU486 at 2.3 Angstrom resolution and with the agonist dexamethasone ligand together with a coactivator peptide at 2.8 Angstrom. The RU- 486 structure was solved in several different crystal forms, two with helix 12 intact ( GR1 and GR3) and one with a protease- digested C terminus ( GR2). In GR1, part of helix 12 is in a position that covers the co- activator pocket, whereas in the GR3, domain swapping is seen between the crystallographically identical subunits in the GR dimer. An arm consisting of the end of helix 11 and beyond stretches out from one molecule, and helix 12 binds to the other LBD, partly blocking the coactivator pocket of that molecule. This type of GR-LBD dimer has not been described before but might be an artifact from crystallization. Furthermore, the subunits of the GR3 dimers are covalently connected via a disulfide bond between the Cys- 736 residues in the two molecules. All three RU- 486 GR- LBD structures show that GR has a very flexible region between the end of helix 11 and the end of helix 12.	Karo Bio AB, Novum, Struct Biol, SE-14157 Huddinge, Sweden; Abbott Labs, Dept Biol Struct, Abbott Pk, IL 60064 USA; Huddinge Univ Hosp, Novum, Karolinska Inst, Dept Med Nutr, SE-14157 Huddinge, Sweden; Huddinge Univ Hosp, Novum, Karolinska Inst, Dept Biosci, SE-14157 Huddinge, Sweden	Karolinska Institutet; Abbott Laboratories; Karolinska Institutet; Karolinska Institutet	Kauppi, B (corresponding author), Karo Bio AB, Novum, Struct Biol, SE-14157 Huddinge, Sweden.	bjorn.kauppi@karobio.se	ID, IMCACAT/D-5867-2014					BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cadepond F, 1997, ANNU REV MED, V48, P129; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CARLSTEDTDUKE J, 1982, P NATL ACAD SCI-BIOL, V79, P4260, DOI 10.1073/pnas.79.14.4260; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAKRABORTI PK, 1992, J BIOL CHEM, V267, P11366; DeLano W. L., 2001, PYMOL USERS MANUAL; Fuller PJ, 2000, KIDNEY INT, V57, P1256, DOI 10.1046/j.1523-1755.2000.00959.x; Funder JW, 1997, ANNU REV MED, V48, P231, DOI 10.1146/annurev.med.48.1.231; GARABEDIAN MJ, 1992, MOL BIOL CELL, V3, P1245, DOI 10.1091/mbc.3.11.1245; Gass EK, 1998, ENDOCRINOLOGY, V139, P1905, DOI 10.1210/en.139.4.1905; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Leonhardt SA, 2002, EXP BIOL MED, V227, P969, DOI 10.1177/153537020222701104; Lind U, 1996, MOL ENDOCRINOL, V10, P1358, DOI 10.1210/me.10.11.1358; Lind U, 1999, J BIOL CHEM, V274, P18515, DOI 10.1074/jbc.274.26.18515; Lind U, 2000, J BIOL CHEM, V275, P19041, DOI 10.1074/jbc.M000228200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; MIESFELD R, 1984, NATURE, V312, P779, DOI 10.1038/312779a0; Myles K, 1996, AM J PHYSIOL-ENDOC M, V270, pE601, DOI 10.1152/ajpendo.1996.270.4.E601; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pandit S, 2002, J BIOL CHEM, V277, P1538, DOI 10.1074/jbc.M105438200; PAYVAR F, 1981, P NATL ACAD SCI-BIOL, V78, P6628, DOI 10.1073/pnas.78.11.6628; PAYVAR F, 1982, J CELL BIOCHEM, V19, P241, DOI 10.1002/jcb.240190305; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Ray DW, 1999, MOL ENDOCRINOL, V13, P1855, DOI 10.1210/me.13.11.1855; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Savory JGA, 2001, MOL CELL BIOL, V21, P781, DOI 10.1128/MCB.21.3.781-793.2001; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; SIMONS SS, 1994, VITAM HORM, V49, P49; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WRANGE O, 1978, J BIOL CHEM, V253, P856	43	275	286	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22748	22754		10.1074/jbc.M212711200	http://dx.doi.org/10.1074/jbc.M212711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686538	hybrid			2022-12-25	WOS:000183503900077
J	Ogrunc, M; Sancar, A				Ogrunc, M; Sancar, A			Identification and characterization of human MUS81-MMS4 structure-specific endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CDS1; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; EXCISION-REPAIR; FISSION YEAST; PROTEIN; ATM; DOWNSTREAM; CHK2	Replication forks may stall when they reach a block on the DNA template such as DNA damage, and the recovery of such stalled replication forks plays a crucial role in the maintenance of genomic stability. Holliday junctions, which are X- shaped DNA structures, are formed at the stalled replication forks and can accumulate if they are not cleaved by structure- specific endonucleases. Recently, a novel nuclease involved in resolving Holliday junction- like structures, Mus81, has been reported in yeast and humans. MUS81 has sequence homology to another DNA nuclease, XPF, which, with its partner ERCC1, makes the 5 ' incision during nucleotide excision repair. MUS81 also has a binding partner named Mms4 in Saccharomyces cerevisiae and Eme1 in Schizosaccharomyces pombe, but no such partner was identified in human cells. Here, we report identification of the binding partner of human MUS81, which we designate hMMS4. Using immunoaffinity purification we show that hMUS81 or hMMS4 alone have no detectable nuclease activity, but that the hMUS81 . hMMS4 complex is a structure- specific nuclease that is capable of resolving fork structures.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [GM 32833] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Brookman KW, 1996, MOL CELL BIOL, V16, P6553; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen XB, 2001, MOL CELL, V8, P1117, DOI 10.1016/S1097-2765(01)00375-6; CONSTANTINOU A, EMBO J, V21, P5577; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Mazin AV, 2003, J BIOL CHEM, V278, P14029, DOI 10.1074/jbc.M212779200; Mullen JR, 2001, GENETICS, V157, P103; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Ozgur S, 2003, BIOCHEMISTRY-US, V42, P2926, DOI 10.1021/bi026963n; Rhind N, 2000, CURR BIOL, V10, pR908, DOI 10.1016/S0960-9822(00)00849-6; RIETHOF DA, 2003, BIOCOMPUTING COMPUTE; SAMSON T, 2000, J BIOL CHEM, V275, P10498; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Whitby MC, 2003, J BIOL CHEM, V278, P6928, DOI 10.1074/jbc.M210006200; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465	30	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21715	21720		10.1074/jbc.M302484200	http://dx.doi.org/10.1074/jbc.M302484200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12686547	hybrid			2022-12-25	WOS:000183354200052
J	Unoki, M; Nakamura, Y				Unoki, M; Nakamura, Y			EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK	ONCOGENE			English	Article						EGR2; BNIP3L; BAK; apoptosis; PTEN	BCL-2 HOMOLOG; GROWTH SUPPRESSION; MEDIATED TRANSFER; GENE; MUTATIONS; PROTEIN; DEATH; PTEN; IDENTIFICATION; MODULATION	EGR2 plays a key role in the PTEN-induced apoptotic pathway. Using adenovirus-mediated gene transfer to 39 cancer cell lines, we found that EGR2 could induce apoptosis in a large proportion of these lines by altering the permeability of mitochondrial membranes, releasing cytochrome c and activating caspase-3, -8, and -9. Analysis by cDNA microarray and subsequent functional studies revealed that EGR2 directly transactivates expression of BNIP3L and BAK. Our results helped to clarify the molecular mechanism of the apoptotic pathway induced by PTEN-EGR2, and suggested that EGR2 may be an excellent target molecule for gene therapy to treat a variety of cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Minaguchi T, 1999, CANCER RES, V59, P6063; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Obata K, 1998, CANCER RES, V58, P2095; Ono K, 2000, CANCER RES, V60, P5007; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Risinger JI, 1997, CANCER RES, V57, P4736; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Wei MC, 2000, GENE DEV, V14, P2060; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	36	85	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2172	2185		10.1038/sj.onc.1206222	http://dx.doi.org/10.1038/sj.onc.1206222			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687019				2022-12-25	WOS:000182066900011
J	Eble, JA; Bruckner, P; Mayer, U				Eble, JA; Bruckner, P; Mayer, U			Vipera lebetina venom contains two disintegrins inhibiting laminin-binding beta(1) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM; HEPARIN-BINDING; CELL-ADHESION; SUBUNIT; DOMAIN; RECOMBINANT; ALPHA-6-BETA-1; PROTEASES; RECEPTORS; VARIANTS	To explain the myotoxic effects of snake venoms, we searched for inhibitors of alpha(7)beta(1) integrin, the major laminin-binding integrin in skeletal muscle. We discovered two inhibitors in the venom of Vipera lebetina. One of them, lebein-1 ( known as lebein), has already been proposed to be a disintegrin because of its RGD-containing primary sequence. The other, lebein-2, is a novel protein that also interacts firmly with alpha(3)beta(1), alpha(6)beta(1), and alpha(7)beta(1) integrins, but not with the collagen-binding alpha(1)beta(1) and alpha(2)beta(1) integrins. Ligand binding of laminin-recognizing beta(1) integrins was efficiently blocked by both lebein-1 and lebein-2. In cell attachment assays, lebein-1 and lebein-2 inhibited myoblast attachment not only to laminin, but also to fibronectin. However, neither lebein-1 nor lebein-2 interacted with alpha(7)beta(1) integrin in an RGD-dependent manner, similar to the interaction of the laminin with alpha(7)beta(1) integrin. Identical divalent cation dependence of integrin binding to laminin and to either of the two inhibitors and their mutually exclusive binding suggest that both lebein-1 and lebein-2 interact with the ligand-binding site of laminin-binding beta(1) integrins by mimicking the yet unknown integrin-binding structure of laminins. Like lebein-1, lebein-2 is a soluble heterodimeric disintegrin of low molecular mass. Together with membrane-bound ADAM-2 and ADAM-9, the two inhibitors seem to form a small group of disintegrins that can bind to laminin-binding beta(1) integrins. Because of their inhibitory capability both in vitro and in vivo, lebein-1 and lebein-2 may be valuable tools in influencing laminin-induced, integrin-mediated cell functions such as cell anchorage, migration, and mechanical force transduction on laminin-rich basement membranes.	Munster Univ Hosp, Inst Physiol Chem, D-48149 Munster, Germany; Univ Manchester, Sch Biol Sci, Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Munster; University of Manchester	Eble, JA (corresponding author), Munster Univ Hosp, Inst Physiol Chem, Waldeyerstr 15, D-48149 Munster, Germany.		Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611; Mayer, Ulrike/0000-0003-2328-0052				ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; Burkin DJ, 1999, CELL TISSUE RES, V296, P183, DOI 10.1007/s004410051279; CALVETE JJ, 1997, INTEGRIN LIGAND INTE, P157; DELWEL GO, 1995, CELL ADHES COMMUN, V3, P143, DOI 10.3109/15419069509081283; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Gasmi A, 2001, BBA-PROTEIN STRUCT M, V1547, P51, DOI 10.1016/S0167-4838(01)00168-6; HARRIS JB, 1985, PHARMACOL THERAPEUT, V31, P79, DOI 10.1016/0163-7258(85)90038-5; Hemler ME, 1999, CELL, V97, P543, DOI 10.1016/S0092-8674(00)80764-3; Heyn M. P., 1975, BIOCHEMISTRY-US, V14, P2447; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; MEBS D, 1990, PHARMACOL THERAPEUT, V48, P223, DOI 10.1016/0163-7258(90)90081-C; Nath D, 2000, J CELL SCI, V113, P2319; SCHULER F, 1995, J CELL SCI, V108, P3795; Shai SY, 2002, CIRC RES, V90, P458, DOI 10.1161/hh0402.105790; Siigur E, 1996, BIOCHEM BIOPH RES CO, V224, P229, DOI 10.1006/bbrc.1996.1012; Siigur J, 2001, HAEMOSTASIS, V31, P123; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; von der Mark H, 2002, J BIOL CHEM, V277, P6012, DOI 10.1074/jbc.M102188200; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Whitman RG, 2001, J COMMON MARK STUD, V39, P189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356	36	41	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26488	26496		10.1074/jbc.M301860200	http://dx.doi.org/10.1074/jbc.M301860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12719418	hybrid			2022-12-25	WOS:000184155700027
J	Taille, C; Almolki, A; Benhamed, M; Zedda, C; Megret, J; Berger, P; Leseche, G; Fadel, E; Yamaguchi, T; Marthan, R; Aubier, M; Boczkowski, J				Taille, C; Almolki, A; Benhamed, M; Zedda, C; Megret, J; Berger, P; Leseche, G; Fadel, E; Yamaguchi, T; Marthan, R; Aubier, M; Boczkowski, J			Heme oxygenase inhibits human airway smooth muscle proliferation via a bilirubin-dependent modulation of ERK1/2 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; JAK-STAT PATHWAY; CARBON-MONOXIDE; OXIDATIVE STRESS; NADPH OXIDASE; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; ALLERGEN EXPOSURE; SENSITIZED RATS; GENE-EXPRESSION	The aim of this study was to investigate whether the heme oxygenase (HO) pathway could modulate proliferation of airway smooth muscle (ASM) and the mechanism( s) involved in this phenomenon. In cultured human ASM cells, 10% fetal calf serum or 50 ng/ml platelet-derived growth factor AB induced cell proliferation, extracellular and intracellular reactive oxygen species (ROS) production and ERK1/2 phosphorylation. Pharmacological HO-1 induction ( by 10 muM hemin or by 20 muM cobalt-protoporphyrin) and HO inhibition ( by 25 muM tin-protoporphyrin or by an antisense oligonucleotide), respectively, reduced and enhanced significantly both cell proliferation and ROS production. Neither the carbon monoxide scavenger myoglobin ( 5 - 20 muM) nor the guanylyl cyclase inhibitor 1H-[1,2,4] oxadiazolo-[4,3-a] quinoxalin-1-one could reverse ASM proliferation induced by tin-protoporphyrin, making a role of the CO-cGMP pathway in HO-modulated proliferation unlikely. By contrast, bilirubin ( 1 muM) and the antioxidant N-acetyl-cysteine ( 1 mM) significantly reduced mitogen-induced cell proliferation, ROS production, and ERK1/2 phosphorylation. Furthermore, both bilirubin and N-acetyl-cysteine and the ERK1/2 inhibitor PD98059 significantly reversed the effects of HO inhibition on ASM proliferation. These results could be relevant to ASM alterations observed in asthma because activation of the HO pathway prevented the increase in bronchial smooth muscle area induced by repeated ovalbumin challenge in immunized guinea pigs, whereas inhibition of HO had the opposite effect. In conclusion, this study provides evidence for an antiproliferative effect of the HO pathway in ASM in vitro and in vivo through a bilirubin-mediated redox modulation of phosphorylation of ERK1/2.	Univ Paris 07, INSERM, U408, F-75018 Paris, France; Univ Victor Segalen, INSERM, E9937, F-33076 Bordeaux 2, France; Hop Beaujon, Serv Chirurg Vasc & Thorac, F-92118 Clichy, France; Ctr Chirurg Marie Lannelongue, Serv Chirurg Thorac, F-92350 Le Plessis Robinson, France; Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1138549, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Marie Lannelongue; Tokyo Medical & Dental University (TMDU)	Boczkowski, J (corresponding author), Univ Paris 07, INSERM, U408, 16 Rue Henri Huchard, F-75018 Paris, France.	jbb2@bichat.inserm.fr	Berger, Patrick/D-8779-2012; Boczkowski, Jorge/S-7474-2018; Taille, Camille/J-3751-2017	Berger, Patrick/0000-0003-4702-0343; Boczkowski, Jorge/0000-0001-6619-5785; Marthan, Roger/0000-0001-5412-5712				ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; Aizawa T, 1999, BIOCHEM BIOPH RES CO, V261, P302, DOI 10.1006/bbrc.1999.1020; Ammit AJ, 2001, J APPL PHYSIOL, V91, P1431, DOI 10.1152/jappl.2001.91.3.1431; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Christou H, 2000, CIRC RES, V86, P1224, DOI 10.1161/01.RES.86.12.1224; Donnelly LE, 2001, AM J RESP CELL MOL, V24, P295, DOI 10.1165/ajrcmb.24.3.4001; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; Durante W, 1999, ARTERIOSCL THROM VAS, V19, P2666, DOI 10.1161/01.ATV.19.11.2666; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Henricks PAJ, 2001, PULM PHARMACOL THER, V14, P409, DOI 10.1006/pupt.2001.0319; JANES CH, 1995, J CLIN INVEST, V95, P2581, DOI 10.1172/JCI117959; Jia YX, 1999, INT ARCH ALLERGY IMM, V120, P141, DOI 10.1159/000024232; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; JOHNSON PRA, 1995, AM J PHYSIOL, V269, P514; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019, DOI 10.1152/ajplung.2001.280.5.L1019; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912, DOI 10.1164/ajrccm.162.5.9909081; Liu XM, 2002, CIRCULATION, V105, P79, DOI 10.1161/hc0102.101369; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; Nakayama M, 2001, ARTERIOSCL THROM VAS, V21, P1373, DOI 10.1161/hq0801.093592; Ozawa N, 2002, J CLIN INVEST, V109, P457, DOI [10.1172/JCI0213190, 10.1172/JCI200213190]; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627, DOI 10.1164/ajrccm.161.2.9902094; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Ravenhall C, 2000, BRIT J PHARMACOL, V131, P17, DOI 10.1038/sj.bjp.0703454; Salmon M, 2000, AM J RESP CELL MOL, V23, P618, DOI 10.1165/ajrcmb.23.5.3909; Samb A, 2002, AM J PHYSIOL-LUNG C, V283, pL596, DOI 10.1152/ajplung.00446.2001; Samb A, 2001, AM J RESP CRIT CARE, V164, P149, DOI 10.1164/ajrccm.164.1.2004030; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Simon AR, 2002, AM J PHYSIOL-LUNG C, V282, pL1296, DOI 10.1152/ajplung.00315.2001; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Song RP, 2002, AM J RESP CELL MOL, V27, P603, DOI 10.1165/rcmb.4851; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Taille C, 2001, AM J RESP CRIT CARE, V163, P753, DOI 10.1164/ajrccm.163.3.2004202; Thabut G, 2002, J BIOL CHEM, V277, P22814, DOI 10.1074/jbc.M200315200; Volti GL, 2002, BIOCHEM BIOPH RES CO, V296, P1077, DOI 10.1016/S0006-291X(02)02054-5; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wong JZ, 1998, AM J PHYSIOL-LUNG C, V274, pL786, DOI 10.1152/ajplung.1998.274.5.L786	49	70	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27160	27168		10.1074/jbc.M300364200	http://dx.doi.org/10.1074/jbc.M300364200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12690112	hybrid			2022-12-25	WOS:000184155700111
J	Delagoutte, E; von Hippel, PH				Delagoutte, E; von Hippel, PH			Function and assembly of the bacteriophage T4 DNA replication complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; RNA PRIMER SYNTHESIS; SEDIMENTATION-VELOCITY EXPERIMENTS; PROTEIN-PROTEIN INTERACTIONS; POLYMERASE-I; LEADING-STRAND; ACTIVE-SITE; ACCESSORY PROTEINS; GENE-41 PROTEIN; NUCLEOTIDE SELECTION	Complexes formed between DNA polymerase and genomic DNA at the replication fork are key elements of the replication machinery. We used sedimentation velocity, fluorescence anisotropy, and surface plasmon resonance to measure the binding interactions between bacteriophage T4 DNA polymerase (gp43) and various model DNA constructs. These results provide quantitative insight into how this replication polymerase performs template-directed 5' --> 3' DNA synthesis and how this function is coordinated with the activities of the other proteins of the replication complex. We find that short (single- and double-stranded) DNA molecules bind a single gp43 polymerase in a nonspecific ( overlap) binding mode with moderate affinity (K-d similar to 150 nM) and a binding site size of similar to10 nucleotides for single- stranded DNA and similar to13 bp for double-stranded DNA. In contrast, gp43 binds in a site-specific (nonoverlap) mode and significantly more tightly (K-d similar to5 nM) to DNA constructs carrying a primer-template junction, with the polymerase covering similar to5 nucleotides downstream and similar to6-7 bp upstream of the 3'-primer terminus. The rate of this specific binding interaction is close to diffusion-controlled. The affinity of gp43 for the primer-template junction is modulated specifically by dNTP substrates, with the next "correct" dNTP strengthening the interaction and an incorrect dNTP weakening the observed binding. These results are discussed in terms of the individual steps of the polymerase-catalyzed single nucleotide addition cycle and the replication complex assembly process. We suggest that changes in the kinetics and thermodynamics of these steps by auxiliary replication proteins constitute a basic mechanism for protein coupling within the replication complex.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.			von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015792, R01GM029158, R01GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29158, GM15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Alley SC, 1999, BIOCHEMISTRY-US, V38, P7696, DOI 10.1021/bi9827971; Bebenek A, 2002, GENETICS, V162, P1003; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dzantiev L, 1999, J BIOL CHEM, V274, P3279, DOI 10.1074/jbc.274.6.3279; FAIRFIELD FR, 1983, J BIOMOL STRUCT DYN, V1, P715, DOI 10.1080/07391102.1983.10507477; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gangurde R, 2002, BIOCHEMISTRY-US, V41, P14552, DOI 10.1021/bi0264216; GILLIN FD, 1975, BIOCHEM BIOPH RES CO, V64, P457, DOI 10.1016/0006-291X(75)90343-5; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; HINTON DM, 1987, J BIOL CHEM, V262, P10873; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kadyrov FA, 2001, J BIOL CHEM, V276, P29559, DOI 10.1074/jbc.M101310200; Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Maga G, 2001, J BIOL CHEM, V276, P18235, DOI 10.1074/jbc.M009599200; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; McGlynn P, 2002, NAT REV MOL CELL BIO, V3, P859, DOI 10.1038/nrm951; MUNN MM, 1991, J BIOL CHEM, V266, P20034; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAUL L, 1983, THESIS U OREGON EUGE; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; REDDY MK, 1992, J BIOL CHEM, V267, P14157; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Singh K, 2003, J BIOL CHEM, V278, P11289, DOI 10.1074/jbc.M211496200; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Steitz T A, 1997, Harvey Lect, V93, P75; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Thompson EHZ, 2002, BIOCHEMISTRY-US, V41, P713, DOI 10.1021/bi0114271; TOPAL MD, 1980, J BIOL CHEM, V255, P1717; Tsodikov OV, 2001, BIOPHYS J, V81, P1960, DOI 10.1016/S0006-3495(01)75847-X; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; von Hippel PH, 2002, BIOPHYS CHEM, V101, P401, DOI 10.1016/S0301-4622(02)00160-6; VONHIPPEL P, 1983, UCLA S MOL CELLULAR, V10, P153; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WU CA, 1992, J BIOL CHEM, V267, P4030; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	76	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25435	25447		10.1074/jbc.M303370200	http://dx.doi.org/10.1074/jbc.M303370200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12700227	hybrid			2022-12-25	WOS:000183920200023
J	Shibata, T; Yamada, T; Ishii, T; Kumazawa, S; Nakamura, H; Masutani, H; Yodoi, J; Uchida, K				Shibata, T; Yamada, T; Ishii, T; Kumazawa, S; Nakamura, H; Masutani, H; Yodoi, J; Uchida, K			Thioredoxin as a molecular target of cyclopentenone prostaglandins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ALZHEIMERS-DISEASE; ANTIINFLAMMATORY DRUGS; BIOLOGICAL-ACTIVITIES; POTENTIAL INDUCERS; FACTOR ADF; GROWTH; INHIBITION; MECHANISMS	Prostaglandin (PG) D-2, a major cyclooxygenase product in a variety of tissues and cells, readily undergoes dehydration to yield the bioactive cyclopentenone-type PGs of the J(2) series, such as 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ(2)). We have shown previously that 15d-PGJ(2) is a potent electrophile that causes intracellular oxidative stress and redox alteration in human neuroblastoma SH-SY5Y cells. In the present study, based on the observation that the electrophilic center of 15d-PGJ(2) was involved in the pro-oxidant effect, we investigated the role of thioredoxin 1 (Trx), an endogenous redox regulator, against 15d-PGJ(2)-induced oxidative cell injury. It was observed that the 15d-PGJ(2)-induced oxidative stress was significantly suppressed by the Trx overexpression. In addition, the treatment of SH-SY5Y cells with biotinylated 15d-PGJ(2) resulted in the formation of a 15d-PGJ(2)-Trx adduct, indicating that 15d-PGJ(2) directly modified the endogenous Trx in the cells. To further examine the mechanism of the 15d-PGJ(2) modification of Trx, human recombinant Trx treated with 15d-PGJ(2) was analyzed by mass spectrometry. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of the 15d-PGJ(2)-treated human recombinant Trx demonstrated the addition of one molecule of 15d-PGJ(2) per protein molecule. Moreover, the electrospray ionization-liquid chromatography/mass spectrometry/mass spectrometry analysis identified two cysteine residues, Cys-35 and Cys-69, as the targets of 15d-PGJ(2). These residues may represent the direct sensors of the electrophilic PGs that induce the intracellular redox alteration and neuronal cell death.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan; Univ Shizuoka, Dept Nutr & Food Sci, Shizuoka 4228529, Japan; Kyoto Univ, Inst Virus Res, Dept Biol Responses, Kyoto 6068507, Japan	Nagoya University; University of Shizuoka; Kyoto University	Uchida, K (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp	; Shibata, Takahiro/I-6872-2014	Uchida, Koji/0000-0003-3894-5299; Masutani, Hiroshi/0000-0001-7633-2827; Shibata, Takahiro/0000-0003-3194-607X				Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baker A, 1997, CANCER RES, V57, P5162; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chinery R, 1999, CANCER RES, V59, P2739; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERVE JCL, 1995, CHEM RES TOXICOL, V8, P934, DOI 10.1021/tx00049a006; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GRAVES AB, 1990, ANN NEUROL, V28, P766, DOI 10.1002/ana.410280607; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JENKINSON ML, 1989, BRIT J RHEUMATOL, V28, P86; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawamoto Y, 2000, J BIOL CHEM, V275, P11291, DOI 10.1074/jbc.275.15.11291; KHAN SH, 1990, P NATL ACAD SCI USA, V87, P9401, DOI 10.1073/pnas.87.23.9401; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kondo M, 2001, J BIOL CHEM, V276, P12076, DOI 10.1074/jbc.M009630200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; LI HM, 1993, BIOCHEMISTRY-US, V32, P5800, DOI 10.1021/bi00073a012; LUCCA U, 1994, BIOL PSYCHIAT, V36, P854, DOI 10.1016/0006-3223(94)90598-3; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; MYLLYKANGASLUOSUJARVI R, 1994, BRIT J RHEUMATOL, V33, P501; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Narayanan PK, 1997, CANCER RES, V57, P3963; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; OFFENBACHER S, 1986, J PERIODONTAL RES, V21, P101, DOI 10.1111/j.1600-0765.1986.tb01443.x; Oliva JL, 2003, P NATL ACAD SCI USA, V100, P4772, DOI 10.1073/pnas.0735842100; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Rovin BH, 2002, KIDNEY INT, V61, P1293, DOI 10.1046/j.1523-1755.2002.00282.x; SHAHABI NA, 1987, EXP CELL BIOL, V55, P18; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; TAGAYA Y, 1990, MOL IMMUNOL, V27, P1279; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K	65	153	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26046	26054		10.1074/jbc.M303690200	http://dx.doi.org/10.1074/jbc.M303690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12709421	hybrid			2022-12-25	WOS:000183920200101
J	Breazeale, SD; Ribeiro, AA; Raetz, CRH				Breazeale, SD; Ribeiro, AA; Raetz, CRH			Origin of lipid A species modified with 4-amino-4-deoxy-L-arabinose in polymyxin-resistant mutants of Escherichia coli - An aminotransferase (ArnB) that generates UDP-4-amino-4-deoxy-L-arabinose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; COMPLETE GENOME SEQUENCE; SALMONELLA-TYPHIMURIUM; PMRA-MUTANTS; ENZYMATIC-SYNTHESIS; NMR-SPECTROSCOPY; MEMBRANE ENZYME; LIPOPOLYSACCHARIDES; PHOSPHOETHANOLAMINE; PHOSPHATE	In Escherichia coli and Salmonella typhimurium, addition of the 4-amino-4-deoxy-L-arabinose (L-Ara4N) moiety to the phosphate group(s) of lipid A is required for resistance to polymyxin and cationic antimicrobial peptides. We have proposed previously (Breazeale, S. D., Ribeiro, A. A., and Raetz, C. R. H. (2002) J. Biol. Chem. 277, 2886-2896) a pathway for L-Ara4N biosynthesis that begins with the ArnA-catalyzed C-4" oxidation and C-6" decarboxylation of UDP-glucuronic acid, followed by the C-4" transamination of the product to generate the novel sugar nucleotide UDP-L-Ara4N. We now show that ArnB (PmrH) encodes the relevant aminotransferase. ArnB was overexpressed using a T7lac promoter-driven construct and shown to catalyze the reversible transfer of the amino group from glutamate to the acceptor, uridine 5'-(beta-L-threo-pentapyranosyl-4"-ulose diphosphate), the intermediate that is synthesized by ArnA from UDP-glucuronic acid. A 1.7-mg sample of the putative UDP-L-Ara4N product generated in vitro was purified by ion exchange chromatography, and its structure was confirmed by H-1 and C-13 NMR spectroscopy. ArnB, which is a cytoplasmic protein, was purified to homogeneity from an overproducing strain of E. coli and shown to contain a pyridoxal phosphate cofactor, as judged by ultraviolet/ visible spectrophotometry. The pyridoxal phosphate was converted to the pyridoxamine form in the presence of excess glutamate. A simple quantitative radiochemical assay was developed for ArnB, which can be used to assay the enzyme either in the forward or the reverse direction. The enzyme is highly selective for glutamate as the amine donor, but the equilibrium constant in the direction of UDP-L-Ara4N formation is unfavorable (similar to0.1). ArnB is a member of a very large family of aminotransferases, but closely related ArnB orthologs are present only in those bacteria capable of synthesizing lipid A species modified with the L-Ara4N moiety.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke NMR Spect Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Agrawal P.K., 1994, ADV BIOPHYS CHEM, V4, P179; AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Albermann C, 2001, GLYCOBIOLOGY, V11, P655, DOI 10.1093/glycob/11.8.655; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brade H., 1999, ENDOTOXIN HLTH DIS; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Chen HW, 2000, P NATL ACAD SCI USA, V97, P11942, DOI 10.1073/pnas.210395097; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Eads JC, 1999, BIOCHEMISTRY-US, V38, P9840, DOI 10.1021/bi990018q; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Groisman EA, 1997, J BACTERIOL, V179, P7040, DOI 10.1128/jb.179.22.7040-7045.1997; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; HEINERT D, 1963, J AM CHEM SOC, V85, P183, DOI 10.1021/ja00885a017; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; NALEWAY JJ, 1988, CARBOHYD RES, V179, P199, DOI 10.1016/0008-6215(88)84118-1; Noland BW, 2002, STRUCTURE, V10, P1569, DOI 10.1016/S0969-2126(02)00879-1; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1972, BIOCHEMISTRY-US, V11, P2229, DOI 10.1021/bi00762a004; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; ROSENTHAL SN, 1976, ADV PHYS ORG CHEM, V13, P280; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; VANHALBEEK H, 1996, ENCY NMR, V2, P1107; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 2000, J BIOL CHEM, V275, P13542, DOI 10.1074/jbc.275.18.13542	51	85	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24731	24739		10.1074/jbc.M304043200	http://dx.doi.org/10.1074/jbc.M304043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704196	hybrid			2022-12-25	WOS:000183824800060
J	Fairclough, RJ; Dode, L; Vanoevelen, J; Andersen, JP; Missiaen, L; Raeymaekers, L; Wuytack, F; Hovnanian, A				Fairclough, RJ; Dode, L; Vanoevelen, J; Andersen, JP; Missiaen, L; Raeymaekers, L; Wuytack, F; Hovnanian, A			Effect of Hailey-Hailey disease mutations on the function of a new variant of human secretory pathway Ca2+/Mn2+-ATPase (hSPCA1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA2+ PUMP; SARCOPLASMIC-RETICULUM; CALCIUM-PUMP; SARCO/ENDOPLASMIC RETICULUM; MESSENGER-RNAS; YEAST GOLGI; ION-PUMP; CA2+-ATPASE; PMR1; CA-2+-ATPASE	ATP2C1, encoding the human secretory pathway Ca2+/Mn2+ ATPase (hSPCA1), was recently identified as the defective gene in Hailey-Hailey Disease (HHD), an autosomal dominant skin disorder characterized by persistent blisters and erosions. To investigate the underlying cause of HHD, we have analyzed the changes in expression level and function of hSPCA1 caused by mutations found in HHD patients. Mutations were introduced into hSPCA1d, a novel splice variant expressed in keratinocytes, described here for the first time. Encoded by the full-length of optional exons 27 and 28, hSPCA1d was longer than previously identified splice variants. The protein competitively transported Ca2+ and Mn2+ with equally high affinity into the Golgi of COS-1 cells. Ca2+- and Mn2+-dependent phosphoenzyme intermediate formation in forward (ATP-fuelled) and reverse (P-i-fuelled) directions was also demonstrated. HHD mutant proteins L341P, C344Y, C411R, T570I, and G789R showed low levels of expression, despite normal levels of mRNA and correct targeting to the Golgi, suggesting instability or abnormal folding of the mutated hSPCA1 polypeptides. P201L had little effect on the enzymatic cycle, whereas I580V caused a block in the E(1)similar to P --> E-2-P conformational transition. D742Y and G309C were devoid of Ca2+- and Mn2+-dependent phosphoenzyme formation from ATP. The capacity to phosphorylate from Pi was retained in these mutants but with a loss of sensitivity to both Ca2+ and Mn2+ in D742Y and a preferential loss of sensitivity to Mn2+ in G309C. These results highlight the crucial role played by Asp-742 in the architecture of the hSPCA1 ion-binding site and reveal a role for Gly-309 in Mn2+ transport selectivity.	Univ Oxford, Wellcome Trust, Ctr Human Genet, Oxford OX3 7BN, England; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	University of Oxford; Wellcome Centre for Human Genetics; KU Leuven; Aarhus University	Hovnanian, A (corresponding author), Purpan Hosp, INSERM, U563, Pavillon Lefebvre,Pl Dr Baylac, F-31059 Toulouse 03, France.	alain.hovnanian@toulouse.inserm.fr	Hovnanian, Alain/I-4711-2017; Vanoevelen, Jo M/F-2686-2013	Hovnanian, Alain/0000-0003-3412-7512; Vanoevelen, Jo M/0000-0003-1830-8858; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Cottrell GS, 2000, BIOCHEMISTRY-US, V39, P15121, DOI 10.1021/bi001585c; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dobson-Stone C, 2002, J INVEST DERMATOL, V118, P338, DOI 10.1046/j.0022-202x.2001.01675.x; Dode L, 1998, J BIOL CHEM, V273, P13982, DOI 10.1074/jbc.273.22.13982; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Gutzmer R, 2001, J INVEST DERMATOL, V116, P926, DOI 10.1046/j.1523-1747.2001.01344.x; Hearn AS, 2001, BIOCHEMISTRY-US, V40, P12051, DOI 10.1021/bi011047f; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KOWARSKI D, 1985, J PHYSIOL-LONDON, V366, P153, DOI 10.1113/jphysiol.1985.sp015790; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; LYTTON J, 1992, J BIOL CHEM, V267, P14483; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Mandal D, 2000, J BIOL CHEM, V275, P23933, DOI 10.1074/jbc.M002619200; Martin V, 2002, J BIOL CHEM, V277, P24442, DOI 10.1074/jbc.M202011200; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sorin A, 1997, J BIOL CHEM, V272, P9895; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; Ton VK, 2002, J BIOL CHEM, V277, P6422, DOI 10.1074/jbc.M110612200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200	46	78	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24721	24730		10.1074/jbc.M300509200	http://dx.doi.org/10.1074/jbc.M300509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707275	hybrid			2022-12-25	WOS:000183824800059
J	Gruszynski, AE; DeMaster, A; Hooper, NM; Bangs, JD				Gruszynski, AE; DeMaster, A; Hooper, NM; Bangs, JD			Surface coat remodeling during differentiation of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLPHOSPHATIDYLINOSITOL MEMBRANE ANCHORS; LEISHMANIA-MAJOR GP63; BLOOD-STREAM FORMS; PHOSPHOLIPASE-C; AFRICAN TRYPANOSOMES; PROCYCLIC STAGE; DEVELOPMENTAL VARIATION; CIS-ACONITATE; GLYCOPROTEIN; TRANSFORMATION	African trypanosomes (Trypanosoma brucei) are digenetic parasites whose lifecycle alternates between the mammalian bloodstream and the midgut of the tsetse fly vector. In mammals, proliferating long slender parasites transform into non-diving short stumpy forms, which differentiate into procyclic forms when ingested by the tsetse fly. A hallmark of differentiation is the replacement of the bloodstream stage surface coat composed of variant surface glycoprotein (VSG) with a new coat composed of procylin. An undefined endoprotease and endogenous glycosylphosphatidylinositol-specific phospholipase C (GPI-PLC) have been implicated in releasing the old VSG coat. However, GPI hydrolysis has been considered unimportant because (i) GPI-PLC null mutants are fully viable and (ii) cytosolic GPI-PLC is localized away from cell surface VSG. Utilizing an in vitro differentiation assay with pleomorphic strains we have investigated these modes of VSG release. Shedding is initially by GPI hydrolysis, which ultimately accounts for a substantial portion of total release. Surface biotinylation assays indicate that GPI-PLC does gain access to extracellular VSG, suggesting that this mode is primed in the starting short stumpy population. Proteolytic release is up-regulated during differentiation and is stereoselectively inhibited by peptidomimetic collagenase inhibitors, implicating a zinc metalloprotease. This protease may be related to TbMSP-B, a trypanosomal homologue of Leishmania major surface protease (MSP) described in the accompanying paper (LaCount, D. J., Gruszynski, A. E., Grandgenett, P. M., Bangs, J. D., and Donelson, J. E. (2003) J. Biol. Chem. 278, 24658-24664). Overall, our results demonstrate that surface coat remodeling during differentiation has multiple mechanisms and that GPI-PLC plays a more significant role in VSG release than previously thought.	Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Univ Leeds, Proteolysis Res Grp, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Leeds	Bangs, JD (corresponding author), Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, 1300 Univ Ave, Madison, WI 53706 USA.			Hooper, Nigel/0000-0002-5811-3484	NIAID NIH HHS [AI07414, AI35739, T32 AI007414, R01 AI035739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035739, T32AI007414, R29AI035739] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander DL, 2002, J CELL SCI, V115, P3253; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; Bangs JD, 2001, MOL BIOCHEM PARASIT, V114, P111, DOI 10.1016/S0166-6851(01)00244-4; BARBET AF, 1978, P NATL ACAD SCI USA, V75, P1989, DOI 10.1073/pnas.75.4.1989; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; Brittingham A, 1999, INFECT IMMUN, V67, P4477, DOI 10.1128/IAI.67.9.4477-4484.1999; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; BROWN R C, 1973, International Journal for Parasitology, V3, P691, DOI 10.1016/0020-7519(73)90095-7; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; BULOW R, 1986, J BIOL CHEM, V261, P1918; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; CZICHOS J, 1986, EXP PARASITOL, V62, P283, DOI 10.1016/0014-4894(86)90033-0; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; Denny PW, 2000, J BIOL CHEM, V275, P11017, DOI 10.1074/jbc.275.15.11017; ElSayed NMA, 1997, J BIOL CHEM, V272, P26742, DOI 10.1074/jbc.272.42.26742; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; FIELD MC, 1991, J BIOL CHEM, V266, P8392; FIELD MC, 1992, J BIOL CHEM, V267, P5324; Geuskens M, 2000, MOL BIOCHEM PARASIT, V108, P269, DOI 10.1016/S0166-6851(00)00228-0; HERELD D, 1986, J BIOL CHEM, V261, P3813; HIRUMI H, 1994, PARASITOL TODAY, V10, P81; Jeffries TR, 2001, J CELL SCI, V114, P2617; LaCount DJ, 2003, J BIOL CHEM, V278, P24658, DOI 10.1074/jbc.M301451200; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; Matthews KR, 1997, J CELL SCI, V110, P2609; Matthews KR, 1998, MOL BIOCHEM PARASIT, V95, P81, DOI 10.1016/S0166-6851(98)00100-5; MATTHEWS KR, 1995, J CELL SCI, V108, P2231; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; MEDINAACOSTA E, 1993, INFECT AGENT DIS, V2, P25; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; MOWATT MR, 1987, MOL CELL BIOL, V7, P2833; Mutomba MC, 1998, MOL BIOCHEM PARASIT, V93, P11, DOI 10.1016/S0166-6851(98)00012-7; OVERATH P, 1986, EUR J BIOCHEM, V160, P175, DOI 10.1111/j.1432-1033.1986.tb09955.x; OVERATH P, 1983, EMBO J, V2, P1721, DOI 10.1002/j.1460-2075.1983.tb01648.x; Paturiaux-Hanocq F, 2000, J BIOL CHEM, V275, P12147, DOI 10.1074/jbc.275.16.12147; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; RIFKIN MR, 1990, P NATL ACAD SCI USA, V87, P801, DOI 10.1073/pnas.87.2.801; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Rolin S, 1996, J BIOL CHEM, V271, P10844, DOI 10.1074/jbc.271.18.10844; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; Schlagenhauf E, 1998, STRUCTURE, V6, P1035, DOI 10.1016/S0969-2126(98)00104-X; SEYFANG A, 1990, J PROTOZOOL, V37, P546, DOI 10.1111/j.1550-7408.1990.tb01263.x; Troeberg L, 1999, EXP PARASITOL, V91, P349, DOI 10.1006/expr.1998.4386; Vassella E, 2000, GENE DEV, V14, P615; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; Voth BR, 1998, MOL BIOCHEM PARASIT, V93, P31, DOI 10.1016/S0166-6851(98)00013-9; Webb H, 1997, J CELL BIOL, V139, P103, DOI 10.1083/jcb.139.1.103; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028; ZIEGELBAUER K, 1990, EUR J BIOCHEM, V192, P373, DOI 10.1111/j.1432-1033.1990.tb19237.x	63	43	43	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24665	24672		10.1074/jbc.M301497200	http://dx.doi.org/10.1074/jbc.M301497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716904	hybrid			2022-12-25	WOS:000183824800052
J	Hayashi, Y; Sanada, K; Hirota, T; Shimizu, F; Fukada, Y				Hayashi, Y; Sanada, K; Hirota, T; Shimizu, F; Fukada, Y			p38 mitogen-activated protein kinase regulates oscillation of chick pineal circadian clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-EPSILON; MAP KINASE; MESSENGER-RNA; CELL-CULTURE; DOUBLE-TIME; TRANSCRIPTION; PERIOD; GENE; LOOP; ENTRAINMENT	Extracellular signal-regulated kinase (ERK) and p38 are members of the mitogen-activated protein kinase (MAPK) family, and in some cases these kinases serve for closely related cellular functions within a cell. In a wide range of animal clock structures, ERK plays an important role in the circadian time-keeping mechanism. Here we found that immunoreactivity to p38 protein was uniformly distributed among cells in the chick pineal gland. On the other hand, a constant level of activated p38 was detected over the day, predominantly in the follicular and parafollicular pinealocytes that are potential circadian clock-containing cells. Chronic application of SB203580, a selective and reversible inhibitor of p38, to the cultured chick pineal cells markedly lengthened the period of the circadian rhythm of the melatonin release (up to 28.7 h). Noticeably, despite no significant temporal change of activated p38 level, a 4-h pulse treatment with SB203580 delayed the phase of the rhythm only when delivered during the subjective day. These results indicate a time-of-day-specific role of continuously activated p38 in the period length regulation of the chick pineal clock and suggest temporally separated regulation of the clock by two MAPKs, nighttime-activated ERK and daytime-working p38.	Univ Tokyo, Dept Biophys & Biochem, Grad Sch Sci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Fukada, Y (corresponding author), Univ Tokyo, Dept Biophys & Biochem, Grad Sch Sci, Bunkyo Ku, Sci Bldg 3,Rm 218A,Yayoi 2-11-16, Tokyo 1130032, Japan.		吉孝, 深田/G-5090-2014; Hirota, Tsuyoshi/D-8158-2015; Hayashi, Yuichiro/O-2163-2017; SANADA, YOSHIKADO/G-5014-2014	Hirota, Tsuyoshi/0000-0003-4876-3608; Hayashi, Yuichiro/0000-0001-9870-0053; Sanada, Kamon/0000-0002-0280-8957				Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; BARRETT RK, 1995, J NEUROSCI, V15, P5681; Bernard M, 1997, J NEUROCHEM, V68, P213; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; GREVE P, 1993, NEUROREPORT, V4, P803, DOI 10.1097/00001756-199306000-00052; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Ko GYP, 2001, NEURON, V29, P255, DOI 10.1016/S0896-6273(01)00195-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Nakahara K, 1997, BRAIN RES, V774, P242, DOI 10.1016/S0006-8993(97)81713-1; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Okano T, 1997, MOL BRAIN RES, V50, P190, DOI 10.1016/S0169-328X(97)00184-8; Okano T, 2001, GENES CELLS, V6, P825, DOI 10.1046/j.1365-2443.2001.00462.x; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROBERTSON LM, 1988, J NEUROSCI, V8, P22; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; ZATZ M, 1991, AM J PHYSIOL, V261, pR1424; ZATZ M, 1991, AM J PHYSIOL, V260, pR769, DOI 10.1152/ajpregu.1991.260.4.R769; ZATZ M, 1994, AM J PHYSIOL, V266, P50	38	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25166	25171		10.1074/jbc.M212726200	http://dx.doi.org/10.1074/jbc.M212726200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12719413	Green Accepted, hybrid			2022-12-25	WOS:000183824800111
J	Kimura, F; Suzu, S; Nakamura, Y; Nakata, Y; Yamada, M; Kuwada, N; Matsumura, T; Yamashita, T; Ikeda, T; Sato, K; Motoyoshi, K				Kimura, F; Suzu, S; Nakamura, Y; Nakata, Y; Yamada, M; Kuwada, N; Matsumura, T; Yamashita, T; Ikeda, T; Sato, K; Motoyoshi, K			Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ZINC-BINDING PROTEIN; FINGER PROTEIN; FLOW-CYTOMETRY; KAPPA-B; TRIPARTITE MOTIF; CELL-SURVIVAL; GM-CSF; GENE; DOMAIN	We have identified a novel RING-B-box-coiled-coil (RBCC) protein (MAIR for macrophage-derived apoptosis-inducing RBCC protein) that consists of an N-terminal RING finger, followed by a B-box zinc finger, a coiled-coil domain, and a B30.2 domain. MAIR mRNA was expressed widely in mouse tissues and was induced by macrophage colony-stimulating factor in murine peritoneal and bone marrow macrophages. MAIR protein initially showed a granular distribution predominantly in the cytoplasm. The addition of zinc to transfectants containing MAIR cDNA as part of a heavy metal-inducible vector caused apoptosis of the cells characterized by cell fragmentation; a reduction in mitochondrial membrane potential; activation of caspase-7, -8, and -9, but not caspase-3; and DNA degradation. We also found that the RING finger and coiled-coil domains were required for MAIR activity by analysis with deletion mutants.	Natl Def Med Coll, Dept Internal Med 3, Tokorozawa, Saitama 3598513, Japan; Morinaga Milk Co Ltd, Biochem Res Lab, Kanagawa 2288583, Japan	National Defense Medical College - Japan; Morinaga Milk Industry Company, Ltd	Motoyoshi, K (corresponding author), Natl Def Med Coll, Dept Internal Med 3, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	motoyosi@me.ndmc.ac.jp	Suzu, Shinya/F-5786-2013	Suzu, Shinya/0000-0003-2531-4770				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; Cao TY, 1997, J CELL SCI, V110, P1563; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHU TW, 1995, GENOMICS, V29, P229, DOI 10.1006/geno.1995.1236; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Doucas V, 2000, BIOCHEM PHARMACOL, V60, P1197, DOI 10.1016/S0006-2952(00)00413-5; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AE, 2001, GENOMICS, V71, P363, DOI 10.1006/geno.2000.6452; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; ElHodiri HM, 1997, DEV BIOL, V190, P1, DOI 10.1006/dbio.1997.8692; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 1999, MOL CELL BIOL, V19, P3808; Henry J, 1998, MOL BIOL EVOL, V15, P1696, DOI 10.1093/oxfordjournals.molbev.a025896; Hida A, 2000, IMMUNOLOGY, V99, P553, DOI 10.1046/j.1365-2567.2000.00985.x; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; ITOH K, 1991, J CLIN INVEST, V87, P177, DOI 10.1172/JCI114968; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KEECH CL, 1995, J AUTOIMMUN, V8, P699, DOI 10.1006/jaut.1995.0052; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Kiener PA, 1997, J EXP MED, V185, P1511, DOI 10.1084/jem.185.8.1511; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI XX, 1994, J CELL BIOL, V124, P7, DOI 10.1083/jcb.124.1.7; Lin H, 2001, BIOCHEM J, V353, P299, DOI 10.1042/0264-6021:3530299; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohnishi T, 1996, J BIOL CHEM, V271, P14510, DOI 10.1074/jbc.271.24.14510; Orimo A, 1999, P NATL ACAD SCI USA, V96, P12027, DOI 10.1073/pnas.96.21.12027; Ozes ON, 1999, NATURE, V401, P82; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Poot M, 1997, CYTOMETRY, V27, P358, DOI 10.1002/(SICI)1097-0320(19970401)27:4<358::AID-CYTO7>3.0.CO;2-8; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; REDDY BA, 1991, NUCLEIC ACIDS RES, V19, P6330, DOI 10.1093/nar/19.22.6330; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; ROGAIA D, 1995, LEUKEMIA, V9, P1467; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Schweiger S, 1999, P NATL ACAD SCI USA, V96, P2794, DOI 10.1073/pnas.96.6.2794; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Suzu S, 1998, BIOCHEM BIOPH RES CO, V245, P120, DOI 10.1006/bbrc.1998.8394; Suzu S, 1997, J IMMUNOL, V159, P1860; Suzu S, 2000, EMBO J, V19, P5114, DOI 10.1093/emboj/19.19.5114; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torok M, 2001, DIFFERENTIATION, V67, P63, DOI 10.1046/j.1432-0436.2001.067003063.x; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	62	32	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25046	25054		10.1074/jbc.M303438200	http://dx.doi.org/10.1074/jbc.M303438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12692137	hybrid			2022-12-25	WOS:000183824800098
J	Kirsch, M; Korth, HG; Stenert, V; Sustmann, R; de Groot, H				Kirsch, M; Korth, HG; Stenert, V; Sustmann, R; de Groot, H			The autoxidation of tetrahydrobiopterin revisited - Proof of superoxide formation from reaction of tetrahydrobiopterin with molecular oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LIVER PHENYLALANINE-HYDROXYLASE; PULSE-RADIOLYSIS; ENDOTHELIAL FUNCTION; BIOLOGICAL-SYSTEMS; HYDROGEN-PEROXIDE; PEROXYNITRIC ACID; AQUEOUS-SOLUTION; CARBON-DIOXIDE; OXIDATION	It has been known for quite some time that tetrahydrobiopterin (H4B) is prone to autoxidation in the presence of molecular oxygen. Evidence has been presented that in this process superoxide radicals may be released, although their intermediacy never has been directly proven. In the present study, the autoxidation of H4B was reinvestigated with the aim to find direct evidence for superoxide formation. By means of two specific assays, namely elicitation of luminescence from lucigenin and ESR-spectrometric detection of the DEPMPO-OOH radical adduct, the release of free superoxide radicals was unequivocally demonstrated. The production of superoxide radicals was further corroborated by interaction with nitric oxide. The kinetics of the autoxidation process was established. Our data fully confirm earlier conclusions that the direct reaction between H4B and oxygen serves as an initiation reaction for the further, rapid reaction of the thus formed superoxide with H4B, thereby very likely establishing a chain reaction process involving reduction of molecular oxygen by the intermediary tetrahydrobiopterin radical. Conclusively, because H4B can per se induce oxidative stress, an in vivo overproduction of this pterin, as is evident in various diseases, may be responsible for the observed acceleration of pathophysiological pathways.	Univ Klinikum Essen, Inst Physiol Chem, D-45122 Essen, Germany; Univ Essen Gesamthsch, Inst Organ Chem, D-45117 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Kirsch, M (corresponding author), Univ Klinikum Essen, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.							ARMAREGO WLF, 1983, EUR J BIOCHEM, V135, P393, DOI 10.1111/j.1432-1033.1983.tb07666.x; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Berg Meye HU., 1983, METHOD ENZYMAT AN, V2, P165; BLAIR JA, 1974, J CHEM SOC PERK T 2, P80, DOI 10.1039/p29740000080; BROWN LAS, 1996, ANTIOX HEALTH DIS, V3, P117; Caccia S, 1999, BIOPHYS CHEM, V76, P63, DOI 10.1016/S0301-4622(98)00219-1; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; d'Uscio LV, 2002, FASEB J, V16, pA434; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; DAVIS MD, 1993, ARCH BIOCHEM BIOPHYS, V304, P9, DOI 10.1006/abbi.1993.1315; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; EBERLEIN G, 1983, J AM CHEM SOC, V105, P6685, DOI 10.1021/ja00360a024; EBERLEIN G, 1984, J AM CHEM SOC, V106, P7916, DOI 10.1021/ja00337a047; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; FISHER DB, 1973, J BIOL CHEM, V248, P4300; Fridovich I, 2001, J BIOL CHEM, V276, P28629, DOI 10.1074/jbc.R100040200; Goldstein S, 1998, INORG CHEM, V37, P3943, DOI 10.1021/ic980051l; Goldstein S, 1997, INORG CHEM, V36, P4156, DOI 10.1021/ic961186z; Goldstein S, 1998, J AM CHEM SOC, V120, P5549, DOI 10.1021/ja9735362; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; HASEGAWA H, 1978, J BIOCHEM-TOKYO, V84, P499, DOI 10.1093/oxfordjournals.jbchem.a132153; HEIKKILA RE, 1973, SCIENCE, V181, P456, DOI 10.1126/science.181.4098.456; HEIKKILA RE, 1975, EXPERIENTIA, V31, P169, DOI 10.1007/BF01990685; Heitzer T, 2000, CIRC RES, V86, pE36, DOI 10.1161/01.RES.86.2.e36; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; Katusic ZS, 2001, AM J PHYSIOL-HEART C, V281, pH981, DOI 10.1152/ajpheart.2001.281.3.H981; KAUFMAN S, 1958, J BIOL CHEM, V230, P931; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kirsch M, 2000, CHEM RES TOXICOL, V13, P451, DOI 10.1021/tx990138z; Kirsch M, 2002, BIOL CHEM, V383, P389, DOI 10.1515/BC.2002.043; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kirsch M, 2001, CHEM-EUR J, V7, P3313, DOI 10.1002/1521-3765(20010803)7:15<3313::AID-CHEM3313>3.0.CO;2-7; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Koshimura K, 1998, J NEUROSCI RES, V54, P664, DOI 10.1002/(SICI)1097-4547(19981201)54:5<664::AID-JNR11>3.0.CO;2-U; KWEE S, 1987, BIOELECTROCH BIOENER, V18, P79, DOI 10.1016/0302-4598(87)85010-9; KWON NS, 1989, J BIOL CHEM, V264, P20496; LIOCHEV SI, 1995, ARCH BIOCHEM BIOPHYS, V318, P408, DOI 10.1006/abbi.1995.1247; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P115, DOI 10.1006/abbi.1997.9766; LOGAGER T, 1993, J PHYS CHEM-US, V97, P10047; Maier W, 2000, J CARDIOVASC PHARM, V35, P173, DOI 10.1097/00005344-200002000-00001; MARKOVITS GY, 1981, INORG CHEM, V20, P445, DOI 10.1021/ic50216a025; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Meineke P, 1999, CHEM-EUR J, V5, P1738, DOI 10.1002/(SICI)1521-3765(19990604)5:6<1738::AID-CHEM1738>3.0.CO;2-T; Meineke P, 2000, BIOL CHEM, V381, P575, DOI 10.1515/BC.2000.074; Merenyi G, 1999, J PHYS CHEM A, V103, P5685, DOI 10.1021/jp984686h; MISRA HP, 1972, J BIOL CHEM, V247, P3170; Mohamed KH, 2001, CHEST, V119, P776, DOI 10.1378/chest.119.3.776; NISHIKIMI M, 1975, ARCH BIOCHEM BIOPHYS, V166, P273, DOI 10.1016/0003-9861(75)90388-4; Patel KB, 2002, FREE RADICAL BIO MED, V32, P203, DOI 10.1016/S0891-5849(01)00777-8; PEARSON AJ, 1974, CHEM IND-LONDON, P233; Pfeiffer S, 1997, J BIOL CHEM, V272, P3465, DOI 10.1074/jbc.272.6.3465; Ramamurthi A, 1997, CHEM RES TOXICOL, V10, P408, DOI 10.1021/tx960183w; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROSS AB, 1998, NDRL NIST SOLUTION K; SCHMIDT HHHW, 1991, FASEB J, V5, pA1591; Schwartz S.E., 1981, ADV ENVIRON SCI ENG, V4, P1; Shimizu S, 1998, LIFE SCI, V63, P1585, DOI 10.1016/S0024-3205(98)00427-5; Stroes E, 1997, J CLIN INVEST, V99, P41, DOI 10.1172/JCI119131; TATZBER F, 1991, ATHEROSCLEROSIS, V89, P203, DOI 10.1016/0021-9150(91)90061-7; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TOTTER JR, 1960, J BIOL CHEM, V235, P1839; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; Vasquez-Vivar J, 2000, ANALUSIS, V28, P487, DOI 10.1051/analusis:2000280487; VasquezVivar J, 1997, FEBS LETT, V403, P127, DOI 10.1016/S0014-5793(97)00036-7; VONSONNTAG C, 1991, ANGEW CHEM INT EDIT, V30, P1229, DOI 10.1002/anie.199112291; Walter R, 2001, PTERIDINES, V12, P93; Wardman P, 2002, J FLUORESC, V12, P65, DOI 10.1023/A:1015363220266; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WOLFE SK, 1975, INORG CHEM, V14, P1049, DOI 10.1021/ic50147a019; Xia Y, 1997, P NATL ACAD SCI USA, V94, P12705, DOI 10.1073/pnas.94.23.12705	74	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24481	24490		10.1074/jbc.M211779200	http://dx.doi.org/10.1074/jbc.M211779200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714605	hybrid			2022-12-25	WOS:000183824800030
J	Nair, P; Schaub, BE; Rohrer, J				Nair, P; Schaub, BE; Rohrer, J			Characterization of the endosomal sorting signal of the cation-dependent mannose 6-phosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; LYSOSOMAL MEMBRANE; CYTOPLASMIC TAIL; PLASMA-MEMBRANE; PROTEINS; BINDING; TRAFFICKING; DOMAIN; MOTIF; IDENTIFICATION	Intracellular cycling of the cation-dependent mannose 6-phosphate receptor (CD-MPR) between different compartments is directed by signals localized in its cytoplasmic tail. A di-aromatic motif (Phe(18)-Trp(19) with Trp(19) as the key residue) in its cytoplasmic tail is required for the sorting of the receptor from late endosomes back to the Golgi apparatus. However, the cationin-dependent mannose 6-phosphate receptor (CI-MPR) lacks such a di-aromatic motif. Therefore the ability of amino acids other than aromatic residues to replace Trp(19) in the CD-MPR cytoplasmic tail was tested. Mutant constructs with bulky hydrophobic residues ( valine, isoleucine, or leucine) instead of Trp(19) exhibited 30-60% decreases in binding to the tail interacting protein of 47 kDa (Tip47),a protein mediating this transport step, and partially prevented receptor delivery to lysosomes. Decreasing hydrophobicity of residues at position 19 resulted in further impairment of Tip47 binding and an increase of receptor accumulation in lysosomes. Intriguingly, mutants mislocalized to lysosomes did not completely co-localize with a lysosomal membrane protein, which might suggest the presence of subdomains within lysosomes. These data indicate that sorting of the CD-MPR in late endosomes requires a distinct di-aromatic motif with only limited possibilities for variations, in contrast to the CI-MPR, which seems to require a putative loop (Pro(49)-Pro-Ala-Pro-Arg-Pro-Gly(55)) along with additional hydrophobic residues in the cytoplasmic tail. This raises the possibility of two separate binding sites on Tip47 because both receptors require binding to Tip47 for endosomal sorting.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	University of Zurich	Rohrer, J (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Rohrer, Jack/0000-0002-2058-490X				AKASAKI K, 1993, J BIOCHEM-TOKYO, V114, P598, DOI 10.1093/oxfordjournals.jbchem.a124223; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; Kornfeld R, 1998, J BIOL CHEM, V273, P23203, DOI 10.1074/jbc.273.36.23203; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Matzner U, 1996, DEV DYNAM, V207, P11, DOI 10.1002/(SICI)1097-0177(199609)207:1<11::AID-AJA2>3.0.CO;2-Z; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Reaves BJ, 1996, J CELL SCI, V109, P749; Rohrer J, 2001, MOL BIOL CELL, V12, P1623, DOI 10.1091/mbc.12.6.1623; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	36	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24753	24758		10.1074/jbc.M300174200	http://dx.doi.org/10.1074/jbc.M300174200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12697764	hybrid			2022-12-25	WOS:000183824800062
J	Kantake, N; Sugiyama, T; Kolodner, RD; Kowalczykowski, SC				Kantake, N; Sugiyama, T; Kolodner, RD; Kowalczykowski, SC			The recombination-deficient mutant RPA (rfa1-t11) is displaced slowly from single-stranded DNA by Rad51 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE RFA1; PRESYNAPTIC COMPLEX-FORMATION; BREAK-INDUCED RECOMBINATION; BINDING-PROTEIN; RECA PROTEIN; MEIOTIC RECOMBINATION; EXCISION-REPAIR; LARGE SUBUNIT; G2/M ARREST; REPLICATION	Replication protein-A (RPA) is involved in many processes of DNA metabolism, including DNA replication, repair, and recombination. Cells carrying a mutation in the largest subunit of RPA (rfa1-t11: K45E) have defects in meiotic recombination, mating-type switching, and survival after DNA damage caused by UV and methyl methanesulfonate, as well as increased genome instability; however, this mutant has no significant defect in DNA replication. We purified the RPA heterotrimer containing the rfa1-t11 substitution (RPA(rfa1-t11)). This mutant RPA binds single-stranded DNA (ssDNA) with the same site size, and the RPA(rfa1-t11).ssDNA complex shows a similar sensitivity to disruption by salt as the wild-type RPA.ssDNA complex. RPA(rfa1-t11) stimulates DNA strand exchange, provided that the Rad51 protein.ssDNA nucleoprotein complex is assembled prior to introduction of the mutant RPA. However, RPA(rfa1-t11) is displaced from ssDNA by Rad51 protein more slowly than wild-type RPA and, as a consequence, Rad51 protein-mediated DNA strand exchange is inhibited when the ssDNA is in a complex with RPA(rfa1-t11). Rad52 protein can stimulate displacement of RPA(rfa1-t11) from ssDNA by Rad51 protein, but the rate of displacement remains slow compared with wild-type RPA. These in vitro results suggest that, in vivo, RPA is bound to ssDNA prior to Rad51 protein and that RPA displacement by Rad51 protein is a critical step in homologous recombination, which is impaired in the rfa1-t11 mutation.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Genet Grad Grp, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Davis, CA 95616 USA; Univ Calif San Diego, Ludwig Inst Canc Res, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Briggs hall, Davis, CA 95616 USA.			Sugiyama, Tomohiko/0000-0003-2942-3667	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026017, R37GM062653, R01GM026017, R01GM062653] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline; NIGMS NIH HHS [GM-26017, GM-62653] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FISHMANLOBELL J, 1992, SCIENCE, V258, P480, DOI 10.1126/science.1411547; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Kantake N, 2002, P NATL ACAD SCI USA, V99, P15327, DOI 10.1073/pnas.252633399; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; Lee SE, 2001, CURR BIOL, V11, P1053, DOI 10.1016/S0960-9822(01)00296-2; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nakagawa T, 2001, J BIOL CHEM, V276, P31487, DOI 10.1074/jbc.M104003200; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; Soustelle C, 2002, GENETICS, V161, P535; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 2002, J BIOL CHEM, V277, P31663, DOI 10.1074/jbc.M203494200; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Umezu K, 1998, GENETICS, V148, P989; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	56	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23410	23417		10.1074/jbc.M302995200	http://dx.doi.org/10.1074/jbc.M302995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697761	Green Published, hybrid			2022-12-25	WOS:000183638600026
J	Sun, YM; Bosmans, F; Zhu, RH; Goudet, C; Xiong, YM; Tytgat, J; Wang, DC				Sun, YM; Bosmans, F; Zhu, RH; Goudet, C; Xiong, YM; Tytgat, J; Wang, DC			Importance of the conserved aromatic residues in the scorpion alpha-like toxin BmK M1 - The hydrophobic surface region revisited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUTHUS-MARTENSII KARSCH; ANDROCTONUS-AUSTRALIS HECTOR; 3-DIMENSIONAL STRUCTURE; SODIUM-CHANNEL; FUNCTIONAL EXPRESSION; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RECEPTOR-SITES; NEUROTOXIN; VENOM	About one-third of the amino acid residues conserved in all scorpion long chain Na+ channel toxins are aromatic residues, some of which constitute the so-called "conserved hydrophobic surface." At present, in-depth structure-function studies of these aromatic residues using site-directed mutagenesis are still rare. In this study, an effective yeast expression system was used to study the role of seven conserved aromatic residues (Tyr(5), Tyr(14), Tyr(21), Tyr(35), Trp(38), Tyr(42), and Trp(47)) from the scorpion toxin BmK M1. Using site-directed mutagenesis, all of these aromatic residues were individually substituted with Gly in association with a more conservative substitution of Phe for Tyr(5), Tyr(14), Tyr(35), or Trp(47). The mutants, which were expressed in Saccharomyces cerevisiae S-78 cells, were then subjected to a bioassay in mice, electrophysiological characterization on cloned Na+ channels (Na(v)1.5), and CD analysis. Our results show an eye-catching correlation between the LD50 values in mice and the EC50 values on Na(v)1.5 channels in oocytes, indicating large mutant-dependent differences that emphasize important specific roles for the conserved aromatic residues in BmK M1. The aromatic side chains of the Tyr(5), Tyr(35), and Trp(47) cluster protruding from the three-stranded beta-sheet seem to be essential for the structure and function of the toxin. Trp(38) and Tyr(42) (located in the beta(2)-sheet and in the loop between the beta(2)- and beta(3)-sheets, respectively) are most likely involved in the pharmacological function of the toxin.	Chinese Acad Sci, Inst Biophys, Ctr Mol Biol, Beijing 100101, Peoples R China; Katholieke Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium	Chinese Academy of Sciences; Institute of Biophysics, CAS; KU Leuven	Wang, DC (corresponding author), Chinese Acad Sci, Inst Biophys, Ctr Mol Biol, 15 Datun Rd, Beijing 100101, Peoples R China.	dcwang@sun5.ibp.ac.cn	Bosmans, Frank/T-5589-2017; Tytgat, Jan/F-1560-2010; Bosmans, Frank/A-9660-2013; Goudet, Cyril/AAE-3415-2020	Bosmans, Frank/0000-0002-6476-235X; Bosmans, Frank/0000-0002-6476-235X; Goudet, Cyril/0000-0002-8255-3535; Tytgat, Jan/0000-0003-1778-6022; Bosmans, Frank/0000-0002-0451-6050				BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; COURAUD F, 1982, TOXICON, V20, P9, DOI 10.1016/0041-0101(82)90138-6; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1980, P NATL ACAD SCI-BIOL, V77, P6496, DOI 10.1073/pnas.77.11.6496; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; Gordon D, 1996, J BIOL CHEM, V271, P8034, DOI 10.1074/jbc.271.14.8034; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Goudet C, 2002, TOXICON, V40, P1239, DOI 10.1016/S0041-0101(02)00142-3; Goudet C, 2001, FEBS LETT, V495, P61, DOI 10.1016/S0014-5793(01)02365-1; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Li HM, 1999, ACTA CRYSTALLOGR D, V55, P341, DOI 10.1107/S0907444998006593; Li HM, 1996, J MOL BIOL, V261, P415, DOI 10.1006/jmbi.1996.0473; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MEIER J, 1986, TOXICON, V24, P395, DOI 10.1016/0041-0101(86)90199-6; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Shao F, 1999, PROTEIN EXPRES PURIF, V17, P358, DOI 10.1006/prep.1999.1127; Sun YM, 2002, J PEPT RES, V60, P247, DOI 10.1034/j.1399-3011.2002.21021.x; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Xiong YM, 1997, TOXICON, V35, P1025, DOI 10.1016/S0041-0101(96)00224-3; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309	27	56	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24125	24131		10.1074/jbc.M211931200	http://dx.doi.org/10.1074/jbc.M211931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692120	hybrid			2022-12-25	WOS:000183638600118
J	Collinson, EJ; Grant, CM				Collinson, EJ; Grant, CM			Role of yeast glutaredoxins as glutathione S-transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; OXIDATIVE STRESS; THIOLTRANSFERASE; IDENTIFICATION; EXPRESSION; PROTECTION; REDUCTASE; THIOREDOXIN; PEROXIDASES	The yeast Saccharomyces cerevisiae contains two glutaredoxins, encoded by GRX1 and GRX2, that are required for resistance to reactive oxygen species. We recently reported that Grx1 is active as a glutathione peroxidase and can directly reduce hydroperoxides ( Collinson, E. J., Wheeler, G. L., Garrido, E. O., Avery, A. M., Avery, S. V., and Grant, C. M. ( 2002) J. Biol. Chem. 277, 16712 - 16717). We now show that Grx2 is also a general hydroperoxidase, and kinetic data indicate that both enzymes have a similar pattern of activity, which is highest with hydrogen peroxide, followed by cumene hydroperoxide and tert- butyl hydroperoxide. Furthermore, both Grx1 and Grx2 are shown be active as glutathione S- transferases ( GSTs), and their activity with model substrates such as 1- chloro- 2,4- dinitrobenzene is similar to their activity with hydroperoxides. Analysis of the Grx1 active site residues shows that Cys- 27, but not Cys- 30, is required for both the peroxidase and transferase activities, indicating that these reactions proceed via a monothiol mechanism. Deletion analysis shows that Grx1 and Grx2 have an overlapping function with yeast GSTs, encoded by GTT1 and GTT2, and are responsible for the majority of cellular GST activity. In addition, multiple mutants lacking GRX1, GRX2, GTT1, and GTT2 show increased sensitivity to stress conditions, including exposure to xenobiotics, heat, and oxidants. In summary, glutaredoxins are multifunctional enzymes with oxidoreductase, peroxidase, and GST activity, and are therefore ideally suited to detoxify the wide range of xenobiotics and oxidants that can be generated during diverse stress conditions.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Manchester	Grant, CM (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.			Grant, Chris/0000-0002-0616-6576				Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; GAN ZR, 1990, ARCH BIOCHEM BIOPHYS, V282, P110, DOI 10.1016/0003-9861(90)90093-E; Garrido EO, 2002, MOL MICROBIOL, V43, P993, DOI 10.1046/j.1365-2958.2002.02795.x; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Girardini J, 2002, EUR J BIOCHEM, V269, P5512, DOI 10.1046/j.1432-1033.2002.03254.x; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Grant CM, 2000, BBA-GENE STRUCT EXPR, V1490, P33, DOI 10.1016/S0167-4781(99)00234-1; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1990, GLUTATHIONE METABOLI, P146; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Lee KO, 2002, BIOCHEM BIOPH RES CO, V296, P1152, DOI 10.1016/S0006-291X(02)02047-8; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Mukhopadhyay R, 2001, J BIOL CHEM, V276, P34738, DOI 10.1074/jbc.M103354200; Pedrajas JR, 2002, BIOCHEM J, V364, P617, DOI 10.1042/BJ20020570; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Sherratt PJ, 1998, BIOCHEM J, V335, P619, DOI 10.1042/bj3350619; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; YANG YF, 1991, J BIOL CHEM, V266, P12759; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	34	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22492	22497		10.1074/jbc.M301387200	http://dx.doi.org/10.1074/jbc.M301387200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684511	hybrid			2022-12-25	WOS:000183503900044
J	Jagatheesan, G; Rajan, S; Petrashevskaya, N; Schwartz, A; Boivin, G; Vahebi, S; DeTombe, P; Solaro, RJ; Labitzke, E; Hilliard, G; Wieczorek, DF				Jagatheesan, G; Rajan, S; Petrashevskaya, N; Schwartz, A; Boivin, G; Vahebi, S; DeTombe, P; Solaro, RJ; Labitzke, E; Hilliard, G; Wieczorek, DF			Functional importance of the carboxyl-terminal region of striated muscle tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TROPOMYOSIN; BETA-TROPOMYOSIN; FILAMENT; EXPRESSION; MUTATION; OVERLAP; BINDING; CELLS; CA2+	Striated muscle tropomyosin (TM) interacts with actin and the troponin complex to regulate calcium-mediated muscle contraction. Previous work by our laboratory established that alpha- and beta-TM isoforms elicit physiological differences in sarcomeric performance. Heart myofilaments containing beta-TM exhibit an increased sensitivity to calcium that is associated with a decrease in the rate of relaxation and a prolonged time of relaxation. To address whether the carboxyl-terminal, troponin T binding domain of beta-TM is responsible for these physiological alterations, we exchanged the 27 terminal amino acids of alpha-TM (amino acids 258-284) for the corresponding region in beta-TM. Hearts of transgenic mice that express this chimeric TM protein exhibit significant decreases in their rates of contraction and relaxation when assessed by ex vivo work-performing cardiac analyses. There are increases in the time to peak pressure and a dramatic increase in end diastolic pressure. In myofilaments, this chimeric protein induces depression of maximum tension and ATPase rate, together with a significant decrease in sensitivity to calcium. Our data are the first to demonstrate that the TM isoform-specific carboxyl terminus is a critical determinant of sarcomere performance and calcium sensitivity in both the whole heart and in isolated myofilaments.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Surg, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; University of Cincinnati	Wieczorek, DF (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		Rajan, Sudarsan/A-6780-2008		NHLBI NIH HHS [HL22231, HL22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, R37HL022231, R01HL022231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; DABROWSKA R, 1983, J MUSCLE RES CELL M, V4, P143, DOI 10.1007/BF00712027; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HEELEY DH, 1989, BIOCHEM J, V258, P831, DOI 10.1042/bj2580831; Landis C, 1999, J BIOL CHEM, V274, P31279, DOI 10.1074/jbc.274.44.31279; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; Muthuchamy M, 1998, J MOL CELL CARDIOL, V30, P1545, DOI 10.1006/jmcc.1998.0720; Muthuchamy M, 1999, CIRC RES, V85, P47; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; PAN BS, 1989, J BIOL CHEM, V264, P8495; Pieples K, 2000, BIOCHEMISTRY-US, V39, P8291, DOI 10.1021/bi000047x; Pieples K, 2002, AM J PHYSIOL-HEART C, V283, pH1344, DOI 10.1152/ajpheart.00351.2002; Prabhakar R, 2001, J MOL CELL CARDIOL, V33, P1815, DOI 10.1006/jmcc.2001.1445; THOMAS L, 1994, BIOPHYS J, V66, pA310; WALSH TP, 1984, J MOL BIOL, V182, P265; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; Wolska BM, 1999, CIRC RES, V84, P745	20	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23204	23211		10.1074/jbc.M303073200	http://dx.doi.org/10.1074/jbc.M303073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690096	hybrid			2022-12-25	WOS:000183503900129
J	Helbig, G; Christopherson, KW; Bhat-Nakshatri, P; Kumar, S; Kishimoto, H; Miller, KD; Broxmeyer, HE; Nakshatri, H				Helbig, G; Christopherson, KW; Bhat-Nakshatri, P; Kumar, S; Kishimoto, H; Miller, KD; Broxmeyer, HE; Nakshatri, H			NF-kappa B promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; TUMOR-CELLS; CONSTITUTIVE ACTIVATION; PROGRESSION; SURVIVAL; GENE; GROWTH; INTERLEUKIN-1-ALPHA; PROLIFERATION; PARTHENOLIDE	Metastasis of cancer cells is a complex process involving multiple steps including invasion, angiogenesis, and trafficking of cancer cells through blood vessels, extravasations, organ-specific homing, and growth. While matrix metalloproteinases, urokinase- type plasminogen activator, and cytokines play a major role in invasion and angiogenesis, chemokines such as stromal derived factor-1alpha (SDF-1alpha) and their receptors such as CXCR4 are thought to play a critical role in motility, homing, and proliferation of cancer cells at specific metastatic sites. We and others have previously reported that the extracellular signal-activated transcription factor NF-kappaB up-regulates the expression of matrix metalloproteinases, urokinase- type plasminogen activator, and cytokines in highly metastatic breast cancer cell lines. In this report, we demonstrate that NF-kappaB regulates the motility of breast cancer cells by directly up-regulating the expression of CXCR4. Overexpression of the inhibitor of kappaB (IkappaB) in breast cancer cells with constitutive NF-kappaB activity resulted in reduced expression of CXCR4 and a corresponding loss of SDF-1alpha-mediated migration in vitro. Introduction of CXCR4 cDNA into IkappaB-expressing cells restored SDF-1alpha-mediated migration. Electrophoretic mobility shift assays and transient transfection assays revealed that the NF-kappaB subunits p65 and p50 bind directly to sequences within the -66 to +7 region of the CXCR4 promoter and activate transcription. We also show that the cell surface expression of CXCR4 and the SDF-1alpha-mediated migration are enhanced in breast cancer cells isolated from mammary fat pad xenografts compared with parental cells grown in culture. A further increase in CXCR4 cell surface expression and SDF-1alpha-mediated migration was observed with cancer cells that metastasized to the lungs. Taken together, these results implicate NF-kappaB in the migration and the organ-specific homing of metastatic breast cancer cells.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, R4-202,1044 W Walnut St, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052	NATIONAL CANCER INSTITUTE [R21CA082208] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053674] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82208] Funding Source: Medline; NHLBI NIH HHS [HL 67384] Funding Source: Medline; NIDDK NIH HHS [DK 53674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2002, ONCOLOGIST, V7, P9, DOI 10.1634/theoncologist.7-1-9; Andela VB, 2000, CANCER RES, V60, P6557; Bachelder RE, 2002, CANCER RES, V62, P7203; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Christopherson KW, 2001, BLOOD, V98, P3562, DOI 10.1182/blood.V98.13.3562; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dong G, 1999, CANCER RES, V59, P3495; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hehner SP, 1999, J IMMUNOL, V163, P5617; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kijowski J, 2001, STEM CELLS, V19, P453, DOI 10.1634/stemcells.19-5-453; Koshiba T, 2000, CLIN CANCER RES, V6, P3530; Lee Y, 2002, BLOOD, V99, P4307, DOI 10.1182/blood.V99.12.4307; Liotta LA, 2001, NATURE, V410, P24, DOI 10.1038/35065180; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; NICOLSON GL, 1993, CANCER METAST REV, V12, P325, DOI 10.1007/BF00665961; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SATO H, 1993, ONCOGENE, V8, P395; Scotton CJ, 2002, CANCER RES, V62, P5930; Sehgal A, 1998, J SURG ONCOL, V69, P239, DOI 10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shibata A, 2002, BREAST CANCER RES TR, V73, P237, DOI 10.1023/A:1015872531675; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Vinante F, 2002, BLOOD, V99, P52, DOI 10.1182/blood.V99.1.52	41	526	572	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21631	21638		10.1074/jbc.M300609200	http://dx.doi.org/10.1074/jbc.M300609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12690099	Green Published, hybrid			2022-12-25	WOS:000183354200041
J	Esposito, F; Chirico, G; Gesualdi, NM; Posadas, I; Ammendola, R; Russo, T; Cirino, G; Cimino, F				Esposito, F; Chirico, G; Gesualdi, NM; Posadas, I; Ammendola, R; Russo, T; Cirino, G; Cimino, F			Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires Src activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; PROOXIDANT CONDITIONS; CELL-SURVIVAL; GENERATION; MECHANISM; PATHWAY; H2O2; EXPRESSION	Reactive oxygen species (ROS) participate as second messengers in the mitogenic signal transduction. Most of the experimental data supporting the role of ROS as signaling molecules have been obtained by using H2O2. Exposure of cells to H2O2 rapidly increases tyrosine phosphorylation of tyrosine kinase receptors (TKRs) in the absence of growth factor binding, thus inducing the activation of downstream signaling cascades, like that of protein kinase B (AKT). Another molecule able to induce an increase of intracellular ROS levels is diethylmaleate (DEM), which acts by depleting the ROS scavenger reduced glutathione (GSH). A comparison of the effects exerted by H2O2 and DEM shows that the latter induces redox modifications milder than those generated by H2O2. We also demonstrated that DEM-induced redox modifications are not accompanied by platelet-derived growth factor-receptor (PDGF-R) and epidermal growth factor-receptor Tyr phosphorylation, although they are able to activate ERKs and AKT, with kinetics different from those observed following H2O2 treatment. The activation of these two pathways is not blocked by AG1296, a selective inhibitor of PDGF-R Tyr kinase, thus confirming that the effects of DEM are not mediated by the TKR phosphorylation. On the contrary, PP2 (4-amino-5-(4-chlorophenyl)7-(t-butyl) pyrazole[3,4-d] pyrimidine), an inhibitor of Src kinase, completely prevents DEM- and H2O2-induced AKT activation but has no effect on the pathway of ERKs. Finally, nitration of Tyr residues in PDGF-R is observed in DEM- treated cells, thus suggesting that ROS-induced modifications different from Tyr phosphorylation can occur at the growth factor-receptor level and can be involved in the regulation of signaling pathways.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy; Univ Naples Federico II, Dipartimento Farmacol Sperimentale, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Esposito, F (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via Pansini 5, Naples, Italy.		Esposito, Franca/K-2024-2016; Russo, Tommaso/K-1331-2016; Posadas, Inmaculada/M-1124-2014	Esposito, Franca/0000-0001-9340-6875; Russo, Tommaso/0000-0003-4426-0106; Posadas, Inmaculada/0000-0003-1854-3372; AMMENDOLA, Rosario/0000-0003-1655-8028; Cirino, Giuseppe/0000-0003-3954-4083				Andrieu-Abadie N, 2001, FREE RADICAL BIO MED, V31, P717, DOI 10.1016/S0891-5849(01)00655-4; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bevan P, 2001, J CELL SCI, V114, P1429; BOYLAND E, 1967, BIOCHEM J, V104, P95, DOI 10.1042/bj1040095; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Esposito F, 2002, METHOD ENZYMOL, V352, P258; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; GYLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209; Hensley K, 2002, ARCH BIOCHEM BIOPHYS, V397, P377, DOI 10.1006/abbi.2001.2630; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Klotz LO, 2002, FREE RADICAL BIO MED, V33, P737, DOI 10.1016/S0891-5849(02)00892-4; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Mallozzi C, 2001, FREE RADICAL BIO MED, V30, P1108, DOI 10.1016/S0891-5849(01)00509-3; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; Minetti M, 2002, FREE RADICAL BIO MED, V33, P744, DOI 10.1016/S0891-5849(02)00891-2; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Monteiro HP, 2002, FREE RADICAL BIO MED, V33, P765, DOI 10.1016/S0891-5849(02)00893-6; Pani G, 2001, IUBMB LIFE, V52, P7, DOI 10.1080/15216540252774702; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Wang XT, 2001, J BIOL CHEM, V276, P28364, DOI 10.1074/jbc.M102693200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	38	99	104	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20828	20834		10.1074/jbc.M211841200	http://dx.doi.org/10.1074/jbc.M211841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12682076	hybrid			2022-12-25	WOS:000183230500051
J	Liu, J; Matyakhina, L; Han, ZQ; Sandrini, F; Bei, T; Stratakis, CA; Papasopoulos, V				Liu, J; Matyakhina, L; Han, ZQ; Sandrini, F; Bei, T; Stratakis, CA; Papasopoulos, V			Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor- and protein kinase A regulatory subunit type 1A (PRKAR1A)-associated protein PAP7 and studies in PRKAR1A mutant cells and tissues	FASEB JOURNAL			English	Article						PBR; adrenal cortex; gonads; chromosome 1; steroidogenesis	DIAZEPAM-BINDING INHIBITOR; LEYDIG TUMOR-CELLS; CARNEY COMPLEX; SPOTTY PIGMENTATION; STEROIDOGENESIS; CHOLESTEROL; GENE; IDENTIFICATION; BIOSYNTHESIS; CHORIOGONADOTROPIN	A mouse protein that interacts with the peripheral-type benzodiazepine receptor (PBR) and cAMP-dependent protein kinase A (PKA) regulatory subunit RIalpha. (PRKAR1A), named PBR and PKA-associated protein 7 (PAP7), was identified and shown to be involved in hormone-induced steroid biosynthesis. We report the identification of the human PAP7 gene, its expression pattern, genomic structure, and chromosomal mapping to 1q32-1q41. Human PAP7 is a 60-kDa protein highly homologous to the rodent protein. PAP7 is widely present in human tissues and highly expressed in seminal vesicles, pituitary, thyroid, pancreas, renal cortex, enteric epithelium, muscles, myocardium and in steroidogenic tissues, including the gonads and adrenal cortex. These tissues are also targets of Carney complex (CNC), a multiple neoplasia syndrome caused by germline inactivating PRKAR1A mutations (PRKAR1A-mut) and associated with primary pigmented nodular adrenocortical disease (PPNAD) and increased steroid synthesis. PAP7 and PRKAR1A expression were studied in PPNAD and in lymphoblasts from patients bearing PRKAR1A-mut. Like PRKAR1A, PAP7 was decreased in CNC lymphocytes and PPNAD nodules, but not in the surrounding cortex. These studies showed that, like in the mouse, human PAP7 is highly expressed in steroidogenic tissues, where it follows the pattern of PRKAR1A expression, suggesting that it participates in PRKAR1A-mediated tumorigenesis and hypercortisolism.	Georgetown Univ, Sch Med,Med Ctr, Dept Cell Biol, Div Hormone Res, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; NICHHD, Sect Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Papasopoulos, V (corresponding author), Georgetown Univ, Sch Med,Med Ctr, Dept Cell Biol, Div Hormone Res, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	papadopv@georgetown.edu	Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000642, Z01HD000642] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; Boujrad N, 1996, ENDOCRINOLOGY, V137, P5727, DOI 10.1210/en.137.12.5727; BOUJRAD N, 1993, P NATL ACAD SCI USA, V90, P5728, DOI 10.1073/pnas.90.12.5728; BOUJRAD N, 1994, ENDOCRINOLOGY, V135, P1576, DOI 10.1210/en.135.4.1576; CARNEY JA, 1995, SEMIN DERMATOL, V14, P90, DOI 10.1016/S1085-5629(05)80003-3; CARNEY JA, 1986, MAYO CLIN PROC, V61, P165, DOI 10.1016/S0025-6196(12)61843-6; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; COSTA E, 1991, LIFE SCI, V49, P325, DOI 10.1016/0024-3205(91)90440-M; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; Jefcoate C, 2002, J CLIN INVEST, V110, P881, DOI 10.1172/JCI200216771; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KNUDSEN J, 1989, BIOCHEM J, V262, P513, DOI 10.1042/bj2620513; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; Lacapere JJ, 2001, BIOCHEM BIOPH RES CO, V284, P536, DOI 10.1006/bbrc.2001.4975; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Mujica AO, 2001, GENE, V280, P175, DOI 10.1016/S0378-1119(01)00780-6; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1992, P NATL ACAD SCI USA, V89, P5113, DOI 10.1073/pnas.89.11.5113; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P1274, DOI 10.1210/jc.82.4.1274; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; Sohda M, 2001, J BIOL CHEM, V276, P45298, DOI 10.1074/jbc.M108961200; Sridaran R, 1999, J MOL ENDOCRINOL, V22, P45, DOI 10.1677/jme.0.0220045; Stocco DM, 1999, BIOESSAYS, V21, P768, DOI 10.1002/(SICI)1521-1878(199909)21:9<768::AID-BIES8>3.3.CO;2-U; Stratakis CA, 2001, J CLIN ENDOCR METAB, V86, P4041, DOI 10.1210/jc.86.9.4041; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, ANN INTERN MED, V131, P585, DOI 10.7326/0003-4819-131-8-199910190-00006; Stratakis CA, 2000, FRONT BIOSCI-LANDMRK, V5, pD353, DOI 10.2741/Stratakis; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075; Zilz A, 1999, ENDOCRINOLOGY, V140, P859, DOI 10.1210/en.140.2.859	41	27	30	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1189	+		10.1096/fj.02-1066fje	http://dx.doi.org/10.1096/fj.02-1066fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692076				2022-12-25	WOS:000182580100047
J	Meier, S; Brauer, AU; Heimrich, B; Schwab, ME; Nitsch, R; Savaskan, NE				Meier, S; Brauer, AU; Heimrich, B; Schwab, ME; Nitsch, R; Savaskan, NE			RETRACTED: Molecular analysis of Nogo expression in the hippocampus during development and following lesion and seizure (Retracted article. See vol. 25, pg. 2853, 2011)	FASEB JOURNAL			English	Article; Retracted Publication						axonal growth inhibitors; entorhinal cortex lesion; reticulons; kainic acid-induced seizure; axonal plasticity	NEURITE GROWTH-INHIBITORS; CHONDROITIN SULFATE PROTEOGLYCAN; ENTORHINAL CORTEX LESION; MYELIN-ASSOCIATED GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; DENTATE GYRUS; ADULT-RAT; AXONAL REGENERATION; MESSENGER-RNA	The Nogo gene encodes an integral membrane protein mainly responsible for the neurite inhibition properties of myelin. Here, we analyzed the expression pattern of Nogo-A, Nogo-B, and Nogo-C and Nogo-66 receptor (Ng66R) mRNA during hippocampal development and lesion-induced axonal sprouting. Nogo-A and Nogo-B and Ng66R transcripts preceded the progress of myelination and were highly expressed at postnatal day zero (P0) in all principal hippocampal cell layers, with the exception of dentate granule cells. Only a slight Nogo-C expression was found at P0 in the principal cell layers of the hippocampus. During adulthood, all Nogo splice variants and their receptor were expressed in the neuronal cell layers of the hippocampus, in contrast to the myelin basic protein mRNA expression pattern, which revealed a neuronal source of Nogo gene expression in addition to oligodendrocytes. After hippocampal denervation, the Nogo genes showed an isoform-specific temporal regulation. All Nogo genes were strongly regulated in the hippocampal cell layers, whereas the Ng66R transcripts showed a significant increase in the contralateral cortex. These data could be confirmed on protein levels. Furthermore, Nogo-A expression was up-regulated after kainate-induced seizures. Our data show that neurons express Nogo genes with a clearly distinguishable pattern during development. This expression is further dynamically and isoform-specifically altered after lesioning during the early phase of structural rearrengements. Thus, our results indicate a role for Nogo-A, -B, and -C during development and during the stabilization phase of hippocampal reorganization. Taken together with these data, the finding that neurons in a highly plastic brain region express Nogo genes supports the hypothesis that Nogo may function beyond its known neuronal growth inhibition activity in shaping neuronal circuits.	Humboldt Univ, Med Sch Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Univ Zurich, Dept Neuromorphol, Brain Res Inst, Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; ETH Zurich	Savaskan, NE (corresponding author), Humboldt Univ, Med Sch Charite, Dept Cell & Neurobiol, Inst Anat, Oskar Hertwig House,Philippstr 12, D-10098 Berlin, Germany.	nicolai.savaskan@charite.de	Nitsch, Robert/AAI-9129-2021; Schwab, Martin E/B-6818-2016; Bräuer, Anja/N-3692-2019; Braeuer, Anja/K-8339-2013; Savaskan, Nicolai/D-2923-2018	Savaskan, Nicolai/0000-0003-1348-094X				Alcantara S, 2000, DEVELOPMENT, V127, P1359; Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022; BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; Bovolenta P, 1997, EUR J NEUROSCI, V9, P977, DOI 10.1111/j.1460-9568.1997.tb01448.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brauer AU, 2001, FASEB J, V15, P2689, DOI 10.1096/fj.01-0235com; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brittis PA, 2001, NEURON, V30, P11, DOI 10.1016/S0896-6273(01)00258-6; Brosamle C, 2000, J NEUROSCI, V20, P8061; Buffo A, 2000, J NEUROSCI, V20, P2275; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DELLER T, 1995, J NEUROSCI, V15, P6868; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; DOU CL, 1994, J NEUROSCI, V14, P7616; Forster E, 2001, DEVELOPMENT, V128, P3029; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; FROTSCHER M, 1993, P NATL ACAD SCI USA, V90, P10400, DOI 10.1073/pnas.90.21.10400; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; Gao PP, 1999, P NATL ACAD SCI USA, V96, P4073, DOI 10.1073/pnas.96.7.4073; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Haas CA, 1999, J NEUROSCI, V19, P9953; Hens J, 1998, CELL TISSUE RES, V292, P229, DOI 10.1007/s004410051054; Holder N, 1999, DEVELOPMENT, V126, P2033; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hu WH, 2002, J NEUROCHEM, V81, P36, DOI 10.1046/j.1471-4159.2002.00788.x; Huber AB, 2002, J NEUROSCI, V22, P3553; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; Josephson A, 2001, EXP NEUROL, V169, P319, DOI 10.1006/exnr.2001.7659; KOVACS A, 2001, SOC NEUR ABSTR, V27, P253; LIU BP, 2002, SCIENCE         0627; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; OERTLE T, 2000, SOC NEUR ABSTR, V26, P573; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; RUST RS, 1991, NEUROCHEM RES, V16, P991, DOI 10.1007/BF00965842; Savaskan NE, 2002, J NEUROCHEM, V83, P1196, DOI 10.1046/j.1471-4159.2002.01233.x; Savaskan NE, 2001, REV NEUROSCIENCE, V12, P195; Savaskan NE, 1999, EUR J NEUROSCI, V11, P316, DOI 10.1046/j.1460-9568.1999.00430.x; Savaskan NE, 2000, EUR J NEUROSCI, V12, P1024, DOI 10.1046/j.1460-9568.2000.00998.x; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Skaper SD, 2001, PROG NEUROBIOL, V65, P593, DOI 10.1016/S0301-0082(01)00017-X; Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3; Skutella T, 1999, DEV BIOL, V211, P277, DOI 10.1006/dbio.1999.9295; SNYDER DC, 1991, J NEUROBIOL, V22, P897, DOI 10.1002/neu.480220903; Stein E, 1999, J NEUROSCI, V19, P8885, DOI 10.1523/JNEUROSCI.19-20-08885.1999; Steup A, 1999, EUR J NEUROSCI, V11, P729, DOI 10.1046/j.1460-9568.1999.00517.x; Steup A, 2000, MOL CELL NEUROSCI, V15, P141, DOI 10.1006/mcne.1999.0818; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108; SUZUKI M, 1994, GLIA, V12, P294, DOI 10.1002/glia.440120406; Tessier-Lavigne M, 2000, SCIENCE, V287, P813, DOI 10.1126/science.287.5454.813; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2002, J NEUROSCI, V22, P5505; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744; Zagrebelsky M, 1998, J NEUROSCI, V18, P7912	82	57	66	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1153	+		10.1096/fj.02-0453fje	http://dx.doi.org/10.1096/fj.02-0453fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692091				2022-12-25	WOS:000182580100048
J	Michaud, SE; Menard, C; Guy, LG; Gennaro, G; Rivard, A				Michaud, SE; Menard, C; Guy, LG; Gennaro, G; Rivard, A			Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1-alpha/VEGF pathway	FASEB JOURNAL			English	Article						neovascularization; smoking; ischemia	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; THERAPEUTIC ANGIOGENESIS; CELL MIGRATION; MOUSE MODEL; DNA-BINDING; FACTOR GENE; TRANSACTIVATION; TRANSCRIPTION; DYSFUNCTION	Smoking is a major risk factor for atherosclerotic diseases. However, the impact of cigarette smoke exposure on neovascularization that develops in response to tissue ischemia is unknown. Here we demonstrate that cigarette smoke extracts inhibit hypoxia-induced in vitro angiogenesis (matrigel assay) in human umbilical vascular endothelial cells. In vivo, mice exposed to cigarette smoke (MES) were shown to have a significant impairment of angiogenesis following surgically induced hindlimb ischemia. The reduced angiogenic response in MES was documented by Laser Doppler flow perfusion studies and capillary density analyses in ischemic hindlimbs. Inhibition of angiogenesis by cigarette smoke in vitro and in vivo was associated with a reduced expression of hypoxia-inducible factor-1alpha, (HIF-1alpha,) and vascular endothelial growth factor (VEGF) in hypoxic conditions. Administration of an adenoviral vector encoding for HIF-1alpha/VP16, a hybrid transcription factor that is stable in hypoxic and normoxic conditions, restored VEGF expression and completely reversed the cigarette smoke inhibition of angiogenesis in hypoxic conditions. Taken together, these results suggest that cigarette smoke exposure impairs angiogenesis by inhibiting VEGF through decreased expression of HIF-1alpha, in hypoxic conditions.	Univ Montreal, Ctr Hosp, Dept Cardiovasc Res, Montreal, PQ H2L 4M1, Canada	Universite de Montreal	Rivard, A (corresponding author), Univ Montreal, Ctr Hosp, Dept Cardiovasc Res, 1560 Sherbrooke Est,Suite Y-3605, Montreal, PQ H2L 4M1, Canada.	rivardal@total.net						Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Couffinhal T, 1998, AM J PATHOL, V152, P1667; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Emanueli C, 2001, CIRCULATION, V103, P125; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JANOFF A, 1977, AM REV RESPIR DIS, V116, P65; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Ma L, 1999, CLIN EXP PHARMACOL P, V26, P828, DOI 10.1046/j.1440-1681.1999.03134.x; MAGERS T, 1995, REPROD TOXICOL, V9, P513, DOI 10.1016/0890-6238(95)02002-0; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789; Melkonian G, 2002, TOXICOL SCI, V68, P237, DOI 10.1093/toxsci/68.1.237; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PETRIK PV, 1995, STROKE, V26, P1409, DOI 10.1161/01.STR.26.8.1409; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Powell J T, 1998, Vasc Med, V3, P21, DOI 10.1191/135886398670269973; Raij L, 2001, J HYPERTENS, V19, P891, DOI 10.1097/00004872-200105000-00009; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Smith RS, 2002, ARTERIOSCL THROM VAS, V22, P1279, DOI 10.1161/01.ATV.0000026613.18742.67; Snajdar RM, 2001, J SURG RES, V96, P10, DOI 10.1006/jsre.2000.6055; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; Takeshita S, 1996, BIOCHEM BIOPH RES CO, V227, P628, DOI 10.1006/bbrc.1996.1556; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tsuchiya M, 2002, CIRCULATION, V105, P1155, DOI 10.1161/hc1002.105935; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Villablanca AC, 2000, CLIN CHEST MED, V21, P159, DOI 10.1016/S0272-5231(05)70015-0; Volm M, 1999, ANTICANCER RES, V19, P333; Wang HJ, 2001, AM J RESP CELL MOL, V25, P772, DOI 10.1165/ajrcmb.25.6.4458; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	43	110	113	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1150	+		10.1096/fj.02-0172fje	http://dx.doi.org/10.1096/fj.02-0172fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709416				2022-12-25	WOS:000182580100014
J	Berthier, S; Paclet, MH; Lerouge, S; Roux, F; Vergnaud, S; Coleman, AW; Morel, F				Berthier, S; Paclet, MH; Lerouge, S; Roux, F; Vergnaud, S; Coleman, AW; Morel, F			Changing the conformation state of cytochrome b(558) initiates NADPH oxidase activation - MRP8/MRP14 regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; CYTOSOLIC PHOSPHOLIPASE A(2); PHAGOCYTE RESPIRATORY BURST; HUMAN NEUTROPHIL ACTIVATION; IMMORTALIZED B-LYMPHOCYTES; CALCIUM-BINDING PROTEINS; ARACHIDONIC-ACID; PLASMA-MEMBRANE; FLAVOCYTOCHROME B(558)	Phagocyte NADPH oxidase generates O-2(.-) for defense mechanisms and cellular signaling. Myeloid-related proteins MRP8 and MRP14 of the S100 family are EF-hand calcium-binding proteins. MRP8 and MRP14 were co-isolated from neutrophils on an anti-p47(phox) matrix with oxidase cytosolic factors and identified by mass spectrometry. MRP8 and MRP14 are absent from Epstein-Barr virus-immortalized B lymphocytes, and, coincidentally, these cells display weak oxidase activity compared with neutrophils. MRP8/MRP14 that was purified from neutrophils enhanced oxidase turnover of B cells in vitro, suggesting that MRP8/MRP14 is involved in the activation process. This was confirmed ex vivo by co-transfection of Epstein-Barr virus-transformed B lymphocytes with genes encoding MRP8 and MRP14. In a semi-recombinant cell-free assay, recombinant MRP8/MRP14 increased the affinity of p67(phox) for cytochrome b(558) synergistically with p47(phox). Moreover, MRP8/MRP14 initiated oxidase activation on its own, through a calcium-dependent specific interaction with cytochrome b(558) as shown by atomic force microscopy and a structure-function relationship investigation. The data suggest that the change of conformation in cytochrome b(558), which initiates the electron transfer, can be mediated by effectors other than oxidase cytosolic factors p67(phox) and p47(phox). Moreover, MRP8/MRP14 dimer behaves as a positive mediator of phagocyte NADPH oxidase regulation.	CHU Grenoble, Enzymol Lab, GREPI EA 2938, F-38043 Grenoble 9, France; Commissariat Energie Atom Grenoble, Lab Chim Prot, F-38054 Grenoble, France; Inst Biol & Chim Prot, F-69367 Lyon, France	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA	Morel, F (corresponding author), CHU Grenoble, Enzymol Lab, GREPI EA 2938, BP 217, F-38043 Grenoble 9, France.		Paclet, Marie-Hélène/AAS-5029-2020; Coleman, Anthony William/K-2208-2019	ROUX-DALVAI, Florence/0000-0002-9961-8964				ABO A, 1992, J BIOL CHEM, V267, P16767; Batot G, 1998, BBA-MOL BASIS DIS, V1406, P188, DOI 10.1016/S0925-4439(98)00004-0; BATOT G, 1995, EUR J BIOCHEM, V234, P208, DOI 10.1111/j.1432-1033.1995.208_c.x; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; Cross AR, 1999, BIOCHEM J, V341, P251, DOI 10.1042/0264-6021:3410251; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; Dang PMC, 2002, P NATL ACAD SCI USA, V99, P4262, DOI 10.1073/pnas.072345299; DeLeo FR, 2000, J BIOL CHEM, V275, P13986, DOI 10.1074/jbc.275.18.13986; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Doussiere J, 2001, BIOCHEM BIOPH RES CO, V285, P1317, DOI 10.1006/bbrc.2001.5324; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P16394, DOI 10.1021/bi991502w; Doussiere J, 2002, EUR J BIOCHEM, V269, P3246, DOI 10.1046/j.1432-1033.2002.03002.x; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; Eue I, 2001, ATHEROSCLEROSIS, V154, P505, DOI 10.1016/S0021-9150(00)00678-X; Foubert TR, 2002, BBA-BIOMEMBRANES, V1567, P221, DOI 10.1016/S0005-2736(02)00619-3; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Geiszt M, 2001, BIOCHEM J, V355, P851, DOI 10.1042/bj3550851; Guignard F, 1996, EUR J BIOCHEM, V241, P265, DOI 10.1111/j.1432-1033.1996.0265t.x; Hessian PA, 2001, EUR J BIOCHEM, V268, P353, DOI 10.1046/j.1432-1327.2001.01894.x; Itou H, 2002, J MOL BIOL, V316, P265, DOI 10.1006/jmbi.2001.5340; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1999, FEBS LETT, V460, P134, DOI 10.1016/S0014-5793(99)01322-8; KOBAYASHI S, 1995, J BIOCHEM, V117, P758, DOI 10.1093/oxfordjournals.jbchem.a124773; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; Kumar RK, 2001, J LEUKOCYTE BIOL, V70, P59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; LEMARCHAND P, 1992, J BIOL CHEM, V267, P19379; MALY FE, 1994, J BIOL CHEM, V269, P18743; MOREL F, 1993, BIOCHIM BIOPHYS ACTA, V1182, P101, DOI 10.1016/0925-4439(93)90159-X; MOREL F, 1994, BBA-GEN SUBJECTS, V1201, P373, DOI 10.1016/0304-4165(94)90065-5; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MOREL F, 1992, M S-MED SCI, V8, P912, DOI 10.4267/10608/3258; Moskwa P, 2002, BIOCHEMISTRY-US, V41, P10710, DOI 10.1021/bi0257033; Nacken W, 2000, EUR J BIOCHEM, V267, P560, DOI 10.1046/j.1432-1327.2000.01040.x; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Paclet MH, 2001, EUR J BIOCHEM, V268, P5197, DOI 10.1046/j.0014-2956.2001.02455.x; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; ROTH J, 1993, BLOOD, V82, P1875; Santoni V, 2000, ELECTROPHORESIS, V21, P3329, DOI 10.1002/1522-2683(20001001)21:16<3329::AID-ELPS3329>3.0.CO;2-F; TANUGICHOLLEY LC, 1995, BLOOD, V85, P242, DOI 10.1182/blood.V85.1.242.bloodjournal851242; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van den Bos C, 1998, PROTEIN EXPRES PURIF, V13, P313, DOI 10.1006/prep.1998.0917; vandenBos C, 1996, J IMMUNOL, V156, P1247; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Vogl T, 1999, J BIOL CHEM, V274, P25291, DOI 10.1074/jbc.274.36.25291; Xu K, 2000, J IMMUNOL, V164, P4916, DOI 10.4049/jimmunol.164.9.4916; Zhao XX, 2002, J BIOL CHEM, V277, P25385, DOI 10.1074/jbc.M203630200	56	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25499	25508		10.1074/jbc.M209755200	http://dx.doi.org/10.1074/jbc.M209755200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719414	hybrid			2022-12-25	WOS:000183920200030
J	Guse, A; Stevenson, CEM; Kuper, J; Buchanan, G; Schwarz, G; Giordano, G; Magalon, A; Mendel, RR; Lawson, DM; Palmer, T				Guse, A; Stevenson, CEM; Kuper, J; Buchanan, G; Schwarz, G; Giordano, G; Magalon, A; Mendel, RR; Lawson, DM; Palmer, T			Biochemical and structural analysis of the molybdenum cofactor biosynthesis protein MobA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MOEA; CRYSTAL-STRUCTURE; MOLYBDOPTERIN SYNTHASE; GENE-PRODUCTS; MECHANISM; LOCUS; BINDING; REFINEMENT; SULFUR; STEPS	Molybdopterin guanine dinucleotide (MGD) is the form of the molybdenum cofactor that is required for the activity of most bacterial molybdoenzymes. MGD is synthesized from molybdopterin (MPT) and GTP in a reaction catalyzed by the MobA protein. Here we report that wild type MobA can be copurified along with bound MPT and MGD, demonstrating a tight binding of both its substrate and product. To study structure-function relationships, we have constructed a number of site-specific mutations of the most highly conserved amino acid residues of the MobA protein family. Variant MobA proteins were characterized for their ability to support the synthesis of active molybdenum enzymes, to bind MPT and MGD, to interact with the molybdenum cofactor biosynthesis proteins MobB and MoeA. They were also characterized by x-ray structural analysis. Our results suggest an essential role for glycine 15 of MobA, either for GTP binding and/or catalysis, and an involvement of glycine 82 in the stabilization of the product-bound form of the enzyme. Surprisingly, the individual and double substitution of asparagines 180 and 182 to aspartate did not affect MPT binding, catalysis, and product stabilization.	John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; John Innes Ctr, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England; Tech Univ Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany; CNRS, Chim Bacterienne Lab, Inst Biol Struct & Microbiol, F-13402 Marseille 09, France; Univ E Anglia, Sch Biol Sci, Ctr Metalloprot Spect & Biol, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Braunschweig University of Technology; Centre National de la Recherche Scientifique (CNRS); University of East Anglia	Palmer, T (corresponding author), John Innes Ctr, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.	tracy.palmer@bbsrc.ac.uk	Guse, Annika/I-1183-2013; Schwarz, Guenter/ABE-9643-2021; Lawson, David M/D-1810-2009	Guse, Annika/0000-0002-8737-9206; Schwarz, Guenter/0000-0002-2118-9338; Palmer, Tracy/0000-0001-9043-2592; Magalon, Axel/0000-0002-3375-738X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchanan G, 2001, ARCH MICROBIOL, V176, P62, DOI 10.1007/s002030100291; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Eaves DJ, 1997, EUR J BIOCHEM, V246, P690, DOI 10.1111/j.1432-1033.1997.t01-1-00690.x; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; IOBBINIVOL C, 1995, MICROBIOL-SGM, V141, P1663; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karimova G, 2000, METHOD ENZYMOL, V328, P59, DOI 10.1016/S0076-6879(00)28390-0; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Lake MW, 2000, J BIOL CHEM, V275, P40211, DOI 10.1074/jbc.M007406200; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magalon A, 2002, J BIOL CHEM, V277, P48199, DOI 10.1074/jbc.M205806200; MILLER JH, 1992, MOL CLONING LAB MANU; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Palmer T, 1998, BBA-GENE STRUCT EXPR, V1395, P135, DOI 10.1016/S0167-4781(97)00145-0; PALMER T, 1994, EUR J BIOCHEM, V222, P687, DOI 10.1111/j.1432-1033.1994.tb18913.x; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schrag JD, 2001, J MOL BIOL, V310, P419, DOI 10.1006/jmbi.2001.4771; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Stevenson CEM, 2000, STRUCTURE, V8, P1115, DOI 10.1016/S0969-2126(00)00518-9; Temple CA, 2000, J BIOL CHEM, V275, P40202, DOI 10.1074/jbc.M007407200; Wuebbens MM, 2000, STRUCTURE, V8, P709, DOI 10.1016/S0969-2126(00)00157-X; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082; Xiang S, 2001, STRUCTURE, V9, P299, DOI 10.1016/S0969-2126(01)00588-3	41	19	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25302	25307		10.1074/jbc.M302639200	http://dx.doi.org/10.1074/jbc.M302639200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719427	hybrid			2022-12-25	WOS:000183920200007
J	Henttinen, T; Jalkanen, S; Yegutkin, GG				Henttinen, T; Jalkanen, S; Yegutkin, GG			Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by ecto-5 '-nucleotidase/CD73-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHOKINASE; ADENYLATE KINASE; AIRWAY SURFACES; ATP RELEASE; CELLS; ADHESION; RECEPTOR; NUCLEOTIDES; METABOLISM; CD73	Extracellular purines are important signaling molecules that mediate both inflammatory (ATP, ADP) and anti-inflammatory (adenosine) effects in the vasculature. The duration and magnitude of purinergic signaling is governed by a network of purine-converting ectoenzymes, and endothelial and lymphoid cells are generally characterized by counteracting ATP-inactivating and ATP-regenerating/adenosine-eliminating, phenotypes, respectively. By using cultured human umbilical vein endothelial cells and normal or leukemic lymphocytes as an in vitro model of leukocyte-endothelial interactions, we have identified a link between the adhesion cascade and extracellular purine turnover. Upon adhesion, lymphocytes suppress endothelial purine metabolism via (i) inhibition of ecto-5'-nucleotidase/CD73-mediated AMP hydrolysis, (ii) rapid deamination of the remaining adenosine, and (iii) maintenance of the sustained pericellular ATP level through continuous nucleotide release and phosphotransfer reactions. Compensation of the loss of adenosine promotes vascular barrier function (measured as a paracellular flux of 70 kDa fluorescein isothiocyanate-dextran) and decreases transendothelial leukocyte migration. Together, these data show that adherent lymphocytes attempt to prevent adenosine formation in the endothelial environment that, as a consequence, may impair the vascular barrier function and facilitate the subsequent step of leukocyte transmigration into the tissue. These leukocyte adhesion-mediated shifts in the local nucleotide and nucleoside concentrations represent a previously unrecognized paracrine mechanism affecting the functional state of the targeted vascular endothelium and coordinately regulating lymphocyte trafficking between the blood and tissues.	Univ Turku, MediCity Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Microbiol, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; University of Turku; Finland National Institute for Health & Welfare	Yegutkin, GG (corresponding author), Univ Turku, MediCity Lab, FIN-20520 Turku, Finland.		Yegutkin, Gennady G./K-3815-2014	Yegutkin, Gennady G./0000-0001-6684-7982				Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bouma MG, 1996, AM J PHYSIOL-CELL PH, V270, pC522, DOI 10.1152/ajpcell.1996.270.2.C522; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Di Virgilio F, 2002, BRIT J PHARMACOL, V135, P831, DOI 10.1038/sj.bjp.0704524; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Kaiser RA, 2002, CIRC RES, V91, P292, DOI 10.1161/01.RES.0000030711.21521.AC; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Marcus AJ, 2001, ARTERIOSCL THROM VAS, V21, P178, DOI 10.1161/01.ATV.21.2.178; MEGHJI P, 1995, BIOCHEM J, V308, P725, DOI 10.1042/bj3080725; Mizumoto N, 2002, NAT MED, V8, P358, DOI 10.1038/nm0402-358; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; Panes J, 1999, BRIT J PHARMACOL, V126, P537, DOI 10.1038/sj.bjp.0702328; PFAU S, 1995, J CELL BIOL, V128, P969, DOI 10.1083/jcb.128.5.969; Picher M, 2003, J BIOL CHEM, V278, P11256, DOI 10.1074/jbc.M208071200; Ralevic V, 1998, PHARMACOL REV, V50, P413; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Richard LF, 1998, AM J PHYSIOL-HEART C, V274, pH35, DOI 10.1152/ajpheart.1998.274.1.H35; ROBSON S, 2000, EMERGING THER TARGET, V4, P155; Sitkovsky MV, 2003, BIOCHEM PHARMACOL, V65, P493, DOI 10.1016/S0006-2952(02)01548-4; Sorensen CE, 2001, J BIOL CHEM, V276, P32925, DOI 10.1074/jbc.M103313200; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Yegutkin GG, 1998, BBA-BIOMEMBRANES, V1373, P227, DOI 10.1016/S0005-2736(98)00108-4; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; Zimmermann H, 1999, NAT MED, V5, P987, DOI 10.1038/12419; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	39	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24888	24895		10.1074/jbc.M300779200	http://dx.doi.org/10.1074/jbc.M300779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707258	hybrid			2022-12-25	WOS:000183824800078
J	Kishimoto, S; Gokoh, M; Oka, S; Muramatsu, M; Kajiwara, T; Waku, K; Sugiura, T				Kishimoto, S; Gokoh, M; Oka, S; Muramatsu, M; Kajiwara, T; Waku, K; Sugiura, T			2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; ANANDAMIDE; AGONIST; LIGAND; 2-ARACHIDONYLGLYCEROL; BIOSYNTHESIS; DEGRADATION; BRAIN; 2-ARACHIDONYL-GLYCEROL	2-Arachidonoylglycerol is an endogenous ligand for the cannabinoid receptors (CB1 and CB2) and has been shown to exhibit a variety of cannabimimetic activities in vitro and in vivo. Recently, we proposed that 2-arachidonoylglycerol is the true endogenous ligand for the cannabinoid receptors, and both receptors (CB1 and CB2) are primarily 2-arachidonoylglycerol receptors. The CB1 receptor is assumed to be involved in the attenuation of neurotransmission. On the other hand, the physiological roles of the CB2 receptor, which is abundantly expressed in several types of leukocytes such as macrophages, still remain unknown. In this study, we examined the effects of 2-arachidonoylglycerol on the motility of HL-60 cells differentiated into macrophage-like cells. We found that 2-arachidonoylglycerol induces the migration of differentiated HL-60 cells. The migration induced by 2-arachidonoylglycerol was blocked by treatment of the cells with either SR144528, a CB2 receptor antagonist, or pertussis toxin, suggesting that the CB2 receptor and G(i)/G(o) are involved in the 2-arachidonoylglycerol-induced migration. Several intracellular signaling molecules such as Rho kinase and mitogen-activated protein kinases were also suggested to be involved. In contrast to 2-arachidonoylglycerol, anandamide, another endogenous cannabinoid receptor ligand, failed to induce the migration. The 2-arachidonoylglycerol-induced migration was also observed for two other types of macrophage-like cells, the U937 cells and THP-1 cells, as well as human peripheral blood monocytes. These results strongly suggest that 2-arachidonoylglycerol induces the migration of several types of leukocytes such as macrophages/monocytes through a CB2 receptor-dependent mechanism thereby stimulating inflammatory reactions and immune responses.	Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan	Teikyo University	Sugiura, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 1990195, Japan.							Adachi T, 2001, J IMMUNOL, V167, P4609, DOI 10.4049/jimmunol.167.8.4609; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Basavarajappa BS, 2000, BBA-MOL BASIS DIS, V1535, P78, DOI 10.1016/S0925-4439(00)00085-5; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; Berdyshev EV, 2001, FASEB J, V15, P2171, DOI 10.1096/fj.01-0181com; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boehme SA, 1999, J IMMUNOL, V163, P1611; CABRAL GA, 2002, BIOL MARIJUANA, P282; Chang YH, 2001, J CELL BIOCHEM, V81, P715, DOI 10.1002/jcb.1103; COLLINS SJ, 1979, J EXP MED, V149, P969, DOI 10.1084/jem.149.4.969; Derkinderen P, 2001, J NEUROCHEM, V77, P957, DOI 10.1046/j.1471-4159.2001.00333.x; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1999, EUR J BIOCHEM, V264, P258, DOI 10.1046/j.1432-1327.1999.00631.x; DIMARZO V, 2002, BIOL MARIJUANA, P125; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; Grimshaw MJ, 2002, EUR J IMMUNOL, V32, P2393, DOI 10.1002/1521-4141(200209)32:9<2393::AID-IMMU2393>3.0.CO;2-4; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Hillard CJ, 2000, PROSTAG OTH LIPID M, V61, P3, DOI 10.1016/S0090-6980(00)00051-4; Iwamura H, 2001, J PHARMACOL EXP THER, V296, P420; Jorda MA, 2002, BLOOD, V99, P2786; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kobayashi Y, 2001, J BIOCHEM-TOKYO, V129, P665, DOI 10.1093/oxfordjournals.jbchem.a002904; Kondo S, 1998, FEBS LETT, V429, P152, DOI 10.1016/S0014-5793(98)00581-X; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Ouyang YL, 1998, MOL PHARMACOL, V53, P676, DOI 10.1124/mol.53.4.676; Parolaro D, 2002, PROSTAG LEUKOTR ESS, V66, P319, DOI 10.1054/plef.2001.0355; Piomelli D, 1998, NEUROBIOL DIS, V5, P462, DOI 10.1006/nbdi.1998.0221; Rueda D, 2000, MOL PHARMACOL, V58, P814, DOI 10.1124/mol.58.4.814; Savinainen JR, 2001, BRIT J PHARMACOL, V134, P664, DOI 10.1038/sj.bjp.0704297; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 2000, CHEM PHYS LIPIDS, V108, P89, DOI 10.1016/S0009-3084(00)00189-4; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; Sugiura T, 2002, J BIOCHEM, V132, P7, DOI 10.1093/oxfordjournals.jbchem.a003200; Sugiura T, 1997, J BIOCHEM-TOKYO, V122, P890; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035	49	109	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24469	24475		10.1074/jbc.M301359200	http://dx.doi.org/10.1074/jbc.M301359200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12711605	hybrid			2022-12-25	WOS:000183824800028
J	Roos-Mattjus, P; Hopkins, KM; Oestreich, AJ; Vroman, BT; Johnson, KL; Naylor, S; Lieberman, HB; Karnitz, LM				Roos-Mattjus, P; Hopkins, KM; Oestreich, AJ; Vroman, BT; Johnson, KL; Naylor, S; Lieberman, HB; Karnitz, LM			Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; SLIDING CLAMP; FACTOR-C; ATR; COMPLEXES; HUS1; CHK1; RESPONSES; HRAD9	Rad9, a key component of genotoxin-activated checkpoint signaling pathways, associates with Hus1 and Rad1 in a heterotrimeric complex (the 9-1-1 complex). Rad9 is inducibly and constitutively phosphorylated. However, the role of Rad9 phosphorylation is unknown. Here we identified nine phosphorylation sites, all of which lie in the carboxyl-terminal 119-amino acid Rad9 tail and examined the role of phosphorylation in geno-toxin-triggered checkpoint activation. Rad9 mutants lacking a Ser-272 phosphorylation site, which is phosphorylated in response to genotoxins, had no effect on survival or checkpoint activation in Mrad9(-/-) mouse ES cells treated with hydroxyurea (HU), ionizing radiation (IR), or ultraviolet radiation (UV). In contrast, additional Rad9 tail phosphorylation sites were essential for Chk1 activation following HU, IR, and UV treatment. Consistent with a role for Chk1 in S-phase arrest, HU- and UV-induced S-phase arrest was abrogated in the Rad9 phosphorylation mutants. In contrast, however, Rad9 did not play a role in IR-induced S-phase arrest. Clonogenic assays revealed that cells expressing a Rad9 mutant lacking phosphorylation sites were as sensitive as Rad9(-/-) cells to UV and HU. Although Rad9 contributed to survival of IR-treated cells, the identified phosphorylation sites only minimally contributed to survival following IR treatment. Collectively, these results demonstrate that the Rad9 phospho-tail is a key participant in the Chk1 activation pathway and point to additional roles for Rad9 in cellular responses to IR.	Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Program Tumor Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biomed Mass Spectrometry & Funct Proteom Facil, Rochester, MN 55905 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Columbia University	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu		Roos-Mattjus, Pia/0000-0002-7187-2012	NCI NIH HHS [CA84321, CA89816] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084321, R56CA084321, R01CA089816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu QH, 2000, GENE DEV, V14, P1448; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Rhind N, 2000, J CELL SCI, V113, P3889; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sarkaria JN, 1999, CANCER RES, V59, P4375; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	58	93	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24428	24437		10.1074/jbc.M301544200	http://dx.doi.org/10.1074/jbc.M301544200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709442	hybrid			2022-12-25	WOS:000183824800024
J	Stains, JP; Lecanda, F; Screen, J; Towler, DA; Civitelli, R				Stains, JP; Lecanda, F; Screen, J; Towler, DA; Civitelli, R			Gap junctional communication modulates gene transcription by altering the recruitment of Sp1 and Sp3 to connexin-response elements in osteoblast promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR COMMUNICATION; PROTEIN-KINASE; CELL-GROWTH; OSTEOCALCIN PROMOTER; O-GLYCOSYLATION; CARCINOMA CELLS; BINDING MOTIFS; MUSCLE CELLS; DNA-BINDING; IN-VITRO	Loss-of-function mutations of gap junction proteins, connexins, represent a mechanism of disease in a variety of tissues. We have shown that recessive ( gene deletion) or dominant (connexin45 overexpression) disruption of connexin43 function results in osteoblast dysfunction and abnormal expression of osteoblast genes, including down-regulation of osteocalcin transcription. To elucidate the molecular mechanisms of gap junction-sensitive transcriptional regulation, we systematically analyzed the rat osteocalcin promoter for sensitivity to gap junctional intercellular communication. We identified an Sp1/Sp3 containing complex that assembles on a minimal element in the -70 to -57 region of the osteocalcin promoter in a gap junction-dependent manner. This CT-rich connexin-response element is necessary and sufficient to confer gap junction sensitivity to the osteocalcin proximal promoter. Repression of osteocalcin transcription occurs as a result of displacement of the stimulatory Sp1 by the inhibitory Sp3 on the promoter when gap junctional communication is perturbed. Modulation of Sp1/Sp3 recruitment also occurs on the collagen Ialpha1 promoter and translates into gap junction-sensitive transcriptional control of collagen Ialpha1 gene expression. Thus, regulation of Sp1/Sp3 recruitment to the promoter may represent a potential general mechanism for transcriptional control of target genes by signals passing through gap junctions.	Washington Univ, Div Bone & Mineral Dis, Dept Internal Med, St Louis, MO 63110 USA; Univ Navarra, Div Histol & Pathol, E-31080 Pamplona, Spain	Washington University (WUSTL); University of Navarra	Civitelli, R (corresponding author), Barnes Jewish Hosp, Div Bone & Mineral Dis, Dept Internal Med, N Campus,216 S Kingshighway Blvd, St Louis, MO 63110 USA.	rcivitel@im.wustl.edu	Civitelli, Roberto/AAA-8260-2019	Civitelli, Roberto/0000-0003-4076-4315; Towler, Dwight/0000-0003-2107-7923	NIAMS NIH HHS [T32 AR07033, R01 AR41255, R01 AR041255] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007033, R01AR041255] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BEITNERJOHNSON D, 1995, MOL ENDOCRINOL, V9, P1147, DOI 10.1210/me.9.9.1147; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; Cesen-Cummings K, 1998, CARCINOGENESIS, V19, P61, DOI 10.1093/carcin/19.1.61; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; CORMACK B, 1997, CURRENT PROTOCOLS MO; Cottrell GT, 2002, AM J PHYSIOL-CELL PH, V282, pC1469, DOI 10.1152/ajpcell.00484.2001; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Flachon V, 2002, EUR J CELL BIOL, V81, P243, DOI 10.1078/0171-9335-00245; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; Fritz S, 2002, J CLIN ENDOCR METAB, V87, P1362, DOI 10.1210/jc.87.3.1362; Garcia-Ruiz I, 2002, J BIOL CHEM, V277, P30551, DOI 10.1074/jbc.M203368200; Gollner H, 2001, MECH DEVELOP, V106, P77, DOI 10.1016/S0925-4773(01)00420-8; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; He DS, 1999, P NATL ACAD SCI USA, V96, P6495, DOI 10.1073/pnas.96.11.6495; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Huang RC, 2002, CANCER RES, V62, P2806; Huang RP, 1998, CANCER RES, V58, P5089; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jiang JX, 1996, P NATL ACAD SCI USA, V93, P1287, DOI 10.1073/pnas.93.3.1287; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kojima T, 2002, EXP CELL RES, V276, P40, DOI 10.1006/excr.2002.5511; KOVAL M, 1995, J CELL BIOL, V130, P987, DOI 10.1083/jcb.130.4.987; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; Lecanda F, 1998, MOL BIOL CELL, V9, P2249, DOI 10.1091/mbc.9.8.2249; Lecanda F, 2000, J CELL BIOL, V151, P931, DOI 10.1083/jcb.151.4.931; Levin M, 2002, J MEMBRANE BIOL, V185, P177, DOI 10.1007/s00232-001-0129-7; Li Z, 1999, BONE, V25, P661, DOI 10.1016/S8756-3282(99)00227-6; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mann V, 2001, J CLIN INVEST, V107, P899, DOI 10.1172/JCI10347; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; Martinez AD, 2002, CIRC RES, V90, P1100, DOI 10.1161/01.RES.0000019580.64013.31; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Nicholson SM, 2001, J NEUROSCI RES, V66, P23, DOI 10.1002/jnr.1194; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Parakati R, 2002, J BIOL CHEM, V277, P9278, DOI 10.1074/jbc.M108411200; Patel SG, 2001, GENE, V270, P171, DOI 10.1016/S0378-1119(01)00478-4; Patel SG, 1999, GENE, V237, P265, DOI 10.1016/S0378-1119(99)00278-4; PHILIPPE J, 1994, DIABETES, V43, P523, DOI 10.2337/diabetes.43.4.523; PITTS JD, 1988, BRIT J CANCER, V58, P52; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; Schiller PC, 2001, J BIOL CHEM, V276, P14133, DOI 10.1074/jbc.M011055200; Schiller PC, 2001, BONE, V28, P362, DOI 10.1016/S8756-3282(00)00458-0; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; SHANG Y, 2002, CELL, V103, P843; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TERAO M, 1990, BIOCHEM J, V268, P641, DOI 10.1042/bj2680641; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; VOZZI C, 1995, J CELL BIOL, V131, P1561, DOI 10.1083/jcb.131.6.1561; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yang RJ, 1997, J CELL BIOCHEM, V64, P77, DOI 10.1002/(SICI)1097-4644(199701)64:1<77::AID-JCB11>3.0.CO;2-H; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200; Zheng XL, 2000, J BIOL CHEM, V275, P31747, DOI 10.1074/jbc.M000621200	76	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24377	24387		10.1074/jbc.M212554200	http://dx.doi.org/10.1074/jbc.M212554200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12700237	hybrid			2022-12-25	WOS:000183824800019
J	Chen, AP; Zhang, L				Chen, AP; Zhang, L			The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; GREEN TEA POLYPHENOLS; COLLAGEN; ACTIVATION; KINASE; CANCER; CONSUMPTION; MODULATION; MECHANISMS; INDUCTION	During hepatic fibrogenesis, quiescent hepatic stellate cells (HSC) become active and trans-differentiate into myofibroblast-like cells. This process coincides with an increase in cell proliferation, loss of stored vitamin A droplets, and excessive production and deposition of extracellular matrix components. HSC activation is coupled with the sequential expression of cytokine receptors, including platelet-derived growth factor-beta receptor (PDGF-betaR). Although the underlying mechanisms remain incompletely understood, it is widely accepted that oxidative stress plays critical roles in activation of HSC during hepatic fibrogenesis. We have recently demonstrated that the antioxidant (-)-epigallocatechin gallate (EGCG), a major component in green tea extracts, significantly inhibited the proliferation of passaged HSC. The aim of the present study is to elucidate the underlying mechanisms. Since PDGF is a potent mitogen for HSC and mediates the early proliferative response, it was hypothesized that EGCG might inhibit HSC proliferation by interfering with the PDGF signal transduction. In this report, we demonstrated that EGCG, in two steps, significantly and effectively inhibited the proliferation of primary and passaged HSC. The polyphenolic compound initiated its inhibitory action by rapidly blocking the phosphorylation of tyrosines in PDGF-betaR elicited by PDGF in serum. This action was short lived, persisting for a few hours. In addition, this antioxidant inhibited the gene expression of PDGF-betaR by blocking the activation of transcription factors activator protein-1 and NF-kappaB, which were required for the gene transcription. The latter action remained effective for no less than 48 hours. These results provided a novel insight into the mechanisms by which EGCG inhibits HSC growth. The inhibitory effect of the natural antioxidant, its long history of beverage consumption without adverse health effects, and higher potent antioxidant capability make it a good candidate for therapeutic treatment and prevention of hepatic fibrosis.	Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Univ Chicago, Dept Med, Gastroenterol Sect, Chicago, IL 60637 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Chicago	Chen, AP (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	achen@lsuhsc.edu			NIDDK NIH HHS [DK47995] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047995] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x; BALLAGI AE, 1995, BIOCHEM BIOPH RES CO, V210, P165, DOI 10.1006/bbrc.1995.1642; Bissell DM, 1998, J GASTROENTEROL, V33, P295, DOI 10.1007/s005350050087; Chen AP, 2002, BIOCHEM J, V368, P695, DOI 10.1042/BJ20020894; Chen AP, 1999, J BIOL CHEM, V274, P158, DOI 10.1074/jbc.274.1.158; Chen AP, 1996, J BIOL CHEM, V271, P25994, DOI 10.1074/jbc.271.42.25994; Chen AP, 2000, MOL CELL BIOL, V20, P2818, DOI 10.1128/MCB.20.8.2818-2826.2000; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; HALLIWELL B, 1991, DRUGS, V42, P569, DOI 10.2165/00003495-199142040-00003; Halliwell B, 1997, NUTR REV, V55, pS44, DOI 10.1111/j.1753-4887.1997.tb06100.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HELDIN P, 1991, EXP CELL RES, V193, P364, DOI 10.1016/0014-4827(91)90108-7; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; HERREN B, 1993, BIOCHIM BIOPHYS ACTA, V1173, P294, DOI 10.1016/0167-4781(93)90127-Y; Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980; Katiyar S K, 1996, World Rev Nutr Diet, V79, P154; Kinnman N, 2001, LAB INVEST, V81, P1709, DOI 10.1038/labinvest.3780384; LEE KS, 1995, J CLIN INVEST, V96, P2461, DOI 10.1172/JCI118304; Lin YL, 1997, MOL PHARMACOL, V52, P465, DOI 10.1124/mol.52.3.465; Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S; Okabe S, 2001, BIOL PHARM BULL, V24, P883, DOI 10.1248/bpb.24.883; PIETRANGELO A, 1995, J CLIN INVEST, V95, P1824, DOI 10.1172/JCI117861; PINZANI M, 1995, HEPATOLOGY, V21, P232, DOI 10.1002/hep.1840210136; Ren FG, 2000, ONCOGENE, V19, P1924, DOI 10.1038/sj.onc.1203511; Rice-Evans C, 1999, P SOC EXP BIOL MED, V220, P262, DOI 10.1046/j.1525-1373.1999.d01-45.x; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shi XL, 2000, MOL CELL BIOCHEM, V206, P125, DOI 10.1023/A:1007012403691; Svegliati-Baroni G, 2001, HEPATOLOGY, V33, P1130, DOI 10.1053/jhep.2001.23788; Trevisanato SI, 2000, NUTR REV, V58, P1, DOI 10.1111/j.1753-4887.2000.tb01818.x; Tsai SH, 2002, J CELL BIOCHEM, V84, P750, DOI 10.1002/jcb.10096; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; Yamashita K, 2000, BIOCHEM BIOPH RES CO, V274, P603, DOI 10.1006/bbrc.2000.3200; Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409; Yang FJ, 2001, MOL PHARMACOL, V60, P528; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334	43	79	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23381	23389		10.1074/jbc.M212042200	http://dx.doi.org/10.1074/jbc.M212042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695518	hybrid			2022-12-25	WOS:000183638600023
J	Garcia-Saez, I; Hopkins, J; Papamicael, C; Franceschini, N; Amicosante, G; Rossolini, GM; Galleni, M; Frere, JM; Dideberg, O				Garcia-Saez, I; Hopkins, J; Papamicael, C; Franceschini, N; Amicosante, G; Rossolini, GM; Galleni, M; Frere, JM; Dideberg, O			The 1.5-angstrom structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING ENZYME-INHIBITORS; BACTEROIDES-FRAGILIS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; FLAVOBACTERIUM MENINGOSEPTICUM; BIPHENYL TETRAZOLES; POTENT INHIBITORS; BINDING; GENE; MOLSCRIPT	The crystal structure of the class-B beta-lactamase, BlaB, from the pathogenic bacterium, Chryseobacterium meningosepticum, in complex with the inhibitor, D-captopril, has been solved at 1.5-Angstrom resolution. The enzyme has the typical alphabeta/betaalpha metallo-beta-lactamase fold and the characteristic two metal binding sites of members of the subclass B1, in which two Zn2+ ions were identified. D-Captopril, a diastereoisomer of the commercial drug, captopril, acts as an inhibitor by displacing the catalytic hydroxyl ion required for antibiotic hydrolysis and intercalating its sulfhydryl group between the two Zn2+ ions. Interestingly, D-captopril is located on one side of the active site cleft. The x-ray structure of the complex of the closely related enzyme, IMP-1, with a mercaptocarboxylate inhibitor, which also contains a sulfhydryl group bound to the two Zn2+ ions, shows the ligand to be located on the opposite side of the active site cleft. A molecule generated by fusion of these two inhibitors would cover the entire cleft, suggesting an interesting approach to the design of highly specific inhibitors.	Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, F-38027 Grenoble 1, France; CNRS Commissariat Energie Atom, Saclay, France; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy; Univ Siena, Dipartimento Biol Mol, Sez Microbiol, I-53100 Siena, Italy; Univ Liege, Enzymol Lab, Ctr Ingn Prot, Inst Chim, B-4000 Sart Tilman Par Liege, Belgium	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; University of Oxford; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of L'Aquila; University of Siena; University of Liege	Dideberg, O (corresponding author), Inst Biol Struct Jean Pierre Ebel, Lab Cristallog Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	otto@ibs.fr		amicosante, gianfranco/0000-0002-6813-2101; FRANCESCHINI, Nicola/0000-0003-2237-0355				AMBLER RP, 1985, FEBS LETT, V189, P207, DOI 10.1016/0014-5793(85)81024-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellais S, 2000, ANTIMICROB AGENTS CH, V44, P3028, DOI 10.1128/AAC.44.11.3028-3034.2000; Bloch KC, 1997, MEDICINE, V76, P30, DOI 10.1097/00005792-199701000-00003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush K, 1998, CLIN INFECT DIS, V27, pS48, DOI 10.1086/514922; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; Diaz N, 2001, J AM CHEM SOC, V123, P9867, DOI 10.1021/ja0113246; DIMODUGNO E, 1999, CURR OPIN ANTIINFECT, V1, P26; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fitzgerald PMD, 1998, BIOCHEMISTRY-US, V37, P6791, DOI 10.1021/bi9730339; Fraser SL, 1997, ANTIMICROB AGENTS CH, V41, P2738, DOI 10.1128/AAC.41.12.2738; Galleni M, 2001, ANTIMICROB AGENTS CH, V45, P660, DOI 10.1128/AAC.45.3.660-663.2001; Garcia-Saez I, 2003, J MOL BIOL, V325, P651, DOI 10.1016/S0022-2836(02)01271-8; GILPIN ML, 1995, J ANTIBIOT, V48, P1081, DOI 10.7164/antibiotics.48.1081; Goto M, 1997, BIOL PHARM BULL, V20, P1136, DOI 10.1248/bpb.20.1136; Greenlee ML, 1999, BIOORG MED CHEM LETT, V9, P2549, DOI 10.1016/S0960-894X(99)00425-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBAWARA S, 1967, BIOCHEM J, V103, P27; Laraki N, 1999, ANTIMICROB AGENTS CH, V43, P890, DOI 10.1128/AAC.43.4.890; Lauretti L, 1999, ANTIMICROB AGENTS CH, V43, P1584, DOI 10.1128/AAC.43.7.1584; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls A., 1992, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAGE MI, 1998, J CHEM SOC CHEM COMM, V10, P1609; Paul-Soto R, 1998, FEBS LETT, V438, P137, DOI 10.1016/S0014-5793(98)01289-7; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Payne DJ, 1997, FEMS MICROBIOL LETT, V157, P171, DOI 10.1016/S0378-1097(97)00472-2; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P1880, DOI 10.1128/AAC.46.6.1880-1886.2002; Payne DJ, 2000, EXPERT OPIN INV DRUG, V9, P247, DOI 10.1517/13543784.9.2.247; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Rasia RM, 2002, BIOCHEMISTRY-US, V41, P1853, DOI 10.1021/bi010933n; Rasmussen BA, 1997, ANTIMICROB AGENTS CH, V41, P223, DOI 10.1128/AAC.41.2.223; Rossolini GM, 1998, BIOCHEM J, V332, P145, DOI 10.1042/bj3320145; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Scrofani SDB, 1999, BIOCHEMISTRY-US, V38, P14507, DOI 10.1021/bi990986t; Senda K, 1996, J CLIN MICROBIOL, V34, P2909, DOI 10.1128/JCM.34.12.2909-2913.1996; SKILES JW, 1986, J MED CHEM, V29, P784, DOI 10.1021/jm00155a032; Smith WHT, 2000, BASIC RES CARDIOL, V95, P8; SUH JT, 1985, J MED CHEM, V28, P57, DOI 10.1021/jm00379a013; Toney JH, 1998, CHEM BIOL, V5, P185, DOI 10.1016/S1074-5521(98)90632-9; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Toney JH, 1999, BIOORG MED CHEM LETT, V9, P2741, DOI 10.1016/S0960-894X(99)00458-8; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Von Graevenitz Alexander, 1995, P520; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Walter MW, 1999, BIOORG CHEM, V27, P35, DOI 10.1006/bioo.1998.1111; Walter MW, 1996, BIOORG MED CHEM LETT, V6, P2455, DOI 10.1016/0960-894X(96)00453-2; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Woodford N, 2000, ANTIMICROB AGENTS CH, V44, P1448, DOI 10.1128/AAC.44.6.1448-1452.2000; Yang KW, 1999, ARCH BIOCHEM BIOPHYS, V368, P1, DOI 10.1006/abbi.1999.1293	55	117	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23868	23873		10.1074/jbc.M301062200	http://dx.doi.org/10.1074/jbc.M301062200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684522	Green Published, hybrid			2022-12-25	WOS:000183638600083
J	Ragolia, L; Palaia, T; Paric, E; Maesaka, JK				Ragolia, L; Palaia, T; Paric, E; Maesaka, JK			Prostaglandin D-2 synthase inhibits the exaggerated growth phenotype of spontaneously hypertensive rat vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-TRACE; CORONARY CIRCULATION; SIGNALING PATHWAYS; DIABETES-MELLITUS; HIGH GLUCOSE; HUMAN HEART; EXPRESSION; APOPTOSIS; INSULIN	Lipocalin-type prostaglandin D-2 synthase (L-PGDS) has recently been linked to a variety of pathophysiological cardiovascular conditions including hypertension and diabetes. In this study, we report on the 50% increase in L-PGDS protein expression observed in vascular smooth muscle cells (VSMC) isolated from spontaneously hypertensive rats (SHR). L-PGDS expression also increased 50% upon the differentiation of normotensive control cells (WKY, from Wistar-Kyoto rats). In addition, we demonstrate differential effects of L-PGDS treatment on cell proliferation and apoptosis in VSMCs isolated from SHR versus WKY controls. L-PGDS (50 mug/ml) was able to significantly inhibit VSMC proliferation and DNA synthesis and induce the apoptotic genes bax, bcl-x, and ei24 in SHR but had no effect on WKY cells. Hyperglycemic conditions also had opposite effects, in which increased glucose concentrations (20 mM) resulted in decreased L-PGDS expression in control cells but actually stimulated L-PGDS expression in SHR. Furthermore, we examined the effect of L-PGDS incubation on insulin-stimulated Akt, glycogen synthase kinase-3beta (GSK-3beta), and ERK phosphorylation. Unexpectedly, we found that when WKY cells were pretreated with L-PGDS, insulin could actually induce apoptosis and failed to stimulate Akt/GSK-3beta phosphorylation. Insulin-stimulated ERK phosphorylation was unaffected by L-PGDS pretreatment in both cell lines. We propose that L-PGDS is involved in the balance of VSMC proliferation and apoptosis and in the increased expression observed in the hypertensive state is an attempt to maintain a proper equilibrium between the two processes via the induction of apoptosis and inhibition of cell proliferation.	Winthrop Univ Hosp, Cellular Biol Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ragolia, L (corresponding author), Winthrop Univ Hosp, Cellular Biol Lab, Suite 505-B,222 Stn Plaza N, Mineola, NY 11501 USA.		Ragolia, Louis/AAW-2383-2021	Ragolia, Louis/0000-0002-8292-5159				Anderson KM, 1997, J BIOL CHEM, V272, P30504, DOI 10.1074/jbc.272.48.30504; Bai HZ, 1999, CIRC RES, V85, P229, DOI 10.1161/01.RES.85.3.229; Balkau B, 1999, DIABETES OBES METAB, V1, pS23, DOI 10.1046/j.1463-1326.1999.0010s1023.x; Begum N, 1998, AM J PHYSIOL-CELL PH, V275, pC42, DOI 10.1152/ajpcell.1998.275.1.C42; Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; Begum N, 2000, AM J PHYSIOL-CELL PH, V278, pC81, DOI 10.1152/ajpcell.2000.278.1.C81; Begum N, 2000, MOL ENDOCRINOL, V14, P1365, DOI 10.1210/me.14.9.1365; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; Benson Steve, 2000, Molecular Cell Biology Research Communications, V3, P159, DOI 10.1006/mcbr.2000.0209; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; BRAUN M, 1992, CIRC RES, V71, P1305, DOI 10.1161/01.RES.71.6.1305; Chen Z, 2001, ARTERIOSCL THROM VAS, V21, P372, DOI 10.1161/01.ATV.21.3.372; Eguchi Y, 1997, P NATL ACAD SCI USA, V94, P14689, DOI 10.1073/pnas.94.26.14689; HADRAVA V, 1989, HYPERTENSION, V13, P589, DOI 10.1161/01.HYP.13.6.589; Hall JL, 2000, CIRC RES, V87, P574, DOI 10.1161/01.RES.87.7.574; Hamano K, 2002, NEPHRON, V92, P77, DOI 10.1159/000064473; HAMET P, 1995, HYPERTENSION, V26, P642, DOI 10.1161/01.HYP.26.4.642; Hirawa N, 2002, HYPERTENSION, V39, P449, DOI 10.1161/hy0202.102835; Hirawa N, 2001, NEPHRON, V87, P321, DOI 10.1159/000045937; Inoue T, 2001, THROMB HAEMOSTASIS, V85, P165; ISHIMITSU T, 1990, JPN CIRC J, V54, P1546, DOI 10.1253/jcj.54.12_1546; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Maesaka JK, 2001, KIDNEY INT, V60, P1692, DOI 10.1046/j.1523-1755.2001.00989.x; Marks JB, 2000, J DIABETES COMPLICAT, V14, P108, DOI 10.1016/S1056-8727(00)00065-9; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Mayr M, 2001, EXP GERONTOL, V36, P969, DOI 10.1016/S0531-5565(01)00090-0; Minami T, 1997, BRIT J PHARMACOL, V122, P605, DOI 10.1038/sj.bjp.0701421; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1041, DOI 10.1210/jc.83.3.1041; Miwa Y, 2000, MOL PHARMACOL, V58, P837, DOI 10.1124/mol.58.4.837; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Naruse M, 2000, Nihon Rinsho, V58, P344; Patel VA, 2001, CIRC RES, V88, P895, DOI 10.1161/hh0901.090305; Ragolia L, 2003, AM J PHYSIOL-CELL PH, V284, pC119, DOI 10.1152/ajpcell.00247.2002; Ragolia L, 2001, NEUROREPORT, V12, P2623, DOI 10.1097/00001756-200108280-00008; Shirahase H, 2000, LIFE SCI, V66, P2173, DOI 10.1016/S0024-3205(00)00544-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Srivastava AK, 2002, INT J MOL MED, V9, P85; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967; Takatsuka J, 1996, CANCER RES, V56, P675; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; Urade Y, 1999, ADV EXP MED BIOL, V469, P49; WHITTLE BJR, 1978, PROSTAG OTH LIPID M, V16, P373, DOI 10.1016/0090-6980(78)90216-2; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622	47	19	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22175	22181		10.1074/jbc.M302769200	http://dx.doi.org/10.1074/jbc.M302769200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12684506	hybrid			2022-12-25	WOS:000183354200107
J	Marchese, C; Maresca, V; Cardinali, G; Belleudi, F; Ceccarelli, S; Bellocci, M; Frati, L; Torrisi, MR; Picardo, M				Marchese, C; Maresca, V; Cardinali, G; Belleudi, F; Ceccarelli, S; Bellocci, M; Frati, L; Torrisi, MR; Picardo, M			UVB-induced activation and internalization of keratinocyte growth factor receptor	ONCOGENE			English	Article						UVB; keratinocyte growth factor receptor; oxidative stress; tyrosine phosphorylation	CULTURED HUMAN KERATINOCYTES; INDUCED EGF-RECEPTOR; HYDROGEN-PEROXIDE; ULTRAVIOLET-LIGHT; INDUCED APOPTOSIS; EXPRESSION; CELLS; KGF; INVOLVEMENT; MODULATION	Ultraviolet irradiation of mammalian cells induces several events that include activation of growth factor receptors and triggering of signal transduction pathway. Most of the UV responses are mediated by the production of reactive oxygen species (ROS) and can be blocked by antioxidants. In this study, we analysed the effect of UVB irradiation at physiologic doses and that of the prooxidant agent cumene hydroperoxide (CUH) on the activation of the receptor for keratinocyte growth factor (KGF), a key mediator of epithelial growth and differentiation. Exposure to both UVB (30-150 mJ/cm(2)) and CUH (200 muM of NIH3T3 KGFR (KGF receptors) transfectants caused a rapid tyrosine phosphorylation and activation of KGFR similar to that induced by KGF, and internalization of the activated receptor. The KGFR expression appeared unmodified by the treatments. Ultrastructural observations of both UVB- and CUH-treated cells showed a normal morphology of the plasma membranes and intracellular organelles. The antioxidant N-acetylcysteine inhibited UVB-induced receptor phosphorylation. The generation of an intracellular oxidative stress was detected as a decrease of catalase activity and of vitamin E, and reduced glutathione levels, whereas superoxide dismutase activity was not significantly modified. A peroxidation of polyunsaturated fatty acids of cell membranes was observed after both treatments, associated with the intracellular oxidative stress. Similar biochemical events were observed on NIH3T3 untransfected control cells, suggesting that KGFR activation follows intracellular generation of ROS and is not associated with a scavenging effect. Taken together our results demonstrate that exposure to UVB and to oxidant stimuli induces a rapid intracellular production of ROS, which in turn are capable of triggering KGFR activation and internalization, similar to those induced by KGF.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; IRCCS, Ist Dermatol Santa Maria & San Gallicano, Rome, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Marchese, C (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.		Picardo, Mauro/A-6978-2011; maresca, vittoria/J-3272-2016; Frati, Luigi/ABI-7437-2020; Cardinali, Giorgia/H-1814-2016; Ceccarelli, Simona/J-4086-2018; Marchese, Cinzia/J-1323-2018	Picardo, Mauro/0000-0003-4899-6639; maresca, vittoria/0000-0001-9239-6978; Cardinali, Giorgia/0000-0002-7527-9451; Ceccarelli, Simona/0000-0001-8789-7719; MARCHESE, CINZIA/0000-0002-9280-8917				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Capone A, 2000, CELL GROWTH DIFFER, V11, P607; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; COFFER PJ, 1995, ONCOGENE, V11, P561; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dimon-Gadal S, 1998, J BIOL CHEM, V273, P22833, DOI 10.1074/jbc.273.35.22833; Finch PW, 1997, AM J PATHOL, V151, P1619; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; FUCHS J, 1990, PHOTODERMATOL PHOTO, V7, P920; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUANG RP, 1995, ONCOGENE, V10, P467; Kayanoki Y, 1996, J BIOCHEM-TOKYO, V119, P817; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; Marchese C, 1997, CELL GROWTH DIFFER, V8, P989; Marchese C, 1998, J CELL SCI, V111, P3517; MARCHESE C, 1995, J EXP MED, V182, P1369, DOI 10.1084/jem.182.5.1369; MARCHESE C, 1990, J CELL PHYSIOL, V144, P326, DOI 10.1002/jcp.1041440219; McGregor WG, 1999, J INVEST DERM SYMP P, V4, P1, DOI 10.1038/sj.jidsp.5640172; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; ONEIL P, 1998, J BIOCH, V24, P41; Peus D, 1998, J INVEST DERMATOL, V110, P966, DOI 10.1046/j.1523-1747.1998.00210.x; Peus D, 1999, FREE RADICAL BIO MED, V27, P1197, DOI 10.1016/S0891-5849(99)00198-7; Picardo M, 1996, J INVEST DERMATOL, V107, P322, DOI 10.1111/1523-1747.ep12363163; PICCOLI G, 1994, J CHROMATOGR A, V676, P239, DOI 10.1016/0021-9673(94)80465-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SHAOUL E, 1995, ONCOGENE, V10, P357; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; VESSEY DA, 1995, J INVEST DERMATOL, V104, P355, DOI 10.1111/1523-1747.ep12665382; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Zhou Y, 1996, Exp Dermatol, V5, P138, DOI 10.1111/j.1600-0625.1996.tb00108.x	41	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2422	2431		10.1038/sj.onc.1206301	http://dx.doi.org/10.1038/sj.onc.1206301			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717419				2022-12-25	WOS:000182383500005
J	Shelton, JG; Steelman, LS; Lee, JT; Knapp, SL; Blalock, WL; Moye, PW; Franklin, RA; Pohnert, SC; Mirza, AM; McMahon, M; McCubrey, JA				Shelton, JG; Steelman, LS; Lee, JT; Knapp, SL; Blalock, WL; Moye, PW; Franklin, RA; Pohnert, SC; Mirza, AM; McMahon, M; McCubrey, JA			Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells	ONCOGENE			English	Article						Raf; PI3K; Akt; apoptosis; signal transduction; hematopoietic cells; cytokine dependence; annexin V binding; autocrine transformation	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; B-RAF; DIFFERENTIAL ABILITIES; NEGATIVE REGULATION; DEREGULATED RAF; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION; BAD	The Raf/MEK/ERK kinase cascade is pivotal in transmitting signals from membrane receptors to transcription factors that control gene expression culminating in the regulation of cell cycle progression. This cascade can prevent cell death through ERK2 and p90(Rsk) activation and phosphorylation of apoptotic and cell cycle regulatory proteins. The PI3K/Akt kinase cascade also controls apoptosis and can phosphorylate many apoptotic and cell cycle regulatory proteins. These pathways are interwoven as Akt can phosphorylate Raf and result in its inactivation, and Raf can be required for the antiapoptotic effects of Akt. In this study, the effects of activated Raf (Raf-1, A-Raf and B-Raf) and PI3K/Akt proteins on abrogation of cytokine dependence in FL5.12 hematopoietic cells were examined. Activated Raf, PI3K or Akt expression, by themselves, did not readily relieve cytokine dependence. The presence of activated Raf and PI3K/Akt increased the isolation of factor-independent cells from 400- to 2506-fold depending upon the particular combination examined. The individual effects of activated Raf and Akt on proliferation, apoptosis and autocrine growth factor synthesis were further examined with hormone-inducible constructs (DeltaRaf-1:AR and DeltaAkt:ER*(Myr(+)). Activation of either Raf or Akt hindered cell death; however, both proliferation and maximal synthesis of autocrine cytokines were dependent upon activation of both signaling' pathways. The effects of small molecular weight inhibitors on DNA synthesis and cytokine gene expression were also examined. The PI3K inhibitor, LY294002, inhibited growth and cytokine gene expression. This effect could be synergistically increased by addition of the MEK inhibitor UO126. These cells will be useful in elucidating the interactions between Raf/MEK/ ERK and PI3K/Akt cascades in proliferation, apoptosis, and leukernogenesis, as well as evaluating the efficacy of signal transduction inhibitors that target these cascades.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Dept Biochem, Greenville, NC 27858 USA; Univ Calif San Francisco, Mt Zion Med Ctr, San Francisco, CA 94115 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu	Blalock, William L/C-6959-2019	Blalock, William L/0000-0002-8045-4840; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156				Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2001, LEUKEMIA, V15, P794, DOI 10.1038/sj.leu.2402109; Blalock WL, 2000, LEUKEMIA, V14, P1080, DOI 10.1038/sj.leu.2401793; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; EYCHENE A, 1995, ONCOGENE, V10, P1159; Gelfanov VM, 2001, BLOOD, V98, P2508, DOI 10.1182/blood.V98.8.2508; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Majewski M, 1999, CANCER RES, V59, P2815; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; McCubrey JA, 2001, ADV ENZYME REGUL, V41, P289, DOI 10.1016/S0065-2571(00)00021-2; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; McCubrey JA, 2001, CANCER DETECT PREV, V25, P375; McCubrey JA, 2000, ADV ENZYME REGUL, V40, P305, DOI 10.1016/S0065-2571(99)00033-3; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; MCCUBREY JA, 2001, CELL CYCLE CHECKPOIN, P17; MCCUBREY JA, 2001, CELL CYCLE CHECKPOIN, P1; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Minshall C, 1996, J IMMUNOL, V156, P939; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mizutani S, 2001, FEBS LETT, V507, P295, DOI 10.1016/S0014-5793(01)02992-1; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moye PW, 2000, LEUKEMIA, V14, P1060, DOI 10.1038/sj.leu.2401792; RAPP UR, 1988, LUNG CANCER, V4, P162; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; STORM SM, 1993, TOXICOL LETT, V67, P201, DOI 10.1016/0378-4274(93)90056-4; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Weber CK, 2001, CANCER RES, V61, P3595; Weinstein-Oppenheimer C, 2000, LEUKEMIA, V14, P1921, DOI 10.1038/sj.leu.2401926; WEINSTEINOPPENH.CR, 2000, PHARMACOL THERAPEUT, V88, P230; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	68	87	94	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2478	2492		10.1038/sj.onc.1206321	http://dx.doi.org/10.1038/sj.onc.1206321			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717425				2022-12-25	WOS:000182383500011
J	Kanaya, T; Kyo, S; Maida, Y; Yatabe, N; Tanaka, M; Nakamura, M; Inoue, M				Kanaya, T; Kyo, S; Maida, Y; Yatabe, N; Tanaka, M; Nakamura, M; Inoue, M			Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers	ONCOGENE			English	Article						MLH1; methylation; promoter; endometrial cancer; microsatellite instability	NONPOLYPOSIS COLON-CANCER; ISLAND METHYLATOR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA; MUTATIONS; HMLH1; PTEN; CARCINOGENESIS; CONSEQUENCES	Silencing of the MLH1 gene by promoter hypermethylation is the mechanism underlying the microsatellite instability (MSI) phenotype in endometrial cancers. However, the profile of CpG methylation in a wide range of MLH1 promoters in endometrial cancers and in the normal endometrium is largely unknown. The present study investigates the region 700 bp upstream of MLH1 covering 48 CpG sites using bisulfite sequencing. Methylation status was classified as full (over 80% of CpGs are methylated), partial (10-80%) or nonmethylation (less than 10%). Of 56 endometrioid endometrial cancers, 16 (29%) were fully methylated, 14 (25%) were partially methylated and 26 (46%) were not methylated. Analyses of MLH1 by immunohistochemical means and of MSI revealed that the degree, rather than region-specific methylation of CpG islands is critical for decreased MLH1 expression and the MSI phenotype. Among 12 patients with methylated cancers, five (42%) patients contained methylated promoters in their normal endometria with profiles similar to those of cancer lesions, and these were associated with the MSI phenotype. In contrast, only one of 31 (3%) normal endometria from patients without endometrial malignancies harbored methylated promoters. These findings suggest that hypermethylation of the MLH1 promoter is frequent in the histologically normal endometrium adjacent to cancers, supporting the notion that hypermethylation of mismatch repair genes is the initial step that triggers various genetic events in endometrial carcinogenesis.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.							BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; Deng GR, 1999, CANCER RES, V59, P2029; Deng GR, 2001, ONCOGENE, V20, P7120, DOI 10.1038/sj.onc.1204891; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gurin CC, 1999, CANCER RES, V59, P462; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KATABUCHI H, 1995, CANCER RES, V55, P5556; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Mutter GL, 2001, CANCER RES, V61, P4311; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nakagawa H, 2001, CANCER RES, V61, P6991; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; Peltomaki P, 1997, ADV CANCER RES, V71, P93, DOI 10.1016/S0065-230X(08)60097-4; Simpkins SB, 1999, HUM MOL GENET, V8, P661, DOI 10.1093/hmg/8.4.661; Tashiro H, 1997, CANCER RES, V57, P3935; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445	27	69	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2352	2360		10.1038/sj.onc.1206365	http://dx.doi.org/10.1038/sj.onc.1206365			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700670	Green Submitted			2022-12-25	WOS:000182231500013
J	von Haefen, C; Wieder, T; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT				von Haefen, C; Wieder, T; Essmann, F; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop	ONCOGENE			English	Article						chemotherapy; apoptosis; mitochondria; amplification loop; BJAB cells; caspase-3; caspase-8; cytochrome c; Bcl-x(L); taxol; paclitaxel	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CANCER CELLS; CASPASE-8 ACTIVATION; SIGNAL-TRANSDUCTION; OCCURS DOWNSTREAM; CARCINOMA-CELLS; PATHWAYS; BCL-2; RADIATION	Caspase-8 is a key effector of death-receptor-triggered apoptosis. In a previous study, we demonstrated, however, that caspase-8 can also be activated in a death receptor-independent manner via the mitochondrial apoptosis pathway, downstream of caspase-3. Here, we show that caspases-3 and -8 mediate a mitochondrial amplification loop that is required for the optimal release of cytochrome c, mitochondrial permeability shift transition, and cell death during apoptosis induced by treatment with the microtubule-damaging agent paclitaxel (Taxol). In contrast, Smac release from mitochondria followed a different pattern, and therefore seems to be regulated independently from cytochrome c release. Taxol-induced cell death was inhibited by the use of synthetic, cell-permeable caspase-3- (zDEVD-fmk) or caspase-8-specific (zIETD-fmk) inhibitors. Apoptosis signaling was not affected by a dominant-negative FADD mutant (FADD-DN), thereby excluding a role of death receptor signaling in the amplification loop and drug-induced apoptosis. The inhibitor experiments were corroborated by the use of BJAB cells overexpressing the natural serpin protease inhibitor, cytokine response modifier A. These data demonstrate that the complete activation of mitochondria, release of cytochrome c, and execution of drug-induced apoptosis require a mitochondrial amplification loop that depends on caspases-3 and -8 activation. In addition, this is the first report to demonstrate death receptor-independent caspase-8 autoprocessing in vivo.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.		Essmann, Frank/ABG-7409-2020; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Biswas RS, 2001, MOL CELL BIOCHEM, V225, P7, DOI 10.1023/A:1012203110027; Bricker K.S., 1978, Kasetsart University Fisheries Research Bulletin, V10, P1; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Das GC, 2001, CANCER LETT, V165, P147, DOI 10.1016/S0304-3835(01)00404-9; DHEIN J, 1992, J IMMUNOL, V149, P3166; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitamura K, 2000, LEUKEMIA, V14, P1743, DOI 10.1038/sj.leu.2401900; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; LAMBERT IH, 1989, J MEMBRANE BIOL, V111, P113, DOI 10.1007/BF01871776; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Perkins CL, 2000, CANCER RES, V60, P1645; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 1998, EUR J PHARMACOL, V343, P87, DOI 10.1016/S0014-2999(97)01520-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	52	149	153	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 17	2003	22	15					2236	2247		10.1038/sj.onc.1206280	http://dx.doi.org/10.1038/sj.onc.1206280			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700660				2022-12-25	WOS:000182231500003
J	Asencio, C; Rodriguez-Aguilera, JC; Ruiz-Ferrer, M; Vela, J; Navas, P				Asencio, C; Rodriguez-Aguilera, JC; Ruiz-Ferrer, M; Vela, J; Navas, P			Silencing of ubiquinone biosynthesis genes extends life span in Caenorhabditis elegans	FASEB JOURNAL			English	Article						coenzyme Q; aging; RNAi; superoxide; mitochondria	O-METHYLTRANSFERASE STEPS; LIVED CLK-1 MUTANTS; COENZYME-Q; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; C-ELEGANS; MITOCHONDRIAL; COMPLEX; PROTEIN; YEAST	Ubiquinone (coenzyme Q; Q) is a key factor in the mitochondria electron transport chain, but it also functions as an antioxidant and as a cofactor of mitochondrial uncoupling proteins. Furthermore, Q isoforms balance in Caenorhabiditis elegans is determined by both dietary intake and endogenous biosynthesis. In the absence of synthesis, withdrawal of dietary Q(8) in adulthood extends life span. Thus, Q plays an important role in the aging process and understanding its synthesis acquires a new impetus. We have identified by RNA interference (RNAi) eight genes, including clk-1, involved in ubiquinone biosynthesis in C. elegans feeding animals with dsRNA-containing Escherichia coli HT115 strains. Silenced C. elegans showed lower levels of both endogenous Q(9) and Q(8) provided by diet, produced less superoxide without a significant modification of mitochondrial electron chain, and extended life span compared with non-interfered animals. E. coli strains harboring dsRNA also interfered with their own Q(8) biosynthesis. These findings suggest that more efficient electron transport between a lower amount of Q and electron transport capacity of the mitochondrial complexes leads to less production of reactive oxygen species that contributes to extension of life span in the nematode C. elegans.	Univ Pablo Olavide, Dept Ciencias Ambientales, Lab Andaluz Biol, E-41013 Seville, Spain	Universidad Pablo de Olavide	Navas, P (corresponding author), Univ Pablo Olavide, Dept Ciencias Ambientales, Lab Andaluz Biol, Ctra Utrera,Km 1, E-41013 Seville, Spain.	pnavas@dex.upo.es	NAVAS, PLACIDO/R-5943-2019; Ruiz-Ferrer, Macarena/M-6168-2015	NAVAS, PLACIDO/0000-0002-4115-7966; Rodriguez Aguilera, Juan Carlos/0000-0002-3371-4128				ASHBY MN, 1992, J BIOL CHEM, V267, P4128; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; Beal MF, 2002, FREE RADICAL RES, V36, P455, DOI 10.1080/10715760290021315; Bolann BJ, 1996, FREE RADICAL RES, V25, P541, DOI 10.3109/10715769609149075; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2001, COENZYME Q MOL MECH, P185; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lenaz G, 1999, BIOFACTORS, V9, P87, DOI 10.1002/biof.5520090202; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Murakami S, 2001, CURR BIOL, V11, P1517, DOI 10.1016/S0960-9822(01)00453-5; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; Okada K, 1997, J BACTERIOL, V179, P3058, DOI 10.1128/jb.179.9.3058-3060.1997; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Shults CW, 2001, NEUROLOGY, V57, P375, DOI 10.1212/WNL.57.3.375; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Turunen M, 2002, FREE RADICAL RES, V36, P437, DOI 10.1080/10715760290021298; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VILLALBA JM, 2001, COENZYME Q MOL MECH, P83; WONG A, 1995, GENETICS, V139, P1247	41	54	65	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1135	+		10.1096/fj.02-1022fje	http://dx.doi.org/10.1096/fj.02-1022fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709403				2022-12-25	WOS:000182580100028
J	Eyupoglu, IY; Bechmann, I; Nitsch, R				Eyupoglu, IY; Bechmann, I; Nitsch, R			Modification of microglia function protects from lesion-induced neuronal alterations and promotes sprouting in the hippocampus	FASEB JOURNAL			English	Article						parvalbumin; dendritic arborization; reinnervation	ENTORHINAL CORTEX LESION; TRANSNEURONAL CHANGES; DENTATE GYRUS; AXONAL REGENERATION; ALZHEIMERS-DISEASE; EXPRESSION; GROWTH; CELLS; RECOVERY; ANTIBODY	Primary neuronal destruction in the central nervous system triggers rapid changes in glial morphology and function, after which activated glial cells contribute to secondary neuronal changes. Here we show that, after entorhinal cortex lesion, activation of microglia, but not other glial cells, leads to massive secondary dendritic changes of deafferentiated hippocampal neurons. Blocking of microglial activation in vivo reduced this secondary neuronal damage and enhanced regenerative axonal sprouting. In contrast, abolishing astrocytes or oligodendroglia did not result in specific neuronal changes. Furthermore, primary damage leads to an interleukin 1beta upregulation, which is attenuated by the immuno-modulator transforming growth factor beta1, whereas tumor necrosis factor alpha is not affected. Modification of microglial activity following denervation of the hippocampus protects neurons from secondary dendritic alterations and therefore enables their reinnervation. These data render activated microglia a putative therapeutic target during the course of axonal degeneration.	Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Nitsch, R (corresponding author), Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany.	robert.nitsch@charite.de	Nitsch, Robert/AAI-9129-2021	Eyupoglu, Ilker/0000-0002-8185-7764				Amaral David G., 1995, P443; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bechmann I, 1997, HISTOCHEM CELL BIOL, V107, P391, DOI 10.1007/s004180050125; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Beyer M, 2000, GLIA, V31, P262, DOI 10.1002/1098-1136(200009)31:3<262::AID-GLIA70>3.0.CO;2-2; Bhat RV, 1996, J NEUROSCI, V16, P4146; BOLOGA L, 1984, DEV NEUROSCI-BASEL, V6, P26, DOI 10.1159/000112329; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; BRAAK H, 1993, HIPPOCAMPUS, V3, P239; BRANN ABZ, 1998, GLIA, V23, P181; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1998, J NEUROCYTOL, V27, P109, DOI 10.1023/A:1006947322342; CELIO MR, 1988, CELL CALCIUM, V9, P81, DOI 10.1016/0143-4160(88)90027-9; CLUSMANN H, 1994, NEUROSCIENCE, V61, P805, DOI 10.1016/0306-4522(94)90403-0; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; Diekmann S, 1996, BRAIN PATHOL, V6, P205, DOI 10.1111/j.1750-3639.1996.tb00846.x; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; EINSTEIN G, 1994, J NEUROSCI, V14, P5077; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Hanisch UK, 2001, EUR J IMMUNOL, V31, P2104, DOI 10.1002/1521-4141(200107)31:7<2104::AID-IMMU2104>3.0.CO;2-3; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Keirstead HS, 1999, EXP NEUROL, V159, P225, DOI 10.1006/exnr.1999.7100; Kluge A, 1998, HIPPOCAMPUS, V8, P57, DOI 10.1002/(SICI)1098-1063(1998)8:1<57::AID-HIPO6>3.3.CO;2-I; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; LYNCH G, 1974, BRAIN RES, V69, P1, DOI 10.1016/0006-8993(74)90365-5; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; MIHARA M, 1991, EUR J IMMUNOL, V21, P2327, DOI 10.1002/eji.1830211006; MILLER S, 1995, ANN NY ACAD SCI, V757, P460, DOI 10.1111/j.1749-6632.1995.tb17506.x; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; NITSCH R, 1993, HIPPOCAMPUS, V3, P481, DOI 10.1002/hipo.450030409; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PAPA M, 1995, J NEUROSCI, V15, P1; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Schilling T, 2001, EUR J NEUROSCI, V14, P463, DOI 10.1046/j.0953-816x.2001.01661.x; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Shrikant P, 1996, J IMMUNOL, V157, P892; SPIEGLER OL, 1999, VISION RES, V39, P169; SPIEGLER OL, 1998, GLIA, V24, P329; SPIEGLER OL, 1996, FASEB J, V10, P1296; Steward O., 1991, CEREB CORTEX, V9, P81; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Van Hoesen G W, 1991, Hippocampus, V1, P1, DOI 10.1002/hipo.450010102	53	46	46	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1110	+		10.1096/fj.02-0825fje	http://dx.doi.org/10.1096/fj.02-0825fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692086				2022-12-25	WOS:000182580100046
J	Venkatachalam, K; Zheng, F; Gill, DL				Venkatachalam, K; Zheng, F; Gill, DL			Regulation of canonical transient receptor potential (TRPC) channel function by diacylglycerol and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; OPERATED HTRP3 CHANNELS; CA2+ ENTRY; CATION CHANNELS; TRISPHOSPHATE RECEPTOR; STORE DEPLETION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; MOLECULAR-BASIS	The mechanism of receptor-induced activation of the ubiquitously expressed family of mammalian canonical transient receptor potential ( TRPC) channels has been the focus of intense study. Primarily responding to phospholipase C (PLC)-coupled receptors, the channels are reported to receive modulatory input from diacylglycerol, endoplasmic reticulum inositol 1,4,5-trisphosphate receptors and Ca2+ stores. Analysis of TRPC5 channels transfected within DT40 B cells and deletion mutants thereof revealed efficient activation in response to PLC-beta or PLC-gamma activation, which was independent of inositol 1,4,5-trisphoshate receptors or the content of stores. In both HEK293 cells and DT40 cells, TRPC5 and TRPC3 channel responses to PLC activation were highly analogous, but only TRPC3 and not TRPC5 channels responded to the addition of the permeant diacylglycerol (DAG) analogue, 1-oleoyl-2-acetyl-sn-glycerol (OAG). However, OAG application or elevated endogenous DAG, resulting from either DAG lipase or DAG kinase inhibition, completely prevented TRPC5 or TRPC4 activation. This inhibitory action of DAG on TRPC5 and TRPC4 channels was clearly mediated by protein kinase C (PKC), in distinction to the stimulatory action of DAG on TRPC3, which is established to be PKC-independent. PKC activation totally blocked TRPC3 channel activation in response to OAG, and the activation was restored by PKC-blockade. PKC inhibition resulted in decreased TRPC3 channel deactivation. Store-operated Ca2+ entry in response to PLC-coupled receptor activation was substantially reduced by OAG or DAG-lipase inhibition in a PKC-dependent manner. However, store-operated Ca2+ entry in response to the pump blocker, thapsigargin, was unaffected by PKC. The results reveal that each TRPC subtype is strongly inhibited by DAG-induced PKC activation, reflecting a likely universal feedback control on TRPCs, and that DAG-mediated PKC-independent activation of TRPC channels is highly subtype-specific. The profound yet distinct control by PKC and DAG of the activation of TRPC channel subtypes is likely the basis of a spectrum of regulatory phenotypes of expressed TRPC channels.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.		Venkatachalam, Kaliyamurthi/GXM-4890-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55426] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huber A, 1998, FEBS LETT, V425, P317, DOI 10.1016/S0014-5793(98)00248-8; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Kanki H, 2001, MOL PHARMACOL, V60, P989, DOI 10.1124/mol.60.5.989; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Litosch I, 1997, BIOCHEM J, V326, P701, DOI 10.1042/bj3260701; Liu MY, 2000, J BIOL CHEM, V275, P12194, DOI 10.1074/jbc.275.16.12194; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Montell C., 2001, SCI STKE; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Putney JW, 2001, J CELL SCI, V114, P2223; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Quest AFG, 1997, ADV EXP MED BIOL, V400, P297; RYU SH, 1990, J BIOL CHEM, V265, P17941; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SHORT AD, 1993, J BIOL CHEM, V268, P25887; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2002, NAT CELL BIOL, V4, pE263, DOI 10.1038/ncb1102-e263; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	55	279	294	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29031	29040		10.1074/jbc.M302751200	http://dx.doi.org/10.1074/jbc.M302751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12721302	hybrid			2022-12-25	WOS:000184421100085
J	Wang, F; Kovacs, M; Hu, AH; Limouze, J; Harvey, EV; Sellers, JR				Wang, F; Kovacs, M; Hu, AH; Limouze, J; Harvey, EV; Sellers, JR			Kinetic mechanism of non-muscle myosin IIB - Functional adaptations for tension generation and maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; ACTOMYOSIN SUBFRAGMENT-1; SKELETAL-MUSCLE; MOTOR DOMAIN; FLUORESCENT-PROBE; SINGLE TRYPTOPHAN; HEAVY-CHAINS; I ATPASE; ACTIN; ADP	Besides driving contraction of various types of muscle tissue, conventional (class II) myosins serve essential cellular functions and are ubiquitously expressed in eukaryotic cells. Three different isoforms in the human myosin complement have been identified as non-muscle class II myosins. Here we report the kinetic characterization of a human non-muscle myosin IIB subfragment-1 construct produced in the baculovirus expression system. Transient kinetic data show that most steps of the actomyosin ATPase cycle are slowed down compared with other class II myosins. The ADP affinity of subfragment-1 is unusually high even in the presence of actin filaments, and the rate of ADP release is close to the steady-state ATPase rate. Thus, non-muscle myosin IIB subfragment-1 spends a significantly higher proportion of its kinetic cycle strongly attached to actin than do the muscle myosins. This feature is even more pronounced at slightly elevated ADP levels, and it may be important in carrying out the cellular functions of this isoform working in small filamentous assemblies.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.		Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001786, ZIAHL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Buxton DB, 2003, J BIOL CHEM, V278, P15449, DOI 10.1074/jbc.M210145200; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; GEEVES MA, 1988, BIOCHEM J, V256, P41, DOI 10.1042/bj2560041; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Khromov A, 1998, BIOPHYS J, V75, P1926, DOI 10.1016/S0006-3495(98)77633-7; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; KRISANDA JM, 1983, AM J PHYSIOL, V244, P385; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MAUPIN P, 1994, J CELL SCI, V107, P3077; Morano I, 2000, NAT CELL BIOL, V2, P371, DOI 10.1038/35014065; NIEDERMAN R, 1975, J CELL BIOL, V67, P72, DOI 10.1083/jcb.67.1.72; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; Sellers J. R., 1999, MYOSINS; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; Takeda K, 2000, CELL MOTIL CYTOSKEL, V46, P59, DOI 10.1002/(SICI)1097-0169(200005)46:1<59::AID-CM6>3.0.CO;2-Q; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200	42	188	192	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27439	27448		10.1074/jbc.M302510200	http://dx.doi.org/10.1074/jbc.M302510200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12704189	hybrid			2022-12-25	WOS:000184242700015
J	Cruz-Vera, LR; Hernandez-Ramon, E; Perez-Zamorano, B; Guarneros, G				Cruz-Vera, LR; Hernandez-Ramon, E; Perez-Zamorano, B; Guarneros, G			The rate of Peptidyl-tRNA dissociation from the ribosome during minigene expression depends on the nature of the last decoding interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; GROWTH-INHIBITION; INITIATION CODON; METABOLIC ROLE; CELL-GROWTH; P-SITE; TRANSLATION; HYDROLASE; ACCUMULATION	The expression of some very short open reading frames (ORFs) in Escherichia coli results in peptidyl-tRNA accumulation that is lethal to cells defective in peptidyl-tRNA hydrolase activity. In an attempt to understand the factors that affect this phenotype, we have surveyed the toxicity of a complete set of two-codon ORFs cloned as minigenes in inducible expression vectors. The minigenes were tested in hydrolase-defective hosts and classified according to their degree of toxicity. In general, minigenes harboring codons belonging to the same box in the standard table of the genetic code mediated similar degrees of toxicity. Moreover, the levels of peptidyl-tRNA accumulation for synonymous minigenes decoded by the same tRNA were comparable. However, two exceptions were observed: (i) expression of minigenes harboring the Arg codons CGA, CGU, and CGC, resulted in the accumulation of different levels of the unique peptidyl-tRNA(Arg-2) and (ii) the toxicity of minigenes containing CUG and UCU codons, each recognized by two different tRNAs, depended on peptidyl-tRNA accumulation of only one of them. Non-toxic, or partly toxic, minigenes prompted higher accumulation levels of peptidyl-tRNA upon deprivation of active RF1, implying that translation termination occurred efficiently. Our data indicate that the nature of the last decoding tRNA is crucial in the rate of peptidyl-tRNA release from the ribosome.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Mexico City 07000, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Guarneros, G (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Genet & Mol Biol, Apartado Postal 14-740, Mexico City 07000, DF, Mexico.		Cruz-Vera, Luis Rogelio/AFV-2807-2022	Cruz-Vera, Luis Rogelio/0000-0002-4593-9957				ARKOV AL, 1993, NUCLEIC ACIDS RES, V21, P2891, DOI 10.1093/nar/21.12.2891; Buckingham RH, 1997, MOL MICROBIOL, V24, P449, DOI 10.1046/j.1365-2958.1997.3711734.x; Chaley MB, 1999, J MOL EVOL, V48, P168, DOI 10.1007/PL00006455; Cruz-Vera LR, 2002, MICROBIOL-SGM, V148, P3457, DOI 10.1099/00221287-148-11-3457; CURRAN JF, 1995, NUCLEIC ACIDS RES, V23, P683, DOI 10.1093/nar/23.4.683; CUZIN F, 1967, P NATL ACAD SCI USA, V58, P2079, DOI 10.1073/pnas.58.5.2079; Dincbas V, 1999, J MOL BIOL, V291, P745, DOI 10.1006/jmbi.1999.3028; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; GARCIAVILLEGAS MR, 1991, EMBO J, V10, P3549, DOI 10.1002/j.1460-2075.1991.tb04919.x; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hernandez-Sanchez J, 1998, EMBO J, V17, P3758, DOI 10.1093/emboj/17.13.3758; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; Heurgue-Hamard V, 2000, EMBO J, V19, P2701, DOI 10.1093/emboj/19.11.2701; Heurgue-Hamard V, 1998, EMBO J, V17, P808, DOI 10.1093/emboj/17.3.808; IRWIN B, 1995, J BIOL CHEM, V270, P22801, DOI 10.1074/jbc.270.39.22801; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; LEVIN DH, 1973, P NATL ACAD SCI USA, V70, P41, DOI 10.1073/pnas.70.1.41; LIM VI, 1992, FEBS LETT, V313, P133, DOI 10.1016/0014-5793(92)81429-P; Lindsley D, 2003, MOL MICROBIOL, V48, P1267, DOI 10.1046/j.1365-2958.2003.03514.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Mankin AS, 1997, J MOL BIOL, V274, P8, DOI 10.1006/jmbi.1997.1387; Menez J, 2000, NUCLEIC ACIDS RES, V28, P4725, DOI 10.1093/nar/28.23.4725; MENNINGER JR, 1976, J BIOL CHEM, V251, P3392; MENNINGER JR, 1978, J BIOL CHEM, V253, P6808; MENNINGER JR, 1979, J BACTERIOL, V137, P694, DOI 10.1128/JB.137.1.694-696.1979; Ontiveros C, 1997, J MOL BIOL, V269, P167, DOI 10.1006/jmbi.1997.1017; RYDEN SM, 1984, MOL GEN GENET, V193, P38, DOI 10.1007/BF00327411; Sagara JI, 1998, NUCLEIC ACIDS RES, V26, P1974, DOI 10.1093/nar/26.8.1974; Sato T, 2001, J BIOCHEM, V129, P851, DOI 10.1093/oxfordjournals.jbchem.a002929; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; Stenstrom CM, 2001, GENE, V263, P273, DOI 10.1016/S0378-1119(00)00550-3; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; Tenson T, 1999, J BACTERIOL, V181, P1617, DOI 10.1128/JB.181.5.1617-1622.1999; Tenson T, 1996, P NATL ACAD SCI USA, V93, P5641, DOI 10.1073/pnas.93.11.5641; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Valadez JG, 2001, MOL MICROBIOL, V39, P361, DOI 10.1046/j.1365-2958.2001.02214.x; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; Zhang SP, 1998, J MOL BIOL, V284, P1243, DOI 10.1006/jmbi.1998.2319	38	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26065	26070		10.1074/jbc.M301129200	http://dx.doi.org/10.1074/jbc.M301129200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716898	hybrid			2022-12-25	WOS:000183920200103
J	Gin, P; Hsu, AY; Rothman, SC; Jonassen, T; Lee, PT; Tzagoloff, A; Clarke, CF				Gin, P; Hsu, AY; Rothman, SC; Jonassen, T; Lee, PT; Tzagoloff, A; Clarke, CF			The Saccharomyces cerevisiae COQ6 gene encodes a mitochondrial flavin-dependent monooxygenase required for coenzyme Q biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; AMINO-ACID-SEQUENCE; UBIQUINONE BIOSYNTHESIS; HYDROXYBENZOATE HYDROXYLASE; CAENORHABDITIS-ELEGANS; SALICYLATE HYDROXYLASE; FUNCTIONAL EXPRESSION; INTERMEMBRANE SPACE; PSEUDOMONAS-PUTIDA; YEAST MITOCHONDRIA	Coenzyme Q (Q) is a lipid that functions as an electron carrier in the mitochondrial respiratory chain in eukaryotes. There are eight complementation groups of Q-deficient Saccharomyces cerevisiae mutants, designated coq1-coq8. Here we have isolated the COQ6 gene by functional complementation and, in contrast to a previous report, find it is not an essential gene. coq6 mutants are unable to grow on nonfermentable carbon sources and do not synthesize Q but instead accumulate the Q biosynthetic intermediate 3-hexaprenyl-4-hydroxybenzoic acid. The Coq6 polypeptide is imported into the mitochondria in a membrane potential-dependent manner. Coq6p is a peripheral membrane protein that localizes to the matrix side of the inner mitochondrial membrane. Based on sequence homology to known proteins, we suggest that COQ6 encodes a flavin-dependent monooxygenase required for one or more steps in Q biosynthesis.	Univ Calif Los Angeles, Dept Biochem & Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Columbia University	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Biochem & Chem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@mbi.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL2274, R01 HL022174] Funding Source: Medline; NIGMS NIH HHS [GM45952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1997, METHODS YEAST GENETI, P145; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Belogrudov GI, 2001, ARCH BIOCHEM BIOPHYS, V392, P48, DOI 10.1006/abbi.2001.2448; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; DIMARCO AA, 1993, GENE, V125, P25, DOI 10.1016/0378-1119(93)90741-K; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; Dutton PL, 2000, COENZYME Q OXIDATION, P65, DOI [10.1201/9781420036701.sec1b, DOI 10.1201/9781420036701.SEC1B]; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; Eppink MHM, 1997, J BACTERIOL, V179, P6680, DOI 10.1128/jb.179.21.6680-6687.1997; FILIPPINI S, 1995, MICROBIOL-UK, V141, P1007, DOI 10.1099/13500872-141-4-1007; Fiori A, 2000, YEAST, V16, P377; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Geromel V, 2002, MOL GENET METAB, V77, P21, DOI 10.1016/S1096-7192(02)00145-2; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gille L, 2000, ARCH BIOCHEM BIOPHYS, V375, P347, DOI 10.1006/abbi.1999.1649; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GOEWERT RR, 1978, FEBS LETT, V87, P219, DOI 10.1016/0014-5793(78)80336-6; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; Jonassen T, 2002, J BIOL CHEM, V277, P45020, DOI 10.1074/jbc.M204758200; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2001, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KALIN M, 1992, J BACTERIOL, V174, P7112; KATAGIRI M, 1966, J BIOL CHEM, V241, P5675; Kwon O, 2000, FEMS MICROBIOL LETT, V186, P157, DOI 10.1016/S0378-1097(00)00134-8; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; MARBOIS BN, 1994, GENE, V138, P213; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Meganathan R, 2001, FEMS MICROBIOL LETT, V203, P131, DOI 10.1016/S0378-1097(01)00330-5; NAKAHIGASHI K, 1992, J BACTERIOL, V174, P7352, DOI 10.1128/jb.174.22.7352-7359.1992; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NURK A, 1991, GENE, V102, P13, DOI 10.1016/0378-1119(91)90531-F; ORSER CS, 1993, J BACTERIOL, V175, P411, DOI 10.1128/JB.175.2.411-416.1993; Palfey B. A., 1995, ACTIVE OXYGEN BIOCH, P37, DOI DOI 10.1007/978-94-011-0609-2_2; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541; SIKORSKI RS, 1989, GENETICS, V122, P19; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Suzuki K, 1996, BBA-BIOENERGETICS, V1275, P154, DOI 10.1016/0005-2728(96)00069-2; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WEIJER WJ, 1983, EUR J BIOCHEM, V133, P109, DOI 10.1111/j.1432-1033.1983.tb07435.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WONG CM, 1994, MICROBIOL-SGM, V140, P2775, DOI 10.1099/00221287-140-10-2775; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; YOUNG IG, 1973, J BACTERIOL, V114, P42, DOI 10.1128/JB.114.1.42-52.1973; YOUNG IG, 1971, J BACTERIOL, V105, P769, DOI 10.1128/JB.105.3.769-778.1971	65	57	59	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25308	25316		10.1074/jbc.M303234200	http://dx.doi.org/10.1074/jbc.M303234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12721307	hybrid			2022-12-25	WOS:000183920200008
J	Christmas, P; Carlesso, N; Shang, HB; Cheng, SM; Weber, BM; Preffer, FI; Scadden, DT; Soberman, RJ				Christmas, P; Carlesso, N; Shang, HB; Cheng, SM; Weber, BM; Preffer, FI; Scadden, DT; Soberman, RJ			Myeloid expression of cytochrome P4504F3 is determined by a lineage-specific alternative promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; B-4 OMEGA-HYDROXYLASE; LEUKOTRIENE B-4; TRANSCRIPTION FACTORS; COREPRESSOR CTBP; HUMAN MONOCYTE; DNA-BINDING; CYP4F3 GENE; IN-VITRO; ACTIVATION	The cytochrome P450 4F3 (CYP4F3) gene encodes two functionally distinct enzymes that differ only by the selection of exon 4 (CYP4F3A) or exon 3 (CYP4F3B). CYP4F3A inactivates leukotriene B-4, a reaction that has significance for controlling inflammation. CYP4F3B converts arachidonic acid to 20-hydroxyeicosatetraenoic acid, a potent activator of protein kinase C. We have previously shown that mRNAs coding for CYP4F3A and CYP4F3B are generated from distinct transcription start sites in neutrophils and liver. We therefore investigated mechanisms that regulate the cell-specific expression of these two isoforms. Initially, we analyzed the distribution of CYP4F3 in human leukocytes and determined a lineage-specific pattern of isoform expression. CYP4F3A is expressed in myeloid cells and is coordinate with myeloid differentiation markers such as CD11b and myeloperoxidase during development in the bone marrow. In contrast, CYP4F3B expression is restricted to a small population of CD3+ T lymphocytes. We identified distinct transcriptional features in myeloid, lymphoid, and hepatic cells that indicate the presence of multiple promoters in the CYP4F3 gene. The hepatic promoter depends on a cluster of hepatocyte nuclear factor sites 123-155 bp upstream of the initiator ATG codon. The myeloid promoter spans 400 bp in a region 468-872 bp upstream of the ATG codon; it is associated with clusters of CACCT sites and can be activated by ZEB-2, a factor primarily characterized as a transcriptional repressor in cells that include lymphocytes. ZEB-2 interacts with C-terminal binding protein and Smads, and this would provide opportunities for integrating environmental signals in myelopoiesis and inflammation.	Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Christmas, P (corresponding author), Massachusetts Gen Hosp E, Renal Unit, 149 Navy Yard,13th St, Charlestown, MA 02129 USA.				NHLBI NIH HHS [HL55718, HL68256] Funding Source: Medline; NIDDK NIH HHS [DK52234, DK59991] Funding Source: Medline; NIGMS NIH HHS [GM-61823] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068256, R56HL068256, R01HL055718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK059991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061823] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brabletz T, 1999, INT IMMUNOL, V11, P1701, DOI 10.1093/intimm/11.10.1701; Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959-437X(00)00226-4; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2001, J BIOL CHEM, V276, P38166; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; Gregoire JM, 1999, J BIOL CHEM, V274, P6567, DOI 10.1074/jbc.274.10.6567; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; Kikuta Y, 1998, DNA CELL BIOL, V17, P221, DOI 10.1089/dna.1998.17.221; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lazarova DL, 2001, CELL GROWTH DIFFER, V12, P319; Lin FM, 1995, AM J PHYSIOL-RENAL, V269, pF806, DOI 10.1152/ajprenal.1995.269.6.F806; McGiff JC, 1999, AM J PHYSIOL-REG I, V277, pR607, DOI 10.1152/ajpregu.1999.277.3.R607; MIGLIORISI G, 1987, AM J PATHOL, V127, P157; Muthalif MM, 1998, P NATL ACAD SCI USA, V95, P12701, DOI 10.1073/pnas.95.21.12701; NUMAO T, 1992, J IMMUNOL, V149, P3309; PETTIPHER ER, 1993, BRIT J PHARMACOL, V110, P423, DOI 10.1111/j.1476-5381.1993.tb13827.x; Phippen TM, 2000, J BIOL CHEM, V275, P37628, DOI 10.1074/jbc.M004234200; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; ROLAPLESZCZYNSKI M, 1985, J IMMUNOL, V135, P1357; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; SHAK S, 1984, J BIOL CHEM, V259, P181; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TERNOWITZ T, 1987, ACTA PATH MICRO IM C, V95, P47; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Urasaki T, 2001, J LEUKOCYTE BIOL, V69, P105; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Weringer EJ, 1999, TRANSPLANTATION, V67, P808, DOI 10.1097/00007890-199903270-00005; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996; Yasui DH, 1998, J IMMUNOL, V160, P4433; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zhang QH, 2002, SCIENCE, V295, P1895; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	46	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25133	25142		10.1074/jbc.M302106200	http://dx.doi.org/10.1074/jbc.M302106200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12709424	hybrid			2022-12-25	WOS:000183824800107
J	Bodo, A; Bakos, E; Szeri, F; Varadi, A; Sarkadi, B				Bodo, A; Bakos, E; Szeri, F; Varadi, A; Sarkadi, B			Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; SUBSTRATE-SPECIFICITY; EXPORT PUMP; RAT; EXPRESSION; GLUCURONIDES; MUTATION; ISOFORM	The multidrug resistance proteins MRP2 (ABCC2) and MRP3 (ABCC3) are key primary active transporters involved in anionic conjugate and drug extrusion from the human liver. The major physiological role of MRP2 is to transport conjugated metabolites into the bile canaliculus, whereas MRP3 is localized in the basolateral membrane of the hepatocytes and transports similar metabolites back to the bloodstream. Both proteins were shown to interact with a large variety of transported substrates, and earlier studies suggested that MRPs may work as co-transporters for different molecules. In the present study we expressed the human MRP2 and MRP3 proteins in insect cells and examined their transport and ATPase characteristics in isolated, inside-out membrane vesicles. We found that the primary active transport of estradiol-17-beta-D-glucuronide (E(2)17betaG), a major product of human steroid metabolism, was differently modulated by bile acids and organic anions in the case of human MRP2 and MRP3. Active E(2)17betaG transport by MRP2 was significantly stimulated by the organic anions indomethacin, furosemide, and probenecid and by several conjugated bile acids. In contrast, all of these agents inhibited E(2)17betaG transport by MRP3. We found that in the case of MRP2, ATP-dependent vesicular bile acid transport was increased by E(2)17betaG, and the results indicated an allosteric cross-stimulation, probably a cotransport of bile acids and glucuronate conjugates through this protein. There was no such stimulation of bile acid transport by MRP3. In conclusion, the different transport modulation of MRPs by bile acids and anionic drugs could play a major role in regulating physiological and pathological metabolite fluxes in the human liver.	Hungarian Acad Sci, Natl Med Ctr, Inst Haematol & Immunol, Membrane Res Grp, H-1113 Budapest, Hungary; Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Sarkadi, B (corresponding author), Hungarian Acad Sci, Natl Med Ctr, Inst Haematol & Immunol, Membrane Res Grp, H-1113 Budapest, Hungary.	sarkadi@biomembrane.hu	Szeri, Flóra/L-6162-2019; Sarkadi, Balazs/I-5024-2013; Szeri, Flora/AAD-3907-2021; Varadi, Andras/A-2055-2012	Szeri, Flóra/0000-0003-2572-6820; Szeri, Flora/0000-0003-2572-6820; 				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Bodo A, 2003, TOXICOL LETT, V140, P133, DOI 10.1016/S0378-4274(02)00497-6; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; BORST P, 1997, SEMIN CANCER BIOL, V8, P3; BROCK WJ, 1984, DRUG METAB DISPOS, V12, P712; Cui YH, 1999, MOL PHARMACOL, V55, P929; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Donner MG, 2001, HEPATOLOGY, V34, P351, DOI 10.1053/jhep.2001.26213; DURHAM S, 1986, J PHARMACOL EXP THER, V237, P490; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hitzl M, 2003, J PHARMACOL EXP THER, V304, P524, DOI 10.1124/jpet.102.043547; Ito K, 2001, J BIOL CHEM, V276, P38108; ITO K, 2001, AM J GASTROINT LIVER, V281, P1034; Iyanagi T, 1998, BBA-MOL BASIS DIS, V1407, P173, DOI 10.1016/S0925-4439(98)00044-1; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keppler D, 1997, BIOL CHEM, V378, P787; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; Konig J, 1999, HEPATOLOGY, V29, P1156, DOI 10.1002/hep.510290404; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844; Loe DW, 1998, CANCER RES, V58, P5130; Muller M, 1996, J BIOL CHEM, V271, P1877; Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498; Noe J, 2002, GASTROENTEROLOGY, V123, P1659, DOI 10.1053/gast.2002.36587; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Scheffer GL, 2002, LAB INVEST, V82, P193, DOI 10.1038/labinvest.3780411; SLIKKER W, 1983, J PHARMACOL EXP THER, V225, P138; Takikawa H, 1996, HEPATOLOGY, V23, P607; van Aubel RAMH, 1998, MOL PHARMACOL, V53, P1062; Vore M, 1997, DRUG METAB REV, V29, P183, DOI 10.3109/03602539709037580; Zelcer N, 2001, J BIOL CHEM, V276, P46400, DOI 10.1074/jbc.M107041200; Zelcer N, 2003, J BIOL CHEM, V278, P23538, DOI 10.1074/jbc.M303504200; Zeng H, 1999, CANCER RES, V59, P5964	39	125	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23529	23537		10.1074/jbc.M303515200	http://dx.doi.org/10.1074/jbc.M303515200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704183	hybrid			2022-12-25	WOS:000183638600041
J	Della Ragione, F; Cucciolla, V; Criniti, V; Indaco, S; Borriello, A; Zappia, V				Della Ragione, F; Cucciolla, V; Criniti, V; Indaco, S; Borriello, A; Zappia, V			p21(Cip1) gene expression is modulated by Egr1 - A novel regulatory mechanism involved in the resveratrol antiproliferative effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR-CELL LINES; TRANSCRIPTION FACTOR; RED WINE; TRANS-RESVERATROL; PHYTOALEXIN RESVERATROL; PLATELET-AGGREGATION; CIS-RESVERATROL; RESPONSE GENE; SP1 SITES	Epidemiological observations indicate that resveratrol, a natural antioxidant stilbene, exerts cardioprotective and chemopreventive effects. Moreover, the molecule induces in vitro cell growth inhibition and differentiation. Using human erythroleukemic K562 cells as model system, we demonstrated that resveratrol induces a remarkable gamma-globin synthesis, the erythroid differentiation being linked to impairment of cell proliferation, increased p21(Cip1) expression and inhibition of cdk2 activity. The up-regulation of p21(Cip1) transcription is prevented by cycloheximide, indicating the requirement of intermediate protein(s), which, in turn, regulate gene expression. The quantitative analysis of some transcription factors involved in the erythroid lineage, namely GATA-1, GATA-2, and Egr1, indicated that resveratrol selectively up-regulates Egr1 by an Erk1/2-dependent mechanism. The presence of an Egr1 consensus sequence in the p21(Cip1) promoter suggested the hypothesis that this transcription factor directly regulates the expression of the cdk inhibitor. Transfection studies with deleted gene promoter constructs, as well as EMSA, pull-down, and chromatin immunoprecipitation experiments substantiated this view, demonstrating that Egr1 binds in vitro and in vivo to the identified consensus sequence of the p21(Cip1) promoter. Moreover, an Egr1 phosphorothioate antisense hinders p21(Cip1) accumulation and the antiproliferative effects of resveratrol. In conclusion, this is the first demonstration that Egr1 controls p21(Cip1) expression by directly interacting with a specific sequence on its gene promoter. The identified regulatory mechanism also contributes to the clarification of the complex chemopreventive and antiproliferative properties of resveratrol.	Second Univ Naples, Dept Biochem & Biophys F Cedrangolo, I-80138 Naples, Italy	Universita della Campania Vanvitelli	Della Ragione, F (corresponding author), Second Univ Naples, Dept Biochem & Biophys F Cedrangolo, Via Costantinopoli 16, I-80138 Naples, Italy.		Borriello, Adriana/K-3464-2018	Della Ragione, Fulvio/0000-0002-0592-4283; BORRIELLO, Adriana/0000-0002-9026-8048				Allen SW, 2001, DRUG METAB DISPOS, V29, P1074; Arai M, 2000, CIRC RES, V86, P8, DOI 10.1161/01.RES.86.1.8; Atten MJ, 2001, BIOCHEM PHARMACOL, V62, P1423, DOI 10.1016/S0006-2952(01)00788-2; Bertelli AAE, 1998, DRUG EXP CLIN RES, V24, P51; Bertelli AAE, 1996, INT J TISSUE REACT, V18, P67; Bertelli AAE, 1996, DRUG EXP CLIN RES, V22, P61; Bhat KPL, 2001, CANCER RES, V61, P6137; Calogero A, 1996, ONCOGENE, V13, P2105; Calogero A, 2001, CLIN CANCER RES, V7, P2788; Carleton M, 2002, J IMMUNOL, V168, P1649, DOI 10.4049/jimmunol.168.4.1649; Clement MV, 1998, BLOOD, V92, P996; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Della Ragione F, 2002, FEBS LETT, V532, P289, DOI 10.1016/S0014-5793(02)03683-9; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; DellaRagione F, 1996, BIOCHEM BIOPH RES CO, V223, P514, DOI 10.1006/bbrc.1996.0926; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322, DOI 10.1152/ajpgi.1999.276.2.G322; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ElAttar TMA, 1999, ANTICANCER RES, V19, P5407; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERARD F, 1981, BLOOD, V58, P1236; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; GOLDBERG DM, 1995, AM J ENOL VITICULT, V46, P159; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Holian O, 2001, J CELL BIOCHEM, P55, DOI 10.1002/jcb.1085; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; Ikonomi P, 2000, GENE, V261, P277, DOI 10.1016/S0378-1119(00)00510-2; Iolascon A, 1998, HEPATOLOGY, V27, P989, DOI 10.1002/hep.510270414; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1998, CANCER GENE THER, V5, P3; LOZZIO BB, 1975, BLOOD, V54, P321; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Minc E, 1999, J BIOL CHEM, V274, P503, DOI 10.1074/jbc.274.1.503; Nakagawa H, 2001, J CANCER RES CLIN, V127, P258, DOI 10.1007/s004320000190; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PACEASCIAK CR, 1995, CLIN CHIM ACTA, V235, P207, DOI 10.1016/0009-8981(95)06045-1; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; Park JW, 2001, CARCINOGENESIS, V22, P1633, DOI 10.1093/carcin/22.10.1633; Piver B, 2001, TOXICOL LETT, V125, P83, DOI 10.1016/S0378-4274(01)00418-0; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Rodrigue CM, 2001, BRIT J HAEMATOL, V113, P500, DOI 10.1046/j.1365-2141.2001.02746.x; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; Schubert R, 1997, PLANT MOL BIOL, V34, P417, DOI 10.1023/A:1005830714852; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Sun NJ, 1998, J NAT PROD, V61, P362, DOI 10.1021/np970488q; Surh YJ, 1999, CANCER LETT, V140, P1, DOI 10.1016/S0304-3835(99)00039-7; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; Wolter F, 2001, J NUTR, V131, P2197, DOI 10.1093/jn/131.8.2197; Wung BS, 1999, CIRC RES, V84, P804; Yun SS, 2002, J BIOL CHEM, V277, P34808, DOI 10.1074/jbc.M205417200; Zoberi I, 2002, CANCER LETT, V175, P165, DOI 10.1016/S0304-3835(01)00719-4	77	81	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23360	23368		10.1074/jbc.M300771200	http://dx.doi.org/10.1074/jbc.M300771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12690110	hybrid			2022-12-25	WOS:000183638600020
J	Hayashi, K; Jones, AM; Ogino, K; Yamazoe, A; Oono, Y; Inoguchi, M; Kondo, H; Nozaki, H				Hayashi, K; Jones, AM; Ogino, K; Yamazoe, A; Oono, Y; Inoguchi, M; Kondo, H; Nozaki, H			Yokonolide B, a novel inhibitor of auxin action, blocks degradation of AUX/IAA factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED GENE-EXPRESSION; PEA PISUM-SATIVUM; ARABIDOPSIS-THALIANA; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN-1; NUCLEAR PROTEINS; ALPHA-AMYLASE; ABSCISIC-ACID; PROTEASOME	Yokonolide B (YkB; also known as A82548A), a spiroketal-macrolide, was isolated from Streptomyces diastatochromogenes B59 in a screen for inhibitors of beta-glucoronidase expression under the control of an auxin-responsive promoter in Arabidopsis. YkB inhibits the expression of auxin-inducible genes as shown using native and synthetic auxin promoters as well as using expression profiling of 8,300 Arabidopsis gene probes but does not affect expression of an abscisic acid- and a gibberellin A(3)-inducible gene. The mechanism of action of YkB is to block AUX/IAA protein degradation; however, YkB is not a general proteasome inhibitor. YkB blocks auxin-dependent cell division and auxin-regulated epinastic growth mediated by auxin-binding protein 1. Gain of function mutants such as shy2-2, slr1, and axr2-1 encoding AUX/IAA transcriptional repressors and loss of function mutants encoding components of the ubiquitin-proteolytic pathway such as axr1-3 and tir1-1, which display increased AUX/IAAs protein stability, are less sensitive to YkB, although axr1 and tir1 mutants were sensitive to MG132, a general proteasome inhibitor, consistent with a site of action downstream of AXR1 and TIR. YkB-treated seedlings displayed similar phenotypes as dominant AUX/IAA mutants. Taken together, these results indicate that YkB acts to block AUX/IAA protein degradation upstream of AXR and TIR, links a shared element upstream of AUX/IAA protein stability to auxin-induced cell division/elongation and to auxin-binding protein 1, and provides a new tool to dissect auxin signal transduction.	Okayama Univ Sci, Dept Biochem, Okayama 7000005, Japan; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Japan Atom Energy Res Inst, Dept Ion Beam Appl Biol, Takasaki, Gumma 3701292, Japan	Okayama University of Science; University of North Carolina; University of North Carolina Chapel Hill; Japan Atomic Energy Agency	Nozaki, H (corresponding author), Okayama Univ Sci, Dept Biochem, 1-1 Ridai Cho, Okayama 7000005, Japan.		Oono, Yutaka/HHN-8582-2022	Oono, Yutaka/0000-0002-9119-9355	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065989] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM65989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BALLAS N, 1993, J MOL BIOL, V233, P580, DOI 10.1006/jmbi.1993.1537; Casimiro I, 2001, PLANT CELL, V13, P843, DOI 10.1105/tpc.13.4.843; Chen JG, 2001, PLANT J, V28, P607, DOI 10.1046/j.1365-313x.2001.01152.x; Cheong YH, 2002, PLANT PHYSIOL, V129, P661, DOI 10.1104/pp.002857; D'Agostino IB, 2000, PLANT PHYSIOL, V124, P1706, DOI 10.1104/pp.124.4.1706; del Pozo JC, 1999, P NATL ACAD SCI USA, V96, P15342, DOI 10.1073/pnas.96.26.15342; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; Desikan R, 2001, PLANT PHYSIOL, V127, P159, DOI 10.1104/pp.127.1.159; Fu XD, 2002, PLANT CELL, V14, P3191, DOI 10.1105/tpc.006197; FUJINAMI K, 1994, J BIOL CHEM, V269, P25905; Fukaki H, 2002, PLANT J, V29, P153, DOI 10.1046/j.0960-7412.2001.01201.x; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; Gray WM, 2001, NATURE, V414, P271, DOI 10.1038/35104500; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Hagen G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117; Hayashi K, 2001, J ANTIBIOT, V54, P573, DOI 10.7164/antibiotics.54.573; Hayashi K, 2000, PHYTOCHEMISTRY, V55, P1, DOI 10.1016/S0031-9422(00)00204-1; HOBBIE L, 1994, PLANT MOL BIOL, V26, P1499, DOI 10.1007/BF00016487; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; Kaur R, 1999, MICROBIOL-UK, V145, P809, DOI 10.1099/13500872-145-4-809; Keller CP, 1998, PLANT PHYSIOL, V118, P557, DOI 10.1104/pp.118.2.557; Kepinski S, 2002, PLANT CELL, V14, pS81, DOI 10.1105/tpc.010447; KIRST HA, 1995, J ANTIBIOT, V48, P990, DOI 10.7164/antibiotics.48.990; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Kusaba M, 1996, PLANT PHYSIOL, V111, P1161, DOI 10.1104/pp.111.4.1161; LANG V, 1992, PLANT MOL BIOL, V20, P951, DOI 10.1007/BF00027165; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Liscum E, 2002, PLANT MOL BIOL, V49, P387, DOI 10.1023/A:1015255030047; Mockaitis K, 2000, PLANT J, V24, P785, DOI 10.1046/j.1365-313x.2000.00921.x; Nagpal P, 2000, PLANT PHYSIOL, V123, P563, DOI 10.1104/pp.123.2.563; OELLER PW, 1995, PLANT J, V7, P37, DOI 10.1046/j.1365-313X.1995.07010037.x; Oono Y, 1998, PLANT CELL, V10, P1649, DOI 10.1105/tpc.10.10.1649; Oono Y, 2002, ANN BOT-LONDON, V89, P77, DOI 10.1093/aob/mcf007; Ouellet F, 2001, PLANT CELL, V13, P829, DOI 10.1105/tpc.13.4.829; Reed JW, 2001, TRENDS PLANT SCI, V6, P420, DOI 10.1016/S1360-1385(01)02042-8; RINDERKNECHT H, 1967, EXPERIENTIA, V23, P805, DOI 10.1007/BF02146851; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; Scherer GFE, 2002, PLANT MOL BIOL, V49, P357, DOI 10.1023/A:1015290510483; Schwechheimer C, 2002, PLANT CELL, V14, P2553, DOI 10.1105/tpc.003434; Smalle J, 2002, PLANT CELL, V14, P17, DOI 10.1105/tpc.010381; Swarup R, 2002, PLANT MOL BIOL, V49, P411; Tian Q, 2002, PLANT CELL, V14, P301, DOI 10.1105/tpc.010283; Tian Q, 1999, DEVELOPMENT, V126, P711; Tiwari SB, 2001, PLANT CELL, V13, P2809, DOI 10.1105/tpc.13.12.2809; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Winicur ZM, 1998, PLANT PHYSIOL, V117, P501, DOI 10.1104/pp.117.2.501; Zenser N, 2001, P NATL ACAD SCI USA, V98, P11795, DOI 10.1073/pnas.211312798	57	52	54	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23797	23806		10.1074/jbc.M300299200	http://dx.doi.org/10.1074/jbc.M300299200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12690101	Green Published, hybrid			2022-12-25	WOS:000183638600074
J	Kuwasako, K; Kitamura, K; Nagoshi, Y; Cao, YN; Eto, T				Kuwasako, K; Kitamura, K; Nagoshi, Y; Cao, YN; Eto, T			Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; CALCITONIN-RECEPTOR; ADRENOMEDULLIN RECEPTORS; TRANSMEMBRANE DOMAIN; EXPRESSION; SECRETION; TERMINUS; CLONING; AMYLIN; RAMPS	When co-expressed with receptor activity-modifying protein (RAMP) 1, calcitonin receptor-like receptor (CRLR) can function as a receptor for both calcitonin gene-related peptide (CGRP) and adrenomedullin (AM). To investigate the structural determinants of ligand binding specificity, we examined the extracellular domain of human (h) RAMP1 using various deletion mutants. Co-expression of the hRAMP1 mutants with hCRLR in HEK-293 cells revealed that deletion of residues 91-94, 96-100, or 101-103 blocked [I-125] CGRP binding and completely abolished intracellular cAMP accumulation normally elicited by CGRP or AM. On the other hand, the deletion of residues 78-80 or 88-90 significantly attenuated only AM-evoked responses. In all of these cases, the receptor heterodimers were fully expressed at the cell surface. Substituting alanine for residues 91-103 one at a time had little effect on CGRP-induced responses, indicating that although this segment is essential for high affinity agonist binding to the receptors, none of the residues directly interacts with either CGRP or AM. This finding suggests that RAMPs probably determine ligand specificity by contributing to the structure of the ligand-binding pocket or by allosteric modulation of the conformation of the receptor. Interestingly, the L94A mutant up-regulated surface expression of the receptor heterodimer to a greater degree than wild-type hRAMP1, thereby increasing CGRP binding and signaling. L94A also significantly increased cell surface expression of the hRAMP1 deletion mutant D101-103 when co-transfected with hCRLR, and expression of a L94A/D101-103 double mutant markedly attenuated the activity of endogenous RAMP1 in HEK-293T cells.	Miyazaki Med Coll, Dept Internal Med 1, Miyazaki 8891692, Japan	University of Miyazaki	Kuwasako, K (corresponding author), Miyazaki Med Coll, Dept Internal Med 1, 5200 Kihara, Miyazaki 8891692, Japan.	kuwasako@fc.miyazaki-med.ac.jp	Kuwasako, Kenji/H-8065-2016					Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Eto T, 2001, PEPTIDES, V22, P1693, DOI 10.1016/S0196-9781(01)00513-7; Fitzsimmons TJ, 2003, J BIOL CHEM, V278, P14313, DOI 10.1074/jbc.M211946200; Flahaut M, 2002, J BIOL CHEM, V277, P14731, DOI 10.1074/jbc.M112084200; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GUAN XM, 1992, J BIOL CHEM, V267, P21995; Hilairet S, 2001, J BIOL CHEM, V276, P29575, DOI 10.1074/jbc.M102722200; Husmann K, 2000, MOL CELL ENDOCRINOL, V162, P35, DOI 10.1016/S0303-7207(00)00212-4; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Kuwasako K, 2003, HYPERTENS RES, V26, pS25, DOI 10.1291/hypres.26.S25; Kuwasako K, 2003, BIOCHEM BIOPH RES CO, V301, P460, DOI 10.1016/S0006-291X(02)03072-3; Kuwasako K, 2002, FEBS LETT, V519, P113, DOI 10.1016/S0014-5793(02)02721-7; Kuwasako K, 2001, J BIOL CHEM, V276, P49459, DOI 10.1074/jbc.M108369200; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mishima K, 2001, BIOCHEM BIOPH RES CO, V287, P264, DOI 10.1006/bbrc.2001.5572; Muff R, 1998, FEBS LETT, V441, P366, DOI 10.1016/S0014-5793(98)01587-7; Nagoshi Y, 2002, EUR J PHARMACOL, V450, P237, DOI 10.1016/S0014-2999(02)02184-2; Oliver KR, 2001, EUR J NEUROSCI, V14, P618, DOI 10.1046/j.0953-816x.2001.01688.x; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Steiner S, 2002, BIOCHEMISTRY-US, V41, P11398, DOI 10.1021/bi020279r; Uemura T, 2002, J HYPERTENS, V20, P1209, DOI 10.1097/00004872-200206000-00035; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	34	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22623	22630		10.1074/jbc.M302571200	http://dx.doi.org/10.1074/jbc.M302571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684503	hybrid			2022-12-25	WOS:000183503900061
J	Lund, EG; Xie, CL; Kotti, T; Turley, SD; Dietschy, JM; Russell, DW				Lund, EG; Xie, CL; Kotti, T; Turley, SD; Dietschy, JM; Russell, DW			Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR LXR; APOLIPOPROTEIN-E; CDNA CLONING; IN-VIVO; OXYSTEROL; 24S-HYDROXYCHOLESTEROL; BILE; HOMEOSTASIS; METABOLISM; PLASMA	Most cholesterol turnover takes place in the liver and involves the conversion of cholesterol into soluble and readily excreted bile acids. The synthesis of bile acids is limited to the liver, but several enzymes in the bile acid biosynthetic pathway are expressed in extra-hepatic tissues and there also may contribute to cholesterol turnover. An example of the latter type of enzyme is cholesterol 24-hydroxylase, a cytochrome P450 (CYP46A1) that is expressed at 100-fold higher levels in the brain than in the liver. Cholesterol 24-hydroxylase catalyzes the synthesis of the oxysterol 24(S)-hydroxycholesterol. To assess the relative contribution of the 24-hydroxylation pathway to cholesterol turnover, we performed balance studies in mice lacking the cholesterol 24-hydroxylase gene (Cyp46a1(-/-) mice). Parameters of hepatic cholesterol and bile acid metabolism in the mutant mice remained unchanged relative to wild type controls. In contrast to the liver, the synthesis of new cholesterol was reduced by similar to40% in the brain, despite steady-state levels of cholesterol being similar in the knockout mice. These data suggest that the synthesis of new cholesterol and the secretion of 24(S)-hydroxycholesterol are closely coupled and that at least 40% of cholesterol turnover in the brain is dependent on the action of cholesterol 24-hydroxylase. We conclude that cholesterol 24-hydroxylase constitutes a major tissue-specific pathway for cholesterol turnover in the brain.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	david.russell@utsouthwestern.edu		Russell, David/0000-0002-0277-403X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL009610, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL09610, P01 HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Bayer S.A., 1991, NEOCORTICAL DEV; Bjorkhem I, 2002, J CLIN INVEST, V110, P725, DOI 10.1172/JCI200216388; Bjorkhem I, 1999, CURR OPIN LIPIDOL, V10, P161, DOI 10.1097/00041433-199904000-00010; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bretillon L, 2000, J LIPID RES, V41, P840; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; DIETSCHY JM, 1984, J LIPID RES, V25, P1469; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; FIELDING CJ, 1995, J LIPID RES, V36, P211; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HOGAN BL, 1995, MANIPULATING MOUSE E; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JESKE DJ, 1980, J LIPID RES, V21, P364; KALUZNY MA, 1985, J LIPID RES, V26, P135; KANDEL Eric, 1991, PRINCIPLES NEURAL SC, P18; Kelly JP., 1991, PRINC NEURAL SCI, V1, P283; LAWSON AM, 1988, BILE ACIDS CHEM PHYS, V4, P167; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Meaney S, 2002, J LIPID RES, V43, P2130, DOI 10.1194/jlr.M200293-JLR200; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; SAMBROOK J, 2000, MOL CLONING LAB MANU; Schwarz M, 1998, J LIPID RES, V39, P1833; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; TURLEY SD, 1994, GASTROENTEROLOGY, V107, P444, DOI 10.1016/0016-5085(94)90170-8; Wang L, 2002, P NATL ACAD SCI USA, V99, P13878, DOI 10.1073/pnas.172510899; WILSON JD, 1970, J CLIN INVEST, V49, P655, DOI 10.1172/JCI106277; Xie CL, 2000, J NEUROPATH EXP NEUR, V59, P1106, DOI 10.1093/jnen/59.12.1106; Xu GR, 1998, METABOLISM, V47, P878, DOI 10.1016/S0026-0495(98)90130-5	52	289	294	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22980	22988		10.1074/jbc.M303415200	http://dx.doi.org/10.1074/jbc.M303415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686551	hybrid			2022-12-25	WOS:000183503900105
J	Nijenhuis, WAJ; Garner, KM; van Rozen, RJ; Adan, RAH				Nijenhuis, WAJ; Garner, KM; van Rozen, RJ; Adan, RAH			Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGOUTI-RELATED PROTEIN; FRAMESHIFT MUTATION; MORBID-OBESITY; FUNCTIONAL-CHARACTERIZATION; MISSENSE MUTATION; GENE; MICE; MC4R; ANTAGONIST; DOMINANT	The melanocortin-4 receptor (MC4R) plays an important role in the regulation of body weight in rodents. Mutations in the coding region of the MC4R are found more frequently in obese individuals, supporting the hypothesis that also in humans deficient melanocortin signaling may lead to obesity. Family studies that were carried out to demonstrate the relevance of single mutations for obesity were mostly inconclusive, most likely due to small sample size and complexity of the trait. In addition, the existing pharmacological data of the mutant receptors are limited in that for most mutations the effect on receptor expression level and Agouti-related protein (AgRP) pharmacology have not been studied. The aim of the present study was to gain further insight into the impact of the MC4R mutations on receptor function. Eleven missense mutations were tested for cell surface expression, affinity for alpha-melanocyte-stimulating hormone (alpha-MSH) and AgRP-(83-132), and the biological response to alpha-MSH. All mutants were poorly expressed at the cell surface, as measured by I-125-[Nle(4)-D-Phe(7)]alpha-MSH binding, and only a few mutants showed altered pharmacology for alpha-MSH and AgRP. Hemagglutinin-tagged mutant receptors were retained in the intracellular environment. These pharmacological data provide a basis to estimate the quantitative effect of MC4R mutations for the development of obesity.	Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Adan, RAH (corresponding author), Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.							Bichet DG, 1998, P ASSOC AM PHYSICIAN, V110, P387; BULTMAN SJ, 1992, CELL, V71, P1195, DOI 10.1016/S0092-8674(05)80067-4; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Cody JD, 1999, HUM GENET, V105, P424, DOI 10.1007/s004390051125; Dubern B, 2001, J PEDIATR-US, V139, P204, DOI 10.1067/mpd.2001.116284; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; Gu W, 1999, DIABETES, V48, P635, DOI 10.2337/diabetes.48.3.635; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Ho GY, 1999, J BIOL CHEM, V274, P35816, DOI 10.1074/jbc.274.50.35816; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kask A, 1998, BIOCHEM BIOPH RES CO, V245, P90, DOI 10.1006/bbrc.1998.8389; Kobayashi H, 2002, DIABETES, V51, P243, DOI 10.2337/diabetes.51.1.243; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Mergen M, 2001, J CLIN ENDOCR METAB, V86, P3448, DOI 10.1210/jc.86.7.3448; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; Milligan G, 2002, NEUROSIGNALS, V11, P29, DOI 10.1159/000057319; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; Oosterom J, 1999, J BIOL CHEM, V274, P16853, DOI 10.1074/jbc.274.24.16853; Oosterom J, 2001, J BIOL CHEM, V276, P931, DOI 10.1074/jbc.M007261200; Rosenfeld RD, 1998, BIOCHEMISTRY-US, V37, P16041, DOI 10.1021/bi981027m; Rosmond R, 2001, DIABETOLOGIA, V44, P1335, DOI 10.1007/s001250100649; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Schioth HB, 1997, FEBS LETT, V410, P223, DOI 10.1016/S0014-5793(97)00593-0; Sina M, 1999, AM J HUM GENET, V65, P1501, DOI 10.1086/302660; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Wenkert D, 1996, MOL CELL ENDOCRINOL, V124, P43, DOI 10.1016/S0303-7207(96)03926-3; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	38	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22939	22945		10.1074/jbc.M211326200	http://dx.doi.org/10.1074/jbc.M211326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690102	hybrid			2022-12-25	WOS:000183503900100
J	Rhee, SH; Jones, BW; Toshchakov, V; Vogel, SN; Fenton, MJ				Rhee, SH; Jones, BW; Toshchakov, V; Vogel, SN; Fenton, MJ			Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; CUTTING EDGE; PKC-DELTA; TLR4; REQUIREMENT; ADAPTER; TYROSINE	Engagement of Toll- like receptor ( TLR) proteins activates multiple signal transduction pathways. These studies show that engagement of TLR2 and TLR4 leads to rapid phosphorylation of the transcription factor STAT1 at serine 727 ( Ser- 727 STAT1) in murine macrophages. Only TLR4 engagement induced STAT1 phosphorylation at tyrosine 701, although this response was delayed compared with Ser- 727 STAT1 phosphorylation. Inhibition of phosphatidylinositol 3 '- kinase using LY294002 blocked TLR4- induced STAT1 tyrosine phosphorylation, but this inhibitor had no effect on STAT1 serine phosphorylation. TLR- induced phosphorylation of Ser- 727 STAT1 could be blocked by the selective p38 mitogen- activated protein kinase inhibitor SB203580. However, activation of p38 was not sufficient to induce Ser- 727 STAT1 phosphorylation in macrophages. TLR2-induced activation of Ser- 727 STAT1 phosphorylation required the adapter protein MyD88, whereas TLR4- induced activation of Ser- 727 STAT1 phosphorylation was not solely dependent on MyD88. Lastly, TLR4- induced activation of Ser- 727 STAT1 phosphorylation could be blocked by rottlerin, a specific inhibitor of protein kinase C-delta. In contrast, rottlerin had no effect on STAT1 phosphorylation induced via TLR2. Together, these data demonstrate that activation STAT1 tyrosine and serine phosphorylation are distinct consequences of TLR engagement in murine macrophages. Furthermore, p38 mitogen- activated protein kinase, protein kinase C-delta, and a novel TLR2- specific signaling pathway appear to be necessary to induce Ser- 727 STAT1 phosphorylation.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Boston University; University System of Maryland; University of Maryland Baltimore	Fenton, MJ (corresponding author), Univ Maryland, Sch Med, Dept Med, MSTF-800 685 W Baltimore St, Baltimore, MD 21201 USA.	mfenton@medicine.umaryland.edu	Toshchakov, Vladimir/C-2798-2014	Toshchakov, Vladimir/0000-0002-7942-2294	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018797, R01AI018797, R56AI018797] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18797, AI42733] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Murakami M, 2002, J BIOL CHEM, V277, P20367, DOI 10.1074/jbc.M202501200; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Weinstein SL, 2000, J LEUKOCYTE BIOL, V67, P405, DOI 10.1002/jlb.67.3.405; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	35	89	94	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22506	22512		10.1074/jbc.M208633200	http://dx.doi.org/10.1074/jbc.M208633200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686553	hybrid			2022-12-25	WOS:000183503900046
J	Arora, T; Liu, B; He, HC; Kim, J; Murphy, TL; Murphy, KM; Modlin, RL; Shuai, K				Arora, T; Liu, B; He, HC; Kim, J; Murphy, TL; Murphy, KM; Modlin, RL; Shuai, K			PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ANDROGEN RECEPTOR; STAT4; PROTEINS; FAMILY; ALPHA; CELLS; INVOLVEMENT; INHIBITION; RESPONSES	In response to interleukin 12 ( IL- 12) stimulation, a latent cytoplasmic transcription factor, Stat4 ( signal transducer and activator of transcription 4), becomes tyrosine- phosphorylated and translocates into the nucleus where it binds to DNA to activate transcription. Cofactors that can directly bind and regulate Stat4 activity have not been described. We report here that PI-ASx, a member of the protein inhibitor of activated STAT ( PIAS) family, is a negative regulator of Stat4. PIASx becomes associated with Stat4 following IL- 12 stimulation in vivo. PIASx inhibits IL- 12- stimulated and Stat4- dependent gene activation in human T cells. PIASx does not inhibit the DNA binding activity of Stat4. Instead PIASx is present in the Stat4- DNA binding complex. Finally the inhibitory activity of PIASx on Stat4-mediated gene activation is abolished by the histone deacetylase inhibitor trichostatin A. Our results suggest that PIASx may function as a co- repressor of Stat4.	Univ Calif Los Angeles, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Dermatol, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Biol Chem, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Washington University (WUSTL)	Shuai, K (corresponding author), Univ Calif Los Angeles, Div Hematol Oncol, Dept Med, 11-934 Factor Bldg,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Modlin, Robert L/M-7941-2014	Modlin, Robert L/0000-0003-4720-031X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043438, R21AI043438] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43438] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Cho SS, 1996, J IMMUNOL, V157, P4781; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; MEGIDISH T, 2002, J BIOL CHEM, V11, P11; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Rogge L, 1998, J IMMUNOL, V161, P6567; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; SCHMIDT D, 2002, P NATL ACAD SCI USA, V26, P26; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tussie-Luna MI, 2002, P NATL ACAD SCI USA, V99, P12807, DOI 10.1073/pnas.192464499; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	33	93	102	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21327	21330		10.1074/jbc.C300119200	http://dx.doi.org/10.1074/jbc.C300119200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12716907	hybrid			2022-12-25	WOS:000183354200004
J	Vazquez, G; Wedel, BJ; Trebak, M; Bird, GS; Putney, JW				Vazquez, G; Wedel, BJ; Trebak, M; Bird, GS; Putney, JW			Expression level of the canonical transient receptor potential 3 (TRPC3) channel determines its mechanism of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; OPERATED CA2+ ENTRY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; SMOOTH-MUSCLE CELLS; TRISPHOSPHATE RECEPTOR; CATION CHANNELS; B-LYMPHOCYTES; DIACYLGLYCEROL; RELEASE; PROTEIN	Studies on the mechanism of activation of canonical transient receptor potential ( TRPC) channels have often yielded conflicting results. In the current study, we have investigated the influence of expression level on the mode of regulation of TRPC3 channels. At relatively low levels of expression in DT40 chicken B- lymphocytes, TRPC3 was activated by the depletion of Ca2+ stores. Expression was increased by either transfecting with a 10- fold greater concentration of plasmid or transfecting with TRPC3 under control of a more efficient avian beta- actin promoter. At higher levels of expression, TRPC3 was no longer store- operated but could be activated through receptor- coupled phospholipase C. Under these expression conditions, TRPC3 was efficiently activated in DT40 cells lacking inositol 1,4,5- trisphosphate receptors. The Ca2+ store- operated channels formed upon expression of TRPC3 at limited levels were blocked by gadolinium; the receptor- activated channels formed upon expression of higher levels of TRPC3 were insensitive to gadolinium. These findings indicate that a single ion channel protein can form or contribute to the formation of channels regulated in two very distinct ways, i. e. either by phospholipase C- derived messengers or Ca2+ store- depletion. The mechanism of regulation of the channels depends on their level of expression.	NIEHS, Lab Signal Transduct, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, US Dept HHS, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021; Trebak, Mohamed/E-7405-2014	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; Kamouchi M, 1999, J PHYSIOL-LONDON, V518, P345, DOI 10.1111/j.1469-7793.1999.0345p.x; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Smolke CD, 2002, BIOTECHNOL BIOENG, V78, P412, DOI 10.1002/bit.10218; Su ZC, 2001, AM J PHYSIOL-CELL PH, V280, pC1284, DOI 10.1152/ajpcell.2001.280.5.C1284; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Trebak M, 2003, J BIOL CHEM, V278, P16244, DOI 10.1074/jbc.M300544200; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Trepakova ES, 2001, J BIOL CHEM, V276, P7782, DOI 10.1074/jbc.M010104200; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	33	120	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21649	21654		10.1074/jbc.M302162200	http://dx.doi.org/10.1074/jbc.M302162200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12686562	hybrid			2022-12-25	WOS:000183354200043
J	Graham, LJ; Veri, MC; DeBell, KE; Noviello, C; Rawat, R; Jen, S; Bonvini, E; Rellahan, B				Graham, LJ; Veri, MC; DeBell, KE; Noviello, C; Rawat, R; Jen, S; Bonvini, E; Rellahan, B			70Z/3 Cbl induces PLC gamma 1 activation in T lymphocytes via an alternate Lat- and Slp-76-independent signaling mechanism	ONCOGENE			English	Article						T lymphocytes; T-cell receptor; signal transduction; PLC gamma 1; c-Cbl	PHOSPHOTYROSINE-BINDING DOMAIN; EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA-1 PLC-GAMMA-1; TEC FAMILY KINASES; CELL RECEPTOR; C-CBL; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATOR; SH2 DOMAIN; ZAP-70	The oncoprotein 70Z/3 Cbl signals in an autonomous fashion or through blockade of endogenous c-Cbl, a negative regulator of signaling. The mechanism of 70Z/3 Cbl-induced signaling was investigated by comparing the molecular requirements for 70Z/3 Cbl- and TCR-induced phospholipase Cgamma1 (PLCgamma1) activation. 70Z/3 Cbl-induced PLCgamma1 tyrosine phosphorylation required, in addition to the PLCgamma1 N-terminal SH2 domain, the C-terminal SH2 and SH3 domains that were dispensable for TCR-induced phosphorylation. Deletion of the leucine zipper of 70Z/3 Cbl did not eliminate 70Z/3 Cbl-induced PLCgamma1 phosphorylation, suggesting that blockage of c-Cbl via dimerization with 70Z/3 Cbl cannot fully explain 70Z/3 Cbl activating characteristics. The complete elimination of PLCgamma1 phosphorylation required deleting the SH3 domain-binding region of 70Z/3 Cbl, consistent with 70Z/3 Cbl binding the PLCgamma1 SH3 domain. 70Z/3 Cbl-induced PLCgamma1 phosphorylation required Zap-70, as for the TCR, and the tyrosine kinase binding domain of 70Z/3 Cbl, which binds Zap-70, but did not require PLCgamma1 binding to Lat, a crucial interaction in TCR-induced PLCgamma1 phosphorylation. Furthermore, 70Z/3 Cbl-induced activation of NFAT, a PLCgamma1/Ca2+-dependent transcriptional event, required Zap-70, but was independent of Slp-76, an adapter required for TCR-induced NFAT activation. These results suggest that 70Z/3 Cbl and PLCgamma1 form a TCR-, Lat- and Slp-76-independent complex that leads to PLCgamma1 phosphorylation and activation.	US FDA, Ctr Biol Evaluat & Res, Div Monoc Antibodies, Immunobiol Lab, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA)	Bonvini, E (corresponding author), HFM-564,29B-3NN10,8800 Rockville Pike, Bethesda, MD 20892 USA.							ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Bunnell SC, 1996, J BIOL CHEM, V271, P25646, DOI 10.1074/jbc.271.41.25646; Chang JS, 1997, CANCER RES, V57, P5465; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Graham LJ, 1998, BIOCHEM BIOPH RES CO, V249, P537, DOI 10.1006/bbrc.1998.9177; Graham LJ, 2000, FEBS LETT, V470, P273, DOI 10.1016/S0014-5793(00)01341-7; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON MD, 1994, HUM PATHOL, V25, P146, DOI 10.1016/0046-8177(94)90270-4; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Schaeffer EM, 2000, CURR OPIN IMMUNOL, V12, P282, DOI 10.1016/S0952-7915(00)00088-1; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 1999, J BIOL CHEM, V274, P29323, DOI 10.1074/jbc.274.41.29323; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Stoica B, 1998, J IMMUNOL, V160, P1059; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; van Leeuwen JEM, 1999, J BIOL CHEM, V274, P5153, DOI 10.1074/jbc.274.8.5153; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang ZH, 1999, J BIOL CHEM, V274, P4883, DOI 10.1074/jbc.274.8.4883; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	5	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2493	2503		10.1038/sj.onc.1206318	http://dx.doi.org/10.1038/sj.onc.1206318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717426				2022-12-25	WOS:000182383500012
J	Sugano, Y; Matsuzaki, K; Tahashi, Y; Furukawa, F; Mori, S; Yamagata, H; Yoshida, K; Matsushita, M; Nishizawa, M; Fujisawa, J; Inoue, K				Sugano, Y; Matsuzaki, K; Tahashi, Y; Furukawa, F; Mori, S; Yamagata, H; Yoshida, K; Matsushita, M; Nishizawa, M; Fujisawa, J; Inoue, K			Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells	ONCOGENE			English	Article						TGF-beta; Smad; HCC; PAI-1; VEGF	PLASMINOGEN-ACTIVATOR INHIBITOR-1; TGF-BETA; HEPATOMA-CELLS; GENE-MUTATIONS; CANCER; UROKINASE; EXPRESSION; RECEPTOR; LIVER; SMAD2	Resistance to growth inhibitory effects of transforming growth factor (TGF)-beta is a frequent consequence of malignant transformation. On the other hand, serum concentrations of TGF-beta, plasminogen activator inhibitor type 1 (PAI-1), and vascular endothelial growth factor (VEGF) are elevated as tumor progresses. The molecular mechanism of autocrine TGF-beta signaling and its effects on PAI-1 and VEGF production in human hepatocellular carcinoma (HCC) is unknown. TGF-beta signaling involves TGF-beta type I receptor-mediated phosphorylation of serine residues within the conserved SSXS motif at the C-terminus of Smad2 and Smad3. To investigate the involvement of autocrine TGF-beta signal in cell growth, PAI-1 and VEGF production of HCC, we made stable transfectants of human HCC line (HuH-7 cells) to express a mutant Smad2(3S-A), in which serine residues of SSXS motif were changed to alanine. The transfectants demonstrated an impaired Smad2 signaling. Along with the resistance to growth inhibition by TGF-beta, forced expression of Smad2(3S-A) induced endogenous TGF-beta secretion. Moreover, this increased TGF-beta enhanced ligand-dependent signaling through the activated Smad3 and Smad4 complex, and transcriptional activities of PAI-1 and VEGF genes. In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production.	Dept Internal Med 3, Moriguchi, Osaka 5708507, Japan; Dept Med Chem, Moriguchi, Osaka 5708507, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708507, Japan	Kansai Medical University	Matsuzaki, K (corresponding author), Dept Internal Med 3, 10-15 Fumizonocho, Moriguchi, Osaka 5708507, Japan.	matsuzak@takii.kmu.ac.jp						Abelev G I, 1971, Adv Cancer Res, V14, P295, DOI 10.1016/S0065-230X(08)60523-0; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Date M, 1998, J HEPATOL, V28, P572, DOI 10.1016/S0168-8278(98)80280-8; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Engel ME, 1998, J CELL BIOCHEM, P111; Fan GS, 1996, ONCOGENE, V12, P1909; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Gutierrez LS, 2000, CANCER RES, V60, P5839; HEALY AM, 1994, J BIOL CHEM, V269, P19095; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, CANCER RES, V60, P1394; Matsuzaki K, 2000, HEPATOLOGY, V32, P218, DOI 10.1053/jhep.2000.9145; MATSUZAKI K, 1990, JPN J CANCER RES, V81, P345, DOI 10.1111/j.1349-7006.1990.tb02574.x; Mise M, 1996, HEPATOLOGY, V23, P455; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Riggins GJ, 1997, CANCER RES, V57, P2578; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; YAMANAKA N, 1990, CANCER, V65, P1104, DOI 10.1002/1097-0142(19900301)65:5<1104::AID-CNCR2820650511>3.0.CO;2-G; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	36	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2309	2321		10.1038/sj.onc.1206305	http://dx.doi.org/10.1038/sj.onc.1206305			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700666				2022-12-25	WOS:000182231500009
J	Gautam, A; Li, ZR; Bepler, G				Gautam, A; Li, ZR; Bepler, G			RRM1-induced metastasis suppression through PTEN-regulated pathways	ONCOGENE			English	Article						ribonucleotide reductase; PTEN; focal adhesion kinase; lung cancer; chromosome 11; metastasis suppression; tumor suppression	FOCAL ADHESION KINASE; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; CHROMOSOME SEGMENT 11P15.5; TUMOR-SUPPRESSOR; LUNG-CANCER; CELL MOTILITY; MESSENGER-RNA; GENE; INHIBITION; PROTEIN	Lung cancer is the leading cause of cancer-related mortality in the United States. Only 15% of patients with this disease survive 5 years or longer. Early metastatic spread is the single most important reason for this poor outcome. The survival of patients with pathological stage I disease, that is, no evidence for metastatic spread, and molecular aberrations on chromosome 11p15.5 is equal to that of patients with stage II disease, that is, metastatic spread to hilar lymph nodes. RRM1 is a gene in this region, and it is haploinsufficient in at least 34% stage I patients. Here, we show that overexpression of RRM1 in human and mouse lung cancer cell lines induced PTEN expression, reduced phosphorylation of focal adhesion kinase (FAK), suppressed migration, invasion, and metastasis formation, and increased survival in an animal model. Increased PTEN expression was required for the RRM1-induced suppression of cell motility and FAK phosphorylation. We conclude that RRM1 functions as a metastasis suppressor gene through induction of PTEN expression.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program ,MRC,MOLONC, Tampa, FL 33612 USA; Roswell Pk Canc Inst, Lung Canc Program, Buffalo, NY 14263 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Roswell Park Cancer Institute	Bepler, G (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program ,MRC,MOLONC, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NCI NIH HHS [R01-CA70317, P30-CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070317, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; Bepler G, 1998, CANCER DETECT PREV, V22, P14; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; CARNEY DN, 1985, CANCER RES, V45, P2913; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CORY JG, 1983, MOL CELL BIOCHEM, V53-4, P257; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; ILLC D, 1995, NATURE, V377, P539; JAKLITSCH MT, 1995, LUNG CANCER, V12, pS17, DOI 10.1016/S0169-5002(10)80003-0; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; OBriant K, 1997, ANTICANCER RES, V17, P3243; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; YUHAS JM, 1975, CANCER RES, V35, P242; Zhao BH, 2001, ONCOGENE, V20, P8154, DOI 10.1038/sj.onc.1205027; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	49	117	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2135	2142		10.1038/sj.onc.1206232	http://dx.doi.org/10.1038/sj.onc.1206232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687015	Bronze			2022-12-25	WOS:000182066900007
J	vom Dahl, S; Schliess, F; Reissmann, R; Gorg, B; Weiergraber, O; Kocalkova, M; Dombrowski, F; Haussinger, D				vom Dahl, S; Schliess, F; Reissmann, R; Gorg, B; Weiergraber, O; Kocalkova, M; Dombrowski, F; Haussinger, D			Involvement of Integrins in osmosensing and signaling toward autophagic proteolysis in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELL-VOLUME; HEPATIC PROTEOLYSIS; ACTIN CYTOSKELETON; GLYCOGEN-SYNTHASE; MESSENGER-RNA; AMINO-ACIDS; MAP KINASE; ACTIVATION; INHIBITION	Inhibition of autophagic proteolysis by hypoosmotic or amino acid-induced hepatocyte swelling requires osmosignaling toward p38(MAPK); however, the upstream osmosensing and signaling events are unknown. These were studied in the intact perfused rat liver with a preserved in situ environment of hepatocytes. It was found that hypoosmotic hepatocyte swelling led to an activation of Src (but not FAK), Erks, and p38(MAPK), which was prevented by the integrin inhibitory hexapeptide GRGDSP, but not its inactive analogue GRGESP. Src inhibition by PP-2 prevented hypoosmotic MAP kinase activation, indicating that the integrin/Src system is located upstream in the osmosignaling toward p38(MAPK) and Erks. Inhibition of the integrin/Src system by the RGD motif-containing peptide or PP-2 also prevented the inhibition of proteolysis and the decrease in autophagic vacuole volume, which is otherwise observed in response to hypoosmotic or glutamine/glycine-induced hepatocyte swelling. These inhibitors, however, did not affect swelling-independent proteolysis inhibition by phenylalanine. In line with a role of p38(MAPK) in triggering the volume regulatory decrease (RVD), PP-2 and the RGD peptide blunted RVD in response to hypoosmotic cell swelling. The data identify integrins and Src as upstream events in the osmosignaling toward MAP kinases, proteolysis, and RVD. They further point to a role of integrins as osmo- and mechanosensors in the intact liver, which may provide a link between cell volume and cell function.	Univ Dusseldorf, Div Gastroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany; Otto Von Guericke Univ, Inst Pathol, D-40225 Magdeburg, Germany	Heinrich Heine University Dusseldorf; Otto von Guericke University	vom Dahl, S (corresponding author), Univ Dusseldorf, Div Gastroenterol Hepatol & Infect Dis, Moorenstr 5, D-40225 Dusseldorf, Germany.		Weiergräber, Oliver H./G-8940-2013; Dahl, Stephan vom/AAF-8456-2021	Weiergräber, Oliver H./0000-0002-2410-3691; Dahl, Stephan vom/0000-0003-0481-0601; Gorg, Boris/0000-0002-4630-9420				Aplin AE, 1998, PHARMACOL REV, V50, P197; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURG MB, 1995, AM J PHYSIOL, V268, P983; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; Feranchak AP, 2001, J CLIN INVEST, V108, P1495, DOI 10.1172/JCI200112190; HALLBRUCKER C, 1991, EUR J BIOCHEM, V197, P717, DOI 10.1111/j.1432-1033.1991.tb15963.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; Haussinger D, 1996, BIOCHEM J, V313, P697; HAUSSINGER D, 1990, HEPATOLOGY, V11, P243, DOI 10.1002/hep.1840110214; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HAUSSINGER D, 1990, BIOCHEM J, V272, P239, DOI 10.1042/bj2700039; Haussinger D, 1996, Prog Liver Dis, V14, P29; HAUSSINGER D, 1991, FEBS LETT, V283, P70, DOI 10.1016/0014-5793(91)80556-I; Hsu SL, 2001, CANCER LETT, V167, P193, DOI 10.1016/S0304-3835(01)00479-7; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KADOWAKI M, 1992, J BIOL CHEM, V267, P22060; Kim RD, 2001, J SURG RES, V100, P176, DOI 10.1006/jsre.2001.6225; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Loomis WF, 1997, J CELL SCI, V110, P1141; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MEIJER AJ, 1993, EUR J BIOCHEM, V215, P449, DOI 10.1111/j.1432-1033.1993.tb18053.x; MEIJER AJ, 1975, J BIOL CHEM, V250, P7728; MEIJER AJ, 1992, J BIOL CHEM, V267, P5823; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152; PFEIFER U, 1984, LAB INVEST, V50, P348; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Schliess F, 2001, BIOL CHEM, V382, P1063, DOI 10.1515/BC.2001.133; SheikhHamad D, 1996, AM J PHYSIOL-CELL PH, V270, pC253, DOI 10.1152/ajpcell.1996.270.1.C253; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; Torimura T, 2001, HEPATOLOGY, V34, P62, DOI 10.1053/jhep.2001.25546; Traxler P, 1997, J MED CHEM, V40, P3601, DOI 10.1021/jm970124v; Trouet D, 2001, AM J PHYSIOL-CELL PH, V281, pC248, DOI 10.1152/ajpcell.2001.281.1.C248; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; vom Dahl S, 2001, CELL PHYSIOL BIOCHEM, V11, P285, DOI 10.1159/000047815; vom Dahl S, 2001, BIOCHEM J, V354, P31, DOI 10.1042/0264-6021:3540031; VOMDAHL S, 1995, BIOCHEM J, V308, P529, DOI 10.1042/bj3080529; vomDahl S, 1996, J NUTR, V126, P395, DOI 10.1093/jn/126.2.395; VOMDAHL S, 1991, BIOL CHEM H-S, V372, P411, DOI 10.1515/bchm3.1991.372.1.411; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200	50	86	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27088	27095		10.1074/jbc.M210699200	http://dx.doi.org/10.1074/jbc.M210699200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12721289	hybrid			2022-12-25	WOS:000184155700102
J	Vehvilainen, P; Hyytiainen, M; Keski-Oja, J				Vehvilainen, P; Hyytiainen, M; Keski-Oja, J			Latent transforming growth factor-beta-binding protein 2 is an adhesion protein for melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; EXTRACELLULAR-MATRIX; TGF-BETA; SULFATE PROTEOGLYCANS; UROKINASE RECEPTOR; HUMAN-PLATELETS; INTEGRIN; INVASION; MICROFIBRILS; COMPONENTS	Of the four latent transforming growth factor (TGF)-beta-binding proteins (LTBPs), LTBP-2 is different in the respect that it does not bind small latent forms of TGF-beta. LTBP-2 is therefore likely to have other roles in the extracellular matrix. LTBP-2 contains an RGD putative integrin recognition site, suggesting a role in cell adhesion. We carried out a study on cell attachment to LTBP-2. Purified recombinant LTBP-2 was used as substratum in cell adhesion and migration studies. We found that, unlike most adherent cell lines, all of the melanoma cell lines tested adhered to LTBP-2 very efficiently and in a concentration-dependent manner. Bowes melanoma cells bound most efficiently to LTBP-2 and were used for further characterization. Cell adhesion assays with recombinant LTBP-2 fragments indicated that the adhesive site is located in an N-terminal region of LTBP-2. The attachment of melanoma cells to LTBP-2 was prevented with monoclonal antibody against beta(1) integrin in a concentration-dependent manner, suggesting an important role for beta(1) integrin in the process. Antibodies against integrin subunits alpha(3) and alpha(6) decreased melanoma cell adhesion as well. The beta(1) and alpha(3) integrins were localized on the cell surface, especially in lamellipodia, as observed by immunofluorescence. In addition to integrin antagonists, heparin also markedly decreased melanoma cell adhesion. LTBP-2 also supported Bowes cell migration in modified Boyden chamber assays in a manner similar to the migration on fibronectin. Current data indicate that LTBP-2 can play a role in melanoma cell adhesion.	Univ Helsinki, Dept Pathol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Helsinki Univ Hosp, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Keski-Oja, J (corresponding author), Univ Helsinki, Dept Pathol, Biomedicum Helsinki, POB 63, FIN-00014 Helsinki, Finland.	Jorma.Keski-Oja@Helsinki.fi						Akula SM, 2002, CELL, V108, P407, DOI 10.1016/S0092-8674(02)00628-1; ALBELDA SM, 1990, CANCER RES, V50, P6757; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Annes JP, 2002, FEBS LETT, V511, P65, DOI 10.1016/S0014-5793(01)03280-X; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; D'Arrigo C, 1998, CONNECT TISSUE RES, V37, P29, DOI 10.3109/03008209809028898; Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080; Dallas SL, 2000, J BONE MINER RES, V15, P68, DOI 10.1359/jbmr.2000.15.1.68; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Hyytiainen M, 1998, J BIOL CHEM, V273, P20669, DOI 10.1074/jbc.273.32.20669; Iida J, 1998, J BIOL CHEM, V273, P5955, DOI 10.1074/jbc.273.10.5955; Iida J, 1996, SEMIN CANCER BIOL, V7, P155, DOI 10.1006/scbi.1996.0021; Ivaska J, 2000, CELL MOL LIFE SCI, V57, P16, DOI 10.1007/s000180050496; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1989, CANCER RES, V49, P2533; Li XW, 1998, INVAS METAST, V18, P1, DOI 10.1159/000024494; Liu SC, 2000, J CELL SCI, V113, P3563; Lu M, 2002, J CELL SCI, V115, P4641, DOI 10.1242/jcs.00145; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREN A, 1994, J BIOL CHEM, V269, P32469; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; POSTLETHWAITE AE, 1987, J EXP MED, V165, P251, DOI 10.1084/jem.165.1.251; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Shipley JM, 2000, MOL CELL BIOL, V20, P4879, DOI 10.1128/MCB.20.13.4879-4887.2000; Sterner-Kock A, 2002, GENE DEV, V16, P2264, DOI 10.1101/gad.229102; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; Unsold C, 2001, J CELL SCI, V114, P187; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Xue W, 1997, CANCER RES, V57, P1682; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YOSHINAGA IG, 1993, MELANOMA RES, V3, P435, DOI 10.1097/00008390-199311000-00006; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 2001, J CELL SCI, V114, P3577	53	47	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24705	24713		10.1074/jbc.M212953200	http://dx.doi.org/10.1074/jbc.M212953200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716902	hybrid			2022-12-25	WOS:000183824800057
J	Gallardo, M; Luna, R; Erdjument-Bromage, H; Tempst, P; Aguilera, A				Gallardo, M; Luna, R; Erdjument-Bromage, H; Tempst, P; Aguilera, A			Nab2p and the Thp1p-Sac3p complex functionally interact at the interface between transcription and mRNA metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; POLYMERASE-II; NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEX; LARGEST SUBUNIT; YEAST GENE; ELONGATION; RECOMBINATION; SUB2P	THP1 is a conserved eukaryotic gene whose null mutations confer, in yeast, transcription and genetic instability phenotypes and RNA export defects similar to those of the THO/TREX complex null mutations. In a search for multicopy suppressors of the transcription defect of thp1Delta cells, we identified the poly(A)(+) RNA-binding heterogeneous nuclear ribonucleoprotein Nab2p. Multicopy NAB2 also suppressed the RNA export defect of thp1Delta cells. This result suggests a functional relationship between Thp1p and Nab2p. Consistently, the leaky mutation nab2-1 conferred a transcription defect and hyper-recombination phenotype similar to those of thp1Delta, although to a minor degree. Reciprocally, a purified His6-tagged Thp1p fusion bound RNA in vitro. In a different approach, we show by Western analyses that a highly purified Thp1p-Sac3p complex does not contain components of THO/TREX and that sac3Delta confers a transcription defect and hyper-recombination phenotype identical to those of thp1Delta. mRNA degradation was not affected in thp1Delta mutants, implying that their expression defects are not due to mRNA decay. This indicates that Thp1p-Sac3p is a structural and functional unit. Altogether, our results suggest that Thp1p-Sac3p and Nab2p are functionally related heterogeneous nuclear ribonucleoproteins that define a further link between mRNA metabolism and transcription.	Univ Seville, Fac Biol, Dept Genet, E-41012 Seville, Spain; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of Sevilla; Memorial Sloan Kettering Cancer Center	Aguilera, A (corresponding author), Univ Seville, Fac Biol, Dept Genet, Ave Reina Mercedes 6, E-41012 Seville, Spain.	aguilo@us.es	Aguilera, Andres/L-1825-2014; LUNA, ROSA/F-3974-2016	Aguilera, Andres/0000-0003-4782-1714; LUNA, ROSA/0000-0002-6131-6610; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	NCI NIH HHS [P30 CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Custodio N, 1999, EMBO J, V18, P2855, DOI 10.1093/emboj/18.10.2855; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fan HY, 2001, MOL CELL BIOL, V21, P5459, DOI 10.1128/MCB.21.16.5459-5470.2001; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Gallardo M, 2001, GENETICS, V157, P79; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; Green DM, 2003, P NATL ACAD SCI USA, V100, P1010, DOI 10.1073/pnas.0336594100; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hammell CM, 2002, MOL CELL BIOL, V22, P6441, DOI 10.1128/MCB.22.18.6441-6457.2002; Hector RE, 2002, EMBO J, V21, P1800, DOI 10.1093/emboj/21.7.1800; Hirose Y, 2000, GENE DEV, V14, P1415; Jensen TH, 2001, MOL CELL, V7, P887, DOI 10.1016/S1097-2765(01)00232-5; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Lei EP, 2003, MOL BIOL CELL, V14, P836, DOI 10.1091/mbc.E02-08-0520; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NOVICK P, 1989, GENETICS, V121, P659; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; Prado F, 1997, EMBO J, V16, P2826, DOI 10.1093/emboj/16.10.2826; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rondon AG, 2003, EMBO J, V22, P612, DOI 10.1093/emboj/cdg047; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; SYMINGTON LS, 1991, EMBO J, V10, P987, DOI 10.1002/j.1460-2075.1991.tb08033.x; Vincent M, 1996, NUCLEIC ACIDS RES, V24, P4649, DOI 10.1093/nar/24.23.4649; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zenklusen D, 2001, FEBS LETT, V498, P150, DOI 10.1016/S0014-5793(01)02482-6	47	87	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24225	24232		10.1074/jbc.M302900200	http://dx.doi.org/10.1074/jbc.M302900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12702719	hybrid			2022-12-25	WOS:000183638600129
J	Kulakova, AN; Wisdom, GB; Kulakov, LA; Quinn, JP				Kulakova, AN; Wisdom, GB; Kulakov, LA; Quinn, JP			The purification and characterization of phosphonopyruvate hydrolase, a novel carbon-phosphorus bond cleavage enzyme from Variovorax sp Pal2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-P BOND; PHOSPHOENOLPYRUVATE MUTASE; PHOSPHONOACETALDEHYDE HYDROLASE; ACTIVE-SITE; MECHANISM; DECARBOXYLASE; ACID; ORGANOPHOSPHONATES; MICROORGANISMS; PHOSPHOMUTASE	Phosphonopyruvate hydrolase, a novel bacterial carbon-phosphorus bond cleavage enzyme, was purified to homogeneity by a series of chromatographic steps from cell extracts of a newly isolated environmental strain of Variovorax sp. Pal2. The enzyme was inducible in the presence of phosphonoalanine or phosphonopyruvate; unusually, its expression was independent of the phosphate status of the cell. The native enzyme had a molecular mass of 63 kDa with a subunit mass of 31.2 kDa. Activity of purified phosphonopyruvate hydrolase was Co2+-dependent and showed a pH optimum of 6.7-7.0. The enzyme had a K-m of 0.53 mM for its sole substrate, phosphonopyruvate, and was inhibited by the analogues phosphonoformic acid, 3-phosphonopropionic acid, and hydroxymethylphosphonic acid. The nucleotide sequence of the phosphonopyruvate hydrolase structural gene indicated that it is a member of the phosphoenolpyruvate phosphomutase/isocitrate lyase superfamily with 41% identity at the amino acid level to the carbon-to-phosphorus bond-forming enzyme phosphoenolpyruvate phosphomutase from Tetrahymena pyriformis. Thus its apparently ancient evolutionary origins differ from those of each of the two carbon-phosphorus hydrolases that have been reported previously; phosphonoacetaldehyde hydrolase is a member of the haloacetate dehalogenase family, whereas phosphonoacetate hydrolase belongs to the alkaline phosphatase superfamily of zinc-dependent hydrolases. Phosphonopyruvate hydrolase is likely to be of considerable significance in global phosphorus cycling, because phosphonopyruvate is known to be a key intermediate in the formation of all naturally occurring compounds that contain the carbon-phosphorus bond.	Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland; Queens Univ Belfast, Environm Sci & Technol Res Ctr, Belfast BT9 5AG, Antrim, North Ireland	Queens University Belfast; Queens University Belfast	Quinn, JP (corresponding author), Queens Univ Belfast, Sch Biol & Biochem, Ctr Med Biol, Belfast BT9 7BL, Antrim, North Ireland.							Baker AS, 1998, BIOCHEMISTRY-US, V37, P9305, DOI 10.1021/bi972677d; Fiske CH, 1925, J BIOL CHEM, V66, P375; Galperin MY, 1998, PROTEIN SCI, V7, P1829, DOI 10.1002/pro.5560070819; HORIGANE A, 1980, BIOCHIM BIOPHYS ACTA, V618, P383; Huang K, 1999, STRUCT FOLD DES, V7, P539, DOI 10.1016/S0969-2126(99)80070-7; Jia Y, 1999, BIOCHEMISTRY-US, V38, P14165, DOI 10.1021/bi990771j; Kim A, 1998, J BIOL CHEM, V273, P4443, DOI 10.1074/jbc.273.8.4443; KITTREDGE JS, 1964, BIOCHEMISTRY-US, V3, P991, DOI 10.1021/bi00895a026; Kulakov LA, 2002, APPL ENVIRON MICROB, V68, P1548, DOI 10.1128/AEM.68.4.1548-1555.2002; LANAUZE JM, 1970, BIOCHIM BIOPHYS ACTA, V212, P332, DOI 10.1016/0005-2744(70)90214-7; MCGRATH JW, 1995, EUR J BIOCHEM, V234, P225, DOI 10.1111/j.1432-1033.1995.225_c.x; McGrath JW, 1997, LETT APPL MICROBIOL, V24, P69, DOI 10.1046/j.1472-765X.1997.00350.x; Morais MC, 2000, ACTA CRYSTALLOGR D, V56, P206, DOI 10.1107/S0907444999015899; Nakashita H, 1997, J ANTIBIOT, V50, P212, DOI 10.7164/antibiotics.50.212; Nakashita H, 2000, BBA-GENE STRUCT EXPR, V1490, P159, DOI 10.1016/S0167-4781(99)00249-3; NAKASHITA H, 1992, J BACTERIOL, V174, P6857, DOI 10.1128/JB.174.21.6857-6861.1992; PASCUAL C, 1995, INT J SYST BACTERIOL, V45, P724, DOI 10.1099/00207713-45-4-724; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schwartz D, 1998, FEMS MICROBIOL LETT, V163, P149, DOI 10.1016/S0378-1097(98)00165-7; SEIDEL HM, 1994, BIOCHEMISTRY-US, V33, P5641, DOI 10.1021/bi00184a037; SEIDEL HM, 1988, NATURE, V335, P457, DOI 10.1038/335457a0; SPARKES MJ, 1990, EUR J BIOCHEM, V194, P373, DOI 10.1111/j.1432-1033.1990.tb15628.x; Ternan NG, 1998, WORLD J MICROB BIOT, V14, P635, DOI 10.1023/A:1008848401799; Ternan NG, 2000, ARCH MICROBIOL, V173, P35, DOI 10.1007/s002030050005; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wanner Barry L., 1994, Biodegradation, V5, P175, DOI 10.1007/BF00696458	27	32	34	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23426	23431		10.1074/jbc.M301871200	http://dx.doi.org/10.1074/jbc.M301871200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697754	hybrid			2022-12-25	WOS:000183638600028
J	Lin, CG; Leu, SJ; Chen, NY; Tebeau, CM; Lin, SX; Yeung, CY; Lau, LF				Lin, CG; Leu, SJ; Chen, NY; Tebeau, CM; Lin, SX; Yeung, CY; Lau, LF			CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; HUMAN SKIN FIBROBLASTS; HEPARAN-SULFATE PROTEOGLYCANS; VEIN ENDOTHELIAL-CELLS; INTEGRIN ALPHA(V)BETA(3); CYR61 CCN1; IN-VIVO; TERMINAL DOMAIN; TUMOR-GROWTH	CCN3 (NOV) is a matricellular protein of the CCN family, which also includes CCN1 (CYR61), CCN2 (CTGF), CCN4 (WISP-1), CCN5 (WISP-2), and CCN6 (WISP-3). During development, CCN3 is expressed widely in derivatives of all three germ layers, and high levels of expression are observed in smooth muscle cells of the arterial vessel wall. Altered expression of CCN3 has been observed in a variety of tumors, including hepatocellular carcinomas, Wilm's tumors, Ewing's sarcomas, gliomas, rhabdomyosarcomas, and adrenocortical carcinomas. To understand its biological functions, we have investigated the activities of purified recombinant CCN3. We show that in endothelial cells, CCN3 supports cell adhesion, induces directed cell migration (chemotaxis), and promotes cell survival. Mechanistically, CCN3 supports human umbilical vein endothelial cell adhesion through multiple cell surface receptors, including integrins alpha(v)beta(3), alpha(5)beta(1), alpha(6)beta(1), and heparan sulfate proteoglycans. In contrast, CCN3-induced cell migration is dependent on integrins alpha(v)beta(3) and alpha(5)beta(1), whereas alpha(6)beta(1) does not play a role in this process. Although CCN3 does not contain a RGD sequence, it binds directly to immobilized integrins alpha(v)beta(3) and alpha(5)beta(1), with half-maximal binding occurring at 10 nM and 50 nM CCN3, respectively. Furthermore, CCN3 induces neovascularization when implanted in rat cornea, demonstrating that it is a novel angiogenic inducer. Together, these findings show that CCN3 is a ligand of integrins alpha(v)beta(3) and alpha(5)beta(1), acts directly upon endothelial cells to stimulate pro-angiogenic activities, and induces angiogenesis in vivo.	Univ Illinois, Chicago Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Munin Corp, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Chicago Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA78044, CA80080, R01 CA046565, R01 CA046565-15, CA46565, CA91376] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA091376, R43CA078044, R01CA046565, R44CA078044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alini M, 1996, DEV BIOL, V176, P124, DOI 10.1006/dbio.1996.9989; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Chevalier G, 1998, AM J PATHOL, V152, P1563; Davis S, 1999, CURR TOP MICROBIOL, V237, P173; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Eliceiri BP, 2000, CANCER J, V6, pS245; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gattone VH, 2002, NEPHRON, V90, P267, DOI 10.1159/000049062; Ghitescu L, 2002, MICROSC RES TECHNIQ, V57, P381, DOI 10.1002/jemt.10091; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; HARLOW E, 1988, ANTIBODIES LAB MANUA, P314; Hirasaki S, 2001, HEPATOL RES, V19, P294, DOI 10.1016/S1386-6346(00)00101-7; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kocialkowski S, 2001, ANAT EMBRYOL, V203, P417, DOI 10.1007/s004290100177; Lafont J, 2002, J BIOL CHEM, V277, P41220, DOI 10.1074/jbc.M204405200; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Li CL, 2002, J CLIN PATHOL-MOL PA, V55, P250, DOI 10.1136/mp.55.4.250; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Martinerie C, 1996, ONCOGENE, V12, P1479; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Ribatti D, 2002, J HEMATOTH STEM CELL, V11, P81, DOI 10.1089/152581602753448559; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Scholz G, 1996, MOL CELL BIOL, V16, P481; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; STEPHENS LE, 1995, GENE DEV, V9, P1883, DOI 10.1101/gad.9.15.1883; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; Trepel M, 2002, CURR OPIN CHEM BIOL, V6, P399, DOI 10.1016/S1367-5931(02)00336-8; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG JT, 1993, DEVELOPMENT, V119, P1093	67	144	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24200	24208		10.1074/jbc.M302028200	http://dx.doi.org/10.1074/jbc.M302028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695522	hybrid			2022-12-25	WOS:000183638600126
J	Liu, X; Charrier, L; Gewirtz, A; Sitaraman, S; Merlin, D				Liu, X; Charrier, L; Gewirtz, A; Sitaraman, S; Merlin, D			CD98 and intracellular adhesion molecule I regulate the activity of amino acid transporter LAT-2 in polarized intestinal epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; SPECIFICITY; EXPRESSION; DOMAINS; FAMILY; ICAM-1	We have previously shown that the heterodimer CD98/LAT- 2 (LAT-2: amino acid transporter) is expressed in the basolateral membrane of intestinal epithelia and is associated with beta(1) integrin (Merlin, D., Sitaraman, S., Liu, X., Easterburn, K., Sun, J., Kucharzik, T., Lewis, B., and Madara, J. L. (2001) J. Biol. Chem. 276, 39282-39289). In the present study we examined the interaction of CD98/LAT2 with intracellular adhesion molecule I (ICAM-1) and the potential of such interaction on the activation of intracellular signal in Caco2-BBE cell monolayers. ICAM-1 was found to be expressed to the basolateral domain and to selectively coimmunoprecipitate with CD98/LAT-2 in Caco2-BBE monolayers. Using antibodies as ligands to CD98 and ICAM-1, we demonstrate that the basolateral cross-linking of CD98 and ICAM-1 differentially affects the intrinsic activity of the LAT-2 transporter. Whereas CD98 ligation decreases the K-m and V-m of the LAT-2 transporter, ICAM-1 ligation increases K-m and V-m of the amino acid transporter LAT-2. In addition, basolateral cross-linking of CD98 or ICAM-1 induces threonine phosphorylation of an similar to160-kDa supramolecular complex that is consistent with CD98/LAT-2-ICAM-1 complex. Together these findings demonstrate that (i) CD98/LAT- 2 interacts with ICAM-1 in Caco2-BBE cell monolayers, and (ii) CD98 and ICAM-1 ligands generate intracellular signals that regulate the amino acids transporter (LAT-2) activity. Our data provide a novel mechanism by which events such as adhesion may be integrated by amino acid transport activity resulting from the direct interaction of cell surface molecules such as CD98 and ICAM-1.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	Emory University; Emory University	Merlin, D (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 615 Michael St, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002802, K01DK002831] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-02831, DK-02802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Dong S, 1996, FEBS LETT, V395, P165, DOI 10.1016/0014-5793(96)01031-9; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fenczik CA, 2001, J BIOL CHEM, V276, P8746, DOI 10.1074/jbc.M011239200; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; KAISERLIAN D, 1991, EUR J IMMUNOL, V21, P2415, DOI 10.1002/eji.1830211018; Maruo Y, 2002, INT J CANCER, V100, P486, DOI 10.1002/ijc.10514; Merlin D, 1998, J CLIN INVEST, V102, P2011, DOI 10.1172/JCI4179; Merlin D, 2001, J BIOL CHEM, V276, P39282, DOI 10.1074/jbc.M105077200; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Verrey F, 2000, PFLUG ARCH EUR J PHY, V440, P503, DOI 10.1007/s004240050001; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	20	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23672	23677		10.1074/jbc.M302777200	http://dx.doi.org/10.1074/jbc.M302777200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12716892	hybrid			2022-12-25	WOS:000183638600059
J	Millholland, JM; Fitch, JM; Cai, CX; Gibney, EP; Beazley, KE; Linsenmayer, TF				Millholland, JM; Fitch, JM; Cai, CX; Gibney, EP; Beazley, KE; Linsenmayer, TF			Ferritoid, a tissue-specific nuclear transport protein for ferritin in corneal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED FENTON REACTIONS; GENE-EXPRESSION; DNA-DAMAGE; MONOCLONAL-ANTIBODIES; OXIDATIVE DAMAGE; CHAIN FERRITINS; LIVER FERRITIN; IMPORT PATHWAY; HORSE SPLEEN; H-CHAIN	Previously we reported that ferritin in corneal epithelial (CE) cells is a nuclear protein that protects DNA from UV damage. Since ferritin is normally cytoplasmic, in CE cells, a mechanism must exist that effects its nuclear localization. We have now determined that this involves a nuclear transport molecule we have termed ferritoid. Ferritoid is specific for CE cells and is developmentally regulated. Structurally, ferritoid contains multiple domains, including a functional SV40-type nuclear localization signal and a ferritin-like region of similar to50% similarity to ferritin itself. This latter domain is likely responsible for the interaction between ferritoid and ferritin detected by co-immunoprecipitation analysis. To test functionally whether ferritoid is capable of transporting ferritin into the nucleus, we performed co-transfections of COS-1 cells with constructs for ferritoid and ferritin. Consistent with the proposed nuclear transport function for ferritoid, co-transfections with full-length constructs for ferritoid and ferritin resulted in a preferential nuclear localization of both molecules; this was not observed when the nuclear localization signal of ferritoid was deleted. Moreover, since ferritoid is structurally similar to ferritin, it may be an example of a nuclear transporter that evolved from the molecule it transports (ferritin).	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Linsenmayer, TF (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Jaharis 329,150 Harrison Ave, Boston, MA 02111 USA.				NEI NIH HHS [EY13127] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013127] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alexandrov N. N., 1995, Pacific Symposium on Biocomputing '96, P53; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BALLA G, 1992, J BIOL CHEM, V267, P18148; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; BROXMEYER HE, 1991, P NATL ACAD SCI USA, V88, P770, DOI 10.1073/pnas.88.3.770; Broyles RH, 2001, P NATL ACAD SCI USA, V98, P9145, DOI 10.1073/pnas.151147098; Cai CX, 1997, J BIOL CHEM, V272, P12831, DOI 10.1074/jbc.272.19.12831; Cai CX, 2001, J CELL SCI, V114, P2327; Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GERL M, 1988, BIOCHEMISTRY-US, V27, P4089, DOI 10.1021/bi00411a027; GUTTERIDGE JMC, 1992, ANN NEUROL S, V32, P16; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HART RW, 1977, P NATL ACAD SCI USA, V74, P5574, DOI 10.1073/pnas.74.12.5574; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Henle ES, 1996, J BIOL CHEM, V271, P21177, DOI 10.1074/jbc.271.35.21177; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Kasetsuwan N, 1999, ARCH OPHTHALMOL-CHIC, V117, P649; LAVOIE DJ, 1978, BIOCHEMISTRY-US, V17, P5448, DOI 10.1021/bi00618a019; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; Luo YZ, 1996, J BIOL CHEM, V271, P21167, DOI 10.1074/jbc.271.35.21167; MELLO AC, 1991, MUTAT RES, V251, P109, DOI 10.1016/0027-5107(91)90220-I; MELLO AC, 1984, BIOCHEM J, V218, P273, DOI 10.1042/bj2180273; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakielny S, 1996, EXP CELL RES, V229, P261, DOI 10.1006/excr.1996.0369; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PASSANITI A, 1989, BIOCHEM J, V258, P413, DOI 10.1042/bj2580413; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Pountney D, 1999, J CELL SCI, V112, P825; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rubin BS, 1997, BRAIN RES, V770, P267, DOI 10.1016/S0006-8993(97)00879-2; Santambrogio P, 1997, BIOCHEM J, V322, P461, DOI 10.1042/bj3220461; SIDJANIN D, 1993, CURR EYE RES, V12, P773, DOI 10.3109/02713689309020382; SMOLIN G, 1987, CORNEA SCI FDN CLIN, P499; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; ZAK NB, 1983, DEV BIOL, V99, P373, DOI 10.1016/0012-1606(83)90287-7	43	25	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23963	23970		10.1074/jbc.M210050200	http://dx.doi.org/10.1074/jbc.M210050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697769	hybrid			2022-12-25	WOS:000183638600095
J	Lee, L; Chu, LCH; Sadowski, PD				Lee, L; Chu, LCH; Sadowski, PD			Cre induces an asymmetric DNA bend in its target loxP site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINATION SYNAPSE; INTEGRASE FAMILY; FLP PROTEIN; SEQUENCE; RESOLUTION; MECHANISM; INTERMEDIATE; SIMILARITIES; SPECIFICITY; CONTACTS	Cre initiates recombination by preferentially exchanging the bottom strands of the loxP site to form a Holliday intermediate, which is then resolved on the top strands. We previously found that the scissile AT and GC base pairs immediately 5' to the scissile phosphodiester bonds are critical in determining this order of strand exchange. We report here that the scissile base pairs also influence the Cre-induced DNA bends, the position of which correlates with the initial site of strand exchange. The binding of one Cre molecule to a loxP site induces a similar to35degrees asymmetric bend adjacent to the scissile GC base pair. The binding of two Cre molecules to a loxP site induces a similar to55degrees asymmetric bend near the center of the spacer region with a slight bias toward the scissile A. Lys-86, which contacts the scissile nucleotides, is important for establishing the bend near the scissile GC base pair when one Cre molecule is bound but has little role in positioning the bend when two Cre molecules are bound to a loxP site. We present a model relating the position of the Cre-induced bends to the order of strand exchange in the Cre-catalyzed recombination reaction.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.		Chu, Linda/V-2544-2019; Chu, Linda/AAD-5662-2019	Chu, Linda/0000-0002-7708-480X; Chu, Linda/0000-0001-9729-2756				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; BEATTY LG, 1988, J MOL BIOL, V204, P283, DOI 10.1016/0022-2836(88)90576-1; CRAIG NL, 1984, CELL, V39, P707, DOI 10.1016/0092-8674(84)90478-1; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P46; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAMILTON DL, 1984, J MOL BIOL, V178, P481, DOI 10.1016/0022-2836(84)90154-2; HOESS R, 1984, COLD SPRING HARB SYM, V49, P761, DOI 10.1101/SQB.1984.049.01.086; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOESS RH, 1990, NUCLEIC ACIDS MOL BI, V4, P99; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; Jayaram M., 2002, MOBILE DNA, P192; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Lee L, 2003, J MOL BIOL, V326, P397, DOI 10.1016/S0022-2836(02)01429-8; Lee L, 2001, J BIOL CHEM, V276, P31092, DOI 10.1074/jbc.M103739200; Luetke KH, 1998, NUCLEIC ACIDS RES, V26, P1401, DOI 10.1093/nar/26.6.1401; MACK A, 1992, NUCLEIC ACIDS RES, V20, P4451, DOI 10.1093/nar/20.17.4451; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; MEYERLEON L, 1988, MOL CELL BIOL, V8, P3784, DOI 10.1128/MCB.8.9.3784; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Ringrose L, 1998, J MOL BIOL, V284, P363, DOI 10.1006/jmbi.1998.2149; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; Shaikh AC, 2000, J BIOL CHEM, V275, P30186, DOI 10.1074/jbc.M005256200; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZWIEB C, 1989, GENE DEV, V3, P606, DOI 10.1101/gad.3.5.606	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23118	23129		10.1074/jbc.M302272200	http://dx.doi.org/10.1074/jbc.M302272200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686545	hybrid			2022-12-25	WOS:000183503900120
J	Bontemps, Y; Vuillermoz, B; Antonicelli, F; Perreau, C; Danan, JL; Maquart, FX; Wegrowski, Y				Bontemps, Y; Vuillermoz, B; Antonicelli, F; Perreau, C; Danan, JL; Maquart, FX; Wegrowski, Y			Specific protein-1 is a universal regulator of UDP-glucose dehydrogenase expression - Its positive involvement in transforming growth factor-beta signaling and inhibition in hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE DIPHOSPHOGLUCOSE DEHYDROGENASE; HEPARAN-SULFATE PROTEOGLYCANS; GENE-EXPRESSION; SMAD PROTEINS; TRANSCRIPTIONAL ACTIVATION; 5'-FLANKING REGION; MOLECULAR-CLONING; BINDING PROTEIN; COLLAGEN GENE; IN-VITRO	UDP-glucose dehydrogenase (UGDH) is a key enzyme of the unique pathway for the synthesis of UDP-glucuronate, the substrate for the numerous glucuronosyl transferases, which act on the synthesis of glycosaminoglycans and glucuronidation reaction of xeno- and endobiotics. Using the bacterial artificial chromosome approach, we have cloned and characterized the human UGDH promoter. The core promoter of -644 nucleotides conferred reporter gene activity in transient transfection assay of a variety of cell types, including MRC5 fibroblasts and the HepG2 hepatoma cell line. The minimal promoter of -100 nucleotides contains a functional inverted TATA box. No consensus CAAT sequence was found up to -2133 nucleotides. The expression of UGDH was up- and down-regulated by transforming growth factor (TGF)-beta and hypoxia, respectively. TGF-beta enhanced the activity of all the deletion constructs, except the minimal promoter. Hypoxia slightly increased the activity of the short promoter-containing constructs but decreased that of the -374 nucleotides and core promoter constructs. The core promoter contained numerous GC-rich sequences for the binding of Sp1 transcription factor. Bisanthracycline, an anti-Sp1 compound, decreased UGDH mRNA expression and inhibited the core promoter constructs activity. Gel mobility shift and supershift assays after TGF-beta stimulation demonstrated an increased DNA binding of the nuclear extract proteins to the two Sp1 sequences located in the -374-bp promoter. By contrast, nuclear extract proteins from hypoxia-treated cells demonstrated a decreased binding of the consensus Sp1 sequence. These results indicate that numerous Sp1 cis-acting sequences of the UGDH core promoter are responsible for up- and down-regulation of the gene after TGF-beta stimulation and in hypoxic conditions, respectively.	Fac Med, Biochem Lab, CNRS, Format Rech Evolut 2534, F-51095 Reims, France; CNRS, UPR 9078, F-92120 Meudon, France	Centre National de la Recherche Scientifique (CNRS); Universite de Reims Champagne-Ardenne; Centre National de la Recherche Scientifique (CNRS)	Wegrowski, Y (corresponding author), Fac Med, Biochem Lab, CNRS, Format Rech Evolut 2534, 51 Rue Cognacq Jay, F-51095 Reims, France.							Ambhaikar M, 1999, MOL REPROD DEV, V52, P360, DOI 10.1002/(SICI)1098-2795(199904)52:4<360::AID-MRD4>3.0.CO;2-I; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; Benevolenskaya EV, 1998, MOL GEN GENET, V260, P131, DOI 10.1007/s004380050879; Binari RC, 1997, DEVELOPMENT, V124, P2623; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Bontemps Y, 2000, BIOCHEM BIOPH RES CO, V275, P981, DOI 10.1006/bbrc.2000.3389; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; Cutroneo KR, 2000, MOL BIOL REP, V27, P191, DOI 10.1023/A:1007206014638; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dubbink HJ, 1999, GENE, V240, P261, DOI 10.1016/S0378-1119(99)00454-0; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; Figueroa JE, 1999, ATHEROSCLEROSIS, V143, P135, DOI 10.1016/S0021-9150(98)00292-5; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAINEY PA, 1972, BIOCHEM J, V128, P215, DOI 10.1042/bj1280215; GRANT S, 1995, LEUKEMIA, V9, P808; GRUBB MF, 1993, BIOCHEM MOL BIOL INT, V30, P819; Hapgood JP, 2001, CELL BIOL INT, V25, P17, DOI 10.1006/cbir.2000.0674; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KARLINSKY JB, 1992, CIRC RES, V71, P782, DOI 10.1161/01.RES.71.4.782; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; KIM Y, 1995, BIOL CHEM H-S, V376, P431; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lapointe J, 1999, ENDOCRINOLOGY, V140, P4486, DOI 10.1210/en.140.10.4486; Marcu O, 1999, CYTOGENET CELL GENET, V86, P244, DOI 10.1159/000015350; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Park IK, 2000, BBA-GENE STRUCT EXPR, V1490, P302, DOI 10.1016/S0167-4781(99)00246-8; Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Saito T, 2001, J BIOL CHEM, V276, P38010; SCOTT JE, 1988, J ANAT, V158, P95; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; TAVIANINI MA, 1984, J BIOL CHEM, V259, P1798; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; VANOOIJ C, 1992, MOL CELL BIOL, V12, P3023, DOI 10.1128/MCB.12.7.3023; Venkatasubbarao K, 2001, CANCER RES, V61, P6239; Verrecchia F, 2001, J INVEST DERMATOL, V116, P755, DOI 10.1046/j.1523-1747.2001.01326.x; Walsh EC, 2001, SCIENCE, V293, P1670, DOI 10.1126/science.293.5535.1670; WASTESON A, 1973, BIOCHEM J, V136, P1069, DOI 10.1042/bj1361069; Wegrowski Y, 1998, BIOCHEM BIOPH RES CO, V250, P206, DOI 10.1006/bbrc.1998.9262; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316	59	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21566	21575		10.1074/jbc.M209366200	http://dx.doi.org/10.1074/jbc.M209366200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12682078	hybrid			2022-12-25	WOS:000183354200033
J	Roussigne, M; Cayrol, C; Clouaire, T; Amalric, F; Girard, JP				Roussigne, M; Cayrol, C; Clouaire, T; Amalric, F; Girard, JP			THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies	ONCOGENE			English	Article						PML nuclear bodies; Par-4; apoptosis; nuclear proteins; protein interaction	BINDING-PROTEIN; DOWN-REGULATION; DLK/ZIP KINASE; EXPRESSION; DAXX; APOPTOSIS; LOCALIZATION; PATHWAY; REPRESSOR; ISOFORMS	Promyelocytic leukemia (PML) nuclear bodies (PML NBs) are discrete subnuclear domains organized by the promyelocytic leukemia protein PML, a tumor suppressor essential for multiple apoptotic pathways. We have recently described a novel family of cellular factors, the THAP proteins, characterized by the presence at their amino-terminus of an evolutionary conserved putative DNA-binding motif, designated THAP domain. Here, we report that THAP1 is a novel nuclear proapoptotic factor associated with PML NBs, which potentiates both serum withdrawal- and TNFalpha-induced apoptosis, and interacts with prostate-apoptosis-response-4 (Par-4), a well characterized proapoptotic factor, previously linked to prostate cancer and neurodegenerative diseases. We show that endogenous Par-4 colocatizes with ectopic THAP1 within PML NBs in primary endothelial cells and fibroblasts. In addition, we found that Par-4 is a component of PML NBs in blood vessels, a major site of PML expression in vivo. Finally, we investigated the role of the THAP domain in THAP1 activities and found that this putative DNA-binding domain is not required for Par-4 binding and localization within PML NBs, but is essential for THAP1 proapoptotic activity. Together, our results provide an unexpected link between a nuclear factor of the THAP family, the proapoptotic protein Par-4 and PML nuclear bodies.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, Lab Biol Vasc, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Girard, JP (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, Lab Biol Vasc, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	GIRARD, Jean-Philippe/F-5229-2010; CAYROL, Corinne/C-2106-2011; CLOUAIRE, THOMAS/L-7396-2017	GIRARD, Jean-Philippe/0000-0002-9154-1691; CAYROL, Corinne/0000-0002-7813-4397; CLOUAIRE, THOMAS/0000-0003-3238-1496; Roussigne, Myriam/0000-0002-4240-4105				Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Hofmann T.G., 2001, NAT CELL BIOL, V10, P10; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Mattson MP, 1999, J MOL NEUROSCI, V13, P17, DOI 10.1385/JMN:13:1-2:17; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; ROUSSIGNE M, 2003, IN PRESS TRENDS BIOC; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	49	113	122	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2432	2442		10.1038/sj.onc.1206271	http://dx.doi.org/10.1038/sj.onc.1206271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717420				2022-12-25	WOS:000182383500006
J	Zhou, CY; Smith, JL; Liu, JS				Zhou, CY; Smith, JL; Liu, JS			Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1	ONCOGENE			English	Article						ovarian cancer; BRCA1; cell cycle; ionizing radiation; paclitaxel	TUMOR-SUPPRESSOR GENE; MUTATION; CYCLE; CARCINOMA; BREAST; P53; PHOSPHORYLATION; AMPLIFICATION; ASSOCIATION; INHIBITOR	BRCA1, the gene responsible for approximately half of all cases of hereditary breast cancer and almost all cases of combined hereditary breast and ovarian cancer, has been implicated in the maintenance of genomic stability through DNA repair. This function is mediated, at least in part, through two tandem BRCA1 C-terminal (BRCT) repeats. The role of BRCA1 in the develepment of ovarian cancer is poorly understood, partially owing to the lack of ovarian cancer cell lines with defective BRCA1 The purpose of this study was to further characterize an endometrioid ovarian cancer cell line, SNU-251, which was previously reported to carry a nonsense mutation (from G to A) at amino acid 1815 of BRCA1. In addition, we examined the role of BRCA1 in the cell cycle and in the responses to the chemotherapy drug paclitaxel and ionizing radiation. Loss of the C-terminal 49 amino acids due to this point mutation did not affect the expression of the truncated BRCA1 protein, but caused a loss of transcriptional activation of the endogenous p21(WAF1/CIP1) gene, and could not sustain arrest in the G(2)/M phase of the cell cycle. The BRCA1 mutation in SNU-251 cells inhibited BRCA1 subnuclear assembly for DNA-damage repair and increased cellular sensitivity to ionizing radiation and paclitaxel. This sensitivity was reversed by reintroduction of ectopic wild-type BRCA1 Our results suggest that the deletion of the C-terminal 49 amino acids of BRCA1 results in a loss of BRCA1 function in the SNU-251 cell line. BRCA1 helps to mediate the resistance to both radiation and paclitaxel. Therefore, SNU-251 may be a useful model for studying the molecular mechanism of BRCA1 in the resistance of ovarian cancer to ionizing radiation and chemotherapy treatment and in the development of hereditary human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med,Unit 85, Houston, TX 77030 USA; Dynagene, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Liu, JS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med,Unit 85, 1515 Holcomber Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org						Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Liu JS, 2000, ONCOGENE, V19, P2767, DOI 10.1038/sj.onc.1203599; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PARK JG, 2002, J J CANC CHEMOTHE S1, V29, P89; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Sato N, 2000, CANCER RES, V60, P7052; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun HB, 2001, AM J CLIN PATHOL, V115, P32; To MD, 1998, AM J PATHOL, V153, P47, DOI 10.1016/S0002-9440(10)65544-7; Tomlinson GE, 1998, CANCER RES, V58, P3237; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yan T, 2001, CANCER RES, V61, P8290; Yuan Y, 1997, GYNECOL ONCOL, V66, P378, DOI 10.1006/gyno.1997.4785; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	34	60	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2396	2404		10.1038/sj.onc.1206319	http://dx.doi.org/10.1038/sj.onc.1206319			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717416				2022-12-25	WOS:000182383500002
J	Benezra, M; Chevallier, N; Morrison, DJ; MacLachlan, TK; El-Deiry, WS; Licht, JD				Benezra, M; Chevallier, N; Morrison, DJ; MacLachlan, TK; El-Deiry, WS; Licht, JD			BRCA1 augments transcription by the NF-kappa B transcription factor by binding to the rel domain of the p65/RelA subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-PREDISPOSING MUTATIONS; BREAST-CANCER; CELL-CYCLE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; LIGASE ACTIVITY; T-LYMPHOCYTES; RING FINGER; FAS-LIGAND; PROTEIN	BRCA1 is a tumor suppressor gene mutated in cases of hereditary breast and ovarian cancer. BRCA1 protein is involved in apoptosis and growth/tumor suppression. In this study, we present evidence that p65/RelA, one of the two subunits of the transcription factor NF-kappaB, binds to the BRCA1 protein. Treatment of 293T cells with the cytokine tumor necrosis factor-alpha induces an interaction between endogenous p65/RelA and BRCA1. GST-protein affinity assay experiments reveal that the Rel homology domain of the p65/RelA subunit of NF-kappaB interacts with multiple sites within the N-terminal region of BRCA1. Transient transfection of BRCA1 significantly enhances the ability of the tumor necrosis factor-alpha or interleukin-1beta to activate transcription from the promoters of NF-kappaB target genes. Mutation of the NF-kappaB-binding sites in the NF-kappaB reporter blocks the effect of BRCA1 on transcription. Also the ability of BRCA1 to activate NF-kappaB target genes is inhibited by a super-stable inhibitor of NF-kappaB and by the chemical inhibitor SN-50. These data indicate that BRCA1 acts as a co-activator with NF-kappaB. In addition, we show that cells infected with an adenovirus expressing BRCA1 up-regulate the endogenous expression of NF-kappaB target genes Fas and interferon-beta. Together, this information suggests that BRCA1 may play a role in cell life-death decisions following cell stress by modulation of the activity of NF-kappaB.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of Pennsylvania	Licht, JD (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1130, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Licht, Jonathan/L-4239-2019	El-Deiry, Wafik/0000-0002-9577-8266; Chevallier, Nathalie/0000-0002-1800-2579; Licht, Jonathan/0000-0002-3942-1369; Morrison, Debra/0000-0002-8265-5910	NATIONAL CANCER INSTITUTE [R01CA094975] Funding Source: NIH RePORTER; NCI NIH HHS [CA80058, CA94975] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bours V, 2000, TOXICOLOGY, V153, P27, DOI 10.1016/S0300-483X(00)00302-4; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2002, CANCER RES, V62, P4222; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dong G, 1999, CANCER RES, V59, P3495; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Felinski EA, 2001, P NATL ACAD SCI USA, V98, P13078, DOI 10.1073/pnas.241337698; Foo SY, 1999, TRENDS GENET, V15, P229; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hottiger MO, 2000, TRENDS MICROBIOL, V8, P560, DOI 10.1016/S0966-842X(00)01874-6; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kitajima I, 1996, J BONE MINER RES, V11, P200; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Schmid RM, 2000, GASTROENTEROLOGY, V118, P1208, DOI 10.1016/S0016-5085(00)70374-X; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Weber BL, 1998, RECENT RESULTS CANC, V152, P49; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	64	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26333	26341		10.1074/jbc.M303076200	http://dx.doi.org/10.1074/jbc.M303076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12700228	hybrid			2022-12-25	WOS:000184155700008
J	Rovner, AS; Fagnant, PM; Trybus, KM				Rovner, AS; Fagnant, PM; Trybus, KM			The two heads of smooth muscle myosin are enzymatically independent but mechanically interactive	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; BETA-CARDIAC MYOSIN; HEAVY-CHAIN; SHORTENING VELOCITY; IN-VITRO; FUNCTIONAL TRANSITIONS; ACTIN-FILAMENTS; MOTOR DOMAIN; F-ACTIN; BINDING	The interaction between the two heads of myosin II during motion and force production is poorly understood. To examine this issue, we developed an expression and purification strategy to isolate homogeneous populations of heterodimeric smooth muscle heavy meromyosins containing heads with different properties. As an extreme example, we characterized a heterodimer containing one native head and one head locked in a "weak binding" state by a point mutation in switch 2 (E470A). The in vitro actin filament motility of this heterodimer was the same as the homodimeric control with two cycling heads, suggesting that only one head of a pair actively interacts with actin to generate maximal velocity. A second naturally occurring heterodimer contained two cycling heads with 2-fold different activity, due to the presence or absence of a 7-amino acid insert near the active site. Enzymatically this (+/-) insert heterodimer was indistinguishable from a ( 50: 50) mixture of the two homodimers, but its motility averaged 17% less than that of the mixture. These data suggest that one head of a heterodimer can disproportionately affect the mechanics of double-headed myosin, a finding relevant to our understanding of heterozygous mutant myosins found in disease states like familial hypertrophic cardiomyopathy.	Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Rovner, AS (corresponding author), Univ Vermont, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL59408] Funding Source: Medline; NIAMS NIH HHS [AR47906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; Babu GJ, 2001, NAT CELL BIOL, V3, P1025, DOI 10.1038/ncb1101-1025; Bing W, 2000, BIOCHEM J, V350, P693, DOI 10.1042/0264-6021:3500693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Conibear PB, 1999, J MUSCLE RES CELL M, V20, P727, DOI 10.1023/A:1005696017544; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; Eddinger TJ, 2001, AM J PHYSIOL-CELL PH, V280, pC309, DOI 10.1152/ajpcell.2001.280.2.C309; Geeves MA, 2002, BIOPHYS J, V82, p374A; GREENE LE, 1981, BIOCHEMISTRY-US, V20, P2120, DOI 10.1021/bi00511a008; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; Joel PB, 2001, J BIOL CHEM, V276, P2998, DOI 10.1074/jbc.M006930200; Kad NM, 2003, BIOPHYS J, V84, p328A; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LITTEN RZ, 1985, CIRC RES, V57, P406, DOI 10.1161/01.RES.57.3.406; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; Meer DP, 2002, BIOPHYS J, V82, p411A; Onishi H, 1998, P NATL ACAD SCI USA, V95, P6653, DOI 10.1073/pnas.95.12.6653; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Palmiter KA, 2000, J MUSCLE RES CELL M, V21, P609, DOI 10.1023/A:1005678905119; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Sweeney HL, 2000, J BIOL CHEM, V275, P41273, DOI 10.1074/jbc.M008310200; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; Tyska MJ, 1999, P NATL ACAD SCI USA, V96, P4402, DOI 10.1073/pnas.96.8.4402; VANBUREN P, 1995, CIRC RES, V77, P439, DOI 10.1161/01.RES.77.2.439; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Yamashita H, 2000, J BIOL CHEM, V275, P28045; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	39	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26938	26945		10.1074/jbc.M303122200	http://dx.doi.org/10.1074/jbc.M303122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12709440	hybrid			2022-12-25	WOS:000184155700083
J	Nam, JO; Kim, JE; Jeong, HW; Lee, SJ; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS				Nam, JO; Kim, JE; Jeong, HW; Lee, SJ; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS			Identification of the alpha(v)beta(3) integrin-interacting motif of beta ig-h3 and its anti-angiogenic effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-IG-H3; CELL-ADHESION; RGD PEPTIDES; TUMOR-GROWTH; CYCLIC RGD; IN-VITRO; DOMAINS; RECEPTOR; MOLECULE; AFFINITY	betaig-h3 is an extracellular matrix protein that mediates adhesion and migration of several cell types through interaction with integrins. In the present study, we tested whether betaig-h3 mediates endothelial cell adhesion and migration, thereby regulating angiogenesis. In this study, we demonstrate that not only betaig-h3 itself but also all four fas-1 domains of betaig-h3 mediate endothelial cell adhesion and migration through interaction with the alpha(v)beta(3) integrin. We found that the alpha(v)beta(3) integrin-interacting motif of the four fas-1 domains of betaig-h3 is the same YH motif that we reported previously to interact with alpha(v)beta(5) integrin. The YH peptide inhibited endothelial cell adhesion and migration in a dose-dependent manner. We demonstrate that the YH peptide has anti-angiogenic activity in vitro and in vivo using an endothelial cell tube formation assay and a Matrigel plug assay, respectively. Our results reveal that betaig-h3 bears alpha(v)beta(3) integrin-interacting motifs that mediate endothelial cell adhesion and migration and, therefore, may regulate angiogenesis.	Kyungpook Natl Univ, Sch Med, Dept Biochem, Cell & Matrix Biol Natl Res Lab, Taegu 700422, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu 700422, South Korea	Kyungpook National University; Kyungpook National University	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem, Cell & Matrix Biol Natl Res Lab, 101 Dongin Dong, Taegu 700422, South Korea.	iskim@knu.ac.kr	김, 인산/I-8988-2014					Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Bae JS, 2002, BIOCHEM BIOPH RES CO, V294, P940, DOI 10.1016/S0006-291X(02)00576-4; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHAUVIN MF, 1994, J BIOL CHEM, V269, P26025; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Eliceiri BP, 2000, CANCER J, V6, pS245; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Ha SW, 2003, J CELL BIOCHEM, V88, P774, DOI 10.1002/jcb.10374; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2003, ONCOGENE, V22, P2045, DOI 10.1038/sj.onc.1206269; Kim JE, 2002, J BIOL CHEM, V277, P46159, DOI 10.1074/jbc.M207055200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kumar CC, 2001, CANCER RES, V61, P2232; Locardi E, 1999, J PEPT SCI, V5, P491, DOI 10.1002/(SICI)1099-1387(199911)5:11<491::AID-PSC218>3.0.CO;2-8; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maile LA, 2002, J BIOL CHEM, V277, P1800, DOI 10.1074/jbc.M108380200; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Xiao Y, 1996, BIOPHYS J, V71, P2869, DOI 10.1016/S0006-3495(96)79484-5	26	115	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25902	25909		10.1074/jbc.M300358200	http://dx.doi.org/10.1074/jbc.M300358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12704192	hybrid			2022-12-25	WOS:000183920200081
J	Yeo, M; Lin, PS; Dahmus, ME; Gill, GN				Yeo, M; Lin, PS; Dahmus, ME; Gill, GN			A novel RNA polymerase IIC-terminal domain phosphatase that preferentially dephosphorylates serine 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CAPPING ENZYME; PROLYL ISOMERASE; CTD PHOSPHATASE; DXDX(T/V) MOTIF; CONSERVED GENE; DISTINCT ROLES; SUBUNIT-IIA; TRANSCRIPTION	The transcription and processing of pre-mRNA in eukaryotic cells are regulated in part by reversible phosphorylation of the C-terminal domain of the largest RNA polymerase (RNAP) II subunit. The CTD phosphatase, FCP1, catalyzes the dephosphorylation of RNAP II and is thought to play a major role in polymerase recycling. This study describes a family of small CTD phosphatases (SCPs) that preferentially catalyze the dephosphorylation of Ser(5) within the consensus repeat. The preferred substrate for SCP1 is RNAP II phosphorylated by TFIIH. Like FCP1, the activity of SCP1 is enhanced by the RAP74 subunit of TFIIF. Expression of SCP1 inhibits activated transcription from a number of promoters, whereas a phosphatase-inactive mutant of SCP1 enhances transcription. Accordingly, SCP1 may play a role in the regulation of gene expression, possibly by controlling the transition from initiation/capping to processive transcript elongation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California San Diego; University of California System; University of California Davis	Gill, GN (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ggill@ucsd.edu	Harrison, Sue Therese/HHZ-9414-2022; Harrison, Susan T L/A-9803-2017	Harrison, Sue Therese/0000-0002-2268-3506; 	NIDDK NIH HHS [DK13149] Funding Source: Medline; NIGMS NIH HHS [GM33300] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Archambault J, 1997, P NATL ACAD SCI USA, V94, P14300, DOI 10.1073/pnas.94.26.14300; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; GERARD M, 1991, J BIOL CHEM, V266, P20940; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hirose Y, 2000, GENE DEV, V14, P1415; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; Ishikawa S, 1997, DNA Res, V4, P35, DOI 10.1093/dnares/4.1.35; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 2000, MOL CELL BIOL, V20, P7438, DOI 10.1128/MCB.20.20.7438-7449.2000; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kops O, 2002, FEBS LETT, V513, P305, DOI 10.1016/S0014-5793(02)02288-3; Lin PS, 2002, J BIOL CHEM, V277, P45949, DOI 10.1074/jbc.M208588200; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Majello B, 2001, FRONT BIOSCI-LANDMRK, V6, pD1358, DOI 10.2741/Majello; Marquet S, 2000, MAMM GENOME, V11, P755, DOI 10.1007/s003350010151; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Siniossoglou S, 2000, J BIOL CHEM, V275, P19352, DOI 10.1074/jbc.M001314200; Siniossoglou S, 1998, EMBO J, V17, P6449, DOI 10.1093/emboj/17.22.6449; Stiller JW, 2002, P NATL ACAD SCI USA, V99, P6091, DOI 10.1073/pnas.082646199; Su YA, 1997, ONCOGENE, V15, P1289, DOI 10.1038/sj.onc.1201294; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; WEST ML, 1995, GENETICS, V140, P1223; Wu XY, 2000, EMBO J, V19, P3727, DOI 10.1093/emboj/19.14.3727; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898; ZHANG J, 1991, J BIOL CHEM, V266, P2290; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zohn IE, 2001, DEV BIOL, V239, P118, DOI 10.1006/dbio.2001.0420	53	164	171	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26078	26085		10.1074/jbc.M301791200	http://dx.doi.org/10.1074/jbc.M301791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12721286	hybrid			2022-12-25	WOS:000183920200105
J	Ishihara, K; Yamagishi, N; Saito, Y; Adachi, H; Kobayashi, Y; Sobue, G; Ohtsuka, K; Hatayama, T				Ishihara, K; Yamagishi, N; Saito, Y; Adachi, H; Kobayashi, Y; Sobue, G; Ohtsuka, K; Hatayama, T			Hsp105 alpha suppresses the aggregation of truncated androgen receptor with expanded CAG repeats and cell toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; BULBAR MUSCULAR-ATROPHY; TRANSGENIC MOUSE MODEL; CREB-BINDING PROTEIN; POLYGLUTAMINE TOXICITY; CHAPERONE SUPPRESSION; MOLECULAR CHAPERONES; HSP70; CLONING; EXPRESSION	Spinal and bulbar muscular atrophy (SBMA) is a neurodegenerative disorder caused by the expansion of a polyglutamine tract in the androgen receptor (AR). The N-terminal fragment of AR containing the expanded polyglutamine tract aggregates in cytoplasm and/or in nucleus and induces cell death. Some chaperones such as Hsp40 and Hsp70 have been identified as important regulators of polyglutamine aggregation and/or cell death in neuronal cells. Recently, Hsp105alpha, expressed at especially high levels in mammalian brain, has been shown to suppress apoptosis in neuronal cells and prevent the aggregation of protein caused by heat shock in vitro. However, its role in polyglutamine-mediated cell death and toxicity has not been studied. In the present study, we examined the effects of Hsp105alpha on the aggregation and cell toxicity caused by expansion of the polyglutamine tract using a cellular model of SBMA. The transient expression of truncated ARs (tARs) containing an expanded polyglutamine tract caused aggregates to form in COS-7 and SK-N-SH cells and concomitantly apoptosis in the cells with the nuclear aggregates. When Hsp105alpha was overexpressed with tAR97 in the cells, Hsp105alpha was colocalized to aggregates of tAR97, and the aggregation and cell toxicity caused by expansion of the polyglutamine tract were markedly reduced. Both beta-sheet and beta-helix domains, but not the ATPase domain, of Hsp105alpha were necessary to suppress the formation of aggregates in vivo and in vitro. Furthermore, Hsp105alpha was found to localize in nuclear inclusions formed by ARs containing an expanded polyglutamine tract in tissues of patients and transgenic mice with SBMA. These findings suggest that overexpression of Hsp105alpha suppresses cell death caused by expansion of the polyglutamine tract without chaperone activity, and the enhanced expression of the essential domains of Hsp105alpha in brain may provide an effective therapeutic approach for CAG repeat diseases.	Kyoto Pharmaceut Univ, Dept Biochem, Yamashima Ku, Kyoto 6078414, Japan; Nagoya Univ, Dept Neurol, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Chubu Univ, Dept Environm Biol, Coll Biosci & Biotechnol, Kasugai, Aichi 4878501, Japan	Kyoto Pharmaceutical University; Nagoya University; Chubu University	Hatayama, T (corresponding author), Kyoto Pharmaceut Univ, Dept Biochem, Yamashima Ku, 5 Nakauchi Cho, Kyoto 6078414, Japan.	hatayama@mb.kyoto-phu.ac.jp	Adachi, Hiroaki/AAM-7812-2020	Adachi, Hiroaki/0000-0002-9302-4663; Ishihara, Keiichi/0000-0001-8748-7218; Saito, Youhei/0000-0002-8545-6925				Adachi H, 2003, J NEUROSCI, V23, P2203; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chai YH, 1999, J NEUROSCI, V19, P10338; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hatayama T, 2001, BIOCHEM BIOPH RES CO, V288, P528, DOI 10.1006/bbrc.2001.5802; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HONDA K, 1989, BIOCHEM BIOPH RES CO, V160, P60, DOI 10.1016/0006-291X(89)91620-3; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Ishihara K, 1999, BBA-GENE STRUCT EXPR, V1444, P138, DOI 10.1016/S0167-4781(98)00254-1; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; MUKAI H, 1993, GENE, V132, P57; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Nagai Y, 2000, J BIOL CHEM, V275, P10437, DOI 10.1074/jbc.275.14.10437; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Plesofsky-Vig N, 1998, J BIOL CHEM, V273, P11335, DOI 10.1074/jbc.273.18.11335; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Schulz JB, 1999, CURR OPIN NEUROL, V12, P433, DOI 10.1097/00019052-199908000-00010; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Storozhenko S, 1996, FEBS LETT, V390, P113, DOI 10.1016/0014-5793(96)00640-0; Wakatsuki T, 1998, BIOL PHARM BULL, V21, P905; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Welch WJ, 1998, NATURE, V392, P23, DOI 10.1038/32049; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yamagishi N, 2000, BIOCHEM BIOPH RES CO, V272, P850, DOI 10.1006/bbrc.2000.2864; YASUDA K, 1995, J BIOL CHEM, V270, P29718, DOI 10.1074/jbc.270.50.29718; Yasuda S, 1999, GENES CELLS, V4, P743, DOI 10.1046/j.1365-2443.1999.00294.x; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	58	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25143	25150		10.1074/jbc.M302975200	http://dx.doi.org/10.1074/jbc.M302975200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714591	hybrid			2022-12-25	WOS:000183824800108
J	Nonaka, T; Fujihashi, M; Kita, A; Hagihara, H; Ozaki, K; Ito, S; Miki, K				Nonaka, T; Fujihashi, M; Kita, A; Hagihara, H; Ozaki, K; Ito, S; Miki, K			Crystal structure of calcium-free alpha-amylase from Bacillus sp strain KSM-K38 (AmyK38) and its sodium ion binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MODEL REFINEMENT; AMINO-ACID-SEQUENCE; X-RAY-DIFFRACTION; PYROCOCCUS-FURIOSUS; RESOLUTION; ENZYMES; TVAII	The crystal structure of a calcium-free alpha-amylase (AmyK38) from Bacillus sp. strain KSM-K38, which resists chelating reagents and chemical oxidants, has been determined by the molecular replacement method and refined to a crystallographic R-factor of 19.9% (R-free of 23.2%) at 2.13-Angstrom resolution. The main chain folding of AmyK38 is almost homologous to that of Bacillus licheniformis alpha-amylase. However, neither a highly conserved calcium ion, which is located at the interface between domains A and B, nor any other calcium ions appear to exist in the AmyK38 molecule, although three sodium ions were found, one of which is located at the position corresponding to that of a highly conserved calcium ion of other alpha-amylases. The existence of these sodium ions was crystallographically confirmed by the structures of three metal-exchanged and mutated enzymes. This is the first case in which the structure of the calcium-free alpha-amylase has been determined by crystallography, and it was suggested that these sodium ions, instead of calcium ions, are used to retain the structure and function of AmyK38.	Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Kao Corp, Biol Sci Labs, Haga, Tochigi 3213497, Japan; Japan Marine Sci & Technol Ctr, Kanagawa 2370061, Japan; RIKEN, Harima Inst SPring 8, Mikazuki, Hyogo 6795148, Japan	Kyoto University; KAO Corporation; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); RIKEN	Miki, K (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.	miki@kuchem.kyoto-u.ac.jp						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; Dong GQ, 1997, APPL ENVIRON MICROB, V63, P3569, DOI 10.1128/AEM.63.9.3569-3576.1997; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Hagihara H, 2001, APPL ENVIRON MICROB, V67, P1744, DOI 10.1128/AEM.67.4.1744-1750.2001; Hagihara H, 2001, EUR J BIOCHEM, V268, P3974, DOI 10.1046/j.1432-1327.2001.02308.x; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V248, P372, DOI 10.1006/bbrc.1998.8970; Ito S, 1998, EXTREMOPHILES, V2, P185, DOI 10.1007/s007920050059; Janecek S, 1997, J MOL EVOL, V45, P322, DOI 10.1007/PL00006236; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; Kamitori S, 1999, J MOL BIOL, V287, P907, DOI 10.1006/jmbi.1999.2647; Kamitori S, 2002, J MOL BIOL, V318, P443, DOI 10.1016/S0022-2836(02)00111-0; KIM CH, 1995, EUR J BIOCHEM, V227, P687, DOI 10.1111/j.1432-1033.1995.tb20189.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Lecker DN, 1998, BIOTECHNOL PROGR, V14, P621, DOI 10.1021/bp980024y; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; Machius M, 1998, STRUCTURE, V6, P281, DOI 10.1016/S0969-2126(98)00032-X; MATSUURA Y, 1980, J BIOCHEM-TOKYO, V87, P1555, DOI 10.1093/oxfordjournals.jbchem.a132896; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORANELLI F, 1987, BIOCHEM CELL BIOL, V65, P899, DOI 10.1139/o87-116; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nielsen JE, 2000, BBA-PROTEIN STRUCT M, V1543, P253, DOI 10.1016/S0167-4838(00)00240-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Savchenko A, 2002, BIOCHEMISTRY-US, V41, P6193, DOI 10.1021/bi012106s; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; VALLEE BL, 1959, J BIOL CHEM, V234, P2901; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665	36	39	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24818	24824		10.1074/jbc.M212763200	http://dx.doi.org/10.1074/jbc.M212763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12719434	hybrid			2022-12-25	WOS:000183824800069
J	Schadel, SA; Heck, M; Maretzki, D; Filipek, S; Teller, DC; Palczewski, K; Hofmann, KP				Schadel, SA; Heck, M; Maretzki, D; Filipek, S; Teller, DC; Palczewski, K; Hofmann, KP			Ligand channeling within a G-protein-coupled receptor - The entry and exit of retinals in native opsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; METARHODOPSIN-II; BINDING-PROTEIN; RHODOPSIN; ACTIVATION; MECHANISM; COMPLEX; PHOTOTRANSDUCTION	Deactivation of light-activated rhodopsin (metarhodopsin II) involves, after rhodopsin kinase and arrestin interactions, the hydrolysis of the covalent bond of all-trans-retinal to the apoprotein. Although the long-lived storage form metarhodopsin III is transiently formed, all-trans-retinal is eventually released from the active site. Here we address the question of whether the release results in a retinal that is freely diffusible in the lipid phase of the photoreceptor membrane. The release reaction is accompanied by an increase in intrinsic protein fluorescence (release signal), which arises from the relief of the fluorescence quenching imposed by the retinal in the active site. An analogous fluorescence decrease (uptake signal) was evoked by exogenous retinoids when they non-covalently bound to native opsin membranes. Uptake of 11-cis-retinal was faster than formation of the retinylidene linkage to the apoprotein. Endogenous all-trans-retinal released from the active site during metarhodopsin II decay did not generate the uptake signal. The data show that in addition to the retinylidene pocket (site I) there are two other retinoid-binding sites within opsin. Site II involved in the uptake signal is an entrance site, while the exit site (site III) is occupied when retinal remains bound after its release from site I. Support for a retinal channeling mechanism comes from the rhodopsin crystal structure, which unveiled two putative hydrophobic binding sites. This mechanism enables a unidirectional process for the release of photoisomerized chromophore and the uptake of newly synthesized 11-cis-retinal for the regeneration of rhodopsin.	Humboldt Univ, Inst Med Phys & Biophys, Klinikum Charite, D-10098 Berlin, Germany; Univ Warsaw, Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Univ Warsaw, Dept Chem, PL-02109 Warsaw, Poland; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hofmann, KP (corresponding author), Humboldt Univ, Inst Med Phys & Biophys, Klinikum Charite, Schumannstr 20-21, D-10098 Berlin, Germany.		Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NEI NIH HHS [EY09339, R01 EY009339] Funding Source: Medline; NIGMS NIH HHS [R01 GM063020, GM-63020] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063020] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DAEMEN FJM, 1978, NATURE, V276, P847, DOI 10.1038/276847a0; DeGrip W J, 1999, Novartis Found Symp, V224, P102; DEGRIP WJ, 1999, NOVART FDN SYMP, V224, P118; EBREY TG, 1971, P NATL ACAD SCI USA, V68, P713, DOI 10.1073/pnas.68.4.713; EBREY TG, 1972, PHOTOCHEM PHOTOBIOL, V15, P585, DOI 10.1111/j.1751-1097.1972.tb06269.x; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FUKADA Y, 1981, BIOCHIM BIOPHYS ACTA, V675, P195, DOI 10.1016/0304-4165(81)90226-9; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hofmann K P, 1999, Novartis Found Symp, V224, P158; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HOFMANN KP, 1999, NOVART FDN SYMP, V224, P175; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Kandori H, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1197, DOI 10.1023/A:1013123016803; KAWAMURA S, 1978, VISION RES, V18, P457, DOI 10.1016/0042-6989(78)90057-3; Kefalov VJ, 2001, NEURON, V29, P749, DOI 10.1016/S0896-6273(01)00249-5; KUHN H, 1982, METHOD ENZYMOL, V81, P489; MATSUMOTO H, 1978, VISION RES, V18, P607, DOI 10.1016/0042-6989(78)90212-2; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Saam J, 2002, BIOPHYS J, V83, P3097, DOI 10.1016/S0006-3495(02)75314-9; Sachs K, 2000, METHOD ENZYMOL, V315, P238; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091	40	94	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24896	24903		10.1074/jbc.M302115200	http://dx.doi.org/10.1074/jbc.M302115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707280	Green Accepted, hybrid			2022-12-25	WOS:000183824800079
J	Takeya, R; Ueno, N; Kami, K; Taura, M; Kohjima, M; Izaki, T; Nunoi, H; Sumimoto, H				Takeya, R; Ueno, N; Kami, K; Taura, M; Kohjima, M; Izaki, T; Nunoi, H; Sumimoto, H			Novel human homologues of p47(phox) and p67(phox) participate in activation of superoxide-producing NADPH oxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; NAD(P)H OXIDASE; SH3 DOMAIN; COMPONENTS P47(PHOX); PHAGOCYTE; PHOSPHORYLATION; RAC; TRANSLOCATION; EXPRESSION; P40(PHOX)	The catalytic core of a superoxide-producing NADPH oxidase (Nox) in phagocytes is gp91(phox)/Nox2, a membrane-integrated protein that forms a heterodimer with p22(phox) to constitute flavocytochrome b(558). The cytochrome becomes activated by interacting with the adaptor proteins p47(phox) and p67(phox) as well as the small GTPase Rac. Here we describe the cloning of human cDNAs for novel proteins homologous to p47(phox) and p67(phox), designated p41(nox) and p51(nox), respectively; the former is encoded by NOXO1 <LF>(Nox organizer 1), and the latter is encoded by NOXA1 (Nox activator 1). The novel homologue p41(nox) interacts with p22(phox) via the two tandem SH3 domains, as does p47(phox). The protein p51(nox) as well as p67(phox) can form a complex with p47(phox) and with p41(nox) via the C-terminal SH3 domain and binds to GTP-bound Rac via the N-terminal domain containing four tetratricopeptide repeat motifs. These bindings seem to play important roles, since p47(phox) and p67(phox) activate the phagocyte oxidase via the same interactions. Indeed, p41(nox) and p51(nox) are capable of replacing the corresponding classical homologue in activation of gp91(phox). Nox1, a homologue of gp91(phox), also can be activated in cells, when it is coexpressed with p41(nox) and p51(nox), with p41(nox) and p67(phox), or with p47(phox) and p51(nox); in the former two cases, Nox1 is partially activated without any stimulants added, suggesting that p41(nox) is normally in an active state. Thus, the novel homologues p41(nox) and p51(nox) likely function together or in combination with a classical one, thereby activating the two Nox family oxidases.	Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Miyazaki Med Coll, Dept Pediat, Miyazaki 8891692, Japan	Kyushu University; University of Miyazaki	Sumimoto, H (corresponding author), Kyushu Univ, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hsumi@bioreg.kyushu-u.ac.jp						Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ago T, 2003, P NATL ACAD SCI USA, V100, P4474, DOI 10.1073/pnas.0735712100; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Biberstine-Kinkade KJ, 2002, J BIOL CHEM, V277, P30368, DOI 10.1074/jbc.M203993200; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Brar SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1212, DOI 10.1152/ajpcell.00496.2001; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DINAUER MC, 1991, P NATL ACAD SCI USA, V88, P11231, DOI 10.1073/pnas.88.24.11231; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Griendling KK, 1997, TRENDS CARDIOVAS MED, V7, P301, DOI 10.1016/S1050-1738(97)00088-1; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hata K, 1997, BIOCHEM BIOPH RES CO, V241, P226, DOI 10.1006/bbrc.1997.7807; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Ito T, 2001, EMBO J, V20, P3938, DOI 10.1093/emboj/20.15.3938; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Lavigne MC, 2001, CIRCULATION, V104, P79, DOI 10.1161/01.CIR.104.1.79; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; Mizuki K, 1998, EUR J BIOCHEM, V251, P573, DOI 10.1046/j.1432-1327.1998.2510573.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Roos D, 1996, BLOOD, V87, P1663; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 1997, MEMBRANE PROTEINS - STRUCTURE, FUNCTION AND EXPRESSION CONTROL: INTERNATIONAL SYMPOSIUM, P235	58	273	288	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25234	25246		10.1074/jbc.M212856200	http://dx.doi.org/10.1074/jbc.M212856200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716910	hybrid			2022-12-25	WOS:000183824800118
J	Morelli, L; Llovera, R; Gonzalez, SA; Affranchino, JL; Prelli, F; Frangione, B; Ghiso, J; Castano, EM				Morelli, L; Llovera, R; Gonzalez, SA; Affranchino, JL; Prelli, F; Frangione, B; Ghiso, J; Castano, EM			Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; A-BETA; PRECURSOR PROTEIN; CEREBRAL-HEMORRHAGE; FIBRIL FORMATION; DUTCH TYPE; CEREBROSPINAL-FLUID; TRANSGENIC MICE; PEPTIDE	Inherited amino acid substitutions at position 21, 22, or 23 of amyloid beta (Abeta) lead to presenile dementia or stroke. Insulin-degrading enzyme (IDE) can hydrolyze Abeta wild type, yet whether IDE is capable of degrading Abeta bearing pathogenic substitutions is not known. We studied the degradation of all of the published Abeta genetic variants by recombinant rat IDE (rIDE). Monomeric Abeta wild type, Flemish (A21G), Italian (E22K), and Iowa ( D23N) variants were readily degraded by rIDE with a similar efficiency. However, proteolysis of Abeta Dutch (E22Q) and Arctic (E22G) was significantly lower as compared with Abeta wild type and the rest of the mutant peptides. In the case of Abeta Dutch, inefficient proteolysis was related to a high content of beta structure as assessed by circular dichroism. All of the Abeta variants were cleaved at Glu(3)-Phe(4) and Phe(4)-Arg(5) in addition to the previously described major sites within positions 13-15 and 18-21. SDS-stable Abeta dimers were highly resistant to proteolysis by rIDE regardless of the variant, suggesting that IDE recognizes a conformation that is available for interaction only in monomeric Abeta. These results raise the possibility that upregulation of IDE may promote the clearance of soluble Abeta in hereditary forms of Abeta diseases.	Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Biol, Catedra Quim Biol Patol,CONICET,IQUIFIB, RA-1113 Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Ctr Virol Anim, RA-1033 Buenos Aires, DF, Argentina; NYU, Dept Pathol, New York, NY 10016 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); New York University	Castano, EM (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Biol, Catedra Quim Biol Patol,CONICET,IQUIFIB, Junin 956,C1113AAD, RA-1113 Buenos Aires, DF, Argentina.			Prelli, Frances/0000-0002-8744-4151	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010491, R01AG008721] Funding Source: NIH RePORTER; NIA NIH HHS [AG10491, AG08721] Funding Source: Medline; NINDS NIH HHS [NS38777] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Authier F, 1996, CLIN INVEST MED, V19, P149; Bading JR, 2002, J DRUG TARGET, V10, P359, DOI 10.1080/10611860290031831; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BAUMEISTER H, 1993, FEBS LETT, V317, P250, DOI 10.1016/0014-5793(93)81286-9; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; Bennett RG, 2000, ENDOCRINOLOGY, V141, P2508, DOI 10.1210/en.141.7.2508; Bennett RG, 2000, J BIOL CHEM, V275, P36621, DOI 10.1074/jbc.M006170200; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; CASTANO EM, 1988, LAB INVEST, V58, P122; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; Castano EM, 1996, J BIOL CHEM, V271, P32185, DOI 10.1074/jbc.271.50.32185; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Chesneau V, 2000, PROTEIN EXPRES PURIF, V19, P91, DOI 10.1006/prep.2000.1217; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; CORIA F, 1987, AM J PATHOL, V129, P422; De Jonghe C, 1998, NEUROBIOL DIS, V5, P281, DOI 10.1006/nbdi.1998.0202; DUCKWORTH WC, 1990, J BIOL CHEM, V265, P2984; Eckman EA, 2001, J BIOL CHEM, V276, P24540, DOI 10.1074/jbc.M007579200; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Gau JT, 2002, AM J PATHOL, V160, P731, DOI 10.1016/S0002-9440(10)64893-6; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; KAMINO K, 1992, AM J HUM GENET, V51, P998; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867; Kurochkin IV, 1998, FEBS LETT, V427, P153, DOI 10.1016/S0014-5793(98)00422-0; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Massi F, 2001, BIOPHYS J, V81, P697, DOI 10.1016/S0006-3495(01)75734-7; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Monro OR, 2002, NEUROBIOL AGING, V23, P405, DOI 10.1016/S0197-4580(01)00317-7; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pallitto MM, 2001, BIOPHYS J, V81, P1805, DOI 10.1016/S0006-3495(01)75831-6; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; PIRTTILA T, 1994, J NEUROL SCI, V127, P90, DOI 10.1016/0022-510X(94)90140-6; PRELLI F, 1990, BIOCHEM BIOPH RES CO, V170, P301, DOI 10.1016/0006-291X(90)91274-V; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; SAIDO TC, 2002, 62412 SOC NEUR; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Song ES, 2001, J BIOL CHEM, V276, P1152, DOI 10.1074/jbc.M008702200; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2001, BIOCHEM J, V355, P869, DOI 10.1042/bj3550869; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	53	70	72	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23221	23226		10.1074/jbc.M300276200	http://dx.doi.org/10.1074/jbc.M300276200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695513	Green Published, hybrid			2022-12-25	WOS:000183638600003
J	Guo, CS; Degnin, C; Fiddler, TA; Stauffer, D; Thayer, MJ				Guo, CS; Degnin, C; Fiddler, TA; Stauffer, D; Thayer, MJ			Regulation of MyoD activity and muscle cell differentiation by MDM2, pRb, and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-EXPRESSION; LOOP-HELIX PROTEINS; RB PROTEIN; MYOGENIC DIFFERENTIATION; FUNCTIONAL INTERACTION; ONCOPROTEIN MDM2; P53; CYCLE; FAMILY; TRANSCRIPTION	Muscle cell differentiation is controlled by a complex set of interactions between tissue restricted transcription factors, ubiquitously expressed transcription factors, and cell cycle regulatory proteins. We previously found that amplification of MDM2 in rhabdomyosarcoma cells interferes with MyoD activity and consequently inhibits overt muscle cell differentiation (1). Recently, we found that MDM2 interacts with Sp1 and inhibits Sp1-dependent transcription and that pRb can restore Sp1 activity by displacing MDM2 from Sp1 (2). In this report, we show that forced expression of Sp1 can restore MyoD activity and restore overt muscle cell differentiation in cells with amplified MDM2. Furthermore, we show that pRb can also restore MyoD activity and muscle cell differentiation in cells with amplified MDM2. Surprisingly, we found that the MyoD-interacting domain of pRb is dispensable for this activity. We show that the C-terminal, MDM2-interacting domain of pRb is both necessary and sufficient to restore muscle cell differentiation in cells with amplified MDM2. We also show that the C-terminal MDM2-interacting domain of pRb can promote premature differentiation of proliferating myoblast cells. Our data support a model in which the pRb-MDM2 interaction modulates Sp1 activity during normal muscle cell differentiation.	Oregon Hlth & Sci Univ, Div Mol Med, Portland, OR 97201 USA	Oregon Health & Science University	Thayer, MJ (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL CANCER INSTITUTE [R01CA097021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044553] Funding Source: NIH RePORTER; NCI NIH HHS [CA97021] Funding Source: Medline; NIAMS NIH HHS [AR44553] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COPPOLA JA, 1990, ONCOGENE, V5, P1731; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MARTELLI F, 1994, ONCOGENE, V9, P3579; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	36	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22615	22622		10.1074/jbc.M301943200	http://dx.doi.org/10.1074/jbc.M301943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12702724	hybrid			2022-12-25	WOS:000183503900060
J	Hutchings, NJ; Clarkson, N; Chalkley, R; Barclay, AN; Brown, MH				Hutchings, NJ; Clarkson, N; Chalkley, R; Barclay, AN; Brown, MH			Linking the T cell surface protein CD2 to the actin-capping protein CAPZ via CMS and CIN85	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH SEQUENCES; ADAPTER PROTEIN; CYTOPLASMIC DOMAIN; CD2-ASSOCIATED PROTEIN; DOWN-REGULATION; NATURAL-KILLER; SH3 DOMAINS; C-CBL; LIGAND; ANTIGEN	Recruitment of CD2 to the immunological synapse in response to antigen is dependent on its proline- rich cytoplasmic tail. A peptide from this region ( CD2: 322 - 339) isolated CMS ( human CD2AP); a related protein, CIN85; and the actin capping protein, CAPZ from a T cell line. In BIAcore(TM) analyses, the N- terminal SH3 domains of CMS and CIN85 bound CD2: 322 - 339 with similar dissociation constants ( K(D) = similar to 100 muM). CAPZ bound the C-terminal half of CMS and CIN85. Direct binding between CMS/ CIN85 and CAPZ provides a link with the actin cytoskeleton. Overexpression of a fragment from the C- terminal half or the N- terminal SH3 domain of CD2AP in a mouse T cell hybridoma resulted in enhanced interleukin-2 production and reduced T cell receptor down-modulation in response to antigen. These adaptor proteins are important in T cell signaling consistent with a role for CD2 in regulating pathways initiated by CMS/ CIN85 and CAPZ.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; UCL Royal Free & Univ Coll Med Sch, Ludwig Inst Canc Res, Univ Coll Branch Cell & Mol Biol, London W1W 7BS, England	University of Oxford; Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	Brown, MH (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	Marion.Brown@path.ox.ac.uk		Chalkley, Robert/0000-0002-9757-7302				Bachmann MF, 1999, J EXP MED, V190, P1383, DOI 10.1084/jem.190.10.1383; Badour K, 2003, IMMUNITY, V18, P141, DOI 10.1016/S1074-7613(02)00516-2; BARRONCASELLA EA, 1995, J BIOL CHEM, V270, P21472, DOI 10.1074/jbc.270.37.21472; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Freund C, 1999, NAT STRUCT BIOL, V6, P656, DOI 10.1038/10712; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; Hart MC, 1997, CELL MOTIL CYTOSKEL, V38, P120, DOI 10.1002/(SICI)1097-0169(1997)38:2<120::AID-CM2>3.0.CO;2-B; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; King PD, 1998, INT IMMUNOL, V10, P1009, DOI 10.1093/intimm/10.7.1009; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Lee KH, 2000, EUR J IMMUNOL, V30, P892, DOI 10.1002/1521-4141(200003)30:3<892::AID-IMMU892>3.0.CO;2-U; Lehtonen S, 2002, AM J PHYSIOL-RENAL, V283, pF734, DOI 10.1152/ajprenal.00312.2001; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; LIU SJ, 1995, BIOPHYS J, V68, P459, DOI 10.1016/S0006-3495(95)80207-9; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mayer BJ, 2001, J CELL SCI, V114, P1253; Melton E, 1996, EUR J IMMUNOL, V26, P2952, DOI 10.1002/eji.1830261222; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Sasada T, 2001, J IMMUNOL, V166, P2394, DOI 10.4049/jimmunol.166.4.2394; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Shaw AS, 2001, IMMUNITY, V15, P683, DOI 10.1016/S1074-7613(01)00237-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Soeno Y, 1998, J MUSCLE RES CELL M, V19, P639, DOI 10.1023/A:1005329114263; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; SPRUYT LL, 1991, J EXP MED, V174, P1407, DOI 10.1084/jem.174.6.1407; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Teh SJ, 1997, BLOOD, V89, P1308, DOI 10.1182/blood.V89.4.1308; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; Verdier F, 2002, EUR J BIOCHEM, V269, P3402, DOI 10.1046/j.1432-1033.2002.03031.x; Wang N, 2001, IMMUNOGENETICS, V53, P382, DOI 10.1007/s002510100337; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Wild MK, 1999, J EXP MED, V190, P31, DOI 10.1084/jem.190.1.31; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zaru R, 2002, J IMMUNOL, V168, P4287, DOI 10.4049/jimmunol.168.9.4287	48	91	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22396	22403		10.1074/jbc.M302540200	http://dx.doi.org/10.1074/jbc.M302540200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690097	hybrid			2022-12-25	WOS:000183503900031
J	Warnecke, C; Griethe, W; Weidemann, A; Jurgensen, JS; Willam, C; Bachmann, S; Ivashchenko, Y; Wagner I; Frei, U; Wiesener, M; Eckardt, KU				Warnecke, C; Griethe, W; Weidemann, A; Jurgensen, JS; Willam, C; Bachmann, S; Ivashchenko, Y; Wagner, I; Frei, U; Wiesener, M; Eckardt, KU			Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors	FASEB JOURNAL			English	Article						transcription factor; ischemic diseases; neoangiogenesis; pharmacotherapy	TRANSCRIPTION FACTORS; HIF-ALPHA; FACTOR-I; HIF-1-ALPHA/VP16 HYBRID; MYOCARDIAL-INFARCTION; FIBROBLAST-CULTURES; GENE-EXPRESSION; KAPPA-B; 4-HYDROXYLASE; PROTEIN	Hypoxia-inducible transcription factors (HIF) mediate complex adaptations to reduced oxygen supply, including neoangiogenesis. Regulation of HIF occurs mainly through oxygen-dependent destruction of its alpha subunit. In the presence of oxygen, two HIFalpha. prolyl residues undergo enzymatic hydroxylation, which is required for its proteasomal degradation. We therefore tested whether pharmacological activation of HIFalpha. by hydroxylase inhibitors may provide a novel therapeutic strategy for the treatment of ischemic diseases. Three distinct prolyl 4-hydroxylase inhibitors-L-mimosine (L-Mim), ethyl 3,4-dihydroxybenzoate (3,4-DHB), and 6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamid (5956711)-demonstrated similar effects to hypoxia (0.5% 02) by inducing HIFalpha. protein in human and rodent cells. L-Mim, 5956711, and, less effectively, 3,4-DHB also induced HIF target genes in cultured cells, including glucose transporter 1 and vascular endothelial growth factor, as well as HIF-dependent reporter gene expression. Systemic administration of L-Mim and 5956711 in rats led to HIFalpha. induction in the kidney. In a sponge model for angiogenesis, repeated local injection of the inhibitors strongly increased invasion of highly vascularized tissue into the sponge centers. In conclusion, structurally distinct inhibitors of prolyl hydroxylation are capable of inducing HIFalpha. and HIF target genes in vitro and in vivo and induce adaptive responses to hypoxia, including angiogenesis.	Humboldt Univ, Dept Nephrol & Med Intens Care, Univ Clin Charite, D-13353 Berlin, Germany; Humboldt Univ, Dept Anat, Univ Clin Charite, D-13353 Berlin, Germany; Aventis Pharma Deutschland GmbH, Dept Cardiovasc Dis, D-65926 Frankfurt, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sanofi-Aventis	Eckardt, KU (corresponding author), Campus Virchow Clin, Charite, Dept Nephrol & Med Intens Care, Augustenburger Pl 1, D-13353 Berlin, Germany.	uwe.eckardt@charite.de						ABBRUZZESE A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P159, DOI 10.1016/0167-4838(91)90053-3; BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CUNLIFFE CJ, 1992, J MED CHEM, V35, P2652, DOI 10.1021/jm00092a016; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; HIROSE Y, 1995, CARCINOGENESIS, V16, P2337, DOI 10.1093/carcin/16.10.2337; HOLMES JHG, 1981, AUST VET J, V57, P257, DOI 10.1111/j.1751-0813.1981.tb05805.x; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ju HS, 1998, BBA-MOL CELL RES, V1448, P51, DOI 10.1016/S0167-4889(98)00114-1; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KOONG AC, 1994, CANCER RES, V54, P1425; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee RJ, 2000, CIRCULATION, V102, P898; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MAJAMAA K, 1987, J INVEST DERMATOL, V89, P405, DOI 10.1111/1523-1747.ep12471775; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MCCAFFREY TA, 1995, J CLIN INVEST, V95, P446, DOI 10.1172/JCI117684; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; SASAKI T, 1987, J BIOL CHEM, V262, P9397; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; SZYSZKA M, 1984, DEUT TIERARZTL WOCH, V91, P262; Vincent KA, 2000, CIRCULATION, V102, P2255; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wykoff CC, 2000, CANCER RES, V60, P7075; Zaman K, 1999, J NEUROSCI, V19, P9821; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	45	177	201	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1186	+		10.1096/fj.02-1062fje	http://dx.doi.org/10.1096/fj.02-1062fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709400				2022-12-25	WOS:000182580100025
J	Ferrer-Sueta, G; Vitturi, D; Batinic-Haberle, I; Fridovich, I; Goldstein, S; Czapski, G; Radi, R				Ferrer-Sueta, G; Vitturi, D; Batinic-Haberle, I; Fridovich, I; Goldstein, S; Czapski, G; Radi, R			Reactions of manganese Porphyrins with peroxynitrite and carbonate radical anion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; PULSE-RADIOLYSIS; NITRIC-OXIDE; AQUEOUS-SOLUTION; METALLOPORPHYRIN ANTIOXIDANT; CATALYTIC ANTIOXIDANTS; FLASH-PHOTOLYSIS; RATE CONSTANTS; IN-VITRO; WATER	We have studied the reaction kinetics of ten manganese porphyrins, differing in their meso substituents, with peroxynitrite (ONOO-) and carbonate radical anion (CO3----) using stopped-flow and pulse radiolysis, respectively. Rate constants for the reactions of Mn(III) porphyrins with ONOO- ranged from 1 X 10(5) to 3.4 X 10(7) M-1 s(-1) and correlated well with previously reported kinetic and thermodynamic data that reflect the resonance and inductive effects of the substituents on the porphyrin ring. Rate constants for the reactions of Mn(III) porphyrins with CO3----. ranged from 2 X 10(8) to 1.2 X 10(9) M-1 s(-1) at pH less than or equal to 8.5 and increased with pH as a consequence of the ionization of the complexes. Mn(II) porphyrins reacted with CO3----. with rate constants ranging from 1 X 10(9) to 5 X 10(9) M-1 s(-1) at pH 10.4. Hence, fast scavenging of ONOO- and CO3----. by manganese porphyrins could occur in vivo because of the catalytic reduction at the expense of a number of cellular reductants. Additionally, we determined the pK(alpha) of the axial water molecules of the Mn(III) complexes at pH 7.5-13.2 by spectrophotometric titration. Results were consistent with two acid-base equilibria for most of the complexes studied. The pK(alpha) values also correlated with the resonance and inductive effects of the substituents. The correlations of E-1/2 with the rate constants with ONOO- and with the pK(alpha) values display a deviation from linearity when N-alkylpyridinium substituents included N-alkyl moieties longer than ethyl, which is interpreted in terms of a decrease in the local dielectric constant.	Univ Republica, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay; Univ Republica, Fac Ciencias, Lab Fisicoquim Biol, Montevideo 11400, Uruguay; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Hebrew Univ Jerusalem, Dept Phys Chem, IL-91904 Jerusalem, Israel	Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay; Duke University; Hebrew University of Jerusalem	Radi, R (corresponding author), Univ Republica, Fac Med, Dept Bioquim, Av Gral Flores 2125, Montevideo 11800, Uruguay.		Vitturi, Dario/Z-3469-2019; Ferrer-Sueta, Gerardo/C-3316-2011	Ferrer-Sueta, Gerardo/0000-0002-8663-8480; Vitturi, Dario/0000-0003-0354-4567				ADAMS GE, 1972, RADIAT RES, V49, P278, DOI 10.2307/3573266; Aslan M, 2001, P NATL ACAD SCI USA, V98, P15215, DOI 10.1073/pnas.221292098; Augusto O, 2002, FREE RADICAL BIO MED, V32, P841, DOI 10.1016/S0891-5849(02)00786-4; Batinic-Haberle I, 1999, INORG CHEM, V38, P4011, DOI 10.1021/ic990118k; Batinic-Haberle I, 2002, J CHEM SOC DALTON, P2689, DOI 10.1039/b201057g; Batinic-Haberle I, 2002, METHOD ENZYMOL, V349, P223, DOI 10.1016/S0076-6879(02)49337-8; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEHAR D, 1970, J PHYS CHEM-US, V74, P2206, DOI 10.1021/j100909a029; Bonini MG, 1999, J BIOL CHEM, V274, P10802, DOI 10.1074/jbc.274.16.10802; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; CARNIERI N, 1982, J CHEM SOC DALTON, P931, DOI 10.1039/dt9820000931; Chen FC, 1999, J ELECTROANAL CHEM, V474, P52, DOI 10.1016/S0022-0728(99)00303-4; CHEN SN, 1973, RADIAT RES, V56, P40, DOI 10.2307/3573789; Czapski G, 1999, J PHYS CHEM A, V103, P3447, DOI 10.1021/jp984769y; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; DUNCAN IA, 1980, J CHEM SOC FARAD T 2, V76, P1415, DOI 10.1039/f29807601415; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; Ferrer-Sueta G, 1997, CHEM RES TOXICOL, V10, P1338, DOI 10.1021/tx970116h; Ferrer-Sueta G, 2002, METHOD ENZYMOL, V349, P23, DOI 10.1016/S0076-6879(02)49318-4; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; HAMBRIGHT P, 1974, INORG CHEM, V13, P3029, DOI 10.1021/ic50142a054; HARRIMAN A, 1979, J CHEM SOC FARAD T 2, V75, P1532, DOI 10.1039/f29797501532; Hodges GR, 1999, J AM CHEM SOC, V121, P10695, DOI 10.1021/ja991077u; HUIE RE, 1991, RADIAT PHYS CHEM, V38, P477; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Lee JB, 1997, BIOORG MED CHEM LETT, V7, P2913, DOI 10.1016/S0960-894X(97)10109-3; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liu MH, 1997, J ELECTROANAL CHEM, V426, P197, DOI 10.1016/S0022-0728(96)04968-6; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; Mackensen GB, 2001, J NEUROSCI, V21, P4582, DOI 10.1523/JNEUROSCI.21-13-04582.2001; Merenyi G, 1999, J PHYS CHEM A, V103, P5685, DOI 10.1021/jp984686h; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; MOREHOUSE KM, 1984, J PHYS CHEM-US, V88, P1575, DOI 10.1021/j150652a027; PASTERNACK RF, 1981, J INORG BIOCHEM, V15, P261, DOI 10.1016/S0162-0134(00)80161-0; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Piganelli JD, 2002, DIABETES, V51, P347, DOI 10.2337/diabetes.51.2.347; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; SCAIFE CWJ, 1980, INORG CHEM, V19, P3244, DOI 10.1021/ic50213a008; Sheng HX, 2002, FREE RADICAL BIO MED, V33, P947, DOI 10.1016/S0891-5849(02)00979-6; Spasojevic I, 2000, NITRIC OXIDE-BIOL CH, V4, P526, DOI 10.1006/niox.2000.0303; Spasojevic I, 2003, J BIOL CHEM, V278, P6831, DOI 10.1074/jbc.M211346200; Vujaskovic Z, 2002, FREE RADICAL BIO MED, V33, P857, DOI 10.1016/S0891-5849(02)00980-2; WEEKS JL, 1966, J PHYS CHEM-US, V70, P2100, DOI 10.1021/j100879a005; Yushmanov VE, 1996, J INORG BIOCHEM, V61, P233, DOI 10.1016/0162-0134(95)00071-2; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200	50	154	161	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27432	27438		10.1074/jbc.M213302200	http://dx.doi.org/10.1074/jbc.M213302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12700236	hybrid			2022-12-25	WOS:000184242700014
J	Lemaillet, G; Walker, B; Lambert, S				Lemaillet, G; Walker, B; Lambert, S			Identification of a conserved ankyrin-binding motif in the family of sodium channel alpha Subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; AXON INITIAL SEGMENTS; NERVOUS-SYSTEM; SPECTRIN; RANVIER; BRAIN; EXPRESSION; BETA-1; LOCALIZATION; NEUROFASCIN	Interactions with ankyrin(G) are crucial to the localization of voltage-gated sodium channels (VGSCs) at the axon initial segment and for neurons to initiate action potentials. However, the molecular nature of these interactions remains unclear. Here we report that VGSC-alpha, but not -beta, subunits bind to ankyrin(G) using pull-down assays. Further dissection of this activity identifies a conserved 9-amino acid motif ((V/A) P(I/L) AXXE(S/D)D) required for ankyrin(G) binding. This motif is also required for the localization of chimeric neurofascin/sodium channel molecules to the initial segment of cultured hippocampal neurons. The conserved nature of this motif suggests that it functions to localize sodium channels to a variety of "excitable" membrane domains both inside and outside of the nervous system.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Neurosci, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lambert, S (corresponding author), Rm 326,4 Biotech,377 Plantat St, Worcester, MA 01605 USA.	stephen.lambert@Umassmed.edu						Arroyo EJ, 2002, J NEUROSCI, V22, P1726, DOI 10.1523/JNEUROSCI.22-05-01726.2002; Bennett V, 1999, J NEUROCYTOL, V28, P303, DOI 10.1023/A:1007005528505; Boiko T, 2001, NEURON, V30, P91, DOI 10.1016/S0896-6273(01)00265-3; Bouzidi M, 2002, J BIOL CHEM, V277, P28996, DOI 10.1074/jbc.M201760200; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; DAVIDSON JM, 1993, J CELL BIOCHEM, P109; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Fjell J, 2000, NEUROREPORT, V11, P199, DOI 10.1097/00001756-200001170-00039; Garrido JJ, 2001, EMBO J, V20, P5950, DOI 10.1093/emboj/20.21.5950; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Goslin K., 1998, CULTURING NERVE CELL, P339; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Komada M, 2002, J CELL BIOL, V156, P337, DOI 10.1083/jcb.200110003; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; Lambert S, 1997, J NEUROSCI, V17, P7025; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Malhotra JD, 2002, J BIOL CHEM, V277, P26681, DOI 10.1074/jbc.M202354200; Meisler MH, 2002, NOVART FDN SYMP, V241, P72; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Ratcliffe CF, 2001, J CELL BIOL, V154, P427, DOI 10.1083/jcb.200102086; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; Srinivasan J, 1998, P NATL ACAD SCI USA, V95, P15753, DOI 10.1073/pnas.95.26.15753; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; Wood SJ, 1998, J CELL BIOL, V140, P675, DOI 10.1083/jcb.140.3.675; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295	34	189	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27333	27339		10.1074/jbc.M303327200	http://dx.doi.org/10.1074/jbc.M303327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12716895	hybrid			2022-12-25	WOS:000184242700002
J	Shukla, A; Raje, M; Guptasarma, P				Shukla, A; Raje, M; Guptasarma, P			A backbone-reversed form of an all-beta alpha-crystallin domain from a small heat-shock protein (retro-HSP12.6) folds and assembles into structured multimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE	The structural consequences of polypeptide backbone reversal ("retro" modification) remain largely unexplored, in particular, for the retro forms of globular all-beta-sheet proteins. To examine whether the backbone-reversed form of a model all-beta-sheet protein can fold and adopt secondary and tertiary structure, we created and examined the recombinant retro form of a 110-residue-long polypeptide, an alpha-crystallin-like small heat-shock protein, HSP12.6, from C. elegans. Following intracellular overexpression in fusion with a histidine affinity tag in Escherichia coli, purification under denaturing conditions, and removal of denaturant through dialysis, retro-HSP12.6 was found to fold to a soluble state. The folded protein was examined using fluorescence and CD spectroscopy, gel filtration chromatography, non-denaturing electrophoresis, differential scanning calorimetry, and electron microscopy and confirmed to have adopted secondary structure and assembled into a multimer. Interestingly, like its parent polypeptide, retro-HSP12.6 did not aggregate upon heating; rather, heating led to a dramatic increase in structural content and the adoption of what would appear to be a very well folded state at high temperatures. However, this was essentially reversed upon cooling with some hysteresis being observed resulting in greater structural content in the heated-cooled protein than in the unheated protein. The heated-cooled samples displayed CD spectra indicative of structural content comparable to that of any naturally occurring globular protein. Attempts are being made to refine crystallization conditions for the folded protein.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Guptasarma, P (corresponding author), Inst Microbial Technol, Sector 39-A, Chandigarh 160036, India.		Guptasarma, Purnananda/C-3976-2009; Shukla, Anshuman/D-2230-2012	Guptasarma, Purnananda/0000-0002-4801-3180; Shukla, Anshuman/0000-0003-0451-8651				GUPTASARMA P, 1992, FEBS LETT, V310, P205, DOI 10.1016/0014-5793(92)81333-H; Guptasarma P, 1996, TRENDS BIOTECHNOL, V14, P42, DOI 10.1016/0167-7799(96)80917-6; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kishan KVR, 2001, PROTEIN SCI, V10, P1046, DOI 10.1110/ps.50401; Lacroix E, 1998, FOLD DES, V3, P79, DOI 10.1016/S1359-0278(98)00013-3; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Mittl PRE, 2000, P NATL ACAD SCI USA, V97, P2562, DOI 10.1073/pnas.97.6.2562; Olszewski KA, 1996, PROTEIN ENG, V9, P5, DOI 10.1093/protein/9.1.5; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722	9	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26505	26510		10.1074/jbc.M303123200	http://dx.doi.org/10.1074/jbc.M303123200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12716883	hybrid			2022-12-25	WOS:000184155700029
J	Enomoto, H; Shiojiri, S; Hoshi, K; Furuichi, T; Fukuyama, R; Yoshida, CA; Kanatani, N; Nakamura, R; Mizuno, A; Zanma, A; Yano, K; Yasuda, H; Higashio, K; Takada, K; Komori, T				Enomoto, H; Shiojiri, S; Hoshi, K; Furuichi, T; Fukuyama, R; Yoshida, CA; Kanatani, N; Nakamura, R; Mizuno, A; Zanma, A; Yano, K; Yasuda, H; Higashio, K; Takada, K; Komori, T			Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2(-/-) mice by RANKL transgene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; OSTEOBLAST DIFFERENTIATION; CBFA1-DEFICIENT MICE; INHIBITORY FACTOR; BONE-DEVELOPMENT; CHONDROCYTE DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; TRANSCRIPTION FACTOR; SKELETAL DEVELOPMENT; SEVERE OSTEOPOROSIS	Receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), and macrophage-colony stimulating factor play essential roles in the regulation of osteoclastogenesis. Runx2-deficient (Runx2(-/-)) mice showed a complete lack of bone formation because of maturational arrest of osteoblasts and disturbed chondrocyte maturation. Further, osteoclasts were absent in these mice, in which OPG and macrophage-colony stimulating factor were normally expressed, but RANKL expression was severely diminished. We investigated the function of Runx2 in osteoclast differentiation. A Runx2(-/-) calvaria-derived cell line (CA120-4), which expressed OPG strongly but RANKL barely, severely suppressed osteoclast differentiation from normal bone marrow cells in co-cultures. Adenoviral introduction of Runx2 into CA120-4 cells induced RANKL expression, suppressed OPG expression, and restored osteoclast differentiation from normal bone marrow cells, whereas the addition of OPG abolished the osteoclast differentiation induced by Runx2. Addition of soluble RANKL (sRANKL) also restored osteoclast differentiation in co-cultures. Forced expression of sRANKL in Runx2(-/-) livers increased the number and size of osteoclast-like cells around calcified cartilage, although vascular invasion into the cartilage was superficial because of incomplete osteoclast differentiation. These findings indicate that Runx2 promotes osteoclast differentiation by inducing RANKL and inhibiting OPG. As the introduction of sRANKL was insufficient for osteoclast differentiation in Runx2(-/-) mice, however, our findings also suggest that additional factor(s) or matrix protein(s), which are induced in terminally differentiated chondrocytes or osteoblasts by Runx2, are required for osteoclastogenesis in early skeletal development.	Osaka Univ, Dept Mol Med, Grad Sch Med, Osaka 5650871, Japan; Osaka Univ, Dept Orthodont & Dentofacial Orthoped, Fac Dent, Osaka 5650871, Japan; Univ Tokyo, Dept Orthopaed Surg, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Setsunan Univ, Dept Pharmacol, Fac Pharmaceut Sci, Osaka 5730101, Japan; Teijin Ltd, Biomed Res Inst, Tokyo 1918512, Japan; Snow Brand Milk Prod Co Ltd, Res Inst Life Sci, Shimotsuga, Tochigi 3290512, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan	Osaka University; Osaka University; University of Tokyo; Setsunan University; Teijin Limited; Snow Brand Milk Products Co., Ltd.; Japan Science & Technology Agency (JST)	Komori, T (corresponding author), Osaka Univ, Dept Mol Med, Grad Sch Med, 2-2 Yamadaoka, Osaka 5650871, Japan.							Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311; FELIX R, 1990, ENDOCRINOLOGY, V127, P2592, DOI 10.1210/endo-127-5-2592; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222-6233.2002; Gilbert S., 1997, DEV BIOL; GONDO Y, 1994, BIOCHEM BIOPH RES CO, V202, P830, DOI 10.1006/bbrc.1994.2005; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Himeno M, 2002, J BONE MINER RES, V17, P1297, DOI 10.1359/jbmr.2002.17.7.1297; Hoshi K, 1999, BONE, V25, P639, DOI 10.1016/S8756-3282(99)00223-9; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Javed A, 2001, MOL CELL BIOL, V21, P2891, DOI 10.1128/MCB.21.8.2891-2905.2001; Kartsogiannis V, 1999, BONE, V25, P525, DOI 10.1016/S8756-3282(99)00214-8; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; Komori T, 1998, CURR OPIN GENET DEV, V8, P494, DOI 10.1016/S0959-437X(98)80123-8; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Mizuno A, 2002, J BONE MINER METAB, V20, P337, DOI 10.1007/s007740200049; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1997, METHOD ENZYMOL, V282, P223; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Thirunavukkarasu K, 2000, J BIOL CHEM, V275, P25163, DOI 10.1074/jbc.M000322200; Thirunavukkarasu K, 2001, J BIOL CHEM, V276, P36241, DOI 10.1074/jbc.M104319200; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tsukii K, 1998, BIOCHEM BIOPH RES CO, V246, P337, DOI 10.1006/bbrc.1998.8610; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wood GW, 1997, MOL REPROD DEV, V46, P62, DOI 10.1002/(SICI)1098-2795(199701)46:1<62::AID-MRD10>3.0.CO;2-5; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Yoshimoto T, 1998, J IMMUNOL, V160, P588; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; ZHAO X, 1992, J BIOCHEM-TOKYO, V111, P736, DOI 10.1093/oxfordjournals.jbchem.a123828	60	132	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23971	23977		10.1074/jbc.M302457200	http://dx.doi.org/10.1074/jbc.M302457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697767	hybrid			2022-12-25	WOS:000183638600096
J	Howell, SA; Wells, I; Fleck, SL; Kettleborough, C; Collins, CR; Blackman, MJ				Howell, SA; Wells, I; Fleck, SL; Kettleborough, C; Collins, CR; Blackman, MJ			A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; PLASMODIUM-FALCIPARUM MEROZOITES; MICRONEME PROTEINS; VACCINE CANDIDATE; PARASITE; INVASION; INHIBIT; EXPRESSION; ANTIBODIES; COMPLEX	Erythrocyte invasion by the malaria merozoite is accompanied by the regulated discharge of apically located secretory organelles called micronemes. Plasmodium falciparum apical membrane antigen-1 ( PfAMA-1), which plays an indispensable role in invasion, translocates from micronemes onto the parasite surface and is proteolytically shed in a soluble form during invasion. We have previously proposed, on the basis of incomplete mass spectrometric mapping data, that PfAMA-1 shedding results from cleavage at two alternative positions. We now show conclusively that the PfAMA-1 ectodomain is shed from the merozoite solely as a result of cleavage at a single site, just 29 residues away from the predicted transmembrane-spanning sequence. Remarkably, this cleavage is mediated by the same membrane-bound parasite serine protease as that responsible for shedding of the merozoite surface protein-1 (MSP-1) complex, an abundant, glycosylphosphatidylinositol-anchored multiprotein complex. Processing of MSP-1 is essential for invasion. Our results indicate the presence on the merozoite surface of a multifunctional serine sheddase with a broad substrate specificity. We further demonstrate that translocation and shedding of PfAMA-1 is an actinin-dependent process.	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; MRC Technol, London NW7 1AD, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Blackman, MJ (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.	mblackm@nimr.mrc.ac.uk						Blackman Michael J., 2000, Current Drug Targets, V1, P59, DOI 10.2174/1389450003349461; Blackman MJ, 1998, J BIOL CHEM, V273, P23398, DOI 10.1074/jbc.273.36.23398; BLACKMAN MJ, 1993, MOL BIOCHEM PARASIT, V62, P103, DOI 10.1016/0166-6851(93)90182-W; Blackman MJ, 2001, MOL BIOCHEM PARASIT, V117, P11, DOI 10.1016/S0166-6851(01)00328-0; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; Blackman MJ, 1996, EXP PARASITOL, V83, P229, DOI 10.1006/expr.1996.0069; Brossier F, 2003, J BIOL CHEM, V278, P6229, DOI 10.1074/jbc.M209837200; Bumstead J, 2000, MOL BIOCHEM PARASIT, V110, P311, DOI 10.1016/S0166-6851(00)00280-2; Carruthers VB, 2000, J BIOL CHEM, V275, P14346, DOI 10.1074/jbc.275.19.14346; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; DEANS JA, 1984, MOL BIOCHEM PARASIT, V11, P189, DOI 10.1016/0166-6851(84)90065-3; DEANS JA, 1982, CLIN EXP IMMUNOL, V49, P297; Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9; FIELD SJ, 1993, CELL MOTIL CYTOSKEL, V25, P43, DOI 10.1002/cm.970250106; Fowler RE, 2001, MOL BIOCHEM PARASIT, V117, P187, DOI 10.1016/S0166-6851(01)00351-6; Fraser TS, 2001, MOL BIOCHEM PARASIT, V117, P49, DOI 10.1016/S0166-6851(01)00326-7; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Garman SC, 2003, J BIOL CHEM, V278, P7264, DOI 10.1074/jbc.M210716200; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000; Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446; Howell SA, 2001, J BIOL CHEM, V276, P31311, DOI 10.1074/jbc.M103076200; Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Li F, 2002, J BIOL CHEM, V277, P50303, DOI 10.1074/jbc.M207985200; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Nair M, 2002, J MOL BIOL, V322, P741, DOI 10.1016/S0022-2836(02)00806-9; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pinder JC, 2000, PARASITOL TODAY, V16, P240, DOI 10.1016/S0169-4758(00)01664-1; Pizarro JC, 2002, ACTA CRYSTALLOGR D, V58, P1246, DOI 10.1107/S0907444902007667; Powers J C, 1977, Methods Enzymol, V46, P197; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; RIDLEY RG, 1991, MOL BIOCHEM PARASIT, V47, P245, DOI 10.1016/0166-6851(91)90184-8; Schnolzer M, 1996, ELECTROPHORESIS, V17, P945, DOI 10.1002/elps.1150170517; Schwager SLU, 2001, BIOCHEMISTRY-US, V40, P15624, DOI 10.1021/bi011063c; Tomley FM, 2001, TRENDS PARASITOL, V17, P81, DOI 10.1016/S1471-4922(00)01761-X; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; Withers-Martinez C, 2002, J BIOL CHEM, V277, P29698, DOI 10.1074/jbc.M203088200	45	113	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23890	23898		10.1074/jbc.M302160200	http://dx.doi.org/10.1074/jbc.M302160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12686561	hybrid			2022-12-25	WOS:000183638600086
J	Kusu, N; Laurikkala, J; Imanishi, M; Usui, H; Konishi, M; Miyake, A; Thesleff, I; Itoh, N				Kusu, N; Laurikkala, J; Imanishi, M; Usui, H; Konishi, M; Miyake, A; Thesleff, I; Itoh, N			Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; CALVARIAL BONE; GELATINASE-B; EXPRESSION; CERBERUS; XENOPUS; FAMILY; MEMBER; CELLS	Sclerosteosis is a progressive sclerosing bone dysplasia. Sclerostin (the SOST gene) was originally identified as the sclerosteosis-causing gene. However, the physiological role of sclerostin remains to be elucidated. Sclerostin was intensely expressed in developing bones of mouse embryos. Punctuated expression of sclerostin was localized on the surfaces of both intramembranously forming skull bones and endochondrally forming long bones. Sclerostin-positive cells were identified as osteoclasts. Recombinant sclerostin protein produced in cultured cells was efficiently secreted as a monomer. We examined effects of sclerostin on the activity of BMP2, BMP4, BMP6, and BMP7 for mouse preosteoblastic MC3T3-E1 cells. Sclerostin inhibited the BMP6 and BMP7 activity but not the BMP2 and BMP4 activity. Sclerostin bound to BMP6 and BMP7 with high affinity but bound to BMP2 and BMP4 with lower affinity. In conclusion, sclerostin is a novel secreted osteoclast-derived BMP antagonist with unique ligand specificity. We suggest that sclerostin negatively regulates the formation of bone by repressing the differentiation and/or function of osteoblasts induced by BMPs. Since sclerostin expression is confined to the bone-resorbing osteoclast, it provides a mechanism whereby bone apposition is inhibited in the vicinity of resorption. Our findings indicate that sclerostin plays an important role in bone remodeling and links bone resorption and bone apposition.	Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Biochem Genet, Sakyo Ku, Kyoto 6068501, Japan	University of Helsinki; Kyoto University	Thesleff, I (corresponding author), Univ Helsinki, Inst Biotechnol, POB 56, Helsinki 00014, Finland.							Balemans W, 2001, HUM MOL GENET, V10, P537, DOI 10.1093/hmg/10.5.537; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Dionne MS, 2001, MOL CELL BIOL, V21, P636, DOI 10.1128/MCB.21.2.636-643.2001; Ebisawa T, 1999, J CELL SCI, V112, P3519; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; RADDI AH, 1994, CURR OPIN GENE DEV, V4, P737; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Rice DPC, 1997, BONE, V21, P479, DOI 10.1016/S8756-3282(97)00182-8; Rice DPC, 1999, EUR J ORAL SCI, V107, P265, DOI 10.1046/j.0909-8836.1999.eos107406.x; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; Stanley E, 1998, MECH DEVELOP, V77, P173, DOI 10.1016/S0925-4773(98)00139-7; Stricker S, 2002, DEV BIOL, V245, P95, DOI 10.1006/dbio.2002.0640; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yokouchi Y, 1999, CELL, V98, P573, DOI 10.1016/S0092-8674(00)80045-8; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	25	199	233	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24113	24117		10.1074/jbc.M301716200	http://dx.doi.org/10.1074/jbc.M301716200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12702725	hybrid			2022-12-25	WOS:000183638600116
J	Takada, Y; Mukhopadhyay, A; Kundu, GC; Mahabeleshwar, GH; Singh, S; Aggarwal, BB				Takada, Y; Mukhopadhyay, A; Kundu, GC; Mahabeleshwar, GH; Singh, S; Aggarwal, BB			Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65 - Evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-INDUCED APOPTOSIS; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; CONSTITUTIVE ACTIVATION; DEPENDENT ACTIVATION; REGULATE ACTIVATION; SIGNAL-TRANSDUCTION; SUBUNIT; CELLS	Although it is well established that reactive oxygen intermediates mediate the NF-kappaB activation induced by most agents, how H2O2 activates this transcription factor is not well understood. We found that treatment of human myeloid KBM-5 cells with H2O2 activated NF-kappaB in a dose- and time-dependent manner much as tumor necrosis factor (TNF) did but unlike TNF, H2O2 had no effect on IkappaBalpha degradation. Unexpectedly, however, like TNF-induced activation, H2O2-induced NF-kappaB activation was blocked by the calpain inhibitor N-Ac-Leu-Leu-norleucinal, suggesting that a proteosomal pathway was involved. Although H2O2 activated IkappaBalpha kinase, it did not induce the serine phosphorylation of IkappaBalpha. Like TNF, H2O2 induced the serine phosphorylation of the p65 subunit of NF-kappaB, leading to its nuclear translocation. We found that H2O2 induced the tyrosine phosphorylation of IkappaBalpha, which is needed for NF-kappaB activation. We present several lines of evidence to suggest that the Syk protein-tyrosine kinase is involved in H2O2-induced NF-kappaB activation. First, H2O2 activated Syk in KBM-5 cells; second, H2O2 failed to activate NF-kappaB in cells that do not express Syk protein; third, overexpression of Syk increased H2O2-induced NF-kappaB activation; and fourth, reduction of Syk transcription using small interfering RNA inhibited H2O2-induced NF-kappaB activation. We also showed that Syk induced the tyrosine phosphorylation of IkappaBalpha, which caused the dissociation, phosphorylation, and nuclear translocation of p65. Thus, overall, our results demonstrate that H2O2 induces NF-kappaB activation, not through serine phosphorylation or degradation of IkappaBalpha, but through Syk-mediated tyrosine phosphorylation of IkappaBalpha.	Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Cytokine Res Lab, Houston, TX 77030 USA; NCCS, Pune 411007, Maharashtra, India; Imgenex, San Diego, CA 92121 USA	University of Texas System; UTMD Anderson Cancer Center; Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunotherapy, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Kundu, Gopal C./ABA-9897-2020; Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01 CA91844] Funding Source: Medline; NIGMS NIH HHS [R43 GM68358-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM068358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dudek EJ, 2001, FREE RADICAL BIO MED, V31, P651, DOI 10.1016/S0891-5849(01)00634-7; Garban HJ, 2001, J BIOL CHEM, V276, P8918, DOI 10.1074/jbc.M008471200; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; Howe CJ, 2002, J BIOL CHEM, V277, P30469, DOI 10.1074/jbc.M205036200; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Kang JL, 2000, TOXICOL APPL PHARM, V169, P59, DOI 10.1006/taap.2000.9039; KOONG AC, 1994, CANCER RES, V54, P1425; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; Majumdar S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/jimmunol.167.5.2911; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Milligan SA, 1998, ARCH BIOCHEM BIOPHYS, V352, P255, DOI 10.1006/abbi.1998.0603; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Musonda CA, 1998, CARCINOGENESIS, V19, P1583, DOI 10.1093/carcin/19.9.1583; Rezaul K, 1998, BIOCHEM BIOPH RES CO, V246, P863, DOI 10.1006/bbrc.1998.8691; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; WILLEBRAND VM, 1998, CELL SIGNAL, V10, P407; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	53	381	397	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24233	24241		10.1074/jbc.M212389200	http://dx.doi.org/10.1074/jbc.M212389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12711606	hybrid			2022-12-25	WOS:000183638600130
J	You, JX; Wang, M; Aoki, T; Tamura, T; Pickart, CM				You, JX; Wang, M; Aoki, T; Tamura, T; Pickart, CM			Proteolytic targeting of transcriptional regulator TIP120B by a HECT domain E3 ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; TBP-INTERACTING PROTEIN; TATA-BINDING PROTEIN; POLYUBIQUITIN CHAINS; CONJUGATING ENZYMES; 26S PROTEASOME; DEGRADATION; FAMILY; E6-AP; P53	Ubiquitin-protein ligases (E3s) of the HECT family share a conserved catalytic region that is homologous to the E6-AP C terminus. The HECT domain defines a large E3 family, but only a handful of these enzymes have been defined with respect to substrate specificity or biological function. We showed previously that the C-terminal domain of one family member, KIAA10, catalyzes the assembly of polyubiquitin chains, whereas the N-terminal domain binds to proteasomes in vitro (You, J., and Pickart, C. M. (2001) J. Biol. Chem. 276, 19871 19878). We show here that KIAA10 also associates with proteasomes within cells but that this association probably involves additional contacts with proteasome sub-units other than the one (S2/Rpn1) identified in our previous work. We report that the N-domain of KIAA10 also mediates an association with TIP120B (TATA-binding protein-interacting protein 120B), a putative transcriptional regulator. Biochemical and co-transfection studies revealed that TIP120B, but not the closely related protein TIP120A, is a specific substrate of KIAA10 in vitro and within C2C12 myoblasts but not in Cos-1 cells. KIAA10 and TIP120B are both highly expressed in human skeletal muscle, suggesting that KIAA10 may regulate TIP120B homeostasis specifically in this tissue.	Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Chiba University	Pickart, CM (corresponding author), Johns Hopkins Univ, Dept Biochem & Mol Biol, Bloomberg Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki T, 2002, BIOCHEM BIOPH RES CO, V296, P1097, DOI 10.1016/S0006-291X(02)02031-4; Aoki T, 1999, BIOCHEM BIOPH RES CO, V261, P911, DOI 10.1006/bbrc.1999.1147; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Makino Y, 1999, GENES CELLS, V4, P529, DOI 10.1046/j.1365-2443.1999.00277.x; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Wang GL, 1999, MOL CELL BIOL, V19, P342; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0	45	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23369	23375		10.1074/jbc.M212887200	http://dx.doi.org/10.1074/jbc.M212887200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692129	hybrid			2022-12-25	WOS:000183638600021
J	Zelcer, N; Huisman, MT; Reid, G; Wieling, P; Breedveld, P; Kuil, A; Knipscheer, P; Schellens, JHM; Schinkel, AH; Borst, P				Zelcer, N; Huisman, MT; Reid, G; Wieling, P; Breedveld, P; Kuil, A; Knipscheer, P; Schellens, JHM; Schinkel, AH; Borst, P			Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; BETA-ESTRADIOL 17-(BETA-D-GLUCURONIDE); SUBSTRATE-SPECIFICITY; LEUKOTRIENE C-4; P-GLYCOPROTEIN; GLUTATHIONE TRANSPORT; ABC TRANSPORTERS; DRUG TRANSPORT; BILE-ACIDS; MRP2	Multidrug resistance protein 2 (MRP2) belongs to the ATP binding cassette family of transporters. Its substrates include organic anions and anticancer drugs. We have used transport assays with vesicles derived from Sf9 insect cells overproducing MRP2 to study the interactions of drugs, organic anions, and bile acids with three MRP2 substrates: estradiol-17-beta-D-glucuronide (E(2)17betaG), methotrexate, and glutathione-S-dinitrophenol. Complex inhibition and stimulation patterns were obtained, different from those observed with the related transporters MRP1 and MRP3. In contrast to a previous report, we found that the rate of E(2)17betaG transport by MRP2 increases sigmoidally with substrate concentration indicative of homotropic cooperativity. Half-maximal transport was obtained at 120 muM E(2)17betaG, in contrast to values < 20 mu M for MRP1 and 3. MRP2 stimulators, such as indomethacin and sulfanitran, strongly increased the affinity of MRP2 for E(2)17 beta G (half-maximal transport rates at 65 and 16 mu M E(2)17 beta G, respectively) and shifted the sigmoidal dependence of transport rate on substrate concentration to a more hyperbolic one, without substantially affecting the maximal transport rate. Sulfanitran also stimulated MRP2 activity in cells, i.e. the transport of saquinavir through monolayers of Madin-Darby canine kidney II cells. Some compounds that stimulate E(2)17 beta G transport, such as penicillin G or pantoprazole, are not detectably transported by MRP2, suggesting that they allosterically stimulate transport without being cotransported with E(2)17 beta G. We propose that MRP2 contains two similar but nonidentical ligand binding sites: one site from which substrate is transported and a second site that regulates the affinity of the transport site for the substrate.	Netherlands Canc Inst, Dept Biol Mol, Div Expt Therapy, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Borst, P (corresponding author), Netherlands Canc Inst, Dept Biol Mol, Div Expt Therapy, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	p.borst@nki.nl	Zelcer, Noam/C-6393-2009	Wielinga, Peter/0000-0002-8830-0010; Reid, Glen/0000-0001-6465-5223; Kuil, Annemieke/0000-0002-8157-7412; Zelcer, Noam/0000-0001-6935-7532				Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Bodo A, 2003, J BIOL CHEM, V278, P23529, DOI 10.1074/jbc.M303515200; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Cantor RS, 1999, BIOPHYS J, V77, P2643, DOI 10.1016/S0006-3495(99)77098-0; Chen CP, 2003, PHARMACEUT RES, V20, P31, DOI 10.1023/A:1022238506509; Chen ZS, 1999, MOL PHARMACOL, V56, P1219, DOI 10.1124/mol.56.6.1219; Chen ZS, 2002, CANCER RES, V62, P3144; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Cupp-Vickery J, 2000, P NATL ACAD SCI USA, V97, P3050, DOI 10.1073/pnas.050406897; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DEELEY RG, 2002, ABC PROTEINS BACTERI, P393; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; Fernandez SBM, 2002, J BIOL CHEM, V277, P31048, DOI 10.1074/jbc.M204267200; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; Heijn M, 1997, BBA-BIOMEMBRANES, V1326, P12, DOI 10.1016/S0005-2736(97)00003-5; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Huisman MT, 2002, AIDS, V16, P2295, DOI 10.1097/00002030-200211220-00009; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Ito K, 2001, AM J PHYSIOL-GASTR L, V281, pG1034, DOI 10.1152/ajpgi.2001.281.4.G1034; Ito K, 2001, J BIOL CHEM, V276, P38108; Jedlitschky G, 1996, CANCER RES, V56, P988; Jedlitschky G, 2002, VITAM HORM, V64, P153, DOI 10.1016/S0083-6729(02)64005-1; Klein M, 1998, J BIOL CHEM, V273, P262, DOI 10.1074/jbc.273.1.262; Kondratov RV, 2001, P NATL ACAD SCI USA, V98, P14078, DOI 10.1073/pnas.241314798; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 2000, BIOCHEM BIOPH RES CO, V275, P795, DOI 10.1006/bbrc.2000.3384; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Paulusma CC, 1999, BIOCHEM J, V338, P393, DOI 10.1042/0264-6021:3380393; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; Rosenberg MF, 2003, J BIOL CHEM, V278, P8294, DOI 10.1074/jbc.M211758200; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharom FJ, 1996, BIOCHEM J, V320, P421, DOI 10.1042/bj3200421; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; VARADI A, 2002, ABC PROTEINS BACTERI, P37; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zelcer N, 2003, BIOCHEM J, V369, P23, DOI 10.1042/BJ20021081; Zelcer N, 2001, J BIOL CHEM, V276, P46400, DOI 10.1074/jbc.M107041200; Zeng H, 2001, CANCER RES, V61, P7225	57	166	169	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23538	23544		10.1074/jbc.M303504200	http://dx.doi.org/10.1074/jbc.M303504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12702717	hybrid			2022-12-25	WOS:000183638600042
J	Cenkci, B; Petersen, JL; Small, GD				Cenkci, B; Petersen, JL; Small, GD			REX1, a novel gene required for DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; NUCLEAR TRANSFORMATION; GENOME; MUTANTS	Nucleotide excision repair is a major pathway for repairing UV light-induced DNA damage in most organisms. Using insertional mutagenesis, we isolated a UV-sensitive mutant of Chlamydomonas reinhardtii that is blocked in the excision of cyclobutane pyrimidine dimers. The mutant is also sensitive to the alkylating agent, methyl methanesulphonate. We have cloned REX1, a novel gene that rescues the mutant. The gene is unusual in a eukaryotic organism in that it is predicted to encode two different proteins, a small protein (8.9 kDa) and a larger protein (31.8 kDa). Neither protein is homologous to known DNA repair proteins. Partial complementation is achieved with subclones of the gene encoding only the 8.9-kDa protein. The 8.9-kDa protein has homologues in many organisms including Saccharomyces cerevisiae, Arabidopsis, and humans. The 31.8-kDa protein appears to be less conserved. These findings may be of general importance for DNA repair in other organisms.	Univ S Dakota, Cellular & Mol Biol Grp, Vermillion, SD 57069 USA	University of South Dakota	Small, GD (corresponding author), Univ S Dakota, Cellular & Mol Biol Grp, 414 E Clark St, Vermillion, SD 57069 USA.	gsmall@usd.edu		Petersen, Jason/0000-0003-4939-5149	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM059857] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R15-GM059857] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398; Britt AB, 1999, TRENDS PLANT SCI, V4, P20, DOI 10.1016/S1360-1385(98)01355-7; Chang M, 2002, P NATL ACAD SCI USA, V99, P16934, DOI 10.1073/pnas.262669299; DEBUCHY R, 1989, EMBO J, V8, P2803, DOI 10.1002/j.1460-2075.1989.tb08426.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P191; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; Hays JB, 2002, DNA REPAIR, V1, P579, DOI 10.1016/S1568-7864(02)00093-9; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; Lumbreras V, 1998, PLANT J, V14, P441, DOI 10.1046/j.1365-313X.1998.00145.x; Narendra T, 2001, CRIT REV BIOCHEM MOL, V36, P337; NEWMAN SM, 1990, GENETICS, V126, P875; Petersen JL, 1999, PLANT MOL BIOL, V40, P1063, DOI 10.1023/A:1006279720960; PODSTAVKOVA S, 1992, MUTAT RES, V293, P65, DOI 10.1016/0921-8777(92)90009-R; Shimogawara K, 1998, GENETICS, V148, P1821; SMALL GD, 1987, MUTAT RES, V181, P31, DOI 10.1016/0027-5107(87)90284-3; Sutherland BM, 1999, METH MOL B, V113, P183; TAM LW, 1995, METHOD CELL BIOL, V47, P519, DOI 10.1016/S0091-679X(08)60855-9; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	19	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22574	22577		10.1074/jbc.M303249200	http://dx.doi.org/10.1074/jbc.M303249200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12697762	hybrid			2022-12-25	WOS:000183503900054
J	Lauwaet, T; Oliveira, MJ; Callewaert, B; De Bruyne, G; Saelens, X; Ankri, S; Vandenabeele, P; Mirelman, D; Mareel, M; Leroy, A				Lauwaet, T; Oliveira, MJ; Callewaert, B; De Bruyne, G; Saelens, X; Ankri, S; Vandenabeele, P; Mirelman, D; Mareel, M; Leroy, A			Proteolysis of enteric cell villin by Entamoeba histolytica cysteine proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; LIVER-ABSCESS FORMATION; IN-VITRO; HOST-CELLS; ACTIN CYTOSKELETON; CANCER-CELLS; CATHEPSIN-B; TROPHOZOITES; EXPRESSION; MECHANISMS	Invasive microorganisms efface enteric microvilli to establish intimate contact with the apical surface of enterocytes. To understand the molecular basis of this effacement in amebic colitis, we seeded Entamoeba histolytica trophozoites on top of differentiated human Caco-2 cell layers. Western blots of detergent lysates from such cocultures showed proteolysis of the actin-bundling protein villin within 1 min of direct contact of living trophozoites with enterocytes. Mixtures of separately prepared lysates excluded detergent colysis as the cause of villin proteolysis. Caspases were not responsible as evidenced by the lack of degradation of specific substrates and the failure of a specific caspase inhibitor to prevent villin proteolysis. A crucial role for amebic cysteine proteinases was shown by prevention of villin proteolysis and associated microvillar alterations through the treatment of trophozoites before coculture with synthetic inhibitors that completely blocked amebic cysteine proteinase activity on zymograms. Moreover, trophozoites of amebic strains pSA8 and SAW760 with strongly reduced cysteine proteinase activity showed a reduced proteolysis of villin in coculture with enteric cells. Salmonella typhimurium and enteropathogenic Escherichia coli disturb microvilli without villin proteolysis, indicating that the latter is not a consequence of the disturbance of microvilli. In conclusion, villin proteolysis is an early event in the molecular cross-talk between enterocytes and amebic trophozoites, causing a disturbance of microvilli.	State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; Weizmann Institute of Science	Leroy, A (corresponding author), State Univ Ghent Hosp, Expt Cancerol Lab, Pintelaan 185, B-9000 Ghent, Belgium.	ancy.leroy@rug.ac.be	MIRELMAN, DAVID/K-1596-2012; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022; Saelens, Xavier/N-5728-2015; Callewaert, Bert/J-6357-2014; Oliveira, Maria Jose/K-3275-2013	Vandenabeele, Peter/0000-0002-6669-8822; Callewaert, Bert/0000-0002-9743-4205; , Xavier/0000-0002-3861-6965; Oliveira, Maria Jose/0000-0002-0724-0272				Ankri S, 1998, MOL MICROBIOL, V28, P777, DOI 10.1046/j.1365-2958.1998.00837.x; Bartles JR, 1998, J CELL BIOL, V143, P107, DOI 10.1083/jcb.143.1.107; Bruchhaus I, 1996, MOL MICROBIOL, V22, P255, DOI 10.1046/j.1365-2958.1996.00111.x; BURCHARD GD, 1993, PARASITOL RES, V79, P140, DOI 10.1007/BF00932260; CLARK CG, 1995, J EUKARYOT MICROBIOL, V42, P590, DOI 10.1111/j.1550-7408.1995.tb05912.x; Cossart P, 1996, SCIENCE, V271, P315, DOI 10.1126/science.271.5247.315; DEBEAUREGARD MAC, 1995, EMBO J, V14, P409, DOI 10.1002/j.1460-2075.1995.tb07017.x; DUDOUET B, 1987, J CELL BIOL, V105, P359, DOI 10.1083/jcb.105.1.359; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Espinosa-Cantellano M, 2000, CLIN MICROBIOL REV, V13, P318, DOI 10.1128/CMR.13.2.318-331.2000; FATH KR, 1995, CURR BIOL, V5, P591, DOI 10.1016/S0960-9822(95)00117-5; Ferrary E, 1999, J CELL BIOL, V146, P819, DOI 10.1083/jcb.146.4.819; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; Goosney DL, 1999, TRENDS CELL BIOL, V9, P11, DOI 10.1016/S0962-8924(98)01418-4; Goosney DL, 1999, EMERG INFECT DIS, V5, P216, DOI 10.3201/eid0502.990205; HARDIN JA, 1992, ANN NY ACAD SCI, V664, P380, DOI 10.1111/j.1749-6632.1992.tb39776.x; HECHT G, 1994, AM J PHYSIOL, V266, pG214, DOI 10.1152/ajpgi.1994.266.2.G214; Hellberg A, 2001, CELL MICROBIOL, V3, P13, DOI 10.1046/j.1462-5822.2001.00086.x; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; HULDT G, 1979, NATURE, V277, P214, DOI 10.1038/277214a0; Huston CD, 2000, CELL MICROBIOL, V2, P617, DOI 10.1046/j.1462-5822.2000.00085.x; KEENE WE, 1990, EXP PARASITOL, V71, P199, DOI 10.1016/0014-4894(90)90022-5; Lauwaet T, 2000, MICROBES INFECT, V2, P923, DOI 10.1016/S1286-4579(00)00394-4; Lauwaet T, 2000, ARCH MED RES, V31, pS124, DOI 10.1016/S0188-4409(00)00146-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; Leippe M, 1995, PARASITOLOGY, V111, P569, DOI 10.1017/S0031182000077040; LEROY A, 1995, INFECT IMMUN, V63, P4253, DOI 10.1128/IAI.63.11.4253-4260.1995; Leroy A, 2000, FASEB J, V14, P1139, DOI 10.1096/fasebj.14.9.1139; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LUSHBAUGH WB, 1985, EXP PARASITOL, V59, P328, DOI 10.1016/0014-4894(85)90088-8; MARTINEZPALOMO A, 1985, J PROTOZOOL, V32, P166, DOI 10.1111/j.1550-7408.1985.tb03033.x; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; PHILLIPS AD, 1992, J PEDIATR GASTR NUTR, V14, P380, DOI 10.1097/00005176-199205000-00003; PINTO M, 1983, BIOL CELL, V47, P323; Que XC, 2000, CLIN MICROBIOL REV, V13, P196, DOI 10.1128/CMR.13.2.196-206.2000; RAVDIN JI, 1981, J CLIN INVEST, V68, P1305, DOI 10.1172/JCI110377; SMITH RE, 1988, ANTICANCER RES, V8, P525; Teixeira JE, 2002, INFECT IMMUN, V70, P1816, DOI 10.1128/IAI.70.4.1816-1823.2002; Vallance BA, 2000, P NATL ACAD SCI USA, V97, P8799, DOI 10.1073/pnas.97.16.8799; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Vaux DL, 1997, MOL CELL BIOL, V17, P6502, DOI 10.1128/MCB.17.11.6502; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Yan L, 2001, INFECT IMMUN, V69, P7911, DOI 10.1128/IAI.69.12.7911-7914.2001; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Zhang Z, 2000, MOL MICROBIOL, V37, P542, DOI 10.1046/j.1365-2958.2000.02037.x; ZIMMERHACKL LB, 1991, J CHROMATOGR, V587, P81, DOI 10.1016/0021-9673(91)85200-Y	49	28	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22650	22656		10.1074/jbc.M300142200	http://dx.doi.org/10.1074/jbc.M300142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690119	hybrid			2022-12-25	WOS:000183503900064
J	Colca, JR; McDonald, WG; Waldon, DJ; Thomasco, LM; Gadwood, RC; Lund, ET; Cavey, GS; Mathews, WR; Adams, LD; Cecil, ET; Pearson, JD; Bock, JH; Mott, JE; Shinabarger, DL; Xiong, LQ; Mankin, AS				Colca, JR; McDonald, WG; Waldon, DJ; Thomasco, LM; Gadwood, RC; Lund, ET; Cavey, GS; Mathews, WR; Adams, LD; Cecil, ET; Pearson, JD; Bock, JH; Mott, JE; Shinabarger, DL; Xiong, LQ; Mankin, AS			Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; PEPTIDYL TRANSFERASE CENTER; TRANSFER-RNA; RESISTANCE MUTATIONS; PROTEIN-SYNTHESIS; STRUCTURAL BASIS; ANTIBACTERIAL AGENTS; FUNCTIONAL SITES; MESSENGER-RNA; P-SITE	Oxazolidinone antibiotics, an important new class of synthetic antibacterials, inhibit protein synthesis by interfering with ribosomal function. The exact site and mechanism of oxazolidinone action has not been elucidated. Although genetic data pointed to the ribosomal peptidyltransferase as the primary site of drug action, some biochemical studies conducted in vitro suggested interaction with different regions of the ribosome. These inconsistent observations obtained in vivo and in vitro have complicated the understanding of oxazolidinone action. To localize the site of oxazolidinone action in the living cell, we have cross-linked a photoactive drug analog to its target in intact, actively growing Staphylococcus aureus. The oxazolidinone cross-linked specifically to 23 S rRNA, tRNA, and two polypeptides. The site of cross-linking to 23 S rRNA was mapped to the universally conserved A-2602. Polypeptides cross-linked were the ribosomal protein L27, whose N terminus may reach the peptidyltransferase center, and LepA, a protein homologous to translation factors. Only ribosome-associated LepA, but not free protein, was cross-linked, indicating that LepA was cross-linked by the ribosome-bound antibiotic. The evidence suggests that a specific oxazolidinone binding site is formed in the translating ribosome in the immediate vicinity of the peptidyltransferase center.	Pharmacia Corp, Kalamazoo, MI 49001 USA; Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	Pfizer; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colca, JR (corresponding author), Pharmacia Corp, 301 Henrietta St, Kalamazoo, MI 49001 USA.	jrcolca@pharmacia.com						ADAMS MA, 1995, CLIN BIOMECH, V10, P3, DOI 10.1016/0268-0033(95)90432-9; [Anonymous], [No title captured]; Aoki H, 2002, ANTIMICROB AGENTS CH, V46, P1080, DOI 10.1128/AAC.46.4.1080-1085.2002; AREVALO MA, 1989, J MED CHEM, V32, P2200, DOI 10.1021/jm00129a027; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Barbachyn MR, 1998, ADV EXP MED BIOL, V456, P219; BARRITAULT D, 1976, EUR J BIOCHEM, V63, P131, DOI 10.1111/j.1432-1033.1976.tb10215.x; BISCHOF O, 1994, J BIOL CHEM, V269, P18315; Brickner SJ, 1996, J MED CHEM, V39, P673, DOI 10.1021/jm9509556; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Burghardt H, 1998, FEBS LETT, V425, P40, DOI 10.1016/S0014-5793(98)00194-X; Caldon CE, 2001, MOL MICROBIOL, V41, P289, DOI 10.1046/j.1365-2958.2001.02536.x; Champney WS, 2002, CURR MICROBIOL, V44, P350, DOI 10.1007/s00284-001-0023-7; COOPERMAN BS, 1988, METHOD ENZYMOL, V164, P523; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DONTSOVA O, 1991, EMBO J, V10, P2613, DOI 10.1002/j.1460-2075.1991.tb07803.x; EUSTICE DC, 1988, BIOCHEM BIOPH RES CO, V150, P965, DOI 10.1016/0006-291X(88)90723-1; EUSTICE DC, 1988, ANTIMICROB AGENTS CH, V32, P1218, DOI 10.1128/AAC.32.8.1218; Ford CW, 1996, ANTIMICROB AGENTS CH, V40, P1508, DOI 10.1128/AAC.40.6.1508; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Hansen JL, 2002, P NATL ACAD SCI USA, V99, P11670, DOI 10.1073/pnas.172404099; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Kloss P, 1999, J MOL BIOL, V294, P93, DOI 10.1006/jmbi.1999.3247; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; Lin AH, 1997, ANTIMICROB AGENTS CH, V41, P2127, DOI 10.1128/AAC.41.10.2127; Mankin AS, 1997, J MOL BIOL, V274, P8, DOI 10.1006/jmbi.1997.1387; MANKIN AS, 1981, FEBS LETT, V131, P253, DOI 10.1016/0014-5793(81)80378-X; Matassova NB, 1999, RNA, V5, P939, DOI 10.1017/S1355838299990210; Merryman C, 1998, PRACT APPROACH SER, V192, P237; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; NICHOLSON AW, 1982, BIOCHEMISTRY-US, V21, P3797, DOI 10.1021/bi00259a013; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; Patel U, 2001, J BIOL CHEM, V276, P37199, DOI 10.1074/jbc.M102966200; Polacek N, 2003, MOL CELL, V11, P103, DOI 10.1016/S1097-2765(02)00825-0; Porse BT, 1999, P NATL ACAD SCI USA, V96, P9003, DOI 10.1073/pnas.96.16.9003; Prystowsky J, 2001, ANTIMICROB AGENTS CH, V45, P2154, DOI 10.1128/AAC.45.7.2154-2156.2001; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; RINKEAPPEL J, 1991, EMBO J, V10, P2195, DOI 10.1002/j.1460-2075.1991.tb07755.x; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Schlunzen F, 2001, NATURE, V413, P814, DOI 10.1038/35101544; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shinabarger D, 1999, Expert Opin Investig Drugs, V8, P1195, DOI 10.1517/13543784.8.8.1195; Shinabarger DL, 1997, ANTIMICROB AGENTS CH, V41, P2132, DOI 10.1128/AAC.41.10.2132; SONENBERG N, 1973, P NATL ACAD SCI USA, V70, P1423, DOI 10.1073/pnas.70.5.1423; Stevens DL, 2002, CLIN INFECT DIS, V34, P1481, DOI 10.1086/340353; Swaney SM, 1998, ANTIMICROB AGENTS CH, V42, P3251, DOI 10.1128/AAC.42.12.3251; SWANEY SM, 1998, 38 INT C ANT AG CHEM; TEJEDOR F, 1985, J ANTIMICROB CHEMOTH, V16, P53, DOI 10.1093/jac/16.suppl_A.53; Thompson J, 2002, J MOL BIOL, V322, P273, DOI 10.1016/S0022-2836(02)00784-2; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P797, DOI 10.1128/AAC.39.4.797; Wower IK, 1998, J BIOL CHEM, V273, P19847, DOI 10.1074/jbc.273.31.19847; Wower J, 2000, J BIOL CHEM, V275, P37887, DOI 10.1074/jbc.M005031200; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; Xiong LQ, 2000, J BACTERIOL, V182, P5325, DOI 10.1128/JB.182.19.5325-5331.2000; Zhou CC, 2002, ANTIMICROB AGENTS CH, V46, P625, DOI 10.1128/AAC.46.3.625-629.2002	59	115	123	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21972	21979		10.1074/jbc.M302109200	http://dx.doi.org/10.1074/jbc.M302109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12690106	hybrid			2022-12-25	WOS:000183354200083
J	Campbell, SJ; Hughes, PM; Iredale, JP; Wilcockson, DC; Waters, S; Docagne, F; Perry, VH; Anthony, DC				Campbell, SJ; Hughes, PM; Iredale, JP; Wilcockson, DC; Waters, S; Docagne, F; Perry, VH; Anthony, DC			CINC-1 is identified as an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury	FASEB JOURNAL			English	Article						MODS; IL-1 beta; cytokine; chemokine; neutrophil	INDUCED NEUTROPHIL CHEMOATTRACTANT; CHEMOKINERGIC NEURONAL PATHWAY; INFLAMMATORY RESPONSE; RAT-LIVER; BLOOD; CYTOKINE; INTERLEUKIN-1-BETA; INDUCTION; EXPRESSION; INJECTION	Following injury or infection, the liver releases acute-phase proteins (APP). After a severe focal injury, this systemic response can be excessive and may lead to multiorgan dysfunction (MODS). CINC-1 is a neutrophil chemoattractant, and we have now established that it also functions as an early APP after injury to the brain or to peripheral tissues. After induction of a focal inflammatory lesion in the brain, there is rapid hepatic and serum CINC-1 induction, which is associated with increases in neutrophil numbers within the liver and within the circulation. CINC-1-mediated recruitment of neutrophils to organs distant from the primary injury site may contribute to MODS. Indeed, we found that enzyme markers of liver tissue injury are increased in the serum following generation of a focal inflammatory lesion in the brain. Neutralization of CINC-1 in the periphery reversed brain-injury-induced neutrophil mobilization and inhibited recruitment of neutrophils to the brain and to the liver. Thus, a significant component of the hepatic acute-phase response is the release of chemokines by the liver, which act to amplify the inflammatory response and modulate the subsequent leukocytosis and secondary tissue damage. Hepatic CINC-1 synthesis following injury presents a novel focus for treatment of inflammation.	Univ Southampton, Sch Biol Sci, Mol Neuropathol Lab, Southampton S016 7PX, Hants, England; Univ Southampton, Sch Biol Sci, CNS, Inflammat Grp, Southampton S016 7PX, Hants, England; Univ Southampton, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton; University of Southampton	Campbell, SJ (corresponding author), Univ Southampton, Sch Biol Sci, Mol Neuropathol Lab, Biomed Sci Bldg, Southampton S016 7PX, Hants, England.	s.j.campbell@soton.ac.uk	Perry, V. Hugh/Y-2935-2019; Anthony, Daniel/F-7765-2010; Docagne, Fabian/S-8308-2018	Anthony, Daniel/0000-0003-1380-6655; Docagne, Fabian/0000-0003-1745-0625; Wilcockson, David/0000-0002-5923-4472; Iredale, John/0000-0003-2174-5127				ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; Anforth HR, 1998, EUR CYTOKINE NETW, V9, P279; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; Bhatia M, 2000, GUT, V47, P838, DOI 10.1136/gut.47.6.838; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Calkins CM, 2002, J ENDOTOXIN RES, V8, P59, DOI 10.1179/096805102125000092; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CSERR HF, 1992, BRAIN PATHOL, V2, P269, DOI 10.1111/j.1750-3639.1992.tb00703.x; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739, DOI 10.1152/ajpregu.1993.265.4.R739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Di Santo E, 1999, NEUROIMMUNOMODULAT, V6, P300, DOI 10.1159/000026388; Ek M, 1998, J NEUROSCI, V18, P9471; Fantuzzi G, 1996, J IMMUNOL, V157, P291; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GEISTERFER M, 1993, CYTOKINE, V5, P1, DOI 10.1016/1043-4666(93)90017-Y; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Hirata I, 2001, DIGESTION, V63, P73, DOI 10.1159/000051915; Iwamura H, 2002, INFLAMM RES, V51, P160, DOI 10.1007/PL00000288; King AG, 2001, BLOOD, V97, P1534, DOI 10.1182/blood.V97.6.1534; Knopf PM, 1998, J IMMUNOL, V161, P692; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Maher JJ, 1997, HEPATOLOGY, V25, P624, DOI 10.1002/hep.510250322; Mercer-Jones MA, 1999, INFLAMMATION, V23, P305; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Nishimoto N, 1994, Gan To Kagaku Ryoho, V21, P1707; OHehir RE, 1996, CLIN EXP ALLERGY, V26, P20, DOI 10.1111/j.1365-2222.1996.tb00052.x; Ohkubo K, 1998, J GASTROEN HEPATOL, V13, P696, DOI 10.1111/j.1440-1746.1998.tb00716.x; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pan WH, 2001, J NEUROIMMUNOL, V115, P64, DOI 10.1016/S0165-5728(01)00256-9; Rees GS, 1999, CYTOKINE, V11, P95, DOI 10.1006/cyto.1998.0408; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; RIVEST S, 1992, BRAIN RES, V587, P13, DOI 10.1016/0006-8993(92)91424-D; Saito JM, 2000, GASTROENTEROLOGY, V118, P1157, DOI 10.1016/S0016-5085(00)70369-6; Sakamoto Y, 1996, NEUROSCIENCE, V75, P133, DOI 10.1016/0306-4522(96)00252-7; Sakamoto Y, 1996, ENDOCRINOLOGY, V137, P4503, DOI 10.1210/en.137.10.4503; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHREIBER G, 1989, ANN NY ACAD SCI, V557, P61; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Tomkinson A, 2001, INT ARCH ALLERGY IMM, V126, P119, DOI 10.1159/000049502; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438, DOI 10.1164/ajrccm.164.8.2007121; Wiekowski MT, 2001, J IMMUNOL, V167, P7102, DOI 10.4049/jimmunol.167.12.7102; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Xu Y. X., 1999, Hematology, V4, P345; Yamada S, 2000, HEPATOLOGY, V32, P278, DOI 10.1053/jhep.2000.9604; Yamagami S, 1999, J LEUKOCYTE BIOL, V65, P744, DOI 10.1002/jlb.65.6.744; Yamamoto J, 1998, EUR J PHARMACOL, V363, P131, DOI 10.1016/S0014-2999(98)00801-2	55	107	110	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1168	+		10.1096/fj.02-0757fje	http://dx.doi.org/10.1096/fj.02-0757fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709409				2022-12-25	WOS:000182580100017
J	Moreno, M; Lombardi, A; De Lange, P; Silvestri, E; Ragni, M; Lanni, A; Goglia, F				Moreno, M; Lombardi, A; De Lange, P; Silvestri, E; Ragni, M; Lanni, A; Goglia, F			Fasting, lipid metabolism, and triiodothyronine in rat gastrocnemius muscle: interrelated roles of uncoupling protein 3, mitochondrial thioesterase, and coenzyme Q	FASEB JOURNAL			English	Article						mitochondria; UCP3; MTEI; T3	BROWN ADIPOSE-TISSUE; FREE FATTY-ACIDS; SKELETAL-MUSCLE; PROTON CONDUCTANCE; THYROID-HORMONE; YEAST MITOCHONDRIA; GENE-EXPRESSION; MESSENGER-RNA; C-13/P-31 NMR; UCP3 GENE	We investigated the role of uncoupling protein 3 (UCP3) during fasting and examined the effect of triiodothyronine (T3) administration in such a condition. The possible involvement of mitochondrial thioesterase (MTE I) and the role of putative cofactors, such as coenzyme Q (CoQ), was also examined. Here, we report that fasting induced a more than twofold elevation in the expression and activity of MTE I, and an increase in UCP3 expression, without any associated uncoupling activity. Administration of T3 to fasting rats further up-regulated UCP3 as well as MTE I expression, markedly enhanced MTE I enzyme activity and prevented the impairment of the uncoupling activity of UCP3 normally seen during fasting. Indeed, T3-treatment induced an UCP3-dependent decrease in mitochondrial membrane potential, which was abolished by the addition of either GDP or superoxide dismutase (SOD). T3 administration also prevented the marked decrease of CoQ levels observed in fasting rats and this provides evidence that also, in vivo, CoQ represents an essential cofactor for the UCP3-mediated uncoupling. The data also show that MTE I and UCP3 are likely involved in the same biochemical mechanism and that UCP3 postulated functions, such as lipid handling and uncoupling, are not mutually exclusive but may coexist in vivo.	Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Naples Federico II, Dipartimento Fisiol Gen & Ambientale, I-80134 Naples, Italy; Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy	University of Sannio; University of Naples Federico II; Universita della Campania Vanvitelli	Goglia, F (corresponding author), Univ Sannio, Dipartimento Sci Biol & Ambientali, Via Port Arsa 1, I-82100 Benevento, Italy.	antonia.lanni@unina2.it; goglia@unisannio.it	de Lange, Pieter/GXA-3052-2022; Ragni, Maurizio/AAB-1527-2020	Ragni, Maurizio/0000-0001-6548-741X; MORENO, Maria/0000-0002-6218-5501; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; BLAKE NG, 1991, ENDOCRINOLOGY, V129, P2714, DOI 10.1210/endo-129-5-2714; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Cadenas S, 2000, BIOCHEM J, V348, P209, DOI 10.1042/0264-6021:3480209; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Clapham JC, 2001, BIOCHEM BIOPH RES CO, V287, P1058, DOI 10.1006/bbrc.2001.5698; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; DULLOO AG, 2001, BR J NUTR, V86, P1; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2001, BIOCHEM SOC T, V29, P763; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Jucker BM, 2000, J BIOL CHEM, V275, P39279, DOI 10.1074/jbc.M007760200; Klingenberg M, 2001, BIOCHEM SOC T, V29, P806; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Lanni A, 1996, J PHYSIOL-LONDON, V494, P831, DOI 10.1113/jphysiol.1996.sp021536; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; Lebon V, 2001, J CLIN INVEST, V108, P733, DOI 10.1172/JCI11775; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Nohl H, 2001, BIOORG CHEM, V29, P1, DOI 10.1006/bioo.2000.1193; OPPENHEIMER JH, 1991, J CLIN INVEST, V87, P125, DOI 10.1172/JCI114961; RANGANATHAN S, 1975, BIOCHEM J, V148, P35, DOI 10.1042/bj1480035; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Simonyan RA, 1998, FEBS LETT, V436, P81, DOI 10.1016/S0014-5793(98)01106-5; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; TAKADA M, 1982, BIOCHIM BIOPHYS ACTA, V679, P308, DOI 10.1016/0005-2728(82)90301-2; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; WIMPFHEIMER C, 1979, SCIENCE, V205, P1272, DOI 10.1126/science.224460; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	49	34	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1112	+		10.1096/fj.02-0839fje	http://dx.doi.org/10.1096/fj.02-0839fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692085				2022-12-25	WOS:000182580100035
J	Zernecke, A; Erl, W; Fraemohs, L; Lietz, M; Weber, C				Zernecke, A; Erl, W; Fraemohs, L; Lietz, M; Weber, C			Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from I kappa B kinase inhibition and cell death induction	FASEB JOURNAL			English	Article						cell adhesion molecules; endothelium; transcription factors	ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GENE-EXPRESSION; MONOCYTE ADHESION; APOPTOSIS; TRANSCRIPTION; SIGNALS; PATHWAY; VCAM-1	The cyclopentenone prostaglandins (cPG) 15-deoxy-Delta(12,14N)-prostaglandin J(2) (dPGJ(2)) and PGA(1) can inhibit multiple steps in nuclear factor (NF)-kappaB signaling and can induce cell death. Here we characterized the effects of dPGJ(2) and PGA(1) on the inflammatory induction of endothelial cell adhesion molecules (CAM). Pretreatment of endothelial cells with dPGJ(2) or PGA(1) at low concentrations dose dependently inhibited the up-regulation of CAM expression and monocyte arrest by tumor necrosis factor (TNF)-alpha, but not expression of inhibitor of apoptosis proteins. Only at high concentrations, cPG enhanced TNF-alpha-induced cell death and inhibited TNF-alpha-induced IkappaB-alpha kinase (IKK) activation, IkappaB-alpha degradation, and NF-kappaB/p65 translocation, while promoting AP-1/c-jun phosphorylation. Expression of an IKK-beta mutant (C179A) resistant to interaction with cPG impaired cell death induction but not inhibition of CAM up-regulation by cPG. Gel shift and reporter gene analysis revealed that cPG at low concentrations directly impaired DNA binding of NF-kappaB and NF-kappaB-dependent transactivation. The synthetic analogs dPGA(1) or dPGA(2) were ineffective, indicating structural specificity of cPG. Thus, the suppression of endothelial CAM up-regulation with cPG is dissociated from cell death sensitization and IKK inhibition above threshold concentrations and related to interference with NF-kappaB binding. Our findings define distinct mechanisms for anti-inflammatory and proapoptotic effects of cPG in endothelial cells.	Univ Munich, Inst Prophylaxe Kreislaufkrankheiten, D-80336 Munich, Germany; Rhein Westfal TH Aachen, Dept Mol Cardiovasc Res, D-52074 Aachen, Germany	University of Munich; RWTH Aachen University	Weber, C (corresponding author), Univ Klinikum Aachen, Pauwelstr 30, D-52074 Aachen, Germany.	cweber@ukaachen.de	Weber, Christian/AAW-2153-2020	Weber, Christian/0000-0003-4610-8714				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Chen NG, 2001, BIOCHEM BIOPH RES CO, V282, P717, DOI 10.1006/bbrc.2001.4628; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Neuzil J, 2001, BIOCHEMISTRY-US, V40, P4686, DOI 10.1021/bi002498n; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	37	24	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1099	+		10.1096/fj.02-0485fje	http://dx.doi.org/10.1096/fj.02-0485fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692090				2022-12-25	WOS:000182580100038
J	Schweickhardt, RL; Jiang, XL; Garone, LM; Brondyk, WH				Schweickhardt, RL; Jiang, XL; Garone, LM; Brondyk, WH			Structure-expression relationship of tumor necrosis factor receptor mutants that increase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; YEAST SURFACE-DISPLAY; PROTEIN; EVOLUTION; AFFINITY	The extracellular domain of the p55 TNF receptor (TN-FrED) is an important therapeutic protein for targeting tumor necrosis factor-alpha (TNF-alpha). The expression level of the TNFrED is low for bioproduction, which is presumably associated with the complication of pairing 24 cysteine residues to form correct disulfide bonds. Here we report the application of the yeast display method to study expression of TNFrED, a multimeric receptor. Randomly mutated libraries of TNFrED were screened, and two mutants were identified that express several-fold higher protein levels compared with the wild type while still retaining normal binding affinity for TNF-alpha. The substituted residues responsible for the higher protein expression in both mutants were identified as proline, and both proline residues are adjacent to cysteine residues involved in disulfide bonds. Analysis of the mutant residues revealed that the improved level of expression is due to conformational restriction of the substituted residues to that of the folded state seen in the crystal structures of TNFrED thereby forcing the neighboring cysteine residues into the correct orientation for proper disulfide bond formation.	Serono Reprod Biol Inst, Rockland, MA 02370 USA		Jiang, XL (corresponding author), Serono Reprod Biol Inst, 1 Technol Pl, Rockland, MA 02370 USA.							BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Bemelmans MHA, 1996, CRIT REV IMMUNOL, V16, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Brenner SE, 2000, NUCLEIC ACIDS RES, V28, P254, DOI 10.1093/nar/28.1.254; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDGINGTON SM, 1992, BIO-TECHNOL, V10, P1413, DOI 10.1038/nbt1192-1413; Eyles SJ, 2000, J MOL BIOL, V301, P737, DOI 10.1006/jmbi.2000.4002; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hamilton K, 2000, Expert Opin Pharmacother, V1, P1041, DOI 10.1517/14656566.1.5.1041; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; Holler PD, 2000, P NATL ACAD SCI USA, V97, P5387, DOI 10.1073/pnas.080078297; Kam L Y, 2000, Expert Opin Pharmacother, V1, P615, DOI 10.1517/14656566.1.4.615; Kieke MC, 1997, PROTEIN ENG, V10, P1303, DOI 10.1093/protein/10.11.1303; Kieke MC, 1999, P NATL ACAD SCI USA, V96, P5651, DOI 10.1073/pnas.96.10.5651; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; Wittrup K. Dane, 1995, Current Opinion in Biotechnology, V6, P203, DOI 10.1016/0958-1669(95)80033-6	23	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					28961	28967		10.1074/jbc.M212019200	http://dx.doi.org/10.1074/jbc.M212019200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12716880	hybrid			2022-12-25	WOS:000184421100076
J	Alvarez, B; Garrido, E; Garcia-Sanz, JA; Carrera, AC				Alvarez, B; Garrido, E; Garcia-Sanz, JA; Carrera, AC			Phosphoinositide 3-kinase activation regulates cell division time by coordinated control of cell mass and cell cycle progression rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; ORGAN GROWTH; TRANSLATION INITIATION; GENETIC-CONTROL; DROSOPHILA; SIZE; PHOSPHORYLATION	Cells must increase their mass in coordination with cell cycle progression to ensure that their size and macromolecular composition remain constant for any given proliferation rate. To this end, growth factors activate early signaling cascades that simultaneously promote cell mass increase and induce cell cycle entry. Nonetheless, the mechanism that controls the concerted regulation of cell growth and cell cycle entry in mammals remains unknown. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B pathway regulates cell cycle entry by inactivating forkhead transcription factors and promoting cyclin D synthesis. PI3K/protein kinase B-derived signals also affect activation of p70 S6 kinase and the mammalian target of rapamycin, enzymes involved in cell growth control. We previously showed that enhancement of PI3K activation accelerates cell cycle entry, whereas reduction of PI3K activation retarded this process. Here we examined whether expression of different PI3K mutants affects cell growth during cell division. We show that diminishing or enhancing the magnitude of PI3K activation in a transient manner reduces or increases, respectively, the protein synthesis rate. Alteration of cell growth and cell cycle entry by PI3K forms appears to be concerted, because it results in lengthening or shortening of cell division time without altering cell size. In support of a central role for PI3K in growth control, expression of a deregulated, constitutive active PI3K mutant affects p70 S6 kinase and mammalian target of rapamycin activities and increases cell size. Together, the results show that transient PI3K activation regulates cell growth and cell cycle in a coordinated manner, which in turn controls cell division time.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Carrera, AC (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Carretera Colmenar Km 15, E-28049 Madrid, Spain.		Garcia-Sanz, Jose A/E-7684-2011; Garcia-Sanz, Jose A./AAA-2956-2019	Garcia-Sanz, Jose A/0000-0002-1153-6025; Garcia-Sanz, Jose A./0000-0002-1153-6025; Carrera, Ana/0000-0002-3999-5434				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; BARBET NC, 1996, MOL CELL BIOL, V3, P1014; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gonzalez-Garcia A, 2002, J BIOL CHEM, V277, P1500, DOI 10.1074/jbc.M103808200; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Neufeld TP, 1998, CURR OPIN CELL BIOL, V10, P784, DOI 10.1016/S0955-0674(98)80122-1; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pimentel B, 2002, DEV BIOL, V247, P295, DOI 10.1006/dbio.2002.0703; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; RODRIGUEZBORLAD.L, 2000, FASEB J, V14, P895; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tapon N, 2001, CURR OPIN CELL BIOL, V13, P731, DOI 10.1016/S0955-0674(00)00284-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	75	47	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26466	26473		10.1074/jbc.M300663200	http://dx.doi.org/10.1074/jbc.M300663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12707257	hybrid			2022-12-25	WOS:000184155700024
J	Harper, N; Hughes, M; MacFarlane, M; Cohen, GM				Harper, N; Hughes, M; MacFarlane, M; Cohen, GM			Fas-associated death domain protein and caspase-8 are not recruited to the tumor necrosis factor receptor 1 signaling complex during tumor necrosis factor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED-PROXIMITY MODEL; INDUCED CELL-DEATH; TNF RECEPTOR; KINASE RIP; MEDIATED APOPTOSIS; TRAIL RECEPTOR-2; CD95 FAS/APO-1; ACTIVATION; FADD	Death receptors are a subfamily of the tumor necrosis factor (TNF) receptor subfamily. They are characterized by a death domain (DD) motif within their intracellular domain, which is required for the induction of apoptosis. Fas-associated death domain protein (FADD) is reported to be the universal adaptor used by death receptors to recruit and activate the initiator caspase-8. CD95, TNF-related apoptosis-inducing ligand (TRAIL-R1), and TRAIL-R2 bind FADD directly, whereas recruitment to TNF-R1 is indirect through another adaptor TNF receptor-associated death domain protein (TRADD). TRADD also binds two other adaptors receptor-interacting protein (RIP) and TNF-receptor-associated factor 2 (TRAF2), which are required for TNF-induced NF-kappaB and c-Jun N-terminal kinase activation, respectively. Analysis of the native TNF signaling complex revealed the recruitment of RIP, TRADD, and TRAF2 but not FADD or caspase-8. TNF failed to induce apoptosis in FADD- and caspase-8-deficient Jurkat cells, indicating that these apoptotic mediators were required for TNF-induced apoptosis. In an in vitro binding assay, the intracellular domain of TNF-R1 bound TRADD, RIP, and TRAF2 but did not bind FADD or caspase-8. Under the same conditions, the intracellular domain of both CD95 and TRAIL-R2 bound both FADD and caspase-8. Taken together these results suggest that apoptosis signaling by TNF is distinct from that induced by CD95 and TRAIL. Although caspase-8 and FADD are obligatory for TNF-mediated apoptosis, they are not recruited to a TNF-induced membrane-bound receptor signaling complex as occurs during CD95 or TRAIL signaling, but instead must be activated elsewhere within the cell.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008					Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; Jones SJ, 1999, J IMMUNOL, V162, P1042; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Ko YG, 1999, J IMMUNOL, V162, P7217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VAN AD, 1996, SCIENCE, V274, P787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	57	154	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25534	25541		10.1074/jbc.M303399200	http://dx.doi.org/10.1074/jbc.M303399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12721308	hybrid			2022-12-25	WOS:000183920200034
J	Jacobs, DM; Saxena, K; Vogtherr, M; Bernado, P; Pons, M; Fiebig, KM				Jacobs, DM; Saxena, K; Vogtherr, M; Bernado, P; Pons, M; Fiebig, KM			Peptide binding induces large scale changes in inter-domain mobility in human Pin1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESIDUAL DIPOLAR COUPLINGS; PROLYL ISOMERASE PIN1; LIQUID-CRYSTALLINE PHASE; NMR SOLUTION STRUCTURE; GLOBULAR-PROTEINS; WW DOMAIN; HYDRODYNAMIC CALCULATIONS; SUBSTRATE RECOGNITION; REGULATORY MECHANISM; BACKBONE DYNAMICS	Pin1 is a peptidyl-prolyl cis/trans isomerase (PPIase) essential for cell cycle regulation. Pin1-catalyzed peptidylprolyl isomerization provides a key conformational switch to activate phosphorylation sites with the common phospho-Ser/Thr-Pro sequence motif. This motif is ubiquitously exploited in cellular response to a variety of signals. Pin1 is able to bind phospho-Ser/Thr-Pro containing sequences at two different sites that compete for the same substrate. One binding site is located within the N-terminal WW domain, which is essential for protein targeting and localization. The other binding site is located in the C-terminal catalytic domain, which is structural homologous to the FK506-binding protein (FKBP) class of PPIases. A flexible linker of 12 residues connects the WW and catalytic domain. To characterize the structure and dynamics of full-length Pin1 in solution, high resolution NMR methods have been used to map the nature of interactions between the two domains of Pin1. In addition, the influence of target peptides on domain interactions has been investigated. The studies reveal a dynamic picture of the domain interactions. N-15 spin relaxation data, differential chemical shift mapping, and residual dipolar coupling data indicate that Pin1 can either behave as two independent domains connected by the flexible linker or as a single intact domain with some amount of hinge bending motion depending on the sequence of the bound peptide. The functional importance of the modulation of relative domain flexibility in light of the multitude of interaction partners of Pin1 is discussed.	Univ Frankfurt, Inst Organ Chem & Chem Biol, D-60439 Frankfurt, Germany; Univ Barcelona, Dept Quim Organ, E-08028 Barcelona, Spain	Goethe University Frankfurt; University of Barcelona	Fiebig, KM (corresponding author), Affinium Pharmaceut, 100 Univ Ave,12th Floor N Tower, Toronto, ON M5J 1V6, Canada.		Bernado, Pau/F-9643-2013; pons, miquel/C-8657-2011	pons, miquel/0000-0002-0586-8322; Bernado, Pau/0000-0001-7395-5922; Fiebig, Klaus/0000-0002-9553-2645				Al-Hashimi HM, 2000, J MAGN RESON, V143, P402, DOI 10.1006/jmre.2000.2049; Bayer E, 2003, J BIOL CHEM, V278, P26183, DOI 10.1074/jbc.M300721200; Bernado P, 2002, J BIOMOL NMR, V23, P139, DOI 10.1023/A:1016359412284; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2001, J AM CHEM SOC, V123, P8634, DOI 10.1021/ja016234f; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Dosset P, 2001, J BIOMOL NMR, V20, P223, DOI 10.1023/A:1011206132740; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Galat A, 2000, EUR J BIOCHEM, V267, P4945, DOI 10.1046/j.1432-1327.2000.01509.x; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176; Jacobs DM, 2002, J BIOMOL NMR, V23, P163, DOI 10.1023/A:1016364324096; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; Kops O, 2002, FEBS LETT, V513, P305, DOI 10.1016/S0014-5793(02)02288-3; Kowalski JA, 2002, BIOPOLYMERS, V63, P111, DOI 10.1002/bip.10020; Landrieu I, 2002, J MOL BIOL, V320, P321, DOI 10.1016/S0022-2836(02)00429-1; Landrieu I, 2001, J BIOL CHEM, V276, P1434, DOI 10.1074/jbc.M006420200; Lavoie SB, 2001, J MOL BIOL, V312, P675, DOI 10.1006/jmbi.2001.4991; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Meiler J, 2001, J AM CHEM SOC, V123, P6098, DOI 10.1021/ja010002z; Meissner A, 1997, J BIOMOL NMR, V10, P89, DOI 10.1023/A:1018331001961; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; PENG JW, 1994, METHOD ENZYMOL, V239, P536; Peti W, 2002, J AM CHEM SOC, V124, P5822, DOI 10.1021/ja011883c; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Ryan KM, 2002, NATURE, V419, P795, DOI 10.1038/419795a; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Sekerina E, 2000, J MOL BIOL, V301, P1003, DOI 10.1006/jmbi.2000.4013; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y; Ulmer TS, 2002, STRUCTURE, V10, P901, DOI 10.1016/S0969-2126(02)00781-5; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Warren JJ, 2001, J MAGN RESON, V149, P271, DOI 10.1006/jmre.2001.2307; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; Wintjens R, 2001, J BIOL CHEM, V276, P25150, DOI 10.1074/jbc.M010327200; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zarnt T, 1997, J MOL BIOL, V271, P827, DOI 10.1006/jmbi.1997.1206; Zhang YX, 2002, BIOCHEMISTRY-US, V41, P11868, DOI 10.1021/bi0262395; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X; Zhou XZ, 1999, CELL MOL LIFE SCI, V56, P788, DOI 10.1007/s000180050026; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	58	87	87	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26174	26182		10.1074/jbc.M300796200	http://dx.doi.org/10.1074/jbc.M300796200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12686540	hybrid			2022-12-25	WOS:000183920200116
J	Schild, L; Huppelsberg, J; Kahlert, S; Keilhoff, G; Reiser, G				Schild, L; Huppelsberg, J; Kahlert, S; Keilhoff, G; Reiser, G			Brain mitochondria are primed by moderate Ca2+ rise upon hypoxia/reoxygenation for functional breakdown and morphological disintegration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; FOCAL CEREBRAL-ISCHEMIA; RAT-LIVER MITOCHONDRIA; CYCLOSPORINE-A; OUTER-MEMBRANE; CELL-DEATH; SUPEROXIDE-DISMUTASE; ARTERY OCCLUSION; CONTACT SITES	In animal models, brain ischemia causes changes in respiratory capacity, mitochondrial morphology, and cytochrome c release from mitochondria as well as a rise in cytosolic Ca2+ concentration. However, the causal relationship of the cellular processes leading to mitochondrial deterioration in brain has not yet been clarified. Here, by applying various techniques, we used isolated rat brain mitochondria to investigate how hypoxia/ reoxygenation and nonphysiological Ca2+ concentrations in the low micromolar range affect active ( state 3) respiration, membrane permeability, swelling, and morphology of mitochondria. Either transient hypoxia or a micromolar rise in extramitochondrial Ca2+ concentration, given as a single insult alone, slightly decreased active respiration. However, the combination of both insults caused devastating effects. These implied almost complete loss of active respiration, release of both NADH and cytochrome c, and rupture of mitochondria, as shown by electron microscopy. Mitochondrial respiration deteriorated even in the presence of cyclosporin A, documenting that membrane permeabilization occurred independent of mitochondrial permeability transition pore. Ca2+ has to enter the mitochondrial matrix in order to mediate this mitochondrial injury, because blockade of the mitochondrial Ca2+-transport system by ruthenium red in combination with CGP37157 completely prevented damage. Furthermore, protection of respiration from Ca2+-mediated damage by the adenine nucleotide ADP, but not by AMP, during hypoxia/ reoxygenation is consistent with the delayed susceptibility of brain mitochondria to prolonged hypoxia, which is observed in vivo.	Univ Magdeburg, Fak Med, Inst Klin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Fak Med, Inst Neurobiochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Fak Med, Inst Med Neurobiol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Univ Magdeburg, Fak Med, Inst Klin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.							Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Anderson MF, 1999, J NEUROCHEM, V73, P1189, DOI 10.1046/j.1471-4159.1999.0731189.x; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; BAKKER A, 1994, BBA-MOL CELL RES, V1224, P583, DOI 10.1016/0167-4889(94)90297-6; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Kahlert S, 2002, FEBS LETT, V529, P351, DOI 10.1016/S0014-5793(02)03394-X; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Lemasters JJ, 2002, ANTIOXID REDOX SIGN, V4, P769, DOI 10.1089/152308602760598918; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Makarov PR, 2002, BRAIN RES, V933, P91, DOI 10.1016/S0006-8993(02)02246-1; Martin LJ, 2000, NEUROBIOL DIS, V7, P169, DOI 10.1006/nbdi.2000.0282; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Namura S, 2001, STROKE, V32, P1906, DOI 10.1161/01.STR.32.8.1906; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P557, DOI 10.1097/00004647-200105000-00010; Polster BM, 2001, J BIOL CHEM, V276, P37887; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Schild L, 1997, BIOCHEM J, V328, P205, DOI 10.1042/bj3280205; Schild L, 1996, ACTA OPHTHALMOL SCAN, V74, P354; Schild L, 2001, FASEB J, V15, P565; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; Solenski NJ, 2002, STROKE, V33, P816, DOI 10.1161/hs0302.104541; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Vachon P, 2002, BRAIN RES, V943, P1, DOI 10.1016/S0006-8993(02)02413-7; Vieira HLA, 1999, CELL MOL LIFE SCI, V56, P971, DOI 10.1007/s000180050486; VONZGLINICKI T, 1991, MECH AGEING DEV, V57, P233, DOI 10.1016/0047-6374(91)90049-6; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhang YL, 1999, J NEUROSCI, V19, P3307	39	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25454	25460		10.1074/jbc.M302743200	http://dx.doi.org/10.1074/jbc.M302743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12702720	hybrid			2022-12-25	WOS:000183920200025
J	Haughn, L; Hawley, RG; Morrison, DK; von Boehmer, H; Hockenbery, DM				Haughn, L; Hawley, RG; Morrison, DK; von Boehmer, H; Hockenbery, DM			BCL-2 and BCL-X-L restrict lineage choice during hematopoietic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-DEFICIENT MICE; CELL-DEATH; MEDIATED ACTIVATION; GROWTH-FACTORS; EXPRESSION; APOPTOSIS; PROTEIN; FAMILY; INHIBITION; RAF-1	Differentiation of hematopoietic cells from multipotential progenitors is regulated by multiple growth factors and cytokines. A prominent feature of these soluble factors is promotion of cell survival, in part mediated by expression of either of the anti-apoptotic proteins, BCL-2 and BCL-X-L. The complex expression pattern of these frequently redundant survival factors during hematopoiesis may indicate a role in lineage determination. To investigate the latter possibility, we analyzed factor-dependent cell-Patersen (FDCP)-Mix multipotent progenitor cells in which we stably expressed BCL-2 or BCL-X-L. Each factor maintained complete survival of interleukin-3 (IL-3)-deprived FDCP-Mix cells but, unexpectedly, directed FDCP-Mix cells along restricted and divergent differentiation pathways. Thus, IL-3-deprived FDCP-Mix BCL-2 cells differentiated exclusively to granulocytes and monocytes/macrophages, whereas FDCP-Mix BCL-X-L cells became erythroid. FDCP-Mix BCL-2 cells grown in IL-3 were distinguished from FDCP-Mix and FDCP-Mix BCL-X-L cells by a striking reduction in cellular levels of Raf-1 protein. Replacement of the BCL-2 BH4 domain with the related BCL-X-L BH4 sequence resulted in a switch of FDCP-Mix BCL-2 cells to erythroid fate accompanied by persistence of Raf-1 protein expression. Moreover, enforced expression of Raf-1 redirected FDCP-Mix BCL-2 cells to an erythroid fate, and prohibited generation of myeloid cells. These results identify novel roles for BCL-2 and BCL-X-L in cell fate decisions beyond cell survival. These effects are associated with differential regulation of Raf-1 expression, perhaps involving the previously identified interaction between BCL-2-BH4 and the catalytic domain of Raf-1.	Fred Hutchinson Canc Res Ctr, Div Human Biol & Clin Res, Seattle, WA 98109 USA; Amer Red Cross, Hematopoiesis Dept, Jerome H Holland Lab, Rockville, MD 20855 USA; NCI, Cellular Growth Mechanisms Sect, Frederick Canc Res & Dev Ctr, NIH, Ft Detrick, MD 21702 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Fred Hutchinson Cancer Center; American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Harvard University; Dana-Farber Cancer Institute	Hockenbery, DM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol & Clin Res, Mailstop D2-190,1100 Fairview Ave N, Seattle, WA 98109 USA.			Hawley, Robert/0000-0003-3512-5818	NATIONAL CANCER INSTITUTE [Z01BC010329, ZIABC010329] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054881] Funding Source: NIH RePORTER; NHLBI NIH HHS [IP50HL54881] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1999, COLD SPRING HARB SYM, V64, P351, DOI 10.1101/sqb.1999.64.351; Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Arcinas M, 2001, CANCER RES, V61, P5202; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Chalandon Y, 2002, BLOOD, V99, P3197, DOI 10.1182/blood.V99.9.3197; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; Harada H, 1998, J ORAL PATHOL MED, V27, P11; Haughn L, 1998, J EXP MED, V188, P1575, DOI 10.1084/jem.188.9.1575; Hawley RG, 1996, ANN NY ACAD SCI, V795, P341, DOI 10.1111/j.1749-6632.1996.tb52687.x; Hu ZB, 1996, LEUKEMIA, V10, P1925; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Josefsen D, 2000, STEM CELLS, V18, P261, DOI 10.1634/stemcells.18-4-261; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LLOYDS D, 1995, BBA-MOL CELL RES, V1267, P65, DOI 10.1016/0167-4889(95)00031-M; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Metcalf D, 1999, SEMIN HEMATOL, V36, P5; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Ogawa M, 1999, INT J HEMATOL, V69, P2; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; PARK JR, 1995, BLOOD, V86, P868; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM SM, 1990, ONCOGENE, V5, P345; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	48	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25158	25165		10.1074/jbc.M212849200	http://dx.doi.org/10.1074/jbc.M212849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721288	hybrid			2022-12-25	WOS:000183824800110
J	Mella, M; Colotti, G; Zamparelli, C; Verzili, D; Ilari, A; Chiancone, E				Mella, M; Colotti, G; Zamparelli, C; Verzili, D; Ilari, A; Chiancone, E			Information transfer in the penta-EF-hand protein sorcin does not operate via the canonical structural/functional pairing - A study with site-specific mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNEXIN ANNEXIN-VII; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; RYANODINE RECEPTOR; CA2+-BINDING PROTEINS; M-CALPAIN; CALCIUM; BINDING; MEMBER; FAMILY	Sorcin is a typical penta-EF-hand protein that participates in Ca2+-regulated processes by translocating reversibly from cytosol to membranes, where it interacts with different target proteins in different tissues. Binding of two Ca2+/monomer triggers translocation, although EF1, EF2, and EF3 are potentially able to bind calcium at micromolar concentrations. To identify the functional pair, the conserved bidentate -Z glutamate in these EF-hands was mutated to yield E53Q-, E94A-, and E124A-sorcin, respectively. Limited structural perturbations occur only in E124A-sorcin due to involvement of Glu-124 in a network of interactions that comprise the long D helix connecting EF3 to EF2. The overall affinity for Ca2+ and for two sorcin targets, annexin VII and the ryanodine receptor, follows the order wildtype > E53Q- > E94A- > E124A-sorcin, indicating that disruption of EF3 has the largest functional impact and that disruption of EF2 and EF1 has progressively smaller effects. Based on this experimental evidence, EF3 and EF2, which are not paired in the canonical manner, are the functional EF-hands. Sorcin is proposed to be activated upon Ca2+ binding to EF3 and transmission of the conformational change at Glu-124 via the D helix to EF2 and from there to EF1 via the canonical structural/functional pairing. This mechanism may be applicable to all penta-EF-hand proteins.	Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Chiancone, E (corresponding author), Univ Roma La Sapienza, CNR, Inst Mol Biol & Pathol, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Colotti, Gianni/D-2015-2010; Colotti, Gianni/AAG-4918-2019; Ilari, Andrea/T-5501-2017; Ilari, Andrea/AAC-7670-2022	Colotti, Gianni/0000-0002-9913-0635; Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X				Andre I, 2002, ANAL BIOCHEM, V305, P195, DOI 10.1006/abio.2002.5661; *BIAC AB, 1994, BIOATECHN HDB VERS A, P4; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; BRYANT DTW, 1985, BIOCHEM J, V226, P613, DOI 10.1042/bj2260613; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Clemen CS, 1999, J MUSCLE RES CELL M, V20, P669, DOI 10.1023/A:1005524623337; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; Fefeu S, 2000, BIOCHEMISTRY-US, V39, P15920, DOI 10.1021/bi001772a; Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Ilari A, 2002, J MOL BIOL, V317, P447, DOI 10.1006/jmbi.2002.5417; Jaren OR, 2000, BIOCHEMISTRY-US, V39, P6881, DOI 10.1021/bi000037w; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Jia J, 2001, STRUCTURE, V9, P267, DOI 10.1016/S0969-2126(01)00585-8; Jia J, 2001, ACTA CRYSTALLOGR D, V57, P1843, DOI 10.1107/S0907444901016511; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; KRAULIS PJ, 1993, J APPL CRYSTALLOGR, V26, P283; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; Lollike K, 2001, J BIOL CHEM, V276, P17762, DOI 10.1074/jbc.M100965200; Meyers MB, 1998, J BIOL CHEM, V273, P18930, DOI 10.1074/jbc.273.30.18930; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; Nelson MR, 1998, BIOMETALS, V11, P297, DOI 10.1023/A:1009253808876; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Salzer U, 2002, BLOOD, V99, P2569, DOI 10.1182/blood.V99.7.2569; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Sun H, 2001, BIOCHEMISTRY-US, V40, P9605, DOI 10.1021/bi0104266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Verzili D, 2000, FEBS LETT, V471, P197, DOI 10.1016/S0014-5793(00)01396-X; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701; Zamparelli C, 1997, FEBS LETT, V409, P1, DOI 10.1016/S0014-5793(97)00464-X; Zamparelli C, 2000, BIOCHEMISTRY-US, V39, P658, DOI 10.1021/bi991648v	40	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24921	24928		10.1074/jbc.M213276200	http://dx.doi.org/10.1074/jbc.M213276200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12711611	hybrid			2022-12-25	WOS:000183824800082
J	Frison, N; Taylor, ME; Soilleux, E; Bousser, MT; Mayer, R; Monsigny, M; Drickamer, K; Roche, AC				Frison, N; Taylor, ME; Soilleux, E; Bousser, MT; Mayer, R; Monsigny, M; Drickamer, K; Roche, AC			Oligolysine-based oligosaccharide clusters - Selective recognition and endocytosis by the mannose receptor and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; C-TYPE LECTIN; CARBOHYDRATE-RECOGNITION; DC-SIGN; BINDING; MACROPHAGES; NEOGLYCOPROTEINS; GLYCOSYNTHONS; GLYCOPROTEINS; PINOCYTOSIS	Dendritic cells are potent antigen-presenting cells that express several membrane lectins, including the mannose receptor and DC-SIGN ( dendritic cell-specific ICAM-3-grabbing nonintegrin). To identify highly specific ligands for these dendritic cell receptors, oligosaccharides were converted into glycosynthons (Os-1) and were used to prepare oligolysine-based glycoclusters, Os-[Lys(Os)](n)-Ala-Cys-NH2. Clusters containing two to six dimannosides as well as clusters containing four or five pentasaccharides (Lewis(a) or Lewis(x)) or hexasaccharides (Lewis(b)) were synthesized. The thiol group of the appended cysteine residue allows easy tagging by a fluorescent probe or convenient substitution with an antigen. Surface plasmon resonance was used to determine the affinity of the different glycoclusters for purified mannose receptor and DC-SIGN, whereas flow cytometry and confocal microscopy analysis allowed assessment of cell uptake of fluoresceinyl-labeled glycoclusters. Dimannoside clusters are recognized by the mannose receptor with an affinity constant close to 10(6) liter.mol(-1) but have a very low affinity for DC-SIGN (less than 104 liter.mol(-1)). Conversely, Lewis clusters have a higher affinity toward DC-SIGN than toward the mannose receptor. Dimannoside clusters are efficiently taken up by human dendritic cells as well as by rat fibroblasts expressing the mannose receptor but not by HeLa cells or rat fibroblasts expressing DC-SIGN; DC-SIGN-expressing cells take up Lewis clusters. The results suggest that ligands containing dimannoside clusters can be used specifically to target the mannose receptor, whereas ligands containing Lewis clusters will be targeted to DC-SIGN.	CNRS, Ctr Biophys Mol, F-45071 Orleans 02, France; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Hutchinson Med Res Council Res Ctr, Cambridge CB 2QQ, England	Centre National de la Recherche Scientifique (CNRS); University of Oxford	Roche, AC (corresponding author), CNRS, Ctr Biophys Mol, Rue Charles Sadron, F-45071 Orleans 02, France.		Soilleux, Elizabeth/G-6265-2011; Monsigny, Michel/AAZ-6728-2020	Soilleux, Elizabeth Jane/0000-0002-4032-7249; Taylor, Maureen/0000-0001-8300-4987				ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; Avrameas A, 1996, EUR J IMMUNOL, V26, P394, DOI 10.1002/eji.1830260219; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bedouet L, 2001, BIOSCIENCE REP, V21, P839, DOI 10.1023/A:1015592926051; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Carriere V, 1999, GLYCOBIOLOGY, V9, P995, DOI 10.1093/glycob/9.10.995; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; Duverger E, 2003, BIOCHIMIE, V85, P167, DOI 10.1016/S0300-9084(03)00060-9; Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118; Engering AJ, 1997, ADV EXP MED BIOL, V417, P183; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Frison N, 2003, BIOCHIMIE, V85, P47, DOI 10.1016/S0300-9084(03)00073-7; Frison N, 2002, BIOCHEM J, V368, P111, DOI 10.1042/BJ20020673; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Goxe B, 2000, IMMUNOL INVEST, V29, P319, DOI 10.3109/08820130009060870; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; Lee Y. C., 1994, NEOGLYCOCONJUGATES P, P23; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MIDOUX P, 1987, CYTOMETRY, V8, P327, DOI 10.1002/cyto.990080314; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; MONSIGNY M, 1984, BIOL CELL, V51, P187, DOI 10.1111/j.1768-322X.1984.tb00298.x; Monsigny M, 2000, Carbohydr Lett, V4, P35; MONSIGNY M, 1988, ANAL BIOCHEM, V175, P525, DOI 10.1016/0003-2697(88)90578-7; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; Napper CE, 2001, J BIOL CHEM, V276, P14759, DOI 10.1074/jbc.M100425200; Quetard C, 1998, BIOCONJUGATE CHEM, V9, P268, DOI 10.1021/bc970122p; ROCHE AC, 1983, J CELL BIOCHEM, V22, P131, DOI 10.1002/jcb.240220302; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SHEPHERD VL, 1981, P NATL ACAD SCI-BIOL, V78, P1019, DOI 10.1073/pnas.78.2.1019; SHINOHARA Y, 1994, EUR J BIOCHEM, V223, P189, DOI 10.1111/j.1432-1033.1994.tb18982.x; Simpson DZ, 1999, BIOCHEM J, V343, P403, DOI 10.1042/0264-6021:3430403; SIPS R, 1948, J CHEM PHYS, V16, P490, DOI 10.1063/1.1746922; Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STAHL PD, 1978, P NATL ACAD SCI USA, V75, P1399, DOI 10.1073/pnas.75.3.1399; STAHL PD, 1984, BIOL CELL, V51, P215, DOI 10.1111/j.1768-322X.1984.tb00301.x; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665	40	108	119	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23922	23929		10.1074/jbc.M302483200	http://dx.doi.org/10.1074/jbc.M302483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695508	hybrid			2022-12-25	WOS:000183638600090
J	Hsu, CL; Chen, YL; Yeh, SY; Ting, HJ; Hu, YC; Lin, H; Wang, X; Chang, CS				Hsu, CL; Chen, YL; Yeh, SY; Ting, HJ; Hu, YC; Lin, H; Wang, X; Chang, CS			The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; COOH-TERMINAL INTERACTION; LIM PROTEIN FHL2; NUCLEAR-RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; HISTONE DEACETYLASE; COMPLEMENTARY-DNA; HUMAN PROSTATE; CONFORMATIONAL CHANGE	Early studies suggested that the signature motif, LXXLL, within steroid hormone receptor p160 coregulators may play important roles for the mediation of receptor-coregulator interaction. Interestingly, several androgen receptor (AR) coregulators, such as ARA70 and ARA55, may not use such a unique motif to mediate their coregulator activity. Here we apply the phage display technique to identify some new signature motifs, (F/W)XXL(F/W) and FXXLY (where F is phenylalanine, W is tryptophan, L is leucine, Y is tyrosine, and X is any amino acid) that can influence the interaction between AR and AR coregulators. Sequence analyses found that several AR coregulators, such as ARA70, ARA55, ARA54, and FHL2, contain FXXL(F/Y) motifs. Both glutathione S-transferase pull-down assays and transient transfection reporter assays demonstrate that these AR coregulators may use the FXXL(F/Y) motif to interact with AR and exert their AR coregulator activity. Exchanging the amino acid of Phe, Trp, or Tyr in this newly identified signature motif cluster may influence these peptides to interact with AR. The motif-containing peptides, as well as ARA70 or ARA54, may require selective flanking sequences for the better interaction with AR. In addition to influencing the AR transactivation, these motifs in AR-interacting peptides/proteins were also able to influence the AR N-/C-terminal interaction. Together, our data suggest that AR interacting peptides and/or AR coregulators may utilize the (F/W)XXL(F/W) and FXXLY motifs to mediate their interaction with AR and exert their influences on the AR transactivation.	Univ Rochester, Med Ctr, Dept Pathol, George H Wipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George H Wipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George H Wipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George H Wipple Lab Canc Res, Rochester, NY 14642 USA.		Chen, Yuh-Ling/AAS-7957-2021; Hu, Yueh-Chiang/AAX-2370-2020	Ting, Huei-Ju/0000-0003-3709-5755; Hu, Yueh-Chiang/0000-0002-7992-0525	NIDDK NIH HHS [DK60905, DK60948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060948, R01DK060905] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Callewaert L, 2003, J BIOL CHEM, V278, P8212, DOI 10.1074/jbc.M210744200; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chang CY, 2002, MOL ENDOCRINOL, V16, P647, DOI 10.1210/me.16.4.647; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; FRITSCH M, 1992, BIOCHEMISTRY-US, V31, P5303, DOI 10.1021/bi00138a009; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gregory CW, 2001, J MOL ENDOCRINOL, V27, P309, DOI 10.1677/jme.0.0270309; Hall JM, 2000, MOL ENDOCRINOL, V14, P2010, DOI 10.1210/me.14.12.2010; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSU C, 2002, 84 END SOC ANN M SAN, P527; Ito K, 2001, EUR J BIOCHEM, V268, P2725, DOI 10.1046/j.1432-1327.2001.02169.x; Jia YF, 2001, J BIOL CHEM, V276, P39911, DOI 10.1074/jbc.M103510200; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kelly C, 1996, CHILD PSYCHOL PSYCHI, V1, P59; Kong YF, 2001, CIRCULATION, V103, P2731; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PARMLEY SF, 1989, ADV EXP MED BIOL, V251, P215; Roy AK, 1999, VITAM HORM, V55, P309; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; SANTORO M, 1994, ONCOGENE, V9, P509; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Shaw PA, 2001, GYNECOL ONCOL, V80, P132, DOI 10.1006/gyno.2000.6068; Shibanuma M, 2002, CELL STRUCT FUNCT, V27, P21, DOI 10.1247/csf.27.21; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TILLEY WD, 1989, P NATL ACAD SCI USA, V86, P327, DOI 10.1073/pnas.86.1.327; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRAPMAN J, 1988, BIOCHEM BIOPH RES CO, V153, P241, DOI 10.1016/S0006-291X(88)81214-2; Wang X, 2002, J BIOL CHEM, V277, P15426, DOI 10.1074/jbc.M111218200; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	63	72	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23691	23698		10.1074/jbc.M211908200	http://dx.doi.org/10.1074/jbc.M211908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12714604	hybrid			2022-12-25	WOS:000183638600062
J	Meyer, EL; Strutz, N; Gahring, LC; Rogers, SW				Meyer, EL; Strutz, N; Gahring, LC; Rogers, SW			Glutamate receptor subunit 3 is modified by site-specific limited proteolysis including cleavage by gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; IDENTIFICATION; LOCALIZATION; HOMER; NMDA; REDISTRIBUTION; MODULATION; COMPLEXES; SEQUENCES; CASPASES	Ionotropic glutamate receptor (GluR) expression and function is regulated through multiple pre- and post-translational mechanisms. We find that limited proteolytic cleavage of GluR3 at two distinct sites generates stable GluR3 short forms that are glycosylated and found in association with other full-length GluRs in the mouse brain and cultured primary neurons. A combination of mutagenesis and transfection into HEK293 cells revealed cleavage by a gamma-secretase-like activity within the membrane-localized re-entry loop at or near the leucine-glycine pair (amino acids 585-586, GluR3sbeta) and a second site within a proline-rich PEST-like sequence in the first cytoplasmic loop (Asp(570)-Pro(571), GluR3salpha). Generation of the prominent GluR3salpha form was effectively abolished in the mutant, GluR3D570A, but inhibitors of lysosomes, the proteasome, caspases, or calpains had no effect. The possible impact of cleavage on receptor function was suggested when the co-expression of the GluR3P571Stop mutant (creating GluR3salpha) co-assembled with other GluR subunits and decreased receptor function in Xenopus oocytes. In transiently transfected HEK293 cells, co-expression of GluR3salpha alters the relative association between GluR1 and GluR3 during assembly, and the presence of the novel C-terminal proline-rich domain of GluR3salpha imparts lateral membrane mobility to GluR complexes. These results suggest that limited proteolysis is another post-translational mechanism through which functional diversity and specialization between closely related GluR subunits is accomplished.	Univ Utah, Sch Med Neurobiol & Anat, Salt Lake City Vet Affairs Geriatr Res Educ & Cli, MREB 403, Salt Lake City, UT 84132 USA; Univ Utah, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Biol, Salt Lake City, UT 84132 USA	Geriatric Research Education & Clinical Center; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Rogers, SW (corresponding author), Univ Utah, Sch Med Neurobiol & Anat, Salt Lake City Vet Affairs Geriatr Res Educ & Cli, MREB 403, 50 N Med Dr, Salt Lake City, UT 84132 USA.	Scott.Rogers@HSC.Utah.Edu		Meyer, Erin/0000-0003-0704-5861	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035181] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35181] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ango F, 2000, J NEUROSCI, V20, P8710; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Carlson NG, 1998, J NEUROBIOL, V35, P29, DOI 10.1002/(SICI)1097-4695(199804)35:1<29::AID-NEU3>3.0.CO;2-D; Carlson NG, 1997, J BIOL CHEM, V272, P11295; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Cuervo AM, 2003, EMBO J, V22, P47, DOI 10.1093/emboj/cdg002; Dingledine R, 1999, PHARMACOL REV, V51, P7; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FRIEDRICH P, 1991, FEBS LETT, V295, P5, DOI 10.1016/0014-5793(91)81371-E; Gahring LC, 2001, J IMMUNOL, V166, P1433, DOI 10.4049/jimmunol.166.3.1433; HOUGH R, 1986, J BIOL CHEM, V261, P2400; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Lah JJ, 1997, J NEUROSCI, V17, P1971; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Meyer EL, 2002, J BIOL CHEM, V277, P10869, DOI 10.1074/jbc.M106744200; Moore CL, 2000, ANN NY ACAD SCI, V920, P197; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Pack-Chung E, 2000, J BIOL CHEM, V275, P14440, DOI 10.1074/jbc.M909882199; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROGERS SW, 1991, J NEUROSCI, V11, P2713; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; SEKIGUCHI M, 1994, J BIOL CHEM, V269, P14559; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SIEGEL SJ, 1995, J NEUROSCI, V15, P2707; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Sriuranpong V, 2002, MOL CELL BIOL, V22, P3129, DOI 10.1128/MCB.22.9.3129-3139.2002; Standley S, 2000, CELL MOL LIFE SCI, V57, P1508, DOI 10.1007/PL00000635; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Strong M, 1996, NEUROLOGY, V47, pS26; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; van Rossum D, 1999, TRENDS NEUROSCI, V22, P290, DOI 10.1016/S0166-2236(99)01404-6; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	46	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23786	23796		10.1074/jbc.M301360200	http://dx.doi.org/10.1074/jbc.M301360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700243	hybrid			2022-12-25	WOS:000183638600073
J	Oosterveen, T; van Vliet, P; Deschamps, J; Meijlink, F				Oosterveen, T; van Vliet, P; Deschamps, J; Meijlink, F			The direct context of a hox retinoic acid response element is crucial for its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC ACTIVATION; NUCLEAR RECEPTORS; EXPRESSION BOUNDARIES; ORPHAN RECEPTORS; LIGAND-BINDING; X-RECEPTORS; BETA-GENE; MOUSE; DNA; IDENTIFICATION	During embryogenesis, target genes of retinoid signaling are able to respond differently to identical concentrations of retinoids. Small differences in the retinoic acid response elements (RARE) may be essential for these distinct responses. Recently, we identified a RARE in a Hox enhancer (dubbed distal element) that is active relatively late during mouse development. We now show that the RARE motif in the distal element is necessary and sufficient for the induction of gene expression by retinoic acid (RA) in P19 embryonic carcinoma cells. Furthermore, the significance of these results was established by RA treatment of transgenic mouse lines carrying the distal element containing the wild-type or a mutated RARE. We compared the in vitro activity of the distal element-RARE with that of the direct repeat with 5-bp spacer RARE of the RARbeta2 gene, which is active during early during mouse development. We found that these RAREs, despite their similarity, responded differently to RA. By making single point mutations we show that the specificity resides in their retinoid X receptor-binding sites and is determined by base pairs located just outside the RARE consensus sequence. We suggest that the context of RARE motifs is important for the distinct transcriptional activities of genes under control of retinoid signaling.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Meijlink, F (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		oosterveen, Tony/ABB-5510-2021	van Vliet, Piet/0000-0002-1986-5835				ASSELINEAU D, 1989, DEV BIOL, V133, P322, DOI 10.1016/0012-1606(89)90037-7; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHARITE J, 1995, DEV BIOL, V171, P294, DOI 10.1006/dbio.1995.1282; CONLON RA, 1992, DEVELOPMENT, V116, P357; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; Dupe V, 2001, DEVELOPMENT, V128, P2199; Dupe V, 1999, DEV BIOL, V208, P30, DOI 10.1006/dbio.1998.9176; EDWARDS MKS, 1983, DEV BIOL, V98, P187, DOI 10.1016/0012-1606(83)90348-2; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Folkers GE, 1996, J STEROID BIOCHEM, V56, P119, DOI 10.1016/0960-0760(95)00229-4; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; Glass CK, 2000, GENE DEV, V14, P121; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; MADER S, 1993, J BIOL CHEM, V268, P591; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Oosterveen T, 2003, EMBO J, V22, P262, DOI 10.1093/emboj/cdg029; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; ROY B, 1995, MOL CELL BIOL, V15, P6481; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SHEN S, 1992, INT J DEV BIOL, V36, P465; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; Valarche I, 1997, INT J DEV BIOL, V41, P705; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; Wendling O, 1999, P NATL ACAD SCI USA, V96, P547, DOI 10.1073/pnas.96.2.547; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040	38	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24103	24107		10.1074/jbc.M300774200	http://dx.doi.org/10.1074/jbc.M300774200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697756	hybrid			2022-12-25	WOS:000183638600114
J	Sharma, S; Sommers, JA; Driscoll, HC; Uzdilla, L; Wilson, TM; Brosh, RM				Sharma, S; Sommers, JA; Driscoll, HC; Uzdilla, L; Wilson, TM; Brosh, RM			The exonucleolytic and endonucleolytic cleavage activities of human exonuclease 1 are stimulated by an interaction with the carboxyl-terminal region of the Werner syndrome protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE EXO1; SYNDROME GENE-PRODUCT; DNA MISMATCH REPAIR; SINGLE-STRANDED-DNA; SYNDROME CELL-LINES; FLAP ENDONUCLEASE-1; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; SYNDROME HELICASE; S-PHASE	Exonuclease 1 ( EXO-1), a member of the RAD2 family of nucleases, has recently been proposed to function in the genetic pathways of DNA recombination, repair, and replication which are important for genome integrity. Although the role of EXO-1 is not well understood, its 5' to 3'-exonuclease and flap endonuclease activities may cleave intermediates that arise during DNA metabolism. In this study, we provide evidence that the Werner syndrome protein (WRN) physically interacts with human EXO-1 and dramatically stimulates both the exonucleolytic and endonucleolytic incision functions of EXO-1. The functional interaction between WRN and EXO-1 is mediated by a protein domain of WRN which interacts with flap endonuclease 1 ( FEN-1). Thus, the genomic instability observed in WRN-/- cells may be at least partially attributed to the lack of interactions between the WRN protein and human nucleases including EXO-1.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Maryland, Radiat Oncol Res Lab, Dept Radiat Oncol, Baltimore, MD 21201 USA; Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Baltimore; University of Hyderabad	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Sharma, Sudha/AAV-6152-2021; Brosh, Robert/AAR-6124-2020	Sharma, Sudha/0000-0003-2765-2482; 	NATIONAL INSTITUTE ON AGING [ZIAAG000741, Z01AG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bennett SE, 1997, CANCER RES, V57, P2956; Bennett SE, 1999, ALFRED BENZON SYMP S, V44, P214; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kao KI, 2002, J BIOL CHEM, V277, P14379, DOI 10.1074/jbc.M110662200; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lewis LK, 2002, GENETICS, V160, P49; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; Moreau S, 2001, GENETICS, V159, P1423; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Pichierri P, 2000, MUTAT RES-FUND MOL M, V456, P45, DOI 10.1016/S0027-5107(00)00109-3; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Qiu JZ, 1999, J BIOL CHEM, V274, P17893, DOI 10.1074/jbc.274.25.17893; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Wu L, 2001, SCIENCE, V292, P229, DOI 10.1126/science.1060832; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	57	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23487	23496		10.1074/jbc.M212798200	http://dx.doi.org/10.1074/jbc.M212798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704184	hybrid			2022-12-25	WOS:000183638600035
J	Fang, WH; Wang, BJ; Wang, CH; Lee, SJ; Chang, YT; Chuang, YK; Lee, CN				Fang, WH; Wang, BJ; Wang, CH; Lee, SJ; Chang, YT; Chuang, YK; Lee, CN			DNA loop repair by Escherichia coli cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL HETEROLOGOUS SEQUENCES; METHYL-DIRECTED REPAIR; SINGLE-STRANDED LOOPS; BASE-PAIR MISMATCHES; SACCHAROMYCES-CEREVISIAE; HETERODUPLEX DNA; MAMMALIAN-CELLS; NUCLEAR EXTRACTS; GENE CONVERSION; REPLICATION	The nick- directed DNA repair efficiency of a set of M13mp18- derived heteroduplexes containing 8-, 12-, 16-, 22-, 27-, 45-, and 429- nucleotide loops was determined by in vitro assay. Unpaired nucleotides of each heteroduplex reside within overlapping recognition sites for two restriction endonucleases, permitting independent evaluation of repair occurring on either DNA strand. Our results show that a strand break located either 3 ' or 5 ' to the loop is sufficient to direct heterology repair to the nicked strand in Escherichia coli extracts. Strandspecific repair by this system requires Mg2+ and the four dNTPs and is equally efficient on insertions and deletions. This activity is distinct from the MutHLS mismatch repair pathway. Strand specificity and repair efficiency are largely independent of the GATC methylation state of the DNA and presence of the products of mismatch repair genes mutH, mutL, and mutS. This study provides evidence for a loop repair pathway in E. coli that is distinct from conventional mismatch repair.	Natl Taiwan Univ, Sch Med Technol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital	Fang, WH (corresponding author), Natl Taiwan Univ, Sch Med Technol, Coll Med, Taipei 100, Taiwan.			FANG, WOEI-HORNG/0000-0003-4728-5931				AYARES D, 1987, MOL CELL BIOL, V7, P1656, DOI 10.1128/MCB.7.5.1656; BISHOP DK, 1986, MOL CELL BIOL, V6, P3401, DOI 10.1128/MCB.6.10.3401; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; CARRAWAY M, 1993, J BACTERIOL, V175, P3972, DOI 10.1128/JB.175.13.3972-3980.1993; Corrette-Bennett SE, 2001, NUCLEIC ACIDS RES, V29, P4134, DOI 10.1093/nar/29.20.4134; Corrette-Bennett SE, 1999, J BIOL CHEM, V274, P17605, DOI 10.1074/jbc.274.25.17605; DOHET C, 1987, MOL GEN GENET, V206, P181, DOI 10.1007/BF00326556; FANG WH, 1993, J BIOL CHEM, V268, P11838; Fang WH, 1997, J BIOL CHEM, V272, P22714, DOI 10.1074/jbc.272.36.22714; FISHEL R, 1989, J BACTERIOL, V171, P3046, DOI 10.1128/jb.171.6.3046-3052.1989; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; HASTINGS PJ, 1988, GENETIC RECOMBINATIO, P397; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; Littman SJ, 1999, J BIOL CHEM, V274, P7474, DOI 10.1074/jbc.274.11.7474; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; REENAN RAG, 1992, GENETICS, V132, P975; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Varlet I, 1996, P NATL ACAD SCI USA, V93, P10156, DOI 10.1073/pnas.93.19.10156; WEISS U, 1988, NUCLEIC ACIDS RES, V16, P2313, DOI 10.1093/nar/16.5.2313; WEISS U, 1989, SOMAT CELL MOLEC GEN, V15, P13, DOI 10.1007/BF01534665; WEISS U, 1987, P NATL ACAD SCI USA, V84, P1619, DOI 10.1073/pnas.84.6.1619; WELSH KM, 1987, J BIOL CHEM, V262, P15624	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22446	22452		10.1074/jbc.M302585200	http://dx.doi.org/10.1074/jbc.M302585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12692132	hybrid			2022-12-25	WOS:000183503900038
J	Pullar, CE; Chen, J; Isseroff, RR				Pullar, CE; Chen, J; Isseroff, RR			PP2A activation by beta 2-adrenergic receptor agonists - Novel regulatory mechanism of keratinocyte migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; EPIDERMAL-GROWTH-FACTOR; BETA-ADRENERGIC-RECEPTORS; OKADAIC ACID; CATALYTIC SUBUNIT; BETA(2)-ADRENERGIC RECEPTOR; CELL-MIGRATION; MAP KINASE; TYROSINE PHOSPHORYLATION; EGF RECEPTOR	Understanding the mechanisms that regulate cell migration is important for devising novel therapies to control metastasis or enhance wound healing. Previously, we demonstrated that beta(2)-adrenergic receptor (beta(2)- AR) activation in keratinocytes inhibited their migration by decreasing the phosphorylation of a critical promigratory signaling component, the extracellular signal- related kinase ( ERK). Here we demonstrate that beta(2)-AR-induced inhibition of migration is mediated by the activation of the serine/ threonine phosphatase PP2A. Pretreating human keratinocytes with the PP2A inhibitor, okadaic acid, prevented the beta(2)-AR- induced inhibition of migration, either as isolated cells or as a confluent sheet of cells repairing an in vitro " wound" and also prevented the beta(2)- AR- induced reduction in ERK phosphorylation. Similar results were obtained with human corneal epithelial cells. In keratinocytes, immunoprecipitation studies revealed that beta(2)- AR activation resulted in the rapid association of beta(2)- AR with PP2A as well as a 37% increase in association of PP2A with ERK2. Finally, beta(2)- AR activation resulted in a rapid and transient 2- fold increase in PP2A activity. Thus, we provide the first evidence that beta(2)- AR activation in keratinocytes modulates migration via a novel pathway utilizing PP2A to alter the promigratory signaling cascade. Exploiting this pathway may result in novel therapeutic approaches for control of epithelial cell migration.	Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA	University of California System; University of California Davis	Isseroff, RR (corresponding author), Univ Calif Davis, Dept Dermatol, TB192,1 Shields Ave, Davis, CA 95616 USA.	rrisseroff@ucdavis.edu	Isseroff, Roslyn Rivkah/AAD-8478-2021	Isseroff, Roslyn Rivkah/0000-0001-7813-0858	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044518] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44518] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDO Y, 1993, J INVEST DERMATOL, V100, P633, DOI 10.1111/1523-1747.ep12472297; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Begum N, 1999, BIOCHEM J, V344, P895, DOI 10.1042/0264-6021:3440895; Benefield J, 1998, INVAS METAST, V17, P210; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; Boknik P, 2000, N-S ARCH PHARMACOL, V362, P222, DOI 10.1007/s002100000283; Brockdorff J, 1997, TISSUE ANTIGENS, V49, P228, DOI 10.1111/j.1399-0039.1997.tb02743.x; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Chen J, 2002, J INVEST DERMATOL, V119, P1261, DOI 10.1046/j.1523-1747.2002.19611.x; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DONALDSON DJ, 1984, COMP BIOCHEM PHYS C, V78, P267, DOI 10.1016/0742-8413(84)90081-1; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Fang KS, 1999, J CELL SCI, V112, P1967; Fang KS, 1998, J INVEST DERMATOL, V111, P751, DOI 10.1046/j.1523-1747.1998.00366.x; FAVRE B, 1994, J BIOL CHEM, V269, P16311; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Gabel S, 1999, OTOLARYNG HEAD NECK, V121, P463, DOI 10.1016/S0194-5998(99)70238-X; Garcia L, 2002, FEBS LETT, V523, P90, DOI 10.1016/S0014-5793(02)02950-2; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; HAAS AF, 1990, J INVEST DERMATOL, V94, P822, DOI 10.1111/1523-1747.ep12874679; HACCARD O, 1990, EUR J BIOCHEM, V192, P633, DOI 10.1111/j.1432-1033.1990.tb19270.x; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Han B, 2002, CORNEA, V21, P505, DOI 10.1097/00003226-200207000-00013; Haruta Y, 1997, Eur J Ophthalmol, V7, P334; ISSEROFF RR, 1987, J LIPID RES, V28, P1342; Jackson J, 1998, INVAS METAST, V17, P199; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Krueger KM, 1997, J BIOL CHEM, V272, P5; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; LI HC, 1979, EUR J BIOCHEM, V102, P363, DOI 10.1111/j.1432-1033.1979.tb04251.x; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1998, METH MOL B, V93, P59; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LIU GS, 1990, J OCUL PHARMACOL, V6, P101, DOI 10.1089/jop.1990.6.101; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Masur K, 2001, CANCER RES, V61, P2866; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McMahon KA, 2001, BIOCHEM J, V358, P431, DOI 10.1042/0264-6021:3580431; Meves A, 2002, ARCH DERMATOL RES, V294, P243, DOI 10.1007/s00403-002-0315-1; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; Murphy CJ, 1998, CORNEA, V17, P529, DOI 10.1097/00003226-199809000-00011; Namboodiripad AN, 1996, AM J PHYSIOL-CELL PH, V270, pC449, DOI 10.1152/ajpcell.1996.270.2.C449; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pullar CE, 1996, J IMMUNOL, V157, P1226; REIDY JJ, 1994, BRIT J OPHTHALMOL, V78, P377, DOI 10.1136/bjo.78.5.377; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SCHALLREUTER KU, 1993, ARCH DERMATOL RES, V285, P216, DOI 10.1007/BF00372012; Schallreuter KU, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P37, DOI 10.1038/jidsymp.1997.9; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Sheridan DM, 1996, J INVEST DERMATOL, V106, P642, DOI 10.1111/1523-1747.ep12345456; Silvestri M, 1999, RESP MED, V93, P416, DOI 10.1053/rmed.1999.0584; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; Spurzem JR, 2002, AM J PHYSIOL-LUNG C, V282, pL1108, DOI 10.1152/ajplung.00148.2001; STEINKRAUS V, 1992, J INVEST DERMATOL, V98, P475, DOI 10.1111/1523-1747.ep12499860; Steinkraus V, 1996, ARCH DERMATOL RES, V288, P549, DOI 10.1007/BF02505253; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; WOODLEY D, 1999, DERMATOL FDN, V33, P1; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; You YS, 2000, YONSEI MED J, V41, P185, DOI 10.3349/ymj.2000.41.2.185; Young MRI, 2002, INT J CANCER, V100, P276, DOI 10.1002/ijc.10491; Young MRI, 1997, ADV EXP MED BIOL, V407, P311; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	91	90	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22555	22562		10.1074/jbc.M300205200	http://dx.doi.org/10.1074/jbc.M300205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12697752	hybrid			2022-12-25	WOS:000183503900052
J	Katata, T; Irie, K; Fukuhara, A; Kawakatsu, T; Yamada, A; Shimizu, K; Takai, Y				Katata, T; Irie, K; Fukuhara, A; Kawakatsu, T; Yamada, A; Shimizu, K; Takai, Y			Involvement of nectin in the localization of IQGAP1 at the cell-cell adhesion sites through the actin cytoskeleton in Madin-Darby canine kidney cells	ONCOGENE			English	Article						nectin; IQGAP1; cadherin; adherens junctions; actin	SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; RASGAP-RELATED PROTEIN; ALPHA-CATENIN; CYTOPLASMIC DOMAIN; JUNCTIONAL COMPLEX; EPITHELIAL-CELLS; SMALL GTPASES; MOLECULE UVOMORULIN; ADHERENS JUNCTION	IQGAP1, a putative downstream target of the Rho family small G proteins, Cdc42 and Rac, localizes at adherens junctions (AJs) in epithelial cells. It has been suggested that IQGAP1 localizes at AJs through its binding to beta-catenin, and negatively regulates the E-cadherin-mediated cell-cell adhesion. Nectin is a Ca2+-independent, immunoglobulin-like cell-cell adhesion molecule that localizes at AJs. Nectin is associated with E-cadherin through their respective cytoplasmic tail-binding proteins, afadin and catenins, and involved in the formation of AJs cooperatively with E-cadherin. Here we investigated a role of nectin in the localization of IQGAP1 at AJs. Ca2+ chelation from the medium causes disruption of the E-cadherin-mediated cell-cell adhesion, but not the nectin-based cell-cell adhesion, in Madin-Darby canine kidney (MDCK) cells. IQGAP1 remained at the residual nectin-based cell-cell adhesion sites where the E-cadherin immunofluorescence signal disappeared. Restoration of Ca2+ in the medium causes re-accumulation of E-cadherin to the residual pectin-based cell-cell adhesion sites to reform AJs. Nectin inhibitors inhibit this re-accumulation of E-cadherin to re-form AJs by impairing the pectin-based cell-cell adhesion. The nectin inhibitors also reduced the localization of IQGAP1 at the cell-cell adhesion sites. When MDCK cells were incubated with microbeads coated with the extracellular fragment of nectin that interacts with cellular nectin, IQGAP1 also accumulated at the bead-MDCK cell contact sites. The accumulation of IQGAP1 at the cell-cell adhesion sites was inhibited by actin filament-disrupting agents, latrunculin A and cytochalasin D. These results indicate that nectin is involved in the localization of IQGAP1 at AJs through the actin cytoskeleton.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778				AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 1999, J CELL SCI, V112, P4491; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HONDA T, 2003, IN PRESS GENES CELLS; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yagi T, 2000, GENE DEV, V14, P1169; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	64	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2097	2109		10.1038/sj.onc.1206255	http://dx.doi.org/10.1038/sj.onc.1206255			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687012				2022-12-25	WOS:000182066900004
J	Csiszar, A; Ungvari, Z; Koller, A; Edwards, JG; Kaley, G				Csiszar, A; Ungvari, Z; Koller, A; Edwards, JG; Kaley, G			Aging-induced proinflammatory shift in cytokine expression profile in rat coronary arteries	FASEB JOURNAL			English	Article						gene expression; biology of aging; coronary heart disease; biomarkers of aging; inflammation	TUMOR-NECROSIS-FACTOR; VASCULAR SMOOTH-MUSCLE; AORTIC ENDOTHELIAL-CELLS; ALPHA TNF-ALPHA; NITRIC-OXIDE; GENE-EXPRESSION; IL-6 PRODUCTION; MESSENGER-RNA; NO SYNTHASE; AGED RATS	The phenotypic and functional changes of coronary arteries with aging promote ischemic heart disease. We hypothesized that these alterations reflect an aging-induced proinflammatory shift in vascular regulatory mechanisms. Thus, in isolated coronary arteries of young (3-month-old) and aged (25-month-old) male Fischer 344 rats the expression of 96 cytokines, chemokines, and their receptors were screened by a cDNA-based microarray technique. In aged vessels expressions of tumor necrosis factor (TNF)-alpha, (3.3x), interleukin (IL)-1beta (3.0x), IL-6 (2.9x), IL-6Ralpha (2.8x) and IL-17 (6.1x) genes were significantly increased over young vessels. Quantitative reverse transcriptase-polymerase chain reaction confirmed these results. Western blotting demonstrated that protein expressions of TNF-alpha,, IL-1beta, IL-6, and IL-17 were also significantly increased in vessels of aged rats compared with those of young rats. Immunofluorescent double labeling showed that in aged vessels IL-1beta and IL-6 are predominantly localized in the endothelium, whereas TNF-alpha, and IL-17 are localized in smooth muscle. Thus, a proinflammatory shift in the profile of vascular cytokine expression may contribute to the aging-induced phenotypic changes in coronary arteries, promoting the development of ischemic heart disease in the elderly.	New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA	New York Medical College	Kaley, G (corresponding author), New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA.	gabor_kaley@nymc.edu	Ákos, Koller/Q-4672-2019; Ungvari, Zoltan/ADU-0095-2022; Ungvari, Zoltan/GZK-8127-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043023] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL043023] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; Baumgarten G, 2002, CIRCULATION, V105, P2192, DOI 10.1161/01.CIR.0000015608.37608.18; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365-2249.2000.01281.x; Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001; Cao CY, 2001, EUR J NEUROSCI, V13, P1781, DOI 10.1046/j.0953-816x.2001.01551.x; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Cartford MC, 2002, J NEUROSCI, V22, P5813; Cernadas MR, 1998, CIRC RES, V83, P279, DOI 10.1161/01.RES.83.3.279; Corsini E, 1996, SCAND J IMMUNOL, V44, P506, DOI 10.1046/j.1365-3083.1996.d01-343.x; Csiszar A, 2002, CIRC RES, V90, P1159, DOI 10.1161/01.RES.0000020401.61826.EA; DAYNES RA, 1993, J IMMUNOL, V150, P5219; De Keulenaer GW, 1998, BIOCHEM J, V329, P653; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; GARFINKEL S, 1994, P NATL ACAD SCI USA, V91, P1559, DOI 10.1073/pnas.91.4.1559; Gerli R, 2000, MECH AGEING DEV, V121, P37; Grammas P, 2001, NEUROBIOL AGING, V22, P837, DOI 10.1016/S0197-4580(01)00276-7; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796; Kim F, 2001, AM J PHYSIOL-CELL PH, V280, pC1057, DOI 10.1152/ajpcell.2001.280.5.C1057; Krishnaswamy G, 1998, MICROVASC RES, V55, P189, DOI 10.1006/mvre.1998.2079; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Lundberg MS, 1999, EXP GERONTOL, V34, P549, DOI 10.1016/S0531-5565(99)00036-4; Marin V, 2001, J IMMUNOL, V167, P3435, DOI 10.4049/jimmunol.167.6.3435; McDouall RM, 2001, ENDOTHELIUM-NEW YORK, V8, P25, DOI 10.3109/10623320109063155; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; NEREM RM, 1984, BIORHEOLOGY, V21, P565; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Saito H, 2001, J BIOL CHEM, V276, P29307, DOI 10.1074/jbc.M103740200; SHIMADA Y, 1990, MECH AGEING DEV, V55, P245, DOI 10.1016/0047-6374(90)90152-6; SIREN AL, 1993, STROKE, V24, P880, DOI 10.1161/01.STR.24.6.880; SIRONI M, 1989, J IMMUNOL, V142, P549; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Stralin P, 2000, ATHEROSCLEROSIS, V151, P433, DOI 10.1016/S0021-9150(99)00427-X; Straub RH, 2001, MECH AGEING DEV, V122, P1591, DOI 10.1016/S0047-6374(01)00289-5; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; Tha KK, 2000, BRAIN RES, V885, P25, DOI 10.1016/S0006-8993(00)02883-3; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Volpato S, 2001, CIRCULATION, V103, P947; WARNER SJC, 1989, J IMMUNOL, V142, P100; Wei YP, 2000, J INTERF CYTOK RES, V20, P403, DOI 10.1089/107999000312342; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; WONG ML, 1995, NEUROIMMUNOMODULAT, V2, P141, DOI 10.1159/000096884; YAMIN M, 1990, AM J RESP CELL MOL, V2, P207, DOI 10.1165/ajrcmb/2.2.207; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634	53	215	225	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1183	+		10.1096/fj.02-1049fje	http://dx.doi.org/10.1096/fj.02-1049fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709402				2022-12-25	WOS:000182580100020
J	Muzumdar, R; Ma, XH; Yang, XM; Atzmon, G; Bernstein, J; Karkanias, G; Barzilai, N				Muzumdar, R; Ma, XH; Yang, XM; Atzmon, G; Bernstein, J; Karkanias, G; Barzilai, N			Physiologic effect of leptin on insulin secretion is mediated mainly through central mechanisms	FASEB JOURNAL			English	Article						melanocortin; leptin; insulin secretion	PANCREATIC BETA-CELLS; IN-VIVO; MELANOCORTIN SYSTEM; VISCERAL ADIPOSITY; MESSENGER-RNA; ISLETS; RAT; EXPRESSION; INHIBITION; RECEPTOR	Leptin has been shown to decrease glucose-stimulated insulin secretion in both in vivo and in vitro studies. As some of the effects of leptin have been elicited through both peripheral and central mechanisms, we assessed whether leptin modulates insulin secretion also through the central nervous system. We infused leptin or saline through implanted intracerebro-ventricular (ICV) catheters to chronically catheterized, conscious rats (n=15), 2 h after initiation of hyperglycemic (similar to11 mM) clamp. On ICV administration of leptin, there was a gradual and progressive decrease in plasma insulin levels by 52% with 30 ng (P<0.005) and by 28% with 20 ng (P<0.05) of leptin compared with ICV saline. The effect of 20 ng leptin ICV was replicated by intravenous (IV) leptin infusion that achieved physiological leptin levels of similar to17 ng/ml (n=5). When the melanocortin (MC) pathway was blocked with a nonselective MC-3/4 antagonist SHU 9119 administered ICV, and either saline or leptin (n=12) was infused IV, intravenous leptin failed to produce a decrease in glucose-stimulated insulin levels. We conclude that leptin decreases insulin levels by a predominantly central mechanism, probably via the melanocortin receptors; and peripheral leptin receptors on the beta-cells do not play a major role. The physiological features of this response suggest a possible role for leptin in the evolution of diabetes in overweight individuals.	Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Dept Med, Montefiore Med Ctr,Div Pediat Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Barzilai, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Dept Med, Montefiore Med Ctr,Div Pediat Endocrinol, Belfer Bldg 701,1300 Morris Pk Ave, Bronx, NY 10461 USA.	barzilai@aecom.yu.edu	Muzumdar, Radhika/D-9860-2014					Barzilai N, 1999, AM J PHYSIOL-ENDOC M, V277, pE291, DOI 10.1152/ajpendo.1999.277.2.E291; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Cases JA, 2001, DIABETES, V50, P348, DOI 10.2337/diabetes.50.2.348; Dunbar JC, 1997, DIABETES, V46, P2040, DOI 10.2337/diabetes.46.12.2040; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Fan T, 2000, ENDOCRINOLOGY, V141, P3072; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kieffer TJ, 1996, BIOCHEM BIOPH RES CO, V224, P522, DOI 10.1006/bbrc.1996.1059; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Ookuma M, 1998, DIABETES, V47, P219, DOI 10.2337/diabetes.47.2.219; Pallett AL, 1997, BIOCHEM BIOPH RES CO, V238, P267, DOI 10.1006/bbrc.1997.7274; Poitout V, 1998, ENDOCRINOLOGY, V139, P822, DOI 10.1210/en.139.3.822; Roduit R, 1997, FEBS LETT, V415, P179, DOI 10.1016/S0014-5793(97)01115-0; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Tanizawa Y, 1997, ENDOCRINOLOGY, V138, P4513, DOI 10.1210/en.138.10.4513; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0	22	57	58	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1130	+		10.1096/fj.02-0991fje	http://dx.doi.org/10.1096/fj.02-0991fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709405				2022-12-25	WOS:000182580100018
J	Xu, J; Yeon, JE; Chang, H; Tison, G; Chen, GJ; Wands, J; de la Monte, S				Xu, J; Yeon, JE; Chang, H; Tison, G; Chen, GJ; Wands, J; de la Monte, S			Ethanol impairs insulin-stimulated neuronal survival in the developing brain - Role of PTEN phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; INDUCED APOPTOTIC NEURODEGENERATION; GLYCOGEN-SYNTHASE KINASE-3; TUMOR-SUPPRESSOR PTEN; RAT-BRAIN; PHOSPHATIDYLINOSITOL 3-KINASE; MITOCHONDRIAL-FUNCTION; RECEPTOR SUBSTRATE-1; CELL-SURVIVAL; GLUCOSE TRANSPORTERS	Gestational exposure to ethanol causes fetal alcohol syndrome, which is associated with cerebellar hypoplasia. Previous in vitro studies demonstrated ethanol-impaired neuronal survival with reduced signaling through the insulin receptor (IRbeta). We examined insulin signaling in an experimental rat model of chronic gestational exposure to ethanol in which the pups exhibited striking cerebellar hypoplasia with increased apoptosis. Immunoprecipitation and Western blot analyses detected reduced levels of tyrosyl-phosphorylated IRbeta, tyrosylphosphorylated insulin receptor substrate-1 (IRS-1), and p85-associated IRS-1 but no alterations in IRbeta, IRS-1, or p85 protein expression in cerebellar tissue from ethanol-exposed pups. In addition, ethanol exposure significantly reduced the levels of total phosphoinositol 3-kinase, Akt kinase, phospho-BAD ( inactive), and glyceraldehyde-3-phosphate dehydrogenase and increased the levels of glycogen synthase kinase-3 activity, activated BAD, phosphatase and tensin homolog deleted in chromosome 10 ( PTEN) protein, and PTEN phosphatase activity in cerebellar tissue. Cerebellar neurons isolated from ethanol-exposed pups had reduced levels of insulin-stimulated phosphoinositol 3-kinase and Akt kinase activities and reduced insulin inhibition of PTEN and glycogen synthase kinase-3 activity. The results demonstrate that cerebellar hypoplasia produced by chronic gestational exposure to ethanol is associated with impaired survival signaling through insulin-regulated pathways, including failure to suppress PTEN function.	Brown Univ, Rhode Isl Hosp, Sch Med, Dept Med, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Sch Med, Dept Pathol, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	de la Monte, S (corresponding author), Brown Univ, Rhode Isl Hosp, Sch Med, Dept Med, Pierre Galletti Res Bldg,55 Claverick St,Rm 419, Providence, RI 02903 USA.	Suzanne_DeLaMonte_MD@Brown.edu	de la monte, suzanne/L-7670-2019	de la monte, suzanne/0000-0001-5886-2306; Chen, Guo-Jun/0000-0001-8148-9810; Tison, Geoffrey H/0000-0002-0310-3326; Xu, Julia/0000-0002-2564-8052	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA011431, R01AA002666, R01AA011431, R37AA011431, R37AA002666] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR15578] Funding Source: Medline; NIAAA NIH HHS [AA02666, AA-02169, AA-11431] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Banerjee K, 1998, ALCOHOL CLIN EXP RES, V22, P2093, DOI 10.1111/j.1530-0277.1998.tb05921.x; BONIFACINO JS, 1988, CURRENT PROTOCOLS MO; BREESE CR, 1994, NEUROSCIENCE, V63, P579, DOI 10.1016/0306-4522(94)90551-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CLARREN SK, 1978, J PEDIATR-US, V92, P64, DOI 10.1016/S0022-3476(78)80072-9; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de la Monte SF, 1999, ALCOHOL CLIN EXP RES, V23, P770, DOI 10.1097/00000374-199905000-00002; de la Monte SM, 2002, CELL MOL LIFE SCI, V59, P882, DOI 10.1007/s00018-002-8475-x; de la Monte SM, 2001, ALCOHOL CLIN EXP RES, V25, P898, DOI 10.1097/00000374-200106000-00016; de la Monte SM, 2001, CELL MOL LIFE SCI, V58, P1950, DOI 10.1007/PL00000829; de la Monte SM, 2000, ALCOHOL CLIN EXP RES, V24, P716, DOI 10.1097/00000374-200005000-00017; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; GAMMELTOFT S, 1985, BIOCHIMIE, V67, P1147, DOI 10.1016/S0300-9084(85)80113-9; GOODYER CG, 1984, ENDOCRINOLOGY, V114, P1187, DOI 10.1210/endo-114-4-1187; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hallak H, 2001, ALCOHOL CLIN EXP RES, V25, P1058, DOI 10.1111/j.1530-0277.2001.tb02317.x; Handa RK, 2000, METAB BRAIN DIS, V15, P211, DOI 10.1007/BF02674530; Hetman M, 2000, J NEUROSCI, V20, P2567; HILL JM, 1986, NEUROSCIENCE, V17, P1127, DOI 10.1016/0306-4522(86)90082-5; Hirsch T, 1998, CELL BIOL TOXICOL, V14, P141, DOI 10.1023/A:1007486022411; Hu IC, 1995, ALCOHOL CLIN EXP RES, V19, P1398, DOI 10.1111/j.1530-0277.1995.tb00998.x; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; LAM K, 1994, J BIOL CHEM, V269, P20648; Liesi P, 1997, J NEUROSCI RES, V48, P439, DOI 10.1002/(SICI)1097-4547(19970601)48:5<439::AID-JNR5>3.0.CO;2-F; Luo J, 1998, BRAIN RES REV, V27, P157, DOI 10.1016/S0165-0173(98)00009-5; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier SE, 2001, ALCOHOL, V23, P49, DOI 10.1016/S0741-8329(00)00133-6; Mao PL, 1998, J BIOL CHEM, V273, P23621, DOI 10.1074/jbc.273.37.23621; Minana R, 2000, J NEUROCHEM, V75, P954, DOI 10.1046/j.1471-4159.2000.0750954.x; MOHAMED SA, 1987, EXP NEUROL, V97, P35, DOI 10.1016/0014-4886(87)90280-9; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; OHARE T, 1990, INT J BIOCHEM, V22, P315, DOI 10.1016/0020-711X(90)90132-M; Olney JW, 2000, APOPTOSIS, V5, P515, DOI 10.1023/A:1009685428847; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Ramachandran V, 2001, ALCOHOL CLIN EXP RES, V25, P862, DOI 10.1097/00000374-200106000-00012; RESNICOFF M, 1994, LAB INVEST, V71, P657; Seiler AEM, 2000, ALCOHOL CLIN EXP RES, V24, P140, DOI 10.1097/00000374-200002000-00002; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; Shpakov A O, 2000, Membr Cell Biol, V13, P455; SINGH SP, 1993, LIFE SCI, V53, P1811, DOI 10.1016/0024-3205(93)90489-P; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SWANSON DJ, 1995, ALCOHOL CLIN EXP RES, V19, P1252, DOI 10.1111/j.1530-0277.1995.tb01608.x; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; URSO T, 1981, LIFE SCI, V28, P1053, DOI 10.1016/0024-3205(81)90752-9; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WANDS JR, 2000, NIH PUBLICATION, P75; Welham MJ, 1997, J BIOL CHEM, V272, P1377, DOI 10.1074/jbc.272.2.1377; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; XU YY, 1995, BIOCHEM J, V310, P125, DOI 10.1042/bj3100125; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yanni PA, 2000, DEV BRAIN RES, V120, P233, DOI 10.1016/S0165-3806(00)00015-8; Zhang FX, 1998, J NEUROCHEM, V71, P196, DOI 10.1046/j.1471-4159.1998.71010196.x	68	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26929	26937		10.1074/jbc.M300401200	http://dx.doi.org/10.1074/jbc.M300401200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12700235	hybrid			2022-12-25	WOS:000184155700082
J	Alphey, MS; Gabrielsen, M; Micossi, E; Leonard, GA; McSweeney, SM; Ravelli, RBG; Tetaud, E; Fairlamb, AH; Bond, CS; Hunter, WN				Alphey, MS; Gabrielsen, M; Micossi, E; Leonard, GA; McSweeney, SM; Ravelli, RBG; Tetaud, E; Fairlamb, AH; Bond, CS; Hunter, WN			Tryparedoxins from Crithidia fasciculata and Trypanosoma brucei - Photoreduction of the redox disulfide using synchrotron radiation and evidence for a conformational switch implicated in function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; CRYSTAL-STRUCTURE; PROTEIN STRUCTURES; TRYPANOTHIONE; RESOLUTION; REDUCTASE; PROGRAM; COEFFICIENTS; REVEALS; DAMAGE	Tryparedoxin (TryX) is a member of the thioredoxin (TrX) fold family involved in the regulation of oxidative stress in parasitic trypanosomatids. Like TrX, TryX carries a characteristic Trp-Cys-Xaa-Xaa-Cys motif, which positions a redox-active disulfide underneath a tryptophan lid. We report the structure of a Crithidia fasciculata tryparedoxin isoform (CfTryX2) in two crystal forms and compare them with structures determined previously. Efforts to chemically generate crystals of reduced TryX1 were unsuccessful, and we carried out a novel experiment to break the redox-active disulfide, formed between Cys-40 and Cys-43, utilizing the intense x-radiation from a third generation synchrotron undulator beamline. A time course study of the S-S bond cleavage is reported with the structure of a TryX1 C43A mutant as the control. When freed from the constraints of a disulfide link to Cys-43, Cys-40 pivots to become slightly more solvent-accessible. In addition, we have determined the structure of Trypanosoma brucei TryX, which, influenced by the molecular packing in the crystal lattice, displays a significantly different orientation of the active site tryptophan lid. This structural change may be of functional significance when TryX interacts with tryparedoxin peroxidase, the final protein in the trypanothione-dependent peroxidase pathway. Comparisons with chloroplast TrX and its substrate fructose 1,6-bisphosphate phosphatase suggest that this movement may represent a general feature of redox regulation in the trypanothione and thioredoxin peroxidase pathways.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; European Synchrotron Radiat Facil, Macromol Crystallog Grp, F-38043 Grenoble 9, France; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaire, F-33077 Bordeaux, France	University of Dundee; European Synchrotron Radiation Facility (ESRF); European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.		Bond, Charles/AAF-9608-2020; Hunter, William/AAE-3947-2019; Fairlamb, Alan/A-5272-2009; Leonard, Gordon/D-2160-2019; Bond, Charles S/B-4094-2011	Bond, Charles/0000-0002-9584-6783; Fairlamb, Alan/0000-0001-5134-0329; Leonard, Gordon/0000-0001-5030-0122; Bond, Charles S/0000-0002-9584-6783; McSweeney, Sean/0000-0002-3758-3161; Ravelli, Raimond/0000-0001-6056-5888; Gabrielsen, Mads/0000-0002-9848-2276				Alphey MS, 1999, J STRUCT BIOL, V126, P76, DOI 10.1006/jsbi.1999.4091; Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; Capitani G, 2000, J MOL BIOL, V302, P135, DOI 10.1006/jmbi.2000.4006; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; MATTHEWS BM, 1976, J MOL BIOL, V33, P491; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Micossi E, 2002, ACTA CRYSTALLOGR D, V58, P21, DOI 10.1107/S0907444901016808; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKKOLA M, 1993, BIOCHEMISTRY-US, V32, P5093, DOI 10.1021/bi00070a017; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; Ravelli RBG, 1997, J APPL CRYSTALLOGR, V30, P551, DOI 10.1107/S0021889897003543; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reckenfelderbaumer N, 2002, J BIOL CHEM, V277, P17548, DOI 10.1074/jbc.M112115200; Weik M, 2002, J SYNCHROTRON RADIAT, V9, P342, DOI 10.1107/S0909049502014589; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623	41	43	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25919	25925		10.1074/jbc.M301526200	http://dx.doi.org/10.1074/jbc.M301526200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12707277	hybrid			2022-12-25	WOS:000183920200083
J	Didichenko, SA; Fragoso, CM; Thelen, M				Didichenko, SA; Fragoso, CM; Thelen, M			Mitotic and stress-induced phosphorylation of HsPI3K-C2 alpha Targets the protein for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II PHOSPHOINOSITIDE 3-KINASE; RNA-POLYMERASE-II; CYCLIN-DEPENDENT KINASES; C2 DOMAIN; DNA-DAMAGE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTORS; CDNA CLONING; IN-VIVO; ACTIVATION	Activation of the phosphoinositide 3-kinases (PI 3-kinases) has been implicated in multiple cellular responses such as proliferation and survival, membrane and cytoskeletal reorganization, and intracellular vesicular trafficking. The activities and subcellular localization of PI 3-kinases were shown to be regulated by phosphorylation. Previously we demonstrated that class II HsPIK3-C2alpha becomes phosphorylated upon inhibition of RNA pol II-dependent transcription (Didichenko, S. A., and Thelen, M. (2001) J. Biol. Chem. 276, 48135-48142). In this study we investigated cell cycle-dependent and genotoxic stress-induced phosphorylation of HsPIK3-C2alpha. We find that the kinase becomes phosphorylated upon exposure of cells to UV irradiation and in proliferating cells at the G(2)/M transition of the cell cycle. Stress-dependent and mitotic phosphorylation of HsPIK3-C2alpha occurs on the same serine residue (Ser(259)) within a recognition motif for proline-directed kinases. Mitotic phosphorylation of HsPIK3-C2alpha can be attributed to Cdc2 activity, and stress-induced phosphorylation of HsPIK3-C2alpha is mediated by JNK/SAPK. The protein level of HsPIK3-C2alpha is regulated by proteolysis in a cell cycle-dependent manner and in response of cells to stress. Phosphorylation appears to be a prerequisite for proteasome-dependent degradation of HsPIK3-C2alpha and may therefore contribute indirectly to the regulation of the activity of the kinase.	Inst Biomed Res, CH-6500 Bellinzona, Switzerland	Universita della Svizzera Italiana	Thelen, M (corresponding author), Inst Biomed Res, Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland.	marcus.thelen@irb.unisi.ch						Al-Mohanna MA, 2001, CARCINOGENESIS, V22, P573, DOI 10.1093/carcin/22.4.573; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Beaudenon SL, 1999, MOL CELL BIOL, V19, P6972; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 2000, J BIOL CHEM, V275, P11943, DOI 10.1074/jbc.275.16.11943; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRISCAVAGE JM, 1995, BIOCHEM BIOPH RES CO, V215, P721, DOI 10.1006/bbrc.1995.2523; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Misawa H, 1998, BIOCHEM BIOPH RES CO, V244, P531, DOI 10.1006/bbrc.1998.8294; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Nguyen VT, 1996, NUCLEIC ACIDS RES, V24, P2924, DOI 10.1093/nar/24.15.2924; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Prives C, 1999, J PATHOL, V187, P112; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Rozycka M, 1998, GENOMICS, V54, P569, DOI 10.1006/geno.1998.5621; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; Sindic A, 2001, J BIOL CHEM, V276, P17754, DOI 10.1074/jbc.M006533200; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	55	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26055	26064		10.1074/jbc.M301657200	http://dx.doi.org/10.1074/jbc.M301657200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719431	hybrid			2022-12-25	WOS:000183920200102
J	Stray, JE; Lindsley, JE				Stray, JE; Lindsley, JE			Biochemical analysis of the yeast condensin Smc2/4 complex - An ATPase that promotes knotting of circular DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; CHROMOSOME CONDENSATION; SACCHAROMYCES-CEREVISIAE; TOPOISOMERASE-II; IN-VITRO; 13S CONDENSIN; STRUCTURAL MAINTENANCE; COHESIN COMPLEX; ABC-ATPASE; PROTEIN	To better understand the contributions that the structural maintenance of chromosome proteins (SMCs) make to condensin activity, we have tested a number of biochemical, biophysical, and DNA-associated attributes of the Smc2p-Smc4p pair from budding yeast. Smc2p and Smc4p form a stable heterodimer, the "Smc2/4 complex," which upon analysis by sedimentation equilibrium appears to reversibly self-associate to form heterotetramers. Individually, neither Smc2p nor Smc4p hydrolyzes ATP; however, ATPase activity is recovered by equal molar mixing of both purified proteins. Hydrolysis activity is unaffected by the presence of DNA. Smc2/4 binds both linearized and circular plasmids, and the binding appears to be independent of adenylate nucleotide. High mole ratios of Smc2/4 to plasmid promote a geometric change in circular DNA that can be trapped as knots by type II topoisomerases but not as supercoils by a type I topoisomerase. Binding titration analyses reveal that two Smc2/4-DNA-bound states exist, one disrupted by and one resistant to salt challenge. Competition-displacement experiments show that Smc2/4-DNA-bound species formed at even high protein to DNA mole ratios remain reversible. Surprisingly, only linear and supercoiled DNA, not nicked-circular DNA, can completely displace Smc2/4 prebound to a labeled, nicked-circular DNA. To explain this geometry-dependent competition, we present two models of DNA binding by SMCs in which two DNA duplexes are captured within the inter-coil space of an Smc2/4 heterodimer. Based on these models, we propose a DNA displacement mechanism to explain how differences in geometry could affect the competitive potential of DNA.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Lindsley, JE (corresponding author), Univ Utah, Sch Med, Dept Biochem, 20 North,1900 East, Salt Lake City, UT 84132 USA.	Janet.Lindsley@hsc.utah.edu			NIGMS NIH HHS [GM51194, 5T32GM07464-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051194, T32GM007464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Bazett-Jones DP, 2002, MOL CELL, V9, P1183, DOI 10.1016/S1097-2765(02)00546-4; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Freeman L, 2000, J CELL BIOL, V149, P811, DOI 10.1083/jcb.149.4.811; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Harvey SH, 2002, GENOME BIOL, V3; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Kimura K, 2000, P NATL ACAD SCI USA, V97, P11972, DOI 10.1073/pnas.220326097; Laue TM, 1995, METHOD ENZYMOL, V259, P427; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LOO TW, 1994, J BIOL CHEM, V269, P7750; Losada A, 2001, BIOESSAYS, V23, P924, DOI 10.1002/bies.1133; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Lowe J, 2001, J MOL BIOL, V306, P25, DOI 10.1006/jmbi.2000.4379; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Morris SNK, 1999, J BIOL CHEM, V274, P3446, DOI 10.1074/jbc.274.6.3446; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Yoshimura SH, 2002, CURR BIOL, V12, P508, DOI 10.1016/S0960-9822(02)00719-4	60	53	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					26238	26248		10.1074/jbc.M302699200	http://dx.doi.org/10.1074/jbc.M302699200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719426	hybrid			2022-12-25	WOS:000183920200123
J	Andersen, C; Maier, E; Kemmer, G; Blass, J; Hilpert, AK; Benz, R; Reidl, J				Andersen, C; Maier, E; Kemmer, G; Blass, J; Hilpert, AK; Benz, R; Reidl, J			Porin OmpP2 of Haemophilus influenzae shows specificity for nicotinamide-derived nucleotide substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; LIPID BILAYER-MEMBRANES; ESCHERICHIA-COLI; HEMOPHILUS-INFLUENZAE; IN-VIVO; CHANNELS; NAD; PERMEABILITY; MUTAGENESIS; LAMB	Haemophilus influenzae has an absolute requirement for NAD ( factor V) because it lacks all biosynthetic enzymes necessary for de novo synthesis of that cofactor. Therefore, growth in vitro requires the presence of NAD itself, NMN, or nicotinamide riboside (NR). To address uptake abilities of these compounds, we investigated outer membrane proteins. By analyzing ompP2 knockout mutants, we found that NAD and NMN uptake was prevented, whereas NR uptake was not. Through investigation of the properties of purified OmpP2 in artificial lipid membrane systems, the substrate specificity of OmpP2 for NAD and NMN was determined, with K-S values of similar to8 and 4mM, respectively, in 0.1 M KCl, whereas no interaction was detected for the nucleoside NR and other purine or pyrimidine nucleotide or nucleoside species. Based on our analysis, we assume that an intrinsic binding site within OmpP2 exists that facilitates diffusion of these compounds across the outer membrane, recognizing carbonyl and exposed phosphate groups. Because OmpP2 was formerly described as a general diffusion porin, an additional property of acting as a facilitator for nicotinamide-based nucleotide transport may have evolved to support and optimize utilization of the essential cofactor sources NAD and NMN in H. influenzae.	Univ Wurzburg, Lehrstuhl Biotechnol, Biozentrum, D-97074 Wurzburg, Germany; Univ Wurzburg, Zentrum Infekt Forsch, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Benz, R (corresponding author), Univ Wurzburg, Lehrstuhl Biotechnol, Biozentrum, D-97074 Wurzburg, Germany.	roland.benz@mail.uni-wuerzburg.de	Reidl, Joachim/O-2107-2016	Reidl, Joachim/0000-0001-5798-9524; Benz, Roland/0000-0002-9510-9265				Andersen C, 1998, EUR J BIOCHEM, V254, P679, DOI 10.1046/j.1432-1327.1998.2540679.x; Arbing MA, 2001, BIOCHEMISTRY-US, V40, P14621, DOI 10.1021/bi015611y; BELL J, 1994, INFECT IMMUN, V62, P2639, DOI 10.1128/IAI.62.6.2639-2643.1994; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1993, ZBL BAKT-INT J MED M, V278, P187, DOI 10.1016/S0934-8840(11)80836-4; BENZ R, 1980, J MEMBRANE BIOL, V56, P19, DOI 10.1007/BF01869348; BENZ R, 1986, J BACTERIOL, V165, P978, DOI 10.1128/jb.165.3.978-986.1986; BENZ R, 1987, J MEMBRANE BIOL, V100, P21, DOI 10.1007/BF02209137; BENZ R, 1985, J BACTERIOL, V162, P722, DOI 10.1128/JB.162.2.722-727.1985; Benz R., 1994, BACTERIAL CELL WALL, P397; CARLONE GM, 1986, J CLIN MICROBIOL, V24, P330, DOI 10.1128/JCM.24.3.330-332.1986; CASTELLAN GW, 1983, PHYSICAL CHEM, P769; COPE LD, 1990, INFECT IMMUN, V58, P3312, DOI 10.1128/IAI.58.10.3312-3318.1990; COULTON JW, 1983, J ANTIMICROB CHEMOTH, V12, P435, DOI 10.1093/jac/12.5.435; CYNAMON MH, 1988, J GEN MICROBIOL, V134, P2789; Edwards JS, 1999, J BIOL CHEM, V274, P17410, DOI 10.1074/jbc.274.25.17410; EVANS NM, 1974, J MED MICROBIOL, V7, P359, DOI 10.1099/00222615-7-3-359; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FUNKHOUSER A, 1991, REV INFECT DIS, V13, P542; Gingrich W, 1944, J BACTERIOL, V47, P535, DOI 10.1128/JB.47.6.535-550.1944; GODEK CP, 1990, ANTIMICROB AGENTS CH, V34, P1473, DOI 10.1128/AAC.34.8.1473; HANSEN EJ, 1988, INFECT IMMUN, V56, P2709, DOI 10.1128/IAI.56.10.2709-2716.1988; Kemmer G, 2001, J BACTERIOL, V183, P3974, DOI 10.1128/JB.183.13.3974-3981.2001; Kraiss A, 1998, APPL ENVIRON MICROB, V64, P4697; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDER IG, 1951, J BIOL CHEM, V189, P889; Lin J, 2002, MICROBES INFECT, V4, P325, DOI 10.1016/S1286-4579(02)01545-9; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUTWYCHE P, 1995, INFECT IMMUN, V63, P3137, DOI 10.1128/IAI.63.8.3137-3142.1995; Maniatis T., 1982, MOL CLONING LAB MANU; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNSON R, 1989, MOL MICROBIOL, V3, P1797, DOI 10.1111/j.1365-2958.1989.tb00165.x; MUNSON RS, 1983, J CLIN INVEST, V72, P677, DOI 10.1172/JCI111017; NIKAIDO H, 1983, J BACTERIOL, V153, P232, DOI 10.1128/JB.153.1.232-240.1983; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; PULLEN JK, 1995, GENE, V152, P85, DOI 10.1016/0378-1119(94)00706-X; Reddy MS, 1996, INFECT IMMUN, V64, P1477, DOI 10.1128/IAI.64.4.1477-1479.1996; Regelink AG, 1999, ANTIMICROB AGENTS CH, V43, P226, DOI 10.1128/AAC.43.2.226; Reidl J, 2000, MOL MICROBIOL, V35, P1573, DOI 10.1046/j.1365-2958.2000.01829.x; Schilling CH, 2000, J THEOR BIOL, V203, P249, DOI 10.1006/jtbi.2000.1088; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Schmidt-Brauns J, 2001, INT J MED MICROBIOL, V291, P219, DOI 10.1078/1438-4221-00122; SCHULEIN K, 1995, MOL MICROBIOL, V17, P757, DOI 10.1111/j.1365-2958.1995.mmi_17040757.x; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; SHIFRINE M, 1960, NATURE, V187, P623, DOI 10.1038/187623a0; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; TURK DC, 1984, J MED MICROBIOL, V18, P1, DOI 10.1099/00222615-18-1-1; VACHON V, 1986, BIOCHIM BIOPHYS ACTA, V861, P74, DOI 10.1016/0005-2736(86)90373-1; VACHON V, 1985, J BACTERIOL, V162, P918, DOI 10.1128/JB.162.3.918-924.1985; WEST IC, 1984, J THEOR BIOL, V110, P11, DOI 10.1016/S0022-5193(84)80011-9; [No title captured]	52	23	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24269	24276		10.1074/jbc.M213087200	http://dx.doi.org/10.1074/jbc.M213087200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12695515	hybrid			2022-12-25	WOS:000183824800006
J	Hutchinson, SL; Wooldridge, L; Tafuro, S; Laugel, B; Glick, M; Boulter, JM; Jakobsen, BK; Price, DA; Sewell, AK				Hutchinson, SL; Wooldridge, L; Tafuro, S; Laugel, B; Glick, M; Boulter, JM; Jakobsen, BK; Price, DA; Sewell, AK			The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; RECEPTOR-LIGAND INTERACTIONS; MEMBRANE COMPARTMENTATION; CD8-ALPHA-BETA CORECEPTOR; LYMPHOCYTE ACTIVATION; NEGATIVE SELECTION; CRYSTAL-STRUCTURE; TYROSINE KINASE; ALPHA-3 DOMAIN; ANTIGEN	T lymphocytes recognize peptides presented in the context of major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells. Recognition specificity is determined by the alphabeta T cell receptor (TCR). The T lymphocyte surface glycoproteins CD8 and CD4 enhance T cell antigen recognition by binding to MHC class I and class II molecules, respectively. Biophysical measurements have determined that equilibrium binding of the TCR with natural agonist peptide-MHC (pMHC) complexes occurs with K-D values of 1-50 muM. The pMHCI/CD8 and pMHCII/CD4 interactions are significantly weaker than this (K-D >100 muM), and the relative roles of TCR/pMHC and pMHC/coreceptor affinity in T cell activation remain controversial. Here, we engineer mutations in the MHCI heavy chain and beta(2)-microglobulin that further reduce or abolish the pMHCI/CD8 interaction to probe the significance of pMHC/coreceptor affinity in T cell activation. We demonstrate that the pMHCI/CD8 coreceptor interaction retains the vast majority of its biological activity at affinities that are reduced by over 15-fold (K-D >2 mM). In contrast to previous reports, we observe that the weak interaction between HLA A68 and CD8, which falls within this spectrum of reduced affinities, retains substantial functional activity. These findings are discussed in the context of current concepts of coreceptor dependence and the mechanism by which TCR coreceptors facilitate T cell activation.	T Cell Modulat Grp, Oxford OX1 3SY, England; John Radcliffe Hosp, MRC, Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Oxford, Oxfrod Ctr Mol Sci, Oxford OX1 3QZ, England; Avidex Ltd, Abingdon OX14 4RX, Oxon, England; NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA	University of Oxford; University of Oxford; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sewell, AK (corresponding author), T Cell Modulat Grp, Peter Medawar Bldg Pathogen Res,S Parks Rd, Oxford OX1 3SY, England.	andy.sewell@ndm.ox.ac.uk	Sewell, Andrew/GPT-4220-2022; Price, David A/C-7876-2013	Sewell, Andrew/0000-0003-3194-3135; Price, David A/0000-0001-9416-2737; Wooldridge, Linda/0000-0002-6213-347X				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; Arcaro A, 2000, J IMMUNOL, V165, P2068, DOI 10.4049/jimmunol.165.4.2068; Arcaro A, 2001, J EXP MED, V194, P1485, DOI 10.1084/jem.194.10.1485; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bosselut R, 1999, J EXP MED, V190, P1517, DOI 10.1084/jem.190.10.1517; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CERUNDOLO V, 1991, P ROY SOC B-BIOL SCI, V244, P169, DOI 10.1098/rspb.1991.0066; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Devine L, 1999, J IMMUNOL, V162, P846; Doucey MA, 2003, J BIOL CHEM, V278, P3257, DOI 10.1074/jbc.M208119200; Doucey MA, 2001, EUR J IMMUNOL, V31, P1561, DOI 10.1002/1521-4141(200105)31:5&lt;1561::AID-IMMU1561&gt;3.0.CO;2-W; ELVIN J, 1993, J IMMUNOL METHODS, V158, P161, DOI 10.1016/0022-1759(93)90210-X; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Gao GF, 2002, TRENDS IMMUNOL, V23, P408, DOI 10.1016/S1471-4906(02)02282-2; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Gao GF, 2000, IMMUNOL TODAY, V21, P630, DOI 10.1016/S0167-5699(00)01750-3; Garcia KC, 1996, NATURE, V384, P577, DOI 10.1038/384577a0; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Glick M, 2002, J BIOL CHEM, V277, P20840, DOI 10.1074/jbc.M201819200; Goulder PJR, 1997, EUR J IMMUNOL, V27, P1515, DOI 10.1002/eji.1830270630; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; Kern P, 1999, J BIOL CHEM, V274, P27237, DOI 10.1074/jbc.274.38.27237; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; Konig R, 2002, CURR OPIN IMMUNOL, V14, P75, DOI 10.1016/S0952-7915(01)00300-4; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; Lim GEK, 1998, EUR J IMMUNOL, V28, P745, DOI 10.1002/(SICI)1521-4141(199802)28:02<745::AID-IMMU745>3.0.CO;2-6; LUESCHER IF, 1995, NATURE, V373, P353, DOI 10.1038/373353a0; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Moody AM, 2001, EUR J IMMUNOL, V31, P2791, DOI 10.1002/1521-4141(200109)31:9<2791::AID-IMMU2791>3.0.CO;2-X; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; Oxenius A, 2002, AIDS, V16, P1285, DOI 10.1097/00002030-200206140-00012; Price DA, 1998, CURR BIOL, V8, P355, DOI 10.1016/S0960-9822(98)70138-1; Purbhoo MA, 2001, J BIOL CHEM, V276, P32786, DOI 10.1074/jbc.M102498200; Purbhoo MA, 1998, P NATL ACAD SCI USA, V95, P4527, DOI 10.1073/pnas.95.8.4527; Renard V, 1996, J EXP MED, V184, P2439, DOI 10.1084/jem.184.6.2439; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SCHONRICH G, 1993, J IMMUNOL, V151, P4098; Sewell AK, 1997, EUR J IMMUNOL, V27, P2323, DOI 10.1002/eji.1830270929; Sewell AK, 1999, NAT MED, V5, P399, DOI 10.1038/7398; Sewell AK, 2001, TRENDS IMMUNOL, V22, P173, DOI 10.1016/S1471-4906(01)01866-X; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sun JR, 1997, J IMMUNOL, V159, P6077; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wang JH, 2001, P NATL ACAD SCI USA, V98, P10799, DOI 10.1073/pnas.191124098; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xiong Y, 2001, J BIOL CHEM, V276, P5659, DOI 10.1074/jbc.M009580200; YOON ST, 1994, IMMUNITY, V1, P563; ZAMOYSKA R, 1994, IMMUNITY, V1, P243, DOI 10.1016/1074-7613(94)90075-2; Zamoyska R, 1998, CURR OPIN IMMUNOL, V10, P82, DOI 10.1016/S0952-7915(98)80036-8; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	68	77	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24285	24293		10.1074/jbc.M300633200	http://dx.doi.org/10.1074/jbc.M300633200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12697765	hybrid, Green Accepted			2022-12-25	WOS:000183824800008
J	Moche, M; Shanklin, J; Ghoshal, A; Lindqvist, Y				Moche, M; Shanklin, J; Ghoshal, A; Lindqvist, Y			Azide and acetate complexes plus two iron-depleted crystal structures of the di-iron enzyme Delta 9 stearoyl-acyl carrier protein desaturase - Implications for oxygen activation and catalytic intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANE MONOOXYGENASE HYDROXYLASE; RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; CARBOXYLATE SHIFT; O-2 ACTIVATION; ACP DESATURASE; ACID; SITE; R2	Delta9 stearoyl-acyl carrier protein (ACP) desaturase is a mu-oxo-bridged di-iron enzyme, which belongs to the structural class I of large helix bundle proteins and that catalyzes the NADPH and O-2-dependent formation of a cis-double bond in stearoyl-ACP. The crystal structures of complexes with azide and acetate, respectively, as well as the apo- and single-iron forms of Delta9 stearoyl-ACP desaturase from Ricinus communis have been determined. In the azide complex, the ligand forms a mu-1,3-bridge between the two iron ions in the active site, replacing a loosely bound water molecule. The structure of the acetate complex is similar, with acetate bridging the di-iron center in the same orientation with respect to the di-iron center. However, in this complex, the iron ligand Glu(196) has changed its coordination mode from bidentate to monodentate, the first crystallographic observation of a carboxylate shift in Delta9 stearoyl-ACP desaturase. The two complexes are proposed to mimic a mu-1,2 peroxo intermediate present during catalytic turnover. There are striking structural similarities between the di-iron center in the Delta9 stearoyl-ACP desaturase-azide complex and in the reduced rubrerythrin-azide complex. This suggests that Delta9 stearoyl-ACP desaturase might catalyze the formation of water from exogenous hydrogen peroxide at a low rate. From the similarity in iron center structure, we propose that the mu-oxo-bridge in oxidized desaturase is bound to the di-iron center as in rubrerythrin and not as reported for the R2 subunit of ribonucleotide reductase and the hydroxylase subunit of methane monooxygenase. The crystal structure of the one-iron depleted desaturase species demonstrates that the affinities for the two iron ions comprising the di-iron center are not equivalent, Fe1 being the higher affinity site and Fe2 being the lower affinity site.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Karolinska Institutet; United States Department of Energy (DOE); Brookhaven National Laboratory	Lindqvist, Y (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	ylva@alfa.mbb.ki.se	Lindqvist, Ylva/F-9009-2010	Shanklin, John/0000-0002-6774-8043; Lindqvist, Ylva/0000-0003-3162-8661; Moche, Martin/0000-0002-4834-7076				ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; Ai JY, 1997, J BIOL INORG CHEM, V2, P37, DOI 10.1007/s007750050104; Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; Assarsson M, 2001, J BIOL CHEM, V276, P26852, DOI 10.1074/jbc.M008190200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; Behrouzian B, 2001, CHEM COMMUN, P401, DOI 10.1039/b008972i; BLOCH K, 1969, ACCOUNTS CHEM RES, V2, P193, DOI 10.1021/ar50019a001; Bollinger JM, 1998, J AM CHEM SOC, V120, P1094, DOI 10.1021/ja973651c; Bollinger JM, 1997, J AM CHEM SOC, V119, P5976, DOI 10.1021/ja970319s; Broadwater JA, 1998, BIOCHEMISTRY-US, V37, P14664, DOI 10.1021/bi981839i; Broadwater JA, 1999, BIOCHEMISTRY-US, V38, P12197, DOI 10.1021/bi9914199; Cahoon EB, 1997, PLANT MOL BIOL, V33, P1105, DOI 10.1023/A:1005821007291; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; Cahoon EB, 1996, J BACTERIOL, V178, P936, DOI 10.1128/jb.178.3.936-939.1996; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; CAHOON EB, 1994, J BIOL CHEM, V269, P27519; Cobessi D, 2002, ACTA CRYSTALLOGR D, V58, P29, DOI 10.1107/S0907444901017267; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Coulter ED, 2000, INORG CHIM ACTA, V297, P231, DOI 10.1016/S0020-1693(99)00374-6; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; deMare F, 1996, NAT STRUCT BIOL, V3, P539, DOI 10.1038/nsb0696-539; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FOX BG, 1993, P NATL ACAD SCI USA, V90, P2486, DOI 10.1073/pnas.90.6.2486; JACOBSON BS, 1974, PLANT PHYSIOL, V54, P484, DOI 10.1104/pp.54.4.484; Jin S, 2002, J AM CHEM SOC, V124, P9845, DOI 10.1021/ja026587u; Jin Y, 2001, J BIOL INORG CHEM, V6, P717, DOI 10.1007/s007750100250; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; Lee SY, 1999, BIOCHEMISTRY-US, V38, P4423, DOI 10.1021/bi982712w; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moenne-Loccoz P, 1998, BIOCHEMISTRY-US, V37, P14659, DOI 10.1021/bi981838q; MURPHY DJ, 1983, BIOCHEM J, V213, P249, DOI 10.1042/bj2130249; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAGAI J, 1966, J BIOL CHEM, V241, P1925; NAGAI J, 1968, J BIOL CHEM, V243, P4626; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; Perutz MF, 1998, ANNU REV BIOPH BIOM, V27, P1, DOI 10.1146/annurev.biophys.27.1.1; Peyou-Ndi MM, 2000, ARCH BIOCHEM BIOPHYS, V376, P399, DOI 10.1006/abbi.2000.1733; RARDIN RL, 1991, NEW J CHEM, V15, P417; Rogge CE, 2002, BIOCHEMISTRY-US, V41, P10141, DOI 10.1021/bi020306d; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; Schultz DJ, 1996, P NATL ACAD SCI USA, V93, P8771, DOI 10.1073/pnas.93.16.8771; Shu LJ, 1998, J BIOL INORG CHEM, V3, P392, DOI 10.1007/s007750050249; Whittington DA, 2001, J AM CHEM SOC, V123, P827, DOI 10.1021/ja003240n; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yang YS, 1999, J AM CHEM SOC, V121, P2770, DOI 10.1021/ja9822714	59	53	57	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25072	25080		10.1074/jbc.M301662200	http://dx.doi.org/10.1074/jbc.M301662200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12704186	Green Submitted, hybrid			2022-12-25	WOS:000183824800101
J	Sarkar, D; Leszczyniecka, M; Kang, DC; Lebedeva, IV; Valerie, K; Dhar, S; Pandita, TK; Fisher, PB				Sarkar, D; Leszczyniecka, M; Kang, DC; Lebedeva, IV; Valerie, K; Dhar, S; Pandita, TK; Fisher, PB			Down-regulation of myc as a potential target for growth arrest induced by human polynucleotide phosphorylase (hPNPase(old-35)) in human melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; CYCLE PROGRESSION; RIBOSOMAL-RNA; TRANSCRIPTIONAL REPRESSOR; TERMINAL DIFFERENTIATION; DEPENDENT TRANSFORMATION; YEAST EXOSOME; CDK2 KINASE; TUMOR-CELLS; P27(KIP1)	Terminal differentiation and senescence share several common properties, including irreversible cessation of growth and changes in gene expression profiles. To identify molecules that converge in both processes, an overlapping pathway screening was employed that identified old-35, which is human polynucleotide phosphorylase (hPNPase(old-35)), a 3',5'-exoribonuclease. We previously demonstrated that hPNPase(old-35) is a type I interferon-inducible gene that is also induced in senescent fibroblasts. In vitro RNA degradation assays confirmed its exoribonuclease properties, and overexpression of hPNPase(old-35) resulted in growth suppression in HO-1 human melanoma cells. The present study examined the molecular mechanism of the growth-arresting property of hPNPase(old-35). When overexpressed by means of a replication-incompetent adenoviral vector (Ad. hPNPase(old-35)), hPNPase(old-35) inhibited cell growth in all cell lines tested. Analysis of cell cycle revealed that infection of HO-1 cells with Ad. hPNPase(old-35) resulted in arrest in the G(1) phase and eventually apoptosis accompanied by marked reduction in the S phase. Infection with Ad. hPNPase(old-35) resulted in reduction in expression of the c-myc mRNA and Myc protein and modulated the expression of proteins regulating G1 checkpoint and apoptosis. In vitro mRNA degradation assays revealed that hPNPase(OLD-35) degraded c-myc mRNA. Overexpression of Myc partially but significantly protected HO-1 cells from Ad. hPNPase(old-35)-induced growth arrest, indicating that Myc down-regulation might directly mediate the growth-inhibitory properties of Ad. hPNPase(old-35). Inhibition of hPNPase(old-35) by an antisense approach provided partial but significant protection against interferon-beta-mediated growth inhibition, thus demonstrating the biological significance of hPNPase(old-35) in interferon action.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Novartis Pharmaceut, E Hanover, NJ 07936 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Washington Univ, Sch Med, Radiat & Canc Biol Div, St Louis, MO 63108 USA	Columbia University; Columbia University; Columbia University; Novartis; Virginia Commonwealth University; Washington University (WUSTL)	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St,P&S Box 23,BB-1505, New York, NY 10032 USA.	pbf1@columbia.edu	Pandita, Tej K/AAM-9188-2020; Valerie, Kristoffer/AAL-8299-2021; Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA097318, R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER; NCI NIH HHS [CA97318, CA35675] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Baginsky S, 2001, RNA, V7, P1464; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Benaud CM, 2001, ONCOGENE, V20, P4554, DOI 10.1038/sj.onc.1204609; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GUARINI L, 1992, PIGM CELL RES, P123; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; JIANG HP, 1995, ONCOGENE, V11, P1179; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; KARN J, 1989, ONCOGENE, V4, P773; Katayose Y, 1997, CANCER RES, V57, P5441; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; McArthur GA, 2002, MOL CELL BIOL, V22, P3014, DOI 10.1128/MCB.22.9.3014-3023.2002; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Ohta Y, 2002, EXP DERMATOL, V11, P439, DOI 10.1034/j.1600-0625.2002.110507.x; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rudolph C, 1998, EXP CELL RES, V239, P361, DOI 10.1006/excr.1997.3906; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Valerie K, 1999, BIOPHARMACEUTICAL DRUG DESIGN AND DEVELOPMENT, P69; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	72	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24542	24551		10.1074/jbc.M302421200	http://dx.doi.org/10.1074/jbc.M302421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721301	hybrid			2022-12-25	WOS:000183824800037
J	Uchil, PD; Satchidanandam, V				Uchil, PD; Satchidanandam, V			Architecture of the flaviviral replication complex - Protease, nuclease, and detergents reveal encasement within double-layered membrane compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT RNA-POLYMERASE; MOUSE HEPATITIS-VIRUS; DOUBLE-STRANDED-RNA; KUNJIN VIRUS; NONSTRUCTURAL PROTEINS; ENDOPLASMIC-RETICULUM; INFECTED CELLS; NS2B-NS3 COMPLEX; IN-SITU; NS3	Flavivirus infection causes extensive proliferation and reorganization of host cell membranes to form specialized structures called convoluted membranes/paracrystalline arrays and vesicle packets (VP), the latter of which is believed to harbor flaviviral replication complexes. Using detergents and trypsin and micrococcal nuclease, we provide for the first time biochemical evidence for a double membrane compartment that encloses the replicative form (RF) RNA of the three pathogenic flaviviruses West Nile, Japanese encephalitis, and dengue viruses. The bounding membrane enclosing the VP was readily solubilized with nonionic detergents, rendering the catalytic amounts of enzymatically active protein component(s) of the replicase machinery partially sensitive to trypsin but allowing limited access for nucleases only to the vRNA and single-stranded tails of the replicative intermediate RNA. The RF co-sedimented at high speed from nonionic detergent extracts of virus-induced heavy membrane fractions along with the released individual inner membrane vesicles whose size of 75-100 nm as well as association with viral NS3 was revealed by immunoelectron microscopy. Viral RF remained nuclease-resistant even after ionic detergents solubilized the more refractory inner VP membrane. All of the viral RNA species became nuclease-sensitive following membrane disruption only upon prior trypsin treatment, suggesting that proteins coat the viral genomic RNA as well as RF within these membranous sites of flaviviral replication. These results collectively demonstrated that the newly formed viral genomic RNA associated with the VP are oriented outwards, while the RF is located inside the nonionic detergent-resistant vesicles.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Satchidanandam, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	vijaya@mcbl.iisc.ernet.in		Uchil, Pradeep/0000-0002-7236-858X				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; BOULTON RW, 1976, VIROLOGY, V69, P416, DOI 10.1016/0042-6822(76)90473-6; CAUCHI MR, 1991, VIROLOGY, V180, P659, DOI 10.1016/0042-6822(91)90079-Q; CHAMBERS TJ, 1993, J VIROL, V67, P6797, DOI 10.1128/JVI.67.11.6797-6807.1993; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; Chang YS, 1999, J VIROL, V73, P6257, DOI 10.1128/JVI.73.8.6257-6264.1999; Chen CJ, 1997, J VIROL, V71, P3466, DOI 10.1128/JVI.71.5.3466-3473.1997; Chen JB, 2000, J VIROL, V74, P4310, DOI 10.1128/JVI.74.9.4310-4318.2000; CHU PWG, 1987, VIROLOGY, V157, P330, DOI 10.1016/0042-6822(87)90275-3; CHU PWG, 1992, ARCH VIROL, V125, P177, DOI 10.1007/BF01309636; CHU PWG, 1985, VIROLOGY, V140, P68, DOI 10.1016/0042-6822(85)90446-5; CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J; CLEAVES GR, 1981, VIROLOGY, V111, P73, DOI 10.1016/0042-6822(81)90654-1; DEGRAAFF M, 1993, VIROLOGY, V194, P878, DOI 10.1006/viro.1993.1335; Egger D, 1996, J VIROL, V70, P8675, DOI 10.1128/JVI.70.12.8675-8683.1996; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; Gong Y, 1998, ARCH VIROL, V143, P399, DOI 10.1007/s007050050296; Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002; Gould E., 1985, VIROLOGY PRACTICAL A, P43; Grief C, 1997, ARCH VIROL, V142, P2347, DOI 10.1007/s007050050247; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; JAN LR, 1995, J GEN VIROL, V76, P573, DOI 10.1099/0022-1317-76-3-573; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; Kummerer BM, 2002, J VIROL, V76, P4773, DOI 10.1128/JVI.76.10.4773-4784.2002; Kuo MD, 1996, J GEN VIROL, V77, P2077, DOI 10.1099/0022-1317-77-9-2077; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Lyle JM, 2002, SCIENCE, V296, P2218, DOI 10.1126/science.1070585; Mackenzie JM, 1998, VIROLOGY, V245, P203, DOI 10.1006/viro.1998.9156; Mackenzie JM, 1999, J VIROL, V73, P9555, DOI 10.1128/JVI.73.11.9555-9567.1999; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; Mackenzie JM, 1996, J VIROL METHODS, V56, P67, DOI 10.1016/0166-0934(95)01916-2; Mackenzie JM, 2001, VIROLOGY, V279, P161, DOI 10.1006/viro.2000.0691; Magliano D, 1998, VIROLOGY, V240, P57, DOI 10.1006/viro.1997.8906; Matusan AE, 2001, J VIROL, V75, P9633, DOI 10.1128/JVI.75.20.9633-9643.2001; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000; RestrepoHartwig MA, 1996, J VIROL, V70, P8908, DOI 10.1128/JVI.70.12.8908-8916.1996; Schaad MC, 1997, EMBO J, V16, P4049, DOI 10.1093/emboj/16.13.4049; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; Sethna PB, 1997, J VIROL, V71, P7744, DOI 10.1128/JVI.71.10.7744-7749.1997; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; TAKEGAMI T, 1989, VIRUS RES, V13, P337; TATA JR, 1972, J MOL BIOL, V67, P231, DOI 10.1016/0022-2836(72)90238-0; Teterina NL, 1997, VIROLOGY, V237, P66, DOI 10.1006/viro.1997.8775; Teterina NL, 2001, J VIROL, V75, P3841, DOI 10.1128/JVI.75.8.3841-3850.2001; Uchil PD, 2003, VIROLOGY, V307, P358, DOI 10.1016/S0042-6822(02)00130-7; van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998; WESTAWAY EG, 1987, ADV VIRUS RES, V33, P45, DOI 10.1016/S0065-3527(08)60316-4; WESTAWAY EG, 1980, VIROLOGY, V106, P107, DOI 10.1016/0042-6822(80)90226-3; Westaway EG, 1999, VIROLOGY, V258, P108, DOI 10.1006/viro.1999.9683; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Westaway EG, 1997, VIROLOGY, V234, P31, DOI 10.1006/viro.1997.8629; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	63	139	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24388	24398		10.1074/jbc.M301717200	http://dx.doi.org/10.1074/jbc.M301717200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12700232	hybrid			2022-12-25	WOS:000183824800020
J	Wu, JJ; Eyre, DR				Wu, JJ; Eyre, DR			Intervertebral disc collagen - Usage of the short form of the alpha 1(IX) chain in bovine nucleus pulposus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDELY SEPARATED PROMOTERS; CROSS-LINKING SITES; IX COLLAGEN; MESSENGER-RNA; HUMAN CARTILAGE; VITREOUS-HUMOR; GENE; PROTEOGLYCAN; CONTAINS; EXPRESSION	Nucleus pulposus, the central zone of the intervertebral disc, is gel-like and has a similar collagen phenotype to that of hyaline cartilage. Amino-terminal protein sequence analysis of the alpha1(IX)COL3 domain purified from bovine nucleus pulposus gave a different sequence to that of the long alpha1(IX) transcript expressed in hyaline cartilage and matched the predicted sequence of short alpha1(IX). The findings indicate that the matrix of bovine nucleus pulposus contains only the short form of alpha1(IX) that lacks the NC4 domain. The sequence encoded by exon 7, predicted from human COL9A1, is absent from both short and long forms of alpha1(IX) from bovine nucleus pulposus and articular cartilage. A structural analysis of the cross-linking sites occupied in type IX collagen from nucleus pulposus showed that usage of the short alpha1(IX) transcript in disc tissue had no apparent effect on cross-linking behavior. As in cartilage, type IX collagen of nucleus pulposus was heavily cross-linked to type II collagen and to other molecules of type IX collagen with a similar site occupancy.	Univ Washington, Dept Orthoped & Sports Med, Orthoped Res Labs, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Wu, JJ (corresponding author), Univ Washington, Dept Orthoped & Sports Med, Orthoped Res Labs, Box 356500, Seattle, WA 98195 USA.				NIAMS NIH HHS [R37 AR037318, R01 AR036794, AR36794, AR37318] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R01AR037318, R37AR036794, R01AR036794] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Annunen S, 1999, SCIENCE, V285, P409, DOI 10.1126/science.285.5426.409; ATLEY LM, 1998, T ORTHOP RES SOC, V23, P850; AYAD S, 1989, BIOCHEM J, V262, P753, DOI 10.1042/bj2620753; Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; Bos KJ, 2001, J MOL BIOL, V306, P1011, DOI 10.1006/jmbi.2000.4429; BREWTON RG, 1991, J BIOL CHEM, V266, P4752; Cohen AJ, 2002, MECH DEVELOP, V114, P177, DOI 10.1016/S0925-4773(02)00053-9; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Eyre DR, 2002, BIOCHEM SOC T, V30, P894, DOI 10.1042/bst0300894; Eyre DR, 2002, BIOCHEM SOC T, V30, P844; FITCH JM, 1995, DEV DYNAM, V202, P42, DOI 10.1002/aja.1002020105; HAYASHI M, 1992, DEV DYNAM, V194, P169, DOI 10.1002/aja.1001940302; Ichimura S, 2000, ARCH BIOCHEM BIOPHYS, V378, P33, DOI 10.1006/abbi.2000.1805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU CY, 1993, DEV DYNAM, V198, P150, DOI 10.1002/aja.1001980208; Matsui Y, 2003, MATRIX BIOL, V22, P123, DOI 10.1016/S0945-053X(02)00102-6; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; Oegema TR, 2002, BIOCHEM SOC T, V30, P839, DOI 10.1042/bst0300839; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Paassilta P, 2001, JAMA-J AM MED ASSOC, V285, P1843, DOI 10.1001/jama.285.14.1843; Pallante KM, 1996, J BIOL CHEM, V271, P25233, DOI 10.1074/jbc.271.41.25233; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1994, EUR J BIOCHEM, V223, P675, DOI 10.1111/j.1432-1033.1994.tb19040.x; SWIDERSKI RE, 1992, DEV DYNAM, V194, P118, DOI 10.1002/aja.1001940205; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; WATT SL, 1992, J BIOL CHEM, V267, P20093; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; WU JJ, 1992, J BIOL CHEM, V267, P23007; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5; YADA T, 1990, J BIOL CHEM, V265, P6992; Zhang YJ, 1997, NUCLEIC ACIDS RES, V25, P2470, DOI 10.1093/nar/25.12.2470; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486; Zhu Y, 2001, DEV DYNAM, V220, P350, DOI 10.1002/dvdy.1115	38	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24521	24525		10.1074/jbc.M302431200	http://dx.doi.org/10.1074/jbc.M302431200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12719416	hybrid			2022-12-25	WOS:000183824800034
J	Zhai, JB; Lin, H; Nie, ZY; Wu, JH; Canete-Soler, R; Schlaepfer, WW; Schalepfer, DD				Zhai, JB; Lin, H; Nie, ZY; Wu, JH; Canete-Soler, R; Schlaepfer, WW; Schalepfer, DD			Direct interaction of focal adhesion kinase with p190RhoGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; LEUKEMIA-ASSOCIATED RHOGEF; TYROSINE PHOSPHORYLATION; NEURITE OUTGROWTH; BINDING PROTEIN; NULL CELLS; RHOA; MIGRATION; GTPASES; FAK	Focal adhesion kinase (FAK) is a protein-tyrosine kinase that associates with multiple cell surface receptors and signaling proteins through which it can modulate the activity of several intracellular signaling pathways. FAK activity can influence the formation of distinct actin cytoskeletal structures such as lamellipodia and stress fibers in part through effects on small Rho GTPases, although the molecular interconnections of these events are not well defined. Here, we report that FAK interacts with p190RhoGEF, a RhoA-specific GDP/GTP exchange factor, in neuronal cells and in brain tissue extracts by co-immunoprecipitation and co-localization analyses. Using a two-hybrid assay and deletion mutagenesis, the binding site of the FAK C-terminal focal adhesion targeting (FAT) domain was identified within the C-terminal coiled-coil domain of p190RhoGEF. Binding was independent of a LD-like binding motif within p190RhoGEF, yet FAK association was disrupted by a mutation (Leu-1034 to Ser) that weakens the helical bundle structure of the FAK FAT domain. Neuro-2a cell binding to laminin increased endogenous FAK and p190RhoGEF tyrosine phosphorylation, and co-transfection of a dominant-negative inhibitor of FAK activity, termed FRNK, inhibited laminin-stimulated p190RhoGEF tyrosine phosphorylation and p21 RhoA GTP binding. Overexpression of FAK in Neuro-2a cells increased both endogenous p190RhoGEF tyrosine phosphorylation and RhoA activity, whereas these events were inhibited by FRNK co-expression. Because insulin-like growth factor 1 treatment of Neuro-2a cells increased FAK tyrosine phosphorylation and enhanced p190RhoGEF-mediated activation of RhoA, our results support the conclusion that FAK association with p190RhoGEF functions as a signaling pathway downstream of integrins and growth factor receptors to stimulate Rho activity.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Penn, Sch Med, Div Neuropathol, Philadelphia, PA 19104 USA	Scripps Research Institute; University of Pennsylvania	Schalepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM26,105500 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA075240, R01CA087038, R29CA075240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015722] Funding Source: NIH RePORTER; NCI NIH HHS [CA075240, CA87038] Funding Source: Medline; NINDS NIH HHS [NS15722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Grimpe B, 2002, PROG BRAIN RES, V137, P333; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Hoffman-Kim D, 2002, MOL CELL NEUROSCI, V21, P81, DOI 10.1006/mcne.2002.1157; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Medley QG, 2003, J BIOL CHEM, V278, P13265, DOI 10.1074/jbc.M300277200; Menegon A, 1999, EUR J NEUROSCI, V11, P3777, DOI 10.1046/j.1460-9568.1999.00798.x; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Owen JD, 1999, MOL CELL BIOL, V19, P4806; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renaudin A, 1999, J NEUROSCI RES, V55, P458, DOI 10.1002/(SICI)1097-4547(19990215)55:4<458::AID-JNR6>3.0.CO;2-D; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sieg DJ, 1999, J CELL SCI, V112, P2677; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Taylor JM, 1999, J CELL SCI, V112, P231; Tumbarello DA, 2002, FEBS LETT, V513, P114, DOI 10.1016/S0014-5793(01)03244-6; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	44	148	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24865	24873		10.1074/jbc.M302381200	http://dx.doi.org/10.1074/jbc.M302381200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12702722	hybrid			2022-12-25	WOS:000183824800075
J	Thornton, C; Yaka, R; Dinh, S; Ron, D				Thornton, C; Yaka, R; Dinh, S; Ron, D			H-Ras modulates N-methyl-D-aspartate receptor function via inhibition of Src tyrosine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; GTPASE-ACTIVATING PROTEIN; SIGNALING PATHWAY; NMDA RECEPTORS; PHOSPHORYLATION; CALPAIN; SUBUNIT; MEMORY; FYN; REQUIREMENT	Tyrosine phosphorylation of the NR2A and NR2B subunits of the N-methyl-D-aspartate (NMDA) receptor by Src protein-tyrosine kinases modulates receptor channel activity and is necessary for the induction of long term potentiation (LTP). Deletion of H-Ras increases both NR2 tyrosine phosphorylation and NMDA receptor-mediated hippocampal LTP. Here we investigated whether H-Ras regulates phosphorylation and function of the NMDA receptor via Src family protein-tyrosine kinases. We identified Src as a novel H-Ras binding partner. H-Ras bound to Src but not Fyn both in vitro and in brain via the Src kinase domain. Cotransfection of H-Ras and Src inhibited Src activity and decreased NR2A tyrosine phosphorylation. Treatment of rat brain slices with Tat-H-Ras depleted NR2A from the synaptic membrane, decreased endogenous Src activity and NR2A phosphorylation, and decreased the magnitude of hippocampal LTP. No change was observed for NR2B. We suggest that H-Ras negatively regulates Src phosphorylation of NR2A and retention of NR2A into the synaptic membrane leading to inhibition of NMDA receptor function. This mechanism is specific for Src and NR2A and has implications for studies in which regulation of NMDA receptor-mediated LTP is important, such as synaptic plasticity, learning, and memory and addiction.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco	Ron, D (corresponding author), Ernest Gallo Clin & Res Ctr, 5858 Horton St,Ste 200, Emeryville, CA 94608 USA.	dorit@itsa.ucsf.edu	Thornton, Claire/AAF-7481-2019	Thornton, Claire/0000-0001-7676-3272	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013438] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01AA/MH13438-01A1, R01 AA013438] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Dingledine R, 1999, PHARMACOL REV, V51, P7; DOSEMECI A, 1995, SYNAPSE, V20, P91, DOI 10.1002/syn.890200113; Dunah AW, 2001, J NEUROSCI, V21, P5546, DOI 10.1523/JNEUROSCI.21-15-05546.2001; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Grimwood S, 1996, J NEUROCHEM, V66, P2239; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim JH, 2003, J NEUROSCI, V23, P1119; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; Kumari M, 2000, PROG DRUG RES, V54, P152; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu XY, 2000, NEUROSCI LETT, V286, P149, DOI 10.1016/S0304-3940(00)01101-0; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Manabe T, 2000, J NEUROSCI, V20, P2504; Marrs GS, 2001, NAT NEUROSCI, V4, P1006, DOI 10.1038/nn717; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Silva AJ, 1997, NAT GENET, V15, P281, DOI 10.1038/ng0397-281; SIMAN R, 1983, J NEUROCHEM, V41, P950, DOI 10.1111/j.1471-4159.1983.tb09039.x; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Suzuki T, 1999, BRAIN RES, V840, P36, DOI 10.1016/S0006-8993(99)01762-X; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yamauchi T, 2002, MASS SPECTROM REV, V21, P266, DOI 10.1002/mas.10033; Yang M, 2001, J NEUROCHEM, V77, P580, DOI 10.1046/j.1471-4159.2001.00255.x; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	61	47	52	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23823	23829		10.1074/jbc.M302389200	http://dx.doi.org/10.1074/jbc.M302389200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695509	Green Accepted			2022-12-25	WOS:000183638600077
J	Wyse, BD; Prior, IA; Qian, HW; Morrow, IC; Nixon, S; Muncke, C; Kurzchalia, TV; Thomas, WG; Parton, RG; Hancock, JF				Wyse, BD; Prior, IA; Qian, HW; Morrow, IC; Nixon, S; Muncke, C; Kurzchalia, TV; Thomas, WG; Parton, RG; Hancock, JF			Caveolin interacts with the angiotensin II type 1 receptor during exocytic transport but not at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE CELLS; LIPID RAFTS; H-RAS; CARBOXYL-TERMINUS; ANCHORED PROTEINS; CYTOPLASMIC TAIL; KNOCKOUT MICE; GENE FAMILY; CHOLESTEROL	The mechanisms involved in angiotensin II type 1 receptor (AT(1)-R) trafficking and membrane localization are largely unknown. In this study, we examined the role of caveolin in these processes. Electron microscopy of plasma membrane sheets shows that the AT(1)-R is not concentrated in caveolae but is clustered in cholesterol-independent microdomains; upon activation, it partially redistributes to lipid rafts. Despite the lack of AT(1)-R in caveolae, AT(1)-R. caveolin complexes are readily detectable in cells co-expressing both proteins. This interaction requires an intact caveolin scaffolding domain because mutant caveolins that lack a functional caveolin scaffolding domain do not interact with AT(1)-R. Expression of an N-terminally truncated caveolin-3, CavDGV, that localizes to lipid bodies, or a point mutant, Cav3-P104L, that accumulates in the Golgi mislocalizes AT(1)-R to lipid bodies and Golgi, respectively. Mislocalization results in aberrant maturation and surface expression of AT(1)-R, effects that are not reversed by supplementing cells with cholesterol. Similarly mutation of aromatic residues in the caveolin-binding site abrogates AT(1)-R cell surface expression. In cells lacking caveolin-1 or caveolin-3, AT(1)-R does not traffic to the cell surface unless caveolin is ectopically expressed. This observation is recapitulated in caveolin-1 null mice that have a 55% reduction in renal AT(1)-R levels compared with controls. Taken together our results indicate that a direct interaction with caveolin is required to traffic the AT(1)-R through the exocytic pathway, but this does not result in AT(1)-R sequestration in caveolae. Caveolin therefore acts as a molecular chaperone rather than a plasma membrane scaffold for AT(1)-R.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Mol & Cellular Pathol, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Baker Heart Res Inst, Melbourne, Vic 3004, Australia; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	University of Queensland; University of Queensland; University of Queensland; University of Queensland; Baker Heart and Diabetes Institute; Max Planck Society	Hancock, JF (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Parton, Robert G/C-5673-2009; Morrow, Isabel/E-8632-2012; Thomas, Walter/I-2208-2015; Nixon, Susan/D-4588-2017	Parton, Robert G/0000-0002-7494-5248; Hancock, John/0000-0003-0542-4710; Prior, Ian/0000-0002-4055-5161; Thomas, Walter/0000-0003-0685-2952; Nixon, Susan/0000-0003-0346-9683				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Betz RC, 2001, NAT GENET, V28, P218, DOI 10.1038/90050; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Dinh DT, 2001, CLIN SCI, V100, P481, DOI 10.1042/CS20000263; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; Holloway AC, 2002, MOL PHARMACOL, V61, P768, DOI 10.1124/mol.61.4.768; Ichiki T, 2001, ARTERIOSCL THROM VAS, V21, P1896, DOI 10.1161/hq1201.099430; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; LeClerc PC, 2002, ENDOCRINOLOGY, V143, P4702, DOI 10.1210/en.2002-220679; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; Mozsolits H, 2002, BIOCHEMISTRY-US, V41, P7830, DOI 10.1021/bi0121813; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nickenig G, 1997, AM J PHYSIOL-HEART C, V272, pH2701, DOI 10.1152/ajpheart.1997.272.6.H2701; Nickenig G, 1999, CIRCULATION, V100, P2131, DOI 10.1161/01.CIR.100.21.2131; Niebauer J, 2001, VASC MED, V6, P133, DOI 10.1177/1358836X0100600302; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Park DS, 2002, AM J PATHOL, V160, P2207, DOI 10.1016/S0002-9440(10)61168-6; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Prattes S, 2000, J CELL SCI, V113, P2977; Prior I. A., 2003, SCI STKE, V2003, pPL9; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Richard DE, 1997, MOL CELL ENDOCRINOL, V129, P209, DOI 10.1016/S0303-7207(97)00065-8; Ringerike T, 2002, J CELL SCI, V115, P1331; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Segal SS, 1999, AM J PHYSIOL-HEART C, V277, pH1167; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Sotgia F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002; Strehlow K, 2000, ANN MED, V32, P386, DOI 10.3109/07853890008995944; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Thomas WG, 1998, MOL ENDOCRINOL, V12, P1513, DOI 10.1210/me.12.10.1513; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Vuagnat A, 2001, J MOL MED-JMM, V79, P175, DOI 10.1007/s001090100205; Woodman SE, 2002, J BIOL CHEM, V277, P38988, DOI 10.1074/jbc.M205511200; WYSE B, 1993, AM J PHYSIOL, V265, pE332, DOI 10.1152/ajpendo.1993.265.2.E332; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yang BC, 1998, ARTERIOSCL THROM VAS, V18, P1433, DOI 10.1161/01.ATV.18.9.1433; Zager RA, 2002, KIDNEY INT, V61, P1674, DOI 10.1046/j.1523-1755.2002.00316.x; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799; Zhu Y, 2000, ARTERIOSCL THROM VAS, V20, P2465, DOI 10.1161/01.ATV.20.11.2465; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	65	106	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23738	23746		10.1074/jbc.M212892200	http://dx.doi.org/10.1074/jbc.M212892200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692121	hybrid			2022-12-25	WOS:000183638600068
J	Besirli, CG; Johnson, EM				Besirli, CG; Johnson, EM			JNK-independent activation of c-Jun during neuronal apoptosis induced by multiple DNA-damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; N-TERMINAL KINASE; PROGRAMMED CELL-DEATH; NERVE GROWTH-FACTOR; DEPRIVED SYMPATHETIC NEURONS; EMBRYONIC CORTICAL-NEURONS; KILLS POSTMITOTIC NEURONS; CYTOSINE-ARABINOSIDE; SIGNAL-TRANSDUCTION; CEP-1347 KT7515	Activation of the JNK pathway and induction of the AP-1 transcription factor c-Jun are critical for neuronal apoptosis caused by a variety of insults. Ara-C-induced DNA damage caused rapid sympathetic neuronal death that was associated with an increase of c-jun expression. In addition, c-Jun was phosphorylated in its N-terminal transactivation domain, which is important for c-Jun-mediated gene transcription. Blocking c-Jun activation by JNK pathway inhibition prevented neuronal death after stress. In contrast, neither the JNK inhibitor SP600125 nor the mixed lineage kinase inhibitor CEP-1347 prevented cytosine arabinoside-induced neuronal death, demonstrating that the JNK pathway was not necessary for DNA damage-induced neuronal apoptosis. Surprisingly, SP600125 or CEP-1347 could not block c-Jun induction or phosphorylation after DNA damage. Pharmacological inhibitors of cyclin-dependent kinase (CDK) activity completely prevented c-Jun phosphorylation after DNA damage. These results demonstrate that c-Jun activation during DNA damage-induced neuronal apoptosis was independent of the classical JNK pathway and was mediated by a novel c-Jun kinase. Based on pharmacological criteria, DNA damage-induced neuronal c-Jun kinase may be a member of the CDK family or be activated by a CDK-like kinase. Activation of this novel kinase and subsequent phosphorylation of c-Jun may be important in neuronal death after DNA damage.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Johnson, EM (corresponding author), 660 S Euclid,Campus Box 8103, St Louis, MO 63110 USA.	ejohnson@pcg.wustl.edu		Besirli, Cagri/0000-0001-7154-2024	NIA NIH HHS [R37AG-12947] Funding Source: Medline; NINDS NIH HHS [R01NS38651] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012947] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson CNG, 1999, J NEUROSCI, V19, P664; BASIRLI CT, 2003, IN PRESS CELL DEATH; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bruckner SR, 2001, J NEUROCHEM, V78, P298, DOI 10.1046/j.1471-4159.2001.00400.x; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Davies MJ, 2001, J PHOTOCH PHOTOBIO B, V63, P114, DOI 10.1016/S1011-1344(01)00208-1; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DESSI F, 1995, J NEUROCHEM, V64, P1980; Eilers A, 2001, J NEUROCHEM, V76, P1439, DOI 10.1046/j.1471-4159.2001.00150.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Geller HM, 2001, J NEUROCHEM, V78, P265, DOI 10.1046/j.1471-4159.2001.00395.x; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Harris CA, 2001, J BIOL CHEM, V276, P37754; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JOHNSON MI, 1983, METHOD ENZYMOL, V103, P334; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lam LT, 2001, GENOME BIOL, V2; LAZARUS HM, 1981, CANCER, V48, P2577, DOI 10.1002/1097-0142(19811215)48:12<2577::AID-CNCR2820481207>3.0.CO;2-Z; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Markus MA, 1997, NEUROBIOL DIS, V4, P122, DOI 10.1006/nbdi.1997.0140; Maroney AC, 1999, J NEUROCHEM, V73, P1901; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Maroney AC, 1998, J NEUROSCI, V18, P104; MARTIN DP, 1990, J NEUROSCI, V10, P184; McCollum AT, 2002, J NEUROCHEM, V82, P1208, DOI 10.1046/j.1471-4159.2002.01057.x; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; RESAR LMS, 1993, CANCER, V71, P117, DOI 10.1002/1097-0142(19930101)71:1<117::AID-CNCR2820710119>3.0.CO;2-K; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Stefanis L, 1999, J NEUROSCI, V19, P6235; SYLVESTER RK, 1987, DRUG INTEL CLIN PHAR, V21, P177; TOMKINS CE, 1994, J CELL SCI, V107, P1499; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; VOGEL H, 1993, CANCER, V71, P1303, DOI 10.1002/1097-0142(19930215)71:4<1303::AID-CNCR2820710422>3.0.CO;2-6; WALLACE TL, 1989, J NEUROSCI, V9, P115; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; WINKELMAN MD, 1983, ANN NEUROL, V14, P520, DOI 10.1002/ana.410140505; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhai SP, 2002, ANN PHARMACOTHER, V36, P905	66	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22357	22366		10.1074/jbc.M300742200	http://dx.doi.org/10.1074/jbc.M300742200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684520	hybrid			2022-12-25	WOS:000183503900026
J	Germain-Desprez, D; Bazinet, M; Bouvier, M; Aubry, M				Germain-Desprez, D; Bazinet, M; Bouvier, M; Aubry, M			Oligomerization of transcriptional intermediary factor 1 regulators and interaction with ZNF74 nuclear matrix protein revealed by bioluminescence resonance energy transfer in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; REPRESSION DOMAIN; TRANSFER BRET; RECEPTORS; HETEROCHROMATIN; COREPRESSOR; FAMILY; KAP-1; TIF1; ACTIVATION	Transcriptional intermediary factor 1 (TIF1) alpha and KAP-1/TIF1beta, two members of the TIF1 family of nuclear cofactors, are ubiquitous co-regulators of nuclear receptors and KRAB motif-containing zinc finger transcription factors, respectively. Despite the functional evidence suggesting a role for TIF1 proteins as modulators of transcription, the study of their interactions with transcriptional machineries in physiologically relevant systems has been difficult. Here, we have developed a bioluminescence resonance energy transfer (BRET) biophysical approach to study protein-protein interactions in the nuclear compartment of living mammalian cells. We report that TIF1alpha and KAP-1 form homo- and heterooligomers in intact mammalian cells. BRET titration experiments indicate that both homo- and hetero-oligomers occur with relatively high affinity suggesting that they could co-exist in cells. Furthermore, we demonstrate that KAP-1 but not TIF1alpha interacts with the KRAB multifinger ZNF74 in the nuclear matrix. Splice variants and point mutants of ZNF74 that lack transcriptional activity were found not to interact with KAP-1 confirming the physiological importance of this interaction in living cells. The interaction of ZNF74 with KAP-1 did not prevent KAP-1 homomerization indicating that the oligomers most likely represent the transcriptionally active species. Furthermore, the detection of ternary ZNF74.KAP-1.TIF1alpha complexes suggests the existence of cross-talk between KAP-1-interacting KRAB proteins and TIF1alpha-interacting nuclear receptors. In addition to providing new insights into the molecular interactions involved in the transcriptional activities of these proteins, this study shows that BRET can be advantageously used as a non-transcription-based oligomerization detection system to study the interaction of transcriptionally active proteins, including nuclear matrix proteins, in living cells.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Aubry, M (corresponding author), Univ Montreal, Dept Biochem, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	Muriel.Aubry@UMontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100				Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Boute N, 2002, TRENDS PHARMACOL SCI, V23, P351, DOI 10.1016/S0165-6147(02)02062-X; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Cote F, 2001, DNA CELL BIOL, V20, P159, DOI 10.1089/104454901300069004; Eidne KA, 2002, TRENDS ENDOCRIN MET, V13, P415, DOI 10.1016/S1043-2760(02)00669-0; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Grondin B, 1997, J BIOL CHEM, V272, P27877, DOI 10.1074/jbc.272.44.27877; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Le Douarin B, 1998, J STEROID BIOCHEM, V65, P43, DOI 10.1016/S0960-0760(97)00175-1; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Losson R, 1997, BIOL CHEM, V378, P579; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; VOM BE, 1996, EMBO J, V15, P110; WITZGALL R, 1994, ANAL BIOCHEM, V223, P291, DOI 10.1006/abio.1994.1587; Wolfe CL, 1996, J BIOL CHEM, V271, P4679; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151	38	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22367	22373		10.1074/jbc.M302234200	http://dx.doi.org/10.1074/jbc.M302234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684500	hybrid			2022-12-25	WOS:000183503900027
J	Mancuso, DJ; Abendschein, DR; Jenkins, CM; Han, XL; Saffitz, JE; Schuessler, RB; Gross, RW				Mancuso, DJ; Abendschein, DR; Jenkins, CM; Han, XL; Saffitz, JE; Schuessler, RB; Gross, RW			Cardiac ischemia activates calcium-independent phospholipase A(2)beta, precipitating ventricular tachyarrhythmias in transgenic mice - Rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMALOGEN-SELECTIVE PHOSPHOLIPASE-A2; ARACHIDONIC-ACID RELEASE; MYOCARDIAL-ISCHEMIA; SUICIDE INHIBITION; POTASSIUM CHANNELS; ANIMAL-MODELS; A(2); IDENTIFICATION; HEART; PURIFICATION	Murine myocardium contains diminutive amounts of calcium-independent phospholipase A(2) (iPLA(2)) activity (<5% that of human heart), and malignant ventricular tachyarrhythmias are infrequent during acute murine myocardial ischemia. Accordingly we considered the possibility that the mouse was a species-specific knockdown of the human pathologic phenotype of ischemia-induced lethal ventricular tachyarrhythmias. Transgenic mice were generated expressing amounts of iPLA(2)beta activity comparable to that present in human myocardium. Coronary artery occlusion in Langendorff perfused hearts from transgenic mice resulted in a 22-fold increase in fatty acids released into the venous eluent (29.4 nmol/ml in transgenic versus 1.35 nmol/ml of eluent in wild-type mice), a 4-fold increase in lysophosphatidylcholine mass in ischemic zones (4.9 nmol/mg in transgenic versus 1.1 nmol/mg of protein in wild-type mice), and malignant ventricular tachyarrhythmias within minutes of ischemia. Neither normally perfused transgenic nor ischemic wild-type hearts demonstrated these alterations. Pretreatment of Langendorff perfused transgenic hearts with the iPLA2 mechanism-based inhibitor (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran2- one ( BEL) just minutes prior to induction of ischemia completely ablated fatty acid release and lysolipid accumulation and rescued transgenic hearts from malignant ventricular tachyarrhythmias. Collectively these results demonstrate that ischemia activates iPLA(2)beta in intact myocardium and that iPLA(2)beta-mediated hydrolysis of membrane phospholipids can induce lethal malignant ventricular tachyarrhythmias during acute cardiac ischemia.	Washington Univ, Sch Med, Dept Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Dept Med, Div Bioorgan Chem & Mol Pharmacol, 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.				NHLBI NIH HHS [2P01HL57278-06A1, 2R01HL41250-10] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278, R01HL041250] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Braunwald E., 2001, HEART DIS TXB CARDIO; Broekemeier KM, 2002, BIOCHEMISTRY-US, V41, P7771, DOI 10.1021/bi020157z; CORR PB, 1982, J MOL CELL CARDIOL, V14, P619, DOI 10.1016/0022-2828(82)90159-6; Curtis MJ, 1998, CARDIOVASC RES, V39, P194, DOI 10.1016/S0008-6363(98)00083-2; Das DK, 2002, METHOD ENZYMOL, V353, P346; FORD DA, 1991, J CLIN INVEST, V88, P331, DOI 10.1172/JCI115296; Ford DA, 2002, PROG LIPID RES, V41, P6, DOI 10.1016/S0163-7827(01)00014-5; Forsell PKAL, 1999, EUR J BIOCHEM, V262, P575, DOI 10.1046/j.1432-1327.1999.00418.x; Gross R W, 1979, Trans Assoc Am Physicians, V92, P136; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Han XL, 1996, J AM CHEM SOC, V118, P451, DOI 10.1021/ja952326r; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HAZEN SL, 1992, CIRC RES, V70, P486, DOI 10.1161/01.RES.70.3.486; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; Headrick JP, 2001, EXP PHYSIOL, V86, P703, DOI 10.1111/j.1469-445X.2001.tb00035.x; Janse MJ, 1998, CARDIOVASC RES, V39, P165, DOI 10.1016/S0008-6363(97)00313-1; Jenkins CM, 2001, J BIOL CHEM, V276, P7129, DOI 10.1074/jbc.M010439200; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; Lerner DL, 2000, CIRCULATION, V101, P547, DOI 10.1161/01.CIR.101.5.547; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; London B, 2001, J CARDIOVASC ELECTR, V12, P1089, DOI 10.1046/j.1540-8167.2001.01089.x; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; Radda GK, 1999, BIOCHEM BIOPH RES CO, V266, P723, DOI 10.1006/bbrc.1999.1890; Ramanadham S, 1999, J BIOL CHEM, V274, P13915, DOI 10.1074/jbc.274.20.13915; ROBBINS J, 1989, GENE, V85, P541, DOI 10.1016/0378-1119(89)90449-6; SAFFITZ JE, 1984, LAB INVEST, V50, P278; Smani T, 2003, J BIOL CHEM, V278, P11909, DOI 10.1074/jbc.M210878200; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Sun D, 2002, INSECT BIOCHEM MOLEC, V32, P1133, DOI 10.1016/S0965-1748(02)00049-8; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tian R, 2001, CIRCULATION, V103, P2961, DOI 10.1161/01.CIR.103.24.2961; Verdouw PD, 1998, CARDIOVASC RES, V39, P121, DOI 10.1016/S0008-6363(98)00069-8; Viehweger K, 2002, PLANT CELL, V14, P1509, DOI 10.1105/tpc.002329; Williams SD, 2002, BIOCHEM J, V362, P23, DOI 10.1042/bj3620023; Wit A. L., 1993, VENTRICULAR ARRHYTHM; WIT AL, 1992, CIRCULATION, V85, P32; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	54	79	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22231	22236		10.1074/jbc.C300033200	http://dx.doi.org/10.1074/jbc.C300033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12719436	hybrid			2022-12-25	WOS:000183503900008
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Permanent activation of the human P-glycoprotein by covalent modification of a residue in the drug-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; CYSTEINE-SCANNING MUTAGENESIS; MULTIDRUG-RESISTANCE; TRANSMEMBRANE DOMAIN; CROSS-LINKING; NUCLEOTIDE; CELLS; HYDROLYSIS; IDENTIFICATION; SUBSTRATE	The human multidrug resistance P-glycoprotein (ABCB1) transports a broad range of structurally diverse compounds out of the cell. The transport cycle involves coupling of drug binding in the transmembrane domains with ATP hydrolysis. Compounds such as verapamil stimulate ATPase activity. We used cysteine-scanning mutagenesis of the transmembrane segments and reaction with the thiol-reactive substrate analog of verapamil, methanethiosulfonate (MTS)-verapamil, to test whether it caused permanent activation of ATP hydrolysis. Here we report that one mutant, I306C(TM5) showed increased ATPase activity (8-fold higher than untreated) when treated with MTS-verapamil and isolated by nickel-chelate chromatography. Drug substrates that either enhance ( calcein acetoxymethyl ester, demecolcine, and vinblastine) or inhibit ( cyclosporin A and trans-( E)-flupentixol) ATPase activity of Cys-less or untreated mutant I306C P-glycoprotein did not affect the activity of MTS-verapamil-treated mutant I306C. Addition of dithiothreitol released the covalently attached verapamil, and ATPase activity returned to basal levels. Pretreatment with substrates such as cyclosporin A, demecolcine, verapamil, vinblastine, or colchicine prevented activation of mutant I306C by MTS-verapamil. The results suggest that MTS-verapamil reacts with I306C in a common drug-binding site. Covalent modification of I306C affects the long range linkage between the drug-binding site and the distal ATP-binding sites. This results in the permanent activation of ATP hydrolysis in the absence of transport. Trapping mutant I306C in a permanently activated state indicates that Ile-306 may be part of the signal to switch on ATP hydrolysis when the drug-binding site is occupied.	Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; GOODNO CC, 1982, METHOD ENZYMOL, V85, P116; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kenyon G L, 1977, Methods Enzymol, V47, P407; Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2003, J BIOL CHEM, V278, P13603, DOI 10.1074/jbc.C300073200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; TAMAI I, 1991, J BIOL CHEM, V266, P16796; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	44	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20449	20452		10.1074/jbc.C300154200	http://dx.doi.org/10.1074/jbc.C300154200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12711602	hybrid			2022-12-25	WOS:000183230500002
J	Post, DE; Van Meir, EG				Post, DE; Van Meir, EG			A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy	ONCOGENE			English	Article						hypoxia; adenovirus; HIF; gene delivery; oncolysis; tumor	REPLICATION-SELECTIVE ADENOVIRUS; GENE-EXPRESSION; CELL; GENERATION; EFFICACY; VECTORS; SYSTEM; MUTANT; GLIOMA	New therapy targeting the hypoxic fraction of tumors needs to be designed as this population of cells is the most resistant to radio- and chemotherapies. Hypoxia-inducible factor (HIF) mediates transcriptional responses to hypoxia by binding to hypoxia-responsive elements (HRE) in target genes. We developed a <(hyp)under bar>oxia/HIF-dependent replicative <(ad)under bar>enovirus (HYPR-Ad) to target hypoxic cells. HYPR-Ad displays hypoxia-dependent E1A expression and conditional cytolysis of hypoxic but not normoxic cells. This work provides proof-of-principle evidence that an attenuated oncolytic adenovirus that selectively lyses cells under hypoxia can be generated. This therapeutic approach can be used to treat all solid tumors that develop hypoxia, regardless of their tissue origin or genetic alterations.	Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Hematol Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Ctr, Mol Neurooncol Lab, Dept Neurosurg, 1365-B Clifton Rd NE,Rm B5103, Atlanta, GA 30322 USA.	evanmei@emory.edu	Core, Vector/CAF-4832-2022	Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA87830] Funding Source: Medline; NINDS NIH HHS [NS41403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETT AJ, 1995, VIRUS RES, V39, P75; Boast K, 1999, HUM GENE THER, V10, P2197, DOI 10.1089/10430349950017185; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; DERY CV, 1987, ONCOGENE, V2, P15; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fulci G, 2003, FRONT BIOSCI-LANDMRK, V8, pE346, DOI 10.2741/976; GLENN GM, 1988, VIRUS RES, V9, P73, DOI 10.1016/0168-1702(88)90051-2; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kirn D, 2001, GENE THER, V8, P89, DOI 10.1038/sj.gt.3301377; Koshikawa N, 2000, CANCER RES, V60, P2936; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Modlich U, 2000, GENE THER, V7, P896, DOI 10.1038/sj.gt.3301177; PARKS CL, 1988, J VIROL, V62, P54, DOI 10.1128/JVI.62.1.54-67.1988; Post DE, 2001, GENE THER, V8, P1801, DOI 10.1038/sj.gt.3301605; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Ruan Hangjun, 1999, Neoplasia (New York), V1, P431, DOI 10.1038/sj.neo.7900059; Ruan HJ, 2001, NEOPLASIA, V3, P255, DOI 10.1038/sj.neo.7900157; Semenza GL, 2000, GENE DEV, V14, P1983; Shibata T, 2000, GENE THER, V7, P493, DOI 10.1038/sj.gt.3301124; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; TOLLEFSON AE, 1999, METH MOLEC MED, V21, P1; Tsukuda K, 2002, CANCER RES, V62, P3438; Zhong H, 1999, CANCER RES, V59, P5830	28	100	116	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2065	2072		10.1038/sj.onc.1206464	http://dx.doi.org/10.1038/sj.onc.1206464			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687009				2022-12-25	WOS:000182066900001
J	Kalabis, J; Patterson, MJ; Enders, GH; Marian, B; Iozzo, RV; Rogler, G; Gimotty, PA; Herlyn, M				Kalabis, J; Patterson, MJ; Enders, GH; Marian, B; Iozzo, RV; Rogler, G; Gimotty, PA; Herlyn, M			Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture	FASEB JOURNAL			English	Article						colon; organotypic culture; LIF	DIFFERENTIATION; GROWTH; EXPRESSION; LINES; PROLIFERATION; INTESTINE; MYOFIBROBLASTS; ESTABLISHMENT; RECEPTORS; PHENOTYPE	The colonic epithelium undergoes a continuous cycle of proliferation, differentiation, and apoptosis. To characterize factors important for colonic homeostasis and its dysregulation, human fetal colonic epithelial cells were isolated and seeded on a collagen type I matrix with embedded colonic fibroblasts. The epithelial cells rapidly spread from clusters and proliferated, and within 3 days, a columnar layer of polarized epithelium surrounded the surface of the constricted collagen matrix. The polarized enterocytes developed brush borders, tight junctions and desmosomes, and goblet and enteroendocrine cells were present. A balance of growth and differentiation was maintained for several weeks in the presence of collagen-embedded fibroblasts and a complex mixture of growth factors. Leukemia inhibitory factor (LIF) was critical for proliferation of enterocytes and inhibited expression of the differentiation marker carbonic anhydrase II. In the presence of LIF, the relative number of goblet cells remained stable, whereas enteroendocrine relative cell number declined. LIF-stimulated epithelial cells remained dependent on the presence of fibroblasts in the matrix. In combination with stem cell factor and endothelin 3, LIF induced formation of disorganized structures of stratified and semi-stratified cells, suggesting that the homeostatic balance in the normal human colon requires cooperation with differentiation-inducing factors.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Vienna, Inst Canc Res, Vienna, Austria; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Regensburg, Dept Internal Med 1, D-8400 Regensburg, Germany; Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Vienna; Jefferson University; University of Regensburg; University of Pennsylvania; Pennsylvania Medicine	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu	Gimotty, Phyllis/GWZ-4136-2022; Rogler, Gerhard/O-5308-2015; Iozzo, Renato/AAS-1980-2020	Gimotty, Phyllis/0000-0002-3850-9799; Rogler, Gerhard/0000-0002-1733-9188; Iozzo, Renato/0000-0002-5908-5112				Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; BAIBAKOV BA, 1994, IN VITRO CELL DEV-AN, V30A, P490, DOI 10.1007/BF02631321; BARTEK J, 1986, HISTOCHEM J, V18, P565, DOI 10.1007/BF01675198; Bekku S, 1998, RES EXP MED, V198, P175, DOI 10.1007/s004330050101; Berking C, 2001, CANCER RES, V61, P8306; CAESAR PA, 1988, BIOCHEM J, V253, P451, DOI 10.1042/bj2530451; DAHLQVIST A, 1966, CLIN SCI, V30, P517; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; EVANS GS, 1994, ANNU REV PHYSIOL, V56, P399; FOSTER HM, 1990, GASTROENTEROLOGY, V99, P1710, DOI 10.1016/0016-5085(90)90477-I; Guimbaud R, 1998, EUR CYTOKINE NETW, V9, P607; Halttunen T, 1996, GASTROENTEROLOGY, V111, P1252, DOI 10.1053/gast.1996.v111.pm8898639; HO SB, 1992, J CELL BIOCHEM, P119; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Jobson TM, 1998, J CLIN INVEST, V101, P2650, DOI 10.1172/JCI1876; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; Karamuk E, 1999, ARTIF ORGANS, V23, P881, DOI 10.1046/j.1525-1594.1999.06308.x; KAYE GI, 1968, GASTROENTEROLOGY, V54, P852; Kedinger M, 1998, ANN NY ACAD SCI, V859, P1, DOI 10.1111/j.1749-6632.1998.tb11107.x; KEDINGER M, 1987, DIFFERENTIATION, V36, P71, DOI 10.1111/j.1432-0436.1987.tb00182.x; Kermorgant S, 2001, AM J PHYSIOL-GASTR L, V281, pG1068, DOI 10.1152/ajpgi.2001.281.4.G1068; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MOYER MP, 1995, METHOD ENZYMOL, V254, P153; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Oda D, 1998, IN VITRO CELL DEV-AN, V34, P211; Oda D, 1998, IN VITRO CELL DEV-AN, V34, P46; Oda DP, 1995, EXP MOL PATHOL, V63, P16, DOI 10.1006/exmp.1995.1026; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; PARENTEAU NL, 1991, J CELL BIOCHEM, V45, P245, DOI 10.1002/jcb.240450304; Pedersen G, 2000, SCAND J GASTROENTERO, V35, P772, DOI 10.1080/003655200750023471; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Perreault N, 1998, BIOCHEM BIOPH RES CO, V248, P121, DOI 10.1006/bbrc.1998.8919; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Quaroni A, 1980, Methods Cell Biol, V21B, P403; Rockman SP, 2001, J GASTROEN HEPATOL, V16, P991, DOI 10.1046/j.1440-1746.2001.02588.x; Rogler G, 1998, LAB INVEST, V78, P889; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Schorkhuber M, 1998, CELL BIOL TOXICOL, V14, P211, DOI 10.1023/A:1007418811589; SORGER T, 1995, IN VITRO CELL DEV-AN, V31, P671; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	47	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1115	+		10.1096/fj.02-0852fje	http://dx.doi.org/10.1096/fj.02-0852fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692084				2022-12-25	WOS:000182580100043
J	Welsch, CA; Hagiwara, S; Goetschy, JF; Movva, NR				Welsch, CA; Hagiwara, S; Goetschy, JF; Movva, NR			Ubiquitin pathway proteins influence the mechanism of action of the novel immunosuppressive drug FTY720 in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATING MATURE LYMPHOCYTES; POSSESSING UNIQUE MECHANISMS; SKIN ALLOGRAFT SURVIVAL; TERM GRAFT ACCEPTANCE; CELL-SURFACE; RESISTANCE; GENE; RATS; CYCLOSPORINE; INHIBITION	FTY720 is an immunosuppressive drug in clinical development for transplant graft protection in humans. This agent is of particular interest because, unlike currently available regimes, it acts to sequester lymphocytes without causing cytotoxicity or blocking differentiation and growth potential. In an effort to elucidate the mechanism of action of FTY720, and identify its downstream effectors, we have screened genomic libraries and spontaneous mutants of the model system Saccharomyces cerevisiae for resistance to FTY720. We identified several proteins and pathways as being involved in the mechanism of action of FTY720. We show specifically that the two amino acid transporters TAT1 and TAT2, the two ubiquitin proteases UBP5 and UBP11, and the heat shock protein CAJ1 confer growth resistance to FTY720 when overexpressed. Another amino acid transporter, GNP1, and the ubiquitin structural gene UBI4 as well as the ubiquitin ligase RSP5, and its binding protein BUL1 confer growth resistance in a mutated form. Supporting the importance of amino acid transport in the growth resistance phenotype of S. cerevisiae to the immunosuppressive agent FTY720, a prototrophic strain was more resistant to FTY720 than the isogenic auxotroph. To further explore these results, the effects on amino acid uptake and protein degradation were measured in the presence of FTY720. Due to the high conservation of these proteins and pathways between yeast and humans, these results may provide valuable insights into the mechanism of action of FTY720 in lymphocyte sequestration in humans.	Novartis Pharma AG, Transplantat Res, CH-4002 Basel, Switzerland; GlaxoSmith Kline KK, Tsukuba Res Labs, Tsukuba, Ibaraki 3004247, Japan	Novartis; Eisai Co Ltd; GlaxoSmithKline	Movva, NR (corresponding author), Novartis Pharma AG, Transplantat Res, WSJ 386-906, CH-4002 Basel, Switzerland.	rao.movva@pharma.novartis.com						Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; ADACHI K, 1995, BIOORG MED CHEM LETT, V5, P853, DOI 10.1016/0960-894X(95)00127-F; Adams A, 1997, METHODS YEAST GENETI; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANT P, V33, P530, DOI 10.1016/S0041-1345(00)02126-6; Candelore MR, 2002, BIOCHEM BIOPH RES CO, V297, P600; Chen JK, 1999, CHEM BIOL, V6, P221, DOI 10.1016/S1074-5521(99)80038-6; Chiba K, 1996, TRANSPLANT P, V28, P1056; Chiba K, 1998, J IMMUNOL, V160, P5037; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Enosawa S, 1996, IMMUNOPHARMACOLOGY, V34, P171, DOI 10.1016/0162-3109(96)00132-4; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Fujita T, 1996, J MED CHEM, V39, P4451, DOI 10.1021/jm960391l; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; Grzanowski A, 2002, CURR GENET, V41, P142, DOI 10.1007/s00294-002-0292-0; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; Hoshino Y, 1996, TRANSPLANT P, V28, P1060; HUSTAD CM, 1995, GENETICS, V140, P255; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Mitsusada M, 1997, TRANSPLANT INT, V10, P343, DOI 10.1007/s001470050068; MUKAI H, 1994, GENE, V145, P125; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; Palmer LK, 2002, GENETICS, V161, P563; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Regenberg B, 2001, YEAST, V18, P1429, DOI 10.1002/yea.792.abs; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; Simon JR, 1999, MOL MICROBIOL, V31, P823, DOI 10.1046/j.1365-2958.1999.01220.x; Skrzypek MS, 1998, J BIOL CHEM, V273, P2829, DOI 10.1074/jbc.273.5.2829; Suthanthiran M, 1996, AM J KIDNEY DIS, V28, P159, DOI 10.1016/S0272-6386(96)90297-8; Suzuki K, 1998, TRANSPLANT P, V30, P1044, DOI 10.1016/S0041-1345(98)00143-2; Suzuki S, 1996, IMMUNOLOGY, V89, P518, DOI 10.1046/j.1365-2567.1996.d01-777.x; Suzuki S, 1996, TRANSPLANT P, V28, P1375; Suzuki S, 1996, Transpl Immunol, V4, P252, DOI 10.1016/S0966-3274(96)80026-8; Suzuki S, 1996, TRANSPLANTATION, V61, P200, DOI 10.1097/00007890-199601270-00006; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; Yashiroda H, 1998, GENE, V225, P39, DOI 10.1016/S0378-1119(98)00535-6; Yashiroda H, 1996, MOL CELL BIOL, V16, P3255; Zhu X, 1996, CURR GENET, V30, P107, DOI 10.1007/s002940050108	59	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26976	26982		10.1074/jbc.M213144200	http://dx.doi.org/10.1074/jbc.M213144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12709439	hybrid			2022-12-25	WOS:000184155700088
J	Prieur, X; Coste, H; Rodriguez, JC				Prieur, X; Coste, H; Rodriguez, JC			The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM TRIGLYCERIDE LEVEL; NUCLEAR RECEPTOR; BILE-ACID; HEART-DISEASE; PROTEIN GENE; C-III; IDENTIFICATION; EXPRESSION; TRANSCRIPTION; CHOLESTEROL	The newly identified apolipoprotein AV (apoAV) gene is a key player in determining plasma triglyceride concentrations. Because hypertriglyceridemia is a major independent risk factor in coronary artery disease, the understanding of the regulation of the expression of this gene is of considerable importance. We presently characterize the structure, the transcription start site, and the promoter of the human apoAV gene. Since the peroxisome proliferator-activated receptor-alpha (PPARalpha) and the farnesoid X-activated receptor (FXR) have been shown to modulate the expression of genes involved in triglyceride metabolism, we evaluated the potential role of these nuclear receptors in the regulation of apoAV transcription. Bile acids and FXR induced the apoAV gene promoter activity. 5'-Deletion, mutagenesis, and gel shift analysis identified a heretofore unknown element at positions -103/-84 consisting of an inverted repeat of two consensus receptor-binding hexads separated by 8 nucleotides (IR8), which was required for the response to bile acid-activated FXR. The isolated IR8 element conferred FXR responsiveness on a heterologous promoter. On the other hand, in apoAV-expressing human hepatic Hep3B cells, transfection of PPARalpha specifically enhanced apoAV promoter activity. By deletion, site-directed mutagenesis, and binding analysis, a PPARalpha response element located 271 bp upstream of the transcription start site was identified. Finally, treatment with a specific PPARalpha activator led to a significant induction of apoAV mRNA expression in hepatocytes. The identification of apoAV as a PPARalpha target gene has major implications with respect to mechanisms whereby pharmacological PPARalpha agonists may exert their beneficial hypotriglyceridemic actions.	GlaxoSmithKline, F-91951 Les Ulis, France	GlaxoSmithKline	Rodriguez, JC (corresponding author), GlaxoSmithKline, 25 Ave Quebec, F-91951 Les Ulis, France.	jcrodrig@freesurf.fr	Prieur, Xavier/D-4760-2015	Prieur, Xavier/0000-0003-0215-5447				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; *APPL BIOS, 2001, US B APPL BIOS, V2; Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Chawla A, 2000, CELL, V103, P1, DOI 10.1016/S0092-8674(00)00097-0; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Coste H, 2002, J BIOL CHEM, V277, P27120, DOI 10.1074/jbc.M203421200; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; Davis RA, 2002, J LIPID RES, V43, P533; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Edwards PA, 2002, J LIPID RES, V43, P2; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; Endo K, 2002, HUM GENET, V111, P570, DOI 10.1007/s00439-002-0825-0; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fruchart JC, 2002, CURR OPIN LIPIDOL, V13, P605, DOI 10.1097/00041433-200212000-00003; Gervois P, 2002, CIRCULATION, V106, P301; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISER JH, 1981, DRUGS, V21, P90, DOI 10.2165/00003495-198121020-00002; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; Miller M, 1998, J AM COLL CARDIOL, V31, P1252, DOI 10.1016/S0735-1097(98)00083-7; Nabika T, 2002, ATHEROSCLEROSIS, V165, P201, DOI 10.1016/S0021-9150(02)00252-6; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Ribalta J, 2002, CLIN CHEM, V48, P1597; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Winegar DA, 2001, J LIPID RES, V42, P1543; Zannis VI, 2001, CURR OPIN LIPIDOL, V12, P181, DOI 10.1097/00041433-200104000-00012	55	162	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25468	25480		10.1074/jbc.M301302200	http://dx.doi.org/10.1074/jbc.M301302200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12709436	Green Published, hybrid			2022-12-25	WOS:000183920200027
J	Masuda, K; Itoh, H; Sakihama, T; Akiyama, C; Takahashi, K; Fukuda, R; Yokomizo, T; Shimizu, T; Kodama, T; Hamakubo, T				Masuda, K; Itoh, H; Sakihama, T; Akiyama, C; Takahashi, K; Fukuda, R; Yokomizo, T; Shimizu, T; Kodama, T; Hamakubo, T			A combinatorial G protein-coupled receptor reconstitution system on budded baculovirus - Evidence for G alpha(i) and G alpha(o) coupling to a human leukotriene B4 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SF9 INSECT-CELL; B-4 RECEPTOR; FUNCTIONAL-CHARACTERIZATION; <S-35>GTP-GAMMA-S BINDING; EXPRESSION VECTORS; FORMYL PEPTIDE; ALPHA-SUBUNIT; P115 RHOGEF; ACTIVATION; MEMBRANES	To investigate the coupling selectivity of G proteins and G protein-coupled receptors (GPCRs), we developed a reconstitution system made up of GPCR and heterotrimeric G proteins on extracellular baculovirus particles (budded virus (BV)). BV released from Sf9 cells infected with a recombinant baculovirus coding for human leukotriene B-4 receptor (BLT1) cDNA exhibited a high level of BLT1 expression (27.3 pmol/mg of protein) and specific [H-3]leukotriene B-4 binding activity (K-d = 3.67 nM). The apparent low affinity of the expressed BLT1 is thought to be due to relative non-availability of the Galpha(i) isoform, which couples to BLT1, in BV. Co-infection of heterotrimeric G protein recombinant viruses led to co-expression of BLT1 and G protein subunits on BV. A guanosine-5/-(beta,gamma-imido)triphosphate-sensitive, high affinity ligand binding was observed in the BLT1 BV co-expressing Galpha(i1)beta(1)gamma(2) (K-d = 0.17 nM). A relatively large amount of high affinity receptor protein was recovered in the co-expressing BV fraction (6.81 pmol/mg of protein). A combination of BLT1 and Galpha(i1) without Gbeta(1)gamma(2) did not exhibit high affinity ligand binding on BV, indicating the low background environment for the GPCR-G protein coupling in this BV reconstitution system. To test other G proteins for coupling, various Galpha subunits were combinatorially expressed in BV with BLT1 and Gbeta(1)gamma(2). The BLT1 BV co-expressing Galpha(oA)beta(1)gamma(2) exhibited a comparably high affinity ligand binding as well as ligand-stimulated guanosine 5'-3-O-(thio)triphosphate binding to Galpha(i1)beta(1)gamma(2). Co-expression of other Galpha isoforms such as Galpha(s), Galpha(11), Galpha(14), Galpha(16), Galpha(12), or Galpha(13) did not exhibit any significant effects on ligand binding affinity in this system. These results reveal that BLT1 and coupled trimeric G proteins were functionally reconstituted on BV and that Galpha(o) as well as Galpha(i) couples to BLT1. This expression system should prove highly useful for pharmacological characterization, biosensor chip applications, and also drug discovery directed at highly important targets of the membrane receptor proteins.	Univ Tokyo, Dept Mol Biol & Med, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; Univ Tokyo, Lab Syst Biol & Med, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan; Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Yokohama, Kanagawa 2228567, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan; Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; Meiji Holdings Co., Ltd.; Nara Institute of Science & Technology; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Hamakubo, T (corresponding author), Univ Tokyo, Dept Mol Biol & Med, Res Ctr Adv Sci & Technol, Meguro Ku, Tokyo 1538904, Japan.		Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553; Masuda, Kazuyuki/0000-0003-3813-8550				Barr AJ, 1997, J BIOL CHEM, V272, P2223; Boundy VA, 1996, J PHARMACOL EXP THER, V276, P784; Bouvier M, 1998, CURR OPIN BIOTECH, V9, P522; Breivogel CS, 1998, J BIOL CHEM, V273, P16865, DOI 10.1074/jbc.273.27.16865; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Brys R, 2000, MOL PHARMACOL, V57, P1132; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; Cordeaux Y, 2001, J BIOL CHEM, V276, P28667, DOI 10.1074/jbc.M008644200; DEBRUMFERNANDES AJ, 1991, J PHARMACOL EXP THER, V259, P1035; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Francken BJB, 2000, MOL PHARMACOL, V57, P1034; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097; Igarashi T, 1999, EUR J BIOCHEM, V259, P419, DOI 10.1046/j.1432-1327.1999.00054.x; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; ITOH H, 1988, J BIOL CHEM, V263, P6656; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee M, 2002, BIOCHEM J, V366, P937, DOI 10.1042/BJ20020453; Leopoldt D, 1997, N-S ARCH PHARMACOL, V356, P216, DOI 10.1007/PL00005044; Loisel TP, 1997, NAT BIOTECHNOL, V15, P1300, DOI 10.1038/nbt1197-1300; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; McIntire WE, 1999, J NEUROCHEM, V73, P633, DOI 10.1046/j.1471-4159.1999.0730633.x; Mosser VA, 2002, J BIOL CHEM, V277, P922, DOI 10.1074/jbc.M104210200; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; Obosi LA, 1996, FEBS LETT, V381, P233, DOI 10.1016/0014-5793(96)00078-6; PARKER EM, 1991, J BIOL CHEM, V266, P519; Possee RD, 1997, CURR OPIN BIOTECH, V8, P569, DOI 10.1016/S0958-1669(97)80030-4; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Strange PG, 1999, BIOCHEM PHARMACOL, V58, P1081; Tate CG, 1996, TRENDS BIOTECHNOL, V14, P426, DOI 10.1016/0167-7799(96)10059-7; Ulloa-Aguirre A, 1999, ARCH MED RES, V30, P420, DOI 10.1016/S0188-0128(99)00041-X; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238; Windh RT, 2002, METHOD ENZYMOL, V344, P3; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	52	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24552	24562		10.1074/jbc.M302801200	http://dx.doi.org/10.1074/jbc.M302801200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721292	hybrid			2022-12-25	WOS:000183824800038
J	Sreenath, T; Thyagarajan, T; Hall, B; Longenecker, G; D'Souza, R; Hong, S; Wright, JT; MacDougall, M; Sauk, J; Kulkarni, AB				Sreenath, T; Thyagarajan, T; Hall, B; Longenecker, G; D'Souza, R; Hong, S; Wright, JT; MacDougall, M; Sauk, J; Kulkarni, AB			Dentin sialophosphoprotein knockout mouse teeth display widened predentin zone and develop defective dentin mineralization similar to human dentinogenesis imperfecta type III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN FIBRILS; TRANSFORMING GROWTH-FACTOR-BETA-1; RAT INCISOR; DSPP GENE; PROTEOGLYCANS; EXPRESSION; MATRIX; PHOSPHOPROTEIN; DECORIN; SIALOPROTEIN	Dentin sialophosphoprotein (Dspp) is mainly expressed in teeth by the odontoblasts and preameloblasts. The Dspp mRNA is translated into a single protein, Dspp, and cleaved into two peptides, dentin sialoprotein and dentin phosphoprotein, that are localized within the dentin matrix. Recently, mutations in this gene were identified in human dentinogenesis imperfecta II (Online Mendelian Inheritance in Man (OMIM) accession number 125490) and in dentin dysplasia II (OMIM accession number 125420) syndromes. Herein, we report the generation of Dspp-null mice that develop tooth defects similar to human dentinogenesis imperfecta III with enlarged pulp chambers, increased width of predentin zone, hypomineralization, and pulp exposure. Electron microscopy revealed an irregular mineralization front and a lack of calcospherites coalescence in the dentin. Interestingly, the levels of biglycan and decorin, small leucine-rich proteoglycans, were increased in the widened predentin zone and in void spaces among the calcospherites in the dentin of null teeth. These enhanced levels correlate well with the defective regions in mineralization and further indicate that these molecules may adversely affect the dentin mineralization process by interfering with coalescence of calcospherites. Overall, our results identify a crucial role for Dspp in orchestrating the events essential during dentin mineralization, including potential regulation of proteoglycan levels.	NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; NIDCR, Gene Targeting Facil, NIH, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Houston, TX 77030 USA; Univ N Carolina, Chapel Hill, NC 27599 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA; Univ Baltimore, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Texas System; University of Texas Health Science Center Houston; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Health San Antonio; University System of Maryland; University of Baltimore	Sreenath, T (corresponding author), 30 Convent Dr,Room 527, Bethesda, MD 20892 USA.	tsreenat@mail.nih.gov; akulkarn@mail.nih.gov	Wright, John Timothy/AAX-5755-2020; MacDougall, Mary/ABG-8212-2021	Sauk, John/0000-0002-9208-5739; D'Souza, Rena/0000-0002-1505-5173	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000698, ZIADE000698] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Balto K, 2002, ORAL SURG ORAL MED O, V93, P461, DOI 10.1067/moe.2002.122641; Begue-Kirn C, 1998, EUR J ORAL SCI, V106, P963, DOI 10.1046/j.0909-8836.1998.eos106510.x; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; Boskey AL, 1997, CALCIFIED TISSUE INT, V61, P298, DOI 10.1007/s002239900339; Butler WT, 1998, EUR J ORAL SCI, V106, P204, DOI 10.1111/j.1600-0722.1998.tb02177.x; Cam Y, 1997, ARCH ORAL BIOL, V42, P385, DOI 10.1016/S0003-9969(97)00017-4; DSOUZA RN, 1992, J HISTOCHEM CYTOCHEM, V40, P359, DOI 10.1177/40.3.1552175; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Embery G, 2001, CRIT REV ORAL BIOL M, V12, P331, DOI 10.1177/10454411010120040401; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; George A, 1996, J BIOL CHEM, V271, P32869, DOI 10.1074/jbc.271.51.32869; Goldberg M, 2002, J DENT RES, V81, P520, DOI 10.1177/154405910208100804; Hall R, 1999, HISTOCHEM J, V31, P761, DOI 10.1023/A:1003945902473; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hoshi K, 1999, J BONE MINER RES, V14, P273, DOI 10.1359/jbmr.1999.14.2.273; KEREBEL B, 1981, J DENT RES, V60, P1655, DOI 10.1177/00220345810600090401; LANDIS WJ, 1993, J STRUCT BIOL, V110, P39, DOI 10.1006/jsbi.1993.1003; LANDIS WJ, 1986, J ULTRA MOL STRUCT R, V94, P217, DOI 10.1016/0889-1605(86)90069-8; LANDIS WJ, 1999, SPACE BIOL B, V12, P15; LEVIN LS, 1983, ORAL SURG ORAL MED O, V56, P267, DOI 10.1016/0030-4220(83)90008-7; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; Rao S, 1971, Birth Defects Orig Artic Ser, V7, P153; Raspanti M, 1997, J STRUCT BIOL, V119, P118, DOI 10.1006/jsbi.1997.3865; SCOTT JE, 1965, HISTOCHEMISTRY, V5, P221, DOI 10.1007/BF00306130; Septier D, 2001, CALCIFIED TISSUE INT, V69, P38, DOI 10.1007/s002230020047; SHIELDS ED, 1973, ARCH ORAL BIOL, V18, P543, DOI 10.1016/0003-9969(73)90075-7; SHOKEIR MHK, 1972, CLIN GENET, V3, P442; SMITH G, 1988, J ORAL PATHOL MED, V17, P55, DOI 10.1111/j.1600-0714.1988.tb01507.x; Sreenath TL, 1999, INT J DEV BIOL, V43, P509; TAKAGI M, 1990, J HISTOCHEM CYTOCHEM, V38, P319, DOI 10.1177/38.3.1689334; TAKAGI Y, 1986, CONNECT TISSUE RES, V14, P279, DOI 10.3109/03008208609017471; TAKEUCHI Y, 1993, J BONE MINER RES, V8, P823; Thyagarajan T, 2001, J BIOL CHEM, V276, P11016, DOI 10.1074/jbc.M010502200; TRAUB W, 1992, MATRIX, V12, P251, DOI 10.1016/S0934-8832(11)80076-4; VEIS A, 1993, J BONE MINER RES, V8, pS493; WEINER S, 1986, FEBS LETT, V206, P262, DOI 10.1016/0014-5793(86)80993-0; Witkop C J Jr, 1966, Ala J Med Sci, V3, P382; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Yoshiba N, 1996, ARCH ORAL BIOL, V41, P351, DOI 10.1016/0003-9969(95)00138-7; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	47	308	320	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24874	24880		10.1074/jbc.M303908200	http://dx.doi.org/10.1074/jbc.M303908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721295	hybrid, Green Published			2022-12-25	WOS:000183824800076
J	Sudhandiran, G; Shaha, C				Sudhandiran, G; Shaha, C			Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; NITRIC-OXIDE PRODUCTION; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; PENTAVALENT ANTIMONY; ANTILEISHMANIAL ACTIVITY; SODIUM STIBOGLUCONATE; DNA-DAMAGE; IN-VIVO; MACROPHAGE	The capability of the obligate intracellular parasites like Leishmania donovani to survive within the host cell parasitophorous vacuoles as nonmotile amastigotes determines disease pathogenesis, but the mechanism of elimination of the parasites from these vacuoles are not well understood. By using the anti-leishmanial drug potassium antimony tartrate, we demonstrate that, upon drug exposure, intracellular L. donovani amastigotes undergo apoptotic death characterized by nuclear DNA fragmentation and externalization of phosphatidylserine. Changes upstream of DNA fragmentation included generation of reactive oxygen species like superoxide, nitric oxide, and hydrogen peroxide that were primarily concentrated in the parasitophorous vacuoles. In the presence of antioxidants like N-acetylcysteine or Mn(III) tetrakis(4-benzoic acid) porphyrin chloride, an inhibitor of inducible nitric-oxide synthase, a diminution of reactive oxygen species generation and improvement of amastigote survival were observed, suggesting a close link between drug-induced oxidative stress and amastigote death. Changes downstream to reactive oxygen species increase involved elevation of intracellular Ca2+ concentrations in both the parasite and the host that was preventable by antioxidants. Flufenamic acid, a non-selective cation channel blocker, decreased the elevation of Ca2+ in both the cell types and reduced amastigote death, thus establishing a central role of Ca2+ in intracellular parasite clearance. This influx of Ca2+ was preceded by a fall in the amastigote mitochondrial membrane potential. Therefore, this study projects the importance of flufenamic acid-sensitive non-selective cation channels as important modulators of antimonial efficacy and lends credence to the suggestion that, within the host cell, apoptosis is the preferred mode of death for the parasites.	Natl Inst Immunol, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Shaha, C (corresponding author), Natl Inst Immunol, New Delhi 110067, India.	cshaha@nii.res.in	Sudhandiran, G/AAG-9967-2019; Ganapasam, Sudhandiran/AAD-4264-2021	Sudhandiran, G/0000-0003-0066-7801; 				Albina JE, 1998, CANCER METAST REV, V17, P39, DOI 10.1023/A:1005904704618; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Amer AO, 2002, CURR OPIN MICROBIOL, V5, P56, DOI 10.1016/S1369-5274(02)00286-2; Antoine JC, 1998, TRENDS MICROBIOL, V6, P392, DOI 10.1016/S0966-842X(98)01324-9; Arnoult D, 2002, CELL DEATH DIFFER, V9, P65, DOI 10.1038/sj.cdd.4400951; BABIOR BM, 1978, NEW ENGL J MED, V298, P721, DOI 10.1056/NEJM197803302981305; Bergamini S, 2001, NITRIC OXIDE-BIOL CH, V5, P349, DOI 10.1006/niox.2001.0356; BERMAN JD, 1985, ANTIMICROB AGENTS CH, V27, P916, DOI 10.1128/AAC.27.6.916; Chang K. P., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P213; CHANG KP, 1976, SCIENCE, V193, P678, DOI 10.1126/science.948742; Das M, 2001, J CELL SCI, V114, P2461; Davies KJA, 2000, IUBMB LIFE, V50, P241, DOI 10.1080/15216540051080895; Day BJ, 1997, ARCH BIOCHEM BIOPHYS, V347, P256, DOI 10.1006/abbi.1997.0341; Ephros M, 1999, ANTIMICROB AGENTS CH, V43, P278, DOI 10.1128/AAC.43.2.278; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Frezard F, 2001, ANTIMICROB AGENTS CH, V45, P913, DOI 10.1128/AAC.45.3.913-916.2001; Geller HM, 2001, J NEUROCHEM, V78, P265, DOI 10.1046/j.1471-4159.2001.00395.x; Harder A, 2001, PARASITOL RES, V87, P778, DOI 10.1007/s004360100404; Holstad M, 1997, GEN PHARMACOL-VASC S, V29, P697, DOI 10.1016/S0306-3623(97)00012-8; Holzmuller P, 2002, INFECT IMMUN, V70, P3727, DOI 10.1128/IAI.70.7.3727-3735.2002; Kane MM, 2000, CURR OPIN HEMATOL, V7, P26, DOI 10.1097/00062752-200001000-00006; Karin M, 2001, IUBMB LIFE, V52, P17; Kim JA, 2000, PHARMACOLOGY, V60, P74, DOI 10.1159/000028350; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; Lee N, 2002, CELL DEATH DIFFER, V9, P53, DOI 10.1038/sj.cdd.4400952; LIEW FY, 1990, J IMMUNOL, V144, P4794; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Milano J, 2000, NUCLEIC ACIDS RES, V28, P968, DOI 10.1093/nar/28.4.968; Moreira MEC, 1996, J CELL PHYSIOL, V167, P305, DOI 10.1002/(SICI)1097-4652(199605)167:2&lt;305::AID-JCP15&gt;3.0.CO;2-6; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741; Pinelli E, 2000, VET PARASITOL, V92, P181, DOI 10.1016/S0304-4017(00)00312-5; Rais S, 2000, ANTIMICROB AGENTS CH, V44, P2406, DOI 10.1128/AAC.44.9.2406-2410.2000; Raisanen SR, 2001, BIOCHEM BIOPH RES CO, V288, P142, DOI 10.1006/bbrc.2001.5715; Rittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6; ROBERTS WL, 1995, ANTIMICROB AGENTS CH, V39, P1234, DOI 10.1128/AAC.39.6.1234; Schirmer R H, 1987, Free Radic Res Commun, V3, P3, DOI 10.3109/10715768709069763; Sereno D, 1998, ANTIMICROB AGENTS CH, V42, P3097, DOI 10.1128/AAC.42.12.3097; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Welburn SC, 1997, MED VET ENTOMOL, V11, P286, DOI 10.1111/j.1365-2915.1997.tb00408.x; Welburn SC, 1999, MEM I OSWALDO CRUZ, V94, P229, DOI 10.1590/S0074-02761999000200020; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V374, P142, DOI 10.1006/abbi.1999.1574; Zangger H, 2002, CELL DEATH DIFFER, V9, P1126, DOI 10.1038/sj.cdd.4401071	49	138	143	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25120	25132		10.1074/jbc.M301975200	http://dx.doi.org/10.1074/jbc.M301975200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707265	hybrid			2022-12-25	WOS:000183824800106
J	Blumer, JB; Bernard, ML; Peterson, YK; Nezu, J; Chung, P; Dunican, DJ; Knoblich, JA; Lanier, SM				Blumer, JB; Bernard, ML; Peterson, YK; Nezu, J; Chung, P; Dunican, DJ; Knoblich, JA; Lanier, SM			Interaction of activator of G-protein signaling 3 (AGS3) with LKB1, a serine/threonine kinase involved in cell polarity and cell cycle progression - Phosphorylation of the G-protein regulatory (GPR) motif as a regulatory mechanism for the interaction of GPR motifs with G(i)alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEUTZ-JEGHERS-SYNDROME; G-ALPHA; IDENTIFICATION; GENE; DIVISION; PARTNER; ENCODES; SUBFAMILY; COMPLEX; CLONING	Activator of G-protein signaling 3 (AGS3) has a modular domain structure consisting of seven tetratricopeptide repeats (TPRs) and four G-protein regulatory (GPR) motifs. Each GPR motif binds to the alpha subunit of G(i)/G(o) (G(i)alpha > G(o)alpha) stabilizing the GDP-bound conformation of Galpha and apparently competing with Gbetagamma for Galpha(GDP) binding. As an initial approach to identify regulatory mechanisms for AGS3-G-protein interactions, a yeast two-hybrid screen was initiated using the TPR and linker region of AGS3 as bait. This screen identified the serine/threonine kinase LKB1, which is involved in the regulation of cell cycle progression and polarity. Protein interaction assays in mammalian systems using transfected cells or brain lysate indicated the regulated formation of a protein complex consisting of LKB1, AGS3, and G-proteins. The interaction between AGS3 and LKB1 was also observed with orthologous proteins in Drosophila where both proteins are involved in cell polarity. LKB1 immunoprecipitates from COS7 cells transfected with LKB1 phosphorylated the GPR domains of AGS3 and the related protein LGN but not the AGS3-TPR domain. GPR domain phosphorylation was completely blocked by a consensus GPR motif peptide, and placement of a phosphate moiety within a consensus GPR motif reduced the ability of the peptide to interact with G-proteins. These data suggest that phosphorylation of GPR domains may be a general mechanism regulating the interaction of GPR-containing proteins with G-proteins. Such a mechanism may be of particular note in regard to localized signal processing in the plasma membrane involving G-protein subunits and/or intracellular functions regulated by heterotrimeric G-proteins that occur independently of a typical G-protein-coupled receptor.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Chugai Pharmaceut Co Ltd, Tsukuba Res Lab, Ibaraki 3004101, Japan; Res Inst Mol Pathol, A-1030 Vienna, Austria; Med Univ S Carolina, Dept Pharmacol, Charleston, SC 29425 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of South Carolina	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Dunican, Dara/A-1208-2010; Bernard, Michael/AAW-3944-2021; Knoblich, Juergen A/C-2974-2015	Dunican, Dara/0000-0001-6563-8089; Knoblich, Juergen A/0000-0002-6751-3404; Blumer, Joe/0000-0002-0020-3815; Lanier, Stephen/0000-0002-2740-7607	NIGMS NIH HHS [T32-GM08716] Funding Source: Medline; NIMH NIH HHS [MH90531, F32MH65092, F32 MH065092] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Bernier G, 1996, GENOMICS, V38, P19, DOI 10.1006/geno.1996.0587; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; GOTTA M, 2003, IN PRESS CURR BIOL; Harashima T, 2002, MOL CELL, V10, P163, DOI 10.1016/S1097-2765(02)00569-5; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hollinger S, 2003, BIOCHEMISTRY-US, V42, P811, DOI 10.1021/bi026664y; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Kang SM, 1997, J BIOL CHEM, V272, P11588; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; Watts JL, 2000, DEVELOPMENT, V127, P1467; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5	32	50	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23217	23220		10.1074/jbc.C200686200	http://dx.doi.org/10.1074/jbc.C200686200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12719437	hybrid			2022-12-25	WOS:000183638600002
J	Camacho, AG; Gual, A; Lurz, R; Tavares, P; Alonso, JC				Camacho, AG; Gual, A; Lurz, R; Tavares, P; Alonso, JC			Bacillus subtilis bacteriophage SPP1 DNA packaging motor requires terminase and portal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-SUBUNIT; NUCLEOPROTEIN COMPLEX; GP17; ENZYME; INHIBITION; INITIATION; SITE; PAC	Initiation of headful packaging of SPP1 DNA concatemers involves the interaction of the terminase, G1P and G2P, and the portal protein, G6P. G1P, which specifically recognizes the non-adjacent pacL and pacR subsites and directs loading of G2P to pacC, interacts with G6P. G2P, which has endonuclease, DNA binding, and ATPase activities, interacts with G1P and does it transiently with G6P. The stoichiometry of G1P on the G1P.G2P complex promotes the transition from a G2P endonuclease to an ATPase. G6P does not alter the endonuclease activity of G2P. Both G1P and G6P, which do not have endogenous ATPase activity, synergistically enhance and modulate the ATPase activity of G2P. Based on these results, we propose a model in which the modulation of the ATPase and endonuclease activities of G2P accounts for the role of the terminase in headful packaging.	CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Madrid 28049, Spain; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; CNRS, Unite Virol Mol & Struct, F-91198 Gif Sur Yvette, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Max Planck Society; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Alonso, JC (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Campus Univ Autonoma Madrid, Madrid 28049, Spain.	jcalonso@cnb.uam.es	Alonso, Juan Carlos/D-2595-2009	Alonso, Juan Carlos/0000-0002-5178-7179; Tavares, Paulo/0000-0002-2566-4546				ARAI K, 1981, J BIOL CHEM, V256, P5253; Ayora S, 1996, J MOL BIOL, V256, P301, DOI 10.1006/jmbi.1996.0087; Baumann RG, 2003, J BIOL CHEM, V278, P4618, DOI 10.1074/jbc.M208574200; Becker B, 1997, J MOL BIOL, V268, P822, DOI 10.1006/jmbi.1997.0997; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; BRAVO A, 1990, NUCLEIC ACIDS RES, V18, P2881, DOI 10.1093/nar/18.10.2881; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; CHAI S, 1992, J MOL BIOL, V224, P87, DOI 10.1016/0022-2836(92)90578-8; CHAI SH, 1994, VIROLOGY, V202, P930, DOI 10.1006/viro.1994.1415; CHAI SH, 1995, J MOL BIOL, V252, P386, DOI 10.1006/jmbi.1995.0505; Chai SH, 1996, NUCLEIC ACIDS RES, V24, P282, DOI 10.1093/nar/24.2.282; DEICHELBOHRER I, 1982, J VIROL, V42, P83, DOI 10.1128/JVI.42.1.83-90.1982; Droge A, 2000, J MOL BIOL, V296, P103, DOI 10.1006/jmbi.1999.3449; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fujisawa H, 1997, GENES CELLS, V2, P537, DOI 10.1046/j.1365-2443.1997.1450343.x; Gual A, 1998, VIROLOGY, V242, P279, DOI 10.1006/viro.1997.9017; Gual A, 2000, J BIOL CHEM, V275, P35311, DOI 10.1074/jbc.M004309200; GUAL A, 1998, THESIS U AUTONOMA MA; Guasch A, 2002, J MOL BIOL, V315, P663, DOI 10.1006/jmbi.2001.5278; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Ibarra B, 2000, J MOL BIOL, V298, P807, DOI 10.1006/jmbi.2000.3712; Leffers G, 2000, J BIOL CHEM, V275, P37127, DOI 10.1074/jbc.M003357200; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Lurz R, 2001, J MOL BIOL, V310, P1027, DOI 10.1006/jmbi.2001.4800; Orlova EV, 1999, NAT STRUCT BIOL, V6, P842; Rao VB, 2001, J MOL BIOL, V314, P401, DOI 10.1006/jmbi.2001.5169; SHIBATA H, 1987, J MOL BIOL, V196, P845, DOI 10.1016/0022-2836(87)90409-8; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; STEVEN AC, 1988, J MOL BIOL, V200, P351, DOI 10.1016/0022-2836(88)90246-X; Tavares P, 1996, J MOL BIOL, V264, P954, DOI 10.1006/jmbi.1996.0689; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Xu H, 2001, NUCLEIC ACIDS RES, V29, P5058, DOI 10.1093/nar/29.24.5058	36	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23251	23259		10.1074/jbc.M301805200	http://dx.doi.org/10.1074/jbc.M301805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12697751	Green Published, hybrid			2022-12-25	WOS:000183638600007
J	Fomenkov, A; Huang, YP; Topaloglu, O; Brechman, A; Osada, M; Fomenkova, T; Yuriditsky, E; Trink, B; Sidransky, D; Ratovitski, E				Fomenkov, A; Huang, YP; Topaloglu, O; Brechman, A; Osada, M; Fomenkova, T; Yuriditsky, E; Trink, B; Sidransky, D; Ratovitski, E			p63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; P53 HOMOLOG P63; B MESSENGER-RNA; SAM DOMAIN; PROTEIN-INTERACTION; BINDING PROTEIN; GENE; CLONING; FGFR2	p63, a p53 family member, is required for craniofacial and limb development as well as proper skin differentiation. However, p63 mutations associated with the ankyloblepharon-ectodermal dysplasia-clefting (AEC) syndrome (Hay-Wells syndrome) were found in the p63 carboxyl-terminal region with a sterile alpha-motif. By two-hybrid screen we identified several proteins that interact with the p63alpha carboxyl terminus and its sterile alpha-motif, including the apobec-1-binding protein-1 (ABBP1). AEC-associated mutations completely abolished the physical interaction between ABBP1 and p63alpha. Moreover the physical association of p63alpha and ABBP1 led to a specific shift of FGFR-2 alternative splicing toward the K-SAM isoform essential for epithelial differentiation. We thus propose that a p63alpha-ABBP1 complex differentially regulates FGFR-2 expression by supporting alternative splicing of the K-SAM isoform of FGFR-2. The inability of mutated p63alpha to support this splicing likely leads to the inhibition of epithelial differentiation and, in turn, accounts for the AEC phenotype.	Johns Hopkins Univ, Sch Med, Dept Dermatol, Head & Neck Canc Res Div, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Dermatol, Head & Neck Canc Res Div, 818 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu; erat@welch.jhu.edu		Yuriditsky, Eugene/0000-0003-2263-9297	NIAID NIH HHS [R01-AI47224] Funding Source: Medline; NIDCR NIH HHS [R01-DE13561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Carstens RP, 1997, ONCOGENE, V15, P3059, DOI 10.1038/sj.onc.1201498; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Du L, 1997, J CELL BIOL, V136, P5, DOI 10.1083/jcb.136.1.5; GATTO FD, 1995, MOL CELL BIOL, V15, P4825; GORRY MC, 1995, HUM MOL GENET, V4, P1387, DOI 10.1093/hmg/4.8.1387; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KHAN FA, 1991, FEBS LETT, V290, P159, DOI 10.1016/0014-5793(91)81249-8; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; Lau PP, 2001, BIOCHEM BIOPH RES CO, V282, P977, DOI 10.1006/bbrc.2001.4679; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Raitskin O, 2001, P NATL ACAD SCI USA, V98, P6571, DOI 10.1073/pnas.111153798; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Sarig G, 1997, BIOCHEM BIOPH RES CO, V237, P617, DOI 10.1006/bbrc.1997.7198; Schultz J, 1997, PROTEIN SCI, V6, P249; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Tao H, 2002, MECH DEVELOP, V116, P39, DOI 10.1016/S0925-4773(02)00131-4; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975	49	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23906	23914		10.1074/jbc.M300746200	http://dx.doi.org/10.1074/jbc.M300746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692135	hybrid			2022-12-25	WOS:000183638600088
J	Ihara, M; Tomimoto, H; Kitayama, H; Morioka, Y; Akiguchi, I; Shibasaki, H; Noda, M; Kinoshita, M				Ihara, M; Tomimoto, H; Kitayama, H; Morioka, Y; Akiguchi, I; Shibasaki, H; Noda, M; Kinoshita, M			Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; HUMAN ALPHA-SYNUCLEIN; LEWY BODIES; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISORDERS; MAMMALIAN SEPTINS; TRANSGENIC MICE; BODY FORMATION; MOUSE-BRAIN; SYNPHILIN-1	alpha-Synuclein-positive cytoplasmic inclusions are a pathological hallmark of several neurodegenerative disorders including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Here we report that Sept4, a member of the septin protein family, is consistently found in these inclusions, whereas five other septins (Sept2, Sept5, Sept6, Sept7, and Sept8) are not found in these inclusions. Sept4 and alpha-synuclein can also be co-immunoprecipitated from normal human brain lysates. When co-expressed in cultured cells, FLAG-tagged Sept4 and Myc-tagged alpha-synuclein formed detergent-insoluble complex, and upon treatment with a proteasome inhibitor, they formed Lewy body-like cytoplasmic inclusions. The tagged Sept4 and alpha-synuclein synergistically accelerated cell death induced by the proteasome inhibitor, and this effect was further enhanced by expression of another Lewy body-associated protein, synphilin-1, tagged with the V5 epitope. Moreover, co-expression of the three proteins (tagged Sept4, alpha-synuclein, and synphilin-1) was sufficient to induce cell death. These data raise the possibility that Sept4 is involved in the formation of cytoplasmic inclusions as well as induction of cell death in alpha-synuclein-associated neurodegenerative disorders.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Ihara, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kawahara Cho, Kyoto 6068507, Japan.		Ihara, Masafumi/O-5020-2019	Ihara, Masafumi/0000-0002-7102-4048				Baba M, 1998, AM J PATHOL, V152, P879; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Chung KKK, 2001, TRENDS NEUROSCI, V24, pS7, DOI 10.1016/S0166-2236(00)01998-6; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Galvin JE, 2001, ARCH NEUROL-CHICAGO, V58, P186, DOI 10.1001/archneur.58.2.186; Gearing M, 2002, ANN NEUROL, V52, P465, DOI 10.1002/ana.10319; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Gilman S, 1998, J AUTONOM NERV SYST, V74, P189; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; KATO K, 1990, EUR J NEUROSCI, V2, P704, DOI 10.1111/j.1460-9568.1990.tb00460.x; Kinoshita A, 2000, J COMP NEUROL, V428, P223, DOI 10.1002/1096-9861(20001211)428:2<223::AID-CNE3>3.0.CO;2-M; Kinoshita A, 1998, AM J PATHOL, V153, P1551, DOI 10.1016/S0002-9440(10)65743-4; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUZUHARA S, 1988, ACTA NEUROPATHOL, V75, P345, DOI 10.1007/BF00687787; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438; Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Perl DP, 1998, ANN NEUROL, V44, pS19, DOI 10.1002/ana.410440705; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 2002, ACTA NEUROPATHOL, V103, P209, DOI 10.1007/s004010100451; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	45	110	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24095	24102		10.1074/jbc.M301352200	http://dx.doi.org/10.1074/jbc.M301352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12695511	hybrid			2022-12-25	WOS:000183638600113
J	Lamy, L; Ticchioni, M; Rouquette-Jazdanian, AK; Samson, M; Deckert, M; Greenberg, AH; Bernard, A				Lamy, L; Ticchioni, M; Rouquette-Jazdanian, AK; Samson, M; Deckert, M; Greenberg, AH; Bernard, A			CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; BCL-X-L; BH3 DOMAIN; MITOCHONDRIAL PROTEIN; PLASMA-MEMBRANE; DEATH; PRESENILIN-1; ACTIVATION; THROMBOSPONDIN-1; LIGATION	CD47 is a surface receptor that induces either coactivation or apoptosis in lymphocytes, depending on the ligand(s) bound. Interestingly, the apoptotic pathway is independent of caspase activation and cytochrome c release and is accompanied by early mitochondrial dysfunction with suppression of mitochondrial membrane potential (DeltaPsim). Using CD47 as bait in a yeast two-hybrid system, we identified the Bcl-2 homology 3 (BH3)-only protein 19 kDa interacting protein-3 (BNIP3), a pro-apoptotic member of the Bcl-2 family, as a novel partner. Interaction between CD47 and the BH3-only protein was confirmed by immunoprecipitation analysis, and CD47-induced apoptosis was inhibited by attenuating BNIP3 expression with antisense oligonucleotides. Finally, we showed that the C-terminal domain of thrombospondin-1 (TSP-1), but not signal-regulatory protein (SIRPalpha1), is the ligand for CD47 involved in inducing cell death. Immunofluorescence analysis of CD47 and BNIP3 revealed a partial colocalization of both molecules under basal conditions. After T cell stimulation via CD47, BNIP3 translocates to the mitochondria to induce apoptosis. These results show that the BH3-dependent apoptotic pathways, previously shown to be activated by intracellular pro-apoptotic events, can also be turned on by surface receptors. This new pathway results in a fast induction of cell death resembling necrosis, which is likely to play an important role in lymphocyte regulation at inflammatory sites and/or in the vicinity of thrombosis.	INSERM, U576, F-06202 Nice 3, France; Immunol Lab, F-06202 Nice 3, France; Fac Med Pasteur, INSERM, U364, F-06107 Nice 2, France; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E OV9, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; University of Manitoba	Bernard, A (corresponding author), Hop Archet 1, INSERM, U576, IFR 50, F-06202 Nice 3, France.	abernard@unice.fr	Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019; Ticchioni, Michel/P-8095-2016	Deckert, Marcel/0000-0003-2094-559X; ROUQUETTE-JAZDANIAN, Alexandre K./0000-0003-2646-0040				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alberici A, 1999, J BIOL CHEM, V274, P30764, DOI 10.1074/jbc.274.43.30764; Avice MN, 2000, J IMMUNOL, V165, P4624, DOI 10.4049/jimmunol.165.8.4624; Bernard G, 1997, J IMMUNOL, V158, P2543; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brittain JE, 2001, J CLIN INVEST, V107, P1555, DOI 10.1172/JCI10817; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Deas O, 1998, J IMMUNOL, V161, P3375; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; FOUCAULT I, 2002, J BIOL CHEM, V24, P24; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Freyberg MA, 2001, BIOCHEM BIOPH RES CO, V286, P141, DOI 10.1006/bbrc.2001.5314; Freyberg MA, 2000, BIOCHEM BIOPH RES CO, V271, P584, DOI 10.1006/bbrc.2000.2678; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Hebert SS, 2003, BIOCHEM BIOPH RES CO, V301, P119, DOI 10.1016/S0006-291X(02)02984-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Imafuku I, 1999, J CELL BIOL, V147, P121, DOI 10.1083/jcb.147.1.121; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Klaus SJ, 1996, J IMMUNOL, V156, P2743; Lesage S, 1997, J IMMUNOL, V159, P4762; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li ZQ, 2001, J IMMUNOL, V166, P2427, DOI 10.4049/jimmunol.166.4.2427; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Reinhold MI, 1999, INT IMMUNOL, V11, P707, DOI 10.1093/intimm/11.5.707; REN G, 2002, FASEB J, V16, pA541; Ricci JE, 2001, EUR CYTOKINE NETW, V12, P126; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Skov S, 1997, J CELL BIOL, V139, P1523, DOI 10.1083/jcb.139.6.1523; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Ticchioni M, 1997, J IMMUNOL, V158, P677; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Xu XM, 1999, J BIOL CHEM, V274, P32543, DOI 10.1074/jbc.274.46.32543; Xu XM, 2002, J BIOL CHEM, V277, P48913, DOI 10.1074/jbc.M209613200; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	55	68	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23915	23921		10.1074/jbc.M301869200	http://dx.doi.org/10.1074/jbc.M301869200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12690108	hybrid			2022-12-25	WOS:000183638600089
J	Millan, C; Castro, E; Torres, M; Shigemoto, R; Sanchez-Prieto, J				Millan, C; Castro, E; Torres, M; Shigemoto, R; Sanchez-Prieto, J			Co-expression of metabotropic glutamate receptor 7 and N-type Ca2+ channels in single cerebrocortical nerve terminals of adult rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNELS; GLUTAMATE-RECEPTOR; SYNAPTIC-TRANSMISSION; TRANSMITTER RELEASE; PRESYNAPTIC LOCALIZATION; DEVELOPMENTAL-CHANGES; C-TERMINUS; INHIBITION; PROTEIN; MODULATION	The modulation of calcium channels by metabotropic glutamate receptors (mGluRs) is a key event in the fine-tuning of neurotransmitter release. Here we report that, in cerebrocortical nerve terminals of adult rats, the inhibition of glutamate release is mediated by mGluR7. In this preparation, the major component of glutamate release is supported by P/Q-type Ca2+ channels (72.7%). However, mGluR7 selectively reduced the release component that is associated with N-type Ca2+ channels (29.9%). Inhibition of P/Q channels by mGluR7 is not masked by the higher efficiency of these channels in driving glutamate release when compared with N-type channels. Thus, activation of mGluR7 failed to reduce the release associated with P/Q channels when the extracellular calcium concentration, ([Ca2+](o)), was reduced from 1.3 to 0.5 mM. Through Ca2+ imaging, we show that Ca2+ channels are distributed in a heterogeneous manner in individual nerve terminals. Indeed, in this preparation, nerve terminals were observed that contain N-type (31.1%; conotoxin GVIA-sensitive) or P/Q-type (64.3%; agatoxin IVA-sensitive) <LF>channels or that were insensitive to these two toxins (4.6%). Interestingly, the great majority of the responses to L-AP4 (95.4%) were observed in nerve terminals containing N-type channels. This specific co-localization of mGluR7 and N-type Ca2+-channels could explain the failure of the receptor to inhibit the P/Q channel-associated release component and also reveal the existence of specific targeting mechanisms to localize the two proteins in the same nerve terminal subset.	Univ Complutense, Dept Bioquim, Fac Vet, E-28040 Madrid, Spain; ULPG, Dept Bioquim Biol Mol & Fisiol, Fac Ciencias Salud, Las Palmas Gran Canaria 35016, Spain; Natl Inst Physiol Sci, Div Cerebral Struct, Okazaki, Aichi 4448585, Japan	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Sanchez-Prieto, J (corresponding author), Univ Complutense, Dept Bioquim, Fac Vet, E-28040 Madrid, Spain.	jsprieto@vet.ucm.es	Shigemoto, Ryuichi/E-3628-2013; Torres, Magdalena/E-6150-2017	Shigemoto, Ryuichi/0000-0001-8761-9444; Torres, Magdalena/0000-0002-3893-8569; Sanchez-Prieto, Jose/0000-0002-8513-3501				BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Corti C, 2002, NEUROSCIENCE, V110, P403, DOI 10.1016/S0306-4522(01)00591-7; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Dev KK, 2000, J NEUROSCI, V20, P7252; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Garcia DE, 1998, J NEUROSCI, V18, P9163; GEREAU RW, 1995, J NEUROSCI, V15, P6879; Herrero I, 1996, EUR J NEUROSCI, V8, P700, DOI 10.1111/j.1460-9568.1996.tb01255.x; Iwasaki S, 2000, J NEUROSCI, V20, P59, DOI 10.1523/JNEUROSCI.20-01-00059.2000; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; Maximov A, 2002, J NEUROSCI, V22, P6939; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Millan C, 2002, J BIOL CHEM, V277, P47796, DOI 10.1074/jbc.M207531200; Millan C, 2002, NEUROSCI LETT, V330, P29, DOI 10.1016/S0304-3940(02)00719-X; Millan C, 2002, J BIOL CHEM, V277, P14092, DOI 10.1074/jbc.M109044200; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Perroy J, 2000, J NEUROSCI, V20, P7896; Perroy J, 2002, EMBO J, V21, P2990, DOI 10.1093/emboj/cdf313; Perroy J, 2001, J BIOL CHEM, V276, P45800, DOI 10.1074/jbc.M106876200; Qian J, 2001, J NEUROSCI, V21, P3721, DOI 10.1523/JNEUROSCI.21-11-03721.2001; Reid CA, 1997, J NEUROSCI, V17, P2738; REUTER H, 1995, NEURON, V14, P773, DOI 10.1016/0896-6273(95)90221-X; SAHARA Y, 1993, J NEUROSCI, V13, P3041; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; SCHOLZ KP, 1995, J NEUROSCI, V15, P4612; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; Simen AA, 2001, J NEUROSCI, V21, P7587, DOI 10.1523/JNEUROSCI.21-19-07587.2001; Stowell JN, 1999, NEURON, V22, P525, DOI 10.1016/S0896-6273(00)80707-2; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; Vazquez E, 1997, EUR J NEUROSCI, V9, P2009, DOI 10.1111/j.1460-9568.1997.tb01369.x; VIGERS AJ, 1991, DEV BRAIN RES, V60, P197, DOI 10.1016/0165-3806(91)90048-N; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wheeler DB, 1996, J NEUROSCI, V16, P2226; Wu LG, 1999, J NEUROSCI, V19, P726; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhang JF, 1996, NEURON, V17, P991, DOI 10.1016/S0896-6273(00)80229-9	48	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23955	23962		10.1074/jbc.M211471200	http://dx.doi.org/10.1074/jbc.M211471200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692128	hybrid			2022-12-25	WOS:000183638600094
J	Lai, JP; Chien, J; Staub, J; Avula, R; Greene, EL; Matthews, TA; Smith, DI; Kaufmann, SH; Roberts, LR; Shridhar, V				Lai, JP; Chien, J; Staub, J; Avula, R; Greene, EL; Matthews, TA; Smith, DI; Kaufmann, SH; Roberts, LR; Shridhar, V			Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CLEAR-CELL CARCINOMA; PLATINUM-BASED CHEMOTHERAPY; DISTINCT HISTOLOGIC TYPE; HUMAN OVARIAN-CANCER; FIBROBLAST-GROWTH; SULFATE PROTEOGLYCANS; CLINICAL CHARACTERISTICS; POOR-PROGNOSIS; EGF RECEPTOR	Emerging data suggest that signaling by heparin-binding growth factors is influenced by the sulfation state of N-acetylglucosamine residues of heparan sulfate proteoglycans (HSPGs). Here we report that the recently identified protein HSulf-1, a heparin-degrading endosulfatase, encodes a cell surface-associated enzyme that diminishes sulfation of cell surface HSPGs. The message encoding this enzyme is readily detectable in a variety of normal tissues, including normal ovarian surface epithelial cells, but is undetectable in 5 of 7 ovarian carcinoma cell lines and markedly diminished or undetectable in similar to75% of ovarian cancers. Similar down-regulation is also observed in breast, pancreatic, renal cells, and hepatocellular carcinoma lines. Re-expression of HSulf-1 in ovarian cancer cell lines resulted in diminished HSPG sulfation, diminished phosphorylation of receptor tyrosine kinases that require sulfated HSPGs as co-receptors for their cognate ligands, and diminished downstream signaling through the extracellular signal-regulated kinase pathway after treatment with fibroblast growth factor-2 or heparin-binding epidermal growth factor. Consistent with these changes, HSulf-1 re-expression resulted in reduced proliferation as well as sensitivity to induction of apoptosis by the broad spectrum kinase inhibitor staurosporine and the chemotherapeutic agent cisplatin. Collectively, these observations provide evidence that HSulf-1 modulates signaling by heparin-binding growth factors, and HSulf-1 down-regulation represents a novel mechanism by which cancer cells can enhance growth factor signaling.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Nephrol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.		Seal, Sudipta/A-7698-2012; Chien, Jeremy/AID-8939-2022	Kaufmann, Scott/0000-0002-4900-7145; Chien, Jeremy/0000-0003-4744-8374; Roberts, Lewis/0000-0001-7885-8574				AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; Behbakht K, 1998, GYNECOL ONCOL, V70, P255, DOI 10.1006/gyno.1998.5071; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Clayton A, 2001, KIDNEY INT, V59, P2084, DOI 10.1046/j.1523-1755.2001.00723.x; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Delehedde M, 2002, BIOCHEM J, V366, P235, DOI 10.1042/BJ20011718; Dent P, 2001, CLIN CANCER RES, V7, P775; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; DIBLASIO AM, 1993, AM J OBSTET GYNECOL, V169, P1517, DOI 10.1016/0002-9378(93)90428-L; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; GALLAGHER JT, 1992, GLYCOBIOLOGY, V2, P523, DOI 10.1093/glycob/2.6.523; Gescher A, 2000, CRIT REV ONCOL HEMAT, V34, P127, DOI 10.1016/S1040-8428(00)00058-5; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gilmour LMR, 2001, CANCER RES, V61, P2169; Goff BA, 1996, GYNECOL ONCOL, V60, P412, DOI 10.1006/gyno.1996.0065; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Lepique AP, 2000, ENDOCR RES, V26, P825, DOI 10.3109/07435800009048605; Liu DF, 2002, SEMIN THROMB HEMOST, V28, P67, DOI 10.1055/s-2002-20565; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MIAO HQ, 1995, J CELL BIOCHEM, V57, P173, DOI 10.1002/jcb.240570202; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Ozols RF, 2000, SEMIN ONCOL, V27, P47; OZOLS RF, 2000, PRINCIPLES PRACTICE; Persons DL, 1999, CLIN CANCER RES, V5, P1007; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reynolds CM, 2002, HYPERTENSION, V39, P525, DOI 10.1161/hy0202.103076; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Shin EY, 2002, J CANCER RES CLIN, V128, P596, DOI 10.1007/s00432-002-0388-4; Shridhar V, 2002, CANCER RES, V62, P262; SOULE HD, 1990, CANCER RES, V50, P6075; Stoffel K. H. W., 1993, BIOL CHEM HOPPESEYLE, V374, P166; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; Wang J, 2002, INT J CANCER, V97, P163, DOI 10.1002/ijc.1593; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	62	197	207	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23107	23117		10.1074/jbc.M302203200	http://dx.doi.org/10.1074/jbc.M302203200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12686563	hybrid			2022-12-25	WOS:000183503900119
J	Rye, KA; Wee, K; Curtiss, LK; Bonnet, DJ; Barter, PJ				Rye, KA; Wee, K; Curtiss, LK; Bonnet, DJ; Barter, PJ			Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; GRADIENT GEL-ELECTROPHORESIS; ESTER TRANSFER PROTEIN; PRE-BETA; PLASMA-LIPOPROTEINS; SALT BRIDGES; APOA-I; CONFORMATION; DISSOCIATION; ASSOCIATION	The high density lipoproteins ( HDL) in human plasma are classified on the basis of apolipoprotein composition into those containing apolipoprotein ( apo) A- I but not apoA- II, ( A- I) HDL, and those containing both apoA- I and apoA- II, ( A- I/ A- II) HDL. Cholesteryl ester transfer protein ( CETP) transfers core lipids between HDL and other lipoproteins. It also remodels ( A- I) HDL into large and small particles in a process that generates lipid- poor, pre-beta-migrating apoA- I. Lipid- poor apoA- I is the initial acceptor of cellular cholesterol and phospholipids in reverse cholesterol transport. The aim of this study is to determine whether lipid- poor apoA- I is also formed when ( A- I/ A-II) rHDL are remodeled by CETP. Spherical reconstituted HDL that were identical in size had comparable lipid/ apolipoprotein ratios and either contained apoA- I only, ( A- I) rHDL, or ( A- I/ A- II) rHDL were incubated for 0 - 24 h with CETP and Intralipid (R). At 6 h, the apoA- I content of the ( A- I) rHDL had decreased by 25% and there was a concomitant formation of lipid- poor apoA- I. By 24 h, all of the ( A- I) rHDL were remodeled into large and small particles. CETP remodeled similar to 32% ( A- I/ A- II) rHDL into small but not large particles. Lipid- poor apoA- I did not dissociate from the ( A- I/ A- II) rHDL. The reasons for these differences were investigated. The binding of monoclonal antibodies to three epitopes in the C- terminal domain of apoA- I was decreased in ( A- I/ A- II) rHDL compared with ( A- I) rHDL. When the ( A- I/ A- II) rHDL were incubated with Gdn- HCl at pH 8.0, the apoA- I unfolded by 15% compared with 100% for the apoA- I in ( A- I) rHDL. When these incubations were repeated at pH 4.0 and 2.0, the apoA- I in the ( A- I) rHDL and the ( A- I/ A- II) rHDL unfolded completely. These results are consistent with salt bridges between apoA- II and the C- terminal domain of apoA- I, enhancing the stability of apoA- I in ( A- I/ A- II) rHDL and possibly contributing to the reduced remodeling and absence of lipid poor apoA- I in the ( A- I/ A- II) rHDL incubations.	Hanson Inst, Lipid Res Lab, Adelaide, SA 5000, Australia; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Adelaide, Dept Med, Royal Adelaide Hosp, Adelaide, SA 5000, Australia	Hanson Institute; Scripps Research Institute; Royal Adelaide Hospital; University of Adelaide	Rye, KA (corresponding author), Hanson Inst, Lipid Res Lab, Adelaide, SA 5000, Australia.							Benetollo C, 1996, EUR J BIOCHEM, V242, P657, DOI 10.1111/j.1432-1033.1996.0657r.x; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Brites FD, 2000, ATHEROSCLEROSIS, V152, P181, DOI 10.1016/S0021-9150(99)00452-9; BURSTEIN M, 1970, J LIPID RES, V11, P583; Calabresi L, 1996, BBA-LIPID LIPID MET, V1304, P32, DOI 10.1016/S0005-2760(96)00102-6; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; Curtiss LK, 2000, BIOCHEMISTRY-US, V39, P5712, DOI 10.1021/bi992902m; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8959; HENNESSY LK, 1993, BIOCHEMISTRY-US, V32, P5759, DOI 10.1021/bi00073a006; Holvoet P, 1996, J BIOL CHEM, V271, P19395, DOI 10.1074/jbc.271.32.19395; HOPKINS GJ, 1982, METABOLISM, V31, P78, DOI 10.1016/0026-0495(82)90048-8; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; JONAS A, 1989, J BIOL CHEM, V264, P4818; KINOSHITA M, 1993, J LIPID RES, V34, P261; Laccotripe M, 1997, J BIOL CHEM, V272, P17511, DOI 10.1074/jbc.272.28.17511; LI ZL, 1994, J LIPID RES, V35, P1698; LIANG HQ, 1994, J LIPID RES, V35, P1187; LINS L, 1995, BBA-LIPID LIPID MET, V1258, P10, DOI 10.1016/0005-2760(95)00080-V; MATZ CE, 1982, J BIOL CHEM, V257, P4535; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PIRAN U, 1979, J LIPID RES, V20, P1040; RYE KA, 1994, J BIOL CHEM, V269, P10298; Rye KA, 1996, J BIOL CHEM, V271, P4243; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; Rye KA, 2002, BIOCHEMISTRY-US, V41, P12538, DOI 10.1021/bi025998k; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Sheldahl C, 1999, BIOPHYS J, V76, P1190, DOI 10.1016/S0006-3495(99)77283-8; Shiroishi M, 2001, J BIOL CHEM, V276, P23042, DOI 10.1074/jbc.M100480200; Sot B, 2002, J BIOL CHEM, V277, P34024, DOI 10.1074/jbc.M205733200; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; SUBBAIAH PV, 1988, BIOCHIM BIOPHYS ACTA, V963, P445, DOI 10.1016/0005-2760(88)90313-X; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; VEZINA CA, 1988, J LIPID RES, V29, P573	37	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22530	22536		10.1074/jbc.M213250200	http://dx.doi.org/10.1074/jbc.M213250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12690114	hybrid			2022-12-25	WOS:000183503900049
J	Yuge, S; Inoue, K; Hyodo, S; Takei, Y				Yuge, S; Inoue, K; Hyodo, S; Takei, Y			A novel guanylin family (guanylin, uroguanylin, and renoguanylin) in eels - Possible osmoregulatory hormones in intestine and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-PEPTIDE; ENTEROCHROMAFFIN CELLS; GOBLET CELLS; WATER-INTAKE; EXPRESSION; CYCLASE; CLONING; RECEPTORS; PROUROGUANYLIN; ADAPTATION	As the intestine is an essential organ for fish osmoregulation, the intestinal hormone guanylins may perform major functions, especially in euryhaline fish such as eels and salmonids. From the intestine of an eel, we identified cDNAs encoding three distinct guanylin- like peptides. Based on the sequence of mature peptide and sites of production, we named them guanylin, uroguanylin, and renoguanylin. Renoguanylin is a novel peptide that possesses the characteristics of both guanylin and uroguanylin and was abundantly expressed in the kidney. By immunohistochemistry, guanylin was localized exclusively in goblet cells, but not enterochromaffin cells, of the intestine. After transfer of eels from fresh water to seawater, mRNA expression of guanylin and uroguanylin did not change for 3 h, but it increased after 24 h. The increase was profound ( 2 - 6- fold) after adaptation to seawater. The expression of uroguanylin was also up- regulated in the kidney of seawater- adapted eels, but that of renoguanylin was not so prominent as other guanylins in both intestine and kidney. Collectively, the novel eel guanylin family appears to have important functions for seawater adaptation, particularly long- term adaptation. Eel guanylin may be secreted from goblet cells into the lumen with mucus in response to increased luminal osmolality and act on the epithelium to regulate water and salt absorption.	Univ Tokyo, Ocean Res Inst, Physiol Lab, Nakano Ku, Tokyo 1648639, Japan	University of Tokyo	Yuge, S (corresponding author), Univ Tokyo, Ocean Res Inst, Physiol Lab, Nakano Ku, 1-15-1 Minamidai, Tokyo 1648639, Japan.	yuge@ori.u-tokyo.ac.jp	; Takei, Yoshio/R-2368-2017	Hyodo, Susumu/0000-0001-8146-2386; Takei, Yoshio/0000-0003-3004-8905				Ando M, 1996, J EXP BIOL, V199, P711; ANDO M, 1992, J COMP PHYSIOL B, V162, P436; CAREY RM, 1978, CIRC RES, V43, P19, DOI 10.1161/01.RES.43.1.19; CETIN Y, 1994, P NATL ACAD SCI USA, V91, P2935, DOI 10.1073/pnas.91.8.2935; Chino N, 1996, LETT PEPT SCI, V3, P45, DOI 10.1007/BF00131085; Comrie MM, 2001, BIOCHEM BIOPH RES CO, V281, P1078, DOI 10.1006/bbrc.2001.4485; Comrie MR, 2001, COMP BIOCHEM PHYS B, V129, P575, DOI 10.1016/S1096-4959(01)00367-0; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; CUTLER CP, 2000, WATER TRANSPORT AQUA, P433; Evans David H., 1993, P315; Fan XH, 1997, ENDOCRINOLOGY, V138, P4636, DOI 10.1210/en.138.11.4636; Fan XH, 1996, BIOCHEM BIOPH RES CO, V219, P457, DOI 10.1006/bbrc.1996.0255; Fonteles MC, 1998, AM J PHYSIOL-RENAL, V275, pF191, DOI 10.1152/ajprenal.1998.275.2.F191; Forte LR, 2000, AM J PHYSIOL-RENAL, V278, pF180, DOI 10.1152/ajprenal.2000.278.2.F180; Forte LR, 1999, ENDOCRINOLOGY, V140, P1800, DOI 10.1210/en.140.4.1800; Forte LR, 2000, ANNU REV PHYSIOL, V62, P673, DOI 10.1146/annurev.physiol.62.1.673; Forte LR, 1997, FASEB J, V11, P1724; Furuya S, 1998, ANAT EMBRYOL, V197, P359, DOI 10.1007/s004290050146; Gay E, 2000, BIOCHEM BIOPH RES CO, V267, P509, DOI 10.1006/bbrc.1999.2000; Hamra FK, 1996, ENDOCRINOLOGY, V137, P257, DOI 10.1210/en.137.1.257; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; HIRANO T, 1974, J EXP BIOL, V61, P737; HIRANO T, 1976, INTESTINAL ION TRANS, P301; Kita T, 1999, AM J PHYSIOL-GASTR L, V277, pG960, DOI 10.1152/ajpgi.1999.277.5.G960; KRAUSE WJ, 1995, ACTA ANAT, V153, P210; Krause WJ, 1997, GEN COMP ENDOCR, V107, P229, DOI 10.1006/gcen.1997.6921; Li ZP, 1996, GASTROENTEROLOGY, V111, P1714, DOI 10.1016/S0016-5085(96)70037-9; LI ZP, 1995, GASTROENTEROLOGY, V109, P1863, DOI 10.1016/0016-5085(95)90753-X; London RM, 1999, AM J PHYSIOL-RENAL, V276, pF882, DOI 10.1152/ajprenal.1999.276.6.F882; Loretz CA, 1997, BIOCHEM BIOPH RES CO, V238, P817, DOI 10.1006/bbrc.1997.7369; Loretz CA, 1997, FISH PHYSIOL BIOCHEM, V17, P319, DOI 10.1023/A:1007772925951; Miyazato M, 1996, FEBS LETT, V398, P170, DOI 10.1016/S0014-5793(96)01235-5; Nakazato M, 1996, BIOCHEM BIOPH RES CO, V220, P586, DOI 10.1006/bbrc.1996.0447; Nakazato M, 2001, J GASTROENTEROL, V36, P219, DOI 10.1007/s005350170106; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Perkins A, 1997, GASTROENTEROLOGY, V113, P1007, DOI 10.1016/S0016-5085(97)70198-7; Potthast R, 2001, ENDOCRINOLOGY, V142, P3087, DOI 10.1210/en.142.7.3087; RANKIN JC, 1981, ANIMAL OSMOREGULATIO, P201; Schulz A, 1999, PROTEIN SCI, V8, P1850, DOI 10.1110/ps.8.9.1850; Schulz A, 1998, J PEPT RES, V52, P518; SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183; Takei Y, 2002, AM J PHYSIOL-REG I, V282, pR940, DOI 10.1152/ajpregu.00389.2001; Takei Y, 2001, AM J PHYSIOL-REG I, V280, pR1727, DOI 10.1152/ajpregu.2001.280.6.R1727; Takei Y, 1998, ZOOL SCI, V15, P677, DOI 10.2108/zsj.15.677; Tsuchida T, 1998, AM J PHYSIOL-REG I, V275, pR1605, DOI 10.1152/ajpregu.1998.275.5.R1605; YAMAMOTO M, 1978, CELL TISSUE RES, V192, P25; YUI R, 1988, ARCH HISTOL CYTOL, V51, P109, DOI 10.1679/aohc.51.109; YUI R, 1990, CELL TISSUE RES, V260, P193, DOI 10.1007/BF00297505	48	57	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22726	22733		10.1074/jbc.M303111200	http://dx.doi.org/10.1074/jbc.M303111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12684514	hybrid			2022-12-25	WOS:000183503900074
J	Comerford, SA; Clouthier, DE; Hinnant, EA; Hammer, RE				Comerford, SA; Clouthier, DE; Hinnant, EA; Hammer, RE			Induction of hepatocyte proliferation and death by modulation of T-Antigen expression	ONCOGENE			English	Article						T-Antigen; apoptosis; Fas; caspase; Akt; hepatocytes	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; NF-KAPPA-B; ZINC-FINGER PROTEIN; TRANSGENIC MICE; INDUCED APOPTOSIS; CELL-DEATH; CYTOCHROME-C; DIFFERENTIAL REGULATION; DEPENDENT APOPTOSIS; GENE-EXPRESSION	Mice expressing SV40 T-Antigen in liver under control of the phosphoenolpyruvate carboxykinase promoter were generated. By altering the carbohydrate content of the diet, TAg expression, the rate of hepatocyte proliferation and apoptosis, and hence hepatocarcinogenesis, could be regulated. Carbohydrate-mediated suppression of TAg resulted in slow hepatic growth that progressed to focal hepatocellular carcinoma (HCC) after a long latency period. In contrast, induction of TAg by feeding mice a low carbohydrate diet resulted in massive hepatomegaly that progressed rapidly to diffuse multifocal HCC. Hepatic TAg expression could be efficiently repressed by switching mice from the tow to the high-carbohydrate diet, which if instigated prior to the development of HCC, resulted in rapid regression through a p53-independent reduction in hepatocyte proliferation and an increase in hepatocyte apoptosis. Although liver growth was accompanied by compensatory hepatocyte apoptosis, an apoptotic deficit developed following chronic exposure to high levels of TAg. This was associated with Akt phosphorylation and increased expression of the antiapoptotic molecules bfl-1/A1, TIAP, and A20. Mice were resistant to Fas-induced hepatocellular apoptosis due to severely impaired caspase activation and failed activation of the mitochondrial amplification loop. This model will be useful to investigate oncogene-mediated disruption of the cell cycle and apoptosis, and to determine which processes constitute fixed, or reversible aspects of the tumorigenic process.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammer, RE (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551; Comerford, Sarah Ann/0000-0002-7452-7759	NIDDK NIH HHS [DK 53789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053789] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Arvelo MB, 2002, HEPATOLOGY, V35, P535, DOI 10.1053/jhep.2002.31309; BEALE EG, 1985, J BIOL CHEM, V260, P748; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Cole SL, 2002, J VIROL, V76, P8420, DOI 10.1128/JVI.76.16.8420-8432.2002; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Gillet R, 2001, BIOCHEM BIOPH RES CO, V284, P369, DOI 10.1006/bbrc.2001.4988; GIRARD J, 1986, BIOL NEONATE, V50, P237, DOI 10.1159/000242605; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MERLINO G, 1994, CANCER INVEST, V12, P203, DOI 10.3109/07357909409024875; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; ROUQUET N, 1995, ONCOGENE, V11, P1061; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; ZIMMER DB, 1990, J HISTOCHEM CYTOCHEM, V38, P171, DOI 10.1177/38.2.1688895; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	74	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2515	2530		10.1038/sj.onc.1206259	http://dx.doi.org/10.1038/sj.onc.1206259			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717428				2022-12-25	WOS:000182383500014
J	MacGillivray, M; Herrera-Abreu, MT; Chow, CW; Shek, C; Wang, Q; Vachon, E; Feng, GS; Siminovitch, KA; McCulloch, CAG; Downey, GP				MacGillivray, M; Herrera-Abreu, MT; Chow, CW; Shek, C; Wang, Q; Vachon, E; Feng, GS; Siminovitch, KA; McCulloch, CAG; Downey, GP			The protein tyrosine phosphatase SHP-2 regulates interleukin-1-induced ERK activation in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FOCAL ADHESION COMPLEXES; FACTOR RECEPTOR-BETA; OXIDE SYNTHASE GENE; GROWTH-FACTOR; IL-1 RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; RHEUMATOID-ARTHRITIS; KINASE ACTIVATION; BINDING-SITE	Focal adhesion complexes are actin-rich, cytoskeletal structures that mediate cell adhesion to the substratum and also selectively regulate signal transduction pathways required for interleukin (IL)-1beta signaling to the MAP kinase, ERK. IL-1-induced ERK activation is markedly diminished in fibroblasts deprived of focal adhesions whereas activation of p38 and JNK is unaffected. While IL-1 signaling is known to involve the activity of protein and lipid kinases including MAP kinases, FAK, and PI3K, little is known about the role of phosphatases in the regulation of IL-1 signal generation and attenuation. Here we demonstrate that SHP-2, a protein tyrosine phosphatase present in focal adhesions, modulates IL-1-induced ERK activation and the transient actin stress fiber disorganization that occurs following IL-1 treatment in human gingival fibroblasts. Using a combination of immunoblotting, immunoprecipitation, and immunostaining we show that SHP-2 is present in nascent focal adhesions and undergoes phosphorylation on tyrosine 542 in response to IL-1 stimulation. Blocking anti-SHP-2 antibodies, electoporated into the cytosol of fibroblasts, inhibited IL-1-induced ERK activation, actin filament assembly, and cell contraction, indicating a role for SHP-2 in these processes. In summary, our data indicate that SHP-2, a focal adhesion-associated protein, participates in IL-1-induced ERK activation likely via an adaptor function.	Univ Hlth Network, Toronto Gen Hosp, Res Inst, Dept Med,Div Respirol, Toronto, ON M5S 1A8, Canada; Burnham Inst, La Jolla, CA 92037 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Sanford Burnham Prebys Medical Discovery Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Downey, GP (corresponding author), Univ Toronto, Div Clin Sci, Rm 6264,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Siminovitch, Katherine/K-1475-2013; Chow, Chung-Wai/AAP-5533-2020	Chow, Chung-Wai/0000-0001-9344-8522; Downey, Gregory P/0000-0003-3253-5862				Aplin AE, 1999, J CELL SCI, V112, P695; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Caron JP, 1996, AM J VET RES, V57, P1631; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Cunnick JM, 2002, J BIOL CHEM, V277, P9498, DOI 10.1074/jbc.M110547200; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DeMali KA, 1999, J BIOL CHEM, V274, P19551, DOI 10.1074/jbc.274.28.19551; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; EDEN E, 1986, J CLIN IMMUNOL, V6, P326, DOI 10.1007/BF00917334; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hamid QA, 2000, CYTOKINE, V12, P1609, DOI 10.1006/cyto.2000.0676; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; KANNO K, 1993, HYPERTENSION, V22, P34, DOI 10.1161/01.HYP.22.1.34; Kim H, 1999, MOL CELL BIOL, V19, P5326; KUMKUMIAN GK, 1989, J IMMUNOL, V143, P833; Laporte JD, 1999, AM J PHYSIOL-LUNG C, V277, pL943, DOI 10.1152/ajplung.1999.277.5.L943; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; LUBINSKI J, 1988, J IMMUNOL, V140, P1903; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; Manes S, 1999, MOL CELL BIOL, V19, P3125; Matthews JS, 1999, CYTOKINE, V11, P643, DOI 10.1006/cyto.1998.0478; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; Strack V, 2002, BIOCHEMISTRY-US, V41, P603, DOI 10.1021/bi011327v; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; TSUJINO M, 1994, CIRCULATION, V90, P375, DOI 10.1161/01.CIR.90.1.375; Valles S, 2002, LAB INVEST, V82, P855, DOI 10.1097/01.LAB.0000020420.07575.3F; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; WARNER JA, 1987, J IMMUNOL, V139, P161; Wesche H, 1998, FEBS LETT, V429, P303, DOI 10.1016/S0014-5793(98)00468-2; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Xu FP, 2001, J BIOL CHEM, V276, P29479, DOI 10.1074/jbc.M104428200; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yucel-Lindberg T, 1999, BIOCHEM BIOPH RES CO, V257, P528, DOI 10.1006/bbrc.1999.0523; Zhu P, 1998, BIOCHEM J, V330, P975, DOI 10.1042/bj3300975	63	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27190	27198		10.1074/jbc.M213083200	http://dx.doi.org/10.1074/jbc.M213083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12721296	hybrid			2022-12-25	WOS:000184155700114
J	Akhtar, MS; Bhakuni, V				Akhtar, MS; Bhakuni, V			Streptococcus pneumoniae hyaluronate lyase contains two noncooperative independent folding/unfolding structural domains - Characterization of functional domain and inhibitors of enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.7 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; ENCODING PNEUMOLYSIN; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; GENE; CLONING; EXPRESSION; DEGRADATION; PROTEINS	Hyaluronate lyase contributes directly to bacterial invasion by degrading hyaluronan, the major component of host extracellular matrix of connective tissues. Streptococcus pneumoniae hyaluronate lyase (SpnHL) is built from two structural domains that interact through interface residues, in addition to being connected by a peptide linker. For the first time we demonstrate that the N- and C-terminal domains of SpnHL fold/unfold independent of each other suggesting the absence of any significant cooperative interactions between them. The C-terminal domain of SpnHL is less stable than the N-terminal domain against thermal and guanidine hydrochloride denaturation. The intact N- terminal domain was purified after limited proteolysis of SpnHL under conditions where only the C-terminal domain was unfolded. Isolated N-terminal domain of SpnHL had similar thermal stability as when present in the native enzyme and was found to be enzymatically active demonstrating that it is capable of carrying out enzymatic reaction on its own. Functional studies demonstrated that guanidine hydrochloride, guanidine isothiocyanate, L-arginine methyl ester, and L-arginine inhibit the enzymatic activity of SpnHL at very low concentrations. This provides a lead for new chemical entities that can be exploited for designing effective inhibitors of SpnHL.	Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI)	Bhakuni, V (corresponding author), Cent Drug Res Inst, Div Mol & Struct Biol, Lucknow 226001, Uttar Pradesh, India.	bhakuniv@rediffmail.com	Akhtar, Sohail/A-2300-2010					Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P7142, DOI 10.1021/bi020080e; Berry AM, 2000, INFECT IMMUN, V68, P133, DOI 10.1128/IAI.68.1.133-140.2000; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; FARRELL AM, 1995, FEMS MICROBIOL LETT, V130, P81, DOI 10.1016/0378-1097(95)00187-A; FELDMAN C, 1991, AM J RESP CELL MOL, V5, P416, DOI 10.1165/ajrcmb/5.5.416; Fethiere J, 1999, J MOL BIOL, V288, P635, DOI 10.1006/jmbi.1999.2698; GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JOHNSTON RB, 1991, REV INFECT DIS, V13, pS509; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P15125, DOI 10.1074/jbc.M011102200; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; LIN B, 1994, J BIOL CHEM, V269, P30113; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; MUFSON MA, 1990, PRINCIPLES PRACTICE, P1539; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; Park Y, 1997, BBA-PROTEIN STRUCT M, V1337, P217, DOI 10.1016/S0167-4838(96)00167-7; PATON JC, 1986, INFECT IMMUN, V54, P50, DOI 10.1128/IAI.54.1.50-55.1986; Ponnuraj K, 2000, J MOL BIOL, V299, P885, DOI 10.1006/jmbi.2000.3817; Prakash K, 2002, PROTEIN SCI, V11, P46, DOI 10.1110/ps.ps.20102; Pritchard DG, 2000, PROTEINS, V40, P126; PRITCHARD DG, 1994, ARCH BIOCHEM BIOPHYS, V315, P431, DOI 10.1006/abbi.1994.1521; Rolland K, 1999, J CLIN MICROBIOL, V37, P1892, DOI 10.1128/JCM.37.6.1892-1898.1999; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; Steiner B, 1997, CAN J MICROBIOL, V43, P315, DOI 10.1139/m97-044; Yoon HJ, 1999, J MOL BIOL, V290, P505, DOI 10.1006/jmbi.1999.2883	29	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25509	25516		10.1074/jbc.M301894200	http://dx.doi.org/10.1074/jbc.M301894200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12719417	hybrid			2022-12-25	WOS:000183920200031
J	Mukhopadhyay, R; Zhou, Y; Rosen, BP				Mukhopadhyay, R; Zhou, Y; Rosen, BP			Directed evolution of a yeast arsenate reductase into a protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; DETOXIFICATION; PURIFICATION; INHIBITION; MECHANISM; POTENT; ACR2P; 1B	Arsenic, which is ubiquitous in the environment and comes from both geochemical and anthropogenic sources, has become a worldwide public health problem. Every organism studied has intrinsic or acquired mechanisms for arsenic detoxification. In Saccharomyces cerevisiae arsenate is detoxified by Acr2p, an arsenate reductase. Acr2p is not a phosphatase but is a homologue of CDC25 phosphatases. It has the HCX5R phosphatase motif but not the glycine-rich phosphate binding motif (GXGXXG) that is found in protein-tyrosine phosphatases. Here we show that creation of a phosphate binding motif through the introduction of glycines at positions 79, 81, and 84 in Acr2p resulted in a gain of phosphotyrosine phosphatase activity and a loss of arsenate reductase activity. Arsenate likely achieved geochemical abundance only after the atmosphere became oxidizing, creating pressure for the evolution of an arsenate reductase from a protein-tyrosine phosphatase. The ease by which an arsenate reductase can be converted into a protein-tyrosine phosphatase supports this hypothesis.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Mukhopadhyay, R (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.			Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; Bennett MS, 2001, P NATL ACAD SCI USA, V98, P13577, DOI 10.1073/pnas.241397198; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; Bordo D, 2002, EMBO REP, V3, P741, DOI 10.1093/embo-reports/kvf150; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Keng YF, 1999, EUR J BIOCHEM, V259, P809, DOI 10.1046/j.1432-1327.1999.00090.x; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; Martin P, 2001, STRUCTURE, V9, P1071, DOI 10.1016/S0969-2126(01)00672-4; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; Mukhopadhyay R, 2002, ENVIRON HEALTH PERSP, V110, P745, DOI 10.1289/ehp.02110s5745; Mukhopadhyay R, 1998, FEMS MICROBIOL LETT, V168, P127, DOI 10.1016/S0378-1097(98)00430-3; Mukhopadhyay R, 2001, J BIOL CHEM, V276, P34738, DOI 10.1074/jbc.M103354200; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; Pathak MK, 2001, J IMMUNOL, V167, P3391, DOI 10.4049/jimmunol.167.6.3391; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sambrook J., 2002, MOL CLONING LAB MANU; Skorey K, 1997, J BIOL CHEM, V272, P22472, DOI 10.1074/jbc.272.36.22472; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Wang QP, 1999, BBA-PROTEIN STRUCT M, V1431, P14, DOI 10.1016/S0167-4838(99)00042-4; Zegers I, 2001, NAT STRUCT BIOL, V8, P843, DOI 10.1038/nsb1001-843; Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	31	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24476	24480		10.1074/jbc.M302610200	http://dx.doi.org/10.1074/jbc.M302610200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12711608	hybrid			2022-12-25	WOS:000183824800029
J	Rossi, SG; Dickerson, IM; Rotundo, RL				Rossi, SG; Dickerson, IM; Rotundo, RL			Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; LOCAL NEUROGENIC REGULATION; CHICK SKELETAL-MUSCLE; CYCLIC-AMP; MOLECULAR-FORMS; END-PLATE; MYOTUBES; CGRP; ALPHA; PHOSPHORYLATION	The calcitonin gene-related peptide (CGRP) is released by motor neurons where it exerts both short and long term effects on skeletal muscle fibers. In addition, sensory neurons release CGRP on the surrounding vasculature where it is in part responsible for local vasodilation following muscle contraction. Although CGRP-binding sites have been demonstrated in whole muscle tissue, the type of CGRP receptor and its associated proteins or its cellular localization within the tissue have not been described. Here we show that the CGRP-binding protein referred to as the calcitonin receptor-like receptor is highly concentrated at the avian neuromuscular junction together with its two accessory proteins, receptor activity modifying protein 1 and CGRP-receptor component protein, required for ligand specificity and signal transduction. Using tissue-cultured skeletal muscle we show that CGRP stimulates an increase in intracellular cAMP that in turn initiates down-regulation of acetylcholinesterase expression at the transcriptional level, and, more specifically, inhibits expression of the synaptically localized collagen-tailed form of the enzyme. Together, these studies suggest a specific role for CGRP released by spinal cord motoneurons in modulating synaptic transmission at the neuromuscular junction by locally inhibiting the expression of acetylcholinesterase, the enzyme responsible for terminating acetylcholine neurotransmission.	Univ Miami, Sch Med, Dept Cell Biol & Anat R124, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33101 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33101 USA	University of Miami; University of Miami; University of Miami	Rotundo, RL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, POB 016960, Miami, FL 33101 USA.	rrotundo@miami.edu		Dickerson, Ian/0000-0002-2480-0606	NIA NIH HHS [R01 AG005917, AG05917] Funding Source: Medline; NIDDK NIH HHS [R01 DK052328, DK052328] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052328] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARDEN WA, 1994, NEUROPEPTIDES, V27, P39, DOI 10.1016/0143-4179(94)90015-9; ASAHINA A, 1995, P NATL ACAD SCI USA, V92, P8323, DOI 10.1073/pnas.92.18.8323; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; Buffelli M, 2001, NEUROSCIENCE, V104, P561, DOI 10.1016/S0306-4522(01)00090-2; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHANGEUX JP, 1992, ANN NY ACAD SCI, V657, P361, DOI 10.1111/j.1749-6632.1992.tb22783.x; Choi RCY, 1998, J NEUROCHEM, V71, P152; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; Choi RCY, 1996, NEUROSCI LETT, V217, P165, DOI 10.1016/0304-3940(96)13102-5; Disa J, 2000, NEUROPEPTIDES, V34, P229, DOI 10.1054/npep.2000.0810; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Evans BN, 2000, J BIOL CHEM, V275, P31438, DOI 10.1074/jbc.M005604200; Fernandez HL, 1996, J APPL PHYSIOL, V80, P357, DOI 10.1152/jappl.1996.80.1.357; Fernandez HL, 1999, BRAIN RES, V844, P83, DOI 10.1016/S0006-8993(99)01891-0; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; FONTAINE B, 1986, NEUROSCI LETT, V71, P59, DOI 10.1016/0304-3940(86)90257-0; HALL ZW, 1973, J NEUROBIOL, V4, P343, DOI 10.1002/neu.480040404; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HALL ZW, 1971, NATURE-NEW BIOL, V232, P62, DOI 10.1038/newbio232062a0; HODGESSAVOLA CA, 1995, NEUROSCI LETT, V190, P117, DOI 10.1016/0304-3940(95)11517-Z; HOFFMAN PW, 1994, J NEUROSCI, V14, P4185; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JANSEN JKS, 1990, PROG NEUROBIOL, V34, P39, DOI 10.1016/0301-0082(90)90025-C; JENNINGS CGB, 1989, BRAIN RES, V504, P199, DOI 10.1016/0006-8993(89)91357-7; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; JUNIORPERIOD LVD, 2001, BRIT J PHARMACOL, V133, P229; LAUFER R, 1989, J BIOL CHEM, V264, P2683; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LU B, 1993, NATURE, V363, P76, DOI 10.1038/363076a0; Lu JT, 1999, MOL CELL NEUROSCI, V14, P99, DOI 10.1006/mcne.1999.0767; LWEBUGAMUKASA JS, 1976, BIOCHEMISTRY-US, V15, P1425, DOI 10.1021/bi00652a012; MAGGI CA, 1995, J AUTON PHARMACOL, V15, P403, DOI 10.1111/j.1474-8673.1995.tb00406.x; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATTEOLI M, 1990, NEUROSCIENCE, V37, P271, DOI 10.1016/0306-4522(90)90213-N; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MILES K, 1987, P NATL ACAD SCI USA, V84, P6591, DOI 10.1073/pnas.84.18.6591; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; NEW HV, 1986, NATURE, V323, P809, DOI 10.1038/323809a0; PENG HB, 1989, J COMP NEUROL, V290, P533; Perkins GA, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-17; POPPER P, 1989, BRAIN RES, V496, P180, DOI 10.1016/0006-8993(89)91064-0; Prado MA, 2001, PEPTIDES, V22, P1773, DOI 10.1016/S0196-9781(01)00517-4; ROA M, 1991, NEUROSCIENCE, V41, P563, DOI 10.1016/0306-4522(91)90349-S; ROSSI SG, 1992, J CELL BIOL, V119, P1657, DOI 10.1083/jcb.119.6.1657; Rossi SG, 2000, J NEUROSCI, V20, P919, DOI 10.1523/JNEUROSCI.20-03-00919.2000; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; ROTUNDO RL, 1988, J BIOL CHEM, V263, P19398; ROTUNDO RL, 1980, CELL, V22, P595, DOI 10.1016/0092-8674(80)90369-4; ROTUNDO RL, 1984, J BIOL CHEM, V259, P3186; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; Rotundo RL, 1994, MYOLOGY, P607; SAKAGUCHI M, 1991, J PHYSIOL-LONDON, V434, P257, DOI 10.1113/jphysiol.1991.sp018468; SALA C, 1995, J NEUROSCI, V15, P520; Salminen S, 1999, TRENDS FOOD SCI TECH, V10, P107, DOI 10.1016/S0924-2244(99)00027-8; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sarkar A, 1997, J NEUROCHEM, V69, P455; SHYNG SL, 1991, NEURON, V6, P469, DOI 10.1016/0896-6273(91)90254-W; UCHIDA S, 1990, J NEUROCHEM, V54, P1000, DOI 10.1111/j.1471-4159.1990.tb02349.x; VANVALEN F, 1990, NEUROSCI LETT, V119, P195, DOI 10.1016/0304-3940(90)90832-T; XU RF, 1995, J CELL PHYSIOL, V165, P30, DOI 10.1002/jcp.1041650105; Yamada M, 1997, BRIT J PHARMACOL, V122, P710, DOI 10.1038/sj.bjp.0701423; Yamada M, 1997, BRIT J PHARMACOL, V122, P703, DOI 10.1038/sj.bjp.0701422	68	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24994	25000		10.1074/jbc.M211379200	http://dx.doi.org/10.1074/jbc.M211379200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707285	hybrid			2022-12-25	WOS:000183824800091
J	Ruffolo, SC; Shore, GC				Ruffolo, SC; Shore, GC			BCL-2 selectively interacts with the BID-induced open conformer of BAK, inhibiting BAK auto-oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; APOPTOSIS; PROTEIN; MITOCHONDRIA; FAMILY; LOCATION; CLEAVAGE; PATHWAY; DOMAIN; MEMBER	Caspase-8 cleaves BID to tBID, which targets mitochondria and induces oligomerization of BAX and BAK within the outer membrane, resulting in release of cytochrome c from the organelle. Here, we have initiated these steps in isolated mitochondria derived from control and BCL-2-overexpressing cells using synthetic BH3 peptides and subsequently analyzed the BCL members by chemical cross-linking. The results show that the BH3 domain of BID interacts with and induces an "open" conformation of BAK, exposing the BAK N terminus. This open ( activated) conformer of BAK potently induces oligomerization of non-activated ("closed") conformers, causing a cascade of BAK auto-oligomerization. Induction of the open conformation of BAK occurs even in the presence of excess BCL-2, but BCL-2 selectively interacts with this open conformer and blocks BAK oligomerization and cytochrome c release, dependent on the ratio of BID BH3 and BCL-2. This mechanism of inhibition by BCL-2 also occurs in intact cells stimulated with Fas or expressing tBID. Although BID BH3 interacts with both BCL-2 and BAK, the results indicate that when BCL-2 is in excess it can sequester the BID BH3-induced activated conformer of BAK, effectively blocking downstream events. This model suggests that the primary mechanism for BCL-2 blockade targets activated BAK rather than sequestering tBID.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Shore, GC (corresponding author), 3655 Promenade Sir William Osler,Rm 906B, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cuconati A, 2002, J VIROL, V76, P4547, DOI 10.1128/JVI.76.9.4547-4558.2002; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	39	123	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25039	25045		10.1074/jbc.M302930200	http://dx.doi.org/10.1074/jbc.M302930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12721291	hybrid			2022-12-25	WOS:000183824800097
J	Ueki, N; Hayman, MJ				Ueki, N; Hayman, MJ			Signal-dependent N-CoR requirement for repression by the Ski oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; ANAPHASE-PROMOTING COMPLEX; VITAMIN-D-RECEPTOR; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; COREPRESSOR COMPLEX; UBIQUITIN LIGASE; SMAD3; SNON; SMRT	The oncoprotein Ski represses transforming growth factor-beta (TGF-beta) and nuclear receptor signaling. To achieve this, Ski has been proposed to recruit the corepressor N-CoR to either the TGF-beta-regulated Smad transcription factors or nuclear receptors. Here we define the role of the Ski/N-CoR interaction in Ski-mediated repression of TGF-beta and vitamin D signaling. We show that Ski can negatively regulate vitamin D-mediated transcription by directly interacting with the vitamin D receptor. More importantly, a Ski single point mutant lacking N-CoR binding revealed that the Ski/N-CoR interaction is essential for repression of vitamin D signaling, but, surprisingly, not TGF-beta signaling. Thus, Ski modulates transcription in either an N-CoR-dependent or -independent manner depending on the signaling pathways targeted.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ueki, N (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; Glass CK, 2000, GENE DEV, V14, P121; Grossel MJ, 1999, NAT BIOTECHNOL, V17, P1232, DOI 10.1038/70792; Guenther MG, 2000, GENE DEV, V14, P1048; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Issa LL, 2001, ENDOCRINOLOGY, V142, P1606, DOI 10.1210/en.142.4.1606; Jepsen K, 2002, J CELL SCI, V115, P689; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; OLSSON I, 1983, CANCER RES, V43, P5862; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	39	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24858	24864		10.1074/jbc.M303447200	http://dx.doi.org/10.1074/jbc.M303447200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12716897	hybrid			2022-12-25	WOS:000183824800074
J	Derudder, E; Dejardin, E; Pritchard, LL; Green, DR; Korner, M; Baud, V				Derudder, E; Dejardin, E; Pritchard, LL; Green, DR; Korner, M; Baud, V			RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation - Critical roles for p100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BREAST-CANCER CELLS; DEFICIENT MICE; IKK-ALPHA; TRANSCRIPTIONAL ACTIVITY; MULTIORGAN INFLAMMATION; IMMUNE-RESPONSES; KINASE COMPLEX; EXPRESSION; PROTEINS	Tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-beta receptor (LTbetaR) signaling both play important roles in inflammatory and immune responses through activation of NF-kappaB. Using various deficient mouse embryonic fibroblast cells, we have compared the signaling pathways leading to NF-kappaB induction in response to TNF-alpha and LTbetaR activation. We demonstrate that LTbetaR ligation induces not only RelA/p50 dimers but also RelB/p50 dimers, whereas TNF-alpha induces only RelA/p50 dimers. LTbetaR-induced binding of RelB/p50 requires processing of p100 that is mediated by IKKalpha but is independent of IKKbeta, NEMO/IKKgamma, and RelA. Moreover, we show that RelB, p50, and p100 can associate in the same complex and that TNF-alpha but not LTbeta signaling increases the association of p100 with RelB/p50 dimers in the nucleus, leading to the specific inhibition of RelB DNA binding. These results suggest that the alternative NF-kappaB pathway based on p100 processing may account not only for the activation of RelB/p52 dimers but also for that of RelB/p50 dimers and that p100 regulates the binding activity of RelB/p50 dimers via at least two distinct mechanisms depending on the signaling pathway involved.	Inst Andre Lwoff, CNRS, UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, F-94801 Villejuif, France; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Centre National de la Recherche Scientifique (CNRS); La Jolla Institute for Immunology	Korner, M (corresponding author), Inst Andre Lwoff, CNRS, UPR 9079, Lab Oncogenese Differenciat & Transduct Signal, 7 Rue Guy Moquet, F-94801 Villejuif, France.		Dejardin, Emmanuel/AAE-9076-2021; Green, Douglas R/N-8083-2018; Baud, Veronique/AAL-3950-2020; Baud, Veronique/F-7699-2013	Green, Douglas R/0000-0002-7332-1417; Baud, Veronique/0000-0002-4090-718X; Baud, Veronique/0000-0002-4090-718X; Derudder, Emmanuel/0000-0003-1421-4045	NCI NIH HHS [CA69381] Funding Source: Medline; NIAID NIH HHS [AI44828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1994, ONCOGENE, V9, P1699; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 1998, ONCOGENE, V16, P3299, DOI 10.1038/sj.onc.1201879; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Rothwarf D.M., 1999, SCI SIGNAL TRANSDUCT; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Saitoh T, 2002, FEBS LETT, V532, P45, DOI 10.1016/S0014-5793(02)03622-0; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shakhov AN, 2001, CYTOKINE GROWTH F R, V12, P107, DOI 10.1016/S1359-6101(01)00004-1; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Weih F, 1997, J IMMUNOL, V158, P5211; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Xia YY, 1999, MOL CELL BIOL, V19, P7688; Xia YY, 1997, AM J PATHOL, V151, P375; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	60	126	129	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23278	23284		10.1074/jbc.M300106200	http://dx.doi.org/10.1074/jbc.M300106200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12709443	hybrid			2022-12-25	WOS:000183638600010
J	Ryu, SW; Lee, SJ; Park, MY; Jun, J; Jung, YK; Kim, E				Ryu, SW; Lee, SJ; Park, MY; Jun, J; Jung, YK; Kim, E			Fas-associated factor 1, FAF1, is a member of Fas death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; MEDIATED APOPTOSIS; CASPASE HOMOLOG; CELL-DEATH; KINASE CK2; RECEPTOR; FADD; INTERACTS; ACTIVATION; CD95	FAF1 has been introduced as a Fas-binding protein. However, the function of FAF1 in apoptotic execution is not established. Based on the fact that FAF1 is a Fas-binding protein, we asked if FAF1 interacted with other members of the Fas-death-inducing signaling complex (Fas-DISC) such as Fas-associated death domain protein ( FADD) and caspase-8. FAF1 could interact with caspase-8 and FADD in vivo as well as in vitro. The death effector domains (DEDs) of caspase-8 and FADD interacted with the amino acid 181-381 region of FAF1, previously known to have apoptotic potential. Considering that FAF1 directly binds to Fas and caspase-8, FAF1 shows similar protein-interacting characteristics to that of FADD. In the coimmunoprecipitation with an anti-Fas antibody (APO-1) in Jurkat cells, endogenous FAF1 was associated with the precipitates in which caspase-8 was present. By confocal microscopic analysis, both Fas and FAF1 were detected in the cytoplasmic membrane before Fas activation, and in the cytoplasm after Fas activation. FADD and caspase-8 colocalized with Fas in Jurkat cells validating the presence of FAF1 in the authentic Fas-DISC. Overexpression of FAF1 in Jurkat cells caused significant apoptotic death. In addition, the FAF1 deletion mutant lacking the N terminus where Fas, FADD, and caspase-8 interact protected Jurkat cells from Fas-induced apoptosis demonstrating dominant-negative phenotype. Cell death by overexpression of FAF1 was suppressed significantly in both FADD- and caspase-8-deficient Jurkat cells when compared with that in their parental Jurkat cells. Collectively, our data show that FAF1 is a member of Fas-DISC acting upstream of caspase-8.	PaiChai Univ, Div Life Sci, Taejon 302735, South Korea; PaiChai Univ, Ctr Biomed Resources, Taejon 302735, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Pai Chai University; Pai Chai University; Gwangju Institute of Science & Technology (GIST)	Kim, E (corresponding author), PaiChai Univ, Div Life Sci, 439-6 Doma 2-Dong, Taejon 302735, South Korea.			Jung, Yong-Keun/0000-0002-9686-3120				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guerra B, 2001, INT J ONCOL, V19, P1117; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hasegawa J, 1996, CANCER RES, V56, P1713; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jensen HH, 2001, INT J BIOCHEM CELL B, V33, P577, DOI 10.1016/S1357-2725(01)00039-5; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kamada S, 1997, ONCOGENE, V15, P285, DOI 10.1038/sj.onc.1201192; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kusk M, 1999, MOL CELL BIOCHEM, V191, P51, DOI 10.1023/A:1006840613986; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Ryu SW, 1999, BIOCHEM BIOPH RES CO, V262, P388, DOI 10.1006/bbrc.1999.1217; Ryu SW, 2001, BIOCHEM BIOPH RES CO, V286, P1027, DOI 10.1006/bbrc.2001.5505; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200	42	81	84	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					24003	24010		10.1074/jbc.M302200200	http://dx.doi.org/10.1074/jbc.M302200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12702723	hybrid			2022-12-25	WOS:000183638600101
J	Sabri, A; Alcott, SG; Elouardighi, H; Pak, E; Derian, C; Andrade-Gordon, P; Kinnally, K; Steinberg, SF				Sabri, A; Alcott, SG; Elouardighi, H; Pak, E; Derian, C; Andrade-Gordon, P; Kinnally, K; Steinberg, SF			Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RECEPTOR; PLASMINOGEN-ACTIVATOR; HUMAN PLATELET; KINASE-C; CLEAVAGE; ELASTASE; CELLS; IDENTIFICATION; CONSEQUENCES; EXPRESSION	Cathepsin G is a neutrophil-derived serine protease that contributes to tissue damage at sites of inflammation. The actions of cathepsin G are reported to be mediated by protease-activated receptor (PAR)-4 (a thrombin receptor) in human platelets. This study provides the first evidence that cathepsin G promotes inositol 1,4,5-trisphosphate accumulation, activates ERK, p38 MAPK, and AKT, and decreases contractile function in cardiomyocytes. Because some cathepsin G responses mimic cardiomyocyte activation by thrombin, a role for PARs was considered. Cathepsin G markedly activates phospholipase C and p38 MAPK in cardiomyocytes from PAR-1(-/-) mice, but it fails to activate phospholipase C, ERK, p38 MAPK, or AKT in PAR-1- or PAR-4-expressing PAR-1(-/-) fibroblasts (which display robust responses to thrombin). These results argue that PAR-1 does not mediate the actions of cathepsin G in cardiomyocytes, and neither PAR-1 nor PAR-4 mediates the actions of cathepsin G in fibroblasts. Of note, prolonged incubation of cardiomyocytes with cathepsin G results in the activation of caspase-3, cleavage of FAK and AKT, sarcomeric disassembly, cell rounding, cell detachment from underlying matrix, and morphologic features of apoptosis. Inhibition of Src family kinases or caspases (with PP1 or benzyloxycarbonyl-VAD-fluoromethyl ketone, respectively) delays FAK and AKT cleavage and cardiomyocyte detachment from substrate. Collectively, these studies describe novel cardiac actions of cathepsin G that do not require PARs and are predicted to assume functional importance at sites of interstitial inflammation in the heart.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA 19477 USA; NYU, New York, NY 10010 USA	Columbia University; Columbia University; Johnson & Johnson; Johnson & Johnson USA; New York University	Steinberg, SF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL-64639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Bird PI, 1999, IMMUNOL CELL BIOL, V77, P47, DOI 10.1046/j.1440-1711.1999.00787.x; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Cumashi A, 2001, THROMB HAEMOSTASIS, V85, P533, DOI 10.1055/s-0037-1615617; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; IACOVIELLO L, 1995, ARTERIOSCL THROM VAS, V15, P2037, DOI 10.1161/01.ATV.15.11.2037; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; Landau E, 2000, J BIOL CHEM, V275, P2281, DOI 10.1074/jbc.275.4.2281; LEROY EC, 1984, J CLIN INVEST, V74, P1003, DOI 10.1172/JCI111467; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Molino M, 1997, J BIOL CHEM, V272, P11133; MUROHARA T, 1995, J PHARMACOL EXP THER, V274, P1246; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; Sabri A, 2003, J BIOL CHEM, V278, P11714, DOI 10.1074/jbc.M213091200; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; SELAK MA, 1994, BIOCHEM J, V297, P269, DOI 10.1042/bj2970269; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Si-Tahar M, 1996, BIOCHEM J, V313, P401, DOI 10.1042/bj3130401; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; WEKSLER BB, 1989, BLOOD, V74, P1627; Yasutake M, 1996, CIRC RES, V79, P705, DOI 10.1161/01.RES.79.4.705	35	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23944	23954		10.1074/jbc.M302718200	http://dx.doi.org/10.1074/jbc.M302718200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707281	hybrid			2022-12-25	WOS:000183638600093
J	Ward, IM; Minn, K; Jorda, KG; Chen, JJ				Ward, IM; Minn, K; Jorda, KG; Chen, JJ			Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC INSTABILITY; DAMAGE; LOCALIZATION; ACTIVATION; BRCA1; ATM; P53	53BP1 participates in the cellular response to DNA damage. Like many proteins involved in the DNA damage response, 53BP1 becomes hyperphosphorylated after radiation and colocalizes with phosphorylated H2AX in megabase regions surrounding the sites of DNA strand breaks. However, it is not yet clear whether the phosphorylation status of 53BP1 determines its localization or vice versa. In this study we mapped a region upstream of the 53BP1 C terminus that is required and sufficient for the recruitment of 53BP1 to these DNA break areas. In vitro assays revealed that this region binds to phosphorylated but not unphosphorylated H2AX. Moreover, using H2AX- deficient cells reconstituted with wild-type or a phosphorylation-deficient mutant of H2AX, we have shown that phosphorylation of H2AX at serine 140 is critical for efficient 53BP1 foci formation, implying that a direct interaction between 53BP1 and phosphorylated H2AX is required for the accumulation of 53BP1 at DNA break sites. On the other hand, radiation-induced phosphorylation of the 53BP1 N terminus by the ATM (ataxia-telangiectasia mutated) kinase is not essential for 53BP1 foci formation and takes place independently of 53BP1 redistribution. Thus, these two damage-induced events, hyperphosphorylation and relocalization of 53BP1, occur independently in the cell.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Columbia Univ, Div Oncol, New York, NY 10032 USA	Mayo Clinic; Columbia University	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, 200 1st St SW, Rochester, MN 55905 USA.							Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Jullien D, 2002, J CELL SCI, V115, P71; Morales JC, 2003, J BIOL CHEM, V278, P14971, DOI 10.1074/jbc.M212484200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983	23	275	288	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19579	19582		10.1074/jbc.C300117200	http://dx.doi.org/10.1074/jbc.C300117200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12697768	hybrid			2022-12-25	WOS:000183078000002
J	Izzotti, A; Balansky, RM; Cartiglia, C; Camoirano, A; Longobardi, M; De Flora, S				Izzotti, A; Balansky, RM; Cartiglia, C; Camoirano, A; Longobardi, M; De Flora, S			Genomic and transcriptional alterations in mouse fetus liver after transplacental exposure to cigarette smoke	FASEB JOURNAL			English	Article						mouse liver development; transplacental cigarette smoke; N-acetylcysteine; genomic alterations; multigene expression analysis	TOBACCO-SPECIFIC NITROSAMINE; SISTER-CHROMATID EXCHANGES; N-ACETYLCYSTEINE; OXIDATIVE STRESS; GENE-EXPRESSION; INTERCELLULAR COMMUNICATION; CHILDHOOD EXPOSURE; MATERNAL EXPOSURE; ADDUCT FORMATION; CANCER-RISK	The transplacental exposure of fetuses to maternal cigarette smoke may increase the risk of developmental impairments, congenital diseases, and childhood cancer. The whole-body exposure of Swiss mice to environmental cigarette smoke (ECS) during pregnancy decreased the number of fetuses per dam, placenta weight, and fetus weight. ECS increased DNA adducts, oxidative nucleotide alterations, and cytogenetic damage in fetus liver. Evaluation by cDNA array of 746 genes showed that 61 of them were expressed in fetus liver under basal conditions. The oral administration of N-acetylcysteine (NAC) during pregnancy enhanced the expression of three genes only, including two glutathione S-transferases and alpha1-antitrypsin precursor, whose deficiency plays a pathogenetic role in congenital emphysema. Transplacental ECS upregulated the expression of 116 genes involved in metabolism, response to oxidative stress, DNA and protein repair, and signal transduction. NAC inhibited the ECS-related genetic damage and upregulation of most genes. ECS stimulated pro-apoptotic genes and genes downregulating the cell cycle, which may justify growth impairments in the developing fetus. Thus, both genetic and epigenetic mechanisms were modulated by ECS. Moreover, hypoxia-related genes and several oncogenes and receptors involved in proliferation and differentiation of leukocytes were induced in the fetal liver, which also bears hematopoietic functions.	Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; Natl Oncol Ctr, BU-1157 Sofia, Bulgaria	University of Genoa; National Oncology Center - Bulgaria	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it		izzotti, alberto/0000-0002-8588-0347				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ANDERSON LM, 1989, CANCER RES, V49, P3770; ARDITO G, 1980, MUTAT RES, V78, P209, DOI 10.1016/0165-1218(80)90100-7; BALANSKY RB, 1992, CANCER LETT, V64, P123, DOI 10.1016/0304-3835(92)90072-4; BALANSKY RM, 1989, MUTAT RES, V223, P1, DOI 10.1016/0165-1218(89)90056-6; BALANSKY RM, 1991, IARC SCI PUBL, V105, P535; BIALKOWSKA A, 2003, IN PRESS ARCH ENV RE; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; Bosio A, 2002, CARCINOGENESIS, V23, P741, DOI 10.1093/carcin/23.5.741; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; BULAY OM, 1971, JNCI-J NATL CANCER I, V46, P397; Bush PG, 2000, PLACENTA, V21, P824, DOI 10.1053/plac.2000.0571; CORREA E, 1990, CANCER RES, V50, P3435; De Flora S, 2003, MUTAT RES-FUND MOL M, V523, P237, DOI 10.1016/S0027-5107(02)00340-8; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; DEFLORA S, 1986, ANTICANCER RES, V6, P1009; DEFLORA S, 1985, CARCINOGENESIS, V6, P1735; DEFLORA S, 1986, CANCER LETT, V32, P235, DOI 10.1016/0304-3835(86)90175-8; Devanaboyina U, 1996, CARCINOGENESIS, V17, P917, DOI 10.1093/carcin/17.5.917; EVERSON RB, 1980, LANCET, V2, P123; Finette BA, 1998, NAT MED, V4, P1144, DOI 10.1038/2640; Freed BM, 2001, TOXICOL SCI, V59, P1, DOI 10.1093/toxsci/59.1.1; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUPTA RC, 1985, CANCER RES, V45, P5656; HANSEN C, 1992, TERATOGEN CARCIN MUT, V12, P51, DOI 10.1002/tcm.1770120202; HAYES JA, 1977, LAB ANIM SCI, V27, P762; Horowitz RS, 1997, J TOXICOL-CLIN TOXIC, V35, P447, DOI 10.3109/15563659709001226; IDELL S, 1983, CLIN CHEST MED, V4, P359; *INT AG RES CANC, 1986, IARC MON EV CARC RIS, V96; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Izzotti A, 1999, MUTAT RES-GEN TOX EN, V446, P215, DOI 10.1016/S1383-5718(99)00189-8; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; Izzotti A, 1998, FREE RADICAL RES, V28, P165, DOI 10.3109/10715769809065802; KARUBE T, 1989, CANCER RES, V49, P3550; LEICHTER J, 1995, GROWTH DEVELOP AGING, V59, P63; Lin LH, 2000, J NEUROCHEM, V74, P1098; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McKarns SC, 2000, TOXICOL IN VITRO, V14, P41, DOI 10.1016/S0887-2333(99)00081-8; Nelson E, 1999, HUM EXP TOXICOL, V18, P257, DOI 10.1191/096032799678840011; NICOLOV IG, 1979, J CANCER RES CLIN, V94, P249, DOI 10.1007/BF00419284; Perera FP, 1999, ENVIRON HEALTH PERSP, V107, P451, DOI 10.1289/ehp.99107s3451; PinoriniGodly MT, 1996, TOXICOLOGY, V107, P209, DOI 10.1016/0300-483X(95)03263-F; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; RANDERATH K, 1989, IARC SCI PUBL, V96, P189; Rappa G, 1997, CANCER RES, V57, P5232; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; SALHAB AS, 1987, CHEM-BIOL INTERACT, V61, P203, DOI 10.1016/0009-2797(87)90001-9; SANDLER DP, 1985, AM J PUBLIC HEALTH, V75, P487, DOI 10.2105/AJPH.75.5.487; SARDAS S, 1995, MUTAT RES-GENET TOX, V341, P249; Sasco AJ, 1999, HUM EXP TOXICOL, V18, P192, DOI 10.1191/096032799678839905; SATOH K, 1988, AM J HUM GENET, V42, P77; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; Tomatis L, 1989, IARC Sci Publ, P1; Trosko JE, 1998, ENVIRON HEALTH PERSP, V106, P331, DOI 10.2307/3433935; Upham BL, 1998, ENVIRON HEALTH PERSP, V106, P975, DOI 10.2307/3434140; Villard PH, 1998, TOXICOL APPL PHARM, V148, P195, DOI 10.1006/taap.1997.8332; Vinson RK, 2001, MUTAT RES-DNA REPAIR, V486, P113, DOI 10.1016/S0921-8777(01)00087-8; Wani G, 1998, CANCER LETT, V125, P123, DOI 10.1016/S0304-3835(97)00507-7; Wilson MR, 2000, EXP CELL RES, V254, P257, DOI 10.1006/excr.1999.4771	62	64	67	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1127	+		10.1096/fj.02-0967fje	http://dx.doi.org/10.1096/fj.02-0967fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709406				2022-12-25	WOS:000182580100021
J	Yuen, BSJ; Owens, PC; Muhlhausler, BS; Roberts, CT; Symonds, ME; Keisler, DH; McFarlane, JR; Kauter, KG; Evens, Y; McMillen, IC				Yuen, BSJ; Owens, PC; Muhlhausler, BS; Roberts, CT; Symonds, ME; Keisler, DH; McFarlane, JR; Kauter, KG; Evens, Y; McMillen, IC			Leptin alters the structural and functional characteristics of adipose tissue before birth	FASEB JOURNAL			English	Article						fetus; lipid; UCP1	MAINTENANCE ENERGY-REQUIREMENTS; MESSENGER-RNA EXPRESSION; FETAL SHEEP; PLASMA LEPTIN; INTRAUTERINE GROWTH; GENE-EXPRESSION; LATE-GESTATION; CORD-BLOOD; UNCOUPLING PROTEIN; MATERNAL NUTRITION	This study aimed to determine for the first time whether leptin can act to alter the structural and functional characteristics of adipose tissue before birth. Leptin (0.48 mg/kg/day) or saline was infused intravenously into fetal sheep for 4 days from either 136 or 137 days of gestation (term=147+/-3 days). Circulating leptin concentrations were increased approximately four- to fivefold by leptin infusion. Leptin infusion resulted in a significant increase in the proportion of smaller lipid locules present within fetal perirenal adipose tissue (PAT), and this was associated with a significant increase in the proportion of multilocular tissue and a significant decrease in the proportion and relative mass of unilocular tissue in fetal PAT. The relative abundance of leptin mRNA in fetal PAT was significantly lower in the leptin-infused group, and there was a positive correlation between the relative abundance of leptin mRNA and the proportion of unilocular adipose tissue in fetal PAT. The amount of uncoupling protein 1 tended to be higher (P=0.06) in leptin-infused compared with saline-infused fetuses. This is the first demonstration that leptin can act to regulate the lipid storage characteristics, leptin synthetic capacity, and potential thermogenic functions of fat before birth.	Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Obstet & Gynecol, Adelaide, SA 5005, Australia; Univ Nottingham Hosp, Sch Human Dev, Acad Div Child Hlth, Nottingham NG7 2UH, England; Univ Missouri, Dept Anim Sci, Columbia, MO USA; Univ New England, Dept Physiol, Armidale, NSW 2350, Australia	University of Adelaide; University of Adelaide; University of Nottingham; University of Missouri System; University of Missouri Columbia; University of New England	McMillen, IC (corresponding author), Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia.	caroline.mcmillen@adelaide.edu.au	McFarlane, James/F-9277-2010; Keisler, Duane H/C-2746-2011; McMillen, Isabella Caroline/N-5540-2019; Roberts, Claire/A-1205-2007	McFarlane, James/0000-0003-4429-5384; Keisler, Duane H/0000-0002-8792-7030; Symonds, Michael/0000-0001-9649-8963; Kauter, Kate/0000-0003-2470-9172; Muhlhausler, Beverly/0000-0002-9021-6790; Roberts, Claire/0000-0002-9250-2192				Adams MB, 1999, J NEUROENDOCRINOL, V11, P569; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; ALEXANDER G, 1978, AUST J BIOL SCI, V31, P489, DOI 10.1071/BI9780489; Aprath-Husmann I, 2001, INT J OBESITY, V25, P1465, DOI 10.1038/sj.ijo.0801737; Bassett JM, 1998, AM J PHYSIOL-REG I, V275, pR112, DOI 10.1152/ajpregu.1998.275.1.R112; Blache D, 2000, J ENDOCRINOL, V165, P625, DOI 10.1677/joe.0.1650625; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; Bray GA, 1997, J CLIN ENDOCR METAB, V82, P2771, DOI 10.1210/jc.82.9.2771; CASTEILLA L, 1994, BIOCHEM J, V297, P93, DOI 10.1042/bj2970093; Cetin I, 2000, PEDIATR RES, V48, P646, DOI 10.1203/00006450-200011000-00016; CHAN YL, 1984, J BIOL CHEM, V259, P224; Chilliard Y, 2001, DOMEST ANIM ENDOCRIN, V21, P271, DOI 10.1016/S0739-7240(01)00124-2; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Commins SP, 1999, ENDOCRINOLOGY, V140, P4772, DOI 10.1210/en.140.10.4772; Delavaud C, 2000, J ENDOCRINOL, V165, P519, DOI 10.1677/joe.0.1650519; Devaskar SU, 2002, AM J PHYSIOL-REG I, V282, pR431, DOI 10.1152/ajpregu.2002.282.2.R431; Edwards LJ, 2001, ENDOCRINOLOGY, V142, P1778, DOI 10.1210/en.142.5.1778; Ehrhardt RA, 2002, AM J PHYSIOL-REG I, V282, pR1628, DOI 10.1152/ajpregu.00750.2001; Forhead AJ, 2002, ENDOCRINOLOGY, V143, P1166, DOI 10.1210/en.143.4.1166; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GEMMELL RT, 1978, AUST J BIOL SCI, V31, P505, DOI 10.1071/BI9780505; Gertler A, 1998, FEBS LETT, V422, P137, DOI 10.1016/S0014-5793(97)01613-X; Havel PJ, 1996, J CLIN ENDOCR METAB, V81, P4406, DOI 10.1210/jc.81.12.4406; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Jaquet D, 1998, J CLIN ENDOCR METAB, V83, P1243, DOI 10.1210/jc.83.4.1243; Kauter K, 2000, J ENDOCRINOL, V166, P127, DOI 10.1677/joe.0.1660127; Koistinen HA, 1997, J CLIN ENDOCR METAB, V82, P3328, DOI 10.1210/jc.82.10.3328; Lonnqvist F, 1997, J CLIN INVEST, V99, P2398, DOI 10.1172/JCI119422; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Mizuno A, 1998, ENDOCRINOLOGY, V139, P3863, DOI 10.1210/en.139.9.3863; Mostyn A, 2002, FASEB J, V16, P1438, DOI 10.1096/fj.02-0077fje; Moulin K, 2001, BIOCHEM J, V356, P659, DOI 10.1042/bj3560659; Muhlhausler BS, 2002, BIOL REPROD, V67, P493, DOI 10.1095/biolreprod67.2.493; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Newby D, 2001, J ANIM SCI, V79, P445; Roberts CT, 2001, PLACENTA, V22, P177, DOI 10.1053/plac.2000.0602; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Schermer SJ, 1996, REPROD FERT DEVELOP, V8, P995, DOI 10.1071/RD9960995; Schubring C, 1997, J CLIN ENDOCR METAB, V82, P1480, DOI 10.1210/jc.82.5.1480; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shekhawat PS, 1998, PEDIATR RES, V43, P338, DOI 10.1203/00006450-199803000-00005; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; SYMONDS ME, 1992, J PHYSIOL-LONDON, V455, P487, DOI 10.1113/jphysiol.1992.sp019313; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas L, 2001, J ENDOCRINOL, V169, P465, DOI 10.1677/joe.0.1690465; Wiznitzer A, 2000, OBSTET GYNECOL, V96, P707, DOI 10.1016/S0029-7844(00)00992-3; Yaspelkis BB, 1999, METABOLISM, V48, P671, DOI 10.1016/S0026-0495(99)90070-7; Yuen BSJ, 2002, BIOL REPROD, V67, P911, DOI 10.1095/biolreprod.101.002931; Yuen BSJ, 1999, J ENDOCRINOL, V163, pR11, DOI 10.1677/joe.0.163R011; Zhang YY, 2002, AM J PHYSIOL-REG I, V282, pR226, DOI 10.1152/ajpregu.00392.2001	53	64	65	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1102	+		10.1096/fj.02-0756fje	http://dx.doi.org/10.1096/fj.02-0756fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709410				2022-12-25	WOS:000182580100031
J	Saito, S; Aoki, H; Ito, A; Ueno, S; Wada, T; Mitsuzuka, K; Satoh, M; Arai, Y; Miyagi, T				Saito, S; Aoki, H; Ito, A; Ueno, S; Wada, T; Mitsuzuka, K; Satoh, M; Arai, Y; Miyagi, T			Human alpha 2,3-sialyltransferase (ST3Gal II) is a stage-specific embryonic antigen-4 synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; HUMAN TERATOCARCINOMA CELLS; MOLECULAR-CLONING; CLINICAL-SIGNIFICANCE; TUMOR MALIGNANCY; EXPRESSION; GANGLIOSIDES; GLYCOLIPIDS; EXTRACTION; DEFINES	Monosialosyl globopentaosylceramide (MSGb5), originally described as stage-specific embryonic antigen-4, is expressed in testicular germ cell tumors and in aggressive cases of human renal cell carcinoma (RCC). Clarification of the molecular mechanisms regulating synthesis of MSGb5 is very important to understand testicular carcinogenesis and the malignant progression of human RCC. For this purpose, we have investigated alpha2,3-sialyltransferase involved in the synthesis of MSGb5. We used the method of expression cloning combined with polymerase chain reaction targeted to sialylmotif to isolate a cDNA clone from RCC cell line ACHN library. The cloned cDNA was found to be identical to the previously cloned ST3Gal II in sequence. A soluble recombinant form of the protein in COS-1 cells showed an enzyme activity of alpha2,3-sialyltransferase toward globopentaosylceramide (Gb5) in addition to asialo-GM1 and GM1a. Transient transfection of COS-7 and ACHN cells with this cDNA induced an increase of MSGb5, whereas stable transfection of antisense ST3Gal II cDNA suppressed expression of MSGb5 in ACHN cells. The ST3Gal II mRNA level was increased in 7 of 8 RCC cell lines and in all six RCC tissues surgically obtained, although it was not necessarily consistent with the MSGb5 level in RCC cell lines. This study indicates that ST3Gal II is a MSGb5 (stage-specific embryonic antigen-4) synthase and that its increased expression level is closely related to renal carcinogenesis.	Tohoku Univ, Grad Sch Med, Dept Urol, Aoba Ku, Sendai, Miyagi 9808574, Japan; Miyagi Prefectural Canc Ctr, Res Inst, Div Biochem, Natori, Miyagi 9811293, Japan	Tohoku University	Saito, S (corresponding author), Tohoku Univ, Grad Sch Med, Dept Urol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808574, Japan.			Ito, Akihiro/0000-0001-7224-1100; Saito, Seiichi/0000-0001-8734-4591				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Deng W, 2000, J NATL CANCER I, V92, P912, DOI 10.1093/jnci/92.11.912; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, FEBS LETT, V531, P88, DOI 10.1016/S0014-5793(02)03479-8; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Ito A, 2001, J BIOL CHEM, V276, P16695, DOI 10.1074/jbc.M011791200; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; Kim YJ, 1996, BIOCHEM BIOPH RES CO, V228, P324, DOI 10.1006/bbrc.1996.1660; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; McKallip R, 1999, J IMMUNOL, V163, P3718; MIYAO N, 1989, UROL RES, V17, P317; OHTANI N, 1991, JPN J UROL, V82, P613; Olie RA, 1996, BRIT J CANCER, V74, P133, DOI 10.1038/bjc.1996.328; SAITO S, 1994, J BIOL CHEM, V269, P5644; Saito S, 2002, ONCOL REP, V9, P1251; SAITO S, 1991, INT J CANCER, V49, P329; SAITO S, 1997, JPN J CANCER RES, V88, P562; Satoh M, 1996, CANCER RES, V56, P1932; Satoh M, 1999, TOHOKU J EXP MED, V189, P95, DOI 10.1620/tjem.189.95; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; Steelant WF, 2002, FEBS LETT, V531, P93, DOI 10.1016/S0014-5793(02)03484-1; THOMSON JA, 1995, P NATL ACAD SCI USA, V92, P7844, DOI 10.1073/pnas.92.17.7844; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Toivonen S, 2001, J BIOL CHEM, V276, P37141, DOI 10.1074/jbc.M105715200; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; WENK J, 1994, INT J CANCER, V58, P108, DOI 10.1002/ijc.2910580118; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200	32	43	70	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					26474	26479		10.1074/jbc.M213223200	http://dx.doi.org/10.1074/jbc.M213223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12716912	hybrid			2022-12-25	WOS:000184155700025
J	Sugii, S; Reid, PC; Ohgami, N; Du, H; Chang, TY				Sugii, S; Reid, PC; Ohgami, N; Du, H; Chang, TY			Distinct endosomal compartments in early trafficking of low density lipoprotein-derived cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; COENZYME-A REDUCTASE; HAMSTER OVARY CELLS; INTRACELLULAR TRAFFICKING; ACIDIC COMPARTMENTS; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; ESTER HYDROLASE; C1 PROTEIN; TRANSPORT	We previously studied the early trafficking of low density lipoprotein (LDL)-derived cholesterol in mutant Chinese hamster ovary cells defective in Niemann-Pick type C1 (NPC1) using cyclodextrin ( CD) to monitor the arrival of cholesterol from the cell interior to the plasma membrane ( PM) (Cruz, J. C., Sugii, S., Yu, C., and Chang, T.-Y. ( 2000) J. Biol. Chem. 275, 4013 - 4021). We found that newly hydrolyzed cholesterol derived from LDL first appears in certain CD-accessible pool(s), which we assumed to be the PM, before accumulating in the late endosome/lysosome, where NPC1 resides. To determine the identity of the early CD-accessible pool( s), in this study, we performed additional experiments, including the use of revised CD incubation protocols. We found that prolonged incubation with CD (> 30 min) caused cholesterol in internal membrane compartment( s) to redistribute to the PM, where it became accessible to CD. In contrast, a short incubation with CD ( 5 - 10 min) did not cause such an effect. We also show that one of the early compartments contains acid lipase (AL), the enzyme required for liberating cholesterol from cholesteryl ester in LDL. Biochemical and microscopic evidence indicates that most of the AL is present in endocytic compartment( s) distinct from the late endosome/lysosome. Our results suggest that cholesterol is liberated from LDL cholesteryl ester in the hydrolytic compartment containing AL and then moves to the NPC1-containing late endosome/lysosome before reaching the PM or the endoplasmic reticulum.	Dartmouth Coll, Sch Med, Dept Biochem, HB 7200, Hanover, NH 03755 USA; Childrens Hosp, Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA	Dartmouth College; Cincinnati Children's Hospital Medical Center	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, HB 7200, Hanover, NH 03755 USA.		Ohgami, Nobutaka/I-4572-2014; Eckhardt, Erik/G-1567-2010	Sugii, Shigeki/0000-0002-2537-9534; Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036709, R01HL036709] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108] Funding Source: Medline; NHLBI NIH HHS [HL 36709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RA, 1994, P NATL ACAD SCI USA, V91, P2718, DOI 10.1073/pnas.91.7.2718; ANDERSON RGW, 1984, P NATL ACAD SCI-BIOL, V81, P4838, DOI 10.1073/pnas.81.15.4838; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1976, J BIOL CHEM, V251, P3277; Buton X, 1999, J BIOL CHEM, V274, P32112, DOI 10.1074/jbc.274.45.32112; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHIN J, 1981, J BIOL CHEM, V256, P6304; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; Du H, 1996, J LIPID RES, V37, P937; FAUST JR, 1977, J BIOL CHEM, V252, P4861; Frolov A, 2001, J BIOL CHEM, V276, P46414, DOI 10.1074/jbc.M108099200; Graham J., 1984, CENTRIFUGATION PRACT, P161; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; Maung KK, 2001, J LIPID RES, V42, P181; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Rothblat GH, 1999, J LIPID RES, V40, P781; RUNQUIST EA, 1991, J BIOL CHEM, V266, P22557; SANDO GN, 1985, J BIOL CHEM, V260, P5186; SATO SB, 1994, J CELL BIOL, V127, P39, DOI 10.1083/jcb.127.1.39; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; SPILLANE DM, 1995, BBA-LIPID LIPID MET, V1254, P283, DOI 10.1016/0005-2760(94)00190-A; SUGII S, 2003, IN PRESS J LIPID RES; Wojtanik KM, 2003, J BIOL CHEM, V278, P14850, DOI 10.1074/jbc.M300488200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	42	75	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27180	27189		10.1074/jbc.M300542200	http://dx.doi.org/10.1074/jbc.M300542200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12721287	hybrid			2022-12-25	WOS:000184155700113
J	Wegele, H; Haslbeck, M; Reinstein, J; Buchner, J				Wegele, H; Haslbeck, M; Reinstein, J; Buchner, J			Sti1 is a novel activator of the Ssa proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; RABBIT RETICULOCYTE LYSATE; IN-VIVO FUNCTION; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; ATPASE ACTIVITY; GLUCOCORTICOID-RECEPTOR; PROGESTERONE-RECEPTOR; STEROID-RECEPTORS; 66-KDA PROTEIN	The molecular chaperones Hsp70 and Hsp90 are involved in the folding and maturation of key regulatory proteins in eukaryotes. Of specific importance in this context is a ternary multichaperone complex in which Hsp70 and Hsp90 are connected by Hop. In Saccharomyces cerevisiae two components of the complex, yeast Hsp90 (yHsp90) and Sti1, the yeast homologue of Hop, had already been identified, but it remained to be shown which of the 14 different yeast Hsp70s are part of the Sti1 complex and what were the functional consequences resulting from this interaction. With a two-hybrid approach and co-immunoprecipitations, we show here that Sti1 specifically interacts with the Ssa group of the cytosolic yeast Hsp70 proteins. Using purified components, we reconstituted the dimeric Ssa1-Sti1 complex and the ternary Ssa1-Sti1-yHsp90 complex in vitro. The dissociation constant between Sti1 and Ssa1 was determined to be 2 orders of magnitude weaker than the affinity of Sti1 for yHsp90. Surprisingly, binding of Sti1 activates the ATPase of Ssa1 by a factor of about 200, which is in contrast to the behavior of Hop in the mammalian Hsp70 system. Analysis of the underlying activation mechanism revealed that ATP hydrolysis is rate-limiting in the Ssa1 ATPase cycle and that this step is accelerated by Sti1. Thus, Sti1 is a potent novel effector for the Hsp70 ATPase.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Mol Physiol, Abt Phys Biochem, D-44227 Dortmund, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Buchner, Johannes/A-2651-2010; Haslbeck, Martin/A-4413-2013	Buchner, Johannes/0000-0003-1282-7737				BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Buchner J, 1998, METHOD ENZYMOL, V290, P409, DOI 10.1016/S0076-6879(98)90034-9; Buchner J, 1998, METHOD ENZYMOL, V290, P418, DOI 10.1016/S0076-6879(98)90035-0; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; CRAIG E, 1999, MOL CHAPERONES FOLDI, P139; CRAIG E, 1989, UCLA S MOL CELL BIOL, V96, P51; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CYR DM, 1992, J BIOL CHEM, V267, P20927; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Gross M, 1996, J BIOL CHEM, V271, P16833, DOI 10.1074/jbc.271.28.16833; Gross M, 1996, J BIOL CHEM, V271, P16842, DOI 10.1074/jbc.271.28.16842; HA JH, 1999, MOL CHAPERONES FOLDI, P573; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HONORE B, 1992, J BIOL CHEM, V267, P8485; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LALORAYA S, 1995, MOL CELL BIOL, V15, P7098; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lopez-Buesa P, 1998, P NATL ACAD SCI USA, V95, P15253, DOI 10.1073/pnas.95.26.15253; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Mayr C, 2000, J BIOL CHEM, V275, P34140, DOI 10.1074/jbc.M005251200; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McClellan AJ, 2000, GENETICS, V156, P501; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MUKAI H, 1993, GENE, V132, P57; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Parsell DA, 1994, BIOL HEAT SHOCK PROT; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Picard D, 1997, BIOCHEM SOC T, V25, P597, DOI 10.1042/bst0250597; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schuck P, 1997, CURR OPIN BIOTECH, V8, P498, DOI 10.1016/S0958-1669(97)80074-2; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; Sondermann H, 2002, J BIOL CHEM, V277, P33220, DOI 10.1074/jbc.M204624200; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Wegele H, 2003, J CHROMATOGR B, V786, P109, DOI 10.1016/S1570-0232(02)00724-9; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; WETZSTEIN M, 1992, J BACTERIOL, V174, P3300, DOI 10.1128/jb.174.10.3300-3310.1992; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	72	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25970	25976		10.1074/jbc.M301548200	http://dx.doi.org/10.1074/jbc.M301548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12716905	hybrid			2022-12-25	WOS:000183920200091
J	Farmery, MR; Tjernberg, LO; Pursglove, SE; Bergman, A; Winblad, B; Naslund, J				Farmery, MR; Tjernberg, LO; Pursglove, SE; Bergman, A; Winblad, B; Naslund, J			Partial purification and characterization of gamma-secretase from post-mortem human brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; INTRAMEMBRANE PROTEOLYSIS; ASPARTYL PROTEASE; BETA-APP; TRANSMEMBRANE CLEAVAGE; INTRACELLULAR DOMAIN; NOTCH RECEPTOR; PRESENILIN; NICASTRIN	One characteristic feature of Alzheimer's disease is the deposition of amyloid beta-peptide (Abeta) as amyloid plaques within specific regions of the human brain. Abeta is derived from the amyloid beta-peptide precursor protein (beta-APP) by the intramembranous cleavage activity of gamma-secretase. Studies in cells have revealed that gamma-secretase is a large multimeric membrane-bound protein complex that is functionally dependent on several proteins, including presenilin, nicastrin, Aph-1, and Pen-2. However, the precise biochemical and molecular nature of gamma-secretase is as yet to be fully elucidated, and no investigations have analyzed gamma-secretase in human brain. To address this we have developed a novel in vitro gamma-secretase activity assay using detergent-solubilized cell membranes and a beta-APP-derived fluorescent probe. We report that human brain-derived gamma-secretase activity co-purifies with a high molecular weight protein complex comprising presenilin, nicastrin, Aph-1, and Pen-2. The inhibitor profile and solubility characteristics of brain-derived gamma-secretase are similar to those described in cells, and proteolysis occurs at the Abeta(40)- and Abeta(42)-generating cleavage sites. The ability to isolate gamma-secretase from post-mortem human brain may facilitate the identification of brain-specific modulators of beta-APP processing and provide new insights into the biology of this important factor in the pathogenesis of Alzheimer's disease.	Karolinska Inst, Neurotec, Novum KASPAC, SE-14157 Huddinge, Sweden; Sumitomo Pharmaceut, Alzheimer Ctr, Novum, Neurotec, SE-14157 Huddinge, Sweden; Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurotec, Sect Expt Geriatr, Novum, SE-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet	Farmery, MR (corresponding author), Karolinska Inst, Neurotec, Novum KASPAC, SE-14157 Huddinge, Sweden.							Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Brookes PS, 2002, PROTEOMICS, V2, P969, DOI 10.1002/1615-9861(200208)2:8<969::AID-PROT969>3.0.CO;2-3; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Evin G, 2001, BIOCHEMISTRY-US, V40, P8359, DOI 10.1021/bi002770t; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hattori C, 2002, BIOCHEM BIOPH RES CO, V293, P1228, DOI 10.1016/S0006-291X(02)00351-0; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Holmes C, 2002, BRIT J PSYCHIAT, V180, P131, DOI 10.1192/bjp.180.2.131; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Maurer I, 2001, SCHIZOPHR RES, V48, P125, DOI 10.1016/S0920-9964(00)00075-X; McLendon C, 2000, FASEB J, V14, P2383; MITZEN EJ, 1974, BRAIN RES, V68, P123, DOI 10.1016/0006-8993(74)90537-X; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Schulke N, 2002, J VIROL, V76, P7760, DOI 10.1128/JVI.76.15.7760-7776.2002; Seiffert D, 2000, MOL BRAIN RES, V84, P115, DOI 10.1016/S0169-328X(00)00230-8; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Thinakaran G, 2001, J MOL NEUROSCI, V17, P183, DOI 10.1385/JMN:17:2:183; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	57	135	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24277	24284		10.1074/jbc.M211992200	http://dx.doi.org/10.1074/jbc.M211992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12697771	hybrid			2022-12-25	WOS:000183824800007
J	Kol, MA; van Dalen, A; de Kroon, AIPM; de Kruijff, B				Kol, MA; van Dalen, A; de Kroon, AIPM; de Kruijff, B			Translocation of phospholipids is facilitated by a subset of membrane-spanning proteins of the bacterial cytoplasmic membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TRANSMEMBRANE MOVEMENT; ALPHA-HELICAL PEPTIDES; ESCHERICHIA-COLI MSBA; LEADER PEPTIDASE; ENDOPLASMIC-RETICULUM; POTASSIUM CHANNEL; INNER MEMBRANE; FLIP-FLOP; FLUORESCENT PHOSPHOLIPIDS; TRANSBILAYER MOVEMENT	The mechanism by which phospholipids are transported across biogenic membranes, such as the bacterial cytoplasmic membrane, is unknown. We hypothesized that this process is mediated by the presence of the membrane-spanning segments of inner membrane proteins, rather than by dedicated flippases. In support of the hypothesis, it was demonstrated that transmembrane alpha-helical peptides, mimicking the membrane-spanning segments, mediate flop of 2-6-(7-nitro-2,1,3-benzoxadiazol-4-yl) aminocaproyl (C-6-NBD)-phospholipids (Kol, M. A., de Kroon, A. I., Rijkers, D. T., Killian, J. A., and de Kruijff, B. (2001) Biochemistry 40, 10500-10506). Here the dithionite reduction assay was used to measure transbilayer equilibration of C-6-NBD-phospholipids in proteoliposomes, composed of Escherichia coli phospholipids and a subset of bacterial membrane proteins. It is shown that two well characterized integral proteins of the bacterial cytoplasmic membrane, leader peptidase and the potassium channel KcsA, induce phospholipid translocation, most likely by their transmembrane domains. In contrast, the ATP-binding cassette transporter from the E. coli inner membrane MsbA, a putative lipid flippase, did not mediate phospholipid translocation, irrespective of the presence of ATP. OmpT, an outer membrane protein from E. coli, did not facilitate flop either, demonstrating specificity of protein-mediated phospholipid translocation. The results are discussed in the light of phospholipid transport across the E. coli inner membrane.	Univ Utrecht, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	Kol, MA (corresponding author), Univ Utrecht, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	m.a.kol@chem.uu.nl	de Kroon, Anton I/O-4119-2016	de Kroon, Anton/0000-0003-1209-756X				Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Buton X, 1996, J BIOL CHEM, V271, P6651, DOI 10.1074/jbc.271.12.6651; Buton X, 2002, BIOCHEMISTRY-US, V41, P13106, DOI 10.1021/bi020385t; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; de Planque MRR, 1998, BIOCHEMISTRY-US, V37, P9333, DOI 10.1021/bi980233r; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FATTAL E, 1994, BIOCHEMISTRY-US, V33, P6721, DOI 10.1021/bi00187a044; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; Huijbregts RPH, 1998, J BIOL CHEM, V273, P18936, DOI 10.1074/jbc.273.30.18936; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; KINGMA RL, 2002, THESIS UTRECHT U NET; Kol MA, 2002, SEMIN CELL DEV BIOL, V13, P163, DOI 10.1016/S1084-9521(02)00044-7; Kol MA, 2003, BIOCHEMISTRY-US, V42, P231, DOI 10.1021/bi0268403; Kol MA, 2001, BIOCHEMISTRY-US, V40, P10500, DOI 10.1021/bi010627+; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; Kramer RA, 2002, EUR J BIOCHEM, V269, P1746, DOI 10.1046/j.1432-1327.2002.02820.x; LANGLEY KE, 1979, P NATL ACAD SCI USA, V76, P6245, DOI 10.1073/pnas.76.12.6245; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; Marx U, 2000, BIOPHYS J, V78, P2628, DOI 10.1016/S0006-3495(00)76807-X; OHNOIWASHITA Y, 1983, J BIOL CHEM, V258, P1895; OHNOIWASHITA Y, 1984, BIOCHEMISTRY-US, V23, P6178, DOI 10.1021/bi00320a044; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; TOMMASSEN J, 1989, J CELL SCI, P73; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; van Dalen A, 2000, EMBO REP, V1, P340, DOI 10.1093/embo-reports/kvd067; van Dalen A, 2002, FEBS LETT, V525, P33, DOI 10.1016/S0014-5793(02)03061-2; van Dalen A, 1999, J BIOL CHEM, V274, P19913, DOI 10.1074/jbc.274.28.19913; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; van Klompenburg W, 1998, FEBS LETT, V431, P75, DOI 10.1016/S0014-5793(98)00733-9; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; vanKlompenburg W, 1995, MOL MEMBR BIOL, V12, P349, DOI 10.3109/09687689509072437; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	42	74	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24586	24593		10.1074/jbc.M301875200	http://dx.doi.org/10.1074/jbc.M301875200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714595	hybrid			2022-12-25	WOS:000183824800041
J	Musse, AA; Merrill, AR				Musse, AA; Merrill, AR			The molecular basis for the pH-activation mechanism in the channel-forming bacterial colicin E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTIFICIAL MEMBRANE-VESICLES; INSERTION-COMPETENT STATE; CRYSTAL-STRUCTURE; ION-CHANNEL; INFLUENZA HEMAGGLUTININ; TRYPTOPHAN RESIDUES; ENDOSOME MEMBRANES; ACID DENATURATION; RECEPTOR-BINDING; PROTEIN TOPOLOGY	The in vitro activity of the channel-forming bacteriocins such as colicin E1 in model membranes requires the specific activation of the protein by an acidic environment in the presence of a membrane potential. Acid activation of the C-terminal domain results in the formation of an insertion-competent intermediate with an enhanced ability to penetrate and perforate cell membranes. We report novel findings of this activation process through the design and study of mutant proteins involving the replacement of conserved Asp residues Asp-408, Asp-410, and Asp-423 within helices 5(a) and 4 in the colicin E1 channel domain that resulted in enhanced membrane binding, bilayer insertion rates, and ion channel activities at near neutral pH values. This activation process involves the destabilization of a critical salt bridge (Asp-410 and Lys-406) and H-bonds (Asp-408 and Ser-405 main chain; Asp-423 and Lys-420 main chain). The helix-to-coil transition of this motif was identified previously by time-resolved Trp fluorescence measurements (Merrill, A. R., Steer, B. A., Prentice, G. A., Weller, M. J., and Szabo, A. G. (1997) Biochemistry 36, 6874-6884), and here we use this approach to demonstrate that disruption of the helical structure of helices 4 and 5(a) results in a shift in this equilibrium to favor the coil state. Finally, we show that the essential components of the pH trigger motif are conserved among the channel-forming colicins and that it likely exists within other bacterial proteins and may even have evolved into more sophisticated devices in a number of microbial species.	Univ Guelph, Guelph Waterloo Ctr Grad Work Chem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Merrill, AR (corresponding author), Univ Guelph, Guelph Waterloo Ctr Grad Work Chem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada.		Merrill, Rod/M-8313-2014					BARRICK D, 1994, J MOL BIOL, V237, P588, DOI 10.1006/jmbi.1994.1257; BRUNDEN KR, 1984, J BIOL CHEM, V259, P190; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Chenal A, 2002, J BIOL CHEM, V277, P43425, DOI 10.1074/jbc.M204148200; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; CRAMER WA, 1983, BIOCHIM BIOPHYS ACTA, V737, P173, DOI 10.1016/0304-4157(83)90016-3; Creighton TE, 1993, PROTEINS STRUCTURES, P140; DANKERT JR, 1982, J BIOL CHEM, V257, P3857; DAVIDSON VL, 1985, P NATL ACAD SCI USA, V82, P1386, DOI 10.1073/pnas.82.5.1386; Elkins P, 1997, STRUCTURE, V5, P443, DOI 10.1016/S0969-2126(97)00200-1; Evans LJA, 1996, BIOCHEMISTRY-US, V35, P13180, DOI 10.1021/bi960990u; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Guidi-Rontani C, 2000, CELL MICROBIOL, V2, P259, DOI 10.1046/j.1462-5822.2000.00057.x; Heymann JB, 1996, BIOCHEMISTRY-US, V35, P2717, DOI 10.1021/bi951535l; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huster D, 2002, BBA-BIOMEMBRANES, V1561, P159, DOI 10.1016/S0005-2736(02)00340-1; HUYGHUESDESPOINTES BMP, 1993, PROTEIN SCI, V2, P80; HUYGHUESDESPOINTES BMP, 1993, PROTEIN SCI, V2, P1604, DOI 10.1002/pro.5560021006; ILLSLEY NP, 1987, BIOCHEMISTRY-US, V26, P1215, DOI 10.1021/bi00379a002; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; Lakowicz J. R., 1999, PRINC FLUORESC SPECT, P445, DOI [DOI 10.1007/978-1-4757-3061-6_16, 10.1007/978-1-4757-3061-6_16]; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; Lindeberg M, 2000, J MOL BIOL, V295, P679, DOI 10.1006/jmbi.1999.3396; MADSHUS IH, 1992, CURR TOP MICROBIOL, V175, P1; MERRILL AR, 1993, BIOCHEMISTRY-US, V32, P6974, DOI 10.1021/bi00078a023; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; Merrill AR, 1997, BIOCHEMISTRY-US, V36, P6874, DOI 10.1021/bi970222i; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; MUGA A, 1993, J BIOL CHEM, V268, P1553; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; New R.R.C., 1990, LIPOSOMES PRACTICAL, P105; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PETERSON AA, 1987, J MEMBRANE BIOL, V99, P197, DOI 10.1007/BF01995700; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P203; PUGSLEY AP, 1984, MICROBIOL SCI, V1, P168; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; Riley MA, 1998, ANNU REV GENET, V32, P255, DOI 10.1146/annurev.genet.32.1.255; Sandvig K, 2002, FEBS LETT, V529, P49, DOI 10.1016/S0014-5793(02)03182-4; SCHENDEL SL, 1994, PROTEIN SCI, V3, P2272, DOI 10.1002/pro.5560031212; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; SHIVER JW, 1988, BIOCHEMISTRY-US, V27, P8421, DOI 10.1021/bi00422a019; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; STEER BA, 1994, BIOCHEMISTRY-US, V33, P1108, DOI 10.1021/bi00171a009; Stroud RM, 1998, CURR OPIN STRUC BIOL, V8, P525, DOI 10.1016/S0959-440X(98)80132-2; Tory MC, 2002, BBA-BIOMEMBRANES, V1564, P435, DOI 10.1016/S0005-2736(02)00493-5; Tory MC, 1999, J BIOL CHEM, V274, P24539, DOI 10.1074/jbc.274.35.24539; Umata T, 1998, J BIOL CHEM, V273, P8351, DOI 10.1074/jbc.273.14.8351; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; Vetter IR, 1998, STRUCTURE, V6, P863, DOI 10.1016/S0969-2126(98)00088-4; Wiener M, 1997, NATURE, V385, P461, DOI 10.1038/385461a0; WORMALD MR, 1991, EUR J BIOCHEM, V191, P155; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; Zakharov SD, 1999, BIOCHEMISTRY-US, V38, P11325, DOI 10.1021/bi9903087; Zakharov SD, 1996, BIOPHYS J, V70, P2774, DOI 10.1016/S0006-3495(96)79847-8	57	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24491	24499		10.1074/jbc.M302371200	http://dx.doi.org/10.1074/jbc.M302371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12714593	hybrid			2022-12-25	WOS:000183824800031
J	Wang, B; Lin, DJ; Li, C; Tucker, P				Wang, B; Lin, DJ; Li, C; Tucker, P			Multiple domains define the expression and regulatory properties of Foxp1 forkhead transcriptional Repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-DOMAIN; T-CELL ACTIVATION; HEAD DOMAIN; PROTEIN; SCURFIN; GENE; RECEPTOR; REPEATS; REGION; MOUSE	The Foxp subfamily of forkhead/HNF3 transcription factors has recently been recognized because of its involvement in autoimmune disease, speech and language disorders, and lung development. Domains unique to this subfamily include a divergent DNA-binding winged helix, a leucine zipper, a zinc finger, and a polyglutamine tract. Little is known about the properties of these proteins that are fundamental to their function as transcription factors nor how the Foxp sequence motifs regulate their transcriptional regulatory properties. We report here a structure/function analysis of the Foxp1 protein. We have analyzed the alternative splice isoforms 1A and 1C and also report the cloning and characterization of a novel isoform Foxp1D that lacks the polyglutamine domain. We have isolated the preferred DNA-binding sites for Foxp1 transcription factors. Foxp1A, C, and D isoforms and the related Foxp2 protein repress gene transcription via binding to this consensus site or to a naturally occurring site within the SV40 and the interleukin-2 promoters. In some cases the strength of Foxp1 repression is mediated by the polyglutamine domain. Unlike previously characterized forkhead factors, Foxp1 proteins can form homodimers or heterodimers with subfamily members. The dimerization domain was localized to an evolutionarily conserved C2H2 zinc finger and leucine zipper motif. Finally, we demonstrate that Foxp1, although broadly expressed, is further regulated by tissue-specific alternative splicing of these functionally important sequence domains. These results suggest that Foxp1 proteins have diverse functional roles in different cell and tissue types.	Univ Texas, Dept Mol Genet, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Austin, TX 78712 USA; Express Technol Inc, San Diego, CA 92121 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Tucker, P (corresponding author), Univ Texas, Dept Mol Genet, 1 Univ Stn,A5000, Austin, TX 78712 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018016, R37AI018016] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18016] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banham AH, 2001, CANCER RES, V61, P8820; BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; HACKER U, 1995, EMBO J, V14, P5306, DOI 10.1002/j.1460-2075.1995.tb00215.x; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Imafuku I, 1998, BIOCHEM BIOPH RES CO, V253, P16, DOI 10.1006/bbrc.1998.9725; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROSE MD, 1990, METHODS YEAST GENETI, P178; Sambrook J, 1989, MOL CLONING LAB MANU, P181; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Shu WG, 2001, J BIOL CHEM, V276, P27488, DOI 10.1074/jbc.M100636200; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; van Dongen MJP, 2000, J MOL BIOL, V296, P351, DOI 10.1006/jmbi.1999.3476; Weigelt J, 2001, BIOCHEMISTRY-US, V40, P5861, DOI 10.1021/bi001663w; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707	32	172	182	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24259	24268		10.1074/jbc.M207174200	http://dx.doi.org/10.1074/jbc.M207174200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12692134	hybrid			2022-12-25	WOS:000183824800005
J	Yokoyama, K; Nakano, M; Imamura, H; Yoshida, M; Tamakoshi, M				Yokoyama, K; Nakano, M; Imamura, H; Yoshida, M; Tamakoshi, M			Rotation of the proteolipid ring in the V-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SUBUNIT OLIGOMER; THERMUS-THERMOPHILUS; EXTREME THERMOPHILE; VACUOLAR (H+)-ATPASES; SYNTHASE; TRANSLOCATION; ARCHITECTURE; EUBACTERIUM; SYSTEM	V0V1-ATPase is a proton-translocating ATPase responsible for acidification of eukaryotic intracellular compartments and for ATP synthesis in archaea and some eubacteria. We demonstrated recently the rotation of the central stalk subunits in V-1, a catalytic sector of V0V1-ATPase (Imamura, H., Nakano, M., Noji, H., Muneyuki, E., Ohkuma, S., Yoshida, M., and Yokoyama, K. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 2312-2315), but the rotation of the proteolipid ring, a predicted counterpart rotor in the membrane V-0 sector, has remained to be proven. V0V1-ATPase that retained sensitivity to N',N'-dicyclohexylcarbodiimide was isolated from Thermus thermophilus, immobilized onto a glass surface through the N termini of the A subunits of V-1, and decorated with a bead attached to a proteolipid subunit of V-0. Rotation of beads was observed in the presence of ATP, and direction of rotation was always counterclock-wise viewed from the membrane side. The rotation proceeded at similar to3.0 rev/s in average at 4 mM ATP and was abolished by N',N'-dicyclohexylcarbodiimide treatment. Thus, the rotation of the central stalk in V-1 accompanies rotation of a proteolipid ring of V-0 in the functioning V0V1-ATPase.	Japan Sci & Technol Corp, ATP Syst Project, Exporatory Res Adv Technol, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Tokyo 1920392, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Tokyo University of Pharmacy & Life Sciences	Yokoyama, K (corresponding author), Japan Sci & Technol Corp, ATP Syst Project, Exporatory Res Adv Technol, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.		Nakano, Masahiro/A-5249-2012; Imamura, Hiromi/AAD-5109-2019; Yokoyama, Ken/AAJ-3582-2020	Nakano, Masahiro/0000-0002-1558-3259; Imamura, Hiromi/0000-0002-1896-0443; Yokoyama, Ken/0000-0002-6813-1096				Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; BOYER PD, 1997, ANNU REV BIOCHEM, V66, P714; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gruber G, 2001, J EXP BIOL, V204, P2597; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nureki O, 2002, ACTA CRYSTALLOGR D, V58, P1129, DOI 10.1107/S0907444902006601; OSHIMA T, 1974, J BIOCHEM-TOKYO, V75, P179, DOI 10.1093/oxfordjournals.jbchem.a130372; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tamakoshi M, 1998, GENE, V222, P125, DOI 10.1016/S0378-1119(98)00482-X; Tamakoshi M, 1999, FEMS MICROBIOL LETT, V173, P431, DOI 10.1016/S0378-1097(99)00101-9; Tamakoshi M, 1997, J BACTERIOL, V179, P4811, DOI 10.1128/jb.179.15.4811-4814.1997; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; Yokoyama K, 1998, J BIOL CHEM, V273, P20504, DOI 10.1074/jbc.273.32.20504; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	28	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24255	24258		10.1074/jbc.M303104200	http://dx.doi.org/10.1074/jbc.M303104200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12707282	hybrid			2022-12-25	WOS:000183824800004
J	Deprez, P; Inestrosa, NC; Krejci, E				Deprez, P; Inestrosa, NC; Krejci, E			Two different heparin-binding domains in the triple-helical domain of ColQ, the collagen tail subunit of synaptic acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; BASIC-AMINO-ACIDS; ASYMMETRIC ACETYLCHOLINESTERASE; NEUROMUSCULAR-JUNCTION; ELECTRIC ORGAN; STABILITY; PEPTIDES; SITES; FORMS; EXPRESSION	ColQ, the collagen tail subunit of asymmetric acetylcholinesterase, is responsible for anchoring the enzyme at the vertebrate synaptic basal lamina by interacting with heparan sulfate proteoglycans. To get insights about this function, the interaction of ColQ with heparin was analyzed. For this, heparin affinity chromatography of the complete oligomeric enzyme carrying different mutations in ColQ was performed. Results demonstrate that only the two predicted heparin-binding domains present in the collagen domain of ColQ are responsible for heparin interaction. Despite their similarity in basic charge distribution, each heparin-binding domain had different affinity for heparin. This difference is not solely determined by the number or nature of the basic residues conforming each site, but rather depends critically on local structural features of the triple helix, which can be influenced even by distant regions within ColQ. Thus, ColQ possesses two heparin-binding domains with different properties that may have non-redundant functions. We hypothesize that these binding sites coordinate acetylcholinesterase positioning within the organized architecture of the neuromuscular junction basal lamina.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Inst Milenio Biol Fundamental & Aplicada, Ctr Regulac Celular & Patol Dr Joaquin V Luco, Santiago, Chile; Ecole Normale Super, CNRS, Unite Mixte REch 8544, Neurobiol Cellulaire & Mol Lab, F-75230 Paris 05, France	Pontificia Universidad Catolica de Chile; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Deprez, P (corresponding author), ETH Honggerberg, CH-8093 Zurich, Switzerland.							Arikawa-Hirasawa E, 2002, NAT NEUROSCI, V5, P119, DOI 10.1038/nn801; Bon S, 2003, NEUROCHEM RES, V28, P523, DOI 10.1023/A:1022821306722; Bon S, 1997, J BIOL CHEM, V272, P3016, DOI 10.1074/jbc.272.5.3016; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Delacoux F, 2000, J BIOL CHEM, V275, P29377, DOI 10.1074/jbc.M004724200; Deprez P, 2000, BIOCHEM J, V350, P283, DOI 10.1042/0264-6021:3500283; Deprez P, 2000, PROTEIN ENG, V13, P27, DOI 10.1093/protein/13.1.27; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; Doss-Pepe E, 2000, BIOCHEMISTRY-US, V39, P14884, DOI 10.1021/bi001108u; DUDAI Y, 1973, P NATL ACAD SCI USA, V70, P2473, DOI 10.1073/pnas.70.9.2473; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Feng GP, 1999, J CELL BIOL, V144, P1349, DOI 10.1083/jcb.144.6.1349; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; INESTROSA NC, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P25; KREJCI E, 1991, EMBO J, V10, P1285, DOI 10.1002/j.1460-2075.1991.tb08070.x; Krejci E, 1999, J NEUROSCI, V19, P10672, DOI 10.1523/JNEUROSCI.19-24-10672.1999; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; MASCOTTI DP, 1995, BIOCHEMISTRY-US, V34, P2908, DOI 10.1021/bi00009a022; Ohno K, 2000, ANN NEUROL, V47, P162, DOI 10.1002/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; PEREZTUR J, 1991, FEBS LETT, V286, P25, DOI 10.1016/0014-5793(91)80932-S; Rotundo RL, 1997, J CELL BIOL, V136, P367, DOI 10.1083/jcb.136.2.367; SANANTONIO JD, 1994, GLYCOBIOLOGY, V4, P327; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; SOREQ H, 1982, P NATL ACAD SCI-BIOL, V79, P830, DOI 10.1073/pnas.79.3.830; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VITAGLIANO L, 1993, BIOCHEMISTRY-US, V32, P7354, DOI 10.1021/bi00080a004; Yang W, 1997, J BIOL CHEM, V272, P28837, DOI 10.1074/jbc.272.46.28837	36	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23233	23242		10.1074/jbc.M301384200	http://dx.doi.org/10.1074/jbc.M301384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684510	hybrid			2022-12-25	WOS:000183638600005
J	Fathallah-Shaykh, HM; He, B; Zhao, LJ; Engelhard, HH; Cerullo, L; Lichtor, T; Byrne, R; Munoz, L; Von Roenn, K; Rosseau, GL; Glick, R; Sherman, C; Farooq, K				Fathallah-Shaykh, HM; He, B; Zhao, LJ; Engelhard, HH; Cerullo, L; Lichtor, T; Byrne, R; Munoz, L; Von Roenn, K; Rosseau, GL; Glick, R; Sherman, C; Farooq, K			Genomic expression discovery predicts pathways and opposing functions behind phenotypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MENINGIOMAS	Discovering states of genetic expression that are true to a high degree of certainty is likely to predict gene function behind biological phenotypes. The states of expression (up- or down-regulated) of 19,200 cDNAs in 10 meningiomas are compared with normal brain by an algorithm that detects only 1 false measurement per 192,000; 364 genes are discovered. The expression data accurately predict activation of signaling pathways and link gene function to specific phenotypes. Meningiomas appear to acquire aberrant phenotypes by disturbing the balanced expression of molecules that promote opposing functions. The findings expose interconnected genes and propose a role of genomic expression discovery in functional genomics of living systems.	Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA; Cook Cty Hosp, Dept Neurosurg, Chicago, IL 60612 USA	Rush University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County	Fathallah-Shaykh, HM (corresponding author), Rush Univ, Med Ctr, 2242 W Harrison St,Suite 200, Chicago, IL 60612 USA.			Fathallah-Shaykh, Hassan/0000-0002-2690-7685; Rosseau, Gail/0000-0002-5392-435X; Engelhard, Herbert/0000-0003-4993-9265	NATIONAL CANCER INSTITUTE [R01CA081367, R29CA078825] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA78825, R01-CA81367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antinheimo J, 2000, NEUROLOGY, V54, P71, DOI 10.1212/WNL.54.1.71; Ayerbe J, 1999, ACTA NEUROCHIR, V141, P921, DOI 10.1007/s007010050398; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Fathallah-Shaykh HM, 2002, ONCOGENE, V21, P7164, DOI 10.1038/sj.onc.1205654; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Langford LA, 1997, HUM PATHOL, V28, P416, DOI 10.1016/S0046-8177(97)90029-0; Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026; Watson MA, 2002, AM J PATHOL, V161, P665, DOI 10.1016/S0002-9440(10)64222-8	9	27	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23830	23833		10.1074/jbc.M302800200	http://dx.doi.org/10.1074/jbc.M302800200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12700229	hybrid			2022-12-25	WOS:000183638600078
J	Griffioen, G; Swinnen, S; Thevelein, JM				Griffioen, G; Swinnen, S; Thevelein, JM			Feedback inhibition on cell wall integrity signaling by Zds1 involves Gsk3 phosphorylation of a cAMP-dependent protein kinase regulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; SACCHAROMYCES-CEREVISIAE; MAP KINASE; BUDDING YEAST; MORPHOGENESIS CHECKPOINT; GENE-EXPRESSION; SHUTTLE VECTORS; RII-ALPHA; A PATHWAY; HOMOLOG	We report here that budding yeast cAMP-dependent protein kinase (cAPK) is controlled by heat stress. A rise in temperature from 30 to 37degreesC was found to result in both a higher expression and an increased cytoplasmic localizationof its regulatory subunit Bcy1. Both of these effects required phosphorylationof serines located in its localization domain. Surprisingly, classic cAPK-controlled processes were found to be independent of Bcy1 phosphorylation, indicating that these modifications do not affect cAPK activity as such. Alternatively, phosphorylation may recruit cAPK to, and thereby control, a specific subsetof ( perhaps novel) cAPK targets that are presumably localized extranuclearly. Zds1 and Zds2 may play a role in this process, since these were found required to retain hyperphosphorylated Bcy1 in the cytoplasm at 37degreesC. Mck1, a homologue of mammalian glycogen synthase kinase 3 and a downstream component ofthe heat-activated Pkc1-Slt2/Mpk1 cell wall integrity pathway, is partly responsible for hyperphosphorylations of Bcy1. Remarkably, Zds1 appears to act as a negative regulator of cell wall integrity signaling, and this activity is dependent in part on the phosphorylation status of Bcy1. Thus, Mck1 phosphorylation of Bcy1 and Zds1 may constitute an unprecedented negative feedback control on the cell wall integrity-signaling pathway.	Katholieke Univ Leuven, Mol Cell Biol Lab, Inst Bot & Microbiol, B-3001 Louvain, Flanders, Belgium; VIB, Dept Mol Microbiol, B-3001 Louvain, Flanders, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB)	Thevelein, JM (corresponding author), Katholieke Univ Leuven, Mol Cell Biol Lab, Inst Bot & Microbiol, Kasteelpk Arenberg 31, B-3001 Louvain, Flanders, Belgium.	johan.thevelein@bio.kuleuven.ac.be	Thevelein, Johan M./A-7897-2013; Thevelein, Johan M./AAK-4203-2021	Thevelein, Johan M./0000-0002-2626-0180; 				Bi EF, 1996, MOL CELL BIOL, V16, P5264; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Carlson CR, 2001, J CELL SCI, V114, P3243; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; Griffioen G, 2000, J BIOL CHEM, V275, P1449, DOI 10.1074/jbc.275.2.1449; Griffioen G, 2002, CURR GENET, V41, P199, DOI 10.1007/s00294-002-0308-9; Griffioen G, 2001, MOL CELL BIOL, V21, P511, DOI 10.1128/MCB.21.2.511-523.2001; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landsverk HB, 2001, J CELL SCI, V114, P3255; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Marini NJ, 1996, EMBO J, V15, P3040, DOI 10.1002/j.1460-2075.1996.tb00667.x; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; McMillan JN, 1999, MOL CELL BIOL, V19, P5981; Miller J.H., 1972, EXPT MOL GENETICS; Mizunuma M, 2001, EMBO J, V20, P1074, DOI 10.1093/emboj/20.5.1074; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Moriya H, 2001, GENE DEV, V15, P1217, DOI 10.1101/gad.884001; Pernambuco MB, 1996, MICROBIOL-SGM, V142, P1775, DOI 10.1099/13500872-142-7-1775; PURWIN C, 1982, BIOCHEM BIOPH RES CO, V107, P1482, DOI 10.1016/S0006-291X(82)80166-6; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; Rose MD., 1990, METHODS YEAST GENETI; Sia RAL, 1996, MOL BIOL CELL, V7, P1657, DOI 10.1091/mbc.7.11.1657; SIKORSKI RS, 1989, GENETICS, V122, P19; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thevelein JM, 2000, ENZYME MICROB TECH, V26, P819, DOI 10.1016/S0141-0229(00)00177-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; UNO I, 1983, J BIOL CHEM, V258, P867; WATANABE Y, 1995, MOL CELL BIOL, V15, P5740; WERNERWASHBURNE M, 1991, J BIOL CHEM, V266, P19704; Yu YX, 1996, MOL CELL BIOL, V16, P5254; Zahringer H, 2000, MOL MICROBIOL, V35, P397, DOI 10.1046/j.1365-2958.2000.01706.x; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	51	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23460	23471		10.1074/jbc.M210691200	http://dx.doi.org/10.1074/jbc.M210691200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12704202	hybrid			2022-12-25	WOS:000183638600032
J	Guo, Z; Boekhoudt, GH; Boss, JM				Guo, Z; Boekhoudt, GH; Boss, JM			Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganous superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL REGULATION; SWI/SNF COMPLEX; FACTOR-ALPHA; SP1 BINDING; C/EBP-BETA; GENE; ACTIVATION; EXPRESSION; PROTEINS	Manganous superoxide dismutase (Mn-SOD), a tumor necrosis factor (TNF)-inducible gene product, plays an important role in removing superoxide anions produced inside mitochondria. Two regulatory regions, the proximal promoter region (PPR), which is upstream from the transcription initiation site, and the TNF-responsive element (TNFRE), which is inside intron 2, are responsible for Mn-SOD expression. To understand how each of these regions contributes to the transcription of Mn-SOD, quantitative reverse transcription-PCR, chromatin immunoprecipitations, and in vivo nuclease sensitivity assays were performed on the murine Mn-SOD gene. These assays demonstrate that Sp1 and nuclear factor (NF)-kappaB p65 are required for Mn-SOD induction by TNF. Sp1 bound the PPR constitutively, whereas NF-kappaB p65 and C/EBP-beta bound the TNFRE only after TNF treatment. Binding of C/EBP-beta to the TNFRE was dependent on the presence of NF-kappaB p65. The chromatin structure within the TNFRE became more accessible to nuclease digestion after TNF treatment. This accessibility required Sp1 and NF-kappaB p65. Treatment of cells with an inhibitor of histone deacetylation, or transient transfection with coactivator-expressing plasmids, enhanced the expression of Mn-SOD. NF-kappaB p65 binding was required for acetylation of histones H3 and H4 at the PPR and the TNFRE. Together, these data suggest communication between the PPR and the TNFRE which involves chromatin remodeling and histone acetylation during the induction process of Mn-SOD in response to TNF.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Boss, JM (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	boss@microbio.emory.edu			NCI NIH HHS [CA96810] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Chan HM, 2001, J CELL SCI, V114, P2363; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Davis CA, 2001, J BIOL CHEM, V276, P37317, DOI 10.1074/jbc.M104378200; Dorsman JC, 1997, J GEN VIROL, V78, P423, DOI 10.1099/0022-1317-78-2-423; DUERKSENHUGHES P, 1989, J IMMUNOL, V143, P4193; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kuo SY, 1999, J BIOL CHEM, V274, P3345, DOI 10.1074/jbc.274.6.3345; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Maehara K, 1999, FEBS LETT, V449, P115, DOI 10.1016/S0014-5793(99)00408-1; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; Ping DS, 1999, J IMMUNOL, V162, P727; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Ping DS, 1999, J BIOL CHEM, V274, P31909, DOI 10.1074/jbc.274.45.31909; Rogers RJ, 2001, J BIOL CHEM, V276, P20419, DOI 10.1074/jbc.M008915200; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VISNER GA, 1990, J BIOL CHEM, V265, P2856; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520	38	61	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23570	23578		10.1074/jbc.M303431200	http://dx.doi.org/10.1074/jbc.M303431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12684509	hybrid			2022-12-25	WOS:000183638600046
J	Kahns, S; Kalai, M; Jakobsen, LD; Clark, BFC; Vandenabeele, P; Jensen, PH				Kahns, S; Kalai, M; Jakobsen, LD; Clark, BFC; Vandenabeele, P; Jensen, PH			Caspase-1 and caspase-8 cleave and inactivate cellular parkin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; TUMOR-NECROSIS-FACTOR; RECESSIVE JUVENILE PARKINSONISM; ALPHA-SYNUCLEIN; CYTOCHROME-C; DISEASE; APOPTOSIS; DEATH; GENE; ACTIVATION	Lesions in the parkin gene cause early onset Parkinson's disease by a loss of dopaminergic neurons, thus demonstrating a vital role for parkin in the survival of these neurons. Parkin is inactivated by caspase cleavage, and the major cleavage site is after Asp(126). Caspases responsible for parkin cleavage were identified by several experimental paradigms. Transient coexpression of caspases and wild type parkin in HEK-293 cells identified caspase-1, -3, and -8 as efficient inducers of parkin cleavage whereas caspase-2, -7, -9, and -11 did not induce cleavage. A D126A parkin mutation abrogates cleavage induced by caspase-1 and -8, but not by caspase-3. In anti-Fas-treated Jurkat T cells, parkin cleavage was inhibited by caspase inhibitors hFlip and CrmA (but not by X-linked inhibitor of apoptosis (XIAP)), indicating that caspase-8 (but not caspase-3) is responsible for the parkin cleavage in this model. Moreover, induction of apoptosis in caspase-3-deficient MCF7 cells, either by caspase-1 or -8 overexpression or by tumor necrosis factor-alpha treatment, led to parkin cleavage. These results demonstrate that caspase-1 and -8 can directly cleave parkin and suggest that death receptor activation and inflammatory stress can cause loss of the ubiquitin ligase activity of parkin, thus causing accumulation of toxic parkin substrates and triggering dopaminergic cell death.	Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; State Univ Ghent VIB, Dept Mol Biomed Res, B-9000 Ghent, Belgium	Aarhus University; Aarhus University; Flanders Institute for Biotechnology (VIB); Ghent University	Jensen, PH (corresponding author), Aarhus Univ, Dept Biochem Med, DK-8000 Aarhus C, Denmark.	phj@biokemi.au.dk	Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Jensen, Poul Henning/0000-0002-4439-9020				Andersen JK, 2001, BIOESSAYS, V23, P640, DOI 10.1002/bies.1089; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Ledesma MD, 2002, J NEUROCHEM, V83, P1431, DOI 10.1046/j.1471-4159.2002.01253.x; Leira F, 2001, TOXICOL IN VITRO, V15, P199, DOI 10.1016/S0887-2333(01)00013-3; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mengesdorf T, 2002, P NATL ACAD SCI USA, V99, P15042, DOI 10.1073/pnas.232588799; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 2000, J NEURAL TRANSM, V107, P335, DOI 10.1007/s007020050028; Nagatsu T, 2002, J NEURAL TRANSM, V109, P731, DOI 10.1007/s007020200061; Northington FJ, 2001, DEV NEUROSCI-BASEL, V23, P186, DOI 10.1159/000046141; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Troy CM, 2002, J NEUROSCI RES, V69, P145, DOI 10.1002/jnr.10294; Van de Craen M, 1998, J MOL BIOL, V284, P1017, DOI 10.1006/jmbi.1998.2226; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	47	61	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23376	23380		10.1074/jbc.M300495200	http://dx.doi.org/10.1074/jbc.M300495200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12692130	hybrid			2022-12-25	WOS:000183638600022
J	Weber, M; Sydlik, C; Quirling, M; Nothdurfter, C; Zwergal, A; Heiss, P; Bell, S; Neumeier, D; Ziegler-Heitbrock, HWL; Brand, K				Weber, M; Sydlik, C; Quirling, M; Nothdurfter, C; Zwergal, A; Heiss, P; Bell, S; Neumeier, D; Ziegler-Heitbrock, HWL; Brand, K			Transcriptional inhibition of interleukin-8 expression in tumor necrosis factor-tolerant cells - Evidence for involvement of C/EBP beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TNF-ALPHA; ENDOTOXIN TOLERANCE; IMMUNE-RESPONSE; P50 SUBUNIT; GENE; RECEPTOR; BINDING; LIPOPOLYSACCHARIDE; OCT-1	There is some evidence that the potent cytokine tumor necrosis factor (TNF) is able to induce tolerance after repeated stimulation of cells. To investigate the molecular mechanisms mediating this phenomenon, the expression of interleukin-8 (IL-8), which is regulated by transcription factors NF-kappaB and C/EBPbeta, was monitored under TNF tolerance conditions. Pretreatment of monocytic cells for 72 h with low TNF doses inhibited TNF-induced (restimulation with a high dose) IL-8 promoter-dependent transcription as well as IL-8 production. Under these conditions neither activation of NF-kappaB nor IkappaB proteolysis was affected after TNF re-stimulation, albeit a slightly reduced IkappaB-alpha level was found in the TNF pretreated but not re-stimulated sample. Remarkably, in tolerant cells an increased binding of C/EBPbeta to its IL-8 promoter-specific DNA motif as well as an elevated association of C/EBPbeta protein with p65-containing NF-kappaB complexes was observed. Finally, overexpression of C/EBPbeta, but not p65 or Oct-1, markedly prevented TNF-induced IL-8 promoter-dependent transcription. Taken together, these data indicate that the expression of IL-8 is inhibited at the transcriptional level in TNF-tolerant cells and C/EBPbeta is involved under these conditions in mediating the negative-regulatory effects, a mechanism that may play a role in inflammatory processes such as sepsis.	Univ Munich, Inst Clin Chem & Pathobiochem, Klinikum Rechts Isar, D-81675 Munich, Germany; Univ Munich, Dept Derm & Allergol, D-80337 Munich, Germany; GSF, Inst Inhalat Biol & Asklepios Fachklin Munchen, Clin Cooperat Grp Aerosols Med, D-82131 Gauting, Germany; Univ Leicester, Dept Immunol, Leicester LE1 9HN, Leics, England	Technical University of Munich; University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Leicester	Brand, K (corresponding author), Univ Munich, Inst Clin Chem & Pathobiochem, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany.							Adib-Conquy M, 2002, J BIOL CHEM, V277, P27927, DOI 10.1074/jbc.M200705200; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Ferlito M, 2001, J LEUKOCYTE BIOL, V70, P821; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; FRAKER DL, 1988, J EXP MED, V168, P95, DOI 10.1084/jem.168.1.95; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; Goldbach JM, 1996, AM J PHYSIOL-REG I, V270, pR749, DOI 10.1152/ajpregu.1996.270.4.R749; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAEGREID A, 1995, J BIOL CHEM, V270, P25418, DOI 10.1074/jbc.270.43.25418; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; PATTON JS, 1987, J CLIN INVEST, V80, P1587, DOI 10.1172/JCI113245; Pope R, 2000, CYTOKINE, V12, P1171, DOI 10.1006/cyto.2000.0691; Poppers DM, 2000, J BIOL CHEM, V275, P29587, DOI 10.1074/jbc.M002806200; Porter MH, 1998, AM J PHYSIOL-REG I, V274, pR741, DOI 10.1152/ajpregu.1998.274.3.R741; Prosch S, 2001, J BIOL CHEM, V276, P40712, DOI 10.1074/jbc.M009815200; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Shah PC, 1997, EMBO J, V16, P7105, DOI 10.1093/emboj/16.23.7105; SIBBET GJ, 1995, J VIROL, V69, P4006, DOI 10.1128/JVI.69.7.4006-4011.1995; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAKAHASHI N, 1993, J IMMUNOTHER, V14, P16, DOI 10.1097/00002371-199307000-00003; TAKAHASHI N, 1995, AM J PHYSIOL-REG I, V269, pR398, DOI 10.1152/ajpregu.1995.269.2.R398; TAKAHASHI N, 1994, CYTOKINE, V6, P235, DOI 10.1016/1043-4666(94)90018-3; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; Wu GD, 1997, J BIOL CHEM, V272, P2396; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; Ziegler-Heitbrock L, 2001, J ENDOTOXIN RES, V7, P219, DOI 10.1177/09680519010070030401; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	47	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23586	23593		10.1074/jbc.M211646200	http://dx.doi.org/10.1074/jbc.M211646200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12707271	hybrid			2022-12-25	WOS:000183638600048
J	Hiltunen, MO; Ruuskanen, M; Huuskonen, J; Mahonen, AJ; Ahonen, M; Rutanen, J; Kosma, VM; Mahonen, A; Kroger, H; Yla-Herttuala, S				Hiltunen, MO; Ruuskanen, M; Huuskonen, J; Mahonen, AJ; Ahonen, M; Rutanen, J; Kosma, VM; Mahonen, A; Kroger, H; Yla-Herttuala, S			Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo	FASEB JOURNAL			English	Article						osteogenesis; gene therapy; osteoporosis	ENDOTHELIAL GROWTH-FACTOR; LOWER-LIMB ARTERY; ANGIOGENESIS; EXPRESSION; ISCHEMIA; DIFFERENTIATION; INJECTION; THERAPY; HYPERPLASIA; PHVEGF(165)	Osteoporosis is a major problem in elderly population. We tested the hypothesis whether vascular endothelial growth factor (VEGF-A) gene transfer is an appropriate way to enhance bone formation and recruitment of osteoblasts in vivo. Adenovirus vectors containing VEGF-A or lacZ cDNAs (1.4x10(10) pfu) were injected locally into right distal femurs of New Zealand White rabbits. Saline was injected into all contralateral distal femurs. One and three weeks after the gene transfers femurs were collected for analyses. X-Gal staining showed that up to 20% of the bone marrow cells were transfected although gene transfer also resulted in biodistribution of the vector and expression of the transgene in liver and spleen. Trabecular bone hard tissue histomorphometry of the distal femurs was performed to analyze the effect of gene transfer on bone turnover. When compared with unilateral lacZ transfected trabecular bone at one-week and three-week time points, VEGF-A gene transfer significantly increased bone formation parameters, such as osteoblast number, osteoid volume, and bone volume. Also, bone resorption surface was greatly reduced. It is concluded that injection of adenovirus vector can transfect bone marrow cells in vivo with a relatively high efficiency. Our results suggest that adenovirus-mediated VEGF-A gene transfer induces bone formation via increasing osteoblast activity and may be useful for the treatment of osteoporosis and other diseases that require efficient osteogenic therapy.	Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Surg, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol & Forens Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Gene Therapy Unit, FIN-70211 Kuopio, Finland; Tampere Univ Hosp, Tampere, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Tampere University; Tampere University Hospital	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Mol Med, POB 1627, FIN-70211 Kuopio, Finland.	Seppo.Ylaherttuala@uku.fi		Yla-Herttuala, Seppo/0000-0001-7593-2708				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Baron R, 1983, PROCESSING UNDECALCI, P13; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Baylink DJ, 1999, MOL MED TODAY, V5, P133, DOI 10.1016/S1357-4310(98)01426-9; BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165; BREIER G, 1992, DEVELOPMENT, V114, P521; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P832, DOI 10.2106/00004623-199173060-00006; Carlevaro MF, 2000, J CELL SCI, V113, P59; Clesham GJ, 1998, GENE THER, V5, P174, DOI 10.1038/sj.gt.3300576; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Hiltunen MO, 2000, FASEB J, V14, P2230, DOI 10.1096/fj.00-0145com; Hiltunen MO, 2000, CIRCULATION, V102, P2262; Huuskonen J, 2001, ANN CHIR GYNAECOL, V90, P37; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P439, DOI 10.1007/BF02411282; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Tsurumi Y, 1997, CIRCULATION, V96, P382; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X	37	65	84	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1147	+		10.1096/fj.02-0514fje	http://dx.doi.org/10.1096/fj.02-0514fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692089				2022-12-25	WOS:000182580100039
